data_2mnu_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2mnu _Structure_validation_residue.Date_analyzed 2016-10-08 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 97.6 m-20 . . . . . 0 N--CA 1.457 -0.121 0 CA-C-O 120.802 0.334 . . . . 0.0 110.501 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 70.1 mt -62.0 151.3 35.55 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.192 -179.054 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 53.5 p -142.55 152.54 42.71 Favored 'General case' 0 CA--C 1.521 -0.152 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.311 -179.825 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . 0.51 ' CD1' ' N ' ' A' ' 14' ' ' PHE . 24.7 m-85 -112.16 143.54 43.05 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.972 -179.552 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 28.5 m -142.87 162.06 17.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.326 179.496 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 91.5 m-20 45.57 61.6 2.54 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.499 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 95.5 mt -85.61 135.54 24.72 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.611 179.316 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -132.37 -168.78 2.11 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.394 179.505 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' ASP . . . . . 0.448 ' N ' ' OD1' ' A' ' 19' ' ' ASP . 28.7 p-10 -90.58 -42.38 10.83 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.748 179.312 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' SER . . . . . 0.431 ' N ' ' OD1' ' A' ' 19' ' ' ASP . 28.4 t -112.69 7.16 18.56 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.848 -179.886 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 30.7 p -154.05 153.36 31.78 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.312 179.947 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 44.0 pt -147.65 149.16 15.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.344 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -99.52 80.56 0.52 Allowed Glycine 0 CA--C 1.526 0.744 0 N-CA-C 111.3 -0.72 . . . . 0.0 111.3 -179.898 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 62.1 mt -68.35 127.83 34.39 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.891 0.377 . . . . 0.0 110.041 -179.919 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 55.9 ttp180 -142.63 136.05 28.74 Favored 'General case' 0 CA--C 1.518 -0.252 0 CA-C-O 121.095 0.474 . . . . 0.0 110.493 -179.819 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' TRP . . . . . 0.55 ' CD2' ' O ' ' A' ' 60' ' ' GLY . 43.0 p90 -140.78 155.79 46.32 Favored 'General case' 0 CA--C 1.518 -0.284 0 CA-C-N 115.835 -0.621 . . . . 0.0 109.85 179.932 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 2.7 m -110.23 101.85 49.3 Favored Pre-proline 0 CA--C 1.534 0.358 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.839 -179.476 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_exo -56.34 150.59 49.29 Favored 'Trans proline' 0 C--N 1.308 -1.576 0 C-N-CA 122.078 1.852 . . . . 0.0 112.518 178.854 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 72.8 mt -87.3 134.9 33.5 Favored 'General case' 0 N--CA 1.465 0.281 0 CA-C-O 121.718 0.771 . . . . 0.0 110.671 -179.881 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 18.6 t-20 -47.13 -32.63 4.42 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-N 115.214 -0.903 . . . . 0.0 110.199 -179.923 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 75.8 m -82.38 -33.43 28.77 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.65 179.273 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 4.3 m -56.47 130.76 46.3 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-O 120.982 0.42 . . . . 0.0 110.221 -179.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' THR . . . . . 0.477 ' OG1' ' N ' ' A' ' 82' ' ' ASN . 6.6 m -54.37 139.53 36.52 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.586 -0.734 . . . . 0.0 109.776 -179.494 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 30.7 mm -93.57 88.97 2.54 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 CA-C-O 121.133 0.492 . . . . 0.0 110.608 -179.275 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 7.9 pt -139.65 149.18 22.64 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.184 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.408 179.588 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -48.68 136.88 17.77 Favored Glycine 0 CA--C 1.519 0.305 0 N-CA-C 110.918 -0.873 . . . . 0.0 110.918 -179.437 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 73.1 m-85 -104.6 160.44 14.95 Favored 'General case' 0 CA--C 1.517 -0.294 0 CA-C-O 120.826 0.346 . . . . 0.0 110.13 -179.818 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 5.3 tmm_? -124.32 124.5 42.52 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.791 -179.789 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . 0.434 ' O ' ' CG1' ' A' ' 39' ' ' ILE . 2.5 pt -99.12 124.77 52.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.075 -0.511 . . . . 0.0 109.936 179.749 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 16.6 m -106.33 135.4 47.89 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.493 -179.545 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.4 p -133.9 142.2 41.94 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.25 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.162 179.878 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . 0.527 ' O ' ' N ' ' A' ' 74' ' ' ASP . 38.3 t -132.55 131.87 60.05 Favored 'Isoleucine or valine' 0 C--N 1.34 0.167 0 N-CA-C 110.06 -0.348 . . . . 0.0 110.06 179.46 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -98.98 142.47 30.43 Favored 'General case' 0 C--N 1.327 -0.406 0 N-CA-C 109.366 -0.605 . . . . 0.0 109.366 179.158 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . 0.404 ' CB ' ' O ' ' A' ' 72' ' ' ASP . . . -101.06 -21.41 15.01 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.876 0.369 . . . . 0.0 110.959 179.412 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -94.07 30.6 7.41 Favored Glycine 0 N--CA 1.465 0.586 0 N-CA-C 110.958 -0.857 . . . . 0.0 110.958 -179.709 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 86.9 mt-10 -150.98 150.74 31.15 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-O 120.966 0.413 . . . . 0.0 110.626 -179.57 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -70.9 -16.46 74.65 Favored Glycine 0 CA--C 1.519 0.339 0 N-CA-C 110.567 -1.013 . . . . 0.0 110.567 179.879 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -137.63 139.32 26.64 Favored Pre-proline 0 CA--C 1.539 0.524 0 C-N-CA 121.058 -0.257 . . . . 0.0 110.401 179.632 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 63.3 Cg_endo -73.76 160.61 43.37 Favored 'Trans proline' 0 N--CA 1.49 1.291 0 C-N-CA 122.44 2.094 . . . . 0.0 112.326 177.833 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 96.7 mt -71.53 150.54 9.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.285 179.334 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 85.9 m-85 -73.1 140.86 47.44 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.728 179.938 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . 0.42 ' N ' ' CD ' ' A' ' 52' ' ' GLU . 0.3 OUTLIER -68.26 -177.21 0.84 Allowed 'General case' 0 CA--C 1.514 -0.408 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.653 179.575 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' ASP . . . . . 0.41 ' CG ' ' OH ' ' A' ' 62' ' ' TYR . 3.5 t70 -149.47 143.38 25.63 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.6 179.361 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 92.7 m-85 -111.33 122.82 48.85 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.366 179.854 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 5.3 p -129.41 139.13 52.54 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.292 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.293 -179.894 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 91.5 m-20 -55.29 158.12 3.29 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.483 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 38.5 t -66.25 -37.01 84.49 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.66 179.937 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 37.9 m -51.59 -33.4 32.55 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.311 -179.598 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.598 ' C ' ' H ' ' A' ' 61' ' ' TYR . 1.9 t -91.78 68.76 0.58 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.179 179.291 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . 0.55 ' O ' ' CD2' ' A' ' 26' ' ' TRP . . . -53.24 -2.64 0.1 Allowed Glycine 0 CA--C 1.528 0.873 0 N-CA-C 110.946 -0.862 . . . . 0.0 110.946 -179.983 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' TYR . . . . . 0.598 ' H ' ' C ' ' A' ' 59' ' ' VAL . 41.2 p90 -122.57 151.64 41.2 Favored 'General case' 0 N--CA 1.464 0.243 0 CA-C-O 121.103 0.478 . . . . 0.0 111.0 -179.6 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' TYR . . . . . 0.41 ' OH ' ' CG ' ' A' ' 53' ' ' ASP . 33.6 t80 -155.78 156.79 35.41 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.726 -0.67 . . . . 0.0 109.772 179.553 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 88.0 m -119.92 136.44 54.51 Favored 'General case' 0 N--CA 1.465 0.301 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.402 -179.569 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -131.9 110.95 17.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.018 -0.537 . . . . 0.0 109.863 178.956 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 2.0 p -122.26 164.15 18.38 Favored 'General case' 0 N--CA 1.464 0.256 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.617 -179.94 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 112.86 8.65 20.15 Favored Glycine 0 CA--C 1.529 0.943 0 CA-C-N 115.561 -0.745 . . . . 0.0 111.74 -179.12 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 10.5 mt -75.48 178.94 5.57 Favored 'General case' 0 C--N 1.325 -0.483 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 178.583 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 58.7 mm-40 -128.04 137.62 31.21 Favored Pre-proline 0 CA--C 1.54 0.584 0 C-N-CA 121.019 -0.272 . . . . 0.0 111.076 179.295 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -73.34 148.67 43.81 Favored 'Trans proline' 0 N--CA 1.496 1.619 0 C-N-CA 122.801 2.334 . . . . 0.0 111.83 179.193 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 75.51 3.83 73.03 Favored Glycine 0 CA--C 1.526 0.768 0 CA-C-N 115.619 -0.719 . . . . 0.0 111.411 179.226 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 2.0 mp -112.23 141.26 28.31 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.401 0 CA-C-O 121.495 0.664 . . . . 0.0 109.579 -179.618 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 72' ' ' ASP . . . . . 0.404 ' O ' ' CB ' ' A' ' 44' ' ' ALA . 1.9 t70 -82.06 111.52 18.28 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 115.137 -0.938 . . . . 0.0 110.633 179.854 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 73' ' ' TYR . . . . . 0.415 ' O ' ' CD1' ' A' ' 75' ' ' ILE . 14.7 m-85 -105.86 119.56 39.48 Favored 'General case' 0 C--O 1.219 -0.546 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.568 179.791 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 74' ' ' ASP . . . . . 0.527 ' N ' ' O ' ' A' ' 42' ' ' VAL . 5.5 m-20 -89.32 118.82 29.27 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.572 -0.74 . . . . 0.0 109.326 179.838 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . 0.415 ' CD1' ' O ' ' A' ' 73' ' ' TYR . 0.0 OUTLIER -115.45 163.81 12.38 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.404 0 CA-C-O 121.066 0.46 . . . . 0.0 110.163 -179.082 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 20.6 t -155.91 121.44 4.9 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.508 -0.769 . . . . 0.0 110.681 178.899 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 5.2 t -101.35 101.09 11.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 N-CA-C 109.901 -0.407 . . . . 0.0 109.901 179.341 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 96.8 mt -91.96 133.46 33.37 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.267 179.763 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 79' ' ' THR . . . . . 0.473 ' CG2' ' O ' ' B' ' 216' ' ' TRP . 0.0 OUTLIER -111.91 107.54 16.59 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 121.108 0.48 . . . . 0.0 109.755 179.551 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 38.3 tp -104.22 115.37 30.28 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.724 -0.671 . . . . 0.0 110.458 179.937 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 2.1 pp -145.95 146.26 19.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.068 -0.514 . . . . 0.0 110.275 179.33 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 82' ' ' ASN . . . . . 0.477 ' N ' ' OG1' ' A' ' 33' ' ' THR . 18.9 t-20 . . . . . 0 C--N 1.328 -0.332 0 CA-C-O 120.844 0.354 . . . . 0.0 111.256 -179.902 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 207' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.467 0.736 0 N-CA-C 111.088 -0.805 . . . . 0.0 111.088 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' B' B ' 208' ' ' SER . . . . . 0.556 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 59.7 p -166.74 171.78 11.15 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.823 0.344 . . . . 0.0 110.825 179.795 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 209' ' ' TRP . . . . . . . . . . . . . 44.4 m95 -83.66 146.33 28.31 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.593 179.041 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 32.0 p -128.64 130.11 46.8 Favored 'General case' 0 N--CA 1.463 0.199 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.287 179.752 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 39.1 t-105 -95.37 117.72 30.83 Favored 'General case' 0 N--CA 1.463 0.221 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.376 179.834 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 212' ' ' GLU . . . . . 0.443 ' O ' ' O ' ' B' ' 215' ' ' LYS . 0.6 OUTLIER -163.81 164.57 23.55 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.708 179.13 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' B' B ' 213' ' ' ASN . . . . . . . . . . . . . 11.7 m120 52.62 39.92 29.12 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.616 176.302 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 49.64 21.68 3.52 Favored Glycine 0 CA--C 1.524 0.647 0 N-CA-C 111.084 -0.806 . . . . 0.0 111.084 179.605 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 215' ' ' LYS . . . . . 0.443 ' O ' ' O ' ' B' ' 212' ' ' GLU . 24.9 mtpt -148.02 152.73 37.93 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.063 0.459 . . . . 0.0 111.51 -179.694 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 216' ' ' TRP . . . . . 0.483 ' CD1' ' N ' ' B' ' 216' ' ' TRP . 24.4 m95 -92.17 119.08 31.47 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.959 -0.564 . . . . 0.0 109.729 179.165 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 217' ' ' THR . . . . . . . . . . . . . 12.4 m -132.72 145.02 50.68 Favored 'General case' 0 N--CA 1.465 0.32 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.469 -179.732 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 218' ' ' TRP . . . . . 0.556 ' CH2' ' N ' ' B' ' 208' ' ' SER . 14.5 t-105 -103.34 118.12 36.03 Favored 'General case' 0 N--CA 1.463 0.199 0 CA-C-N 116.008 -0.542 . . . . 0.0 109.922 179.563 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 95.7 mttt -141.15 165.74 26.7 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.952 -179.729 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -176.03 -161.02 24.47 Favored Glycine 0 CA--C 1.521 0.435 0 CA-C-N 115.492 -0.776 . . . . 0.0 111.421 -179.589 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 221' ' ' ILE . . . . . 0.417 ' O ' ' CG2' ' B' ' 222' ' ' ILE . 22.6 mt -52.75 -74.74 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 C-N-CA 120.598 -0.441 . . . . 0.0 110.295 -177.839 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 222' ' ' ILE . . . . . 0.527 ' O ' ' O ' ' B' ' 223' ' ' ARG . 22.1 pt -160.47 -166.72 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.389 -0.369 . . . . 0.0 110.064 179.776 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 223' ' ' ARG . . . . . 0.527 ' O ' ' O ' ' B' ' 222' ' ' ILE . 34.1 ptt85 -42.01 175.17 0.0 OUTLIER 'General case' 0 C--N 1.333 -0.129 0 CA-C-O 121.525 0.678 . . . . 0.0 110.532 178.842 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 224' ' ' LEU . . . . . 0.554 ' CD2' ' N ' ' B' ' 224' ' ' LEU . 3.1 mm? -60.55 122.68 15.27 Favored 'General case' 0 C--N 1.315 -0.905 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.954 -179.379 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 43.1 tt0 . . . . . 0 CA--C 1.517 -0.315 0 CA-C-N 115.623 -0.717 . . . . 0.0 110.343 179.678 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . 0.537 ' OD1' ' N ' ' A' ' 12' ' ' LEU . 55.9 t0 . . . . . 0 N--CA 1.465 0.277 0 CA-C-O 120.801 0.334 . . . . 0.0 110.241 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . 0.537 ' N ' ' OD1' ' A' ' 11' ' ' ASP . 6.0 tp -65.3 142.8 58.13 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.49 -179.963 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' SER . . . . . 0.456 ' O ' ' O ' ' A' ' 25' ' ' ARG . 93.5 p -141.99 152.53 43.52 Favored 'General case' 0 N--CA 1.463 0.214 0 CA-C-O 121.076 0.465 . . . . 0.0 110.544 179.325 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . 0.522 ' CD1' ' N ' ' A' ' 14' ' ' PHE . 24.3 m-85 -111.46 146.25 37.57 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.511 -179.251 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 31.9 m -147.06 153.86 12.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-O 120.818 0.342 . . . . 0.0 110.395 179.285 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 32.6 t70 58.89 56.87 3.85 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.426 179.854 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 94.0 mt -83.51 133.31 29.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 115.914 -0.585 . . . . 0.0 110.393 179.667 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.439 ' OG1' ' O ' ' A' ' 21' ' ' SER . 0.2 OUTLIER -131.17 -167.73 1.89 Allowed 'General case' 0 N--CA 1.471 0.606 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.206 -179.74 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' ASP . . . . . 0.474 ' N ' ' OD1' ' A' ' 19' ' ' ASP . 0.4 OUTLIER -75.89 -53.24 8.74 Favored 'General case' 0 CA--C 1.517 -0.307 0 CA-C-O 120.993 0.425 . . . . 0.0 110.876 179.21 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' SER . . . . . 0.427 ' CB ' ' O ' ' A' ' 67' ' ' LEU . 33.4 p -121.13 14.31 11.37 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.968 -177.796 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' SER . . . . . 0.439 ' O ' ' OG1' ' A' ' 18' ' ' THR . 95.5 p -144.96 125.05 13.61 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.116 0.484 . . . . 0.0 110.112 179.953 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 47.1 pt -127.39 140.67 48.46 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.323 0 CA-C-N 115.912 -0.586 . . . . 0.0 109.492 -179.823 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -103.69 91.57 0.83 Allowed Glycine 0 N--CA 1.467 0.704 0 N-CA-C 111.436 -0.665 . . . . 0.0 111.436 -179.397 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . 0.465 ' CD2' ' N ' ' A' ' 24' ' ' LEU . 4.0 mm? -61.51 138.53 58.28 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.793 0.33 . . . . 0.0 110.234 -179.812 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . 0.456 ' O ' ' O ' ' A' ' 13' ' ' SER . 13.9 tpt180 -145.38 134.89 23.22 Favored 'General case' 0 C--N 1.334 -0.091 0 CA-C-O 121.455 0.645 . . . . 0.0 110.288 179.873 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' TRP . . . . . 0.511 ' CE2' ' O ' ' A' ' 60' ' ' GLY . 18.7 p90 -145.81 156.3 43.49 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.47 -0.786 . . . . 0.0 109.519 179.21 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 2.7 m -105.5 104.4 47.9 Favored Pre-proline 0 CA--C 1.534 0.344 0 CA-C-O 119.546 -0.264 . . . . 0.0 111.161 -179.153 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_exo -54.48 153.2 23.83 Favored 'Trans proline' 0 C--N 1.31 -1.483 0 C-N-CA 121.381 1.388 . . . . 0.0 113.011 178.523 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.464 ' O ' ' N ' ' A' ' 32' ' ' SER . 75.2 mt -102.57 134.86 45.22 Favored 'General case' 0 N--CA 1.467 0.392 0 CA-C-N 114.946 -1.024 . . . . 0.0 111.04 179.854 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 18.3 t-20 -45.39 -31.1 1.52 Allowed 'General case' 0 C--N 1.314 -0.964 0 CA-C-N 114.86 -1.063 . . . . 0.0 110.263 179.883 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 50.8 m -87.79 -28.85 21.42 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.292 178.998 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' SER . . . . . 0.464 ' N ' ' O ' ' A' ' 29' ' ' LEU . 3.4 m -56.23 117.56 3.89 Favored 'General case' 0 CA--C 1.529 0.162 0 CA-C-O 121.318 0.58 . . . . 0.0 110.145 179.935 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' THR . . . . . 0.594 ' CB ' ' H ' ' A' ' 82' ' ' ASN . 12.2 m -51.83 145.55 9.51 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-N 114.919 -1.037 . . . . 0.0 109.182 -179.126 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 30.1 mm -92.08 93.42 4.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.998 0.428 . . . . 0.0 110.825 -178.113 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.44 ' O ' ' OG ' ' A' ' 57' ' ' SER . 8.1 pt -150.97 128.84 2.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 115.871 -0.604 . . . . 0.0 109.875 179.027 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -47.01 130.38 12.75 Favored Glycine 0 CA--C 1.521 0.413 0 N-CA-C 111.4 -0.68 . . . . 0.0 111.4 -178.941 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 95.2 m-85 -87.36 179.64 6.56 Favored 'General case' 0 C--N 1.33 -0.279 0 N-CA-C 109.976 -0.379 . . . . 0.0 109.976 179.551 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' ARG . . . . . 0.714 HH21 ' H ' ' A' ' 40' ' ' THR . 0.0 OUTLIER -131.59 123.08 27.17 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.93 179.885 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . 0.49 ' O ' ' CG1' ' A' ' 39' ' ' ILE . 1.7 pt -107.08 118.0 53.99 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.532 0 CA-C-O 121.203 0.525 . . . . 0.0 110.103 179.546 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' THR . . . . . 0.714 ' H ' HH21 ' A' ' 38' ' ' ARG . 52.9 m -103.25 138.94 39.36 Favored 'General case' 0 N--CA 1.47 0.537 0 O-C-N 122.037 -0.415 . . . . 0.0 110.127 -179.39 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.4 p -129.1 141.13 47.4 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.476 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.351 -179.873 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . 0.495 ' O ' ' N ' ' A' ' 74' ' ' ASP . 37.4 t -131.9 132.73 61.53 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.166 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.203 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -96.66 132.91 41.83 Favored 'General case' 0 C--N 1.327 -0.401 0 N-CA-C 109.468 -0.567 . . . . 0.0 109.468 179.173 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -91.65 -19.16 22.97 Favored 'General case' 0 C--N 1.328 -0.333 0 C-N-CA 120.748 -0.381 . . . . 0.0 110.681 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -99.07 25.04 29.82 Favored Glycine 0 N--CA 1.466 0.67 0 N-CA-C 111.208 -0.757 . . . . 0.0 111.208 -179.729 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -138.96 146.95 41.6 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 120.853 0.358 . . . . 0.0 110.587 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -66.99 -21.18 71.4 Favored Glycine 0 CA--C 1.526 0.728 0 N-CA-C 111.126 -0.79 . . . . 0.0 111.126 179.811 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -138.16 140.59 29.26 Favored Pre-proline 0 CA--C 1.545 0.784 0 O-C-N 122.66 -0.318 . . . . 0.0 110.553 -179.977 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -74.11 163.79 35.86 Favored 'Trans proline' 0 N--CA 1.495 1.589 0 C-N-CA 122.656 2.238 . . . . 0.0 112.051 178.478 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . 0.451 ' CG2' ' N ' ' A' ' 51' ' ' PHE . 5.1 mp -86.66 159.99 3.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 115.693 -0.685 . . . . 0.0 111.103 -179.733 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' PHE . . . . . 0.451 ' N ' ' CG2' ' A' ' 50' ' ' ILE . 88.8 m-85 -73.13 142.77 47.47 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.782 -0.645 . . . . 0.0 111.091 -179.802 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -64.32 -175.25 0.15 Allowed 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 115.492 -0.776 . . . . 0.0 110.412 179.007 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -142.74 134.26 26.45 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.123 179.891 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 96.0 m-85 -111.01 119.98 40.84 Favored 'General case' 0 N--CA 1.465 0.322 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.675 -179.809 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 9.8 p -130.42 142.28 44.13 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.414 0 CA-C-O 120.557 0.218 . . . . 0.0 110.592 -179.906 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 99.4 m-20 -63.4 149.35 46.13 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.384 179.925 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' SER . . . . . 0.44 ' OG ' ' O ' ' A' ' 35' ' ' ILE . 13.8 m -63.24 -32.49 73.91 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.72 0.295 . . . . 0.0 110.984 179.757 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 70.9 m -54.36 -40.45 68.12 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.352 -0.386 . . . . 0.0 110.581 -179.538 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.597 ' C ' ' H ' ' A' ' 61' ' ' TYR . 35.1 t -61.29 -44.08 97.77 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 -179.638 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . 0.511 ' O ' ' CE2' ' A' ' 26' ' ' TRP . . . 68.96 -29.78 0.3 Allowed Glycine 0 CA--C 1.529 0.945 0 N-CA-C 111.346 -0.702 . . . . 0.0 111.346 179.846 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' TYR . . . . . 0.597 ' H ' ' C ' ' A' ' 59' ' ' VAL . 44.9 t80 -112.6 155.48 24.32 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-O 121.225 0.536 . . . . 0.0 111.163 -179.15 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' TYR . . . . . 0.474 ' CD2' ' CD1' ' A' ' 39' ' ' ILE . 24.2 t80 -155.68 159.37 39.49 Favored 'General case' 0 N--CA 1.454 -0.227 0 CA-C-N 115.539 -0.755 . . . . 0.0 109.694 178.617 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 90.9 m -127.7 135.47 50.22 Favored 'General case' 0 N--CA 1.465 0.307 0 CA-C-O 120.834 0.349 . . . . 0.0 110.34 -179.924 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -131.46 107.01 12.8 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 N-CA-C 109.172 -0.677 . . . . 0.0 109.172 178.489 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 2.3 p -120.89 162.88 19.09 Favored 'General case' 0 CA--C 1.514 -0.428 0 CA-C-O 120.911 0.386 . . . . 0.0 110.469 -179.707 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 106.62 24.67 6.6 Favored Glycine 0 CA--C 1.52 0.365 0 N-CA-C 110.889 -0.884 . . . . 0.0 110.889 179.873 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.427 ' O ' ' CB ' ' A' ' 20' ' ' SER . 6.9 mt -97.64 107.58 20.1 Favored 'General case' 0 CA--C 1.53 0.175 0 N-CA-C 109.405 -0.591 . . . . 0.0 109.405 179.897 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 66.8 mm-40 -46.36 135.53 7.29 Favored Pre-proline 0 C--N 1.319 -0.753 0 N-CA-C 112.019 0.377 . . . . 0.0 112.019 -178.44 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 95.1 Cg_endo -74.28 156.25 46.3 Favored 'Trans proline' 0 N--CA 1.498 1.789 0 C-N-CA 122.718 2.278 . . . . 0.0 111.219 178.753 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 72.56 -7.39 8.87 Favored Glycine 0 CA--C 1.528 0.864 0 C-N-CA 121.08 -0.581 . . . . 0.0 111.792 179.145 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 1.7 mp -103.74 143.32 15.82 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.366 0 CA-C-O 121.236 0.541 . . . . 0.0 109.702 -179.739 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 1.7 t0 -82.02 118.7 23.2 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.152 -0.931 . . . . 0.0 110.651 179.891 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 73' ' ' TYR . . . . . . . . . . . . . 13.8 m-85 -109.74 120.59 42.96 Favored 'General case' 0 C--O 1.221 -0.4 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.899 -179.784 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 74' ' ' ASP . . . . . 0.495 ' N ' ' O ' ' A' ' 42' ' ' VAL . 69.6 m-20 -89.55 116.63 27.85 Favored 'General case' 0 C--N 1.318 -0.783 0 CA-C-N 115.565 -0.743 . . . . 0.0 109.862 179.357 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -116.1 165.58 11.23 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.383 0 CA-C-O 121.098 0.475 . . . . 0.0 110.262 -179.658 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 11.1 p -153.18 148.85 27.39 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.559 -0.746 . . . . 0.0 110.274 179.08 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 53.5 t -129.33 135.61 61.33 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 N-CA-C 109.26 -0.644 . . . . 0.0 109.26 179.3 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 93.9 mt -127.49 128.11 69.49 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.314 0 CA-C-O 120.854 0.359 . . . . 0.0 110.849 179.315 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 97.1 m -100.93 109.6 21.56 Favored 'General case' 0 C--N 1.331 -0.219 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 179.037 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 37.0 tp -117.95 118.97 33.43 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.638 -179.792 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 2.2 pp -137.41 161.61 34.13 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.166 0 CA-C-N 115.957 -0.565 . . . . 0.0 109.786 178.801 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 82' ' ' ASN . . . . . 0.594 ' H ' ' CB ' ' A' ' 33' ' ' THR . 16.2 t-20 . . . . . 0 C--N 1.329 -0.304 0 CA-C-O 120.772 0.32 . . . . 0.0 110.899 -179.928 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 207' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.463 0.48 0 N-CA-C 111.098 -0.801 . . . . 0.0 111.098 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' B' B ' 208' ' ' SER . . . . . 0.533 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 38.7 p -165.13 169.33 16.28 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.624 0.249 . . . . 0.0 110.778 179.591 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 209' ' ' TRP . . . . . . . . . . . . . 86.3 m95 -88.05 150.07 23.61 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.202 179.632 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 69.3 p -129.03 129.76 45.74 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-O 120.801 0.334 . . . . 0.0 110.481 179.522 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 52.0 t-105 -91.75 110.32 21.65 Favored 'General case' 0 N--CA 1.463 0.219 0 CA-C-N 116.477 -0.329 . . . . 0.0 110.272 179.609 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 212' ' ' GLU . . . . . 0.527 ' O ' ' O ' ' B' ' 215' ' ' LYS . 2.0 pt-20 -162.78 171.74 16.29 Favored 'General case' 0 C--O 1.22 -0.457 0 CA-C-O 120.977 0.418 . . . . 0.0 110.582 179.454 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 213' ' ' ASN . . . . . 0.511 ' C ' ' H ' ' B' ' 215' ' ' LYS . 13.8 m120 49.77 30.26 3.68 Favored 'General case' 0 C--N 1.317 -0.834 0 C-N-CA 120.237 -0.585 . . . . 0.0 111.721 176.788 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 66.48 -13.13 0.43 Allowed Glycine 0 CA--C 1.532 1.105 0 C-N-CA 121.087 -0.578 . . . . 0.0 111.973 179.229 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 215' ' ' LYS . . . . . 0.527 ' O ' ' O ' ' B' ' 212' ' ' GLU . 67.5 mttm -126.05 156.25 40.25 Favored 'General case' 0 N--CA 1.468 0.432 0 CA-C-O 121.143 0.497 . . . . 0.0 110.67 -179.445 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 216' ' ' TRP . . . . . 0.475 ' CD1' ' N ' ' B' ' 216' ' ' TRP . 32.4 m95 -86.53 125.12 33.54 Favored 'General case' 0 C--N 1.328 -0.348 0 C-N-CA 120.837 -0.345 . . . . 0.0 110.095 179.796 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 217' ' ' THR . . . . . . . . . . . . . 18.5 m -124.42 138.42 54.36 Favored 'General case' 0 N--CA 1.468 0.427 0 CA-C-O 120.893 0.378 . . . . 0.0 110.359 -179.45 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 218' ' ' TRP . . . . . 0.533 ' CH2' ' N ' ' B' ' 208' ' ' SER . 24.5 t-105 -105.7 106.7 17.32 Favored 'General case' 0 N--CA 1.462 0.148 0 CA-C-N 116.13 -0.486 . . . . 0.0 109.88 179.343 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 74.4 mttt -135.46 171.47 14.4 Favored 'General case' 0 N--CA 1.466 0.355 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.646 -179.331 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -177.86 -162.75 28.4 Favored Glycine 0 CA--C 1.526 0.765 0 N-CA-C 110.857 -0.897 . . . . 0.0 110.857 179.57 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 221' ' ' ILE . . . . . 0.409 ' O ' ' CG2' ' B' ' 222' ' ' ILE . 0.8 OUTLIER -53.6 -74.2 0.05 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.384 0 C-N-CA 120.98 -0.288 . . . . 0.0 111.082 -178.73 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' B' B ' 222' ' ' ILE . . . . . 0.482 ' O ' ' O ' ' B' ' 223' ' ' ARG . 20.6 pt -160.75 -165.79 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 116.276 -0.42 . . . . 0.0 109.895 -179.545 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 223' ' ' ARG . . . . . 0.482 ' O ' ' O ' ' B' ' 222' ' ' ILE . 0.7 OUTLIER -43.37 174.9 0.0 OUTLIER 'General case' 0 N--CA 1.452 -0.363 0 CA-C-O 121.52 0.676 . . . . 0.0 110.814 179.154 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' B' B ' 224' ' ' LEU . . . . . 0.557 ' H ' ' CD2' ' B' ' 224' ' ' LEU . 2.6 mm? -61.28 116.11 4.36 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-N 115.51 -0.768 . . . . 0.0 110.634 -179.78 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 80.8 tt0 . . . . . 0 N--CA 1.465 0.277 0 CA-C-N 115.407 -0.815 . . . . 0.0 110.315 -179.987 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 98.0 m-20 . . . . . 0 CA--C 1.529 0.155 0 CA-C-O 120.931 0.396 . . . . 0.0 110.801 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 7.2 tt -75.84 154.07 36.4 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.273 179.754 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' SER . . . . . 0.433 ' O ' ' O ' ' A' ' 25' ' ' ARG . 17.7 p -140.26 151.39 45.09 Favored 'General case' 0 N--CA 1.462 0.156 0 CA-C-O 121.093 0.473 . . . . 0.0 110.226 178.862 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . 0.547 ' CD1' ' N ' ' A' ' 14' ' ' PHE . 18.0 m-85 -111.48 148.41 33.22 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.707 -0.679 . . . . 0.0 110.747 -179.194 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 25.3 m -148.25 155.57 9.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 120.966 0.412 . . . . 0.0 110.305 179.172 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 39.3 t0 62.72 29.9 16.8 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.6 -0.727 . . . . 0.0 110.891 -179.968 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 68.1 mt -56.68 131.97 20.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 179.716 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.433 ' OG1' ' O ' ' A' ' 21' ' ' SER . 0.2 OUTLIER -132.13 -168.78 2.1 Favored 'General case' 0 N--CA 1.47 0.538 0 CA-C-N 116.385 -0.37 . . . . 0.0 110.246 -179.551 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' ASP . . . . . 0.47 ' N ' ' OD1' ' A' ' 19' ' ' ASP . 22.4 p-10 -78.72 -48.47 14.86 Favored 'General case' 0 C--N 1.332 -0.169 0 C-N-CA 120.811 -0.356 . . . . 0.0 110.951 179.295 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' SER . . . . . 0.632 ' HG ' ' H ' ' A' ' 67' ' ' LEU . 27.8 t -120.73 12.78 11.45 Favored 'General case' 0 N--CA 1.462 0.165 0 CA-C-O 120.518 0.199 . . . . 0.0 110.734 -178.882 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' SER . . . . . 0.433 ' O ' ' OG1' ' A' ' 18' ' ' THR . 92.8 p -146.63 131.03 17.62 Favored 'General case' 0 N--CA 1.463 0.19 0 CA-C-O 120.83 0.348 . . . . 0.0 110.095 -179.9 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 47.5 pt -127.5 142.14 44.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.159 -0.473 . . . . 0.0 109.991 -179.687 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -100.53 83.01 0.52 Allowed Glycine 0 N--CA 1.465 0.596 0 N-CA-C 110.414 -1.074 . . . . 0.0 110.414 179.951 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 16.7 mt -69.42 125.31 26.31 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.895 0.379 . . . . 0.0 110.0 -179.719 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . 0.433 ' O ' ' O ' ' A' ' 13' ' ' SER . 66.8 ttt180 -140.01 142.7 36.25 Favored 'General case' 0 N--CA 1.464 0.233 0 CA-C-O 121.268 0.556 . . . . 0.0 110.915 179.998 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' TRP . . . . . 0.528 ' CD2' ' O ' ' A' ' 60' ' ' GLY . 8.8 p90 -142.94 158.08 43.95 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.483 -0.78 . . . . 0.0 109.755 -179.61 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 4.1 m -103.06 103.92 37.06 Favored Pre-proline 0 CA--C 1.536 0.413 0 CA-C-O 119.592 -0.242 . . . . 0.0 111.058 -179.351 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 31.9 Cg_exo -55.17 153.7 25.76 Favored 'Trans proline' 0 C--N 1.312 -1.37 0 C-N-CA 121.616 1.544 . . . . 0.0 113.103 178.828 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.484 ' O ' ' N ' ' A' ' 32' ' ' SER . 75.1 mt -100.98 133.32 45.65 Favored 'General case' 0 N--CA 1.466 0.342 0 CA-C-N 115.047 -0.979 . . . . 0.0 110.966 179.658 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 26.4 t-20 -44.79 -30.57 0.99 Allowed 'General case' 0 C--N 1.315 -0.898 0 CA-C-N 114.695 -1.138 . . . . 0.0 110.258 179.772 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 64.3 m -89.16 -27.45 20.69 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 115.797 -0.638 . . . . 0.0 110.718 178.978 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' SER . . . . . 0.484 ' N ' ' O ' ' A' ' 29' ' ' LEU . 3.3 m -56.38 120.65 8.0 Favored 'General case' 0 N--CA 1.462 0.155 0 CA-C-O 121.575 0.703 . . . . 0.0 110.262 179.876 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' THR . . . . . 0.459 ' OG1' ' N ' ' A' ' 82' ' ' ASN . 6.4 m -52.9 147.27 9.38 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 114.866 -1.061 . . . . 0.0 109.725 -179.103 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 25.0 mm -93.18 93.35 4.11 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 116.4 -0.363 . . . . 0.0 110.888 -178.632 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.539 ' O ' ' CE1' ' A' ' 37' ' ' TYR . 9.0 pt -151.17 131.15 3.69 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.175 179.477 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -54.61 136.32 44.41 Favored Glycine 0 CA--C 1.524 0.609 0 N-CA-C 111.096 -0.802 . . . . 0.0 111.096 -179.252 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' TYR . . . . . 0.539 ' CE1' ' O ' ' A' ' 35' ' ' ILE . 5.0 m-85 -97.87 179.92 4.64 Favored 'General case' 0 C--N 1.332 -0.18 0 N-CA-C 109.683 -0.488 . . . . 0.0 109.683 179.679 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' ARG . . . . . 0.526 ' NH1' ' OE2' ' A' ' 52' ' ' GLU . 5.1 tmm_? -129.14 124.81 35.65 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.492 179.728 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . 0.47 ' CD1' ' CD2' ' A' ' 62' ' ' TYR . 1.8 pt -101.51 118.54 48.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 115.96 -0.564 . . . . 0.0 109.871 179.68 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 35.2 m -102.7 134.35 46.22 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.578 -179.032 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.6 p -130.89 143.53 40.61 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.522 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.424 -179.691 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . 0.526 ' O ' ' N ' ' A' ' 74' ' ' ASP . 43.0 t -134.4 135.06 54.46 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.261 0 CA-C-O 120.875 0.369 . . . . 0.0 110.369 179.834 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -97.34 133.27 42.17 Favored 'General case' 0 C--N 1.33 -0.256 0 N-CA-C 109.515 -0.55 . . . . 0.0 109.515 179.169 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . 0.417 ' CB ' ' O ' ' A' ' 72' ' ' ASP . . . -89.87 -40.74 12.23 Favored 'General case' 0 C--N 1.33 -0.246 0 C-N-CA 120.577 -0.449 . . . . 0.0 110.635 179.444 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -80.72 30.21 2.58 Favored Glycine 0 CA--C 1.524 0.602 0 N-CA-C 111.405 -0.678 . . . . 0.0 111.405 -179.817 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 80.0 mm-40 -140.42 146.76 38.72 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 121.079 0.466 . . . . 0.0 110.415 179.753 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -69.98 -20.37 76.17 Favored Glycine 0 CA--C 1.527 0.785 0 N-CA-C 111.133 -0.787 . . . . 0.0 111.133 179.711 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . 0.415 HD13 HG22 ' A' ' 48' ' ' ILE . 0.2 OUTLIER -135.6 142.46 41.08 Favored Pre-proline 0 CA--C 1.545 0.779 0 CA-C-N 116.735 0.268 . . . . 0.0 110.361 -179.482 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -72.14 164.86 34.35 Favored 'Trans proline' 0 N--CA 1.495 1.583 0 C-N-CA 122.457 2.105 . . . . 0.0 111.573 178.451 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . 0.671 ' CD1' ' H ' ' A' ' 50' ' ' ILE . 0.6 OUTLIER -86.65 159.72 3.11 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 116.022 -0.536 . . . . 0.0 110.619 -179.579 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 84.8 m-85 -75.02 141.32 43.92 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.752 179.893 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . 0.526 ' OE2' ' NH1' ' A' ' 38' ' ' ARG . 4.4 pt-20 -70.23 -175.88 1.07 Allowed 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.501 179.54 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -147.1 141.39 26.27 Favored 'General case' 0 CA--C 1.534 0.337 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.172 179.803 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 34.3 m-85 -113.56 119.56 37.93 Favored 'General case' 0 N--CA 1.469 0.481 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.452 -179.866 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 9.3 p -128.21 140.62 48.69 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.462 0 CA-C-O 120.966 0.412 . . . . 0.0 110.554 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 97.4 m-20 -65.04 153.77 39.76 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.556 179.964 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' SER . . . . . 0.425 ' OG ' ' OH ' ' A' ' 37' ' ' TYR . 4.0 t -64.22 -33.51 75.96 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.662 179.921 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 52.1 m -52.99 -40.59 63.88 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.638 -179.419 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.516 ' C ' ' H ' ' A' ' 61' ' ' TYR . 21.1 t -61.28 -43.55 96.74 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 N-CA-C 110.019 -0.363 . . . . 0.0 110.019 -179.582 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . 0.528 ' O ' ' CD2' ' A' ' 26' ' ' TRP . . . 72.5 -38.11 0.71 Allowed Glycine 0 CA--C 1.525 0.7 0 N-CA-C 111.359 -0.696 . . . . 0.0 111.359 179.389 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' TYR . . . . . 0.516 ' H ' ' C ' ' A' ' 59' ' ' VAL . 32.1 p90 -114.62 158.82 21.21 Favored 'General case' 0 N--CA 1.47 0.54 0 CA-C-O 121.016 0.436 . . . . 0.0 110.993 -179.026 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' TYR . . . . . 0.47 ' CD2' ' CD1' ' A' ' 39' ' ' ILE . 29.1 t80 -151.62 158.37 43.39 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 109.394 -0.595 . . . . 0.0 109.394 179.336 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 53.8 m -120.65 133.68 55.34 Favored 'General case' 0 N--CA 1.465 0.297 0 CA-C-O 120.831 0.348 . . . . 0.0 110.095 179.74 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -131.81 103.46 6.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 N-CA-C 109.373 -0.603 . . . . 0.0 109.373 178.845 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 3.4 p -116.36 162.48 17.46 Favored 'General case' 0 CA--C 1.512 -0.514 0 CA-C-O 121.077 0.465 . . . . 0.0 110.452 179.772 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 106.38 23.53 7.23 Favored Glycine 0 CA--C 1.521 0.424 0 N-CA-C 111.177 -0.769 . . . . 0.0 111.177 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.632 ' H ' ' HG ' ' A' ' 20' ' ' SER . 10.8 mt -97.43 109.91 22.57 Favored 'General case' 0 C--O 1.227 -0.115 0 N-CA-C 109.063 -0.717 . . . . 0.0 109.063 179.499 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 68' ' ' GLU . . . . . 0.439 ' H ' ' HH ' ' A' ' 73' ' ' TYR . 66.4 mm-40 -51.18 135.18 30.52 Favored Pre-proline 0 C--N 1.319 -0.745 0 C-N-CA 120.611 -0.435 . . . . 0.0 111.843 -178.039 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 69' ' ' PRO . . . . . 0.429 ' C ' ' H ' ' A' ' 71' ' ' ILE . 96.8 Cg_endo -74.08 157.46 46.6 Favored 'Trans proline' 0 N--CA 1.499 1.85 0 C-N-CA 122.878 2.385 . . . . 0.0 111.132 178.83 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 72.31 -8.74 6.44 Favored Glycine 0 CA--C 1.525 0.678 0 C-N-CA 120.879 -0.677 . . . . 0.0 111.594 179.306 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . 0.429 ' H ' ' C ' ' A' ' 69' ' ' PRO . 1.8 mp -103.88 140.67 21.37 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.373 0 CA-C-O 121.496 0.665 . . . . 0.0 109.642 -179.683 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 72' ' ' ASP . . . . . 0.417 ' O ' ' CB ' ' A' ' 44' ' ' ALA . 2.3 t0 -79.54 116.99 20.07 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 114.783 -1.098 . . . . 0.0 110.457 -179.524 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 73' ' ' TYR . . . . . 0.439 ' HH ' ' H ' ' A' ' 68' ' ' GLU . 11.5 m-85 -108.11 120.78 43.32 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.495 -179.771 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 74' ' ' ASP . . . . . 0.526 ' N ' ' O ' ' A' ' 42' ' ' VAL . 23.1 m-20 -88.51 114.63 25.33 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 115.275 -0.875 . . . . 0.0 109.831 -179.903 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -113.26 164.05 9.68 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.36 0 CA-C-O 121.217 0.532 . . . . 0.0 110.363 -179.747 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 2.6 p -152.42 124.63 8.13 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.183 -0.917 . . . . 0.0 109.918 179.539 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 70.7 t -106.14 131.45 55.73 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 N-CA-C 109.11 -0.7 . . . . 0.0 109.11 179.818 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 97.4 mt -128.17 131.25 69.47 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.317 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.898 -179.886 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 9.0 t -106.95 122.41 46.37 Favored 'General case' 0 N--CA 1.463 0.192 0 CA-C-N 115.76 -0.654 . . . . 0.0 109.529 179.122 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 42.4 mt -119.86 113.01 19.94 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.478 -179.312 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 2.2 pp -146.66 144.26 20.28 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.25 0 CA-C-O 120.725 0.298 . . . . 0.0 110.327 178.651 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 82' ' ' ASN . . . . . 0.459 ' N ' ' OG1' ' A' ' 33' ' ' THR . 42.3 t30 . . . . . 0 C--N 1.33 -0.279 0 CA-C-N 116.381 -0.372 . . . . 0.0 111.509 -179.683 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 207' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.466 0.645 0 N-CA-C 110.99 -0.844 . . . . 0.0 110.99 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' B' B ' 208' ' ' SER . . . . . 0.567 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 46.4 p -166.16 170.38 13.41 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.975 0.417 . . . . 0.0 110.794 179.384 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 209' ' ' TRP . . . . . . . . . . . . . 76.4 m95 -90.77 154.87 19.21 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.385 179.505 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 61.5 p -129.75 129.85 44.65 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.43 179.471 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 51.5 t-105 -90.99 109.62 20.86 Favored 'General case' 0 N--CA 1.465 0.283 0 CA-C-N 116.352 -0.386 . . . . 0.0 110.314 179.696 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 212' ' ' GLU . . . . . 0.493 ' O ' ' O ' ' B' ' 215' ' ' LYS . 1.8 pt-20 -162.26 170.54 18.79 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.332 -0.394 . . . . 0.0 110.571 179.515 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 213' ' ' ASN . . . . . 0.536 ' C ' ' H ' ' B' ' 215' ' ' LYS . 93.9 m-20 49.68 30.09 3.48 Favored 'General case' 0 C--N 1.318 -0.793 0 C-N-CA 120.393 -0.523 . . . . 0.0 111.467 177.259 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 64.04 -10.25 0.26 Allowed Glycine 0 CA--C 1.529 0.944 0 C-N-CA 120.97 -0.634 . . . . 0.0 111.732 179.415 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 215' ' ' LYS . . . . . 0.536 ' H ' ' C ' ' B' ' 213' ' ' ASN . 27.1 mtpt -123.92 153.73 40.74 Favored 'General case' 0 N--CA 1.467 0.424 0 CA-C-O 121.056 0.455 . . . . 0.0 111.004 -179.411 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 216' ' ' TRP . . . . . 0.448 ' CD1' ' N ' ' B' ' 216' ' ' TRP . 39.5 m95 -86.62 120.84 28.37 Favored 'General case' 0 C--N 1.326 -0.415 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 179.599 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 217' ' ' THR . . . . . . . . . . . . . 22.7 m -123.89 136.81 54.59 Favored 'General case' 0 N--CA 1.467 0.415 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.27 -179.512 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 218' ' ' TRP . . . . . 0.567 ' CH2' ' N ' ' B' ' 208' ' ' SER . 18.6 t-105 -104.16 108.77 20.3 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.034 179.628 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 76.5 mttt -133.11 169.61 16.61 Favored 'General case' 0 CA--C 1.515 -0.37 0 CA-C-N 115.828 -0.624 . . . . 0.0 110.425 -179.791 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -178.1 -161.8 26.83 Favored Glycine 0 N--CA 1.446 -0.64 0 N-CA-C 110.688 -0.965 . . . . 0.0 110.688 179.612 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 221' ' ' ILE . . . . . 0.405 ' O ' ' CG2' ' B' ' 222' ' ' ILE . 24.8 mt -53.91 -72.84 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 C-N-CA 120.702 -0.399 . . . . 0.0 110.33 -178.431 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 222' ' ' ILE . . . . . 0.515 ' O ' ' O ' ' B' ' 223' ' ' ARG . 22.8 pt -160.3 -166.36 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.172 -0.467 . . . . 0.0 109.859 179.932 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 223' ' ' ARG . . . . . 0.515 ' O ' ' O ' ' B' ' 222' ' ' ILE . 23.5 ptt180 -40.87 174.16 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 121.57 0.7 . . . . 0.0 110.999 178.883 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 224' ' ' LEU . . . . . 0.527 ' CD2' ' N ' ' B' ' 224' ' ' LEU . 2.7 mm? -61.97 109.79 1.37 Allowed 'General case' 0 C--N 1.315 -0.901 0 CA-C-N 115.398 -0.819 . . . . 0.0 110.531 -179.839 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 43.4 tt0 . . . . . 0 C--N 1.33 -0.278 0 CA-C-N 115.219 -0.9 . . . . 0.0 110.328 -179.939 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 45.5 t0 . . . . . 0 N--CA 1.465 0.289 0 CA-C-O 120.906 0.384 . . . . 0.0 110.579 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 47.6 tp -63.51 140.3 58.86 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.968 -0.56 . . . . 0.0 109.986 -179.339 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 86.2 p -139.51 154.99 47.8 Favored 'General case' 0 C--O 1.234 0.238 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.456 179.823 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . 0.511 ' CD1' ' N ' ' A' ' 14' ' ' PHE . 18.4 m-85 -111.92 145.47 39.49 Favored 'General case' 0 N--CA 1.464 0.257 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.589 -179.76 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 26.7 m -146.04 161.36 11.09 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.401 179.707 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 97.1 m-20 52.56 30.81 9.03 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.796 179.683 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.422 ' C ' ' HG1' ' A' ' 18' ' ' THR . 84.1 mt -58.39 141.11 15.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 115.98 -0.554 . . . . 0.0 110.246 179.994 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.47 ' CB ' ' O ' ' A' ' 21' ' ' SER . 0.2 OUTLIER -140.98 -166.34 2.14 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.652 -179.621 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' ASP . . . . . 0.413 ' OD1' ' N ' ' A' ' 19' ' ' ASP . 7.6 p-10 -88.76 -46.92 8.6 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.71 -0.677 . . . . 0.0 110.946 179.653 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 41.3 m -115.23 8.42 15.51 Favored 'General case' 0 N--CA 1.468 0.449 0 CA-C-N 116.47 -0.332 . . . . 0.0 110.593 -179.648 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' SER . . . . . 0.47 ' O ' ' CB ' ' A' ' 18' ' ' THR . 29.6 p -151.09 145.44 25.48 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.986 0.422 . . . . 0.0 110.553 179.691 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 41.4 pt -142.49 146.95 21.61 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.113 179.839 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -102.1 84.46 0.5 Allowed Glycine 0 CA--C 1.522 0.518 0 N-CA-C 111.1 -0.8 . . . . 0.0 111.1 179.957 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 92.5 mt -69.86 122.48 19.34 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.817 0.341 . . . . 0.0 110.159 -179.865 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 65.7 ttt-85 -136.0 144.47 45.35 Favored 'General case' 0 CA--C 1.517 -0.291 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.116 -179.844 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' TRP . . . . . . . . . . . . . 35.1 p90 -145.99 157.27 43.88 Favored 'General case' 0 CA--C 1.518 -0.26 0 CA-C-N 116.407 -0.361 . . . . 0.0 110.074 -179.9 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 4.6 m -111.85 96.33 32.9 Favored Pre-proline 0 C--O 1.234 0.268 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.475 179.545 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_exo -54.1 143.72 61.42 Favored 'Trans proline' 0 C--N 1.307 -1.653 0 C-N-CA 122.177 1.918 . . . . 0.0 112.496 179.39 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 66.5 mt -79.4 140.01 37.55 Favored 'General case' 0 CA--C 1.517 -0.291 0 CA-C-O 121.481 0.658 . . . . 0.0 111.014 -179.841 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . 0.437 ' OD1' ' O ' ' A' ' 30' ' ' ASN . 59.8 t-20 -51.67 -33.95 36.1 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.243 -0.889 . . . . 0.0 109.806 179.902 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 51.4 m -79.43 -32.94 42.89 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.52 179.41 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 14.0 m -62.32 136.99 58.17 Favored 'General case' 0 CA--C 1.528 0.129 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.178 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' THR . . . . . 0.504 ' CB ' ' H ' ' A' ' 82' ' ' ASN . 7.1 m -64.89 141.59 58.72 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.967 -0.561 . . . . 0.0 110.395 179.857 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 15.5 mm -95.03 95.36 4.99 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.201 0 CA-C-O 120.936 0.398 . . . . 0.0 110.548 -179.962 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.494 ' O ' ' OG ' ' A' ' 57' ' ' SER . 11.3 pt -142.47 132.12 22.75 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.192 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.402 179.723 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -38.11 122.05 1.11 Allowed Glycine 0 CA--C 1.524 0.603 0 N-CA-C 111.424 -0.671 . . . . 0.0 111.424 -179.595 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 76.4 m-85 -89.48 176.47 6.89 Favored 'General case' 0 CA--C 1.515 -0.391 0 CA-C-O 120.907 0.384 . . . . 0.0 110.113 -179.946 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' ARG . . . . . 0.646 HH11 ' HG1' ' A' ' 40' ' ' THR . 6.2 tmm_? -135.35 126.74 28.51 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.635 179.946 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . 0.452 ' O ' ' CG1' ' A' ' 39' ' ' ILE . 1.8 pt -102.43 125.27 56.71 Favored 'Isoleucine or valine' 0 C--O 1.233 0.208 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.003 179.603 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' THR . . . . . 0.646 ' HG1' HH11 ' A' ' 38' ' ' ARG . 15.9 m -106.81 133.02 52.1 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.448 -179.858 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.2 p -128.34 138.9 53.36 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.312 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.108 179.925 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . 0.534 ' O ' ' N ' ' A' ' 74' ' ' ASP . 39.2 t -133.27 133.78 57.79 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.114 0 CA-C-N 116.418 -0.356 . . . . 0.0 110.195 179.671 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -95.95 136.53 36.27 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.269 179.292 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -90.35 -46.29 8.48 Favored 'General case' 0 N--CA 1.464 0.256 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.545 179.844 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -64.82 -30.65 78.55 Favored Glycine 0 CA--C 1.523 0.577 0 N-CA-C 111.042 -0.823 . . . . 0.0 111.042 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 36.6 mm-40 -96.07 134.73 38.76 Favored 'General case' 0 C--N 1.331 -0.197 0 N-CA-C 109.482 -0.562 . . . . 0.0 109.482 -179.24 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -63.69 -21.81 65.47 Favored Glycine 0 CA--C 1.51 -0.242 0 N-CA-C 111.087 -0.805 . . . . 0.0 111.087 -178.922 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -114.46 136.11 22.33 Favored Pre-proline 0 CA--C 1.54 0.574 0 C-N-CA 120.983 -0.287 . . . . 0.0 110.577 179.709 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -78.58 169.75 19.34 Favored 'Trans proline' 0 C--N 1.309 -1.523 0 C-N-CA 122.792 2.328 . . . . 0.0 112.002 176.498 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 4.7 mp -96.43 133.53 37.43 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.183 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.561 179.564 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 83.0 m-85 -49.71 149.31 2.54 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.617 -179.871 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 5.9 pt-20 -75.3 -178.06 3.79 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.204 179.766 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -143.76 132.57 22.61 Favored 'General case' 0 N--CA 1.45 -0.429 0 CA-C-N 115.848 -0.614 . . . . 0.0 110.855 179.839 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 96.9 m-85 -104.6 119.47 39.06 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.206 179.449 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 10.6 p -126.27 134.22 66.95 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.295 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.295 179.979 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 98.2 m-20 -56.87 138.46 53.64 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.417 -179.866 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' SER . . . . . 0.494 ' OG ' ' O ' ' A' ' 35' ' ' ILE . 5.0 m -59.04 -32.49 69.8 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.38 179.871 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 59.2 m -55.31 -33.59 63.44 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.395 -179.904 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 95.6 t -64.2 -45.74 95.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.438 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 61.58 26.75 67.03 Favored Glycine 0 CA--C 1.527 0.792 0 N-CA-C 110.656 -0.978 . . . . 0.0 110.656 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' TYR . . . . . 0.437 ' OH ' ' OG1' ' A' ' 63' ' ' THR . 48.5 t80 -167.88 152.2 6.45 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 121.275 0.56 . . . . 0.0 111.134 -179.333 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' TYR . . . . . 0.413 ' N ' ' CG ' ' A' ' 61' ' ' TYR . 23.6 t80 -158.59 159.04 35.02 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.069 178.827 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' THR . . . . . 0.437 ' OG1' ' OH ' ' A' ' 61' ' ' TYR . 85.8 m -126.6 135.75 51.64 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.711 -179.819 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -132.04 108.1 13.56 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.334 0 CA-C-N 115.946 -0.57 . . . . 0.0 109.743 179.127 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 2.6 p -116.98 159.64 22.18 Favored 'General case' 0 CA--C 1.518 -0.259 0 CA-C-O 121.0 0.429 . . . . 0.0 110.844 179.971 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 109.21 3.03 31.43 Favored Glycine 0 CA--C 1.527 0.802 0 CA-C-N 115.7 -0.682 . . . . 0.0 111.528 -179.503 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 3.8 mt -79.49 110.86 15.19 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 121.067 0.461 . . . . 0.0 110.024 -179.259 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 9.3 mt-10 -48.09 139.1 10.08 Favored Pre-proline 0 C--N 1.319 -0.741 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.013 -178.834 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -75.09 162.41 36.93 Favored 'Trans proline' 0 N--CA 1.494 1.558 0 C-N-CA 122.888 2.392 . . . . 0.0 112.401 179.426 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 46.7 22.15 1.03 Allowed Glycine 0 N--CA 1.443 -0.885 0 CA-C-N 115.27 -0.877 . . . . 0.0 111.617 179.2 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . 0.442 ' CG2' ' CD1' ' A' ' 73' ' ' TYR . 0.9 OUTLIER -109.5 166.2 4.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 121.349 0.595 . . . . 0.0 109.814 -179.708 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 72' ' ' ASP . . . . . 0.405 ' OD1' ' C ' ' A' ' 72' ' ' ASP . 4.3 t0 -102.05 101.02 11.34 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.355 -0.839 . . . . 0.0 111.82 179.476 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 73' ' ' TYR . . . . . 0.444 ' O ' ' CD1' ' A' ' 75' ' ' ILE . 2.2 m-30 -109.58 125.38 52.48 Favored 'General case' 0 C--O 1.219 -0.537 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.585 179.049 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 74' ' ' ASP . . . . . 0.534 ' N ' ' O ' ' A' ' 42' ' ' VAL . 79.7 m-20 -89.0 117.05 27.74 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 114.993 -1.003 . . . . 0.0 109.397 179.891 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . 0.444 ' CD1' ' O ' ' A' ' 73' ' ' TYR . 0.0 OUTLIER -116.54 168.63 7.89 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.306 0 CA-C-O 121.155 0.502 . . . . 0.0 110.079 -179.019 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 45.3 t -154.66 150.46 27.68 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.445 -0.798 . . . . 0.0 110.877 179.539 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 12.0 t -130.38 100.97 5.34 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.272 0 N-CA-C 109.613 -0.514 . . . . 0.0 109.613 178.958 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 96.2 mt -88.82 130.44 38.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.59 -179.782 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 91.8 m -112.53 106.66 15.16 Favored 'General case' 0 CA--C 1.518 -0.276 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 179.59 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 6.6 tt -121.3 122.29 39.56 Favored 'General case' 0 CA--C 1.519 -0.249 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.315 -179.906 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 81' ' ' ILE . . . . . 0.498 ' HB ' ' H ' ' A' ' 33' ' ' THR . 2.2 pp -134.19 151.29 32.05 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.175 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.295 179.611 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 82' ' ' ASN . . . . . 0.504 ' H ' ' CB ' ' A' ' 33' ' ' THR . 57.1 t-20 . . . . . 0 C--N 1.329 -0.29 0 CA-C-N 116.478 -0.328 . . . . 0.0 111.193 179.94 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 207' ' ' GLY . . . . . 0.427 ' C ' ' CH2' ' B' ' 218' ' ' TRP . . . . . . . . 0 N--CA 1.467 0.736 0 N-CA-C 111.174 -0.771 . . . . 0.0 111.174 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 208' ' ' SER . . . . . 0.458 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 97.4 p -162.92 170.28 18.39 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.829 0.347 . . . . 0.0 110.717 179.759 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 209' ' ' TRP . . . . . . . . . . . . . 79.0 m95 -85.32 131.42 34.41 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.183 179.682 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 44.6 p -113.8 140.69 48.1 Favored 'General case' 0 N--CA 1.463 0.221 0 CA-C-N 116.409 -0.359 . . . . 0.0 110.61 -179.752 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 54.5 t-105 -96.55 118.26 32.66 Favored 'General case' 0 N--CA 1.464 0.226 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.134 179.914 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 212' ' ' GLU . . . . . 0.477 ' O ' ' O ' ' B' ' 215' ' ' LYS . 0.9 OUTLIER -165.72 167.75 16.79 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.971 179.076 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' B' B ' 213' ' ' ASN . . . . . . . . . . . . . 12.7 m120 50.41 35.23 10.54 Favored 'General case' 0 C--N 1.321 -0.648 0 C-N-CA 120.603 -0.439 . . . . 0.0 111.02 176.168 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 52.24 14.75 2.29 Favored Glycine 0 CA--C 1.525 0.66 0 N-CA-C 111.364 -0.694 . . . . 0.0 111.364 179.661 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 215' ' ' LYS . . . . . 0.477 ' O ' ' O ' ' B' ' 212' ' ' GLU . 8.1 mtmp? -144.52 151.38 39.04 Favored 'General case' 0 C--N 1.333 -0.124 0 CA-C-O 121.161 0.505 . . . . 0.0 110.657 179.793 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 216' ' ' TRP . . . . . . . . . . . . . 66.2 m95 -85.58 120.95 27.59 Favored 'General case' 0 C--N 1.329 -0.289 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 -179.911 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 217' ' ' THR . . . . . . . . . . . . . 21.5 m -130.75 142.29 50.41 Favored 'General case' 0 C--O 1.233 0.229 0 CA-C-O 121.051 0.453 . . . . 0.0 110.617 -179.578 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 218' ' ' TRP . . . . . 0.458 ' CH2' ' N ' ' B' ' 208' ' ' SER . 16.4 t-105 -104.31 121.45 43.38 Favored 'General case' 0 N--CA 1.462 0.137 0 CA-C-N 115.925 -0.579 . . . . 0.0 109.921 179.501 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 52.1 mtmt -144.73 171.56 14.23 Favored 'General case' 0 N--CA 1.464 0.246 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.826 -179.524 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -175.44 -161.03 24.2 Favored Glycine 0 CA--C 1.524 0.627 0 CA-C-N 115.614 -0.721 . . . . 0.0 111.322 -179.663 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 221' ' ' ILE . . . . . 0.411 ' O ' ' CG2' ' B' ' 222' ' ' ILE . 18.8 mt -51.29 -73.27 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 C-N-CA 120.737 -0.385 . . . . 0.0 110.592 -177.973 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 222' ' ' ILE . . . . . 0.464 ' O ' ' O ' ' B' ' 223' ' ' ARG . 16.2 pt -158.89 -167.26 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.451 179.808 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 223' ' ' ARG . . . . . 0.508 ' NH1' ' OE1' ' B' ' 225' ' ' GLU . 0.1 OUTLIER -46.12 177.08 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.651 -0.704 . . . . 0.0 110.399 179.146 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' B' B ' 224' ' ' LEU . . . . . 0.554 ' CD2' ' N ' ' B' ' 224' ' ' LEU . 3.4 mm? -58.68 126.14 26.39 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.414 -178.833 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 225' ' ' GLU . . . . . 0.508 ' OE1' ' NH1' ' B' ' 223' ' ' ARG . 29.7 tp10 . . . . . 0 C--N 1.332 -0.162 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.167 -179.758 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 97.6 m-20 . . . . . 0 N--CA 1.464 0.227 0 CA-C-O 120.915 0.388 . . . . 0.0 110.336 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 7.4 tt -64.81 144.65 57.11 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.383 -179.74 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' SER . . . . . 0.458 ' O ' ' O ' ' A' ' 25' ' ' ARG . 87.1 p -139.18 159.54 41.91 Favored 'General case' 0 N--CA 1.462 0.125 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.653 179.734 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . 0.424 ' CD1' ' N ' ' A' ' 14' ' ' PHE . 19.1 m-85 -111.35 145.47 38.81 Favored 'General case' 0 N--CA 1.465 0.308 0 CA-C-N 115.978 -0.556 . . . . 0.0 110.572 -179.775 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 17.4 m -144.9 157.4 14.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.463 179.659 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 98.9 m-20 47.76 60.24 3.66 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.314 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.403 HG21 HD12 ' A' ' 17' ' ' ILE . 98.2 mt -82.46 140.51 16.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.538 179.757 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.438 ' CB ' ' O ' ' A' ' 21' ' ' SER . 0.3 OUTLIER -138.54 -168.33 2.37 Favored 'General case' 0 N--CA 1.466 0.325 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.449 179.917 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' ASP . . . . . 0.505 ' N ' ' OD1' ' A' ' 19' ' ' ASP . 15.8 p-10 -88.55 -43.63 11.26 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.618 179.509 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' SER . . . . . 0.42 ' OG ' ' O ' ' A' ' 67' ' ' LEU . 50.8 m -117.51 9.77 13.32 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.833 -179.65 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' SER . . . . . 0.438 ' O ' ' CB ' ' A' ' 18' ' ' THR . 9.4 m -150.1 141.76 23.58 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.262 179.829 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 44.3 pt -136.76 146.17 28.96 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.417 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.337 179.915 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -101.63 81.3 0.43 Allowed Glycine 0 CA--C 1.524 0.621 0 N-CA-C 110.887 -0.885 . . . . 0.0 110.887 179.692 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 16.4 mt -67.23 123.91 21.62 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 110.025 -0.361 . . . . 0.0 110.025 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . 0.458 ' O ' ' O ' ' A' ' 13' ' ' SER . 72.5 ttp85 -142.24 135.82 29.22 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.381 -179.804 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' TRP . . . . . . . . . . . . . 3.8 p90 -141.28 158.74 43.48 Favored 'General case' 0 C--N 1.326 -0.444 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 -179.811 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 4.1 m -108.03 102.35 45.51 Favored Pre-proline 0 CA--C 1.537 0.461 0 CA-C-N 116.725 -0.216 . . . . 0.0 110.418 179.504 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_exo -54.91 145.85 60.1 Favored 'Trans proline' 0 C--N 1.308 -1.571 0 C-N-CA 121.8 1.667 . . . . 0.0 112.874 179.547 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 71.1 mt -85.07 138.3 32.51 Favored 'General case' 0 CA--C 1.515 -0.371 0 CA-C-O 121.44 0.638 . . . . 0.0 110.567 179.866 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . 0.421 ' OD1' ' O ' ' A' ' 30' ' ' ASN . 61.2 t-20 -48.63 -34.54 11.91 Favored 'General case' 0 C--N 1.314 -0.946 0 CA-C-N 115.187 -0.915 . . . . 0.0 110.152 -179.962 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 38.3 m -80.68 -33.05 35.78 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.508 179.03 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 6.9 m -59.17 131.64 51.64 Favored 'General case' 0 CA--C 1.528 0.116 0 CA-C-O 120.963 0.411 . . . . 0.0 110.368 -179.839 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' THR . . . . . 0.468 ' CB ' ' H ' ' A' ' 82' ' ' ASN . 4.3 m -62.14 145.41 53.44 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.032 179.984 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 12.5 mm -93.92 94.42 4.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-O 120.921 0.391 . . . . 0.0 110.645 -179.606 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.478 ' O ' ' OG ' ' A' ' 57' ' ' SER . 15.8 pt -147.57 133.04 11.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.844 -0.617 . . . . 0.0 110.563 -179.88 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -47.86 130.43 17.43 Favored Glycine 0 CA--C 1.52 0.357 0 N-CA-C 110.979 -0.848 . . . . 0.0 110.979 -179.864 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' TYR . . . . . 0.438 ' CG ' ' O ' ' A' ' 37' ' ' TYR . 3.8 p90 -106.25 126.84 52.73 Favored 'General case' 0 C--N 1.33 -0.278 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 179.377 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' ARG . . . . . 0.529 ' NH1' ' OG1' ' A' ' 40' ' ' THR . 3.3 tmm_? -76.4 131.31 39.04 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.275 -0.421 . . . . 0.0 111.128 -179.321 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . 0.454 ' O ' ' CG1' ' A' ' 39' ' ' ILE . 2.2 pt -98.19 123.94 50.98 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.159 0 CA-C-N 115.956 -0.566 . . . . 0.0 109.531 179.526 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' THR . . . . . 0.529 ' OG1' ' NH1' ' A' ' 38' ' ' ARG . 1.6 m -103.38 131.12 50.72 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 120.802 0.334 . . . . 0.0 110.56 -179.303 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.3 p -130.48 138.68 53.19 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.052 179.442 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . 0.517 ' N ' ' O ' ' A' ' 74' ' ' ASP . 39.7 t -133.1 131.88 58.64 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.248 0 N-CA-C 110.101 -0.333 . . . . 0.0 110.101 -179.99 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -96.25 139.54 32.25 Favored 'General case' 0 C--N 1.327 -0.377 0 N-CA-C 109.54 -0.541 . . . . 0.0 109.54 179.099 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . 0.41 ' CB ' ' O ' ' A' ' 72' ' ' ASP . . . -92.21 -41.71 10.28 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.762 0.315 . . . . 0.0 110.857 179.636 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -65.66 -31.73 80.87 Favored Glycine 0 CA--C 1.526 0.735 0 N-CA-C 111.388 -0.685 . . . . 0.0 111.388 -179.357 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 32.0 mt-10 -97.94 129.66 44.84 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 121.168 0.509 . . . . 0.0 109.651 -179.64 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -60.37 -8.55 9.42 Favored Glycine 0 CA--C 1.518 0.233 0 N-CA-C 110.701 -0.959 . . . . 0.0 110.701 -179.272 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . 0.417 HD12 HG23 ' A' ' 48' ' ' ILE . 0.4 OUTLIER -124.08 134.39 25.39 Favored Pre-proline 0 CA--C 1.538 0.512 0 C-N-CA 121.298 -0.161 . . . . 0.0 110.588 179.529 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -77.99 160.63 30.26 Favored 'Trans proline' 0 C--N 1.314 -1.273 0 C-N-CA 122.477 2.118 . . . . 0.0 112.054 177.602 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . 0.413 HD13 HG22 ' A' ' 50' ' ' ILE . 96.1 mt -80.71 137.69 20.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.199 179.188 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 90.0 m-85 -55.88 142.05 36.79 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.949 0.404 . . . . 0.0 110.724 -179.702 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . 0.446 ' CD ' ' H ' ' A' ' 52' ' ' GLU . 0.4 OUTLIER -77.72 146.21 36.08 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.376 179.778 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -109.81 144.83 37.69 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.406 179.829 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 93.5 m-85 -109.46 118.82 37.65 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.266 179.944 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 9.3 p -125.95 137.47 57.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.441 -179.747 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 84.1 m-20 -67.63 141.41 56.75 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.297 179.592 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' SER . . . . . 0.478 ' OG ' ' O ' ' A' ' 35' ' ' ILE . 9.6 m -57.98 -28.5 64.44 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.417 179.886 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 23.4 m -55.94 -33.64 64.92 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.542 179.959 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.473 ' O ' ' CD2' ' A' ' 61' ' ' TYR . 50.6 t -60.49 -45.18 97.34 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 116.394 -0.367 . . . . 0.0 110.15 -179.395 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 71.36 14.51 74.44 Favored Glycine 0 CA--C 1.529 0.922 0 N-CA-C 111.074 -0.81 . . . . 0.0 111.074 179.388 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' TYR . . . . . 0.473 ' CD2' ' O ' ' A' ' 59' ' ' VAL . 27.6 p90 -172.27 158.34 4.43 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.795 0.331 . . . . 0.0 111.348 179.43 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 23.6 t80 -155.94 155.6 33.09 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.356 -0.384 . . . . 0.0 110.144 177.955 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 94.4 m -121.09 134.7 55.27 Favored 'General case' 0 N--CA 1.463 0.224 0 CA-C-O 121.072 0.463 . . . . 0.0 110.429 -179.814 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -131.86 103.35 6.78 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.197 0 CA-C-N 115.954 -0.566 . . . . 0.0 109.862 178.961 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 2.3 p -112.84 162.87 15.3 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 121.031 0.444 . . . . 0.0 110.683 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 111.38 5.62 26.2 Favored Glycine 0 CA--C 1.527 0.83 0 CA-C-N 115.482 -0.781 . . . . 0.0 111.583 -179.272 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.42 ' O ' ' OG ' ' A' ' 20' ' ' SER . 9.1 mt -81.21 109.04 15.36 Favored 'General case' 0 C--N 1.329 -0.286 0 N-CA-C 109.479 -0.563 . . . . 0.0 109.479 179.379 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 17.5 mm-40 -57.81 137.42 83.11 Favored Pre-proline 0 C--N 1.321 -0.651 0 CA-C-N 116.288 -0.414 . . . . 0.0 111.569 -178.303 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 80.8 Cg_endo -74.29 151.76 43.7 Favored 'Trans proline' 0 N--CA 1.494 1.542 0 C-N-CA 122.695 2.263 . . . . 0.0 111.732 178.93 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 76.58 6.41 84.44 Favored Glycine 0 CA--C 1.528 0.856 0 CA-C-N 115.644 -0.707 . . . . 0.0 111.413 179.229 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 2.4 mp -117.05 143.99 25.93 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.392 0 CA-C-O 121.398 0.618 . . . . 0.0 109.728 -179.717 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 72' ' ' ASP . . . . . 0.41 ' O ' ' CB ' ' A' ' 44' ' ' ALA . 4.4 t70 -84.06 112.26 20.05 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 114.987 -1.006 . . . . 0.0 110.626 -179.657 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 73' ' ' TYR . . . . . 0.545 ' O ' ' CD1' ' A' ' 75' ' ' ILE . 11.9 m-85 -107.54 120.61 42.68 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.467 179.73 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 74' ' ' ASP . . . . . 0.517 ' O ' ' N ' ' A' ' 42' ' ' VAL . 72.6 m-20 -88.04 119.42 28.4 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.348 -0.842 . . . . 0.0 109.414 179.474 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . 0.642 ' CD1' ' N ' ' A' ' 75' ' ' ILE . 0.0 OUTLIER -120.15 166.44 14.57 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-O 121.005 0.431 . . . . 0.0 110.311 -178.521 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 21.2 t -155.92 125.61 6.39 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.659 -0.701 . . . . 0.0 110.623 179.204 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 11.4 t -102.0 100.79 11.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 N-CA-C 109.621 -0.511 . . . . 0.0 109.621 179.126 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 90.4 mt -87.95 126.3 41.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.717 -179.766 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 79' ' ' THR . . . . . 0.431 ' OG1' ' O ' ' B' ' 216' ' ' TRP . 16.4 p -106.93 110.03 22.08 Favored 'General case' 0 N--CA 1.464 0.235 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 179.514 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 35.9 tp -117.57 124.58 49.01 Favored 'General case' 0 N--CA 1.464 0.231 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.445 179.98 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 81' ' ' ILE . . . . . 0.409 ' HB ' ' H ' ' A' ' 33' ' ' THR . 2.1 pp -145.9 145.34 20.28 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-N 116.004 -0.543 . . . . 0.0 110.259 179.338 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 82' ' ' ASN . . . . . 0.468 ' H ' ' CB ' ' A' ' 33' ' ' THR . 47.2 t30 . . . . . 0 C--N 1.329 -0.311 0 CA-C-N 116.522 -0.308 . . . . 0.0 110.808 -179.743 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 207' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.465 0.615 0 N-CA-C 110.818 -0.913 . . . . 0.0 110.818 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' B' B ' 208' ' ' SER . . . . . 0.455 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 53.9 p -164.35 171.67 14.48 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 120.876 0.37 . . . . 0.0 110.686 -179.893 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 209' ' ' TRP . . . . . . . . . . . . . 76.5 m95 -87.51 134.98 33.53 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.216 179.575 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 70.2 p -110.62 131.74 54.79 Favored 'General case' 0 N--CA 1.467 0.423 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.552 -179.847 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 50.5 t-105 -93.16 115.2 27.84 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 120.875 0.369 . . . . 0.0 110.432 179.689 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 212' ' ' GLU . . . . . 0.484 ' O ' ' O ' ' B' ' 215' ' ' LYS . 1.4 pt-20 -164.89 170.54 15.21 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.077 -0.51 . . . . 0.0 111.085 179.199 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 213' ' ' ASN . . . . . . . . . . . . . 16.3 m120 48.58 34.19 4.76 Favored 'General case' 0 C--N 1.322 -0.619 0 C-N-CA 120.398 -0.521 . . . . 0.0 111.342 176.384 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 54.27 11.75 2.65 Favored Glycine 0 CA--C 1.529 0.932 0 N-CA-C 111.627 -0.589 . . . . 0.0 111.627 179.794 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 215' ' ' LYS . . . . . 0.484 ' O ' ' O ' ' B' ' 212' ' ' GLU . 65.9 mttm -142.86 150.77 40.31 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 121.038 0.446 . . . . 0.0 110.732 179.995 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 216' ' ' TRP . . . . . 0.436 ' CD1' ' N ' ' B' ' 216' ' ' TRP . 35.0 m95 -87.74 127.15 35.31 Favored 'General case' 0 C--N 1.33 -0.281 0 N-CA-C 109.954 -0.387 . . . . 0.0 109.954 179.742 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 217' ' ' THR . . . . . . . . . . . . . 21.7 m -136.14 145.0 45.34 Favored 'General case' 0 N--CA 1.463 0.217 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.359 -179.784 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 218' ' ' TRP . . . . . 0.455 ' CH2' ' N ' ' B' ' 208' ' ' SER . 24.8 t-105 -102.6 120.83 41.23 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 116.048 -0.524 . . . . 0.0 109.796 179.53 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 97.4 mttt -136.56 164.33 28.44 Favored 'General case' 0 N--CA 1.465 0.308 0 CA-C-O 121.083 0.468 . . . . 0.0 110.739 -179.62 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -176.13 -162.75 27.55 Favored Glycine 0 CA--C 1.523 0.575 0 N-CA-C 111.134 -0.786 . . . . 0.0 111.134 -179.942 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 221' ' ' ILE . . . . . 0.423 ' O ' ' CG2' ' B' ' 222' ' ' ILE . 0.9 OUTLIER -58.75 -78.71 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 C-N-CA 120.459 -0.496 . . . . 0.0 110.965 -178.254 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' B' B ' 222' ' ' ILE . . . . . 0.461 ' O ' ' O ' ' B' ' 223' ' ' ARG . 19.1 pt -159.12 -162.84 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 N-CA-C 110.043 -0.355 . . . . 0.0 110.043 -179.085 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 223' ' ' ARG . . . . . 0.461 ' O ' ' O ' ' B' ' 222' ' ' ILE . 0.0 OUTLIER -43.76 173.64 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 121.271 0.558 . . . . 0.0 110.545 178.648 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' B' B ' 224' ' ' LEU . . . . . 0.601 ' H ' ' CD2' ' B' ' 224' ' ' LEU . 2.6 mm? -59.42 138.46 57.65 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-N 115.67 -0.695 . . . . 0.0 110.581 -179.707 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 80.0 tt0 . . . . . 0 C--N 1.332 -0.178 0 CA-C-N 115.389 -0.823 . . . . 0.0 110.41 -179.492 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 45.2 t0 . . . . . 0 N--CA 1.463 0.223 0 CA-C-O 120.809 0.338 . . . . 0.0 110.271 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 5.7 tt -70.22 134.96 48.57 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.552 179.846 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 82.5 p -142.61 162.32 35.78 Favored 'General case' 0 N--CA 1.462 0.143 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.401 179.631 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . 0.411 ' CD1' ' N ' ' A' ' 14' ' ' PHE . 57.3 m-85 -110.27 147.64 33.45 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.905 -0.588 . . . . 0.0 110.67 -179.642 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 17.7 m -144.19 152.93 15.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.399 179.737 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 24.9 t70 60.66 34.24 20.1 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.544 -179.823 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 96.4 mt -57.02 134.65 21.3 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.191 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.035 179.709 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.431 ' OG1' ' O ' ' A' ' 21' ' ' SER . 0.2 OUTLIER -136.49 -168.89 2.34 Favored 'General case' 0 N--CA 1.469 0.478 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.388 -179.831 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' ASP . . . . . 0.485 ' N ' ' OD1' ' A' ' 19' ' ' ASP . 18.6 p-10 -76.48 -50.62 13.58 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.798 179.49 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' SER . . . . . 0.447 ' OG ' ' O ' ' A' ' 67' ' ' LEU . 69.8 m -121.61 15.76 11.13 Favored 'General case' 0 N--CA 1.462 0.173 0 CA-C-N 116.677 -0.238 . . . . 0.0 110.679 -179.33 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' SER . . . . . 0.431 ' O ' ' OG1' ' A' ' 18' ' ' THR . 25.2 p -145.97 127.09 14.69 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-O 121.041 0.448 . . . . 0.0 110.545 -179.612 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 38.4 pt -128.69 141.29 46.96 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.3 0 CA-C-N 115.947 -0.569 . . . . 0.0 109.57 -179.81 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -102.29 88.73 0.7 Allowed Glycine 0 CA--C 1.523 0.566 0 N-CA-C 111.8 -0.52 . . . . 0.0 111.8 -179.316 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 10.3 mp -61.06 148.59 39.79 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 121.072 0.463 . . . . 0.0 110.349 179.963 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 50.2 ttt180 -157.4 136.57 11.83 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.683 -0.69 . . . . 0.0 110.98 179.827 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' TRP . . . . . 0.535 ' CH2' ' OH ' ' A' ' 37' ' ' TYR . 34.5 p90 -139.74 159.39 42.28 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.821 -0.627 . . . . 0.0 109.915 -179.93 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 3.7 m -107.71 99.77 31.31 Favored Pre-proline 0 CA--C 1.537 0.443 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.986 -179.363 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 38.7 Cg_exo -56.64 153.39 36.2 Favored 'Trans proline' 0 C--N 1.31 -1.454 0 C-N-CA 122.093 1.862 . . . . 0.0 112.956 178.84 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.485 ' O ' ' N ' ' A' ' 32' ' ' SER . 41.7 mt -110.41 135.91 50.38 Favored 'General case' 0 N--CA 1.469 0.492 0 CA-C-O 121.76 0.79 . . . . 0.0 110.876 -179.845 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 28.1 t-20 -45.61 -30.05 1.4 Allowed 'General case' 0 C--N 1.315 -0.902 0 CA-C-N 114.902 -1.045 . . . . 0.0 110.477 179.852 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 69.3 m -89.83 -23.83 21.59 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.623 179.282 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' SER . . . . . 0.485 ' N ' ' O ' ' A' ' 29' ' ' LEU . 4.7 m -65.09 120.03 11.91 Favored 'General case' 0 N--CA 1.464 0.233 0 CA-C-O 121.204 0.525 . . . . 0.0 110.163 179.998 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 23.7 m -55.82 140.69 41.42 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.602 -0.727 . . . . 0.0 109.516 179.578 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 29.8 mm -94.7 99.01 8.73 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.343 0 CA-C-O 120.854 0.359 . . . . 0.0 111.367 -178.625 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.436 ' O ' ' OG ' ' A' ' 57' ' ' SER . 0.1 OUTLIER -140.11 155.78 24.28 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.21 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.152 179.466 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -74.55 97.74 1.0 Allowed Glycine 0 CA--C 1.524 0.609 0 N-CA-C 110.793 -0.923 . . . . 0.0 110.793 179.877 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' TYR . . . . . 0.535 ' OH ' ' CH2' ' A' ' 26' ' ' TRP . 2.0 p90 -78.79 126.99 31.45 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 110.01 -0.367 . . . . 0.0 110.01 179.787 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 5.4 tmm_? -78.01 132.39 37.78 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 120.975 0.417 . . . . 0.0 111.092 -179.69 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . 0.458 ' O ' ' CG1' ' A' ' 39' ' ' ILE . 1.9 pt -98.46 121.27 48.83 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.217 0 N-CA-C 109.155 -0.683 . . . . 0.0 109.155 179.146 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 13.6 m -99.66 135.81 40.52 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 120.852 0.358 . . . . 0.0 110.948 -179.04 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.3 p -133.15 139.88 48.38 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.364 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.031 179.531 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . 0.511 ' O ' ' N ' ' A' ' 74' ' ' ASP . 38.7 t -131.68 131.66 62.27 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.252 0 N-CA-C 109.969 -0.382 . . . . 0.0 109.969 179.616 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -97.91 133.51 42.31 Favored 'General case' 0 C--N 1.326 -0.414 0 N-CA-C 109.448 -0.575 . . . . 0.0 109.448 179.148 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -94.01 -14.14 26.2 Favored 'General case' 0 C--N 1.329 -0.309 0 C-N-CA 120.956 -0.298 . . . . 0.0 111.005 -179.57 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -99.38 21.81 43.67 Favored Glycine 0 N--CA 1.465 0.609 0 N-CA-C 111.293 -0.723 . . . . 0.0 111.293 -179.518 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -143.74 150.25 38.34 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 121.163 0.506 . . . . 0.0 110.316 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -68.4 -19.35 72.49 Favored Glycine 0 CA--C 1.524 0.647 0 N-CA-C 110.822 -0.911 . . . . 0.0 110.822 179.976 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -134.06 139.73 34.08 Favored Pre-proline 0 CA--C 1.542 0.642 0 O-C-N 122.828 -0.219 . . . . 0.0 110.658 179.943 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_endo -73.79 164.47 34.61 Favored 'Trans proline' 0 N--CA 1.491 1.363 0 C-N-CA 122.613 2.209 . . . . 0.0 111.902 178.102 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 96.6 mt -79.16 155.01 4.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.608 179.603 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -71.59 141.64 50.01 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.42 179.986 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . 0.46 ' CD ' ' H ' ' A' ' 52' ' ' GLU . 0.4 OUTLIER -77.21 144.09 38.54 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.729 179.603 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -104.05 148.57 26.08 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.521 179.7 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' PHE . . . . . 0.465 ' CD1' ' N ' ' A' ' 54' ' ' PHE . 15.9 m-85 -115.48 120.25 38.9 Favored 'General case' 0 N--CA 1.462 0.144 0 CA-C-N 115.758 -0.655 . . . . 0.0 110.038 179.664 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 8.3 p -130.41 144.05 39.13 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.307 0 CA-C-O 120.64 0.257 . . . . 0.0 110.381 -179.957 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 98.7 m-20 -66.27 146.75 54.25 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.591 179.51 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' SER . . . . . 0.436 ' OG ' ' O ' ' A' ' 35' ' ' ILE . 0.9 OUTLIER -65.92 -31.89 73.08 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.602 179.841 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 42.9 m -53.84 -36.19 62.3 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.619 -179.579 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 86.9 t -59.27 -43.66 90.38 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 116.438 -0.346 . . . . 0.0 110.41 -179.558 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 64.93 23.94 69.73 Favored Glycine 0 CA--C 1.526 0.721 0 N-CA-C 110.403 -1.079 . . . . 0.0 110.403 179.65 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' TYR . . . . . 0.416 ' CG ' ' N ' ' A' ' 62' ' ' TYR . 38.0 t80 -170.42 153.81 4.47 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 121.018 0.437 . . . . 0.0 111.495 -179.549 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' TYR . . . . . 0.417 ' CD2' ' CD1' ' A' ' 39' ' ' ILE . 19.1 t80 -158.73 160.96 36.96 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.337 178.582 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 85.5 m -126.26 134.35 51.2 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.068 -0.514 . . . . 0.0 110.271 179.881 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -133.05 100.64 3.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.033 -0.53 . . . . 0.0 109.684 178.972 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 1.4 p -114.68 164.21 14.37 Favored 'General case' 0 CA--C 1.513 -0.478 0 CA-C-O 120.969 0.414 . . . . 0.0 110.507 -179.89 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 107.34 23.75 6.81 Favored Glycine 0 CA--C 1.519 0.319 0 N-CA-C 111.162 -0.775 . . . . 0.0 111.162 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.447 ' O ' ' OG ' ' A' ' 20' ' ' SER . 10.0 mt -97.22 106.38 18.7 Favored 'General case' 0 N--CA 1.464 0.226 0 N-CA-C 109.532 -0.544 . . . . 0.0 109.532 179.804 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 5.2 mm-40 -46.63 137.34 7.27 Favored Pre-proline 0 C--N 1.316 -0.854 0 CA-C-N 116.101 -0.5 . . . . 0.0 111.827 -178.421 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -73.98 156.67 47.59 Favored 'Trans proline' 0 N--CA 1.497 1.705 0 C-N-CA 122.674 2.249 . . . . 0.0 111.255 178.665 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 71.69 -5.68 10.99 Favored Glycine 0 CA--C 1.527 0.789 0 C-N-CA 120.947 -0.645 . . . . 0.0 111.685 179.307 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . 0.473 ' O ' ' NH1' ' B' ' 223' ' ' ARG . 1.7 mp -103.61 144.32 14.27 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.437 0 CA-C-O 121.26 0.552 . . . . 0.0 109.611 -179.807 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 2.3 t70 -84.39 119.19 24.82 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.14 -0.936 . . . . 0.0 110.469 179.291 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 73' ' ' TYR . . . . . . . . . . . . . 19.0 m-85 -110.14 120.22 41.76 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.75 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 74' ' ' ASP . . . . . 0.511 ' N ' ' O ' ' A' ' 42' ' ' VAL . 14.8 m-20 -90.17 117.1 28.67 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 115.619 -0.719 . . . . 0.0 109.788 179.639 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -114.05 165.2 9.34 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-O 121.147 0.498 . . . . 0.0 110.059 -179.29 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 1.3 p -154.59 121.36 5.49 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.721 -0.672 . . . . 0.0 110.525 179.681 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 14.2 t -96.5 99.66 9.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 179.057 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 95.4 mt -88.35 115.62 28.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.115 179.634 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 79' ' ' THR . . . . . 0.456 ' OG1' ' O ' ' B' ' 216' ' ' TRP . 43.4 p -99.21 117.39 33.57 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.249 179.95 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 20.1 mt -121.4 110.32 15.94 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.864 179.904 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 1.2 pp -142.24 138.15 29.8 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.088 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.383 179.211 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 59.7 t-20 . . . . . 0 C--N 1.33 -0.28 0 CA-C-N 115.955 -0.566 . . . . 0.0 111.244 -179.249 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' B' B ' 207' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.465 0.598 0 N-CA-C 111.142 -0.783 . . . . 0.0 111.142 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' B' B ' 208' ' ' SER . . . . . 0.538 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 30.7 p -166.47 170.04 13.27 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 120.829 0.347 . . . . 0.0 110.831 179.626 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 209' ' ' TRP . . . . . . . . . . . . . 86.1 m95 -86.29 149.32 25.14 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.373 179.637 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 59.1 p -129.06 128.78 44.26 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.345 179.247 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 54.1 t-105 -91.61 111.55 23.11 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.215 -179.977 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 212' ' ' GLU . . . . . 0.424 ' O ' ' O ' ' B' ' 215' ' ' LYS . 1.7 pt-20 -161.78 167.02 25.65 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.543 179.322 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 213' ' ' ASN . . . . . . . . . . . . . 93.7 m-20 49.79 35.05 8.38 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.929 -0.578 . . . . 0.0 111.159 176.722 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 51.46 17.93 3.29 Favored Glycine 0 CA--C 1.527 0.843 0 N-CA-C 111.37 -0.692 . . . . 0.0 111.37 179.934 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 215' ' ' LYS . . . . . 0.424 ' O ' ' O ' ' B' ' 212' ' ' GLU . 54.1 mtmt -142.58 149.45 39.03 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 120.851 0.357 . . . . 0.0 110.963 179.662 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 216' ' ' TRP . . . . . 0.456 ' O ' ' OG1' ' A' ' 79' ' ' THR . 59.8 m95 -88.83 116.4 27.08 Favored 'General case' 0 C--N 1.331 -0.23 0 N-CA-C 109.444 -0.576 . . . . 0.0 109.444 179.249 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 217' ' ' THR . . . . . . . . . . . . . 17.8 m -124.81 140.34 53.02 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-O 120.976 0.417 . . . . 0.0 110.804 -179.265 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 218' ' ' TRP . . . . . 0.538 ' CH2' ' N ' ' B' ' 208' ' ' SER . 30.6 t-105 -102.8 105.35 15.75 Favored 'General case' 0 C--N 1.333 -0.121 0 CA-C-N 115.74 -0.664 . . . . 0.0 109.473 179.229 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 75.8 mttt -131.11 167.06 19.75 Favored 'General case' 0 N--CA 1.467 0.418 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.753 -179.375 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -178.24 -162.76 28.58 Favored Glycine 0 CA--C 1.523 0.588 0 N-CA-C 111.018 -0.833 . . . . 0.0 111.018 179.447 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 221' ' ' ILE . . . . . 0.425 ' O ' ' CG2' ' B' ' 222' ' ' ILE . 2.1 mp -55.24 -73.87 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 C-N-CA 120.66 -0.416 . . . . 0.0 110.694 -178.565 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 222' ' ' ILE . . . . . 0.487 ' O ' ' O ' ' B' ' 223' ' ' ARG . 23.1 pt -160.61 -164.64 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.268 -179.599 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 223' ' ' ARG . . . . . 0.487 ' O ' ' O ' ' B' ' 222' ' ' ILE . 35.5 ptt-85 -41.73 173.1 0.0 OUTLIER 'General case' 0 CA--C 1.529 0.168 0 CA-C-O 121.352 0.596 . . . . 0.0 110.554 178.54 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 224' ' ' LEU . . . . . 0.665 ' H ' ' CD2' ' B' ' 224' ' ' LEU . 1.4 mm? -64.83 110.42 2.41 Favored 'General case' 0 C--N 1.313 -0.982 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.826 -179.597 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 83.5 tt0 . . . . . 0 C--N 1.33 -0.271 0 CA-C-N 115.252 -0.886 . . . . 0.0 110.365 179.849 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . 0.428 ' OD1' ' O ' ' A' ' 11' ' ' ASP . 53.9 p-10 . . . . . 0 N--CA 1.464 0.244 0 CA-C-O 121.148 0.499 . . . . 0.0 110.522 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . 0.426 ' H ' ' HE1' ' B' ' 209' ' ' TRP . 4.9 tt -66.47 144.43 56.5 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.592 179.922 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' SER . . . . . 0.499 ' O ' ' O ' ' A' ' 25' ' ' ARG . 85.5 p -141.44 156.07 45.81 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.98 0.419 . . . . 0.0 110.749 179.67 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . 0.532 ' CD1' ' N ' ' A' ' 14' ' ' PHE . 1.9 m-85 -112.64 153.31 27.83 Favored 'General case' 0 N--CA 1.464 0.263 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.337 -179.813 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 10.5 m -147.7 151.5 13.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.345 179.669 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 26.8 t0 62.89 37.07 12.36 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.622 -179.946 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.407 HD11 HG22 ' A' ' 17' ' ' ILE . 43.7 mt -56.94 133.45 21.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.055 179.698 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -136.54 -171.09 2.82 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.242 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' ASP . . . . . 0.47 ' N ' ' OD1' ' A' ' 19' ' ' ASP . 20.5 p-10 -75.85 -49.72 17.17 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.91 179.743 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' SER . . . . . 0.47 ' OG ' ' O ' ' A' ' 67' ' ' LEU . 51.0 m -122.36 17.11 10.59 Favored 'General case' 0 N--CA 1.465 0.324 0 CA-C-N 116.437 -0.347 . . . . 0.0 110.805 -179.698 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 1.5 m -145.62 129.83 17.6 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.706 0.289 . . . . 0.0 110.265 -179.425 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 36.5 pt -132.42 142.78 41.74 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 N-CA-C 109.599 -0.519 . . . . 0.0 109.599 179.67 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -101.48 85.9 0.58 Allowed Glycine 0 CA--C 1.523 0.541 0 N-CA-C 111.055 -0.818 . . . . 0.0 111.055 -179.413 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 55.4 mt -69.82 118.48 12.73 Favored 'General case' 0 C--N 1.33 -0.255 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . 0.553 ' HE ' ' CB ' ' A' ' 61' ' ' TYR . 31.5 ttm180 -142.99 132.5 23.6 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 121.004 0.431 . . . . 0.0 111.188 179.973 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' TRP . . . . . 0.468 ' CD1' ' O ' ' A' ' 26' ' ' TRP . 35.3 p90 -147.6 133.88 19.52 Favored 'General case' 0 C--N 1.326 -0.444 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 179.643 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 1.9 m -68.36 115.99 35.22 Favored Pre-proline 0 C--N 1.326 -0.43 0 C-N-CA 120.218 -0.593 . . . . 0.0 111.292 -178.97 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_exo -53.49 154.55 15.1 Favored 'Trans proline' 0 N--CA 1.492 1.431 0 C-N-CA 122.171 1.914 . . . . 0.0 112.709 178.258 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.464 ' O ' ' N ' ' A' ' 32' ' ' SER . 75.4 mt -93.66 132.03 38.4 Favored 'General case' 0 N--CA 1.467 0.404 0 CA-C-O 122.006 0.907 . . . . 0.0 110.89 179.926 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 40.4 t30 -43.13 -32.26 0.69 Allowed 'General case' 0 C--N 1.316 -0.863 0 CA-C-N 115.336 -0.847 . . . . 0.0 110.502 179.984 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 20.8 m -86.96 -30.44 21.29 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.692 179.365 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' SER . . . . . 0.464 ' N ' ' O ' ' A' ' 29' ' ' LEU . 2.1 m -50.26 111.32 0.51 Allowed 'General case' 0 CA--C 1.529 0.166 0 CA-C-O 121.11 0.481 . . . . 0.0 110.524 -179.783 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' THR . . . . . 0.425 ' CB ' ' H ' ' A' ' 82' ' ' ASN . 8.1 m -51.12 148.7 4.27 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.554 -0.748 . . . . 0.0 109.348 -179.646 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 5.3 mm -92.88 91.36 3.33 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.277 0 CA-C-O 121.391 0.615 . . . . 0.0 111.168 -178.825 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.487 ' O ' ' OG ' ' A' ' 57' ' ' SER . 12.0 pt -147.96 126.15 3.5 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 115.24 -0.891 . . . . 0.0 110.565 179.554 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -46.89 126.41 10.03 Favored Glycine 0 CA--C 1.521 0.465 0 N-CA-C 110.847 -0.901 . . . . 0.0 110.847 -179.718 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' TYR . . . . . 0.482 ' CE1' ' CG1' ' A' ' 55' ' ' VAL . 28.3 p90 -95.8 175.24 6.59 Favored 'General case' 0 C--N 1.329 -0.307 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 179.851 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 9.0 tmm_? -126.36 123.0 36.99 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.718 -179.843 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . 0.471 ' O ' ' CG1' ' A' ' 39' ' ' ILE . 1.9 pt -94.14 120.22 43.21 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 N-CA-C 109.602 -0.518 . . . . 0.0 109.602 -179.856 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 10.1 m -96.14 128.48 43.08 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.15 -179.289 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.0 p -123.06 134.12 67.09 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 CA-C-N 116.077 -0.511 . . . . 0.0 109.873 -179.981 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . 0.407 ' O ' ' N ' ' A' ' 74' ' ' ASP . 24.5 t -129.35 128.45 66.42 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.173 0 CA-C-O 120.831 0.348 . . . . 0.0 110.132 179.846 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -97.36 128.99 44.66 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 109.054 -0.721 . . . . 0.0 109.054 179.372 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -88.12 -24.27 23.43 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 120.869 0.366 . . . . 0.0 110.981 -179.624 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -86.43 20.59 21.66 Favored Glycine 0 N--CA 1.462 0.375 0 N-CA-C 111.202 -0.759 . . . . 0.0 111.202 -179.696 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 79.8 mm-40 -144.75 150.12 36.69 Favored 'General case' 0 C--O 1.233 0.224 0 CA-C-O 121.041 0.448 . . . . 0.0 110.324 -179.702 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -69.32 -20.33 75.09 Favored Glycine 0 N--CA 1.452 -0.269 0 N-CA-C 110.645 -0.982 . . . . 0.0 110.645 -179.852 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -131.42 139.01 34.05 Favored Pre-proline 0 N--CA 1.469 0.495 0 C-N-CA 120.952 -0.299 . . . . 0.0 110.528 179.673 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 68.6 Cg_endo -75.27 165.06 31.69 Favored 'Trans proline' 0 C--N 1.31 -1.458 0 C-N-CA 122.734 2.289 . . . . 0.0 112.027 177.676 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . 0.451 ' CG2' ' N ' ' A' ' 51' ' ' PHE . 96.6 mt -79.6 160.42 4.29 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-N 115.782 -0.644 . . . . 0.0 110.229 179.55 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' PHE . . . . . 0.451 ' N ' ' CG2' ' A' ' 50' ' ' ILE . 92.5 m-85 -74.36 142.33 45.09 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.734 179.918 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . 0.459 ' CD ' ' H ' ' A' ' 52' ' ' GLU . 0.2 OUTLIER -77.58 142.07 39.17 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.15 179.561 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' ASP . . . . . 0.42 ' CG ' ' OH ' ' A' ' 62' ' ' TYR . 0.5 OUTLIER -100.57 151.55 21.47 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 120.993 0.425 . . . . 0.0 110.051 -179.827 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 90.0 m-85 -115.09 122.06 44.98 Favored 'General case' 0 C--O 1.232 0.17 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.352 179.738 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.482 ' CG1' ' CE1' ' A' ' 37' ' ' TYR . 9.5 p -131.96 142.22 43.49 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.295 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.393 -179.974 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 99.3 m-20 -63.66 150.0 45.28 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.793 -0.64 . . . . 0.0 110.37 179.69 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' SER . . . . . 0.487 ' OG ' ' O ' ' A' ' 35' ' ' ILE . 4.7 m -64.71 -34.84 79.27 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.875 179.909 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 68.0 m -51.17 -36.54 41.59 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.303 -179.026 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.513 ' C ' ' H ' ' A' ' 61' ' ' TYR . 22.7 t -64.38 -42.39 95.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.092 179.884 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 72.01 -40.05 0.69 Allowed Glycine 0 CA--C 1.531 1.069 0 N-CA-C 111.048 -0.821 . . . . 0.0 111.048 179.766 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' TYR . . . . . 0.553 ' CB ' ' HE ' ' A' ' 25' ' ' ARG . 31.1 p90 -110.68 161.01 16.17 Favored 'General case' 0 N--CA 1.466 0.368 0 CA-C-O 121.093 0.473 . . . . 0.0 111.08 -179.035 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' TYR . . . . . 0.42 ' OH ' ' CG ' ' A' ' 53' ' ' ASP . 31.5 t80 -155.95 163.04 40.24 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.015 -0.539 . . . . 0.0 109.949 179.492 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 57.6 m -119.6 131.47 55.5 Favored 'General case' 0 N--CA 1.467 0.422 0 CA-C-O 121.025 0.44 . . . . 0.0 110.628 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -134.27 108.91 11.76 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 115.765 -0.652 . . . . 0.0 109.981 179.324 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 1.2 p -128.35 167.37 17.06 Favored 'General case' 0 CA--C 1.514 -0.441 0 CA-C-O 121.023 0.44 . . . . 0.0 110.47 179.939 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 108.33 24.34 6.25 Favored Glycine 0 CA--C 1.522 0.496 0 CA-C-N 115.614 -0.721 . . . . 0.0 111.502 -179.793 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.47 ' O ' ' OG ' ' A' ' 20' ' ' SER . 3.9 mt -99.61 106.42 18.38 Favored 'General case' 0 CA--C 1.517 -0.29 0 N-CA-C 109.197 -0.668 . . . . 0.0 109.197 -179.401 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -48.19 140.08 9.65 Favored Pre-proline 0 C--N 1.311 -1.097 0 CA-C-N 115.669 -0.696 . . . . 0.0 111.112 -178.247 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 68.5 Cg_endo -73.38 156.29 50.48 Favored 'Trans proline' 0 N--CA 1.5 1.896 0 C-N-CA 122.993 2.462 . . . . 0.0 111.596 178.344 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 74.61 -2.09 49.25 Favored Glycine 0 CA--C 1.525 0.718 0 CA-C-N 115.563 -0.744 . . . . 0.0 111.698 179.259 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 1.6 mp -110.46 140.5 29.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-O 121.557 0.694 . . . . 0.0 109.582 -179.283 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 1.6 t70 -80.54 122.78 27.46 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 114.877 -1.056 . . . . 0.0 110.297 179.649 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 73' ' ' TYR . . . . . . . . . . . . . 12.5 m-85 -114.94 122.65 46.91 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.686 -0.688 . . . . 0.0 110.809 179.785 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 74' ' ' ASP . . . . . 0.407 ' N ' ' O ' ' A' ' 42' ' ' VAL . 66.3 m-20 -94.32 110.78 22.52 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 108.597 -0.89 . . . . 0.0 108.597 178.692 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . 0.439 ' N ' HD12 ' A' ' 75' ' ' ILE . 0.0 OUTLIER -126.39 111.95 28.11 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.249 0 CA-C-N 116.654 -0.248 . . . . 0.0 111.27 179.954 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 23.8 t -105.43 125.66 51.24 Favored 'General case' 0 CA--C 1.518 -0.253 0 N-CA-C 109.576 -0.527 . . . . 0.0 109.576 179.247 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 84.4 t -88.71 99.52 9.24 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-O 120.939 0.4 . . . . 0.0 110.06 179.747 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 94.4 mt -82.52 135.99 23.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.356 179.914 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 30.5 p -113.26 117.71 32.62 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.231 179.623 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 1.8 mp -109.77 110.78 21.89 Favored 'General case' 0 N--CA 1.467 0.386 0 CA-C-O 121.194 0.521 . . . . 0.0 110.648 -179.822 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 2.0 pp -146.55 143.69 20.62 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.213 179.274 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 82' ' ' ASN . . . . . 0.425 ' H ' ' CB ' ' A' ' 33' ' ' THR . 22.5 t-20 . . . . . 0 C--N 1.328 -0.333 0 CA-C-O 120.876 0.369 . . . . 0.0 111.213 179.821 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 207' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.466 0.672 0 N-CA-C 111.054 -0.818 . . . . 0.0 111.054 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' B' B ' 208' ' ' SER . . . . . 0.589 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 97.6 p -167.07 170.88 11.53 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.805 0.336 . . . . 0.0 110.622 179.748 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 209' ' ' TRP . . . . . 0.426 ' HE1' ' H ' ' A' ' 12' ' ' LEU . 79.5 m95 -86.99 155.86 20.0 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.45 179.67 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 31.6 p -133.47 133.52 42.37 Favored 'General case' 0 N--CA 1.463 0.217 0 CA-C-N 116.434 -0.348 . . . . 0.0 110.414 179.745 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 58.0 t-105 -95.78 113.85 25.52 Favored 'General case' 0 N--CA 1.463 0.214 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.627 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 212' ' ' GLU . . . . . 0.43 ' O ' ' O ' ' B' ' 215' ' ' LYS . 0.9 OUTLIER -162.29 163.1 28.26 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.5 179.591 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' B' B ' 213' ' ' ASN . . . . . . . . . . . . . 17.8 m120 51.31 34.14 11.12 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.067 177.346 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 55.21 18.17 12.73 Favored Glycine 0 CA--C 1.527 0.808 0 N-CA-C 111.298 -0.721 . . . . 0.0 111.298 179.831 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 215' ' ' LYS . . . . . 0.43 ' O ' ' O ' ' B' ' 212' ' ' GLU . 56.1 mtmt -143.3 149.76 38.27 Favored 'General case' 0 C--O 1.232 0.165 0 CA-C-O 120.834 0.349 . . . . 0.0 110.95 179.895 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 216' ' ' TRP . . . . . . . . . . . . . 48.9 m95 -87.67 113.71 23.6 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.179 -0.464 . . . . 0.0 109.764 179.507 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 217' ' ' THR . . . . . . . . . . . . . 16.3 m -119.82 134.93 55.06 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.519 -179.339 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 218' ' ' TRP . . . . . 0.589 ' CH2' ' N ' ' B' ' 208' ' ' SER . 29.1 t-105 -95.88 105.0 16.96 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.875 -0.602 . . . . 0.0 109.907 179.27 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 6.9 mtmt -130.5 167.8 18.07 Favored 'General case' 0 CA--C 1.515 -0.398 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.778 -179.357 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -178.45 -163.35 29.68 Favored Glycine 0 CA--C 1.524 0.625 0 N-CA-C 111.138 -0.785 . . . . 0.0 111.138 179.41 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 221' ' ' ILE . . . . . 0.424 ' O ' ' CG2' ' B' ' 222' ' ' ILE . 20.1 mt -55.86 -73.24 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 C-N-CA 120.645 -0.422 . . . . 0.0 110.263 -178.146 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 222' ' ' ILE . . . . . 0.479 ' O ' ' O ' ' B' ' 223' ' ' ARG . 18.9 pt -160.53 -166.8 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 O-C-N 123.402 0.439 . . . . 0.0 110.462 179.994 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 223' ' ' ARG . . . . . 0.479 ' O ' ' O ' ' B' ' 222' ' ' ILE . 33.4 ptt180 -43.3 172.71 0.0 OUTLIER 'General case' 0 C--O 1.231 0.098 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.497 179.082 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 224' ' ' LEU . . . . . 0.596 ' H ' ' CD2' ' B' ' 224' ' ' LEU . 2.2 mm? -65.5 107.2 1.61 Allowed 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 121.48 0.657 . . . . 0.0 110.322 -178.766 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 82.0 tt0 . . . . . 0 N--CA 1.452 -0.336 0 CA-C-N 115.084 -0.962 . . . . 0.0 110.01 179.919 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . 0.424 ' OD1' ' O ' ' A' ' 11' ' ' ASP . 51.2 p-10 . . . . . 0 CA--C 1.518 -0.26 0 CA-C-O 120.996 0.426 . . . . 0.0 110.561 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 6.9 tt -63.86 142.56 58.36 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.135 -179.542 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 83.9 p -139.4 155.47 47.61 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.665 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . 0.492 ' CD1' ' N ' ' A' ' 14' ' ' PHE . 20.9 m-85 -110.79 144.66 39.43 Favored 'General case' 0 C--O 1.233 0.204 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.498 -179.691 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 15.5 m -145.49 162.28 12.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.598 -179.973 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 98.4 m-20 51.6 32.65 9.4 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.524 179.621 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 86.5 mt -58.84 140.29 17.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.267 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.438 ' CB ' ' O ' ' A' ' 21' ' ' SER . 0.2 OUTLIER -143.25 -166.3 2.28 Favored 'General case' 0 N--CA 1.465 0.305 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.601 -179.653 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' ASP . . . . . 0.441 ' OD1' ' N ' ' A' ' 20' ' ' SER . 28.7 p-10 -90.73 -45.25 8.96 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.693 -0.685 . . . . 0.0 110.875 179.546 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' SER . . . . . 0.441 ' N ' ' OD1' ' A' ' 19' ' ' ASP . 10.2 t -114.39 7.17 16.25 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-O 120.821 0.343 . . . . 0.0 110.92 -179.513 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' SER . . . . . 0.438 ' O ' ' CB ' ' A' ' 18' ' ' THR . 45.2 m -151.62 146.52 25.88 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.976 0.417 . . . . 0.0 110.439 179.898 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 40.8 pt -144.98 147.88 18.45 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-N 116.469 -0.332 . . . . 0.0 110.291 179.847 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -101.41 84.04 0.51 Allowed Glycine 0 CA--C 1.525 0.675 0 N-CA-C 111.038 -0.825 . . . . 0.0 111.038 -179.678 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 83.7 mt -71.39 124.6 24.96 Favored 'General case' 0 C--N 1.33 -0.282 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 -179.752 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 73.8 ttt-85 -138.94 139.92 38.14 Favored 'General case' 0 CA--C 1.52 -0.177 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.464 -179.593 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' TRP . . . . . . . . . . . . . 49.0 p90 -146.48 154.77 41.96 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.073 179.745 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 2.9 m -109.97 103.31 53.21 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-N 116.466 -0.334 . . . . 0.0 110.583 179.888 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_exo -53.87 145.03 52.85 Favored 'Trans proline' 0 C--N 1.307 -1.642 0 C-N-CA 122.07 1.846 . . . . 0.0 112.591 179.172 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 64.6 mt -78.91 139.86 38.2 Favored 'General case' 0 CA--C 1.518 -0.252 0 CA-C-O 121.697 0.76 . . . . 0.0 110.789 -179.643 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 38.1 t30 -51.07 -37.1 43.59 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-N 115.131 -0.94 . . . . 0.0 109.916 179.656 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 15.5 m -75.75 -34.86 60.29 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.64 178.975 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 10.8 m -60.11 132.95 55.51 Favored 'General case' 0 C--O 1.232 0.158 0 CA-C-O 120.975 0.417 . . . . 0.0 110.179 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' THR . . . . . 0.419 ' H ' ' HB ' ' A' ' 81' ' ' ILE . 5.6 m -57.78 145.22 35.59 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.17 -179.886 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . 0.438 HG23 HD12 ' A' ' 34' ' ' ILE . 26.8 mm -93.99 91.29 3.11 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 CA-C-O 121.012 0.434 . . . . 0.0 110.631 -179.513 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 21.6 pt -143.39 140.41 26.36 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.498 179.707 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -44.33 128.47 6.95 Favored Glycine 0 CA--C 1.521 0.463 0 N-CA-C 111.096 -0.801 . . . . 0.0 111.096 -179.781 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 75.0 m-85 -91.54 175.9 6.74 Favored 'General case' 0 CA--C 1.517 -0.302 0 CA-C-O 120.89 0.376 . . . . 0.0 110.187 179.849 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -137.26 125.49 23.15 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.588 -179.939 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . 0.438 ' O ' ' CG1' ' A' ' 39' ' ' ILE . 2.3 pt -101.68 124.81 55.71 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.251 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.1 -179.97 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 8.4 m -104.07 133.49 48.93 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.384 -179.275 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.3 p -132.98 139.38 49.67 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.296 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.319 179.756 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . 0.543 ' N ' ' O ' ' A' ' 74' ' ' ASP . 39.5 t -133.9 132.88 56.58 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.175 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.245 179.74 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -97.04 141.72 29.85 Favored 'General case' 0 C--N 1.326 -0.414 0 N-CA-C 109.702 -0.481 . . . . 0.0 109.702 179.15 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . 0.409 ' CB ' ' O ' ' A' ' 72' ' ' ASP . . . -95.13 -40.43 9.61 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.821 0.344 . . . . 0.0 110.769 179.659 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -66.17 -32.64 82.87 Favored Glycine 0 CA--C 1.526 0.758 0 N-CA-C 111.295 -0.722 . . . . 0.0 111.295 -179.737 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 63.2 mt-10 -98.16 131.42 44.55 Favored 'General case' 0 C--N 1.333 -0.146 0 N-CA-C 109.598 -0.519 . . . . 0.0 109.598 -179.694 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -59.01 -21.64 53.33 Favored Glycine 0 N--CA 1.454 -0.117 0 N-CA-C 110.609 -0.997 . . . . 0.0 110.609 -179.079 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -111.72 134.46 21.29 Favored Pre-proline 0 CA--C 1.535 0.4 0 C-N-CA 121.133 -0.227 . . . . 0.0 110.474 179.556 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 63.9 Cg_endo -76.71 163.92 30.91 Favored 'Trans proline' 0 C--N 1.31 -1.47 0 C-N-CA 122.638 2.226 . . . . 0.0 111.884 177.751 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 96.6 mt -82.93 133.97 27.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 115.975 -0.557 . . . . 0.0 109.949 179.134 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 76.0 m-85 -56.15 136.54 52.6 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 121.054 0.454 . . . . 0.0 110.824 -179.355 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 4.7 pt-20 -68.79 -175.08 0.65 Allowed 'General case' 0 CA--C 1.516 -0.33 0 CA-C-N 115.706 -0.679 . . . . 0.0 110.372 179.461 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' ASP . . . . . 0.512 ' CG ' ' HH ' ' A' ' 62' ' ' TYR . 3.6 t70 -156.38 156.0 33.14 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.674 179.04 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' PHE . . . . . 0.578 ' CD1' ' N ' ' A' ' 54' ' ' PHE . 2.1 m-85 -122.12 130.85 53.6 Favored 'General case' 0 N--CA 1.465 0.324 0 CA-C-O 120.889 0.376 . . . . 0.0 110.114 179.729 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 9.7 p -130.01 138.19 54.63 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.186 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.418 -179.836 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 97.8 m-20 -53.66 144.33 18.02 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.457 -179.702 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 38.7 t -63.33 -35.81 81.61 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.703 179.994 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 36.6 m -57.11 -31.88 65.76 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.551 -179.717 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 94.0 t -64.96 -46.47 91.57 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.537 -179.913 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 56.19 25.89 48.52 Favored Glycine 0 CA--C 1.525 0.713 0 N-CA-C 110.7 -0.96 . . . . 0.0 110.7 -179.899 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' TYR . . . . . 0.493 ' CD1' ' C ' ' A' ' 61' ' ' TYR . 7.7 t80 -159.52 146.79 16.9 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-O 121.208 0.528 . . . . 0.0 111.035 -179.201 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' TYR . . . . . 0.512 ' HH ' ' CG ' ' A' ' 53' ' ' ASP . 33.9 t80 -159.99 161.79 34.18 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.152 178.611 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 96.5 m -131.15 139.17 49.74 Favored 'General case' 0 N--CA 1.464 0.244 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.689 179.995 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -131.14 104.63 9.5 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.263 0 CA-C-N 116.188 -0.46 . . . . 0.0 109.982 179.061 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 4.6 p -109.05 155.45 20.92 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.342 179.78 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 108.32 44.38 1.17 Allowed Glycine 0 CA--C 1.525 0.682 0 N-CA-C 111.184 -0.766 . . . . 0.0 111.184 -179.705 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 19.9 mt -116.45 103.57 10.58 Favored 'General case' 0 CA--C 1.519 -0.222 0 CA-C-O 121.194 0.521 . . . . 0.0 109.827 179.679 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 55.4 mm-40 -51.24 138.19 27.68 Favored Pre-proline 0 C--N 1.317 -0.806 0 CA-C-N 115.783 -0.644 . . . . 0.0 111.44 -178.433 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -75.35 150.54 36.82 Favored 'Trans proline' 0 N--CA 1.496 1.665 0 C-N-CA 122.725 2.284 . . . . 0.0 111.635 178.687 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 70.69 17.32 74.86 Favored Glycine 0 CA--C 1.527 0.803 0 CA-C-N 115.55 -0.75 . . . . 0.0 111.361 179.14 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 1.5 mp -119.66 149.62 22.27 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.337 0 CA-C-O 121.413 0.625 . . . . 0.0 109.36 -179.503 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 72' ' ' ASP . . . . . 0.409 ' O ' ' CB ' ' A' ' 44' ' ' ALA . 2.4 t70 -89.39 108.97 19.94 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.15 -0.932 . . . . 0.0 110.652 -179.902 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 73' ' ' TYR . . . . . 0.446 ' O ' ' CD1' ' A' ' 75' ' ' ILE . 22.4 m-85 -104.3 119.53 39.17 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.348 179.772 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 74' ' ' ASP . . . . . 0.543 ' O ' ' N ' ' A' ' 42' ' ' VAL . 8.5 m-20 -88.2 118.43 27.78 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.531 -0.758 . . . . 0.0 109.247 179.466 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . 0.446 ' CD1' ' O ' ' A' ' 73' ' ' TYR . 0.0 OUTLIER -120.02 167.22 13.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-O 121.098 0.475 . . . . 0.0 110.272 -179.124 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 76' ' ' SER . . . . . 0.401 ' HG ' ' C ' ' A' ' 75' ' ' ILE . 1.8 m -154.92 126.92 7.64 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.622 -0.717 . . . . 0.0 110.591 179.248 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 21.7 t -106.02 100.26 10.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 179.178 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 23.8 mt -101.9 140.9 19.27 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.225 0 CA-C-N 116.052 -0.522 . . . . 0.0 109.909 -179.651 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 19.5 m -120.05 113.59 20.73 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.571 -179.767 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -106.68 127.93 53.77 Favored 'General case' 0 N--CA 1.463 0.22 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.434 179.796 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 81' ' ' ILE . . . . . 0.419 ' HB ' ' H ' ' A' ' 33' ' ' THR . 1.9 pp -141.38 145.01 25.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 115.632 -0.713 . . . . 0.0 110.219 179.565 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 37.6 t30 . . . . . 0 C--N 1.329 -0.286 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.707 -179.73 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' B' B ' 207' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.464 0.555 0 N-CA-C 111.088 -0.805 . . . . 0.0 111.088 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' B' B ' 208' ' ' SER . . . . . 0.432 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 92.3 p -165.37 171.57 13.28 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.866 0.365 . . . . 0.0 110.746 -179.922 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 209' ' ' TRP . . . . . . . . . . . . . 80.0 m95 -81.43 146.18 30.39 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.456 179.784 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 65.2 p -128.76 132.42 47.92 Favored 'General case' 0 N--CA 1.464 0.255 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.616 -179.951 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 50.3 t-105 -91.94 116.54 29.01 Favored 'General case' 0 C--O 1.232 0.15 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.241 179.649 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 212' ' ' GLU . . . . . 0.489 ' O ' ' O ' ' B' ' 215' ' ' LYS . 1.7 pt-20 -165.46 168.19 16.85 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.972 179.261 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 213' ' ' ASN . . . . . . . . . . . . . 91.8 m-20 49.51 36.73 10.72 Favored 'General case' 0 C--N 1.322 -0.602 0 C-N-CA 120.525 -0.47 . . . . 0.0 111.217 176.634 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 50.86 16.32 1.71 Allowed Glycine 0 CA--C 1.525 0.671 0 N-CA-C 111.266 -0.734 . . . . 0.0 111.266 179.658 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 215' ' ' LYS . . . . . 0.489 ' O ' ' O ' ' B' ' 212' ' ' GLU . 50.3 mtmt -145.66 151.45 38.07 Favored 'General case' 0 C--N 1.333 -0.142 0 CA-C-O 120.942 0.401 . . . . 0.0 110.81 179.704 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 216' ' ' TRP . . . . . . . . . . . . . 53.8 m95 -87.79 123.3 32.43 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.044 179.58 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 217' ' ' THR . . . . . . . . . . . . . 12.9 m -133.7 145.21 49.69 Favored 'General case' 0 N--CA 1.464 0.269 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.502 -179.607 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 218' ' ' TRP . . . . . 0.432 ' CH2' ' N ' ' B' ' 208' ' ' SER . 14.4 t-105 -106.08 119.58 39.58 Favored 'General case' 0 N--CA 1.463 0.175 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.018 179.188 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 47.3 mtpt -141.26 169.79 16.95 Favored 'General case' 0 CA--C 1.52 -0.198 0 CA-C-O 120.92 0.39 . . . . 0.0 110.464 -179.49 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -176.04 -161.38 25.12 Favored Glycine 0 CA--C 1.526 0.732 0 N-CA-C 111.279 -0.729 . . . . 0.0 111.279 -179.883 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 221' ' ' ILE . . . . . 0.426 ' O ' ' CG2' ' B' ' 222' ' ' ILE . 2.2 mp -51.03 -73.24 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 C-N-CA 120.678 -0.409 . . . . 0.0 110.679 -178.283 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 222' ' ' ILE . . . . . 0.476 ' O ' ' O ' ' B' ' 223' ' ' ARG . 21.8 pt -159.75 -166.34 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.624 -179.584 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 223' ' ' ARG . . . . . 0.476 ' O ' ' O ' ' B' ' 222' ' ' ILE . 46.9 ptt85 -46.03 178.32 0.0 OUTLIER 'General case' 0 CA--C 1.516 -0.337 0 CA-C-N 115.756 -0.657 . . . . 0.0 110.563 179.281 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 224' ' ' LEU . . . . . 0.567 ' CD2' ' N ' ' B' ' 224' ' ' LEU . 3.1 mm? -59.41 121.71 12.16 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 115.687 -0.688 . . . . 0.0 110.533 -179.135 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 78.5 tt0 . . . . . 0 C--N 1.331 -0.228 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.4 179.986 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 54.7 p30 . . . . . 0 C--O 1.231 0.102 0 CA-C-O 120.822 0.344 . . . . 0.0 110.667 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 70.4 mt -63.57 151.89 40.25 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.343 -179.291 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 85.9 p -141.13 149.83 42.04 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-N 116.059 -0.518 . . . . 0.0 110.31 179.916 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . 0.519 ' CD1' ' N ' ' A' ' 14' ' ' PHE . 18.3 m-85 -111.37 145.8 38.26 Favored 'General case' 0 N--CA 1.464 0.235 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.569 -179.627 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 18.2 m -147.71 161.75 7.36 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.117 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.495 179.88 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 41.0 t0 56.06 29.32 14.29 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.66 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 96.5 mt -56.19 138.97 16.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.249 179.797 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.45 ' CB ' ' O ' ' A' ' 21' ' ' SER . 0.2 OUTLIER -139.96 -167.12 2.23 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.479 -179.69 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' ASP . . . . . 0.506 ' OD1' ' N ' ' A' ' 20' ' ' SER . 32.3 p-10 -89.63 -43.47 10.73 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.731 179.601 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' SER . . . . . 0.633 ' HG ' ' H ' ' A' ' 67' ' ' LEU . 10.2 t -117.54 8.75 13.0 Favored 'General case' 0 N--CA 1.465 0.317 0 CA-C-O 120.754 0.312 . . . . 0.0 110.889 -179.716 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' SER . . . . . 0.45 ' O ' ' CB ' ' A' ' 18' ' ' THR . 18.2 p -150.56 137.69 19.36 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.974 0.416 . . . . 0.0 110.35 -179.919 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 41.9 pt -132.07 145.68 34.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.467 -0.333 . . . . 0.0 110.159 179.921 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -97.86 81.96 0.66 Allowed Glycine 0 CA--C 1.525 0.675 0 N-CA-C 110.965 -0.854 . . . . 0.0 110.965 -179.805 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 94.9 mt -70.95 119.5 15.16 Favored 'General case' 0 C--N 1.33 -0.274 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 -179.882 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 70.1 ttt180 -138.15 142.08 40.11 Favored 'General case' 0 CA--C 1.519 -0.229 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.988 179.901 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' TRP . . . . . 0.543 ' CD2' ' O ' ' A' ' 60' ' ' GLY . 25.4 p90 -143.11 156.08 44.73 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.763 -0.653 . . . . 0.0 109.977 -179.87 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 3.2 m -109.84 101.96 48.71 Favored Pre-proline 0 N--CA 1.465 0.322 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.757 179.828 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 42.4 Cg_exo -54.94 144.57 67.07 Favored 'Trans proline' 0 C--N 1.304 -1.769 0 C-N-CA 122.108 1.872 . . . . 0.0 112.34 179.153 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 65.8 mt -83.47 139.77 32.73 Favored 'General case' 0 CA--C 1.52 -0.196 0 CA-C-O 121.813 0.816 . . . . 0.0 110.718 179.801 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 26.0 t-20 -47.94 -33.05 7.14 Favored 'General case' 0 C--N 1.319 -0.75 0 CA-C-N 115.268 -0.878 . . . . 0.0 110.19 -179.914 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 52.5 m -84.86 -30.9 24.08 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.627 179.506 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 4.9 m -58.15 131.23 49.92 Favored 'General case' 0 N--CA 1.462 0.144 0 CA-C-O 121.25 0.547 . . . . 0.0 110.444 179.912 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' THR . . . . . 0.693 ' HG1' ' N ' ' A' ' 82' ' ' ASN . 3.9 m -59.78 140.17 56.75 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.505 -0.77 . . . . 0.0 110.021 -179.801 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 58.2 mt -94.11 92.26 3.47 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.19 0 CA-C-O 120.865 0.364 . . . . 0.0 110.774 -179.778 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.433 ' O ' ' OG ' ' A' ' 57' ' ' SER . 9.5 pt -142.29 131.85 23.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.43 179.408 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -37.95 114.85 0.33 Allowed Glycine 0 CA--C 1.523 0.553 0 N-CA-C 111.442 -0.663 . . . . 0.0 111.442 -179.297 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 96.5 m-85 -79.8 177.27 9.02 Favored 'General case' 0 CA--C 1.515 -0.392 0 N-CA-C 110.019 -0.363 . . . . 0.0 110.019 -179.901 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 5.5 tmm_? -135.01 126.21 28.09 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.039 179.922 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 6.5 pt -95.35 155.33 3.33 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.391 0 N-CA-C 109.472 -0.566 . . . . 0.0 109.472 179.892 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 3.4 m -136.29 131.34 34.28 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.627 0.251 . . . . 0.0 110.624 -179.713 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.1 p -134.56 137.82 50.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.314 179.464 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . 0.538 ' N ' ' O ' ' A' ' 74' ' ' ASP . 41.5 t -134.83 135.92 52.66 Favored 'Isoleucine or valine' 0 C--O 1.23 0.058 0 CA-C-N 116.509 -0.314 . . . . 0.0 110.369 179.621 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -97.3 138.05 35.36 Favored 'General case' 0 C--N 1.33 -0.269 0 N-CA-C 109.628 -0.508 . . . . 0.0 109.628 179.231 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . 0.409 ' CB ' ' O ' ' A' ' 72' ' ' ASP . . . -90.54 -47.51 7.65 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.783 0.325 . . . . 0.0 110.708 179.723 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -61.64 -29.39 71.84 Favored Glycine 0 CA--C 1.525 0.711 0 N-CA-C 111.084 -0.806 . . . . 0.0 111.084 -179.863 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 91.2 mt-10 -95.94 127.56 42.06 Favored 'General case' 0 CA--C 1.52 -0.203 0 N-CA-C 109.357 -0.609 . . . . 0.0 109.357 -179.424 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -59.2 -22.0 54.69 Favored Glycine 0 CA--C 1.508 -0.389 0 N-CA-C 110.82 -0.912 . . . . 0.0 110.82 -179.229 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -110.16 135.04 20.58 Favored Pre-proline 0 CA--C 1.539 0.543 0 C-N-CA 120.858 -0.337 . . . . 0.0 110.235 179.702 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 62.3 Cg_endo -75.8 167.8 25.56 Favored 'Trans proline' 0 C--N 1.309 -1.517 0 C-N-CA 122.605 2.203 . . . . 0.0 111.732 177.344 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . 0.562 ' CD1' ' N ' ' A' ' 50' ' ' ILE . 1.7 mp -91.58 144.85 8.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 115.598 -0.728 . . . . 0.0 110.152 179.526 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 96.0 m-85 -65.84 142.2 58.01 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.702 -179.534 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . 0.502 ' CD ' ' H ' ' A' ' 52' ' ' GLU . 0.0 OUTLIER -73.87 -176.84 2.59 Favored 'General case' 0 CA--C 1.514 -0.424 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.602 179.664 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 3.6 t70 -151.45 147.45 26.88 Favored 'General case' 0 N--CA 1.452 -0.34 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.78 179.475 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 54.2 m-85 -115.7 124.8 51.76 Favored 'General case' 0 N--CA 1.463 0.219 0 CA-C-N 116.466 -0.334 . . . . 0.0 110.204 179.725 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 9.9 p -127.4 136.52 60.35 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.211 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.425 -179.886 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 99.8 m-20 -57.15 145.7 30.4 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.015 -0.538 . . . . 0.0 110.502 -179.707 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' SER . . . . . 0.433 ' OG ' ' O ' ' A' ' 35' ' ' ILE . 35.3 m -59.49 -33.46 71.36 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.61 179.917 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 49.5 m -52.68 -35.92 56.12 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.596 -179.901 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.509 ' O ' ' CD2' ' A' ' 61' ' ' TYR . 21.2 t -69.68 -43.72 79.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.348 179.853 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . 0.543 ' O ' ' CD2' ' A' ' 26' ' ' TRP . . . 68.68 -43.94 0.36 Allowed Glycine 0 CA--C 1.531 1.046 0 N-CA-C 110.943 -0.863 . . . . 0.0 110.943 179.903 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' TYR . . . . . 0.509 ' CD2' ' O ' ' A' ' 59' ' ' VAL . 25.0 p90 -102.49 157.71 16.73 Favored 'General case' 0 N--CA 1.463 0.223 0 CA-C-O 121.257 0.551 . . . . 0.0 111.139 -179.208 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 32.5 t80 -156.67 160.33 39.26 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.979 -0.555 . . . . 0.0 109.907 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 91.2 m -123.45 136.04 54.4 Favored 'General case' 0 C--O 1.233 0.206 0 CA-C-O 120.887 0.375 . . . . 0.0 110.699 -179.882 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -132.01 99.68 3.81 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 CA-C-N 116.035 -0.53 . . . . 0.0 109.818 179.249 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 2.2 p -106.73 159.25 16.36 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.91 0.386 . . . . 0.0 110.6 179.91 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 108.74 41.47 1.45 Allowed Glycine 0 CA--C 1.523 0.544 0 N-CA-C 111.41 -0.676 . . . . 0.0 111.41 -179.674 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.633 ' H ' ' HG ' ' A' ' 20' ' ' SER . 10.3 mt -116.43 107.88 15.34 Favored 'General case' 0 CA--C 1.517 -0.307 0 CA-C-O 121.346 0.593 . . . . 0.0 109.728 -179.868 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 53.0 mm-40 -53.85 136.07 55.95 Favored Pre-proline 0 C--N 1.318 -0.795 0 CA-C-N 115.611 -0.722 . . . . 0.0 111.622 -178.209 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo -75.34 155.43 41.37 Favored 'Trans proline' 0 N--CA 1.498 1.774 0 C-N-CA 122.952 2.434 . . . . 0.0 111.722 178.783 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 71.66 8.37 67.33 Favored Glycine 0 CA--C 1.526 0.777 0 CA-C-N 115.375 -0.829 . . . . 0.0 111.477 179.153 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 1.6 mp -118.03 145.4 24.0 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.298 0 CA-C-O 121.541 0.686 . . . . 0.0 109.381 -179.416 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 72' ' ' ASP . . . . . 0.409 ' O ' ' CB ' ' A' ' 44' ' ' ALA . 2.9 t70 -82.13 112.53 19.25 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-N 114.768 -1.105 . . . . 0.0 110.829 -179.579 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 73' ' ' TYR . . . . . 0.415 ' O ' ' CD1' ' A' ' 75' ' ' ILE . 13.3 m-85 -105.29 120.57 41.89 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.507 179.648 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 74' ' ' ASP . . . . . 0.538 ' O ' ' N ' ' A' ' 42' ' ' VAL . 74.0 m-20 -88.48 117.62 27.55 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.338 -0.846 . . . . 0.0 109.417 179.808 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . 0.415 ' CD1' ' O ' ' A' ' 73' ' ' TYR . 0.0 OUTLIER -117.97 163.57 15.03 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.362 0 CA-C-O 121.075 0.464 . . . . 0.0 110.011 -179.194 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -154.91 123.5 6.08 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.42 -0.809 . . . . 0.0 110.583 179.29 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 88.5 t -102.14 104.15 16.02 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 178.709 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 92.8 mt -96.95 132.71 40.79 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.224 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.349 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 79' ' ' THR . . . . . 0.45 ' O ' ' CG2' ' A' ' 79' ' ' THR . 14.0 t -112.15 120.25 41.17 Favored 'General case' 0 CA--C 1.514 -0.41 0 CA-C-N 116.173 -0.467 . . . . 0.0 109.946 -179.823 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -121.54 115.46 22.87 Favored 'General case' 0 N--CA 1.464 0.234 0 CA-C-N 116.306 -0.407 . . . . 0.0 110.422 -179.781 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 1.9 pp -138.25 145.14 28.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.268 -0.424 . . . . 0.0 109.921 179.049 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 82' ' ' ASN . . . . . 0.693 ' N ' ' HG1' ' A' ' 33' ' ' THR . 60.7 t30 . . . . . 0 C--N 1.329 -0.298 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.792 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 207' ' ' GLY . . . . . 0.416 ' C ' ' CH2' ' B' ' 218' ' ' TRP . . . . . . . . 0 N--CA 1.465 0.62 0 N-CA-C 110.99 -0.844 . . . . 0.0 110.99 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 208' ' ' SER . . . . . 0.535 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 52.0 p -166.46 171.81 11.5 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.711 0.291 . . . . 0.0 110.703 179.664 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 209' ' ' TRP . . . . . . . . . . . . . 42.6 m95 -85.22 147.33 26.64 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.504 179.052 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 51.1 p -129.47 129.86 45.13 Favored 'General case' 0 C--O 1.232 0.176 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.7 179.876 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 42.5 t-105 -91.82 118.11 30.4 Favored 'General case' 0 C--N 1.334 -0.074 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.137 179.801 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 212' ' ' GLU . . . . . 0.443 ' O ' ' O ' ' B' ' 215' ' ' LYS . 1.0 OUTLIER -166.09 168.44 15.47 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.829 179.321 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' B' B ' 213' ' ' ASN . . . . . . . . . . . . . 93.1 m-20 49.47 37.55 12.36 Favored 'General case' 0 C--N 1.323 -0.566 0 C-N-CA 120.471 -0.492 . . . . 0.0 111.404 176.671 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 49.61 17.1 1.21 Allowed Glycine 0 CA--C 1.526 0.744 0 N-CA-C 111.337 -0.705 . . . . 0.0 111.337 179.703 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 215' ' ' LYS . . . . . 0.443 ' O ' ' O ' ' B' ' 212' ' ' GLU . 53.0 mtmt -142.99 150.25 39.4 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-O 121.169 0.509 . . . . 0.0 110.798 179.935 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 216' ' ' TRP . . . . . . . . . . . . . 59.5 m95 -89.49 118.48 29.17 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.012 -0.54 . . . . 0.0 109.818 179.631 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 217' ' ' THR . . . . . . . . . . . . . 17.7 m -131.23 144.51 51.38 Favored 'General case' 0 N--CA 1.466 0.328 0 CA-C-O 120.924 0.392 . . . . 0.0 110.524 -179.634 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 218' ' ' TRP . . . . . 0.535 ' CH2' ' N ' ' B' ' 208' ' ' SER . 12.0 t-105 -104.83 117.4 33.97 Favored 'General case' 0 C--N 1.328 -0.346 0 N-CA-C 109.532 -0.544 . . . . 0.0 109.532 179.262 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 50.5 mtpt -142.98 168.77 18.93 Favored 'General case' 0 CA--C 1.518 -0.253 0 CA-C-O 121.112 0.482 . . . . 0.0 110.485 -179.275 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -175.76 -162.25 26.5 Favored Glycine 0 CA--C 1.523 0.571 0 CA-C-N 115.603 -0.726 . . . . 0.0 111.389 -179.861 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 221' ' ' ILE . . . . . 0.42 ' O ' ' CG2' ' B' ' 222' ' ' ILE . 0.8 OUTLIER -53.34 -75.96 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 C-N-CA 120.641 -0.423 . . . . 0.0 110.872 -178.648 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' B' B ' 222' ' ' ILE . . . . . 0.483 ' O ' ' O ' ' B' ' 223' ' ' ARG . 23.1 pt -158.97 -165.37 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.323 -179.232 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 223' ' ' ARG . . . . . 0.483 ' O ' ' O ' ' B' ' 222' ' ' ILE . 52.7 ptt85 -42.94 172.87 0.0 OUTLIER 'General case' 0 C--O 1.234 0.276 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.299 179.133 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 224' ' ' LEU . . . . . 0.623 ' H ' ' CD2' ' B' ' 224' ' ' LEU . 1.7 mm? -68.37 111.59 4.72 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-O 121.296 0.57 . . . . 0.0 110.461 -179.378 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 26.7 tp10 . . . . . 0 C--N 1.329 -0.324 0 CA-C-N 115.196 -0.911 . . . . 0.0 110.37 179.745 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 . . . . . 0 C--O 1.234 0.255 0 CA-C-O 121.387 0.613 . . . . 0.0 110.446 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -74.18 153.26 39.57 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 114.965 -1.016 . . . . 0.0 109.806 -179.923 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 49.1 p -140.1 154.8 47.14 Favored 'General case' 0 C--N 1.333 -0.13 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.28 179.056 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . 0.472 ' CD1' ' N ' ' A' ' 14' ' ' PHE . 32.2 m-85 -103.69 146.35 28.73 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.562 -179.645 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 20.8 m -149.17 162.81 4.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.251 -0.432 . . . . 0.0 110.373 179.863 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 97.4 m-20 54.85 26.97 8.35 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.769 179.991 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 96.6 mt -56.06 136.16 18.87 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-O 121.007 0.432 . . . . 0.0 110.085 179.951 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.597 ' HG1' ' H ' ' A' ' 21' ' ' SER . 1.1 p -135.62 -166.79 1.91 Allowed 'General case' 0 CA--C 1.511 -0.548 0 CA-C-N 115.678 -0.692 . . . . 0.0 110.137 -179.977 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' ASP . . . . . 0.532 ' OD1' ' N ' ' A' ' 20' ' ' SER . 37.0 p-10 -90.46 -41.45 11.43 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.244 -0.889 . . . . 0.0 111.12 178.979 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' SER . . . . . 0.532 ' N ' ' OD1' ' A' ' 19' ' ' ASP . 5.7 t -114.8 9.44 16.3 Favored 'General case' 0 N--CA 1.468 0.432 0 CA-C-N 116.323 -0.398 . . . . 0.0 110.984 -179.012 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' SER . . . . . 0.597 ' H ' ' HG1' ' A' ' 18' ' ' THR . 27.9 p -154.85 158.05 38.79 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.118 179.61 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 42.9 pt -148.69 148.83 15.59 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.15 -179.912 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -100.88 78.82 0.42 Allowed Glycine 0 N--CA 1.467 0.721 0 N-CA-C 110.889 -0.884 . . . . 0.0 110.889 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . 0.442 ' O ' ' CD1' ' A' ' 61' ' ' TYR . 20.9 mt -63.78 130.65 45.05 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.875 0.369 . . . . 0.0 110.233 -179.474 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 18.0 tpt180 -144.72 134.21 23.26 Favored 'General case' 0 CA--C 1.515 -0.372 0 CA-C-O 121.302 0.572 . . . . 0.0 110.201 -179.61 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' TRP . . . . . . . . . . . . . 39.8 p90 -147.82 153.83 39.68 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.082 -0.963 . . . . 0.0 110.015 179.213 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 3.1 m -110.32 100.61 45.19 Favored Pre-proline 0 CA--C 1.532 0.266 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.652 -179.964 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_exo -54.32 149.44 37.41 Favored 'Trans proline' 0 C--N 1.305 -1.752 0 C-N-CA 121.505 1.47 . . . . 0.0 112.877 179.347 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 64.1 mt -79.98 135.81 36.48 Favored 'General case' 0 CA--C 1.513 -0.471 0 CA-C-O 121.906 0.86 . . . . 0.0 110.67 -179.833 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 37.8 t30 -49.81 -34.88 20.92 Favored 'General case' 0 C--N 1.312 -1.054 0 CA-C-N 114.814 -1.084 . . . . 0.0 110.116 179.971 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 63.5 m -78.55 -33.74 47.59 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.721 -0.672 . . . . 0.0 110.784 179.027 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 4.9 m -57.87 133.82 55.77 Favored 'General case' 0 N--CA 1.462 0.147 0 CA-C-O 121.132 0.492 . . . . 0.0 110.138 -179.857 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' THR . . . . . 0.518 ' OG1' ' N ' ' A' ' 82' ' ' ASN . 5.2 m -58.33 143.55 44.52 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.84 -0.618 . . . . 0.0 109.845 -179.801 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 20.9 mm -94.19 90.97 2.95 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-O 120.925 0.393 . . . . 0.0 110.802 -179.428 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.466 ' O ' ' OG ' ' A' ' 57' ' ' SER . 8.8 pt -143.36 127.02 13.67 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.212 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.204 179.582 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -40.58 121.27 1.81 Allowed Glycine 0 CA--C 1.521 0.441 0 N-CA-C 111.372 -0.691 . . . . 0.0 111.372 -179.571 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' TYR . . . . . 0.477 ' CE2' ' OG ' ' A' ' 57' ' ' SER . 98.9 m-85 -85.37 178.26 7.52 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.548 -0.326 . . . . 0.0 110.168 179.796 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 6.6 tmm_? -131.44 128.52 39.67 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.448 179.741 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . 0.479 ' CD1' ' CD2' ' A' ' 62' ' ' TYR . 1.8 pt -101.24 123.56 54.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.045 179.827 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 11.8 m -103.67 130.46 51.14 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.441 -0.345 . . . . 0.0 110.44 -179.862 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.1 p -128.59 138.12 55.47 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.55 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.023 179.919 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . 0.516 ' O ' ' N ' ' A' ' 74' ' ' ASP . 39.2 t -132.19 130.96 61.04 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.319 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 179.486 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -95.87 141.09 29.72 Favored 'General case' 0 C--N 1.324 -0.516 0 N-CA-C 109.207 -0.664 . . . . 0.0 109.207 179.199 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . 0.405 ' CB ' ' O ' ' A' ' 72' ' ' ASP . . . -93.84 -39.4 10.73 Favored 'General case' 0 C--N 1.327 -0.371 0 C-N-CA 120.652 -0.419 . . . . 0.0 110.69 179.652 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -66.13 -31.2 78.56 Favored Glycine 0 CA--C 1.526 0.78 0 N-CA-C 111.623 -0.591 . . . . 0.0 111.623 -179.545 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 51.6 mt-10 -98.3 133.05 43.25 Favored 'General case' 0 CA--C 1.518 -0.253 0 N-CA-C 109.539 -0.541 . . . . 0.0 109.539 -179.626 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -59.51 -21.73 55.0 Favored Glycine 0 CA--C 1.521 0.44 0 N-CA-C 110.845 -0.902 . . . . 0.0 110.845 -179.217 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -114.03 135.27 22.08 Favored Pre-proline 0 N--CA 1.473 0.685 0 CA-C-N 116.672 0.236 . . . . 0.0 110.626 179.854 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -76.49 162.33 33.4 Favored 'Trans proline' 0 N--CA 1.492 1.433 0 C-N-CA 122.519 2.146 . . . . 0.0 111.426 178.258 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 96.3 mt -81.74 134.34 27.29 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-N 116.151 -0.477 . . . . 0.0 109.953 179.335 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 97.9 m-85 -54.85 141.93 31.24 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.942 0.401 . . . . 0.0 110.797 -179.492 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 2.9 pt-20 -80.99 151.97 28.2 Favored 'General case' 0 CA--C 1.517 -0.296 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.262 179.796 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 2.0 t70 -120.52 160.3 23.45 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.764 179.714 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' PHE . . . . . 0.549 ' CD1' ' N ' ' A' ' 54' ' ' PHE . 6.1 m-85 -121.18 128.66 52.69 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.089 179.839 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 9.8 p -128.23 138.12 55.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 116.352 -0.385 . . . . 0.0 110.361 -179.701 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 98.8 m-20 -56.92 143.36 37.94 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.666 -179.662 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' SER . . . . . 0.477 ' OG ' ' CE2' ' A' ' 37' ' ' TYR . 17.7 m -61.72 -34.24 75.44 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.889 179.893 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 37.5 m -57.04 -32.91 66.67 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.441 -179.808 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 92.8 t -65.55 -45.65 91.93 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.683 179.892 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 56.56 25.1 49.5 Favored Glycine 0 CA--C 1.527 0.821 0 N-CA-C 110.937 -0.865 . . . . 0.0 110.937 179.892 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' TYR . . . . . 0.442 ' CD1' ' O ' ' A' ' 24' ' ' LEU . 52.5 t80 -160.28 146.24 15.34 Favored 'General case' 0 N--CA 1.464 0.236 0 CA-C-O 121.141 0.496 . . . . 0.0 111.178 -179.359 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' TYR . . . . . 0.479 ' CD2' ' CD1' ' A' ' 39' ' ' ILE . 30.9 t80 -158.26 159.38 35.93 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.139 179.011 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 48.9 m -128.07 137.29 52.09 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.486 -179.423 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -131.13 101.75 5.68 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.34 0 CA-C-N 115.95 -0.568 . . . . 0.0 109.615 178.912 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 4.7 p -110.54 162.44 14.7 Favored 'General case' 0 N--CA 1.464 0.23 0 CA-C-O 121.006 0.432 . . . . 0.0 110.558 179.868 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 109.05 5.88 30.35 Favored Glycine 0 CA--C 1.527 0.832 0 CA-C-N 115.639 -0.709 . . . . 0.0 111.335 -179.655 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 12.1 mt -79.24 109.2 13.34 Favored 'General case' 0 C--N 1.329 -0.315 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.841 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 7.4 mm-40 -55.25 138.89 66.37 Favored Pre-proline 0 C--N 1.321 -0.65 0 C-N-CA 120.63 -0.428 . . . . 0.0 111.576 -178.236 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 95.8 Cg_endo -74.56 151.59 42.06 Favored 'Trans proline' 0 N--CA 1.493 1.495 0 C-N-CA 122.627 2.218 . . . . 0.0 111.725 179.113 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 72.4 10.15 74.41 Favored Glycine 0 CA--C 1.528 0.877 0 CA-C-N 115.161 -0.927 . . . . 0.0 111.642 179.229 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 1.7 mp -115.48 142.6 27.92 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.655 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 -179.727 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 72' ' ' ASP . . . . . 0.405 ' O ' ' CB ' ' A' ' 44' ' ' ALA . 2.3 t70 -81.73 110.88 17.47 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-N 115.162 -0.926 . . . . 0.0 110.311 179.977 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 73' ' ' TYR . . . . . 0.526 ' O ' ' CD1' ' A' ' 75' ' ' ILE . 14.8 m-85 -106.07 117.95 35.35 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.198 -179.911 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 74' ' ' ASP . . . . . 0.516 ' N ' ' O ' ' A' ' 42' ' ' VAL . 72.2 m-20 -88.16 119.83 28.93 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.145 -0.934 . . . . 0.0 109.331 179.754 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . 0.635 ' CD1' ' N ' ' A' ' 75' ' ' ILE . 0.0 OUTLIER -121.36 166.27 16.06 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.307 0 CA-C-O 121.067 0.46 . . . . 0.0 110.424 -179.103 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 22.5 t -155.15 151.3 28.07 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.745 -0.661 . . . . 0.0 110.122 179.26 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 2.4 t -125.3 109.7 22.65 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.335 0 N-CA-C 109.25 -0.648 . . . . 0.0 109.25 178.899 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 90.8 mt -97.27 123.11 49.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-O 120.891 0.377 . . . . 0.0 110.239 179.924 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 79' ' ' THR . . . . . 0.427 ' OG1' ' O ' ' B' ' 216' ' ' TRP . 19.6 p -103.48 111.4 23.83 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.059 179.752 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 35.4 tp -120.44 121.13 37.84 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.096 179.646 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 81' ' ' ILE . . . . . 0.427 ' HB ' ' H ' ' A' ' 33' ' ' THR . 2.3 pp -143.05 149.87 18.23 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 CA-C-N 116.081 -0.508 . . . . 0.0 110.189 179.634 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 82' ' ' ASN . . . . . 0.518 ' N ' ' OG1' ' A' ' 33' ' ' THR . 40.9 t30 . . . . . 0 C--N 1.33 -0.262 0 CA-C-N 116.443 -0.344 . . . . 0.0 111.159 179.916 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 207' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.466 0.648 0 N-CA-C 111.125 -0.79 . . . . 0.0 111.125 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' B' B ' 208' ' ' SER . . . . . 0.52 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 90.6 p -169.67 172.96 6.55 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.892 0.377 . . . . 0.0 110.864 -179.553 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 209' ' ' TRP . . . . . . . . . . . . . 69.1 m95 -92.74 153.52 18.86 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-N 115.815 -0.63 . . . . 0.0 110.488 179.289 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 49.8 p -135.04 140.27 45.45 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.521 179.631 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 61.0 t-105 -90.18 114.7 26.73 Favored 'General case' 0 C--N 1.332 -0.154 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.214 179.583 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 212' ' ' GLU . . . . . 0.522 ' O ' ' O ' ' B' ' 215' ' ' LYS . 3.8 tt0 -161.85 154.06 19.52 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.583 179.684 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 213' ' ' ASN . . . . . 0.442 ' C ' ' H ' ' B' ' 215' ' ' LYS . 83.5 m-20 56.72 40.62 29.07 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 115.421 -0.809 . . . . 0.0 111.78 177.022 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 51.19 11.41 0.64 Allowed Glycine 0 CA--C 1.528 0.854 0 N-CA-C 111.64 -0.584 . . . . 0.0 111.64 179.571 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 215' ' ' LYS . . . . . 0.522 ' O ' ' O ' ' B' ' 212' ' ' GLU . 80.6 mttt -141.61 151.33 43.03 Favored 'General case' 0 C--O 1.225 -0.212 0 CA-C-O 121.109 0.481 . . . . 0.0 110.963 -179.854 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 216' ' ' TRP . . . . . 0.479 ' CD1' ' N ' ' B' ' 216' ' ' TRP . 24.8 m95 -85.85 119.42 26.14 Favored 'General case' 0 C--N 1.327 -0.406 0 C-N-CA 120.731 -0.387 . . . . 0.0 110.049 179.701 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 217' ' ' THR . . . . . . . . . . . . . 16.7 m -125.86 142.1 51.67 Favored 'General case' 0 N--CA 1.467 0.395 0 N-CA-C 110.109 -0.33 . . . . 0.0 110.109 -179.525 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 218' ' ' TRP . . . . . 0.52 ' CH2' ' N ' ' B' ' 208' ' ' SER . 13.7 t-105 -103.49 117.15 33.78 Favored 'General case' 0 N--CA 1.463 0.186 0 CA-C-N 115.906 -0.588 . . . . 0.0 109.439 179.445 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 8.1 mtmp? -143.24 163.01 34.12 Favored 'General case' 0 CA--C 1.516 -0.355 0 CA-C-O 121.21 0.529 . . . . 0.0 110.634 -179.477 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -176.56 -160.27 23.46 Favored Glycine 0 CA--C 1.523 0.568 0 N-CA-C 111.185 -0.766 . . . . 0.0 111.185 -179.536 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 221' ' ' ILE . . . . . 0.409 ' O ' ' CG2' ' B' ' 222' ' ' ILE . 0.7 OUTLIER -51.05 -75.38 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 C-N-CA 120.778 -0.369 . . . . 0.0 110.566 -178.854 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' B' B ' 222' ' ' ILE . . . . . 0.508 ' O ' ' O ' ' B' ' 223' ' ' ARG . 17.0 pt -160.25 -165.76 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 CA-C-N 116.327 -0.397 . . . . 0.0 109.991 -179.653 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 223' ' ' ARG . . . . . 0.508 ' O ' ' O ' ' B' ' 222' ' ' ILE . 22.5 ptt180 -42.33 175.38 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 121.472 0.653 . . . . 0.0 110.841 178.864 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 224' ' ' LEU . . . . . 0.517 ' CD2' ' N ' ' B' ' 224' ' ' LEU . 3.6 mm? -61.31 123.5 17.93 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 115.497 -0.774 . . . . 0.0 110.65 -179.753 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 79.9 tt0 . . . . . 0 CA--C 1.518 -0.282 0 CA-C-N 115.385 -0.825 . . . . 0.0 110.221 179.817 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 99.3 m-20 . . . . . 0 CA--C 1.519 -0.23 0 CA-C-O 120.873 0.368 . . . . 0.0 110.355 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 6.3 tt -64.2 142.99 58.22 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.154 -179.31 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 83.6 p -140.49 154.43 46.59 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.648 179.697 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . 0.505 ' CD1' ' N ' ' A' ' 14' ' ' PHE . 21.5 m-85 -111.41 144.77 40.09 Favored 'General case' 0 N--CA 1.464 0.274 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.668 -179.739 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 31.2 m -146.27 161.75 10.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.321 -0.399 . . . . 0.0 110.614 179.793 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 98.2 m-20 53.87 31.08 12.55 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.499 179.764 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.403 ' C ' ' HG1' ' A' ' 18' ' ' THR . 99.2 mt -57.09 140.91 14.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.258 -179.972 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.444 ' CB ' ' O ' ' A' ' 21' ' ' SER . 0.2 OUTLIER -141.28 -168.11 2.55 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-N 116.009 -0.542 . . . . 0.0 110.326 -179.778 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' ASP . . . . . 0.477 ' N ' ' OD1' ' A' ' 19' ' ' ASP . 21.0 p-10 -88.88 -45.23 9.87 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.874 179.467 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 22.4 m -114.45 7.99 16.39 Favored 'General case' 0 N--CA 1.468 0.465 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.882 -179.543 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' SER . . . . . 0.444 ' O ' ' CB ' ' A' ' 18' ' ' THR . 34.4 t -151.55 145.53 25.21 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.156 0.503 . . . . 0.0 110.232 179.551 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 45.3 pt -138.89 146.29 26.39 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.587 0 CA-C-N 115.802 -0.635 . . . . 0.0 110.352 -179.618 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -99.1 82.19 0.57 Allowed Glycine 0 CA--C 1.524 0.612 0 N-CA-C 110.903 -0.879 . . . . 0.0 110.903 -179.953 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 94.2 mt -70.02 121.8 18.13 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.856 0.36 . . . . 0.0 110.182 179.884 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 59.9 ttp180 -141.28 136.14 31.32 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.164 179.949 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' TRP . . . . . . . . . . . . . 37.8 p90 -139.21 156.04 47.38 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.897 -0.592 . . . . 0.0 109.925 -179.795 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 3.5 m -110.59 98.89 39.09 Favored Pre-proline 0 C--N 1.33 -0.239 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.481 179.718 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 39.9 Cg_exo -53.66 147.63 39.01 Favored 'Trans proline' 0 C--N 1.303 -1.821 0 C-N-CA 121.63 1.554 . . . . 0.0 112.911 179.772 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 59.9 mt -87.76 141.93 28.22 Favored 'General case' 0 CA--C 1.511 -0.55 0 CA-C-N 115.437 -0.801 . . . . 0.0 110.398 -179.873 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 18.3 t-20 -50.07 -37.14 32.1 Favored 'General case' 0 C--N 1.315 -0.909 0 CA-C-N 114.908 -1.042 . . . . 0.0 110.067 -179.831 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 70.3 m -78.24 -33.5 49.74 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.547 178.755 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 14.1 m -60.83 131.09 49.58 Favored 'General case' 0 N--CA 1.463 0.194 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.067 -179.881 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 5.1 m -65.91 142.18 57.98 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.253 -179.971 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . 0.408 HG23 HD13 ' A' ' 34' ' ' ILE . 16.3 mm -94.82 90.75 2.79 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.19 0 CA-C-N 116.339 -0.392 . . . . 0.0 110.616 -179.848 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.473 ' O ' ' OG ' ' A' ' 57' ' ' SER . 24.9 pt -134.25 144.43 35.3 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.381 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.25 179.923 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -43.4 112.66 0.57 Allowed Glycine 0 CA--C 1.517 0.169 0 C-N-CA 120.59 -0.814 . . . . 0.0 111.58 -179.167 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' TYR . . . . . 0.516 ' CE1' ' O ' ' A' ' 38' ' ' ARG . 0.9 OUTLIER -91.4 120.46 32.27 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 109.062 -0.718 . . . . 0.0 109.062 179.205 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' ARG . . . . . 0.516 ' O ' ' CE1' ' A' ' 37' ' ' TYR . 4.7 tmm_? -90.07 133.87 34.59 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.912 -0.586 . . . . 0.0 110.65 179.941 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 6.3 pt -93.67 154.76 3.24 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.314 0 CA-C-N 116.153 -0.476 . . . . 0.0 109.806 179.926 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 2.1 m -131.19 130.03 42.46 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.486 -0.325 . . . . 0.0 110.394 179.409 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.3 p -134.47 136.1 53.17 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.496 0 CA-C-O 120.94 0.4 . . . . 0.0 110.697 179.83 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . 0.511 ' O ' ' N ' ' A' ' 74' ' ' ASP . 32.1 t -131.15 127.6 60.87 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.319 0 N-CA-C 109.5 -0.556 . . . . 0.0 109.5 179.362 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -94.58 141.22 28.85 Favored 'General case' 0 C--N 1.324 -0.539 0 N-CA-C 109.516 -0.549 . . . . 0.0 109.516 179.357 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . 0.528 ' C ' ' H ' ' A' ' 46' ' ' GLU . . . -96.63 -43.5 7.55 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.922 0.391 . . . . 0.0 110.872 179.783 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -74.24 30.82 0.97 Allowed Glycine 0 CA--C 1.525 0.659 0 N-CA-C 110.863 -0.895 . . . . 0.0 110.863 -179.957 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . 0.528 ' H ' ' C ' ' A' ' 44' ' ' ALA . 79.8 mm-40 -146.17 150.73 36.42 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 121.11 0.481 . . . . 0.0 110.695 -179.526 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -76.25 -14.67 82.1 Favored Glycine 0 CA--C 1.521 0.448 0 N-CA-C 110.711 -0.956 . . . . 0.0 110.711 179.752 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . 0.4 HG22 HD11 ' A' ' 48' ' ' ILE . 0.3 OUTLIER -138.34 139.5 25.38 Favored Pre-proline 0 CA--C 1.54 0.589 0 C-N-CA 120.961 -0.296 . . . . 0.0 110.464 179.581 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 70.6 Cg_endo -75.27 161.92 37.22 Favored 'Trans proline' 0 N--CA 1.491 1.349 0 C-N-CA 122.64 2.227 . . . . 0.0 111.84 177.957 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . 0.425 HD12 HG23 ' A' ' 50' ' ' ILE . 96.3 mt -76.63 140.8 16.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.431 179.129 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 88.8 m-85 -62.84 141.7 58.54 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.459 -179.76 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . 0.466 ' CD ' ' H ' ' A' ' 52' ' ' GLU . 0.1 OUTLIER -76.92 146.36 37.63 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.46 179.714 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 4.8 t70 -113.18 150.94 31.55 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.66 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 72.7 m-85 -111.03 122.03 46.85 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.237 179.708 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 10.8 p -127.89 137.97 56.06 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.366 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.482 -179.963 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 89.7 m-20 -64.38 139.8 58.8 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.203 179.368 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 57' ' ' SER . . . . . 0.473 ' OG ' ' O ' ' A' ' 35' ' ' ILE . 2.8 m -59.47 -28.94 67.45 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.467 -179.83 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 37.6 m -55.8 -32.01 63.14 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.573 -179.998 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.498 ' O ' ' CD2' ' A' ' 61' ' ' TYR . 50.1 t -61.88 -44.2 98.51 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 -179.099 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 70.39 13.73 71.09 Favored Glycine 0 CA--C 1.53 0.977 0 N-CA-C 111.033 -0.827 . . . . 0.0 111.033 179.473 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 61' ' ' TYR . . . . . 0.498 ' CD2' ' O ' ' A' ' 59' ' ' VAL . 26.4 p90 -171.9 158.56 4.84 Favored 'General case' 0 C--O 1.225 -0.226 0 CA-C-O 120.993 0.425 . . . . 0.0 111.583 179.594 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 35.1 t80 -155.99 154.72 31.55 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.054 177.972 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 86.3 m -116.32 133.04 56.46 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.4 -179.456 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -131.08 100.84 4.91 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.275 0 N-CA-C 109.475 -0.565 . . . . 0.0 109.475 179.152 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 2.4 p -110.33 163.47 13.62 Favored 'General case' 0 N--CA 1.464 0.239 0 CA-C-O 121.007 0.432 . . . . 0.0 110.706 -179.869 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 110.08 9.79 23.56 Favored Glycine 0 CA--C 1.528 0.851 0 CA-C-N 115.496 -0.775 . . . . 0.0 111.49 -179.56 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 8.1 mt -83.52 107.61 16.11 Favored 'General case' 0 C--N 1.33 -0.274 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 179.829 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 17.5 mm-40 -57.58 138.53 81.81 Favored Pre-proline 0 C--N 1.32 -0.694 0 C-N-CA 120.321 -0.552 . . . . 0.0 111.609 -178.295 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 90.2 Cg_endo -74.54 154.65 45.02 Favored 'Trans proline' 0 N--CA 1.496 1.637 0 C-N-CA 122.762 2.308 . . . . 0.0 111.825 178.942 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 73.35 7.92 73.92 Favored Glycine 0 CA--C 1.528 0.865 0 CA-C-N 115.282 -0.872 . . . . 0.0 111.767 179.075 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . 0.547 ' O ' ' NH1' ' B' ' 223' ' ' ARG . 1.7 mp -117.11 147.24 20.62 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.406 0 N-CA-C 109.291 -0.633 . . . . 0.0 109.291 -179.504 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 72' ' ' ASP . . . . . 0.409 ' O ' ' CB ' ' A' ' 44' ' ' ALA . 2.8 t0 -84.76 113.99 21.73 Favored 'General case' 0 C--N 1.318 -0.766 0 CA-C-N 115.176 -0.92 . . . . 0.0 110.402 -179.6 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 73' ' ' TYR . . . . . 0.41 ' O ' ' CD1' ' A' ' 75' ' ' ILE . 15.6 m-85 -107.93 119.88 40.7 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.324 -179.966 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 74' ' ' ASP . . . . . 0.511 ' N ' ' O ' ' A' ' 42' ' ' VAL . 14.8 m-20 -89.71 118.96 29.71 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 115.327 -0.851 . . . . 0.0 108.805 179.535 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . 0.41 ' CD1' ' O ' ' A' ' 73' ' ' TYR . 0.0 OUTLIER -113.24 162.65 11.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-O 121.282 0.563 . . . . 0.0 110.263 -178.642 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -153.53 118.89 5.18 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.289 -0.869 . . . . 0.0 110.484 179.708 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . 0.445 ' CG1' ' O ' ' A' ' 77' ' ' VAL . 8.7 p -103.39 101.38 12.13 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.242 0 N-CA-C 109.517 -0.549 . . . . 0.0 109.517 178.995 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 91.4 mt -92.0 101.13 12.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.621 -179.847 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 44.9 p -77.68 111.64 13.67 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.807 -0.633 . . . . 0.0 109.388 179.049 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 4.8 tp -111.54 120.63 42.77 Favored 'General case' 0 N--CA 1.465 0.288 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.963 -179.234 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 2.1 pp -146.61 142.3 20.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.065 -0.516 . . . . 0.0 109.974 179.095 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 56.0 t-20 . . . . . 0 C--N 1.331 -0.234 0 CA-C-O 120.721 0.296 . . . . 0.0 110.9 -179.648 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' B' B ' 207' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.466 0.637 0 N-CA-C 111.174 -0.77 . . . . 0.0 111.174 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' B' B ' 208' ' ' SER . . . . . 0.539 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 91.7 p -166.88 172.14 10.62 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 120.907 0.384 . . . . 0.0 110.701 -179.805 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 209' ' ' TRP . . . . . . . . . . . . . 78.4 m95 -88.63 130.66 35.23 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.189 179.369 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 82.1 p -109.5 132.81 53.79 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-N 116.392 -0.367 . . . . 0.0 110.496 -179.796 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 47.7 t-105 -93.73 117.81 30.58 Favored 'General case' 0 N--CA 1.463 0.208 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.072 179.796 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 212' ' ' GLU . . . . . 0.44 ' O ' ' O ' ' B' ' 215' ' ' LYS . 0.8 OUTLIER -164.22 167.41 20.04 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.779 179.035 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' B' B ' 213' ' ' ASN . . . . . . . . . . . . . 92.4 m-20 49.06 37.11 9.88 Favored 'General case' 0 C--N 1.324 -0.516 0 C-N-CA 120.522 -0.471 . . . . 0.0 111.349 176.603 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 50.89 16.85 1.93 Allowed Glycine 0 CA--C 1.526 0.723 0 N-CA-C 111.335 -0.706 . . . . 0.0 111.335 179.868 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 215' ' ' LYS . . . . . 0.44 ' O ' ' O ' ' B' ' 212' ' ' GLU . 20.3 mtpt -143.0 149.75 38.72 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.986 0.422 . . . . 0.0 110.889 -179.839 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 216' ' ' TRP . . . . . . . . . . . . . 50.1 m95 -86.12 115.76 23.9 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.028 -0.533 . . . . 0.0 109.712 179.115 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 217' ' ' THR . . . . . . . . . . . . . 18.1 m -126.95 139.92 52.7 Favored 'General case' 0 N--CA 1.466 0.343 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.439 -179.512 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 218' ' ' TRP . . . . . 0.539 ' CH2' ' N ' ' B' ' 208' ' ' SER . 12.9 t-105 -106.45 116.38 31.82 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.016 178.984 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 52.8 mtmt -143.9 174.5 10.78 Favored 'General case' 0 CA--C 1.514 -0.432 0 CA-C-O 121.137 0.494 . . . . 0.0 110.644 -179.85 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -176.38 -160.21 23.27 Favored Glycine 0 CA--C 1.523 0.572 0 C-N-CA 120.544 -0.836 . . . . 0.0 111.226 -179.576 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 221' ' ' ILE . . . . . 0.409 ' O ' ' CG2' ' B' ' 222' ' ' ILE . 10.2 mm -51.27 -73.59 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.892 0.377 . . . . 0.0 110.485 -178.059 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 222' ' ' ILE . . . . . 0.498 ' O ' ' O ' ' B' ' 223' ' ' ARG . 23.7 pt -159.48 -166.39 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.755 0 CA-C-N 115.646 -0.706 . . . . 0.0 110.706 -179.943 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 223' ' ' ARG . . . . . 0.547 ' NH1' ' O ' ' A' ' 71' ' ' ILE . 32.0 ptt-85 -42.76 174.6 0.0 OUTLIER 'General case' 0 CA--C 1.52 -0.186 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.77 179.003 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 224' ' ' LEU . . . . . 0.605 ' H ' ' CD2' ' B' ' 224' ' ' LEU . 2.4 mm? -59.67 128.23 35.91 Favored 'General case' 0 C--N 1.315 -0.906 0 CA-C-N 115.786 -0.643 . . . . 0.0 110.542 -179.517 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 42.5 tt0 . . . . . 0 CA--C 1.52 -0.188 0 CA-C-N 115.349 -0.841 . . . . 0.0 110.391 -179.843 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 97.2 m-20 . . . . . 0 N--CA 1.463 0.199 0 CA-C-O 120.876 0.369 . . . . 0.0 110.395 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 6.7 tt -63.92 149.15 47.82 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.396 -179.74 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' SER . . . . . 0.419 ' O ' ' O ' ' A' ' 25' ' ' ARG . 83.3 p -139.15 156.85 46.83 Favored 'General case' 0 N--CA 1.461 0.114 0 CA-C-O 121.166 0.508 . . . . 0.0 110.42 179.757 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . 0.501 ' CD1' ' N ' ' A' ' 14' ' ' PHE . 30.6 m-85 -110.84 146.37 36.57 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.555 -0.748 . . . . 0.0 110.81 -179.515 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 15.6 m -146.74 157.01 10.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.447 -0.342 . . . . 0.0 110.649 179.4 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 98.9 m-20 54.59 31.53 15.23 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.934 179.656 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.422 HG21 HD11 ' A' ' 17' ' ' ILE . 97.2 mt -56.92 140.89 14.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.383 -179.803 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.418 ' CB ' ' O ' ' A' ' 21' ' ' SER . 0.2 OUTLIER -140.87 -168.6 2.63 Favored 'General case' 0 CA--C 1.533 0.292 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.509 -179.798 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' ASP . . . . . 0.483 ' OD1' ' N ' ' A' ' 19' ' ' ASP . 11.8 p-10 -90.3 -41.91 11.27 Favored 'General case' 0 N--CA 1.465 0.299 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.689 179.509 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 15.1 m -114.62 5.74 15.51 Favored 'General case' 0 N--CA 1.464 0.252 0 CA-C-N 116.014 -0.539 . . . . 0.0 111.152 -179.395 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' SER . . . . . 0.418 ' O ' ' CB ' ' A' ' 18' ' ' THR . 29.2 t -151.68 148.43 27.92 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 121.046 0.45 . . . . 0.0 110.365 179.624 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 42.6 pt -140.71 145.53 25.42 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.194 179.789 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -102.27 81.42 0.4 Allowed Glycine 0 CA--C 1.524 0.618 0 N-CA-C 110.998 -0.841 . . . . 0.0 110.998 -179.991 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 96.3 mt -68.54 121.6 16.73 Favored 'General case' 0 C--N 1.33 -0.272 0 C-N-CA 120.775 -0.37 . . . . 0.0 110.015 -179.992 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . 0.419 ' O ' ' O ' ' A' ' 13' ' ' SER . 58.8 ttt85 -142.75 137.64 29.93 Favored 'General case' 0 C--N 1.333 -0.123 0 CA-C-O 120.956 0.407 . . . . 0.0 110.372 -179.806 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' TRP . . . . . 0.454 ' C ' ' CD1' ' A' ' 26' ' ' TRP . 0.1 OUTLIER -143.0 161.54 37.85 Favored 'General case' 0 N--CA 1.466 0.349 0 N-CA-C 109.089 -0.708 . . . . 0.0 109.089 179.599 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 5.0 m -100.88 103.18 23.17 Favored Pre-proline 0 C--N 1.327 -0.379 0 N-CA-C 108.612 -0.885 . . . . 0.0 108.612 178.73 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 33.4 Cg_exo -54.72 149.62 39.84 Favored 'Trans proline' 0 C--N 1.308 -1.594 0 C-N-CA 120.883 1.055 . . . . 0.0 112.754 -179.03 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 69.6 mt -87.49 133.06 33.82 Favored 'General case' 0 CA--C 1.51 -0.569 0 CA-C-O 121.601 0.715 . . . . 0.0 111.066 -179.637 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 24.3 t-20 -46.9 -33.69 4.79 Favored 'General case' 0 C--N 1.314 -0.94 0 CA-C-N 115.064 -0.971 . . . . 0.0 110.225 179.527 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 63.4 m -80.74 -34.18 34.59 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.53 178.83 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 5.2 m -56.57 127.12 29.73 Favored 'General case' 0 C--O 1.232 0.136 0 C-N-CA 120.732 -0.387 . . . . 0.0 109.998 -179.715 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' THR . . . . . 0.434 ' H ' ' HB ' ' A' ' 81' ' ' ILE . 33.2 m -61.61 152.5 30.47 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.048 179.875 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 24.4 mm -97.5 94.05 3.71 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.343 0 CA-C-N 116.579 -0.282 . . . . 0.0 111.49 -178.24 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.432 HD11 ' N ' ' A' ' 35' ' ' ILE . 0.1 OUTLIER -137.59 155.09 30.55 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.324 0 CA-C-O 120.792 0.329 . . . . 0.0 110.511 179.305 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -63.22 113.57 6.02 Favored Glycine 0 CA--C 1.521 0.457 0 C-N-CA 120.472 -0.871 . . . . 0.0 111.178 179.785 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 69.2 m-85 -80.73 141.53 34.73 Favored 'General case' 0 C--N 1.328 -0.358 0 N-CA-C 110.072 -0.344 . . . . 0.0 110.072 179.525 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 5.3 tmm_? -105.54 119.84 40.14 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.549 179.974 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . 0.474 ' O ' ' CG1' ' A' ' 39' ' ' ILE . 1.9 pt -95.47 122.88 47.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 115.835 -0.62 . . . . 0.0 109.693 179.79 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 94.8 m -109.61 131.64 54.87 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.824 0.345 . . . . 0.0 110.511 -179.276 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 1.8 p -128.8 144.12 39.05 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.349 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.523 -179.505 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . 0.506 ' O ' ' N ' ' A' ' 74' ' ' ASP . 40.4 t -132.45 131.87 60.3 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.191 0 CA-C-O 120.899 0.38 . . . . 0.0 110.019 179.542 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -98.44 140.01 33.33 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 109.296 -0.631 . . . . 0.0 109.296 179.22 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . 0.406 ' CB ' ' O ' ' A' ' 72' ' ' ASP . . . -98.26 -18.44 18.39 Favored 'General case' 0 CA--C 1.529 0.135 0 C-N-CA 120.67 -0.412 . . . . 0.0 110.776 179.926 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -98.54 30.73 9.1 Favored Glycine 0 CA--C 1.529 0.956 0 N-CA-C 110.753 -0.939 . . . . 0.0 110.753 179.821 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . 0.409 ' OE2' ' OH ' ' A' ' 73' ' ' TYR . 45.1 mt-10 -146.78 149.01 32.51 Favored 'General case' 0 CA--C 1.521 -0.16 0 CA-C-O 121.131 0.491 . . . . 0.0 110.691 179.97 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -68.96 -20.95 75.09 Favored Glycine 0 CA--C 1.527 0.823 0 N-CA-C 111.014 -0.834 . . . . 0.0 111.014 179.736 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . 0.403 HD11 HG22 ' A' ' 48' ' ' ILE . 0.3 OUTLIER -136.61 141.11 34.21 Favored Pre-proline 0 CA--C 1.54 0.579 0 C-N-CA 121.131 -0.228 . . . . 0.0 110.476 179.995 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 69.4 Cg_endo -73.36 162.22 40.8 Favored 'Trans proline' 0 N--CA 1.496 1.672 0 C-N-CA 122.752 2.301 . . . . 0.0 111.821 179.059 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . 0.419 HD12 HG23 ' A' ' 50' ' ' ILE . 96.7 mt -76.49 151.77 5.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.522 179.793 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 82.6 m-85 -70.75 146.41 49.83 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.707 -179.54 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . 0.445 ' H ' ' CD ' ' A' ' 52' ' ' GLU . 0.5 OUTLIER -82.96 145.0 29.61 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.682 179.55 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -112.4 153.14 27.76 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.492 -0.777 . . . . 0.0 110.388 -179.717 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 54' ' ' PHE . . . . . 0.581 ' CD1' ' N ' ' A' ' 54' ' ' PHE . 2.7 m-85 -119.0 128.7 54.64 Favored 'General case' 0 N--CA 1.466 0.356 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.227 -179.758 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 9.6 p -131.26 139.06 51.8 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.3 0 CA-C-O 120.683 0.277 . . . . 0.0 110.828 -179.65 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 71.4 m-20 -58.51 142.47 48.82 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.262 179.581 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 7.2 t -60.88 -35.21 76.04 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.733 179.86 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 58.5 m -56.31 -34.11 66.2 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.923 -179.603 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 90.7 t -62.38 -45.8 97.93 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.389 -179.84 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 61.75 23.17 62.87 Favored Glycine 0 CA--C 1.525 0.713 0 N-CA-C 110.745 -0.942 . . . . 0.0 110.745 179.942 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 61' ' ' TYR . . . . . 0.437 ' OH ' ' OG1' ' A' ' 63' ' ' THR . 37.2 t80 -164.65 150.16 10.09 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-O 121.095 0.474 . . . . 0.0 111.423 -179.412 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 62' ' ' TYR . . . . . 0.432 ' CD2' ' CD1' ' A' ' 39' ' ' ILE . 18.4 t80 -156.7 154.32 29.87 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.73 -0.668 . . . . 0.0 110.33 178.715 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 63' ' ' THR . . . . . 0.437 ' OG1' ' OH ' ' A' ' 61' ' ' TYR . 73.1 m -117.55 132.55 56.51 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.16 -0.473 . . . . 0.0 109.893 179.472 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -130.63 113.63 25.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 N-CA-C 109.327 -0.62 . . . . 0.0 109.327 178.914 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 2.1 p -124.76 158.83 32.33 Favored 'General case' 0 CA--C 1.516 -0.331 0 CA-C-O 120.987 0.422 . . . . 0.0 110.394 -179.83 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 108.11 39.61 1.8 Allowed Glycine 0 CA--C 1.525 0.682 0 N-CA-C 110.818 -0.913 . . . . 0.0 110.818 -179.937 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 14.5 mt -112.52 106.96 15.53 Favored 'General case' 0 N--CA 1.467 0.404 0 N-CA-C 108.742 -0.836 . . . . 0.0 108.742 179.087 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 4.1 mm-40 -54.34 136.79 60.37 Favored Pre-proline 0 C--N 1.323 -0.561 0 C-N-CA 120.86 -0.336 . . . . 0.0 111.727 -178.095 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 90.0 Cg_endo -74.26 154.52 46.38 Favored 'Trans proline' 0 N--CA 1.493 1.466 0 C-N-CA 122.779 2.319 . . . . 0.0 111.54 178.877 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 71.05 8.42 64.66 Favored Glycine 0 CA--C 1.529 0.963 0 CA-C-N 115.533 -0.758 . . . . 0.0 111.507 179.563 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 1.6 mp -116.05 143.9 24.97 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.543 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 -179.975 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 72' ' ' ASP . . . . . 0.406 ' O ' ' CB ' ' A' ' 44' ' ' ALA . 2.0 t0 -81.93 112.59 19.17 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-N 115.307 -0.861 . . . . 0.0 110.149 -179.849 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 73' ' ' TYR . . . . . 0.409 ' OH ' ' OE2' ' A' ' 46' ' ' GLU . 13.7 m-85 -107.38 120.01 40.97 Favored 'General case' 0 C--O 1.223 -0.326 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.354 -179.814 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 74' ' ' ASP . . . . . 0.506 ' N ' ' O ' ' A' ' 42' ' ' VAL . 7.3 m-20 -89.04 114.86 26.12 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 115.34 -0.845 . . . . 0.0 109.375 179.601 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . 0.415 ' CD1' ' N ' ' A' ' 75' ' ' ILE . 0.0 OUTLIER -112.35 167.31 5.8 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.198 0 CA-C-O 121.273 0.558 . . . . 0.0 110.405 -179.434 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 11.6 p -154.46 151.65 29.2 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 115.124 -0.944 . . . . 0.0 110.283 179.392 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -131.32 101.75 5.56 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.351 0 N-CA-C 108.744 -0.836 . . . . 0.0 108.744 179.49 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 96.2 mt -86.62 123.87 40.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 C-N-CA 120.913 -0.315 . . . . 0.0 110.34 -179.673 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 90.5 m -105.26 109.02 20.85 Favored 'General case' 0 N--CA 1.465 0.301 0 CA-C-N 116.358 -0.383 . . . . 0.0 109.971 179.66 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 6.7 tt -121.09 119.02 31.24 Favored 'General case' 0 CA--C 1.517 -0.292 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.449 179.965 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 81' ' ' ILE . . . . . 0.434 ' HB ' ' H ' ' A' ' 33' ' ' THR . 2.0 pp -140.28 143.44 29.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.289 179.22 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--N 1.327 -0.384 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.803 -179.476 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 207' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.464 0.515 0 N-CA-C 110.838 -0.905 . . . . 0.0 110.838 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' B' B ' 208' ' ' SER . . . . . . . . . . . . . 44.6 p -163.82 170.33 17.02 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 120.717 0.294 . . . . 0.0 110.701 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 209' ' ' TRP . . . . . . . . . . . . . 86.5 m95 -83.33 126.56 32.83 Favored 'General case' 0 C--N 1.329 -0.286 0 C-N-CA 120.845 -0.342 . . . . 0.0 110.167 179.34 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 77.4 p -108.94 138.91 44.54 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-N 116.514 -0.312 . . . . 0.0 110.723 -179.745 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 58.2 t-105 -95.67 116.09 28.36 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-N 116.033 -0.531 . . . . 0.0 110.337 179.68 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 212' ' ' GLU . . . . . 0.524 ' OE2' ' NZ ' ' B' ' 219' ' ' LYS . 1.4 pt-20 -163.46 167.03 22.06 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.509 179.312 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 213' ' ' ASN . . . . . . . . . . . . . 12.4 m120 49.3 34.23 6.11 Favored 'General case' 0 C--N 1.324 -0.522 0 C-N-CA 120.53 -0.468 . . . . 0.0 111.698 176.962 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 54.73 12.34 3.48 Favored Glycine 0 CA--C 1.528 0.865 0 C-N-CA 120.917 -0.659 . . . . 0.0 111.604 179.463 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 215' ' ' LYS . . . . . 0.469 ' O ' ' O ' ' B' ' 212' ' ' GLU . 67.6 mttm -141.86 150.98 42.29 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-O 120.863 0.364 . . . . 0.0 110.76 -179.798 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 216' ' ' TRP . . . . . 0.437 ' CD1' ' N ' ' B' ' 216' ' ' TRP . 37.4 m95 -84.91 117.54 23.98 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.174 179.875 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 217' ' ' THR . . . . . . . . . . . . . 26.7 m -125.85 137.49 53.76 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.531 -179.568 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 218' ' ' TRP . . . . . . . . . . . . . 25.0 t-105 -98.53 120.02 38.25 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.234 179.483 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 219' ' ' LYS . . . . . 0.524 ' NZ ' ' OE2' ' B' ' 212' ' ' GLU . 53.7 mtmt -141.69 165.79 26.51 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.72 -179.809 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -176.44 -160.97 24.59 Favored Glycine 0 CA--C 1.522 0.504 0 N-CA-C 111.185 -0.766 . . . . 0.0 111.185 -179.887 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 221' ' ' ILE . . . . . 0.425 ' O ' ' CG2' ' B' ' 222' ' ' ILE . 0.8 OUTLIER -53.43 -76.73 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.387 0 C-N-CA 120.682 -0.407 . . . . 0.0 110.987 -178.44 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' B' B ' 222' ' ' ILE . . . . . 0.439 ' O ' ' O ' ' B' ' 223' ' ' ARG . 20.2 pt -160.72 -166.24 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 N-CA-C 109.994 -0.373 . . . . 0.0 109.994 -179.633 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 223' ' ' ARG . . . . . 0.439 ' O ' ' O ' ' B' ' 222' ' ' ILE . 33.2 ptt85 -45.41 174.57 0.0 OUTLIER 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.805 178.362 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 224' ' ' LEU . . . . . 0.539 ' CD2' ' N ' ' B' ' 224' ' ' LEU . 3.0 mm? -59.44 123.46 16.89 Favored 'General case' 0 C--N 1.318 -0.791 0 CA-C-N 115.317 -0.856 . . . . 0.0 110.211 -179.244 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 79.7 tt0 . . . . . 0 C--N 1.33 -0.265 0 CA-C-N 115.387 -0.824 . . . . 0.0 110.167 -179.648 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 96.5 m-20 . . . . . 0 N--CA 1.464 0.259 0 CA-C-O 120.984 0.421 . . . . 0.0 110.438 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 6.6 tt -64.27 145.16 56.46 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.429 -179.676 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 86.8 p -140.3 153.01 46.33 Favored 'General case' 0 N--CA 1.463 0.212 0 CA-C-N 116.328 -0.397 . . . . 0.0 110.662 179.909 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . 0.533 ' CD1' ' N ' ' A' ' 14' ' ' PHE . 12.5 m-85 -111.17 146.74 36.35 Favored 'General case' 0 N--CA 1.465 0.301 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.379 -179.612 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 21.9 m -146.01 160.88 11.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.633 179.81 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 38.2 t0 55.46 31.53 17.15 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.66 179.636 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 96.5 mt -56.57 137.77 18.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 121.07 0.462 . . . . 0.0 110.148 179.962 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.461 ' CB ' ' O ' ' A' ' 21' ' ' SER . 0.3 OUTLIER -140.32 -167.01 2.23 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.817 -0.628 . . . . 0.0 110.651 -179.559 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' ASP . . . . . 0.525 ' OD1' ' N ' ' A' ' 19' ' ' ASP . 14.5 p-10 -91.6 -41.97 10.47 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 115.691 -0.686 . . . . 0.0 111.006 179.468 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 13.7 m -116.97 6.88 13.05 Favored 'General case' 0 N--CA 1.466 0.344 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.677 -179.584 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' SER . . . . . 0.461 ' O ' ' CB ' ' A' ' 18' ' ' THR . 16.8 p -151.65 145.79 25.33 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 121.101 0.477 . . . . 0.0 110.443 179.968 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 44.2 pt -140.26 146.29 24.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.02 179.941 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -99.31 81.76 0.56 Allowed Glycine 0 CA--C 1.523 0.593 0 N-CA-C 111.419 -0.672 . . . . 0.0 111.419 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 84.0 mt -66.79 121.98 16.65 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.768 0.318 . . . . 0.0 110.296 -179.967 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 4.6 tmm_? -139.62 138.69 36.37 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.62 179.877 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' TRP . . . . . . . . . . . . . 42.0 p90 -143.0 158.28 43.75 Favored 'General case' 0 CA--C 1.517 -0.308 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.399 179.921 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 3.5 m -111.16 97.1 33.67 Favored Pre-proline 0 CA--C 1.534 0.337 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.393 179.854 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_exo -53.23 146.3 40.2 Favored 'Trans proline' 0 C--N 1.308 -1.581 0 C-N-CA 122.476 2.117 . . . . 0.0 112.23 179.879 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 52.3 mt -84.32 138.53 32.84 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 121.337 0.589 . . . . 0.0 111.039 -179.96 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 2.3 t-20 -49.08 -33.49 11.71 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.47 -0.786 . . . . 0.0 110.152 179.829 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 70.6 m -81.63 -34.17 31.02 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.593 179.667 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 9.1 m -58.24 134.92 56.96 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 121.103 0.478 . . . . 0.0 110.185 -179.881 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' THR . . . . . 0.459 ' OG1' ' N ' ' A' ' 82' ' ' ASN . 3.7 m -61.44 142.74 56.78 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.465 179.912 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . 0.406 HG21 HD13 ' A' ' 34' ' ' ILE . 28.9 mm -94.37 92.69 3.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.969 0.414 . . . . 0.0 110.324 -179.896 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 15.2 pt -143.09 135.86 25.13 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.155 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.359 179.697 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -39.24 132.4 1.95 Allowed Glycine 0 CA--C 1.524 0.642 0 N-CA-C 111.171 -0.771 . . . . 0.0 111.171 -179.705 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 95.6 m-85 -103.03 138.98 39.17 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.844 0.354 . . . . 0.0 110.197 -179.771 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 5.3 tmm_? -99.1 124.64 44.27 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.629 -179.699 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . 0.451 ' O ' ' CG1' ' A' ' 39' ' ' ILE . 2.1 pt -99.09 124.51 52.39 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 116.341 -0.391 . . . . 0.0 109.97 179.701 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 5.4 m -105.52 134.0 49.35 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.621 -179.822 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.1 p -132.39 141.52 45.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.308 179.541 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . 0.541 ' N ' ' O ' ' A' ' 74' ' ' ASP . 41.4 t -133.41 133.47 57.64 Favored 'Isoleucine or valine' 0 C--O 1.231 0.104 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.339 179.6 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -98.55 139.58 34.07 Favored 'General case' 0 C--N 1.328 -0.33 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 178.732 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -91.81 -43.91 9.26 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.284 -0.417 . . . . 0.0 111.027 179.815 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -63.49 -32.35 83.84 Favored Glycine 0 CA--C 1.524 0.614 0 N-CA-C 111.275 -0.73 . . . . 0.0 111.275 -179.477 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . 0.434 ' C ' ' H ' ' A' ' 48' ' ' ILE . 38.4 mm-40 -97.92 126.53 43.36 Favored 'General case' 0 C--N 1.332 -0.19 0 N-CA-C 109.616 -0.512 . . . . 0.0 109.616 -179.582 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -59.17 -6.92 4.57 Favored Glycine 0 CA--C 1.511 -0.187 0 N-CA-C 110.918 -0.873 . . . . 0.0 110.918 -179.082 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . 0.434 ' H ' ' C ' ' A' ' 46' ' ' GLU . 0.4 OUTLIER -124.23 133.44 24.7 Favored Pre-proline 0 CA--C 1.537 0.477 0 C-N-CA 120.905 -0.318 . . . . 0.0 110.257 179.461 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 60.7 Cg_endo -76.71 164.22 30.52 Favored 'Trans proline' 0 C--N 1.307 -1.618 0 C-N-CA 122.59 2.193 . . . . 0.0 112.286 177.48 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 95.9 mt -85.22 145.38 8.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 115.771 -0.65 . . . . 0.0 110.268 179.023 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 79.7 m-85 -63.79 142.81 58.27 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.527 -179.886 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . 0.446 ' N ' ' CD ' ' A' ' 52' ' ' GLU . 0.1 OUTLIER -70.58 -178.01 1.68 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.582 179.776 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 4.0 m-20 -146.51 138.25 24.68 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.884 179.499 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 89.3 m-85 -108.13 120.01 41.13 Favored 'General case' 0 N--CA 1.463 0.187 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.279 179.266 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 9.9 p -127.28 136.52 60.42 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.285 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.377 179.881 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 97.4 m-20 -56.89 142.99 39.26 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.463 -179.855 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 11.4 t -61.79 -35.15 77.34 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.716 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 37.7 m -55.44 -32.33 62.65 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.724 -179.718 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 98.6 t -63.76 -46.14 95.32 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.587 -179.889 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 59.36 27.09 62.65 Favored Glycine 0 CA--C 1.527 0.827 0 N-CA-C 110.859 -0.896 . . . . 0.0 110.859 -179.931 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 52.7 t80 -166.52 149.89 7.09 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 121.224 0.535 . . . . 0.0 110.945 -179.415 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 62' ' ' TYR . . . . . 0.412 ' CD2' ' CD1' ' A' ' 39' ' ' ILE . 25.7 t80 -158.81 159.26 34.92 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.971 -0.558 . . . . 0.0 110.141 179.003 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 85.3 m -125.28 136.28 53.36 Favored 'General case' 0 N--CA 1.464 0.233 0 CA-C-N 116.378 -0.373 . . . . 0.0 110.392 -179.714 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -131.87 105.93 10.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.185 179.37 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 3.2 p -114.1 156.23 24.56 Favored 'General case' 0 CA--C 1.516 -0.358 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.515 179.632 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 109.63 40.46 1.46 Allowed Glycine 0 CA--C 1.523 0.589 0 N-CA-C 111.245 -0.742 . . . . 0.0 111.245 -179.754 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 18.5 mt -113.69 102.34 10.16 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-O 121.126 0.488 . . . . 0.0 109.918 179.579 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 12.3 mm-40 -48.66 135.42 13.41 Favored Pre-proline 0 C--N 1.317 -0.805 0 CA-C-N 115.609 -0.723 . . . . 0.0 111.042 -178.558 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 70.9 Cg_endo -75.33 153.01 39.92 Favored 'Trans proline' 0 N--CA 1.496 1.673 0 C-N-CA 122.882 2.388 . . . . 0.0 111.61 178.8 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 72.43 12.04 76.72 Favored Glycine 0 CA--C 1.521 0.425 0 N-CA-C 111.186 -0.766 . . . . 0.0 111.186 179.479 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . 0.537 ' O ' ' NH1' ' B' ' 223' ' ' ARG . 1.7 mp -118.38 147.92 21.56 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.381 0 CA-C-O 121.251 0.548 . . . . 0.0 109.897 -179.878 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 3.1 t70 -86.51 112.39 21.49 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.257 -0.883 . . . . 0.0 110.752 179.947 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 73' ' ' TYR . . . . . 0.429 ' O ' ' CD1' ' A' ' 75' ' ' ILE . 14.8 m-85 -106.25 119.58 39.62 Favored 'General case' 0 C--O 1.218 -0.601 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.027 179.494 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 74' ' ' ASP . . . . . 0.541 ' O ' ' N ' ' A' ' 42' ' ' VAL . 72.1 m-20 -88.29 117.53 27.27 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.741 -0.663 . . . . 0.0 109.576 179.442 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . 0.429 ' CD1' ' O ' ' A' ' 73' ' ' TYR . 0.0 OUTLIER -114.59 165.97 9.03 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-O 121.038 0.447 . . . . 0.0 110.344 -179.457 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -155.14 120.73 5.04 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.586 -0.734 . . . . 0.0 110.976 179.273 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 8.9 t -100.31 101.88 12.69 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 N-CA-C 109.835 -0.431 . . . . 0.0 109.835 179.22 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 95.7 mt -88.8 126.86 41.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.648 -179.756 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 96.6 m -108.36 111.31 23.17 Favored 'General case' 0 CA--C 1.517 -0.303 0 CA-C-O 121.011 0.434 . . . . 0.0 109.984 179.7 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 51.4 tp -120.73 125.04 46.63 Favored 'General case' 0 CA--C 1.519 -0.234 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.875 179.965 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 81' ' ' ILE . . . . . 0.442 ' HB ' ' H ' ' A' ' 33' ' ' THR . 2.0 pp -144.69 143.83 22.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.279 178.991 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 82' ' ' ASN . . . . . 0.459 ' N ' ' OG1' ' A' ' 33' ' ' THR . 62.8 t-20 . . . . . 0 C--N 1.328 -0.331 0 CA-C-N 116.334 -0.394 . . . . 0.0 111.204 -179.856 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 207' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.464 0.551 0 N-CA-C 111.241 -0.743 . . . . 0.0 111.241 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' B' B ' 208' ' ' SER . . . . . 0.5 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 33.2 p -164.49 172.26 13.55 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.726 0.298 . . . . 0.0 110.767 -179.676 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 209' ' ' TRP . . . . . . . . . . . . . 73.2 m95 -85.35 151.15 24.24 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.284 -0.417 . . . . 0.0 110.357 179.529 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 81.6 p -131.66 137.64 48.42 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.387 -0.37 . . . . 0.0 110.903 -179.964 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 47.4 t-105 -95.54 115.45 27.44 Favored 'General case' 0 C--N 1.331 -0.199 0 N-CA-C 109.87 -0.418 . . . . 0.0 109.87 179.402 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 212' ' ' GLU . . . . . 0.512 ' O ' ' O ' ' B' ' 215' ' ' LYS . 2.8 tt0 -161.33 150.7 16.54 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.578 179.59 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 213' ' ' ASN . . . . . 0.434 ' C ' ' H ' ' B' ' 215' ' ' LYS . 13.2 m120 59.68 42.2 17.37 Favored 'General case' 0 N--CA 1.448 -0.53 0 CA-C-N 115.901 -0.591 . . . . 0.0 111.166 177.145 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 49.86 12.95 0.5 Allowed Glycine 0 CA--C 1.521 0.417 0 N-CA-C 111.63 -0.588 . . . . 0.0 111.63 179.161 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 215' ' ' LYS . . . . . 0.512 ' O ' ' O ' ' B' ' 212' ' ' GLU . 68.1 mttm -142.04 150.58 41.46 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.054 0.454 . . . . 0.0 110.457 -179.997 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 216' ' ' TRP . . . . . . . . . . . . . 45.7 m95 -86.13 122.31 29.97 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.42 -0.355 . . . . 0.0 110.119 -179.941 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 217' ' ' THR . . . . . . . . . . . . . 18.8 m -129.19 141.51 51.14 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.934 0.397 . . . . 0.0 110.426 -179.677 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 218' ' ' TRP . . . . . 0.5 ' CH2' ' N ' ' B' ' 208' ' ' SER . 16.7 t-105 -105.43 118.02 35.5 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-N 115.888 -0.596 . . . . 0.0 109.742 179.477 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 24.0 mtmm -142.13 173.76 11.23 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.798 -179.882 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -176.39 -161.27 25.09 Favored Glycine 0 CA--C 1.523 0.57 0 N-CA-C 111.243 -0.743 . . . . 0.0 111.243 -179.698 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 221' ' ' ILE . . . . . 0.415 ' O ' ' CG2' ' B' ' 222' ' ' ILE . 30.5 mt -52.39 -73.39 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 C-N-CA 120.812 -0.355 . . . . 0.0 110.228 -178.534 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 222' ' ' ILE . . . . . 0.485 ' O ' ' O ' ' B' ' 223' ' ' ARG . 20.5 pt -158.97 -165.89 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.208 0 CA-C-N 116.301 -0.408 . . . . 0.0 110.458 -179.932 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 223' ' ' ARG . . . . . 0.537 ' NH1' ' O ' ' A' ' 71' ' ' ILE . 30.7 ptt-85 -44.31 174.55 0.0 OUTLIER 'General case' 0 N--CA 1.456 -0.17 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.281 179.378 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 224' ' ' LEU . . . . . 0.583 ' H ' ' CD2' ' B' ' 224' ' ' LEU . 2.6 mm? -62.13 117.97 6.73 Favored 'General case' 0 C--N 1.316 -0.886 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.768 -179.516 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 81.7 tt0 . . . . . 0 C--N 1.329 -0.298 0 CA-C-N 115.612 -0.722 . . . . 0.0 110.642 -179.93 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 4.1 p30 . . . . . 0 CA--C 1.52 -0.2 0 CA-C-O 120.772 0.32 . . . . 0.0 110.494 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -68.02 151.41 47.11 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.307 -179.784 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' SER . . . . . 0.44 ' O ' ' O ' ' A' ' 25' ' ' ARG . 61.6 p -143.25 149.39 37.83 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.608 179.568 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . 0.527 ' CD1' ' N ' ' A' ' 14' ' ' PHE . 17.4 m-85 -112.34 147.02 37.24 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.879 -0.6 . . . . 0.0 110.649 -179.599 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 23.3 m -147.54 156.61 9.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.398 179.43 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 38.2 t0 60.78 28.47 18.21 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.616 179.897 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 96.5 mt -55.88 132.39 19.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.062 179.799 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.434 ' OG1' ' O ' ' A' ' 21' ' ' SER . 0.2 OUTLIER -131.12 -169.36 2.16 Favored 'General case' 0 N--CA 1.467 0.409 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.469 -179.839 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' ASP . . . . . 0.477 ' N ' ' OD1' ' A' ' 19' ' ' ASP . 17.5 p-10 -77.65 -49.26 14.9 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.963 179.513 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' SER . . . . . 0.513 ' OG ' ' N ' ' A' ' 67' ' ' LEU . 31.1 t -120.46 13.39 11.79 Favored 'General case' 0 N--CA 1.466 0.358 0 CA-C-N 116.511 -0.313 . . . . 0.0 110.704 -179.252 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' SER . . . . . 0.434 ' O ' ' OG1' ' A' ' 18' ' ' THR . 3.8 m -146.56 129.8 16.62 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.237 -179.307 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 47.7 pt -125.78 142.25 43.09 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-N 116.288 -0.415 . . . . 0.0 109.979 179.756 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -98.28 83.08 0.65 Allowed Glycine 0 CA--C 1.523 0.593 0 N-CA-C 110.507 -1.037 . . . . 0.0 110.507 -179.345 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 92.0 mt -65.57 128.09 34.52 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 110.013 -0.365 . . . . 0.0 110.013 -179.634 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . 0.44 ' O ' ' O ' ' A' ' 13' ' ' SER . 1.2 tpp180 -147.75 134.86 20.4 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.045 179.832 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' TRP . . . . . 0.554 ' CE3' ' O ' ' A' ' 60' ' ' GLY . 4.9 p90 -140.29 128.45 22.32 Favored 'General case' 0 C--O 1.223 -0.299 0 N-CA-C 109.223 -0.658 . . . . 0.0 109.223 177.73 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' THR . . . . . 0.405 ' H ' ' HG1' ' A' ' 27' ' ' THR . 1.9 m -68.34 113.27 14.32 Favored Pre-proline 0 CA--C 1.538 0.49 0 C-N-CA 120.528 -0.469 . . . . 0.0 111.011 -179.633 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 32.7 Cg_exo -59.53 152.39 62.28 Favored 'Trans proline' 0 N--CA 1.498 1.744 0 C-N-CA 121.993 1.795 . . . . 0.0 112.599 178.473 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.43 ' O ' ' N ' ' A' ' 32' ' ' SER . 77.9 mt -102.16 133.43 47.03 Favored 'General case' 0 CA--C 1.518 -0.254 0 CA-C-O 121.682 0.754 . . . . 0.0 110.651 179.728 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 11.7 t-20 -42.79 -30.54 0.4 Allowed 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 115.352 -0.84 . . . . 0.0 110.47 -179.725 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 58.1 m -87.88 -36.64 17.07 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.483 179.087 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' SER . . . . . 0.43 ' N ' ' O ' ' A' ' 29' ' ' LEU . 3.1 m -45.73 113.54 0.62 Allowed 'General case' 0 N--CA 1.461 0.115 0 CA-C-O 121.091 0.472 . . . . 0.0 110.306 -179.661 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' THR . . . . . 0.519 ' OG1' ' N ' ' A' ' 82' ' ' ASN . 7.2 m -52.24 150.01 4.97 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.601 -0.727 . . . . 0.0 109.448 -179.251 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 19.6 mm -93.92 92.65 3.66 Favored 'Isoleucine or valine' 0 C--O 1.232 0.135 0 CA-C-O 121.11 0.481 . . . . 0.0 110.995 -178.51 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 6.6 pt -151.23 124.84 1.34 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.252 179.288 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -48.25 131.4 19.84 Favored Glycine 0 CA--C 1.519 0.336 0 N-CA-C 110.786 -0.925 . . . . 0.0 110.786 -179.624 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' TYR . . . . . 0.571 ' O ' ' CD1' ' A' ' 37' ' ' TYR . 0.6 OUTLIER -104.13 130.07 51.85 Favored 'General case' 0 C--N 1.329 -0.322 0 N-CA-C 109.691 -0.485 . . . . 0.0 109.691 -179.895 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' ARG . . . . . 0.516 ' NH1' ' OG1' ' A' ' 40' ' ' THR . 7.9 tmm_? -79.59 132.27 36.23 Favored 'General case' 0 C--N 1.325 -0.472 0 C-N-CA 120.743 -0.383 . . . . 0.0 111.003 -179.895 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . 0.448 ' O ' ' CG1' ' A' ' 39' ' ' ILE . 1.9 pt -104.51 122.58 57.65 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.329 0 N-CA-C 109.585 -0.524 . . . . 0.0 109.585 179.179 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 40' ' ' THR . . . . . 0.516 ' OG1' ' NH1' ' A' ' 38' ' ' ARG . 7.1 m -99.44 136.52 39.26 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.425 -179.022 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.4 p -133.31 141.55 44.25 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.288 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.133 179.855 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . 0.499 ' O ' ' N ' ' A' ' 74' ' ' ASP . 39.9 t -132.59 132.48 59.96 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.24 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 179.607 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -99.35 136.62 39.03 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 116.09 -0.504 . . . . 0.0 109.651 178.921 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . 0.403 ' CB ' ' O ' ' A' ' 72' ' ' ASP . . . -99.02 -15.43 19.07 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-O 120.806 0.336 . . . . 0.0 110.85 -179.801 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -99.62 24.99 30.0 Favored Glycine 0 CA--C 1.525 0.7 0 N-CA-C 111.093 -0.803 . . . . 0.0 111.093 -179.44 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 93.5 mt-10 -145.95 149.37 34.05 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.97 0.414 . . . . 0.0 110.337 179.936 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -66.59 -21.06 70.54 Favored Glycine 0 CA--C 1.519 0.302 0 N-CA-C 110.67 -0.972 . . . . 0.0 110.67 179.896 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -132.23 139.58 35.35 Favored Pre-proline 0 CA--C 1.539 0.527 0 C-N-CA 121.224 -0.19 . . . . 0.0 110.524 179.873 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 61.3 Cg_endo -73.93 161.87 40.4 Favored 'Trans proline' 0 N--CA 1.49 1.281 0 C-N-CA 122.469 2.113 . . . . 0.0 111.96 177.613 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 96.8 mt -77.48 149.96 5.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.461 179.354 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 76.1 m-85 -72.47 141.59 48.59 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.678 179.78 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . 0.414 ' N ' ' CD ' ' A' ' 52' ' ' GLU . 0.2 OUTLIER -61.77 -177.07 0.1 Allowed 'General case' 0 CA--C 1.517 -0.321 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.418 179.275 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -144.33 135.29 25.16 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 115.637 -0.71 . . . . 0.0 110.301 179.706 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 86.7 m-85 -108.46 116.55 32.19 Favored 'General case' 0 N--CA 1.465 0.287 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.374 179.697 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 9.2 p -130.35 143.77 39.99 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.291 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.145 179.77 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 95.5 m-20 -66.79 151.16 48.02 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.595 179.626 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 4.4 t -64.99 -32.04 73.58 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.628 179.86 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 50.4 m -52.57 -38.58 60.23 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.485 -179.703 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.462 ' C ' ' H ' ' A' ' 61' ' ' TYR . 23.8 t -60.66 -43.03 94.0 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 -179.942 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . 0.554 ' O ' ' CE3' ' A' ' 26' ' ' TRP . . . 75.19 -40.91 1.27 Allowed Glycine 0 CA--C 1.529 0.919 0 N-CA-C 110.846 -0.902 . . . . 0.0 110.846 179.651 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 61' ' ' TYR . . . . . 0.462 ' H ' ' C ' ' A' ' 59' ' ' VAL . 26.9 p90 -113.46 158.64 20.43 Favored 'General case' 0 N--CA 1.469 0.495 0 CA-C-O 121.048 0.451 . . . . 0.0 111.245 -178.881 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 62' ' ' TYR . . . . . 0.411 ' CD2' ' CD1' ' A' ' 39' ' ' ILE . 33.3 t80 -152.93 149.5 28.29 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 179.541 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 79.8 m -112.4 133.93 54.22 Favored 'General case' 0 CA--C 1.52 -0.195 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.468 -179.445 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -132.36 100.09 3.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 115.854 -0.612 . . . . 0.0 109.834 178.762 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 2.0 p -114.37 164.18 14.29 Favored 'General case' 0 CA--C 1.515 -0.38 0 CA-C-O 120.908 0.385 . . . . 0.0 110.524 -179.942 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 107.79 25.63 5.87 Favored Glycine 0 CA--C 1.524 0.622 0 N-CA-C 111.172 -0.771 . . . . 0.0 111.172 179.75 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.513 ' N ' ' OG ' ' A' ' 20' ' ' SER . 11.9 mt -100.72 109.44 21.47 Favored 'General case' 0 N--CA 1.465 0.318 0 N-CA-C 109.284 -0.636 . . . . 0.0 109.284 179.944 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 55.5 mm-40 -52.04 139.53 33.57 Favored Pre-proline 0 C--N 1.316 -0.887 0 C-N-CA 120.496 -0.482 . . . . 0.0 112.054 -178.589 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 69' ' ' PRO . . . . . 0.46 ' C ' ' H ' ' A' ' 71' ' ' ILE . 74.4 Cg_endo -73.91 157.52 47.24 Favored 'Trans proline' 0 N--CA 1.498 1.748 0 C-N-CA 122.86 2.373 . . . . 0.0 111.253 178.574 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 69.97 -8.54 3.49 Favored Glycine 0 CA--C 1.527 0.822 0 CA-C-N 115.844 -0.616 . . . . 0.0 111.653 178.855 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . 0.524 ' O ' ' NH1' ' B' ' 223' ' ' ARG . 1.6 mp -98.76 149.19 5.53 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 N-CA-C 109.229 -0.656 . . . . 0.0 109.229 -179.702 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 72' ' ' ASP . . . . . 0.403 ' O ' ' CB ' ' A' ' 44' ' ' ALA . 2.7 t70 -89.51 115.61 27.06 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.165 -0.925 . . . . 0.0 110.422 179.657 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 73' ' ' TYR . . . . . . . . . . . . . 20.9 m-85 -108.48 119.74 40.38 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.425 179.951 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 74' ' ' ASP . . . . . 0.499 ' N ' ' O ' ' A' ' 42' ' ' VAL . 13.4 m-20 -89.8 118.13 29.16 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 115.548 -0.751 . . . . 0.0 109.646 179.824 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -115.9 164.24 12.42 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-O 121.192 0.52 . . . . 0.0 109.919 -179.139 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -152.92 128.88 10.3 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.659 -0.7 . . . . 0.0 110.216 179.667 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 62.8 t -108.27 131.79 57.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 179.461 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 96.5 mt -124.51 124.45 68.32 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 115.991 -0.549 . . . . 0.0 110.344 179.458 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 95.1 m -100.86 114.41 28.23 Favored 'General case' 0 C--O 1.232 0.181 0 CA-C-O 120.922 0.391 . . . . 0.0 110.081 179.636 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . 0.452 ' CD2' ' NZ ' ' B' ' 215' ' ' LYS . 9.6 mt -118.68 113.96 22.0 Favored 'General case' 0 CA--C 1.518 -0.251 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.253 -179.988 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 2.3 pp -147.47 144.84 19.4 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.042 179.146 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 82' ' ' ASN . . . . . 0.519 ' N ' ' OG1' ' A' ' 33' ' ' THR . 39.9 t30 . . . . . 0 C--N 1.327 -0.391 0 CA-C-O 120.942 0.401 . . . . 0.0 111.189 179.892 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 207' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.463 0.486 0 N-CA-C 110.957 -0.857 . . . . 0.0 110.957 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' B' B ' 208' ' ' SER . . . . . 0.536 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 98.9 p -164.52 168.35 18.41 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.862 0.363 . . . . 0.0 110.711 179.238 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 209' ' ' TRP . . . . . . . . . . . . . 85.4 m95 -88.89 150.95 22.63 Favored 'General case' 0 C--O 1.233 0.205 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.522 179.54 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 82.3 p -129.09 129.0 44.67 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-N 116.487 -0.324 . . . . 0.0 110.394 179.532 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 58.7 t-105 -91.41 110.62 21.93 Favored 'General case' 0 C--N 1.333 -0.112 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.586 179.82 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 212' ' ' GLU . . . . . 0.437 ' O ' ' O ' ' B' ' 215' ' ' LYS . 0.6 OUTLIER -161.26 165.93 28.45 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.541 179.654 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' B' B ' 213' ' ' ASN . . . . . . . . . . . . . 69.7 m-20 51.02 35.25 12.33 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.89 -0.595 . . . . 0.0 110.978 176.436 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 51.17 19.97 4.35 Favored Glycine 0 CA--C 1.525 0.661 0 N-CA-C 110.954 -0.858 . . . . 0.0 110.954 179.946 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 215' ' ' LYS . . . . . 0.452 ' NZ ' ' CD2' ' A' ' 80' ' ' LEU . 14.9 mtpt -145.79 150.58 36.46 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 121.066 0.46 . . . . 0.0 110.985 179.983 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 216' ' ' TRP . . . . . . . . . . . . . 52.4 m95 -87.19 114.43 23.79 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.866 -0.606 . . . . 0.0 109.883 179.233 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 217' ' ' THR . . . . . . . . . . . . . 46.4 m -118.36 135.07 54.54 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.694 -179.587 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 218' ' ' TRP . . . . . 0.536 ' CH2' ' N ' ' B' ' 208' ' ' SER . 29.5 t-105 -106.39 104.0 13.59 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 115.907 -0.588 . . . . 0.0 109.876 178.868 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 16.7 mtpp -134.38 173.8 11.23 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.558 -179.303 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -179.53 -160.94 26.05 Favored Glycine 0 CA--C 1.524 0.599 0 N-CA-C 110.761 -0.936 . . . . 0.0 110.761 179.819 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 221' ' ' ILE . . . . . 0.447 ' H ' ' CD1' ' B' ' 221' ' ' ILE . 1.9 mp -54.1 -73.14 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 C-N-CA 120.66 -0.416 . . . . 0.0 110.261 -178.804 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 222' ' ' ILE . . . . . 0.536 ' O ' ' O ' ' B' ' 223' ' ' ARG . 21.8 pt -160.51 -165.28 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.212 -179.799 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 223' ' ' ARG . . . . . 0.536 ' O ' ' O ' ' B' ' 222' ' ' ILE . 35.9 ptt-85 -40.28 174.03 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.973 178.605 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 224' ' ' LEU . . . . . 0.591 ' H ' ' CD2' ' B' ' 224' ' ' LEU . 2.2 mm? -63.45 110.16 1.86 Allowed 'General case' 0 N--CA 1.447 -0.613 0 CA-C-N 115.799 -0.637 . . . . 0.0 111.079 -179.673 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 33.8 tp10 . . . . . 0 C--N 1.329 -0.325 0 CA-C-N 115.394 -0.821 . . . . 0.0 110.002 -179.865 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 97.7 m-20 . . . . . 0 N--CA 1.463 0.201 0 CA-C-O 120.717 0.294 . . . . 0.0 110.254 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 56.5 tp -66.27 138.35 57.59 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.562 -179.969 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 16.1 p -139.6 152.93 47.22 Favored 'General case' 0 N--CA 1.463 0.192 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.384 179.555 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . 0.516 ' CD1' ' N ' ' A' ' 14' ' ' PHE . 27.7 m-85 -111.54 144.12 41.29 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.837 -179.407 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 27.6 m -143.49 164.29 15.52 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.415 179.527 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 98.8 m-20 50.37 30.46 4.55 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.95 179.79 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 96.7 mt -55.78 138.51 16.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-O 120.921 0.391 . . . . 0.0 110.202 179.507 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.464 ' CB ' ' O ' ' A' ' 21' ' ' SER . 0.2 OUTLIER -135.7 -166.75 1.91 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.034 -179.48 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' ASP . . . . . 0.469 ' N ' ' OD1' ' A' ' 19' ' ' ASP . 27.8 p-10 -84.94 -46.58 11.11 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.831 179.489 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' SER . . . . . 0.457 ' N ' ' OD1' ' A' ' 19' ' ' ASP . 43.0 m -120.74 12.56 11.41 Favored 'General case' 0 N--CA 1.467 0.389 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.852 179.99 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' SER . . . . . 0.464 ' O ' ' CB ' ' A' ' 18' ' ' THR . 85.9 p -150.26 143.55 25.01 Favored 'General case' 0 N--CA 1.465 0.283 0 CA-C-O 121.037 0.446 . . . . 0.0 110.335 -179.943 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 40.7 pt -140.46 145.0 26.47 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.361 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.217 -179.992 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -96.31 85.85 0.89 Allowed Glycine 0 CA--C 1.522 0.497 0 N-CA-C 110.882 -0.887 . . . . 0.0 110.882 -179.906 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 89.9 mt -62.3 121.02 12.12 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 120.905 0.383 . . . . 0.0 110.05 -179.782 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . 0.503 ' NH1' ' O ' ' A' ' 26' ' ' TRP . 28.0 tpt85 -138.03 135.25 35.71 Favored 'General case' 0 CA--C 1.517 -0.301 0 CA-C-O 121.115 0.483 . . . . 0.0 110.199 -179.468 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' TRP . . . . . 0.503 ' O ' ' NH1' ' A' ' 25' ' ' ARG . 46.1 p90 -147.52 155.45 41.88 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.555 -0.748 . . . . 0.0 109.604 179.851 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 6.2 m -111.34 98.12 38.62 Favored Pre-proline 0 C--N 1.33 -0.249 0 N-CA-C 110.102 -0.332 . . . . 0.0 110.102 179.66 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 32.5 Cg_exo -54.53 144.81 61.31 Favored 'Trans proline' 0 C--N 1.306 -1.692 0 C-N-CA 121.604 1.536 . . . . 0.0 113.275 179.909 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 57.1 mt -79.01 138.16 37.9 Favored 'General case' 0 CA--C 1.506 -0.743 0 CA-C-N 115.49 -0.777 . . . . 0.0 110.627 -179.567 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 34.1 t30 -50.45 -34.21 23.93 Favored 'General case' 0 C--N 1.313 -1.021 0 CA-C-N 114.856 -1.066 . . . . 0.0 110.098 179.523 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 49.2 m -79.82 -32.58 40.7 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.629 -0.714 . . . . 0.0 110.412 179.118 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 8.0 m -60.0 137.7 58.02 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.197 -179.932 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' THR . . . . . 0.575 ' CB ' ' H ' ' A' ' 82' ' ' ASN . 11.7 m -67.41 143.1 56.47 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.22 -179.645 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . 0.409 HG21 HD11 ' A' ' 34' ' ' ILE . 28.8 mm -94.05 94.04 4.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 121.0 0.429 . . . . 0.0 110.176 -179.564 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 10.7 pt -143.49 131.4 18.67 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.274 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.416 -179.973 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -41.84 118.23 1.46 Allowed Glycine 0 CA--C 1.519 0.328 0 N-CA-C 111.318 -0.713 . . . . 0.0 111.318 -179.599 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' TYR . . . . . 0.407 ' HH ' ' CG2' ' A' ' 81' ' ' ILE . 94.6 m-85 -85.09 178.88 7.39 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.875 0.369 . . . . 0.0 110.11 179.376 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' ARG . . . . . 0.549 ' NE ' ' OE1' ' A' ' 52' ' ' GLU . 0.0 OUTLIER -132.48 125.99 31.95 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.727 179.92 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . 0.46 ' CD1' ' CD2' ' A' ' 62' ' ' TYR . 2.5 pt -100.24 123.81 53.35 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 115.657 -0.701 . . . . 0.0 110.018 179.78 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 40' ' ' THR . . . . . 0.449 ' OG1' ' NE ' ' A' ' 38' ' ' ARG . 28.2 m -109.04 133.09 53.46 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.612 -179.07 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.2 p -130.51 138.44 53.74 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.305 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.288 179.844 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . 0.467 ' O ' ' N ' ' A' ' 74' ' ' ASP . 31.7 t -131.94 130.95 61.69 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.269 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 179.979 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -96.44 135.87 37.73 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.765 -0.652 . . . . 0.0 109.32 179.677 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -92.57 -47.24 7.22 Favored 'General case' 0 N--CA 1.464 0.24 0 C-N-CA 120.673 -0.411 . . . . 0.0 110.839 179.93 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -62.09 -29.55 73.09 Favored Glycine 0 N--CA 1.464 0.559 0 N-CA-C 110.891 -0.883 . . . . 0.0 110.891 179.997 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . 0.429 ' OE2' ' OH ' ' A' ' 73' ' ' TYR . 84.8 mt-10 -95.57 130.44 42.43 Favored 'General case' 0 C--N 1.328 -0.369 0 N-CA-C 109.477 -0.564 . . . . 0.0 109.477 -179.552 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -58.18 -21.17 45.98 Favored Glycine 0 CA--C 1.528 0.869 0 N-CA-C 110.857 -0.897 . . . . 0.0 110.857 -178.941 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -119.25 136.32 24.42 Favored Pre-proline 0 N--CA 1.472 0.661 0 CA-C-N 116.715 0.258 . . . . 0.0 110.543 179.676 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -77.9 167.5 23.63 Favored 'Trans proline' 0 N--CA 1.49 1.295 0 C-N-CA 122.409 2.072 . . . . 0.0 111.428 178.079 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 87.2 mt -86.22 141.66 14.14 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.235 0 CA-C-O 120.826 0.346 . . . . 0.0 110.245 179.081 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 76.3 m-85 -60.85 138.95 58.09 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.633 179.986 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . 0.549 ' OE1' ' NE ' ' A' ' 38' ' ' ARG . 5.9 pt-20 -69.64 -178.62 1.51 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.455 179.798 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 4.5 t70 -153.38 148.7 27.02 Favored 'General case' 0 N--CA 1.45 -0.444 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.748 179.367 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 58.0 m-85 -115.93 125.28 52.36 Favored 'General case' 0 N--CA 1.464 0.257 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.139 -179.929 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.9 p -125.64 134.49 66.56 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.341 0 CA-C-N 116.471 -0.331 . . . . 0.0 110.208 -179.985 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 98.9 m-20 -53.41 140.15 28.46 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.322 -179.653 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 10.4 t -60.4 -34.16 73.54 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.002 -0.544 . . . . 0.0 110.573 -179.763 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 43.7 m -55.24 -34.34 63.91 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.547 -179.731 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 99.9 t -62.31 -46.51 96.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.579 -179.871 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 61.25 26.38 65.98 Favored Glycine 0 CA--C 1.527 0.796 0 N-CA-C 110.568 -1.013 . . . . 0.0 110.568 179.635 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 52.6 t80 -167.44 152.03 6.89 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 121.121 0.486 . . . . 0.0 111.091 -179.513 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 62' ' ' TYR . . . . . 0.46 ' CD2' ' CD1' ' A' ' 39' ' ' ILE . 29.1 t80 -159.64 162.05 35.11 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 115.724 -0.671 . . . . 0.0 110.281 178.702 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 99.0 m -127.44 134.68 49.84 Favored 'General case' 0 N--CA 1.463 0.217 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.296 179.835 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -130.76 113.83 25.9 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.334 0 N-CA-C 109.513 -0.551 . . . . 0.0 109.513 178.877 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 1.9 p -122.93 157.33 32.84 Favored 'General case' 0 N--CA 1.467 0.418 0 CA-C-O 120.907 0.384 . . . . 0.0 110.413 -179.66 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 107.59 40.62 1.72 Allowed Glycine 0 CA--C 1.523 0.581 0 N-CA-C 110.628 -0.989 . . . . 0.0 110.628 -179.729 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.405 ' O ' ' OG ' ' A' ' 20' ' ' SER . 1.4 mt -116.79 110.83 18.9 Favored 'General case' 0 N--CA 1.465 0.304 0 N-CA-C 109.502 -0.555 . . . . 0.0 109.502 -179.896 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 27.6 mm-40 -48.84 141.34 10.27 Favored Pre-proline 0 C--N 1.322 -0.628 0 C-N-CA 120.862 -0.335 . . . . 0.0 111.249 -178.486 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 91.4 Cg_endo -74.89 158.37 42.66 Favored 'Trans proline' 0 N--CA 1.491 1.341 0 C-N-CA 122.481 2.121 . . . . 0.0 112.558 179.511 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 70' ' ' GLY . . . . . 0.409 ' N ' ' NH2' ' B' ' 223' ' ' ARG . . . 48.53 27.55 6.01 Favored Glycine 0 CA--C 1.529 0.951 0 CA-C-N 114.837 -1.074 . . . . 0.0 111.182 179.305 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . 0.714 ' H ' HH21 ' B' ' 223' ' ' ARG . 0.9 OUTLIER -114.0 166.36 7.93 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.483 0 CA-C-O 121.13 0.491 . . . . 0.0 109.698 -179.578 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 3.2 t70 -101.17 100.27 10.8 Favored 'General case' 0 N--CA 1.446 -0.649 0 CA-C-N 115.6 -0.727 . . . . 0.0 111.411 -178.715 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 73' ' ' TYR . . . . . 0.43 ' CD1' ' CG2' ' A' ' 71' ' ' ILE . 2.2 m-30 -110.81 124.69 52.51 Favored 'General case' 0 C--O 1.22 -0.472 0 CA-C-O 121.322 0.582 . . . . 0.0 110.341 179.16 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 74' ' ' ASP . . . . . 0.467 ' N ' ' O ' ' A' ' 42' ' ' VAL . 21.5 m-20 -89.11 116.11 27.13 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 114.894 -1.048 . . . . 0.0 109.485 -179.909 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -116.17 162.1 14.43 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.221 0 CA-C-O 121.219 0.533 . . . . 0.0 110.084 -179.383 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 3.0 m -154.04 150.69 28.51 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.259 -0.882 . . . . 0.0 110.755 179.502 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 4.1 p -132.9 101.14 4.2 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.245 0 CA-C-N 115.824 -0.625 . . . . 0.0 109.398 178.421 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 78' ' ' ILE . . . . . 0.405 HD12 HG22 ' A' ' 78' ' ' ILE . 94.6 mt -82.95 127.81 39.32 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.183 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.451 -179.522 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 5.0 p -108.21 105.89 15.82 Favored 'General case' 0 N--CA 1.464 0.251 0 CA-C-N 116.143 -0.481 . . . . 0.0 109.709 179.422 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 7.0 tp -121.68 130.59 53.57 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.353 -179.867 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 81' ' ' ILE . . . . . 0.407 ' CG2' ' HH ' ' A' ' 37' ' ' TYR . 1.6 pp -131.3 168.37 24.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.098 -0.501 . . . . 0.0 109.908 179.136 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 82' ' ' ASN . . . . . 0.575 ' H ' ' CB ' ' A' ' 33' ' ' THR . 9.8 t-20 . . . . . 0 C--N 1.33 -0.263 0 CA-C-O 120.813 0.34 . . . . 0.0 110.634 -179.992 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 207' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.464 0.536 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' B' B ' 208' ' ' SER . . . . . 0.497 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 97.1 p -164.14 170.03 16.96 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.81 0.338 . . . . 0.0 110.741 179.636 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 209' ' ' TRP . . . . . . . . . . . . . 71.9 m95 -82.93 145.59 29.3 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.412 179.529 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 40.3 p -127.33 131.29 50.45 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.565 179.942 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 41.4 t-105 -91.68 118.58 30.78 Favored 'General case' 0 N--CA 1.466 0.366 0 CA-C-N 116.18 -0.463 . . . . 0.0 109.928 179.596 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 212' ' ' GLU . . . . . 0.487 ' O ' ' O ' ' B' ' 215' ' ' LYS . 1.9 pt-20 -165.75 171.61 12.71 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.898 178.893 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 213' ' ' ASN . . . . . 0.402 ' C ' ' H ' ' B' ' 215' ' ' LYS . 93.9 m-20 48.07 38.08 8.99 Favored 'General case' 0 C--N 1.324 -0.537 0 C-N-CA 120.338 -0.545 . . . . 0.0 111.997 176.629 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 51.34 12.46 0.91 Allowed Glycine 0 CA--C 1.53 0.974 0 N-CA-C 111.536 -0.626 . . . . 0.0 111.536 179.644 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 215' ' ' LYS . . . . . 0.487 ' O ' ' O ' ' B' ' 212' ' ' GLU . 7.5 mtmp? -143.95 151.37 39.68 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.849 0.357 . . . . 0.0 110.962 -179.778 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 216' ' ' TRP . . . . . . . . . . . . . 49.0 m95 -87.0 124.93 33.72 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.25 179.285 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 217' ' ' THR . . . . . . . . . . . . . 5.0 m -138.63 148.1 43.69 Favored 'General case' 0 C--O 1.235 0.293 0 CA-C-O 121.052 0.453 . . . . 0.0 110.341 -179.809 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 218' ' ' TRP . . . . . 0.497 ' CH2' ' N ' ' B' ' 208' ' ' SER . 15.5 t-105 -105.25 121.66 44.32 Favored 'General case' 0 C--N 1.332 -0.167 0 CA-C-N 115.894 -0.593 . . . . 0.0 110.156 179.797 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 97.5 mttt -147.17 169.56 19.07 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.899 -179.996 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -174.83 -162.22 25.94 Favored Glycine 0 CA--C 1.522 0.496 0 N-CA-C 111.155 -0.778 . . . . 0.0 111.155 -179.884 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 221' ' ' ILE . . . . . 0.636 ' CG2' ' H ' ' B' ' 222' ' ' ILE . 12.2 tt -50.35 -69.71 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 C-N-CA 121.073 -0.251 . . . . 0.0 110.971 -177.977 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 222' ' ' ILE . . . . . 0.636 ' H ' ' CG2' ' B' ' 221' ' ' ILE . 9.6 pt -159.55 -165.2 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.317 -0.83 0 N-CA-C 109.327 -0.62 . . . . 0.0 109.327 178.377 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 223' ' ' ARG . . . . . 0.714 HH21 ' H ' ' A' ' 71' ' ' ILE . 39.1 ptt85 -44.47 174.98 0.0 OUTLIER 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 121.445 0.641 . . . . 0.0 111.04 178.717 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 224' ' ' LEU . . . . . 0.547 ' CD2' ' N ' ' B' ' 224' ' ' LEU . 3.2 mm? -59.95 127.48 32.1 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-N 115.046 -0.979 . . . . 0.0 110.377 -179.737 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 31.0 tp10 . . . . . 0 C--N 1.327 -0.41 0 CA-C-N 115.738 -0.665 . . . . 0.0 110.155 -179.959 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 99.4 m-20 . . . . . 0 C--O 1.233 0.185 0 CA-C-O 120.691 0.282 . . . . 0.0 110.385 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -60.85 139.0 58.09 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.152 -178.16 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 96.3 p -143.27 144.55 32.17 Favored 'General case' 0 CA--C 1.521 -0.168 0 CA-C-N 115.837 -0.62 . . . . 0.0 110.621 179.931 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . 0.512 ' CD1' ' N ' ' A' ' 14' ' ' PHE . 11.5 m-85 -112.34 143.77 42.89 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.397 -0.82 . . . . 0.0 110.754 -179.22 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 30.1 m -141.27 164.28 20.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.346 179.712 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 27.7 t70 53.63 34.22 18.24 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.08 179.849 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 1.9 mp -56.51 132.06 20.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 N-CA-C 109.57 -0.53 . . . . 0.0 109.57 179.936 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -132.8 -169.13 2.19 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-N 116.021 -0.536 . . . . 0.0 109.916 179.711 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' ASP . . . . . 0.474 ' N ' ' OD1' ' A' ' 19' ' ' ASP . 20.7 p-10 -91.24 -41.84 10.74 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.698 179.388 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' SER . . . . . 0.6 ' HG ' ' H ' ' A' ' 67' ' ' LEU . 43.1 t -113.52 6.44 17.07 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-N 116.363 -0.38 . . . . 0.0 110.99 -179.304 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 38.3 t -154.1 152.61 30.64 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 121.131 0.491 . . . . 0.0 110.202 179.971 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 38.2 pt -142.2 146.26 22.76 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.049 179.816 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -94.75 82.82 0.92 Allowed Glycine 0 CA--C 1.524 0.652 0 N-CA-C 111.076 -0.81 . . . . 0.0 111.076 -179.723 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 76.1 mt -71.14 118.33 13.8 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 121.043 0.449 . . . . 0.0 110.211 179.901 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 56.4 ttt-85 -140.83 137.03 32.98 Favored 'General case' 0 CA--C 1.517 -0.318 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.436 179.935 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' TRP . . . . . . . . . . . . . 41.3 p90 -144.5 156.56 44.23 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.624 -0.716 . . . . 0.0 110.278 -179.36 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 2.2 m -108.05 102.31 45.35 Favored Pre-proline 0 CA--C 1.533 0.302 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.676 -179.953 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 41.7 Cg_exo -53.8 150.04 30.99 Favored 'Trans proline' 0 C--N 1.305 -1.761 0 C-N-CA 121.464 1.443 . . . . 0.0 112.673 179.274 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 60.9 mt -92.3 137.9 31.97 Favored 'General case' 0 CA--C 1.514 -0.425 0 CA-C-O 121.811 0.815 . . . . 0.0 110.809 -179.764 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 28.8 t-20 -47.56 -35.44 9.05 Favored 'General case' 0 C--N 1.313 -1.007 0 CA-C-N 115.056 -0.974 . . . . 0.0 110.092 179.952 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 53.0 m -79.8 -33.72 40.24 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.438 178.847 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 6.0 m -58.36 124.27 18.94 Favored 'General case' 0 CA--C 1.529 0.146 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.055 -179.86 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' THR . . . . . 0.556 ' CB ' ' H ' ' A' ' 82' ' ' ASN . 5.6 m -57.22 146.57 27.85 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.102 -179.762 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 20.5 mm -94.37 91.37 3.08 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.173 0 CA-C-O 121.047 0.451 . . . . 0.0 110.765 -179.377 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.478 ' O ' ' OG ' ' A' ' 57' ' ' SER . 22.1 pt -145.21 128.76 11.51 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.244 0 CA-C-N 115.714 -0.675 . . . . 0.0 110.597 179.815 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -42.65 125.84 4.44 Favored Glycine 0 CA--C 1.523 0.572 0 N-CA-C 111.086 -0.805 . . . . 0.0 111.086 -179.512 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 35.9 m-85 -90.83 -179.9 5.62 Favored 'General case' 0 CA--C 1.517 -0.29 0 N-CA-C 110.024 -0.362 . . . . 0.0 110.024 -179.88 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -131.45 121.34 24.37 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.553 179.753 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . 0.439 ' O ' ' CG1' ' A' ' 39' ' ' ILE . 2.3 pt -95.95 124.29 48.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.008 -0.542 . . . . 0.0 109.716 179.828 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 4.8 m -106.74 132.77 52.33 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.398 -179.361 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.4 p -130.07 137.75 55.69 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.319 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.287 -179.979 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . 0.524 ' O ' ' N ' ' A' ' 74' ' ' ASP . 40.1 t -131.02 131.65 63.95 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.298 0 N-CA-C 109.743 -0.465 . . . . 0.0 109.743 179.671 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -97.92 141.26 31.11 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.137 -0.483 . . . . 0.0 109.817 179.273 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . 0.407 ' CB ' ' O ' ' A' ' 72' ' ' ASP . . . -100.29 -23.68 14.73 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-O 120.828 0.347 . . . . 0.0 110.672 179.874 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -90.88 31.06 5.78 Favored Glycine 0 N--CA 1.466 0.636 0 N-CA-C 110.776 -0.93 . . . . 0.0 110.776 -179.963 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 64.2 mt-10 -151.8 150.8 30.55 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.951 0.405 . . . . 0.0 110.649 -179.738 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -72.1 -17.67 77.39 Favored Glycine 0 CA--C 1.524 0.62 0 N-CA-C 110.781 -0.928 . . . . 0.0 110.781 179.633 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -133.94 139.04 32.14 Favored Pre-proline 0 CA--C 1.544 0.738 0 CA-C-N 116.772 0.286 . . . . 0.0 110.507 -179.978 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 68.4 Cg_endo -73.89 161.84 40.54 Favored 'Trans proline' 0 N--CA 1.494 1.558 0 C-N-CA 122.631 2.221 . . . . 0.0 111.949 178.31 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . 0.446 ' CG2' ' N ' ' A' ' 51' ' ' PHE . 96.3 mt -75.72 159.26 5.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.381 179.419 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 51' ' ' PHE . . . . . 0.446 ' N ' ' CG2' ' A' ' 50' ' ' ILE . 0.9 OUTLIER -78.32 142.21 37.9 Favored 'General case' 0 CA--C 1.531 0.24 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.727 179.871 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . 0.467 ' N ' ' CD ' ' A' ' 52' ' ' GLU . 0.0 OUTLIER -71.01 -178.48 1.97 Allowed 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.39 179.433 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 53' ' ' ASP . . . . . 0.432 ' OD1' ' OH ' ' A' ' 62' ' ' TYR . 0.2 OUTLIER -148.27 139.74 23.56 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.147 179.75 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 96.2 m-85 -109.32 123.58 49.53 Favored 'General case' 0 N--CA 1.464 0.241 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.478 -179.94 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 5.9 p -131.48 141.29 46.2 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.245 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.215 -179.976 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 84.9 m-20 -58.92 151.03 22.71 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.591 -179.777 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 57' ' ' SER . . . . . 0.478 ' OG ' ' O ' ' A' ' 35' ' ' ILE . 3.7 m -61.66 -34.48 75.78 Favored 'General case' 0 C--O 1.233 0.22 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.84 179.839 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 69.2 m -53.5 -34.59 58.63 Favored 'General case' 0 C--N 1.326 -0.444 0 N-CA-C 109.943 -0.392 . . . . 0.0 109.943 -179.661 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.72 ' C ' ' H ' ' A' ' 61' ' ' TYR . 4.1 t -83.19 76.06 1.09 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.859 -179.826 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -58.72 26.53 0.02 OUTLIER Glycine 0 CA--C 1.539 1.589 0 N-CA-C 111.549 -0.62 . . . . 0.0 111.549 -179.641 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 61' ' ' TYR . . . . . 0.72 ' H ' ' C ' ' A' ' 59' ' ' VAL . 35.8 p90 -160.69 150.58 17.61 Favored 'General case' 0 N--CA 1.453 -0.325 0 CA-C-O 121.125 0.488 . . . . 0.0 111.6 179.986 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 62' ' ' TYR . . . . . 0.432 ' OH ' ' OD1' ' A' ' 53' ' ' ASP . 37.1 t80 -153.6 147.85 25.83 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.688 -0.687 . . . . 0.0 109.583 179.093 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 29.8 m -108.74 132.63 53.76 Favored 'General case' 0 N--CA 1.464 0.235 0 CA-C-O 121.037 0.446 . . . . 0.0 110.563 -179.31 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -132.03 106.16 10.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 115.924 -0.58 . . . . 0.0 109.723 178.662 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 2.6 p -114.55 162.06 17.22 Favored 'General case' 0 N--CA 1.465 0.283 0 CA-C-O 120.978 0.418 . . . . 0.0 110.543 179.95 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 108.58 41.07 1.52 Allowed Glycine 0 CA--C 1.524 0.655 0 N-CA-C 111.256 -0.737 . . . . 0.0 111.256 -179.942 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.6 ' H ' ' HG ' ' A' ' 20' ' ' SER . 14.3 mt -115.2 109.07 17.45 Favored 'General case' 0 N--CA 1.466 0.353 0 N-CA-C 109.211 -0.662 . . . . 0.0 109.211 179.456 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 33.6 mm-40 -60.11 140.83 90.74 Favored Pre-proline 0 C--N 1.321 -0.642 0 C-N-CA 120.623 -0.431 . . . . 0.0 111.788 -178.403 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 93.8 Cg_endo -74.63 155.74 44.74 Favored 'Trans proline' 0 N--CA 1.497 1.682 0 C-N-CA 122.686 2.258 . . . . 0.0 111.73 178.802 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 71.61 7.55 65.15 Favored Glycine 0 CA--C 1.525 0.694 0 CA-C-N 115.635 -0.711 . . . . 0.0 111.629 179.128 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 1.6 mp -116.18 144.0 24.9 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.469 0 CA-C-O 121.441 0.639 . . . . 0.0 109.463 -179.934 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 72' ' ' ASP . . . . . 0.407 ' O ' ' CB ' ' A' ' 44' ' ' ALA . 2.1 t70 -84.73 114.18 21.86 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.143 -0.935 . . . . 0.0 110.869 179.943 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 73' ' ' TYR . . . . . . . . . . . . . 23.7 m-85 -106.53 122.16 45.74 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 121.251 0.548 . . . . 0.0 110.306 179.849 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 74' ' ' ASP . . . . . 0.524 ' N ' ' O ' ' A' ' 42' ' ' VAL . 11.7 m-20 -91.42 117.5 29.74 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.209 -0.905 . . . . 0.0 109.432 179.625 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -115.27 165.92 9.85 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.422 0 CA-C-O 120.957 0.408 . . . . 0.0 110.267 -179.045 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -154.84 121.94 5.56 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.391 179.208 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 63.1 t -101.1 102.6 13.68 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 N-CA-C 109.335 -0.617 . . . . 0.0 109.335 179.011 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 95.9 mt -93.64 131.05 41.69 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.229 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.571 -179.591 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 71.3 m -109.28 111.27 22.75 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.078 -0.51 . . . . 0.0 109.917 179.391 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 37.6 tp -116.47 120.72 39.69 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.496 179.915 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 2.8 pp -142.68 153.97 17.65 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.278 179.397 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 82' ' ' ASN . . . . . 0.556 ' H ' ' CB ' ' A' ' 33' ' ' THR . 14.3 t-20 . . . . . 0 C--N 1.33 -0.279 0 CA-C-O 121.028 0.442 . . . . 0.0 110.932 179.963 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 207' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.464 0.501 0 N-CA-C 111.021 -0.831 . . . . 0.0 111.021 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' B' B ' 208' ' ' SER . . . . . 0.531 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 98.7 p -165.17 170.9 14.37 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 120.706 0.288 . . . . 0.0 110.734 179.83 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 209' ' ' TRP . . . . . . . . . . . . . 72.2 m95 -87.58 131.43 34.4 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.315 179.607 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 68.8 p -110.15 133.39 53.27 Favored 'General case' 0 N--CA 1.465 0.313 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.405 -179.951 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 49.8 t-105 -94.93 118.36 31.68 Favored 'General case' 0 N--CA 1.463 0.199 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.059 179.795 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 212' ' ' GLU . . . . . 0.469 ' O ' ' O ' ' B' ' 215' ' ' LYS . 1.7 pt-20 -164.7 170.64 15.36 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.731 178.903 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 213' ' ' ASN . . . . . . . . . . . . . 13.8 m120 48.82 36.18 7.68 Favored 'General case' 0 C--N 1.323 -0.577 0 C-N-CA 120.321 -0.552 . . . . 0.0 111.615 175.951 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 51.88 13.82 1.64 Allowed Glycine 0 CA--C 1.529 0.94 0 N-CA-C 111.536 -0.626 . . . . 0.0 111.536 179.676 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 215' ' ' LYS . . . . . 0.469 ' O ' ' O ' ' B' ' 212' ' ' GLU . 67.5 mttm -143.09 150.87 40.1 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-O 121.082 0.468 . . . . 0.0 110.625 179.875 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 216' ' ' TRP . . . . . . . . . . . . . 64.4 m95 -84.82 118.03 24.23 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.013 179.856 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 217' ' ' THR . . . . . . . . . . . . . 19.3 m -127.5 139.86 52.52 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-O 121.197 0.522 . . . . 0.0 110.452 -179.393 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 218' ' ' TRP . . . . . 0.531 ' CH2' ' N ' ' B' ' 208' ' ' SER . 19.7 t-105 -106.22 117.25 33.55 Favored 'General case' 0 C--O 1.231 0.1 0 CA-C-N 115.849 -0.614 . . . . 0.0 109.922 179.227 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 54.4 mtmt -143.71 172.07 13.33 Favored 'General case' 0 CA--C 1.516 -0.343 0 CA-C-O 120.989 0.423 . . . . 0.0 110.642 -179.748 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -176.42 -160.73 24.18 Favored Glycine 0 CA--C 1.525 0.669 0 C-N-CA 120.585 -0.817 . . . . 0.0 111.305 -179.727 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 221' ' ' ILE . . . . . 0.403 ' O ' ' CG2' ' B' ' 222' ' ' ILE . 20.2 mt -54.7 -73.65 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 C-N-CA 120.649 -0.42 . . . . 0.0 110.448 -178.046 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 222' ' ' ILE . . . . . 0.502 ' O ' ' O ' ' B' ' 223' ' ' ARG . 21.7 pt -159.85 -165.08 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 N-CA-C 109.907 -0.405 . . . . 0.0 109.907 -179.761 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 223' ' ' ARG . . . . . 0.502 ' O ' ' O ' ' B' ' 222' ' ' ILE . 37.0 ptt180 -40.9 172.13 0.0 OUTLIER 'General case' 0 N--CA 1.456 -0.174 0 CA-C-O 121.175 0.512 . . . . 0.0 110.923 178.89 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 224' ' ' LEU . . . . . 0.712 ' H ' ' CD2' ' B' ' 224' ' ' LEU . 0.4 OUTLIER -58.55 147.8 30.86 Favored 'General case' 0 C--N 1.318 -0.794 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.638 -179.091 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 23.5 tp10 . . . . . 0 CA--C 1.515 -0.392 0 CA-C-N 115.551 -0.75 . . . . 0.0 110.511 -178.858 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 55.2 p-10 . . . . . 0 C--O 1.231 0.116 0 CA-C-O 120.746 0.308 . . . . 0.0 110.673 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 7.3 tt -65.1 150.9 47.32 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.444 -179.679 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' SER . . . . . 0.417 ' O ' ' O ' ' A' ' 25' ' ' ARG . 18.1 p -139.85 157.53 45.56 Favored 'General case' 0 N--CA 1.463 0.204 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.385 179.696 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . 0.48 ' CD1' ' N ' ' A' ' 14' ' ' PHE . 31.5 m-85 -110.33 144.77 38.57 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.652 -179.325 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 16.7 m -145.69 156.62 12.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.294 179.402 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 98.8 m-20 55.75 35.93 26.28 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.64 -179.885 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.445 HG22 HD12 ' A' ' 17' ' ' ILE . 96.4 mt -61.12 139.07 20.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.31 179.816 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.473 ' CB ' ' O ' ' A' ' 21' ' ' SER . 0.2 OUTLIER -140.84 -167.33 2.34 Favored 'General case' 0 N--CA 1.469 0.494 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.194 -179.986 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' ASP . . . . . 0.496 ' OD1' ' N ' ' A' ' 20' ' ' SER . 30.9 p-10 -88.75 -43.54 11.2 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.819 179.384 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' SER . . . . . 0.513 ' HG ' ' H ' ' A' ' 67' ' ' LEU . 4.4 t -116.41 6.73 13.68 Favored 'General case' 0 N--CA 1.466 0.353 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.976 -179.42 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' SER . . . . . 0.473 ' O ' ' CB ' ' A' ' 18' ' ' THR . 16.4 p -150.57 140.3 21.74 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 121.257 0.551 . . . . 0.0 110.508 179.853 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 28.4 pt -139.65 144.13 29.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 N-CA-C 109.394 -0.595 . . . . 0.0 109.394 -179.868 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -106.4 91.33 0.72 Allowed Glycine 0 N--CA 1.466 0.637 0 N-CA-C 111.496 -0.642 . . . . 0.0 111.496 -179.323 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 11.2 mp -69.63 130.55 42.69 Favored 'General case' 0 C--N 1.328 -0.354 0 C-N-CA 120.478 -0.489 . . . . 0.0 109.842 179.844 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . 0.417 ' O ' ' O ' ' A' ' 13' ' ' SER . 67.5 ttp85 -140.83 135.26 31.22 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.196 179.615 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' TRP . . . . . . . . . . . . . 48.3 p90 -143.51 156.47 44.63 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.988 -0.551 . . . . 0.0 109.983 179.719 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 4.4 m -109.54 101.11 44.9 Favored Pre-proline 0 CA--C 1.531 0.23 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.162 179.906 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 42.0 Cg_exo -53.14 150.84 23.41 Favored 'Trans proline' 0 C--N 1.307 -1.613 0 C-N-CA 121.635 1.557 . . . . 0.0 113.199 179.823 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 54.2 mt -91.3 141.94 28.24 Favored 'General case' 0 CA--C 1.513 -0.466 0 CA-C-N 115.127 -0.942 . . . . 0.0 110.885 179.867 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 53.6 t-20 -50.87 -38.14 47.7 Favored 'General case' 0 C--N 1.314 -0.976 0 CA-C-N 114.743 -1.117 . . . . 0.0 110.149 179.575 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 23.2 m -76.98 -33.57 57.61 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.454 178.874 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 15.1 m -60.48 127.84 33.71 Favored 'General case' 0 N--CA 1.461 0.108 0 CA-C-O 121.027 0.441 . . . . 0.0 110.16 179.893 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' THR . . . . . 0.487 ' OG1' ' N ' ' A' ' 82' ' ' ASN . 5.5 m -57.96 142.98 44.68 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.292 179.99 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 20.6 mm -93.82 89.24 2.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 120.904 0.383 . . . . 0.0 110.839 -179.299 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.469 ' O ' ' OG ' ' A' ' 57' ' ' SER . 14.7 pt -142.04 129.76 20.88 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.341 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.498 179.633 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -39.87 121.08 1.5 Allowed Glycine 0 CA--C 1.523 0.543 0 N-CA-C 111.555 -0.618 . . . . 0.0 111.555 -179.56 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 37' ' ' TYR . . . . . 0.436 ' CE2' ' OG ' ' A' ' 57' ' ' SER . 97.7 m-85 -83.19 178.92 7.88 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.942 0.401 . . . . 0.0 110.09 179.91 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 38' ' ' ARG . . . . . 0.54 ' NH1' ' OG1' ' A' ' 40' ' ' THR . 4.2 tmt_? -134.21 123.74 24.81 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 121.134 0.492 . . . . 0.0 110.561 179.775 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 2.8 pt -94.46 152.95 3.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 115.894 -0.593 . . . . 0.0 109.537 -179.856 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 40' ' ' THR . . . . . 0.54 ' OG1' ' NH1' ' A' ' 38' ' ' ARG . 27.3 m -136.09 133.12 36.98 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.75 0.31 . . . . 0.0 110.491 179.814 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.0 p -132.59 134.95 58.31 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.326 0 CA-C-O 120.812 0.339 . . . . 0.0 110.577 179.796 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . 0.5 ' O ' ' N ' ' A' ' 74' ' ' ASP . 30.0 t -129.44 126.68 63.89 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.216 0 N-CA-C 110.017 -0.364 . . . . 0.0 110.017 179.307 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -93.33 138.67 31.46 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 109.32 -0.622 . . . . 0.0 109.32 179.504 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . 0.409 ' CB ' ' O ' ' A' ' 72' ' ' ASP . . . -97.53 -19.25 18.49 Favored 'General case' 0 C--N 1.329 -0.286 0 C-N-CA 120.695 -0.402 . . . . 0.0 110.877 -179.97 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -96.61 30.95 8.03 Favored Glycine 0 CA--C 1.525 0.701 0 N-CA-C 110.971 -0.852 . . . . 0.0 110.971 179.906 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 71.5 mt-10 -146.21 149.92 34.84 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.974 0.416 . . . . 0.0 110.556 179.996 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -68.28 -21.11 73.87 Favored Glycine 0 CA--C 1.523 0.54 0 N-CA-C 111.073 -0.811 . . . . 0.0 111.073 179.571 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -137.86 140.21 28.77 Favored Pre-proline 0 CA--C 1.546 0.814 0 CA-C-N 116.833 0.316 . . . . 0.0 110.603 179.672 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 68.9 Cg_endo -72.78 163.03 39.6 Favored 'Trans proline' 0 N--CA 1.495 1.569 0 C-N-CA 122.768 2.312 . . . . 0.0 112.107 178.755 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . 0.436 HD13 HG22 ' A' ' 50' ' ' ILE . 96.8 mt -75.58 158.6 5.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.551 179.602 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 51' ' ' PHE . . . . . 0.435 ' N ' ' CG2' ' A' ' 50' ' ' ILE . 96.7 m-85 -75.94 147.77 38.67 Favored 'General case' 0 C--N 1.333 -0.143 0 CA-C-O 121.019 0.438 . . . . 0.0 111.134 -179.72 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . 0.479 ' CD ' ' H ' ' A' ' 52' ' ' GLU . 0.3 OUTLIER -83.28 146.94 28.26 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.441 179.478 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -116.91 153.55 32.37 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.756 -0.656 . . . . 0.0 110.499 -179.492 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 54' ' ' PHE . . . . . 0.565 ' CD1' ' N ' ' A' ' 54' ' ' PHE . 5.7 m-85 -119.79 129.47 54.47 Favored 'General case' 0 N--CA 1.462 0.132 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.146 -179.85 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 9.4 p -129.77 138.91 52.95 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.393 0 CA-C-O 120.73 0.3 . . . . 0.0 110.843 -179.769 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 94.4 m-20 -61.08 144.86 52.69 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.695 179.964 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 57' ' ' SER . . . . . 0.469 ' OG ' ' O ' ' A' ' 35' ' ' ILE . 10.2 m -61.94 -32.14 72.53 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.706 179.878 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 75.5 m -56.2 -36.43 68.4 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.582 -179.756 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 74.3 t -62.32 -45.05 99.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.511 -179.848 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 60.45 24.87 62.17 Favored Glycine 0 CA--C 1.528 0.864 0 N-CA-C 110.507 -1.037 . . . . 0.0 110.507 -179.95 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 61' ' ' TYR . . . . . 0.432 ' OH ' ' OG1' ' A' ' 63' ' ' THR . 52.6 t80 -166.34 151.09 7.92 Favored 'General case' 0 CA--C 1.53 0.176 0 CA-C-O 121.214 0.531 . . . . 0.0 111.423 -179.513 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 17.4 t80 -158.01 158.25 34.52 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.672 -0.694 . . . . 0.0 110.378 178.566 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 63' ' ' THR . . . . . 0.432 ' OG1' ' OH ' ' A' ' 61' ' ' TYR . 69.3 m -127.7 136.74 51.98 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.198 179.728 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -130.16 104.62 10.45 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 N-CA-C 109.33 -0.619 . . . . 0.0 109.33 179.413 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 4.2 p -111.75 157.38 20.59 Favored 'General case' 0 N--CA 1.466 0.335 0 CA-C-O 120.946 0.403 . . . . 0.0 110.498 -179.849 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 107.68 40.79 1.68 Allowed Glycine 0 CA--C 1.524 0.594 0 N-CA-C 111.074 -0.81 . . . . 0.0 111.074 179.94 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.513 ' H ' ' HG ' ' A' ' 20' ' ' SER . 16.6 mt -113.0 106.65 14.95 Favored 'General case' 0 N--CA 1.462 0.168 0 N-CA-C 108.99 -0.744 . . . . 0.0 108.99 179.215 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 52.4 mm-40 -51.97 135.91 37.8 Favored Pre-proline 0 C--N 1.319 -0.72 0 CA-C-N 116.376 -0.375 . . . . 0.0 111.626 -178.059 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 93.4 Cg_endo -74.98 155.44 43.03 Favored 'Trans proline' 0 N--CA 1.496 1.658 0 C-N-CA 122.55 2.166 . . . . 0.0 111.476 178.602 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 70' ' ' GLY . . . . . 0.484 ' H ' HH22 ' B' ' 223' ' ' ARG . . . 71.11 5.66 59.1 Favored Glycine 0 CA--C 1.525 0.671 0 CA-C-N 115.65 -0.705 . . . . 0.0 111.54 179.469 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 1.6 mp -113.43 143.39 23.21 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.47 0 N-CA-C 109.315 -0.624 . . . . 0.0 109.315 179.859 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 72' ' ' ASP . . . . . 0.409 ' O ' ' CB ' ' A' ' 44' ' ' ALA . 1.8 t70 -80.26 113.86 18.75 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.387 -0.824 . . . . 0.0 110.683 179.949 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 73' ' ' TYR . . . . . . . . . . . . . 14.0 m-85 -109.14 120.19 41.78 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 121.264 0.554 . . . . 0.0 110.694 -179.699 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 74' ' ' ASP . . . . . 0.5 ' N ' ' O ' ' A' ' 42' ' ' VAL . 9.6 m-20 -89.11 119.55 29.72 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-N 115.378 -0.828 . . . . 0.0 109.175 179.387 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -119.17 166.38 13.61 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.466 0 CA-C-O 121.019 0.438 . . . . 0.0 110.304 -179.306 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 22.9 t -156.13 152.41 27.89 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.574 -0.739 . . . . 0.0 110.312 178.529 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 2.4 t -128.78 101.95 7.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 N-CA-C 109.556 -0.535 . . . . 0.0 109.556 178.664 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 72.4 mt -88.47 127.56 41.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 N-CA-C 109.974 -0.38 . . . . 0.0 109.974 -179.433 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 87.3 m -105.66 114.22 28.25 Favored 'General case' 0 N--CA 1.465 0.284 0 CA-C-N 116.213 -0.449 . . . . 0.0 109.963 179.967 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 49.1 mt -118.2 117.42 29.11 Favored 'General case' 0 N--CA 1.464 0.229 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.533 -179.722 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 81' ' ' ILE . . . . . 0.405 ' HB ' ' H ' ' A' ' 33' ' ' THR . 2.3 pp -145.26 146.67 19.52 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.181 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.39 179.032 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 82' ' ' ASN . . . . . 0.487 ' N ' ' OG1' ' A' ' 33' ' ' THR . 23.0 t-20 . . . . . 0 C--N 1.329 -0.294 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.259 -179.578 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 207' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.462 0.428 0 N-CA-C 111.125 -0.79 . . . . 0.0 111.125 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' B' B ' 208' ' ' SER . . . . . 0.536 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 97.1 p -165.86 170.58 13.67 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.809 0.337 . . . . 0.0 110.818 179.877 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 209' ' ' TRP . . . . . . . . . . . . . 66.9 m95 -88.27 147.6 24.74 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.462 179.666 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 82.4 p -127.96 129.26 46.5 Favored 'General case' 0 C--O 1.234 0.257 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.631 179.868 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 48.9 t-105 -89.62 116.67 27.93 Favored 'General case' 0 N--CA 1.463 0.176 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.04 179.5 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 212' ' ' GLU . . . . . 0.457 ' O ' ' O ' ' B' ' 215' ' ' LYS . 1.0 OUTLIER -164.91 170.24 15.55 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.556 179.073 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' B' B ' 213' ' ' ASN . . . . . . . . . . . . . 14.2 m120 48.23 35.96 6.16 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.916 176.56 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 51.97 13.65 1.64 Allowed Glycine 0 CA--C 1.528 0.899 0 C-N-CA 120.992 -0.623 . . . . 0.0 111.668 179.656 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 215' ' ' LYS . . . . . 0.457 ' O ' ' O ' ' B' ' 212' ' ' GLU . 66.8 mttm -142.84 150.81 40.4 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-O 120.994 0.426 . . . . 0.0 110.839 179.826 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 216' ' ' TRP . . . . . . . . . . . . . 52.1 m95 -86.81 118.77 26.42 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.089 179.86 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 217' ' ' THR . . . . . . . . . . . . . 19.6 m -128.85 142.42 50.97 Favored 'General case' 0 N--CA 1.467 0.387 0 CA-C-O 120.938 0.399 . . . . 0.0 110.184 -179.772 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 218' ' ' TRP . . . . . 0.536 ' CH2' ' N ' ' B' ' 208' ' ' SER . 15.2 t-105 -104.91 118.51 36.72 Favored 'General case' 0 C--N 1.33 -0.269 0 N-CA-C 109.356 -0.609 . . . . 0.0 109.356 179.246 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 52.5 mtmt -145.86 167.4 23.33 Favored 'General case' 0 CA--C 1.517 -0.305 0 CA-C-O 121.33 0.586 . . . . 0.0 110.704 -179.411 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -175.81 -161.13 24.56 Favored Glycine 0 CA--C 1.523 0.573 0 CA-C-N 115.383 -0.826 . . . . 0.0 111.486 -179.736 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 221' ' ' ILE . . . . . 0.423 ' O ' ' CG2' ' B' ' 222' ' ' ILE . 0.8 OUTLIER -52.59 -75.71 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 C-N-CA 120.69 -0.404 . . . . 0.0 111.065 -178.667 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' B' B ' 222' ' ' ILE . . . . . 0.472 ' O ' ' O ' ' B' ' 223' ' ' ARG . 22.1 pt -160.87 -165.08 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 N-CA-C 109.97 -0.382 . . . . 0.0 109.97 -179.405 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 223' ' ' ARG . . . . . 0.484 HH22 ' H ' ' A' ' 70' ' ' GLY . 39.5 ptt180 -43.28 173.5 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.804 -0.635 . . . . 0.0 110.669 178.579 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 224' ' ' LEU . . . . . 0.723 ' H ' ' CD2' ' B' ' 224' ' ' LEU . 0.7 OUTLIER -61.67 126.09 26.12 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.33 -179.859 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 35.5 tp10 . . . . . 0 C--N 1.329 -0.303 0 CA-C-N 115.712 -0.676 . . . . 0.0 110.277 179.803 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 . . . . . 0 CA--C 1.519 -0.216 0 CA-C-O 120.956 0.407 . . . . 0.0 110.372 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . 0.528 ' CD2' ' CZ ' ' A' ' 14' ' ' PHE . 7.0 tt -67.15 145.34 55.38 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.579 -179.83 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' SER . . . . . 0.431 ' O ' ' O ' ' A' ' 25' ' ' ARG . 53.9 p -143.09 152.79 42.23 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.497 179.642 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . 0.554 ' CD1' ' N ' ' A' ' 14' ' ' PHE . 8.3 m-85 -111.77 148.73 32.9 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.391 -179.763 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 18.5 m -146.37 158.01 11.32 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.205 179.711 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 95.2 m-20 58.91 30.27 19.95 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.613 -0.721 . . . . 0.0 110.849 -179.921 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 83.2 mt -56.3 130.5 18.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 N-CA-C 109.862 -0.422 . . . . 0.0 109.862 179.65 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.429 ' OG1' ' O ' ' A' ' 21' ' ' SER . 0.2 OUTLIER -129.52 -169.1 2.05 Favored 'General case' 0 N--CA 1.466 0.374 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.579 -179.886 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' ASP . . . . . 0.488 ' N ' ' OD1' ' A' ' 19' ' ' ASP . 16.2 p-10 -78.35 -48.52 15.41 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.997 179.428 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' SER . . . . . 0.7 ' HG ' ' H ' ' A' ' 67' ' ' LEU . 28.2 t -121.16 13.35 11.2 Favored 'General case' 0 N--CA 1.464 0.231 0 CA-C-O 120.728 0.299 . . . . 0.0 110.596 -179.161 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' SER . . . . . 0.429 ' O ' ' OG1' ' A' ' 18' ' ' THR . 25.1 p -146.69 129.14 15.91 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 116.475 -0.329 . . . . 0.0 110.352 -179.625 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 46.4 pt -126.25 142.57 42.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.239 0 CA-C-N 116.2 -0.455 . . . . 0.0 109.959 -179.886 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -97.1 82.26 0.72 Allowed Glycine 0 CA--C 1.523 0.542 0 N-CA-C 110.873 -0.891 . . . . 0.0 110.873 -179.563 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 90.7 mt -65.26 122.53 17.31 Favored 'General case' 0 C--N 1.33 -0.276 0 N-CA-C 109.945 -0.391 . . . . 0.0 109.945 -179.815 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . 0.431 ' O ' ' O ' ' A' ' 13' ' ' SER . 72.2 ttt180 -141.2 138.78 33.58 Favored 'General case' 0 N--CA 1.462 0.168 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.722 -179.873 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' TRP . . . . . 0.534 ' CE2' ' O ' ' A' ' 60' ' ' GLY . 33.3 p90 -146.33 121.06 9.86 Favored 'General case' 0 CA--C 1.513 -0.453 0 CA-C-N 115.792 -0.64 . . . . 0.0 109.764 179.882 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 2.1 m -66.49 113.91 14.9 Favored Pre-proline 0 CA--C 1.536 0.412 0 C-N-CA 120.642 -0.423 . . . . 0.0 111.091 -178.619 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 36.1 Cg_exo -58.84 153.07 52.86 Favored 'Trans proline' 0 N--CA 1.493 1.461 0 C-N-CA 122.101 1.867 . . . . 0.0 112.742 178.693 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 80.2 mt -104.94 136.05 45.15 Favored 'General case' 0 N--CA 1.469 0.479 0 CA-C-O 122.008 0.909 . . . . 0.0 110.833 179.876 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 42.4 t30 -44.88 -32.43 1.59 Allowed 'General case' 0 C--N 1.316 -0.877 0 CA-C-N 115.064 -0.971 . . . . 0.0 110.223 -179.709 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 58.7 m -85.64 -33.84 21.51 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.868 -0.606 . . . . 0.0 110.582 179.198 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 3.6 m -51.52 115.48 1.63 Allowed 'General case' 0 N--CA 1.461 0.095 0 CA-C-O 121.261 0.553 . . . . 0.0 110.17 -179.929 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' THR . . . . . 0.522 ' OG1' ' N ' ' A' ' 82' ' ' ASN . 11.7 m -50.94 143.54 10.04 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.561 -0.745 . . . . 0.0 109.264 -179.081 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . 0.432 HG21 HD12 ' A' ' 34' ' ' ILE . 32.8 mm -92.45 90.95 3.23 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.215 0 CA-C-O 121.236 0.541 . . . . 0.0 111.258 -178.156 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.576 ' O ' ' CE1' ' A' ' 37' ' ' TYR . 6.7 pt -149.19 125.95 2.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 115.507 -0.77 . . . . 0.0 110.241 179.225 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -39.56 140.45 0.78 Allowed Glycine 0 CA--C 1.527 0.788 0 N-CA-C 110.957 -0.857 . . . . 0.0 110.957 -179.72 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 37' ' ' TYR . . . . . 0.576 ' CE1' ' O ' ' A' ' 35' ' ' ILE . 16.8 m-85 -110.49 144.83 38.72 Favored 'General case' 0 CA--C 1.518 -0.286 0 N-CA-C 109.867 -0.42 . . . . 0.0 109.867 -179.504 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 38' ' ' ARG . . . . . 0.663 ' NH1' ' HG1' ' A' ' 40' ' ' THR . 2.3 tmm_? -98.86 125.93 44.39 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.612 -179.834 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . 0.419 ' O ' ' CG1' ' A' ' 39' ' ' ILE . 2.8 pt -98.45 121.07 48.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.1 -0.5 . . . . 0.0 109.834 179.777 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 40' ' ' THR . . . . . 0.663 ' HG1' ' NH1' ' A' ' 38' ' ' ARG . 20.7 m -101.29 136.2 41.53 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.288 -179.175 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.2 p -134.22 142.76 40.06 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.338 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.249 179.965 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . 0.485 ' O ' ' N ' ' A' ' 74' ' ' ASP . 37.7 t -131.73 130.54 61.98 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.145 0 N-CA-C 109.984 -0.376 . . . . 0.0 109.984 179.46 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -97.49 133.63 41.81 Favored 'General case' 0 C--N 1.327 -0.379 0 N-CA-C 109.434 -0.58 . . . . 0.0 109.434 179.216 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . 0.409 ' CB ' ' O ' ' A' ' 72' ' ' ASP . . . -94.57 -21.21 18.99 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.769 0.318 . . . . 0.0 110.738 179.912 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -91.4 18.07 53.55 Favored Glycine 0 CA--C 1.523 0.588 0 N-CA-C 110.912 -0.875 . . . . 0.0 110.912 -179.682 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 33.2 mm-40 -139.93 149.53 43.44 Favored 'General case' 0 C--N 1.333 -0.136 0 CA-C-O 121.106 0.479 . . . . 0.0 110.521 -179.559 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -69.5 -18.94 74.12 Favored Glycine 0 N--CA 1.453 -0.194 0 N-CA-C 110.518 -1.033 . . . . 0.0 110.518 179.941 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -132.26 140.06 36.82 Favored Pre-proline 0 N--CA 1.468 0.446 0 C-N-CA 121.119 -0.232 . . . . 0.0 110.585 179.699 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 59.6 Cg_endo -73.22 159.39 47.32 Favored 'Trans proline' 0 N--CA 1.49 1.307 0 C-N-CA 122.431 2.087 . . . . 0.0 112.051 177.685 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 96.7 mt -75.49 153.41 6.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.193 179.484 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 80.5 m-85 -72.51 142.29 48.51 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.676 179.912 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . 0.422 ' N ' ' CD ' ' A' ' 52' ' ' GLU . 0.0 OUTLIER -65.77 -176.15 0.35 Allowed 'General case' 0 CA--C 1.514 -0.441 0 CA-C-N 115.739 -0.664 . . . . 0.0 110.405 179.441 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 53' ' ' ASP . . . . . 0.416 ' CG ' ' OH ' ' A' ' 62' ' ' TYR . 1.0 OUTLIER -145.59 138.66 26.14 Favored 'General case' 0 N--CA 1.452 -0.34 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.358 179.392 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 61.4 m-85 -110.0 116.42 31.56 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.397 179.898 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 10.5 p -128.18 140.82 48.15 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.348 0 CA-C-O 120.934 0.397 . . . . 0.0 110.118 179.949 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 83.9 m-20 -62.9 150.49 41.85 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.248 179.734 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 15.3 t -64.12 -33.8 76.6 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.663 -179.932 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 69.5 m -51.43 -37.69 49.83 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.382 -179.51 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.554 ' C ' ' H ' ' A' ' 61' ' ' TYR . 11.3 t -63.74 -42.97 97.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.362 179.68 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . 0.534 ' O ' ' CE2' ' A' ' 26' ' ' TRP . . . 70.44 -36.38 0.45 Allowed Glycine 0 CA--C 1.532 1.116 0 N-CA-C 111.037 -0.825 . . . . 0.0 111.037 179.653 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 61' ' ' TYR . . . . . 0.554 ' H ' ' C ' ' A' ' 59' ' ' VAL . 25.9 p90 -115.99 159.76 21.19 Favored 'General case' 0 N--CA 1.466 0.373 0 CA-C-O 121.146 0.498 . . . . 0.0 111.007 -179.084 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 62' ' ' TYR . . . . . 0.416 ' OH ' ' CG ' ' A' ' 53' ' ' ASP . 31.1 t80 -154.47 162.28 41.23 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.107 -0.497 . . . . 0.0 109.755 179.599 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 99.2 m -119.36 132.77 55.91 Favored 'General case' 0 N--CA 1.467 0.376 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.414 -179.781 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -133.06 107.57 11.75 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.311 0 CA-C-N 115.859 -0.61 . . . . 0.0 109.647 179.046 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 1.1 p -123.46 164.52 18.76 Favored 'General case' 0 CA--C 1.513 -0.443 0 CA-C-O 121.019 0.438 . . . . 0.0 110.34 -179.836 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 108.81 24.41 6.09 Favored Glycine 0 CA--C 1.524 0.598 0 CA-C-N 115.396 -0.82 . . . . 0.0 111.48 -179.773 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.7 ' H ' ' HG ' ' A' ' 20' ' ' SER . 11.8 mt -100.66 109.14 21.17 Favored 'General case' 0 CA--C 1.517 -0.322 0 N-CA-C 109.31 -0.626 . . . . 0.0 109.31 179.909 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 31.9 mm-40 -52.5 139.73 37.88 Favored Pre-proline 0 C--N 1.312 -1.023 0 C-N-CA 120.486 -0.485 . . . . 0.0 112.011 -178.214 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -73.08 155.47 52.39 Favored 'Trans proline' 0 N--CA 1.498 1.755 0 C-N-CA 122.857 2.371 . . . . 0.0 111.387 178.63 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 72.93 -5.96 15.48 Favored Glycine 0 CA--C 1.525 0.702 0 CA-C-N 115.637 -0.71 . . . . 0.0 111.927 179.269 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 1.7 mp -101.27 149.15 6.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 N-CA-C 109.346 -0.613 . . . . 0.0 109.346 -179.551 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 72' ' ' ASP . . . . . 0.409 ' O ' ' CB ' ' A' ' 44' ' ' ALA . 2.5 t70 -89.68 115.99 27.46 Favored 'General case' 0 C--N 1.32 -0.7 0 CA-C-N 114.979 -1.01 . . . . 0.0 110.269 179.686 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 73' ' ' TYR . . . . . . . . . . . . . 25.6 m-85 -109.81 119.55 39.69 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.453 179.899 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 74' ' ' ASP . . . . . 0.485 ' N ' ' O ' ' A' ' 42' ' ' VAL . 8.9 m-20 -89.94 116.79 28.26 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.702 -0.681 . . . . 0.0 109.426 179.887 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -113.98 165.4 9.02 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.293 0 CA-C-O 121.171 0.51 . . . . 0.0 109.995 -179.094 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 33.5 t -155.97 118.56 4.15 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.6 -0.727 . . . . 0.0 110.584 179.0 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 2.7 t -92.16 100.77 11.76 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 C-N-CA 120.479 -0.488 . . . . 0.0 109.73 179.498 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 96.3 mt -87.44 115.79 28.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.075 -179.99 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 70.3 m -100.44 118.8 37.41 Favored 'General case' 0 CA--C 1.517 -0.318 0 CA-C-N 116.211 -0.45 . . . . 0.0 109.938 179.725 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 2.1 tt -122.66 108.74 13.43 Favored 'General case' 0 N--CA 1.463 0.201 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.628 -179.892 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 2.1 pp -139.37 142.93 32.13 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 N-CA-C 109.974 -0.38 . . . . 0.0 109.974 178.936 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 82' ' ' ASN . . . . . 0.522 ' N ' ' OG1' ' A' ' 33' ' ' THR . 39.5 t-20 . . . . . 0 C--N 1.328 -0.333 0 C-N-CA 120.89 -0.324 . . . . 0.0 111.233 -179.894 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 207' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.467 0.712 0 N-CA-C 111.105 -0.798 . . . . 0.0 111.105 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' B' B ' 208' ' ' SER . . . . . 0.555 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 54.8 p -165.66 170.83 13.71 Favored 'General case' 0 N--CA 1.454 -0.248 0 CA-C-O 120.804 0.335 . . . . 0.0 110.719 179.287 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 209' ' ' TRP . . . . . . . . . . . . . 59.0 m95 -88.13 156.08 19.44 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.531 179.473 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 66.9 p -130.19 131.77 45.74 Favored 'General case' 0 N--CA 1.464 0.247 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.447 179.558 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 53.0 t-105 -95.81 110.41 22.58 Favored 'General case' 0 N--CA 1.464 0.269 0 CA-C-N 116.29 -0.413 . . . . 0.0 110.591 -179.988 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 212' ' ' GLU . . . . . 0.44 ' O ' ' O ' ' B' ' 215' ' ' LYS . 1.8 pt-20 -162.0 168.45 22.76 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.669 179.516 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 213' ' ' ASN . . . . . . . . . . . . . 14.8 m120 51.53 34.5 12.5 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.955 -0.566 . . . . 0.0 111.066 176.966 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 50.56 19.89 3.46 Favored Glycine 0 CA--C 1.526 0.745 0 N-CA-C 111.156 -0.777 . . . . 0.0 111.156 179.981 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 215' ' ' LYS . . . . . 0.44 ' O ' ' O ' ' B' ' 212' ' ' GLU . 80.1 mttt -146.21 150.81 36.54 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 120.933 0.397 . . . . 0.0 110.602 179.723 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 216' ' ' TRP . . . . . . . . . . . . . 53.5 m95 -87.39 117.38 26.12 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.055 179.789 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 217' ' ' THR . . . . . . . . . . . . . 17.1 m -128.5 136.91 51.44 Favored 'General case' 0 C--O 1.234 0.248 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.129 -179.798 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 218' ' ' TRP . . . . . 0.555 ' CH2' ' N ' ' B' ' 208' ' ' SER . 14.2 t-105 -100.34 112.98 25.36 Favored 'General case' 0 N--CA 1.463 0.199 0 CA-C-N 116.044 -0.526 . . . . 0.0 109.99 179.606 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 92.7 mttt -130.24 167.52 18.31 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.74 -179.912 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -178.29 -162.89 28.83 Favored Glycine 0 CA--C 1.524 0.605 0 N-CA-C 111.089 -0.804 . . . . 0.0 111.089 179.878 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 221' ' ' ILE . . . . . 0.412 ' O ' ' CG2' ' B' ' 222' ' ' ILE . 21.5 mt -56.0 -73.52 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 C-N-CA 120.422 -0.511 . . . . 0.0 110.307 -178.116 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 222' ' ' ILE . . . . . 0.539 ' O ' ' O ' ' B' ' 223' ' ' ARG . 22.6 pt -160.37 -165.2 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.086 179.797 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 223' ' ' ARG . . . . . 0.539 ' O ' ' O ' ' B' ' 222' ' ' ILE . 26.7 ptt180 -40.24 172.18 0.0 OUTLIER 'General case' 0 CA--C 1.52 -0.201 0 CA-C-O 121.278 0.561 . . . . 0.0 110.88 179.293 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 224' ' ' LEU . . . . . 0.528 ' CD2' ' N ' ' B' ' 224' ' ' LEU . 2.8 mm? -61.38 120.73 11.01 Favored 'General case' 0 C--N 1.316 -0.861 0 CA-C-O 121.428 0.632 . . . . 0.0 110.929 -178.924 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 83.1 tt0 . . . . . 0 N--CA 1.452 -0.35 0 CA-C-N 115.295 -0.866 . . . . 0.0 109.935 -179.988 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 56.0 p30 . . . . . 0 CA--C 1.52 -0.185 0 CA-C-O 121.054 0.454 . . . . 0.0 110.448 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . 0.485 ' CD2' ' CE1' ' A' ' 14' ' ' PHE . 6.9 tt -67.55 139.77 56.95 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.938 -0.573 . . . . 0.0 110.493 -179.637 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' SER . . . . . 0.434 ' O ' ' O ' ' A' ' 25' ' ' ARG . 83.1 p -138.95 154.16 48.28 Favored 'General case' 0 N--CA 1.463 0.208 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.589 179.35 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . 0.501 ' CD1' ' N ' ' A' ' 14' ' ' PHE . 15.9 m-85 -111.31 146.15 37.57 Favored 'General case' 0 N--CA 1.463 0.188 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.514 -179.645 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 19.0 m -144.7 163.93 13.42 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.511 179.902 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 99.4 m-20 54.64 33.29 18.94 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.023 -0.535 . . . . 0.0 111.062 179.647 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 1.6 mp -58.42 132.17 23.04 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.542 0 CA-C-O 121.222 0.534 . . . . 0.0 109.883 -179.759 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.457 ' CB ' ' O ' ' A' ' 21' ' ' SER . 0.2 OUTLIER -136.2 -166.26 1.85 Allowed 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.212 -0.904 . . . . 0.0 110.652 -179.872 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' ASP . . . . . 0.504 ' OD1' ' N ' ' A' ' 20' ' ' SER . 34.3 p-10 -91.87 -41.95 10.33 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.495 -0.775 . . . . 0.0 111.115 179.366 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' SER . . . . . 0.504 ' N ' ' OD1' ' A' ' 19' ' ' ASP . 25.9 t -118.51 6.85 11.74 Favored 'General case' 0 N--CA 1.467 0.378 0 CA-C-N 116.444 -0.344 . . . . 0.0 110.848 -179.431 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' SER . . . . . 0.457 ' O ' ' CB ' ' A' ' 18' ' ' THR . 48.0 m -151.57 147.92 27.37 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.437 179.961 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 35.8 pt -147.22 147.7 17.29 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 N-CA-C 109.897 -0.408 . . . . 0.0 109.897 179.558 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -101.83 83.43 0.48 Allowed Glycine 0 CA--C 1.524 0.603 0 N-CA-C 111.507 -0.637 . . . . 0.0 111.507 -179.647 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 84.6 mt -66.37 124.56 23.05 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 109.656 -0.498 . . . . 0.0 109.656 179.899 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . 0.434 ' O ' ' O ' ' A' ' 13' ' ' SER . 69.6 ttt180 -139.11 141.13 38.11 Favored 'General case' 0 N--CA 1.463 0.188 0 CA-C-O 120.948 0.404 . . . . 0.0 110.49 -179.714 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' TRP . . . . . . . . . . . . . 35.1 p90 -144.04 155.01 43.83 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.106 179.795 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 2.5 m -111.77 97.9 39.29 Favored Pre-proline 0 CA--C 1.534 0.336 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.507 179.82 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_exo -53.35 142.62 57.0 Favored 'Trans proline' 0 C--N 1.305 -1.728 0 C-N-CA 122.081 1.854 . . . . 0.0 112.478 179.472 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 59.9 mt -81.21 144.24 31.75 Favored 'General case' 0 CA--C 1.518 -0.274 0 CA-C-O 121.412 0.625 . . . . 0.0 110.91 179.877 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 21.0 t-20 -52.04 -36.9 51.73 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 115.392 -0.822 . . . . 0.0 109.799 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 38.5 m -78.28 -35.17 48.32 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.518 179.257 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 14.4 m -58.14 134.17 56.24 Favored 'General case' 0 N--CA 1.461 0.096 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.231 -179.872 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' THR . . . . . 0.548 ' HG1' ' N ' ' A' ' 82' ' ' ASN . 2.7 m -61.82 140.02 58.29 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.084 -179.718 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 6.0 mm -94.28 90.17 2.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 121.065 0.459 . . . . 0.0 110.693 -179.696 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 19.0 pt -139.19 138.11 41.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.549 179.742 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -42.23 135.81 3.56 Favored Glycine 0 CA--C 1.52 0.406 0 N-CA-C 111.004 -0.838 . . . . 0.0 111.004 -179.622 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 -103.2 174.62 5.79 Favored 'General case' 0 CA--C 1.517 -0.317 0 CA-C-O 120.898 0.38 . . . . 0.0 110.179 -179.846 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 38' ' ' ARG . . . . . 0.776 HH11 ' HG1' ' A' ' 40' ' ' THR . 2.3 tmm_? -134.92 126.25 28.31 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.592 179.961 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . 0.475 ' O ' ' CG1' ' A' ' 39' ' ' ILE . 1.8 pt -99.92 122.2 51.52 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.176 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.127 179.684 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 40' ' ' THR . . . . . 0.776 ' HG1' HH11 ' A' ' 38' ' ' ARG . 24.2 m -104.95 134.38 48.15 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.451 -179.846 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.1 p -133.14 140.65 46.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.351 179.839 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . 0.536 ' N ' ' O ' ' A' ' 74' ' ' ASP . 37.6 t -133.25 131.67 58.18 Favored 'Isoleucine or valine' 0 N--CA 1.458 -0.074 0 N-CA-C 110.158 -0.312 . . . . 0.0 110.158 179.714 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -96.5 138.86 33.45 Favored 'General case' 0 C--N 1.329 -0.304 0 N-CA-C 109.709 -0.478 . . . . 0.0 109.709 178.947 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . 0.408 ' CB ' ' O ' ' A' ' 72' ' ' ASP . . . -93.81 -41.17 9.79 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.487 -0.324 . . . . 0.0 110.835 179.617 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -65.35 -31.85 81.76 Favored Glycine 0 CA--C 1.525 0.689 0 N-CA-C 111.256 -0.738 . . . . 0.0 111.256 -179.763 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 42.3 mm-40 -97.46 133.44 42.05 Favored 'General case' 0 C--N 1.33 -0.24 0 N-CA-C 109.576 -0.528 . . . . 0.0 109.576 -179.483 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -60.32 -21.92 57.72 Favored Glycine 0 CA--C 1.511 -0.217 0 N-CA-C 111.021 -0.832 . . . . 0.0 111.021 -178.987 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . 0.415 HG23 HD13 ' A' ' 48' ' ' ILE . 0.3 OUTLIER -113.11 134.7 21.78 Favored Pre-proline 0 CA--C 1.536 0.407 0 C-N-CA 120.961 -0.295 . . . . 0.0 110.59 179.665 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 71.2 Cg_endo -77.24 163.51 30.21 Favored 'Trans proline' 0 C--N 1.308 -1.564 0 C-N-CA 122.592 2.194 . . . . 0.0 112.202 177.006 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 87.0 mt -83.03 138.26 19.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.044 179.062 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 93.7 m-85 -60.74 142.03 56.31 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.623 -179.829 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 5.6 pt-20 -82.96 151.49 25.87 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.166 179.92 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 53' ' ' ASP . . . . . 0.417 ' CG ' ' OH ' ' A' ' 62' ' ' TYR . 1.7 t70 -120.05 162.91 18.47 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.683 179.451 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 54' ' ' PHE . . . . . 0.59 ' CD1' ' N ' ' A' ' 54' ' ' PHE . 2.4 m-85 -124.02 130.79 53.16 Favored 'General case' 0 C--O 1.232 0.169 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.195 179.662 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 8.7 p -127.69 136.4 60.52 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.449 -179.914 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 97.6 m-20 -58.84 141.29 53.67 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.482 -179.847 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 39.9 t -58.77 -32.84 69.66 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.58 179.857 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 69.1 m -56.23 -35.54 67.46 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.622 -179.836 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 84.1 t -63.44 -46.33 95.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.523 179.982 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 60.86 26.24 65.03 Favored Glycine 0 CA--C 1.528 0.895 0 N-CA-C 110.745 -0.942 . . . . 0.0 110.745 179.863 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 61' ' ' TYR . . . . . 0.442 ' OH ' ' OG1' ' A' ' 63' ' ' THR . 42.6 t80 -167.93 150.58 5.68 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 121.206 0.527 . . . . 0.0 111.103 -179.621 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 62' ' ' TYR . . . . . 0.417 ' OH ' ' CG ' ' A' ' 53' ' ' ASP . 26.7 t80 -157.58 156.27 31.63 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.092 178.831 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 63' ' ' THR . . . . . 0.442 ' OG1' ' OH ' ' A' ' 61' ' ' TYR . 76.3 m -122.64 136.2 54.81 Favored 'General case' 0 N--CA 1.465 0.282 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.728 -179.938 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -130.75 124.9 57.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.026 179.195 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 3.3 p -131.46 155.06 48.02 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.656 179.791 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 109.99 40.63 1.39 Allowed Glycine 0 CA--C 1.524 0.622 0 CA-C-N 115.719 -0.673 . . . . 0.0 111.522 -179.708 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 14.3 mt -112.91 99.31 7.78 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-O 121.274 0.559 . . . . 0.0 109.661 179.47 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 10.6 mm-40 -47.14 135.27 8.88 Favored Pre-proline 0 C--N 1.316 -0.849 0 CA-C-N 115.486 -0.779 . . . . 0.0 111.45 -178.382 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo -75.5 149.89 35.32 Favored 'Trans proline' 0 N--CA 1.496 1.646 0 C-N-CA 122.764 2.309 . . . . 0.0 111.761 178.86 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 75.39 13.61 82.71 Favored Glycine 0 CA--C 1.524 0.648 0 N-CA-C 111.23 -0.748 . . . . 0.0 111.23 179.202 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 2.2 mp -121.0 149.71 23.93 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.354 0 CA-C-O 121.528 0.68 . . . . 0.0 109.629 -179.637 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 72' ' ' ASP . . . . . 0.408 ' O ' ' CB ' ' A' ' 44' ' ' ALA . 2.3 t70 -87.25 112.08 21.67 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 114.854 -1.066 . . . . 0.0 110.621 -179.76 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 73' ' ' TYR . . . . . 0.461 ' O ' ' CD1' ' A' ' 75' ' ' ILE . 11.8 m-85 -107.87 118.33 36.46 Favored 'General case' 0 C--O 1.216 -0.69 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.735 179.71 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 74' ' ' ASP . . . . . 0.536 ' O ' ' N ' ' A' ' 42' ' ' VAL . 76.6 m-20 -86.97 119.01 26.74 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.495 -0.775 . . . . 0.0 109.496 179.708 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . 0.461 ' CD1' ' O ' ' A' ' 73' ' ' TYR . 0.0 OUTLIER -116.02 164.43 12.37 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.344 0 CA-C-O 121.171 0.51 . . . . 0.0 110.155 -179.166 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 3.0 m -154.43 121.52 5.63 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 115.466 -0.788 . . . . 0.0 110.849 179.394 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 11.9 t -101.44 102.23 13.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 179.272 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 78' ' ' ILE . . . . . 0.401 HG21 HD13 ' A' ' 78' ' ' ILE . 94.5 mt -89.84 127.32 42.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.405 -0.361 . . . . 0.0 110.517 -179.684 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 99.7 m -109.41 111.68 23.36 Favored 'General case' 0 N--CA 1.465 0.319 0 CA-C-N 116.12 -0.491 . . . . 0.0 109.996 179.708 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 13.9 mt -117.93 122.11 42.42 Favored 'General case' 0 CA--C 1.517 -0.297 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.693 -179.968 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 2.1 pp -145.45 134.66 17.66 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.15 179.533 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 82' ' ' ASN . . . . . 0.548 ' N ' ' HG1' ' A' ' 33' ' ' THR . 24.1 t-20 . . . . . 0 C--N 1.323 -0.58 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.777 179.851 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 207' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.466 0.665 0 N-CA-C 111.204 -0.758 . . . . 0.0 111.204 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' B' B ' 208' ' ' SER . . . . . 0.493 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 94.7 p -165.76 172.79 11.37 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.861 0.362 . . . . 0.0 110.697 -179.718 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 209' ' ' TRP . . . . . . . . . . . . . 79.1 m95 -84.44 131.53 34.66 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.309 179.656 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 81.4 p -109.41 130.02 55.52 Favored 'General case' 0 N--CA 1.464 0.273 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.546 -179.95 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 52.9 t-105 -92.38 116.91 29.39 Favored 'General case' 0 C--O 1.233 0.204 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.232 179.832 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 212' ' ' GLU . . . . . 0.458 ' O ' ' O ' ' B' ' 215' ' ' LYS . 1.7 pt-20 -165.82 167.53 16.8 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.948 179.333 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 213' ' ' ASN . . . . . . . . . . . . . 96.7 m-20 50.4 36.46 13.21 Favored 'General case' 0 C--N 1.321 -0.641 0 C-N-CA 120.605 -0.438 . . . . 0.0 111.012 176.325 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 50.21 17.07 1.59 Allowed Glycine 0 CA--C 1.523 0.56 0 N-CA-C 111.476 -0.65 . . . . 0.0 111.476 179.853 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 215' ' ' LYS . . . . . 0.458 ' O ' ' O ' ' B' ' 212' ' ' GLU . 52.1 mtmt -144.99 151.13 38.1 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 121.055 0.455 . . . . 0.0 110.684 179.652 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 216' ' ' TRP . . . . . 0.48 ' CD1' ' N ' ' B' ' 216' ' ' TRP . 24.2 m95 -87.27 119.79 27.89 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.053 179.945 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 217' ' ' THR . . . . . . . . . . . . . 21.6 m -130.95 142.81 50.38 Favored 'General case' 0 N--CA 1.464 0.238 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.432 -179.707 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 218' ' ' TRP . . . . . 0.493 ' CH2' ' N ' ' B' ' 208' ' ' SER . 15.7 t-105 -105.57 119.57 39.45 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-N 115.854 -0.612 . . . . 0.0 109.856 179.407 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 51.3 mtmt -142.95 171.78 13.58 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.817 -179.766 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -176.84 -160.28 23.62 Favored Glycine 0 CA--C 1.522 0.497 0 N-CA-C 111.237 -0.745 . . . . 0.0 111.237 -179.544 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 221' ' ' ILE . . . . . 0.411 ' O ' ' CG2' ' B' ' 222' ' ' ILE . 10.1 mm -50.7 -73.53 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 C-N-CA 120.781 -0.368 . . . . 0.0 110.638 -178.237 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 222' ' ' ILE . . . . . 0.5 ' O ' ' O ' ' B' ' 223' ' ' ARG . 21.4 pt -158.8 -166.65 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.723 0 CA-C-N 115.707 -0.678 . . . . 0.0 110.949 -179.795 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 223' ' ' ARG . . . . . 0.5 ' O ' ' O ' ' B' ' 222' ' ' ILE . 21.2 ptt-85 -43.42 175.77 0.0 OUTLIER 'General case' 0 CA--C 1.521 -0.164 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.692 179.353 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 224' ' ' LEU . . . . . 0.573 ' CD2' ' N ' ' B' ' 224' ' ' LEU . 3.4 mm? -62.14 115.89 4.51 Favored 'General case' 0 C--N 1.317 -0.807 0 CA-C-N 115.989 -0.55 . . . . 0.0 110.789 -179.738 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 78.5 tt0 . . . . . 0 C--N 1.33 -0.272 0 CA-C-N 115.564 -0.744 . . . . 0.0 110.529 179.81 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 52.6 p30 . . . . . 0 N--CA 1.464 0.23 0 CA-C-O 120.948 0.404 . . . . 0.0 110.388 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 59.8 tp -65.31 145.98 55.51 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.024 -0.534 . . . . 0.0 110.397 -179.985 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' SER . . . . . 0.47 ' O ' ' O ' ' A' ' 25' ' ' ARG . 14.2 p -143.49 150.16 38.56 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-O 121.184 0.516 . . . . 0.0 110.614 179.299 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . 0.566 ' CD1' ' N ' ' A' ' 14' ' ' PHE . 9.4 m-85 -112.16 145.74 39.3 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.0 -0.545 . . . . 0.0 110.625 -179.714 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 19.1 m -142.07 159.47 20.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.353 179.417 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 94.5 m-20 56.9 31.42 19.69 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.69 -0.686 . . . . 0.0 110.94 -179.66 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 96.3 mt -55.6 131.83 18.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.93 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.426 ' OG1' ' O ' ' A' ' 21' ' ' SER . 0.2 OUTLIER -131.72 -169.52 2.21 Favored 'General case' 0 N--CA 1.468 0.463 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.47 -179.562 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' ASP . . . . . 0.477 ' N ' ' OD1' ' A' ' 19' ' ' ASP . 17.9 p-10 -77.19 -49.67 14.65 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.982 179.594 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' SER . . . . . 0.457 ' CB ' ' O ' ' A' ' 67' ' ' LEU . 70.7 m -121.43 14.62 11.17 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 116.622 -0.263 . . . . 0.0 110.661 -179.176 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' SER . . . . . 0.426 ' O ' ' OG1' ' A' ' 18' ' ' THR . 2.4 m -146.48 129.87 16.75 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.088 -179.525 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 44.6 pt -125.95 141.75 44.69 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.322 0 CA-C-N 116.078 -0.51 . . . . 0.0 109.715 179.681 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -99.41 82.39 0.56 Allowed Glycine 0 CA--C 1.522 0.531 0 N-CA-C 110.953 -0.859 . . . . 0.0 110.953 -179.537 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 76.5 mt -63.32 124.38 21.1 Favored 'General case' 0 C--N 1.328 -0.354 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 -179.834 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . 0.47 ' O ' ' O ' ' A' ' 13' ' ' SER . 67.9 ttp85 -140.66 140.01 34.9 Favored 'General case' 0 C--N 1.332 -0.155 0 CA-C-O 121.245 0.545 . . . . 0.0 110.736 -179.868 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' TRP . . . . . . . . . . . . . 22.0 p90 -144.49 157.99 43.97 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.108 -179.56 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 2.6 m -103.92 105.29 47.61 Favored Pre-proline 0 CA--C 1.536 0.438 0 CA-C-N 116.56 -0.291 . . . . 0.0 110.686 -179.903 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 31.6 Cg_exo -55.02 153.15 26.87 Favored 'Trans proline' 0 N--CA 1.493 1.484 0 C-N-CA 122.041 1.827 . . . . 0.0 112.972 178.802 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 74.5 mt -103.55 135.25 45.5 Favored 'General case' 0 CA--C 1.515 -0.372 0 CA-C-O 121.832 0.825 . . . . 0.0 110.597 -179.941 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 19.2 t-20 -44.18 -31.46 0.98 Allowed 'General case' 0 C--N 1.318 -0.764 0 CA-C-N 115.09 -0.959 . . . . 0.0 110.436 -179.844 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 66.2 m -86.93 -35.9 18.65 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.395 179.151 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 3.4 m -47.66 114.34 0.88 Allowed 'General case' 0 CA--C 1.528 0.127 0 CA-C-O 121.167 0.508 . . . . 0.0 110.051 -179.819 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' THR . . . . . 0.708 ' HG1' ' N ' ' A' ' 82' ' ' ASN . 7.8 m -52.77 146.03 11.24 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.499 -0.773 . . . . 0.0 109.633 -179.483 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 27.6 mm -93.38 91.68 3.37 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.199 0 CA-C-O 121.167 0.508 . . . . 0.0 110.932 -178.45 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.53 ' O ' ' CE1' ' A' ' 37' ' ' TYR . 9.0 pt -145.8 128.17 9.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.232 179.645 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -47.84 135.93 14.88 Favored Glycine 0 CA--C 1.52 0.371 0 N-CA-C 110.805 -0.918 . . . . 0.0 110.805 -179.456 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 37' ' ' TYR . . . . . 0.53 ' CE1' ' O ' ' A' ' 35' ' ' ILE . 10.1 m-85 -100.97 179.86 4.26 Favored 'General case' 0 C--N 1.33 -0.241 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 -179.898 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 5.4 tmm_? -132.43 122.37 24.87 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.473 179.731 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . 0.469 ' O ' ' CG1' ' A' ' 39' ' ' ILE . 1.8 pt -97.84 118.17 43.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 115.924 -0.58 . . . . 0.0 109.89 179.633 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 20.9 m -98.3 134.16 41.71 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.216 -179.383 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.4 p -132.01 140.97 46.68 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.262 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.369 -179.999 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . 0.49 ' O ' ' N ' ' A' ' 74' ' ' ASP . 36.2 t -132.21 131.72 60.93 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.177 0 CA-C-O 120.979 0.419 . . . . 0.0 109.903 179.311 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -96.85 132.98 42.05 Favored 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 109.46 -0.571 . . . . 0.0 109.46 178.987 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -93.93 -14.68 25.71 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.766 0.317 . . . . 0.0 110.825 -179.843 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -99.86 18.88 55.27 Favored Glycine 0 CA--C 1.525 0.678 0 N-CA-C 111.025 -0.83 . . . . 0.0 111.025 -179.495 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 29.4 mm-40 -138.86 149.17 44.58 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 121.179 0.514 . . . . 0.0 110.368 -179.919 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -68.87 -17.3 71.31 Favored Glycine 0 CA--C 1.519 0.283 0 N-CA-C 110.552 -1.019 . . . . 0.0 110.552 179.864 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -135.31 139.03 30.35 Favored Pre-proline 0 CA--C 1.538 0.518 0 C-N-CA 121.192 -0.203 . . . . 0.0 110.683 179.842 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -73.31 158.65 48.21 Favored 'Trans proline' 0 N--CA 1.491 1.351 0 C-N-CA 122.565 2.176 . . . . 0.0 111.813 178.252 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . 0.42 HD13 HG21 ' A' ' 50' ' ' ILE . 96.4 mt -73.87 150.2 7.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.247 179.254 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 86.0 m-85 -70.04 137.19 51.07 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.715 179.94 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . 0.421 ' N ' ' CD ' ' A' ' 52' ' ' GLU . 0.0 OUTLIER -59.28 -175.65 0.03 OUTLIER 'General case' 0 CA--C 1.513 -0.446 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.449 179.212 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 53' ' ' ASP . . . . . 0.415 ' OD2' ' OH ' ' A' ' 62' ' ' TYR . 2.4 t0 -148.06 144.13 27.67 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.802 -0.636 . . . . 0.0 110.486 179.173 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 89.0 m-85 -116.74 122.93 45.9 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-N 116.363 -0.381 . . . . 0.0 110.572 179.812 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 9.5 p -132.06 142.7 42.18 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.425 0 CA-C-N 116.405 -0.361 . . . . 0.0 110.126 179.972 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 94.8 m-20 -61.13 151.87 30.03 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.377 179.952 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 11.3 t -62.72 -35.57 80.15 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.661 179.89 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 42.9 m -50.89 -37.21 42.3 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.162 -179.623 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.686 ' C ' ' H ' ' A' ' 61' ' ' TYR . 3.3 t -79.86 83.85 1.23 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.55 179.826 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -62.37 28.39 0.07 OUTLIER Glycine 0 CA--C 1.535 1.286 0 N-CA-C 111.103 -0.799 . . . . 0.0 111.103 179.672 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 61' ' ' TYR . . . . . 0.686 ' H ' ' C ' ' A' ' 59' ' ' VAL . 55.2 p90 -166.27 154.19 10.29 Favored 'General case' 0 N--CA 1.451 -0.389 0 CA-C-O 121.14 0.495 . . . . 0.0 111.879 -179.527 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 62' ' ' TYR . . . . . 0.415 ' OH ' ' OD2' ' A' ' 53' ' ' ASP . 23.6 t80 -154.74 148.91 25.94 Favored 'General case' 0 N--CA 1.454 -0.27 0 CA-C-N 115.727 -0.67 . . . . 0.0 109.731 178.794 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 50.1 m -110.69 132.97 53.74 Favored 'General case' 0 N--CA 1.463 0.224 0 CA-C-O 120.909 0.385 . . . . 0.0 110.325 -179.189 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -133.1 100.86 3.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 115.826 -0.625 . . . . 0.0 109.84 178.166 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 1.7 p -114.26 165.25 12.87 Favored 'General case' 0 CA--C 1.514 -0.441 0 CA-C-O 121.227 0.536 . . . . 0.0 110.445 179.882 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 108.67 24.33 6.16 Favored Glycine 0 CA--C 1.525 0.68 0 CA-C-N 115.444 -0.798 . . . . 0.0 111.295 -179.933 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.457 ' O ' ' CB ' ' A' ' 20' ' ' SER . 12.7 mt -98.69 106.55 18.83 Favored 'General case' 0 C--O 1.225 -0.22 0 N-CA-C 109.335 -0.617 . . . . 0.0 109.335 179.388 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 49.3 mm-40 -48.43 138.42 11.41 Favored Pre-proline 0 C--N 1.318 -0.792 0 CA-C-N 116.319 -0.4 . . . . 0.0 111.971 -178.323 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -73.36 154.04 50.81 Favored 'Trans proline' 0 N--CA 1.498 1.743 0 C-N-CA 122.749 2.299 . . . . 0.0 111.298 178.736 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 73.76 -6.0 20.95 Favored Glycine 0 CA--C 1.527 0.809 0 CA-C-N 115.839 -0.619 . . . . 0.0 111.647 179.209 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 1.8 mp -102.53 140.53 20.67 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.424 0 CA-C-O 121.326 0.584 . . . . 0.0 109.626 -179.847 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 1.9 t70 -81.42 118.7 22.9 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-N 114.995 -1.002 . . . . 0.0 109.922 179.434 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 73' ' ' TYR . . . . . . . . . . . . . 17.6 m-85 -110.85 119.68 39.9 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.828 -0.623 . . . . 0.0 110.44 179.949 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 74' ' ' ASP . . . . . 0.49 ' N ' ' O ' ' A' ' 42' ' ' VAL . 24.8 m-20 -89.43 117.42 28.34 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.613 -0.721 . . . . 0.0 109.574 179.579 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -114.64 166.23 8.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 121.041 0.448 . . . . 0.0 110.179 -179.339 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 1.1 p -155.11 122.64 5.65 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.589 -0.732 . . . . 0.0 110.559 179.243 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 20.6 t -96.7 127.35 48.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 N-CA-C 109.355 -0.609 . . . . 0.0 109.355 178.962 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 96.7 mt -117.19 120.02 63.69 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.416 0 CA-C-N 116.479 -0.328 . . . . 0.0 110.485 179.974 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 93.4 m -101.54 116.79 33.56 Favored 'General case' 0 C--N 1.331 -0.21 0 N-CA-C 109.715 -0.476 . . . . 0.0 109.715 179.265 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 16.9 tp -121.35 116.8 25.48 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.724 -179.931 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 2.2 pp -147.15 143.29 20.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.321 178.553 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 82' ' ' ASN . . . . . 0.708 ' N ' ' HG1' ' A' ' 33' ' ' THR . 27.2 t-20 . . . . . 0 C--N 1.329 -0.287 0 CA-C-O 120.83 0.348 . . . . 0.0 111.05 -179.818 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 207' ' ' GLY . . . . . 0.417 ' C ' ' CH2' ' B' ' 218' ' ' TRP . . . . . . . . 0 N--CA 1.466 0.654 0 N-CA-C 110.802 -0.919 . . . . 0.0 110.802 . . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 208' ' ' SER . . . . . 0.532 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 45.1 p -162.2 166.16 25.93 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.803 0.335 . . . . 0.0 110.643 179.068 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 209' ' ' TRP . . . . . . . . . . . . . 84.7 m95 -85.23 152.84 23.03 Favored 'General case' 0 C--N 1.332 -0.167 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.463 179.603 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 210' ' ' THR . . . . . 0.447 ' OG1' ' O ' ' B' ' 217' ' ' THR . 49.4 p -129.47 129.79 45.05 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-N 116.354 -0.385 . . . . 0.0 110.355 179.504 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 57.8 t-105 -92.54 110.17 21.58 Favored 'General case' 0 N--CA 1.462 0.17 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.761 179.657 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 212' ' ' GLU . . . . . 0.443 ' O ' ' O ' ' B' ' 215' ' ' LYS . 1.4 pt-20 -161.17 165.8 28.89 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.54 179.745 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 213' ' ' ASN . . . . . . . . . . . . . 15.9 m120 51.07 33.77 9.75 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.118 176.906 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 53.35 14.79 3.49 Favored Glycine 0 CA--C 1.527 0.814 0 N-CA-C 111.502 -0.639 . . . . 0.0 111.502 179.993 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 215' ' ' LYS . . . . . 0.443 ' O ' ' O ' ' B' ' 212' ' ' GLU . 9.7 mtmp? -140.91 149.33 41.75 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-O 121.047 0.451 . . . . 0.0 110.663 179.895 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 216' ' ' TRP . . . . . . . . . . . . . 48.3 m95 -84.73 114.73 22.26 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.079 -0.51 . . . . 0.0 109.932 179.757 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 217' ' ' THR . . . . . 0.447 ' O ' ' OG1' ' B' ' 210' ' ' THR . 18.3 m -119.25 133.03 55.97 Favored 'General case' 0 N--CA 1.464 0.263 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.279 -179.312 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 218' ' ' TRP . . . . . 0.532 ' CH2' ' N ' ' B' ' 208' ' ' SER . 19.6 t-105 -105.33 107.5 18.52 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.014 -0.539 . . . . 0.0 109.874 179.5 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 51.1 mtmt -132.82 176.2 8.68 Favored 'General case' 0 CA--C 1.514 -0.44 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.285 -179.48 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -178.87 -162.38 28.2 Favored Glycine 0 CA--C 1.525 0.685 0 N-CA-C 110.998 -0.841 . . . . 0.0 110.998 179.288 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 221' ' ' ILE . . . . . 0.418 ' O ' ' CG2' ' B' ' 222' ' ' ILE . 2.3 mp -55.84 -73.11 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 C-N-CA 120.817 -0.353 . . . . 0.0 110.466 -178.321 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 222' ' ' ILE . . . . . 0.489 ' O ' ' O ' ' B' ' 223' ' ' ARG . 23.0 pt -160.1 -165.27 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.167 -179.685 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 223' ' ' ARG . . . . . 0.489 ' O ' ' O ' ' B' ' 222' ' ' ILE . 39.1 ptt180 -41.12 171.54 0.0 OUTLIER 'General case' 0 C--N 1.334 -0.092 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.956 178.778 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 224' ' ' LEU . . . . . 0.623 ' H ' ' CD2' ' B' ' 224' ' ' LEU . 1.9 mm? -65.16 110.61 2.6 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-O 121.383 0.611 . . . . 0.0 110.941 -179.642 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 82.7 tt0 . . . . . 0 C--N 1.329 -0.307 0 CA-C-N 115.251 -0.886 . . . . 0.0 109.966 179.656 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.338 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 32.8 p -156.55 -157.25 0.69 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.743 0.306 . . . . 0.0 110.542 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 69.7 mm-40 -75.87 88.28 2.88 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.765 179.825 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.6 m -146.0 74.49 13.22 Favored Pre-proline 0 C--N 1.331 -0.2 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.417 179.696 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 62.8 Cg_endo -80.81 118.63 3.47 Favored 'Trans proline' 0 C--N 1.31 -1.459 0 C-N-CA 122.516 2.144 . . . . 0.0 112.079 179.803 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 89.2 mm-40 -87.95 -169.88 2.76 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.372 179.936 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 70.3 mt -75.68 127.15 32.44 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.236 -179.819 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 18.5 p -90.19 133.98 34.56 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.532 -179.908 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 97.6 m-20 -85.16 149.52 25.47 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.978 -0.556 . . . . 0.0 110.501 179.928 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 70.1 mt -62.0 151.3 35.55 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.192 -179.054 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 53.5 p -142.55 152.54 42.71 Favored 'General case' 0 CA--C 1.521 -0.152 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.311 -179.825 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . 0.51 ' CD1' ' N ' ' A' ' 14' ' ' PHE . 24.7 m-85 -112.16 143.54 43.05 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.972 -179.552 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 28.5 m -142.87 162.06 17.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.326 179.496 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 91.5 m-20 45.57 61.6 2.54 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.499 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 95.5 mt -85.61 135.54 24.72 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.611 179.316 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -132.37 -168.78 2.11 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.394 179.505 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . 0.448 ' N ' ' OD1' ' A' ' 19' ' ' ASP . 28.7 p-10 -90.58 -42.38 10.83 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.748 179.312 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' SER . . . . . 0.431 ' N ' ' OD1' ' A' ' 19' ' ' ASP . 28.4 t -112.69 7.16 18.56 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.848 -179.886 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 30.7 p -154.05 153.36 31.78 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.312 179.947 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 44.0 pt -147.65 149.16 15.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.344 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -99.52 80.56 0.52 Allowed Glycine 0 CA--C 1.526 0.744 0 N-CA-C 111.3 -0.72 . . . . 0.0 111.3 -179.898 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 62.1 mt -68.35 127.83 34.39 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.891 0.377 . . . . 0.0 110.041 -179.919 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 55.9 ttp180 -142.63 136.05 28.74 Favored 'General case' 0 CA--C 1.518 -0.252 0 CA-C-O 121.095 0.474 . . . . 0.0 110.493 -179.819 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' TRP . . . . . 0.55 ' CD2' ' O ' ' A' ' 60' ' ' GLY . 43.0 p90 -140.78 155.79 46.32 Favored 'General case' 0 CA--C 1.518 -0.284 0 CA-C-N 115.835 -0.621 . . . . 0.0 109.85 179.932 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 2.7 m -110.23 101.85 49.3 Favored Pre-proline 0 CA--C 1.534 0.358 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.839 -179.476 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_exo -56.34 150.59 49.29 Favored 'Trans proline' 0 C--N 1.308 -1.576 0 C-N-CA 122.078 1.852 . . . . 0.0 112.518 178.854 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 72.8 mt -87.3 134.9 33.5 Favored 'General case' 0 N--CA 1.465 0.281 0 CA-C-O 121.718 0.771 . . . . 0.0 110.671 -179.881 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 18.6 t-20 -47.13 -32.63 4.42 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-N 115.214 -0.903 . . . . 0.0 110.199 -179.923 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 75.8 m -82.38 -33.43 28.77 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.65 179.273 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 4.3 m -56.47 130.76 46.3 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-O 120.982 0.42 . . . . 0.0 110.221 -179.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' THR . . . . . 0.477 ' OG1' ' N ' ' A' ' 82' ' ' ASN . 6.6 m -54.37 139.53 36.52 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.586 -0.734 . . . . 0.0 109.776 -179.494 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 30.7 mm -93.57 88.97 2.54 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 CA-C-O 121.133 0.492 . . . . 0.0 110.608 -179.275 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 7.9 pt -139.65 149.18 22.64 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.184 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.408 179.588 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -48.68 136.88 17.77 Favored Glycine 0 CA--C 1.519 0.305 0 N-CA-C 110.918 -0.873 . . . . 0.0 110.918 -179.437 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 73.1 m-85 -104.6 160.44 14.95 Favored 'General case' 0 CA--C 1.517 -0.294 0 CA-C-O 120.826 0.346 . . . . 0.0 110.13 -179.818 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 5.3 tmm_? -124.32 124.5 42.52 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.791 -179.789 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . 0.434 ' O ' ' CG1' ' A' ' 39' ' ' ILE . 2.5 pt -99.12 124.77 52.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.075 -0.511 . . . . 0.0 109.936 179.749 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 16.6 m -106.33 135.4 47.89 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.493 -179.545 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.4 p -133.9 142.2 41.94 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.25 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.162 179.878 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . 0.527 ' O ' ' N ' ' A' ' 74' ' ' ASP . 38.3 t -132.55 131.87 60.05 Favored 'Isoleucine or valine' 0 C--N 1.34 0.167 0 N-CA-C 110.06 -0.348 . . . . 0.0 110.06 179.46 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -98.98 142.47 30.43 Favored 'General case' 0 C--N 1.327 -0.406 0 N-CA-C 109.366 -0.605 . . . . 0.0 109.366 179.158 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . 0.404 ' CB ' ' O ' ' A' ' 72' ' ' ASP . . . -101.06 -21.41 15.01 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.876 0.369 . . . . 0.0 110.959 179.412 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -94.07 30.6 7.41 Favored Glycine 0 N--CA 1.465 0.586 0 N-CA-C 110.958 -0.857 . . . . 0.0 110.958 -179.709 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 86.9 mt-10 -150.98 150.74 31.15 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-O 120.966 0.413 . . . . 0.0 110.626 -179.57 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -70.9 -16.46 74.65 Favored Glycine 0 CA--C 1.519 0.339 0 N-CA-C 110.567 -1.013 . . . . 0.0 110.567 179.879 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -137.63 139.32 26.64 Favored Pre-proline 0 CA--C 1.539 0.524 0 C-N-CA 121.058 -0.257 . . . . 0.0 110.401 179.632 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 63.3 Cg_endo -73.76 160.61 43.37 Favored 'Trans proline' 0 N--CA 1.49 1.291 0 C-N-CA 122.44 2.094 . . . . 0.0 112.326 177.833 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 96.7 mt -71.53 150.54 9.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.285 179.334 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 85.9 m-85 -73.1 140.86 47.44 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.728 179.938 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . 0.42 ' N ' ' CD ' ' A' ' 52' ' ' GLU . 0.3 OUTLIER -68.26 -177.21 0.84 Allowed 'General case' 0 CA--C 1.514 -0.408 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.653 179.575 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . 0.41 ' CG ' ' OH ' ' A' ' 62' ' ' TYR . 3.5 t70 -149.47 143.38 25.63 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.6 179.361 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 92.7 m-85 -111.33 122.82 48.85 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.366 179.854 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 5.3 p -129.41 139.13 52.54 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.292 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.293 -179.894 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 91.5 m-20 -55.29 158.12 3.29 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.483 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 38.5 t -66.25 -37.01 84.49 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.66 179.937 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 37.9 m -51.59 -33.4 32.55 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.311 -179.598 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.598 ' C ' ' H ' ' A' ' 61' ' ' TYR . 1.9 t -91.78 68.76 0.58 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.179 179.291 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . 0.55 ' O ' ' CD2' ' A' ' 26' ' ' TRP . . . -53.24 -2.64 0.1 Allowed Glycine 0 CA--C 1.528 0.873 0 N-CA-C 110.946 -0.862 . . . . 0.0 110.946 -179.983 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . 0.598 ' H ' ' C ' ' A' ' 59' ' ' VAL . 41.2 p90 -122.57 151.64 41.2 Favored 'General case' 0 N--CA 1.464 0.243 0 CA-C-O 121.103 0.478 . . . . 0.0 111.0 -179.6 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' TYR . . . . . 0.41 ' OH ' ' CG ' ' A' ' 53' ' ' ASP . 33.6 t80 -155.78 156.79 35.41 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.726 -0.67 . . . . 0.0 109.772 179.553 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 88.0 m -119.92 136.44 54.51 Favored 'General case' 0 N--CA 1.465 0.301 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.402 -179.569 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -131.9 110.95 17.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.018 -0.537 . . . . 0.0 109.863 178.956 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 2.0 p -122.26 164.15 18.38 Favored 'General case' 0 N--CA 1.464 0.256 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.617 -179.94 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 112.86 8.65 20.15 Favored Glycine 0 CA--C 1.529 0.943 0 CA-C-N 115.561 -0.745 . . . . 0.0 111.74 -179.12 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 10.5 mt -75.48 178.94 5.57 Favored 'General case' 0 C--N 1.325 -0.483 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 178.583 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 58.7 mm-40 -128.04 137.62 31.21 Favored Pre-proline 0 CA--C 1.54 0.584 0 C-N-CA 121.019 -0.272 . . . . 0.0 111.076 179.295 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -73.34 148.67 43.81 Favored 'Trans proline' 0 N--CA 1.496 1.619 0 C-N-CA 122.801 2.334 . . . . 0.0 111.83 179.193 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 75.51 3.83 73.03 Favored Glycine 0 CA--C 1.526 0.768 0 CA-C-N 115.619 -0.719 . . . . 0.0 111.411 179.226 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 2.0 mp -112.23 141.26 28.31 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.401 0 CA-C-O 121.495 0.664 . . . . 0.0 109.579 -179.618 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' ASP . . . . . 0.404 ' O ' ' CB ' ' A' ' 44' ' ' ALA . 1.9 t70 -82.06 111.52 18.28 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 115.137 -0.938 . . . . 0.0 110.633 179.854 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' TYR . . . . . 0.415 ' O ' ' CD1' ' A' ' 75' ' ' ILE . 14.7 m-85 -105.86 119.56 39.48 Favored 'General case' 0 C--O 1.219 -0.546 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.568 179.791 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' ASP . . . . . 0.527 ' N ' ' O ' ' A' ' 42' ' ' VAL . 5.5 m-20 -89.32 118.82 29.27 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.572 -0.74 . . . . 0.0 109.326 179.838 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . 0.415 ' CD1' ' O ' ' A' ' 73' ' ' TYR . 0.0 OUTLIER -115.45 163.81 12.38 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.404 0 CA-C-O 121.066 0.46 . . . . 0.0 110.163 -179.082 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 20.6 t -155.91 121.44 4.9 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.508 -0.769 . . . . 0.0 110.681 178.899 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 5.2 t -101.35 101.09 11.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 N-CA-C 109.901 -0.407 . . . . 0.0 109.901 179.341 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 96.8 mt -91.96 133.46 33.37 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.267 179.763 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' THR . . . . . 0.473 ' CG2' ' O ' ' B' ' 216' ' ' TRP . 0.0 OUTLIER -111.91 107.54 16.59 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 121.108 0.48 . . . . 0.0 109.755 179.551 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 38.3 tp -104.22 115.37 30.28 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.724 -0.671 . . . . 0.0 110.458 179.937 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 2.1 pp -145.95 146.26 19.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.068 -0.514 . . . . 0.0 110.275 179.33 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' ASN . . . . . 0.477 ' N ' ' OG1' ' A' ' 33' ' ' THR . 18.9 t-20 -69.32 -48.71 60.68 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.844 0.354 . . . . 0.0 111.256 -179.902 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 106.91 165.31 22.33 Favored Glycine 0 N--CA 1.465 0.618 0 N-CA-C 110.843 -0.903 . . . . 0.0 110.843 179.745 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -72.66 175.56 43.87 Favored Glycine 0 CA--C 1.525 0.676 0 N-CA-C 110.753 -0.939 . . . . 0.0 110.753 -179.97 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 48.0 mp0 -63.84 123.73 19.68 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.829 0.347 . . . . 0.0 110.419 -179.81 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 23.2 p -79.57 168.47 19.36 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.519 179.831 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . 72.74 58.41 0.36 Allowed Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.493 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -71.22 -88.73 0.0 OUTLIER 'Trans proline' 0 C--N 1.306 -1.695 0 C-N-CA 122.587 2.191 . . . . 0.0 111.934 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -138.26 122.34 17.96 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.56 179.932 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 16.3 p -147.54 -176.58 5.3 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.492 179.828 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 45.4 tp -90.15 125.81 35.58 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.384 179.941 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -90.02 134.05 34.47 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.446 179.948 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 35.4 mt-30 -73.12 127.86 33.81 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.53 -179.931 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 50.8 tt0 -170.31 126.66 0.79 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.393 179.927 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 41.9 m . . . . . 0 C--O 1.22 -0.474 0 CA-C-O 118.057 -0.973 . . . . 0.0 110.486 179.953 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' B' B ' 201' ' ' SER . . . . . . . . . . . . . 48.1 p . . . . . 0 N--CA 1.491 1.597 0 N-CA-C 109.346 -0.613 . . . . 0.0 109.346 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' B' B ' 202' ' ' SER . . . . . . . . . . . . . 17.5 m -70.18 139.33 52.35 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.019 -179.988 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 203' ' ' SER . . . . . . . . . . . . . 1.4 p -105.95 151.13 39.95 Favored Pre-proline 0 CA--C 1.536 0.433 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.586 -179.726 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 204' ' ' PRO . . . . . . . . . . . . . 75.0 Cg_exo -45.33 -47.37 12.92 Favored 'Trans proline' 0 N--CA 1.492 1.421 0 C-N-CA 122.485 2.123 . . . . 0.0 112.116 179.381 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 205' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -151.23 148.68 14.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.398 179.823 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 206' ' ' GLN . . . . . . . . . . . . . 17.9 pt20 -144.91 144.78 31.26 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.871 0.367 . . . . 0.0 110.25 178.604 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 207' ' ' GLY . . . . . . . . . . . . . . . -104.95 -130.55 6.82 Favored Glycine 0 N--CA 1.467 0.736 0 N-CA-C 111.088 -0.805 . . . . 0.0 111.088 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 208' ' ' SER . . . . . 0.556 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 59.7 p -166.74 171.78 11.15 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.823 0.344 . . . . 0.0 110.825 179.795 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 209' ' ' TRP . . . . . . . . . . . . . 44.4 m95 -83.66 146.33 28.31 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.593 179.041 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 32.0 p -128.64 130.11 46.8 Favored 'General case' 0 N--CA 1.463 0.199 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.287 179.752 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 39.1 t-105 -95.37 117.72 30.83 Favored 'General case' 0 N--CA 1.463 0.221 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.376 179.834 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 212' ' ' GLU . . . . . 0.443 ' O ' ' O ' ' B' ' 215' ' ' LYS . 0.6 OUTLIER -163.81 164.57 23.55 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.708 179.13 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 213' ' ' ASN . . . . . . . . . . . . . 11.7 m120 52.62 39.92 29.12 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.616 176.302 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 49.64 21.68 3.52 Favored Glycine 0 CA--C 1.524 0.647 0 N-CA-C 111.084 -0.806 . . . . 0.0 111.084 179.605 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 215' ' ' LYS . . . . . 0.443 ' O ' ' O ' ' B' ' 212' ' ' GLU . 24.9 mtpt -148.02 152.73 37.93 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.063 0.459 . . . . 0.0 111.51 -179.694 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 216' ' ' TRP . . . . . 0.483 ' CD1' ' N ' ' B' ' 216' ' ' TRP . 24.4 m95 -92.17 119.08 31.47 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.959 -0.564 . . . . 0.0 109.729 179.165 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 217' ' ' THR . . . . . . . . . . . . . 12.4 m -132.72 145.02 50.68 Favored 'General case' 0 N--CA 1.465 0.32 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.469 -179.732 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 218' ' ' TRP . . . . . 0.556 ' CH2' ' N ' ' B' ' 208' ' ' SER . 14.5 t-105 -103.34 118.12 36.03 Favored 'General case' 0 N--CA 1.463 0.199 0 CA-C-N 116.008 -0.542 . . . . 0.0 109.922 179.563 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 95.7 mttt -141.15 165.74 26.7 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.952 -179.729 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -176.03 -161.02 24.47 Favored Glycine 0 CA--C 1.521 0.435 0 CA-C-N 115.492 -0.776 . . . . 0.0 111.421 -179.589 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 221' ' ' ILE . . . . . 0.417 ' O ' ' CG2' ' B' ' 222' ' ' ILE . 22.6 mt -52.75 -74.74 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 C-N-CA 120.598 -0.441 . . . . 0.0 110.295 -177.839 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 222' ' ' ILE . . . . . 0.527 ' O ' ' O ' ' B' ' 223' ' ' ARG . 22.1 pt -160.47 -166.72 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.389 -0.369 . . . . 0.0 110.064 179.776 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 223' ' ' ARG . . . . . 0.527 ' O ' ' O ' ' B' ' 222' ' ' ILE . 34.1 ptt85 -42.01 175.17 0.0 OUTLIER 'General case' 0 C--N 1.333 -0.129 0 CA-C-O 121.525 0.678 . . . . 0.0 110.532 178.842 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 224' ' ' LEU . . . . . 0.554 ' CD2' ' N ' ' B' ' 224' ' ' LEU . 3.1 mm? -60.55 122.68 15.27 Favored 'General case' 0 C--N 1.315 -0.905 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.954 -179.379 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 43.1 tt0 -85.22 140.51 30.83 Favored 'General case' 0 CA--C 1.517 -0.315 0 CA-C-N 115.623 -0.717 . . . . 0.0 110.343 179.678 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 226' ' ' GLN . . . . . . . . . . . . . 74.1 mt-30 . . . . . 0 C--O 1.22 -0.461 0 CA-C-O 117.926 -1.035 . . . . 0.0 111.071 -179.852 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.317 0 N-CA-C 109.404 -1.479 . . . . 0.0 109.404 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 37.9 t -63.22 138.89 58.69 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.804 0.335 . . . . 0.0 110.204 179.861 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -108.67 117.38 34.03 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-N 116.163 -0.472 . . . . 0.0 109.966 179.729 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 5.5 m -90.29 153.34 46.44 Favored Pre-proline 0 CA--C 1.536 0.438 0 CA-C-N 116.561 -0.291 . . . . 0.0 110.566 -179.468 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_exo -52.59 146.8 32.7 Favored 'Trans proline' 0 N--CA 1.498 1.757 0 C-N-CA 121.851 1.701 . . . . 0.0 112.232 179.128 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . 0.543 ' CD ' ' H ' ' A' ' 8' ' ' GLN . 0.1 OUTLIER -65.44 -84.79 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.778 -0.646 . . . . 0.0 110.198 179.872 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 74.8 mt -99.31 127.25 45.29 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.914 -0.585 . . . . 0.0 110.233 -179.95 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 14.9 t -84.56 177.68 7.99 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.341 -179.915 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . 0.537 ' OD1' ' N ' ' A' ' 12' ' ' LEU . 55.9 t0 -132.32 153.07 51.08 Favored 'General case' 0 N--CA 1.465 0.277 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.241 179.97 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . 0.537 ' N ' ' OD1' ' A' ' 11' ' ' ASP . 6.0 tp -65.3 142.8 58.13 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.49 -179.963 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' SER . . . . . 0.456 ' O ' ' O ' ' A' ' 25' ' ' ARG . 93.5 p -141.99 152.53 43.52 Favored 'General case' 0 N--CA 1.463 0.214 0 CA-C-O 121.076 0.465 . . . . 0.0 110.544 179.325 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . 0.522 ' CD1' ' N ' ' A' ' 14' ' ' PHE . 24.3 m-85 -111.46 146.25 37.57 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.511 -179.251 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 31.9 m -147.06 153.86 12.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-O 120.818 0.342 . . . . 0.0 110.395 179.285 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 32.6 t70 58.89 56.87 3.85 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.426 179.854 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 94.0 mt -83.51 133.31 29.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 115.914 -0.585 . . . . 0.0 110.393 179.667 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.439 ' OG1' ' O ' ' A' ' 21' ' ' SER . 0.2 OUTLIER -131.17 -167.73 1.89 Allowed 'General case' 0 N--CA 1.471 0.606 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.206 -179.74 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . 0.474 ' N ' ' OD1' ' A' ' 19' ' ' ASP . 0.4 OUTLIER -75.89 -53.24 8.74 Favored 'General case' 0 CA--C 1.517 -0.307 0 CA-C-O 120.993 0.425 . . . . 0.0 110.876 179.21 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' SER . . . . . 0.427 ' CB ' ' O ' ' A' ' 67' ' ' LEU . 33.4 p -121.13 14.31 11.37 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.968 -177.796 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' SER . . . . . 0.439 ' O ' ' OG1' ' A' ' 18' ' ' THR . 95.5 p -144.96 125.05 13.61 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.116 0.484 . . . . 0.0 110.112 179.953 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 47.1 pt -127.39 140.67 48.46 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.323 0 CA-C-N 115.912 -0.586 . . . . 0.0 109.492 -179.823 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -103.69 91.57 0.83 Allowed Glycine 0 N--CA 1.467 0.704 0 N-CA-C 111.436 -0.665 . . . . 0.0 111.436 -179.397 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . 0.465 ' CD2' ' N ' ' A' ' 24' ' ' LEU . 4.0 mm? -61.51 138.53 58.28 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.793 0.33 . . . . 0.0 110.234 -179.812 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . 0.456 ' O ' ' O ' ' A' ' 13' ' ' SER . 13.9 tpt180 -145.38 134.89 23.22 Favored 'General case' 0 C--N 1.334 -0.091 0 CA-C-O 121.455 0.645 . . . . 0.0 110.288 179.873 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' TRP . . . . . 0.511 ' CE2' ' O ' ' A' ' 60' ' ' GLY . 18.7 p90 -145.81 156.3 43.49 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.47 -0.786 . . . . 0.0 109.519 179.21 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 2.7 m -105.5 104.4 47.9 Favored Pre-proline 0 CA--C 1.534 0.344 0 CA-C-O 119.546 -0.264 . . . . 0.0 111.161 -179.153 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_exo -54.48 153.2 23.83 Favored 'Trans proline' 0 C--N 1.31 -1.483 0 C-N-CA 121.381 1.388 . . . . 0.0 113.011 178.523 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.464 ' O ' ' N ' ' A' ' 32' ' ' SER . 75.2 mt -102.57 134.86 45.22 Favored 'General case' 0 N--CA 1.467 0.392 0 CA-C-N 114.946 -1.024 . . . . 0.0 111.04 179.854 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 18.3 t-20 -45.39 -31.1 1.52 Allowed 'General case' 0 C--N 1.314 -0.964 0 CA-C-N 114.86 -1.063 . . . . 0.0 110.263 179.883 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 50.8 m -87.79 -28.85 21.42 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.292 178.998 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' SER . . . . . 0.464 ' N ' ' O ' ' A' ' 29' ' ' LEU . 3.4 m -56.23 117.56 3.89 Favored 'General case' 0 CA--C 1.529 0.162 0 CA-C-O 121.318 0.58 . . . . 0.0 110.145 179.935 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' THR . . . . . 0.594 ' CB ' ' H ' ' A' ' 82' ' ' ASN . 12.2 m -51.83 145.55 9.51 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-N 114.919 -1.037 . . . . 0.0 109.182 -179.126 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 30.1 mm -92.08 93.42 4.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.998 0.428 . . . . 0.0 110.825 -178.113 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.44 ' O ' ' OG ' ' A' ' 57' ' ' SER . 8.1 pt -150.97 128.84 2.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 115.871 -0.604 . . . . 0.0 109.875 179.027 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -47.01 130.38 12.75 Favored Glycine 0 CA--C 1.521 0.413 0 N-CA-C 111.4 -0.68 . . . . 0.0 111.4 -178.941 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 95.2 m-85 -87.36 179.64 6.56 Favored 'General case' 0 C--N 1.33 -0.279 0 N-CA-C 109.976 -0.379 . . . . 0.0 109.976 179.551 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . 0.714 HH21 ' H ' ' A' ' 40' ' ' THR . 0.0 OUTLIER -131.59 123.08 27.17 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.93 179.885 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . 0.49 ' O ' ' CG1' ' A' ' 39' ' ' ILE . 1.7 pt -107.08 118.0 53.99 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.532 0 CA-C-O 121.203 0.525 . . . . 0.0 110.103 179.546 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' THR . . . . . 0.714 ' H ' HH21 ' A' ' 38' ' ' ARG . 52.9 m -103.25 138.94 39.36 Favored 'General case' 0 N--CA 1.47 0.537 0 O-C-N 122.037 -0.415 . . . . 0.0 110.127 -179.39 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.4 p -129.1 141.13 47.4 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.476 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.351 -179.873 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . 0.495 ' O ' ' N ' ' A' ' 74' ' ' ASP . 37.4 t -131.9 132.73 61.53 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.166 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.203 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -96.66 132.91 41.83 Favored 'General case' 0 C--N 1.327 -0.401 0 N-CA-C 109.468 -0.567 . . . . 0.0 109.468 179.173 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -91.65 -19.16 22.97 Favored 'General case' 0 C--N 1.328 -0.333 0 C-N-CA 120.748 -0.381 . . . . 0.0 110.681 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -99.07 25.04 29.82 Favored Glycine 0 N--CA 1.466 0.67 0 N-CA-C 111.208 -0.757 . . . . 0.0 111.208 -179.729 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -138.96 146.95 41.6 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 120.853 0.358 . . . . 0.0 110.587 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -66.99 -21.18 71.4 Favored Glycine 0 CA--C 1.526 0.728 0 N-CA-C 111.126 -0.79 . . . . 0.0 111.126 179.811 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -138.16 140.59 29.26 Favored Pre-proline 0 CA--C 1.545 0.784 0 O-C-N 122.66 -0.318 . . . . 0.0 110.553 -179.977 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -74.11 163.79 35.86 Favored 'Trans proline' 0 N--CA 1.495 1.589 0 C-N-CA 122.656 2.238 . . . . 0.0 112.051 178.478 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . 0.451 ' CG2' ' N ' ' A' ' 51' ' ' PHE . 5.1 mp -86.66 159.99 3.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 115.693 -0.685 . . . . 0.0 111.103 -179.733 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' PHE . . . . . 0.451 ' N ' ' CG2' ' A' ' 50' ' ' ILE . 88.8 m-85 -73.13 142.77 47.47 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.782 -0.645 . . . . 0.0 111.091 -179.802 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -64.32 -175.25 0.15 Allowed 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 115.492 -0.776 . . . . 0.0 110.412 179.007 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -142.74 134.26 26.45 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.123 179.891 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 96.0 m-85 -111.01 119.98 40.84 Favored 'General case' 0 N--CA 1.465 0.322 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.675 -179.809 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 9.8 p -130.42 142.28 44.13 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.414 0 CA-C-O 120.557 0.218 . . . . 0.0 110.592 -179.906 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 99.4 m-20 -63.4 149.35 46.13 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.384 179.925 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' SER . . . . . 0.44 ' OG ' ' O ' ' A' ' 35' ' ' ILE . 13.8 m -63.24 -32.49 73.91 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.72 0.295 . . . . 0.0 110.984 179.757 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 70.9 m -54.36 -40.45 68.12 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.352 -0.386 . . . . 0.0 110.581 -179.538 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.597 ' C ' ' H ' ' A' ' 61' ' ' TYR . 35.1 t -61.29 -44.08 97.77 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 -179.638 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . 0.511 ' O ' ' CE2' ' A' ' 26' ' ' TRP . . . 68.96 -29.78 0.3 Allowed Glycine 0 CA--C 1.529 0.945 0 N-CA-C 111.346 -0.702 . . . . 0.0 111.346 179.846 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . 0.597 ' H ' ' C ' ' A' ' 59' ' ' VAL . 44.9 t80 -112.6 155.48 24.32 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-O 121.225 0.536 . . . . 0.0 111.163 -179.15 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' TYR . . . . . 0.474 ' CD2' ' CD1' ' A' ' 39' ' ' ILE . 24.2 t80 -155.68 159.37 39.49 Favored 'General case' 0 N--CA 1.454 -0.227 0 CA-C-N 115.539 -0.755 . . . . 0.0 109.694 178.617 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 90.9 m -127.7 135.47 50.22 Favored 'General case' 0 N--CA 1.465 0.307 0 CA-C-O 120.834 0.349 . . . . 0.0 110.34 -179.924 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -131.46 107.01 12.8 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 N-CA-C 109.172 -0.677 . . . . 0.0 109.172 178.489 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 2.3 p -120.89 162.88 19.09 Favored 'General case' 0 CA--C 1.514 -0.428 0 CA-C-O 120.911 0.386 . . . . 0.0 110.469 -179.707 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 106.62 24.67 6.6 Favored Glycine 0 CA--C 1.52 0.365 0 N-CA-C 110.889 -0.884 . . . . 0.0 110.889 179.873 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.427 ' O ' ' CB ' ' A' ' 20' ' ' SER . 6.9 mt -97.64 107.58 20.1 Favored 'General case' 0 CA--C 1.53 0.175 0 N-CA-C 109.405 -0.591 . . . . 0.0 109.405 179.897 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 66.8 mm-40 -46.36 135.53 7.29 Favored Pre-proline 0 C--N 1.319 -0.753 0 N-CA-C 112.019 0.377 . . . . 0.0 112.019 -178.44 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 95.1 Cg_endo -74.28 156.25 46.3 Favored 'Trans proline' 0 N--CA 1.498 1.789 0 C-N-CA 122.718 2.278 . . . . 0.0 111.219 178.753 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 72.56 -7.39 8.87 Favored Glycine 0 CA--C 1.528 0.864 0 C-N-CA 121.08 -0.581 . . . . 0.0 111.792 179.145 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 1.7 mp -103.74 143.32 15.82 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.366 0 CA-C-O 121.236 0.541 . . . . 0.0 109.702 -179.739 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 1.7 t0 -82.02 118.7 23.2 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.152 -0.931 . . . . 0.0 110.651 179.891 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' TYR . . . . . . . . . . . . . 13.8 m-85 -109.74 120.59 42.96 Favored 'General case' 0 C--O 1.221 -0.4 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.899 -179.784 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' ASP . . . . . 0.495 ' N ' ' O ' ' A' ' 42' ' ' VAL . 69.6 m-20 -89.55 116.63 27.85 Favored 'General case' 0 C--N 1.318 -0.783 0 CA-C-N 115.565 -0.743 . . . . 0.0 109.862 179.357 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -116.1 165.58 11.23 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.383 0 CA-C-O 121.098 0.475 . . . . 0.0 110.262 -179.658 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 11.1 p -153.18 148.85 27.39 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.559 -0.746 . . . . 0.0 110.274 179.08 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 53.5 t -129.33 135.61 61.33 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 N-CA-C 109.26 -0.644 . . . . 0.0 109.26 179.3 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 93.9 mt -127.49 128.11 69.49 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.314 0 CA-C-O 120.854 0.359 . . . . 0.0 110.849 179.315 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 97.1 m -100.93 109.6 21.56 Favored 'General case' 0 C--N 1.331 -0.219 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 179.037 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 37.0 tp -117.95 118.97 33.43 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.638 -179.792 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 2.2 pp -137.41 161.61 34.13 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.166 0 CA-C-N 115.957 -0.565 . . . . 0.0 109.786 178.801 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' ASN . . . . . 0.594 ' H ' ' CB ' ' A' ' 33' ' ' THR . 16.2 t-20 -64.9 -43.36 93.1 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.772 0.32 . . . . 0.0 110.899 -179.928 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 151.71 123.41 1.05 Allowed Glycine 0 CA--C 1.525 0.666 0 N-CA-C 110.97 -0.852 . . . . 0.0 110.97 179.755 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -96.45 -179.45 35.19 Favored Glycine 0 CA--C 1.525 0.695 0 N-CA-C 110.814 -0.914 . . . . 0.0 110.814 179.806 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -71.35 153.82 42.05 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.884 0.373 . . . . 0.0 110.322 179.848 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 19.7 m -61.55 146.36 49.04 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.483 -179.973 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -167.32 74.17 1.01 Allowed Pre-proline 0 C--N 1.329 -0.285 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.423 -179.986 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 34.3 Cg_exo -59.51 145.51 97.78 Favored 'Trans proline' 0 C--N 1.306 -1.671 0 C-N-CA 122.675 2.25 . . . . 0.0 111.927 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 2.0 t -122.65 127.86 49.88 Favored 'General case' 0 N--CA 1.467 0.402 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.635 -179.881 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 17.5 p -87.51 175.34 7.99 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.549 179.88 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . 0.464 ' CD1' ' N ' ' A' ' 91' ' ' LEU . 9.6 mp -56.32 174.11 0.15 Allowed 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.0 -0.545 . . . . 0.0 110.205 179.793 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -42.2 141.89 0.85 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.868 -0.606 . . . . 0.0 110.786 -179.87 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 18.4 pt20 -65.31 151.53 46.01 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.7 -179.957 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 58.5 tt0 53.01 80.62 0.1 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.488 -179.973 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 70.2 p . . . . . 0 C--O 1.221 -0.42 0 CA-C-O 117.942 -1.027 . . . . 0.0 110.532 -179.997 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' B' B ' 201' ' ' SER . . . . . . . . . . . . . 74.7 m . . . . . 0 N--CA 1.49 1.565 0 N-CA-C 109.405 -0.591 . . . . 0.0 109.405 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' B' B ' 202' ' ' SER . . . . . . . . . . . . . 30.7 t -66.68 141.68 57.69 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.193 179.527 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 203' ' ' SER . . . . . . . . . . . . . 60.5 p -126.05 108.89 24.66 Favored Pre-proline 0 CA--C 1.537 0.48 0 N-CA-C 109.878 -0.415 . . . . 0.0 109.878 179.728 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 204' ' ' PRO . . . . . . . . . . . . . 66.6 Cg_endo -76.22 -58.54 0.04 OUTLIER 'Trans proline' 0 N--CA 1.491 1.375 0 C-N-CA 121.384 1.39 . . . . 0.0 112.136 -179.472 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 205' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -150.28 146.36 16.65 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.168 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.133 -179.765 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 206' ' ' GLN . . . . . . . . . . . . . 50.6 mt-30 -137.17 137.46 39.19 Favored 'General case' 0 C--N 1.327 -0.403 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 178.828 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 207' ' ' GLY . . . . . . . . . . . . . . . -97.88 -141.45 12.24 Favored Glycine 0 N--CA 1.463 0.48 0 N-CA-C 111.098 -0.801 . . . . 0.0 111.098 -179.685 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 208' ' ' SER . . . . . 0.533 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 38.7 p -165.13 169.33 16.28 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.624 0.249 . . . . 0.0 110.778 179.591 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 209' ' ' TRP . . . . . . . . . . . . . 86.3 m95 -88.05 150.07 23.61 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.202 179.632 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 69.3 p -129.03 129.76 45.74 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-O 120.801 0.334 . . . . 0.0 110.481 179.522 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 52.0 t-105 -91.75 110.32 21.65 Favored 'General case' 0 N--CA 1.463 0.219 0 CA-C-N 116.477 -0.329 . . . . 0.0 110.272 179.609 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 212' ' ' GLU . . . . . 0.527 ' O ' ' O ' ' B' ' 215' ' ' LYS . 2.0 pt-20 -162.78 171.74 16.29 Favored 'General case' 0 C--O 1.22 -0.457 0 CA-C-O 120.977 0.418 . . . . 0.0 110.582 179.454 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 213' ' ' ASN . . . . . 0.511 ' C ' ' H ' ' B' ' 215' ' ' LYS . 13.8 m120 49.77 30.26 3.68 Favored 'General case' 0 C--N 1.317 -0.834 0 C-N-CA 120.237 -0.585 . . . . 0.0 111.721 176.788 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 66.48 -13.13 0.43 Allowed Glycine 0 CA--C 1.532 1.105 0 C-N-CA 121.087 -0.578 . . . . 0.0 111.973 179.229 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 215' ' ' LYS . . . . . 0.527 ' O ' ' O ' ' B' ' 212' ' ' GLU . 67.5 mttm -126.05 156.25 40.25 Favored 'General case' 0 N--CA 1.468 0.432 0 CA-C-O 121.143 0.497 . . . . 0.0 110.67 -179.445 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 216' ' ' TRP . . . . . 0.475 ' CD1' ' N ' ' B' ' 216' ' ' TRP . 32.4 m95 -86.53 125.12 33.54 Favored 'General case' 0 C--N 1.328 -0.348 0 C-N-CA 120.837 -0.345 . . . . 0.0 110.095 179.796 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 217' ' ' THR . . . . . . . . . . . . . 18.5 m -124.42 138.42 54.36 Favored 'General case' 0 N--CA 1.468 0.427 0 CA-C-O 120.893 0.378 . . . . 0.0 110.359 -179.45 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 218' ' ' TRP . . . . . 0.533 ' CH2' ' N ' ' B' ' 208' ' ' SER . 24.5 t-105 -105.7 106.7 17.32 Favored 'General case' 0 N--CA 1.462 0.148 0 CA-C-N 116.13 -0.486 . . . . 0.0 109.88 179.343 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 74.4 mttt -135.46 171.47 14.4 Favored 'General case' 0 N--CA 1.466 0.355 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.646 -179.331 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -177.86 -162.75 28.4 Favored Glycine 0 CA--C 1.526 0.765 0 N-CA-C 110.857 -0.897 . . . . 0.0 110.857 179.57 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 221' ' ' ILE . . . . . 0.409 ' O ' ' CG2' ' B' ' 222' ' ' ILE . 0.8 OUTLIER -53.6 -74.2 0.05 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.384 0 C-N-CA 120.98 -0.288 . . . . 0.0 111.082 -178.73 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' B' B ' 222' ' ' ILE . . . . . 0.482 ' O ' ' O ' ' B' ' 223' ' ' ARG . 20.6 pt -160.75 -165.79 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 116.276 -0.42 . . . . 0.0 109.895 -179.545 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 223' ' ' ARG . . . . . 0.482 ' O ' ' O ' ' B' ' 222' ' ' ILE . 0.7 OUTLIER -43.37 174.9 0.0 OUTLIER 'General case' 0 N--CA 1.452 -0.363 0 CA-C-O 121.52 0.676 . . . . 0.0 110.814 179.154 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' B' B ' 224' ' ' LEU . . . . . 0.557 ' H ' ' CD2' ' B' ' 224' ' ' LEU . 2.6 mm? -61.28 116.11 4.36 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-N 115.51 -0.768 . . . . 0.0 110.634 -179.78 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 80.8 tt0 -103.59 149.31 25.02 Favored 'General case' 0 N--CA 1.465 0.277 0 CA-C-N 115.407 -0.815 . . . . 0.0 110.315 -179.987 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 226' ' ' GLN . . . . . . . . . . . . . 88.8 mt-30 . . . . . 0 C--N 1.325 -0.471 0 CA-C-O 117.986 -1.007 . . . . 0.0 110.724 -179.822 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.324 0 N-CA-C 109.422 -1.471 . . . . 0.0 109.422 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 97.1 p -76.67 -118.72 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.312 0 N-CA-C 110.258 -0.275 . . . . 0.0 110.258 179.916 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -67.2 141.4 57.33 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.475 179.839 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 12.1 t -138.2 75.87 39.51 Favored Pre-proline 0 N--CA 1.465 0.302 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.203 179.979 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_exo -53.82 135.42 62.81 Favored 'Trans proline' 0 C--N 1.307 -1.628 0 C-N-CA 122.328 2.019 . . . . 0.0 111.537 179.958 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . 0.401 ' HG3' ' H ' ' A' ' 9' ' ' LEU . 1.9 pt20 -119.14 -88.93 0.61 Allowed 'General case' 0 N--CA 1.467 0.375 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.307 -179.709 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.401 ' H ' ' HG3' ' A' ' 8' ' ' GLN . 59.1 mt -87.6 115.41 25.02 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.413 -179.789 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 8.8 t -75.61 143.98 42.02 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.764 -179.916 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 98.0 m-20 -82.9 150.49 26.45 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.801 179.981 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 7.2 tt -75.84 154.07 36.4 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.273 179.754 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' SER . . . . . 0.433 ' O ' ' O ' ' A' ' 25' ' ' ARG . 17.7 p -140.26 151.39 45.09 Favored 'General case' 0 N--CA 1.462 0.156 0 CA-C-O 121.093 0.473 . . . . 0.0 110.226 178.862 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . 0.547 ' CD1' ' N ' ' A' ' 14' ' ' PHE . 18.0 m-85 -111.48 148.41 33.22 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.707 -0.679 . . . . 0.0 110.747 -179.194 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 25.3 m -148.25 155.57 9.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 120.966 0.412 . . . . 0.0 110.305 179.172 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 39.3 t0 62.72 29.9 16.8 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.6 -0.727 . . . . 0.0 110.891 -179.968 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 68.1 mt -56.68 131.97 20.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 179.716 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.433 ' OG1' ' O ' ' A' ' 21' ' ' SER . 0.2 OUTLIER -132.13 -168.78 2.1 Favored 'General case' 0 N--CA 1.47 0.538 0 CA-C-N 116.385 -0.37 . . . . 0.0 110.246 -179.551 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . 0.47 ' N ' ' OD1' ' A' ' 19' ' ' ASP . 22.4 p-10 -78.72 -48.47 14.86 Favored 'General case' 0 C--N 1.332 -0.169 0 C-N-CA 120.811 -0.356 . . . . 0.0 110.951 179.295 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' SER . . . . . 0.632 ' HG ' ' H ' ' A' ' 67' ' ' LEU . 27.8 t -120.73 12.78 11.45 Favored 'General case' 0 N--CA 1.462 0.165 0 CA-C-O 120.518 0.199 . . . . 0.0 110.734 -178.882 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' SER . . . . . 0.433 ' O ' ' OG1' ' A' ' 18' ' ' THR . 92.8 p -146.63 131.03 17.62 Favored 'General case' 0 N--CA 1.463 0.19 0 CA-C-O 120.83 0.348 . . . . 0.0 110.095 -179.9 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 47.5 pt -127.5 142.14 44.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.159 -0.473 . . . . 0.0 109.991 -179.687 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -100.53 83.01 0.52 Allowed Glycine 0 N--CA 1.465 0.596 0 N-CA-C 110.414 -1.074 . . . . 0.0 110.414 179.951 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 16.7 mt -69.42 125.31 26.31 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.895 0.379 . . . . 0.0 110.0 -179.719 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . 0.433 ' O ' ' O ' ' A' ' 13' ' ' SER . 66.8 ttt180 -140.01 142.7 36.25 Favored 'General case' 0 N--CA 1.464 0.233 0 CA-C-O 121.268 0.556 . . . . 0.0 110.915 179.998 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' TRP . . . . . 0.528 ' CD2' ' O ' ' A' ' 60' ' ' GLY . 8.8 p90 -142.94 158.08 43.95 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.483 -0.78 . . . . 0.0 109.755 -179.61 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 4.1 m -103.06 103.92 37.06 Favored Pre-proline 0 CA--C 1.536 0.413 0 CA-C-O 119.592 -0.242 . . . . 0.0 111.058 -179.351 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 31.9 Cg_exo -55.17 153.7 25.76 Favored 'Trans proline' 0 C--N 1.312 -1.37 0 C-N-CA 121.616 1.544 . . . . 0.0 113.103 178.828 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.484 ' O ' ' N ' ' A' ' 32' ' ' SER . 75.1 mt -100.98 133.32 45.65 Favored 'General case' 0 N--CA 1.466 0.342 0 CA-C-N 115.047 -0.979 . . . . 0.0 110.966 179.658 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 26.4 t-20 -44.79 -30.57 0.99 Allowed 'General case' 0 C--N 1.315 -0.898 0 CA-C-N 114.695 -1.138 . . . . 0.0 110.258 179.772 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 64.3 m -89.16 -27.45 20.69 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 115.797 -0.638 . . . . 0.0 110.718 178.978 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' SER . . . . . 0.484 ' N ' ' O ' ' A' ' 29' ' ' LEU . 3.3 m -56.38 120.65 8.0 Favored 'General case' 0 N--CA 1.462 0.155 0 CA-C-O 121.575 0.703 . . . . 0.0 110.262 179.876 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' THR . . . . . 0.459 ' OG1' ' N ' ' A' ' 82' ' ' ASN . 6.4 m -52.9 147.27 9.38 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 114.866 -1.061 . . . . 0.0 109.725 -179.103 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 25.0 mm -93.18 93.35 4.11 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 116.4 -0.363 . . . . 0.0 110.888 -178.632 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.539 ' O ' ' CE1' ' A' ' 37' ' ' TYR . 9.0 pt -151.17 131.15 3.69 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.175 179.477 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -54.61 136.32 44.41 Favored Glycine 0 CA--C 1.524 0.609 0 N-CA-C 111.096 -0.802 . . . . 0.0 111.096 -179.252 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' TYR . . . . . 0.539 ' CE1' ' O ' ' A' ' 35' ' ' ILE . 5.0 m-85 -97.87 179.92 4.64 Favored 'General case' 0 C--N 1.332 -0.18 0 N-CA-C 109.683 -0.488 . . . . 0.0 109.683 179.679 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . 0.526 ' NH1' ' OE2' ' A' ' 52' ' ' GLU . 5.1 tmm_? -129.14 124.81 35.65 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.492 179.728 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . 0.47 ' CD1' ' CD2' ' A' ' 62' ' ' TYR . 1.8 pt -101.51 118.54 48.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 115.96 -0.564 . . . . 0.0 109.871 179.68 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 35.2 m -102.7 134.35 46.22 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.578 -179.032 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.6 p -130.89 143.53 40.61 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.522 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.424 -179.691 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . 0.526 ' O ' ' N ' ' A' ' 74' ' ' ASP . 43.0 t -134.4 135.06 54.46 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.261 0 CA-C-O 120.875 0.369 . . . . 0.0 110.369 179.834 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -97.34 133.27 42.17 Favored 'General case' 0 C--N 1.33 -0.256 0 N-CA-C 109.515 -0.55 . . . . 0.0 109.515 179.169 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . 0.417 ' CB ' ' O ' ' A' ' 72' ' ' ASP . . . -89.87 -40.74 12.23 Favored 'General case' 0 C--N 1.33 -0.246 0 C-N-CA 120.577 -0.449 . . . . 0.0 110.635 179.444 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -80.72 30.21 2.58 Favored Glycine 0 CA--C 1.524 0.602 0 N-CA-C 111.405 -0.678 . . . . 0.0 111.405 -179.817 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 80.0 mm-40 -140.42 146.76 38.72 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 121.079 0.466 . . . . 0.0 110.415 179.753 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -69.98 -20.37 76.17 Favored Glycine 0 CA--C 1.527 0.785 0 N-CA-C 111.133 -0.787 . . . . 0.0 111.133 179.711 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . 0.415 HD13 HG22 ' A' ' 48' ' ' ILE . 0.2 OUTLIER -135.6 142.46 41.08 Favored Pre-proline 0 CA--C 1.545 0.779 0 CA-C-N 116.735 0.268 . . . . 0.0 110.361 -179.482 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -72.14 164.86 34.35 Favored 'Trans proline' 0 N--CA 1.495 1.583 0 C-N-CA 122.457 2.105 . . . . 0.0 111.573 178.451 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . 0.671 ' CD1' ' H ' ' A' ' 50' ' ' ILE . 0.6 OUTLIER -86.65 159.72 3.11 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 116.022 -0.536 . . . . 0.0 110.619 -179.579 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 84.8 m-85 -75.02 141.32 43.92 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.752 179.893 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . 0.526 ' OE2' ' NH1' ' A' ' 38' ' ' ARG . 4.4 pt-20 -70.23 -175.88 1.07 Allowed 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.501 179.54 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -147.1 141.39 26.27 Favored 'General case' 0 CA--C 1.534 0.337 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.172 179.803 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 34.3 m-85 -113.56 119.56 37.93 Favored 'General case' 0 N--CA 1.469 0.481 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.452 -179.866 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 9.3 p -128.21 140.62 48.69 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.462 0 CA-C-O 120.966 0.412 . . . . 0.0 110.554 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 97.4 m-20 -65.04 153.77 39.76 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.556 179.964 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' SER . . . . . 0.425 ' OG ' ' OH ' ' A' ' 37' ' ' TYR . 4.0 t -64.22 -33.51 75.96 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.662 179.921 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 52.1 m -52.99 -40.59 63.88 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.638 -179.419 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.516 ' C ' ' H ' ' A' ' 61' ' ' TYR . 21.1 t -61.28 -43.55 96.74 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 N-CA-C 110.019 -0.363 . . . . 0.0 110.019 -179.582 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . 0.528 ' O ' ' CD2' ' A' ' 26' ' ' TRP . . . 72.5 -38.11 0.71 Allowed Glycine 0 CA--C 1.525 0.7 0 N-CA-C 111.359 -0.696 . . . . 0.0 111.359 179.389 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . 0.516 ' H ' ' C ' ' A' ' 59' ' ' VAL . 32.1 p90 -114.62 158.82 21.21 Favored 'General case' 0 N--CA 1.47 0.54 0 CA-C-O 121.016 0.436 . . . . 0.0 110.993 -179.026 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' TYR . . . . . 0.47 ' CD2' ' CD1' ' A' ' 39' ' ' ILE . 29.1 t80 -151.62 158.37 43.39 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 109.394 -0.595 . . . . 0.0 109.394 179.336 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 53.8 m -120.65 133.68 55.34 Favored 'General case' 0 N--CA 1.465 0.297 0 CA-C-O 120.831 0.348 . . . . 0.0 110.095 179.74 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -131.81 103.46 6.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 N-CA-C 109.373 -0.603 . . . . 0.0 109.373 178.845 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 3.4 p -116.36 162.48 17.46 Favored 'General case' 0 CA--C 1.512 -0.514 0 CA-C-O 121.077 0.465 . . . . 0.0 110.452 179.772 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 106.38 23.53 7.23 Favored Glycine 0 CA--C 1.521 0.424 0 N-CA-C 111.177 -0.769 . . . . 0.0 111.177 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.632 ' H ' ' HG ' ' A' ' 20' ' ' SER . 10.8 mt -97.43 109.91 22.57 Favored 'General case' 0 C--O 1.227 -0.115 0 N-CA-C 109.063 -0.717 . . . . 0.0 109.063 179.499 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . 0.439 ' H ' ' HH ' ' A' ' 73' ' ' TYR . 66.4 mm-40 -51.18 135.18 30.52 Favored Pre-proline 0 C--N 1.319 -0.745 0 C-N-CA 120.611 -0.435 . . . . 0.0 111.843 -178.039 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . 0.429 ' C ' ' H ' ' A' ' 71' ' ' ILE . 96.8 Cg_endo -74.08 157.46 46.6 Favored 'Trans proline' 0 N--CA 1.499 1.85 0 C-N-CA 122.878 2.385 . . . . 0.0 111.132 178.83 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 72.31 -8.74 6.44 Favored Glycine 0 CA--C 1.525 0.678 0 C-N-CA 120.879 -0.677 . . . . 0.0 111.594 179.306 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . 0.429 ' H ' ' C ' ' A' ' 69' ' ' PRO . 1.8 mp -103.88 140.67 21.37 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.373 0 CA-C-O 121.496 0.665 . . . . 0.0 109.642 -179.683 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' ASP . . . . . 0.417 ' O ' ' CB ' ' A' ' 44' ' ' ALA . 2.3 t0 -79.54 116.99 20.07 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 114.783 -1.098 . . . . 0.0 110.457 -179.524 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' TYR . . . . . 0.439 ' HH ' ' H ' ' A' ' 68' ' ' GLU . 11.5 m-85 -108.11 120.78 43.32 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.495 -179.771 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' ASP . . . . . 0.526 ' N ' ' O ' ' A' ' 42' ' ' VAL . 23.1 m-20 -88.51 114.63 25.33 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 115.275 -0.875 . . . . 0.0 109.831 -179.903 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -113.26 164.05 9.68 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.36 0 CA-C-O 121.217 0.532 . . . . 0.0 110.363 -179.747 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 2.6 p -152.42 124.63 8.13 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.183 -0.917 . . . . 0.0 109.918 179.539 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 70.7 t -106.14 131.45 55.73 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 N-CA-C 109.11 -0.7 . . . . 0.0 109.11 179.818 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 97.4 mt -128.17 131.25 69.47 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.317 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.898 -179.886 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 9.0 t -106.95 122.41 46.37 Favored 'General case' 0 N--CA 1.463 0.192 0 CA-C-N 115.76 -0.654 . . . . 0.0 109.529 179.122 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 42.4 mt -119.86 113.01 19.94 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.478 -179.312 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 2.2 pp -146.66 144.26 20.28 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.25 0 CA-C-O 120.725 0.298 . . . . 0.0 110.327 178.651 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' ASN . . . . . 0.459 ' N ' ' OG1' ' A' ' 33' ' ' THR . 42.3 t30 -66.77 -47.7 71.34 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.381 -0.372 . . . . 0.0 111.509 -179.683 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . 0.436 ' H ' ' HG1' ' A' ' 33' ' ' THR . . . 88.06 8.69 71.79 Favored Glycine 0 CA--C 1.525 0.71 0 N-CA-C 111.191 -0.764 . . . . 0.0 111.191 179.661 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -71.94 166.5 53.35 Favored Glycine 0 CA--C 1.527 0.793 0 N-CA-C 110.815 -0.914 . . . . 0.0 110.815 179.887 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 96.0 mt-10 -74.26 83.79 1.88 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.837 0.351 . . . . 0.0 110.485 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 18.7 m -83.85 153.74 23.86 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.529 179.874 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . 61.86 56.09 2.87 Favored Pre-proline 0 C--N 1.327 -0.383 0 CA-C-N 116.341 -0.391 . . . . 0.0 110.599 179.892 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo -66.8 149.8 83.4 Favored 'Trans proline' 0 C--N 1.307 -1.621 0 C-N-CA 122.647 2.231 . . . . 0.0 111.99 -179.847 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -69.79 133.25 47.23 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.466 179.989 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 53.2 p -137.61 162.9 32.55 Favored 'General case' 0 N--CA 1.464 0.248 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.401 -179.972 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . 0.414 ' CD1' ' N ' ' A' ' 91' ' ' LEU . 10.5 mp -81.56 124.97 29.97 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.05 -179.934 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -96.48 138.69 33.7 Favored 'General case' 0 N--CA 1.463 0.199 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.423 179.779 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 52.0 mt-30 -69.92 127.59 33.41 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.43 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 55.1 tt0 48.26 86.73 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.59 -179.853 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 2.7 t . . . . . 0 C--O 1.218 -0.562 0 CA-C-O 118.108 -0.949 . . . . 0.0 110.572 179.869 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' B' B ' 201' ' ' SER . . . . . . . . . . . . . 17.3 t . . . . . 0 N--CA 1.49 1.546 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' B' B ' 202' ' ' SER . . . . . . . . . . . . . 20.2 m -70.56 142.14 51.79 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.419 -0.355 . . . . 0.0 110.243 179.754 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 203' ' ' SER . . . . . 0.46 ' H ' ' HG ' ' B' ' 203' ' ' SER . 2.1 p -104.15 152.08 39.11 Favored Pre-proline 0 CA--C 1.539 0.52 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.356 -179.661 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 204' ' ' PRO . . . . . . . . . . . . . 76.5 Cg_exo -45.42 -45.85 15.05 Favored 'Trans proline' 0 N--CA 1.494 1.541 0 C-N-CA 121.998 1.799 . . . . 0.0 112.247 179.876 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 205' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -149.65 144.74 17.79 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.186 0 CA-C-N 116.434 -0.348 . . . . 0.0 110.449 179.954 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 206' ' ' GLN . . . . . 0.403 ' CG ' ' OG ' ' B' ' 203' ' ' SER . 33.4 mt-30 -137.96 139.06 39.52 Favored 'General case' 0 C--N 1.329 -0.296 0 N-CA-C 109.973 -0.38 . . . . 0.0 109.973 179.476 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 207' ' ' GLY . . . . . . . . . . . . . . . -102.39 -130.62 7.06 Favored Glycine 0 N--CA 1.466 0.645 0 N-CA-C 110.99 -0.844 . . . . 0.0 110.99 -179.864 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 208' ' ' SER . . . . . 0.567 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 46.4 p -166.16 170.38 13.41 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.975 0.417 . . . . 0.0 110.794 179.384 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 209' ' ' TRP . . . . . . . . . . . . . 76.4 m95 -90.77 154.87 19.21 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.385 179.505 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 61.5 p -129.75 129.85 44.65 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.43 179.471 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 51.5 t-105 -90.99 109.62 20.86 Favored 'General case' 0 N--CA 1.465 0.283 0 CA-C-N 116.352 -0.386 . . . . 0.0 110.314 179.696 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 212' ' ' GLU . . . . . 0.493 ' O ' ' O ' ' B' ' 215' ' ' LYS . 1.8 pt-20 -162.26 170.54 18.79 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.332 -0.394 . . . . 0.0 110.571 179.515 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 213' ' ' ASN . . . . . 0.536 ' C ' ' H ' ' B' ' 215' ' ' LYS . 93.9 m-20 49.68 30.09 3.48 Favored 'General case' 0 C--N 1.318 -0.793 0 C-N-CA 120.393 -0.523 . . . . 0.0 111.467 177.259 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 64.04 -10.25 0.26 Allowed Glycine 0 CA--C 1.529 0.944 0 C-N-CA 120.97 -0.634 . . . . 0.0 111.732 179.415 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 215' ' ' LYS . . . . . 0.536 ' H ' ' C ' ' B' ' 213' ' ' ASN . 27.1 mtpt -123.92 153.73 40.74 Favored 'General case' 0 N--CA 1.467 0.424 0 CA-C-O 121.056 0.455 . . . . 0.0 111.004 -179.411 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 216' ' ' TRP . . . . . 0.448 ' CD1' ' N ' ' B' ' 216' ' ' TRP . 39.5 m95 -86.62 120.84 28.37 Favored 'General case' 0 C--N 1.326 -0.415 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 179.599 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 217' ' ' THR . . . . . . . . . . . . . 22.7 m -123.89 136.81 54.59 Favored 'General case' 0 N--CA 1.467 0.415 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.27 -179.512 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 218' ' ' TRP . . . . . 0.567 ' CH2' ' N ' ' B' ' 208' ' ' SER . 18.6 t-105 -104.16 108.77 20.3 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.034 179.628 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 76.5 mttt -133.11 169.61 16.61 Favored 'General case' 0 CA--C 1.515 -0.37 0 CA-C-N 115.828 -0.624 . . . . 0.0 110.425 -179.791 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -178.1 -161.8 26.83 Favored Glycine 0 N--CA 1.446 -0.64 0 N-CA-C 110.688 -0.965 . . . . 0.0 110.688 179.612 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 221' ' ' ILE . . . . . 0.405 ' O ' ' CG2' ' B' ' 222' ' ' ILE . 24.8 mt -53.91 -72.84 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 C-N-CA 120.702 -0.399 . . . . 0.0 110.33 -178.431 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 222' ' ' ILE . . . . . 0.515 ' O ' ' O ' ' B' ' 223' ' ' ARG . 22.8 pt -160.3 -166.36 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.172 -0.467 . . . . 0.0 109.859 179.932 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 223' ' ' ARG . . . . . 0.515 ' O ' ' O ' ' B' ' 222' ' ' ILE . 23.5 ptt180 -40.87 174.16 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 121.57 0.7 . . . . 0.0 110.999 178.883 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 224' ' ' LEU . . . . . 0.527 ' CD2' ' N ' ' B' ' 224' ' ' LEU . 2.7 mm? -61.97 109.79 1.37 Allowed 'General case' 0 C--N 1.315 -0.901 0 CA-C-N 115.398 -0.819 . . . . 0.0 110.531 -179.839 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 43.4 tt0 -83.04 143.93 30.26 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.219 -0.9 . . . . 0.0 110.328 -179.939 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 226' ' ' GLN . . . . . . . . . . . . . 8.8 tp-100 . . . . . 0 N--CA 1.448 -0.571 0 CA-C-O 117.879 -1.057 . . . . 0.0 110.374 -179.876 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.28 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 30.9 p -154.99 162.96 40.94 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.808 0.337 . . . . 0.0 110.57 -179.889 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -73.85 145.29 45.01 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.465 179.95 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 21.6 t -145.37 75.38 13.71 Favored Pre-proline 0 C--N 1.331 -0.226 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.314 179.99 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 39.3 Cg_exo -59.97 144.9 99.42 Favored 'Trans proline' 0 C--N 1.307 -1.653 0 C-N-CA 122.879 2.386 . . . . 0.0 111.862 179.957 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 87.1 mt-30 -132.01 3.59 4.06 Favored 'General case' 0 N--CA 1.467 0.386 0 CA-C-O 121.088 0.47 . . . . 0.0 110.828 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.404 ' H ' HD12 ' A' ' 9' ' ' LEU . 0.3 OUTLIER -97.23 98.29 9.88 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.934 -0.576 . . . . 0.0 110.259 -179.853 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' THR . . . . . 0.451 ' CG2' ' N ' ' A' ' 11' ' ' ASP . 90.3 m -77.3 165.3 24.64 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.215 179.703 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . 0.451 ' N ' ' CG2' ' A' ' 10' ' ' THR . 45.5 t0 -121.68 155.46 35.13 Favored 'General case' 0 N--CA 1.465 0.289 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.579 -179.911 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 47.6 tp -63.51 140.3 58.86 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.968 -0.56 . . . . 0.0 109.986 -179.339 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 86.2 p -139.51 154.99 47.8 Favored 'General case' 0 C--O 1.234 0.238 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.456 179.823 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . 0.511 ' CD1' ' N ' ' A' ' 14' ' ' PHE . 18.4 m-85 -111.92 145.47 39.49 Favored 'General case' 0 N--CA 1.464 0.257 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.589 -179.76 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 26.7 m -146.04 161.36 11.09 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.401 179.707 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 97.1 m-20 52.56 30.81 9.03 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.796 179.683 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.422 ' C ' ' HG1' ' A' ' 18' ' ' THR . 84.1 mt -58.39 141.11 15.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 115.98 -0.554 . . . . 0.0 110.246 179.994 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.47 ' CB ' ' O ' ' A' ' 21' ' ' SER . 0.2 OUTLIER -140.98 -166.34 2.14 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.652 -179.621 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . 0.413 ' OD1' ' N ' ' A' ' 19' ' ' ASP . 7.6 p-10 -88.76 -46.92 8.6 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.71 -0.677 . . . . 0.0 110.946 179.653 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 41.3 m -115.23 8.42 15.51 Favored 'General case' 0 N--CA 1.468 0.449 0 CA-C-N 116.47 -0.332 . . . . 0.0 110.593 -179.648 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' SER . . . . . 0.47 ' O ' ' CB ' ' A' ' 18' ' ' THR . 29.6 p -151.09 145.44 25.48 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.986 0.422 . . . . 0.0 110.553 179.691 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 41.4 pt -142.49 146.95 21.61 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.113 179.839 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -102.1 84.46 0.5 Allowed Glycine 0 CA--C 1.522 0.518 0 N-CA-C 111.1 -0.8 . . . . 0.0 111.1 179.957 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 92.5 mt -69.86 122.48 19.34 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.817 0.341 . . . . 0.0 110.159 -179.865 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 65.7 ttt-85 -136.0 144.47 45.35 Favored 'General case' 0 CA--C 1.517 -0.291 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.116 -179.844 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' TRP . . . . . . . . . . . . . 35.1 p90 -145.99 157.27 43.88 Favored 'General case' 0 CA--C 1.518 -0.26 0 CA-C-N 116.407 -0.361 . . . . 0.0 110.074 -179.9 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 4.6 m -111.85 96.33 32.9 Favored Pre-proline 0 C--O 1.234 0.268 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.475 179.545 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_exo -54.1 143.72 61.42 Favored 'Trans proline' 0 C--N 1.307 -1.653 0 C-N-CA 122.177 1.918 . . . . 0.0 112.496 179.39 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 66.5 mt -79.4 140.01 37.55 Favored 'General case' 0 CA--C 1.517 -0.291 0 CA-C-O 121.481 0.658 . . . . 0.0 111.014 -179.841 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . 0.437 ' OD1' ' O ' ' A' ' 30' ' ' ASN . 59.8 t-20 -51.67 -33.95 36.1 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.243 -0.889 . . . . 0.0 109.806 179.902 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 51.4 m -79.43 -32.94 42.89 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.52 179.41 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 14.0 m -62.32 136.99 58.17 Favored 'General case' 0 CA--C 1.528 0.129 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.178 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' THR . . . . . 0.504 ' CB ' ' H ' ' A' ' 82' ' ' ASN . 7.1 m -64.89 141.59 58.72 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.967 -0.561 . . . . 0.0 110.395 179.857 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 15.5 mm -95.03 95.36 4.99 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.201 0 CA-C-O 120.936 0.398 . . . . 0.0 110.548 -179.962 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.494 ' O ' ' OG ' ' A' ' 57' ' ' SER . 11.3 pt -142.47 132.12 22.75 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.192 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.402 179.723 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -38.11 122.05 1.11 Allowed Glycine 0 CA--C 1.524 0.603 0 N-CA-C 111.424 -0.671 . . . . 0.0 111.424 -179.595 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 76.4 m-85 -89.48 176.47 6.89 Favored 'General case' 0 CA--C 1.515 -0.391 0 CA-C-O 120.907 0.384 . . . . 0.0 110.113 -179.946 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . 0.646 HH11 ' HG1' ' A' ' 40' ' ' THR . 6.2 tmm_? -135.35 126.74 28.51 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.635 179.946 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . 0.452 ' O ' ' CG1' ' A' ' 39' ' ' ILE . 1.8 pt -102.43 125.27 56.71 Favored 'Isoleucine or valine' 0 C--O 1.233 0.208 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.003 179.603 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' THR . . . . . 0.646 ' HG1' HH11 ' A' ' 38' ' ' ARG . 15.9 m -106.81 133.02 52.1 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.448 -179.858 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.2 p -128.34 138.9 53.36 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.312 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.108 179.925 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . 0.534 ' O ' ' N ' ' A' ' 74' ' ' ASP . 39.2 t -133.27 133.78 57.79 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.114 0 CA-C-N 116.418 -0.356 . . . . 0.0 110.195 179.671 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -95.95 136.53 36.27 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.269 179.292 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -90.35 -46.29 8.48 Favored 'General case' 0 N--CA 1.464 0.256 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.545 179.844 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -64.82 -30.65 78.55 Favored Glycine 0 CA--C 1.523 0.577 0 N-CA-C 111.042 -0.823 . . . . 0.0 111.042 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 36.6 mm-40 -96.07 134.73 38.76 Favored 'General case' 0 C--N 1.331 -0.197 0 N-CA-C 109.482 -0.562 . . . . 0.0 109.482 -179.24 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -63.69 -21.81 65.47 Favored Glycine 0 CA--C 1.51 -0.242 0 N-CA-C 111.087 -0.805 . . . . 0.0 111.087 -178.922 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -114.46 136.11 22.33 Favored Pre-proline 0 CA--C 1.54 0.574 0 C-N-CA 120.983 -0.287 . . . . 0.0 110.577 179.709 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -78.58 169.75 19.34 Favored 'Trans proline' 0 C--N 1.309 -1.523 0 C-N-CA 122.792 2.328 . . . . 0.0 112.002 176.498 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 4.7 mp -96.43 133.53 37.43 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.183 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.561 179.564 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 83.0 m-85 -49.71 149.31 2.54 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.617 -179.871 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 5.9 pt-20 -75.3 -178.06 3.79 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.204 179.766 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -143.76 132.57 22.61 Favored 'General case' 0 N--CA 1.45 -0.429 0 CA-C-N 115.848 -0.614 . . . . 0.0 110.855 179.839 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 96.9 m-85 -104.6 119.47 39.06 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.206 179.449 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 10.6 p -126.27 134.22 66.95 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.295 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.295 179.979 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 98.2 m-20 -56.87 138.46 53.64 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.417 -179.866 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' SER . . . . . 0.494 ' OG ' ' O ' ' A' ' 35' ' ' ILE . 5.0 m -59.04 -32.49 69.8 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.38 179.871 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 59.2 m -55.31 -33.59 63.44 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.395 -179.904 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 95.6 t -64.2 -45.74 95.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.438 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 61.58 26.75 67.03 Favored Glycine 0 CA--C 1.527 0.792 0 N-CA-C 110.656 -0.978 . . . . 0.0 110.656 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . 0.437 ' OH ' ' OG1' ' A' ' 63' ' ' THR . 48.5 t80 -167.88 152.2 6.45 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 121.275 0.56 . . . . 0.0 111.134 -179.333 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' TYR . . . . . 0.413 ' N ' ' CG ' ' A' ' 61' ' ' TYR . 23.6 t80 -158.59 159.04 35.02 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.069 178.827 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' THR . . . . . 0.437 ' OG1' ' OH ' ' A' ' 61' ' ' TYR . 85.8 m -126.6 135.75 51.64 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.711 -179.819 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -132.04 108.1 13.56 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.334 0 CA-C-N 115.946 -0.57 . . . . 0.0 109.743 179.127 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 2.6 p -116.98 159.64 22.18 Favored 'General case' 0 CA--C 1.518 -0.259 0 CA-C-O 121.0 0.429 . . . . 0.0 110.844 179.971 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 109.21 3.03 31.43 Favored Glycine 0 CA--C 1.527 0.802 0 CA-C-N 115.7 -0.682 . . . . 0.0 111.528 -179.503 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 3.8 mt -79.49 110.86 15.19 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 121.067 0.461 . . . . 0.0 110.024 -179.259 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 9.3 mt-10 -48.09 139.1 10.08 Favored Pre-proline 0 C--N 1.319 -0.741 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.013 -178.834 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -75.09 162.41 36.93 Favored 'Trans proline' 0 N--CA 1.494 1.558 0 C-N-CA 122.888 2.392 . . . . 0.0 112.401 179.426 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 46.7 22.15 1.03 Allowed Glycine 0 N--CA 1.443 -0.885 0 CA-C-N 115.27 -0.877 . . . . 0.0 111.617 179.2 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . 0.442 ' CG2' ' CD1' ' A' ' 73' ' ' TYR . 0.9 OUTLIER -109.5 166.2 4.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 121.349 0.595 . . . . 0.0 109.814 -179.708 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' ASP . . . . . 0.405 ' OD1' ' C ' ' A' ' 72' ' ' ASP . 4.3 t0 -102.05 101.02 11.34 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.355 -0.839 . . . . 0.0 111.82 179.476 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' TYR . . . . . 0.444 ' O ' ' CD1' ' A' ' 75' ' ' ILE . 2.2 m-30 -109.58 125.38 52.48 Favored 'General case' 0 C--O 1.219 -0.537 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.585 179.049 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' ASP . . . . . 0.534 ' N ' ' O ' ' A' ' 42' ' ' VAL . 79.7 m-20 -89.0 117.05 27.74 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 114.993 -1.003 . . . . 0.0 109.397 179.891 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . 0.444 ' CD1' ' O ' ' A' ' 73' ' ' TYR . 0.0 OUTLIER -116.54 168.63 7.89 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.306 0 CA-C-O 121.155 0.502 . . . . 0.0 110.079 -179.019 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 45.3 t -154.66 150.46 27.68 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.445 -0.798 . . . . 0.0 110.877 179.539 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 12.0 t -130.38 100.97 5.34 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.272 0 N-CA-C 109.613 -0.514 . . . . 0.0 109.613 178.958 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 96.2 mt -88.82 130.44 38.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.59 -179.782 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 91.8 m -112.53 106.66 15.16 Favored 'General case' 0 CA--C 1.518 -0.276 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 179.59 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 6.6 tt -121.3 122.29 39.56 Favored 'General case' 0 CA--C 1.519 -0.249 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.315 -179.906 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' ILE . . . . . 0.498 ' HB ' ' H ' ' A' ' 33' ' ' THR . 2.2 pp -134.19 151.29 32.05 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.175 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.295 179.611 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' ASN . . . . . 0.504 ' H ' ' CB ' ' A' ' 33' ' ' THR . 57.1 t-20 -66.64 -54.57 21.89 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.478 -0.328 . . . . 0.0 111.193 179.94 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 42.57 -103.46 0.04 OUTLIER Glycine 0 CA--C 1.523 0.581 0 N-CA-C 110.986 -0.846 . . . . 0.0 110.986 179.822 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -80.24 -172.46 44.69 Favored Glycine 0 CA--C 1.522 0.527 0 N-CA-C 110.96 -0.856 . . . . 0.0 110.96 179.919 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 93.5 mt-10 -49.63 133.46 21.01 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.91 0.386 . . . . 0.0 110.326 -179.578 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 30.2 t -82.15 167.12 19.05 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.435 -179.932 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . 57.53 162.21 0.08 OUTLIER Pre-proline 0 C--N 1.325 -0.468 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.567 179.919 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -73.82 10.64 1.3 Allowed 'Trans proline' 0 C--N 1.309 -1.507 0 C-N-CA 122.605 2.204 . . . . 0.0 111.957 179.187 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 37.2 m -61.88 131.56 50.15 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.421 179.941 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 83.0 m -125.61 129.3 49.38 Favored 'General case' 0 N--CA 1.464 0.229 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.528 -179.981 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . 0.446 ' CD1' ' N ' ' A' ' 91' ' ' LEU . 10.1 mp -77.32 143.24 38.94 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.489 -179.881 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 66.8 p -67.49 137.12 55.56 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.47 180.0 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 77.5 mt-30 -57.69 105.41 0.25 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.414 -179.805 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 65.7 tt0 -64.6 -42.88 95.26 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.535 -179.961 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 93.0 m . . . . . 0 C--O 1.22 -0.488 0 CA-C-O 117.929 -1.034 . . . . 0.0 110.482 -179.896 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' B' B ' 201' ' ' SER . . . . . . . . . . . . . 41.5 t . . . . . 0 N--CA 1.491 1.581 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' B' B ' 202' ' ' SER . . . . . . . . . . . . . 29.7 t -66.99 132.89 48.85 Favored 'General case' 0 CA--C 1.517 -0.299 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.143 -179.985 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 203' ' ' SER . . . . . . . . . . . . . 79.3 p -129.84 109.12 17.01 Favored Pre-proline 0 CA--C 1.539 0.541 0 CA-C-N 116.4 -0.364 . . . . 0.0 110.657 179.449 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 204' ' ' PRO . . . . . . . . . . . . . 58.6 Cg_endo -75.99 -49.23 0.13 Allowed 'Trans proline' 0 N--CA 1.494 1.511 0 C-N-CA 122.454 2.103 . . . . 0.0 112.213 -179.933 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 205' ' ' ILE . . . . . 0.417 ' CG1' ' N ' ' B' ' 206' ' ' GLN . 15.5 tt -102.5 162.42 3.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 115.967 -0.56 . . . . 0.0 109.542 -178.616 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 206' ' ' GLN . . . . . 0.417 ' N ' ' CG1' ' B' ' 205' ' ' ILE . 63.7 tt0 -176.48 87.67 0.03 OUTLIER 'General case' 0 N--CA 1.45 -0.457 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.262 -179.184 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 207' ' ' GLY . . . . . 0.427 ' C ' ' CH2' ' B' ' 218' ' ' TRP . . . -110.87 -145.97 10.53 Favored Glycine 0 N--CA 1.467 0.736 0 N-CA-C 111.174 -0.771 . . . . 0.0 111.174 179.884 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 208' ' ' SER . . . . . 0.458 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 97.4 p -162.92 170.28 18.39 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.829 0.347 . . . . 0.0 110.717 179.759 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 209' ' ' TRP . . . . . . . . . . . . . 79.0 m95 -85.32 131.42 34.41 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.183 179.682 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 44.6 p -113.8 140.69 48.1 Favored 'General case' 0 N--CA 1.463 0.221 0 CA-C-N 116.409 -0.359 . . . . 0.0 110.61 -179.752 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 54.5 t-105 -96.55 118.26 32.66 Favored 'General case' 0 N--CA 1.464 0.226 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.134 179.914 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 212' ' ' GLU . . . . . 0.477 ' O ' ' O ' ' B' ' 215' ' ' LYS . 0.9 OUTLIER -165.72 167.75 16.79 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.971 179.076 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' B' B ' 213' ' ' ASN . . . . . . . . . . . . . 12.7 m120 50.41 35.23 10.54 Favored 'General case' 0 C--N 1.321 -0.648 0 C-N-CA 120.603 -0.439 . . . . 0.0 111.02 176.168 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 52.24 14.75 2.29 Favored Glycine 0 CA--C 1.525 0.66 0 N-CA-C 111.364 -0.694 . . . . 0.0 111.364 179.661 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 215' ' ' LYS . . . . . 0.477 ' O ' ' O ' ' B' ' 212' ' ' GLU . 8.1 mtmp? -144.52 151.38 39.04 Favored 'General case' 0 C--N 1.333 -0.124 0 CA-C-O 121.161 0.505 . . . . 0.0 110.657 179.793 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 216' ' ' TRP . . . . . . . . . . . . . 66.2 m95 -85.58 120.95 27.59 Favored 'General case' 0 C--N 1.329 -0.289 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 -179.911 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 217' ' ' THR . . . . . . . . . . . . . 21.5 m -130.75 142.29 50.41 Favored 'General case' 0 C--O 1.233 0.229 0 CA-C-O 121.051 0.453 . . . . 0.0 110.617 -179.578 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 218' ' ' TRP . . . . . 0.458 ' CH2' ' N ' ' B' ' 208' ' ' SER . 16.4 t-105 -104.31 121.45 43.38 Favored 'General case' 0 N--CA 1.462 0.137 0 CA-C-N 115.925 -0.579 . . . . 0.0 109.921 179.501 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 52.1 mtmt -144.73 171.56 14.23 Favored 'General case' 0 N--CA 1.464 0.246 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.826 -179.524 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -175.44 -161.03 24.2 Favored Glycine 0 CA--C 1.524 0.627 0 CA-C-N 115.614 -0.721 . . . . 0.0 111.322 -179.663 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 221' ' ' ILE . . . . . 0.411 ' O ' ' CG2' ' B' ' 222' ' ' ILE . 18.8 mt -51.29 -73.27 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 C-N-CA 120.737 -0.385 . . . . 0.0 110.592 -177.973 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 222' ' ' ILE . . . . . 0.464 ' O ' ' O ' ' B' ' 223' ' ' ARG . 16.2 pt -158.89 -167.26 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.451 179.808 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 223' ' ' ARG . . . . . 0.508 ' NH1' ' OE1' ' B' ' 225' ' ' GLU . 0.1 OUTLIER -46.12 177.08 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.651 -0.704 . . . . 0.0 110.399 179.146 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' B' B ' 224' ' ' LEU . . . . . 0.554 ' CD2' ' N ' ' B' ' 224' ' ' LEU . 3.4 mm? -58.68 126.14 26.39 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.414 -178.833 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 225' ' ' GLU . . . . . 0.508 ' OE1' ' NH1' ' B' ' 223' ' ' ARG . 29.7 tp10 -101.97 152.96 20.33 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.167 -179.758 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 226' ' ' GLN . . . . . . . . . . . . . 95.9 mt-30 . . . . . 0 C--O 1.219 -0.503 0 CA-C-O 118.031 -0.985 . . . . 0.0 110.549 -179.883 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.309 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 12.0 p -74.56 157.52 35.32 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.968 0.413 . . . . 0.0 110.523 179.919 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 32.6 tp10 -74.39 145.87 43.41 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.202 -179.864 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 4.1 t -132.35 76.51 72.3 Favored Pre-proline 0 N--CA 1.466 0.348 0 CA-C-O 120.719 0.295 . . . . 0.0 110.48 -179.841 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -78.61 143.73 19.24 Favored 'Trans proline' 0 C--N 1.311 -1.411 0 C-N-CA 122.627 2.218 . . . . 0.0 111.922 -179.946 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . 0.459 ' CD ' ' H ' ' A' ' 8' ' ' GLN . 0.4 OUTLIER -100.7 7.39 43.91 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.234 179.766 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 54.7 mt -89.9 114.22 25.97 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.179 -179.793 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 76.4 p -130.24 156.45 44.6 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 116.013 -0.539 . . . . 0.0 110.241 -179.9 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 97.6 m-20 -116.82 153.83 31.79 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.336 -179.823 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 7.4 tt -64.81 144.65 57.11 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.383 -179.74 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' SER . . . . . 0.458 ' O ' ' O ' ' A' ' 25' ' ' ARG . 87.1 p -139.18 159.54 41.91 Favored 'General case' 0 N--CA 1.462 0.125 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.653 179.734 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . 0.424 ' CD1' ' N ' ' A' ' 14' ' ' PHE . 19.1 m-85 -111.35 145.47 38.81 Favored 'General case' 0 N--CA 1.465 0.308 0 CA-C-N 115.978 -0.556 . . . . 0.0 110.572 -179.775 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 17.4 m -144.9 157.4 14.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.463 179.659 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 98.9 m-20 47.76 60.24 3.66 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.314 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.403 HG21 HD12 ' A' ' 17' ' ' ILE . 98.2 mt -82.46 140.51 16.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.538 179.757 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.438 ' CB ' ' O ' ' A' ' 21' ' ' SER . 0.3 OUTLIER -138.54 -168.33 2.37 Favored 'General case' 0 N--CA 1.466 0.325 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.449 179.917 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . 0.505 ' N ' ' OD1' ' A' ' 19' ' ' ASP . 15.8 p-10 -88.55 -43.63 11.26 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.618 179.509 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' SER . . . . . 0.42 ' OG ' ' O ' ' A' ' 67' ' ' LEU . 50.8 m -117.51 9.77 13.32 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.833 -179.65 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' SER . . . . . 0.438 ' O ' ' CB ' ' A' ' 18' ' ' THR . 9.4 m -150.1 141.76 23.58 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.262 179.829 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 44.3 pt -136.76 146.17 28.96 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.417 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.337 179.915 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -101.63 81.3 0.43 Allowed Glycine 0 CA--C 1.524 0.621 0 N-CA-C 110.887 -0.885 . . . . 0.0 110.887 179.692 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 16.4 mt -67.23 123.91 21.62 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 110.025 -0.361 . . . . 0.0 110.025 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . 0.458 ' O ' ' O ' ' A' ' 13' ' ' SER . 72.5 ttp85 -142.24 135.82 29.22 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.381 -179.804 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' TRP . . . . . . . . . . . . . 3.8 p90 -141.28 158.74 43.48 Favored 'General case' 0 C--N 1.326 -0.444 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 -179.811 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 4.1 m -108.03 102.35 45.51 Favored Pre-proline 0 CA--C 1.537 0.461 0 CA-C-N 116.725 -0.216 . . . . 0.0 110.418 179.504 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_exo -54.91 145.85 60.1 Favored 'Trans proline' 0 C--N 1.308 -1.571 0 C-N-CA 121.8 1.667 . . . . 0.0 112.874 179.547 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 71.1 mt -85.07 138.3 32.51 Favored 'General case' 0 CA--C 1.515 -0.371 0 CA-C-O 121.44 0.638 . . . . 0.0 110.567 179.866 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . 0.421 ' OD1' ' O ' ' A' ' 30' ' ' ASN . 61.2 t-20 -48.63 -34.54 11.91 Favored 'General case' 0 C--N 1.314 -0.946 0 CA-C-N 115.187 -0.915 . . . . 0.0 110.152 -179.962 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 38.3 m -80.68 -33.05 35.78 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.508 179.03 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 6.9 m -59.17 131.64 51.64 Favored 'General case' 0 CA--C 1.528 0.116 0 CA-C-O 120.963 0.411 . . . . 0.0 110.368 -179.839 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' THR . . . . . 0.468 ' CB ' ' H ' ' A' ' 82' ' ' ASN . 4.3 m -62.14 145.41 53.44 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.032 179.984 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 12.5 mm -93.92 94.42 4.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-O 120.921 0.391 . . . . 0.0 110.645 -179.606 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.478 ' O ' ' OG ' ' A' ' 57' ' ' SER . 15.8 pt -147.57 133.04 11.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.844 -0.617 . . . . 0.0 110.563 -179.88 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -47.86 130.43 17.43 Favored Glycine 0 CA--C 1.52 0.357 0 N-CA-C 110.979 -0.848 . . . . 0.0 110.979 -179.864 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' TYR . . . . . 0.438 ' CG ' ' O ' ' A' ' 37' ' ' TYR . 3.8 p90 -106.25 126.84 52.73 Favored 'General case' 0 C--N 1.33 -0.278 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 179.377 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . 0.529 ' NH1' ' OG1' ' A' ' 40' ' ' THR . 3.3 tmm_? -76.4 131.31 39.04 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.275 -0.421 . . . . 0.0 111.128 -179.321 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . 0.454 ' O ' ' CG1' ' A' ' 39' ' ' ILE . 2.2 pt -98.19 123.94 50.98 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.159 0 CA-C-N 115.956 -0.566 . . . . 0.0 109.531 179.526 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' THR . . . . . 0.529 ' OG1' ' NH1' ' A' ' 38' ' ' ARG . 1.6 m -103.38 131.12 50.72 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 120.802 0.334 . . . . 0.0 110.56 -179.303 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.3 p -130.48 138.68 53.19 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.052 179.442 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . 0.517 ' N ' ' O ' ' A' ' 74' ' ' ASP . 39.7 t -133.1 131.88 58.64 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.248 0 N-CA-C 110.101 -0.333 . . . . 0.0 110.101 -179.99 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -96.25 139.54 32.25 Favored 'General case' 0 C--N 1.327 -0.377 0 N-CA-C 109.54 -0.541 . . . . 0.0 109.54 179.099 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . 0.41 ' CB ' ' O ' ' A' ' 72' ' ' ASP . . . -92.21 -41.71 10.28 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.762 0.315 . . . . 0.0 110.857 179.636 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -65.66 -31.73 80.87 Favored Glycine 0 CA--C 1.526 0.735 0 N-CA-C 111.388 -0.685 . . . . 0.0 111.388 -179.357 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 32.0 mt-10 -97.94 129.66 44.84 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 121.168 0.509 . . . . 0.0 109.651 -179.64 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -60.37 -8.55 9.42 Favored Glycine 0 CA--C 1.518 0.233 0 N-CA-C 110.701 -0.959 . . . . 0.0 110.701 -179.272 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . 0.417 HD12 HG23 ' A' ' 48' ' ' ILE . 0.4 OUTLIER -124.08 134.39 25.39 Favored Pre-proline 0 CA--C 1.538 0.512 0 C-N-CA 121.298 -0.161 . . . . 0.0 110.588 179.529 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -77.99 160.63 30.26 Favored 'Trans proline' 0 C--N 1.314 -1.273 0 C-N-CA 122.477 2.118 . . . . 0.0 112.054 177.602 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . 0.413 HD13 HG22 ' A' ' 50' ' ' ILE . 96.1 mt -80.71 137.69 20.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.199 179.188 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 90.0 m-85 -55.88 142.05 36.79 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.949 0.404 . . . . 0.0 110.724 -179.702 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . 0.446 ' CD ' ' H ' ' A' ' 52' ' ' GLU . 0.4 OUTLIER -77.72 146.21 36.08 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.376 179.778 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -109.81 144.83 37.69 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.406 179.829 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 93.5 m-85 -109.46 118.82 37.65 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.266 179.944 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 9.3 p -125.95 137.47 57.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.441 -179.747 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 84.1 m-20 -67.63 141.41 56.75 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.297 179.592 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' SER . . . . . 0.478 ' OG ' ' O ' ' A' ' 35' ' ' ILE . 9.6 m -57.98 -28.5 64.44 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.417 179.886 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 23.4 m -55.94 -33.64 64.92 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.542 179.959 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.473 ' O ' ' CD2' ' A' ' 61' ' ' TYR . 50.6 t -60.49 -45.18 97.34 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 116.394 -0.367 . . . . 0.0 110.15 -179.395 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 71.36 14.51 74.44 Favored Glycine 0 CA--C 1.529 0.922 0 N-CA-C 111.074 -0.81 . . . . 0.0 111.074 179.388 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . 0.473 ' CD2' ' O ' ' A' ' 59' ' ' VAL . 27.6 p90 -172.27 158.34 4.43 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.795 0.331 . . . . 0.0 111.348 179.43 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 23.6 t80 -155.94 155.6 33.09 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.356 -0.384 . . . . 0.0 110.144 177.955 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 94.4 m -121.09 134.7 55.27 Favored 'General case' 0 N--CA 1.463 0.224 0 CA-C-O 121.072 0.463 . . . . 0.0 110.429 -179.814 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -131.86 103.35 6.78 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.197 0 CA-C-N 115.954 -0.566 . . . . 0.0 109.862 178.961 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 2.3 p -112.84 162.87 15.3 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 121.031 0.444 . . . . 0.0 110.683 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 111.38 5.62 26.2 Favored Glycine 0 CA--C 1.527 0.83 0 CA-C-N 115.482 -0.781 . . . . 0.0 111.583 -179.272 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.42 ' O ' ' OG ' ' A' ' 20' ' ' SER . 9.1 mt -81.21 109.04 15.36 Favored 'General case' 0 C--N 1.329 -0.286 0 N-CA-C 109.479 -0.563 . . . . 0.0 109.479 179.379 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 17.5 mm-40 -57.81 137.42 83.11 Favored Pre-proline 0 C--N 1.321 -0.651 0 CA-C-N 116.288 -0.414 . . . . 0.0 111.569 -178.303 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 80.8 Cg_endo -74.29 151.76 43.7 Favored 'Trans proline' 0 N--CA 1.494 1.542 0 C-N-CA 122.695 2.263 . . . . 0.0 111.732 178.93 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 76.58 6.41 84.44 Favored Glycine 0 CA--C 1.528 0.856 0 CA-C-N 115.644 -0.707 . . . . 0.0 111.413 179.229 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 2.4 mp -117.05 143.99 25.93 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.392 0 CA-C-O 121.398 0.618 . . . . 0.0 109.728 -179.717 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' ASP . . . . . 0.41 ' O ' ' CB ' ' A' ' 44' ' ' ALA . 4.4 t70 -84.06 112.26 20.05 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 114.987 -1.006 . . . . 0.0 110.626 -179.657 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' TYR . . . . . 0.545 ' O ' ' CD1' ' A' ' 75' ' ' ILE . 11.9 m-85 -107.54 120.61 42.68 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.467 179.73 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' ASP . . . . . 0.517 ' O ' ' N ' ' A' ' 42' ' ' VAL . 72.6 m-20 -88.04 119.42 28.4 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.348 -0.842 . . . . 0.0 109.414 179.474 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . 0.642 ' CD1' ' N ' ' A' ' 75' ' ' ILE . 0.0 OUTLIER -120.15 166.44 14.57 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-O 121.005 0.431 . . . . 0.0 110.311 -178.521 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 21.2 t -155.92 125.61 6.39 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.659 -0.701 . . . . 0.0 110.623 179.204 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 11.4 t -102.0 100.79 11.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 N-CA-C 109.621 -0.511 . . . . 0.0 109.621 179.126 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 90.4 mt -87.95 126.3 41.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.717 -179.766 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' THR . . . . . 0.431 ' OG1' ' O ' ' B' ' 216' ' ' TRP . 16.4 p -106.93 110.03 22.08 Favored 'General case' 0 N--CA 1.464 0.235 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 179.514 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 35.9 tp -117.57 124.58 49.01 Favored 'General case' 0 N--CA 1.464 0.231 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.445 179.98 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' ILE . . . . . 0.409 ' HB ' ' H ' ' A' ' 33' ' ' THR . 2.1 pp -145.9 145.34 20.28 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-N 116.004 -0.543 . . . . 0.0 110.259 179.338 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' ASN . . . . . 0.468 ' H ' ' CB ' ' A' ' 33' ' ' THR . 47.2 t30 -62.44 -58.96 5.73 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.522 -0.308 . . . . 0.0 110.808 -179.743 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 71.67 -158.42 53.5 Favored Glycine 0 CA--C 1.522 0.507 0 N-CA-C 110.896 -0.882 . . . . 0.0 110.896 179.629 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -89.87 114.43 4.36 Favored Glycine 0 CA--C 1.522 0.507 0 N-CA-C 110.707 -0.957 . . . . 0.0 110.707 179.793 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 76.7 mt-10 -88.66 140.29 29.6 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.726 0.298 . . . . 0.0 110.337 179.964 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 39.7 t -96.05 119.58 34.8 Favored 'General case' 0 C--N 1.332 -0.155 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.24 179.851 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . 0.604 ' N ' ' CD ' ' A' ' 88' ' ' PRO . . . -105.48 -42.86 0.16 Allowed Pre-proline 0 N--CA 1.466 0.355 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.188 179.844 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . 0.604 ' CD ' ' N ' ' A' ' 87' ' ' ALA . 26.6 Cg_exo -61.12 14.25 0.05 OUTLIER 'Trans proline' 0 N--CA 1.496 1.631 0 C-N-CA 122.792 2.328 . . . . 0.0 112.532 -179.782 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' THR . . . . . 0.597 ' H ' ' C ' ' A' ' 87' ' ' ALA . 14.8 t -113.6 128.05 56.29 Favored 'General case' 0 C--N 1.334 -0.1 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.268 179.974 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 68.8 p -129.55 121.54 27.35 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.109 179.847 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 4.9 mp -103.21 132.65 49.3 Favored 'General case' 0 CA--C 1.52 -0.198 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.58 179.818 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 70.1 p -81.1 164.97 22.03 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.467 179.959 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 93' ' ' GLN . . . . . 0.424 ' O ' ' O ' ' A' ' 94' ' ' GLN . 99.0 mm-40 -76.74 130.28 37.48 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.456 -179.937 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 0.424 ' O ' ' O ' ' A' ' 93' ' ' GLN . 98.5 mm-40 52.79 170.76 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.52 179.925 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 48.2 p . . . . . 0 C--O 1.219 -0.509 0 CA-C-O 117.977 -1.011 . . . . 0.0 110.542 179.965 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' B' B ' 201' ' ' SER . . . . . . . . . . . . . 95.4 p . . . . . 0 N--CA 1.49 1.546 0 N-CA-C 109.354 -0.61 . . . . 0.0 109.354 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' B' B ' 202' ' ' SER . . . . . . . . . . . . . 25.8 p -77.27 154.44 32.95 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.248 179.849 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 203' ' ' SER . . . . . 0.448 ' C ' ' H ' ' B' ' 205' ' ' ILE . 2.3 p -117.45 151.76 48.56 Favored Pre-proline 0 N--CA 1.466 0.339 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.548 -179.831 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 204' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -66.04 6.06 0.55 Allowed 'Trans proline' 0 N--CA 1.495 1.574 0 C-N-CA 122.591 2.194 . . . . 0.0 111.82 179.831 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 205' ' ' ILE . . . . . 0.448 ' H ' ' C ' ' B' ' 203' ' ' SER . 2.6 tp -142.28 141.58 28.28 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.286 0 CA-C-O 121.144 0.497 . . . . 0.0 111.286 179.717 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 206' ' ' GLN . . . . . . . . . . . . . 12.2 pt20 -174.28 75.55 0.03 OUTLIER 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 115.519 -0.764 . . . . 0.0 111.096 178.894 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 207' ' ' GLY . . . . . . . . . . . . . . . -110.52 -140.32 8.46 Favored Glycine 0 N--CA 1.465 0.615 0 N-CA-C 110.818 -0.913 . . . . 0.0 110.818 179.834 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 208' ' ' SER . . . . . 0.455 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 53.9 p -164.35 171.67 14.48 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 120.876 0.37 . . . . 0.0 110.686 -179.893 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 209' ' ' TRP . . . . . . . . . . . . . 76.5 m95 -87.51 134.98 33.53 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.216 179.575 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 70.2 p -110.62 131.74 54.79 Favored 'General case' 0 N--CA 1.467 0.423 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.552 -179.847 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 50.5 t-105 -93.16 115.2 27.84 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 120.875 0.369 . . . . 0.0 110.432 179.689 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 212' ' ' GLU . . . . . 0.484 ' O ' ' O ' ' B' ' 215' ' ' LYS . 1.4 pt-20 -164.89 170.54 15.21 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.077 -0.51 . . . . 0.0 111.085 179.199 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 213' ' ' ASN . . . . . . . . . . . . . 16.3 m120 48.58 34.19 4.76 Favored 'General case' 0 C--N 1.322 -0.619 0 C-N-CA 120.398 -0.521 . . . . 0.0 111.342 176.384 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 54.27 11.75 2.65 Favored Glycine 0 CA--C 1.529 0.932 0 N-CA-C 111.627 -0.589 . . . . 0.0 111.627 179.794 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 215' ' ' LYS . . . . . 0.484 ' O ' ' O ' ' B' ' 212' ' ' GLU . 65.9 mttm -142.86 150.77 40.31 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 121.038 0.446 . . . . 0.0 110.732 179.995 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 216' ' ' TRP . . . . . 0.436 ' CD1' ' N ' ' B' ' 216' ' ' TRP . 35.0 m95 -87.74 127.15 35.31 Favored 'General case' 0 C--N 1.33 -0.281 0 N-CA-C 109.954 -0.387 . . . . 0.0 109.954 179.742 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 217' ' ' THR . . . . . . . . . . . . . 21.7 m -136.14 145.0 45.34 Favored 'General case' 0 N--CA 1.463 0.217 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.359 -179.784 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 218' ' ' TRP . . . . . 0.455 ' CH2' ' N ' ' B' ' 208' ' ' SER . 24.8 t-105 -102.6 120.83 41.23 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 116.048 -0.524 . . . . 0.0 109.796 179.53 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 97.4 mttt -136.56 164.33 28.44 Favored 'General case' 0 N--CA 1.465 0.308 0 CA-C-O 121.083 0.468 . . . . 0.0 110.739 -179.62 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -176.13 -162.75 27.55 Favored Glycine 0 CA--C 1.523 0.575 0 N-CA-C 111.134 -0.786 . . . . 0.0 111.134 -179.942 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 221' ' ' ILE . . . . . 0.423 ' O ' ' CG2' ' B' ' 222' ' ' ILE . 0.9 OUTLIER -58.75 -78.71 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 C-N-CA 120.459 -0.496 . . . . 0.0 110.965 -178.254 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' B' B ' 222' ' ' ILE . . . . . 0.461 ' O ' ' O ' ' B' ' 223' ' ' ARG . 19.1 pt -159.12 -162.84 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 N-CA-C 110.043 -0.355 . . . . 0.0 110.043 -179.085 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 223' ' ' ARG . . . . . 0.461 ' O ' ' O ' ' B' ' 222' ' ' ILE . 0.0 OUTLIER -43.76 173.64 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 121.271 0.558 . . . . 0.0 110.545 178.648 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' B' B ' 224' ' ' LEU . . . . . 0.601 ' H ' ' CD2' ' B' ' 224' ' ' LEU . 2.6 mm? -59.42 138.46 57.65 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-N 115.67 -0.695 . . . . 0.0 110.581 -179.707 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 80.0 tt0 -112.03 149.72 31.65 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 115.389 -0.823 . . . . 0.0 110.41 -179.492 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 226' ' ' GLN . . . . . . . . . . . . . 7.6 tp-100 . . . . . 0 N--CA 1.448 -0.574 0 CA-C-O 117.874 -1.06 . . . . 0.0 110.418 -179.98 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.258 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 39.0 t -86.94 103.64 15.51 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.742 0.306 . . . . 0.0 110.264 179.84 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -125.31 122.29 36.46 Favored 'General case' 0 N--CA 1.465 0.325 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.311 179.817 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 4.9 m -144.95 148.48 38.96 Favored Pre-proline 0 CA--C 1.533 0.289 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.513 179.756 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -67.64 144.52 66.46 Favored 'Trans proline' 0 N--CA 1.494 1.556 0 C-N-CA 122.446 2.097 . . . . 0.0 111.834 179.857 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . 0.455 ' NE2' ' N ' ' A' ' 8' ' ' GLN . 0.0 OUTLIER -168.5 65.19 0.07 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.426 179.976 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 3.9 mp -114.67 126.06 54.46 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 121.054 0.454 . . . . 0.0 110.439 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 13.8 t -95.62 130.75 42.4 Favored 'General case' 0 CA--C 1.52 -0.198 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.542 -179.547 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 45.2 t0 -115.85 101.54 8.89 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.271 179.926 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 5.7 tt -70.22 134.96 48.57 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.552 179.846 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 82.5 p -142.61 162.32 35.78 Favored 'General case' 0 N--CA 1.462 0.143 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.401 179.631 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . 0.411 ' CD1' ' N ' ' A' ' 14' ' ' PHE . 57.3 m-85 -110.27 147.64 33.45 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.905 -0.588 . . . . 0.0 110.67 -179.642 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 17.7 m -144.19 152.93 15.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.399 179.737 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 24.9 t70 60.66 34.24 20.1 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.544 -179.823 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 96.4 mt -57.02 134.65 21.3 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.191 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.035 179.709 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.431 ' OG1' ' O ' ' A' ' 21' ' ' SER . 0.2 OUTLIER -136.49 -168.89 2.34 Favored 'General case' 0 N--CA 1.469 0.478 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.388 -179.831 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . 0.485 ' N ' ' OD1' ' A' ' 19' ' ' ASP . 18.6 p-10 -76.48 -50.62 13.58 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.798 179.49 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' SER . . . . . 0.447 ' OG ' ' O ' ' A' ' 67' ' ' LEU . 69.8 m -121.61 15.76 11.13 Favored 'General case' 0 N--CA 1.462 0.173 0 CA-C-N 116.677 -0.238 . . . . 0.0 110.679 -179.33 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' SER . . . . . 0.431 ' O ' ' OG1' ' A' ' 18' ' ' THR . 25.2 p -145.97 127.09 14.69 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-O 121.041 0.448 . . . . 0.0 110.545 -179.612 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 38.4 pt -128.69 141.29 46.96 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.3 0 CA-C-N 115.947 -0.569 . . . . 0.0 109.57 -179.81 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -102.29 88.73 0.7 Allowed Glycine 0 CA--C 1.523 0.566 0 N-CA-C 111.8 -0.52 . . . . 0.0 111.8 -179.316 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 10.3 mp -61.06 148.59 39.79 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 121.072 0.463 . . . . 0.0 110.349 179.963 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 50.2 ttt180 -157.4 136.57 11.83 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.683 -0.69 . . . . 0.0 110.98 179.827 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' TRP . . . . . 0.535 ' CH2' ' OH ' ' A' ' 37' ' ' TYR . 34.5 p90 -139.74 159.39 42.28 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.821 -0.627 . . . . 0.0 109.915 -179.93 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 3.7 m -107.71 99.77 31.31 Favored Pre-proline 0 CA--C 1.537 0.443 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.986 -179.363 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 38.7 Cg_exo -56.64 153.39 36.2 Favored 'Trans proline' 0 C--N 1.31 -1.454 0 C-N-CA 122.093 1.862 . . . . 0.0 112.956 178.84 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.485 ' O ' ' N ' ' A' ' 32' ' ' SER . 41.7 mt -110.41 135.91 50.38 Favored 'General case' 0 N--CA 1.469 0.492 0 CA-C-O 121.76 0.79 . . . . 0.0 110.876 -179.845 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 28.1 t-20 -45.61 -30.05 1.4 Allowed 'General case' 0 C--N 1.315 -0.902 0 CA-C-N 114.902 -1.045 . . . . 0.0 110.477 179.852 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 69.3 m -89.83 -23.83 21.59 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.623 179.282 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' SER . . . . . 0.485 ' N ' ' O ' ' A' ' 29' ' ' LEU . 4.7 m -65.09 120.03 11.91 Favored 'General case' 0 N--CA 1.464 0.233 0 CA-C-O 121.204 0.525 . . . . 0.0 110.163 179.998 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 23.7 m -55.82 140.69 41.42 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.602 -0.727 . . . . 0.0 109.516 179.578 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 29.8 mm -94.7 99.01 8.73 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.343 0 CA-C-O 120.854 0.359 . . . . 0.0 111.367 -178.625 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.436 ' O ' ' OG ' ' A' ' 57' ' ' SER . 0.1 OUTLIER -140.11 155.78 24.28 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.21 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.152 179.466 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -74.55 97.74 1.0 Allowed Glycine 0 CA--C 1.524 0.609 0 N-CA-C 110.793 -0.923 . . . . 0.0 110.793 179.877 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' TYR . . . . . 0.535 ' OH ' ' CH2' ' A' ' 26' ' ' TRP . 2.0 p90 -78.79 126.99 31.45 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 110.01 -0.367 . . . . 0.0 110.01 179.787 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 5.4 tmm_? -78.01 132.39 37.78 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 120.975 0.417 . . . . 0.0 111.092 -179.69 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . 0.458 ' O ' ' CG1' ' A' ' 39' ' ' ILE . 1.9 pt -98.46 121.27 48.83 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.217 0 N-CA-C 109.155 -0.683 . . . . 0.0 109.155 179.146 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 13.6 m -99.66 135.81 40.52 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 120.852 0.358 . . . . 0.0 110.948 -179.04 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.3 p -133.15 139.88 48.38 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.364 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.031 179.531 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . 0.511 ' O ' ' N ' ' A' ' 74' ' ' ASP . 38.7 t -131.68 131.66 62.27 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.252 0 N-CA-C 109.969 -0.382 . . . . 0.0 109.969 179.616 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -97.91 133.51 42.31 Favored 'General case' 0 C--N 1.326 -0.414 0 N-CA-C 109.448 -0.575 . . . . 0.0 109.448 179.148 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -94.01 -14.14 26.2 Favored 'General case' 0 C--N 1.329 -0.309 0 C-N-CA 120.956 -0.298 . . . . 0.0 111.005 -179.57 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -99.38 21.81 43.67 Favored Glycine 0 N--CA 1.465 0.609 0 N-CA-C 111.293 -0.723 . . . . 0.0 111.293 -179.518 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -143.74 150.25 38.34 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 121.163 0.506 . . . . 0.0 110.316 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -68.4 -19.35 72.49 Favored Glycine 0 CA--C 1.524 0.647 0 N-CA-C 110.822 -0.911 . . . . 0.0 110.822 179.976 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -134.06 139.73 34.08 Favored Pre-proline 0 CA--C 1.542 0.642 0 O-C-N 122.828 -0.219 . . . . 0.0 110.658 179.943 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_endo -73.79 164.47 34.61 Favored 'Trans proline' 0 N--CA 1.491 1.363 0 C-N-CA 122.613 2.209 . . . . 0.0 111.902 178.102 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 96.6 mt -79.16 155.01 4.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.608 179.603 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -71.59 141.64 50.01 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.42 179.986 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . 0.46 ' CD ' ' H ' ' A' ' 52' ' ' GLU . 0.4 OUTLIER -77.21 144.09 38.54 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.729 179.603 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -104.05 148.57 26.08 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.521 179.7 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' PHE . . . . . 0.465 ' CD1' ' N ' ' A' ' 54' ' ' PHE . 15.9 m-85 -115.48 120.25 38.9 Favored 'General case' 0 N--CA 1.462 0.144 0 CA-C-N 115.758 -0.655 . . . . 0.0 110.038 179.664 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 8.3 p -130.41 144.05 39.13 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.307 0 CA-C-O 120.64 0.257 . . . . 0.0 110.381 -179.957 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 98.7 m-20 -66.27 146.75 54.25 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.591 179.51 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' SER . . . . . 0.436 ' OG ' ' O ' ' A' ' 35' ' ' ILE . 0.9 OUTLIER -65.92 -31.89 73.08 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.602 179.841 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 42.9 m -53.84 -36.19 62.3 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.619 -179.579 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 86.9 t -59.27 -43.66 90.38 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 116.438 -0.346 . . . . 0.0 110.41 -179.558 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 64.93 23.94 69.73 Favored Glycine 0 CA--C 1.526 0.721 0 N-CA-C 110.403 -1.079 . . . . 0.0 110.403 179.65 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . 0.416 ' CG ' ' N ' ' A' ' 62' ' ' TYR . 38.0 t80 -170.42 153.81 4.47 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 121.018 0.437 . . . . 0.0 111.495 -179.549 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' TYR . . . . . 0.417 ' CD2' ' CD1' ' A' ' 39' ' ' ILE . 19.1 t80 -158.73 160.96 36.96 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.337 178.582 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 85.5 m -126.26 134.35 51.2 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.068 -0.514 . . . . 0.0 110.271 179.881 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -133.05 100.64 3.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.033 -0.53 . . . . 0.0 109.684 178.972 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 1.4 p -114.68 164.21 14.37 Favored 'General case' 0 CA--C 1.513 -0.478 0 CA-C-O 120.969 0.414 . . . . 0.0 110.507 -179.89 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 107.34 23.75 6.81 Favored Glycine 0 CA--C 1.519 0.319 0 N-CA-C 111.162 -0.775 . . . . 0.0 111.162 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.447 ' O ' ' OG ' ' A' ' 20' ' ' SER . 10.0 mt -97.22 106.38 18.7 Favored 'General case' 0 N--CA 1.464 0.226 0 N-CA-C 109.532 -0.544 . . . . 0.0 109.532 179.804 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 5.2 mm-40 -46.63 137.34 7.27 Favored Pre-proline 0 C--N 1.316 -0.854 0 CA-C-N 116.101 -0.5 . . . . 0.0 111.827 -178.421 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -73.98 156.67 47.59 Favored 'Trans proline' 0 N--CA 1.497 1.705 0 C-N-CA 122.674 2.249 . . . . 0.0 111.255 178.665 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 71.69 -5.68 10.99 Favored Glycine 0 CA--C 1.527 0.789 0 C-N-CA 120.947 -0.645 . . . . 0.0 111.685 179.307 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . 0.473 ' O ' ' NH1' ' B' ' 223' ' ' ARG . 1.7 mp -103.61 144.32 14.27 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.437 0 CA-C-O 121.26 0.552 . . . . 0.0 109.611 -179.807 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 2.3 t70 -84.39 119.19 24.82 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.14 -0.936 . . . . 0.0 110.469 179.291 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' TYR . . . . . . . . . . . . . 19.0 m-85 -110.14 120.22 41.76 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.75 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' ASP . . . . . 0.511 ' N ' ' O ' ' A' ' 42' ' ' VAL . 14.8 m-20 -90.17 117.1 28.67 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 115.619 -0.719 . . . . 0.0 109.788 179.639 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -114.05 165.2 9.34 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-O 121.147 0.498 . . . . 0.0 110.059 -179.29 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 1.3 p -154.59 121.36 5.49 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.721 -0.672 . . . . 0.0 110.525 179.681 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 14.2 t -96.5 99.66 9.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 179.057 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 95.4 mt -88.35 115.62 28.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.115 179.634 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' THR . . . . . 0.456 ' OG1' ' O ' ' B' ' 216' ' ' TRP . 43.4 p -99.21 117.39 33.57 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.249 179.95 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 20.1 mt -121.4 110.32 15.94 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.864 179.904 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' ILE . . . . . 0.421 HD13 ' N ' ' A' ' 83' ' ' GLY . 1.2 pp -142.24 138.15 29.8 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.088 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.383 179.211 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 59.7 t-20 -65.72 -50.47 64.73 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.955 -0.566 . . . . 0.0 111.244 -179.249 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . 0.421 ' N ' HD13 ' A' ' 81' ' ' ILE . . . 83.77 -162.5 39.38 Favored Glycine 0 CA--C 1.521 0.428 0 N-CA-C 110.951 -0.86 . . . . 0.0 110.951 179.257 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -80.43 175.22 54.95 Favored Glycine 0 CA--C 1.525 0.683 0 N-CA-C 110.762 -0.935 . . . . 0.0 110.762 -179.99 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . 0.582 ' CD ' ' H ' ' A' ' 85' ' ' GLU . 1.2 pm0 -69.75 149.4 48.03 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 120.898 0.38 . . . . 0.0 110.528 179.922 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 52.9 p -48.88 109.36 0.25 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.379 -179.914 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . 0.448 ' N ' ' CD ' ' A' ' 88' ' ' PRO . . . -172.9 53.38 0.16 Allowed Pre-proline 0 C--N 1.328 -0.35 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.587 179.837 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . 0.448 ' CD ' ' N ' ' A' ' 87' ' ' ALA . 51.9 Cg_endo -68.17 157.1 63.25 Favored 'Trans proline' 0 C--N 1.308 -1.574 0 C-N-CA 122.627 2.218 . . . . 0.0 111.877 179.824 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 4.9 t -138.85 157.84 45.31 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.259 -179.881 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 88.7 m -116.52 128.66 55.64 Favored 'General case' 0 N--CA 1.467 0.386 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.266 -179.868 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . 0.464 ' CD1' ' N ' ' A' ' 91' ' ' LEU . 9.4 mp -75.67 156.83 34.39 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.855 -0.612 . . . . 0.0 110.397 -179.819 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 62.2 p -64.89 164.43 12.53 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.318 -179.638 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 93' ' ' GLN . . . . . 0.448 ' O ' ' O ' ' A' ' 94' ' ' GLN . 7.8 tp-100 -79.74 118.63 21.72 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.321 -179.734 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 0.448 ' O ' ' O ' ' A' ' 93' ' ' GLN . 67.3 tp60 56.77 116.97 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.47 179.961 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 29.7 m . . . . . 0 C--O 1.22 -0.493 0 CA-C-O 117.991 -1.004 . . . . 0.0 110.555 179.939 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' B' B ' 201' ' ' SER . . . . . . . . . . . . . 31.1 m . . . . . 0 N--CA 1.489 1.487 0 N-CA-C 109.411 -0.589 . . . . 0.0 109.411 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' B' B ' 202' ' ' SER . . . . . . . . . . . . . 40.4 t -68.89 146.89 52.43 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.288 179.805 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 203' ' ' SER . . . . . . . . . . . . . 5.5 t -131.92 101.66 15.17 Favored Pre-proline 0 CA--C 1.534 0.337 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 178.277 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 204' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_exo -58.09 -58.76 0.68 Allowed 'Trans proline' 0 N--CA 1.498 1.75 0 C-N-CA 122.09 1.86 . . . . 0.0 112.389 178.165 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 205' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -150.17 144.73 17.4 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.3 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.391 -179.867 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 206' ' ' GLN . . . . . . . . . . . . . 88.1 mt-30 -138.2 139.27 39.23 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.193 -0.458 . . . . 0.0 109.981 178.948 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 207' ' ' GLY . . . . . . . . . . . . . . . -100.0 -136.1 9.21 Favored Glycine 0 N--CA 1.465 0.598 0 N-CA-C 111.142 -0.783 . . . . 0.0 111.142 -179.774 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 208' ' ' SER . . . . . 0.538 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 30.7 p -166.47 170.04 13.27 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 120.829 0.347 . . . . 0.0 110.831 179.626 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 209' ' ' TRP . . . . . . . . . . . . . 86.1 m95 -86.29 149.32 25.14 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.373 179.637 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 59.1 p -129.06 128.78 44.26 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.345 179.247 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 54.1 t-105 -91.61 111.55 23.11 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.215 -179.977 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 212' ' ' GLU . . . . . 0.424 ' O ' ' O ' ' B' ' 215' ' ' LYS . 1.7 pt-20 -161.78 167.02 25.65 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.543 179.322 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 213' ' ' ASN . . . . . . . . . . . . . 93.7 m-20 49.79 35.05 8.38 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.929 -0.578 . . . . 0.0 111.159 176.722 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 51.46 17.93 3.29 Favored Glycine 0 CA--C 1.527 0.843 0 N-CA-C 111.37 -0.692 . . . . 0.0 111.37 179.934 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 215' ' ' LYS . . . . . 0.424 ' O ' ' O ' ' B' ' 212' ' ' GLU . 54.1 mtmt -142.58 149.45 39.03 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 120.851 0.357 . . . . 0.0 110.963 179.662 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 216' ' ' TRP . . . . . 0.456 ' O ' ' OG1' ' A' ' 79' ' ' THR . 59.8 m95 -88.83 116.4 27.08 Favored 'General case' 0 C--N 1.331 -0.23 0 N-CA-C 109.444 -0.576 . . . . 0.0 109.444 179.249 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 217' ' ' THR . . . . . . . . . . . . . 17.8 m -124.81 140.34 53.02 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-O 120.976 0.417 . . . . 0.0 110.804 -179.265 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 218' ' ' TRP . . . . . 0.538 ' CH2' ' N ' ' B' ' 208' ' ' SER . 30.6 t-105 -102.8 105.35 15.75 Favored 'General case' 0 C--N 1.333 -0.121 0 CA-C-N 115.74 -0.664 . . . . 0.0 109.473 179.229 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 75.8 mttt -131.11 167.06 19.75 Favored 'General case' 0 N--CA 1.467 0.418 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.753 -179.375 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -178.24 -162.76 28.58 Favored Glycine 0 CA--C 1.523 0.588 0 N-CA-C 111.018 -0.833 . . . . 0.0 111.018 179.447 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 221' ' ' ILE . . . . . 0.425 ' O ' ' CG2' ' B' ' 222' ' ' ILE . 2.1 mp -55.24 -73.87 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 C-N-CA 120.66 -0.416 . . . . 0.0 110.694 -178.565 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 222' ' ' ILE . . . . . 0.487 ' O ' ' O ' ' B' ' 223' ' ' ARG . 23.1 pt -160.61 -164.64 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.268 -179.599 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 223' ' ' ARG . . . . . 0.487 ' O ' ' O ' ' B' ' 222' ' ' ILE . 35.5 ptt-85 -41.73 173.1 0.0 OUTLIER 'General case' 0 CA--C 1.529 0.168 0 CA-C-O 121.352 0.596 . . . . 0.0 110.554 178.54 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 224' ' ' LEU . . . . . 0.665 ' H ' ' CD2' ' B' ' 224' ' ' LEU . 1.4 mm? -64.83 110.42 2.41 Favored 'General case' 0 C--N 1.313 -0.982 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.826 -179.597 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 83.5 tt0 -97.97 151.53 20.2 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.252 -0.886 . . . . 0.0 110.365 179.849 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 226' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.219 -0.524 0 CA-C-O 117.95 -1.024 . . . . 0.0 110.402 179.953 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.392 0 N-CA-C 109.456 -1.458 . . . . 0.0 109.456 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 4.6 m 47.39 41.5 12.65 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.743 0.306 . . . . 0.0 110.689 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 17.3 pt-20 -52.03 140.58 20.14 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.388 -179.924 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 4.5 m -82.71 148.71 58.57 Favored Pre-proline 0 C--N 1.327 -0.403 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.721 -179.726 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -69.09 113.45 3.27 Favored 'Trans proline' 0 N--CA 1.495 1.584 0 C-N-CA 122.502 2.134 . . . . 0.0 111.705 179.673 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 87.0 mt-30 -95.81 123.58 39.44 Favored 'General case' 0 C--N 1.333 -0.149 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.106 179.61 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 56.8 mt -97.88 114.32 26.36 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.256 -179.95 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 77.9 p -84.2 164.0 19.38 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.278 179.875 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . 0.428 ' OD1' ' O ' ' A' ' 11' ' ' ASP . 53.9 p-10 -108.55 144.62 35.97 Favored 'General case' 0 N--CA 1.464 0.244 0 CA-C-O 121.148 0.499 . . . . 0.0 110.522 -179.952 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . 0.426 ' H ' ' HE1' ' B' ' 209' ' ' TRP . 4.9 tt -66.47 144.43 56.5 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.592 179.922 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' SER . . . . . 0.499 ' O ' ' O ' ' A' ' 25' ' ' ARG . 85.5 p -141.44 156.07 45.81 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.98 0.419 . . . . 0.0 110.749 179.67 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . 0.532 ' CD1' ' N ' ' A' ' 14' ' ' PHE . 1.9 m-85 -112.64 153.31 27.83 Favored 'General case' 0 N--CA 1.464 0.263 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.337 -179.813 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 10.5 m -147.7 151.5 13.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.345 179.669 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 26.8 t0 62.89 37.07 12.36 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.622 -179.946 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.407 HD11 HG22 ' A' ' 17' ' ' ILE . 43.7 mt -56.94 133.45 21.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.055 179.698 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -136.54 -171.09 2.82 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.242 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . 0.47 ' N ' ' OD1' ' A' ' 19' ' ' ASP . 20.5 p-10 -75.85 -49.72 17.17 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.91 179.743 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' SER . . . . . 0.47 ' OG ' ' O ' ' A' ' 67' ' ' LEU . 51.0 m -122.36 17.11 10.59 Favored 'General case' 0 N--CA 1.465 0.324 0 CA-C-N 116.437 -0.347 . . . . 0.0 110.805 -179.698 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 1.5 m -145.62 129.83 17.6 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.706 0.289 . . . . 0.0 110.265 -179.425 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 36.5 pt -132.42 142.78 41.74 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 N-CA-C 109.599 -0.519 . . . . 0.0 109.599 179.67 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -101.48 85.9 0.58 Allowed Glycine 0 CA--C 1.523 0.541 0 N-CA-C 111.055 -0.818 . . . . 0.0 111.055 -179.413 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 55.4 mt -69.82 118.48 12.73 Favored 'General case' 0 C--N 1.33 -0.255 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . 0.553 ' HE ' ' CB ' ' A' ' 61' ' ' TYR . 31.5 ttm180 -142.99 132.5 23.6 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 121.004 0.431 . . . . 0.0 111.188 179.973 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' TRP . . . . . 0.468 ' CD1' ' O ' ' A' ' 26' ' ' TRP . 35.3 p90 -147.6 133.88 19.52 Favored 'General case' 0 C--N 1.326 -0.444 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 179.643 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 1.9 m -68.36 115.99 35.22 Favored Pre-proline 0 C--N 1.326 -0.43 0 C-N-CA 120.218 -0.593 . . . . 0.0 111.292 -178.97 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_exo -53.49 154.55 15.1 Favored 'Trans proline' 0 N--CA 1.492 1.431 0 C-N-CA 122.171 1.914 . . . . 0.0 112.709 178.258 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.464 ' O ' ' N ' ' A' ' 32' ' ' SER . 75.4 mt -93.66 132.03 38.4 Favored 'General case' 0 N--CA 1.467 0.404 0 CA-C-O 122.006 0.907 . . . . 0.0 110.89 179.926 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 40.4 t30 -43.13 -32.26 0.69 Allowed 'General case' 0 C--N 1.316 -0.863 0 CA-C-N 115.336 -0.847 . . . . 0.0 110.502 179.984 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 20.8 m -86.96 -30.44 21.29 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.692 179.365 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' SER . . . . . 0.464 ' N ' ' O ' ' A' ' 29' ' ' LEU . 2.1 m -50.26 111.32 0.51 Allowed 'General case' 0 CA--C 1.529 0.166 0 CA-C-O 121.11 0.481 . . . . 0.0 110.524 -179.783 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' THR . . . . . 0.425 ' CB ' ' H ' ' A' ' 82' ' ' ASN . 8.1 m -51.12 148.7 4.27 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.554 -0.748 . . . . 0.0 109.348 -179.646 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 5.3 mm -92.88 91.36 3.33 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.277 0 CA-C-O 121.391 0.615 . . . . 0.0 111.168 -178.825 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.487 ' O ' ' OG ' ' A' ' 57' ' ' SER . 12.0 pt -147.96 126.15 3.5 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 115.24 -0.891 . . . . 0.0 110.565 179.554 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -46.89 126.41 10.03 Favored Glycine 0 CA--C 1.521 0.465 0 N-CA-C 110.847 -0.901 . . . . 0.0 110.847 -179.718 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' TYR . . . . . 0.482 ' CE1' ' CG1' ' A' ' 55' ' ' VAL . 28.3 p90 -95.8 175.24 6.59 Favored 'General case' 0 C--N 1.329 -0.307 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 179.851 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 9.0 tmm_? -126.36 123.0 36.99 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.718 -179.843 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . 0.471 ' O ' ' CG1' ' A' ' 39' ' ' ILE . 1.9 pt -94.14 120.22 43.21 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 N-CA-C 109.602 -0.518 . . . . 0.0 109.602 -179.856 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 10.1 m -96.14 128.48 43.08 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.15 -179.289 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.0 p -123.06 134.12 67.09 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 CA-C-N 116.077 -0.511 . . . . 0.0 109.873 -179.981 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . 0.407 ' O ' ' N ' ' A' ' 74' ' ' ASP . 24.5 t -129.35 128.45 66.42 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.173 0 CA-C-O 120.831 0.348 . . . . 0.0 110.132 179.846 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -97.36 128.99 44.66 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 109.054 -0.721 . . . . 0.0 109.054 179.372 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -88.12 -24.27 23.43 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 120.869 0.366 . . . . 0.0 110.981 -179.624 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -86.43 20.59 21.66 Favored Glycine 0 N--CA 1.462 0.375 0 N-CA-C 111.202 -0.759 . . . . 0.0 111.202 -179.696 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 79.8 mm-40 -144.75 150.12 36.69 Favored 'General case' 0 C--O 1.233 0.224 0 CA-C-O 121.041 0.448 . . . . 0.0 110.324 -179.702 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -69.32 -20.33 75.09 Favored Glycine 0 N--CA 1.452 -0.269 0 N-CA-C 110.645 -0.982 . . . . 0.0 110.645 -179.852 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -131.42 139.01 34.05 Favored Pre-proline 0 N--CA 1.469 0.495 0 C-N-CA 120.952 -0.299 . . . . 0.0 110.528 179.673 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 68.6 Cg_endo -75.27 165.06 31.69 Favored 'Trans proline' 0 C--N 1.31 -1.458 0 C-N-CA 122.734 2.289 . . . . 0.0 112.027 177.676 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . 0.451 ' CG2' ' N ' ' A' ' 51' ' ' PHE . 96.6 mt -79.6 160.42 4.29 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-N 115.782 -0.644 . . . . 0.0 110.229 179.55 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' PHE . . . . . 0.451 ' N ' ' CG2' ' A' ' 50' ' ' ILE . 92.5 m-85 -74.36 142.33 45.09 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.734 179.918 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . 0.459 ' CD ' ' H ' ' A' ' 52' ' ' GLU . 0.2 OUTLIER -77.58 142.07 39.17 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.15 179.561 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . 0.42 ' CG ' ' OH ' ' A' ' 62' ' ' TYR . 0.5 OUTLIER -100.57 151.55 21.47 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 120.993 0.425 . . . . 0.0 110.051 -179.827 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 90.0 m-85 -115.09 122.06 44.98 Favored 'General case' 0 C--O 1.232 0.17 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.352 179.738 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.482 ' CG1' ' CE1' ' A' ' 37' ' ' TYR . 9.5 p -131.96 142.22 43.49 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.295 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.393 -179.974 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 99.3 m-20 -63.66 150.0 45.28 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.793 -0.64 . . . . 0.0 110.37 179.69 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' SER . . . . . 0.487 ' OG ' ' O ' ' A' ' 35' ' ' ILE . 4.7 m -64.71 -34.84 79.27 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.875 179.909 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 68.0 m -51.17 -36.54 41.59 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.303 -179.026 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.513 ' C ' ' H ' ' A' ' 61' ' ' TYR . 22.7 t -64.38 -42.39 95.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.092 179.884 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 72.01 -40.05 0.69 Allowed Glycine 0 CA--C 1.531 1.069 0 N-CA-C 111.048 -0.821 . . . . 0.0 111.048 179.766 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . 0.553 ' CB ' ' HE ' ' A' ' 25' ' ' ARG . 31.1 p90 -110.68 161.01 16.17 Favored 'General case' 0 N--CA 1.466 0.368 0 CA-C-O 121.093 0.473 . . . . 0.0 111.08 -179.035 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' TYR . . . . . 0.42 ' OH ' ' CG ' ' A' ' 53' ' ' ASP . 31.5 t80 -155.95 163.04 40.24 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.015 -0.539 . . . . 0.0 109.949 179.492 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 57.6 m -119.6 131.47 55.5 Favored 'General case' 0 N--CA 1.467 0.422 0 CA-C-O 121.025 0.44 . . . . 0.0 110.628 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -134.27 108.91 11.76 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 115.765 -0.652 . . . . 0.0 109.981 179.324 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 1.2 p -128.35 167.37 17.06 Favored 'General case' 0 CA--C 1.514 -0.441 0 CA-C-O 121.023 0.44 . . . . 0.0 110.47 179.939 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 108.33 24.34 6.25 Favored Glycine 0 CA--C 1.522 0.496 0 CA-C-N 115.614 -0.721 . . . . 0.0 111.502 -179.793 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.47 ' O ' ' OG ' ' A' ' 20' ' ' SER . 3.9 mt -99.61 106.42 18.38 Favored 'General case' 0 CA--C 1.517 -0.29 0 N-CA-C 109.197 -0.668 . . . . 0.0 109.197 -179.401 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -48.19 140.08 9.65 Favored Pre-proline 0 C--N 1.311 -1.097 0 CA-C-N 115.669 -0.696 . . . . 0.0 111.112 -178.247 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 68.5 Cg_endo -73.38 156.29 50.48 Favored 'Trans proline' 0 N--CA 1.5 1.896 0 C-N-CA 122.993 2.462 . . . . 0.0 111.596 178.344 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 74.61 -2.09 49.25 Favored Glycine 0 CA--C 1.525 0.718 0 CA-C-N 115.563 -0.744 . . . . 0.0 111.698 179.259 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 1.6 mp -110.46 140.5 29.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-O 121.557 0.694 . . . . 0.0 109.582 -179.283 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 1.6 t70 -80.54 122.78 27.46 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 114.877 -1.056 . . . . 0.0 110.297 179.649 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' TYR . . . . . . . . . . . . . 12.5 m-85 -114.94 122.65 46.91 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.686 -0.688 . . . . 0.0 110.809 179.785 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' ASP . . . . . 0.407 ' N ' ' O ' ' A' ' 42' ' ' VAL . 66.3 m-20 -94.32 110.78 22.52 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 108.597 -0.89 . . . . 0.0 108.597 178.692 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . 0.439 ' N ' HD12 ' A' ' 75' ' ' ILE . 0.0 OUTLIER -126.39 111.95 28.11 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.249 0 CA-C-N 116.654 -0.248 . . . . 0.0 111.27 179.954 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 23.8 t -105.43 125.66 51.24 Favored 'General case' 0 CA--C 1.518 -0.253 0 N-CA-C 109.576 -0.527 . . . . 0.0 109.576 179.247 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 84.4 t -88.71 99.52 9.24 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-O 120.939 0.4 . . . . 0.0 110.06 179.747 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 94.4 mt -82.52 135.99 23.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.356 179.914 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 30.5 p -113.26 117.71 32.62 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.231 179.623 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 1.8 mp -109.77 110.78 21.89 Favored 'General case' 0 N--CA 1.467 0.386 0 CA-C-O 121.194 0.521 . . . . 0.0 110.648 -179.822 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 2.0 pp -146.55 143.69 20.62 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.213 179.274 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' ASN . . . . . 0.425 ' H ' ' CB ' ' A' ' 33' ' ' THR . 22.5 t-20 -66.37 -49.43 66.92 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.876 0.369 . . . . 0.0 111.213 179.821 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 111.66 109.51 3.08 Favored Glycine 0 N--CA 1.465 0.597 0 N-CA-C 110.79 -0.924 . . . . 0.0 110.79 179.657 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -63.22 105.51 1.06 Allowed Glycine 0 CA--C 1.525 0.716 0 N-CA-C 110.676 -0.97 . . . . 0.0 110.676 179.967 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -93.49 128.7 39.7 Favored 'General case' 0 N--CA 1.463 0.209 0 CA-C-O 120.79 0.329 . . . . 0.0 110.339 179.929 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 66.0 m -62.85 140.81 58.82 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.101 -0.5 . . . . 0.0 109.997 -179.871 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -122.65 150.42 58.14 Favored Pre-proline 0 CA--C 1.535 0.402 0 CA-C-N 116.321 -0.399 . . . . 0.0 110.525 -179.862 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -69.27 161.85 44.2 Favored 'Trans proline' 0 N--CA 1.496 1.639 0 C-N-CA 122.816 2.344 . . . . 0.0 111.82 179.152 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 41.4 p -129.79 150.6 51.02 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.34 -179.823 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 45.0 p -138.45 172.02 13.5 Favored 'General case' 0 CA--C 1.52 -0.186 0 CA-C-N 115.894 -0.593 . . . . 0.0 110.72 -179.832 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . 0.545 ' N ' ' CD2' ' A' ' 91' ' ' LEU . 3.7 mm? -76.95 140.74 40.55 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.537 -179.543 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 64.6 p -69.77 137.25 51.75 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.47 -179.988 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 99.4 mm-40 -74.85 134.47 41.68 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.5 179.917 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 0.513 ' CD ' ' H ' ' A' ' 94' ' ' GLN . 2.2 pm0 -67.32 143.21 56.52 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.648 179.867 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 78.6 p . . . . . 0 C--O 1.221 -0.434 0 CA-C-O 118.086 -0.959 . . . . 0.0 110.371 179.744 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' B' B ' 201' ' ' SER . . . . . . . . . . . . . 3.7 p . . . . . 0 N--CA 1.491 1.592 0 N-CA-C 109.348 -0.612 . . . . 0.0 109.348 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' B' B ' 202' ' ' SER . . . . . . . . . . . . . 38.2 t -71.31 149.17 46.38 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.318 -179.936 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 203' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -90.44 151.29 44.14 Favored Pre-proline 0 CA--C 1.533 0.315 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.536 -179.888 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 204' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -65.19 -43.81 10.55 Favored 'Trans proline' 0 N--CA 1.495 1.614 0 C-N-CA 122.909 2.406 . . . . 0.0 112.1 -179.758 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 205' ' ' ILE . . . . . 0.406 HD13 HG21 ' B' ' 205' ' ' ILE . 1.6 tt -149.77 145.55 17.39 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.193 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.629 -179.523 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 206' ' ' GLN . . . . . . . . . . . . . 15.3 pt20 -146.77 144.35 29.32 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.995 -0.548 . . . . 0.0 109.781 178.873 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 207' ' ' GLY . . . . . . . . . . . . . . . -105.81 -131.16 6.85 Favored Glycine 0 N--CA 1.466 0.672 0 N-CA-C 111.054 -0.818 . . . . 0.0 111.054 -179.919 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 208' ' ' SER . . . . . 0.589 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 97.6 p -167.07 170.88 11.53 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.805 0.336 . . . . 0.0 110.622 179.748 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 209' ' ' TRP . . . . . 0.426 ' HE1' ' H ' ' A' ' 12' ' ' LEU . 79.5 m95 -86.99 155.86 20.0 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.45 179.67 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 31.6 p -133.47 133.52 42.37 Favored 'General case' 0 N--CA 1.463 0.217 0 CA-C-N 116.434 -0.348 . . . . 0.0 110.414 179.745 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 58.0 t-105 -95.78 113.85 25.52 Favored 'General case' 0 N--CA 1.463 0.214 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.627 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 212' ' ' GLU . . . . . 0.43 ' O ' ' O ' ' B' ' 215' ' ' LYS . 0.9 OUTLIER -162.29 163.1 28.26 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.5 179.591 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' B' B ' 213' ' ' ASN . . . . . . . . . . . . . 17.8 m120 51.31 34.14 11.12 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.067 177.346 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 55.21 18.17 12.73 Favored Glycine 0 CA--C 1.527 0.808 0 N-CA-C 111.298 -0.721 . . . . 0.0 111.298 179.831 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 215' ' ' LYS . . . . . 0.43 ' O ' ' O ' ' B' ' 212' ' ' GLU . 56.1 mtmt -143.3 149.76 38.27 Favored 'General case' 0 C--O 1.232 0.165 0 CA-C-O 120.834 0.349 . . . . 0.0 110.95 179.895 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 216' ' ' TRP . . . . . . . . . . . . . 48.9 m95 -87.67 113.71 23.6 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.179 -0.464 . . . . 0.0 109.764 179.507 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 217' ' ' THR . . . . . . . . . . . . . 16.3 m -119.82 134.93 55.06 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.519 -179.339 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 218' ' ' TRP . . . . . 0.589 ' CH2' ' N ' ' B' ' 208' ' ' SER . 29.1 t-105 -95.88 105.0 16.96 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.875 -0.602 . . . . 0.0 109.907 179.27 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 6.9 mtmt -130.5 167.8 18.07 Favored 'General case' 0 CA--C 1.515 -0.398 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.778 -179.357 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -178.45 -163.35 29.68 Favored Glycine 0 CA--C 1.524 0.625 0 N-CA-C 111.138 -0.785 . . . . 0.0 111.138 179.41 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 221' ' ' ILE . . . . . 0.424 ' O ' ' CG2' ' B' ' 222' ' ' ILE . 20.1 mt -55.86 -73.24 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 C-N-CA 120.645 -0.422 . . . . 0.0 110.263 -178.146 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 222' ' ' ILE . . . . . 0.479 ' O ' ' O ' ' B' ' 223' ' ' ARG . 18.9 pt -160.53 -166.8 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 O-C-N 123.402 0.439 . . . . 0.0 110.462 179.994 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 223' ' ' ARG . . . . . 0.479 ' O ' ' O ' ' B' ' 222' ' ' ILE . 33.4 ptt180 -43.3 172.71 0.0 OUTLIER 'General case' 0 C--O 1.231 0.098 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.497 179.082 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 224' ' ' LEU . . . . . 0.596 ' H ' ' CD2' ' B' ' 224' ' ' LEU . 2.2 mm? -65.5 107.2 1.61 Allowed 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 121.48 0.657 . . . . 0.0 110.322 -178.766 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 82.0 tt0 -90.04 154.23 19.97 Favored 'General case' 0 N--CA 1.452 -0.336 0 CA-C-N 115.084 -0.962 . . . . 0.0 110.01 179.919 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 226' ' ' GLN . . . . . . . . . . . . . 57.1 tt0 . . . . . 0 C--O 1.221 -0.438 0 CA-C-O 117.958 -1.02 . . . . 0.0 110.898 179.987 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.22 0 N-CA-C 109.469 -1.453 . . . . 0.0 109.469 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 29.5 m -137.02 -49.87 0.63 Allowed 'General case' 0 N--CA 1.464 0.262 0 CA-C-O 120.615 0.245 . . . . 0.0 110.751 -179.973 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 66.1 tt0 -129.68 119.27 23.24 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-O 120.918 0.39 . . . . 0.0 110.153 -179.877 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.406 ' CG1' ' O ' ' A' ' 6' ' ' VAL . 7.3 p -145.41 85.44 7.96 Favored Pre-proline 0 C--N 1.332 -0.18 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.396 -179.883 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_exo -56.93 139.37 89.39 Favored 'Trans proline' 0 C--N 1.307 -1.624 0 C-N-CA 122.472 2.115 . . . . 0.0 111.669 -179.784 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 59.5 tt0 -104.76 -21.59 13.34 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.376 179.915 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 1.9 tt -106.79 112.43 25.4 Favored 'General case' 0 C--O 1.232 0.151 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 -179.769 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 9.0 t -97.99 172.78 7.42 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.257 179.936 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . 0.424 ' OD1' ' O ' ' A' ' 11' ' ' ASP . 51.2 p-10 -137.4 142.59 41.69 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.996 0.426 . . . . 0.0 110.561 179.961 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 6.9 tt -63.86 142.56 58.36 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.135 -179.542 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 83.9 p -139.4 155.47 47.61 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.665 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . 0.492 ' CD1' ' N ' ' A' ' 14' ' ' PHE . 20.9 m-85 -110.79 144.66 39.43 Favored 'General case' 0 C--O 1.233 0.204 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.498 -179.691 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 15.5 m -145.49 162.28 12.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.598 -179.973 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 98.4 m-20 51.6 32.65 9.4 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.524 179.621 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 86.5 mt -58.84 140.29 17.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.267 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.438 ' CB ' ' O ' ' A' ' 21' ' ' SER . 0.2 OUTLIER -143.25 -166.3 2.28 Favored 'General case' 0 N--CA 1.465 0.305 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.601 -179.653 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . 0.441 ' OD1' ' N ' ' A' ' 20' ' ' SER . 28.7 p-10 -90.73 -45.25 8.96 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.693 -0.685 . . . . 0.0 110.875 179.546 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' SER . . . . . 0.441 ' N ' ' OD1' ' A' ' 19' ' ' ASP . 10.2 t -114.39 7.17 16.25 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-O 120.821 0.343 . . . . 0.0 110.92 -179.513 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' SER . . . . . 0.438 ' O ' ' CB ' ' A' ' 18' ' ' THR . 45.2 m -151.62 146.52 25.88 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.976 0.417 . . . . 0.0 110.439 179.898 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 40.8 pt -144.98 147.88 18.45 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-N 116.469 -0.332 . . . . 0.0 110.291 179.847 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -101.41 84.04 0.51 Allowed Glycine 0 CA--C 1.525 0.675 0 N-CA-C 111.038 -0.825 . . . . 0.0 111.038 -179.678 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 83.7 mt -71.39 124.6 24.96 Favored 'General case' 0 C--N 1.33 -0.282 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 -179.752 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 73.8 ttt-85 -138.94 139.92 38.14 Favored 'General case' 0 CA--C 1.52 -0.177 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.464 -179.593 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' TRP . . . . . . . . . . . . . 49.0 p90 -146.48 154.77 41.96 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.073 179.745 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 2.9 m -109.97 103.31 53.21 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-N 116.466 -0.334 . . . . 0.0 110.583 179.888 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_exo -53.87 145.03 52.85 Favored 'Trans proline' 0 C--N 1.307 -1.642 0 C-N-CA 122.07 1.846 . . . . 0.0 112.591 179.172 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 64.6 mt -78.91 139.86 38.2 Favored 'General case' 0 CA--C 1.518 -0.252 0 CA-C-O 121.697 0.76 . . . . 0.0 110.789 -179.643 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 38.1 t30 -51.07 -37.1 43.59 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-N 115.131 -0.94 . . . . 0.0 109.916 179.656 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 15.5 m -75.75 -34.86 60.29 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.64 178.975 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 10.8 m -60.11 132.95 55.51 Favored 'General case' 0 C--O 1.232 0.158 0 CA-C-O 120.975 0.417 . . . . 0.0 110.179 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' THR . . . . . 0.419 ' H ' ' HB ' ' A' ' 81' ' ' ILE . 5.6 m -57.78 145.22 35.59 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.17 -179.886 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . 0.438 HG23 HD12 ' A' ' 34' ' ' ILE . 26.8 mm -93.99 91.29 3.11 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 CA-C-O 121.012 0.434 . . . . 0.0 110.631 -179.513 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 21.6 pt -143.39 140.41 26.36 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.498 179.707 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -44.33 128.47 6.95 Favored Glycine 0 CA--C 1.521 0.463 0 N-CA-C 111.096 -0.801 . . . . 0.0 111.096 -179.781 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 75.0 m-85 -91.54 175.9 6.74 Favored 'General case' 0 CA--C 1.517 -0.302 0 CA-C-O 120.89 0.376 . . . . 0.0 110.187 179.849 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -137.26 125.49 23.15 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.588 -179.939 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . 0.438 ' O ' ' CG1' ' A' ' 39' ' ' ILE . 2.3 pt -101.68 124.81 55.71 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.251 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.1 -179.97 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 8.4 m -104.07 133.49 48.93 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.384 -179.275 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.3 p -132.98 139.38 49.67 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.296 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.319 179.756 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . 0.543 ' N ' ' O ' ' A' ' 74' ' ' ASP . 39.5 t -133.9 132.88 56.58 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.175 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.245 179.74 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -97.04 141.72 29.85 Favored 'General case' 0 C--N 1.326 -0.414 0 N-CA-C 109.702 -0.481 . . . . 0.0 109.702 179.15 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . 0.409 ' CB ' ' O ' ' A' ' 72' ' ' ASP . . . -95.13 -40.43 9.61 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.821 0.344 . . . . 0.0 110.769 179.659 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -66.17 -32.64 82.87 Favored Glycine 0 CA--C 1.526 0.758 0 N-CA-C 111.295 -0.722 . . . . 0.0 111.295 -179.737 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 63.2 mt-10 -98.16 131.42 44.55 Favored 'General case' 0 C--N 1.333 -0.146 0 N-CA-C 109.598 -0.519 . . . . 0.0 109.598 -179.694 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -59.01 -21.64 53.33 Favored Glycine 0 N--CA 1.454 -0.117 0 N-CA-C 110.609 -0.997 . . . . 0.0 110.609 -179.079 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -111.72 134.46 21.29 Favored Pre-proline 0 CA--C 1.535 0.4 0 C-N-CA 121.133 -0.227 . . . . 0.0 110.474 179.556 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 63.9 Cg_endo -76.71 163.92 30.91 Favored 'Trans proline' 0 C--N 1.31 -1.47 0 C-N-CA 122.638 2.226 . . . . 0.0 111.884 177.751 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 96.6 mt -82.93 133.97 27.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 115.975 -0.557 . . . . 0.0 109.949 179.134 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 76.0 m-85 -56.15 136.54 52.6 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 121.054 0.454 . . . . 0.0 110.824 -179.355 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 4.7 pt-20 -68.79 -175.08 0.65 Allowed 'General case' 0 CA--C 1.516 -0.33 0 CA-C-N 115.706 -0.679 . . . . 0.0 110.372 179.461 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . 0.512 ' CG ' ' HH ' ' A' ' 62' ' ' TYR . 3.6 t70 -156.38 156.0 33.14 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.674 179.04 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' PHE . . . . . 0.578 ' CD1' ' N ' ' A' ' 54' ' ' PHE . 2.1 m-85 -122.12 130.85 53.6 Favored 'General case' 0 N--CA 1.465 0.324 0 CA-C-O 120.889 0.376 . . . . 0.0 110.114 179.729 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 9.7 p -130.01 138.19 54.63 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.186 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.418 -179.836 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 97.8 m-20 -53.66 144.33 18.02 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.457 -179.702 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 38.7 t -63.33 -35.81 81.61 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.703 179.994 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 36.6 m -57.11 -31.88 65.76 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.551 -179.717 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 94.0 t -64.96 -46.47 91.57 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.537 -179.913 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 56.19 25.89 48.52 Favored Glycine 0 CA--C 1.525 0.713 0 N-CA-C 110.7 -0.96 . . . . 0.0 110.7 -179.899 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . 0.493 ' CD1' ' C ' ' A' ' 61' ' ' TYR . 7.7 t80 -159.52 146.79 16.9 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-O 121.208 0.528 . . . . 0.0 111.035 -179.201 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' TYR . . . . . 0.512 ' HH ' ' CG ' ' A' ' 53' ' ' ASP . 33.9 t80 -159.99 161.79 34.18 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.152 178.611 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 96.5 m -131.15 139.17 49.74 Favored 'General case' 0 N--CA 1.464 0.244 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.689 179.995 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -131.14 104.63 9.5 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.263 0 CA-C-N 116.188 -0.46 . . . . 0.0 109.982 179.061 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 4.6 p -109.05 155.45 20.92 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.342 179.78 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 108.32 44.38 1.17 Allowed Glycine 0 CA--C 1.525 0.682 0 N-CA-C 111.184 -0.766 . . . . 0.0 111.184 -179.705 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 19.9 mt -116.45 103.57 10.58 Favored 'General case' 0 CA--C 1.519 -0.222 0 CA-C-O 121.194 0.521 . . . . 0.0 109.827 179.679 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 55.4 mm-40 -51.24 138.19 27.68 Favored Pre-proline 0 C--N 1.317 -0.806 0 CA-C-N 115.783 -0.644 . . . . 0.0 111.44 -178.433 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -75.35 150.54 36.82 Favored 'Trans proline' 0 N--CA 1.496 1.665 0 C-N-CA 122.725 2.284 . . . . 0.0 111.635 178.687 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 70.69 17.32 74.86 Favored Glycine 0 CA--C 1.527 0.803 0 CA-C-N 115.55 -0.75 . . . . 0.0 111.361 179.14 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 1.5 mp -119.66 149.62 22.27 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.337 0 CA-C-O 121.413 0.625 . . . . 0.0 109.36 -179.503 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' ASP . . . . . 0.409 ' O ' ' CB ' ' A' ' 44' ' ' ALA . 2.4 t70 -89.39 108.97 19.94 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.15 -0.932 . . . . 0.0 110.652 -179.902 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' TYR . . . . . 0.446 ' O ' ' CD1' ' A' ' 75' ' ' ILE . 22.4 m-85 -104.3 119.53 39.17 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.348 179.772 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' ASP . . . . . 0.543 ' O ' ' N ' ' A' ' 42' ' ' VAL . 8.5 m-20 -88.2 118.43 27.78 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.531 -0.758 . . . . 0.0 109.247 179.466 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . 0.446 ' CD1' ' O ' ' A' ' 73' ' ' TYR . 0.0 OUTLIER -120.02 167.22 13.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-O 121.098 0.475 . . . . 0.0 110.272 -179.124 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' SER . . . . . 0.401 ' HG ' ' C ' ' A' ' 75' ' ' ILE . 1.8 m -154.92 126.92 7.64 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.622 -0.717 . . . . 0.0 110.591 179.248 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 21.7 t -106.02 100.26 10.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 179.178 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 23.8 mt -101.9 140.9 19.27 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.225 0 CA-C-N 116.052 -0.522 . . . . 0.0 109.909 -179.651 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 19.5 m -120.05 113.59 20.73 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.571 -179.767 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -106.68 127.93 53.77 Favored 'General case' 0 N--CA 1.463 0.22 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.434 179.796 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' ILE . . . . . 0.419 ' HB ' ' H ' ' A' ' 33' ' ' THR . 1.9 pp -141.38 145.01 25.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 115.632 -0.713 . . . . 0.0 110.219 179.565 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 37.6 t30 -56.24 -66.18 0.48 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.707 -179.73 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 157.44 103.36 0.2 Allowed Glycine 0 CA--C 1.522 0.53 0 N-CA-C 110.873 -0.891 . . . . 0.0 110.873 179.849 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -90.4 177.36 42.38 Favored Glycine 0 CA--C 1.524 0.607 0 N-CA-C 110.827 -0.909 . . . . 0.0 110.827 179.919 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . 0.48 ' OE1' ' N ' ' A' ' 85' ' ' GLU . 55.9 mp0 -80.96 122.66 27.54 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.86 0.362 . . . . 0.0 110.466 -179.944 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 83.0 p -74.3 157.89 34.99 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.409 -179.913 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -78.11 160.46 73.46 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.364 -179.807 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 44.7 Cg_endo -68.83 -14.51 39.1 Favored 'Trans proline' 0 C--N 1.309 -1.551 0 C-N-CA 122.857 2.372 . . . . 0.0 111.956 179.347 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 4.9 t -141.83 161.87 36.89 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.565 -179.632 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 68.5 p -132.07 152.35 51.24 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.434 179.94 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . 0.436 ' CD1' ' N ' ' A' ' 91' ' ' LEU . 10.1 mp -93.14 144.09 25.62 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.406 -179.855 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 34.6 p -64.8 137.31 57.7 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.066 -0.516 . . . . 0.0 110.329 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 29.2 pt20 -95.34 160.76 14.38 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.553 179.917 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 45.5 tt0 63.09 -125.87 0.59 Allowed 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.175 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 15.8 p . . . . . 0 C--O 1.222 -0.361 0 CA-C-O 117.892 -1.051 . . . . 0.0 110.335 179.983 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' B' B ' 201' ' ' SER . . . . . . . . . . . . . 57.6 p . . . . . 0 N--CA 1.49 1.534 0 N-CA-C 109.323 -0.621 . . . . 0.0 109.323 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' B' B ' 202' ' ' SER . . . . . . . . . . . . . 41.5 t -70.58 138.13 50.62 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.185 179.903 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 203' ' ' SER . . . . . . . . . . . . . 10.3 m -111.2 150.13 41.55 Favored Pre-proline 0 CA--C 1.532 0.274 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.578 179.921 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 204' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_exo -41.25 -33.91 1.56 Allowed 'Trans proline' 0 C--N 1.312 -1.38 0 C-N-CA 122.771 2.314 . . . . 0.0 112.165 179.432 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 205' ' ' ILE . . . . . 0.427 ' CG1' ' N ' ' B' ' 206' ' ' GLN . 11.7 tt -152.79 159.02 3.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.266 179.883 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 206' ' ' GLN . . . . . 0.427 ' N ' ' CG1' ' B' ' 205' ' ' ILE . 9.2 pt20 -170.68 78.66 0.08 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.463 179.25 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 207' ' ' GLY . . . . . . . . . . . . . . . -110.32 -147.3 11.38 Favored Glycine 0 N--CA 1.464 0.555 0 N-CA-C 111.088 -0.805 . . . . 0.0 111.088 -179.936 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 208' ' ' SER . . . . . 0.432 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 92.3 p -165.37 171.57 13.28 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.866 0.365 . . . . 0.0 110.746 -179.922 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 209' ' ' TRP . . . . . . . . . . . . . 80.0 m95 -81.43 146.18 30.39 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.456 179.784 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 65.2 p -128.76 132.42 47.92 Favored 'General case' 0 N--CA 1.464 0.255 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.616 -179.951 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 50.3 t-105 -91.94 116.54 29.01 Favored 'General case' 0 C--O 1.232 0.15 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.241 179.649 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 212' ' ' GLU . . . . . 0.489 ' O ' ' O ' ' B' ' 215' ' ' LYS . 1.7 pt-20 -165.46 168.19 16.85 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.972 179.261 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 213' ' ' ASN . . . . . . . . . . . . . 91.8 m-20 49.51 36.73 10.72 Favored 'General case' 0 C--N 1.322 -0.602 0 C-N-CA 120.525 -0.47 . . . . 0.0 111.217 176.634 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 50.86 16.32 1.71 Allowed Glycine 0 CA--C 1.525 0.671 0 N-CA-C 111.266 -0.734 . . . . 0.0 111.266 179.658 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 215' ' ' LYS . . . . . 0.489 ' O ' ' O ' ' B' ' 212' ' ' GLU . 50.3 mtmt -145.66 151.45 38.07 Favored 'General case' 0 C--N 1.333 -0.142 0 CA-C-O 120.942 0.401 . . . . 0.0 110.81 179.704 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 216' ' ' TRP . . . . . . . . . . . . . 53.8 m95 -87.79 123.3 32.43 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.044 179.58 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 217' ' ' THR . . . . . . . . . . . . . 12.9 m -133.7 145.21 49.69 Favored 'General case' 0 N--CA 1.464 0.269 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.502 -179.607 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 218' ' ' TRP . . . . . 0.432 ' CH2' ' N ' ' B' ' 208' ' ' SER . 14.4 t-105 -106.08 119.58 39.58 Favored 'General case' 0 N--CA 1.463 0.175 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.018 179.188 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 47.3 mtpt -141.26 169.79 16.95 Favored 'General case' 0 CA--C 1.52 -0.198 0 CA-C-O 120.92 0.39 . . . . 0.0 110.464 -179.49 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -176.04 -161.38 25.12 Favored Glycine 0 CA--C 1.526 0.732 0 N-CA-C 111.279 -0.729 . . . . 0.0 111.279 -179.883 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 221' ' ' ILE . . . . . 0.426 ' O ' ' CG2' ' B' ' 222' ' ' ILE . 2.2 mp -51.03 -73.24 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 C-N-CA 120.678 -0.409 . . . . 0.0 110.679 -178.283 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 222' ' ' ILE . . . . . 0.476 ' O ' ' O ' ' B' ' 223' ' ' ARG . 21.8 pt -159.75 -166.34 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.624 -179.584 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 223' ' ' ARG . . . . . 0.476 ' O ' ' O ' ' B' ' 222' ' ' ILE . 46.9 ptt85 -46.03 178.32 0.0 OUTLIER 'General case' 0 CA--C 1.516 -0.337 0 CA-C-N 115.756 -0.657 . . . . 0.0 110.563 179.281 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 224' ' ' LEU . . . . . 0.567 ' CD2' ' N ' ' B' ' 224' ' ' LEU . 3.1 mm? -59.41 121.71 12.16 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 115.687 -0.688 . . . . 0.0 110.533 -179.135 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 78.5 tt0 -104.2 152.87 21.64 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.4 179.986 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 226' ' ' GLN . . . . . . . . . . . . . 35.8 mt-30 . . . . . 0 C--O 1.219 -0.517 0 CA-C-O 118.023 -0.989 . . . . 0.0 110.583 -179.868 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.246 0 N-CA-C 109.431 -1.468 . . . . 0.0 109.431 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 25.8 t 54.07 78.91 0.15 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.834 0.35 . . . . 0.0 110.52 -179.868 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 80.3 mm-40 -109.7 120.4 42.37 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.43 -179.906 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 1.2 m -88.98 151.09 46.6 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.451 -179.644 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 41.6 Cg_endo -66.56 148.74 83.97 Favored 'Trans proline' 0 C--N 1.311 -1.437 0 C-N-CA 122.702 2.268 . . . . 0.0 111.865 179.556 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 77.9 mt-30 -127.24 121.64 31.77 Favored 'General case' 0 N--CA 1.464 0.256 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.31 179.618 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.494 ' CD1' ' N ' ' A' ' 9' ' ' LEU . 9.1 mp -90.13 130.61 36.27 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.043 -0.526 . . . . 0.0 109.855 -179.962 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -87.64 133.49 33.81 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.203 -179.957 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 54.7 p30 -79.77 163.24 24.61 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.667 -179.77 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 70.4 mt -63.57 151.89 40.25 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.343 -179.291 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 85.9 p -141.13 149.83 42.04 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-N 116.059 -0.518 . . . . 0.0 110.31 179.916 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . 0.519 ' CD1' ' N ' ' A' ' 14' ' ' PHE . 18.3 m-85 -111.37 145.8 38.26 Favored 'General case' 0 N--CA 1.464 0.235 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.569 -179.627 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 18.2 m -147.71 161.75 7.36 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.117 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.495 179.88 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 41.0 t0 56.06 29.32 14.29 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.66 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 96.5 mt -56.19 138.97 16.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.249 179.797 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.45 ' CB ' ' O ' ' A' ' 21' ' ' SER . 0.2 OUTLIER -139.96 -167.12 2.23 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.479 -179.69 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . 0.506 ' OD1' ' N ' ' A' ' 20' ' ' SER . 32.3 p-10 -89.63 -43.47 10.73 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.731 179.601 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' SER . . . . . 0.633 ' HG ' ' H ' ' A' ' 67' ' ' LEU . 10.2 t -117.54 8.75 13.0 Favored 'General case' 0 N--CA 1.465 0.317 0 CA-C-O 120.754 0.312 . . . . 0.0 110.889 -179.716 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' SER . . . . . 0.45 ' O ' ' CB ' ' A' ' 18' ' ' THR . 18.2 p -150.56 137.69 19.36 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.974 0.416 . . . . 0.0 110.35 -179.919 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 41.9 pt -132.07 145.68 34.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.467 -0.333 . . . . 0.0 110.159 179.921 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -97.86 81.96 0.66 Allowed Glycine 0 CA--C 1.525 0.675 0 N-CA-C 110.965 -0.854 . . . . 0.0 110.965 -179.805 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 94.9 mt -70.95 119.5 15.16 Favored 'General case' 0 C--N 1.33 -0.274 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 -179.882 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 70.1 ttt180 -138.15 142.08 40.11 Favored 'General case' 0 CA--C 1.519 -0.229 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.988 179.901 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' TRP . . . . . 0.543 ' CD2' ' O ' ' A' ' 60' ' ' GLY . 25.4 p90 -143.11 156.08 44.73 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.763 -0.653 . . . . 0.0 109.977 -179.87 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 3.2 m -109.84 101.96 48.71 Favored Pre-proline 0 N--CA 1.465 0.322 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.757 179.828 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 42.4 Cg_exo -54.94 144.57 67.07 Favored 'Trans proline' 0 C--N 1.304 -1.769 0 C-N-CA 122.108 1.872 . . . . 0.0 112.34 179.153 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 65.8 mt -83.47 139.77 32.73 Favored 'General case' 0 CA--C 1.52 -0.196 0 CA-C-O 121.813 0.816 . . . . 0.0 110.718 179.801 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 26.0 t-20 -47.94 -33.05 7.14 Favored 'General case' 0 C--N 1.319 -0.75 0 CA-C-N 115.268 -0.878 . . . . 0.0 110.19 -179.914 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 52.5 m -84.86 -30.9 24.08 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.627 179.506 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 4.9 m -58.15 131.23 49.92 Favored 'General case' 0 N--CA 1.462 0.144 0 CA-C-O 121.25 0.547 . . . . 0.0 110.444 179.912 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' THR . . . . . 0.693 ' HG1' ' N ' ' A' ' 82' ' ' ASN . 3.9 m -59.78 140.17 56.75 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.505 -0.77 . . . . 0.0 110.021 -179.801 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 58.2 mt -94.11 92.26 3.47 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.19 0 CA-C-O 120.865 0.364 . . . . 0.0 110.774 -179.778 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.433 ' O ' ' OG ' ' A' ' 57' ' ' SER . 9.5 pt -142.29 131.85 23.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.43 179.408 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -37.95 114.85 0.33 Allowed Glycine 0 CA--C 1.523 0.553 0 N-CA-C 111.442 -0.663 . . . . 0.0 111.442 -179.297 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 96.5 m-85 -79.8 177.27 9.02 Favored 'General case' 0 CA--C 1.515 -0.392 0 N-CA-C 110.019 -0.363 . . . . 0.0 110.019 -179.901 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 5.5 tmm_? -135.01 126.21 28.09 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.039 179.922 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 6.5 pt -95.35 155.33 3.33 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.391 0 N-CA-C 109.472 -0.566 . . . . 0.0 109.472 179.892 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 3.4 m -136.29 131.34 34.28 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.627 0.251 . . . . 0.0 110.624 -179.713 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.1 p -134.56 137.82 50.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.314 179.464 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . 0.538 ' N ' ' O ' ' A' ' 74' ' ' ASP . 41.5 t -134.83 135.92 52.66 Favored 'Isoleucine or valine' 0 C--O 1.23 0.058 0 CA-C-N 116.509 -0.314 . . . . 0.0 110.369 179.621 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -97.3 138.05 35.36 Favored 'General case' 0 C--N 1.33 -0.269 0 N-CA-C 109.628 -0.508 . . . . 0.0 109.628 179.231 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . 0.409 ' CB ' ' O ' ' A' ' 72' ' ' ASP . . . -90.54 -47.51 7.65 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.783 0.325 . . . . 0.0 110.708 179.723 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -61.64 -29.39 71.84 Favored Glycine 0 CA--C 1.525 0.711 0 N-CA-C 111.084 -0.806 . . . . 0.0 111.084 -179.863 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 91.2 mt-10 -95.94 127.56 42.06 Favored 'General case' 0 CA--C 1.52 -0.203 0 N-CA-C 109.357 -0.609 . . . . 0.0 109.357 -179.424 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -59.2 -22.0 54.69 Favored Glycine 0 CA--C 1.508 -0.389 0 N-CA-C 110.82 -0.912 . . . . 0.0 110.82 -179.229 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -110.16 135.04 20.58 Favored Pre-proline 0 CA--C 1.539 0.543 0 C-N-CA 120.858 -0.337 . . . . 0.0 110.235 179.702 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 62.3 Cg_endo -75.8 167.8 25.56 Favored 'Trans proline' 0 C--N 1.309 -1.517 0 C-N-CA 122.605 2.203 . . . . 0.0 111.732 177.344 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . 0.562 ' CD1' ' N ' ' A' ' 50' ' ' ILE . 1.7 mp -91.58 144.85 8.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 115.598 -0.728 . . . . 0.0 110.152 179.526 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 96.0 m-85 -65.84 142.2 58.01 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.702 -179.534 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . 0.502 ' CD ' ' H ' ' A' ' 52' ' ' GLU . 0.0 OUTLIER -73.87 -176.84 2.59 Favored 'General case' 0 CA--C 1.514 -0.424 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.602 179.664 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 3.6 t70 -151.45 147.45 26.88 Favored 'General case' 0 N--CA 1.452 -0.34 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.78 179.475 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 54.2 m-85 -115.7 124.8 51.76 Favored 'General case' 0 N--CA 1.463 0.219 0 CA-C-N 116.466 -0.334 . . . . 0.0 110.204 179.725 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 9.9 p -127.4 136.52 60.35 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.211 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.425 -179.886 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 99.8 m-20 -57.15 145.7 30.4 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.015 -0.538 . . . . 0.0 110.502 -179.707 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' SER . . . . . 0.433 ' OG ' ' O ' ' A' ' 35' ' ' ILE . 35.3 m -59.49 -33.46 71.36 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.61 179.917 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 49.5 m -52.68 -35.92 56.12 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.596 -179.901 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.509 ' O ' ' CD2' ' A' ' 61' ' ' TYR . 21.2 t -69.68 -43.72 79.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.348 179.853 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . 0.543 ' O ' ' CD2' ' A' ' 26' ' ' TRP . . . 68.68 -43.94 0.36 Allowed Glycine 0 CA--C 1.531 1.046 0 N-CA-C 110.943 -0.863 . . . . 0.0 110.943 179.903 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . 0.509 ' CD2' ' O ' ' A' ' 59' ' ' VAL . 25.0 p90 -102.49 157.71 16.73 Favored 'General case' 0 N--CA 1.463 0.223 0 CA-C-O 121.257 0.551 . . . . 0.0 111.139 -179.208 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 32.5 t80 -156.67 160.33 39.26 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.979 -0.555 . . . . 0.0 109.907 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 91.2 m -123.45 136.04 54.4 Favored 'General case' 0 C--O 1.233 0.206 0 CA-C-O 120.887 0.375 . . . . 0.0 110.699 -179.882 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -132.01 99.68 3.81 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 CA-C-N 116.035 -0.53 . . . . 0.0 109.818 179.249 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 2.2 p -106.73 159.25 16.36 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.91 0.386 . . . . 0.0 110.6 179.91 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 108.74 41.47 1.45 Allowed Glycine 0 CA--C 1.523 0.544 0 N-CA-C 111.41 -0.676 . . . . 0.0 111.41 -179.674 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.633 ' H ' ' HG ' ' A' ' 20' ' ' SER . 10.3 mt -116.43 107.88 15.34 Favored 'General case' 0 CA--C 1.517 -0.307 0 CA-C-O 121.346 0.593 . . . . 0.0 109.728 -179.868 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 53.0 mm-40 -53.85 136.07 55.95 Favored Pre-proline 0 C--N 1.318 -0.795 0 CA-C-N 115.611 -0.722 . . . . 0.0 111.622 -178.209 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo -75.34 155.43 41.37 Favored 'Trans proline' 0 N--CA 1.498 1.774 0 C-N-CA 122.952 2.434 . . . . 0.0 111.722 178.783 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 71.66 8.37 67.33 Favored Glycine 0 CA--C 1.526 0.777 0 CA-C-N 115.375 -0.829 . . . . 0.0 111.477 179.153 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 1.6 mp -118.03 145.4 24.0 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.298 0 CA-C-O 121.541 0.686 . . . . 0.0 109.381 -179.416 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' ASP . . . . . 0.409 ' O ' ' CB ' ' A' ' 44' ' ' ALA . 2.9 t70 -82.13 112.53 19.25 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-N 114.768 -1.105 . . . . 0.0 110.829 -179.579 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' TYR . . . . . 0.415 ' O ' ' CD1' ' A' ' 75' ' ' ILE . 13.3 m-85 -105.29 120.57 41.89 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.507 179.648 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' ASP . . . . . 0.538 ' O ' ' N ' ' A' ' 42' ' ' VAL . 74.0 m-20 -88.48 117.62 27.55 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.338 -0.846 . . . . 0.0 109.417 179.808 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . 0.415 ' CD1' ' O ' ' A' ' 73' ' ' TYR . 0.0 OUTLIER -117.97 163.57 15.03 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.362 0 CA-C-O 121.075 0.464 . . . . 0.0 110.011 -179.194 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -154.91 123.5 6.08 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.42 -0.809 . . . . 0.0 110.583 179.29 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 88.5 t -102.14 104.15 16.02 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 178.709 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 92.8 mt -96.95 132.71 40.79 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.224 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.349 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' THR . . . . . 0.45 ' O ' ' CG2' ' A' ' 79' ' ' THR . 14.0 t -112.15 120.25 41.17 Favored 'General case' 0 CA--C 1.514 -0.41 0 CA-C-N 116.173 -0.467 . . . . 0.0 109.946 -179.823 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -121.54 115.46 22.87 Favored 'General case' 0 N--CA 1.464 0.234 0 CA-C-N 116.306 -0.407 . . . . 0.0 110.422 -179.781 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 1.9 pp -138.25 145.14 28.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.268 -0.424 . . . . 0.0 109.921 179.049 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' ASN . . . . . 0.693 ' N ' ' HG1' ' A' ' 33' ' ' THR . 60.7 t30 -65.34 -58.85 4.88 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.792 179.965 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . 0.595 ' H ' ' HG1' ' A' ' 33' ' ' THR . . . 63.66 69.76 1.24 Allowed Glycine 0 CA--C 1.523 0.553 0 N-CA-C 110.881 -0.888 . . . . 0.0 110.881 179.897 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -46.29 123.02 6.69 Favored Glycine 0 CA--C 1.523 0.577 0 N-CA-C 110.806 -0.918 . . . . 0.0 110.806 -179.942 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -93.25 148.21 22.24 Favored 'General case' 0 N--CA 1.463 0.194 0 CA-C-O 120.801 0.334 . . . . 0.0 110.475 -179.923 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 21.1 m -66.21 144.79 56.41 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.37 -179.851 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . 58.64 74.83 0.57 Allowed Pre-proline 0 C--N 1.329 -0.293 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.591 179.956 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_exo -59.34 144.38 99.42 Favored 'Trans proline' 0 C--N 1.305 -1.737 0 C-N-CA 122.942 2.428 . . . . 0.0 111.982 179.793 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 4.6 p -83.86 164.48 19.44 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.128 -179.901 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 75.8 m -130.01 133.95 47.09 Favored 'General case' 0 N--CA 1.465 0.284 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.647 -179.94 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . 0.503 ' CD1' ' N ' ' A' ' 91' ' ' LEU . 8.8 mp -73.31 132.7 43.4 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.137 -179.736 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 61.6 p -84.21 166.89 17.18 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.516 179.919 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 28.9 mm100 -60.16 100.42 0.09 Allowed 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.284 -0.417 . . . . 0.0 110.514 179.99 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 52.0 mt-30 -64.74 -40.2 94.91 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.577 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 13.2 m . . . . . 0 C--O 1.219 -0.501 0 CA-C-O 117.804 -1.093 . . . . 0.0 110.374 -179.91 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' B' B ' 201' ' ' SER . . . . . . . . . . . . . 65.0 p . . . . . 0 N--CA 1.491 1.599 0 N-CA-C 109.291 -0.633 . . . . 0.0 109.291 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' B' B ' 202' ' ' SER . . . . . . . . . . . . . 88.3 p -66.65 153.29 43.52 Favored 'General case' 0 CA--C 1.515 -0.386 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.3 -179.901 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 203' ' ' SER . . . . . . . . . . . . . 4.8 p -107.7 150.63 40.46 Favored Pre-proline 0 CA--C 1.538 0.492 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.575 -179.857 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 204' ' ' PRO . . . . . . . . . . . . . 74.8 Cg_exo -45.67 -48.02 12.74 Favored 'Trans proline' 0 N--CA 1.494 1.505 0 C-N-CA 122.226 1.95 . . . . 0.0 112.182 179.424 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 205' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -151.36 147.35 15.51 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.469 179.825 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 206' ' ' GLN . . . . . . . . . . . . . 14.3 pt20 -143.06 144.17 32.15 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.465 -0.334 . . . . 0.0 110.509 178.943 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 207' ' ' GLY . . . . . 0.416 ' C ' ' CH2' ' B' ' 218' ' ' TRP . . . -105.67 -135.59 8.25 Favored Glycine 0 N--CA 1.465 0.62 0 N-CA-C 110.99 -0.844 . . . . 0.0 110.99 179.827 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 208' ' ' SER . . . . . 0.535 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 52.0 p -166.46 171.81 11.5 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.711 0.291 . . . . 0.0 110.703 179.664 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 209' ' ' TRP . . . . . . . . . . . . . 42.6 m95 -85.22 147.33 26.64 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.504 179.052 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 51.1 p -129.47 129.86 45.13 Favored 'General case' 0 C--O 1.232 0.176 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.7 179.876 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 42.5 t-105 -91.82 118.11 30.4 Favored 'General case' 0 C--N 1.334 -0.074 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.137 179.801 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 212' ' ' GLU . . . . . 0.443 ' O ' ' O ' ' B' ' 215' ' ' LYS . 1.0 OUTLIER -166.09 168.44 15.47 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.829 179.321 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' B' B ' 213' ' ' ASN . . . . . . . . . . . . . 93.1 m-20 49.47 37.55 12.36 Favored 'General case' 0 C--N 1.323 -0.566 0 C-N-CA 120.471 -0.492 . . . . 0.0 111.404 176.671 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 49.61 17.1 1.21 Allowed Glycine 0 CA--C 1.526 0.744 0 N-CA-C 111.337 -0.705 . . . . 0.0 111.337 179.703 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 215' ' ' LYS . . . . . 0.443 ' O ' ' O ' ' B' ' 212' ' ' GLU . 53.0 mtmt -142.99 150.25 39.4 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-O 121.169 0.509 . . . . 0.0 110.798 179.935 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 216' ' ' TRP . . . . . . . . . . . . . 59.5 m95 -89.49 118.48 29.17 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.012 -0.54 . . . . 0.0 109.818 179.631 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 217' ' ' THR . . . . . . . . . . . . . 17.7 m -131.23 144.51 51.38 Favored 'General case' 0 N--CA 1.466 0.328 0 CA-C-O 120.924 0.392 . . . . 0.0 110.524 -179.634 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 218' ' ' TRP . . . . . 0.535 ' CH2' ' N ' ' B' ' 208' ' ' SER . 12.0 t-105 -104.83 117.4 33.97 Favored 'General case' 0 C--N 1.328 -0.346 0 N-CA-C 109.532 -0.544 . . . . 0.0 109.532 179.262 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 50.5 mtpt -142.98 168.77 18.93 Favored 'General case' 0 CA--C 1.518 -0.253 0 CA-C-O 121.112 0.482 . . . . 0.0 110.485 -179.275 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -175.76 -162.25 26.5 Favored Glycine 0 CA--C 1.523 0.571 0 CA-C-N 115.603 -0.726 . . . . 0.0 111.389 -179.861 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 221' ' ' ILE . . . . . 0.42 ' O ' ' CG2' ' B' ' 222' ' ' ILE . 0.8 OUTLIER -53.34 -75.96 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 C-N-CA 120.641 -0.423 . . . . 0.0 110.872 -178.648 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' B' B ' 222' ' ' ILE . . . . . 0.483 ' O ' ' O ' ' B' ' 223' ' ' ARG . 23.1 pt -158.97 -165.37 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.323 -179.232 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 223' ' ' ARG . . . . . 0.483 ' O ' ' O ' ' B' ' 222' ' ' ILE . 52.7 ptt85 -42.94 172.87 0.0 OUTLIER 'General case' 0 C--O 1.234 0.276 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.299 179.133 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 224' ' ' LEU . . . . . 0.623 ' H ' ' CD2' ' B' ' 224' ' ' LEU . 1.7 mm? -68.37 111.59 4.72 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-O 121.296 0.57 . . . . 0.0 110.461 -179.378 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 26.7 tp10 -82.63 151.04 26.48 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.196 -0.911 . . . . 0.0 110.37 179.745 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 226' ' ' GLN . . . . . . . . . . . . . 94.5 mt-30 . . . . . 0 C--N 1.326 -0.448 0 CA-C-O 117.938 -1.029 . . . . 0.0 110.654 -179.823 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.174 0 N-CA-C 109.538 -1.425 . . . . 0.0 109.538 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 87.8 p -155.08 129.31 8.93 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.802 0.334 . . . . 0.0 110.385 179.799 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 72.0 mm-40 -108.62 76.43 1.02 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.218 -0.446 . . . . 0.0 109.93 179.66 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 22.4 t -76.61 116.6 58.03 Favored Pre-proline 0 CA--C 1.539 0.526 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.823 -179.674 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_exo -55.37 128.11 29.08 Favored 'Trans proline' 0 N--CA 1.5 1.901 0 C-N-CA 121.646 1.564 . . . . 0.0 112.077 179.341 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER 170.67 -0.75 0.0 OUTLIER 'General case' 0 N--CA 1.465 0.297 0 CA-C-O 120.694 0.283 . . . . 0.0 110.465 179.312 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.414 ' N ' ' CD1' ' A' ' 9' ' ' LEU . 10.6 mp -91.04 122.12 33.43 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 120.952 0.406 . . . . 0.0 109.908 179.851 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 33.9 p -107.9 125.3 51.32 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.421 -179.861 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -88.82 143.27 27.01 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.446 179.715 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -74.18 153.26 39.57 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 114.965 -1.016 . . . . 0.0 109.806 -179.923 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 49.1 p -140.1 154.8 47.14 Favored 'General case' 0 C--N 1.333 -0.13 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.28 179.056 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . 0.472 ' CD1' ' N ' ' A' ' 14' ' ' PHE . 32.2 m-85 -103.69 146.35 28.73 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.562 -179.645 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 20.8 m -149.17 162.81 4.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.251 -0.432 . . . . 0.0 110.373 179.863 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 97.4 m-20 54.85 26.97 8.35 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.769 179.991 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 96.6 mt -56.06 136.16 18.87 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-O 121.007 0.432 . . . . 0.0 110.085 179.951 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.597 ' HG1' ' H ' ' A' ' 21' ' ' SER . 1.1 p -135.62 -166.79 1.91 Allowed 'General case' 0 CA--C 1.511 -0.548 0 CA-C-N 115.678 -0.692 . . . . 0.0 110.137 -179.977 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . 0.532 ' OD1' ' N ' ' A' ' 20' ' ' SER . 37.0 p-10 -90.46 -41.45 11.43 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.244 -0.889 . . . . 0.0 111.12 178.979 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' SER . . . . . 0.532 ' N ' ' OD1' ' A' ' 19' ' ' ASP . 5.7 t -114.8 9.44 16.3 Favored 'General case' 0 N--CA 1.468 0.432 0 CA-C-N 116.323 -0.398 . . . . 0.0 110.984 -179.012 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' SER . . . . . 0.597 ' H ' ' HG1' ' A' ' 18' ' ' THR . 27.9 p -154.85 158.05 38.79 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.118 179.61 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 42.9 pt -148.69 148.83 15.59 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.15 -179.912 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -100.88 78.82 0.42 Allowed Glycine 0 N--CA 1.467 0.721 0 N-CA-C 110.889 -0.884 . . . . 0.0 110.889 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . 0.442 ' O ' ' CD1' ' A' ' 61' ' ' TYR . 20.9 mt -63.78 130.65 45.05 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.875 0.369 . . . . 0.0 110.233 -179.474 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 18.0 tpt180 -144.72 134.21 23.26 Favored 'General case' 0 CA--C 1.515 -0.372 0 CA-C-O 121.302 0.572 . . . . 0.0 110.201 -179.61 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' TRP . . . . . . . . . . . . . 39.8 p90 -147.82 153.83 39.68 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.082 -0.963 . . . . 0.0 110.015 179.213 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 3.1 m -110.32 100.61 45.19 Favored Pre-proline 0 CA--C 1.532 0.266 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.652 -179.964 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_exo -54.32 149.44 37.41 Favored 'Trans proline' 0 C--N 1.305 -1.752 0 C-N-CA 121.505 1.47 . . . . 0.0 112.877 179.347 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 64.1 mt -79.98 135.81 36.48 Favored 'General case' 0 CA--C 1.513 -0.471 0 CA-C-O 121.906 0.86 . . . . 0.0 110.67 -179.833 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 37.8 t30 -49.81 -34.88 20.92 Favored 'General case' 0 C--N 1.312 -1.054 0 CA-C-N 114.814 -1.084 . . . . 0.0 110.116 179.971 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 63.5 m -78.55 -33.74 47.59 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.721 -0.672 . . . . 0.0 110.784 179.027 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 4.9 m -57.87 133.82 55.77 Favored 'General case' 0 N--CA 1.462 0.147 0 CA-C-O 121.132 0.492 . . . . 0.0 110.138 -179.857 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' THR . . . . . 0.518 ' OG1' ' N ' ' A' ' 82' ' ' ASN . 5.2 m -58.33 143.55 44.52 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.84 -0.618 . . . . 0.0 109.845 -179.801 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 20.9 mm -94.19 90.97 2.95 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-O 120.925 0.393 . . . . 0.0 110.802 -179.428 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.466 ' O ' ' OG ' ' A' ' 57' ' ' SER . 8.8 pt -143.36 127.02 13.67 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.212 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.204 179.582 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -40.58 121.27 1.81 Allowed Glycine 0 CA--C 1.521 0.441 0 N-CA-C 111.372 -0.691 . . . . 0.0 111.372 -179.571 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' TYR . . . . . 0.477 ' CE2' ' OG ' ' A' ' 57' ' ' SER . 98.9 m-85 -85.37 178.26 7.52 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.548 -0.326 . . . . 0.0 110.168 179.796 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 6.6 tmm_? -131.44 128.52 39.67 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.448 179.741 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . 0.479 ' CD1' ' CD2' ' A' ' 62' ' ' TYR . 1.8 pt -101.24 123.56 54.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.045 179.827 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 11.8 m -103.67 130.46 51.14 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.441 -0.345 . . . . 0.0 110.44 -179.862 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.1 p -128.59 138.12 55.47 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.55 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.023 179.919 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . 0.516 ' O ' ' N ' ' A' ' 74' ' ' ASP . 39.2 t -132.19 130.96 61.04 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.319 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 179.486 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -95.87 141.09 29.72 Favored 'General case' 0 C--N 1.324 -0.516 0 N-CA-C 109.207 -0.664 . . . . 0.0 109.207 179.199 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . 0.405 ' CB ' ' O ' ' A' ' 72' ' ' ASP . . . -93.84 -39.4 10.73 Favored 'General case' 0 C--N 1.327 -0.371 0 C-N-CA 120.652 -0.419 . . . . 0.0 110.69 179.652 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -66.13 -31.2 78.56 Favored Glycine 0 CA--C 1.526 0.78 0 N-CA-C 111.623 -0.591 . . . . 0.0 111.623 -179.545 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 51.6 mt-10 -98.3 133.05 43.25 Favored 'General case' 0 CA--C 1.518 -0.253 0 N-CA-C 109.539 -0.541 . . . . 0.0 109.539 -179.626 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -59.51 -21.73 55.0 Favored Glycine 0 CA--C 1.521 0.44 0 N-CA-C 110.845 -0.902 . . . . 0.0 110.845 -179.217 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -114.03 135.27 22.08 Favored Pre-proline 0 N--CA 1.473 0.685 0 CA-C-N 116.672 0.236 . . . . 0.0 110.626 179.854 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -76.49 162.33 33.4 Favored 'Trans proline' 0 N--CA 1.492 1.433 0 C-N-CA 122.519 2.146 . . . . 0.0 111.426 178.258 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 96.3 mt -81.74 134.34 27.29 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-N 116.151 -0.477 . . . . 0.0 109.953 179.335 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 97.9 m-85 -54.85 141.93 31.24 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.942 0.401 . . . . 0.0 110.797 -179.492 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 2.9 pt-20 -80.99 151.97 28.2 Favored 'General case' 0 CA--C 1.517 -0.296 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.262 179.796 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 2.0 t70 -120.52 160.3 23.45 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.764 179.714 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' PHE . . . . . 0.549 ' CD1' ' N ' ' A' ' 54' ' ' PHE . 6.1 m-85 -121.18 128.66 52.69 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.089 179.839 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 9.8 p -128.23 138.12 55.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 116.352 -0.385 . . . . 0.0 110.361 -179.701 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 98.8 m-20 -56.92 143.36 37.94 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.666 -179.662 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' SER . . . . . 0.477 ' OG ' ' CE2' ' A' ' 37' ' ' TYR . 17.7 m -61.72 -34.24 75.44 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.889 179.893 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 37.5 m -57.04 -32.91 66.67 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.441 -179.808 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 92.8 t -65.55 -45.65 91.93 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.683 179.892 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 56.56 25.1 49.5 Favored Glycine 0 CA--C 1.527 0.821 0 N-CA-C 110.937 -0.865 . . . . 0.0 110.937 179.892 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . 0.442 ' CD1' ' O ' ' A' ' 24' ' ' LEU . 52.5 t80 -160.28 146.24 15.34 Favored 'General case' 0 N--CA 1.464 0.236 0 CA-C-O 121.141 0.496 . . . . 0.0 111.178 -179.359 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' TYR . . . . . 0.479 ' CD2' ' CD1' ' A' ' 39' ' ' ILE . 30.9 t80 -158.26 159.38 35.93 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.139 179.011 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 48.9 m -128.07 137.29 52.09 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.486 -179.423 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -131.13 101.75 5.68 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.34 0 CA-C-N 115.95 -0.568 . . . . 0.0 109.615 178.912 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 4.7 p -110.54 162.44 14.7 Favored 'General case' 0 N--CA 1.464 0.23 0 CA-C-O 121.006 0.432 . . . . 0.0 110.558 179.868 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 109.05 5.88 30.35 Favored Glycine 0 CA--C 1.527 0.832 0 CA-C-N 115.639 -0.709 . . . . 0.0 111.335 -179.655 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 12.1 mt -79.24 109.2 13.34 Favored 'General case' 0 C--N 1.329 -0.315 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.841 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 7.4 mm-40 -55.25 138.89 66.37 Favored Pre-proline 0 C--N 1.321 -0.65 0 C-N-CA 120.63 -0.428 . . . . 0.0 111.576 -178.236 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 95.8 Cg_endo -74.56 151.59 42.06 Favored 'Trans proline' 0 N--CA 1.493 1.495 0 C-N-CA 122.627 2.218 . . . . 0.0 111.725 179.113 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 72.4 10.15 74.41 Favored Glycine 0 CA--C 1.528 0.877 0 CA-C-N 115.161 -0.927 . . . . 0.0 111.642 179.229 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 1.7 mp -115.48 142.6 27.92 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.655 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 -179.727 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' ASP . . . . . 0.405 ' O ' ' CB ' ' A' ' 44' ' ' ALA . 2.3 t70 -81.73 110.88 17.47 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-N 115.162 -0.926 . . . . 0.0 110.311 179.977 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' TYR . . . . . 0.526 ' O ' ' CD1' ' A' ' 75' ' ' ILE . 14.8 m-85 -106.07 117.95 35.35 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.198 -179.911 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' ASP . . . . . 0.516 ' N ' ' O ' ' A' ' 42' ' ' VAL . 72.2 m-20 -88.16 119.83 28.93 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.145 -0.934 . . . . 0.0 109.331 179.754 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . 0.635 ' CD1' ' N ' ' A' ' 75' ' ' ILE . 0.0 OUTLIER -121.36 166.27 16.06 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.307 0 CA-C-O 121.067 0.46 . . . . 0.0 110.424 -179.103 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 22.5 t -155.15 151.3 28.07 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.745 -0.661 . . . . 0.0 110.122 179.26 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 2.4 t -125.3 109.7 22.65 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.335 0 N-CA-C 109.25 -0.648 . . . . 0.0 109.25 178.899 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 90.8 mt -97.27 123.11 49.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-O 120.891 0.377 . . . . 0.0 110.239 179.924 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' THR . . . . . 0.427 ' OG1' ' O ' ' B' ' 216' ' ' TRP . 19.6 p -103.48 111.4 23.83 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.059 179.752 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 35.4 tp -120.44 121.13 37.84 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.096 179.646 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' ILE . . . . . 0.427 ' HB ' ' H ' ' A' ' 33' ' ' THR . 2.3 pp -143.05 149.87 18.23 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 CA-C-N 116.081 -0.508 . . . . 0.0 110.189 179.634 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' ASN . . . . . 0.518 ' N ' ' OG1' ' A' ' 33' ' ' THR . 40.9 t30 -68.23 -47.45 67.77 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.443 -0.344 . . . . 0.0 111.159 179.916 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 107.81 -126.68 8.4 Favored Glycine 0 CA--C 1.526 0.775 0 N-CA-C 110.876 -0.889 . . . . 0.0 110.876 179.729 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -66.73 146.24 48.09 Favored Glycine 0 CA--C 1.524 0.608 0 N-CA-C 110.875 -0.89 . . . . 0.0 110.875 -179.892 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -67.61 154.23 41.92 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.808 0.337 . . . . 0.0 110.6 -179.928 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 25.1 p -71.32 162.82 28.81 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.339 179.916 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . 0.568 ' N ' ' CD ' ' A' ' 88' ' ' PRO . . . -179.26 -44.45 0.0 OUTLIER Pre-proline 0 CA--C 1.535 0.385 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.193 -179.689 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . 0.568 ' CD ' ' N ' ' A' ' 87' ' ' ALA . 35.2 Cg_exo -60.21 -177.56 0.16 Allowed 'Trans proline' 0 N--CA 1.497 1.68 0 C-N-CA 122.569 2.179 . . . . 0.0 112.235 -179.648 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 26.3 m -61.82 130.61 46.54 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.174 -179.961 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.4 m -142.29 162.65 34.93 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.036 179.897 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 2.2 pp -58.0 135.29 56.93 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.182 -179.897 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 64.3 p -89.38 122.58 32.74 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.476 -179.866 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 54.7 tt0 -78.77 143.24 36.31 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.39 179.949 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 0.428 ' CD ' ' H ' ' A' ' 94' ' ' GLN . 27.0 mp0 -65.75 130.46 43.34 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.446 179.957 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 36.7 p . . . . . 0 C--O 1.22 -0.467 0 CA-C-O 118.013 -0.994 . . . . 0.0 110.533 179.975 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' B' B ' 201' ' ' SER . . . . . . . . . . . . . 14.7 p . . . . . 0 N--CA 1.491 1.611 0 N-CA-C 109.278 -0.638 . . . . 0.0 109.278 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' B' B ' 202' ' ' SER . . . . . . . . . . . . . 70.4 m -69.02 146.86 52.33 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.195 -0.457 . . . . 0.0 109.855 179.852 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 203' ' ' SER . . . . . . . . . . . . . 82.6 p -123.82 107.54 31.1 Favored Pre-proline 0 CA--C 1.541 0.617 0 N-CA-C 110.096 -0.335 . . . . 0.0 110.096 179.351 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 204' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo -77.22 -57.23 0.04 OUTLIER 'Trans proline' 0 N--CA 1.493 1.468 0 C-N-CA 121.964 1.776 . . . . 0.0 112.024 -179.865 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 205' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -150.77 147.36 15.83 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.22 179.868 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 206' ' ' GLN . . . . . . . . . . . . . 61.3 tt0 -146.14 144.61 30.08 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.148 179.245 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 207' ' ' GLY . . . . . . . . . . . . . . . -107.12 -132.28 6.93 Favored Glycine 0 N--CA 1.466 0.648 0 N-CA-C 111.125 -0.79 . . . . 0.0 111.125 179.993 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 208' ' ' SER . . . . . 0.52 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 90.6 p -169.67 172.96 6.55 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.892 0.377 . . . . 0.0 110.864 -179.553 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 209' ' ' TRP . . . . . . . . . . . . . 69.1 m95 -92.74 153.52 18.86 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-N 115.815 -0.63 . . . . 0.0 110.488 179.289 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 49.8 p -135.04 140.27 45.45 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.521 179.631 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 61.0 t-105 -90.18 114.7 26.73 Favored 'General case' 0 C--N 1.332 -0.154 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.214 179.583 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 212' ' ' GLU . . . . . 0.522 ' O ' ' O ' ' B' ' 215' ' ' LYS . 3.8 tt0 -161.85 154.06 19.52 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.583 179.684 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 213' ' ' ASN . . . . . 0.442 ' C ' ' H ' ' B' ' 215' ' ' LYS . 83.5 m-20 56.72 40.62 29.07 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 115.421 -0.809 . . . . 0.0 111.78 177.022 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 51.19 11.41 0.64 Allowed Glycine 0 CA--C 1.528 0.854 0 N-CA-C 111.64 -0.584 . . . . 0.0 111.64 179.571 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 215' ' ' LYS . . . . . 0.522 ' O ' ' O ' ' B' ' 212' ' ' GLU . 80.6 mttt -141.61 151.33 43.03 Favored 'General case' 0 C--O 1.225 -0.212 0 CA-C-O 121.109 0.481 . . . . 0.0 110.963 -179.854 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 216' ' ' TRP . . . . . 0.479 ' CD1' ' N ' ' B' ' 216' ' ' TRP . 24.8 m95 -85.85 119.42 26.14 Favored 'General case' 0 C--N 1.327 -0.406 0 C-N-CA 120.731 -0.387 . . . . 0.0 110.049 179.701 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 217' ' ' THR . . . . . . . . . . . . . 16.7 m -125.86 142.1 51.67 Favored 'General case' 0 N--CA 1.467 0.395 0 N-CA-C 110.109 -0.33 . . . . 0.0 110.109 -179.525 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 218' ' ' TRP . . . . . 0.52 ' CH2' ' N ' ' B' ' 208' ' ' SER . 13.7 t-105 -103.49 117.15 33.78 Favored 'General case' 0 N--CA 1.463 0.186 0 CA-C-N 115.906 -0.588 . . . . 0.0 109.439 179.445 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 8.1 mtmp? -143.24 163.01 34.12 Favored 'General case' 0 CA--C 1.516 -0.355 0 CA-C-O 121.21 0.529 . . . . 0.0 110.634 -179.477 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -176.56 -160.27 23.46 Favored Glycine 0 CA--C 1.523 0.568 0 N-CA-C 111.185 -0.766 . . . . 0.0 111.185 -179.536 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 221' ' ' ILE . . . . . 0.409 ' O ' ' CG2' ' B' ' 222' ' ' ILE . 0.7 OUTLIER -51.05 -75.38 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 C-N-CA 120.778 -0.369 . . . . 0.0 110.566 -178.854 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' B' B ' 222' ' ' ILE . . . . . 0.508 ' O ' ' O ' ' B' ' 223' ' ' ARG . 17.0 pt -160.25 -165.76 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 CA-C-N 116.327 -0.397 . . . . 0.0 109.991 -179.653 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 223' ' ' ARG . . . . . 0.508 ' O ' ' O ' ' B' ' 222' ' ' ILE . 22.5 ptt180 -42.33 175.38 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 121.472 0.653 . . . . 0.0 110.841 178.864 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 224' ' ' LEU . . . . . 0.517 ' CD2' ' N ' ' B' ' 224' ' ' LEU . 3.6 mm? -61.31 123.5 17.93 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 115.497 -0.774 . . . . 0.0 110.65 -179.753 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 79.9 tt0 -80.39 143.21 33.67 Favored 'General case' 0 CA--C 1.518 -0.282 0 CA-C-N 115.385 -0.825 . . . . 0.0 110.221 179.817 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 226' ' ' GLN . . . . . 0.511 ' N ' ' OE1' ' B' ' 226' ' ' GLN . 0.9 OUTLIER . . . . . 0 C--N 1.323 -0.547 0 CA-C-O 118.016 -0.992 . . . . 0.0 110.569 -179.618 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.285 0 N-CA-C 109.571 -1.411 . . . . 0.0 109.571 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 97.4 p -76.69 164.57 25.75 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 120.728 0.299 . . . . 0.0 110.656 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 80.7 mm-40 -67.01 147.49 53.16 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.749 -179.914 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 12.2 p -66.33 124.23 87.52 Favored Pre-proline 0 CA--C 1.54 0.565 0 C-N-CA 120.525 -0.47 . . . . 0.0 110.709 -179.435 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 66.2 Cg_endo -75.97 126.01 9.06 Favored 'Trans proline' 0 N--CA 1.495 1.612 0 C-N-CA 121.902 1.734 . . . . 0.0 112.027 179.679 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 98.0 mt-30 -102.42 138.03 39.88 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.065 179.727 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 5.7 tp -80.82 108.92 14.89 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.294 -179.684 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 74.4 p -84.93 164.22 18.47 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.471 179.568 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 99.3 m-20 -128.9 155.43 45.29 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.355 -179.958 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 6.3 tt -64.2 142.99 58.22 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.154 -179.31 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 83.6 p -140.49 154.43 46.59 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.648 179.697 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . 0.505 ' CD1' ' N ' ' A' ' 14' ' ' PHE . 21.5 m-85 -111.41 144.77 40.09 Favored 'General case' 0 N--CA 1.464 0.274 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.668 -179.739 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 31.2 m -146.27 161.75 10.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.321 -0.399 . . . . 0.0 110.614 179.793 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 98.2 m-20 53.87 31.08 12.55 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.499 179.764 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.403 ' C ' ' HG1' ' A' ' 18' ' ' THR . 99.2 mt -57.09 140.91 14.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.258 -179.972 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.444 ' CB ' ' O ' ' A' ' 21' ' ' SER . 0.2 OUTLIER -141.28 -168.11 2.55 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-N 116.009 -0.542 . . . . 0.0 110.326 -179.778 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . 0.477 ' N ' ' OD1' ' A' ' 19' ' ' ASP . 21.0 p-10 -88.88 -45.23 9.87 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.874 179.467 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 22.4 m -114.45 7.99 16.39 Favored 'General case' 0 N--CA 1.468 0.465 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.882 -179.543 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' SER . . . . . 0.444 ' O ' ' CB ' ' A' ' 18' ' ' THR . 34.4 t -151.55 145.53 25.21 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.156 0.503 . . . . 0.0 110.232 179.551 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 45.3 pt -138.89 146.29 26.39 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.587 0 CA-C-N 115.802 -0.635 . . . . 0.0 110.352 -179.618 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -99.1 82.19 0.57 Allowed Glycine 0 CA--C 1.524 0.612 0 N-CA-C 110.903 -0.879 . . . . 0.0 110.903 -179.953 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 94.2 mt -70.02 121.8 18.13 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.856 0.36 . . . . 0.0 110.182 179.884 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 59.9 ttp180 -141.28 136.14 31.32 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.164 179.949 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' TRP . . . . . . . . . . . . . 37.8 p90 -139.21 156.04 47.38 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.897 -0.592 . . . . 0.0 109.925 -179.795 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 3.5 m -110.59 98.89 39.09 Favored Pre-proline 0 C--N 1.33 -0.239 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.481 179.718 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 39.9 Cg_exo -53.66 147.63 39.01 Favored 'Trans proline' 0 C--N 1.303 -1.821 0 C-N-CA 121.63 1.554 . . . . 0.0 112.911 179.772 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 59.9 mt -87.76 141.93 28.22 Favored 'General case' 0 CA--C 1.511 -0.55 0 CA-C-N 115.437 -0.801 . . . . 0.0 110.398 -179.873 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 18.3 t-20 -50.07 -37.14 32.1 Favored 'General case' 0 C--N 1.315 -0.909 0 CA-C-N 114.908 -1.042 . . . . 0.0 110.067 -179.831 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 70.3 m -78.24 -33.5 49.74 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.547 178.755 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 14.1 m -60.83 131.09 49.58 Favored 'General case' 0 N--CA 1.463 0.194 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.067 -179.881 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 5.1 m -65.91 142.18 57.98 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.253 -179.971 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . 0.408 HG23 HD13 ' A' ' 34' ' ' ILE . 16.3 mm -94.82 90.75 2.79 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.19 0 CA-C-N 116.339 -0.392 . . . . 0.0 110.616 -179.848 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.473 ' O ' ' OG ' ' A' ' 57' ' ' SER . 24.9 pt -134.25 144.43 35.3 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.381 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.25 179.923 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -43.4 112.66 0.57 Allowed Glycine 0 CA--C 1.517 0.169 0 C-N-CA 120.59 -0.814 . . . . 0.0 111.58 -179.167 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' TYR . . . . . 0.516 ' CE1' ' O ' ' A' ' 38' ' ' ARG . 0.9 OUTLIER -91.4 120.46 32.27 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 109.062 -0.718 . . . . 0.0 109.062 179.205 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . 0.516 ' O ' ' CE1' ' A' ' 37' ' ' TYR . 4.7 tmm_? -90.07 133.87 34.59 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.912 -0.586 . . . . 0.0 110.65 179.941 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 6.3 pt -93.67 154.76 3.24 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.314 0 CA-C-N 116.153 -0.476 . . . . 0.0 109.806 179.926 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 2.1 m -131.19 130.03 42.46 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.486 -0.325 . . . . 0.0 110.394 179.409 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.3 p -134.47 136.1 53.17 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.496 0 CA-C-O 120.94 0.4 . . . . 0.0 110.697 179.83 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . 0.511 ' O ' ' N ' ' A' ' 74' ' ' ASP . 32.1 t -131.15 127.6 60.87 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.319 0 N-CA-C 109.5 -0.556 . . . . 0.0 109.5 179.362 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -94.58 141.22 28.85 Favored 'General case' 0 C--N 1.324 -0.539 0 N-CA-C 109.516 -0.549 . . . . 0.0 109.516 179.357 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . 0.528 ' C ' ' H ' ' A' ' 46' ' ' GLU . . . -96.63 -43.5 7.55 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.922 0.391 . . . . 0.0 110.872 179.783 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -74.24 30.82 0.97 Allowed Glycine 0 CA--C 1.525 0.659 0 N-CA-C 110.863 -0.895 . . . . 0.0 110.863 -179.957 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . 0.528 ' H ' ' C ' ' A' ' 44' ' ' ALA . 79.8 mm-40 -146.17 150.73 36.42 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 121.11 0.481 . . . . 0.0 110.695 -179.526 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -76.25 -14.67 82.1 Favored Glycine 0 CA--C 1.521 0.448 0 N-CA-C 110.711 -0.956 . . . . 0.0 110.711 179.752 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . 0.4 HG22 HD11 ' A' ' 48' ' ' ILE . 0.3 OUTLIER -138.34 139.5 25.38 Favored Pre-proline 0 CA--C 1.54 0.589 0 C-N-CA 120.961 -0.296 . . . . 0.0 110.464 179.581 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 70.6 Cg_endo -75.27 161.92 37.22 Favored 'Trans proline' 0 N--CA 1.491 1.349 0 C-N-CA 122.64 2.227 . . . . 0.0 111.84 177.957 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . 0.425 HD12 HG23 ' A' ' 50' ' ' ILE . 96.3 mt -76.63 140.8 16.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.431 179.129 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 88.8 m-85 -62.84 141.7 58.54 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.459 -179.76 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . 0.466 ' CD ' ' H ' ' A' ' 52' ' ' GLU . 0.1 OUTLIER -76.92 146.36 37.63 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.46 179.714 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 4.8 t70 -113.18 150.94 31.55 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.66 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 72.7 m-85 -111.03 122.03 46.85 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.237 179.708 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 10.8 p -127.89 137.97 56.06 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.366 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.482 -179.963 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 89.7 m-20 -64.38 139.8 58.8 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.203 179.368 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' SER . . . . . 0.473 ' OG ' ' O ' ' A' ' 35' ' ' ILE . 2.8 m -59.47 -28.94 67.45 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.467 -179.83 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 37.6 m -55.8 -32.01 63.14 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.573 -179.998 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.498 ' O ' ' CD2' ' A' ' 61' ' ' TYR . 50.1 t -61.88 -44.2 98.51 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 -179.099 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 70.39 13.73 71.09 Favored Glycine 0 CA--C 1.53 0.977 0 N-CA-C 111.033 -0.827 . . . . 0.0 111.033 179.473 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . 0.498 ' CD2' ' O ' ' A' ' 59' ' ' VAL . 26.4 p90 -171.9 158.56 4.84 Favored 'General case' 0 C--O 1.225 -0.226 0 CA-C-O 120.993 0.425 . . . . 0.0 111.583 179.594 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 35.1 t80 -155.99 154.72 31.55 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.054 177.972 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 86.3 m -116.32 133.04 56.46 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.4 -179.456 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -131.08 100.84 4.91 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.275 0 N-CA-C 109.475 -0.565 . . . . 0.0 109.475 179.152 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 2.4 p -110.33 163.47 13.62 Favored 'General case' 0 N--CA 1.464 0.239 0 CA-C-O 121.007 0.432 . . . . 0.0 110.706 -179.869 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 110.08 9.79 23.56 Favored Glycine 0 CA--C 1.528 0.851 0 CA-C-N 115.496 -0.775 . . . . 0.0 111.49 -179.56 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 8.1 mt -83.52 107.61 16.11 Favored 'General case' 0 C--N 1.33 -0.274 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 179.829 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 17.5 mm-40 -57.58 138.53 81.81 Favored Pre-proline 0 C--N 1.32 -0.694 0 C-N-CA 120.321 -0.552 . . . . 0.0 111.609 -178.295 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 90.2 Cg_endo -74.54 154.65 45.02 Favored 'Trans proline' 0 N--CA 1.496 1.637 0 C-N-CA 122.762 2.308 . . . . 0.0 111.825 178.942 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 73.35 7.92 73.92 Favored Glycine 0 CA--C 1.528 0.865 0 CA-C-N 115.282 -0.872 . . . . 0.0 111.767 179.075 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . 0.547 ' O ' ' NH1' ' B' ' 223' ' ' ARG . 1.7 mp -117.11 147.24 20.62 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.406 0 N-CA-C 109.291 -0.633 . . . . 0.0 109.291 -179.504 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 72' ' ' ASP . . . . . 0.409 ' O ' ' CB ' ' A' ' 44' ' ' ALA . 2.8 t0 -84.76 113.99 21.73 Favored 'General case' 0 C--N 1.318 -0.766 0 CA-C-N 115.176 -0.92 . . . . 0.0 110.402 -179.6 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 73' ' ' TYR . . . . . 0.41 ' O ' ' CD1' ' A' ' 75' ' ' ILE . 15.6 m-85 -107.93 119.88 40.7 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.324 -179.966 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 74' ' ' ASP . . . . . 0.511 ' N ' ' O ' ' A' ' 42' ' ' VAL . 14.8 m-20 -89.71 118.96 29.71 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 115.327 -0.851 . . . . 0.0 108.805 179.535 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . 0.41 ' CD1' ' O ' ' A' ' 73' ' ' TYR . 0.0 OUTLIER -113.24 162.65 11.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-O 121.282 0.563 . . . . 0.0 110.263 -178.642 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -153.53 118.89 5.18 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.289 -0.869 . . . . 0.0 110.484 179.708 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . 0.445 ' CG1' ' O ' ' A' ' 77' ' ' VAL . 8.7 p -103.39 101.38 12.13 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.242 0 N-CA-C 109.517 -0.549 . . . . 0.0 109.517 178.995 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 91.4 mt -92.0 101.13 12.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.621 -179.847 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 44.9 p -77.68 111.64 13.67 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.807 -0.633 . . . . 0.0 109.388 179.049 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 4.8 tp -111.54 120.63 42.77 Favored 'General case' 0 N--CA 1.465 0.288 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.963 -179.234 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 2.1 pp -146.61 142.3 20.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.065 -0.516 . . . . 0.0 109.974 179.095 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 56.0 t-20 -60.41 -56.25 23.69 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 120.721 0.296 . . . . 0.0 110.9 -179.648 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 71.42 108.82 0.05 OUTLIER Glycine 0 CA--C 1.524 0.635 0 N-CA-C 110.855 -0.898 . . . . 0.0 110.855 179.317 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -55.05 176.16 0.54 Allowed Glycine 0 CA--C 1.525 0.698 0 N-CA-C 110.766 -0.933 . . . . 0.0 110.766 179.872 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 98.5 mt-10 -64.17 141.1 58.89 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.789 0.328 . . . . 0.0 110.675 -179.734 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 6.5 m -70.82 141.92 51.32 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.493 179.866 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . 0.472 ' N ' ' CD ' ' A' ' 88' ' ' PRO . . . -178.59 52.48 0.06 OUTLIER Pre-proline 0 C--N 1.329 -0.294 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.475 179.892 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . 0.472 ' CD ' ' N ' ' A' ' 87' ' ' ALA . 42.4 Cg_endo -66.3 151.02 84.35 Favored 'Trans proline' 0 C--N 1.309 -1.514 0 C-N-CA 122.743 2.295 . . . . 0.0 111.732 179.882 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 96.4 m -95.7 120.2 35.54 Favored 'General case' 0 N--CA 1.463 0.189 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.14 179.938 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.472 ' CG2' ' N ' ' A' ' 91' ' ' LEU . 53.4 m -86.99 162.9 17.38 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.337 -179.998 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . 0.472 ' N ' ' CG2' ' A' ' 90' ' ' THR . 9.9 mp -75.85 138.81 41.35 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.296 -179.946 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 68.6 p -81.06 163.79 22.94 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.368 -179.923 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 99.3 mm-40 -83.26 139.15 33.26 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.42 -179.793 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 37.4 tp60 -69.72 -137.51 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.28 -179.841 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.22 -0.497 0 CA-C-O 118.089 -0.958 . . . . 0.0 110.328 -179.954 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 201' ' ' SER . . . . . . . . . . . . . 51.7 m . . . . . 0 N--CA 1.489 1.493 0 N-CA-C 109.285 -0.635 . . . . 0.0 109.285 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' B' B ' 202' ' ' SER . . . . . . . . . . . . . 14.9 m -72.77 141.8 48.11 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.021 179.819 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 203' ' ' SER . . . . . . . . . . . . . 25.9 t -129.77 106.62 16.92 Favored Pre-proline 0 CA--C 1.539 0.534 0 N-CA-C 110.092 -0.336 . . . . 0.0 110.092 179.128 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 204' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -81.19 7.15 5.13 Favored 'Trans proline' 0 N--CA 1.493 1.449 0 C-N-CA 122.177 1.918 . . . . 0.0 111.97 179.466 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 205' ' ' ILE . . . . . . . . . . . . . 9.9 tp -144.69 144.15 22.26 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.328 0 CA-C-O 121.144 0.497 . . . . 0.0 111.225 179.866 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 206' ' ' GLN . . . . . . . . . . . . . 8.5 pt20 -179.05 76.31 0.01 OUTLIER 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 115.242 -0.89 . . . . 0.0 110.775 179.272 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 207' ' ' GLY . . . . . . . . . . . . . . . -109.52 -139.53 8.51 Favored Glycine 0 N--CA 1.466 0.637 0 N-CA-C 111.174 -0.77 . . . . 0.0 111.174 -179.882 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 208' ' ' SER . . . . . 0.539 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 91.7 p -166.88 172.14 10.62 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 120.907 0.384 . . . . 0.0 110.701 -179.805 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 209' ' ' TRP . . . . . . . . . . . . . 78.4 m95 -88.63 130.66 35.23 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.189 179.369 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 82.1 p -109.5 132.81 53.79 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-N 116.392 -0.367 . . . . 0.0 110.496 -179.796 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 47.7 t-105 -93.73 117.81 30.58 Favored 'General case' 0 N--CA 1.463 0.208 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.072 179.796 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 212' ' ' GLU . . . . . 0.44 ' O ' ' O ' ' B' ' 215' ' ' LYS . 0.8 OUTLIER -164.22 167.41 20.04 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.779 179.035 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' B' B ' 213' ' ' ASN . . . . . . . . . . . . . 92.4 m-20 49.06 37.11 9.88 Favored 'General case' 0 C--N 1.324 -0.516 0 C-N-CA 120.522 -0.471 . . . . 0.0 111.349 176.603 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 50.89 16.85 1.93 Allowed Glycine 0 CA--C 1.526 0.723 0 N-CA-C 111.335 -0.706 . . . . 0.0 111.335 179.868 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 215' ' ' LYS . . . . . 0.44 ' O ' ' O ' ' B' ' 212' ' ' GLU . 20.3 mtpt -143.0 149.75 38.72 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.986 0.422 . . . . 0.0 110.889 -179.839 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 216' ' ' TRP . . . . . . . . . . . . . 50.1 m95 -86.12 115.76 23.9 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.028 -0.533 . . . . 0.0 109.712 179.115 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 217' ' ' THR . . . . . . . . . . . . . 18.1 m -126.95 139.92 52.7 Favored 'General case' 0 N--CA 1.466 0.343 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.439 -179.512 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 218' ' ' TRP . . . . . 0.539 ' CH2' ' N ' ' B' ' 208' ' ' SER . 12.9 t-105 -106.45 116.38 31.82 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.016 178.984 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 52.8 mtmt -143.9 174.5 10.78 Favored 'General case' 0 CA--C 1.514 -0.432 0 CA-C-O 121.137 0.494 . . . . 0.0 110.644 -179.85 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -176.38 -160.21 23.27 Favored Glycine 0 CA--C 1.523 0.572 0 C-N-CA 120.544 -0.836 . . . . 0.0 111.226 -179.576 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 221' ' ' ILE . . . . . 0.409 ' O ' ' CG2' ' B' ' 222' ' ' ILE . 10.2 mm -51.27 -73.59 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.892 0.377 . . . . 0.0 110.485 -178.059 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 222' ' ' ILE . . . . . 0.498 ' O ' ' O ' ' B' ' 223' ' ' ARG . 23.7 pt -159.48 -166.39 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.755 0 CA-C-N 115.646 -0.706 . . . . 0.0 110.706 -179.943 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 223' ' ' ARG . . . . . 0.547 ' NH1' ' O ' ' A' ' 71' ' ' ILE . 32.0 ptt-85 -42.76 174.6 0.0 OUTLIER 'General case' 0 CA--C 1.52 -0.186 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.77 179.003 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 224' ' ' LEU . . . . . 0.605 ' H ' ' CD2' ' B' ' 224' ' ' LEU . 2.4 mm? -59.67 128.23 35.91 Favored 'General case' 0 C--N 1.315 -0.906 0 CA-C-N 115.786 -0.643 . . . . 0.0 110.542 -179.517 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 42.5 tt0 -107.36 145.88 32.31 Favored 'General case' 0 CA--C 1.52 -0.188 0 CA-C-N 115.349 -0.841 . . . . 0.0 110.391 -179.843 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 226' ' ' GLN . . . . . . . . . . . . . 64.8 tp60 . . . . . 0 N--CA 1.451 -0.406 0 CA-C-O 117.925 -1.036 . . . . 0.0 110.197 179.947 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.341 0 N-CA-C 109.6 -1.4 . . . . 0.0 109.6 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 41.0 t -152.02 95.38 2.07 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.865 0.364 . . . . 0.0 110.618 179.933 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 19.0 pt-20 -84.78 152.58 23.56 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.498 179.809 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.404 ' O ' ' CG1' ' A' ' 6' ' ' VAL . 9.1 p -145.07 77.95 12.73 Favored Pre-proline 0 N--CA 1.463 0.215 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.458 -179.968 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 32.2 Cg_exo -56.57 139.33 87.49 Favored 'Trans proline' 0 C--N 1.309 -1.538 0 C-N-CA 122.354 2.036 . . . . 0.0 111.911 -179.797 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 64.8 tt0 -84.95 -32.09 23.24 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.361 179.951 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 81.6 mt -84.94 129.97 34.71 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.465 179.991 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 75.0 p -130.8 159.41 37.41 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.526 179.968 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 97.2 m-20 -104.37 155.46 18.76 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.395 -179.834 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 6.7 tt -63.92 149.15 47.82 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.396 -179.74 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' SER . . . . . 0.419 ' O ' ' O ' ' A' ' 25' ' ' ARG . 83.3 p -139.15 156.85 46.83 Favored 'General case' 0 N--CA 1.461 0.114 0 CA-C-O 121.166 0.508 . . . . 0.0 110.42 179.757 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . 0.501 ' CD1' ' N ' ' A' ' 14' ' ' PHE . 30.6 m-85 -110.84 146.37 36.57 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.555 -0.748 . . . . 0.0 110.81 -179.515 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 15.6 m -146.74 157.01 10.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.447 -0.342 . . . . 0.0 110.649 179.4 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 98.9 m-20 54.59 31.53 15.23 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.934 179.656 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.422 HG21 HD11 ' A' ' 17' ' ' ILE . 97.2 mt -56.92 140.89 14.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.383 -179.803 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.418 ' CB ' ' O ' ' A' ' 21' ' ' SER . 0.2 OUTLIER -140.87 -168.6 2.63 Favored 'General case' 0 CA--C 1.533 0.292 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.509 -179.798 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . 0.483 ' OD1' ' N ' ' A' ' 19' ' ' ASP . 11.8 p-10 -90.3 -41.91 11.27 Favored 'General case' 0 N--CA 1.465 0.299 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.689 179.509 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 15.1 m -114.62 5.74 15.51 Favored 'General case' 0 N--CA 1.464 0.252 0 CA-C-N 116.014 -0.539 . . . . 0.0 111.152 -179.395 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' SER . . . . . 0.418 ' O ' ' CB ' ' A' ' 18' ' ' THR . 29.2 t -151.68 148.43 27.92 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 121.046 0.45 . . . . 0.0 110.365 179.624 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 42.6 pt -140.71 145.53 25.42 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.194 179.789 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -102.27 81.42 0.4 Allowed Glycine 0 CA--C 1.524 0.618 0 N-CA-C 110.998 -0.841 . . . . 0.0 110.998 -179.991 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 96.3 mt -68.54 121.6 16.73 Favored 'General case' 0 C--N 1.33 -0.272 0 C-N-CA 120.775 -0.37 . . . . 0.0 110.015 -179.992 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . 0.419 ' O ' ' O ' ' A' ' 13' ' ' SER . 58.8 ttt85 -142.75 137.64 29.93 Favored 'General case' 0 C--N 1.333 -0.123 0 CA-C-O 120.956 0.407 . . . . 0.0 110.372 -179.806 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' TRP . . . . . 0.454 ' C ' ' CD1' ' A' ' 26' ' ' TRP . 0.1 OUTLIER -143.0 161.54 37.85 Favored 'General case' 0 N--CA 1.466 0.349 0 N-CA-C 109.089 -0.708 . . . . 0.0 109.089 179.599 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 5.0 m -100.88 103.18 23.17 Favored Pre-proline 0 C--N 1.327 -0.379 0 N-CA-C 108.612 -0.885 . . . . 0.0 108.612 178.73 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 33.4 Cg_exo -54.72 149.62 39.84 Favored 'Trans proline' 0 C--N 1.308 -1.594 0 C-N-CA 120.883 1.055 . . . . 0.0 112.754 -179.03 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 69.6 mt -87.49 133.06 33.82 Favored 'General case' 0 CA--C 1.51 -0.569 0 CA-C-O 121.601 0.715 . . . . 0.0 111.066 -179.637 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 24.3 t-20 -46.9 -33.69 4.79 Favored 'General case' 0 C--N 1.314 -0.94 0 CA-C-N 115.064 -0.971 . . . . 0.0 110.225 179.527 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 63.4 m -80.74 -34.18 34.59 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.53 178.83 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 5.2 m -56.57 127.12 29.73 Favored 'General case' 0 C--O 1.232 0.136 0 C-N-CA 120.732 -0.387 . . . . 0.0 109.998 -179.715 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' THR . . . . . 0.434 ' H ' ' HB ' ' A' ' 81' ' ' ILE . 33.2 m -61.61 152.5 30.47 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.048 179.875 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 24.4 mm -97.5 94.05 3.71 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.343 0 CA-C-N 116.579 -0.282 . . . . 0.0 111.49 -178.24 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.432 HD11 ' N ' ' A' ' 35' ' ' ILE . 0.1 OUTLIER -137.59 155.09 30.55 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.324 0 CA-C-O 120.792 0.329 . . . . 0.0 110.511 179.305 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -63.22 113.57 6.02 Favored Glycine 0 CA--C 1.521 0.457 0 C-N-CA 120.472 -0.871 . . . . 0.0 111.178 179.785 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 69.2 m-85 -80.73 141.53 34.73 Favored 'General case' 0 C--N 1.328 -0.358 0 N-CA-C 110.072 -0.344 . . . . 0.0 110.072 179.525 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 5.3 tmm_? -105.54 119.84 40.14 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.549 179.974 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . 0.474 ' O ' ' CG1' ' A' ' 39' ' ' ILE . 1.9 pt -95.47 122.88 47.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 115.835 -0.62 . . . . 0.0 109.693 179.79 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 94.8 m -109.61 131.64 54.87 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.824 0.345 . . . . 0.0 110.511 -179.276 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 1.8 p -128.8 144.12 39.05 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.349 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.523 -179.505 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . 0.506 ' O ' ' N ' ' A' ' 74' ' ' ASP . 40.4 t -132.45 131.87 60.3 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.191 0 CA-C-O 120.899 0.38 . . . . 0.0 110.019 179.542 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -98.44 140.01 33.33 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 109.296 -0.631 . . . . 0.0 109.296 179.22 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . 0.406 ' CB ' ' O ' ' A' ' 72' ' ' ASP . . . -98.26 -18.44 18.39 Favored 'General case' 0 CA--C 1.529 0.135 0 C-N-CA 120.67 -0.412 . . . . 0.0 110.776 179.926 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -98.54 30.73 9.1 Favored Glycine 0 CA--C 1.529 0.956 0 N-CA-C 110.753 -0.939 . . . . 0.0 110.753 179.821 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . 0.409 ' OE2' ' OH ' ' A' ' 73' ' ' TYR . 45.1 mt-10 -146.78 149.01 32.51 Favored 'General case' 0 CA--C 1.521 -0.16 0 CA-C-O 121.131 0.491 . . . . 0.0 110.691 179.97 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -68.96 -20.95 75.09 Favored Glycine 0 CA--C 1.527 0.823 0 N-CA-C 111.014 -0.834 . . . . 0.0 111.014 179.736 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . 0.403 HD11 HG22 ' A' ' 48' ' ' ILE . 0.3 OUTLIER -136.61 141.11 34.21 Favored Pre-proline 0 CA--C 1.54 0.579 0 C-N-CA 121.131 -0.228 . . . . 0.0 110.476 179.995 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 69.4 Cg_endo -73.36 162.22 40.8 Favored 'Trans proline' 0 N--CA 1.496 1.672 0 C-N-CA 122.752 2.301 . . . . 0.0 111.821 179.059 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . 0.419 HD12 HG23 ' A' ' 50' ' ' ILE . 96.7 mt -76.49 151.77 5.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.522 179.793 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 82.6 m-85 -70.75 146.41 49.83 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.707 -179.54 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . 0.445 ' H ' ' CD ' ' A' ' 52' ' ' GLU . 0.5 OUTLIER -82.96 145.0 29.61 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.682 179.55 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -112.4 153.14 27.76 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.492 -0.777 . . . . 0.0 110.388 -179.717 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' PHE . . . . . 0.581 ' CD1' ' N ' ' A' ' 54' ' ' PHE . 2.7 m-85 -119.0 128.7 54.64 Favored 'General case' 0 N--CA 1.466 0.356 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.227 -179.758 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 9.6 p -131.26 139.06 51.8 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.3 0 CA-C-O 120.683 0.277 . . . . 0.0 110.828 -179.65 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 71.4 m-20 -58.51 142.47 48.82 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.262 179.581 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 7.2 t -60.88 -35.21 76.04 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.733 179.86 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 58.5 m -56.31 -34.11 66.2 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.923 -179.603 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 90.7 t -62.38 -45.8 97.93 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.389 -179.84 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 61.75 23.17 62.87 Favored Glycine 0 CA--C 1.525 0.713 0 N-CA-C 110.745 -0.942 . . . . 0.0 110.745 179.942 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . 0.437 ' OH ' ' OG1' ' A' ' 63' ' ' THR . 37.2 t80 -164.65 150.16 10.09 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-O 121.095 0.474 . . . . 0.0 111.423 -179.412 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' TYR . . . . . 0.432 ' CD2' ' CD1' ' A' ' 39' ' ' ILE . 18.4 t80 -156.7 154.32 29.87 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.73 -0.668 . . . . 0.0 110.33 178.715 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' THR . . . . . 0.437 ' OG1' ' OH ' ' A' ' 61' ' ' TYR . 73.1 m -117.55 132.55 56.51 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.16 -0.473 . . . . 0.0 109.893 179.472 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -130.63 113.63 25.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 N-CA-C 109.327 -0.62 . . . . 0.0 109.327 178.914 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 2.1 p -124.76 158.83 32.33 Favored 'General case' 0 CA--C 1.516 -0.331 0 CA-C-O 120.987 0.422 . . . . 0.0 110.394 -179.83 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 108.11 39.61 1.8 Allowed Glycine 0 CA--C 1.525 0.682 0 N-CA-C 110.818 -0.913 . . . . 0.0 110.818 -179.937 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 14.5 mt -112.52 106.96 15.53 Favored 'General case' 0 N--CA 1.467 0.404 0 N-CA-C 108.742 -0.836 . . . . 0.0 108.742 179.087 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 4.1 mm-40 -54.34 136.79 60.37 Favored Pre-proline 0 C--N 1.323 -0.561 0 C-N-CA 120.86 -0.336 . . . . 0.0 111.727 -178.095 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 90.0 Cg_endo -74.26 154.52 46.38 Favored 'Trans proline' 0 N--CA 1.493 1.466 0 C-N-CA 122.779 2.319 . . . . 0.0 111.54 178.877 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 71.05 8.42 64.66 Favored Glycine 0 CA--C 1.529 0.963 0 CA-C-N 115.533 -0.758 . . . . 0.0 111.507 179.563 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 1.6 mp -116.05 143.9 24.97 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.543 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 -179.975 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 72' ' ' ASP . . . . . 0.406 ' O ' ' CB ' ' A' ' 44' ' ' ALA . 2.0 t0 -81.93 112.59 19.17 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-N 115.307 -0.861 . . . . 0.0 110.149 -179.849 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 73' ' ' TYR . . . . . 0.409 ' OH ' ' OE2' ' A' ' 46' ' ' GLU . 13.7 m-85 -107.38 120.01 40.97 Favored 'General case' 0 C--O 1.223 -0.326 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.354 -179.814 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 74' ' ' ASP . . . . . 0.506 ' N ' ' O ' ' A' ' 42' ' ' VAL . 7.3 m-20 -89.04 114.86 26.12 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 115.34 -0.845 . . . . 0.0 109.375 179.601 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . 0.415 ' CD1' ' N ' ' A' ' 75' ' ' ILE . 0.0 OUTLIER -112.35 167.31 5.8 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.198 0 CA-C-O 121.273 0.558 . . . . 0.0 110.405 -179.434 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 11.6 p -154.46 151.65 29.2 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 115.124 -0.944 . . . . 0.0 110.283 179.392 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -131.32 101.75 5.56 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.351 0 N-CA-C 108.744 -0.836 . . . . 0.0 108.744 179.49 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 96.2 mt -86.62 123.87 40.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 C-N-CA 120.913 -0.315 . . . . 0.0 110.34 -179.673 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 90.5 m -105.26 109.02 20.85 Favored 'General case' 0 N--CA 1.465 0.301 0 CA-C-N 116.358 -0.383 . . . . 0.0 109.971 179.66 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 6.7 tt -121.09 119.02 31.24 Favored 'General case' 0 CA--C 1.517 -0.292 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.449 179.965 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 81' ' ' ILE . . . . . 0.434 ' HB ' ' H ' ' A' ' 33' ' ' THR . 2.0 pp -140.28 143.44 29.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.289 179.22 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 82' ' ' ASN . . . . . 0.526 ' C ' ' H ' ' A' ' 84' ' ' GLY . 0.7 OUTLIER -65.22 -54.19 33.14 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.803 -179.476 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 61.53 -1.28 1.13 Allowed Glycine 0 CA--C 1.525 0.712 0 N-CA-C 111.037 -0.825 . . . . 0.0 111.037 179.289 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . 0.526 ' H ' ' C ' ' A' ' 82' ' ' ASN . . . -96.23 105.83 3.28 Favored Glycine 0 CA--C 1.525 0.685 0 N-CA-C 110.939 -0.865 . . . . 0.0 110.939 -179.903 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 17.0 pt-20 -84.09 155.98 22.39 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.836 0.35 . . . . 0.0 110.37 179.821 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 8.6 m -72.38 153.04 41.67 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.702 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . 0.442 ' CB ' ' CD ' ' A' ' 88' ' ' PRO . . . 71.67 -179.85 0.05 OUTLIER Pre-proline 0 CA--C 1.537 0.455 0 CA-C-N 115.879 -0.601 . . . . 0.0 110.571 179.656 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . 0.442 ' CD ' ' CB ' ' A' ' 87' ' ' ALA . 22.1 Cg_exo -63.33 153.28 75.37 Favored 'Trans proline' 0 N--CA 1.497 1.713 0 C-N-CA 122.548 2.166 . . . . 0.0 111.93 179.723 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.7 p -129.18 158.75 38.13 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.179 -179.637 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -142.4 -177.73 5.41 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.186 179.983 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . 0.529 ' N ' ' CD2' ' A' ' 91' ' ' LEU . 3.6 mm? -90.83 133.05 35.51 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.468 179.963 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 92' ' ' THR . . . . . 0.511 ' HG1' ' N ' ' A' ' 93' ' ' GLN . 0.9 OUTLIER -79.04 153.02 30.55 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.813 -0.631 . . . . 0.0 110.319 -179.792 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 93' ' ' GLN . . . . . 0.511 ' N ' ' HG1' ' A' ' 92' ' ' THR . 98.7 mm-40 -76.82 137.25 39.11 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.528 -179.993 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 97.3 mt-30 -64.76 90.3 0.08 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.39 -179.948 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 18.6 p . . . . . 0 C--O 1.22 -0.452 0 CA-C-O 118.001 -1.0 . . . . 0.0 110.515 179.982 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' B' B ' 201' ' ' SER . . . . . . . . . . . . . 18.7 p . . . . . 0 N--CA 1.492 1.636 0 N-CA-C 109.435 -0.58 . . . . 0.0 109.435 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' B' B ' 202' ' ' SER . . . . . . . . . . . . . 38.7 t -70.94 155.58 40.64 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.149 179.9 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 203' ' ' SER . . . . . . . . . . . . . 2.8 p -89.23 150.91 45.84 Favored Pre-proline 0 CA--C 1.538 0.491 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.317 -179.617 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 204' ' ' PRO . . . . . . . . . . . . . 56.9 Cg_endo -70.49 6.45 1.55 Allowed 'Trans proline' 0 N--CA 1.5 1.893 0 C-N-CA 122.443 2.095 . . . . 0.0 112.008 179.984 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 205' ' ' ILE . . . . . . . . . . . . . 10.9 tt -150.79 151.13 12.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-O 121.032 0.444 . . . . 0.0 111.075 179.699 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 206' ' ' GLN . . . . . . . . . . . . . 69.3 mt-30 -156.83 75.61 0.84 Allowed 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.692 -0.685 . . . . 0.0 110.534 178.711 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 207' ' ' GLY . . . . . . . . . . . . . . . -107.65 -159.9 20.86 Favored Glycine 0 N--CA 1.464 0.515 0 N-CA-C 110.838 -0.905 . . . . 0.0 110.838 -179.847 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 208' ' ' SER . . . . . . . . . . . . . 44.6 p -163.82 170.33 17.02 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 120.717 0.294 . . . . 0.0 110.701 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 209' ' ' TRP . . . . . . . . . . . . . 86.5 m95 -83.33 126.56 32.83 Favored 'General case' 0 C--N 1.329 -0.286 0 C-N-CA 120.845 -0.342 . . . . 0.0 110.167 179.34 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 77.4 p -108.94 138.91 44.54 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-N 116.514 -0.312 . . . . 0.0 110.723 -179.745 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 58.2 t-105 -95.67 116.09 28.36 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-N 116.033 -0.531 . . . . 0.0 110.337 179.68 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 212' ' ' GLU . . . . . 0.524 ' OE2' ' NZ ' ' B' ' 219' ' ' LYS . 1.4 pt-20 -163.46 167.03 22.06 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.509 179.312 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 213' ' ' ASN . . . . . . . . . . . . . 12.4 m120 49.3 34.23 6.11 Favored 'General case' 0 C--N 1.324 -0.522 0 C-N-CA 120.53 -0.468 . . . . 0.0 111.698 176.962 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 54.73 12.34 3.48 Favored Glycine 0 CA--C 1.528 0.865 0 C-N-CA 120.917 -0.659 . . . . 0.0 111.604 179.463 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 215' ' ' LYS . . . . . 0.469 ' O ' ' O ' ' B' ' 212' ' ' GLU . 67.6 mttm -141.86 150.98 42.29 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-O 120.863 0.364 . . . . 0.0 110.76 -179.798 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 216' ' ' TRP . . . . . 0.437 ' CD1' ' N ' ' B' ' 216' ' ' TRP . 37.4 m95 -84.91 117.54 23.98 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.174 179.875 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 217' ' ' THR . . . . . . . . . . . . . 26.7 m -125.85 137.49 53.76 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.531 -179.568 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 218' ' ' TRP . . . . . . . . . . . . . 25.0 t-105 -98.53 120.02 38.25 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.234 179.483 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 219' ' ' LYS . . . . . 0.524 ' NZ ' ' OE2' ' B' ' 212' ' ' GLU . 53.7 mtmt -141.69 165.79 26.51 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.72 -179.809 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -176.44 -160.97 24.59 Favored Glycine 0 CA--C 1.522 0.504 0 N-CA-C 111.185 -0.766 . . . . 0.0 111.185 -179.887 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 221' ' ' ILE . . . . . 0.425 ' O ' ' CG2' ' B' ' 222' ' ' ILE . 0.8 OUTLIER -53.43 -76.73 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.387 0 C-N-CA 120.682 -0.407 . . . . 0.0 110.987 -178.44 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' B' B ' 222' ' ' ILE . . . . . 0.439 ' O ' ' O ' ' B' ' 223' ' ' ARG . 20.2 pt -160.72 -166.24 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 N-CA-C 109.994 -0.373 . . . . 0.0 109.994 -179.633 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 223' ' ' ARG . . . . . 0.439 ' O ' ' O ' ' B' ' 222' ' ' ILE . 33.2 ptt85 -45.41 174.57 0.0 OUTLIER 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.805 178.362 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 224' ' ' LEU . . . . . 0.539 ' CD2' ' N ' ' B' ' 224' ' ' LEU . 3.0 mm? -59.44 123.46 16.89 Favored 'General case' 0 C--N 1.318 -0.791 0 CA-C-N 115.317 -0.856 . . . . 0.0 110.211 -179.244 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 79.7 tt0 -115.97 150.15 37.64 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.387 -0.824 . . . . 0.0 110.167 -179.648 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 226' ' ' GLN . . . . . . . . . . . . . 68.0 tp60 . . . . . 0 N--CA 1.448 -0.54 0 CA-C-O 117.979 -1.01 . . . . 0.0 110.263 -179.798 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.158 0 N-CA-C 109.603 -1.399 . . . . 0.0 109.603 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 31.0 m -150.02 105.44 3.39 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.854 0.359 . . . . 0.0 110.381 179.962 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 4.6 pt-20 -98.96 100.01 11.13 Favored 'General case' 0 N--CA 1.464 0.264 0 CA-C-O 121.085 0.469 . . . . 0.0 110.479 179.995 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.3 m -81.09 153.2 72.01 Favored Pre-proline 0 N--CA 1.449 -0.495 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.529 -179.778 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_exo -50.58 143.64 27.7 Favored 'Trans proline' 0 N--CA 1.491 1.381 0 C-N-CA 122.546 2.164 . . . . 0.0 112.194 179.047 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 15.2 pt20 -160.58 -147.29 0.15 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.059 -0.518 . . . . 0.0 110.61 -179.838 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 26.6 tp -57.33 130.4 46.07 Favored 'General case' 0 N--CA 1.449 -0.493 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.29 -179.567 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 43.6 p -82.01 167.46 18.83 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.424 -179.96 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 96.5 m-20 -135.81 142.89 44.92 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-O 120.984 0.421 . . . . 0.0 110.438 -179.879 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 6.6 tt -64.27 145.16 56.46 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.429 -179.676 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 86.8 p -140.3 153.01 46.33 Favored 'General case' 0 N--CA 1.463 0.212 0 CA-C-N 116.328 -0.397 . . . . 0.0 110.662 179.909 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . 0.533 ' CD1' ' N ' ' A' ' 14' ' ' PHE . 12.5 m-85 -111.17 146.74 36.35 Favored 'General case' 0 N--CA 1.465 0.301 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.379 -179.612 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 21.9 m -146.01 160.88 11.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.633 179.81 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 38.2 t0 55.46 31.53 17.15 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.66 179.636 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 96.5 mt -56.57 137.77 18.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 121.07 0.462 . . . . 0.0 110.148 179.962 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.461 ' CB ' ' O ' ' A' ' 21' ' ' SER . 0.3 OUTLIER -140.32 -167.01 2.23 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.817 -0.628 . . . . 0.0 110.651 -179.559 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . 0.525 ' OD1' ' N ' ' A' ' 19' ' ' ASP . 14.5 p-10 -91.6 -41.97 10.47 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 115.691 -0.686 . . . . 0.0 111.006 179.468 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 13.7 m -116.97 6.88 13.05 Favored 'General case' 0 N--CA 1.466 0.344 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.677 -179.584 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' SER . . . . . 0.461 ' O ' ' CB ' ' A' ' 18' ' ' THR . 16.8 p -151.65 145.79 25.33 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 121.101 0.477 . . . . 0.0 110.443 179.968 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 44.2 pt -140.26 146.29 24.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.02 179.941 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -99.31 81.76 0.56 Allowed Glycine 0 CA--C 1.523 0.593 0 N-CA-C 111.419 -0.672 . . . . 0.0 111.419 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 84.0 mt -66.79 121.98 16.65 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.768 0.318 . . . . 0.0 110.296 -179.967 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 4.6 tmm_? -139.62 138.69 36.37 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.62 179.877 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' TRP . . . . . . . . . . . . . 42.0 p90 -143.0 158.28 43.75 Favored 'General case' 0 CA--C 1.517 -0.308 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.399 179.921 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 3.5 m -111.16 97.1 33.67 Favored Pre-proline 0 CA--C 1.534 0.337 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.393 179.854 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_exo -53.23 146.3 40.2 Favored 'Trans proline' 0 C--N 1.308 -1.581 0 C-N-CA 122.476 2.117 . . . . 0.0 112.23 179.879 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 52.3 mt -84.32 138.53 32.84 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 121.337 0.589 . . . . 0.0 111.039 -179.96 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 2.3 t-20 -49.08 -33.49 11.71 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.47 -0.786 . . . . 0.0 110.152 179.829 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 70.6 m -81.63 -34.17 31.02 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.593 179.667 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 9.1 m -58.24 134.92 56.96 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 121.103 0.478 . . . . 0.0 110.185 -179.881 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' THR . . . . . 0.459 ' OG1' ' N ' ' A' ' 82' ' ' ASN . 3.7 m -61.44 142.74 56.78 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.465 179.912 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . 0.406 HG21 HD13 ' A' ' 34' ' ' ILE . 28.9 mm -94.37 92.69 3.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.969 0.414 . . . . 0.0 110.324 -179.896 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 15.2 pt -143.09 135.86 25.13 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.155 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.359 179.697 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -39.24 132.4 1.95 Allowed Glycine 0 CA--C 1.524 0.642 0 N-CA-C 111.171 -0.771 . . . . 0.0 111.171 -179.705 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 95.6 m-85 -103.03 138.98 39.17 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.844 0.354 . . . . 0.0 110.197 -179.771 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 5.3 tmm_? -99.1 124.64 44.27 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.629 -179.699 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . 0.451 ' O ' ' CG1' ' A' ' 39' ' ' ILE . 2.1 pt -99.09 124.51 52.39 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 116.341 -0.391 . . . . 0.0 109.97 179.701 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 5.4 m -105.52 134.0 49.35 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.621 -179.822 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.1 p -132.39 141.52 45.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.308 179.541 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . 0.541 ' N ' ' O ' ' A' ' 74' ' ' ASP . 41.4 t -133.41 133.47 57.64 Favored 'Isoleucine or valine' 0 C--O 1.231 0.104 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.339 179.6 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -98.55 139.58 34.07 Favored 'General case' 0 C--N 1.328 -0.33 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 178.732 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -91.81 -43.91 9.26 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.284 -0.417 . . . . 0.0 111.027 179.815 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -63.49 -32.35 83.84 Favored Glycine 0 CA--C 1.524 0.614 0 N-CA-C 111.275 -0.73 . . . . 0.0 111.275 -179.477 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . 0.434 ' C ' ' H ' ' A' ' 48' ' ' ILE . 38.4 mm-40 -97.92 126.53 43.36 Favored 'General case' 0 C--N 1.332 -0.19 0 N-CA-C 109.616 -0.512 . . . . 0.0 109.616 -179.582 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -59.17 -6.92 4.57 Favored Glycine 0 CA--C 1.511 -0.187 0 N-CA-C 110.918 -0.873 . . . . 0.0 110.918 -179.082 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . 0.434 ' H ' ' C ' ' A' ' 46' ' ' GLU . 0.4 OUTLIER -124.23 133.44 24.7 Favored Pre-proline 0 CA--C 1.537 0.477 0 C-N-CA 120.905 -0.318 . . . . 0.0 110.257 179.461 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 60.7 Cg_endo -76.71 164.22 30.52 Favored 'Trans proline' 0 C--N 1.307 -1.618 0 C-N-CA 122.59 2.193 . . . . 0.0 112.286 177.48 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 95.9 mt -85.22 145.38 8.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 115.771 -0.65 . . . . 0.0 110.268 179.023 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 79.7 m-85 -63.79 142.81 58.27 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.527 -179.886 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . 0.446 ' N ' ' CD ' ' A' ' 52' ' ' GLU . 0.1 OUTLIER -70.58 -178.01 1.68 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.582 179.776 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 4.0 m-20 -146.51 138.25 24.68 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.884 179.499 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 89.3 m-85 -108.13 120.01 41.13 Favored 'General case' 0 N--CA 1.463 0.187 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.279 179.266 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 9.9 p -127.28 136.52 60.42 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.285 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.377 179.881 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 97.4 m-20 -56.89 142.99 39.26 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.463 -179.855 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 11.4 t -61.79 -35.15 77.34 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.716 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 37.7 m -55.44 -32.33 62.65 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.724 -179.718 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 98.6 t -63.76 -46.14 95.32 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.587 -179.889 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 59.36 27.09 62.65 Favored Glycine 0 CA--C 1.527 0.827 0 N-CA-C 110.859 -0.896 . . . . 0.0 110.859 -179.931 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 52.7 t80 -166.52 149.89 7.09 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 121.224 0.535 . . . . 0.0 110.945 -179.415 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' TYR . . . . . 0.412 ' CD2' ' CD1' ' A' ' 39' ' ' ILE . 25.7 t80 -158.81 159.26 34.92 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.971 -0.558 . . . . 0.0 110.141 179.003 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 85.3 m -125.28 136.28 53.36 Favored 'General case' 0 N--CA 1.464 0.233 0 CA-C-N 116.378 -0.373 . . . . 0.0 110.392 -179.714 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -131.87 105.93 10.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.185 179.37 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 3.2 p -114.1 156.23 24.56 Favored 'General case' 0 CA--C 1.516 -0.358 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.515 179.632 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 109.63 40.46 1.46 Allowed Glycine 0 CA--C 1.523 0.589 0 N-CA-C 111.245 -0.742 . . . . 0.0 111.245 -179.754 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 18.5 mt -113.69 102.34 10.16 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-O 121.126 0.488 . . . . 0.0 109.918 179.579 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 12.3 mm-40 -48.66 135.42 13.41 Favored Pre-proline 0 C--N 1.317 -0.805 0 CA-C-N 115.609 -0.723 . . . . 0.0 111.042 -178.558 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 70.9 Cg_endo -75.33 153.01 39.92 Favored 'Trans proline' 0 N--CA 1.496 1.673 0 C-N-CA 122.882 2.388 . . . . 0.0 111.61 178.8 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 72.43 12.04 76.72 Favored Glycine 0 CA--C 1.521 0.425 0 N-CA-C 111.186 -0.766 . . . . 0.0 111.186 179.479 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . 0.537 ' O ' ' NH1' ' B' ' 223' ' ' ARG . 1.7 mp -118.38 147.92 21.56 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.381 0 CA-C-O 121.251 0.548 . . . . 0.0 109.897 -179.878 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 3.1 t70 -86.51 112.39 21.49 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.257 -0.883 . . . . 0.0 110.752 179.947 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 73' ' ' TYR . . . . . 0.429 ' O ' ' CD1' ' A' ' 75' ' ' ILE . 14.8 m-85 -106.25 119.58 39.62 Favored 'General case' 0 C--O 1.218 -0.601 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.027 179.494 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 74' ' ' ASP . . . . . 0.541 ' O ' ' N ' ' A' ' 42' ' ' VAL . 72.1 m-20 -88.29 117.53 27.27 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.741 -0.663 . . . . 0.0 109.576 179.442 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . 0.429 ' CD1' ' O ' ' A' ' 73' ' ' TYR . 0.0 OUTLIER -114.59 165.97 9.03 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-O 121.038 0.447 . . . . 0.0 110.344 -179.457 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -155.14 120.73 5.04 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.586 -0.734 . . . . 0.0 110.976 179.273 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 8.9 t -100.31 101.88 12.69 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 N-CA-C 109.835 -0.431 . . . . 0.0 109.835 179.22 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 95.7 mt -88.8 126.86 41.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.648 -179.756 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 96.6 m -108.36 111.31 23.17 Favored 'General case' 0 CA--C 1.517 -0.303 0 CA-C-O 121.011 0.434 . . . . 0.0 109.984 179.7 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 51.4 tp -120.73 125.04 46.63 Favored 'General case' 0 CA--C 1.519 -0.234 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.875 179.965 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 81' ' ' ILE . . . . . 0.442 ' HB ' ' H ' ' A' ' 33' ' ' THR . 2.0 pp -144.69 143.83 22.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.279 178.991 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 82' ' ' ASN . . . . . 0.459 ' N ' ' OG1' ' A' ' 33' ' ' THR . 62.8 t-20 -64.47 -53.01 54.92 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.334 -0.394 . . . . 0.0 111.204 -179.856 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . 0.432 ' N ' ' OG1' ' A' ' 33' ' ' THR . . . 106.45 155.08 20.84 Favored Glycine 0 CA--C 1.521 0.461 0 N-CA-C 110.665 -0.974 . . . . 0.0 110.665 179.457 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -91.23 112.95 4.22 Favored Glycine 0 CA--C 1.524 0.634 0 N-CA-C 110.823 -0.911 . . . . 0.0 110.823 179.889 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . 0.532 ' OE1' ' N ' ' A' ' 85' ' ' GLU . 58.2 mp0 -84.71 147.63 26.81 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.871 0.367 . . . . 0.0 110.663 179.933 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 30.5 t -78.05 131.01 37.14 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.352 179.904 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . 0.474 ' N ' ' HD2' ' A' ' 88' ' ' PRO . . . -67.96 -61.39 4.23 Favored Pre-proline 0 C--N 1.325 -0.468 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.232 179.187 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . 0.474 ' HD2' ' N ' ' A' ' 87' ' ' ALA . 26.5 Cg_endo -61.11 144.76 99.32 Favored 'Trans proline' 0 C--N 1.308 -1.571 0 C-N-CA 122.642 2.228 . . . . 0.0 111.781 -179.757 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -136.04 124.58 23.59 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.484 179.546 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 92.9 m -133.1 132.34 41.6 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.368 179.872 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -89.84 154.78 19.62 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.194 -179.894 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 76.9 p -68.99 136.67 52.84 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.481 179.77 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 29.4 mm100 -95.71 116.6 29.11 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.446 179.904 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 84.9 mt-30 -67.24 -34.23 77.0 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.481 179.829 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 60.3 p . . . . . 0 C--O 1.22 -0.496 0 CA-C-O 117.958 -1.02 . . . . 0.0 110.486 -179.79 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' B' B ' 201' ' ' SER . . . . . . . . . . . . . 59.4 p . . . . . 0 N--CA 1.49 1.567 0 N-CA-C 109.326 -0.62 . . . . 0.0 109.326 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' B' B ' 202' ' ' SER . . . . . . . . . . . . . 28.3 m -72.2 145.63 47.88 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.4 -179.961 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 203' ' ' SER . . . . . 0.581 ' HG ' ' N ' ' B' ' 204' ' ' PRO . 0.9 OUTLIER -95.25 151.67 38.88 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.552 -179.872 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' B' B ' 204' ' ' PRO . . . . . 0.581 ' N ' ' HG ' ' B' ' 203' ' ' SER . 56.2 Cg_endo -71.43 4.17 3.12 Favored 'Trans proline' 0 C--N 1.312 -1.369 0 C-N-CA 122.711 2.274 . . . . 0.0 112.04 179.773 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 205' ' ' ILE . . . . . 0.487 ' H ' ' HG ' ' B' ' 203' ' ' SER . 10.7 tp -148.4 151.36 13.38 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.328 0 CA-C-O 120.755 0.312 . . . . 0.0 111.173 179.754 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 206' ' ' GLN . . . . . . . . . . . . . 8.8 pt20 -173.87 78.47 0.03 OUTLIER 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.623 179.501 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 207' ' ' GLY . . . . . . . . . . . . . . . -108.63 -147.05 12.3 Favored Glycine 0 N--CA 1.464 0.551 0 N-CA-C 111.241 -0.743 . . . . 0.0 111.241 179.879 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 208' ' ' SER . . . . . 0.5 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 33.2 p -164.49 172.26 13.55 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.726 0.298 . . . . 0.0 110.767 -179.676 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 209' ' ' TRP . . . . . . . . . . . . . 73.2 m95 -85.35 151.15 24.24 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.284 -0.417 . . . . 0.0 110.357 179.529 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 81.6 p -131.66 137.64 48.42 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.387 -0.37 . . . . 0.0 110.903 -179.964 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 47.4 t-105 -95.54 115.45 27.44 Favored 'General case' 0 C--N 1.331 -0.199 0 N-CA-C 109.87 -0.418 . . . . 0.0 109.87 179.402 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 212' ' ' GLU . . . . . 0.512 ' O ' ' O ' ' B' ' 215' ' ' LYS . 2.8 tt0 -161.33 150.7 16.54 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.578 179.59 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 213' ' ' ASN . . . . . 0.434 ' C ' ' H ' ' B' ' 215' ' ' LYS . 13.2 m120 59.68 42.2 17.37 Favored 'General case' 0 N--CA 1.448 -0.53 0 CA-C-N 115.901 -0.591 . . . . 0.0 111.166 177.145 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 49.86 12.95 0.5 Allowed Glycine 0 CA--C 1.521 0.417 0 N-CA-C 111.63 -0.588 . . . . 0.0 111.63 179.161 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 215' ' ' LYS . . . . . 0.512 ' O ' ' O ' ' B' ' 212' ' ' GLU . 68.1 mttm -142.04 150.58 41.46 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.054 0.454 . . . . 0.0 110.457 -179.997 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 216' ' ' TRP . . . . . . . . . . . . . 45.7 m95 -86.13 122.31 29.97 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.42 -0.355 . . . . 0.0 110.119 -179.941 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 217' ' ' THR . . . . . . . . . . . . . 18.8 m -129.19 141.51 51.14 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.934 0.397 . . . . 0.0 110.426 -179.677 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 218' ' ' TRP . . . . . 0.5 ' CH2' ' N ' ' B' ' 208' ' ' SER . 16.7 t-105 -105.43 118.02 35.5 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-N 115.888 -0.596 . . . . 0.0 109.742 179.477 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 24.0 mtmm -142.13 173.76 11.23 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.798 -179.882 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -176.39 -161.27 25.09 Favored Glycine 0 CA--C 1.523 0.57 0 N-CA-C 111.243 -0.743 . . . . 0.0 111.243 -179.698 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 221' ' ' ILE . . . . . 0.415 ' O ' ' CG2' ' B' ' 222' ' ' ILE . 30.5 mt -52.39 -73.39 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 C-N-CA 120.812 -0.355 . . . . 0.0 110.228 -178.534 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 222' ' ' ILE . . . . . 0.485 ' O ' ' O ' ' B' ' 223' ' ' ARG . 20.5 pt -158.97 -165.89 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.208 0 CA-C-N 116.301 -0.408 . . . . 0.0 110.458 -179.932 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 223' ' ' ARG . . . . . 0.537 ' NH1' ' O ' ' A' ' 71' ' ' ILE . 30.7 ptt-85 -44.31 174.55 0.0 OUTLIER 'General case' 0 N--CA 1.456 -0.17 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.281 179.378 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 224' ' ' LEU . . . . . 0.583 ' H ' ' CD2' ' B' ' 224' ' ' LEU . 2.6 mm? -62.13 117.97 6.73 Favored 'General case' 0 C--N 1.316 -0.886 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.768 -179.516 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 81.7 tt0 -85.0 149.8 25.34 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.612 -0.722 . . . . 0.0 110.642 -179.93 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 226' ' ' GLN . . . . . . . . . . . . . 53.4 tt0 . . . . . 0 C--O 1.22 -0.453 0 CA-C-O 117.951 -1.024 . . . . 0.0 110.485 179.958 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.411 0 N-CA-C 109.479 -1.449 . . . . 0.0 109.479 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 21.6 m -69.83 142.33 53.13 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.855 0.359 . . . . 0.0 110.307 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 15.9 pt-20 -69.15 137.3 53.23 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.483 -179.942 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 7.3 p -84.01 116.64 65.77 Favored Pre-proline 0 CA--C 1.54 0.571 0 C-N-CA 120.863 -0.335 . . . . 0.0 110.677 -179.561 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 71.3 Cg_endo -75.54 143.05 26.98 Favored 'Trans proline' 0 N--CA 1.495 1.575 0 C-N-CA 121.997 1.798 . . . . 0.0 112.21 -179.993 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 96.9 mm-40 -82.02 -163.78 0.71 Allowed 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.383 -0.371 . . . . 0.0 110.083 179.842 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.444 ' CD1' ' N ' ' A' ' 9' ' ' LEU . 10.2 mp -77.06 129.4 36.0 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.263 -179.998 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 6.1 p -81.53 149.44 28.68 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.329 179.832 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 4.1 p30 -92.2 165.03 13.34 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.494 179.929 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -68.02 151.41 47.11 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.307 -179.784 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' SER . . . . . 0.44 ' O ' ' O ' ' A' ' 25' ' ' ARG . 61.6 p -143.25 149.39 37.83 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.608 179.568 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . 0.527 ' CD1' ' N ' ' A' ' 14' ' ' PHE . 17.4 m-85 -112.34 147.02 37.24 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.879 -0.6 . . . . 0.0 110.649 -179.599 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 23.3 m -147.54 156.61 9.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.398 179.43 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 38.2 t0 60.78 28.47 18.21 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.616 179.897 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 96.5 mt -55.88 132.39 19.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.062 179.799 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.434 ' OG1' ' O ' ' A' ' 21' ' ' SER . 0.2 OUTLIER -131.12 -169.36 2.16 Favored 'General case' 0 N--CA 1.467 0.409 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.469 -179.839 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . 0.477 ' N ' ' OD1' ' A' ' 19' ' ' ASP . 17.5 p-10 -77.65 -49.26 14.9 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.963 179.513 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' SER . . . . . 0.513 ' OG ' ' N ' ' A' ' 67' ' ' LEU . 31.1 t -120.46 13.39 11.79 Favored 'General case' 0 N--CA 1.466 0.358 0 CA-C-N 116.511 -0.313 . . . . 0.0 110.704 -179.252 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' SER . . . . . 0.434 ' O ' ' OG1' ' A' ' 18' ' ' THR . 3.8 m -146.56 129.8 16.62 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.237 -179.307 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 47.7 pt -125.78 142.25 43.09 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-N 116.288 -0.415 . . . . 0.0 109.979 179.756 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -98.28 83.08 0.65 Allowed Glycine 0 CA--C 1.523 0.593 0 N-CA-C 110.507 -1.037 . . . . 0.0 110.507 -179.345 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 92.0 mt -65.57 128.09 34.52 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 110.013 -0.365 . . . . 0.0 110.013 -179.634 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . 0.44 ' O ' ' O ' ' A' ' 13' ' ' SER . 1.2 tpp180 -147.75 134.86 20.4 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.045 179.832 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' TRP . . . . . 0.554 ' CE3' ' O ' ' A' ' 60' ' ' GLY . 4.9 p90 -140.29 128.45 22.32 Favored 'General case' 0 C--O 1.223 -0.299 0 N-CA-C 109.223 -0.658 . . . . 0.0 109.223 177.73 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' THR . . . . . 0.405 ' H ' ' HG1' ' A' ' 27' ' ' THR . 1.9 m -68.34 113.27 14.32 Favored Pre-proline 0 CA--C 1.538 0.49 0 C-N-CA 120.528 -0.469 . . . . 0.0 111.011 -179.633 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 32.7 Cg_exo -59.53 152.39 62.28 Favored 'Trans proline' 0 N--CA 1.498 1.744 0 C-N-CA 121.993 1.795 . . . . 0.0 112.599 178.473 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.43 ' O ' ' N ' ' A' ' 32' ' ' SER . 77.9 mt -102.16 133.43 47.03 Favored 'General case' 0 CA--C 1.518 -0.254 0 CA-C-O 121.682 0.754 . . . . 0.0 110.651 179.728 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 11.7 t-20 -42.79 -30.54 0.4 Allowed 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 115.352 -0.84 . . . . 0.0 110.47 -179.725 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 58.1 m -87.88 -36.64 17.07 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.483 179.087 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' SER . . . . . 0.43 ' N ' ' O ' ' A' ' 29' ' ' LEU . 3.1 m -45.73 113.54 0.62 Allowed 'General case' 0 N--CA 1.461 0.115 0 CA-C-O 121.091 0.472 . . . . 0.0 110.306 -179.661 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' THR . . . . . 0.519 ' OG1' ' N ' ' A' ' 82' ' ' ASN . 7.2 m -52.24 150.01 4.97 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.601 -0.727 . . . . 0.0 109.448 -179.251 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 19.6 mm -93.92 92.65 3.66 Favored 'Isoleucine or valine' 0 C--O 1.232 0.135 0 CA-C-O 121.11 0.481 . . . . 0.0 110.995 -178.51 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 6.6 pt -151.23 124.84 1.34 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.252 179.288 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -48.25 131.4 19.84 Favored Glycine 0 CA--C 1.519 0.336 0 N-CA-C 110.786 -0.925 . . . . 0.0 110.786 -179.624 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' TYR . . . . . 0.571 ' O ' ' CD1' ' A' ' 37' ' ' TYR . 0.6 OUTLIER -104.13 130.07 51.85 Favored 'General case' 0 C--N 1.329 -0.322 0 N-CA-C 109.691 -0.485 . . . . 0.0 109.691 -179.895 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . 0.516 ' NH1' ' OG1' ' A' ' 40' ' ' THR . 7.9 tmm_? -79.59 132.27 36.23 Favored 'General case' 0 C--N 1.325 -0.472 0 C-N-CA 120.743 -0.383 . . . . 0.0 111.003 -179.895 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . 0.448 ' O ' ' CG1' ' A' ' 39' ' ' ILE . 1.9 pt -104.51 122.58 57.65 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.329 0 N-CA-C 109.585 -0.524 . . . . 0.0 109.585 179.179 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' THR . . . . . 0.516 ' OG1' ' NH1' ' A' ' 38' ' ' ARG . 7.1 m -99.44 136.52 39.26 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.425 -179.022 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.4 p -133.31 141.55 44.25 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.288 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.133 179.855 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . 0.499 ' O ' ' N ' ' A' ' 74' ' ' ASP . 39.9 t -132.59 132.48 59.96 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.24 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 179.607 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -99.35 136.62 39.03 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 116.09 -0.504 . . . . 0.0 109.651 178.921 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . 0.403 ' CB ' ' O ' ' A' ' 72' ' ' ASP . . . -99.02 -15.43 19.07 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-O 120.806 0.336 . . . . 0.0 110.85 -179.801 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -99.62 24.99 30.0 Favored Glycine 0 CA--C 1.525 0.7 0 N-CA-C 111.093 -0.803 . . . . 0.0 111.093 -179.44 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 93.5 mt-10 -145.95 149.37 34.05 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.97 0.414 . . . . 0.0 110.337 179.936 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -66.59 -21.06 70.54 Favored Glycine 0 CA--C 1.519 0.302 0 N-CA-C 110.67 -0.972 . . . . 0.0 110.67 179.896 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -132.23 139.58 35.35 Favored Pre-proline 0 CA--C 1.539 0.527 0 C-N-CA 121.224 -0.19 . . . . 0.0 110.524 179.873 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 61.3 Cg_endo -73.93 161.87 40.4 Favored 'Trans proline' 0 N--CA 1.49 1.281 0 C-N-CA 122.469 2.113 . . . . 0.0 111.96 177.613 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 96.8 mt -77.48 149.96 5.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.461 179.354 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 76.1 m-85 -72.47 141.59 48.59 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.678 179.78 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . 0.414 ' N ' ' CD ' ' A' ' 52' ' ' GLU . 0.2 OUTLIER -61.77 -177.07 0.1 Allowed 'General case' 0 CA--C 1.517 -0.321 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.418 179.275 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -144.33 135.29 25.16 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 115.637 -0.71 . . . . 0.0 110.301 179.706 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 86.7 m-85 -108.46 116.55 32.19 Favored 'General case' 0 N--CA 1.465 0.287 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.374 179.697 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 9.2 p -130.35 143.77 39.99 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.291 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.145 179.77 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 95.5 m-20 -66.79 151.16 48.02 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.595 179.626 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 4.4 t -64.99 -32.04 73.58 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.628 179.86 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 50.4 m -52.57 -38.58 60.23 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.485 -179.703 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.462 ' C ' ' H ' ' A' ' 61' ' ' TYR . 23.8 t -60.66 -43.03 94.0 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 -179.942 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . 0.554 ' O ' ' CE3' ' A' ' 26' ' ' TRP . . . 75.19 -40.91 1.27 Allowed Glycine 0 CA--C 1.529 0.919 0 N-CA-C 110.846 -0.902 . . . . 0.0 110.846 179.651 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . 0.462 ' H ' ' C ' ' A' ' 59' ' ' VAL . 26.9 p90 -113.46 158.64 20.43 Favored 'General case' 0 N--CA 1.469 0.495 0 CA-C-O 121.048 0.451 . . . . 0.0 111.245 -178.881 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' TYR . . . . . 0.411 ' CD2' ' CD1' ' A' ' 39' ' ' ILE . 33.3 t80 -152.93 149.5 28.29 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 179.541 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 79.8 m -112.4 133.93 54.22 Favored 'General case' 0 CA--C 1.52 -0.195 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.468 -179.445 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -132.36 100.09 3.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 115.854 -0.612 . . . . 0.0 109.834 178.762 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 2.0 p -114.37 164.18 14.29 Favored 'General case' 0 CA--C 1.515 -0.38 0 CA-C-O 120.908 0.385 . . . . 0.0 110.524 -179.942 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 107.79 25.63 5.87 Favored Glycine 0 CA--C 1.524 0.622 0 N-CA-C 111.172 -0.771 . . . . 0.0 111.172 179.75 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.513 ' N ' ' OG ' ' A' ' 20' ' ' SER . 11.9 mt -100.72 109.44 21.47 Favored 'General case' 0 N--CA 1.465 0.318 0 N-CA-C 109.284 -0.636 . . . . 0.0 109.284 179.944 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 55.5 mm-40 -52.04 139.53 33.57 Favored Pre-proline 0 C--N 1.316 -0.887 0 C-N-CA 120.496 -0.482 . . . . 0.0 112.054 -178.589 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . 0.46 ' C ' ' H ' ' A' ' 71' ' ' ILE . 74.4 Cg_endo -73.91 157.52 47.24 Favored 'Trans proline' 0 N--CA 1.498 1.748 0 C-N-CA 122.86 2.373 . . . . 0.0 111.253 178.574 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 69.97 -8.54 3.49 Favored Glycine 0 CA--C 1.527 0.822 0 CA-C-N 115.844 -0.616 . . . . 0.0 111.653 178.855 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . 0.524 ' O ' ' NH1' ' B' ' 223' ' ' ARG . 1.6 mp -98.76 149.19 5.53 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 N-CA-C 109.229 -0.656 . . . . 0.0 109.229 -179.702 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 72' ' ' ASP . . . . . 0.403 ' O ' ' CB ' ' A' ' 44' ' ' ALA . 2.7 t70 -89.51 115.61 27.06 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.165 -0.925 . . . . 0.0 110.422 179.657 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 73' ' ' TYR . . . . . . . . . . . . . 20.9 m-85 -108.48 119.74 40.38 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.425 179.951 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 74' ' ' ASP . . . . . 0.499 ' N ' ' O ' ' A' ' 42' ' ' VAL . 13.4 m-20 -89.8 118.13 29.16 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 115.548 -0.751 . . . . 0.0 109.646 179.824 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -115.9 164.24 12.42 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-O 121.192 0.52 . . . . 0.0 109.919 -179.139 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -152.92 128.88 10.3 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.659 -0.7 . . . . 0.0 110.216 179.667 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 62.8 t -108.27 131.79 57.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 179.461 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 96.5 mt -124.51 124.45 68.32 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 115.991 -0.549 . . . . 0.0 110.344 179.458 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 95.1 m -100.86 114.41 28.23 Favored 'General case' 0 C--O 1.232 0.181 0 CA-C-O 120.922 0.391 . . . . 0.0 110.081 179.636 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . 0.452 ' CD2' ' NZ ' ' B' ' 215' ' ' LYS . 9.6 mt -118.68 113.96 22.0 Favored 'General case' 0 CA--C 1.518 -0.251 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.253 -179.988 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 2.3 pp -147.47 144.84 19.4 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.042 179.146 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 82' ' ' ASN . . . . . 0.519 ' N ' ' OG1' ' A' ' 33' ' ' THR . 39.9 t30 -64.66 -47.55 78.06 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 120.942 0.401 . . . . 0.0 111.189 179.892 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 90.71 161.92 37.8 Favored Glycine 0 CA--C 1.521 0.466 0 N-CA-C 110.923 -0.871 . . . . 0.0 110.923 179.578 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -78.87 176.95 54.4 Favored Glycine 0 CA--C 1.524 0.63 0 N-CA-C 110.76 -0.936 . . . . 0.0 110.76 179.914 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 80.1 mm-40 -52.25 166.07 0.19 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.879 0.371 . . . . 0.0 110.442 -179.984 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 33.2 t -59.62 139.74 56.94 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.588 -179.659 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . 60.03 72.47 0.76 Allowed Pre-proline 0 C--N 1.328 -0.333 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.456 -179.895 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_exo -52.81 -37.67 76.93 Favored 'Trans proline' 0 C--N 1.308 -1.575 0 C-N-CA 122.937 2.424 . . . . 0.0 112.283 -179.86 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 6.2 t -130.65 125.33 33.75 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.528 179.994 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 9.6 p -86.73 168.03 13.91 Favored 'General case' 0 C--N 1.333 -0.15 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.302 179.707 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . 0.456 ' CD1' ' N ' ' A' ' 91' ' ' LEU . 10.0 mp -89.39 121.79 31.98 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-O 121.07 0.462 . . . . 0.0 110.086 -179.785 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 61.5 p -84.86 164.9 18.14 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.921 -0.582 . . . . 0.0 110.337 179.893 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 88.4 mt-30 -72.73 136.6 45.57 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.462 -179.94 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 0.42 ' C ' ' HG1' ' A' ' 95' ' ' THR . 8.5 tp-100 -63.15 -40.5 97.73 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.403 -179.792 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 95' ' ' THR . . . . . 0.42 ' HG1' ' C ' ' A' ' 94' ' ' GLN . 13.4 m . . . . . 0 C--O 1.222 -0.354 0 CA-C-O 117.999 -1.0 . . . . 0.0 110.543 -179.983 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 201' ' ' SER . . . . . . . . . . . . . 22.0 t . . . . . 0 N--CA 1.49 1.538 0 N-CA-C 109.337 -0.616 . . . . 0.0 109.337 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' B' B ' 202' ' ' SER . . . . . . . . . . . . . 15.9 p -69.08 141.11 54.83 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.624 -179.828 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 203' ' ' SER . . . . . . . . . . . . . 1.8 m -89.54 152.04 46.74 Favored Pre-proline 0 CA--C 1.535 0.388 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.616 -179.625 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 204' ' ' PRO . . . . . . . . . . . . . 25.9 Cg_endo -60.67 -48.69 10.35 Favored 'Trans proline' 0 N--CA 1.496 1.664 0 C-N-CA 122.733 2.288 . . . . 0.0 111.744 -179.744 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 205' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -149.69 145.14 17.66 Favored 'Isoleucine or valine' 0 C--O 1.233 0.212 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.402 -179.893 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 206' ' ' GLN . . . . . . . . . . . . . 49.4 tt0 -138.54 139.46 38.7 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.374 178.894 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 207' ' ' GLY . . . . . . . . . . . . . . . -97.61 -133.66 7.97 Favored Glycine 0 N--CA 1.463 0.486 0 N-CA-C 110.957 -0.857 . . . . 0.0 110.957 180.0 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 208' ' ' SER . . . . . 0.536 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 98.9 p -164.52 168.35 18.41 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.862 0.363 . . . . 0.0 110.711 179.238 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 209' ' ' TRP . . . . . . . . . . . . . 85.4 m95 -88.89 150.95 22.63 Favored 'General case' 0 C--O 1.233 0.205 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.522 179.54 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 82.3 p -129.09 129.0 44.67 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-N 116.487 -0.324 . . . . 0.0 110.394 179.532 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 58.7 t-105 -91.41 110.62 21.93 Favored 'General case' 0 C--N 1.333 -0.112 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.586 179.82 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 212' ' ' GLU . . . . . 0.437 ' O ' ' O ' ' B' ' 215' ' ' LYS . 0.6 OUTLIER -161.26 165.93 28.45 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.541 179.654 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' B' B ' 213' ' ' ASN . . . . . . . . . . . . . 69.7 m-20 51.02 35.25 12.33 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.89 -0.595 . . . . 0.0 110.978 176.436 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 51.17 19.97 4.35 Favored Glycine 0 CA--C 1.525 0.661 0 N-CA-C 110.954 -0.858 . . . . 0.0 110.954 179.946 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 215' ' ' LYS . . . . . 0.452 ' NZ ' ' CD2' ' A' ' 80' ' ' LEU . 14.9 mtpt -145.79 150.58 36.46 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 121.066 0.46 . . . . 0.0 110.985 179.983 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 216' ' ' TRP . . . . . . . . . . . . . 52.4 m95 -87.19 114.43 23.79 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.866 -0.606 . . . . 0.0 109.883 179.233 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 217' ' ' THR . . . . . . . . . . . . . 46.4 m -118.36 135.07 54.54 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.694 -179.587 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 218' ' ' TRP . . . . . 0.536 ' CH2' ' N ' ' B' ' 208' ' ' SER . 29.5 t-105 -106.39 104.0 13.59 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 115.907 -0.588 . . . . 0.0 109.876 178.868 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 16.7 mtpp -134.38 173.8 11.23 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.558 -179.303 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -179.53 -160.94 26.05 Favored Glycine 0 CA--C 1.524 0.599 0 N-CA-C 110.761 -0.936 . . . . 0.0 110.761 179.819 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 221' ' ' ILE . . . . . 0.447 ' H ' ' CD1' ' B' ' 221' ' ' ILE . 1.9 mp -54.1 -73.14 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 C-N-CA 120.66 -0.416 . . . . 0.0 110.261 -178.804 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 222' ' ' ILE . . . . . 0.536 ' O ' ' O ' ' B' ' 223' ' ' ARG . 21.8 pt -160.51 -165.28 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.212 -179.799 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 223' ' ' ARG . . . . . 0.536 ' O ' ' O ' ' B' ' 222' ' ' ILE . 35.9 ptt-85 -40.28 174.03 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.973 178.605 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 224' ' ' LEU . . . . . 0.591 ' H ' ' CD2' ' B' ' 224' ' ' LEU . 2.2 mm? -63.45 110.16 1.86 Allowed 'General case' 0 N--CA 1.447 -0.613 0 CA-C-N 115.799 -0.637 . . . . 0.0 111.079 -179.673 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 33.8 tp10 -95.83 148.52 22.51 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.394 -0.821 . . . . 0.0 110.002 -179.865 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 226' ' ' GLN . . . . . . . . . . . . . 15.7 tt0 . . . . . 0 C--O 1.22 -0.482 0 CA-C-O 118.076 -0.964 . . . . 0.0 110.749 -179.873 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.306 0 N-CA-C 109.536 -1.426 . . . . 0.0 109.536 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 34.7 t -66.64 140.74 57.94 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.736 0.303 . . . . 0.0 110.549 179.977 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 42.4 tt0 -75.06 148.39 39.84 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.328 179.875 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.0 m -129.22 81.29 70.77 Favored Pre-proline 0 N--CA 1.464 0.264 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.243 -179.966 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_exo -56.46 140.99 90.18 Favored 'Trans proline' 0 N--CA 1.495 1.581 0 C-N-CA 122.426 2.084 . . . . 0.0 111.605 -179.97 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 26.1 mt-30 -108.97 123.31 48.91 Favored 'General case' 0 CA--C 1.52 -0.2 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.33 -179.875 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 55.3 tp -84.8 108.04 17.27 Favored 'General case' 0 C--N 1.33 -0.26 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 179.546 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' THR . . . . . 0.406 ' O ' ' OD1' ' A' ' 11' ' ' ASP . 7.1 t -103.79 173.48 6.29 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.949 -0.569 . . . . 0.0 109.939 179.908 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . 0.406 ' OD1' ' O ' ' A' ' 10' ' ' THR . 97.7 m-20 -138.04 163.76 30.78 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.254 179.994 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 56.5 tp -66.27 138.35 57.59 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.562 -179.969 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 16.1 p -139.6 152.93 47.22 Favored 'General case' 0 N--CA 1.463 0.192 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.384 179.555 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . 0.516 ' CD1' ' N ' ' A' ' 14' ' ' PHE . 27.7 m-85 -111.54 144.12 41.29 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.837 -179.407 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 27.6 m -143.49 164.29 15.52 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.415 179.527 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 98.8 m-20 50.37 30.46 4.55 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.95 179.79 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 96.7 mt -55.78 138.51 16.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-O 120.921 0.391 . . . . 0.0 110.202 179.507 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.464 ' CB ' ' O ' ' A' ' 21' ' ' SER . 0.2 OUTLIER -135.7 -166.75 1.91 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.034 -179.48 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . 0.469 ' N ' ' OD1' ' A' ' 19' ' ' ASP . 27.8 p-10 -84.94 -46.58 11.11 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.831 179.489 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' SER . . . . . 0.457 ' N ' ' OD1' ' A' ' 19' ' ' ASP . 43.0 m -120.74 12.56 11.41 Favored 'General case' 0 N--CA 1.467 0.389 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.852 179.99 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' SER . . . . . 0.464 ' O ' ' CB ' ' A' ' 18' ' ' THR . 85.9 p -150.26 143.55 25.01 Favored 'General case' 0 N--CA 1.465 0.283 0 CA-C-O 121.037 0.446 . . . . 0.0 110.335 -179.943 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 40.7 pt -140.46 145.0 26.47 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.361 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.217 -179.992 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -96.31 85.85 0.89 Allowed Glycine 0 CA--C 1.522 0.497 0 N-CA-C 110.882 -0.887 . . . . 0.0 110.882 -179.906 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 89.9 mt -62.3 121.02 12.12 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 120.905 0.383 . . . . 0.0 110.05 -179.782 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . 0.503 ' NH1' ' O ' ' A' ' 26' ' ' TRP . 28.0 tpt85 -138.03 135.25 35.71 Favored 'General case' 0 CA--C 1.517 -0.301 0 CA-C-O 121.115 0.483 . . . . 0.0 110.199 -179.468 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' TRP . . . . . 0.503 ' O ' ' NH1' ' A' ' 25' ' ' ARG . 46.1 p90 -147.52 155.45 41.88 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.555 -0.748 . . . . 0.0 109.604 179.851 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 6.2 m -111.34 98.12 38.62 Favored Pre-proline 0 C--N 1.33 -0.249 0 N-CA-C 110.102 -0.332 . . . . 0.0 110.102 179.66 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 32.5 Cg_exo -54.53 144.81 61.31 Favored 'Trans proline' 0 C--N 1.306 -1.692 0 C-N-CA 121.604 1.536 . . . . 0.0 113.275 179.909 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 57.1 mt -79.01 138.16 37.9 Favored 'General case' 0 CA--C 1.506 -0.743 0 CA-C-N 115.49 -0.777 . . . . 0.0 110.627 -179.567 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 34.1 t30 -50.45 -34.21 23.93 Favored 'General case' 0 C--N 1.313 -1.021 0 CA-C-N 114.856 -1.066 . . . . 0.0 110.098 179.523 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 49.2 m -79.82 -32.58 40.7 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.629 -0.714 . . . . 0.0 110.412 179.118 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 8.0 m -60.0 137.7 58.02 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.197 -179.932 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' THR . . . . . 0.575 ' CB ' ' H ' ' A' ' 82' ' ' ASN . 11.7 m -67.41 143.1 56.47 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.22 -179.645 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . 0.409 HG21 HD11 ' A' ' 34' ' ' ILE . 28.8 mm -94.05 94.04 4.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 121.0 0.429 . . . . 0.0 110.176 -179.564 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 10.7 pt -143.49 131.4 18.67 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.274 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.416 -179.973 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -41.84 118.23 1.46 Allowed Glycine 0 CA--C 1.519 0.328 0 N-CA-C 111.318 -0.713 . . . . 0.0 111.318 -179.599 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' TYR . . . . . 0.407 ' HH ' ' CG2' ' A' ' 81' ' ' ILE . 94.6 m-85 -85.09 178.88 7.39 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.875 0.369 . . . . 0.0 110.11 179.376 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . 0.549 ' NE ' ' OE1' ' A' ' 52' ' ' GLU . 0.0 OUTLIER -132.48 125.99 31.95 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.727 179.92 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . 0.46 ' CD1' ' CD2' ' A' ' 62' ' ' TYR . 2.5 pt -100.24 123.81 53.35 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 115.657 -0.701 . . . . 0.0 110.018 179.78 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' THR . . . . . 0.449 ' OG1' ' NE ' ' A' ' 38' ' ' ARG . 28.2 m -109.04 133.09 53.46 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.612 -179.07 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.2 p -130.51 138.44 53.74 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.305 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.288 179.844 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . 0.467 ' O ' ' N ' ' A' ' 74' ' ' ASP . 31.7 t -131.94 130.95 61.69 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.269 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 179.979 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -96.44 135.87 37.73 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.765 -0.652 . . . . 0.0 109.32 179.677 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -92.57 -47.24 7.22 Favored 'General case' 0 N--CA 1.464 0.24 0 C-N-CA 120.673 -0.411 . . . . 0.0 110.839 179.93 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -62.09 -29.55 73.09 Favored Glycine 0 N--CA 1.464 0.559 0 N-CA-C 110.891 -0.883 . . . . 0.0 110.891 179.997 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . 0.429 ' OE2' ' OH ' ' A' ' 73' ' ' TYR . 84.8 mt-10 -95.57 130.44 42.43 Favored 'General case' 0 C--N 1.328 -0.369 0 N-CA-C 109.477 -0.564 . . . . 0.0 109.477 -179.552 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -58.18 -21.17 45.98 Favored Glycine 0 CA--C 1.528 0.869 0 N-CA-C 110.857 -0.897 . . . . 0.0 110.857 -178.941 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -119.25 136.32 24.42 Favored Pre-proline 0 N--CA 1.472 0.661 0 CA-C-N 116.715 0.258 . . . . 0.0 110.543 179.676 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -77.9 167.5 23.63 Favored 'Trans proline' 0 N--CA 1.49 1.295 0 C-N-CA 122.409 2.072 . . . . 0.0 111.428 178.079 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 87.2 mt -86.22 141.66 14.14 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.235 0 CA-C-O 120.826 0.346 . . . . 0.0 110.245 179.081 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 76.3 m-85 -60.85 138.95 58.09 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.633 179.986 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . 0.549 ' OE1' ' NE ' ' A' ' 38' ' ' ARG . 5.9 pt-20 -69.64 -178.62 1.51 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.455 179.798 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 4.5 t70 -153.38 148.7 27.02 Favored 'General case' 0 N--CA 1.45 -0.444 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.748 179.367 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 58.0 m-85 -115.93 125.28 52.36 Favored 'General case' 0 N--CA 1.464 0.257 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.139 -179.929 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.9 p -125.64 134.49 66.56 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.341 0 CA-C-N 116.471 -0.331 . . . . 0.0 110.208 -179.985 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 98.9 m-20 -53.41 140.15 28.46 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.322 -179.653 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 10.4 t -60.4 -34.16 73.54 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.002 -0.544 . . . . 0.0 110.573 -179.763 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 43.7 m -55.24 -34.34 63.91 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.547 -179.731 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 99.9 t -62.31 -46.51 96.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.579 -179.871 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 61.25 26.38 65.98 Favored Glycine 0 CA--C 1.527 0.796 0 N-CA-C 110.568 -1.013 . . . . 0.0 110.568 179.635 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 52.6 t80 -167.44 152.03 6.89 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 121.121 0.486 . . . . 0.0 111.091 -179.513 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' TYR . . . . . 0.46 ' CD2' ' CD1' ' A' ' 39' ' ' ILE . 29.1 t80 -159.64 162.05 35.11 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 115.724 -0.671 . . . . 0.0 110.281 178.702 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 99.0 m -127.44 134.68 49.84 Favored 'General case' 0 N--CA 1.463 0.217 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.296 179.835 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -130.76 113.83 25.9 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.334 0 N-CA-C 109.513 -0.551 . . . . 0.0 109.513 178.877 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 1.9 p -122.93 157.33 32.84 Favored 'General case' 0 N--CA 1.467 0.418 0 CA-C-O 120.907 0.384 . . . . 0.0 110.413 -179.66 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 107.59 40.62 1.72 Allowed Glycine 0 CA--C 1.523 0.581 0 N-CA-C 110.628 -0.989 . . . . 0.0 110.628 -179.729 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.405 ' O ' ' OG ' ' A' ' 20' ' ' SER . 1.4 mt -116.79 110.83 18.9 Favored 'General case' 0 N--CA 1.465 0.304 0 N-CA-C 109.502 -0.555 . . . . 0.0 109.502 -179.896 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 27.6 mm-40 -48.84 141.34 10.27 Favored Pre-proline 0 C--N 1.322 -0.628 0 C-N-CA 120.862 -0.335 . . . . 0.0 111.249 -178.486 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 91.4 Cg_endo -74.89 158.37 42.66 Favored 'Trans proline' 0 N--CA 1.491 1.341 0 C-N-CA 122.481 2.121 . . . . 0.0 112.558 179.511 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . 0.409 ' N ' ' NH2' ' B' ' 223' ' ' ARG . . . 48.53 27.55 6.01 Favored Glycine 0 CA--C 1.529 0.951 0 CA-C-N 114.837 -1.074 . . . . 0.0 111.182 179.305 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . 0.714 ' H ' HH21 ' B' ' 223' ' ' ARG . 0.9 OUTLIER -114.0 166.36 7.93 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.483 0 CA-C-O 121.13 0.491 . . . . 0.0 109.698 -179.578 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 3.2 t70 -101.17 100.27 10.8 Favored 'General case' 0 N--CA 1.446 -0.649 0 CA-C-N 115.6 -0.727 . . . . 0.0 111.411 -178.715 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 73' ' ' TYR . . . . . 0.43 ' CD1' ' CG2' ' A' ' 71' ' ' ILE . 2.2 m-30 -110.81 124.69 52.51 Favored 'General case' 0 C--O 1.22 -0.472 0 CA-C-O 121.322 0.582 . . . . 0.0 110.341 179.16 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 74' ' ' ASP . . . . . 0.467 ' N ' ' O ' ' A' ' 42' ' ' VAL . 21.5 m-20 -89.11 116.11 27.13 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 114.894 -1.048 . . . . 0.0 109.485 -179.909 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -116.17 162.1 14.43 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.221 0 CA-C-O 121.219 0.533 . . . . 0.0 110.084 -179.383 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 3.0 m -154.04 150.69 28.51 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.259 -0.882 . . . . 0.0 110.755 179.502 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 4.1 p -132.9 101.14 4.2 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.245 0 CA-C-N 115.824 -0.625 . . . . 0.0 109.398 178.421 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . 0.405 HD12 HG22 ' A' ' 78' ' ' ILE . 94.6 mt -82.95 127.81 39.32 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.183 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.451 -179.522 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 5.0 p -108.21 105.89 15.82 Favored 'General case' 0 N--CA 1.464 0.251 0 CA-C-N 116.143 -0.481 . . . . 0.0 109.709 179.422 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 7.0 tp -121.68 130.59 53.57 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.353 -179.867 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 81' ' ' ILE . . . . . 0.407 ' CG2' ' HH ' ' A' ' 37' ' ' TYR . 1.6 pp -131.3 168.37 24.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.098 -0.501 . . . . 0.0 109.908 179.136 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 82' ' ' ASN . . . . . 0.575 ' H ' ' CB ' ' A' ' 33' ' ' THR . 9.8 t-20 -64.53 -43.03 95.31 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.813 0.34 . . . . 0.0 110.634 -179.992 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 157.8 115.85 0.46 Allowed Glycine 0 CA--C 1.526 0.753 0 N-CA-C 111.277 -0.729 . . . . 0.0 111.277 179.864 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -97.01 -174.6 34.75 Favored Glycine 0 CA--C 1.526 0.763 0 N-CA-C 110.85 -0.9 . . . . 0.0 110.85 179.74 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 16.6 pt-20 -75.52 132.38 40.7 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.845 0.355 . . . . 0.0 110.414 179.934 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 86' ' ' SER . . . . . 0.409 ' O ' ' CB ' ' A' ' 87' ' ' ALA . 90.3 p -81.4 164.25 22.23 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.34 179.914 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . 0.409 ' CB ' ' O ' ' A' ' 86' ' ' SER . . . 169.02 154.0 0.15 Allowed Pre-proline 0 CA--C 1.534 0.359 0 CA-C-N 116.401 -0.363 . . . . 0.0 110.418 179.617 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 43.4 Cg_endo -67.04 151.8 81.27 Favored 'Trans proline' 0 N--CA 1.495 1.608 0 C-N-CA 122.72 2.28 . . . . 0.0 111.656 179.791 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 71.8 m -81.72 121.68 26.7 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.271 179.942 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 38.2 p -144.72 163.04 35.21 Favored 'General case' 0 C--N 1.332 -0.163 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.304 -179.94 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . 0.473 ' CD1' ' N ' ' A' ' 91' ' ' LEU . 9.6 mp -89.9 128.95 36.31 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.394 -0.366 . . . . 0.0 110.081 179.914 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 42.1 p -89.61 135.35 33.66 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.46 179.99 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 14.1 pt20 -75.07 139.87 43.1 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.593 -180.0 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 97.7 mt-30 -85.23 61.47 6.89 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.519 179.989 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 88.5 m . . . . . 0 C--O 1.219 -0.504 0 CA-C-O 118.042 -0.98 . . . . 0.0 110.558 179.982 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' B' B ' 201' ' ' SER . . . . . . . . . . . . . 39.4 t . . . . . 0 N--CA 1.489 1.496 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' B' B ' 202' ' ' SER . . . . . . . . . . . . . 48.5 t -65.17 141.69 58.59 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.192 -0.458 . . . . 0.0 109.825 179.626 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 203' ' ' SER . . . . . . . . . . . . . 27.6 p -123.83 108.24 30.71 Favored Pre-proline 0 CA--C 1.54 0.593 0 N-CA-C 110.067 -0.346 . . . . 0.0 110.067 179.795 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 204' ' ' PRO . . . . . . . . . . . . . 58.6 Cg_endo -76.73 -56.82 0.05 OUTLIER 'Trans proline' 0 N--CA 1.495 1.563 0 C-N-CA 121.729 1.619 . . . . 0.0 112.009 -179.758 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 205' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -150.17 144.69 17.41 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.3 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.107 -179.995 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 206' ' ' GLN . . . . . 0.437 ' N ' ' OE1' ' B' ' 206' ' ' GLN . 5.7 pm0 -146.38 145.28 30.22 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.999 -0.546 . . . . 0.0 109.795 179.572 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 207' ' ' GLY . . . . . . . . . . . . . . . -109.31 -131.9 6.36 Favored Glycine 0 N--CA 1.464 0.536 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 -179.793 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 208' ' ' SER . . . . . 0.497 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 97.1 p -164.14 170.03 16.96 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.81 0.338 . . . . 0.0 110.741 179.636 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 209' ' ' TRP . . . . . . . . . . . . . 71.9 m95 -82.93 145.59 29.3 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.412 179.529 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 40.3 p -127.33 131.29 50.45 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.565 179.942 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 41.4 t-105 -91.68 118.58 30.78 Favored 'General case' 0 N--CA 1.466 0.366 0 CA-C-N 116.18 -0.463 . . . . 0.0 109.928 179.596 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 212' ' ' GLU . . . . . 0.487 ' O ' ' O ' ' B' ' 215' ' ' LYS . 1.9 pt-20 -165.75 171.61 12.71 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.898 178.893 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 213' ' ' ASN . . . . . 0.402 ' C ' ' H ' ' B' ' 215' ' ' LYS . 93.9 m-20 48.07 38.08 8.99 Favored 'General case' 0 C--N 1.324 -0.537 0 C-N-CA 120.338 -0.545 . . . . 0.0 111.997 176.629 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 51.34 12.46 0.91 Allowed Glycine 0 CA--C 1.53 0.974 0 N-CA-C 111.536 -0.626 . . . . 0.0 111.536 179.644 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 215' ' ' LYS . . . . . 0.487 ' O ' ' O ' ' B' ' 212' ' ' GLU . 7.5 mtmp? -143.95 151.37 39.68 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.849 0.357 . . . . 0.0 110.962 -179.778 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 216' ' ' TRP . . . . . . . . . . . . . 49.0 m95 -87.0 124.93 33.72 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.25 179.285 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 217' ' ' THR . . . . . . . . . . . . . 5.0 m -138.63 148.1 43.69 Favored 'General case' 0 C--O 1.235 0.293 0 CA-C-O 121.052 0.453 . . . . 0.0 110.341 -179.809 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 218' ' ' TRP . . . . . 0.497 ' CH2' ' N ' ' B' ' 208' ' ' SER . 15.5 t-105 -105.25 121.66 44.32 Favored 'General case' 0 C--N 1.332 -0.167 0 CA-C-N 115.894 -0.593 . . . . 0.0 110.156 179.797 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 97.5 mttt -147.17 169.56 19.07 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.899 -179.996 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -174.83 -162.22 25.94 Favored Glycine 0 CA--C 1.522 0.496 0 N-CA-C 111.155 -0.778 . . . . 0.0 111.155 -179.884 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 221' ' ' ILE . . . . . 0.636 ' CG2' ' H ' ' B' ' 222' ' ' ILE . 12.2 tt -50.35 -69.71 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 C-N-CA 121.073 -0.251 . . . . 0.0 110.971 -177.977 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 222' ' ' ILE . . . . . 0.636 ' H ' ' CG2' ' B' ' 221' ' ' ILE . 9.6 pt -159.55 -165.2 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.317 -0.83 0 N-CA-C 109.327 -0.62 . . . . 0.0 109.327 178.377 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 223' ' ' ARG . . . . . 0.714 HH21 ' H ' ' A' ' 71' ' ' ILE . 39.1 ptt85 -44.47 174.98 0.0 OUTLIER 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 121.445 0.641 . . . . 0.0 111.04 178.717 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 224' ' ' LEU . . . . . 0.547 ' CD2' ' N ' ' B' ' 224' ' ' LEU . 3.2 mm? -59.95 127.48 32.1 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-N 115.046 -0.979 . . . . 0.0 110.377 -179.737 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 31.0 tp10 -83.03 150.56 26.27 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.738 -0.665 . . . . 0.0 110.155 -179.959 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 226' ' ' GLN . . . . . . . . . . . . . 54.1 tt0 . . . . . 0 C--N 1.326 -0.455 0 CA-C-O 117.891 -1.052 . . . . 0.0 110.625 -179.72 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . 0.43 ' H1 ' ' H ' ' A' ' 4' ' ' SER . . . . . . . . 0 N--CA 1.49 2.24 0 N-CA-C 109.525 -1.43 . . . . 0.0 109.525 . . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' SER . . . . . 0.43 ' H ' ' H1 ' ' A' ' 3' ' ' GLY . 59.9 p -79.5 80.53 5.87 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.842 0.353 . . . . 0.0 110.357 179.845 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 72.0 mm-40 -86.18 85.39 7.35 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.26 179.782 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.3 m -86.57 149.18 48.27 Favored Pre-proline 0 CA--C 1.532 0.283 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.516 -179.732 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -66.7 145.47 75.69 Favored 'Trans proline' 0 N--CA 1.494 1.536 0 C-N-CA 122.517 2.145 . . . . 0.0 111.907 179.598 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 2.9 pt20 -137.55 130.66 30.57 Favored 'General case' 0 N--CA 1.463 0.193 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.146 179.459 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -103.71 125.07 49.95 Favored 'General case' 0 C--N 1.33 -0.25 0 N-CA-C 109.619 -0.512 . . . . 0.0 109.619 -179.848 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 55.3 p -130.97 154.77 47.8 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 121.026 0.441 . . . . 0.0 110.25 179.355 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 99.4 m-20 -84.8 171.16 12.5 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.385 -179.986 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -60.85 139.0 58.09 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.152 -178.16 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 96.3 p -143.27 144.55 32.17 Favored 'General case' 0 CA--C 1.521 -0.168 0 CA-C-N 115.837 -0.62 . . . . 0.0 110.621 179.931 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . 0.512 ' CD1' ' N ' ' A' ' 14' ' ' PHE . 11.5 m-85 -112.34 143.77 42.89 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.397 -0.82 . . . . 0.0 110.754 -179.22 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 30.1 m -141.27 164.28 20.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.346 179.712 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 27.7 t70 53.63 34.22 18.24 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.08 179.849 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 1.9 mp -56.51 132.06 20.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 N-CA-C 109.57 -0.53 . . . . 0.0 109.57 179.936 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -132.8 -169.13 2.19 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-N 116.021 -0.536 . . . . 0.0 109.916 179.711 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . 0.474 ' N ' ' OD1' ' A' ' 19' ' ' ASP . 20.7 p-10 -91.24 -41.84 10.74 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.698 179.388 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' SER . . . . . 0.6 ' HG ' ' H ' ' A' ' 67' ' ' LEU . 43.1 t -113.52 6.44 17.07 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-N 116.363 -0.38 . . . . 0.0 110.99 -179.304 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 38.3 t -154.1 152.61 30.64 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 121.131 0.491 . . . . 0.0 110.202 179.971 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 38.2 pt -142.2 146.26 22.76 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.049 179.816 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -94.75 82.82 0.92 Allowed Glycine 0 CA--C 1.524 0.652 0 N-CA-C 111.076 -0.81 . . . . 0.0 111.076 -179.723 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 76.1 mt -71.14 118.33 13.8 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 121.043 0.449 . . . . 0.0 110.211 179.901 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 56.4 ttt-85 -140.83 137.03 32.98 Favored 'General case' 0 CA--C 1.517 -0.318 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.436 179.935 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' TRP . . . . . . . . . . . . . 41.3 p90 -144.5 156.56 44.23 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.624 -0.716 . . . . 0.0 110.278 -179.36 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 2.2 m -108.05 102.31 45.35 Favored Pre-proline 0 CA--C 1.533 0.302 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.676 -179.953 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 41.7 Cg_exo -53.8 150.04 30.99 Favored 'Trans proline' 0 C--N 1.305 -1.761 0 C-N-CA 121.464 1.443 . . . . 0.0 112.673 179.274 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 60.9 mt -92.3 137.9 31.97 Favored 'General case' 0 CA--C 1.514 -0.425 0 CA-C-O 121.811 0.815 . . . . 0.0 110.809 -179.764 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 28.8 t-20 -47.56 -35.44 9.05 Favored 'General case' 0 C--N 1.313 -1.007 0 CA-C-N 115.056 -0.974 . . . . 0.0 110.092 179.952 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 53.0 m -79.8 -33.72 40.24 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.438 178.847 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 6.0 m -58.36 124.27 18.94 Favored 'General case' 0 CA--C 1.529 0.146 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.055 -179.86 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' THR . . . . . 0.556 ' CB ' ' H ' ' A' ' 82' ' ' ASN . 5.6 m -57.22 146.57 27.85 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.102 -179.762 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 20.5 mm -94.37 91.37 3.08 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.173 0 CA-C-O 121.047 0.451 . . . . 0.0 110.765 -179.377 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.478 ' O ' ' OG ' ' A' ' 57' ' ' SER . 22.1 pt -145.21 128.76 11.51 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.244 0 CA-C-N 115.714 -0.675 . . . . 0.0 110.597 179.815 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -42.65 125.84 4.44 Favored Glycine 0 CA--C 1.523 0.572 0 N-CA-C 111.086 -0.805 . . . . 0.0 111.086 -179.512 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 35.9 m-85 -90.83 -179.9 5.62 Favored 'General case' 0 CA--C 1.517 -0.29 0 N-CA-C 110.024 -0.362 . . . . 0.0 110.024 -179.88 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -131.45 121.34 24.37 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.553 179.753 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . 0.439 ' O ' ' CG1' ' A' ' 39' ' ' ILE . 2.3 pt -95.95 124.29 48.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.008 -0.542 . . . . 0.0 109.716 179.828 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 4.8 m -106.74 132.77 52.33 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.398 -179.361 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.4 p -130.07 137.75 55.69 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.319 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.287 -179.979 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . 0.524 ' O ' ' N ' ' A' ' 74' ' ' ASP . 40.1 t -131.02 131.65 63.95 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.298 0 N-CA-C 109.743 -0.465 . . . . 0.0 109.743 179.671 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -97.92 141.26 31.11 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.137 -0.483 . . . . 0.0 109.817 179.273 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . 0.407 ' CB ' ' O ' ' A' ' 72' ' ' ASP . . . -100.29 -23.68 14.73 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-O 120.828 0.347 . . . . 0.0 110.672 179.874 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -90.88 31.06 5.78 Favored Glycine 0 N--CA 1.466 0.636 0 N-CA-C 110.776 -0.93 . . . . 0.0 110.776 -179.963 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 64.2 mt-10 -151.8 150.8 30.55 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.951 0.405 . . . . 0.0 110.649 -179.738 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -72.1 -17.67 77.39 Favored Glycine 0 CA--C 1.524 0.62 0 N-CA-C 110.781 -0.928 . . . . 0.0 110.781 179.633 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -133.94 139.04 32.14 Favored Pre-proline 0 CA--C 1.544 0.738 0 CA-C-N 116.772 0.286 . . . . 0.0 110.507 -179.978 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 68.4 Cg_endo -73.89 161.84 40.54 Favored 'Trans proline' 0 N--CA 1.494 1.558 0 C-N-CA 122.631 2.221 . . . . 0.0 111.949 178.31 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . 0.446 ' CG2' ' N ' ' A' ' 51' ' ' PHE . 96.3 mt -75.72 159.26 5.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.381 179.419 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' PHE . . . . . 0.446 ' N ' ' CG2' ' A' ' 50' ' ' ILE . 0.9 OUTLIER -78.32 142.21 37.9 Favored 'General case' 0 CA--C 1.531 0.24 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.727 179.871 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . 0.467 ' N ' ' CD ' ' A' ' 52' ' ' GLU . 0.0 OUTLIER -71.01 -178.48 1.97 Allowed 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.39 179.433 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . 0.432 ' OD1' ' OH ' ' A' ' 62' ' ' TYR . 0.2 OUTLIER -148.27 139.74 23.56 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.147 179.75 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 96.2 m-85 -109.32 123.58 49.53 Favored 'General case' 0 N--CA 1.464 0.241 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.478 -179.94 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 5.9 p -131.48 141.29 46.2 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.245 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.215 -179.976 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 84.9 m-20 -58.92 151.03 22.71 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.591 -179.777 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' SER . . . . . 0.478 ' OG ' ' O ' ' A' ' 35' ' ' ILE . 3.7 m -61.66 -34.48 75.78 Favored 'General case' 0 C--O 1.233 0.22 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.84 179.839 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 69.2 m -53.5 -34.59 58.63 Favored 'General case' 0 C--N 1.326 -0.444 0 N-CA-C 109.943 -0.392 . . . . 0.0 109.943 -179.661 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.72 ' C ' ' H ' ' A' ' 61' ' ' TYR . 4.1 t -83.19 76.06 1.09 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.859 -179.826 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -58.72 26.53 0.02 OUTLIER Glycine 0 CA--C 1.539 1.589 0 N-CA-C 111.549 -0.62 . . . . 0.0 111.549 -179.641 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . 0.72 ' H ' ' C ' ' A' ' 59' ' ' VAL . 35.8 p90 -160.69 150.58 17.61 Favored 'General case' 0 N--CA 1.453 -0.325 0 CA-C-O 121.125 0.488 . . . . 0.0 111.6 179.986 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 62' ' ' TYR . . . . . 0.432 ' OH ' ' OD1' ' A' ' 53' ' ' ASP . 37.1 t80 -153.6 147.85 25.83 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.688 -0.687 . . . . 0.0 109.583 179.093 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 29.8 m -108.74 132.63 53.76 Favored 'General case' 0 N--CA 1.464 0.235 0 CA-C-O 121.037 0.446 . . . . 0.0 110.563 -179.31 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -132.03 106.16 10.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 115.924 -0.58 . . . . 0.0 109.723 178.662 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 2.6 p -114.55 162.06 17.22 Favored 'General case' 0 N--CA 1.465 0.283 0 CA-C-O 120.978 0.418 . . . . 0.0 110.543 179.95 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 108.58 41.07 1.52 Allowed Glycine 0 CA--C 1.524 0.655 0 N-CA-C 111.256 -0.737 . . . . 0.0 111.256 -179.942 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.6 ' H ' ' HG ' ' A' ' 20' ' ' SER . 14.3 mt -115.2 109.07 17.45 Favored 'General case' 0 N--CA 1.466 0.353 0 N-CA-C 109.211 -0.662 . . . . 0.0 109.211 179.456 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 33.6 mm-40 -60.11 140.83 90.74 Favored Pre-proline 0 C--N 1.321 -0.642 0 C-N-CA 120.623 -0.431 . . . . 0.0 111.788 -178.403 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 93.8 Cg_endo -74.63 155.74 44.74 Favored 'Trans proline' 0 N--CA 1.497 1.682 0 C-N-CA 122.686 2.258 . . . . 0.0 111.73 178.802 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 71.61 7.55 65.15 Favored Glycine 0 CA--C 1.525 0.694 0 CA-C-N 115.635 -0.711 . . . . 0.0 111.629 179.128 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 1.6 mp -116.18 144.0 24.9 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.469 0 CA-C-O 121.441 0.639 . . . . 0.0 109.463 -179.934 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 72' ' ' ASP . . . . . 0.407 ' O ' ' CB ' ' A' ' 44' ' ' ALA . 2.1 t70 -84.73 114.18 21.86 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.143 -0.935 . . . . 0.0 110.869 179.943 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 73' ' ' TYR . . . . . . . . . . . . . 23.7 m-85 -106.53 122.16 45.74 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 121.251 0.548 . . . . 0.0 110.306 179.849 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 74' ' ' ASP . . . . . 0.524 ' N ' ' O ' ' A' ' 42' ' ' VAL . 11.7 m-20 -91.42 117.5 29.74 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.209 -0.905 . . . . 0.0 109.432 179.625 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -115.27 165.92 9.85 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.422 0 CA-C-O 120.957 0.408 . . . . 0.0 110.267 -179.045 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -154.84 121.94 5.56 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.391 179.208 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 63.1 t -101.1 102.6 13.68 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 N-CA-C 109.335 -0.617 . . . . 0.0 109.335 179.011 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 95.9 mt -93.64 131.05 41.69 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.229 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.571 -179.591 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 71.3 m -109.28 111.27 22.75 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.078 -0.51 . . . . 0.0 109.917 179.391 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 37.6 tp -116.47 120.72 39.69 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.496 179.915 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 2.8 pp -142.68 153.97 17.65 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.278 179.397 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 82' ' ' ASN . . . . . 0.556 ' H ' ' CB ' ' A' ' 33' ' ' THR . 14.3 t-20 -65.69 -44.17 87.01 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 121.028 0.442 . . . . 0.0 110.932 179.963 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 90.14 158.23 34.24 Favored Glycine 0 CA--C 1.524 0.647 0 N-CA-C 111.0 -0.84 . . . . 0.0 111.0 179.761 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -81.63 156.74 37.18 Favored Glycine 0 CA--C 1.523 0.533 0 N-CA-C 110.757 -0.937 . . . . 0.0 110.757 179.868 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -88.88 137.6 32.17 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.822 0.344 . . . . 0.0 110.412 179.86 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 45.0 t -65.68 147.76 52.86 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.444 179.952 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -155.05 162.33 27.46 Favored Pre-proline 0 CA--C 1.534 0.35 0 CA-C-N 116.449 -0.341 . . . . 0.0 110.332 179.995 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 56.8 Cg_endo -71.12 113.58 3.63 Favored 'Trans proline' 0 N--CA 1.494 1.523 0 C-N-CA 122.5 2.133 . . . . 0.0 111.705 179.494 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 29.8 m -142.13 147.55 36.86 Favored 'General case' 0 N--CA 1.464 0.235 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.387 179.843 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 12.9 p -85.91 -175.42 5.57 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.324 179.979 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 44.3 tp -57.58 125.4 22.74 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.293 -179.528 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 69.3 p -84.27 166.75 17.22 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.407 179.975 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 88.6 mt-30 -57.29 103.01 0.1 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.583 -179.856 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 65.0 tt0 -152.21 124.01 7.95 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.442 179.946 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 2.7 t . . . . . 0 C--O 1.219 -0.501 0 CA-C-O 118.008 -0.996 . . . . 0.0 110.598 179.883 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' B' B ' 201' ' ' SER . . . . . . . . . . . . . 30.7 t . . . . . 0 N--CA 1.491 1.577 0 N-CA-C 109.33 -0.618 . . . . 0.0 109.33 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' B' B ' 202' ' ' SER . . . . . . . . . . . . . 11.1 p -73.19 159.8 32.92 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.369 -179.816 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 203' ' ' SER . . . . . . . . . . . . . 1.4 p -89.73 152.59 47.05 Favored Pre-proline 0 CA--C 1.535 0.392 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.435 -179.692 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 204' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_endo -64.57 -6.81 12.88 Favored 'Trans proline' 0 N--CA 1.496 1.634 0 C-N-CA 122.702 2.268 . . . . 0.0 111.846 179.951 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 205' ' ' ILE . . . . . . . . . . . . . 18.2 tt -150.33 152.5 11.53 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.258 0 CA-C-O 121.114 0.483 . . . . 0.0 111.181 -179.972 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 206' ' ' GLN . . . . . . . . . . . . . 6.4 pt20 -178.37 76.4 0.02 OUTLIER 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.757 -0.656 . . . . 0.0 110.82 179.329 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 207' ' ' GLY . . . . . . . . . . . . . . . -108.44 -142.85 10.2 Favored Glycine 0 N--CA 1.464 0.501 0 N-CA-C 111.021 -0.831 . . . . 0.0 111.021 -179.776 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 208' ' ' SER . . . . . 0.531 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 98.7 p -165.17 170.9 14.37 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 120.706 0.288 . . . . 0.0 110.734 179.83 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 209' ' ' TRP . . . . . . . . . . . . . 72.2 m95 -87.58 131.43 34.4 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.315 179.607 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 68.8 p -110.15 133.39 53.27 Favored 'General case' 0 N--CA 1.465 0.313 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.405 -179.951 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 49.8 t-105 -94.93 118.36 31.68 Favored 'General case' 0 N--CA 1.463 0.199 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.059 179.795 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 212' ' ' GLU . . . . . 0.469 ' O ' ' O ' ' B' ' 215' ' ' LYS . 1.7 pt-20 -164.7 170.64 15.36 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.731 178.903 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 213' ' ' ASN . . . . . . . . . . . . . 13.8 m120 48.82 36.18 7.68 Favored 'General case' 0 C--N 1.323 -0.577 0 C-N-CA 120.321 -0.552 . . . . 0.0 111.615 175.951 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 51.88 13.82 1.64 Allowed Glycine 0 CA--C 1.529 0.94 0 N-CA-C 111.536 -0.626 . . . . 0.0 111.536 179.676 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 215' ' ' LYS . . . . . 0.469 ' O ' ' O ' ' B' ' 212' ' ' GLU . 67.5 mttm -143.09 150.87 40.1 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-O 121.082 0.468 . . . . 0.0 110.625 179.875 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 216' ' ' TRP . . . . . . . . . . . . . 64.4 m95 -84.82 118.03 24.23 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.013 179.856 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 217' ' ' THR . . . . . . . . . . . . . 19.3 m -127.5 139.86 52.52 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-O 121.197 0.522 . . . . 0.0 110.452 -179.393 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 218' ' ' TRP . . . . . 0.531 ' CH2' ' N ' ' B' ' 208' ' ' SER . 19.7 t-105 -106.22 117.25 33.55 Favored 'General case' 0 C--O 1.231 0.1 0 CA-C-N 115.849 -0.614 . . . . 0.0 109.922 179.227 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 54.4 mtmt -143.71 172.07 13.33 Favored 'General case' 0 CA--C 1.516 -0.343 0 CA-C-O 120.989 0.423 . . . . 0.0 110.642 -179.748 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -176.42 -160.73 24.18 Favored Glycine 0 CA--C 1.525 0.669 0 C-N-CA 120.585 -0.817 . . . . 0.0 111.305 -179.727 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 221' ' ' ILE . . . . . 0.403 ' O ' ' CG2' ' B' ' 222' ' ' ILE . 20.2 mt -54.7 -73.65 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 C-N-CA 120.649 -0.42 . . . . 0.0 110.448 -178.046 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 222' ' ' ILE . . . . . 0.502 ' O ' ' O ' ' B' ' 223' ' ' ARG . 21.7 pt -159.85 -165.08 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 N-CA-C 109.907 -0.405 . . . . 0.0 109.907 -179.761 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 223' ' ' ARG . . . . . 0.502 ' O ' ' O ' ' B' ' 222' ' ' ILE . 37.0 ptt180 -40.9 172.13 0.0 OUTLIER 'General case' 0 N--CA 1.456 -0.174 0 CA-C-O 121.175 0.512 . . . . 0.0 110.923 178.89 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 224' ' ' LEU . . . . . 0.712 ' H ' ' CD2' ' B' ' 224' ' ' LEU . 0.4 OUTLIER -58.55 147.8 30.86 Favored 'General case' 0 C--N 1.318 -0.794 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.638 -179.091 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 23.5 tp10 -78.17 148.94 33.86 Favored 'General case' 0 CA--C 1.515 -0.392 0 CA-C-N 115.551 -0.75 . . . . 0.0 110.511 -178.858 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 226' ' ' GLN . . . . . . . . . . . . . 90.9 mm-40 . . . . . 0 C--O 1.219 -0.518 0 CA-C-O 118.029 -0.986 . . . . 0.0 110.461 -179.372 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . 0.427 ' O ' ' O ' ' A' ' 4' ' ' SER . . . . . . . . 0 N--CA 1.488 2.16 0 N-CA-C 109.456 -1.458 . . . . 0.0 109.456 . . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' SER . . . . . 0.427 ' O ' ' O ' ' A' ' 3' ' ' GLY . 6.8 p 57.56 116.31 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.914 0.388 . . . . 0.0 110.491 -179.892 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -74.81 176.28 7.21 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.409 179.911 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 7.4 p -125.03 82.68 61.25 Favored Pre-proline 0 N--CA 1.466 0.368 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.343 179.923 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_exo -56.71 162.49 8.48 Favored 'Trans proline' 0 N--CA 1.494 1.532 0 C-N-CA 122.594 2.196 . . . . 0.0 111.835 179.605 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 52.6 tp60 69.79 72.3 0.23 Allowed 'General case' 0 C--N 1.332 -0.155 0 CA-C-N 115.958 -0.565 . . . . 0.0 110.38 -179.739 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.423 ' CD1' ' N ' ' A' ' 9' ' ' LEU . 10.5 mp -90.45 130.64 36.5 Favored 'General case' 0 C--N 1.333 -0.133 0 CA-C-N 116.202 -0.454 . . . . 0.0 109.894 -179.991 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -123.8 120.96 34.15 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.266 -179.737 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 55.2 p-10 -86.81 165.67 15.81 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.673 179.941 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 7.3 tt -65.1 150.9 47.32 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.444 -179.679 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' SER . . . . . 0.417 ' O ' ' O ' ' A' ' 25' ' ' ARG . 18.1 p -139.85 157.53 45.56 Favored 'General case' 0 N--CA 1.463 0.204 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.385 179.696 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . 0.48 ' CD1' ' N ' ' A' ' 14' ' ' PHE . 31.5 m-85 -110.33 144.77 38.57 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.652 -179.325 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 16.7 m -145.69 156.62 12.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.294 179.402 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 98.8 m-20 55.75 35.93 26.28 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.64 -179.885 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.445 HG22 HD12 ' A' ' 17' ' ' ILE . 96.4 mt -61.12 139.07 20.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.31 179.816 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.473 ' CB ' ' O ' ' A' ' 21' ' ' SER . 0.2 OUTLIER -140.84 -167.33 2.34 Favored 'General case' 0 N--CA 1.469 0.494 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.194 -179.986 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . 0.496 ' OD1' ' N ' ' A' ' 20' ' ' SER . 30.9 p-10 -88.75 -43.54 11.2 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.819 179.384 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' SER . . . . . 0.513 ' HG ' ' H ' ' A' ' 67' ' ' LEU . 4.4 t -116.41 6.73 13.68 Favored 'General case' 0 N--CA 1.466 0.353 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.976 -179.42 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' SER . . . . . 0.473 ' O ' ' CB ' ' A' ' 18' ' ' THR . 16.4 p -150.57 140.3 21.74 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 121.257 0.551 . . . . 0.0 110.508 179.853 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 28.4 pt -139.65 144.13 29.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 N-CA-C 109.394 -0.595 . . . . 0.0 109.394 -179.868 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -106.4 91.33 0.72 Allowed Glycine 0 N--CA 1.466 0.637 0 N-CA-C 111.496 -0.642 . . . . 0.0 111.496 -179.323 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 11.2 mp -69.63 130.55 42.69 Favored 'General case' 0 C--N 1.328 -0.354 0 C-N-CA 120.478 -0.489 . . . . 0.0 109.842 179.844 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . 0.417 ' O ' ' O ' ' A' ' 13' ' ' SER . 67.5 ttp85 -140.83 135.26 31.22 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.196 179.615 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' TRP . . . . . . . . . . . . . 48.3 p90 -143.51 156.47 44.63 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.988 -0.551 . . . . 0.0 109.983 179.719 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 4.4 m -109.54 101.11 44.9 Favored Pre-proline 0 CA--C 1.531 0.23 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.162 179.906 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 42.0 Cg_exo -53.14 150.84 23.41 Favored 'Trans proline' 0 C--N 1.307 -1.613 0 C-N-CA 121.635 1.557 . . . . 0.0 113.199 179.823 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 54.2 mt -91.3 141.94 28.24 Favored 'General case' 0 CA--C 1.513 -0.466 0 CA-C-N 115.127 -0.942 . . . . 0.0 110.885 179.867 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 53.6 t-20 -50.87 -38.14 47.7 Favored 'General case' 0 C--N 1.314 -0.976 0 CA-C-N 114.743 -1.117 . . . . 0.0 110.149 179.575 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 23.2 m -76.98 -33.57 57.61 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.454 178.874 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 15.1 m -60.48 127.84 33.71 Favored 'General case' 0 N--CA 1.461 0.108 0 CA-C-O 121.027 0.441 . . . . 0.0 110.16 179.893 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' THR . . . . . 0.487 ' OG1' ' N ' ' A' ' 82' ' ' ASN . 5.5 m -57.96 142.98 44.68 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.292 179.99 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 20.6 mm -93.82 89.24 2.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 120.904 0.383 . . . . 0.0 110.839 -179.299 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.469 ' O ' ' OG ' ' A' ' 57' ' ' SER . 14.7 pt -142.04 129.76 20.88 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.341 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.498 179.633 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -39.87 121.08 1.5 Allowed Glycine 0 CA--C 1.523 0.543 0 N-CA-C 111.555 -0.618 . . . . 0.0 111.555 -179.56 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' TYR . . . . . 0.436 ' CE2' ' OG ' ' A' ' 57' ' ' SER . 97.7 m-85 -83.19 178.92 7.88 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.942 0.401 . . . . 0.0 110.09 179.91 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . 0.54 ' NH1' ' OG1' ' A' ' 40' ' ' THR . 4.2 tmt_? -134.21 123.74 24.81 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 121.134 0.492 . . . . 0.0 110.561 179.775 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 2.8 pt -94.46 152.95 3.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 115.894 -0.593 . . . . 0.0 109.537 -179.856 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' THR . . . . . 0.54 ' OG1' ' NH1' ' A' ' 38' ' ' ARG . 27.3 m -136.09 133.12 36.98 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.75 0.31 . . . . 0.0 110.491 179.814 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.0 p -132.59 134.95 58.31 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.326 0 CA-C-O 120.812 0.339 . . . . 0.0 110.577 179.796 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . 0.5 ' O ' ' N ' ' A' ' 74' ' ' ASP . 30.0 t -129.44 126.68 63.89 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.216 0 N-CA-C 110.017 -0.364 . . . . 0.0 110.017 179.307 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -93.33 138.67 31.46 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 109.32 -0.622 . . . . 0.0 109.32 179.504 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . 0.409 ' CB ' ' O ' ' A' ' 72' ' ' ASP . . . -97.53 -19.25 18.49 Favored 'General case' 0 C--N 1.329 -0.286 0 C-N-CA 120.695 -0.402 . . . . 0.0 110.877 -179.97 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -96.61 30.95 8.03 Favored Glycine 0 CA--C 1.525 0.701 0 N-CA-C 110.971 -0.852 . . . . 0.0 110.971 179.906 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 71.5 mt-10 -146.21 149.92 34.84 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.974 0.416 . . . . 0.0 110.556 179.996 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -68.28 -21.11 73.87 Favored Glycine 0 CA--C 1.523 0.54 0 N-CA-C 111.073 -0.811 . . . . 0.0 111.073 179.571 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -137.86 140.21 28.77 Favored Pre-proline 0 CA--C 1.546 0.814 0 CA-C-N 116.833 0.316 . . . . 0.0 110.603 179.672 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 68.9 Cg_endo -72.78 163.03 39.6 Favored 'Trans proline' 0 N--CA 1.495 1.569 0 C-N-CA 122.768 2.312 . . . . 0.0 112.107 178.755 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . 0.436 HD13 HG22 ' A' ' 50' ' ' ILE . 96.8 mt -75.58 158.6 5.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.551 179.602 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' PHE . . . . . 0.435 ' N ' ' CG2' ' A' ' 50' ' ' ILE . 96.7 m-85 -75.94 147.77 38.67 Favored 'General case' 0 C--N 1.333 -0.143 0 CA-C-O 121.019 0.438 . . . . 0.0 111.134 -179.72 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . 0.479 ' CD ' ' H ' ' A' ' 52' ' ' GLU . 0.3 OUTLIER -83.28 146.94 28.26 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.441 179.478 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -116.91 153.55 32.37 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.756 -0.656 . . . . 0.0 110.499 -179.492 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 54' ' ' PHE . . . . . 0.565 ' CD1' ' N ' ' A' ' 54' ' ' PHE . 5.7 m-85 -119.79 129.47 54.47 Favored 'General case' 0 N--CA 1.462 0.132 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.146 -179.85 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 9.4 p -129.77 138.91 52.95 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.393 0 CA-C-O 120.73 0.3 . . . . 0.0 110.843 -179.769 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 94.4 m-20 -61.08 144.86 52.69 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.695 179.964 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 57' ' ' SER . . . . . 0.469 ' OG ' ' O ' ' A' ' 35' ' ' ILE . 10.2 m -61.94 -32.14 72.53 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.706 179.878 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 75.5 m -56.2 -36.43 68.4 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.582 -179.756 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 74.3 t -62.32 -45.05 99.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.511 -179.848 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 60.45 24.87 62.17 Favored Glycine 0 CA--C 1.528 0.864 0 N-CA-C 110.507 -1.037 . . . . 0.0 110.507 -179.95 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . 0.432 ' OH ' ' OG1' ' A' ' 63' ' ' THR . 52.6 t80 -166.34 151.09 7.92 Favored 'General case' 0 CA--C 1.53 0.176 0 CA-C-O 121.214 0.531 . . . . 0.0 111.423 -179.513 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 17.4 t80 -158.01 158.25 34.52 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.672 -0.694 . . . . 0.0 110.378 178.566 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 63' ' ' THR . . . . . 0.432 ' OG1' ' OH ' ' A' ' 61' ' ' TYR . 69.3 m -127.7 136.74 51.98 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.198 179.728 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -130.16 104.62 10.45 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 N-CA-C 109.33 -0.619 . . . . 0.0 109.33 179.413 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 4.2 p -111.75 157.38 20.59 Favored 'General case' 0 N--CA 1.466 0.335 0 CA-C-O 120.946 0.403 . . . . 0.0 110.498 -179.849 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 107.68 40.79 1.68 Allowed Glycine 0 CA--C 1.524 0.594 0 N-CA-C 111.074 -0.81 . . . . 0.0 111.074 179.94 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.513 ' H ' ' HG ' ' A' ' 20' ' ' SER . 16.6 mt -113.0 106.65 14.95 Favored 'General case' 0 N--CA 1.462 0.168 0 N-CA-C 108.99 -0.744 . . . . 0.0 108.99 179.215 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 52.4 mm-40 -51.97 135.91 37.8 Favored Pre-proline 0 C--N 1.319 -0.72 0 CA-C-N 116.376 -0.375 . . . . 0.0 111.626 -178.059 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 93.4 Cg_endo -74.98 155.44 43.03 Favored 'Trans proline' 0 N--CA 1.496 1.658 0 C-N-CA 122.55 2.166 . . . . 0.0 111.476 178.602 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . 0.484 ' H ' HH22 ' B' ' 223' ' ' ARG . . . 71.11 5.66 59.1 Favored Glycine 0 CA--C 1.525 0.671 0 CA-C-N 115.65 -0.705 . . . . 0.0 111.54 179.469 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 1.6 mp -113.43 143.39 23.21 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.47 0 N-CA-C 109.315 -0.624 . . . . 0.0 109.315 179.859 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 72' ' ' ASP . . . . . 0.409 ' O ' ' CB ' ' A' ' 44' ' ' ALA . 1.8 t70 -80.26 113.86 18.75 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.387 -0.824 . . . . 0.0 110.683 179.949 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 73' ' ' TYR . . . . . . . . . . . . . 14.0 m-85 -109.14 120.19 41.78 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 121.264 0.554 . . . . 0.0 110.694 -179.699 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 74' ' ' ASP . . . . . 0.5 ' N ' ' O ' ' A' ' 42' ' ' VAL . 9.6 m-20 -89.11 119.55 29.72 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-N 115.378 -0.828 . . . . 0.0 109.175 179.387 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -119.17 166.38 13.61 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.466 0 CA-C-O 121.019 0.438 . . . . 0.0 110.304 -179.306 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 22.9 t -156.13 152.41 27.89 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.574 -0.739 . . . . 0.0 110.312 178.529 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 2.4 t -128.78 101.95 7.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 N-CA-C 109.556 -0.535 . . . . 0.0 109.556 178.664 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 72.4 mt -88.47 127.56 41.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 N-CA-C 109.974 -0.38 . . . . 0.0 109.974 -179.433 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 87.3 m -105.66 114.22 28.25 Favored 'General case' 0 N--CA 1.465 0.284 0 CA-C-N 116.213 -0.449 . . . . 0.0 109.963 179.967 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 49.1 mt -118.2 117.42 29.11 Favored 'General case' 0 N--CA 1.464 0.229 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.533 -179.722 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 81' ' ' ILE . . . . . 0.405 ' HB ' ' H ' ' A' ' 33' ' ' THR . 2.3 pp -145.26 146.67 19.52 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.181 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.39 179.032 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 82' ' ' ASN . . . . . 0.487 ' N ' ' OG1' ' A' ' 33' ' ' THR . 23.0 t-20 -65.87 -48.45 71.5 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.259 -179.578 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . 0.403 ' N ' HD13 ' A' ' 81' ' ' ILE . . . 102.45 -108.3 3.3 Favored Glycine 0 CA--C 1.523 0.566 0 N-CA-C 110.921 -0.872 . . . . 0.0 110.921 179.606 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -71.79 134.23 21.85 Favored Glycine 0 CA--C 1.523 0.535 0 N-CA-C 110.81 -0.916 . . . . 0.0 110.81 -179.918 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -70.19 117.39 11.69 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.731 0.301 . . . . 0.0 110.311 179.955 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 86' ' ' SER . . . . . 0.441 ' O ' ' O ' ' A' ' 87' ' ' ALA . 46.0 t -67.38 134.61 51.79 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.428 -179.908 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . 0.441 ' O ' ' O ' ' A' ' 86' ' ' SER . . . 56.23 155.0 0.07 OUTLIER Pre-proline 0 CA--C 1.534 0.36 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.609 179.803 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_endo -66.62 143.34 67.94 Favored 'Trans proline' 0 N--CA 1.493 1.478 0 C-N-CA 122.485 2.123 . . . . 0.0 111.886 179.701 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 7.6 p -85.25 167.65 15.45 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.595 -0.73 . . . . 0.0 110.356 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 63.9 p -128.92 152.15 48.87 Favored 'General case' 0 N--CA 1.466 0.334 0 CA-C-O 121.239 0.542 . . . . 0.0 110.588 179.874 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . 0.559 ' H ' ' CD2' ' A' ' 91' ' ' LEU . 1.6 pt? -74.6 150.66 39.58 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.712 -0.676 . . . . 0.0 110.799 179.852 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 82.7 p -74.65 139.24 43.42 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.169 179.443 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 50.2 tt0 -69.62 125.18 25.93 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.437 -0.347 . . . . 0.0 110.402 -179.896 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 94.5 mm-40 -101.79 129.64 48.04 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.517 -179.864 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 40.4 p . . . . . 0 C--O 1.22 -0.47 0 CA-C-O 117.974 -1.013 . . . . 0.0 110.684 179.956 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' B' B ' 201' ' ' SER . . . . . . . . . . . . . 24.6 p . . . . . 0 N--CA 1.491 1.614 0 N-CA-C 109.439 -0.578 . . . . 0.0 109.439 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' B' B ' 202' ' ' SER . . . . . . . . . . . . . 40.6 t -68.01 139.13 56.31 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.267 179.5 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 203' ' ' SER . . . . . . . . . . . . . 78.1 p -126.0 108.9 24.8 Favored Pre-proline 0 CA--C 1.537 0.479 0 N-CA-C 110.068 -0.345 . . . . 0.0 110.068 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 204' ' ' PRO . . . . . . . . . . . . . 60.8 Cg_endo -76.1 -58.25 0.05 OUTLIER 'Trans proline' 0 N--CA 1.492 1.402 0 C-N-CA 121.561 1.507 . . . . 0.0 112.069 -179.592 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 205' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -149.1 143.47 18.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.312 179.864 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 206' ' ' GLN . . . . . . . . . . . . . 3.4 pt20 -141.06 141.95 34.22 Favored 'General case' 0 C--N 1.329 -0.315 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 179.623 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 207' ' ' GLY . . . . . . . . . . . . . . . -103.92 -130.75 6.98 Favored Glycine 0 N--CA 1.462 0.428 0 N-CA-C 111.125 -0.79 . . . . 0.0 111.125 -179.791 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 208' ' ' SER . . . . . 0.536 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 97.1 p -165.86 170.58 13.67 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.809 0.337 . . . . 0.0 110.818 179.877 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 209' ' ' TRP . . . . . . . . . . . . . 66.9 m95 -88.27 147.6 24.74 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.462 179.666 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 82.4 p -127.96 129.26 46.5 Favored 'General case' 0 C--O 1.234 0.257 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.631 179.868 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 48.9 t-105 -89.62 116.67 27.93 Favored 'General case' 0 N--CA 1.463 0.176 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.04 179.5 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 212' ' ' GLU . . . . . 0.457 ' O ' ' O ' ' B' ' 215' ' ' LYS . 1.0 OUTLIER -164.91 170.24 15.55 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.556 179.073 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' B' B ' 213' ' ' ASN . . . . . . . . . . . . . 14.2 m120 48.23 35.96 6.16 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.916 176.56 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 51.97 13.65 1.64 Allowed Glycine 0 CA--C 1.528 0.899 0 C-N-CA 120.992 -0.623 . . . . 0.0 111.668 179.656 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 215' ' ' LYS . . . . . 0.457 ' O ' ' O ' ' B' ' 212' ' ' GLU . 66.8 mttm -142.84 150.81 40.4 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-O 120.994 0.426 . . . . 0.0 110.839 179.826 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 216' ' ' TRP . . . . . . . . . . . . . 52.1 m95 -86.81 118.77 26.42 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.089 179.86 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 217' ' ' THR . . . . . . . . . . . . . 19.6 m -128.85 142.42 50.97 Favored 'General case' 0 N--CA 1.467 0.387 0 CA-C-O 120.938 0.399 . . . . 0.0 110.184 -179.772 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 218' ' ' TRP . . . . . 0.536 ' CH2' ' N ' ' B' ' 208' ' ' SER . 15.2 t-105 -104.91 118.51 36.72 Favored 'General case' 0 C--N 1.33 -0.269 0 N-CA-C 109.356 -0.609 . . . . 0.0 109.356 179.246 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 52.5 mtmt -145.86 167.4 23.33 Favored 'General case' 0 CA--C 1.517 -0.305 0 CA-C-O 121.33 0.586 . . . . 0.0 110.704 -179.411 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -175.81 -161.13 24.56 Favored Glycine 0 CA--C 1.523 0.573 0 CA-C-N 115.383 -0.826 . . . . 0.0 111.486 -179.736 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 221' ' ' ILE . . . . . 0.423 ' O ' ' CG2' ' B' ' 222' ' ' ILE . 0.8 OUTLIER -52.59 -75.71 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 C-N-CA 120.69 -0.404 . . . . 0.0 111.065 -178.667 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' B' B ' 222' ' ' ILE . . . . . 0.472 ' O ' ' O ' ' B' ' 223' ' ' ARG . 22.1 pt -160.87 -165.08 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 N-CA-C 109.97 -0.382 . . . . 0.0 109.97 -179.405 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 223' ' ' ARG . . . . . 0.484 HH22 ' H ' ' A' ' 70' ' ' GLY . 39.5 ptt180 -43.28 173.5 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.804 -0.635 . . . . 0.0 110.669 178.579 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 224' ' ' LEU . . . . . 0.723 ' H ' ' CD2' ' B' ' 224' ' ' LEU . 0.7 OUTLIER -61.67 126.09 26.12 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.33 -179.859 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 35.5 tp10 -82.54 149.15 27.67 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.712 -0.676 . . . . 0.0 110.277 179.803 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 226' ' ' GLN . . . . . . . . . . . . . 15.0 mm100 . . . . . 0 C--N 1.324 -0.522 0 CA-C-O 118.062 -0.971 . . . . 0.0 110.672 -179.875 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.222 0 N-CA-C 109.548 -1.421 . . . . 0.0 109.548 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 22.4 t -149.51 93.7 2.1 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 120.729 0.299 . . . . 0.0 110.377 179.878 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 95.3 mt-10 -105.99 115.85 30.93 Favored 'General case' 0 CA--C 1.519 -0.249 0 CA-C-N 116.237 -0.438 . . . . 0.0 109.998 179.929 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 5.7 m -145.12 149.2 41.08 Favored Pre-proline 0 CA--C 1.532 0.265 0 CA-C-N 116.401 -0.363 . . . . 0.0 110.589 179.968 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 42.4 Cg_endo -67.19 84.42 0.34 Allowed 'Trans proline' 0 N--CA 1.495 1.602 0 C-N-CA 122.558 2.172 . . . . 0.0 111.815 179.7 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 12.0 pt20 -66.08 -36.86 84.33 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.363 179.48 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 45.0 tp -98.84 125.44 44.22 Favored 'General case' 0 N--CA 1.463 0.186 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.333 -179.785 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 34.4 p -125.11 129.77 50.88 Favored 'General case' 0 C--O 1.234 0.254 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.513 179.739 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -88.6 154.05 20.63 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.899 -0.591 . . . . 0.0 110.372 179.808 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . 0.528 ' CD2' ' CZ ' ' A' ' 14' ' ' PHE . 7.0 tt -67.15 145.34 55.38 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.579 -179.83 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' SER . . . . . 0.431 ' O ' ' O ' ' A' ' 25' ' ' ARG . 53.9 p -143.09 152.79 42.23 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.497 179.642 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . 0.554 ' CD1' ' N ' ' A' ' 14' ' ' PHE . 8.3 m-85 -111.77 148.73 32.9 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.391 -179.763 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 18.5 m -146.37 158.01 11.32 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.205 179.711 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 95.2 m-20 58.91 30.27 19.95 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.613 -0.721 . . . . 0.0 110.849 -179.921 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 83.2 mt -56.3 130.5 18.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 N-CA-C 109.862 -0.422 . . . . 0.0 109.862 179.65 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.429 ' OG1' ' O ' ' A' ' 21' ' ' SER . 0.2 OUTLIER -129.52 -169.1 2.05 Favored 'General case' 0 N--CA 1.466 0.374 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.579 -179.886 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . 0.488 ' N ' ' OD1' ' A' ' 19' ' ' ASP . 16.2 p-10 -78.35 -48.52 15.41 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.997 179.428 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' SER . . . . . 0.7 ' HG ' ' H ' ' A' ' 67' ' ' LEU . 28.2 t -121.16 13.35 11.2 Favored 'General case' 0 N--CA 1.464 0.231 0 CA-C-O 120.728 0.299 . . . . 0.0 110.596 -179.161 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' SER . . . . . 0.429 ' O ' ' OG1' ' A' ' 18' ' ' THR . 25.1 p -146.69 129.14 15.91 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 116.475 -0.329 . . . . 0.0 110.352 -179.625 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 46.4 pt -126.25 142.57 42.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.239 0 CA-C-N 116.2 -0.455 . . . . 0.0 109.959 -179.886 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -97.1 82.26 0.72 Allowed Glycine 0 CA--C 1.523 0.542 0 N-CA-C 110.873 -0.891 . . . . 0.0 110.873 -179.563 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 90.7 mt -65.26 122.53 17.31 Favored 'General case' 0 C--N 1.33 -0.276 0 N-CA-C 109.945 -0.391 . . . . 0.0 109.945 -179.815 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . 0.431 ' O ' ' O ' ' A' ' 13' ' ' SER . 72.2 ttt180 -141.2 138.78 33.58 Favored 'General case' 0 N--CA 1.462 0.168 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.722 -179.873 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' TRP . . . . . 0.534 ' CE2' ' O ' ' A' ' 60' ' ' GLY . 33.3 p90 -146.33 121.06 9.86 Favored 'General case' 0 CA--C 1.513 -0.453 0 CA-C-N 115.792 -0.64 . . . . 0.0 109.764 179.882 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 2.1 m -66.49 113.91 14.9 Favored Pre-proline 0 CA--C 1.536 0.412 0 C-N-CA 120.642 -0.423 . . . . 0.0 111.091 -178.619 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 36.1 Cg_exo -58.84 153.07 52.86 Favored 'Trans proline' 0 N--CA 1.493 1.461 0 C-N-CA 122.101 1.867 . . . . 0.0 112.742 178.693 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 80.2 mt -104.94 136.05 45.15 Favored 'General case' 0 N--CA 1.469 0.479 0 CA-C-O 122.008 0.909 . . . . 0.0 110.833 179.876 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 42.4 t30 -44.88 -32.43 1.59 Allowed 'General case' 0 C--N 1.316 -0.877 0 CA-C-N 115.064 -0.971 . . . . 0.0 110.223 -179.709 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 58.7 m -85.64 -33.84 21.51 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.868 -0.606 . . . . 0.0 110.582 179.198 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 3.6 m -51.52 115.48 1.63 Allowed 'General case' 0 N--CA 1.461 0.095 0 CA-C-O 121.261 0.553 . . . . 0.0 110.17 -179.929 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' THR . . . . . 0.522 ' OG1' ' N ' ' A' ' 82' ' ' ASN . 11.7 m -50.94 143.54 10.04 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.561 -0.745 . . . . 0.0 109.264 -179.081 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . 0.432 HG21 HD12 ' A' ' 34' ' ' ILE . 32.8 mm -92.45 90.95 3.23 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.215 0 CA-C-O 121.236 0.541 . . . . 0.0 111.258 -178.156 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.576 ' O ' ' CE1' ' A' ' 37' ' ' TYR . 6.7 pt -149.19 125.95 2.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 115.507 -0.77 . . . . 0.0 110.241 179.225 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -39.56 140.45 0.78 Allowed Glycine 0 CA--C 1.527 0.788 0 N-CA-C 110.957 -0.857 . . . . 0.0 110.957 -179.72 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' TYR . . . . . 0.576 ' CE1' ' O ' ' A' ' 35' ' ' ILE . 16.8 m-85 -110.49 144.83 38.72 Favored 'General case' 0 CA--C 1.518 -0.286 0 N-CA-C 109.867 -0.42 . . . . 0.0 109.867 -179.504 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . 0.663 ' NH1' ' HG1' ' A' ' 40' ' ' THR . 2.3 tmm_? -98.86 125.93 44.39 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.612 -179.834 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . 0.419 ' O ' ' CG1' ' A' ' 39' ' ' ILE . 2.8 pt -98.45 121.07 48.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.1 -0.5 . . . . 0.0 109.834 179.777 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' THR . . . . . 0.663 ' HG1' ' NH1' ' A' ' 38' ' ' ARG . 20.7 m -101.29 136.2 41.53 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.288 -179.175 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.2 p -134.22 142.76 40.06 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.338 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.249 179.965 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . 0.485 ' O ' ' N ' ' A' ' 74' ' ' ASP . 37.7 t -131.73 130.54 61.98 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.145 0 N-CA-C 109.984 -0.376 . . . . 0.0 109.984 179.46 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -97.49 133.63 41.81 Favored 'General case' 0 C--N 1.327 -0.379 0 N-CA-C 109.434 -0.58 . . . . 0.0 109.434 179.216 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . 0.409 ' CB ' ' O ' ' A' ' 72' ' ' ASP . . . -94.57 -21.21 18.99 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.769 0.318 . . . . 0.0 110.738 179.912 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -91.4 18.07 53.55 Favored Glycine 0 CA--C 1.523 0.588 0 N-CA-C 110.912 -0.875 . . . . 0.0 110.912 -179.682 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 33.2 mm-40 -139.93 149.53 43.44 Favored 'General case' 0 C--N 1.333 -0.136 0 CA-C-O 121.106 0.479 . . . . 0.0 110.521 -179.559 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -69.5 -18.94 74.12 Favored Glycine 0 N--CA 1.453 -0.194 0 N-CA-C 110.518 -1.033 . . . . 0.0 110.518 179.941 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -132.26 140.06 36.82 Favored Pre-proline 0 N--CA 1.468 0.446 0 C-N-CA 121.119 -0.232 . . . . 0.0 110.585 179.699 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 59.6 Cg_endo -73.22 159.39 47.32 Favored 'Trans proline' 0 N--CA 1.49 1.307 0 C-N-CA 122.431 2.087 . . . . 0.0 112.051 177.685 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 96.7 mt -75.49 153.41 6.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.193 179.484 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 80.5 m-85 -72.51 142.29 48.51 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.676 179.912 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . 0.422 ' N ' ' CD ' ' A' ' 52' ' ' GLU . 0.0 OUTLIER -65.77 -176.15 0.35 Allowed 'General case' 0 CA--C 1.514 -0.441 0 CA-C-N 115.739 -0.664 . . . . 0.0 110.405 179.441 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . 0.416 ' CG ' ' OH ' ' A' ' 62' ' ' TYR . 1.0 OUTLIER -145.59 138.66 26.14 Favored 'General case' 0 N--CA 1.452 -0.34 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.358 179.392 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 61.4 m-85 -110.0 116.42 31.56 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.397 179.898 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 10.5 p -128.18 140.82 48.15 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.348 0 CA-C-O 120.934 0.397 . . . . 0.0 110.118 179.949 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 83.9 m-20 -62.9 150.49 41.85 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.248 179.734 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 15.3 t -64.12 -33.8 76.6 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.663 -179.932 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 69.5 m -51.43 -37.69 49.83 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.382 -179.51 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.554 ' C ' ' H ' ' A' ' 61' ' ' TYR . 11.3 t -63.74 -42.97 97.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.362 179.68 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . 0.534 ' O ' ' CE2' ' A' ' 26' ' ' TRP . . . 70.44 -36.38 0.45 Allowed Glycine 0 CA--C 1.532 1.116 0 N-CA-C 111.037 -0.825 . . . . 0.0 111.037 179.653 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . 0.554 ' H ' ' C ' ' A' ' 59' ' ' VAL . 25.9 p90 -115.99 159.76 21.19 Favored 'General case' 0 N--CA 1.466 0.373 0 CA-C-O 121.146 0.498 . . . . 0.0 111.007 -179.084 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 62' ' ' TYR . . . . . 0.416 ' OH ' ' CG ' ' A' ' 53' ' ' ASP . 31.1 t80 -154.47 162.28 41.23 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.107 -0.497 . . . . 0.0 109.755 179.599 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 99.2 m -119.36 132.77 55.91 Favored 'General case' 0 N--CA 1.467 0.376 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.414 -179.781 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -133.06 107.57 11.75 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.311 0 CA-C-N 115.859 -0.61 . . . . 0.0 109.647 179.046 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 1.1 p -123.46 164.52 18.76 Favored 'General case' 0 CA--C 1.513 -0.443 0 CA-C-O 121.019 0.438 . . . . 0.0 110.34 -179.836 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 108.81 24.41 6.09 Favored Glycine 0 CA--C 1.524 0.598 0 CA-C-N 115.396 -0.82 . . . . 0.0 111.48 -179.773 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.7 ' H ' ' HG ' ' A' ' 20' ' ' SER . 11.8 mt -100.66 109.14 21.17 Favored 'General case' 0 CA--C 1.517 -0.322 0 N-CA-C 109.31 -0.626 . . . . 0.0 109.31 179.909 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 31.9 mm-40 -52.5 139.73 37.88 Favored Pre-proline 0 C--N 1.312 -1.023 0 C-N-CA 120.486 -0.485 . . . . 0.0 112.011 -178.214 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -73.08 155.47 52.39 Favored 'Trans proline' 0 N--CA 1.498 1.755 0 C-N-CA 122.857 2.371 . . . . 0.0 111.387 178.63 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 72.93 -5.96 15.48 Favored Glycine 0 CA--C 1.525 0.702 0 CA-C-N 115.637 -0.71 . . . . 0.0 111.927 179.269 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 1.7 mp -101.27 149.15 6.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 N-CA-C 109.346 -0.613 . . . . 0.0 109.346 -179.551 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 72' ' ' ASP . . . . . 0.409 ' O ' ' CB ' ' A' ' 44' ' ' ALA . 2.5 t70 -89.68 115.99 27.46 Favored 'General case' 0 C--N 1.32 -0.7 0 CA-C-N 114.979 -1.01 . . . . 0.0 110.269 179.686 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 73' ' ' TYR . . . . . . . . . . . . . 25.6 m-85 -109.81 119.55 39.69 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.453 179.899 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 74' ' ' ASP . . . . . 0.485 ' N ' ' O ' ' A' ' 42' ' ' VAL . 8.9 m-20 -89.94 116.79 28.26 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.702 -0.681 . . . . 0.0 109.426 179.887 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -113.98 165.4 9.02 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.293 0 CA-C-O 121.171 0.51 . . . . 0.0 109.995 -179.094 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 33.5 t -155.97 118.56 4.15 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.6 -0.727 . . . . 0.0 110.584 179.0 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 2.7 t -92.16 100.77 11.76 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 C-N-CA 120.479 -0.488 . . . . 0.0 109.73 179.498 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 96.3 mt -87.44 115.79 28.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.075 -179.99 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 70.3 m -100.44 118.8 37.41 Favored 'General case' 0 CA--C 1.517 -0.318 0 CA-C-N 116.211 -0.45 . . . . 0.0 109.938 179.725 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 2.1 tt -122.66 108.74 13.43 Favored 'General case' 0 N--CA 1.463 0.201 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.628 -179.892 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 2.1 pp -139.37 142.93 32.13 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 N-CA-C 109.974 -0.38 . . . . 0.0 109.974 178.936 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 82' ' ' ASN . . . . . 0.522 ' N ' ' OG1' ' A' ' 33' ' ' THR . 39.5 t-20 -66.37 -49.8 65.67 Favored 'General case' 0 C--N 1.328 -0.333 0 C-N-CA 120.89 -0.324 . . . . 0.0 111.233 -179.894 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 82.13 -150.67 29.22 Favored Glycine 0 CA--C 1.523 0.538 0 N-CA-C 110.956 -0.858 . . . . 0.0 110.956 179.781 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -73.54 -171.65 23.08 Favored Glycine 0 CA--C 1.527 0.801 0 N-CA-C 110.768 -0.933 . . . . 0.0 110.768 -179.993 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 5.5 pm0 -57.55 140.76 49.99 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.839 0.352 . . . . 0.0 110.335 179.929 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 94.0 p -56.23 108.47 0.47 Allowed 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.32 179.895 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -174.88 176.0 0.73 Allowed Pre-proline 0 C--N 1.327 -0.385 0 C-N-CA 120.529 -0.469 . . . . 0.0 110.653 179.475 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_exo -58.22 138.1 84.14 Favored 'Trans proline' 0 N--CA 1.495 1.609 0 C-N-CA 122.375 2.05 . . . . 0.0 111.63 179.132 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 86.9 m -134.19 127.83 32.76 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.341 -0.39 . . . . 0.0 110.428 179.43 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 47.9 p -150.1 131.38 14.58 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.232 179.824 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . 0.41 ' CD1' ' N ' ' A' ' 91' ' ' LEU . 10.6 mp -97.17 129.19 44.57 Favored 'General case' 0 N--CA 1.463 0.201 0 CA-C-O 121.002 0.429 . . . . 0.0 110.193 179.864 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 67.5 p -75.47 134.88 40.73 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.437 179.903 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 98.9 mt-30 -78.52 133.04 37.42 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.53 179.902 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 99.0 mm-40 46.55 -168.03 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.628 179.997 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 6.5 m . . . . . 0 C--O 1.218 -0.56 0 CA-C-O 118.04 -0.981 . . . . 0.0 110.483 -179.875 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' B' B ' 201' ' ' SER . . . . . . . . . . . . . 33.0 t . . . . . 0 N--CA 1.489 1.514 0 N-CA-C 109.414 -0.587 . . . . 0.0 109.414 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' B' B ' 202' ' ' SER . . . . . . . . . . . . . 40.6 t -71.37 148.99 46.45 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.582 179.972 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 203' ' ' SER . . . . . . . . . . . . . 2.3 p -88.89 150.76 46.23 Favored Pre-proline 0 CA--C 1.533 0.327 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.373 -179.413 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 204' ' ' PRO . . . . . . . . . . . . . 32.6 Cg_endo -63.93 -45.71 9.97 Favored 'Trans proline' 0 N--CA 1.497 1.705 0 C-N-CA 122.842 2.361 . . . . 0.0 111.809 -179.779 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 205' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -149.55 144.86 17.85 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.351 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.409 -179.698 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 206' ' ' GLN . . . . . 0.474 ' N ' ' CD ' ' B' ' 206' ' ' GLN . 2.2 pm0 -143.4 143.32 31.58 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.192 178.925 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 207' ' ' GLY . . . . . . . . . . . . . . . -107.52 -125.66 5.38 Favored Glycine 0 N--CA 1.467 0.712 0 N-CA-C 111.105 -0.798 . . . . 0.0 111.105 -179.888 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 208' ' ' SER . . . . . 0.555 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 54.8 p -165.66 170.83 13.71 Favored 'General case' 0 N--CA 1.454 -0.248 0 CA-C-O 120.804 0.335 . . . . 0.0 110.719 179.287 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 209' ' ' TRP . . . . . . . . . . . . . 59.0 m95 -88.13 156.08 19.44 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.531 179.473 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 66.9 p -130.19 131.77 45.74 Favored 'General case' 0 N--CA 1.464 0.247 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.447 179.558 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 53.0 t-105 -95.81 110.41 22.58 Favored 'General case' 0 N--CA 1.464 0.269 0 CA-C-N 116.29 -0.413 . . . . 0.0 110.591 -179.988 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 212' ' ' GLU . . . . . 0.44 ' O ' ' O ' ' B' ' 215' ' ' LYS . 1.8 pt-20 -162.0 168.45 22.76 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.669 179.516 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 213' ' ' ASN . . . . . . . . . . . . . 14.8 m120 51.53 34.5 12.5 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.955 -0.566 . . . . 0.0 111.066 176.966 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 50.56 19.89 3.46 Favored Glycine 0 CA--C 1.526 0.745 0 N-CA-C 111.156 -0.777 . . . . 0.0 111.156 179.981 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 215' ' ' LYS . . . . . 0.44 ' O ' ' O ' ' B' ' 212' ' ' GLU . 80.1 mttt -146.21 150.81 36.54 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 120.933 0.397 . . . . 0.0 110.602 179.723 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 216' ' ' TRP . . . . . . . . . . . . . 53.5 m95 -87.39 117.38 26.12 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.055 179.789 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 217' ' ' THR . . . . . . . . . . . . . 17.1 m -128.5 136.91 51.44 Favored 'General case' 0 C--O 1.234 0.248 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.129 -179.798 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 218' ' ' TRP . . . . . 0.555 ' CH2' ' N ' ' B' ' 208' ' ' SER . 14.2 t-105 -100.34 112.98 25.36 Favored 'General case' 0 N--CA 1.463 0.199 0 CA-C-N 116.044 -0.526 . . . . 0.0 109.99 179.606 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 92.7 mttt -130.24 167.52 18.31 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.74 -179.912 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -178.29 -162.89 28.83 Favored Glycine 0 CA--C 1.524 0.605 0 N-CA-C 111.089 -0.804 . . . . 0.0 111.089 179.878 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 221' ' ' ILE . . . . . 0.412 ' O ' ' CG2' ' B' ' 222' ' ' ILE . 21.5 mt -56.0 -73.52 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 C-N-CA 120.422 -0.511 . . . . 0.0 110.307 -178.116 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 222' ' ' ILE . . . . . 0.539 ' O ' ' O ' ' B' ' 223' ' ' ARG . 22.6 pt -160.37 -165.2 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.086 179.797 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 223' ' ' ARG . . . . . 0.539 ' O ' ' O ' ' B' ' 222' ' ' ILE . 26.7 ptt180 -40.24 172.18 0.0 OUTLIER 'General case' 0 CA--C 1.52 -0.201 0 CA-C-O 121.278 0.561 . . . . 0.0 110.88 179.293 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 224' ' ' LEU . . . . . 0.528 ' CD2' ' N ' ' B' ' 224' ' ' LEU . 2.8 mm? -61.38 120.73 11.01 Favored 'General case' 0 C--N 1.316 -0.861 0 CA-C-O 121.428 0.632 . . . . 0.0 110.929 -178.924 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 83.1 tt0 -79.47 136.36 36.9 Favored 'General case' 0 N--CA 1.452 -0.35 0 CA-C-N 115.295 -0.866 . . . . 0.0 109.935 -179.988 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 226' ' ' GLN . . . . . . . . . . . . . 32.4 tp60 . . . . . 0 N--CA 1.446 -0.667 0 CA-C-O 117.921 -1.038 . . . . 0.0 110.755 179.89 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.254 0 N-CA-C 109.623 -1.391 . . . . 0.0 109.623 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 78.8 p -77.6 -9.4 58.93 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.893 0.378 . . . . 0.0 110.758 -179.909 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 58.1 mp0 -61.05 138.08 58.21 Favored 'General case' 0 CA--C 1.514 -0.433 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.18 179.968 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 8.1 p -114.72 127.63 26.65 Favored Pre-proline 0 CA--C 1.54 0.586 0 CA-C-N 116.268 -0.423 . . . . 0.0 110.628 -179.965 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -76.08 117.0 4.52 Favored 'Trans proline' 0 N--CA 1.493 1.458 0 C-N-CA 122.411 2.074 . . . . 0.0 112.036 179.721 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 54.0 tt0 -174.45 138.86 0.55 Allowed 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.298 179.733 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 40.5 tp -118.57 107.28 13.56 Favored 'General case' 0 N--CA 1.462 0.13 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.526 179.449 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 52.3 p -88.32 168.03 13.03 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.451 179.462 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 56.0 p30 -140.28 163.94 31.43 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-O 121.054 0.454 . . . . 0.0 110.448 -179.908 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . 0.485 ' CD2' ' CE1' ' A' ' 14' ' ' PHE . 6.9 tt -67.55 139.77 56.95 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.938 -0.573 . . . . 0.0 110.493 -179.637 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' SER . . . . . 0.434 ' O ' ' O ' ' A' ' 25' ' ' ARG . 83.1 p -138.95 154.16 48.28 Favored 'General case' 0 N--CA 1.463 0.208 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.589 179.35 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . 0.501 ' CD1' ' N ' ' A' ' 14' ' ' PHE . 15.9 m-85 -111.31 146.15 37.57 Favored 'General case' 0 N--CA 1.463 0.188 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.514 -179.645 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 19.0 m -144.7 163.93 13.42 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.511 179.902 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 99.4 m-20 54.64 33.29 18.94 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.023 -0.535 . . . . 0.0 111.062 179.647 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 1.6 mp -58.42 132.17 23.04 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.542 0 CA-C-O 121.222 0.534 . . . . 0.0 109.883 -179.759 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.457 ' CB ' ' O ' ' A' ' 21' ' ' SER . 0.2 OUTLIER -136.2 -166.26 1.85 Allowed 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.212 -0.904 . . . . 0.0 110.652 -179.872 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . 0.504 ' OD1' ' N ' ' A' ' 20' ' ' SER . 34.3 p-10 -91.87 -41.95 10.33 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.495 -0.775 . . . . 0.0 111.115 179.366 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' SER . . . . . 0.504 ' N ' ' OD1' ' A' ' 19' ' ' ASP . 25.9 t -118.51 6.85 11.74 Favored 'General case' 0 N--CA 1.467 0.378 0 CA-C-N 116.444 -0.344 . . . . 0.0 110.848 -179.431 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' SER . . . . . 0.457 ' O ' ' CB ' ' A' ' 18' ' ' THR . 48.0 m -151.57 147.92 27.37 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.437 179.961 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 35.8 pt -147.22 147.7 17.29 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 N-CA-C 109.897 -0.408 . . . . 0.0 109.897 179.558 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -101.83 83.43 0.48 Allowed Glycine 0 CA--C 1.524 0.603 0 N-CA-C 111.507 -0.637 . . . . 0.0 111.507 -179.647 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 84.6 mt -66.37 124.56 23.05 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 109.656 -0.498 . . . . 0.0 109.656 179.899 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . 0.434 ' O ' ' O ' ' A' ' 13' ' ' SER . 69.6 ttt180 -139.11 141.13 38.11 Favored 'General case' 0 N--CA 1.463 0.188 0 CA-C-O 120.948 0.404 . . . . 0.0 110.49 -179.714 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' TRP . . . . . . . . . . . . . 35.1 p90 -144.04 155.01 43.83 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.106 179.795 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 2.5 m -111.77 97.9 39.29 Favored Pre-proline 0 CA--C 1.534 0.336 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.507 179.82 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_exo -53.35 142.62 57.0 Favored 'Trans proline' 0 C--N 1.305 -1.728 0 C-N-CA 122.081 1.854 . . . . 0.0 112.478 179.472 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 59.9 mt -81.21 144.24 31.75 Favored 'General case' 0 CA--C 1.518 -0.274 0 CA-C-O 121.412 0.625 . . . . 0.0 110.91 179.877 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 21.0 t-20 -52.04 -36.9 51.73 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 115.392 -0.822 . . . . 0.0 109.799 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 38.5 m -78.28 -35.17 48.32 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.518 179.257 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 14.4 m -58.14 134.17 56.24 Favored 'General case' 0 N--CA 1.461 0.096 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.231 -179.872 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' THR . . . . . 0.548 ' HG1' ' N ' ' A' ' 82' ' ' ASN . 2.7 m -61.82 140.02 58.29 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.084 -179.718 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 6.0 mm -94.28 90.17 2.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 121.065 0.459 . . . . 0.0 110.693 -179.696 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 19.0 pt -139.19 138.11 41.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.549 179.742 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -42.23 135.81 3.56 Favored Glycine 0 CA--C 1.52 0.406 0 N-CA-C 111.004 -0.838 . . . . 0.0 111.004 -179.622 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 -103.2 174.62 5.79 Favored 'General case' 0 CA--C 1.517 -0.317 0 CA-C-O 120.898 0.38 . . . . 0.0 110.179 -179.846 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . 0.776 HH11 ' HG1' ' A' ' 40' ' ' THR . 2.3 tmm_? -134.92 126.25 28.31 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.592 179.961 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . 0.475 ' O ' ' CG1' ' A' ' 39' ' ' ILE . 1.8 pt -99.92 122.2 51.52 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.176 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.127 179.684 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' THR . . . . . 0.776 ' HG1' HH11 ' A' ' 38' ' ' ARG . 24.2 m -104.95 134.38 48.15 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.451 -179.846 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.1 p -133.14 140.65 46.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.351 179.839 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . 0.536 ' N ' ' O ' ' A' ' 74' ' ' ASP . 37.6 t -133.25 131.67 58.18 Favored 'Isoleucine or valine' 0 N--CA 1.458 -0.074 0 N-CA-C 110.158 -0.312 . . . . 0.0 110.158 179.714 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -96.5 138.86 33.45 Favored 'General case' 0 C--N 1.329 -0.304 0 N-CA-C 109.709 -0.478 . . . . 0.0 109.709 178.947 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . 0.408 ' CB ' ' O ' ' A' ' 72' ' ' ASP . . . -93.81 -41.17 9.79 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.487 -0.324 . . . . 0.0 110.835 179.617 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -65.35 -31.85 81.76 Favored Glycine 0 CA--C 1.525 0.689 0 N-CA-C 111.256 -0.738 . . . . 0.0 111.256 -179.763 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 42.3 mm-40 -97.46 133.44 42.05 Favored 'General case' 0 C--N 1.33 -0.24 0 N-CA-C 109.576 -0.528 . . . . 0.0 109.576 -179.483 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -60.32 -21.92 57.72 Favored Glycine 0 CA--C 1.511 -0.217 0 N-CA-C 111.021 -0.832 . . . . 0.0 111.021 -178.987 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . 0.415 HG23 HD13 ' A' ' 48' ' ' ILE . 0.3 OUTLIER -113.11 134.7 21.78 Favored Pre-proline 0 CA--C 1.536 0.407 0 C-N-CA 120.961 -0.295 . . . . 0.0 110.59 179.665 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 71.2 Cg_endo -77.24 163.51 30.21 Favored 'Trans proline' 0 C--N 1.308 -1.564 0 C-N-CA 122.592 2.194 . . . . 0.0 112.202 177.006 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 87.0 mt -83.03 138.26 19.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.044 179.062 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 93.7 m-85 -60.74 142.03 56.31 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.623 -179.829 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 5.6 pt-20 -82.96 151.49 25.87 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.166 179.92 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . 0.417 ' CG ' ' OH ' ' A' ' 62' ' ' TYR . 1.7 t70 -120.05 162.91 18.47 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.683 179.451 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 54' ' ' PHE . . . . . 0.59 ' CD1' ' N ' ' A' ' 54' ' ' PHE . 2.4 m-85 -124.02 130.79 53.16 Favored 'General case' 0 C--O 1.232 0.169 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.195 179.662 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 8.7 p -127.69 136.4 60.52 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.449 -179.914 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 97.6 m-20 -58.84 141.29 53.67 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.482 -179.847 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 39.9 t -58.77 -32.84 69.66 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.58 179.857 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 69.1 m -56.23 -35.54 67.46 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.622 -179.836 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 84.1 t -63.44 -46.33 95.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.523 179.982 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 60.86 26.24 65.03 Favored Glycine 0 CA--C 1.528 0.895 0 N-CA-C 110.745 -0.942 . . . . 0.0 110.745 179.863 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . 0.442 ' OH ' ' OG1' ' A' ' 63' ' ' THR . 42.6 t80 -167.93 150.58 5.68 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 121.206 0.527 . . . . 0.0 111.103 -179.621 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 62' ' ' TYR . . . . . 0.417 ' OH ' ' CG ' ' A' ' 53' ' ' ASP . 26.7 t80 -157.58 156.27 31.63 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.092 178.831 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 63' ' ' THR . . . . . 0.442 ' OG1' ' OH ' ' A' ' 61' ' ' TYR . 76.3 m -122.64 136.2 54.81 Favored 'General case' 0 N--CA 1.465 0.282 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.728 -179.938 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -130.75 124.9 57.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.026 179.195 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 3.3 p -131.46 155.06 48.02 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.656 179.791 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 109.99 40.63 1.39 Allowed Glycine 0 CA--C 1.524 0.622 0 CA-C-N 115.719 -0.673 . . . . 0.0 111.522 -179.708 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 14.3 mt -112.91 99.31 7.78 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-O 121.274 0.559 . . . . 0.0 109.661 179.47 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 10.6 mm-40 -47.14 135.27 8.88 Favored Pre-proline 0 C--N 1.316 -0.849 0 CA-C-N 115.486 -0.779 . . . . 0.0 111.45 -178.382 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo -75.5 149.89 35.32 Favored 'Trans proline' 0 N--CA 1.496 1.646 0 C-N-CA 122.764 2.309 . . . . 0.0 111.761 178.86 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 75.39 13.61 82.71 Favored Glycine 0 CA--C 1.524 0.648 0 N-CA-C 111.23 -0.748 . . . . 0.0 111.23 179.202 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 2.2 mp -121.0 149.71 23.93 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.354 0 CA-C-O 121.528 0.68 . . . . 0.0 109.629 -179.637 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 72' ' ' ASP . . . . . 0.408 ' O ' ' CB ' ' A' ' 44' ' ' ALA . 2.3 t70 -87.25 112.08 21.67 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 114.854 -1.066 . . . . 0.0 110.621 -179.76 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 73' ' ' TYR . . . . . 0.461 ' O ' ' CD1' ' A' ' 75' ' ' ILE . 11.8 m-85 -107.87 118.33 36.46 Favored 'General case' 0 C--O 1.216 -0.69 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.735 179.71 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 74' ' ' ASP . . . . . 0.536 ' O ' ' N ' ' A' ' 42' ' ' VAL . 76.6 m-20 -86.97 119.01 26.74 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.495 -0.775 . . . . 0.0 109.496 179.708 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . 0.461 ' CD1' ' O ' ' A' ' 73' ' ' TYR . 0.0 OUTLIER -116.02 164.43 12.37 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.344 0 CA-C-O 121.171 0.51 . . . . 0.0 110.155 -179.166 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 3.0 m -154.43 121.52 5.63 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 115.466 -0.788 . . . . 0.0 110.849 179.394 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 11.9 t -101.44 102.23 13.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 179.272 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . 0.401 HG21 HD13 ' A' ' 78' ' ' ILE . 94.5 mt -89.84 127.32 42.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.405 -0.361 . . . . 0.0 110.517 -179.684 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 99.7 m -109.41 111.68 23.36 Favored 'General case' 0 N--CA 1.465 0.319 0 CA-C-N 116.12 -0.491 . . . . 0.0 109.996 179.708 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 13.9 mt -117.93 122.11 42.42 Favored 'General case' 0 CA--C 1.517 -0.297 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.693 -179.968 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 2.1 pp -145.45 134.66 17.66 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.15 179.533 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 82' ' ' ASN . . . . . 0.548 ' N ' ' HG1' ' A' ' 33' ' ' THR . 24.1 t-20 -45.6 -73.26 0.04 OUTLIER 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.777 179.851 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . 0.421 ' O ' ' O ' ' A' ' 82' ' ' ASN . . . 37.51 93.27 0.01 OUTLIER Glycine 0 CA--C 1.527 0.783 0 N-CA-C 111.109 -0.796 . . . . 0.0 111.109 179.863 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -50.38 120.19 8.21 Favored Glycine 0 CA--C 1.524 0.621 0 N-CA-C 110.805 -0.918 . . . . 0.0 110.805 -179.49 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -98.97 127.46 44.89 Favored 'General case' 0 N--CA 1.465 0.285 0 CA-C-O 120.786 0.327 . . . . 0.0 110.579 179.793 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 22.1 p -74.12 157.49 35.92 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.392 -179.859 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . 0.423 ' N ' ' CD ' ' A' ' 88' ' ' PRO . . . 54.53 55.02 11.37 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.587 -179.978 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . 0.423 ' CD ' ' N ' ' A' ' 87' ' ' ALA . 42.9 Cg_endo -67.31 148.21 79.55 Favored 'Trans proline' 0 C--N 1.307 -1.642 0 C-N-CA 122.849 2.366 . . . . 0.0 111.914 179.951 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 86.6 m -82.02 127.87 33.52 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.2 179.621 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 74.9 p -114.22 135.85 53.6 Favored 'General case' 0 N--CA 1.464 0.235 0 CA-C-O 120.942 0.401 . . . . 0.0 110.455 179.89 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . 0.449 ' CD1' ' N ' ' A' ' 91' ' ' LEU . 10.0 mp -76.92 147.1 37.18 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.398 -179.732 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 82.7 p -73.63 168.56 19.09 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.407 179.952 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 57.6 tt0 -64.22 114.1 4.0 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.457 -179.79 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 99.2 mt-30 -66.0 -40.32 91.02 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.614 179.892 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 41.1 p . . . . . 0 C--O 1.219 -0.521 0 CA-C-O 118.099 -0.953 . . . . 0.0 110.56 -179.945 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' B' B ' 201' ' ' SER . . . . . . . . . . . . . 23.4 m . . . . . 0 N--CA 1.489 1.475 0 N-CA-C 109.384 -0.599 . . . . 0.0 109.384 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' B' B ' 202' ' ' SER . . . . . . . . . . . . . 23.1 m -72.46 149.41 44.22 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.231 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 203' ' ' SER . . . . . . . . . . . . . 5.4 m -130.03 150.21 75.35 Favored Pre-proline 0 CA--C 1.533 0.319 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.62 179.769 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 204' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_exo -39.83 -28.42 0.24 Allowed 'Trans proline' 0 C--N 1.311 -1.421 0 C-N-CA 122.928 2.418 . . . . 0.0 112.193 179.324 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 205' ' ' ILE . . . . . . . . . . . . . 15.3 tt -151.28 155.98 6.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.092 -0.504 . . . . 0.0 111.412 179.765 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 206' ' ' GLN . . . . . . . . . . . . . 9.1 tp-100 -173.28 77.7 0.04 OUTLIER 'General case' 0 N--CA 1.452 -0.35 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.084 179.052 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 207' ' ' GLY . . . . . . . . . . . . . . . -111.42 -142.65 9.0 Favored Glycine 0 N--CA 1.466 0.665 0 N-CA-C 111.204 -0.758 . . . . 0.0 111.204 179.639 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 208' ' ' SER . . . . . 0.493 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 94.7 p -165.76 172.79 11.37 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.861 0.362 . . . . 0.0 110.697 -179.718 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 209' ' ' TRP . . . . . . . . . . . . . 79.1 m95 -84.44 131.53 34.66 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.309 179.656 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 81.4 p -109.41 130.02 55.52 Favored 'General case' 0 N--CA 1.464 0.273 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.546 -179.95 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 52.9 t-105 -92.38 116.91 29.39 Favored 'General case' 0 C--O 1.233 0.204 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.232 179.832 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 212' ' ' GLU . . . . . 0.458 ' O ' ' O ' ' B' ' 215' ' ' LYS . 1.7 pt-20 -165.82 167.53 16.8 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.948 179.333 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 213' ' ' ASN . . . . . . . . . . . . . 96.7 m-20 50.4 36.46 13.21 Favored 'General case' 0 C--N 1.321 -0.641 0 C-N-CA 120.605 -0.438 . . . . 0.0 111.012 176.325 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 50.21 17.07 1.59 Allowed Glycine 0 CA--C 1.523 0.56 0 N-CA-C 111.476 -0.65 . . . . 0.0 111.476 179.853 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 215' ' ' LYS . . . . . 0.458 ' O ' ' O ' ' B' ' 212' ' ' GLU . 52.1 mtmt -144.99 151.13 38.1 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 121.055 0.455 . . . . 0.0 110.684 179.652 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 216' ' ' TRP . . . . . 0.48 ' CD1' ' N ' ' B' ' 216' ' ' TRP . 24.2 m95 -87.27 119.79 27.89 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.053 179.945 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 217' ' ' THR . . . . . . . . . . . . . 21.6 m -130.95 142.81 50.38 Favored 'General case' 0 N--CA 1.464 0.238 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.432 -179.707 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 218' ' ' TRP . . . . . 0.493 ' CH2' ' N ' ' B' ' 208' ' ' SER . 15.7 t-105 -105.57 119.57 39.45 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-N 115.854 -0.612 . . . . 0.0 109.856 179.407 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 51.3 mtmt -142.95 171.78 13.58 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.817 -179.766 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -176.84 -160.28 23.62 Favored Glycine 0 CA--C 1.522 0.497 0 N-CA-C 111.237 -0.745 . . . . 0.0 111.237 -179.544 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 221' ' ' ILE . . . . . 0.411 ' O ' ' CG2' ' B' ' 222' ' ' ILE . 10.1 mm -50.7 -73.53 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 C-N-CA 120.781 -0.368 . . . . 0.0 110.638 -178.237 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 222' ' ' ILE . . . . . 0.5 ' O ' ' O ' ' B' ' 223' ' ' ARG . 21.4 pt -158.8 -166.65 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.723 0 CA-C-N 115.707 -0.678 . . . . 0.0 110.949 -179.795 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 223' ' ' ARG . . . . . 0.5 ' O ' ' O ' ' B' ' 222' ' ' ILE . 21.2 ptt-85 -43.42 175.77 0.0 OUTLIER 'General case' 0 CA--C 1.521 -0.164 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.692 179.353 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 224' ' ' LEU . . . . . 0.573 ' CD2' ' N ' ' B' ' 224' ' ' LEU . 3.4 mm? -62.14 115.89 4.51 Favored 'General case' 0 C--N 1.317 -0.807 0 CA-C-N 115.989 -0.55 . . . . 0.0 110.789 -179.738 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 78.5 tt0 -84.58 148.79 26.28 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.564 -0.744 . . . . 0.0 110.529 179.81 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 226' ' ' GLN . . . . . . . . . . . . . 11.5 tt0 . . . . . 0 C--O 1.221 -0.443 0 CA-C-O 118.023 -0.989 . . . . 0.0 110.583 179.821 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.263 0 N-CA-C 109.481 -1.447 . . . . 0.0 109.481 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 49.2 m -60.14 -42.87 95.78 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.721 0.296 . . . . 0.0 110.745 179.987 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 12.5 pt-20 -118.78 59.65 0.82 Allowed 'General case' 0 N--CA 1.466 0.365 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.546 179.96 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 10.8 t -141.25 76.17 22.01 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.484 179.749 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 35.1 Cg_exo -58.89 144.13 99.02 Favored 'Trans proline' 0 N--CA 1.495 1.585 0 C-N-CA 122.666 2.244 . . . . 0.0 112.006 179.826 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 98.9 mm-40 -75.31 131.24 40.16 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.147 179.84 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 2.5 pp -121.11 129.97 53.53 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.339 -179.943 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 61.1 p -130.68 158.15 40.84 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.194 179.888 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 52.6 p30 -109.33 167.34 10.19 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.388 179.942 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 59.8 tp -65.31 145.98 55.51 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.024 -0.534 . . . . 0.0 110.397 -179.985 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' SER . . . . . 0.47 ' O ' ' O ' ' A' ' 25' ' ' ARG . 14.2 p -143.49 150.16 38.56 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-O 121.184 0.516 . . . . 0.0 110.614 179.299 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . 0.566 ' CD1' ' N ' ' A' ' 14' ' ' PHE . 9.4 m-85 -112.16 145.74 39.3 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.0 -0.545 . . . . 0.0 110.625 -179.714 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 19.1 m -142.07 159.47 20.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.353 179.417 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 94.5 m-20 56.9 31.42 19.69 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.69 -0.686 . . . . 0.0 110.94 -179.66 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 96.3 mt -55.6 131.83 18.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.93 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.426 ' OG1' ' O ' ' A' ' 21' ' ' SER . 0.2 OUTLIER -131.72 -169.52 2.21 Favored 'General case' 0 N--CA 1.468 0.463 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.47 -179.562 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . 0.477 ' N ' ' OD1' ' A' ' 19' ' ' ASP . 17.9 p-10 -77.19 -49.67 14.65 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.982 179.594 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' SER . . . . . 0.457 ' CB ' ' O ' ' A' ' 67' ' ' LEU . 70.7 m -121.43 14.62 11.17 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 116.622 -0.263 . . . . 0.0 110.661 -179.176 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' SER . . . . . 0.426 ' O ' ' OG1' ' A' ' 18' ' ' THR . 2.4 m -146.48 129.87 16.75 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.088 -179.525 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 44.6 pt -125.95 141.75 44.69 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.322 0 CA-C-N 116.078 -0.51 . . . . 0.0 109.715 179.681 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -99.41 82.39 0.56 Allowed Glycine 0 CA--C 1.522 0.531 0 N-CA-C 110.953 -0.859 . . . . 0.0 110.953 -179.537 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 76.5 mt -63.32 124.38 21.1 Favored 'General case' 0 C--N 1.328 -0.354 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 -179.834 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . 0.47 ' O ' ' O ' ' A' ' 13' ' ' SER . 67.9 ttp85 -140.66 140.01 34.9 Favored 'General case' 0 C--N 1.332 -0.155 0 CA-C-O 121.245 0.545 . . . . 0.0 110.736 -179.868 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' TRP . . . . . . . . . . . . . 22.0 p90 -144.49 157.99 43.97 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.108 -179.56 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 2.6 m -103.92 105.29 47.61 Favored Pre-proline 0 CA--C 1.536 0.438 0 CA-C-N 116.56 -0.291 . . . . 0.0 110.686 -179.903 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 31.6 Cg_exo -55.02 153.15 26.87 Favored 'Trans proline' 0 N--CA 1.493 1.484 0 C-N-CA 122.041 1.827 . . . . 0.0 112.972 178.802 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 74.5 mt -103.55 135.25 45.5 Favored 'General case' 0 CA--C 1.515 -0.372 0 CA-C-O 121.832 0.825 . . . . 0.0 110.597 -179.941 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 19.2 t-20 -44.18 -31.46 0.98 Allowed 'General case' 0 C--N 1.318 -0.764 0 CA-C-N 115.09 -0.959 . . . . 0.0 110.436 -179.844 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 66.2 m -86.93 -35.9 18.65 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.395 179.151 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 3.4 m -47.66 114.34 0.88 Allowed 'General case' 0 CA--C 1.528 0.127 0 CA-C-O 121.167 0.508 . . . . 0.0 110.051 -179.819 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' THR . . . . . 0.708 ' HG1' ' N ' ' A' ' 82' ' ' ASN . 7.8 m -52.77 146.03 11.24 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.499 -0.773 . . . . 0.0 109.633 -179.483 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 27.6 mm -93.38 91.68 3.37 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.199 0 CA-C-O 121.167 0.508 . . . . 0.0 110.932 -178.45 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.53 ' O ' ' CE1' ' A' ' 37' ' ' TYR . 9.0 pt -145.8 128.17 9.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.232 179.645 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -47.84 135.93 14.88 Favored Glycine 0 CA--C 1.52 0.371 0 N-CA-C 110.805 -0.918 . . . . 0.0 110.805 -179.456 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' TYR . . . . . 0.53 ' CE1' ' O ' ' A' ' 35' ' ' ILE . 10.1 m-85 -100.97 179.86 4.26 Favored 'General case' 0 C--N 1.33 -0.241 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 -179.898 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 5.4 tmm_? -132.43 122.37 24.87 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.473 179.731 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . 0.469 ' O ' ' CG1' ' A' ' 39' ' ' ILE . 1.8 pt -97.84 118.17 43.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 115.924 -0.58 . . . . 0.0 109.89 179.633 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 20.9 m -98.3 134.16 41.71 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.216 -179.383 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.4 p -132.01 140.97 46.68 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.262 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.369 -179.999 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . 0.49 ' O ' ' N ' ' A' ' 74' ' ' ASP . 36.2 t -132.21 131.72 60.93 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.177 0 CA-C-O 120.979 0.419 . . . . 0.0 109.903 179.311 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -96.85 132.98 42.05 Favored 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 109.46 -0.571 . . . . 0.0 109.46 178.987 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -93.93 -14.68 25.71 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.766 0.317 . . . . 0.0 110.825 -179.843 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -99.86 18.88 55.27 Favored Glycine 0 CA--C 1.525 0.678 0 N-CA-C 111.025 -0.83 . . . . 0.0 111.025 -179.495 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 29.4 mm-40 -138.86 149.17 44.58 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 121.179 0.514 . . . . 0.0 110.368 -179.919 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -68.87 -17.3 71.31 Favored Glycine 0 CA--C 1.519 0.283 0 N-CA-C 110.552 -1.019 . . . . 0.0 110.552 179.864 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -135.31 139.03 30.35 Favored Pre-proline 0 CA--C 1.538 0.518 0 C-N-CA 121.192 -0.203 . . . . 0.0 110.683 179.842 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -73.31 158.65 48.21 Favored 'Trans proline' 0 N--CA 1.491 1.351 0 C-N-CA 122.565 2.176 . . . . 0.0 111.813 178.252 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . 0.42 HD13 HG21 ' A' ' 50' ' ' ILE . 96.4 mt -73.87 150.2 7.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.247 179.254 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 86.0 m-85 -70.04 137.19 51.07 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.715 179.94 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . 0.421 ' N ' ' CD ' ' A' ' 52' ' ' GLU . 0.0 OUTLIER -59.28 -175.65 0.03 OUTLIER 'General case' 0 CA--C 1.513 -0.446 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.449 179.212 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . 0.415 ' OD2' ' OH ' ' A' ' 62' ' ' TYR . 2.4 t0 -148.06 144.13 27.67 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.802 -0.636 . . . . 0.0 110.486 179.173 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 89.0 m-85 -116.74 122.93 45.9 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-N 116.363 -0.381 . . . . 0.0 110.572 179.812 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 9.5 p -132.06 142.7 42.18 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.425 0 CA-C-N 116.405 -0.361 . . . . 0.0 110.126 179.972 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 94.8 m-20 -61.13 151.87 30.03 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.377 179.952 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 11.3 t -62.72 -35.57 80.15 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.661 179.89 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 42.9 m -50.89 -37.21 42.3 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.162 -179.623 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.686 ' C ' ' H ' ' A' ' 61' ' ' TYR . 3.3 t -79.86 83.85 1.23 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.55 179.826 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -62.37 28.39 0.07 OUTLIER Glycine 0 CA--C 1.535 1.286 0 N-CA-C 111.103 -0.799 . . . . 0.0 111.103 179.672 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . 0.686 ' H ' ' C ' ' A' ' 59' ' ' VAL . 55.2 p90 -166.27 154.19 10.29 Favored 'General case' 0 N--CA 1.451 -0.389 0 CA-C-O 121.14 0.495 . . . . 0.0 111.879 -179.527 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 62' ' ' TYR . . . . . 0.415 ' OH ' ' OD2' ' A' ' 53' ' ' ASP . 23.6 t80 -154.74 148.91 25.94 Favored 'General case' 0 N--CA 1.454 -0.27 0 CA-C-N 115.727 -0.67 . . . . 0.0 109.731 178.794 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 50.1 m -110.69 132.97 53.74 Favored 'General case' 0 N--CA 1.463 0.224 0 CA-C-O 120.909 0.385 . . . . 0.0 110.325 -179.189 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -133.1 100.86 3.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 115.826 -0.625 . . . . 0.0 109.84 178.166 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 1.7 p -114.26 165.25 12.87 Favored 'General case' 0 CA--C 1.514 -0.441 0 CA-C-O 121.227 0.536 . . . . 0.0 110.445 179.882 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 108.67 24.33 6.16 Favored Glycine 0 CA--C 1.525 0.68 0 CA-C-N 115.444 -0.798 . . . . 0.0 111.295 -179.933 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.457 ' O ' ' CB ' ' A' ' 20' ' ' SER . 12.7 mt -98.69 106.55 18.83 Favored 'General case' 0 C--O 1.225 -0.22 0 N-CA-C 109.335 -0.617 . . . . 0.0 109.335 179.388 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 49.3 mm-40 -48.43 138.42 11.41 Favored Pre-proline 0 C--N 1.318 -0.792 0 CA-C-N 116.319 -0.4 . . . . 0.0 111.971 -178.323 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -73.36 154.04 50.81 Favored 'Trans proline' 0 N--CA 1.498 1.743 0 C-N-CA 122.749 2.299 . . . . 0.0 111.298 178.736 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 73.76 -6.0 20.95 Favored Glycine 0 CA--C 1.527 0.809 0 CA-C-N 115.839 -0.619 . . . . 0.0 111.647 179.209 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 1.8 mp -102.53 140.53 20.67 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.424 0 CA-C-O 121.326 0.584 . . . . 0.0 109.626 -179.847 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 1.9 t70 -81.42 118.7 22.9 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-N 114.995 -1.002 . . . . 0.0 109.922 179.434 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 73' ' ' TYR . . . . . . . . . . . . . 17.6 m-85 -110.85 119.68 39.9 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.828 -0.623 . . . . 0.0 110.44 179.949 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 74' ' ' ASP . . . . . 0.49 ' N ' ' O ' ' A' ' 42' ' ' VAL . 24.8 m-20 -89.43 117.42 28.34 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.613 -0.721 . . . . 0.0 109.574 179.579 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -114.64 166.23 8.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 121.041 0.448 . . . . 0.0 110.179 -179.339 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 1.1 p -155.11 122.64 5.65 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.589 -0.732 . . . . 0.0 110.559 179.243 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 20.6 t -96.7 127.35 48.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 N-CA-C 109.355 -0.609 . . . . 0.0 109.355 178.962 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 96.7 mt -117.19 120.02 63.69 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.416 0 CA-C-N 116.479 -0.328 . . . . 0.0 110.485 179.974 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 93.4 m -101.54 116.79 33.56 Favored 'General case' 0 C--N 1.331 -0.21 0 N-CA-C 109.715 -0.476 . . . . 0.0 109.715 179.265 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 16.9 tp -121.35 116.8 25.48 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.724 -179.931 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 2.2 pp -147.15 143.29 20.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.321 178.553 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 82' ' ' ASN . . . . . 0.708 ' N ' ' HG1' ' A' ' 33' ' ' THR . 27.2 t-20 -64.72 -48.9 72.92 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.83 0.348 . . . . 0.0 111.05 -179.818 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . 0.518 ' H ' ' HG1' ' A' ' 33' ' ' THR . . . 97.73 126.02 5.32 Favored Glycine 0 N--CA 1.465 0.572 0 N-CA-C 111.082 -0.807 . . . . 0.0 111.082 179.671 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -68.27 161.63 50.14 Favored Glycine 0 CA--C 1.523 0.568 0 N-CA-C 110.748 -0.941 . . . . 0.0 110.748 179.947 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 96.4 mt-10 -58.17 134.98 56.97 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.803 0.335 . . . . 0.0 110.57 -179.897 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 20.1 m -72.03 144.88 48.62 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.09 179.898 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . 0.55 ' N ' ' CD ' ' A' ' 88' ' ' PRO . . . 177.19 -46.19 0.0 OUTLIER Pre-proline 0 C--N 1.328 -0.357 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.176 -179.573 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . 0.55 ' CD ' ' N ' ' A' ' 87' ' ' ALA . 50.1 Cg_exo -54.14 -39.71 84.83 Favored 'Trans proline' 0 N--CA 1.497 1.694 0 C-N-CA 122.472 2.115 . . . . 0.0 112.387 -179.176 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 39.1 m -138.77 128.48 24.86 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 115.738 -0.664 . . . . 0.0 110.6 179.969 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 44.5 p -140.53 169.8 16.98 Favored 'General case' 0 C--N 1.332 -0.167 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.328 179.494 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 69.5 mt -88.33 129.51 35.37 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.178 -179.774 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 68.7 p -83.37 165.43 19.27 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.362 -179.931 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 99.3 mt-30 -81.96 130.06 34.96 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.526 -179.987 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 29.8 mm100 55.06 -162.1 0.15 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.524 179.927 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 18.7 m . . . . . 0 C--O 1.218 -0.56 0 CA-C-O 117.997 -1.001 . . . . 0.0 110.487 -179.917 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' B' B ' 201' ' ' SER . . . . . . . . . . . . . 5.5 m . . . . . 0 N--CA 1.488 1.443 0 N-CA-C 109.412 -0.588 . . . . 0.0 109.412 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' B' B ' 202' ' ' SER . . . . . . . . . . . . . 85.2 p -72.07 150.7 43.69 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.425 -179.876 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 203' ' ' SER . . . . . . . . . . . . . 1.6 m -93.29 152.21 40.95 Favored Pre-proline 0 CA--C 1.537 0.459 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.631 -179.716 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 204' ' ' PRO . . . . . . . . . . . . . 19.8 Cg_endo -59.38 -44.75 30.79 Favored 'Trans proline' 0 N--CA 1.498 1.763 0 C-N-CA 122.689 2.259 . . . . 0.0 111.659 -179.661 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 205' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -149.45 144.07 18.02 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.358 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.575 -179.993 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 206' ' ' GLN . . . . . . . . . . . . . 16.6 pt20 -136.22 138.72 42.14 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.137 179.086 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 207' ' ' GLY . . . . . 0.417 ' C ' ' CH2' ' B' ' 218' ' ' TRP . . . -100.87 -135.89 9.11 Favored Glycine 0 N--CA 1.466 0.654 0 N-CA-C 110.802 -0.919 . . . . 0.0 110.802 -179.855 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 208' ' ' SER . . . . . 0.532 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 45.1 p -162.2 166.16 25.93 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.803 0.335 . . . . 0.0 110.643 179.068 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 209' ' ' TRP . . . . . . . . . . . . . 84.7 m95 -85.23 152.84 23.03 Favored 'General case' 0 C--N 1.332 -0.167 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.463 179.603 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 210' ' ' THR . . . . . 0.447 ' OG1' ' O ' ' B' ' 217' ' ' THR . 49.4 p -129.47 129.79 45.05 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-N 116.354 -0.385 . . . . 0.0 110.355 179.504 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 57.8 t-105 -92.54 110.17 21.58 Favored 'General case' 0 N--CA 1.462 0.17 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.761 179.657 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 212' ' ' GLU . . . . . 0.443 ' O ' ' O ' ' B' ' 215' ' ' LYS . 1.4 pt-20 -161.17 165.8 28.89 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.54 179.745 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 213' ' ' ASN . . . . . . . . . . . . . 15.9 m120 51.07 33.77 9.75 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.118 176.906 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 53.35 14.79 3.49 Favored Glycine 0 CA--C 1.527 0.814 0 N-CA-C 111.502 -0.639 . . . . 0.0 111.502 179.993 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 215' ' ' LYS . . . . . 0.443 ' O ' ' O ' ' B' ' 212' ' ' GLU . 9.7 mtmp? -140.91 149.33 41.75 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-O 121.047 0.451 . . . . 0.0 110.663 179.895 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 216' ' ' TRP . . . . . . . . . . . . . 48.3 m95 -84.73 114.73 22.26 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.079 -0.51 . . . . 0.0 109.932 179.757 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 217' ' ' THR . . . . . 0.447 ' O ' ' OG1' ' B' ' 210' ' ' THR . 18.3 m -119.25 133.03 55.97 Favored 'General case' 0 N--CA 1.464 0.263 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.279 -179.312 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 218' ' ' TRP . . . . . 0.532 ' CH2' ' N ' ' B' ' 208' ' ' SER . 19.6 t-105 -105.33 107.5 18.52 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.014 -0.539 . . . . 0.0 109.874 179.5 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 51.1 mtmt -132.82 176.2 8.68 Favored 'General case' 0 CA--C 1.514 -0.44 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.285 -179.48 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -178.87 -162.38 28.2 Favored Glycine 0 CA--C 1.525 0.685 0 N-CA-C 110.998 -0.841 . . . . 0.0 110.998 179.288 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 221' ' ' ILE . . . . . 0.418 ' O ' ' CG2' ' B' ' 222' ' ' ILE . 2.3 mp -55.84 -73.11 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 C-N-CA 120.817 -0.353 . . . . 0.0 110.466 -178.321 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 222' ' ' ILE . . . . . 0.489 ' O ' ' O ' ' B' ' 223' ' ' ARG . 23.0 pt -160.1 -165.27 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.167 -179.685 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 223' ' ' ARG . . . . . 0.489 ' O ' ' O ' ' B' ' 222' ' ' ILE . 39.1 ptt180 -41.12 171.54 0.0 OUTLIER 'General case' 0 C--N 1.334 -0.092 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.956 178.778 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 224' ' ' LEU . . . . . 0.623 ' H ' ' CD2' ' B' ' 224' ' ' LEU . 1.9 mm? -65.16 110.61 2.6 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-O 121.383 0.611 . . . . 0.0 110.941 -179.642 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 82.7 tt0 -86.35 148.28 25.67 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.251 -0.886 . . . . 0.0 109.966 179.656 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 226' ' ' GLN . . . . . . . . . . . . . 99.6 mm-40 . . . . . 0 C--O 1.218 -0.572 0 CA-C-O 118.063 -0.97 . . . . 0.0 110.389 -179.798 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 97.6 m-20 . . . . . 0 N--CA 1.457 -0.121 0 CA-C-O 120.802 0.334 . . . . 0.0 110.501 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.521 HD11 ' CZ2' ' B' ' 209' ' ' TRP . 70.1 mt -62.0 151.3 35.55 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.192 -179.054 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 53.5 p -142.55 152.54 42.71 Favored 'General case' 0 CA--C 1.521 -0.152 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.311 -179.825 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 14' ' ' PHE . . . . . 0.56 ' CD2' HD11 ' B' ' 224' ' ' LEU . 24.7 m-85 -112.16 143.54 43.05 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.972 -179.552 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 28.5 m -142.87 162.06 17.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.326 179.496 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 91.5 m-20 45.57 61.6 2.54 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.499 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 95.5 mt -85.61 135.54 24.72 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.611 179.316 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.4 HG22 ' H ' ' A' ' 19' ' ' ASP . 0.2 OUTLIER -132.37 -168.78 2.11 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.394 179.505 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 19' ' ' ASP . . . . . 0.458 ' OD1' ' N ' ' A' ' 20' ' ' SER . 28.7 p-10 -90.58 -42.38 10.83 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.748 179.312 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 20' ' ' SER . . . . . 0.458 ' N ' ' OD1' ' A' ' 19' ' ' ASP . 28.4 t -112.69 7.16 18.56 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.848 -179.886 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 30.7 p -154.05 153.36 31.78 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.312 179.947 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 44.0 pt -147.65 149.16 15.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.344 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -99.52 80.56 0.52 Allowed Glycine 0 CA--C 1.526 0.744 0 N-CA-C 111.3 -0.72 . . . . 0.0 111.3 -179.898 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 62.1 mt -68.35 127.83 34.39 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.891 0.377 . . . . 0.0 110.041 -179.919 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 55.9 ttp180 -142.63 136.05 28.74 Favored 'General case' 0 CA--C 1.518 -0.252 0 CA-C-O 121.095 0.474 . . . . 0.0 110.493 -179.819 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 26' ' ' TRP . . . . . 0.55 ' CD2' ' O ' ' A' ' 60' ' ' GLY . 43.0 p90 -140.78 155.79 46.32 Favored 'General case' 0 CA--C 1.518 -0.284 0 CA-C-N 115.835 -0.621 . . . . 0.0 109.85 179.932 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 2.7 m -110.23 101.85 49.3 Favored Pre-proline 0 CA--C 1.534 0.358 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.839 -179.476 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_exo -56.34 150.59 49.29 Favored 'Trans proline' 0 C--N 1.308 -1.576 0 C-N-CA 122.078 1.852 . . . . 0.0 112.518 178.854 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 72.8 mt -87.3 134.9 33.5 Favored 'General case' 0 N--CA 1.465 0.281 0 CA-C-O 121.718 0.771 . . . . 0.0 110.671 -179.881 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 18.6 t-20 -47.13 -32.63 4.42 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-N 115.214 -0.903 . . . . 0.0 110.199 -179.923 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 75.8 m -82.38 -33.43 28.77 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.65 179.273 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 4.3 m -56.47 130.76 46.3 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-O 120.982 0.42 . . . . 0.0 110.221 -179.96 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 33' ' ' THR . . . . . 0.477 ' OG1' ' N ' ' A' ' 82' ' ' ASN . 6.6 m -54.37 139.53 36.52 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.586 -0.734 . . . . 0.0 109.776 -179.494 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 30.7 mm -93.57 88.97 2.54 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 CA-C-O 121.133 0.492 . . . . 0.0 110.608 -179.275 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.42 HD11 ' HA ' ' A' ' 81' ' ' ILE . 7.9 pt -139.65 149.18 22.64 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.184 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.408 179.588 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -48.68 136.88 17.77 Favored Glycine 0 CA--C 1.519 0.305 0 N-CA-C 110.918 -0.873 . . . . 0.0 110.918 -179.437 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 73.1 m-85 -104.6 160.44 14.95 Favored 'General case' 0 CA--C 1.517 -0.294 0 CA-C-O 120.826 0.346 . . . . 0.0 110.13 -179.818 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 5.3 tmm_? -124.32 124.5 42.52 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.791 -179.789 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.434 ' O ' ' CG1' ' A' ' 39' ' ' ILE . 2.5 pt -99.12 124.77 52.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.075 -0.511 . . . . 0.0 109.936 179.749 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 16.6 m -106.33 135.4 47.89 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.493 -179.545 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.4 p -133.9 142.2 41.94 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.25 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.162 179.878 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 42' ' ' VAL . . . . . 0.527 ' O ' ' N ' ' A' ' 74' ' ' ASP . 38.3 t -132.55 131.87 60.05 Favored 'Isoleucine or valine' 0 C--N 1.34 0.167 0 N-CA-C 110.06 -0.348 . . . . 0.0 110.06 179.46 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.554 ' HB2' ' CE2' ' A' ' 73' ' ' TYR . . . -98.98 142.47 30.43 Favored 'General case' 0 C--N 1.327 -0.406 0 N-CA-C 109.366 -0.605 . . . . 0.0 109.366 179.158 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 44' ' ' ALA . . . . . 0.549 ' HB3' ' O ' ' A' ' 72' ' ' ASP . . . -101.06 -21.41 15.01 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.876 0.369 . . . . 0.0 110.959 179.412 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -94.07 30.6 7.41 Favored Glycine 0 N--CA 1.465 0.586 0 N-CA-C 110.958 -0.857 . . . . 0.0 110.958 -179.709 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 86.9 mt-10 -150.98 150.74 31.15 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-O 120.966 0.413 . . . . 0.0 110.626 -179.57 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -70.9 -16.46 74.65 Favored Glycine 0 CA--C 1.519 0.339 0 N-CA-C 110.567 -1.013 . . . . 0.0 110.567 179.879 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -137.63 139.32 26.64 Favored Pre-proline 0 CA--C 1.539 0.524 0 C-N-CA 121.058 -0.257 . . . . 0.0 110.401 179.632 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 63.3 Cg_endo -73.76 160.61 43.37 Favored 'Trans proline' 0 N--CA 1.49 1.291 0 C-N-CA 122.44 2.094 . . . . 0.0 112.326 177.833 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 96.7 mt -71.53 150.54 9.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.285 179.334 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 85.9 m-85 -73.1 140.86 47.44 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.728 179.938 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 52' ' ' GLU . . . . . 0.42 ' N ' ' CD ' ' A' ' 52' ' ' GLU . 0.3 OUTLIER -68.26 -177.21 0.84 Allowed 'General case' 0 CA--C 1.514 -0.408 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.653 179.575 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 53' ' ' ASP . . . . . 0.41 ' CG ' ' OH ' ' A' ' 62' ' ' TYR . 3.5 t70 -149.47 143.38 25.63 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.6 179.361 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 92.7 m-85 -111.33 122.82 48.85 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.366 179.854 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 5.3 p -129.41 139.13 52.54 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.292 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.293 -179.894 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 91.5 m-20 -55.29 158.12 3.29 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.483 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 38.5 t -66.25 -37.01 84.49 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.66 179.937 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 37.9 m -51.59 -33.4 32.55 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.311 -179.598 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.571 ' C ' ' H ' ' A' ' 61' ' ' TYR . 1.9 t -91.78 68.76 0.58 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.179 179.291 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 60' ' ' GLY . . . . . 0.55 ' O ' ' CD2' ' A' ' 26' ' ' TRP . . . -53.24 -2.64 0.1 Allowed Glycine 0 CA--C 1.528 0.873 0 N-CA-C 110.946 -0.862 . . . . 0.0 110.946 -179.983 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 61' ' ' TYR . . . . . 0.571 ' H ' ' C ' ' A' ' 59' ' ' VAL . 41.2 p90 -122.57 151.64 41.2 Favored 'General case' 0 N--CA 1.464 0.243 0 CA-C-O 121.103 0.478 . . . . 0.0 111.0 -179.6 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 62' ' ' TYR . . . . . 0.41 ' OH ' ' CG ' ' A' ' 53' ' ' ASP . 33.6 t80 -155.78 156.79 35.41 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.726 -0.67 . . . . 0.0 109.772 179.553 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 88.0 m -119.92 136.44 54.51 Favored 'General case' 0 N--CA 1.465 0.301 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.402 -179.569 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -131.9 110.95 17.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.018 -0.537 . . . . 0.0 109.863 178.956 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 2.0 p -122.26 164.15 18.38 Favored 'General case' 0 N--CA 1.464 0.256 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.617 -179.94 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 112.86 8.65 20.15 Favored Glycine 0 CA--C 1.529 0.943 0 CA-C-N 115.561 -0.745 . . . . 0.0 111.74 -179.12 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 10.5 mt -75.48 178.94 5.57 Favored 'General case' 0 C--N 1.325 -0.483 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 178.583 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 58.7 mm-40 -128.04 137.62 31.21 Favored Pre-proline 0 CA--C 1.54 0.584 0 C-N-CA 121.019 -0.272 . . . . 0.0 111.076 179.295 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -73.34 148.67 43.81 Favored 'Trans proline' 0 N--CA 1.496 1.619 0 C-N-CA 122.801 2.334 . . . . 0.0 111.83 179.193 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 75.51 3.83 73.03 Favored Glycine 0 CA--C 1.526 0.768 0 CA-C-N 115.619 -0.719 . . . . 0.0 111.411 179.226 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 2.0 mp -112.23 141.26 28.31 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.401 0 CA-C-O 121.495 0.664 . . . . 0.0 109.579 -179.618 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 72' ' ' ASP . . . . . 0.549 ' O ' ' HB3' ' A' ' 44' ' ' ALA . 1.9 t70 -82.06 111.52 18.28 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 115.137 -0.938 . . . . 0.0 110.633 179.854 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 73' ' ' TYR . . . . . 0.554 ' CE2' ' HB2' ' A' ' 43' ' ' ALA . 14.7 m-85 -105.86 119.56 39.48 Favored 'General case' 0 C--O 1.219 -0.546 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.568 179.791 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 74' ' ' ASP . . . . . 0.527 ' N ' ' O ' ' A' ' 42' ' ' VAL . 5.5 m-20 -89.32 118.82 29.27 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.572 -0.74 . . . . 0.0 109.326 179.838 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 75' ' ' ILE . . . . . 0.629 HD11 ' N ' ' B' ' 223' ' ' ARG . 0.0 OUTLIER -115.45 163.81 12.38 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.404 0 CA-C-O 121.066 0.46 . . . . 0.0 110.163 -179.082 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 20.6 t -155.91 121.44 4.9 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.508 -0.769 . . . . 0.0 110.681 178.899 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 5.2 t -101.35 101.09 11.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 N-CA-C 109.901 -0.407 . . . . 0.0 109.901 179.341 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 96.8 mt -91.96 133.46 33.37 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.267 179.763 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 79' ' ' THR . . . . . 0.473 ' CG2' ' O ' ' B' ' 216' ' ' TRP . 0.0 OUTLIER -111.91 107.54 16.59 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 121.108 0.48 . . . . 0.0 109.755 179.551 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 38.3 tp -104.22 115.37 30.28 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.724 -0.671 . . . . 0.0 110.458 179.937 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 81' ' ' ILE . . . . . 0.42 ' HA ' HD11 ' A' ' 35' ' ' ILE . 2.1 pp -145.95 146.26 19.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.068 -0.514 . . . . 0.0 110.275 179.33 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 82' ' ' ASN . . . . . 0.477 ' N ' ' OG1' ' A' ' 33' ' ' THR . 18.9 t-20 . . . . . 0 C--N 1.328 -0.332 0 CA-C-O 120.844 0.354 . . . . 0.0 111.256 -179.902 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 207' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.467 0.736 0 N-CA-C 111.088 -0.805 . . . . 0.0 111.088 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' B' B ' 208' ' ' SER . . . . . 0.556 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 59.7 p -166.74 171.78 11.15 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.823 0.344 . . . . 0.0 110.825 179.795 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 209' ' ' TRP . . . . . 0.521 ' CZ2' HD11 ' A' ' 12' ' ' LEU . 44.4 m95 -83.66 146.33 28.31 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.593 179.041 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 32.0 p -128.64 130.11 46.8 Favored 'General case' 0 N--CA 1.463 0.199 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.287 179.752 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 39.1 t-105 -95.37 117.72 30.83 Favored 'General case' 0 N--CA 1.463 0.221 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.376 179.834 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 212' ' ' GLU . . . . . 0.443 ' O ' ' O ' ' B' ' 215' ' ' LYS . 0.6 OUTLIER -163.81 164.57 23.55 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.708 179.13 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' B' B ' 213' ' ' ASN . . . . . . . . . . . . . 78.9 m-20 52.62 39.92 29.12 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.616 176.302 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 49.64 21.68 3.52 Favored Glycine 0 CA--C 1.524 0.647 0 N-CA-C 111.084 -0.806 . . . . 0.0 111.084 179.605 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 215' ' ' LYS . . . . . 0.443 ' O ' ' O ' ' B' ' 212' ' ' GLU . 24.9 mtpt -148.02 152.73 37.93 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.063 0.459 . . . . 0.0 111.51 -179.694 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 216' ' ' TRP . . . . . 0.483 ' CD1' ' N ' ' B' ' 216' ' ' TRP . 24.4 m95 -92.17 119.08 31.47 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.959 -0.564 . . . . 0.0 109.729 179.165 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 217' ' ' THR . . . . . . . . . . . . . 12.4 m -132.72 145.02 50.68 Favored 'General case' 0 N--CA 1.465 0.32 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.469 -179.732 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 218' ' ' TRP . . . . . 0.556 ' CH2' ' N ' ' B' ' 208' ' ' SER . 14.5 t-105 -103.34 118.12 36.03 Favored 'General case' 0 N--CA 1.463 0.199 0 CA-C-N 116.008 -0.542 . . . . 0.0 109.922 179.563 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 95.7 mttt -141.15 165.74 26.7 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.952 -179.729 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -176.03 -161.02 24.47 Favored Glycine 0 CA--C 1.521 0.435 0 CA-C-N 115.492 -0.776 . . . . 0.0 111.421 -179.589 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 221' ' ' ILE . . . . . 0.546 ' O ' HG23 ' B' ' 222' ' ' ILE . 22.6 mt -52.75 -74.74 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 C-N-CA 120.598 -0.441 . . . . 0.0 110.295 -177.839 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 222' ' ' ILE . . . . . 0.546 HG23 ' O ' ' B' ' 221' ' ' ILE . 22.1 pt -160.47 -166.72 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.389 -0.369 . . . . 0.0 110.064 179.776 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 223' ' ' ARG . . . . . 0.629 ' N ' HD11 ' A' ' 75' ' ' ILE . 34.1 ptt85 -42.01 175.17 0.0 OUTLIER 'General case' 0 C--N 1.333 -0.129 0 CA-C-O 121.525 0.678 . . . . 0.0 110.532 178.842 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 224' ' ' LEU . . . . . 0.704 HD22 ' N ' ' B' ' 224' ' ' LEU . 3.1 mm? -60.55 122.68 15.27 Favored 'General case' 0 C--N 1.315 -0.905 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.954 -179.379 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 43.1 tt0 . . . . . 0 CA--C 1.517 -0.315 0 CA-C-N 115.623 -0.717 . . . . 0.0 110.343 179.678 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 11' ' ' ASP . . . . . 0.537 ' OD1' ' N ' ' A' ' 12' ' ' LEU . 55.9 t0 . . . . . 0 N--CA 1.465 0.277 0 CA-C-O 120.801 0.334 . . . . 0.0 110.241 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.537 ' N ' ' OD1' ' A' ' 11' ' ' ASP . 6.0 tp -65.3 142.8 58.13 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.49 -179.963 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 13' ' ' SER . . . . . 0.456 ' O ' ' O ' ' A' ' 25' ' ' ARG . 93.5 p -141.99 152.53 43.52 Favored 'General case' 0 N--CA 1.463 0.214 0 CA-C-O 121.076 0.465 . . . . 0.0 110.544 179.325 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 14' ' ' PHE . . . . . 0.538 ' CD2' HD11 ' B' ' 224' ' ' LEU . 24.3 m-85 -111.46 146.25 37.57 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.511 -179.251 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 31.9 m -147.06 153.86 12.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-O 120.818 0.342 . . . . 0.0 110.395 179.285 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 32.6 t70 58.89 56.87 3.85 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.426 179.854 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 94.0 mt -83.51 133.31 29.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 115.914 -0.585 . . . . 0.0 110.393 179.667 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.44 HG22 ' H ' ' A' ' 19' ' ' ASP . 0.2 OUTLIER -131.17 -167.73 1.89 Allowed 'General case' 0 N--CA 1.471 0.606 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.206 -179.74 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 19' ' ' ASP . . . . . 0.474 ' OD1' ' N ' ' A' ' 19' ' ' ASP . 0.4 OUTLIER -75.89 -53.24 8.74 Favored 'General case' 0 CA--C 1.517 -0.307 0 CA-C-O 120.993 0.425 . . . . 0.0 110.876 179.21 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 20' ' ' SER . . . . . 0.427 ' CB ' ' O ' ' A' ' 67' ' ' LEU . 33.4 p -121.13 14.31 11.37 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.968 -177.796 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 21' ' ' SER . . . . . 0.401 ' HB2' HG22 ' A' ' 65' ' ' THR . 95.5 p -144.96 125.05 13.61 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.116 0.484 . . . . 0.0 110.112 179.953 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 47.1 pt -127.39 140.67 48.46 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.323 0 CA-C-N 115.912 -0.586 . . . . 0.0 109.492 -179.823 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -103.69 91.57 0.83 Allowed Glycine 0 N--CA 1.467 0.704 0 N-CA-C 111.436 -0.665 . . . . 0.0 111.436 -179.397 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.506 HD22 ' N ' ' A' ' 24' ' ' LEU . 4.0 mm? -61.51 138.53 58.28 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.793 0.33 . . . . 0.0 110.234 -179.812 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 25' ' ' ARG . . . . . 0.456 ' O ' ' O ' ' A' ' 13' ' ' SER . 13.9 tpt180 -145.38 134.89 23.22 Favored 'General case' 0 C--N 1.334 -0.091 0 CA-C-O 121.455 0.645 . . . . 0.0 110.288 179.873 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 26' ' ' TRP . . . . . 0.511 ' CE2' ' O ' ' A' ' 60' ' ' GLY . 18.7 p90 -145.81 156.3 43.49 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.47 -0.786 . . . . 0.0 109.519 179.21 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 2.7 m -105.5 104.4 47.9 Favored Pre-proline 0 CA--C 1.534 0.344 0 CA-C-O 119.546 -0.264 . . . . 0.0 111.161 -179.153 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_exo -54.48 153.2 23.83 Favored 'Trans proline' 0 C--N 1.31 -1.483 0 C-N-CA 121.381 1.388 . . . . 0.0 113.011 178.523 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.464 ' O ' ' N ' ' A' ' 32' ' ' SER . 75.2 mt -102.57 134.86 45.22 Favored 'General case' 0 N--CA 1.467 0.392 0 CA-C-N 114.946 -1.024 . . . . 0.0 111.04 179.854 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 18.3 t-20 -45.39 -31.1 1.52 Allowed 'General case' 0 C--N 1.314 -0.964 0 CA-C-N 114.86 -1.063 . . . . 0.0 110.263 179.883 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 50.8 m -87.79 -28.85 21.42 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.292 178.998 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 32' ' ' SER . . . . . 0.464 ' N ' ' O ' ' A' ' 29' ' ' LEU . 3.4 m -56.23 117.56 3.89 Favored 'General case' 0 CA--C 1.529 0.162 0 CA-C-O 121.318 0.58 . . . . 0.0 110.145 179.935 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 33' ' ' THR . . . . . 0.631 ' CB ' ' H ' ' A' ' 82' ' ' ASN . 12.2 m -51.83 145.55 9.51 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-N 114.919 -1.037 . . . . 0.0 109.182 -179.126 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 30.1 mm -92.08 93.42 4.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.998 0.428 . . . . 0.0 110.825 -178.113 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.597 HD11 ' HA ' ' A' ' 81' ' ' ILE . 8.1 pt -150.97 128.84 2.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 115.871 -0.604 . . . . 0.0 109.875 179.027 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -47.01 130.38 12.75 Favored Glycine 0 CA--C 1.521 0.413 0 N-CA-C 111.4 -0.68 . . . . 0.0 111.4 -178.941 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 95.2 m-85 -87.36 179.64 6.56 Favored 'General case' 0 C--N 1.33 -0.279 0 N-CA-C 109.976 -0.379 . . . . 0.0 109.976 179.551 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 38' ' ' ARG . . . . . 0.683 ' NH2' ' H ' ' A' ' 40' ' ' THR . 0.0 OUTLIER -131.59 123.08 27.17 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.93 179.885 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.49 ' O ' ' CG1' ' A' ' 39' ' ' ILE . 1.7 pt -107.08 118.0 53.99 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.532 0 CA-C-O 121.203 0.525 . . . . 0.0 110.103 179.546 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 40' ' ' THR . . . . . 0.683 ' H ' ' NH2' ' A' ' 38' ' ' ARG . 52.9 m -103.25 138.94 39.36 Favored 'General case' 0 N--CA 1.47 0.537 0 O-C-N 122.037 -0.415 . . . . 0.0 110.127 -179.39 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.4 p -129.1 141.13 47.4 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.476 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.351 -179.873 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 42' ' ' VAL . . . . . 0.495 ' O ' ' N ' ' A' ' 74' ' ' ASP . 37.4 t -131.9 132.73 61.53 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.166 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.203 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -96.66 132.91 41.83 Favored 'General case' 0 C--N 1.327 -0.401 0 N-CA-C 109.468 -0.567 . . . . 0.0 109.468 179.173 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 44' ' ' ALA . . . . . 0.607 ' HB3' ' O ' ' A' ' 72' ' ' ASP . . . -91.65 -19.16 22.97 Favored 'General case' 0 C--N 1.328 -0.333 0 C-N-CA 120.748 -0.381 . . . . 0.0 110.681 179.994 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -99.07 25.04 29.82 Favored Glycine 0 N--CA 1.466 0.67 0 N-CA-C 111.208 -0.757 . . . . 0.0 111.208 -179.729 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -138.96 146.95 41.6 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 120.853 0.358 . . . . 0.0 110.587 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -66.99 -21.18 71.4 Favored Glycine 0 CA--C 1.526 0.728 0 N-CA-C 111.126 -0.79 . . . . 0.0 111.126 179.811 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -138.16 140.59 29.26 Favored Pre-proline 0 CA--C 1.545 0.784 0 O-C-N 122.66 -0.318 . . . . 0.0 110.553 -179.977 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -74.11 163.79 35.86 Favored 'Trans proline' 0 N--CA 1.495 1.589 0 C-N-CA 122.656 2.238 . . . . 0.0 112.051 178.478 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 50' ' ' ILE . . . . . 0.556 HG22 ' N ' ' A' ' 51' ' ' PHE . 5.1 mp -86.66 159.99 3.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 115.693 -0.685 . . . . 0.0 111.103 -179.733 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 51' ' ' PHE . . . . . 0.556 ' N ' HG22 ' A' ' 50' ' ' ILE . 88.8 m-85 -73.13 142.77 47.47 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.782 -0.645 . . . . 0.0 111.091 -179.802 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -64.32 -175.25 0.15 Allowed 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 115.492 -0.776 . . . . 0.0 110.412 179.007 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -142.74 134.26 26.45 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.123 179.891 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 96.0 m-85 -111.01 119.98 40.84 Favored 'General case' 0 N--CA 1.465 0.322 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.675 -179.809 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 9.8 p -130.42 142.28 44.13 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.414 0 CA-C-O 120.557 0.218 . . . . 0.0 110.592 -179.906 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 99.4 m-20 -63.4 149.35 46.13 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.384 179.925 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 57' ' ' SER . . . . . 0.44 ' OG ' ' O ' ' A' ' 35' ' ' ILE . 13.8 m -63.24 -32.49 73.91 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.72 0.295 . . . . 0.0 110.984 179.757 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 70.9 m -54.36 -40.45 68.12 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.352 -0.386 . . . . 0.0 110.581 -179.538 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.56 ' C ' ' H ' ' A' ' 61' ' ' TYR . 35.1 t -61.29 -44.08 97.77 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 -179.638 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 60' ' ' GLY . . . . . 0.511 ' O ' ' CE2' ' A' ' 26' ' ' TRP . . . 68.96 -29.78 0.3 Allowed Glycine 0 CA--C 1.529 0.945 0 N-CA-C 111.346 -0.702 . . . . 0.0 111.346 179.846 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 61' ' ' TYR . . . . . 0.56 ' H ' ' C ' ' A' ' 59' ' ' VAL . 44.9 t80 -112.6 155.48 24.32 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-O 121.225 0.536 . . . . 0.0 111.163 -179.15 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 62' ' ' TYR . . . . . 0.474 ' CD2' ' CD1' ' A' ' 39' ' ' ILE . 24.2 t80 -155.68 159.37 39.49 Favored 'General case' 0 N--CA 1.454 -0.227 0 CA-C-N 115.539 -0.755 . . . . 0.0 109.694 178.617 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 90.9 m -127.7 135.47 50.22 Favored 'General case' 0 N--CA 1.465 0.307 0 CA-C-O 120.834 0.349 . . . . 0.0 110.34 -179.924 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -131.46 107.01 12.8 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 N-CA-C 109.172 -0.677 . . . . 0.0 109.172 178.489 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.401 HG22 ' HB2' ' A' ' 21' ' ' SER . 2.3 p -120.89 162.88 19.09 Favored 'General case' 0 CA--C 1.514 -0.428 0 CA-C-O 120.911 0.386 . . . . 0.0 110.469 -179.707 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 106.62 24.67 6.6 Favored Glycine 0 CA--C 1.52 0.365 0 N-CA-C 110.889 -0.884 . . . . 0.0 110.889 179.873 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.427 ' O ' ' CB ' ' A' ' 20' ' ' SER . 6.9 mt -97.64 107.58 20.1 Favored 'General case' 0 CA--C 1.53 0.175 0 N-CA-C 109.405 -0.591 . . . . 0.0 109.405 179.897 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 66.8 mm-40 -46.36 135.53 7.29 Favored Pre-proline 0 C--N 1.319 -0.753 0 N-CA-C 112.019 0.377 . . . . 0.0 112.019 -178.44 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 95.1 Cg_endo -74.28 156.25 46.3 Favored 'Trans proline' 0 N--CA 1.498 1.789 0 C-N-CA 122.718 2.278 . . . . 0.0 111.219 178.753 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 72.56 -7.39 8.87 Favored Glycine 0 CA--C 1.528 0.864 0 C-N-CA 121.08 -0.581 . . . . 0.0 111.792 179.145 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 1.7 mp -103.74 143.32 15.82 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.366 0 CA-C-O 121.236 0.541 . . . . 0.0 109.702 -179.739 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 72' ' ' ASP . . . . . 0.607 ' O ' ' HB3' ' A' ' 44' ' ' ALA . 1.7 t0 -82.02 118.7 23.2 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.152 -0.931 . . . . 0.0 110.651 179.891 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 73' ' ' TYR . . . . . 0.506 ' O ' HD13 ' A' ' 75' ' ' ILE . 13.8 m-85 -109.74 120.59 42.96 Favored 'General case' 0 C--O 1.221 -0.4 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.899 -179.784 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 74' ' ' ASP . . . . . 0.495 ' N ' ' O ' ' A' ' 42' ' ' VAL . 69.6 m-20 -89.55 116.63 27.85 Favored 'General case' 0 C--N 1.318 -0.783 0 CA-C-N 115.565 -0.743 . . . . 0.0 109.862 179.357 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 75' ' ' ILE . . . . . 0.6 HD11 ' N ' ' B' ' 223' ' ' ARG . 0.0 OUTLIER -116.1 165.58 11.23 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.383 0 CA-C-O 121.098 0.475 . . . . 0.0 110.262 -179.658 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 11.1 p -153.18 148.85 27.39 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.559 -0.746 . . . . 0.0 110.274 179.08 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.535 ' O ' HG23 ' B' ' 217' ' ' THR . 53.5 t -129.33 135.61 61.33 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 N-CA-C 109.26 -0.644 . . . . 0.0 109.26 179.3 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 78' ' ' ILE . . . . . 0.663 HD12 ' NH1' ' A' ' 38' ' ' ARG . 93.9 mt -127.49 128.11 69.49 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.314 0 CA-C-O 120.854 0.359 . . . . 0.0 110.849 179.315 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 97.1 m -100.93 109.6 21.56 Favored 'General case' 0 C--N 1.331 -0.219 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 179.037 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 37.0 tp -117.95 118.97 33.43 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.638 -179.792 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 81' ' ' ILE . . . . . 0.676 ' O ' HD12 ' A' ' 81' ' ' ILE . 2.2 pp -137.41 161.61 34.13 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.166 0 CA-C-N 115.957 -0.565 . . . . 0.0 109.786 178.801 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 82' ' ' ASN . . . . . 0.631 ' H ' ' CB ' ' A' ' 33' ' ' THR . 16.2 t-20 . . . . . 0 C--N 1.329 -0.304 0 CA-C-O 120.772 0.32 . . . . 0.0 110.899 -179.928 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 207' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.463 0.48 0 N-CA-C 111.098 -0.801 . . . . 0.0 111.098 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' B' B ' 208' ' ' SER . . . . . 0.533 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 38.7 p -165.13 169.33 16.28 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.624 0.249 . . . . 0.0 110.778 179.591 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 209' ' ' TRP . . . . . . . . . . . . . 86.3 m95 -88.05 150.07 23.61 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.202 179.632 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 69.3 p -129.03 129.76 45.74 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-O 120.801 0.334 . . . . 0.0 110.481 179.522 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 52.0 t-105 -91.75 110.32 21.65 Favored 'General case' 0 N--CA 1.463 0.219 0 CA-C-N 116.477 -0.329 . . . . 0.0 110.272 179.609 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 212' ' ' GLU . . . . . 0.527 ' O ' ' O ' ' B' ' 215' ' ' LYS . 2.0 pt-20 -162.78 171.74 16.29 Favored 'General case' 0 C--O 1.22 -0.457 0 CA-C-O 120.977 0.418 . . . . 0.0 110.582 179.454 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 213' ' ' ASN . . . . . 0.492 ' C ' ' H ' ' B' ' 215' ' ' LYS . 13.8 m120 49.77 30.26 3.68 Favored 'General case' 0 C--N 1.317 -0.834 0 C-N-CA 120.237 -0.585 . . . . 0.0 111.721 176.788 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 66.48 -13.13 0.43 Allowed Glycine 0 CA--C 1.532 1.105 0 C-N-CA 121.087 -0.578 . . . . 0.0 111.973 179.229 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 215' ' ' LYS . . . . . 0.527 ' O ' ' O ' ' B' ' 212' ' ' GLU . 67.5 mttm -126.05 156.25 40.25 Favored 'General case' 0 N--CA 1.468 0.432 0 CA-C-O 121.143 0.497 . . . . 0.0 110.67 -179.445 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 216' ' ' TRP . . . . . 0.475 ' CD1' ' N ' ' B' ' 216' ' ' TRP . 32.4 m95 -86.53 125.12 33.54 Favored 'General case' 0 C--N 1.328 -0.348 0 C-N-CA 120.837 -0.345 . . . . 0.0 110.095 179.796 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 217' ' ' THR . . . . . 0.535 HG23 ' O ' ' A' ' 77' ' ' VAL . 18.5 m -124.42 138.42 54.36 Favored 'General case' 0 N--CA 1.468 0.427 0 CA-C-O 120.893 0.378 . . . . 0.0 110.359 -179.45 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 218' ' ' TRP . . . . . 0.533 ' CH2' ' N ' ' B' ' 208' ' ' SER . 24.5 t-105 -105.7 106.7 17.32 Favored 'General case' 0 N--CA 1.462 0.148 0 CA-C-N 116.13 -0.486 . . . . 0.0 109.88 179.343 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 74.4 mttt -135.46 171.47 14.4 Favored 'General case' 0 N--CA 1.466 0.355 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.646 -179.331 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -177.86 -162.75 28.4 Favored Glycine 0 CA--C 1.526 0.765 0 N-CA-C 110.857 -0.897 . . . . 0.0 110.857 179.57 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 221' ' ' ILE . . . . . 0.548 ' O ' HG23 ' B' ' 222' ' ' ILE . 0.8 OUTLIER -53.6 -74.2 0.05 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.384 0 C-N-CA 120.98 -0.288 . . . . 0.0 111.082 -178.73 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' B' B ' 222' ' ' ILE . . . . . 0.548 HG23 ' O ' ' B' ' 221' ' ' ILE . 20.6 pt -160.75 -165.79 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 116.276 -0.42 . . . . 0.0 109.895 -179.545 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 223' ' ' ARG . . . . . 0.6 ' N ' HD11 ' A' ' 75' ' ' ILE . 0.7 OUTLIER -43.37 174.9 0.0 OUTLIER 'General case' 0 N--CA 1.452 -0.363 0 CA-C-O 121.52 0.676 . . . . 0.0 110.814 179.154 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' B' B ' 224' ' ' LEU . . . . . 0.744 HD22 ' N ' ' B' ' 224' ' ' LEU . 2.6 mm? -61.28 116.11 4.36 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-N 115.51 -0.768 . . . . 0.0 110.634 -179.78 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 80.8 tt0 . . . . . 0 N--CA 1.465 0.277 0 CA-C-N 115.407 -0.815 . . . . 0.0 110.315 -179.987 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 98.0 m-20 . . . . . 0 CA--C 1.529 0.155 0 CA-C-O 120.931 0.396 . . . . 0.0 110.801 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 7.2 tt -75.84 154.07 36.4 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.273 179.754 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 13' ' ' SER . . . . . 0.433 ' O ' ' O ' ' A' ' 25' ' ' ARG . 17.7 p -140.26 151.39 45.09 Favored 'General case' 0 N--CA 1.462 0.156 0 CA-C-O 121.093 0.473 . . . . 0.0 110.226 178.862 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 14' ' ' PHE . . . . . 0.547 ' CD1' ' N ' ' A' ' 14' ' ' PHE . 18.0 m-85 -111.48 148.41 33.22 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.707 -0.679 . . . . 0.0 110.747 -179.194 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 25.3 m -148.25 155.57 9.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 120.966 0.412 . . . . 0.0 110.305 179.172 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 39.3 t0 62.72 29.9 16.8 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.6 -0.727 . . . . 0.0 110.891 -179.968 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 68.1 mt -56.68 131.97 20.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 179.716 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.414 ' CB ' ' O ' ' A' ' 21' ' ' SER . 0.2 OUTLIER -132.13 -168.78 2.1 Favored 'General case' 0 N--CA 1.47 0.538 0 CA-C-N 116.385 -0.37 . . . . 0.0 110.246 -179.551 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 19' ' ' ASP . . . . . 0.47 ' N ' ' OD1' ' A' ' 19' ' ' ASP . 22.4 p-10 -78.72 -48.47 14.86 Favored 'General case' 0 C--N 1.332 -0.169 0 C-N-CA 120.811 -0.356 . . . . 0.0 110.951 179.295 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 20' ' ' SER . . . . . 0.484 ' OG ' ' N ' ' A' ' 67' ' ' LEU . 27.8 t -120.73 12.78 11.45 Favored 'General case' 0 N--CA 1.462 0.165 0 CA-C-O 120.518 0.199 . . . . 0.0 110.734 -178.882 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 21' ' ' SER . . . . . 0.549 ' HB2' HG22 ' A' ' 65' ' ' THR . 92.8 p -146.63 131.03 17.62 Favored 'General case' 0 N--CA 1.463 0.19 0 CA-C-O 120.83 0.348 . . . . 0.0 110.095 -179.9 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 47.5 pt -127.5 142.14 44.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.159 -0.473 . . . . 0.0 109.991 -179.687 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -100.53 83.01 0.52 Allowed Glycine 0 N--CA 1.465 0.596 0 N-CA-C 110.414 -1.074 . . . . 0.0 110.414 179.951 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 16.7 mt -69.42 125.31 26.31 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.895 0.379 . . . . 0.0 110.0 -179.719 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 25' ' ' ARG . . . . . 0.433 ' O ' ' O ' ' A' ' 13' ' ' SER . 66.8 ttt180 -140.01 142.7 36.25 Favored 'General case' 0 N--CA 1.464 0.233 0 CA-C-O 121.268 0.556 . . . . 0.0 110.915 179.998 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 26' ' ' TRP . . . . . 0.528 ' CD2' ' O ' ' A' ' 60' ' ' GLY . 8.8 p90 -142.94 158.08 43.95 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.483 -0.78 . . . . 0.0 109.755 -179.61 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 4.1 m -103.06 103.92 37.06 Favored Pre-proline 0 CA--C 1.536 0.413 0 CA-C-O 119.592 -0.242 . . . . 0.0 111.058 -179.351 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 31.9 Cg_exo -55.17 153.7 25.76 Favored 'Trans proline' 0 C--N 1.312 -1.37 0 C-N-CA 121.616 1.544 . . . . 0.0 113.103 178.828 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.484 ' O ' ' N ' ' A' ' 32' ' ' SER . 75.1 mt -100.98 133.32 45.65 Favored 'General case' 0 N--CA 1.466 0.342 0 CA-C-N 115.047 -0.979 . . . . 0.0 110.966 179.658 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 26.4 t-20 -44.79 -30.57 0.99 Allowed 'General case' 0 C--N 1.315 -0.898 0 CA-C-N 114.695 -1.138 . . . . 0.0 110.258 179.772 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 64.3 m -89.16 -27.45 20.69 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 115.797 -0.638 . . . . 0.0 110.718 178.978 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 32' ' ' SER . . . . . 0.484 ' N ' ' O ' ' A' ' 29' ' ' LEU . 3.3 m -56.38 120.65 8.0 Favored 'General case' 0 N--CA 1.462 0.155 0 CA-C-O 121.575 0.703 . . . . 0.0 110.262 179.876 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 33' ' ' THR . . . . . 0.474 ' CB ' ' H ' ' A' ' 82' ' ' ASN . 6.4 m -52.9 147.27 9.38 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 114.866 -1.061 . . . . 0.0 109.725 -179.103 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 25.0 mm -93.18 93.35 4.11 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 116.4 -0.363 . . . . 0.0 110.888 -178.632 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.539 ' O ' ' CE1' ' A' ' 37' ' ' TYR . 9.0 pt -151.17 131.15 3.69 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.175 179.477 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -54.61 136.32 44.41 Favored Glycine 0 CA--C 1.524 0.609 0 N-CA-C 111.096 -0.802 . . . . 0.0 111.096 -179.252 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 37' ' ' TYR . . . . . 0.539 ' CE1' ' O ' ' A' ' 35' ' ' ILE . 5.0 m-85 -97.87 179.92 4.64 Favored 'General case' 0 C--N 1.332 -0.18 0 N-CA-C 109.683 -0.488 . . . . 0.0 109.683 179.679 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 38' ' ' ARG . . . . . 0.526 ' NH1' ' OE2' ' A' ' 52' ' ' GLU . 5.1 tmm_? -129.14 124.81 35.65 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.492 179.728 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.47 ' CD1' ' CD2' ' A' ' 62' ' ' TYR . 1.8 pt -101.51 118.54 48.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 115.96 -0.564 . . . . 0.0 109.871 179.68 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 35.2 m -102.7 134.35 46.22 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.578 -179.032 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.663 HG22 HD13 ' A' ' 50' ' ' ILE . 2.6 p -130.89 143.53 40.61 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.522 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.424 -179.691 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 42' ' ' VAL . . . . . 0.526 ' O ' ' N ' ' A' ' 74' ' ' ASP . 43.0 t -134.4 135.06 54.46 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.261 0 CA-C-O 120.875 0.369 . . . . 0.0 110.369 179.834 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.83 ' HB2' HD11 ' A' ' 50' ' ' ILE . . . -97.34 133.27 42.17 Favored 'General case' 0 C--N 1.33 -0.256 0 N-CA-C 109.515 -0.55 . . . . 0.0 109.515 179.169 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 44' ' ' ALA . . . . . 0.578 ' HB3' ' O ' ' A' ' 72' ' ' ASP . . . -89.87 -40.74 12.23 Favored 'General case' 0 C--N 1.33 -0.246 0 C-N-CA 120.577 -0.449 . . . . 0.0 110.635 179.444 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -80.72 30.21 2.58 Favored Glycine 0 CA--C 1.524 0.602 0 N-CA-C 111.405 -0.678 . . . . 0.0 111.405 -179.817 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 80.0 mm-40 -140.42 146.76 38.72 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 121.079 0.466 . . . . 0.0 110.415 179.753 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -69.98 -20.37 76.17 Favored Glycine 0 CA--C 1.527 0.785 0 N-CA-C 111.133 -0.787 . . . . 0.0 111.133 179.711 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -135.6 142.46 41.08 Favored Pre-proline 0 CA--C 1.545 0.779 0 CA-C-N 116.735 0.268 . . . . 0.0 110.361 -179.482 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -72.14 164.86 34.35 Favored 'Trans proline' 0 N--CA 1.495 1.583 0 C-N-CA 122.457 2.105 . . . . 0.0 111.573 178.451 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 50' ' ' ILE . . . . . 1.037 ' H ' HD12 ' A' ' 50' ' ' ILE . 0.6 OUTLIER -86.65 159.72 3.11 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 116.022 -0.536 . . . . 0.0 110.619 -179.579 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 84.8 m-85 -75.02 141.32 43.92 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.752 179.893 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 52' ' ' GLU . . . . . 0.526 ' OE2' ' NH1' ' A' ' 38' ' ' ARG . 4.4 pt-20 -70.23 -175.88 1.07 Allowed 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.501 179.54 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -147.1 141.39 26.27 Favored 'General case' 0 CA--C 1.534 0.337 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.172 179.803 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 34.3 m-85 -113.56 119.56 37.93 Favored 'General case' 0 N--CA 1.469 0.481 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.452 -179.866 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 9.3 p -128.21 140.62 48.69 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.462 0 CA-C-O 120.966 0.412 . . . . 0.0 110.554 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 97.4 m-20 -65.04 153.77 39.76 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.556 179.964 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 57' ' ' SER . . . . . 0.425 ' OG ' ' OH ' ' A' ' 37' ' ' TYR . 4.0 t -64.22 -33.51 75.96 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.662 179.921 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 52.1 m -52.99 -40.59 63.88 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.638 -179.419 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.5 ' O ' ' CD2' ' A' ' 61' ' ' TYR . 21.1 t -61.28 -43.55 96.74 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 N-CA-C 110.019 -0.363 . . . . 0.0 110.019 -179.582 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 60' ' ' GLY . . . . . 0.528 ' O ' ' CD2' ' A' ' 26' ' ' TRP . . . 72.5 -38.11 0.71 Allowed Glycine 0 CA--C 1.525 0.7 0 N-CA-C 111.359 -0.696 . . . . 0.0 111.359 179.389 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 61' ' ' TYR . . . . . 0.5 ' CD2' ' O ' ' A' ' 59' ' ' VAL . 32.1 p90 -114.62 158.82 21.21 Favored 'General case' 0 N--CA 1.47 0.54 0 CA-C-O 121.016 0.436 . . . . 0.0 110.993 -179.026 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 62' ' ' TYR . . . . . 0.47 ' CD2' ' CD1' ' A' ' 39' ' ' ILE . 29.1 t80 -151.62 158.37 43.39 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 109.394 -0.595 . . . . 0.0 109.394 179.336 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 53.8 m -120.65 133.68 55.34 Favored 'General case' 0 N--CA 1.465 0.297 0 CA-C-O 120.831 0.348 . . . . 0.0 110.095 179.74 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -131.81 103.46 6.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 N-CA-C 109.373 -0.603 . . . . 0.0 109.373 178.845 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.549 HG22 ' HB2' ' A' ' 21' ' ' SER . 3.4 p -116.36 162.48 17.46 Favored 'General case' 0 CA--C 1.512 -0.514 0 CA-C-O 121.077 0.465 . . . . 0.0 110.452 179.772 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 106.38 23.53 7.23 Favored Glycine 0 CA--C 1.521 0.424 0 N-CA-C 111.177 -0.769 . . . . 0.0 111.177 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.484 ' N ' ' OG ' ' A' ' 20' ' ' SER . 10.8 mt -97.43 109.91 22.57 Favored 'General case' 0 C--O 1.227 -0.115 0 N-CA-C 109.063 -0.717 . . . . 0.0 109.063 179.499 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 66.4 mm-40 -51.18 135.18 30.52 Favored Pre-proline 0 C--N 1.319 -0.745 0 C-N-CA 120.611 -0.435 . . . . 0.0 111.843 -178.039 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 96.8 Cg_endo -74.08 157.46 46.6 Favored 'Trans proline' 0 N--CA 1.499 1.85 0 C-N-CA 122.878 2.385 . . . . 0.0 111.132 178.83 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 72.31 -8.74 6.44 Favored Glycine 0 CA--C 1.525 0.678 0 C-N-CA 120.879 -0.677 . . . . 0.0 111.594 179.306 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 1.8 mp -103.88 140.67 21.37 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.373 0 CA-C-O 121.496 0.665 . . . . 0.0 109.642 -179.683 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 72' ' ' ASP . . . . . 0.578 ' O ' ' HB3' ' A' ' 44' ' ' ALA . 2.3 t0 -79.54 116.99 20.07 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 114.783 -1.098 . . . . 0.0 110.457 -179.524 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 73' ' ' TYR . . . . . 0.519 ' O ' HD13 ' A' ' 75' ' ' ILE . 11.5 m-85 -108.11 120.78 43.32 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.495 -179.771 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 74' ' ' ASP . . . . . 0.526 ' N ' ' O ' ' A' ' 42' ' ' VAL . 23.1 m-20 -88.51 114.63 25.33 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 115.275 -0.875 . . . . 0.0 109.831 -179.903 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 75' ' ' ILE . . . . . 0.602 HD11 ' N ' ' B' ' 223' ' ' ARG . 0.0 OUTLIER -113.26 164.05 9.68 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.36 0 CA-C-O 121.217 0.532 . . . . 0.0 110.363 -179.747 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 2.6 p -152.42 124.63 8.13 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.183 -0.917 . . . . 0.0 109.918 179.539 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 70.7 t -106.14 131.45 55.73 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 N-CA-C 109.11 -0.7 . . . . 0.0 109.11 179.818 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 97.4 mt -128.17 131.25 69.47 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.317 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.898 -179.886 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 79' ' ' THR . . . . . 0.535 HG23 ' O ' ' A' ' 79' ' ' THR . 9.0 t -106.95 122.41 46.37 Favored 'General case' 0 N--CA 1.463 0.192 0 CA-C-N 115.76 -0.654 . . . . 0.0 109.529 179.122 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 42.4 mt -119.86 113.01 19.94 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.478 -179.312 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 81' ' ' ILE . . . . . 0.505 ' HA ' HD11 ' A' ' 35' ' ' ILE . 2.2 pp -146.66 144.26 20.28 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.25 0 CA-C-O 120.725 0.298 . . . . 0.0 110.327 178.651 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 82' ' ' ASN . . . . . 0.474 ' H ' ' CB ' ' A' ' 33' ' ' THR . 42.3 t30 . . . . . 0 C--N 1.33 -0.279 0 CA-C-N 116.381 -0.372 . . . . 0.0 111.509 -179.683 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 207' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.466 0.645 0 N-CA-C 110.99 -0.844 . . . . 0.0 110.99 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' B' B ' 208' ' ' SER . . . . . 0.567 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 46.4 p -166.16 170.38 13.41 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.975 0.417 . . . . 0.0 110.794 179.384 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 209' ' ' TRP . . . . . . . . . . . . . 76.4 m95 -90.77 154.87 19.21 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.385 179.505 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 61.5 p -129.75 129.85 44.65 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.43 179.471 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 51.5 t-105 -90.99 109.62 20.86 Favored 'General case' 0 N--CA 1.465 0.283 0 CA-C-N 116.352 -0.386 . . . . 0.0 110.314 179.696 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 212' ' ' GLU . . . . . 0.493 ' O ' ' O ' ' B' ' 215' ' ' LYS . 1.8 pt-20 -162.26 170.54 18.79 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.332 -0.394 . . . . 0.0 110.571 179.515 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 213' ' ' ASN . . . . . 0.528 ' C ' ' H ' ' B' ' 215' ' ' LYS . 93.9 m-20 49.68 30.09 3.48 Favored 'General case' 0 C--N 1.318 -0.793 0 C-N-CA 120.393 -0.523 . . . . 0.0 111.467 177.259 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 64.04 -10.25 0.26 Allowed Glycine 0 CA--C 1.529 0.944 0 C-N-CA 120.97 -0.634 . . . . 0.0 111.732 179.415 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 215' ' ' LYS . . . . . 0.528 ' H ' ' C ' ' B' ' 213' ' ' ASN . 27.1 mtpt -123.92 153.73 40.74 Favored 'General case' 0 N--CA 1.467 0.424 0 CA-C-O 121.056 0.455 . . . . 0.0 111.004 -179.411 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 216' ' ' TRP . . . . . 0.448 ' CD1' ' N ' ' B' ' 216' ' ' TRP . 39.5 m95 -86.62 120.84 28.37 Favored 'General case' 0 C--N 1.326 -0.415 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 179.599 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 217' ' ' THR . . . . . . . . . . . . . 22.7 m -123.89 136.81 54.59 Favored 'General case' 0 N--CA 1.467 0.415 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.27 -179.512 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 218' ' ' TRP . . . . . 0.567 ' CH2' ' N ' ' B' ' 208' ' ' SER . 18.6 t-105 -104.16 108.77 20.3 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.034 179.628 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 76.5 mttt -133.11 169.61 16.61 Favored 'General case' 0 CA--C 1.515 -0.37 0 CA-C-N 115.828 -0.624 . . . . 0.0 110.425 -179.791 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -178.1 -161.8 26.83 Favored Glycine 0 N--CA 1.446 -0.64 0 N-CA-C 110.688 -0.965 . . . . 0.0 110.688 179.612 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 221' ' ' ILE . . . . . 0.533 ' O ' HG23 ' B' ' 222' ' ' ILE . 24.8 mt -53.91 -72.84 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 C-N-CA 120.702 -0.399 . . . . 0.0 110.33 -178.431 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 222' ' ' ILE . . . . . 0.533 HG23 ' O ' ' B' ' 221' ' ' ILE . 22.8 pt -160.3 -166.36 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.172 -0.467 . . . . 0.0 109.859 179.932 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 223' ' ' ARG . . . . . 0.602 ' N ' HD11 ' A' ' 75' ' ' ILE . 23.5 ptt180 -40.87 174.16 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 121.57 0.7 . . . . 0.0 110.999 178.883 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 224' ' ' LEU . . . . . 0.733 HD22 ' N ' ' B' ' 224' ' ' LEU . 2.7 mm? -61.97 109.79 1.37 Allowed 'General case' 0 C--N 1.315 -0.901 0 CA-C-N 115.398 -0.819 . . . . 0.0 110.531 -179.839 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 43.4 tt0 . . . . . 0 C--N 1.33 -0.278 0 CA-C-N 115.219 -0.9 . . . . 0.0 110.328 -179.939 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 45.5 t0 . . . . . 0 N--CA 1.465 0.289 0 CA-C-O 120.906 0.384 . . . . 0.0 110.579 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 47.6 tp -63.51 140.3 58.86 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.968 -0.56 . . . . 0.0 109.986 -179.339 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 86.2 p -139.51 154.99 47.8 Favored 'General case' 0 C--O 1.234 0.238 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.456 179.823 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 14' ' ' PHE . . . . . 0.564 ' CD2' HD11 ' B' ' 224' ' ' LEU . 18.4 m-85 -111.92 145.47 39.49 Favored 'General case' 0 N--CA 1.464 0.257 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.589 -179.76 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 26.7 m -146.04 161.36 11.09 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.401 179.707 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 97.1 m-20 52.56 30.81 9.03 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.796 179.683 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 84.1 mt -58.39 141.11 15.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 115.98 -0.554 . . . . 0.0 110.246 179.994 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.47 ' CB ' ' O ' ' A' ' 21' ' ' SER . 0.2 OUTLIER -140.98 -166.34 2.14 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.652 -179.621 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 7.6 p-10 -88.76 -46.92 8.6 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.71 -0.677 . . . . 0.0 110.946 179.653 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 41.3 m -115.23 8.42 15.51 Favored 'General case' 0 N--CA 1.468 0.449 0 CA-C-N 116.47 -0.332 . . . . 0.0 110.593 -179.648 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 21' ' ' SER . . . . . 0.47 ' O ' ' CB ' ' A' ' 18' ' ' THR . 29.6 p -151.09 145.44 25.48 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.986 0.422 . . . . 0.0 110.553 179.691 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 22' ' ' ILE . . . . . 0.466 HD12 HD21 ' A' ' 24' ' ' LEU . 41.4 pt -142.49 146.95 21.61 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.113 179.839 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -102.1 84.46 0.5 Allowed Glycine 0 CA--C 1.522 0.518 0 N-CA-C 111.1 -0.8 . . . . 0.0 111.1 179.957 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.466 HD21 HD12 ' A' ' 22' ' ' ILE . 92.5 mt -69.86 122.48 19.34 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.817 0.341 . . . . 0.0 110.159 -179.865 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 65.7 ttt-85 -136.0 144.47 45.35 Favored 'General case' 0 CA--C 1.517 -0.291 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.116 -179.844 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 26' ' ' TRP . . . . . 0.447 ' HE1' ' HG3' ' A' ' 28' ' ' PRO . 35.1 p90 -145.99 157.27 43.88 Favored 'General case' 0 CA--C 1.518 -0.26 0 CA-C-N 116.407 -0.361 . . . . 0.0 110.074 -179.9 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 4.6 m -111.85 96.33 32.9 Favored Pre-proline 0 C--O 1.234 0.268 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.475 179.545 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.447 ' HG3' ' HE1' ' A' ' 26' ' ' TRP . 46.4 Cg_exo -54.1 143.72 61.42 Favored 'Trans proline' 0 C--N 1.307 -1.653 0 C-N-CA 122.177 1.918 . . . . 0.0 112.496 179.39 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 66.5 mt -79.4 140.01 37.55 Favored 'General case' 0 CA--C 1.517 -0.291 0 CA-C-O 121.481 0.658 . . . . 0.0 111.014 -179.841 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 30' ' ' ASN . . . . . 0.437 ' OD1' ' O ' ' A' ' 30' ' ' ASN . 59.8 t-20 -51.67 -33.95 36.1 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.243 -0.889 . . . . 0.0 109.806 179.902 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 51.4 m -79.43 -32.94 42.89 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.52 179.41 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 14.0 m -62.32 136.99 58.17 Favored 'General case' 0 CA--C 1.528 0.129 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.178 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 33' ' ' THR . . . . . 0.591 ' H ' ' HB ' ' A' ' 81' ' ' ILE . 7.1 m -64.89 141.59 58.72 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.967 -0.561 . . . . 0.0 110.395 179.857 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 15.5 mm -95.03 95.36 4.99 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.201 0 CA-C-O 120.936 0.398 . . . . 0.0 110.548 -179.962 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.494 ' O ' ' OG ' ' A' ' 57' ' ' SER . 11.3 pt -142.47 132.12 22.75 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.192 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.402 179.723 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -38.11 122.05 1.11 Allowed Glycine 0 CA--C 1.524 0.603 0 N-CA-C 111.424 -0.671 . . . . 0.0 111.424 -179.595 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 76.4 m-85 -89.48 176.47 6.89 Favored 'General case' 0 CA--C 1.515 -0.391 0 CA-C-O 120.907 0.384 . . . . 0.0 110.113 -179.946 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 6.2 tmm_? -135.35 126.74 28.51 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.635 179.946 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.452 ' O ' ' CG1' ' A' ' 39' ' ' ILE . 1.8 pt -102.43 125.27 56.71 Favored 'Isoleucine or valine' 0 C--O 1.233 0.208 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.003 179.603 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 15.9 m -106.81 133.02 52.1 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.448 -179.858 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.2 p -128.34 138.9 53.36 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.312 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.108 179.925 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 42' ' ' VAL . . . . . 0.526 ' O ' ' N ' ' A' ' 74' ' ' ASP . 39.2 t -133.27 133.78 57.79 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.114 0 CA-C-N 116.418 -0.356 . . . . 0.0 110.195 179.671 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -95.95 136.53 36.27 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.269 179.292 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 44' ' ' ALA . . . . . 0.592 ' HB3' ' O ' ' A' ' 72' ' ' ASP . . . -90.35 -46.29 8.48 Favored 'General case' 0 N--CA 1.464 0.256 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.545 179.844 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -64.82 -30.65 78.55 Favored Glycine 0 CA--C 1.523 0.577 0 N-CA-C 111.042 -0.823 . . . . 0.0 111.042 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 36.6 mm-40 -96.07 134.73 38.76 Favored 'General case' 0 C--N 1.331 -0.197 0 N-CA-C 109.482 -0.562 . . . . 0.0 109.482 -179.24 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -63.69 -21.81 65.47 Favored Glycine 0 CA--C 1.51 -0.242 0 N-CA-C 111.087 -0.805 . . . . 0.0 111.087 -178.922 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -114.46 136.11 22.33 Favored Pre-proline 0 CA--C 1.54 0.574 0 C-N-CA 120.983 -0.287 . . . . 0.0 110.577 179.709 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -78.58 169.75 19.34 Favored 'Trans proline' 0 C--N 1.309 -1.523 0 C-N-CA 122.792 2.328 . . . . 0.0 112.002 176.498 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 4.7 mp -96.43 133.53 37.43 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.183 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.561 179.564 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 83.0 m-85 -49.71 149.31 2.54 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.617 -179.871 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 5.9 pt-20 -75.3 -178.06 3.79 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.204 179.766 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -143.76 132.57 22.61 Favored 'General case' 0 N--CA 1.45 -0.429 0 CA-C-N 115.848 -0.614 . . . . 0.0 110.855 179.839 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 96.9 m-85 -104.6 119.47 39.06 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.206 179.449 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 10.6 p -126.27 134.22 66.95 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.295 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.295 179.979 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 98.2 m-20 -56.87 138.46 53.64 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.417 -179.866 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 57' ' ' SER . . . . . 0.494 ' OG ' ' O ' ' A' ' 35' ' ' ILE . 5.0 m -59.04 -32.49 69.8 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.38 179.871 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 59.2 m -55.31 -33.59 63.44 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.395 -179.904 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 95.6 t -64.2 -45.74 95.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.438 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 61.58 26.75 67.03 Favored Glycine 0 CA--C 1.527 0.792 0 N-CA-C 110.656 -0.978 . . . . 0.0 110.656 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 61' ' ' TYR . . . . . 0.413 ' CG ' ' N ' ' A' ' 62' ' ' TYR . 48.5 t80 -167.88 152.2 6.45 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 121.275 0.56 . . . . 0.0 111.134 -179.333 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 62' ' ' TYR . . . . . 0.413 ' N ' ' CG ' ' A' ' 61' ' ' TYR . 23.6 t80 -158.59 159.04 35.02 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.069 178.827 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 85.8 m -126.6 135.75 51.64 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.711 -179.819 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -132.04 108.1 13.56 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.334 0 CA-C-N 115.946 -0.57 . . . . 0.0 109.743 179.127 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 2.6 p -116.98 159.64 22.18 Favored 'General case' 0 CA--C 1.518 -0.259 0 CA-C-O 121.0 0.429 . . . . 0.0 110.844 179.971 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 109.21 3.03 31.43 Favored Glycine 0 CA--C 1.527 0.802 0 CA-C-N 115.7 -0.682 . . . . 0.0 111.528 -179.503 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 3.8 mt -79.49 110.86 15.19 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 121.067 0.461 . . . . 0.0 110.024 -179.259 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 9.3 mt-10 -48.09 139.1 10.08 Favored Pre-proline 0 C--N 1.319 -0.741 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.013 -178.834 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -75.09 162.41 36.93 Favored 'Trans proline' 0 N--CA 1.494 1.558 0 C-N-CA 122.888 2.392 . . . . 0.0 112.401 179.426 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 46.7 22.15 1.03 Allowed Glycine 0 N--CA 1.443 -0.885 0 CA-C-N 115.27 -0.877 . . . . 0.0 111.617 179.2 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 71' ' ' ILE . . . . . 0.442 ' CG2' ' CD1' ' A' ' 73' ' ' TYR . 0.9 OUTLIER -109.5 166.2 4.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 121.349 0.595 . . . . 0.0 109.814 -179.708 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 72' ' ' ASP . . . . . 0.592 ' O ' ' HB3' ' A' ' 44' ' ' ALA . 4.3 t0 -102.05 101.02 11.34 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.355 -0.839 . . . . 0.0 111.82 179.476 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 73' ' ' TYR . . . . . 0.55 ' O ' HD13 ' A' ' 75' ' ' ILE . 2.2 m-30 -109.58 125.38 52.48 Favored 'General case' 0 C--O 1.219 -0.537 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.585 179.049 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 74' ' ' ASP . . . . . 0.526 ' N ' ' O ' ' A' ' 42' ' ' VAL . 79.7 m-20 -89.0 117.05 27.74 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 114.993 -1.003 . . . . 0.0 109.397 179.891 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 75' ' ' ILE . . . . . 0.641 HD11 ' N ' ' B' ' 223' ' ' ARG . 0.0 OUTLIER -116.54 168.63 7.89 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.306 0 CA-C-O 121.155 0.502 . . . . 0.0 110.079 -179.019 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 45.3 t -154.66 150.46 27.68 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.445 -0.798 . . . . 0.0 110.877 179.539 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.408 ' O ' HG23 ' B' ' 217' ' ' THR . 12.0 t -130.38 100.97 5.34 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.272 0 N-CA-C 109.613 -0.514 . . . . 0.0 109.613 178.958 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 96.2 mt -88.82 130.44 38.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.59 -179.782 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 91.8 m -112.53 106.66 15.16 Favored 'General case' 0 CA--C 1.518 -0.276 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 179.59 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 80' ' ' LEU . . . . . 0.535 ' C ' HD23 ' A' ' 80' ' ' LEU . 6.6 tt -121.3 122.29 39.56 Favored 'General case' 0 CA--C 1.519 -0.249 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.315 -179.906 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 81' ' ' ILE . . . . . 0.591 ' HB ' ' H ' ' A' ' 33' ' ' THR . 2.2 pp -134.19 151.29 32.05 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.175 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.295 179.611 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 82' ' ' ASN . . . . . 0.535 ' H ' ' CB ' ' A' ' 33' ' ' THR . 57.1 t-20 . . . . . 0 C--N 1.329 -0.29 0 CA-C-N 116.478 -0.328 . . . . 0.0 111.193 179.94 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 207' ' ' GLY . . . . . 0.427 ' C ' ' CH2' ' B' ' 218' ' ' TRP . . . . . . . . 0 N--CA 1.467 0.736 0 N-CA-C 111.174 -0.771 . . . . 0.0 111.174 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 208' ' ' SER . . . . . 0.458 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 97.4 p -162.92 170.28 18.39 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.829 0.347 . . . . 0.0 110.717 179.759 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 209' ' ' TRP . . . . . . . . . . . . . 79.0 m95 -85.32 131.42 34.41 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.183 179.682 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 44.6 p -113.8 140.69 48.1 Favored 'General case' 0 N--CA 1.463 0.221 0 CA-C-N 116.409 -0.359 . . . . 0.0 110.61 -179.752 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 54.5 t-105 -96.55 118.26 32.66 Favored 'General case' 0 N--CA 1.464 0.226 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.134 179.914 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 212' ' ' GLU . . . . . 0.477 ' O ' ' O ' ' B' ' 215' ' ' LYS . 0.9 OUTLIER -165.72 167.75 16.79 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.971 179.076 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' B' B ' 213' ' ' ASN . . . . . . . . . . . . . 12.7 m120 50.41 35.23 10.54 Favored 'General case' 0 C--N 1.321 -0.648 0 C-N-CA 120.603 -0.439 . . . . 0.0 111.02 176.168 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 52.24 14.75 2.29 Favored Glycine 0 CA--C 1.525 0.66 0 N-CA-C 111.364 -0.694 . . . . 0.0 111.364 179.661 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 215' ' ' LYS . . . . . 0.477 ' O ' ' O ' ' B' ' 212' ' ' GLU . 8.1 mtmp? -144.52 151.38 39.04 Favored 'General case' 0 C--N 1.333 -0.124 0 CA-C-O 121.161 0.505 . . . . 0.0 110.657 179.793 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 216' ' ' TRP . . . . . . . . . . . . . 66.2 m95 -85.58 120.95 27.59 Favored 'General case' 0 C--N 1.329 -0.289 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 -179.911 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 217' ' ' THR . . . . . 0.408 HG23 ' O ' ' A' ' 77' ' ' VAL . 21.5 m -130.75 142.29 50.41 Favored 'General case' 0 C--O 1.233 0.229 0 CA-C-O 121.051 0.453 . . . . 0.0 110.617 -179.578 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 218' ' ' TRP . . . . . 0.458 ' CH2' ' N ' ' B' ' 208' ' ' SER . 16.4 t-105 -104.31 121.45 43.38 Favored 'General case' 0 N--CA 1.462 0.137 0 CA-C-N 115.925 -0.579 . . . . 0.0 109.921 179.501 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 52.1 mtmt -144.73 171.56 14.23 Favored 'General case' 0 N--CA 1.464 0.246 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.826 -179.524 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -175.44 -161.03 24.2 Favored Glycine 0 CA--C 1.524 0.627 0 CA-C-N 115.614 -0.721 . . . . 0.0 111.322 -179.663 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 221' ' ' ILE . . . . . 0.547 ' O ' HG23 ' B' ' 222' ' ' ILE . 18.8 mt -51.29 -73.27 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 C-N-CA 120.737 -0.385 . . . . 0.0 110.592 -177.973 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 222' ' ' ILE . . . . . 0.547 HG23 ' O ' ' B' ' 221' ' ' ILE . 16.2 pt -158.89 -167.26 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.451 179.808 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 223' ' ' ARG . . . . . 0.641 ' N ' HD11 ' A' ' 75' ' ' ILE . 0.1 OUTLIER -46.12 177.08 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.651 -0.704 . . . . 0.0 110.399 179.146 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' B' B ' 224' ' ' LEU . . . . . 0.683 HD22 ' N ' ' B' ' 224' ' ' LEU . 3.4 mm? -58.68 126.14 26.39 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.414 -178.833 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 225' ' ' GLU . . . . . 0.508 ' OE1' ' NH1' ' B' ' 223' ' ' ARG . 29.7 tp10 . . . . . 0 C--N 1.332 -0.162 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.167 -179.758 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 97.6 m-20 . . . . . 0 N--CA 1.464 0.227 0 CA-C-O 120.915 0.388 . . . . 0.0 110.336 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 7.4 tt -64.81 144.65 57.11 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.383 -179.74 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 13' ' ' SER . . . . . 0.458 ' O ' ' O ' ' A' ' 25' ' ' ARG . 87.1 p -139.18 159.54 41.91 Favored 'General case' 0 N--CA 1.462 0.125 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.653 179.734 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 14' ' ' PHE . . . . . 0.424 ' CD1' ' N ' ' A' ' 14' ' ' PHE . 19.1 m-85 -111.35 145.47 38.81 Favored 'General case' 0 N--CA 1.465 0.308 0 CA-C-N 115.978 -0.556 . . . . 0.0 110.572 -179.775 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 17.4 m -144.9 157.4 14.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.463 179.659 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 98.9 m-20 47.76 60.24 3.66 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.314 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 98.2 mt -82.46 140.51 16.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.538 179.757 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.438 ' CB ' ' O ' ' A' ' 21' ' ' SER . 0.3 OUTLIER -138.54 -168.33 2.37 Favored 'General case' 0 N--CA 1.466 0.325 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.449 179.917 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 19' ' ' ASP . . . . . 0.475 ' OD1' ' N ' ' A' ' 19' ' ' ASP . 15.8 p-10 -88.55 -43.63 11.26 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.618 179.509 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 20' ' ' SER . . . . . 0.417 ' OG ' ' O ' ' A' ' 67' ' ' LEU . 50.8 m -117.51 9.77 13.32 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.833 -179.65 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 21' ' ' SER . . . . . 0.438 ' O ' ' CB ' ' A' ' 18' ' ' THR . 9.4 m -150.1 141.76 23.58 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.262 179.829 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 44.3 pt -136.76 146.17 28.96 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.417 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.337 179.915 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -101.63 81.3 0.43 Allowed Glycine 0 CA--C 1.524 0.621 0 N-CA-C 110.887 -0.885 . . . . 0.0 110.887 179.692 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 16.4 mt -67.23 123.91 21.62 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 110.025 -0.361 . . . . 0.0 110.025 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 25' ' ' ARG . . . . . 0.458 ' O ' ' O ' ' A' ' 13' ' ' SER . 72.5 ttp85 -142.24 135.82 29.22 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.381 -179.804 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 26' ' ' TRP . . . . . . . . . . . . . 3.8 p90 -141.28 158.74 43.48 Favored 'General case' 0 C--N 1.326 -0.444 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 -179.811 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 4.1 m -108.03 102.35 45.51 Favored Pre-proline 0 CA--C 1.537 0.461 0 CA-C-N 116.725 -0.216 . . . . 0.0 110.418 179.504 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_exo -54.91 145.85 60.1 Favored 'Trans proline' 0 C--N 1.308 -1.571 0 C-N-CA 121.8 1.667 . . . . 0.0 112.874 179.547 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 71.1 mt -85.07 138.3 32.51 Favored 'General case' 0 CA--C 1.515 -0.371 0 CA-C-O 121.44 0.638 . . . . 0.0 110.567 179.866 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 30' ' ' ASN . . . . . 0.421 ' OD1' ' O ' ' A' ' 30' ' ' ASN . 61.2 t-20 -48.63 -34.54 11.91 Favored 'General case' 0 C--N 1.314 -0.946 0 CA-C-N 115.187 -0.915 . . . . 0.0 110.152 -179.962 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 38.3 m -80.68 -33.05 35.78 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.508 179.03 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 6.9 m -59.17 131.64 51.64 Favored 'General case' 0 CA--C 1.528 0.116 0 CA-C-O 120.963 0.411 . . . . 0.0 110.368 -179.839 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 33' ' ' THR . . . . . 0.494 ' CB ' ' H ' ' A' ' 82' ' ' ASN . 4.3 m -62.14 145.41 53.44 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.032 179.984 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 12.5 mm -93.92 94.42 4.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-O 120.921 0.391 . . . . 0.0 110.645 -179.606 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.478 ' O ' ' OG ' ' A' ' 57' ' ' SER . 15.8 pt -147.57 133.04 11.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.844 -0.617 . . . . 0.0 110.563 -179.88 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -47.86 130.43 17.43 Favored Glycine 0 CA--C 1.52 0.357 0 N-CA-C 110.979 -0.848 . . . . 0.0 110.979 -179.864 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 37' ' ' TYR . . . . . 0.468 ' CE2' HG22 ' A' ' 39' ' ' ILE . 3.8 p90 -106.25 126.84 52.73 Favored 'General case' 0 C--N 1.33 -0.278 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 179.377 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 38' ' ' ARG . . . . . 0.529 ' NH1' ' OG1' ' A' ' 40' ' ' THR . 3.3 tmm_? -76.4 131.31 39.04 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.275 -0.421 . . . . 0.0 111.128 -179.321 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.468 HG22 ' CE2' ' A' ' 37' ' ' TYR . 2.2 pt -98.19 123.94 50.98 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.159 0 CA-C-N 115.956 -0.566 . . . . 0.0 109.531 179.526 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 40' ' ' THR . . . . . 0.529 ' OG1' ' NH1' ' A' ' 38' ' ' ARG . 1.6 m -103.38 131.12 50.72 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 120.802 0.334 . . . . 0.0 110.56 -179.303 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.3 p -130.48 138.68 53.19 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.052 179.442 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 42' ' ' VAL . . . . . 0.517 ' N ' ' O ' ' A' ' 74' ' ' ASP . 39.7 t -133.1 131.88 58.64 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.248 0 N-CA-C 110.101 -0.333 . . . . 0.0 110.101 -179.99 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.596 ' HB2' ' CE2' ' A' ' 73' ' ' TYR . . . -96.25 139.54 32.25 Favored 'General case' 0 C--N 1.327 -0.377 0 N-CA-C 109.54 -0.541 . . . . 0.0 109.54 179.099 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 44' ' ' ALA . . . . . 0.537 ' HB3' ' O ' ' A' ' 72' ' ' ASP . . . -92.21 -41.71 10.28 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.762 0.315 . . . . 0.0 110.857 179.636 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -65.66 -31.73 80.87 Favored Glycine 0 CA--C 1.526 0.735 0 N-CA-C 111.388 -0.685 . . . . 0.0 111.388 -179.357 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 32.0 mt-10 -97.94 129.66 44.84 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 121.168 0.509 . . . . 0.0 109.651 -179.64 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -60.37 -8.55 9.42 Favored Glycine 0 CA--C 1.518 0.233 0 N-CA-C 110.701 -0.959 . . . . 0.0 110.701 -179.272 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -124.08 134.39 25.39 Favored Pre-proline 0 CA--C 1.538 0.512 0 C-N-CA 121.298 -0.161 . . . . 0.0 110.588 179.529 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -77.99 160.63 30.26 Favored 'Trans proline' 0 C--N 1.314 -1.273 0 C-N-CA 122.477 2.118 . . . . 0.0 112.054 177.602 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 96.1 mt -80.71 137.69 20.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.199 179.188 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 90.0 m-85 -55.88 142.05 36.79 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.949 0.404 . . . . 0.0 110.724 -179.702 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 52' ' ' GLU . . . . . 0.518 ' CD ' ' H ' ' A' ' 52' ' ' GLU . 0.4 OUTLIER -77.72 146.21 36.08 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.376 179.778 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -109.81 144.83 37.69 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.406 179.829 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 93.5 m-85 -109.46 118.82 37.65 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.266 179.944 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 9.3 p -125.95 137.47 57.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.441 -179.747 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 84.1 m-20 -67.63 141.41 56.75 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.297 179.592 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 57' ' ' SER . . . . . 0.478 ' OG ' ' O ' ' A' ' 35' ' ' ILE . 9.6 m -57.98 -28.5 64.44 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.417 179.886 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 23.4 m -55.94 -33.64 64.92 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.542 179.959 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.473 ' O ' ' CD2' ' A' ' 61' ' ' TYR . 50.6 t -60.49 -45.18 97.34 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 116.394 -0.367 . . . . 0.0 110.15 -179.395 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 71.36 14.51 74.44 Favored Glycine 0 CA--C 1.529 0.922 0 N-CA-C 111.074 -0.81 . . . . 0.0 111.074 179.388 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 61' ' ' TYR . . . . . 0.473 ' CD2' ' O ' ' A' ' 59' ' ' VAL . 27.6 p90 -172.27 158.34 4.43 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.795 0.331 . . . . 0.0 111.348 179.43 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 23.6 t80 -155.94 155.6 33.09 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.356 -0.384 . . . . 0.0 110.144 177.955 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 94.4 m -121.09 134.7 55.27 Favored 'General case' 0 N--CA 1.463 0.224 0 CA-C-O 121.072 0.463 . . . . 0.0 110.429 -179.814 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -131.86 103.35 6.78 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.197 0 CA-C-N 115.954 -0.566 . . . . 0.0 109.862 178.961 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 2.3 p -112.84 162.87 15.3 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 121.031 0.444 . . . . 0.0 110.683 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 111.38 5.62 26.2 Favored Glycine 0 CA--C 1.527 0.83 0 CA-C-N 115.482 -0.781 . . . . 0.0 111.583 -179.272 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.425 ' CB ' HH21 ' B' ' 223' ' ' ARG . 9.1 mt -81.21 109.04 15.36 Favored 'General case' 0 C--N 1.329 -0.286 0 N-CA-C 109.479 -0.563 . . . . 0.0 109.479 179.379 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 17.5 mm-40 -57.81 137.42 83.11 Favored Pre-proline 0 C--N 1.321 -0.651 0 CA-C-N 116.288 -0.414 . . . . 0.0 111.569 -178.303 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 69' ' ' PRO . . . . . 0.411 ' O ' HD12 ' A' ' 71' ' ' ILE . 80.8 Cg_endo -74.29 151.76 43.7 Favored 'Trans proline' 0 N--CA 1.494 1.542 0 C-N-CA 122.695 2.263 . . . . 0.0 111.732 178.93 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 76.58 6.41 84.44 Favored Glycine 0 CA--C 1.528 0.856 0 CA-C-N 115.644 -0.707 . . . . 0.0 111.413 179.229 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 71' ' ' ILE . . . . . 0.411 HD12 ' O ' ' A' ' 69' ' ' PRO . 2.4 mp -117.05 143.99 25.93 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.392 0 CA-C-O 121.398 0.618 . . . . 0.0 109.728 -179.717 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 72' ' ' ASP . . . . . 0.537 ' O ' ' HB3' ' A' ' 44' ' ' ALA . 4.4 t70 -84.06 112.26 20.05 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 114.987 -1.006 . . . . 0.0 110.626 -179.657 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 73' ' ' TYR . . . . . 0.596 ' CE2' ' HB2' ' A' ' 43' ' ' ALA . 11.9 m-85 -107.54 120.61 42.68 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.467 179.73 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 74' ' ' ASP . . . . . 0.517 ' O ' ' N ' ' A' ' 42' ' ' VAL . 72.6 m-20 -88.04 119.42 28.4 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.348 -0.842 . . . . 0.0 109.414 179.474 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 75' ' ' ILE . . . . . 0.907 ' N ' HD13 ' A' ' 75' ' ' ILE . 0.0 OUTLIER -120.15 166.44 14.57 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-O 121.005 0.431 . . . . 0.0 110.311 -178.521 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 21.2 t -155.92 125.61 6.39 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.659 -0.701 . . . . 0.0 110.623 179.204 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 11.4 t -102.0 100.79 11.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 N-CA-C 109.621 -0.511 . . . . 0.0 109.621 179.126 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 90.4 mt -87.95 126.3 41.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.717 -179.766 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 79' ' ' THR . . . . . 0.431 ' OG1' ' O ' ' B' ' 216' ' ' TRP . 16.4 p -106.93 110.03 22.08 Favored 'General case' 0 N--CA 1.464 0.235 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 179.514 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 35.9 tp -117.57 124.58 49.01 Favored 'General case' 0 N--CA 1.464 0.231 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.445 179.98 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 81' ' ' ILE . . . . . 0.483 ' HB ' ' H ' ' A' ' 33' ' ' THR . 2.1 pp -145.9 145.34 20.28 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-N 116.004 -0.543 . . . . 0.0 110.259 179.338 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 82' ' ' ASN . . . . . 0.494 ' H ' ' CB ' ' A' ' 33' ' ' THR . 47.2 t30 . . . . . 0 C--N 1.329 -0.311 0 CA-C-N 116.522 -0.308 . . . . 0.0 110.808 -179.743 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 207' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.465 0.615 0 N-CA-C 110.818 -0.913 . . . . 0.0 110.818 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' B' B ' 208' ' ' SER . . . . . 0.455 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 53.9 p -164.35 171.67 14.48 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 120.876 0.37 . . . . 0.0 110.686 -179.893 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 209' ' ' TRP . . . . . . . . . . . . . 76.5 m95 -87.51 134.98 33.53 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.216 179.575 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 70.2 p -110.62 131.74 54.79 Favored 'General case' 0 N--CA 1.467 0.423 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.552 -179.847 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 50.5 t-105 -93.16 115.2 27.84 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 120.875 0.369 . . . . 0.0 110.432 179.689 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 212' ' ' GLU . . . . . 0.484 ' O ' ' O ' ' B' ' 215' ' ' LYS . 1.4 pt-20 -164.89 170.54 15.21 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.077 -0.51 . . . . 0.0 111.085 179.199 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 213' ' ' ASN . . . . . . . . . . . . . 16.3 m120 48.58 34.19 4.76 Favored 'General case' 0 C--N 1.322 -0.619 0 C-N-CA 120.398 -0.521 . . . . 0.0 111.342 176.384 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 54.27 11.75 2.65 Favored Glycine 0 CA--C 1.529 0.932 0 N-CA-C 111.627 -0.589 . . . . 0.0 111.627 179.794 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 215' ' ' LYS . . . . . 0.484 ' O ' ' O ' ' B' ' 212' ' ' GLU . 65.9 mttm -142.86 150.77 40.31 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 121.038 0.446 . . . . 0.0 110.732 179.995 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 216' ' ' TRP . . . . . 0.436 ' CD1' ' N ' ' B' ' 216' ' ' TRP . 35.0 m95 -87.74 127.15 35.31 Favored 'General case' 0 C--N 1.33 -0.281 0 N-CA-C 109.954 -0.387 . . . . 0.0 109.954 179.742 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 217' ' ' THR . . . . . . . . . . . . . 21.7 m -136.14 145.0 45.34 Favored 'General case' 0 N--CA 1.463 0.217 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.359 -179.784 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 218' ' ' TRP . . . . . 0.455 ' CH2' ' N ' ' B' ' 208' ' ' SER . 24.8 t-105 -102.6 120.83 41.23 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 116.048 -0.524 . . . . 0.0 109.796 179.53 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 97.4 mttt -136.56 164.33 28.44 Favored 'General case' 0 N--CA 1.465 0.308 0 CA-C-O 121.083 0.468 . . . . 0.0 110.739 -179.62 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -176.13 -162.75 27.55 Favored Glycine 0 CA--C 1.523 0.575 0 N-CA-C 111.134 -0.786 . . . . 0.0 111.134 -179.942 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 221' ' ' ILE . . . . . 0.533 ' O ' HG23 ' B' ' 222' ' ' ILE . 0.9 OUTLIER -58.75 -78.71 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 C-N-CA 120.459 -0.496 . . . . 0.0 110.965 -178.254 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' B' B ' 222' ' ' ILE . . . . . 0.533 HG23 ' O ' ' B' ' 221' ' ' ILE . 19.1 pt -159.12 -162.84 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 N-CA-C 110.043 -0.355 . . . . 0.0 110.043 -179.085 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 223' ' ' ARG . . . . . 0.544 ' HD2' ' H ' ' B' ' 223' ' ' ARG . 0.0 OUTLIER -43.76 173.64 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 121.271 0.558 . . . . 0.0 110.545 178.648 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' B' B ' 224' ' ' LEU . . . . . 0.747 HD22 ' N ' ' B' ' 224' ' ' LEU . 2.6 mm? -59.42 138.46 57.65 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-N 115.67 -0.695 . . . . 0.0 110.581 -179.707 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 80.0 tt0 . . . . . 0 C--N 1.332 -0.178 0 CA-C-N 115.389 -0.823 . . . . 0.0 110.41 -179.492 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 45.2 t0 . . . . . 0 N--CA 1.463 0.223 0 CA-C-O 120.809 0.338 . . . . 0.0 110.271 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 5.7 tt -70.22 134.96 48.57 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.552 179.846 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 82.5 p -142.61 162.32 35.78 Favored 'General case' 0 N--CA 1.462 0.143 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.401 179.631 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 14' ' ' PHE . . . . . 0.411 ' CD1' ' N ' ' A' ' 14' ' ' PHE . 57.3 m-85 -110.27 147.64 33.45 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.905 -0.588 . . . . 0.0 110.67 -179.642 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 17.7 m -144.19 152.93 15.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.399 179.737 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 24.9 t70 60.66 34.24 20.1 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.544 -179.823 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 96.4 mt -57.02 134.65 21.3 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.191 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.035 179.709 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.438 ' OG1' ' O ' ' A' ' 21' ' ' SER . 0.2 OUTLIER -136.49 -168.89 2.34 Favored 'General case' 0 N--CA 1.469 0.478 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.388 -179.831 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 19' ' ' ASP . . . . . 0.485 ' N ' ' OD1' ' A' ' 19' ' ' ASP . 18.6 p-10 -76.48 -50.62 13.58 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.798 179.49 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 20' ' ' SER . . . . . 0.441 ' CB ' ' O ' ' A' ' 67' ' ' LEU . 69.8 m -121.61 15.76 11.13 Favored 'General case' 0 N--CA 1.462 0.173 0 CA-C-N 116.677 -0.238 . . . . 0.0 110.679 -179.33 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 21' ' ' SER . . . . . 0.527 ' HB2' HG22 ' A' ' 65' ' ' THR . 25.2 p -145.97 127.09 14.69 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-O 121.041 0.448 . . . . 0.0 110.545 -179.612 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 38.4 pt -128.69 141.29 46.96 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.3 0 CA-C-N 115.947 -0.569 . . . . 0.0 109.57 -179.81 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -102.29 88.73 0.7 Allowed Glycine 0 CA--C 1.523 0.566 0 N-CA-C 111.8 -0.52 . . . . 0.0 111.8 -179.316 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 10.3 mp -61.06 148.59 39.79 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 121.072 0.463 . . . . 0.0 110.349 179.963 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 50.2 ttt180 -157.4 136.57 11.83 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.683 -0.69 . . . . 0.0 110.98 179.827 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 26' ' ' TRP . . . . . 0.521 ' CH2' ' OH ' ' A' ' 37' ' ' TYR . 34.5 p90 -139.74 159.39 42.28 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.821 -0.627 . . . . 0.0 109.915 -179.93 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 3.7 m -107.71 99.77 31.31 Favored Pre-proline 0 CA--C 1.537 0.443 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.986 -179.363 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 38.7 Cg_exo -56.64 153.39 36.2 Favored 'Trans proline' 0 C--N 1.31 -1.454 0 C-N-CA 122.093 1.862 . . . . 0.0 112.956 178.84 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.513 ' H ' ' HB2' ' A' ' 32' ' ' SER . 41.7 mt -110.41 135.91 50.38 Favored 'General case' 0 N--CA 1.469 0.492 0 CA-C-O 121.76 0.79 . . . . 0.0 110.876 -179.845 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 28.1 t-20 -45.61 -30.05 1.4 Allowed 'General case' 0 C--N 1.315 -0.902 0 CA-C-N 114.902 -1.045 . . . . 0.0 110.477 179.852 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 69.3 m -89.83 -23.83 21.59 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.623 179.282 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 32' ' ' SER . . . . . 0.513 ' HB2' ' H ' ' A' ' 29' ' ' LEU . 4.7 m -65.09 120.03 11.91 Favored 'General case' 0 N--CA 1.464 0.233 0 CA-C-O 121.204 0.525 . . . . 0.0 110.163 179.998 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 23.7 m -55.82 140.69 41.42 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.602 -0.727 . . . . 0.0 109.516 179.578 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 29.8 mm -94.7 99.01 8.73 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.343 0 CA-C-O 120.854 0.359 . . . . 0.0 111.367 -178.625 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.56 HD11 ' HA ' ' A' ' 81' ' ' ILE . 0.1 OUTLIER -140.11 155.78 24.28 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.21 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.152 179.466 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -74.55 97.74 1.0 Allowed Glycine 0 CA--C 1.524 0.609 0 N-CA-C 110.793 -0.923 . . . . 0.0 110.793 179.877 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 37' ' ' TYR . . . . . 0.521 ' OH ' ' CH2' ' A' ' 26' ' ' TRP . 2.0 p90 -78.79 126.99 31.45 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 110.01 -0.367 . . . . 0.0 110.01 179.787 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 5.4 tmm_? -78.01 132.39 37.78 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 120.975 0.417 . . . . 0.0 111.092 -179.69 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.458 ' O ' ' CG1' ' A' ' 39' ' ' ILE . 1.9 pt -98.46 121.27 48.83 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.217 0 N-CA-C 109.155 -0.683 . . . . 0.0 109.155 179.146 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 13.6 m -99.66 135.81 40.52 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 120.852 0.358 . . . . 0.0 110.948 -179.04 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.3 p -133.15 139.88 48.38 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.364 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.031 179.531 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 42' ' ' VAL . . . . . 0.511 ' O ' ' N ' ' A' ' 74' ' ' ASP . 38.7 t -131.68 131.66 62.27 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.252 0 N-CA-C 109.969 -0.382 . . . . 0.0 109.969 179.616 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -97.91 133.51 42.31 Favored 'General case' 0 C--N 1.326 -0.414 0 N-CA-C 109.448 -0.575 . . . . 0.0 109.448 179.148 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 44' ' ' ALA . . . . . 0.627 ' HB3' ' O ' ' A' ' 72' ' ' ASP . . . -94.01 -14.14 26.2 Favored 'General case' 0 C--N 1.329 -0.309 0 C-N-CA 120.956 -0.298 . . . . 0.0 111.005 -179.57 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -99.38 21.81 43.67 Favored Glycine 0 N--CA 1.465 0.609 0 N-CA-C 111.293 -0.723 . . . . 0.0 111.293 -179.518 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -143.74 150.25 38.34 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 121.163 0.506 . . . . 0.0 110.316 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -68.4 -19.35 72.49 Favored Glycine 0 CA--C 1.524 0.647 0 N-CA-C 110.822 -0.911 . . . . 0.0 110.822 179.976 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -134.06 139.73 34.08 Favored Pre-proline 0 CA--C 1.542 0.642 0 O-C-N 122.828 -0.219 . . . . 0.0 110.658 179.943 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_endo -73.79 164.47 34.61 Favored 'Trans proline' 0 N--CA 1.491 1.363 0 C-N-CA 122.613 2.209 . . . . 0.0 111.902 178.102 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 50' ' ' ILE . . . . . 0.434 HG22 ' N ' ' A' ' 51' ' ' PHE . 96.6 mt -79.16 155.01 4.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.608 179.603 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 51' ' ' PHE . . . . . 0.434 ' N ' HG22 ' A' ' 50' ' ' ILE . 98.3 m-85 -71.59 141.64 50.01 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.42 179.986 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 52' ' ' GLU . . . . . 0.529 ' CD ' ' H ' ' A' ' 52' ' ' GLU . 0.4 OUTLIER -77.21 144.09 38.54 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.729 179.603 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -104.05 148.57 26.08 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.521 179.7 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 54' ' ' PHE . . . . . 0.465 ' CD1' ' N ' ' A' ' 54' ' ' PHE . 15.9 m-85 -115.48 120.25 38.9 Favored 'General case' 0 N--CA 1.462 0.144 0 CA-C-N 115.758 -0.655 . . . . 0.0 110.038 179.664 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 8.3 p -130.41 144.05 39.13 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.307 0 CA-C-O 120.64 0.257 . . . . 0.0 110.381 -179.957 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 98.7 m-20 -66.27 146.75 54.25 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.591 179.51 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -65.92 -31.89 73.08 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.602 179.841 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 42.9 m -53.84 -36.19 62.3 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.619 -179.579 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 86.9 t -59.27 -43.66 90.38 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 116.438 -0.346 . . . . 0.0 110.41 -179.558 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 64.93 23.94 69.73 Favored Glycine 0 CA--C 1.526 0.721 0 N-CA-C 110.403 -1.079 . . . . 0.0 110.403 179.65 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 61' ' ' TYR . . . . . 0.416 ' CG ' ' N ' ' A' ' 62' ' ' TYR . 38.0 t80 -170.42 153.81 4.47 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 121.018 0.437 . . . . 0.0 111.495 -179.549 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 62' ' ' TYR . . . . . 0.417 ' CD2' ' CD1' ' A' ' 39' ' ' ILE . 19.1 t80 -158.73 160.96 36.96 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.337 178.582 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 85.5 m -126.26 134.35 51.2 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.068 -0.514 . . . . 0.0 110.271 179.881 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -133.05 100.64 3.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.033 -0.53 . . . . 0.0 109.684 178.972 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.527 HG22 ' HB2' ' A' ' 21' ' ' SER . 1.4 p -114.68 164.21 14.37 Favored 'General case' 0 CA--C 1.513 -0.478 0 CA-C-O 120.969 0.414 . . . . 0.0 110.507 -179.89 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 107.34 23.75 6.81 Favored Glycine 0 CA--C 1.519 0.319 0 N-CA-C 111.162 -0.775 . . . . 0.0 111.162 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.441 ' O ' ' CB ' ' A' ' 20' ' ' SER . 10.0 mt -97.22 106.38 18.7 Favored 'General case' 0 N--CA 1.464 0.226 0 N-CA-C 109.532 -0.544 . . . . 0.0 109.532 179.804 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 5.2 mm-40 -46.63 137.34 7.27 Favored Pre-proline 0 C--N 1.316 -0.854 0 CA-C-N 116.101 -0.5 . . . . 0.0 111.827 -178.421 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -73.98 156.67 47.59 Favored 'Trans proline' 0 N--CA 1.497 1.705 0 C-N-CA 122.674 2.249 . . . . 0.0 111.255 178.665 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 71.69 -5.68 10.99 Favored Glycine 0 CA--C 1.527 0.789 0 C-N-CA 120.947 -0.645 . . . . 0.0 111.685 179.307 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 71' ' ' ILE . . . . . 0.473 ' O ' ' NH1' ' B' ' 223' ' ' ARG . 1.7 mp -103.61 144.32 14.27 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.437 0 CA-C-O 121.26 0.552 . . . . 0.0 109.611 -179.807 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 72' ' ' ASP . . . . . 0.627 ' O ' ' HB3' ' A' ' 44' ' ' ALA . 2.3 t70 -84.39 119.19 24.82 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.14 -0.936 . . . . 0.0 110.469 179.291 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 73' ' ' TYR . . . . . 0.479 ' O ' HD13 ' A' ' 75' ' ' ILE . 19.0 m-85 -110.14 120.22 41.76 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.75 -179.999 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 74' ' ' ASP . . . . . 0.511 ' N ' ' O ' ' A' ' 42' ' ' VAL . 14.8 m-20 -90.17 117.1 28.67 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 115.619 -0.719 . . . . 0.0 109.788 179.639 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 75' ' ' ILE . . . . . 0.484 ' N ' HD13 ' A' ' 75' ' ' ILE . 0.0 OUTLIER -114.05 165.2 9.34 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-O 121.147 0.498 . . . . 0.0 110.059 -179.29 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 1.3 p -154.59 121.36 5.49 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.721 -0.672 . . . . 0.0 110.525 179.681 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.443 ' O ' HG23 ' B' ' 217' ' ' THR . 14.2 t -96.5 99.66 9.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 179.057 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 95.4 mt -88.35 115.62 28.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.115 179.634 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 79' ' ' THR . . . . . 0.456 ' OG1' ' O ' ' B' ' 216' ' ' TRP . 43.4 p -99.21 117.39 33.57 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.249 179.95 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 20.1 mt -121.4 110.32 15.94 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.864 179.904 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 81' ' ' ILE . . . . . 0.594 ' C ' HD12 ' A' ' 81' ' ' ILE . 1.2 pp -142.24 138.15 29.8 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.088 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.383 179.211 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 59.7 t-20 . . . . . 0 C--N 1.33 -0.28 0 CA-C-N 115.955 -0.566 . . . . 0.0 111.244 -179.249 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' B' B ' 207' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.465 0.598 0 N-CA-C 111.142 -0.783 . . . . 0.0 111.142 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' B' B ' 208' ' ' SER . . . . . 0.538 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 30.7 p -166.47 170.04 13.27 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 120.829 0.347 . . . . 0.0 110.831 179.626 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 209' ' ' TRP . . . . . . . . . . . . . 86.1 m95 -86.29 149.32 25.14 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.373 179.637 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 59.1 p -129.06 128.78 44.26 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.345 179.247 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 54.1 t-105 -91.61 111.55 23.11 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.215 -179.977 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 212' ' ' GLU . . . . . 0.424 ' O ' ' O ' ' B' ' 215' ' ' LYS . 1.7 pt-20 -161.78 167.02 25.65 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.543 179.322 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 213' ' ' ASN . . . . . . . . . . . . . 93.7 m-20 49.79 35.05 8.38 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.929 -0.578 . . . . 0.0 111.159 176.722 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 51.46 17.93 3.29 Favored Glycine 0 CA--C 1.527 0.843 0 N-CA-C 111.37 -0.692 . . . . 0.0 111.37 179.934 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 215' ' ' LYS . . . . . 0.424 ' O ' ' O ' ' B' ' 212' ' ' GLU . 54.1 mtmt -142.58 149.45 39.03 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 120.851 0.357 . . . . 0.0 110.963 179.662 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 216' ' ' TRP . . . . . 0.456 ' O ' ' OG1' ' A' ' 79' ' ' THR . 59.8 m95 -88.83 116.4 27.08 Favored 'General case' 0 C--N 1.331 -0.23 0 N-CA-C 109.444 -0.576 . . . . 0.0 109.444 179.249 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 217' ' ' THR . . . . . 0.443 HG23 ' O ' ' A' ' 77' ' ' VAL . 17.8 m -124.81 140.34 53.02 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-O 120.976 0.417 . . . . 0.0 110.804 -179.265 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 218' ' ' TRP . . . . . 0.538 ' CH2' ' N ' ' B' ' 208' ' ' SER . 30.6 t-105 -102.8 105.35 15.75 Favored 'General case' 0 C--N 1.333 -0.121 0 CA-C-N 115.74 -0.664 . . . . 0.0 109.473 179.229 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 75.8 mttt -131.11 167.06 19.75 Favored 'General case' 0 N--CA 1.467 0.418 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.753 -179.375 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -178.24 -162.76 28.58 Favored Glycine 0 CA--C 1.523 0.588 0 N-CA-C 111.018 -0.833 . . . . 0.0 111.018 179.447 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 221' ' ' ILE . . . . . 0.555 ' O ' HG23 ' B' ' 222' ' ' ILE . 2.1 mp -55.24 -73.87 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 C-N-CA 120.66 -0.416 . . . . 0.0 110.694 -178.565 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 222' ' ' ILE . . . . . 0.555 HG23 ' O ' ' B' ' 221' ' ' ILE . 23.1 pt -160.61 -164.64 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.268 -179.599 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 223' ' ' ARG . . . . . 0.487 ' O ' ' O ' ' B' ' 222' ' ' ILE . 35.5 ptt-85 -41.73 173.1 0.0 OUTLIER 'General case' 0 CA--C 1.529 0.168 0 CA-C-O 121.352 0.596 . . . . 0.0 110.554 178.54 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 224' ' ' LEU . . . . . 0.988 ' H ' HD22 ' B' ' 224' ' ' LEU . 1.4 mm? -64.83 110.42 2.41 Favored 'General case' 0 C--N 1.313 -0.982 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.826 -179.597 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 83.5 tt0 . . . . . 0 C--N 1.33 -0.271 0 CA-C-N 115.252 -0.886 . . . . 0.0 110.365 179.849 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 11' ' ' ASP . . . . . 0.428 ' OD1' ' O ' ' A' ' 11' ' ' ASP . 53.9 p-10 . . . . . 0 N--CA 1.464 0.244 0 CA-C-O 121.148 0.499 . . . . 0.0 110.522 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.433 ' H ' ' HE1' ' B' ' 209' ' ' TRP . 4.9 tt -66.47 144.43 56.5 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.592 179.922 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 13' ' ' SER . . . . . 0.499 ' O ' ' O ' ' A' ' 25' ' ' ARG . 85.5 p -141.44 156.07 45.81 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.98 0.419 . . . . 0.0 110.749 179.67 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 14' ' ' PHE . . . . . 0.532 ' CD1' ' N ' ' A' ' 14' ' ' PHE . 1.9 m-85 -112.64 153.31 27.83 Favored 'General case' 0 N--CA 1.464 0.263 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.337 -179.813 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 10.5 m -147.7 151.5 13.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.345 179.669 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 26.8 t0 62.89 37.07 12.36 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.622 -179.946 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 43.7 mt -56.94 133.45 21.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.055 179.698 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -136.54 -171.09 2.82 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.242 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 19' ' ' ASP . . . . . 0.47 ' N ' ' OD1' ' A' ' 19' ' ' ASP . 20.5 p-10 -75.85 -49.72 17.17 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.91 179.743 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 20' ' ' SER . . . . . 0.47 ' OG ' ' O ' ' A' ' 67' ' ' LEU . 51.0 m -122.36 17.11 10.59 Favored 'General case' 0 N--CA 1.465 0.324 0 CA-C-N 116.437 -0.347 . . . . 0.0 110.805 -179.698 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 1.5 m -145.62 129.83 17.6 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.706 0.289 . . . . 0.0 110.265 -179.425 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 22' ' ' ILE . . . . . 0.678 HD12 HD21 ' A' ' 24' ' ' LEU . 36.5 pt -132.42 142.78 41.74 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 N-CA-C 109.599 -0.519 . . . . 0.0 109.599 179.67 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -101.48 85.9 0.58 Allowed Glycine 0 CA--C 1.523 0.541 0 N-CA-C 111.055 -0.818 . . . . 0.0 111.055 -179.413 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.678 HD21 HD12 ' A' ' 22' ' ' ILE . 55.4 mt -69.82 118.48 12.73 Favored 'General case' 0 C--N 1.33 -0.255 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 179.996 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 25' ' ' ARG . . . . . 0.585 ' HE ' ' CB ' ' A' ' 61' ' ' TYR . 31.5 ttm180 -142.99 132.5 23.6 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 121.004 0.431 . . . . 0.0 111.188 179.973 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 26' ' ' TRP . . . . . 0.468 ' CD1' ' O ' ' A' ' 26' ' ' TRP . 35.3 p90 -147.6 133.88 19.52 Favored 'General case' 0 C--N 1.326 -0.444 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 179.643 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 1.9 m -68.36 115.99 35.22 Favored Pre-proline 0 C--N 1.326 -0.43 0 C-N-CA 120.218 -0.593 . . . . 0.0 111.292 -178.97 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_exo -53.49 154.55 15.1 Favored 'Trans proline' 0 N--CA 1.492 1.431 0 C-N-CA 122.171 1.914 . . . . 0.0 112.709 178.258 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.464 ' O ' ' N ' ' A' ' 32' ' ' SER . 75.4 mt -93.66 132.03 38.4 Favored 'General case' 0 N--CA 1.467 0.404 0 CA-C-O 122.006 0.907 . . . . 0.0 110.89 179.926 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 40.4 t30 -43.13 -32.26 0.69 Allowed 'General case' 0 C--N 1.316 -0.863 0 CA-C-N 115.336 -0.847 . . . . 0.0 110.502 179.984 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 20.8 m -86.96 -30.44 21.29 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.692 179.365 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 32' ' ' SER . . . . . 0.464 ' N ' ' O ' ' A' ' 29' ' ' LEU . 2.1 m -50.26 111.32 0.51 Allowed 'General case' 0 CA--C 1.529 0.166 0 CA-C-O 121.11 0.481 . . . . 0.0 110.524 -179.783 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 33' ' ' THR . . . . . 0.449 ' CB ' ' H ' ' A' ' 82' ' ' ASN . 8.1 m -51.12 148.7 4.27 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.554 -0.748 . . . . 0.0 109.348 -179.646 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 5.3 mm -92.88 91.36 3.33 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.277 0 CA-C-O 121.391 0.615 . . . . 0.0 111.168 -178.825 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.541 HD11 ' HA ' ' A' ' 81' ' ' ILE . 12.0 pt -147.96 126.15 3.5 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 115.24 -0.891 . . . . 0.0 110.565 179.554 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -46.89 126.41 10.03 Favored Glycine 0 CA--C 1.521 0.465 0 N-CA-C 110.847 -0.901 . . . . 0.0 110.847 -179.718 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 37' ' ' TYR . . . . . 0.482 ' CE1' ' CG1' ' A' ' 55' ' ' VAL . 28.3 p90 -95.8 175.24 6.59 Favored 'General case' 0 C--N 1.329 -0.307 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 179.851 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 9.0 tmm_? -126.36 123.0 36.99 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.718 -179.843 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.471 ' O ' ' CG1' ' A' ' 39' ' ' ILE . 1.9 pt -94.14 120.22 43.21 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 N-CA-C 109.602 -0.518 . . . . 0.0 109.602 -179.856 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 10.1 m -96.14 128.48 43.08 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.15 -179.289 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.0 p -123.06 134.12 67.09 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 CA-C-N 116.077 -0.511 . . . . 0.0 109.873 -179.981 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 42' ' ' VAL . . . . . 0.407 ' O ' ' N ' ' A' ' 74' ' ' ASP . 24.5 t -129.35 128.45 66.42 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.173 0 CA-C-O 120.831 0.348 . . . . 0.0 110.132 179.846 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.511 ' HB2' ' CE2' ' A' ' 73' ' ' TYR . . . -97.36 128.99 44.66 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 109.054 -0.721 . . . . 0.0 109.054 179.372 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 44' ' ' ALA . . . . . 0.606 ' HB3' ' O ' ' A' ' 72' ' ' ASP . . . -88.12 -24.27 23.43 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 120.869 0.366 . . . . 0.0 110.981 -179.624 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -86.43 20.59 21.66 Favored Glycine 0 N--CA 1.462 0.375 0 N-CA-C 111.202 -0.759 . . . . 0.0 111.202 -179.696 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 79.8 mm-40 -144.75 150.12 36.69 Favored 'General case' 0 C--O 1.233 0.224 0 CA-C-O 121.041 0.448 . . . . 0.0 110.324 -179.702 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -69.32 -20.33 75.09 Favored Glycine 0 N--CA 1.452 -0.269 0 N-CA-C 110.645 -0.982 . . . . 0.0 110.645 -179.852 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -131.42 139.01 34.05 Favored Pre-proline 0 N--CA 1.469 0.495 0 C-N-CA 120.952 -0.299 . . . . 0.0 110.528 179.673 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 68.6 Cg_endo -75.27 165.06 31.69 Favored 'Trans proline' 0 C--N 1.31 -1.458 0 C-N-CA 122.734 2.289 . . . . 0.0 112.027 177.676 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 50' ' ' ILE . . . . . 0.527 HG22 ' N ' ' A' ' 51' ' ' PHE . 96.6 mt -79.6 160.42 4.29 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-N 115.782 -0.644 . . . . 0.0 110.229 179.55 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 51' ' ' PHE . . . . . 0.527 ' N ' HG22 ' A' ' 50' ' ' ILE . 92.5 m-85 -74.36 142.33 45.09 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.734 179.918 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 52' ' ' GLU . . . . . 0.532 ' CD ' ' H ' ' A' ' 52' ' ' GLU . 0.2 OUTLIER -77.58 142.07 39.17 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.15 179.561 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 53' ' ' ASP . . . . . 0.42 ' CG ' ' OH ' ' A' ' 62' ' ' TYR . 0.5 OUTLIER -100.57 151.55 21.47 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 120.993 0.425 . . . . 0.0 110.051 -179.827 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 90.0 m-85 -115.09 122.06 44.98 Favored 'General case' 0 C--O 1.232 0.17 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.352 179.738 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.482 ' CG1' ' CE1' ' A' ' 37' ' ' TYR . 9.5 p -131.96 142.22 43.49 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.295 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.393 -179.974 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 99.3 m-20 -63.66 150.0 45.28 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.793 -0.64 . . . . 0.0 110.37 179.69 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 57' ' ' SER . . . . . 0.487 ' OG ' ' O ' ' A' ' 35' ' ' ILE . 4.7 m -64.71 -34.84 79.27 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.875 179.909 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 68.0 m -51.17 -36.54 41.59 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.303 -179.026 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.48 ' C ' ' H ' ' A' ' 61' ' ' TYR . 22.7 t -64.38 -42.39 95.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.092 179.884 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 72.01 -40.05 0.69 Allowed Glycine 0 CA--C 1.531 1.069 0 N-CA-C 111.048 -0.821 . . . . 0.0 111.048 179.766 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 61' ' ' TYR . . . . . 0.585 ' CB ' ' HE ' ' A' ' 25' ' ' ARG . 31.1 p90 -110.68 161.01 16.17 Favored 'General case' 0 N--CA 1.466 0.368 0 CA-C-O 121.093 0.473 . . . . 0.0 111.08 -179.035 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 62' ' ' TYR . . . . . 0.42 ' OH ' ' CG ' ' A' ' 53' ' ' ASP . 31.5 t80 -155.95 163.04 40.24 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.015 -0.539 . . . . 0.0 109.949 179.492 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 57.6 m -119.6 131.47 55.5 Favored 'General case' 0 N--CA 1.467 0.422 0 CA-C-O 121.025 0.44 . . . . 0.0 110.628 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -134.27 108.91 11.76 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 115.765 -0.652 . . . . 0.0 109.981 179.324 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 1.2 p -128.35 167.37 17.06 Favored 'General case' 0 CA--C 1.514 -0.441 0 CA-C-O 121.023 0.44 . . . . 0.0 110.47 179.939 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 108.33 24.34 6.25 Favored Glycine 0 CA--C 1.522 0.496 0 CA-C-N 115.614 -0.721 . . . . 0.0 111.502 -179.793 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.47 ' O ' ' OG ' ' A' ' 20' ' ' SER . 3.9 mt -99.61 106.42 18.38 Favored 'General case' 0 CA--C 1.517 -0.29 0 N-CA-C 109.197 -0.668 . . . . 0.0 109.197 -179.401 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 68' ' ' GLU . . . . . 0.423 ' HG2' ' H ' ' A' ' 68' ' ' GLU . 0.0 OUTLIER -48.19 140.08 9.65 Favored Pre-proline 0 C--N 1.311 -1.097 0 CA-C-N 115.669 -0.696 . . . . 0.0 111.112 -178.247 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 68.5 Cg_endo -73.38 156.29 50.48 Favored 'Trans proline' 0 N--CA 1.5 1.896 0 C-N-CA 122.993 2.462 . . . . 0.0 111.596 178.344 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 74.61 -2.09 49.25 Favored Glycine 0 CA--C 1.525 0.718 0 CA-C-N 115.563 -0.744 . . . . 0.0 111.698 179.259 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 1.6 mp -110.46 140.5 29.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-O 121.557 0.694 . . . . 0.0 109.582 -179.283 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 72' ' ' ASP . . . . . 0.606 ' O ' ' HB3' ' A' ' 44' ' ' ALA . 1.6 t70 -80.54 122.78 27.46 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 114.877 -1.056 . . . . 0.0 110.297 179.649 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 73' ' ' TYR . . . . . 0.522 ' O ' HD13 ' A' ' 75' ' ' ILE . 12.5 m-85 -114.94 122.65 46.91 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.686 -0.688 . . . . 0.0 110.809 179.785 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 74' ' ' ASP . . . . . 0.407 ' N ' ' O ' ' A' ' 42' ' ' VAL . 66.3 m-20 -94.32 110.78 22.52 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 108.597 -0.89 . . . . 0.0 108.597 178.692 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 75' ' ' ILE . . . . . 0.522 HD13 ' O ' ' A' ' 73' ' ' TYR . 0.0 OUTLIER -126.39 111.95 28.11 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.249 0 CA-C-N 116.654 -0.248 . . . . 0.0 111.27 179.954 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 23.8 t -105.43 125.66 51.24 Favored 'General case' 0 CA--C 1.518 -0.253 0 N-CA-C 109.576 -0.527 . . . . 0.0 109.576 179.247 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 84.4 t -88.71 99.52 9.24 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-O 120.939 0.4 . . . . 0.0 110.06 179.747 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 94.4 mt -82.52 135.99 23.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.356 179.914 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 30.5 p -113.26 117.71 32.62 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.231 179.623 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 1.8 mp -109.77 110.78 21.89 Favored 'General case' 0 N--CA 1.467 0.386 0 CA-C-O 121.194 0.521 . . . . 0.0 110.648 -179.822 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 81' ' ' ILE . . . . . 0.541 ' HA ' HD11 ' A' ' 35' ' ' ILE . 2.0 pp -146.55 143.69 20.62 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.213 179.274 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 82' ' ' ASN . . . . . 0.449 ' H ' ' CB ' ' A' ' 33' ' ' THR . 22.5 t-20 . . . . . 0 C--N 1.328 -0.333 0 CA-C-O 120.876 0.369 . . . . 0.0 111.213 179.821 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 207' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.466 0.672 0 N-CA-C 111.054 -0.818 . . . . 0.0 111.054 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' B' B ' 208' ' ' SER . . . . . 0.589 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 97.6 p -167.07 170.88 11.53 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.805 0.336 . . . . 0.0 110.622 179.748 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 209' ' ' TRP . . . . . 0.433 ' HE1' ' H ' ' A' ' 12' ' ' LEU . 79.5 m95 -86.99 155.86 20.0 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.45 179.67 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 31.6 p -133.47 133.52 42.37 Favored 'General case' 0 N--CA 1.463 0.217 0 CA-C-N 116.434 -0.348 . . . . 0.0 110.414 179.745 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 58.0 t-105 -95.78 113.85 25.52 Favored 'General case' 0 N--CA 1.463 0.214 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.627 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 212' ' ' GLU . . . . . 0.43 ' O ' ' O ' ' B' ' 215' ' ' LYS . 0.9 OUTLIER -162.29 163.1 28.26 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.5 179.591 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' B' B ' 213' ' ' ASN . . . . . . . . . . . . . 17.8 m120 51.31 34.14 11.12 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.067 177.346 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 55.21 18.17 12.73 Favored Glycine 0 CA--C 1.527 0.808 0 N-CA-C 111.298 -0.721 . . . . 0.0 111.298 179.831 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 215' ' ' LYS . . . . . 0.43 ' O ' ' O ' ' B' ' 212' ' ' GLU . 56.1 mtmt -143.3 149.76 38.27 Favored 'General case' 0 C--O 1.232 0.165 0 CA-C-O 120.834 0.349 . . . . 0.0 110.95 179.895 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 216' ' ' TRP . . . . . . . . . . . . . 48.9 m95 -87.67 113.71 23.6 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.179 -0.464 . . . . 0.0 109.764 179.507 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 217' ' ' THR . . . . . . . . . . . . . 16.3 m -119.82 134.93 55.06 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.519 -179.339 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 218' ' ' TRP . . . . . 0.589 ' CH2' ' N ' ' B' ' 208' ' ' SER . 29.1 t-105 -95.88 105.0 16.96 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.875 -0.602 . . . . 0.0 109.907 179.27 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 6.9 mtmt -130.5 167.8 18.07 Favored 'General case' 0 CA--C 1.515 -0.398 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.778 -179.357 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -178.45 -163.35 29.68 Favored Glycine 0 CA--C 1.524 0.625 0 N-CA-C 111.138 -0.785 . . . . 0.0 111.138 179.41 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 221' ' ' ILE . . . . . 0.575 ' O ' HG23 ' B' ' 222' ' ' ILE . 20.1 mt -55.86 -73.24 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 C-N-CA 120.645 -0.422 . . . . 0.0 110.263 -178.146 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 222' ' ' ILE . . . . . 0.575 HG23 ' O ' ' B' ' 221' ' ' ILE . 18.9 pt -160.53 -166.8 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 O-C-N 123.402 0.439 . . . . 0.0 110.462 179.994 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 223' ' ' ARG . . . . . 0.479 ' O ' ' O ' ' B' ' 222' ' ' ILE . 33.4 ptt180 -43.3 172.71 0.0 OUTLIER 'General case' 0 C--O 1.231 0.098 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.497 179.082 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 224' ' ' LEU . . . . . 0.79 HD22 ' N ' ' B' ' 224' ' ' LEU . 2.2 mm? -65.5 107.2 1.61 Allowed 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 121.48 0.657 . . . . 0.0 110.322 -178.766 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 82.0 tt0 . . . . . 0 N--CA 1.452 -0.336 0 CA-C-N 115.084 -0.962 . . . . 0.0 110.01 179.919 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 11' ' ' ASP . . . . . 0.424 ' OD1' ' O ' ' A' ' 11' ' ' ASP . 51.2 p-10 . . . . . 0 CA--C 1.518 -0.26 0 CA-C-O 120.996 0.426 . . . . 0.0 110.561 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 6.9 tt -63.86 142.56 58.36 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.135 -179.542 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 83.9 p -139.4 155.47 47.61 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.665 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 14' ' ' PHE . . . . . 0.52 ' CD2' HD11 ' B' ' 224' ' ' LEU . 20.9 m-85 -110.79 144.66 39.43 Favored 'General case' 0 C--O 1.233 0.204 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.498 -179.691 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 15.5 m -145.49 162.28 12.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.598 -179.973 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 98.4 m-20 51.6 32.65 9.4 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.524 179.621 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 86.5 mt -58.84 140.29 17.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.267 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.438 ' CB ' ' O ' ' A' ' 21' ' ' SER . 0.2 OUTLIER -143.25 -166.3 2.28 Favored 'General case' 0 N--CA 1.465 0.305 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.601 -179.653 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 19' ' ' ASP . . . . . 0.441 ' OD1' ' N ' ' A' ' 20' ' ' SER . 28.7 p-10 -90.73 -45.25 8.96 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.693 -0.685 . . . . 0.0 110.875 179.546 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 20' ' ' SER . . . . . 0.441 ' N ' ' OD1' ' A' ' 19' ' ' ASP . 10.2 t -114.39 7.17 16.25 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-O 120.821 0.343 . . . . 0.0 110.92 -179.513 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 21' ' ' SER . . . . . 0.438 ' O ' ' CB ' ' A' ' 18' ' ' THR . 45.2 m -151.62 146.52 25.88 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.976 0.417 . . . . 0.0 110.439 179.898 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 22' ' ' ILE . . . . . 0.459 HD12 HD21 ' A' ' 24' ' ' LEU . 40.8 pt -144.98 147.88 18.45 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-N 116.469 -0.332 . . . . 0.0 110.291 179.847 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -101.41 84.04 0.51 Allowed Glycine 0 CA--C 1.525 0.675 0 N-CA-C 111.038 -0.825 . . . . 0.0 111.038 -179.678 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.459 HD21 HD12 ' A' ' 22' ' ' ILE . 83.7 mt -71.39 124.6 24.96 Favored 'General case' 0 C--N 1.33 -0.282 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 -179.752 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 73.8 ttt-85 -138.94 139.92 38.14 Favored 'General case' 0 CA--C 1.52 -0.177 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.464 -179.593 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 26' ' ' TRP . . . . . . . . . . . . . 49.0 p90 -146.48 154.77 41.96 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.073 179.745 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 2.9 m -109.97 103.31 53.21 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-N 116.466 -0.334 . . . . 0.0 110.583 179.888 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_exo -53.87 145.03 52.85 Favored 'Trans proline' 0 C--N 1.307 -1.642 0 C-N-CA 122.07 1.846 . . . . 0.0 112.591 179.172 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 64.6 mt -78.91 139.86 38.2 Favored 'General case' 0 CA--C 1.518 -0.252 0 CA-C-O 121.697 0.76 . . . . 0.0 110.789 -179.643 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 38.1 t30 -51.07 -37.1 43.59 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-N 115.131 -0.94 . . . . 0.0 109.916 179.656 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 15.5 m -75.75 -34.86 60.29 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.64 178.975 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 10.8 m -60.11 132.95 55.51 Favored 'General case' 0 C--O 1.232 0.158 0 CA-C-O 120.975 0.417 . . . . 0.0 110.179 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 33' ' ' THR . . . . . 0.503 ' H ' ' HB ' ' A' ' 81' ' ' ILE . 5.6 m -57.78 145.22 35.59 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.17 -179.886 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 26.8 mm -93.99 91.29 3.11 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 CA-C-O 121.012 0.434 . . . . 0.0 110.631 -179.513 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 21.6 pt -143.39 140.41 26.36 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.498 179.707 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -44.33 128.47 6.95 Favored Glycine 0 CA--C 1.521 0.463 0 N-CA-C 111.096 -0.801 . . . . 0.0 111.096 -179.781 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 75.0 m-85 -91.54 175.9 6.74 Favored 'General case' 0 CA--C 1.517 -0.302 0 CA-C-O 120.89 0.376 . . . . 0.0 110.187 179.849 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -137.26 125.49 23.15 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.588 -179.939 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.438 ' O ' ' CG1' ' A' ' 39' ' ' ILE . 2.3 pt -101.68 124.81 55.71 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.251 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.1 -179.97 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 8.4 m -104.07 133.49 48.93 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.384 -179.275 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.3 p -132.98 139.38 49.67 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.296 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.319 179.756 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 42' ' ' VAL . . . . . 0.543 ' N ' ' O ' ' A' ' 74' ' ' ASP . 39.5 t -133.9 132.88 56.58 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.175 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.245 179.74 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.426 ' HB2' ' CE1' ' A' ' 73' ' ' TYR . . . -97.04 141.72 29.85 Favored 'General case' 0 C--N 1.326 -0.414 0 N-CA-C 109.702 -0.481 . . . . 0.0 109.702 179.15 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 44' ' ' ALA . . . . . 0.501 ' HB3' ' O ' ' A' ' 72' ' ' ASP . . . -95.13 -40.43 9.61 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.821 0.344 . . . . 0.0 110.769 179.659 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -66.17 -32.64 82.87 Favored Glycine 0 CA--C 1.526 0.758 0 N-CA-C 111.295 -0.722 . . . . 0.0 111.295 -179.737 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 63.2 mt-10 -98.16 131.42 44.55 Favored 'General case' 0 C--N 1.333 -0.146 0 N-CA-C 109.598 -0.519 . . . . 0.0 109.598 -179.694 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -59.01 -21.64 53.33 Favored Glycine 0 N--CA 1.454 -0.117 0 N-CA-C 110.609 -0.997 . . . . 0.0 110.609 -179.079 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -111.72 134.46 21.29 Favored Pre-proline 0 CA--C 1.535 0.4 0 C-N-CA 121.133 -0.227 . . . . 0.0 110.474 179.556 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 63.9 Cg_endo -76.71 163.92 30.91 Favored 'Trans proline' 0 C--N 1.31 -1.47 0 C-N-CA 122.638 2.226 . . . . 0.0 111.884 177.751 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 96.6 mt -82.93 133.97 27.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 115.975 -0.557 . . . . 0.0 109.949 179.134 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 76.0 m-85 -56.15 136.54 52.6 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 121.054 0.454 . . . . 0.0 110.824 -179.355 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 4.7 pt-20 -68.79 -175.08 0.65 Allowed 'General case' 0 CA--C 1.516 -0.33 0 CA-C-N 115.706 -0.679 . . . . 0.0 110.372 179.461 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 53' ' ' ASP . . . . . 0.426 ' CG ' ' OH ' ' A' ' 62' ' ' TYR . 3.6 t70 -156.38 156.0 33.14 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.674 179.04 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 54' ' ' PHE . . . . . 0.578 ' CD1' ' N ' ' A' ' 54' ' ' PHE . 2.1 m-85 -122.12 130.85 53.6 Favored 'General case' 0 N--CA 1.465 0.324 0 CA-C-O 120.889 0.376 . . . . 0.0 110.114 179.729 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 9.7 p -130.01 138.19 54.63 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.186 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.418 -179.836 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 97.8 m-20 -53.66 144.33 18.02 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.457 -179.702 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 38.7 t -63.33 -35.81 81.61 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.703 179.994 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 36.6 m -57.11 -31.88 65.76 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.551 -179.717 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 94.0 t -64.96 -46.47 91.57 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.537 -179.913 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 56.19 25.89 48.52 Favored Glycine 0 CA--C 1.525 0.713 0 N-CA-C 110.7 -0.96 . . . . 0.0 110.7 -179.899 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 61' ' ' TYR . . . . . 0.493 ' CD1' ' C ' ' A' ' 61' ' ' TYR . 7.7 t80 -159.52 146.79 16.9 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-O 121.208 0.528 . . . . 0.0 111.035 -179.201 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 62' ' ' TYR . . . . . 0.435 ' CD2' ' CD1' ' A' ' 39' ' ' ILE . 33.9 t80 -159.99 161.79 34.18 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.152 178.611 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 96.5 m -131.15 139.17 49.74 Favored 'General case' 0 N--CA 1.464 0.244 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.689 179.995 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -131.14 104.63 9.5 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.263 0 CA-C-N 116.188 -0.46 . . . . 0.0 109.982 179.061 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 4.6 p -109.05 155.45 20.92 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.342 179.78 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 108.32 44.38 1.17 Allowed Glycine 0 CA--C 1.525 0.682 0 N-CA-C 111.184 -0.766 . . . . 0.0 111.184 -179.705 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 19.9 mt -116.45 103.57 10.58 Favored 'General case' 0 CA--C 1.519 -0.222 0 CA-C-O 121.194 0.521 . . . . 0.0 109.827 179.679 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 55.4 mm-40 -51.24 138.19 27.68 Favored Pre-proline 0 C--N 1.317 -0.806 0 CA-C-N 115.783 -0.644 . . . . 0.0 111.44 -178.433 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 69' ' ' PRO . . . . . 0.41 ' O ' HD12 ' A' ' 71' ' ' ILE . 72.1 Cg_endo -75.35 150.54 36.82 Favored 'Trans proline' 0 N--CA 1.496 1.665 0 C-N-CA 122.725 2.284 . . . . 0.0 111.635 178.687 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 70.69 17.32 74.86 Favored Glycine 0 CA--C 1.527 0.803 0 CA-C-N 115.55 -0.75 . . . . 0.0 111.361 179.14 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 71' ' ' ILE . . . . . 0.41 HD12 ' O ' ' A' ' 69' ' ' PRO . 1.5 mp -119.66 149.62 22.27 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.337 0 CA-C-O 121.413 0.625 . . . . 0.0 109.36 -179.503 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 72' ' ' ASP . . . . . 0.501 ' O ' ' HB3' ' A' ' 44' ' ' ALA . 2.4 t70 -89.39 108.97 19.94 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.15 -0.932 . . . . 0.0 110.652 -179.902 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 73' ' ' TYR . . . . . 0.554 ' O ' HD13 ' A' ' 75' ' ' ILE . 22.4 m-85 -104.3 119.53 39.17 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.348 179.772 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 74' ' ' ASP . . . . . 0.543 ' O ' ' N ' ' A' ' 42' ' ' VAL . 8.5 m-20 -88.2 118.43 27.78 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.531 -0.758 . . . . 0.0 109.247 179.466 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 75' ' ' ILE . . . . . 0.624 HD11 ' N ' ' B' ' 223' ' ' ARG . 0.0 OUTLIER -120.02 167.22 13.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-O 121.098 0.475 . . . . 0.0 110.272 -179.124 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 1.8 m -154.92 126.92 7.64 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.622 -0.717 . . . . 0.0 110.591 179.248 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.486 ' O ' HG23 ' B' ' 217' ' ' THR . 21.7 t -106.02 100.26 10.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 179.178 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 78' ' ' ILE . . . . . 0.427 HG22 ' CD2' ' A' ' 80' ' ' LEU . 23.8 mt -101.9 140.9 19.27 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.225 0 CA-C-N 116.052 -0.522 . . . . 0.0 109.909 -179.651 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 79' ' ' THR . . . . . 0.48 ' C ' HD22 ' A' ' 80' ' ' LEU . 19.5 m -120.05 113.59 20.73 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.571 -179.767 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 80' ' ' LEU . . . . . 0.48 HD22 ' C ' ' A' ' 79' ' ' THR . 4.4 mm? -106.68 127.93 53.77 Favored 'General case' 0 N--CA 1.463 0.22 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.434 179.796 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 81' ' ' ILE . . . . . 0.503 ' HB ' ' H ' ' A' ' 33' ' ' THR . 1.9 pp -141.38 145.01 25.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 115.632 -0.713 . . . . 0.0 110.219 179.565 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 82' ' ' ASN . . . . . 0.409 ' H ' ' CB ' ' A' ' 33' ' ' THR . 37.6 t30 . . . . . 0 C--N 1.329 -0.286 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.707 -179.73 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 207' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.464 0.555 0 N-CA-C 111.088 -0.805 . . . . 0.0 111.088 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' B' B ' 208' ' ' SER . . . . . 0.432 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 92.3 p -165.37 171.57 13.28 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.866 0.365 . . . . 0.0 110.746 -179.922 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 209' ' ' TRP . . . . . . . . . . . . . 80.0 m95 -81.43 146.18 30.39 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.456 179.784 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 65.2 p -128.76 132.42 47.92 Favored 'General case' 0 N--CA 1.464 0.255 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.616 -179.951 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 50.3 t-105 -91.94 116.54 29.01 Favored 'General case' 0 C--O 1.232 0.15 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.241 179.649 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 212' ' ' GLU . . . . . 0.489 ' O ' ' O ' ' B' ' 215' ' ' LYS . 1.7 pt-20 -165.46 168.19 16.85 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.972 179.261 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 213' ' ' ASN . . . . . . . . . . . . . 91.8 m-20 49.51 36.73 10.72 Favored 'General case' 0 C--N 1.322 -0.602 0 C-N-CA 120.525 -0.47 . . . . 0.0 111.217 176.634 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 50.86 16.32 1.71 Allowed Glycine 0 CA--C 1.525 0.671 0 N-CA-C 111.266 -0.734 . . . . 0.0 111.266 179.658 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 215' ' ' LYS . . . . . 0.489 ' O ' ' O ' ' B' ' 212' ' ' GLU . 50.3 mtmt -145.66 151.45 38.07 Favored 'General case' 0 C--N 1.333 -0.142 0 CA-C-O 120.942 0.401 . . . . 0.0 110.81 179.704 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 216' ' ' TRP . . . . . . . . . . . . . 53.8 m95 -87.79 123.3 32.43 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.044 179.58 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 217' ' ' THR . . . . . 0.486 HG23 ' O ' ' A' ' 77' ' ' VAL . 12.9 m -133.7 145.21 49.69 Favored 'General case' 0 N--CA 1.464 0.269 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.502 -179.607 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 218' ' ' TRP . . . . . 0.432 ' CH2' ' N ' ' B' ' 208' ' ' SER . 14.4 t-105 -106.08 119.58 39.58 Favored 'General case' 0 N--CA 1.463 0.175 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.018 179.188 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 47.3 mtpt -141.26 169.79 16.95 Favored 'General case' 0 CA--C 1.52 -0.198 0 CA-C-O 120.92 0.39 . . . . 0.0 110.464 -179.49 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -176.04 -161.38 25.12 Favored Glycine 0 CA--C 1.526 0.732 0 N-CA-C 111.279 -0.729 . . . . 0.0 111.279 -179.883 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 221' ' ' ILE . . . . . 0.58 ' H ' HD12 ' B' ' 221' ' ' ILE . 2.2 mp -51.03 -73.24 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 C-N-CA 120.678 -0.409 . . . . 0.0 110.679 -178.283 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 222' ' ' ILE . . . . . 0.552 HG23 ' O ' ' B' ' 221' ' ' ILE . 21.8 pt -159.75 -166.34 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.624 -179.584 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 223' ' ' ARG . . . . . 0.624 ' N ' HD11 ' A' ' 75' ' ' ILE . 46.9 ptt85 -46.03 178.32 0.0 OUTLIER 'General case' 0 CA--C 1.516 -0.337 0 CA-C-N 115.756 -0.657 . . . . 0.0 110.563 179.281 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 224' ' ' LEU . . . . . 0.688 HD22 ' N ' ' B' ' 224' ' ' LEU . 3.1 mm? -59.41 121.71 12.16 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 115.687 -0.688 . . . . 0.0 110.533 -179.135 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 78.5 tt0 . . . . . 0 C--N 1.331 -0.228 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.4 179.986 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 54.7 p30 . . . . . 0 C--O 1.231 0.102 0 CA-C-O 120.822 0.344 . . . . 0.0 110.667 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 70.4 mt -63.57 151.89 40.25 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.343 -179.291 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 85.9 p -141.13 149.83 42.04 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-N 116.059 -0.518 . . . . 0.0 110.31 179.916 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' PHE . . . . . 0.519 ' CD1' ' N ' ' A' ' 14' ' ' PHE . 18.3 m-85 -111.37 145.8 38.26 Favored 'General case' 0 N--CA 1.464 0.235 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.569 -179.627 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 18.2 m -147.71 161.75 7.36 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.117 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.495 179.88 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 41.0 t0 56.06 29.32 14.29 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.66 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 96.5 mt -56.19 138.97 16.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.249 179.797 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.45 ' CB ' ' O ' ' A' ' 21' ' ' SER . 0.2 OUTLIER -139.96 -167.12 2.23 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.479 -179.69 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 19' ' ' ASP . . . . . 0.506 ' OD1' ' N ' ' A' ' 20' ' ' SER . 32.3 p-10 -89.63 -43.47 10.73 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.731 179.601 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 20' ' ' SER . . . . . 0.506 ' N ' ' OD1' ' A' ' 19' ' ' ASP . 10.2 t -117.54 8.75 13.0 Favored 'General case' 0 N--CA 1.465 0.317 0 CA-C-O 120.754 0.312 . . . . 0.0 110.889 -179.716 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 21' ' ' SER . . . . . 0.45 ' O ' ' CB ' ' A' ' 18' ' ' THR . 18.2 p -150.56 137.69 19.36 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.974 0.416 . . . . 0.0 110.35 -179.919 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 41.9 pt -132.07 145.68 34.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.467 -0.333 . . . . 0.0 110.159 179.921 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -97.86 81.96 0.66 Allowed Glycine 0 CA--C 1.525 0.675 0 N-CA-C 110.965 -0.854 . . . . 0.0 110.965 -179.805 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 94.9 mt -70.95 119.5 15.16 Favored 'General case' 0 C--N 1.33 -0.274 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 -179.882 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 70.1 ttt180 -138.15 142.08 40.11 Favored 'General case' 0 CA--C 1.519 -0.229 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.988 179.901 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 26' ' ' TRP . . . . . 0.543 ' CD2' ' O ' ' A' ' 60' ' ' GLY . 25.4 p90 -143.11 156.08 44.73 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.763 -0.653 . . . . 0.0 109.977 -179.87 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 3.2 m -109.84 101.96 48.71 Favored Pre-proline 0 N--CA 1.465 0.322 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.757 179.828 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 42.4 Cg_exo -54.94 144.57 67.07 Favored 'Trans proline' 0 C--N 1.304 -1.769 0 C-N-CA 122.108 1.872 . . . . 0.0 112.34 179.153 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 65.8 mt -83.47 139.77 32.73 Favored 'General case' 0 CA--C 1.52 -0.196 0 CA-C-O 121.813 0.816 . . . . 0.0 110.718 179.801 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 26.0 t-20 -47.94 -33.05 7.14 Favored 'General case' 0 C--N 1.319 -0.75 0 CA-C-N 115.268 -0.878 . . . . 0.0 110.19 -179.914 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 52.5 m -84.86 -30.9 24.08 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.627 179.506 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 4.9 m -58.15 131.23 49.92 Favored 'General case' 0 N--CA 1.462 0.144 0 CA-C-O 121.25 0.547 . . . . 0.0 110.444 179.912 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 33' ' ' THR . . . . . 0.448 ' H ' ' HB ' ' A' ' 81' ' ' ILE . 3.9 m -59.78 140.17 56.75 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.505 -0.77 . . . . 0.0 110.021 -179.801 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 58.2 mt -94.11 92.26 3.47 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.19 0 CA-C-O 120.865 0.364 . . . . 0.0 110.774 -179.778 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.433 ' O ' ' OG ' ' A' ' 57' ' ' SER . 9.5 pt -142.29 131.85 23.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.43 179.408 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -37.95 114.85 0.33 Allowed Glycine 0 CA--C 1.523 0.553 0 N-CA-C 111.442 -0.663 . . . . 0.0 111.442 -179.297 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 96.5 m-85 -79.8 177.27 9.02 Favored 'General case' 0 CA--C 1.515 -0.392 0 N-CA-C 110.019 -0.363 . . . . 0.0 110.019 -179.901 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 5.5 tmm_? -135.01 126.21 28.09 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.039 179.922 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 6.5 pt -95.35 155.33 3.33 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.391 0 N-CA-C 109.472 -0.566 . . . . 0.0 109.472 179.892 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 3.4 m -136.29 131.34 34.28 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.627 0.251 . . . . 0.0 110.624 -179.713 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.691 HG22 HD13 ' A' ' 50' ' ' ILE . 2.1 p -134.56 137.82 50.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.314 179.464 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 42' ' ' VAL . . . . . 0.538 ' N ' ' O ' ' A' ' 74' ' ' ASP . 41.5 t -134.83 135.92 52.66 Favored 'Isoleucine or valine' 0 C--O 1.23 0.058 0 CA-C-N 116.509 -0.314 . . . . 0.0 110.369 179.621 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.787 ' HB2' HD11 ' A' ' 50' ' ' ILE . . . -97.3 138.05 35.36 Favored 'General case' 0 C--N 1.33 -0.269 0 N-CA-C 109.628 -0.508 . . . . 0.0 109.628 179.231 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 44' ' ' ALA . . . . . 0.518 ' HB3' ' O ' ' A' ' 72' ' ' ASP . . . -90.54 -47.51 7.65 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.783 0.325 . . . . 0.0 110.708 179.723 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -61.64 -29.39 71.84 Favored Glycine 0 CA--C 1.525 0.711 0 N-CA-C 111.084 -0.806 . . . . 0.0 111.084 -179.863 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 91.2 mt-10 -95.94 127.56 42.06 Favored 'General case' 0 CA--C 1.52 -0.203 0 N-CA-C 109.357 -0.609 . . . . 0.0 109.357 -179.424 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -59.2 -22.0 54.69 Favored Glycine 0 CA--C 1.508 -0.389 0 N-CA-C 110.82 -0.912 . . . . 0.0 110.82 -179.229 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -110.16 135.04 20.58 Favored Pre-proline 0 CA--C 1.539 0.543 0 C-N-CA 120.858 -0.337 . . . . 0.0 110.235 179.702 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 62.3 Cg_endo -75.8 167.8 25.56 Favored 'Trans proline' 0 C--N 1.309 -1.517 0 C-N-CA 122.605 2.203 . . . . 0.0 111.732 177.344 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 50' ' ' ILE . . . . . 0.88 ' H ' HD12 ' A' ' 50' ' ' ILE . 1.7 mp -91.58 144.85 8.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 115.598 -0.728 . . . . 0.0 110.152 179.526 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 96.0 m-85 -65.84 142.2 58.01 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.702 -179.534 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 52' ' ' GLU . . . . . 0.578 ' CD ' ' H ' ' A' ' 52' ' ' GLU . 0.0 OUTLIER -73.87 -176.84 2.59 Favored 'General case' 0 CA--C 1.514 -0.424 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.602 179.664 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 3.6 t70 -151.45 147.45 26.88 Favored 'General case' 0 N--CA 1.452 -0.34 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.78 179.475 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 54.2 m-85 -115.7 124.8 51.76 Favored 'General case' 0 N--CA 1.463 0.219 0 CA-C-N 116.466 -0.334 . . . . 0.0 110.204 179.725 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 9.9 p -127.4 136.52 60.35 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.211 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.425 -179.886 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 99.8 m-20 -57.15 145.7 30.4 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.015 -0.538 . . . . 0.0 110.502 -179.707 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 57' ' ' SER . . . . . 0.433 ' OG ' ' O ' ' A' ' 35' ' ' ILE . 35.3 m -59.49 -33.46 71.36 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.61 179.917 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 49.5 m -52.68 -35.92 56.12 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.596 -179.901 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.522 HG12 ' O ' ' A' ' 61' ' ' TYR . 21.2 t -69.68 -43.72 79.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.348 179.853 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 60' ' ' GLY . . . . . 0.543 ' O ' ' CD2' ' A' ' 26' ' ' TRP . . . 68.68 -43.94 0.36 Allowed Glycine 0 CA--C 1.531 1.046 0 N-CA-C 110.943 -0.863 . . . . 0.0 110.943 179.903 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 61' ' ' TYR . . . . . 0.522 ' O ' HG12 ' A' ' 59' ' ' VAL . 25.0 p90 -102.49 157.71 16.73 Favored 'General case' 0 N--CA 1.463 0.223 0 CA-C-O 121.257 0.551 . . . . 0.0 111.139 -179.208 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 32.5 t80 -156.67 160.33 39.26 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.979 -0.555 . . . . 0.0 109.907 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 91.2 m -123.45 136.04 54.4 Favored 'General case' 0 C--O 1.233 0.206 0 CA-C-O 120.887 0.375 . . . . 0.0 110.699 -179.882 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -132.01 99.68 3.81 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 CA-C-N 116.035 -0.53 . . . . 0.0 109.818 179.249 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 2.2 p -106.73 159.25 16.36 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.91 0.386 . . . . 0.0 110.6 179.91 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 108.74 41.47 1.45 Allowed Glycine 0 CA--C 1.523 0.544 0 N-CA-C 111.41 -0.676 . . . . 0.0 111.41 -179.674 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 10.3 mt -116.43 107.88 15.34 Favored 'General case' 0 CA--C 1.517 -0.307 0 CA-C-O 121.346 0.593 . . . . 0.0 109.728 -179.868 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 53.0 mm-40 -53.85 136.07 55.95 Favored Pre-proline 0 C--N 1.318 -0.795 0 CA-C-N 115.611 -0.722 . . . . 0.0 111.622 -178.209 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo -75.34 155.43 41.37 Favored 'Trans proline' 0 N--CA 1.498 1.774 0 C-N-CA 122.952 2.434 . . . . 0.0 111.722 178.783 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 71.66 8.37 67.33 Favored Glycine 0 CA--C 1.526 0.777 0 CA-C-N 115.375 -0.829 . . . . 0.0 111.477 179.153 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 1.6 mp -118.03 145.4 24.0 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.298 0 CA-C-O 121.541 0.686 . . . . 0.0 109.381 -179.416 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 72' ' ' ASP . . . . . 0.518 ' O ' ' HB3' ' A' ' 44' ' ' ALA . 2.9 t70 -82.13 112.53 19.25 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-N 114.768 -1.105 . . . . 0.0 110.829 -179.579 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 73' ' ' TYR . . . . . 0.547 ' O ' HD13 ' A' ' 75' ' ' ILE . 13.3 m-85 -105.29 120.57 41.89 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.507 179.648 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 74' ' ' ASP . . . . . 0.538 ' O ' ' N ' ' A' ' 42' ' ' VAL . 74.0 m-20 -88.48 117.62 27.55 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.338 -0.846 . . . . 0.0 109.417 179.808 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 75' ' ' ILE . . . . . 0.562 HD11 ' N ' ' B' ' 223' ' ' ARG . 0.0 OUTLIER -117.97 163.57 15.03 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.362 0 CA-C-O 121.075 0.464 . . . . 0.0 110.011 -179.194 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -154.91 123.5 6.08 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.42 -0.809 . . . . 0.0 110.583 179.29 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 88.5 t -102.14 104.15 16.02 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 178.709 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 92.8 mt -96.95 132.71 40.79 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.224 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.349 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 79' ' ' THR . . . . . 0.609 HG23 ' O ' ' A' ' 79' ' ' THR . 14.0 t -112.15 120.25 41.17 Favored 'General case' 0 CA--C 1.514 -0.41 0 CA-C-N 116.173 -0.467 . . . . 0.0 109.946 -179.823 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 80' ' ' LEU . . . . . 0.577 HD13 ' N ' ' A' ' 81' ' ' ILE . 0.2 OUTLIER -121.54 115.46 22.87 Favored 'General case' 0 N--CA 1.464 0.234 0 CA-C-N 116.306 -0.407 . . . . 0.0 110.422 -179.781 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 81' ' ' ILE . . . . . 0.577 ' N ' HD13 ' A' ' 80' ' ' LEU . 1.9 pp -138.25 145.14 28.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.268 -0.424 . . . . 0.0 109.921 179.049 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 82' ' ' ASN . . . . . 0.406 ' H ' ' CB ' ' A' ' 33' ' ' THR . 60.7 t30 . . . . . 0 C--N 1.329 -0.298 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.792 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 207' ' ' GLY . . . . . 0.416 ' C ' ' CH2' ' B' ' 218' ' ' TRP . . . . . . . . 0 N--CA 1.465 0.62 0 N-CA-C 110.99 -0.844 . . . . 0.0 110.99 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 208' ' ' SER . . . . . 0.535 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 52.0 p -166.46 171.81 11.5 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.711 0.291 . . . . 0.0 110.703 179.664 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 209' ' ' TRP . . . . . . . . . . . . . 42.6 m95 -85.22 147.33 26.64 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.504 179.052 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 51.1 p -129.47 129.86 45.13 Favored 'General case' 0 C--O 1.232 0.176 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.7 179.876 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 42.5 t-105 -91.82 118.11 30.4 Favored 'General case' 0 C--N 1.334 -0.074 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.137 179.801 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 212' ' ' GLU . . . . . 0.443 ' O ' ' O ' ' B' ' 215' ' ' LYS . 1.0 OUTLIER -166.09 168.44 15.47 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.829 179.321 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' B' B ' 213' ' ' ASN . . . . . . . . . . . . . 93.1 m-20 49.47 37.55 12.36 Favored 'General case' 0 C--N 1.323 -0.566 0 C-N-CA 120.471 -0.492 . . . . 0.0 111.404 176.671 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 49.61 17.1 1.21 Allowed Glycine 0 CA--C 1.526 0.744 0 N-CA-C 111.337 -0.705 . . . . 0.0 111.337 179.703 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 215' ' ' LYS . . . . . 0.443 ' O ' ' O ' ' B' ' 212' ' ' GLU . 53.0 mtmt -142.99 150.25 39.4 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-O 121.169 0.509 . . . . 0.0 110.798 179.935 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 216' ' ' TRP . . . . . 0.534 ' O ' HG22 ' A' ' 79' ' ' THR . 59.5 m95 -89.49 118.48 29.17 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.012 -0.54 . . . . 0.0 109.818 179.631 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 217' ' ' THR . . . . . . . . . . . . . 17.7 m -131.23 144.51 51.38 Favored 'General case' 0 N--CA 1.466 0.328 0 CA-C-O 120.924 0.392 . . . . 0.0 110.524 -179.634 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 218' ' ' TRP . . . . . 0.535 ' CH2' ' N ' ' B' ' 208' ' ' SER . 12.0 t-105 -104.83 117.4 33.97 Favored 'General case' 0 C--N 1.328 -0.346 0 N-CA-C 109.532 -0.544 . . . . 0.0 109.532 179.262 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 50.5 mtpt -142.98 168.77 18.93 Favored 'General case' 0 CA--C 1.518 -0.253 0 CA-C-O 121.112 0.482 . . . . 0.0 110.485 -179.275 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -175.76 -162.25 26.5 Favored Glycine 0 CA--C 1.523 0.571 0 CA-C-N 115.603 -0.726 . . . . 0.0 111.389 -179.861 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 221' ' ' ILE . . . . . 0.521 ' O ' HG23 ' B' ' 222' ' ' ILE . 0.8 OUTLIER -53.34 -75.96 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 C-N-CA 120.641 -0.423 . . . . 0.0 110.872 -178.648 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' B' B ' 222' ' ' ILE . . . . . 0.521 HG23 ' O ' ' B' ' 221' ' ' ILE . 23.1 pt -158.97 -165.37 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.323 -179.232 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 223' ' ' ARG . . . . . 0.562 ' N ' HD11 ' A' ' 75' ' ' ILE . 52.7 ptt85 -42.94 172.87 0.0 OUTLIER 'General case' 0 C--O 1.234 0.276 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.299 179.133 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 224' ' ' LEU . . . . . 0.872 ' H ' HD22 ' B' ' 224' ' ' LEU . 1.7 mm? -68.37 111.59 4.72 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-O 121.296 0.57 . . . . 0.0 110.461 -179.378 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 26.7 tp10 . . . . . 0 C--N 1.329 -0.324 0 CA-C-N 115.196 -0.911 . . . . 0.0 110.37 179.745 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 . . . . . 0 C--O 1.234 0.255 0 CA-C-O 121.387 0.613 . . . . 0.0 110.446 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.403 HD23 ' N ' ' A' ' 12' ' ' LEU . 0.1 OUTLIER -74.18 153.26 39.57 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 114.965 -1.016 . . . . 0.0 109.806 -179.923 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 49.1 p -140.1 154.8 47.14 Favored 'General case' 0 C--N 1.333 -0.13 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.28 179.056 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 14' ' ' PHE . . . . . 0.472 ' CD1' ' N ' ' A' ' 14' ' ' PHE . 32.2 m-85 -103.69 146.35 28.73 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.562 -179.645 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 20.8 m -149.17 162.81 4.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.251 -0.432 . . . . 0.0 110.373 179.863 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 97.4 m-20 54.85 26.97 8.35 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.769 179.991 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 96.6 mt -56.06 136.16 18.87 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-O 121.007 0.432 . . . . 0.0 110.085 179.951 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.653 ' HG1' ' H ' ' A' ' 21' ' ' SER . 1.1 p -135.62 -166.79 1.91 Allowed 'General case' 0 CA--C 1.511 -0.548 0 CA-C-N 115.678 -0.692 . . . . 0.0 110.137 -179.977 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 19' ' ' ASP . . . . . 0.532 ' OD1' ' N ' ' A' ' 20' ' ' SER . 37.0 p-10 -90.46 -41.45 11.43 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.244 -0.889 . . . . 0.0 111.12 178.979 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 20' ' ' SER . . . . . 0.532 ' N ' ' OD1' ' A' ' 19' ' ' ASP . 5.7 t -114.8 9.44 16.3 Favored 'General case' 0 N--CA 1.468 0.432 0 CA-C-N 116.323 -0.398 . . . . 0.0 110.984 -179.012 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 21' ' ' SER . . . . . 0.653 ' H ' ' HG1' ' A' ' 18' ' ' THR . 27.9 p -154.85 158.05 38.79 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.118 179.61 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 42.9 pt -148.69 148.83 15.59 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.15 -179.912 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -100.88 78.82 0.42 Allowed Glycine 0 N--CA 1.467 0.721 0 N-CA-C 110.889 -0.884 . . . . 0.0 110.889 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.442 ' O ' ' CD1' ' A' ' 61' ' ' TYR . 20.9 mt -63.78 130.65 45.05 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.875 0.369 . . . . 0.0 110.233 -179.474 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 18.0 tpt180 -144.72 134.21 23.26 Favored 'General case' 0 CA--C 1.515 -0.372 0 CA-C-O 121.302 0.572 . . . . 0.0 110.201 -179.61 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 26' ' ' TRP . . . . . . . . . . . . . 39.8 p90 -147.82 153.83 39.68 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.082 -0.963 . . . . 0.0 110.015 179.213 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 3.1 m -110.32 100.61 45.19 Favored Pre-proline 0 CA--C 1.532 0.266 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.652 -179.964 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_exo -54.32 149.44 37.41 Favored 'Trans proline' 0 C--N 1.305 -1.752 0 C-N-CA 121.505 1.47 . . . . 0.0 112.877 179.347 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 64.1 mt -79.98 135.81 36.48 Favored 'General case' 0 CA--C 1.513 -0.471 0 CA-C-O 121.906 0.86 . . . . 0.0 110.67 -179.833 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 37.8 t30 -49.81 -34.88 20.92 Favored 'General case' 0 C--N 1.312 -1.054 0 CA-C-N 114.814 -1.084 . . . . 0.0 110.116 179.971 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 63.5 m -78.55 -33.74 47.59 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.721 -0.672 . . . . 0.0 110.784 179.027 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 4.9 m -57.87 133.82 55.77 Favored 'General case' 0 N--CA 1.462 0.147 0 CA-C-O 121.132 0.492 . . . . 0.0 110.138 -179.857 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 33' ' ' THR . . . . . 0.518 ' OG1' ' N ' ' A' ' 82' ' ' ASN . 5.2 m -58.33 143.55 44.52 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.84 -0.618 . . . . 0.0 109.845 -179.801 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 20.9 mm -94.19 90.97 2.95 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-O 120.925 0.393 . . . . 0.0 110.802 -179.428 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.466 ' O ' ' OG ' ' A' ' 57' ' ' SER . 8.8 pt -143.36 127.02 13.67 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.212 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.204 179.582 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -40.58 121.27 1.81 Allowed Glycine 0 CA--C 1.521 0.441 0 N-CA-C 111.372 -0.691 . . . . 0.0 111.372 -179.571 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 37' ' ' TYR . . . . . 0.443 ' CE2' ' OG ' ' A' ' 57' ' ' SER . 98.9 m-85 -85.37 178.26 7.52 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.548 -0.326 . . . . 0.0 110.168 179.796 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 6.6 tmm_? -131.44 128.52 39.67 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.448 179.741 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.479 ' CD1' ' CD2' ' A' ' 62' ' ' TYR . 1.8 pt -101.24 123.56 54.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.045 179.827 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 11.8 m -103.67 130.46 51.14 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.441 -0.345 . . . . 0.0 110.44 -179.862 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.1 p -128.59 138.12 55.47 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.55 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.023 179.919 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 42' ' ' VAL . . . . . 0.513 ' O ' ' N ' ' A' ' 74' ' ' ASP . 39.2 t -132.19 130.96 61.04 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.319 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 179.486 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.471 ' HB2' ' CE2' ' A' ' 73' ' ' TYR . . . -95.87 141.09 29.72 Favored 'General case' 0 C--N 1.324 -0.516 0 N-CA-C 109.207 -0.664 . . . . 0.0 109.207 179.199 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 44' ' ' ALA . . . . . 0.491 ' HB3' ' O ' ' A' ' 72' ' ' ASP . . . -93.84 -39.4 10.73 Favored 'General case' 0 C--N 1.327 -0.371 0 C-N-CA 120.652 -0.419 . . . . 0.0 110.69 179.652 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -66.13 -31.2 78.56 Favored Glycine 0 CA--C 1.526 0.78 0 N-CA-C 111.623 -0.591 . . . . 0.0 111.623 -179.545 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 51.6 mt-10 -98.3 133.05 43.25 Favored 'General case' 0 CA--C 1.518 -0.253 0 N-CA-C 109.539 -0.541 . . . . 0.0 109.539 -179.626 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -59.51 -21.73 55.0 Favored Glycine 0 CA--C 1.521 0.44 0 N-CA-C 110.845 -0.902 . . . . 0.0 110.845 -179.217 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -114.03 135.27 22.08 Favored Pre-proline 0 N--CA 1.473 0.685 0 CA-C-N 116.672 0.236 . . . . 0.0 110.626 179.854 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -76.49 162.33 33.4 Favored 'Trans proline' 0 N--CA 1.492 1.433 0 C-N-CA 122.519 2.146 . . . . 0.0 111.426 178.258 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 96.3 mt -81.74 134.34 27.29 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-N 116.151 -0.477 . . . . 0.0 109.953 179.335 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 97.9 m-85 -54.85 141.93 31.24 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.942 0.401 . . . . 0.0 110.797 -179.492 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 2.9 pt-20 -80.99 151.97 28.2 Favored 'General case' 0 CA--C 1.517 -0.296 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.262 179.796 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 2.0 t70 -120.52 160.3 23.45 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.764 179.714 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 54' ' ' PHE . . . . . 0.549 ' CD1' ' N ' ' A' ' 54' ' ' PHE . 6.1 m-85 -121.18 128.66 52.69 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.089 179.839 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 9.8 p -128.23 138.12 55.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 116.352 -0.385 . . . . 0.0 110.361 -179.701 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 98.8 m-20 -56.92 143.36 37.94 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.666 -179.662 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 57' ' ' SER . . . . . 0.466 ' OG ' ' O ' ' A' ' 35' ' ' ILE . 17.7 m -61.72 -34.24 75.44 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.889 179.893 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 37.5 m -57.04 -32.91 66.67 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.441 -179.808 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 92.8 t -65.55 -45.65 91.93 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.683 179.892 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 56.56 25.1 49.5 Favored Glycine 0 CA--C 1.527 0.821 0 N-CA-C 110.937 -0.865 . . . . 0.0 110.937 179.892 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 61' ' ' TYR . . . . . 0.442 ' CD1' ' O ' ' A' ' 24' ' ' LEU . 52.5 t80 -160.28 146.24 15.34 Favored 'General case' 0 N--CA 1.464 0.236 0 CA-C-O 121.141 0.496 . . . . 0.0 111.178 -179.359 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 62' ' ' TYR . . . . . 0.479 ' CD2' ' CD1' ' A' ' 39' ' ' ILE . 30.9 t80 -158.26 159.38 35.93 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.139 179.011 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 48.9 m -128.07 137.29 52.09 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.486 -179.423 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -131.13 101.75 5.68 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.34 0 CA-C-N 115.95 -0.568 . . . . 0.0 109.615 178.912 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 4.7 p -110.54 162.44 14.7 Favored 'General case' 0 N--CA 1.464 0.23 0 CA-C-O 121.006 0.432 . . . . 0.0 110.558 179.868 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 109.05 5.88 30.35 Favored Glycine 0 CA--C 1.527 0.832 0 CA-C-N 115.639 -0.709 . . . . 0.0 111.335 -179.655 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 12.1 mt -79.24 109.2 13.34 Favored 'General case' 0 C--N 1.329 -0.315 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.841 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 7.4 mm-40 -55.25 138.89 66.37 Favored Pre-proline 0 C--N 1.321 -0.65 0 C-N-CA 120.63 -0.428 . . . . 0.0 111.576 -178.236 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 95.8 Cg_endo -74.56 151.59 42.06 Favored 'Trans proline' 0 N--CA 1.493 1.495 0 C-N-CA 122.627 2.218 . . . . 0.0 111.725 179.113 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 72.4 10.15 74.41 Favored Glycine 0 CA--C 1.528 0.877 0 CA-C-N 115.161 -0.927 . . . . 0.0 111.642 179.229 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 1.7 mp -115.48 142.6 27.92 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.655 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 -179.727 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 72' ' ' ASP . . . . . 0.491 ' O ' ' HB3' ' A' ' 44' ' ' ALA . 2.3 t70 -81.73 110.88 17.47 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-N 115.162 -0.926 . . . . 0.0 110.311 179.977 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 73' ' ' TYR . . . . . 0.526 ' O ' ' CD1' ' A' ' 75' ' ' ILE . 14.8 m-85 -106.07 117.95 35.35 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.198 -179.911 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 74' ' ' ASP . . . . . 0.513 ' N ' ' O ' ' A' ' 42' ' ' VAL . 72.2 m-20 -88.16 119.83 28.93 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.145 -0.934 . . . . 0.0 109.331 179.754 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 75' ' ' ILE . . . . . 0.901 ' N ' HD13 ' A' ' 75' ' ' ILE . 0.0 OUTLIER -121.36 166.27 16.06 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.307 0 CA-C-O 121.067 0.46 . . . . 0.0 110.424 -179.103 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 22.5 t -155.15 151.3 28.07 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.745 -0.661 . . . . 0.0 110.122 179.26 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.429 ' O ' HG23 ' B' ' 217' ' ' THR . 2.4 t -125.3 109.7 22.65 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.335 0 N-CA-C 109.25 -0.648 . . . . 0.0 109.25 178.899 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 90.8 mt -97.27 123.11 49.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-O 120.891 0.377 . . . . 0.0 110.239 179.924 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 79' ' ' THR . . . . . 0.426 ' OG1' ' O ' ' B' ' 216' ' ' TRP . 19.6 p -103.48 111.4 23.83 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.059 179.752 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 35.4 tp -120.44 121.13 37.84 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.096 179.646 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 81' ' ' ILE . . . . . 0.513 ' HB ' ' H ' ' A' ' 33' ' ' THR . 2.3 pp -143.05 149.87 18.23 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 CA-C-N 116.081 -0.508 . . . . 0.0 110.189 179.634 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 82' ' ' ASN . . . . . 0.518 ' N ' ' OG1' ' A' ' 33' ' ' THR . 40.9 t30 . . . . . 0 C--N 1.33 -0.262 0 CA-C-N 116.443 -0.344 . . . . 0.0 111.159 179.916 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 207' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.466 0.648 0 N-CA-C 111.125 -0.79 . . . . 0.0 111.125 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' B' B ' 208' ' ' SER . . . . . 0.52 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 90.6 p -169.67 172.96 6.55 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.892 0.377 . . . . 0.0 110.864 -179.553 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 209' ' ' TRP . . . . . . . . . . . . . 69.1 m95 -92.74 153.52 18.86 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-N 115.815 -0.63 . . . . 0.0 110.488 179.289 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 49.8 p -135.04 140.27 45.45 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.521 179.631 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 61.0 t-105 -90.18 114.7 26.73 Favored 'General case' 0 C--N 1.332 -0.154 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.214 179.583 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 212' ' ' GLU . . . . . 0.522 ' O ' ' O ' ' B' ' 215' ' ' LYS . 3.8 tt0 -161.85 154.06 19.52 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.583 179.684 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 213' ' ' ASN . . . . . 0.446 ' N ' ' HG3' ' B' ' 212' ' ' GLU . 83.5 m-20 56.72 40.62 29.07 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 115.421 -0.809 . . . . 0.0 111.78 177.022 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 51.19 11.41 0.64 Allowed Glycine 0 CA--C 1.528 0.854 0 N-CA-C 111.64 -0.584 . . . . 0.0 111.64 179.571 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 215' ' ' LYS . . . . . 0.522 ' O ' ' O ' ' B' ' 212' ' ' GLU . 80.6 mttt -141.61 151.33 43.03 Favored 'General case' 0 C--O 1.225 -0.212 0 CA-C-O 121.109 0.481 . . . . 0.0 110.963 -179.854 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 216' ' ' TRP . . . . . 0.479 ' CD1' ' N ' ' B' ' 216' ' ' TRP . 24.8 m95 -85.85 119.42 26.14 Favored 'General case' 0 C--N 1.327 -0.406 0 C-N-CA 120.731 -0.387 . . . . 0.0 110.049 179.701 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 217' ' ' THR . . . . . 0.429 HG23 ' O ' ' A' ' 77' ' ' VAL . 16.7 m -125.86 142.1 51.67 Favored 'General case' 0 N--CA 1.467 0.395 0 N-CA-C 110.109 -0.33 . . . . 0.0 110.109 -179.525 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 218' ' ' TRP . . . . . 0.52 ' CH2' ' N ' ' B' ' 208' ' ' SER . 13.7 t-105 -103.49 117.15 33.78 Favored 'General case' 0 N--CA 1.463 0.186 0 CA-C-N 115.906 -0.588 . . . . 0.0 109.439 179.445 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 8.1 mtmp? -143.24 163.01 34.12 Favored 'General case' 0 CA--C 1.516 -0.355 0 CA-C-O 121.21 0.529 . . . . 0.0 110.634 -179.477 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -176.56 -160.27 23.46 Favored Glycine 0 CA--C 1.523 0.568 0 N-CA-C 111.185 -0.766 . . . . 0.0 111.185 -179.536 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 221' ' ' ILE . . . . . 0.529 ' O ' HG23 ' B' ' 222' ' ' ILE . 0.7 OUTLIER -51.05 -75.38 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 C-N-CA 120.778 -0.369 . . . . 0.0 110.566 -178.854 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' B' B ' 222' ' ' ILE . . . . . 0.529 HG23 ' O ' ' B' ' 221' ' ' ILE . 17.0 pt -160.25 -165.76 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 CA-C-N 116.327 -0.397 . . . . 0.0 109.991 -179.653 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 223' ' ' ARG . . . . . 0.508 ' O ' ' O ' ' B' ' 222' ' ' ILE . 22.5 ptt180 -42.33 175.38 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 121.472 0.653 . . . . 0.0 110.841 178.864 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 224' ' ' LEU . . . . . 0.644 HD22 ' N ' ' B' ' 224' ' ' LEU . 3.6 mm? -61.31 123.5 17.93 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 115.497 -0.774 . . . . 0.0 110.65 -179.753 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 79.9 tt0 . . . . . 0 CA--C 1.518 -0.282 0 CA-C-N 115.385 -0.825 . . . . 0.0 110.221 179.817 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 99.3 m-20 . . . . . 0 CA--C 1.519 -0.23 0 CA-C-O 120.873 0.368 . . . . 0.0 110.355 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 6.3 tt -64.2 142.99 58.22 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.154 -179.31 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 83.6 p -140.49 154.43 46.59 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.648 179.697 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 14' ' ' PHE . . . . . 0.505 ' CD1' ' N ' ' A' ' 14' ' ' PHE . 21.5 m-85 -111.41 144.77 40.09 Favored 'General case' 0 N--CA 1.464 0.274 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.668 -179.739 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.409 HG11 ' NH2' ' A' ' 25' ' ' ARG . 31.2 m -146.27 161.75 10.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.321 -0.399 . . . . 0.0 110.614 179.793 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 98.2 m-20 53.87 31.08 12.55 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.499 179.764 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 99.2 mt -57.09 140.91 14.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.258 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.444 ' CB ' ' O ' ' A' ' 21' ' ' SER . 0.2 OUTLIER -141.28 -168.11 2.55 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-N 116.009 -0.542 . . . . 0.0 110.326 -179.778 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 19' ' ' ASP . . . . . 0.477 ' N ' ' OD1' ' A' ' 19' ' ' ASP . 21.0 p-10 -88.88 -45.23 9.87 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.874 179.467 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 22.4 m -114.45 7.99 16.39 Favored 'General case' 0 N--CA 1.468 0.465 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.882 -179.543 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 21' ' ' SER . . . . . 0.444 ' O ' ' CB ' ' A' ' 18' ' ' THR . 34.4 t -151.55 145.53 25.21 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.156 0.503 . . . . 0.0 110.232 179.551 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 22' ' ' ILE . . . . . 0.425 HD12 HD21 ' A' ' 24' ' ' LEU . 45.3 pt -138.89 146.29 26.39 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.587 0 CA-C-N 115.802 -0.635 . . . . 0.0 110.352 -179.618 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -99.1 82.19 0.57 Allowed Glycine 0 CA--C 1.524 0.612 0 N-CA-C 110.903 -0.879 . . . . 0.0 110.903 -179.953 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.425 HD21 HD12 ' A' ' 22' ' ' ILE . 94.2 mt -70.02 121.8 18.13 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.856 0.36 . . . . 0.0 110.182 179.884 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 25' ' ' ARG . . . . . 0.409 ' NH2' HG11 ' A' ' 15' ' ' VAL . 59.9 ttp180 -141.28 136.14 31.32 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.164 179.949 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 26' ' ' TRP . . . . . . . . . . . . . 37.8 p90 -139.21 156.04 47.38 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.897 -0.592 . . . . 0.0 109.925 -179.795 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 3.5 m -110.59 98.89 39.09 Favored Pre-proline 0 C--N 1.33 -0.239 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.481 179.718 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 39.9 Cg_exo -53.66 147.63 39.01 Favored 'Trans proline' 0 C--N 1.303 -1.821 0 C-N-CA 121.63 1.554 . . . . 0.0 112.911 179.772 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 59.9 mt -87.76 141.93 28.22 Favored 'General case' 0 CA--C 1.511 -0.55 0 CA-C-N 115.437 -0.801 . . . . 0.0 110.398 -179.873 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 18.3 t-20 -50.07 -37.14 32.1 Favored 'General case' 0 C--N 1.315 -0.909 0 CA-C-N 114.908 -1.042 . . . . 0.0 110.067 -179.831 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 70.3 m -78.24 -33.5 49.74 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.547 178.755 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 14.1 m -60.83 131.09 49.58 Favored 'General case' 0 N--CA 1.463 0.194 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.067 -179.881 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 33' ' ' THR . . . . . 0.455 ' H ' ' HB ' ' A' ' 81' ' ' ILE . 5.1 m -65.91 142.18 57.98 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.253 -179.971 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 16.3 mm -94.82 90.75 2.79 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.19 0 CA-C-N 116.339 -0.392 . . . . 0.0 110.616 -179.848 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.473 ' O ' ' OG ' ' A' ' 57' ' ' SER . 24.9 pt -134.25 144.43 35.3 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.381 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.25 179.923 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -43.4 112.66 0.57 Allowed Glycine 0 CA--C 1.517 0.169 0 C-N-CA 120.59 -0.814 . . . . 0.0 111.58 -179.167 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 37' ' ' TYR . . . . . 0.866 ' OH ' HG23 ' A' ' 77' ' ' VAL . 0.9 OUTLIER -91.4 120.46 32.27 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 109.062 -0.718 . . . . 0.0 109.062 179.205 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 38' ' ' ARG . . . . . 0.516 ' O ' ' CE1' ' A' ' 37' ' ' TYR . 4.7 tmm_? -90.07 133.87 34.59 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.912 -0.586 . . . . 0.0 110.65 179.941 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 6.3 pt -93.67 154.76 3.24 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.314 0 CA-C-N 116.153 -0.476 . . . . 0.0 109.806 179.926 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 2.1 m -131.19 130.03 42.46 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.486 -0.325 . . . . 0.0 110.394 179.409 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.3 p -134.47 136.1 53.17 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.496 0 CA-C-O 120.94 0.4 . . . . 0.0 110.697 179.83 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 42' ' ' VAL . . . . . 0.511 ' O ' ' N ' ' A' ' 74' ' ' ASP . 32.1 t -131.15 127.6 60.87 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.319 0 N-CA-C 109.5 -0.556 . . . . 0.0 109.5 179.362 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -94.58 141.22 28.85 Favored 'General case' 0 C--N 1.324 -0.539 0 N-CA-C 109.516 -0.549 . . . . 0.0 109.516 179.357 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 44' ' ' ALA . . . . . 0.557 ' HB3' ' O ' ' A' ' 72' ' ' ASP . . . -96.63 -43.5 7.55 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.922 0.391 . . . . 0.0 110.872 179.783 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -74.24 30.82 0.97 Allowed Glycine 0 CA--C 1.525 0.659 0 N-CA-C 110.863 -0.895 . . . . 0.0 110.863 -179.957 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 46' ' ' GLU . . . . . 0.486 ' H ' ' C ' ' A' ' 44' ' ' ALA . 79.8 mm-40 -146.17 150.73 36.42 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 121.11 0.481 . . . . 0.0 110.695 -179.526 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -76.25 -14.67 82.1 Favored Glycine 0 CA--C 1.521 0.448 0 N-CA-C 110.711 -0.956 . . . . 0.0 110.711 179.752 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -138.34 139.5 25.38 Favored Pre-proline 0 CA--C 1.54 0.589 0 C-N-CA 120.961 -0.296 . . . . 0.0 110.464 179.581 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 70.6 Cg_endo -75.27 161.92 37.22 Favored 'Trans proline' 0 N--CA 1.491 1.349 0 C-N-CA 122.64 2.227 . . . . 0.0 111.84 177.957 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 96.3 mt -76.63 140.8 16.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.431 179.129 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 88.8 m-85 -62.84 141.7 58.54 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.459 -179.76 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 52' ' ' GLU . . . . . 0.534 ' CD ' ' H ' ' A' ' 52' ' ' GLU . 0.1 OUTLIER -76.92 146.36 37.63 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.46 179.714 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 4.8 t70 -113.18 150.94 31.55 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.66 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 72.7 m-85 -111.03 122.03 46.85 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.237 179.708 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 10.8 p -127.89 137.97 56.06 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.366 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.482 -179.963 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 89.7 m-20 -64.38 139.8 58.8 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.203 179.368 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 57' ' ' SER . . . . . 0.473 ' OG ' ' O ' ' A' ' 35' ' ' ILE . 2.8 m -59.47 -28.94 67.45 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.467 -179.83 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 37.6 m -55.8 -32.01 63.14 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.573 -179.998 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.498 ' O ' ' CD2' ' A' ' 61' ' ' TYR . 50.1 t -61.88 -44.2 98.51 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 -179.099 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 70.39 13.73 71.09 Favored Glycine 0 CA--C 1.53 0.977 0 N-CA-C 111.033 -0.827 . . . . 0.0 111.033 179.473 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 61' ' ' TYR . . . . . 0.498 ' CD2' ' O ' ' A' ' 59' ' ' VAL . 26.4 p90 -171.9 158.56 4.84 Favored 'General case' 0 C--O 1.225 -0.226 0 CA-C-O 120.993 0.425 . . . . 0.0 111.583 179.594 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 35.1 t80 -155.99 154.72 31.55 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.054 177.972 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 86.3 m -116.32 133.04 56.46 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.4 -179.456 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -131.08 100.84 4.91 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.275 0 N-CA-C 109.475 -0.565 . . . . 0.0 109.475 179.152 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.42 HG22 ' OG ' ' A' ' 21' ' ' SER . 2.4 p -110.33 163.47 13.62 Favored 'General case' 0 N--CA 1.464 0.239 0 CA-C-O 121.007 0.432 . . . . 0.0 110.706 -179.869 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 110.08 9.79 23.56 Favored Glycine 0 CA--C 1.528 0.851 0 CA-C-N 115.496 -0.775 . . . . 0.0 111.49 -179.56 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 8.1 mt -83.52 107.61 16.11 Favored 'General case' 0 C--N 1.33 -0.274 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 179.829 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 17.5 mm-40 -57.58 138.53 81.81 Favored Pre-proline 0 C--N 1.32 -0.694 0 C-N-CA 120.321 -0.552 . . . . 0.0 111.609 -178.295 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 90.2 Cg_endo -74.54 154.65 45.02 Favored 'Trans proline' 0 N--CA 1.496 1.637 0 C-N-CA 122.762 2.308 . . . . 0.0 111.825 178.942 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 73.35 7.92 73.92 Favored Glycine 0 CA--C 1.528 0.865 0 CA-C-N 115.282 -0.872 . . . . 0.0 111.767 179.075 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 71' ' ' ILE . . . . . 0.547 ' O ' ' NH1' ' B' ' 223' ' ' ARG . 1.7 mp -117.11 147.24 20.62 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.406 0 N-CA-C 109.291 -0.633 . . . . 0.0 109.291 -179.504 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 72' ' ' ASP . . . . . 0.557 ' O ' ' HB3' ' A' ' 44' ' ' ALA . 2.8 t0 -84.76 113.99 21.73 Favored 'General case' 0 C--N 1.318 -0.766 0 CA-C-N 115.176 -0.92 . . . . 0.0 110.402 -179.6 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 73' ' ' TYR . . . . . 0.507 ' O ' HD13 ' A' ' 75' ' ' ILE . 15.6 m-85 -107.93 119.88 40.7 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.324 -179.966 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 74' ' ' ASP . . . . . 0.511 ' N ' ' O ' ' A' ' 42' ' ' VAL . 14.8 m-20 -89.71 118.96 29.71 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 115.327 -0.851 . . . . 0.0 108.805 179.535 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 75' ' ' ILE . . . . . 0.625 HD11 ' N ' ' B' ' 223' ' ' ARG . 0.0 OUTLIER -113.24 162.65 11.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-O 121.282 0.563 . . . . 0.0 110.263 -178.642 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -153.53 118.89 5.18 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.289 -0.869 . . . . 0.0 110.484 179.708 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.866 HG23 ' OH ' ' A' ' 37' ' ' TYR . 8.7 p -103.39 101.38 12.13 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.242 0 N-CA-C 109.517 -0.549 . . . . 0.0 109.517 178.995 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 91.4 mt -92.0 101.13 12.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.621 -179.847 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 44.9 p -77.68 111.64 13.67 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.807 -0.633 . . . . 0.0 109.388 179.049 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 80' ' ' LEU . . . . . 0.587 HD12 ' NZ ' ' B' ' 215' ' ' LYS . 4.8 tp -111.54 120.63 42.77 Favored 'General case' 0 N--CA 1.465 0.288 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.963 -179.234 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 81' ' ' ILE . . . . . 0.455 ' HB ' ' H ' ' A' ' 33' ' ' THR . 2.1 pp -146.61 142.3 20.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.065 -0.516 . . . . 0.0 109.974 179.095 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 56.0 t-20 . . . . . 0 C--N 1.331 -0.234 0 CA-C-O 120.721 0.296 . . . . 0.0 110.9 -179.648 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' B' B ' 207' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.466 0.637 0 N-CA-C 111.174 -0.77 . . . . 0.0 111.174 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' B' B ' 208' ' ' SER . . . . . 0.539 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 91.7 p -166.88 172.14 10.62 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 120.907 0.384 . . . . 0.0 110.701 -179.805 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 209' ' ' TRP . . . . . . . . . . . . . 78.4 m95 -88.63 130.66 35.23 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.189 179.369 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 82.1 p -109.5 132.81 53.79 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-N 116.392 -0.367 . . . . 0.0 110.496 -179.796 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 47.7 t-105 -93.73 117.81 30.58 Favored 'General case' 0 N--CA 1.463 0.208 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.072 179.796 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 212' ' ' GLU . . . . . 0.44 ' O ' ' O ' ' B' ' 215' ' ' LYS . 0.8 OUTLIER -164.22 167.41 20.04 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.779 179.035 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' B' B ' 213' ' ' ASN . . . . . . . . . . . . . 92.4 m-20 49.06 37.11 9.88 Favored 'General case' 0 C--N 1.324 -0.516 0 C-N-CA 120.522 -0.471 . . . . 0.0 111.349 176.603 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 50.89 16.85 1.93 Allowed Glycine 0 CA--C 1.526 0.723 0 N-CA-C 111.335 -0.706 . . . . 0.0 111.335 179.868 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 215' ' ' LYS . . . . . 0.587 ' NZ ' HD12 ' A' ' 80' ' ' LEU . 20.3 mtpt -143.0 149.75 38.72 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.986 0.422 . . . . 0.0 110.889 -179.839 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 216' ' ' TRP . . . . . . . . . . . . . 50.1 m95 -86.12 115.76 23.9 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.028 -0.533 . . . . 0.0 109.712 179.115 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 217' ' ' THR . . . . . . . . . . . . . 18.1 m -126.95 139.92 52.7 Favored 'General case' 0 N--CA 1.466 0.343 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.439 -179.512 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 218' ' ' TRP . . . . . 0.626 ' O ' HG12 ' A' ' 77' ' ' VAL . 12.9 t-105 -106.45 116.38 31.82 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.016 178.984 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 52.8 mtmt -143.9 174.5 10.78 Favored 'General case' 0 CA--C 1.514 -0.432 0 CA-C-O 121.137 0.494 . . . . 0.0 110.644 -179.85 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -176.38 -160.21 23.27 Favored Glycine 0 CA--C 1.523 0.572 0 C-N-CA 120.544 -0.836 . . . . 0.0 111.226 -179.576 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 221' ' ' ILE . . . . . 0.532 ' O ' HG23 ' B' ' 222' ' ' ILE . 10.2 mm -51.27 -73.59 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.892 0.377 . . . . 0.0 110.485 -178.059 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 222' ' ' ILE . . . . . 0.532 HG23 ' O ' ' B' ' 221' ' ' ILE . 23.7 pt -159.48 -166.39 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.755 0 CA-C-N 115.646 -0.706 . . . . 0.0 110.706 -179.943 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 223' ' ' ARG . . . . . 0.625 ' N ' HD11 ' A' ' 75' ' ' ILE . 32.0 ptt-85 -42.76 174.6 0.0 OUTLIER 'General case' 0 CA--C 1.52 -0.186 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.77 179.003 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 224' ' ' LEU . . . . . 0.759 HD22 ' N ' ' B' ' 224' ' ' LEU . 2.4 mm? -59.67 128.23 35.91 Favored 'General case' 0 C--N 1.315 -0.906 0 CA-C-N 115.786 -0.643 . . . . 0.0 110.542 -179.517 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 42.5 tt0 . . . . . 0 CA--C 1.52 -0.188 0 CA-C-N 115.349 -0.841 . . . . 0.0 110.391 -179.843 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 97.2 m-20 . . . . . 0 N--CA 1.463 0.199 0 CA-C-O 120.876 0.369 . . . . 0.0 110.395 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 6.7 tt -63.92 149.15 47.82 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.396 -179.74 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 13' ' ' SER . . . . . 0.419 ' O ' ' O ' ' A' ' 25' ' ' ARG . 83.3 p -139.15 156.85 46.83 Favored 'General case' 0 N--CA 1.461 0.114 0 CA-C-O 121.166 0.508 . . . . 0.0 110.42 179.757 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 14' ' ' PHE . . . . . 0.501 ' CD1' ' N ' ' A' ' 14' ' ' PHE . 30.6 m-85 -110.84 146.37 36.57 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.555 -0.748 . . . . 0.0 110.81 -179.515 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 15.6 m -146.74 157.01 10.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.447 -0.342 . . . . 0.0 110.649 179.4 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 98.9 m-20 54.59 31.53 15.23 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.934 179.656 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 97.2 mt -56.92 140.89 14.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.383 -179.803 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.418 ' CB ' ' O ' ' A' ' 21' ' ' SER . 0.2 OUTLIER -140.87 -168.6 2.63 Favored 'General case' 0 CA--C 1.533 0.292 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.509 -179.798 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 19' ' ' ASP . . . . . 0.483 ' OD1' ' N ' ' A' ' 19' ' ' ASP . 11.8 p-10 -90.3 -41.91 11.27 Favored 'General case' 0 N--CA 1.465 0.299 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.689 179.509 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 15.1 m -114.62 5.74 15.51 Favored 'General case' 0 N--CA 1.464 0.252 0 CA-C-N 116.014 -0.539 . . . . 0.0 111.152 -179.395 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 21' ' ' SER . . . . . 0.418 ' O ' ' CB ' ' A' ' 18' ' ' THR . 29.2 t -151.68 148.43 27.92 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 121.046 0.45 . . . . 0.0 110.365 179.624 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 42.6 pt -140.71 145.53 25.42 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.194 179.789 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -102.27 81.42 0.4 Allowed Glycine 0 CA--C 1.524 0.618 0 N-CA-C 110.998 -0.841 . . . . 0.0 110.998 -179.991 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 96.3 mt -68.54 121.6 16.73 Favored 'General case' 0 C--N 1.33 -0.272 0 C-N-CA 120.775 -0.37 . . . . 0.0 110.015 -179.992 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 25' ' ' ARG . . . . . 0.419 ' O ' ' O ' ' A' ' 13' ' ' SER . 58.8 ttt85 -142.75 137.64 29.93 Favored 'General case' 0 C--N 1.333 -0.123 0 CA-C-O 120.956 0.407 . . . . 0.0 110.372 -179.806 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 26' ' ' TRP . . . . . 0.454 ' C ' ' CD1' ' A' ' 26' ' ' TRP . 0.1 OUTLIER -143.0 161.54 37.85 Favored 'General case' 0 N--CA 1.466 0.349 0 N-CA-C 109.089 -0.708 . . . . 0.0 109.089 179.599 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 5.0 m -100.88 103.18 23.17 Favored Pre-proline 0 C--N 1.327 -0.379 0 N-CA-C 108.612 -0.885 . . . . 0.0 108.612 178.73 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 33.4 Cg_exo -54.72 149.62 39.84 Favored 'Trans proline' 0 C--N 1.308 -1.594 0 C-N-CA 120.883 1.055 . . . . 0.0 112.754 -179.03 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 69.6 mt -87.49 133.06 33.82 Favored 'General case' 0 CA--C 1.51 -0.569 0 CA-C-O 121.601 0.715 . . . . 0.0 111.066 -179.637 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 24.3 t-20 -46.9 -33.69 4.79 Favored 'General case' 0 C--N 1.314 -0.94 0 CA-C-N 115.064 -0.971 . . . . 0.0 110.225 179.527 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 63.4 m -80.74 -34.18 34.59 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.53 178.83 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 5.2 m -56.57 127.12 29.73 Favored 'General case' 0 C--O 1.232 0.136 0 C-N-CA 120.732 -0.387 . . . . 0.0 109.998 -179.715 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 33' ' ' THR . . . . . 0.495 ' H ' ' HB ' ' A' ' 81' ' ' ILE . 33.2 m -61.61 152.5 30.47 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.048 179.875 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 24.4 mm -97.5 94.05 3.71 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.343 0 CA-C-N 116.579 -0.282 . . . . 0.0 111.49 -178.24 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.485 ' N ' HD13 ' A' ' 35' ' ' ILE . 0.1 OUTLIER -137.59 155.09 30.55 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.324 0 CA-C-O 120.792 0.329 . . . . 0.0 110.511 179.305 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -63.22 113.57 6.02 Favored Glycine 0 CA--C 1.521 0.457 0 C-N-CA 120.472 -0.871 . . . . 0.0 111.178 179.785 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 69.2 m-85 -80.73 141.53 34.73 Favored 'General case' 0 C--N 1.328 -0.358 0 N-CA-C 110.072 -0.344 . . . . 0.0 110.072 179.525 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 38' ' ' ARG . . . . . 0.43 HH11 ' HG3' ' A' ' 52' ' ' GLU . 5.3 tmm_? -105.54 119.84 40.14 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.549 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.474 ' O ' ' CG1' ' A' ' 39' ' ' ILE . 1.9 pt -95.47 122.88 47.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 115.835 -0.62 . . . . 0.0 109.693 179.79 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 94.8 m -109.61 131.64 54.87 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.824 0.345 . . . . 0.0 110.511 -179.276 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.417 HG13 ' HB ' ' A' ' 50' ' ' ILE . 1.8 p -128.8 144.12 39.05 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.349 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.523 -179.505 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 42' ' ' VAL . . . . . 0.506 ' O ' ' N ' ' A' ' 74' ' ' ASP . 40.4 t -132.45 131.87 60.3 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.191 0 CA-C-O 120.899 0.38 . . . . 0.0 110.019 179.542 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.526 ' HB2' ' CE2' ' A' ' 73' ' ' TYR . . . -98.44 140.01 33.33 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 109.296 -0.631 . . . . 0.0 109.296 179.22 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 44' ' ' ALA . . . . . 0.552 ' HB3' ' O ' ' A' ' 72' ' ' ASP . . . -98.26 -18.44 18.39 Favored 'General case' 0 CA--C 1.529 0.135 0 C-N-CA 120.67 -0.412 . . . . 0.0 110.776 179.926 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -98.54 30.73 9.1 Favored Glycine 0 CA--C 1.529 0.956 0 N-CA-C 110.753 -0.939 . . . . 0.0 110.753 179.821 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 45.1 mt-10 -146.78 149.01 32.51 Favored 'General case' 0 CA--C 1.521 -0.16 0 CA-C-O 121.131 0.491 . . . . 0.0 110.691 179.97 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -68.96 -20.95 75.09 Favored Glycine 0 CA--C 1.527 0.823 0 N-CA-C 111.014 -0.834 . . . . 0.0 111.014 179.736 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -136.61 141.11 34.21 Favored Pre-proline 0 CA--C 1.54 0.579 0 C-N-CA 121.131 -0.228 . . . . 0.0 110.476 179.995 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 69.4 Cg_endo -73.36 162.22 40.8 Favored 'Trans proline' 0 N--CA 1.496 1.672 0 C-N-CA 122.752 2.301 . . . . 0.0 111.821 179.059 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 50' ' ' ILE . . . . . 0.417 ' HB ' HG13 ' A' ' 41' ' ' VAL . 96.7 mt -76.49 151.77 5.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.522 179.793 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 82.6 m-85 -70.75 146.41 49.83 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.707 -179.54 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 52' ' ' GLU . . . . . 0.522 ' CD ' ' H ' ' A' ' 52' ' ' GLU . 0.5 OUTLIER -82.96 145.0 29.61 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.682 179.55 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -112.4 153.14 27.76 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.492 -0.777 . . . . 0.0 110.388 -179.717 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 54' ' ' PHE . . . . . 0.581 ' CD1' ' N ' ' A' ' 54' ' ' PHE . 2.7 m-85 -119.0 128.7 54.64 Favored 'General case' 0 N--CA 1.466 0.356 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.227 -179.758 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 9.6 p -131.26 139.06 51.8 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.3 0 CA-C-O 120.683 0.277 . . . . 0.0 110.828 -179.65 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 71.4 m-20 -58.51 142.47 48.82 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.262 179.581 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 7.2 t -60.88 -35.21 76.04 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.733 179.86 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 58.5 m -56.31 -34.11 66.2 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.923 -179.603 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 90.7 t -62.38 -45.8 97.93 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.389 -179.84 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 61.75 23.17 62.87 Favored Glycine 0 CA--C 1.525 0.713 0 N-CA-C 110.745 -0.942 . . . . 0.0 110.745 179.942 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 37.2 t80 -164.65 150.16 10.09 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-O 121.095 0.474 . . . . 0.0 111.423 -179.412 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 62' ' ' TYR . . . . . 0.432 ' CD2' ' CD1' ' A' ' 39' ' ' ILE . 18.4 t80 -156.7 154.32 29.87 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.73 -0.668 . . . . 0.0 110.33 178.715 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 73.1 m -117.55 132.55 56.51 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.16 -0.473 . . . . 0.0 109.893 179.472 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -130.63 113.63 25.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 N-CA-C 109.327 -0.62 . . . . 0.0 109.327 178.914 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.412 HG22 ' OG ' ' A' ' 21' ' ' SER . 2.1 p -124.76 158.83 32.33 Favored 'General case' 0 CA--C 1.516 -0.331 0 CA-C-O 120.987 0.422 . . . . 0.0 110.394 -179.83 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 108.11 39.61 1.8 Allowed Glycine 0 CA--C 1.525 0.682 0 N-CA-C 110.818 -0.913 . . . . 0.0 110.818 -179.937 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 14.5 mt -112.52 106.96 15.53 Favored 'General case' 0 N--CA 1.467 0.404 0 N-CA-C 108.742 -0.836 . . . . 0.0 108.742 179.087 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 4.1 mm-40 -54.34 136.79 60.37 Favored Pre-proline 0 C--N 1.323 -0.561 0 C-N-CA 120.86 -0.336 . . . . 0.0 111.727 -178.095 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 90.0 Cg_endo -74.26 154.52 46.38 Favored 'Trans proline' 0 N--CA 1.493 1.466 0 C-N-CA 122.779 2.319 . . . . 0.0 111.54 178.877 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 71.05 8.42 64.66 Favored Glycine 0 CA--C 1.529 0.963 0 CA-C-N 115.533 -0.758 . . . . 0.0 111.507 179.563 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 1.6 mp -116.05 143.9 24.97 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.543 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 -179.975 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 72' ' ' ASP . . . . . 0.552 ' O ' ' HB3' ' A' ' 44' ' ' ALA . 2.0 t0 -81.93 112.59 19.17 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-N 115.307 -0.861 . . . . 0.0 110.149 -179.849 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 73' ' ' TYR . . . . . 0.526 ' CE2' ' HB2' ' A' ' 43' ' ' ALA . 13.7 m-85 -107.38 120.01 40.97 Favored 'General case' 0 C--O 1.223 -0.326 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.354 -179.814 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 74' ' ' ASP . . . . . 0.506 ' N ' ' O ' ' A' ' 42' ' ' VAL . 7.3 m-20 -89.04 114.86 26.12 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 115.34 -0.845 . . . . 0.0 109.375 179.601 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 75' ' ' ILE . . . . . 0.675 HD11 ' N ' ' B' ' 223' ' ' ARG . 0.0 OUTLIER -112.35 167.31 5.8 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.198 0 CA-C-O 121.273 0.558 . . . . 0.0 110.405 -179.434 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 11.6 p -154.46 151.65 29.2 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 115.124 -0.944 . . . . 0.0 110.283 179.392 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -131.32 101.75 5.56 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.351 0 N-CA-C 108.744 -0.836 . . . . 0.0 108.744 179.49 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 96.2 mt -86.62 123.87 40.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 C-N-CA 120.913 -0.315 . . . . 0.0 110.34 -179.673 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 90.5 m -105.26 109.02 20.85 Favored 'General case' 0 N--CA 1.465 0.301 0 CA-C-N 116.358 -0.383 . . . . 0.0 109.971 179.66 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 6.7 tt -121.09 119.02 31.24 Favored 'General case' 0 CA--C 1.517 -0.292 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.449 179.965 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 81' ' ' ILE . . . . . 0.495 ' HB ' ' H ' ' A' ' 33' ' ' THR . 2.0 pp -140.28 143.44 29.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.289 179.22 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 56.8 t-20 . . . . . 0 C--N 1.327 -0.384 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.803 -179.476 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' B' B ' 207' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.464 0.515 0 N-CA-C 110.838 -0.905 . . . . 0.0 110.838 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' B' B ' 208' ' ' SER . . . . . . . . . . . . . 44.6 p -163.82 170.33 17.02 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 120.717 0.294 . . . . 0.0 110.701 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 209' ' ' TRP . . . . . . . . . . . . . 86.5 m95 -83.33 126.56 32.83 Favored 'General case' 0 C--N 1.329 -0.286 0 C-N-CA 120.845 -0.342 . . . . 0.0 110.167 179.34 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 77.4 p -108.94 138.91 44.54 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-N 116.514 -0.312 . . . . 0.0 110.723 -179.745 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 58.2 t-105 -95.67 116.09 28.36 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-N 116.033 -0.531 . . . . 0.0 110.337 179.68 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 212' ' ' GLU . . . . . 0.469 ' O ' ' O ' ' B' ' 215' ' ' LYS . 1.4 pt-20 -163.46 167.03 22.06 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.509 179.312 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 213' ' ' ASN . . . . . . . . . . . . . 78.9 m-20 49.3 34.23 6.11 Favored 'General case' 0 C--N 1.324 -0.522 0 C-N-CA 120.53 -0.468 . . . . 0.0 111.698 176.962 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 54.73 12.34 3.48 Favored Glycine 0 CA--C 1.528 0.865 0 C-N-CA 120.917 -0.659 . . . . 0.0 111.604 179.463 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 215' ' ' LYS . . . . . 0.469 ' O ' ' O ' ' B' ' 212' ' ' GLU . 67.6 mttm -141.86 150.98 42.29 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-O 120.863 0.364 . . . . 0.0 110.76 -179.798 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 216' ' ' TRP . . . . . 0.437 ' CD1' ' N ' ' B' ' 216' ' ' TRP . 37.4 m95 -84.91 117.54 23.98 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.174 179.875 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 217' ' ' THR . . . . . . . . . . . . . 26.7 m -125.85 137.49 53.76 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.531 -179.568 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 218' ' ' TRP . . . . . . . . . . . . . 25.0 t-105 -98.53 120.02 38.25 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.234 179.483 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 53.7 mtmt -141.69 165.79 26.51 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.72 -179.809 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -176.44 -160.97 24.59 Favored Glycine 0 CA--C 1.522 0.504 0 N-CA-C 111.185 -0.766 . . . . 0.0 111.185 -179.887 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 221' ' ' ILE . . . . . 0.555 ' O ' HG23 ' B' ' 222' ' ' ILE . 0.8 OUTLIER -53.43 -76.73 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.387 0 C-N-CA 120.682 -0.407 . . . . 0.0 110.987 -178.44 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' B' B ' 222' ' ' ILE . . . . . 0.555 HG23 ' O ' ' B' ' 221' ' ' ILE . 20.2 pt -160.72 -166.24 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 N-CA-C 109.994 -0.373 . . . . 0.0 109.994 -179.633 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 223' ' ' ARG . . . . . 0.675 ' N ' HD11 ' A' ' 75' ' ' ILE . 33.2 ptt85 -45.41 174.57 0.0 OUTLIER 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.805 178.362 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 224' ' ' LEU . . . . . 0.679 HD22 ' N ' ' B' ' 224' ' ' LEU . 3.0 mm? -59.44 123.46 16.89 Favored 'General case' 0 C--N 1.318 -0.791 0 CA-C-N 115.317 -0.856 . . . . 0.0 110.211 -179.244 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 79.7 tt0 . . . . . 0 C--N 1.33 -0.265 0 CA-C-N 115.387 -0.824 . . . . 0.0 110.167 -179.648 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 96.5 m-20 . . . . . 0 N--CA 1.464 0.259 0 CA-C-O 120.984 0.421 . . . . 0.0 110.438 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 6.6 tt -64.27 145.16 56.46 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.429 -179.676 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 86.8 p -140.3 153.01 46.33 Favored 'General case' 0 N--CA 1.463 0.212 0 CA-C-N 116.328 -0.397 . . . . 0.0 110.662 179.909 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 14' ' ' PHE . . . . . 0.533 ' CD1' ' N ' ' A' ' 14' ' ' PHE . 12.5 m-85 -111.17 146.74 36.35 Favored 'General case' 0 N--CA 1.465 0.301 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.379 -179.612 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 21.9 m -146.01 160.88 11.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.633 179.81 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 38.2 t0 55.46 31.53 17.15 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.66 179.636 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 96.5 mt -56.57 137.77 18.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 121.07 0.462 . . . . 0.0 110.148 179.962 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.461 ' CB ' ' O ' ' A' ' 21' ' ' SER . 0.3 OUTLIER -140.32 -167.01 2.23 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.817 -0.628 . . . . 0.0 110.651 -179.559 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 19' ' ' ASP . . . . . 0.525 ' OD1' ' N ' ' A' ' 19' ' ' ASP . 14.5 p-10 -91.6 -41.97 10.47 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 115.691 -0.686 . . . . 0.0 111.006 179.468 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 13.7 m -116.97 6.88 13.05 Favored 'General case' 0 N--CA 1.466 0.344 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.677 -179.584 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 21' ' ' SER . . . . . 0.461 ' O ' ' CB ' ' A' ' 18' ' ' THR . 16.8 p -151.65 145.79 25.33 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 121.101 0.477 . . . . 0.0 110.443 179.968 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 44.2 pt -140.26 146.29 24.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.02 179.941 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -99.31 81.76 0.56 Allowed Glycine 0 CA--C 1.523 0.593 0 N-CA-C 111.419 -0.672 . . . . 0.0 111.419 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 84.0 mt -66.79 121.98 16.65 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.768 0.318 . . . . 0.0 110.296 -179.967 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 4.6 tmm_? -139.62 138.69 36.37 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.62 179.877 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 26' ' ' TRP . . . . . . . . . . . . . 42.0 p90 -143.0 158.28 43.75 Favored 'General case' 0 CA--C 1.517 -0.308 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.399 179.921 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 3.5 m -111.16 97.1 33.67 Favored Pre-proline 0 CA--C 1.534 0.337 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.393 179.854 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_exo -53.23 146.3 40.2 Favored 'Trans proline' 0 C--N 1.308 -1.581 0 C-N-CA 122.476 2.117 . . . . 0.0 112.23 179.879 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 52.3 mt -84.32 138.53 32.84 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 121.337 0.589 . . . . 0.0 111.039 -179.96 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 31.8 t30 -49.08 -33.49 11.71 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.47 -0.786 . . . . 0.0 110.152 179.829 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 70.6 m -81.63 -34.17 31.02 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.593 179.667 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 9.1 m -58.24 134.92 56.96 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 121.103 0.478 . . . . 0.0 110.185 -179.881 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 33' ' ' THR . . . . . 0.526 ' H ' ' HB ' ' A' ' 81' ' ' ILE . 3.7 m -61.44 142.74 56.78 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.465 179.912 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 28.9 mm -94.37 92.69 3.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.969 0.414 . . . . 0.0 110.324 -179.896 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 15.2 pt -143.09 135.86 25.13 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.155 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.359 179.697 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -39.24 132.4 1.95 Allowed Glycine 0 CA--C 1.524 0.642 0 N-CA-C 111.171 -0.771 . . . . 0.0 111.171 -179.705 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 95.6 m-85 -103.03 138.98 39.17 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.844 0.354 . . . . 0.0 110.197 -179.771 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 5.3 tmm_? -99.1 124.64 44.27 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.629 -179.699 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.451 ' O ' ' CG1' ' A' ' 39' ' ' ILE . 2.1 pt -99.09 124.51 52.39 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 116.341 -0.391 . . . . 0.0 109.97 179.701 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 5.4 m -105.52 134.0 49.35 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.621 -179.822 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.1 p -132.39 141.52 45.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.308 179.541 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 42' ' ' VAL . . . . . 0.538 ' O ' ' N ' ' A' ' 74' ' ' ASP . 41.4 t -133.41 133.47 57.64 Favored 'Isoleucine or valine' 0 C--O 1.231 0.104 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.339 179.6 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.548 ' HB2' ' CE2' ' A' ' 73' ' ' TYR . . . -98.55 139.58 34.07 Favored 'General case' 0 C--N 1.328 -0.33 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 178.732 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 44' ' ' ALA . . . . . 0.513 ' HB3' ' O ' ' A' ' 72' ' ' ASP . . . -91.81 -43.91 9.26 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.284 -0.417 . . . . 0.0 111.027 179.815 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -63.49 -32.35 83.84 Favored Glycine 0 CA--C 1.524 0.614 0 N-CA-C 111.275 -0.73 . . . . 0.0 111.275 -179.477 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 38.4 mm-40 -97.92 126.53 43.36 Favored 'General case' 0 C--N 1.332 -0.19 0 N-CA-C 109.616 -0.512 . . . . 0.0 109.616 -179.582 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -59.17 -6.92 4.57 Favored Glycine 0 CA--C 1.511 -0.187 0 N-CA-C 110.918 -0.873 . . . . 0.0 110.918 -179.082 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -124.23 133.44 24.7 Favored Pre-proline 0 CA--C 1.537 0.477 0 C-N-CA 120.905 -0.318 . . . . 0.0 110.257 179.461 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 60.7 Cg_endo -76.71 164.22 30.52 Favored 'Trans proline' 0 C--N 1.307 -1.618 0 C-N-CA 122.59 2.193 . . . . 0.0 112.286 177.48 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 95.9 mt -85.22 145.38 8.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 115.771 -0.65 . . . . 0.0 110.268 179.023 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 79.7 m-85 -63.79 142.81 58.27 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.527 -179.886 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 52' ' ' GLU . . . . . 0.446 ' N ' ' CD ' ' A' ' 52' ' ' GLU . 0.1 OUTLIER -70.58 -178.01 1.68 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.582 179.776 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 53' ' ' ASP . . . . . 0.411 ' HB2' HD11 ' A' ' 39' ' ' ILE . 4.0 m-20 -146.51 138.25 24.68 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.884 179.499 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 89.3 m-85 -108.13 120.01 41.13 Favored 'General case' 0 N--CA 1.463 0.187 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.279 179.266 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 9.9 p -127.28 136.52 60.42 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.285 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.377 179.881 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 97.4 m-20 -56.89 142.99 39.26 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.463 -179.855 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 11.4 t -61.79 -35.15 77.34 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.716 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 37.7 m -55.44 -32.33 62.65 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.724 -179.718 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 98.6 t -63.76 -46.14 95.32 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.587 -179.889 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 59.36 27.09 62.65 Favored Glycine 0 CA--C 1.527 0.827 0 N-CA-C 110.859 -0.896 . . . . 0.0 110.859 -179.931 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 52.7 t80 -166.52 149.89 7.09 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 121.224 0.535 . . . . 0.0 110.945 -179.415 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 62' ' ' TYR . . . . . 0.412 ' CD2' ' CD1' ' A' ' 39' ' ' ILE . 25.7 t80 -158.81 159.26 34.92 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.971 -0.558 . . . . 0.0 110.141 179.003 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 85.3 m -125.28 136.28 53.36 Favored 'General case' 0 N--CA 1.464 0.233 0 CA-C-N 116.378 -0.373 . . . . 0.0 110.392 -179.714 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -131.87 105.93 10.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.185 179.37 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 3.2 p -114.1 156.23 24.56 Favored 'General case' 0 CA--C 1.516 -0.358 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.515 179.632 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 109.63 40.46 1.46 Allowed Glycine 0 CA--C 1.523 0.589 0 N-CA-C 111.245 -0.742 . . . . 0.0 111.245 -179.754 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 18.5 mt -113.69 102.34 10.16 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-O 121.126 0.488 . . . . 0.0 109.918 179.579 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 12.3 mm-40 -48.66 135.42 13.41 Favored Pre-proline 0 C--N 1.317 -0.805 0 CA-C-N 115.609 -0.723 . . . . 0.0 111.042 -178.558 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 69' ' ' PRO . . . . . 0.407 ' O ' HD12 ' A' ' 71' ' ' ILE . 70.9 Cg_endo -75.33 153.01 39.92 Favored 'Trans proline' 0 N--CA 1.496 1.673 0 C-N-CA 122.882 2.388 . . . . 0.0 111.61 178.8 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 72.43 12.04 76.72 Favored Glycine 0 CA--C 1.521 0.425 0 N-CA-C 111.186 -0.766 . . . . 0.0 111.186 179.479 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 71' ' ' ILE . . . . . 0.537 ' O ' ' NH1' ' B' ' 223' ' ' ARG . 1.7 mp -118.38 147.92 21.56 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.381 0 CA-C-O 121.251 0.548 . . . . 0.0 109.897 -179.878 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 72' ' ' ASP . . . . . 0.513 ' O ' ' HB3' ' A' ' 44' ' ' ALA . 3.1 t70 -86.51 112.39 21.49 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.257 -0.883 . . . . 0.0 110.752 179.947 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 73' ' ' TYR . . . . . 0.548 ' CE2' ' HB2' ' A' ' 43' ' ' ALA . 14.8 m-85 -106.25 119.58 39.62 Favored 'General case' 0 C--O 1.218 -0.601 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.027 179.494 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 74' ' ' ASP . . . . . 0.538 ' N ' ' O ' ' A' ' 42' ' ' VAL . 72.1 m-20 -88.29 117.53 27.27 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.741 -0.663 . . . . 0.0 109.576 179.442 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 75' ' ' ILE . . . . . 0.643 HD11 ' N ' ' B' ' 223' ' ' ARG . 0.0 OUTLIER -114.59 165.97 9.03 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-O 121.038 0.447 . . . . 0.0 110.344 -179.457 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -155.14 120.73 5.04 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.586 -0.734 . . . . 0.0 110.976 179.273 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.448 ' O ' HG23 ' B' ' 217' ' ' THR . 8.9 t -100.31 101.88 12.69 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 N-CA-C 109.835 -0.431 . . . . 0.0 109.835 179.22 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 95.7 mt -88.8 126.86 41.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.648 -179.756 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 96.6 m -108.36 111.31 23.17 Favored 'General case' 0 CA--C 1.517 -0.303 0 CA-C-O 121.011 0.434 . . . . 0.0 109.984 179.7 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 51.4 tp -120.73 125.04 46.63 Favored 'General case' 0 CA--C 1.519 -0.234 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.875 179.965 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 81' ' ' ILE . . . . . 0.526 ' HB ' ' H ' ' A' ' 33' ' ' THR . 2.0 pp -144.69 143.83 22.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.279 178.991 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 82' ' ' ASN . . . . . 0.459 ' N ' ' OG1' ' A' ' 33' ' ' THR . 62.8 t-20 . . . . . 0 C--N 1.328 -0.331 0 CA-C-N 116.334 -0.394 . . . . 0.0 111.204 -179.856 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 207' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.464 0.551 0 N-CA-C 111.241 -0.743 . . . . 0.0 111.241 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' B' B ' 208' ' ' SER . . . . . 0.5 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 33.2 p -164.49 172.26 13.55 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.726 0.298 . . . . 0.0 110.767 -179.676 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 209' ' ' TRP . . . . . . . . . . . . . 73.2 m95 -85.35 151.15 24.24 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.284 -0.417 . . . . 0.0 110.357 179.529 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 81.6 p -131.66 137.64 48.42 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.387 -0.37 . . . . 0.0 110.903 -179.964 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 47.4 t-105 -95.54 115.45 27.44 Favored 'General case' 0 C--N 1.331 -0.199 0 N-CA-C 109.87 -0.418 . . . . 0.0 109.87 179.402 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 212' ' ' GLU . . . . . 0.512 ' O ' ' O ' ' B' ' 215' ' ' LYS . 2.8 tt0 -161.33 150.7 16.54 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.578 179.59 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 213' ' ' ASN . . . . . 0.425 ' N ' ' HG3' ' B' ' 212' ' ' GLU . 13.2 m120 59.68 42.2 17.37 Favored 'General case' 0 N--CA 1.448 -0.53 0 CA-C-N 115.901 -0.591 . . . . 0.0 111.166 177.145 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 49.86 12.95 0.5 Allowed Glycine 0 CA--C 1.521 0.417 0 N-CA-C 111.63 -0.588 . . . . 0.0 111.63 179.161 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 215' ' ' LYS . . . . . 0.512 ' O ' ' O ' ' B' ' 212' ' ' GLU . 68.1 mttm -142.04 150.58 41.46 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.054 0.454 . . . . 0.0 110.457 -179.997 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 216' ' ' TRP . . . . . . . . . . . . . 45.7 m95 -86.13 122.31 29.97 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.42 -0.355 . . . . 0.0 110.119 -179.941 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 217' ' ' THR . . . . . 0.448 HG23 ' O ' ' A' ' 77' ' ' VAL . 18.8 m -129.19 141.51 51.14 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.934 0.397 . . . . 0.0 110.426 -179.677 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 218' ' ' TRP . . . . . 0.5 ' CH2' ' N ' ' B' ' 208' ' ' SER . 16.7 t-105 -105.43 118.02 35.5 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-N 115.888 -0.596 . . . . 0.0 109.742 179.477 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 24.0 mtmm -142.13 173.76 11.23 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.798 -179.882 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -176.39 -161.27 25.09 Favored Glycine 0 CA--C 1.523 0.57 0 N-CA-C 111.243 -0.743 . . . . 0.0 111.243 -179.698 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 221' ' ' ILE . . . . . 0.561 ' O ' HG23 ' B' ' 222' ' ' ILE . 30.5 mt -52.39 -73.39 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 C-N-CA 120.812 -0.355 . . . . 0.0 110.228 -178.534 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 222' ' ' ILE . . . . . 0.561 HG23 ' O ' ' B' ' 221' ' ' ILE . 20.5 pt -158.97 -165.89 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.208 0 CA-C-N 116.301 -0.408 . . . . 0.0 110.458 -179.932 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 223' ' ' ARG . . . . . 0.643 ' N ' HD11 ' A' ' 75' ' ' ILE . 30.7 ptt-85 -44.31 174.55 0.0 OUTLIER 'General case' 0 N--CA 1.456 -0.17 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.281 179.378 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 224' ' ' LEU . . . . . 0.787 HD22 ' N ' ' B' ' 224' ' ' LEU . 2.6 mm? -62.13 117.97 6.73 Favored 'General case' 0 C--N 1.316 -0.886 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.768 -179.516 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 81.7 tt0 . . . . . 0 C--N 1.329 -0.298 0 CA-C-N 115.612 -0.722 . . . . 0.0 110.642 -179.93 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 4.1 p30 . . . . . 0 CA--C 1.52 -0.2 0 CA-C-O 120.772 0.32 . . . . 0.0 110.494 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.622 HD23 ' H ' ' A' ' 13' ' ' SER . 0.5 OUTLIER -68.02 151.41 47.11 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.307 -179.784 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 13' ' ' SER . . . . . 0.622 ' H ' HD23 ' A' ' 12' ' ' LEU . 61.6 p -143.25 149.39 37.83 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.608 179.568 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 14' ' ' PHE . . . . . 0.527 ' CD1' ' N ' ' A' ' 14' ' ' PHE . 17.4 m-85 -112.34 147.02 37.24 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.879 -0.6 . . . . 0.0 110.649 -179.599 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 23.3 m -147.54 156.61 9.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.398 179.43 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 38.2 t0 60.78 28.47 18.21 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.616 179.897 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 96.5 mt -55.88 132.39 19.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.062 179.799 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.437 HG22 ' H ' ' A' ' 19' ' ' ASP . 0.2 OUTLIER -131.12 -169.36 2.16 Favored 'General case' 0 N--CA 1.467 0.409 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.469 -179.839 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 19' ' ' ASP . . . . . 0.477 ' N ' ' OD1' ' A' ' 19' ' ' ASP . 17.5 p-10 -77.65 -49.26 14.9 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.963 179.513 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 20' ' ' SER . . . . . 0.513 ' OG ' ' N ' ' A' ' 67' ' ' LEU . 31.1 t -120.46 13.39 11.79 Favored 'General case' 0 N--CA 1.466 0.358 0 CA-C-N 116.511 -0.313 . . . . 0.0 110.704 -179.252 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 21' ' ' SER . . . . . 0.529 ' HB3' HG22 ' A' ' 65' ' ' THR . 3.8 m -146.56 129.8 16.62 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.237 -179.307 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 22' ' ' ILE . . . . . 0.516 HD12 HD21 ' A' ' 24' ' ' LEU . 47.7 pt -125.78 142.25 43.09 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-N 116.288 -0.415 . . . . 0.0 109.979 179.756 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -98.28 83.08 0.65 Allowed Glycine 0 CA--C 1.523 0.593 0 N-CA-C 110.507 -1.037 . . . . 0.0 110.507 -179.345 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.516 HD21 HD12 ' A' ' 22' ' ' ILE . 92.0 mt -65.57 128.09 34.52 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 110.013 -0.365 . . . . 0.0 110.013 -179.634 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 25' ' ' ARG . . . . . 0.44 ' O ' ' O ' ' A' ' 13' ' ' SER . 1.2 tpp180 -147.75 134.86 20.4 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.045 179.832 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 26' ' ' TRP . . . . . 0.554 ' CE3' ' O ' ' A' ' 60' ' ' GLY . 4.9 p90 -140.29 128.45 22.32 Favored 'General case' 0 C--O 1.223 -0.299 0 N-CA-C 109.223 -0.658 . . . . 0.0 109.223 177.73 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 1.9 m -68.34 113.27 14.32 Favored Pre-proline 0 CA--C 1.538 0.49 0 C-N-CA 120.528 -0.469 . . . . 0.0 111.011 -179.633 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 32.7 Cg_exo -59.53 152.39 62.28 Favored 'Trans proline' 0 N--CA 1.498 1.744 0 C-N-CA 121.993 1.795 . . . . 0.0 112.599 178.473 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.433 ' H ' ' HB2' ' A' ' 32' ' ' SER . 77.9 mt -102.16 133.43 47.03 Favored 'General case' 0 CA--C 1.518 -0.254 0 CA-C-O 121.682 0.754 . . . . 0.0 110.651 179.728 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 11.7 t-20 -42.79 -30.54 0.4 Allowed 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 115.352 -0.84 . . . . 0.0 110.47 -179.725 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 58.1 m -87.88 -36.64 17.07 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.483 179.087 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 32' ' ' SER . . . . . 0.433 ' HB2' ' H ' ' A' ' 29' ' ' LEU . 3.1 m -45.73 113.54 0.62 Allowed 'General case' 0 N--CA 1.461 0.115 0 CA-C-O 121.091 0.472 . . . . 0.0 110.306 -179.661 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 33' ' ' THR . . . . . 0.519 ' OG1' ' N ' ' A' ' 82' ' ' ASN . 7.2 m -52.24 150.01 4.97 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.601 -0.727 . . . . 0.0 109.448 -179.251 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 19.6 mm -93.92 92.65 3.66 Favored 'Isoleucine or valine' 0 C--O 1.232 0.135 0 CA-C-O 121.11 0.481 . . . . 0.0 110.995 -178.51 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.6 HD11 ' HA ' ' A' ' 81' ' ' ILE . 6.6 pt -151.23 124.84 1.34 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.252 179.288 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -48.25 131.4 19.84 Favored Glycine 0 CA--C 1.519 0.336 0 N-CA-C 110.786 -0.925 . . . . 0.0 110.786 -179.624 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 37' ' ' TYR . . . . . 0.571 ' O ' ' CD1' ' A' ' 37' ' ' TYR . 0.6 OUTLIER -104.13 130.07 51.85 Favored 'General case' 0 C--N 1.329 -0.322 0 N-CA-C 109.691 -0.485 . . . . 0.0 109.691 -179.895 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 38' ' ' ARG . . . . . 0.516 ' NH1' ' OG1' ' A' ' 40' ' ' THR . 7.9 tmm_? -79.59 132.27 36.23 Favored 'General case' 0 C--N 1.325 -0.472 0 C-N-CA 120.743 -0.383 . . . . 0.0 111.003 -179.895 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.559 HG22 ' CE2' ' A' ' 37' ' ' TYR . 1.9 pt -104.51 122.58 57.65 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.329 0 N-CA-C 109.585 -0.524 . . . . 0.0 109.585 179.179 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 40' ' ' THR . . . . . 0.516 ' OG1' ' NH1' ' A' ' 38' ' ' ARG . 7.1 m -99.44 136.52 39.26 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.425 -179.022 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.4 p -133.31 141.55 44.25 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.288 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.133 179.855 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 42' ' ' VAL . . . . . 0.499 ' O ' ' N ' ' A' ' 74' ' ' ASP . 39.9 t -132.59 132.48 59.96 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.24 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 179.607 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.438 ' HB2' ' CE2' ' A' ' 73' ' ' TYR . . . -99.35 136.62 39.03 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 116.09 -0.504 . . . . 0.0 109.651 178.921 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 44' ' ' ALA . . . . . 0.632 ' HB3' ' O ' ' A' ' 72' ' ' ASP . . . -99.02 -15.43 19.07 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-O 120.806 0.336 . . . . 0.0 110.85 -179.801 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -99.62 24.99 30.0 Favored Glycine 0 CA--C 1.525 0.7 0 N-CA-C 111.093 -0.803 . . . . 0.0 111.093 -179.44 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 93.5 mt-10 -145.95 149.37 34.05 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.97 0.414 . . . . 0.0 110.337 179.936 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -66.59 -21.06 70.54 Favored Glycine 0 CA--C 1.519 0.302 0 N-CA-C 110.67 -0.972 . . . . 0.0 110.67 179.896 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -132.23 139.58 35.35 Favored Pre-proline 0 CA--C 1.539 0.527 0 C-N-CA 121.224 -0.19 . . . . 0.0 110.524 179.873 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 61.3 Cg_endo -73.93 161.87 40.4 Favored 'Trans proline' 0 N--CA 1.49 1.281 0 C-N-CA 122.469 2.113 . . . . 0.0 111.96 177.613 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 96.8 mt -77.48 149.96 5.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.461 179.354 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 76.1 m-85 -72.47 141.59 48.59 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.678 179.78 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 52' ' ' GLU . . . . . 0.414 ' N ' ' CD ' ' A' ' 52' ' ' GLU . 0.2 OUTLIER -61.77 -177.07 0.1 Allowed 'General case' 0 CA--C 1.517 -0.321 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.418 179.275 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -144.33 135.29 25.16 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 115.637 -0.71 . . . . 0.0 110.301 179.706 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 86.7 m-85 -108.46 116.55 32.19 Favored 'General case' 0 N--CA 1.465 0.287 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.374 179.697 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 9.2 p -130.35 143.77 39.99 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.291 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.145 179.77 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 95.5 m-20 -66.79 151.16 48.02 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.595 179.626 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 4.4 t -64.99 -32.04 73.58 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.628 179.86 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 50.4 m -52.57 -38.58 60.23 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.485 -179.703 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.467 HG12 ' O ' ' A' ' 61' ' ' TYR . 23.8 t -60.66 -43.03 94.0 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 -179.942 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 60' ' ' GLY . . . . . 0.554 ' O ' ' CE3' ' A' ' 26' ' ' TRP . . . 75.19 -40.91 1.27 Allowed Glycine 0 CA--C 1.529 0.919 0 N-CA-C 110.846 -0.902 . . . . 0.0 110.846 179.651 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 61' ' ' TYR . . . . . 0.467 ' O ' HG12 ' A' ' 59' ' ' VAL . 26.9 p90 -113.46 158.64 20.43 Favored 'General case' 0 N--CA 1.469 0.495 0 CA-C-O 121.048 0.451 . . . . 0.0 111.245 -178.881 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 62' ' ' TYR . . . . . 0.411 ' CD2' ' CD1' ' A' ' 39' ' ' ILE . 33.3 t80 -152.93 149.5 28.29 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 179.541 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 79.8 m -112.4 133.93 54.22 Favored 'General case' 0 CA--C 1.52 -0.195 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.468 -179.445 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -132.36 100.09 3.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 115.854 -0.612 . . . . 0.0 109.834 178.762 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.529 HG22 ' HB3' ' A' ' 21' ' ' SER . 2.0 p -114.37 164.18 14.29 Favored 'General case' 0 CA--C 1.515 -0.38 0 CA-C-O 120.908 0.385 . . . . 0.0 110.524 -179.942 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 107.79 25.63 5.87 Favored Glycine 0 CA--C 1.524 0.622 0 N-CA-C 111.172 -0.771 . . . . 0.0 111.172 179.75 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.513 ' N ' ' OG ' ' A' ' 20' ' ' SER . 11.9 mt -100.72 109.44 21.47 Favored 'General case' 0 N--CA 1.465 0.318 0 N-CA-C 109.284 -0.636 . . . . 0.0 109.284 179.944 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 55.5 mm-40 -52.04 139.53 33.57 Favored Pre-proline 0 C--N 1.316 -0.887 0 C-N-CA 120.496 -0.482 . . . . 0.0 112.054 -178.589 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 69' ' ' PRO . . . . . 0.428 ' C ' ' H ' ' A' ' 71' ' ' ILE . 74.4 Cg_endo -73.91 157.52 47.24 Favored 'Trans proline' 0 N--CA 1.498 1.748 0 C-N-CA 122.86 2.373 . . . . 0.0 111.253 178.574 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 69.97 -8.54 3.49 Favored Glycine 0 CA--C 1.527 0.822 0 CA-C-N 115.844 -0.616 . . . . 0.0 111.653 178.855 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 71' ' ' ILE . . . . . 0.524 ' O ' ' NH1' ' B' ' 223' ' ' ARG . 1.6 mp -98.76 149.19 5.53 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 N-CA-C 109.229 -0.656 . . . . 0.0 109.229 -179.702 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 72' ' ' ASP . . . . . 0.632 ' O ' ' HB3' ' A' ' 44' ' ' ALA . 2.7 t70 -89.51 115.61 27.06 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.165 -0.925 . . . . 0.0 110.422 179.657 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 73' ' ' TYR . . . . . 0.493 ' O ' HD13 ' A' ' 75' ' ' ILE . 20.9 m-85 -108.48 119.74 40.38 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.425 179.951 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 74' ' ' ASP . . . . . 0.499 ' N ' ' O ' ' A' ' 42' ' ' VAL . 13.4 m-20 -89.8 118.13 29.16 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 115.548 -0.751 . . . . 0.0 109.646 179.824 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 75' ' ' ILE . . . . . 0.493 HD13 ' O ' ' A' ' 73' ' ' TYR . 0.0 OUTLIER -115.9 164.24 12.42 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-O 121.192 0.52 . . . . 0.0 109.919 -179.139 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -152.92 128.88 10.3 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.659 -0.7 . . . . 0.0 110.216 179.667 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 62.8 t -108.27 131.79 57.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 179.461 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 96.5 mt -124.51 124.45 68.32 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 115.991 -0.549 . . . . 0.0 110.344 179.458 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 95.1 m -100.86 114.41 28.23 Favored 'General case' 0 C--O 1.232 0.181 0 CA-C-O 120.922 0.391 . . . . 0.0 110.081 179.636 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 80' ' ' LEU . . . . . 0.754 HD23 ' HZ1' ' B' ' 215' ' ' LYS . 9.6 mt -118.68 113.96 22.0 Favored 'General case' 0 CA--C 1.518 -0.251 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.253 -179.988 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 81' ' ' ILE . . . . . 0.6 ' HA ' HD11 ' A' ' 35' ' ' ILE . 2.3 pp -147.47 144.84 19.4 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.042 179.146 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 82' ' ' ASN . . . . . 0.519 ' N ' ' OG1' ' A' ' 33' ' ' THR . 39.9 t30 . . . . . 0 C--N 1.327 -0.391 0 CA-C-O 120.942 0.401 . . . . 0.0 111.189 179.892 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 207' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.463 0.486 0 N-CA-C 110.957 -0.857 . . . . 0.0 110.957 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' B' B ' 208' ' ' SER . . . . . 0.536 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 98.9 p -164.52 168.35 18.41 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.862 0.363 . . . . 0.0 110.711 179.238 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 209' ' ' TRP . . . . . . . . . . . . . 85.4 m95 -88.89 150.95 22.63 Favored 'General case' 0 C--O 1.233 0.205 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.522 179.54 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 82.3 p -129.09 129.0 44.67 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-N 116.487 -0.324 . . . . 0.0 110.394 179.532 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 58.7 t-105 -91.41 110.62 21.93 Favored 'General case' 0 C--N 1.333 -0.112 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.586 179.82 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 212' ' ' GLU . . . . . 0.437 ' O ' ' O ' ' B' ' 215' ' ' LYS . 0.6 OUTLIER -161.26 165.93 28.45 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.541 179.654 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' B' B ' 213' ' ' ASN . . . . . . . . . . . . . 69.7 m-20 51.02 35.25 12.33 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.89 -0.595 . . . . 0.0 110.978 176.436 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 51.17 19.97 4.35 Favored Glycine 0 CA--C 1.525 0.661 0 N-CA-C 110.954 -0.858 . . . . 0.0 110.954 179.946 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 215' ' ' LYS . . . . . 0.754 ' HZ1' HD23 ' A' ' 80' ' ' LEU . 14.9 mtpt -145.79 150.58 36.46 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 121.066 0.46 . . . . 0.0 110.985 179.983 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 216' ' ' TRP . . . . . . . . . . . . . 52.4 m95 -87.19 114.43 23.79 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.866 -0.606 . . . . 0.0 109.883 179.233 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 217' ' ' THR . . . . . . . . . . . . . 46.4 m -118.36 135.07 54.54 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.694 -179.587 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 218' ' ' TRP . . . . . 0.536 ' CH2' ' N ' ' B' ' 208' ' ' SER . 29.5 t-105 -106.39 104.0 13.59 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 115.907 -0.588 . . . . 0.0 109.876 178.868 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 16.7 mtpp -134.38 173.8 11.23 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.558 -179.303 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -179.53 -160.94 26.05 Favored Glycine 0 CA--C 1.524 0.599 0 N-CA-C 110.761 -0.936 . . . . 0.0 110.761 179.819 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 221' ' ' ILE . . . . . 0.688 ' H ' HD12 ' B' ' 221' ' ' ILE . 1.9 mp -54.1 -73.14 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 C-N-CA 120.66 -0.416 . . . . 0.0 110.261 -178.804 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 222' ' ' ILE . . . . . 0.553 HG23 ' O ' ' B' ' 221' ' ' ILE . 21.8 pt -160.51 -165.28 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.212 -179.799 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 223' ' ' ARG . . . . . 0.536 ' O ' ' O ' ' B' ' 222' ' ' ILE . 35.9 ptt-85 -40.28 174.03 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.973 178.605 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 224' ' ' LEU . . . . . 0.789 HD22 ' N ' ' B' ' 224' ' ' LEU . 2.2 mm? -63.45 110.16 1.86 Allowed 'General case' 0 N--CA 1.447 -0.613 0 CA-C-N 115.799 -0.637 . . . . 0.0 111.079 -179.673 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 33.8 tp10 . . . . . 0 C--N 1.329 -0.325 0 CA-C-N 115.394 -0.821 . . . . 0.0 110.002 -179.865 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 97.7 m-20 . . . . . 0 N--CA 1.463 0.201 0 CA-C-O 120.717 0.294 . . . . 0.0 110.254 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 56.5 tp -66.27 138.35 57.59 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.562 -179.969 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 16.1 p -139.6 152.93 47.22 Favored 'General case' 0 N--CA 1.463 0.192 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.384 179.555 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 14' ' ' PHE . . . . . 0.516 ' CD1' ' N ' ' A' ' 14' ' ' PHE . 27.7 m-85 -111.54 144.12 41.29 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.837 -179.407 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 27.6 m -143.49 164.29 15.52 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.415 179.527 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 98.8 m-20 50.37 30.46 4.55 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.95 179.79 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 96.7 mt -55.78 138.51 16.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-O 120.921 0.391 . . . . 0.0 110.202 179.507 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.464 ' CB ' ' O ' ' A' ' 21' ' ' SER . 0.2 OUTLIER -135.7 -166.75 1.91 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.034 -179.48 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 19' ' ' ASP . . . . . 0.469 ' N ' ' OD1' ' A' ' 19' ' ' ASP . 27.8 p-10 -84.94 -46.58 11.11 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.831 179.489 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 20' ' ' SER . . . . . 0.464 ' N ' ' OD1' ' A' ' 19' ' ' ASP . 43.0 m -120.74 12.56 11.41 Favored 'General case' 0 N--CA 1.467 0.389 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.852 179.99 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 21' ' ' SER . . . . . 0.464 ' O ' ' CB ' ' A' ' 18' ' ' THR . 85.9 p -150.26 143.55 25.01 Favored 'General case' 0 N--CA 1.465 0.283 0 CA-C-O 121.037 0.446 . . . . 0.0 110.335 -179.943 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 40.7 pt -140.46 145.0 26.47 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.361 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.217 -179.992 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -96.31 85.85 0.89 Allowed Glycine 0 CA--C 1.522 0.497 0 N-CA-C 110.882 -0.887 . . . . 0.0 110.882 -179.906 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 89.9 mt -62.3 121.02 12.12 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 120.905 0.383 . . . . 0.0 110.05 -179.782 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 25' ' ' ARG . . . . . 0.503 ' NH1' ' O ' ' A' ' 26' ' ' TRP . 28.0 tpt85 -138.03 135.25 35.71 Favored 'General case' 0 CA--C 1.517 -0.301 0 CA-C-O 121.115 0.483 . . . . 0.0 110.199 -179.468 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 26' ' ' TRP . . . . . 0.503 ' O ' ' NH1' ' A' ' 25' ' ' ARG . 46.1 p90 -147.52 155.45 41.88 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.555 -0.748 . . . . 0.0 109.604 179.851 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 6.2 m -111.34 98.12 38.62 Favored Pre-proline 0 C--N 1.33 -0.249 0 N-CA-C 110.102 -0.332 . . . . 0.0 110.102 179.66 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 32.5 Cg_exo -54.53 144.81 61.31 Favored 'Trans proline' 0 C--N 1.306 -1.692 0 C-N-CA 121.604 1.536 . . . . 0.0 113.275 179.909 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 57.1 mt -79.01 138.16 37.9 Favored 'General case' 0 CA--C 1.506 -0.743 0 CA-C-N 115.49 -0.777 . . . . 0.0 110.627 -179.567 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 34.1 t30 -50.45 -34.21 23.93 Favored 'General case' 0 C--N 1.313 -1.021 0 CA-C-N 114.856 -1.066 . . . . 0.0 110.098 179.523 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 49.2 m -79.82 -32.58 40.7 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.629 -0.714 . . . . 0.0 110.412 179.118 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 8.0 m -60.0 137.7 58.02 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.197 -179.932 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 33' ' ' THR . . . . . 0.611 ' CB ' ' H ' ' A' ' 82' ' ' ASN . 11.7 m -67.41 143.1 56.47 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.22 -179.645 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 28.8 mm -94.05 94.04 4.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 121.0 0.429 . . . . 0.0 110.176 -179.564 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 10.7 pt -143.49 131.4 18.67 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.274 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.416 -179.973 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -41.84 118.23 1.46 Allowed Glycine 0 CA--C 1.519 0.328 0 N-CA-C 111.318 -0.713 . . . . 0.0 111.318 -179.599 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 94.6 m-85 -85.09 178.88 7.39 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.875 0.369 . . . . 0.0 110.11 179.376 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 38' ' ' ARG . . . . . 0.549 ' NE ' ' OE1' ' A' ' 52' ' ' GLU . 0.0 OUTLIER -132.48 125.99 31.95 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.727 179.92 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.46 ' CD1' ' CD2' ' A' ' 62' ' ' TYR . 2.5 pt -100.24 123.81 53.35 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 115.657 -0.701 . . . . 0.0 110.018 179.78 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 40' ' ' THR . . . . . 0.449 ' OG1' ' NE ' ' A' ' 38' ' ' ARG . 28.2 m -109.04 133.09 53.46 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.612 -179.07 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.2 p -130.51 138.44 53.74 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.305 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.288 179.844 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 42' ' ' VAL . . . . . 0.467 ' O ' ' N ' ' A' ' 74' ' ' ASP . 31.7 t -131.94 130.95 61.69 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.269 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 179.979 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.455 ' HB1' ' CE1' ' A' ' 73' ' ' TYR . . . -96.44 135.87 37.73 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.765 -0.652 . . . . 0.0 109.32 179.677 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 44' ' ' ALA . . . . . 0.607 ' HB3' ' O ' ' A' ' 72' ' ' ASP . . . -92.57 -47.24 7.22 Favored 'General case' 0 N--CA 1.464 0.24 0 C-N-CA 120.673 -0.411 . . . . 0.0 110.839 179.93 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -62.09 -29.55 73.09 Favored Glycine 0 N--CA 1.464 0.559 0 N-CA-C 110.891 -0.883 . . . . 0.0 110.891 179.997 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 46' ' ' GLU . . . . . 0.429 ' OE2' ' OH ' ' A' ' 73' ' ' TYR . 84.8 mt-10 -95.57 130.44 42.43 Favored 'General case' 0 C--N 1.328 -0.369 0 N-CA-C 109.477 -0.564 . . . . 0.0 109.477 -179.552 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -58.18 -21.17 45.98 Favored Glycine 0 CA--C 1.528 0.869 0 N-CA-C 110.857 -0.897 . . . . 0.0 110.857 -178.941 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -119.25 136.32 24.42 Favored Pre-proline 0 N--CA 1.472 0.661 0 CA-C-N 116.715 0.258 . . . . 0.0 110.543 179.676 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -77.9 167.5 23.63 Favored 'Trans proline' 0 N--CA 1.49 1.295 0 C-N-CA 122.409 2.072 . . . . 0.0 111.428 178.079 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 87.2 mt -86.22 141.66 14.14 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.235 0 CA-C-O 120.826 0.346 . . . . 0.0 110.245 179.081 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 76.3 m-85 -60.85 138.95 58.09 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.633 179.986 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 52' ' ' GLU . . . . . 0.549 ' OE1' ' NE ' ' A' ' 38' ' ' ARG . 5.9 pt-20 -69.64 -178.62 1.51 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.455 179.798 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 4.5 t70 -153.38 148.7 27.02 Favored 'General case' 0 N--CA 1.45 -0.444 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.748 179.367 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 58.0 m-85 -115.93 125.28 52.36 Favored 'General case' 0 N--CA 1.464 0.257 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.139 -179.929 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.9 p -125.64 134.49 66.56 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.341 0 CA-C-N 116.471 -0.331 . . . . 0.0 110.208 -179.985 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 98.9 m-20 -53.41 140.15 28.46 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.322 -179.653 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 10.4 t -60.4 -34.16 73.54 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.002 -0.544 . . . . 0.0 110.573 -179.763 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 43.7 m -55.24 -34.34 63.91 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.547 -179.731 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 99.9 t -62.31 -46.51 96.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.579 -179.871 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 61.25 26.38 65.98 Favored Glycine 0 CA--C 1.527 0.796 0 N-CA-C 110.568 -1.013 . . . . 0.0 110.568 179.635 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 52.6 t80 -167.44 152.03 6.89 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 121.121 0.486 . . . . 0.0 111.091 -179.513 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 62' ' ' TYR . . . . . 0.46 ' CD2' ' CD1' ' A' ' 39' ' ' ILE . 29.1 t80 -159.64 162.05 35.11 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 115.724 -0.671 . . . . 0.0 110.281 178.702 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 99.0 m -127.44 134.68 49.84 Favored 'General case' 0 N--CA 1.463 0.217 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.296 179.835 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -130.76 113.83 25.9 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.334 0 N-CA-C 109.513 -0.551 . . . . 0.0 109.513 178.877 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 1.9 p -122.93 157.33 32.84 Favored 'General case' 0 N--CA 1.467 0.418 0 CA-C-O 120.907 0.384 . . . . 0.0 110.413 -179.66 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 107.59 40.62 1.72 Allowed Glycine 0 CA--C 1.523 0.581 0 N-CA-C 110.628 -0.989 . . . . 0.0 110.628 -179.729 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 1.4 mt -116.79 110.83 18.9 Favored 'General case' 0 N--CA 1.465 0.304 0 N-CA-C 109.502 -0.555 . . . . 0.0 109.502 -179.896 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 27.6 mm-40 -48.84 141.34 10.27 Favored Pre-proline 0 C--N 1.322 -0.628 0 C-N-CA 120.862 -0.335 . . . . 0.0 111.249 -178.486 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 91.4 Cg_endo -74.89 158.37 42.66 Favored 'Trans proline' 0 N--CA 1.491 1.341 0 C-N-CA 122.481 2.121 . . . . 0.0 112.558 179.511 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 70' ' ' GLY . . . . . 0.409 ' N ' ' NH2' ' B' ' 223' ' ' ARG . . . 48.53 27.55 6.01 Favored Glycine 0 CA--C 1.529 0.951 0 CA-C-N 114.837 -1.074 . . . . 0.0 111.182 179.305 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 71' ' ' ILE . . . . . 0.736 ' H ' HH21 ' B' ' 223' ' ' ARG . 0.9 OUTLIER -114.0 166.36 7.93 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.483 0 CA-C-O 121.13 0.491 . . . . 0.0 109.698 -179.578 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 72' ' ' ASP . . . . . 0.607 ' O ' ' HB3' ' A' ' 44' ' ' ALA . 3.2 t70 -101.17 100.27 10.8 Favored 'General case' 0 N--CA 1.446 -0.649 0 CA-C-N 115.6 -0.727 . . . . 0.0 111.411 -178.715 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 73' ' ' TYR . . . . . 0.503 ' O ' HD13 ' A' ' 75' ' ' ILE . 2.2 m-30 -110.81 124.69 52.51 Favored 'General case' 0 C--O 1.22 -0.472 0 CA-C-O 121.322 0.582 . . . . 0.0 110.341 179.16 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 74' ' ' ASP . . . . . 0.467 ' N ' ' O ' ' A' ' 42' ' ' VAL . 21.5 m-20 -89.11 116.11 27.13 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 114.894 -1.048 . . . . 0.0 109.485 -179.909 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 75' ' ' ILE . . . . . 0.578 HD11 ' N ' ' B' ' 223' ' ' ARG . 0.0 OUTLIER -116.17 162.1 14.43 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.221 0 CA-C-O 121.219 0.533 . . . . 0.0 110.084 -179.383 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 3.0 m -154.04 150.69 28.51 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.259 -0.882 . . . . 0.0 110.755 179.502 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.511 ' O ' HG13 ' A' ' 77' ' ' VAL . 4.1 p -132.9 101.14 4.2 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.245 0 CA-C-N 115.824 -0.625 . . . . 0.0 109.398 178.421 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 94.6 mt -82.95 127.81 39.32 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.183 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.451 -179.522 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 5.0 p -108.21 105.89 15.82 Favored 'General case' 0 N--CA 1.464 0.251 0 CA-C-N 116.143 -0.481 . . . . 0.0 109.709 179.422 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 7.0 tp -121.68 130.59 53.57 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.353 -179.867 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 81' ' ' ILE . . . . . 0.581 ' O ' HD12 ' A' ' 81' ' ' ILE . 1.6 pp -131.3 168.37 24.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.098 -0.501 . . . . 0.0 109.908 179.136 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 82' ' ' ASN . . . . . 0.611 ' H ' ' CB ' ' A' ' 33' ' ' THR . 9.8 t-20 . . . . . 0 C--N 1.33 -0.263 0 CA-C-O 120.813 0.34 . . . . 0.0 110.634 -179.992 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 207' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.464 0.536 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' B' B ' 208' ' ' SER . . . . . 0.497 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 97.1 p -164.14 170.03 16.96 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.81 0.338 . . . . 0.0 110.741 179.636 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 209' ' ' TRP . . . . . . . . . . . . . 71.9 m95 -82.93 145.59 29.3 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.412 179.529 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 40.3 p -127.33 131.29 50.45 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.565 179.942 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 41.4 t-105 -91.68 118.58 30.78 Favored 'General case' 0 N--CA 1.466 0.366 0 CA-C-N 116.18 -0.463 . . . . 0.0 109.928 179.596 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 212' ' ' GLU . . . . . 0.487 ' O ' ' O ' ' B' ' 215' ' ' LYS . 1.9 pt-20 -165.75 171.61 12.71 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.898 178.893 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 213' ' ' ASN . . . . . . . . . . . . . 93.9 m-20 48.07 38.08 8.99 Favored 'General case' 0 C--N 1.324 -0.537 0 C-N-CA 120.338 -0.545 . . . . 0.0 111.997 176.629 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 51.34 12.46 0.91 Allowed Glycine 0 CA--C 1.53 0.974 0 N-CA-C 111.536 -0.626 . . . . 0.0 111.536 179.644 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 215' ' ' LYS . . . . . 0.487 ' O ' ' O ' ' B' ' 212' ' ' GLU . 7.5 mtmp? -143.95 151.37 39.68 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.849 0.357 . . . . 0.0 110.962 -179.778 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 216' ' ' TRP . . . . . . . . . . . . . 49.0 m95 -87.0 124.93 33.72 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.25 179.285 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 217' ' ' THR . . . . . . . . . . . . . 5.0 m -138.63 148.1 43.69 Favored 'General case' 0 C--O 1.235 0.293 0 CA-C-O 121.052 0.453 . . . . 0.0 110.341 -179.809 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 218' ' ' TRP . . . . . 0.497 ' CH2' ' N ' ' B' ' 208' ' ' SER . 15.5 t-105 -105.25 121.66 44.32 Favored 'General case' 0 C--N 1.332 -0.167 0 CA-C-N 115.894 -0.593 . . . . 0.0 110.156 179.797 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 97.5 mttt -147.17 169.56 19.07 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.899 -179.996 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -174.83 -162.22 25.94 Favored Glycine 0 CA--C 1.522 0.496 0 N-CA-C 111.155 -0.778 . . . . 0.0 111.155 -179.884 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 221' ' ' ILE . . . . . 0.837 HG23 ' H ' ' B' ' 222' ' ' ILE . 12.2 tt -50.35 -69.71 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 C-N-CA 121.073 -0.251 . . . . 0.0 110.971 -177.977 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 222' ' ' ILE . . . . . 0.837 ' H ' HG23 ' B' ' 221' ' ' ILE . 9.6 pt -159.55 -165.2 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.317 -0.83 0 N-CA-C 109.327 -0.62 . . . . 0.0 109.327 178.377 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 223' ' ' ARG . . . . . 0.736 HH21 ' H ' ' A' ' 71' ' ' ILE . 39.1 ptt85 -44.47 174.98 0.0 OUTLIER 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 121.445 0.641 . . . . 0.0 111.04 178.717 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 224' ' ' LEU . . . . . 0.686 HD22 ' N ' ' B' ' 224' ' ' LEU . 3.2 mm? -59.95 127.48 32.1 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-N 115.046 -0.979 . . . . 0.0 110.377 -179.737 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 31.0 tp10 . . . . . 0 C--N 1.327 -0.41 0 CA-C-N 115.738 -0.665 . . . . 0.0 110.155 -179.959 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 99.4 m-20 . . . . . 0 C--O 1.233 0.185 0 CA-C-O 120.691 0.282 . . . . 0.0 110.385 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.551 HD13 ' H ' ' A' ' 13' ' ' SER . 0.1 OUTLIER -60.85 139.0 58.09 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.152 -178.16 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 13' ' ' SER . . . . . 0.551 ' H ' HD13 ' A' ' 12' ' ' LEU . 96.3 p -143.27 144.55 32.17 Favored 'General case' 0 CA--C 1.521 -0.168 0 CA-C-N 115.837 -0.62 . . . . 0.0 110.621 179.931 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 14' ' ' PHE . . . . . 0.512 ' CD1' ' N ' ' A' ' 14' ' ' PHE . 11.5 m-85 -112.34 143.77 42.89 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.397 -0.82 . . . . 0.0 110.754 -179.22 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 30.1 m -141.27 164.28 20.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.346 179.712 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 27.7 t70 53.63 34.22 18.24 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.08 179.849 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.49 ' N ' HD12 ' A' ' 17' ' ' ILE . 1.9 mp -56.51 132.06 20.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 N-CA-C 109.57 -0.53 . . . . 0.0 109.57 179.936 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -132.8 -169.13 2.19 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-N 116.021 -0.536 . . . . 0.0 109.916 179.711 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 20.7 p-10 -91.24 -41.84 10.74 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.698 179.388 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 43.1 t -113.52 6.44 17.07 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-N 116.363 -0.38 . . . . 0.0 110.99 -179.304 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 21' ' ' SER . . . . . 0.432 ' OG ' HG22 ' A' ' 65' ' ' THR . 38.3 t -154.1 152.61 30.64 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 121.131 0.491 . . . . 0.0 110.202 179.971 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 38.2 pt -142.2 146.26 22.76 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.049 179.816 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -94.75 82.82 0.92 Allowed Glycine 0 CA--C 1.524 0.652 0 N-CA-C 111.076 -0.81 . . . . 0.0 111.076 -179.723 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 76.1 mt -71.14 118.33 13.8 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 121.043 0.449 . . . . 0.0 110.211 179.901 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 56.4 ttt-85 -140.83 137.03 32.98 Favored 'General case' 0 CA--C 1.517 -0.318 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.436 179.935 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 26' ' ' TRP . . . . . . . . . . . . . 41.3 p90 -144.5 156.56 44.23 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.624 -0.716 . . . . 0.0 110.278 -179.36 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 2.2 m -108.05 102.31 45.35 Favored Pre-proline 0 CA--C 1.533 0.302 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.676 -179.953 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 41.7 Cg_exo -53.8 150.04 30.99 Favored 'Trans proline' 0 C--N 1.305 -1.761 0 C-N-CA 121.464 1.443 . . . . 0.0 112.673 179.274 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 60.9 mt -92.3 137.9 31.97 Favored 'General case' 0 CA--C 1.514 -0.425 0 CA-C-O 121.811 0.815 . . . . 0.0 110.809 -179.764 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 28.8 t-20 -47.56 -35.44 9.05 Favored 'General case' 0 C--N 1.313 -1.007 0 CA-C-N 115.056 -0.974 . . . . 0.0 110.092 179.952 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 53.0 m -79.8 -33.72 40.24 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.438 178.847 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 6.0 m -58.36 124.27 18.94 Favored 'General case' 0 CA--C 1.529 0.146 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.055 -179.86 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 33' ' ' THR . . . . . 0.587 ' CB ' ' H ' ' A' ' 82' ' ' ASN . 5.6 m -57.22 146.57 27.85 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.102 -179.762 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 20.5 mm -94.37 91.37 3.08 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.173 0 CA-C-O 121.047 0.451 . . . . 0.0 110.765 -179.377 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.486 HD11 ' HA ' ' A' ' 81' ' ' ILE . 22.1 pt -145.21 128.76 11.51 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.244 0 CA-C-N 115.714 -0.675 . . . . 0.0 110.597 179.815 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -42.65 125.84 4.44 Favored Glycine 0 CA--C 1.523 0.572 0 N-CA-C 111.086 -0.805 . . . . 0.0 111.086 -179.512 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 35.9 m-85 -90.83 -179.9 5.62 Favored 'General case' 0 CA--C 1.517 -0.29 0 N-CA-C 110.024 -0.362 . . . . 0.0 110.024 -179.88 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -131.45 121.34 24.37 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.553 179.753 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.439 ' O ' ' CG1' ' A' ' 39' ' ' ILE . 2.3 pt -95.95 124.29 48.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.008 -0.542 . . . . 0.0 109.716 179.828 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 4.8 m -106.74 132.77 52.33 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.398 -179.361 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.4 p -130.07 137.75 55.69 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.319 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.287 -179.979 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 42' ' ' VAL . . . . . 0.524 ' O ' ' N ' ' A' ' 74' ' ' ASP . 40.1 t -131.02 131.65 63.95 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.298 0 N-CA-C 109.743 -0.465 . . . . 0.0 109.743 179.671 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -97.92 141.26 31.11 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.137 -0.483 . . . . 0.0 109.817 179.273 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 44' ' ' ALA . . . . . 0.565 ' HB3' ' O ' ' A' ' 72' ' ' ASP . . . -100.29 -23.68 14.73 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-O 120.828 0.347 . . . . 0.0 110.672 179.874 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -90.88 31.06 5.78 Favored Glycine 0 N--CA 1.466 0.636 0 N-CA-C 110.776 -0.93 . . . . 0.0 110.776 -179.963 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 64.2 mt-10 -151.8 150.8 30.55 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.951 0.405 . . . . 0.0 110.649 -179.738 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -72.1 -17.67 77.39 Favored Glycine 0 CA--C 1.524 0.62 0 N-CA-C 110.781 -0.928 . . . . 0.0 110.781 179.633 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -133.94 139.04 32.14 Favored Pre-proline 0 CA--C 1.544 0.738 0 CA-C-N 116.772 0.286 . . . . 0.0 110.507 -179.978 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 68.4 Cg_endo -73.89 161.84 40.54 Favored 'Trans proline' 0 N--CA 1.494 1.558 0 C-N-CA 122.631 2.221 . . . . 0.0 111.949 178.31 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 50' ' ' ILE . . . . . 0.492 HG22 ' N ' ' A' ' 51' ' ' PHE . 96.3 mt -75.72 159.26 5.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.381 179.419 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 51' ' ' PHE . . . . . 0.492 ' N ' HG22 ' A' ' 50' ' ' ILE . 0.9 OUTLIER -78.32 142.21 37.9 Favored 'General case' 0 CA--C 1.531 0.24 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.727 179.871 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 52' ' ' GLU . . . . . 0.51 ' CD ' ' H ' ' A' ' 52' ' ' GLU . 0.0 OUTLIER -71.01 -178.48 1.97 Allowed 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.39 179.433 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 53' ' ' ASP . . . . . 0.428 ' OD1' ' OH ' ' A' ' 62' ' ' TYR . 0.2 OUTLIER -148.27 139.74 23.56 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.147 179.75 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 96.2 m-85 -109.32 123.58 49.53 Favored 'General case' 0 N--CA 1.464 0.241 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.478 -179.94 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 5.9 p -131.48 141.29 46.2 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.245 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.215 -179.976 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 84.9 m-20 -58.92 151.03 22.71 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.591 -179.777 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 57' ' ' SER . . . . . 0.478 ' OG ' ' O ' ' A' ' 35' ' ' ILE . 3.7 m -61.66 -34.48 75.78 Favored 'General case' 0 C--O 1.233 0.22 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.84 179.839 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 69.2 m -53.5 -34.59 58.63 Favored 'General case' 0 C--N 1.326 -0.444 0 N-CA-C 109.943 -0.392 . . . . 0.0 109.943 -179.661 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.672 ' C ' ' H ' ' A' ' 61' ' ' TYR . 4.1 t -83.19 76.06 1.09 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.859 -179.826 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -58.72 26.53 0.02 OUTLIER Glycine 0 CA--C 1.539 1.589 0 N-CA-C 111.549 -0.62 . . . . 0.0 111.549 -179.641 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 61' ' ' TYR . . . . . 0.672 ' H ' ' C ' ' A' ' 59' ' ' VAL . 35.8 p90 -160.69 150.58 17.61 Favored 'General case' 0 N--CA 1.453 -0.325 0 CA-C-O 121.125 0.488 . . . . 0.0 111.6 179.986 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 62' ' ' TYR . . . . . 0.428 ' OH ' ' OD1' ' A' ' 53' ' ' ASP . 37.1 t80 -153.6 147.85 25.83 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.688 -0.687 . . . . 0.0 109.583 179.093 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 29.8 m -108.74 132.63 53.76 Favored 'General case' 0 N--CA 1.464 0.235 0 CA-C-O 121.037 0.446 . . . . 0.0 110.563 -179.31 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -132.03 106.16 10.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 115.924 -0.58 . . . . 0.0 109.723 178.662 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.432 HG22 ' OG ' ' A' ' 21' ' ' SER . 2.6 p -114.55 162.06 17.22 Favored 'General case' 0 N--CA 1.465 0.283 0 CA-C-O 120.978 0.418 . . . . 0.0 110.543 179.95 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 108.58 41.07 1.52 Allowed Glycine 0 CA--C 1.524 0.655 0 N-CA-C 111.256 -0.737 . . . . 0.0 111.256 -179.942 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 14.3 mt -115.2 109.07 17.45 Favored 'General case' 0 N--CA 1.466 0.353 0 N-CA-C 109.211 -0.662 . . . . 0.0 109.211 179.456 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 33.6 mm-40 -60.11 140.83 90.74 Favored Pre-proline 0 C--N 1.321 -0.642 0 C-N-CA 120.623 -0.431 . . . . 0.0 111.788 -178.403 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 93.8 Cg_endo -74.63 155.74 44.74 Favored 'Trans proline' 0 N--CA 1.497 1.682 0 C-N-CA 122.686 2.258 . . . . 0.0 111.73 178.802 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 71.61 7.55 65.15 Favored Glycine 0 CA--C 1.525 0.694 0 CA-C-N 115.635 -0.711 . . . . 0.0 111.629 179.128 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 1.6 mp -116.18 144.0 24.9 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.469 0 CA-C-O 121.441 0.639 . . . . 0.0 109.463 -179.934 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 72' ' ' ASP . . . . . 0.565 ' O ' ' HB3' ' A' ' 44' ' ' ALA . 2.1 t70 -84.73 114.18 21.86 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.143 -0.935 . . . . 0.0 110.869 179.943 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 73' ' ' TYR . . . . . 0.467 ' O ' HD13 ' A' ' 75' ' ' ILE . 23.7 m-85 -106.53 122.16 45.74 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 121.251 0.548 . . . . 0.0 110.306 179.849 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 74' ' ' ASP . . . . . 0.524 ' N ' ' O ' ' A' ' 42' ' ' VAL . 11.7 m-20 -91.42 117.5 29.74 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.209 -0.905 . . . . 0.0 109.432 179.625 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 75' ' ' ILE . . . . . 0.556 HD11 ' N ' ' B' ' 223' ' ' ARG . 0.0 OUTLIER -115.27 165.92 9.85 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.422 0 CA-C-O 120.957 0.408 . . . . 0.0 110.267 -179.045 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -154.84 121.94 5.56 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.391 179.208 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.467 ' O ' HG23 ' B' ' 217' ' ' THR . 63.1 t -101.1 102.6 13.68 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 N-CA-C 109.335 -0.617 . . . . 0.0 109.335 179.011 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 95.9 mt -93.64 131.05 41.69 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.229 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.571 -179.591 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 71.3 m -109.28 111.27 22.75 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.078 -0.51 . . . . 0.0 109.917 179.391 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 37.6 tp -116.47 120.72 39.69 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.496 179.915 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 81' ' ' ILE . . . . . 0.707 ' O ' HD12 ' A' ' 81' ' ' ILE . 2.8 pp -142.68 153.97 17.65 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.278 179.397 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 82' ' ' ASN . . . . . 0.587 ' H ' ' CB ' ' A' ' 33' ' ' THR . 14.3 t-20 . . . . . 0 C--N 1.33 -0.279 0 CA-C-O 121.028 0.442 . . . . 0.0 110.932 179.963 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 207' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.464 0.501 0 N-CA-C 111.021 -0.831 . . . . 0.0 111.021 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' B' B ' 208' ' ' SER . . . . . 0.531 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 98.7 p -165.17 170.9 14.37 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 120.706 0.288 . . . . 0.0 110.734 179.83 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 209' ' ' TRP . . . . . . . . . . . . . 72.2 m95 -87.58 131.43 34.4 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.315 179.607 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 68.8 p -110.15 133.39 53.27 Favored 'General case' 0 N--CA 1.465 0.313 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.405 -179.951 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 49.8 t-105 -94.93 118.36 31.68 Favored 'General case' 0 N--CA 1.463 0.199 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.059 179.795 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 212' ' ' GLU . . . . . 0.469 ' O ' ' O ' ' B' ' 215' ' ' LYS . 1.7 pt-20 -164.7 170.64 15.36 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.731 178.903 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 213' ' ' ASN . . . . . . . . . . . . . 13.8 m120 48.82 36.18 7.68 Favored 'General case' 0 C--N 1.323 -0.577 0 C-N-CA 120.321 -0.552 . . . . 0.0 111.615 175.951 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 51.88 13.82 1.64 Allowed Glycine 0 CA--C 1.529 0.94 0 N-CA-C 111.536 -0.626 . . . . 0.0 111.536 179.676 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 215' ' ' LYS . . . . . 0.469 ' O ' ' O ' ' B' ' 212' ' ' GLU . 67.5 mttm -143.09 150.87 40.1 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-O 121.082 0.468 . . . . 0.0 110.625 179.875 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 216' ' ' TRP . . . . . . . . . . . . . 64.4 m95 -84.82 118.03 24.23 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.013 179.856 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 217' ' ' THR . . . . . 0.467 HG23 ' O ' ' A' ' 77' ' ' VAL . 19.3 m -127.5 139.86 52.52 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-O 121.197 0.522 . . . . 0.0 110.452 -179.393 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 218' ' ' TRP . . . . . 0.531 ' CH2' ' N ' ' B' ' 208' ' ' SER . 19.7 t-105 -106.22 117.25 33.55 Favored 'General case' 0 C--O 1.231 0.1 0 CA-C-N 115.849 -0.614 . . . . 0.0 109.922 179.227 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 54.4 mtmt -143.71 172.07 13.33 Favored 'General case' 0 CA--C 1.516 -0.343 0 CA-C-O 120.989 0.423 . . . . 0.0 110.642 -179.748 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -176.42 -160.73 24.18 Favored Glycine 0 CA--C 1.525 0.669 0 C-N-CA 120.585 -0.817 . . . . 0.0 111.305 -179.727 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 221' ' ' ILE . . . . . 0.544 ' O ' HG23 ' B' ' 222' ' ' ILE . 20.2 mt -54.7 -73.65 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 C-N-CA 120.649 -0.42 . . . . 0.0 110.448 -178.046 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 222' ' ' ILE . . . . . 0.544 HG23 ' O ' ' B' ' 221' ' ' ILE . 21.7 pt -159.85 -165.08 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 N-CA-C 109.907 -0.405 . . . . 0.0 109.907 -179.761 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 223' ' ' ARG . . . . . 0.556 ' N ' HD11 ' A' ' 75' ' ' ILE . 37.0 ptt180 -40.9 172.13 0.0 OUTLIER 'General case' 0 N--CA 1.456 -0.174 0 CA-C-O 121.175 0.512 . . . . 0.0 110.923 178.89 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 224' ' ' LEU . . . . . 1.072 ' H ' HD22 ' B' ' 224' ' ' LEU . 0.4 OUTLIER -58.55 147.8 30.86 Favored 'General case' 0 C--N 1.318 -0.794 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.638 -179.091 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 23.5 tp10 . . . . . 0 CA--C 1.515 -0.392 0 CA-C-N 115.551 -0.75 . . . . 0.0 110.511 -178.858 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 11' ' ' ASP . . . . . 0.421 ' HB2' ' HE1' ' B' ' 209' ' ' TRP . 55.2 p-10 . . . . . 0 C--O 1.231 0.116 0 CA-C-O 120.746 0.308 . . . . 0.0 110.673 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 7.3 tt -65.1 150.9 47.32 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.444 -179.679 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 13' ' ' SER . . . . . 0.417 ' O ' ' O ' ' A' ' 25' ' ' ARG . 18.1 p -139.85 157.53 45.56 Favored 'General case' 0 N--CA 1.463 0.204 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.385 179.696 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 14' ' ' PHE . . . . . 0.48 ' CD1' ' N ' ' A' ' 14' ' ' PHE . 31.5 m-85 -110.33 144.77 38.57 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.652 -179.325 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 16.7 m -145.69 156.62 12.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.294 179.402 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 98.8 m-20 55.75 35.93 26.28 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.64 -179.885 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 96.4 mt -61.12 139.07 20.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.31 179.816 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.473 ' CB ' ' O ' ' A' ' 21' ' ' SER . 0.2 OUTLIER -140.84 -167.33 2.34 Favored 'General case' 0 N--CA 1.469 0.494 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.194 -179.986 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 19' ' ' ASP . . . . . 0.496 ' OD1' ' N ' ' A' ' 20' ' ' SER . 30.9 p-10 -88.75 -43.54 11.2 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.819 179.384 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 20' ' ' SER . . . . . 0.496 ' N ' ' OD1' ' A' ' 19' ' ' ASP . 4.4 t -116.41 6.73 13.68 Favored 'General case' 0 N--CA 1.466 0.353 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.976 -179.42 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 21' ' ' SER . . . . . 0.473 ' O ' ' CB ' ' A' ' 18' ' ' THR . 16.4 p -150.57 140.3 21.74 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 121.257 0.551 . . . . 0.0 110.508 179.853 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 28.4 pt -139.65 144.13 29.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 N-CA-C 109.394 -0.595 . . . . 0.0 109.394 -179.868 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -106.4 91.33 0.72 Allowed Glycine 0 N--CA 1.466 0.637 0 N-CA-C 111.496 -0.642 . . . . 0.0 111.496 -179.323 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.466 ' N ' HD12 ' A' ' 24' ' ' LEU . 11.2 mp -69.63 130.55 42.69 Favored 'General case' 0 C--N 1.328 -0.354 0 C-N-CA 120.478 -0.489 . . . . 0.0 109.842 179.844 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 25' ' ' ARG . . . . . 0.417 ' O ' ' O ' ' A' ' 13' ' ' SER . 67.5 ttp85 -140.83 135.26 31.22 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.196 179.615 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 26' ' ' TRP . . . . . . . . . . . . . 48.3 p90 -143.51 156.47 44.63 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.988 -0.551 . . . . 0.0 109.983 179.719 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 4.4 m -109.54 101.11 44.9 Favored Pre-proline 0 CA--C 1.531 0.23 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.162 179.906 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 42.0 Cg_exo -53.14 150.84 23.41 Favored 'Trans proline' 0 C--N 1.307 -1.613 0 C-N-CA 121.635 1.557 . . . . 0.0 113.199 179.823 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 54.2 mt -91.3 141.94 28.24 Favored 'General case' 0 CA--C 1.513 -0.466 0 CA-C-N 115.127 -0.942 . . . . 0.0 110.885 179.867 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 53.6 t-20 -50.87 -38.14 47.7 Favored 'General case' 0 C--N 1.314 -0.976 0 CA-C-N 114.743 -1.117 . . . . 0.0 110.149 179.575 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 23.2 m -76.98 -33.57 57.61 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.454 178.874 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 15.1 m -60.48 127.84 33.71 Favored 'General case' 0 N--CA 1.461 0.108 0 CA-C-O 121.027 0.441 . . . . 0.0 110.16 179.893 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 33' ' ' THR . . . . . 0.487 ' OG1' ' N ' ' A' ' 82' ' ' ASN . 5.5 m -57.96 142.98 44.68 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.292 179.99 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 20.6 mm -93.82 89.24 2.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 120.904 0.383 . . . . 0.0 110.839 -179.299 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.469 ' O ' ' OG ' ' A' ' 57' ' ' SER . 14.7 pt -142.04 129.76 20.88 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.341 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.498 179.633 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -39.87 121.08 1.5 Allowed Glycine 0 CA--C 1.523 0.543 0 N-CA-C 111.555 -0.618 . . . . 0.0 111.555 -179.56 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 37' ' ' TYR . . . . . 0.423 ' CE2' ' OG ' ' A' ' 57' ' ' SER . 97.7 m-85 -83.19 178.92 7.88 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.942 0.401 . . . . 0.0 110.09 179.91 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 38' ' ' ARG . . . . . 0.54 ' NH1' ' OG1' ' A' ' 40' ' ' THR . 4.2 tmt_? -134.21 123.74 24.81 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 121.134 0.492 . . . . 0.0 110.561 179.775 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 2.8 pt -94.46 152.95 3.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 115.894 -0.593 . . . . 0.0 109.537 -179.856 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 40' ' ' THR . . . . . 0.54 ' OG1' ' NH1' ' A' ' 38' ' ' ARG . 27.3 m -136.09 133.12 36.98 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.75 0.31 . . . . 0.0 110.491 179.814 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.415 HG13 ' HB ' ' A' ' 50' ' ' ILE . 2.0 p -132.59 134.95 58.31 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.326 0 CA-C-O 120.812 0.339 . . . . 0.0 110.577 179.796 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 42' ' ' VAL . . . . . 0.488 ' O ' ' N ' ' A' ' 74' ' ' ASP . 30.0 t -129.44 126.68 63.89 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.216 0 N-CA-C 110.017 -0.364 . . . . 0.0 110.017 179.307 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.548 ' HB2' ' CE2' ' A' ' 73' ' ' TYR . . . -93.33 138.67 31.46 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 109.32 -0.622 . . . . 0.0 109.32 179.504 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 44' ' ' ALA . . . . . 0.578 ' HB3' ' O ' ' A' ' 72' ' ' ASP . . . -97.53 -19.25 18.49 Favored 'General case' 0 C--N 1.329 -0.286 0 C-N-CA 120.695 -0.402 . . . . 0.0 110.877 -179.97 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -96.61 30.95 8.03 Favored Glycine 0 CA--C 1.525 0.701 0 N-CA-C 110.971 -0.852 . . . . 0.0 110.971 179.906 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 71.5 mt-10 -146.21 149.92 34.84 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.974 0.416 . . . . 0.0 110.556 179.996 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -68.28 -21.11 73.87 Favored Glycine 0 CA--C 1.523 0.54 0 N-CA-C 111.073 -0.811 . . . . 0.0 111.073 179.571 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -137.86 140.21 28.77 Favored Pre-proline 0 CA--C 1.546 0.814 0 CA-C-N 116.833 0.316 . . . . 0.0 110.603 179.672 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 68.9 Cg_endo -72.78 163.03 39.6 Favored 'Trans proline' 0 N--CA 1.495 1.569 0 C-N-CA 122.768 2.312 . . . . 0.0 112.107 178.755 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 50' ' ' ILE . . . . . 0.502 HG22 ' N ' ' A' ' 51' ' ' PHE . 96.8 mt -75.58 158.6 5.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.551 179.602 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 51' ' ' PHE . . . . . 0.502 ' N ' HG22 ' A' ' 50' ' ' ILE . 96.7 m-85 -75.94 147.77 38.67 Favored 'General case' 0 C--N 1.333 -0.143 0 CA-C-O 121.019 0.438 . . . . 0.0 111.134 -179.72 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 52' ' ' GLU . . . . . 0.556 ' CD ' ' H ' ' A' ' 52' ' ' GLU . 0.3 OUTLIER -83.28 146.94 28.26 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.441 179.478 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -116.91 153.55 32.37 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.756 -0.656 . . . . 0.0 110.499 -179.492 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 54' ' ' PHE . . . . . 0.565 ' CD1' ' N ' ' A' ' 54' ' ' PHE . 5.7 m-85 -119.79 129.47 54.47 Favored 'General case' 0 N--CA 1.462 0.132 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.146 -179.85 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 9.4 p -129.77 138.91 52.95 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.393 0 CA-C-O 120.73 0.3 . . . . 0.0 110.843 -179.769 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 94.4 m-20 -61.08 144.86 52.69 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.695 179.964 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 57' ' ' SER . . . . . 0.469 ' OG ' ' O ' ' A' ' 35' ' ' ILE . 10.2 m -61.94 -32.14 72.53 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.706 179.878 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 75.5 m -56.2 -36.43 68.4 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.582 -179.756 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 74.3 t -62.32 -45.05 99.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.511 -179.848 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 60.45 24.87 62.17 Favored Glycine 0 CA--C 1.528 0.864 0 N-CA-C 110.507 -1.037 . . . . 0.0 110.507 -179.95 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 61' ' ' TYR . . . . . 0.432 ' OH ' ' OG1' ' A' ' 63' ' ' THR . 52.6 t80 -166.34 151.09 7.92 Favored 'General case' 0 CA--C 1.53 0.176 0 CA-C-O 121.214 0.531 . . . . 0.0 111.423 -179.513 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 17.4 t80 -158.01 158.25 34.52 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.672 -0.694 . . . . 0.0 110.378 178.566 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 63' ' ' THR . . . . . 0.432 ' OG1' ' OH ' ' A' ' 61' ' ' TYR . 69.3 m -127.7 136.74 51.98 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.198 179.728 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -130.16 104.62 10.45 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 N-CA-C 109.33 -0.619 . . . . 0.0 109.33 179.413 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 4.2 p -111.75 157.38 20.59 Favored 'General case' 0 N--CA 1.466 0.335 0 CA-C-O 120.946 0.403 . . . . 0.0 110.498 -179.849 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 107.68 40.79 1.68 Allowed Glycine 0 CA--C 1.524 0.594 0 N-CA-C 111.074 -0.81 . . . . 0.0 111.074 179.94 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 16.6 mt -113.0 106.65 14.95 Favored 'General case' 0 N--CA 1.462 0.168 0 N-CA-C 108.99 -0.744 . . . . 0.0 108.99 179.215 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 52.4 mm-40 -51.97 135.91 37.8 Favored Pre-proline 0 C--N 1.319 -0.72 0 CA-C-N 116.376 -0.375 . . . . 0.0 111.626 -178.059 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 93.4 Cg_endo -74.98 155.44 43.03 Favored 'Trans proline' 0 N--CA 1.496 1.658 0 C-N-CA 122.55 2.166 . . . . 0.0 111.476 178.602 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 70' ' ' GLY . . . . . 0.515 ' H ' HH22 ' B' ' 223' ' ' ARG . . . 71.11 5.66 59.1 Favored Glycine 0 CA--C 1.525 0.671 0 CA-C-N 115.65 -0.705 . . . . 0.0 111.54 179.469 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 1.6 mp -113.43 143.39 23.21 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.47 0 N-CA-C 109.315 -0.624 . . . . 0.0 109.315 179.859 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 72' ' ' ASP . . . . . 0.578 ' O ' ' HB3' ' A' ' 44' ' ' ALA . 1.8 t70 -80.26 113.86 18.75 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.387 -0.824 . . . . 0.0 110.683 179.949 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 73' ' ' TYR . . . . . 0.548 ' CE2' ' HB2' ' A' ' 43' ' ' ALA . 14.0 m-85 -109.14 120.19 41.78 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 121.264 0.554 . . . . 0.0 110.694 -179.699 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 74' ' ' ASP . . . . . 0.488 ' N ' ' O ' ' A' ' 42' ' ' VAL . 9.6 m-20 -89.11 119.55 29.72 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-N 115.378 -0.828 . . . . 0.0 109.175 179.387 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 75' ' ' ILE . . . . . 0.535 HD11 ' N ' ' B' ' 223' ' ' ARG . 0.0 OUTLIER -119.17 166.38 13.61 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.466 0 CA-C-O 121.019 0.438 . . . . 0.0 110.304 -179.306 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 22.9 t -156.13 152.41 27.89 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.574 -0.739 . . . . 0.0 110.312 178.529 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 2.4 t -128.78 101.95 7.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 N-CA-C 109.556 -0.535 . . . . 0.0 109.556 178.664 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 72.4 mt -88.47 127.56 41.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 N-CA-C 109.974 -0.38 . . . . 0.0 109.974 -179.433 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 87.3 m -105.66 114.22 28.25 Favored 'General case' 0 N--CA 1.465 0.284 0 CA-C-N 116.213 -0.449 . . . . 0.0 109.963 179.967 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 49.1 mt -118.2 117.42 29.11 Favored 'General case' 0 N--CA 1.464 0.229 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.533 -179.722 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 81' ' ' ILE . . . . . 0.474 ' HB ' ' H ' ' A' ' 33' ' ' THR . 2.3 pp -145.26 146.67 19.52 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.181 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.39 179.032 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 82' ' ' ASN . . . . . 0.487 ' N ' ' OG1' ' A' ' 33' ' ' THR . 23.0 t-20 . . . . . 0 C--N 1.329 -0.294 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.259 -179.578 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 207' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.462 0.428 0 N-CA-C 111.125 -0.79 . . . . 0.0 111.125 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' B' B ' 208' ' ' SER . . . . . 0.536 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 97.1 p -165.86 170.58 13.67 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.809 0.337 . . . . 0.0 110.818 179.877 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 209' ' ' TRP . . . . . 0.421 ' HE1' ' HB2' ' A' ' 11' ' ' ASP . 66.9 m95 -88.27 147.6 24.74 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.462 179.666 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 82.4 p -127.96 129.26 46.5 Favored 'General case' 0 C--O 1.234 0.257 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.631 179.868 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 48.9 t-105 -89.62 116.67 27.93 Favored 'General case' 0 N--CA 1.463 0.176 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.04 179.5 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 212' ' ' GLU . . . . . 0.457 ' O ' ' O ' ' B' ' 215' ' ' LYS . 1.0 OUTLIER -164.91 170.24 15.55 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.556 179.073 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' B' B ' 213' ' ' ASN . . . . . . . . . . . . . 14.2 m120 48.23 35.96 6.16 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.916 176.56 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 51.97 13.65 1.64 Allowed Glycine 0 CA--C 1.528 0.899 0 C-N-CA 120.992 -0.623 . . . . 0.0 111.668 179.656 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 215' ' ' LYS . . . . . 0.457 ' O ' ' O ' ' B' ' 212' ' ' GLU . 66.8 mttm -142.84 150.81 40.4 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-O 120.994 0.426 . . . . 0.0 110.839 179.826 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 216' ' ' TRP . . . . . . . . . . . . . 52.1 m95 -86.81 118.77 26.42 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.089 179.86 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 217' ' ' THR . . . . . . . . . . . . . 19.6 m -128.85 142.42 50.97 Favored 'General case' 0 N--CA 1.467 0.387 0 CA-C-O 120.938 0.399 . . . . 0.0 110.184 -179.772 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 218' ' ' TRP . . . . . 0.536 ' CH2' ' N ' ' B' ' 208' ' ' SER . 15.2 t-105 -104.91 118.51 36.72 Favored 'General case' 0 C--N 1.33 -0.269 0 N-CA-C 109.356 -0.609 . . . . 0.0 109.356 179.246 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 52.5 mtmt -145.86 167.4 23.33 Favored 'General case' 0 CA--C 1.517 -0.305 0 CA-C-O 121.33 0.586 . . . . 0.0 110.704 -179.411 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -175.81 -161.13 24.56 Favored Glycine 0 CA--C 1.523 0.573 0 CA-C-N 115.383 -0.826 . . . . 0.0 111.486 -179.736 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 221' ' ' ILE . . . . . 0.548 ' O ' HG23 ' B' ' 222' ' ' ILE . 0.8 OUTLIER -52.59 -75.71 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 C-N-CA 120.69 -0.404 . . . . 0.0 111.065 -178.667 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' B' B ' 222' ' ' ILE . . . . . 0.548 HG23 ' O ' ' B' ' 221' ' ' ILE . 22.1 pt -160.87 -165.08 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 N-CA-C 109.97 -0.382 . . . . 0.0 109.97 -179.405 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 223' ' ' ARG . . . . . 0.535 ' N ' HD11 ' A' ' 75' ' ' ILE . 39.5 ptt180 -43.28 173.5 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.804 -0.635 . . . . 0.0 110.669 178.579 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 224' ' ' LEU . . . . . 1.053 ' H ' HD22 ' B' ' 224' ' ' LEU . 0.7 OUTLIER -61.67 126.09 26.12 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.33 -179.859 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 35.5 tp10 . . . . . 0 C--N 1.329 -0.303 0 CA-C-N 115.712 -0.676 . . . . 0.0 110.277 179.803 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 . . . . . 0 CA--C 1.519 -0.216 0 CA-C-O 120.956 0.407 . . . . 0.0 110.372 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.528 ' CD2' ' CZ ' ' A' ' 14' ' ' PHE . 7.0 tt -67.15 145.34 55.38 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.579 -179.83 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 13' ' ' SER . . . . . 0.431 ' O ' ' O ' ' A' ' 25' ' ' ARG . 53.9 p -143.09 152.79 42.23 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.497 179.642 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 14' ' ' PHE . . . . . 0.554 ' CD1' ' N ' ' A' ' 14' ' ' PHE . 8.3 m-85 -111.77 148.73 32.9 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.391 -179.763 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 18.5 m -146.37 158.01 11.32 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.205 179.711 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 95.2 m-20 58.91 30.27 19.95 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.613 -0.721 . . . . 0.0 110.849 -179.921 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 83.2 mt -56.3 130.5 18.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 N-CA-C 109.862 -0.422 . . . . 0.0 109.862 179.65 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.441 HG22 ' H ' ' A' ' 19' ' ' ASP . 0.2 OUTLIER -129.52 -169.1 2.05 Favored 'General case' 0 N--CA 1.466 0.374 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.579 -179.886 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 19' ' ' ASP . . . . . 0.488 ' N ' ' OD1' ' A' ' 19' ' ' ASP . 16.2 p-10 -78.35 -48.52 15.41 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.997 179.428 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 20' ' ' SER . . . . . 0.47 ' OG ' ' N ' ' A' ' 67' ' ' LEU . 28.2 t -121.16 13.35 11.2 Favored 'General case' 0 N--CA 1.464 0.231 0 CA-C-O 120.728 0.299 . . . . 0.0 110.596 -179.161 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 21' ' ' SER . . . . . 0.463 ' HB2' HG22 ' A' ' 65' ' ' THR . 25.1 p -146.69 129.14 15.91 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 116.475 -0.329 . . . . 0.0 110.352 -179.625 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 22' ' ' ILE . . . . . 0.595 HD12 HD21 ' A' ' 24' ' ' LEU . 46.4 pt -126.25 142.57 42.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.239 0 CA-C-N 116.2 -0.455 . . . . 0.0 109.959 -179.886 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -97.1 82.26 0.72 Allowed Glycine 0 CA--C 1.523 0.542 0 N-CA-C 110.873 -0.891 . . . . 0.0 110.873 -179.563 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.595 HD21 HD12 ' A' ' 22' ' ' ILE . 90.7 mt -65.26 122.53 17.31 Favored 'General case' 0 C--N 1.33 -0.276 0 N-CA-C 109.945 -0.391 . . . . 0.0 109.945 -179.815 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 25' ' ' ARG . . . . . 0.431 ' O ' ' O ' ' A' ' 13' ' ' SER . 72.2 ttt180 -141.2 138.78 33.58 Favored 'General case' 0 N--CA 1.462 0.168 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.722 -179.873 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 26' ' ' TRP . . . . . 0.534 ' CE2' ' O ' ' A' ' 60' ' ' GLY . 33.3 p90 -146.33 121.06 9.86 Favored 'General case' 0 CA--C 1.513 -0.453 0 CA-C-N 115.792 -0.64 . . . . 0.0 109.764 179.882 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 2.1 m -66.49 113.91 14.9 Favored Pre-proline 0 CA--C 1.536 0.412 0 C-N-CA 120.642 -0.423 . . . . 0.0 111.091 -178.619 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 36.1 Cg_exo -58.84 153.07 52.86 Favored 'Trans proline' 0 N--CA 1.493 1.461 0 C-N-CA 122.101 1.867 . . . . 0.0 112.742 178.693 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.459 ' H ' ' HB2' ' A' ' 32' ' ' SER . 80.2 mt -104.94 136.05 45.15 Favored 'General case' 0 N--CA 1.469 0.479 0 CA-C-O 122.008 0.909 . . . . 0.0 110.833 179.876 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 42.4 t30 -44.88 -32.43 1.59 Allowed 'General case' 0 C--N 1.316 -0.877 0 CA-C-N 115.064 -0.971 . . . . 0.0 110.223 -179.709 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 58.7 m -85.64 -33.84 21.51 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.868 -0.606 . . . . 0.0 110.582 179.198 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 32' ' ' SER . . . . . 0.459 ' HB2' ' H ' ' A' ' 29' ' ' LEU . 3.6 m -51.52 115.48 1.63 Allowed 'General case' 0 N--CA 1.461 0.095 0 CA-C-O 121.261 0.553 . . . . 0.0 110.17 -179.929 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 33' ' ' THR . . . . . 0.522 ' OG1' ' N ' ' A' ' 82' ' ' ASN . 11.7 m -50.94 143.54 10.04 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.561 -0.745 . . . . 0.0 109.264 -179.081 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 32.8 mm -92.45 90.95 3.23 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.215 0 CA-C-O 121.236 0.541 . . . . 0.0 111.258 -178.156 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.576 ' O ' ' CE1' ' A' ' 37' ' ' TYR . 6.7 pt -149.19 125.95 2.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 115.507 -0.77 . . . . 0.0 110.241 179.225 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -39.56 140.45 0.78 Allowed Glycine 0 CA--C 1.527 0.788 0 N-CA-C 110.957 -0.857 . . . . 0.0 110.957 -179.72 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 37' ' ' TYR . . . . . 0.576 ' CE1' ' O ' ' A' ' 35' ' ' ILE . 16.8 m-85 -110.49 144.83 38.72 Favored 'General case' 0 CA--C 1.518 -0.286 0 N-CA-C 109.867 -0.42 . . . . 0.0 109.867 -179.504 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 38' ' ' ARG . . . . . 0.516 ' NH1' ' OG1' ' A' ' 40' ' ' THR . 2.3 tmm_? -98.86 125.93 44.39 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.612 -179.834 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.419 ' O ' ' CG1' ' A' ' 39' ' ' ILE . 2.8 pt -98.45 121.07 48.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.1 -0.5 . . . . 0.0 109.834 179.777 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 40' ' ' THR . . . . . 0.516 ' OG1' ' NH1' ' A' ' 38' ' ' ARG . 20.7 m -101.29 136.2 41.53 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.288 -179.175 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.2 p -134.22 142.76 40.06 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.338 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.249 179.965 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 42' ' ' VAL . . . . . 0.485 ' O ' ' N ' ' A' ' 74' ' ' ASP . 37.7 t -131.73 130.54 61.98 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.145 0 N-CA-C 109.984 -0.376 . . . . 0.0 109.984 179.46 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -97.49 133.63 41.81 Favored 'General case' 0 C--N 1.327 -0.379 0 N-CA-C 109.434 -0.58 . . . . 0.0 109.434 179.216 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 44' ' ' ALA . . . . . 0.626 ' HB3' ' O ' ' A' ' 72' ' ' ASP . . . -94.57 -21.21 18.99 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.769 0.318 . . . . 0.0 110.738 179.912 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -91.4 18.07 53.55 Favored Glycine 0 CA--C 1.523 0.588 0 N-CA-C 110.912 -0.875 . . . . 0.0 110.912 -179.682 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 33.2 mm-40 -139.93 149.53 43.44 Favored 'General case' 0 C--N 1.333 -0.136 0 CA-C-O 121.106 0.479 . . . . 0.0 110.521 -179.559 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -69.5 -18.94 74.12 Favored Glycine 0 N--CA 1.453 -0.194 0 N-CA-C 110.518 -1.033 . . . . 0.0 110.518 179.941 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -132.26 140.06 36.82 Favored Pre-proline 0 N--CA 1.468 0.446 0 C-N-CA 121.119 -0.232 . . . . 0.0 110.585 179.699 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 59.6 Cg_endo -73.22 159.39 47.32 Favored 'Trans proline' 0 N--CA 1.49 1.307 0 C-N-CA 122.431 2.087 . . . . 0.0 112.051 177.685 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 50' ' ' ILE . . . . . 0.407 HG22 ' N ' ' A' ' 51' ' ' PHE . 96.7 mt -75.49 153.41 6.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.193 179.484 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 51' ' ' PHE . . . . . 0.407 ' N ' HG22 ' A' ' 50' ' ' ILE . 80.5 m-85 -72.51 142.29 48.51 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.676 179.912 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 52' ' ' GLU . . . . . 0.422 ' N ' ' CD ' ' A' ' 52' ' ' GLU . 0.0 OUTLIER -65.77 -176.15 0.35 Allowed 'General case' 0 CA--C 1.514 -0.441 0 CA-C-N 115.739 -0.664 . . . . 0.0 110.405 179.441 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 53' ' ' ASP . . . . . 0.416 ' CG ' ' OH ' ' A' ' 62' ' ' TYR . 1.0 OUTLIER -145.59 138.66 26.14 Favored 'General case' 0 N--CA 1.452 -0.34 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.358 179.392 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 61.4 m-85 -110.0 116.42 31.56 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.397 179.898 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 10.5 p -128.18 140.82 48.15 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.348 0 CA-C-O 120.934 0.397 . . . . 0.0 110.118 179.949 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 83.9 m-20 -62.9 150.49 41.85 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.248 179.734 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 15.3 t -64.12 -33.8 76.6 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.663 -179.932 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 69.5 m -51.43 -37.69 49.83 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.382 -179.51 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.525 ' C ' ' H ' ' A' ' 61' ' ' TYR . 11.3 t -63.74 -42.97 97.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.362 179.68 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 60' ' ' GLY . . . . . 0.534 ' O ' ' CE2' ' A' ' 26' ' ' TRP . . . 70.44 -36.38 0.45 Allowed Glycine 0 CA--C 1.532 1.116 0 N-CA-C 111.037 -0.825 . . . . 0.0 111.037 179.653 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 61' ' ' TYR . . . . . 0.525 ' H ' ' C ' ' A' ' 59' ' ' VAL . 25.9 p90 -115.99 159.76 21.19 Favored 'General case' 0 N--CA 1.466 0.373 0 CA-C-O 121.146 0.498 . . . . 0.0 111.007 -179.084 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 62' ' ' TYR . . . . . 0.416 ' OH ' ' CG ' ' A' ' 53' ' ' ASP . 31.1 t80 -154.47 162.28 41.23 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.107 -0.497 . . . . 0.0 109.755 179.599 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 99.2 m -119.36 132.77 55.91 Favored 'General case' 0 N--CA 1.467 0.376 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.414 -179.781 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -133.06 107.57 11.75 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.311 0 CA-C-N 115.859 -0.61 . . . . 0.0 109.647 179.046 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.463 HG22 ' HB2' ' A' ' 21' ' ' SER . 1.1 p -123.46 164.52 18.76 Favored 'General case' 0 CA--C 1.513 -0.443 0 CA-C-O 121.019 0.438 . . . . 0.0 110.34 -179.836 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 108.81 24.41 6.09 Favored Glycine 0 CA--C 1.524 0.598 0 CA-C-N 115.396 -0.82 . . . . 0.0 111.48 -179.773 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.47 ' N ' ' OG ' ' A' ' 20' ' ' SER . 11.8 mt -100.66 109.14 21.17 Favored 'General case' 0 CA--C 1.517 -0.322 0 N-CA-C 109.31 -0.626 . . . . 0.0 109.31 179.909 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 31.9 mm-40 -52.5 139.73 37.88 Favored Pre-proline 0 C--N 1.312 -1.023 0 C-N-CA 120.486 -0.485 . . . . 0.0 112.011 -178.214 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -73.08 155.47 52.39 Favored 'Trans proline' 0 N--CA 1.498 1.755 0 C-N-CA 122.857 2.371 . . . . 0.0 111.387 178.63 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 72.93 -5.96 15.48 Favored Glycine 0 CA--C 1.525 0.702 0 CA-C-N 115.637 -0.71 . . . . 0.0 111.927 179.269 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 1.7 mp -101.27 149.15 6.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 N-CA-C 109.346 -0.613 . . . . 0.0 109.346 -179.551 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 72' ' ' ASP . . . . . 0.626 ' O ' ' HB3' ' A' ' 44' ' ' ALA . 2.5 t70 -89.68 115.99 27.46 Favored 'General case' 0 C--N 1.32 -0.7 0 CA-C-N 114.979 -1.01 . . . . 0.0 110.269 179.686 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 73' ' ' TYR . . . . . 0.507 ' O ' HD13 ' A' ' 75' ' ' ILE . 25.6 m-85 -109.81 119.55 39.69 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.453 179.899 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 74' ' ' ASP . . . . . 0.485 ' N ' ' O ' ' A' ' 42' ' ' VAL . 8.9 m-20 -89.94 116.79 28.26 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.702 -0.681 . . . . 0.0 109.426 179.887 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 75' ' ' ILE . . . . . 0.569 HD11 ' N ' ' B' ' 223' ' ' ARG . 0.0 OUTLIER -113.98 165.4 9.02 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.293 0 CA-C-O 121.171 0.51 . . . . 0.0 109.995 -179.094 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 33.5 t -155.97 118.56 4.15 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.6 -0.727 . . . . 0.0 110.584 179.0 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 2.7 t -92.16 100.77 11.76 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 C-N-CA 120.479 -0.488 . . . . 0.0 109.73 179.498 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 96.3 mt -87.44 115.79 28.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.075 -179.99 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 70.3 m -100.44 118.8 37.41 Favored 'General case' 0 CA--C 1.517 -0.318 0 CA-C-N 116.211 -0.45 . . . . 0.0 109.938 179.725 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 80' ' ' LEU . . . . . 0.447 ' C ' HD23 ' A' ' 80' ' ' LEU . 2.1 tt -122.66 108.74 13.43 Favored 'General case' 0 N--CA 1.463 0.201 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.628 -179.892 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 81' ' ' ILE . . . . . 0.44 ' N ' HD23 ' A' ' 80' ' ' LEU . 2.1 pp -139.37 142.93 32.13 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 N-CA-C 109.974 -0.38 . . . . 0.0 109.974 178.936 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 82' ' ' ASN . . . . . 0.522 ' N ' ' OG1' ' A' ' 33' ' ' THR . 39.5 t-20 . . . . . 0 C--N 1.328 -0.333 0 C-N-CA 120.89 -0.324 . . . . 0.0 111.233 -179.894 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 207' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.467 0.712 0 N-CA-C 111.105 -0.798 . . . . 0.0 111.105 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' B' B ' 208' ' ' SER . . . . . 0.555 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 54.8 p -165.66 170.83 13.71 Favored 'General case' 0 N--CA 1.454 -0.248 0 CA-C-O 120.804 0.335 . . . . 0.0 110.719 179.287 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 209' ' ' TRP . . . . . . . . . . . . . 59.0 m95 -88.13 156.08 19.44 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.531 179.473 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 66.9 p -130.19 131.77 45.74 Favored 'General case' 0 N--CA 1.464 0.247 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.447 179.558 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 53.0 t-105 -95.81 110.41 22.58 Favored 'General case' 0 N--CA 1.464 0.269 0 CA-C-N 116.29 -0.413 . . . . 0.0 110.591 -179.988 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 212' ' ' GLU . . . . . 0.44 ' O ' ' O ' ' B' ' 215' ' ' LYS . 1.8 pt-20 -162.0 168.45 22.76 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.669 179.516 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 213' ' ' ASN . . . . . . . . . . . . . 14.8 m120 51.53 34.5 12.5 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.955 -0.566 . . . . 0.0 111.066 176.966 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 50.56 19.89 3.46 Favored Glycine 0 CA--C 1.526 0.745 0 N-CA-C 111.156 -0.777 . . . . 0.0 111.156 179.981 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 215' ' ' LYS . . . . . 0.44 ' O ' ' O ' ' B' ' 212' ' ' GLU . 80.1 mttt -146.21 150.81 36.54 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 120.933 0.397 . . . . 0.0 110.602 179.723 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 216' ' ' TRP . . . . . . . . . . . . . 53.5 m95 -87.39 117.38 26.12 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.055 179.789 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 217' ' ' THR . . . . . . . . . . . . . 17.1 m -128.5 136.91 51.44 Favored 'General case' 0 C--O 1.234 0.248 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.129 -179.798 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 218' ' ' TRP . . . . . 0.555 ' CH2' ' N ' ' B' ' 208' ' ' SER . 14.2 t-105 -100.34 112.98 25.36 Favored 'General case' 0 N--CA 1.463 0.199 0 CA-C-N 116.044 -0.526 . . . . 0.0 109.99 179.606 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 92.7 mttt -130.24 167.52 18.31 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.74 -179.912 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -178.29 -162.89 28.83 Favored Glycine 0 CA--C 1.524 0.605 0 N-CA-C 111.089 -0.804 . . . . 0.0 111.089 179.878 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 221' ' ' ILE . . . . . 0.551 ' O ' HG23 ' B' ' 222' ' ' ILE . 21.5 mt -56.0 -73.52 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 C-N-CA 120.422 -0.511 . . . . 0.0 110.307 -178.116 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 222' ' ' ILE . . . . . 0.551 HG23 ' O ' ' B' ' 221' ' ' ILE . 22.6 pt -160.37 -165.2 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.086 179.797 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 223' ' ' ARG . . . . . 0.569 ' N ' HD11 ' A' ' 75' ' ' ILE . 26.7 ptt180 -40.24 172.18 0.0 OUTLIER 'General case' 0 CA--C 1.52 -0.201 0 CA-C-O 121.278 0.561 . . . . 0.0 110.88 179.293 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 224' ' ' LEU . . . . . 0.725 HD22 ' N ' ' B' ' 224' ' ' LEU . 2.8 mm? -61.38 120.73 11.01 Favored 'General case' 0 C--N 1.316 -0.861 0 CA-C-O 121.428 0.632 . . . . 0.0 110.929 -178.924 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 83.1 tt0 . . . . . 0 N--CA 1.452 -0.35 0 CA-C-N 115.295 -0.866 . . . . 0.0 109.935 -179.988 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 56.0 p30 . . . . . 0 CA--C 1.52 -0.185 0 CA-C-O 121.054 0.454 . . . . 0.0 110.448 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.485 ' CD2' ' CE1' ' A' ' 14' ' ' PHE . 6.9 tt -67.55 139.77 56.95 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.938 -0.573 . . . . 0.0 110.493 -179.637 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 13' ' ' SER . . . . . 0.434 ' O ' ' O ' ' A' ' 25' ' ' ARG . 83.1 p -138.95 154.16 48.28 Favored 'General case' 0 N--CA 1.463 0.208 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.589 179.35 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 14' ' ' PHE . . . . . 0.501 ' CD1' ' N ' ' A' ' 14' ' ' PHE . 15.9 m-85 -111.31 146.15 37.57 Favored 'General case' 0 N--CA 1.463 0.188 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.514 -179.645 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 19.0 m -144.7 163.93 13.42 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.511 179.902 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 99.4 m-20 54.64 33.29 18.94 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.023 -0.535 . . . . 0.0 111.062 179.647 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 1.6 mp -58.42 132.17 23.04 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.542 0 CA-C-O 121.222 0.534 . . . . 0.0 109.883 -179.759 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.457 ' CB ' ' O ' ' A' ' 21' ' ' SER . 0.2 OUTLIER -136.2 -166.26 1.85 Allowed 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.212 -0.904 . . . . 0.0 110.652 -179.872 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 19' ' ' ASP . . . . . 0.522 ' OD1' ' N ' ' A' ' 20' ' ' SER . 34.3 p-10 -91.87 -41.95 10.33 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.495 -0.775 . . . . 0.0 111.115 179.366 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 20' ' ' SER . . . . . 0.522 ' N ' ' OD1' ' A' ' 19' ' ' ASP . 25.9 t -118.51 6.85 11.74 Favored 'General case' 0 N--CA 1.467 0.378 0 CA-C-N 116.444 -0.344 . . . . 0.0 110.848 -179.431 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 21' ' ' SER . . . . . 0.457 ' O ' ' CB ' ' A' ' 18' ' ' THR . 48.0 m -151.57 147.92 27.37 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.437 179.961 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 22' ' ' ILE . . . . . 0.52 HD12 HD21 ' A' ' 24' ' ' LEU . 35.8 pt -147.22 147.7 17.29 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 N-CA-C 109.897 -0.408 . . . . 0.0 109.897 179.558 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -101.83 83.43 0.48 Allowed Glycine 0 CA--C 1.524 0.603 0 N-CA-C 111.507 -0.637 . . . . 0.0 111.507 -179.647 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.52 HD21 HD12 ' A' ' 22' ' ' ILE . 84.6 mt -66.37 124.56 23.05 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 109.656 -0.498 . . . . 0.0 109.656 179.899 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 25' ' ' ARG . . . . . 0.434 ' O ' ' O ' ' A' ' 13' ' ' SER . 69.6 ttt180 -139.11 141.13 38.11 Favored 'General case' 0 N--CA 1.463 0.188 0 CA-C-O 120.948 0.404 . . . . 0.0 110.49 -179.714 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 26' ' ' TRP . . . . . . . . . . . . . 35.1 p90 -144.04 155.01 43.83 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.106 179.795 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 2.5 m -111.77 97.9 39.29 Favored Pre-proline 0 CA--C 1.534 0.336 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.507 179.82 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_exo -53.35 142.62 57.0 Favored 'Trans proline' 0 C--N 1.305 -1.728 0 C-N-CA 122.081 1.854 . . . . 0.0 112.478 179.472 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 59.9 mt -81.21 144.24 31.75 Favored 'General case' 0 CA--C 1.518 -0.274 0 CA-C-O 121.412 0.625 . . . . 0.0 110.91 179.877 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 21.0 t-20 -52.04 -36.9 51.73 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 115.392 -0.822 . . . . 0.0 109.799 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 38.5 m -78.28 -35.17 48.32 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.518 179.257 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 14.4 m -58.14 134.17 56.24 Favored 'General case' 0 N--CA 1.461 0.096 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.231 -179.872 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 33' ' ' THR . . . . . 0.452 ' H ' ' HB ' ' A' ' 81' ' ' ILE . 2.7 m -61.82 140.02 58.29 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.084 -179.718 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 6.0 mm -94.28 90.17 2.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 121.065 0.459 . . . . 0.0 110.693 -179.696 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 19.0 pt -139.19 138.11 41.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.549 179.742 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -42.23 135.81 3.56 Favored Glycine 0 CA--C 1.52 0.406 0 N-CA-C 111.004 -0.838 . . . . 0.0 111.004 -179.622 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 -103.2 174.62 5.79 Favored 'General case' 0 CA--C 1.517 -0.317 0 CA-C-O 120.898 0.38 . . . . 0.0 110.179 -179.846 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 2.3 tmm_? -134.92 126.25 28.31 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.592 179.961 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.475 ' O ' ' CG1' ' A' ' 39' ' ' ILE . 1.8 pt -99.92 122.2 51.52 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.176 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.127 179.684 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 24.2 m -104.95 134.38 48.15 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.451 -179.846 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.1 p -133.14 140.65 46.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.351 179.839 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 42' ' ' VAL . . . . . 0.528 ' O ' ' N ' ' A' ' 74' ' ' ASP . 37.6 t -133.25 131.67 58.18 Favored 'Isoleucine or valine' 0 N--CA 1.458 -0.074 0 N-CA-C 110.158 -0.312 . . . . 0.0 110.158 179.714 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.604 ' HB2' ' CE2' ' A' ' 73' ' ' TYR . . . -96.5 138.86 33.45 Favored 'General case' 0 C--N 1.329 -0.304 0 N-CA-C 109.709 -0.478 . . . . 0.0 109.709 178.947 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 44' ' ' ALA . . . . . 0.564 ' HB3' ' O ' ' A' ' 72' ' ' ASP . . . -93.81 -41.17 9.79 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.487 -0.324 . . . . 0.0 110.835 179.617 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -65.35 -31.85 81.76 Favored Glycine 0 CA--C 1.525 0.689 0 N-CA-C 111.256 -0.738 . . . . 0.0 111.256 -179.763 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 42.3 mm-40 -97.46 133.44 42.05 Favored 'General case' 0 C--N 1.33 -0.24 0 N-CA-C 109.576 -0.528 . . . . 0.0 109.576 -179.483 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -60.32 -21.92 57.72 Favored Glycine 0 CA--C 1.511 -0.217 0 N-CA-C 111.021 -0.832 . . . . 0.0 111.021 -178.987 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -113.11 134.7 21.78 Favored Pre-proline 0 CA--C 1.536 0.407 0 C-N-CA 120.961 -0.295 . . . . 0.0 110.59 179.665 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 71.2 Cg_endo -77.24 163.51 30.21 Favored 'Trans proline' 0 C--N 1.308 -1.564 0 C-N-CA 122.592 2.194 . . . . 0.0 112.202 177.006 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 87.0 mt -83.03 138.26 19.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.044 179.062 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 93.7 m-85 -60.74 142.03 56.31 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.623 -179.829 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 5.6 pt-20 -82.96 151.49 25.87 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.166 179.92 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 53' ' ' ASP . . . . . 0.417 ' CG ' ' OH ' ' A' ' 62' ' ' TYR . 1.7 t70 -120.05 162.91 18.47 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.683 179.451 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 54' ' ' PHE . . . . . 0.59 ' CD1' ' N ' ' A' ' 54' ' ' PHE . 2.4 m-85 -124.02 130.79 53.16 Favored 'General case' 0 C--O 1.232 0.169 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.195 179.662 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 8.7 p -127.69 136.4 60.52 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.449 -179.914 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 97.6 m-20 -58.84 141.29 53.67 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.482 -179.847 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 39.9 t -58.77 -32.84 69.66 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.58 179.857 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 69.1 m -56.23 -35.54 67.46 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.622 -179.836 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 84.1 t -63.44 -46.33 95.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.523 179.982 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 60.86 26.24 65.03 Favored Glycine 0 CA--C 1.528 0.895 0 N-CA-C 110.745 -0.942 . . . . 0.0 110.745 179.863 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 42.6 t80 -167.93 150.58 5.68 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 121.206 0.527 . . . . 0.0 111.103 -179.621 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 62' ' ' TYR . . . . . 0.417 ' OH ' ' CG ' ' A' ' 53' ' ' ASP . 26.7 t80 -157.58 156.27 31.63 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.092 178.831 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 76.3 m -122.64 136.2 54.81 Favored 'General case' 0 N--CA 1.465 0.282 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.728 -179.938 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -130.75 124.9 57.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.026 179.195 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 3.3 p -131.46 155.06 48.02 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.656 179.791 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 109.99 40.63 1.39 Allowed Glycine 0 CA--C 1.524 0.622 0 CA-C-N 115.719 -0.673 . . . . 0.0 111.522 -179.708 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 14.3 mt -112.91 99.31 7.78 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-O 121.274 0.559 . . . . 0.0 109.661 179.47 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 10.6 mm-40 -47.14 135.27 8.88 Favored Pre-proline 0 C--N 1.316 -0.849 0 CA-C-N 115.486 -0.779 . . . . 0.0 111.45 -178.382 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 69' ' ' PRO . . . . . 0.446 ' O ' HD12 ' A' ' 71' ' ' ILE . 72.4 Cg_endo -75.5 149.89 35.32 Favored 'Trans proline' 0 N--CA 1.496 1.646 0 C-N-CA 122.764 2.309 . . . . 0.0 111.761 178.86 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 70' ' ' GLY . . . . . 0.413 ' C ' HD12 ' A' ' 71' ' ' ILE . . . 75.39 13.61 82.71 Favored Glycine 0 CA--C 1.524 0.648 0 N-CA-C 111.23 -0.748 . . . . 0.0 111.23 179.202 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 71' ' ' ILE . . . . . 0.446 HD12 ' O ' ' A' ' 69' ' ' PRO . 2.2 mp -121.0 149.71 23.93 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.354 0 CA-C-O 121.528 0.68 . . . . 0.0 109.629 -179.637 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 72' ' ' ASP . . . . . 0.564 ' O ' ' HB3' ' A' ' 44' ' ' ALA . 2.3 t70 -87.25 112.08 21.67 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 114.854 -1.066 . . . . 0.0 110.621 -179.76 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 73' ' ' TYR . . . . . 0.604 ' CE2' ' HB2' ' A' ' 43' ' ' ALA . 11.8 m-85 -107.87 118.33 36.46 Favored 'General case' 0 C--O 1.216 -0.69 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.735 179.71 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 74' ' ' ASP . . . . . 0.528 ' N ' ' O ' ' A' ' 42' ' ' VAL . 76.6 m-20 -86.97 119.01 26.74 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.495 -0.775 . . . . 0.0 109.496 179.708 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 75' ' ' ILE . . . . . 0.615 HD11 ' N ' ' B' ' 223' ' ' ARG . 0.0 OUTLIER -116.02 164.43 12.37 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.344 0 CA-C-O 121.171 0.51 . . . . 0.0 110.155 -179.166 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 3.0 m -154.43 121.52 5.63 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 115.466 -0.788 . . . . 0.0 110.849 179.394 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 11.9 t -101.44 102.23 13.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 179.272 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 94.5 mt -89.84 127.32 42.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.405 -0.361 . . . . 0.0 110.517 -179.684 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 99.7 m -109.41 111.68 23.36 Favored 'General case' 0 N--CA 1.465 0.319 0 CA-C-N 116.12 -0.491 . . . . 0.0 109.996 179.708 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 13.9 mt -117.93 122.11 42.42 Favored 'General case' 0 CA--C 1.517 -0.297 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.693 -179.968 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 81' ' ' ILE . . . . . 0.452 ' HB ' ' H ' ' A' ' 33' ' ' THR . 2.1 pp -145.45 134.66 17.66 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.15 179.533 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 24.1 t-20 . . . . . 0 C--N 1.323 -0.58 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.777 179.851 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' B' B ' 207' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.466 0.665 0 N-CA-C 111.204 -0.758 . . . . 0.0 111.204 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' B' B ' 208' ' ' SER . . . . . 0.493 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 94.7 p -165.76 172.79 11.37 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.861 0.362 . . . . 0.0 110.697 -179.718 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 209' ' ' TRP . . . . . . . . . . . . . 79.1 m95 -84.44 131.53 34.66 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.309 179.656 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 81.4 p -109.41 130.02 55.52 Favored 'General case' 0 N--CA 1.464 0.273 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.546 -179.95 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 52.9 t-105 -92.38 116.91 29.39 Favored 'General case' 0 C--O 1.233 0.204 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.232 179.832 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 212' ' ' GLU . . . . . 0.458 ' O ' ' O ' ' B' ' 215' ' ' LYS . 1.7 pt-20 -165.82 167.53 16.8 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.948 179.333 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 213' ' ' ASN . . . . . . . . . . . . . 96.7 m-20 50.4 36.46 13.21 Favored 'General case' 0 C--N 1.321 -0.641 0 C-N-CA 120.605 -0.438 . . . . 0.0 111.012 176.325 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 50.21 17.07 1.59 Allowed Glycine 0 CA--C 1.523 0.56 0 N-CA-C 111.476 -0.65 . . . . 0.0 111.476 179.853 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 215' ' ' LYS . . . . . 0.458 ' O ' ' O ' ' B' ' 212' ' ' GLU . 52.1 mtmt -144.99 151.13 38.1 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 121.055 0.455 . . . . 0.0 110.684 179.652 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 216' ' ' TRP . . . . . 0.48 ' CD1' ' N ' ' B' ' 216' ' ' TRP . 24.2 m95 -87.27 119.79 27.89 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.053 179.945 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 217' ' ' THR . . . . . . . . . . . . . 21.6 m -130.95 142.81 50.38 Favored 'General case' 0 N--CA 1.464 0.238 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.432 -179.707 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 218' ' ' TRP . . . . . 0.493 ' CH2' ' N ' ' B' ' 208' ' ' SER . 15.7 t-105 -105.57 119.57 39.45 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-N 115.854 -0.612 . . . . 0.0 109.856 179.407 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 51.3 mtmt -142.95 171.78 13.58 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.817 -179.766 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -176.84 -160.28 23.62 Favored Glycine 0 CA--C 1.522 0.497 0 N-CA-C 111.237 -0.745 . . . . 0.0 111.237 -179.544 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 221' ' ' ILE . . . . . 0.535 ' O ' HG23 ' B' ' 222' ' ' ILE . 10.1 mm -50.7 -73.53 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 C-N-CA 120.781 -0.368 . . . . 0.0 110.638 -178.237 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 222' ' ' ILE . . . . . 0.535 HG23 ' O ' ' B' ' 221' ' ' ILE . 21.4 pt -158.8 -166.65 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.723 0 CA-C-N 115.707 -0.678 . . . . 0.0 110.949 -179.795 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 223' ' ' ARG . . . . . 0.615 ' N ' HD11 ' A' ' 75' ' ' ILE . 21.2 ptt-85 -43.42 175.77 0.0 OUTLIER 'General case' 0 CA--C 1.521 -0.164 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.692 179.353 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 224' ' ' LEU . . . . . 0.694 HD22 ' N ' ' B' ' 224' ' ' LEU . 3.4 mm? -62.14 115.89 4.51 Favored 'General case' 0 C--N 1.317 -0.807 0 CA-C-N 115.989 -0.55 . . . . 0.0 110.789 -179.738 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 78.5 tt0 . . . . . 0 C--N 1.33 -0.272 0 CA-C-N 115.564 -0.744 . . . . 0.0 110.529 179.81 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 52.6 p30 . . . . . 0 N--CA 1.464 0.23 0 CA-C-O 120.948 0.404 . . . . 0.0 110.388 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 59.8 tp -65.31 145.98 55.51 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.024 -0.534 . . . . 0.0 110.397 -179.985 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 13' ' ' SER . . . . . 0.47 ' O ' ' O ' ' A' ' 25' ' ' ARG . 14.2 p -143.49 150.16 38.56 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-O 121.184 0.516 . . . . 0.0 110.614 179.299 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 14' ' ' PHE . . . . . 0.566 ' CD1' ' N ' ' A' ' 14' ' ' PHE . 9.4 m-85 -112.16 145.74 39.3 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.0 -0.545 . . . . 0.0 110.625 -179.714 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 19.1 m -142.07 159.47 20.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.353 179.417 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 94.5 m-20 56.9 31.42 19.69 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.69 -0.686 . . . . 0.0 110.94 -179.66 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 96.3 mt -55.6 131.83 18.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.93 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.433 HG22 ' H ' ' A' ' 19' ' ' ASP . 0.2 OUTLIER -131.72 -169.52 2.21 Favored 'General case' 0 N--CA 1.468 0.463 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.47 -179.562 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 19' ' ' ASP . . . . . 0.476 ' N ' ' OD1' ' A' ' 19' ' ' ASP . 17.9 p-10 -77.19 -49.67 14.65 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.982 179.594 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 20' ' ' SER . . . . . 0.457 ' CB ' ' O ' ' A' ' 67' ' ' LEU . 70.7 m -121.43 14.62 11.17 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 116.622 -0.263 . . . . 0.0 110.661 -179.176 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 21' ' ' SER . . . . . 0.514 ' HB3' HG22 ' A' ' 65' ' ' THR . 2.4 m -146.48 129.87 16.75 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.088 -179.525 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 22' ' ' ILE . . . . . 0.702 HD12 HD21 ' A' ' 24' ' ' LEU . 44.6 pt -125.95 141.75 44.69 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.322 0 CA-C-N 116.078 -0.51 . . . . 0.0 109.715 179.681 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -99.41 82.39 0.56 Allowed Glycine 0 CA--C 1.522 0.531 0 N-CA-C 110.953 -0.859 . . . . 0.0 110.953 -179.537 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.702 HD21 HD12 ' A' ' 22' ' ' ILE . 76.5 mt -63.32 124.38 21.1 Favored 'General case' 0 C--N 1.328 -0.354 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 -179.834 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 25' ' ' ARG . . . . . 0.47 ' O ' ' O ' ' A' ' 13' ' ' SER . 67.9 ttp85 -140.66 140.01 34.9 Favored 'General case' 0 C--N 1.332 -0.155 0 CA-C-O 121.245 0.545 . . . . 0.0 110.736 -179.868 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 26' ' ' TRP . . . . . . . . . . . . . 22.0 p90 -144.49 157.99 43.97 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.108 -179.56 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 2.6 m -103.92 105.29 47.61 Favored Pre-proline 0 CA--C 1.536 0.438 0 CA-C-N 116.56 -0.291 . . . . 0.0 110.686 -179.903 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 31.6 Cg_exo -55.02 153.15 26.87 Favored 'Trans proline' 0 N--CA 1.493 1.484 0 C-N-CA 122.041 1.827 . . . . 0.0 112.972 178.802 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.442 ' H ' ' HB2' ' A' ' 32' ' ' SER . 74.5 mt -103.55 135.25 45.5 Favored 'General case' 0 CA--C 1.515 -0.372 0 CA-C-O 121.832 0.825 . . . . 0.0 110.597 -179.941 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 19.2 t-20 -44.18 -31.46 0.98 Allowed 'General case' 0 C--N 1.318 -0.764 0 CA-C-N 115.09 -0.959 . . . . 0.0 110.436 -179.844 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 66.2 m -86.93 -35.9 18.65 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.395 179.151 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 32' ' ' SER . . . . . 0.442 ' HB2' ' H ' ' A' ' 29' ' ' LEU . 3.4 m -47.66 114.34 0.88 Allowed 'General case' 0 CA--C 1.528 0.127 0 CA-C-O 121.167 0.508 . . . . 0.0 110.051 -179.819 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 7.8 m -52.77 146.03 11.24 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.499 -0.773 . . . . 0.0 109.633 -179.483 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 27.6 mm -93.38 91.68 3.37 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.199 0 CA-C-O 121.167 0.508 . . . . 0.0 110.932 -178.45 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.53 ' O ' ' CE1' ' A' ' 37' ' ' TYR . 9.0 pt -145.8 128.17 9.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.232 179.645 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -47.84 135.93 14.88 Favored Glycine 0 CA--C 1.52 0.371 0 N-CA-C 110.805 -0.918 . . . . 0.0 110.805 -179.456 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 37' ' ' TYR . . . . . 0.53 ' CE1' ' O ' ' A' ' 35' ' ' ILE . 10.1 m-85 -100.97 179.86 4.26 Favored 'General case' 0 C--N 1.33 -0.241 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 -179.898 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 5.4 tmm_? -132.43 122.37 24.87 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.473 179.731 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.469 ' O ' ' CG1' ' A' ' 39' ' ' ILE . 1.8 pt -97.84 118.17 43.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 115.924 -0.58 . . . . 0.0 109.89 179.633 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 20.9 m -98.3 134.16 41.71 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.216 -179.383 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.4 p -132.01 140.97 46.68 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.262 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.369 -179.999 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 42' ' ' VAL . . . . . 0.49 ' O ' ' N ' ' A' ' 74' ' ' ASP . 36.2 t -132.21 131.72 60.93 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.177 0 CA-C-O 120.979 0.419 . . . . 0.0 109.903 179.311 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.468 ' HB2' ' CE2' ' A' ' 73' ' ' TYR . . . -96.85 132.98 42.05 Favored 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 109.46 -0.571 . . . . 0.0 109.46 178.987 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 44' ' ' ALA . . . . . 0.62 ' HB3' ' O ' ' A' ' 72' ' ' ASP . . . -93.93 -14.68 25.71 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.766 0.317 . . . . 0.0 110.825 -179.843 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -99.86 18.88 55.27 Favored Glycine 0 CA--C 1.525 0.678 0 N-CA-C 111.025 -0.83 . . . . 0.0 111.025 -179.495 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 29.4 mm-40 -138.86 149.17 44.58 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 121.179 0.514 . . . . 0.0 110.368 -179.919 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -68.87 -17.3 71.31 Favored Glycine 0 CA--C 1.519 0.283 0 N-CA-C 110.552 -1.019 . . . . 0.0 110.552 179.864 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -135.31 139.03 30.35 Favored Pre-proline 0 CA--C 1.538 0.518 0 C-N-CA 121.192 -0.203 . . . . 0.0 110.683 179.842 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -73.31 158.65 48.21 Favored 'Trans proline' 0 N--CA 1.491 1.351 0 C-N-CA 122.565 2.176 . . . . 0.0 111.813 178.252 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 96.4 mt -73.87 150.2 7.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.247 179.254 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 86.0 m-85 -70.04 137.19 51.07 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.715 179.94 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 52' ' ' GLU . . . . . 0.421 ' N ' ' CD ' ' A' ' 52' ' ' GLU . 0.0 OUTLIER -59.28 -175.65 0.03 OUTLIER 'General case' 0 CA--C 1.513 -0.446 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.449 179.212 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 53' ' ' ASP . . . . . 0.41 ' CG ' ' OH ' ' A' ' 62' ' ' TYR . 2.4 t0 -148.06 144.13 27.67 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.802 -0.636 . . . . 0.0 110.486 179.173 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 89.0 m-85 -116.74 122.93 45.9 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-N 116.363 -0.381 . . . . 0.0 110.572 179.812 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 9.5 p -132.06 142.7 42.18 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.425 0 CA-C-N 116.405 -0.361 . . . . 0.0 110.126 179.972 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 94.8 m-20 -61.13 151.87 30.03 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.377 179.952 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 11.3 t -62.72 -35.57 80.15 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.661 179.89 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 42.9 m -50.89 -37.21 42.3 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.162 -179.623 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.639 ' C ' ' H ' ' A' ' 61' ' ' TYR . 3.3 t -79.86 83.85 1.23 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.55 179.826 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -62.37 28.39 0.07 OUTLIER Glycine 0 CA--C 1.535 1.286 0 N-CA-C 111.103 -0.799 . . . . 0.0 111.103 179.672 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 61' ' ' TYR . . . . . 0.639 ' H ' ' C ' ' A' ' 59' ' ' VAL . 55.2 p90 -166.27 154.19 10.29 Favored 'General case' 0 N--CA 1.451 -0.389 0 CA-C-O 121.14 0.495 . . . . 0.0 111.879 -179.527 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 62' ' ' TYR . . . . . 0.41 ' OH ' ' CG ' ' A' ' 53' ' ' ASP . 23.6 t80 -154.74 148.91 25.94 Favored 'General case' 0 N--CA 1.454 -0.27 0 CA-C-N 115.727 -0.67 . . . . 0.0 109.731 178.794 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 50.1 m -110.69 132.97 53.74 Favored 'General case' 0 N--CA 1.463 0.224 0 CA-C-O 120.909 0.385 . . . . 0.0 110.325 -179.189 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -133.1 100.86 3.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 115.826 -0.625 . . . . 0.0 109.84 178.166 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.514 HG22 ' HB3' ' A' ' 21' ' ' SER . 1.7 p -114.26 165.25 12.87 Favored 'General case' 0 CA--C 1.514 -0.441 0 CA-C-O 121.227 0.536 . . . . 0.0 110.445 179.882 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 108.67 24.33 6.16 Favored Glycine 0 CA--C 1.525 0.68 0 CA-C-N 115.444 -0.798 . . . . 0.0 111.295 -179.933 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.457 ' O ' ' CB ' ' A' ' 20' ' ' SER . 12.7 mt -98.69 106.55 18.83 Favored 'General case' 0 C--O 1.225 -0.22 0 N-CA-C 109.335 -0.617 . . . . 0.0 109.335 179.388 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 49.3 mm-40 -48.43 138.42 11.41 Favored Pre-proline 0 C--N 1.318 -0.792 0 CA-C-N 116.319 -0.4 . . . . 0.0 111.971 -178.323 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -73.36 154.04 50.81 Favored 'Trans proline' 0 N--CA 1.498 1.743 0 C-N-CA 122.749 2.299 . . . . 0.0 111.298 178.736 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 73.76 -6.0 20.95 Favored Glycine 0 CA--C 1.527 0.809 0 CA-C-N 115.839 -0.619 . . . . 0.0 111.647 179.209 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 1.8 mp -102.53 140.53 20.67 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.424 0 CA-C-O 121.326 0.584 . . . . 0.0 109.626 -179.847 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 72' ' ' ASP . . . . . 0.62 ' O ' ' HB3' ' A' ' 44' ' ' ALA . 1.9 t70 -81.42 118.7 22.9 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-N 114.995 -1.002 . . . . 0.0 109.922 179.434 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 73' ' ' TYR . . . . . 0.499 ' O ' HD13 ' A' ' 75' ' ' ILE . 17.6 m-85 -110.85 119.68 39.9 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.828 -0.623 . . . . 0.0 110.44 179.949 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 74' ' ' ASP . . . . . 0.49 ' N ' ' O ' ' A' ' 42' ' ' VAL . 24.8 m-20 -89.43 117.42 28.34 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.613 -0.721 . . . . 0.0 109.574 179.579 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 75' ' ' ILE . . . . . 0.522 HD11 ' N ' ' B' ' 223' ' ' ARG . 0.0 OUTLIER -114.64 166.23 8.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 121.041 0.448 . . . . 0.0 110.179 -179.339 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 1.1 p -155.11 122.64 5.65 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.589 -0.732 . . . . 0.0 110.559 179.243 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.61 ' O ' HG23 ' B' ' 217' ' ' THR . 20.6 t -96.7 127.35 48.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 N-CA-C 109.355 -0.609 . . . . 0.0 109.355 178.962 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 96.7 mt -117.19 120.02 63.69 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.416 0 CA-C-N 116.479 -0.328 . . . . 0.0 110.485 179.974 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 93.4 m -101.54 116.79 33.56 Favored 'General case' 0 C--N 1.331 -0.21 0 N-CA-C 109.715 -0.476 . . . . 0.0 109.715 179.265 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 16.9 tp -121.35 116.8 25.48 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.724 -179.931 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 81' ' ' ILE . . . . . 0.503 ' HA ' HD11 ' A' ' 35' ' ' ILE . 2.2 pp -147.15 143.29 20.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.321 178.553 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 27.2 t-20 . . . . . 0 C--N 1.329 -0.287 0 CA-C-O 120.83 0.348 . . . . 0.0 111.05 -179.818 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' B' B ' 207' ' ' GLY . . . . . 0.417 ' C ' ' CH2' ' B' ' 218' ' ' TRP . . . . . . . . 0 N--CA 1.466 0.654 0 N-CA-C 110.802 -0.919 . . . . 0.0 110.802 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 208' ' ' SER . . . . . 0.532 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 45.1 p -162.2 166.16 25.93 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.803 0.335 . . . . 0.0 110.643 179.068 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 209' ' ' TRP . . . . . . . . . . . . . 84.7 m95 -85.23 152.84 23.03 Favored 'General case' 0 C--N 1.332 -0.167 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.463 179.603 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 210' ' ' THR . . . . . 0.428 ' OG1' ' O ' ' B' ' 217' ' ' THR . 49.4 p -129.47 129.79 45.05 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-N 116.354 -0.385 . . . . 0.0 110.355 179.504 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 57.8 t-105 -92.54 110.17 21.58 Favored 'General case' 0 N--CA 1.462 0.17 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.761 179.657 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 212' ' ' GLU . . . . . 0.443 ' O ' ' O ' ' B' ' 215' ' ' LYS . 1.4 pt-20 -161.17 165.8 28.89 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.54 179.745 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 213' ' ' ASN . . . . . . . . . . . . . 15.9 m120 51.07 33.77 9.75 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.118 176.906 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 53.35 14.79 3.49 Favored Glycine 0 CA--C 1.527 0.814 0 N-CA-C 111.502 -0.639 . . . . 0.0 111.502 179.993 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 215' ' ' LYS . . . . . 0.443 ' O ' ' O ' ' B' ' 212' ' ' GLU . 9.7 mtmp? -140.91 149.33 41.75 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-O 121.047 0.451 . . . . 0.0 110.663 179.895 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 216' ' ' TRP . . . . . . . . . . . . . 48.3 m95 -84.73 114.73 22.26 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.079 -0.51 . . . . 0.0 109.932 179.757 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 217' ' ' THR . . . . . 0.61 HG23 ' O ' ' A' ' 77' ' ' VAL . 18.3 m -119.25 133.03 55.97 Favored 'General case' 0 N--CA 1.464 0.263 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.279 -179.312 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 218' ' ' TRP . . . . . 0.532 ' CH2' ' N ' ' B' ' 208' ' ' SER . 19.6 t-105 -105.33 107.5 18.52 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.014 -0.539 . . . . 0.0 109.874 179.5 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 219' ' ' LYS . . . . . 0.481 ' HG3' HG22 ' B' ' 217' ' ' THR . 51.1 mtmt -132.82 176.2 8.68 Favored 'General case' 0 CA--C 1.514 -0.44 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.285 -179.48 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -178.87 -162.38 28.2 Favored Glycine 0 CA--C 1.525 0.685 0 N-CA-C 110.998 -0.841 . . . . 0.0 110.998 179.288 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 221' ' ' ILE . . . . . 0.597 ' H ' HD12 ' B' ' 221' ' ' ILE . 2.3 mp -55.84 -73.11 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 C-N-CA 120.817 -0.353 . . . . 0.0 110.466 -178.321 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 222' ' ' ILE . . . . . 0.54 HG23 ' O ' ' B' ' 221' ' ' ILE . 23.0 pt -160.1 -165.27 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.167 -179.685 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 223' ' ' ARG . . . . . 0.522 ' N ' HD11 ' A' ' 75' ' ' ILE . 39.1 ptt180 -41.12 171.54 0.0 OUTLIER 'General case' 0 C--N 1.334 -0.092 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.956 178.778 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 224' ' ' LEU . . . . . 0.834 ' H ' HD22 ' B' ' 224' ' ' LEU . 1.9 mm? -65.16 110.61 2.6 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-O 121.383 0.611 . . . . 0.0 110.941 -179.642 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 82.7 tt0 . . . . . 0 C--N 1.329 -0.307 0 CA-C-N 115.251 -0.886 . . . . 0.0 109.966 179.656 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.338 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 32.8 p -156.55 -157.25 0.69 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.743 0.306 . . . . 0.0 110.542 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 69.7 mm-40 -75.87 88.28 2.88 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.765 179.825 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.6 m -146.0 74.49 13.22 Favored Pre-proline 0 C--N 1.331 -0.2 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.417 179.696 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 62.8 Cg_endo -80.81 118.63 3.47 Favored 'Trans proline' 0 C--N 1.31 -1.459 0 C-N-CA 122.516 2.144 . . . . 0.0 112.079 179.803 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 89.2 mm-40 -87.95 -169.88 2.76 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.372 179.936 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 70.3 mt -75.68 127.15 32.44 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.236 -179.819 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 18.5 p -90.19 133.98 34.56 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.532 -179.908 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 97.6 m-20 -85.16 149.52 25.47 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.978 -0.556 . . . . 0.0 110.501 179.928 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.521 HD11 ' CZ2' ' B' ' 209' ' ' TRP . 70.1 mt -62.0 151.3 35.55 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.192 -179.054 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 53.5 p -142.55 152.54 42.71 Favored 'General case' 0 CA--C 1.521 -0.152 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.311 -179.825 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' PHE . . . . . 0.56 ' CD2' HD11 ' B' ' 224' ' ' LEU . 24.7 m-85 -112.16 143.54 43.05 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.972 -179.552 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 28.5 m -142.87 162.06 17.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.326 179.496 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 91.5 m-20 45.57 61.6 2.54 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.499 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 95.5 mt -85.61 135.54 24.72 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.611 179.316 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.4 HG22 ' H ' ' A' ' 19' ' ' ASP . 0.2 OUTLIER -132.37 -168.78 2.11 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.394 179.505 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 19' ' ' ASP . . . . . 0.458 ' OD1' ' N ' ' A' ' 20' ' ' SER . 28.7 p-10 -90.58 -42.38 10.83 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.748 179.312 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 20' ' ' SER . . . . . 0.458 ' N ' ' OD1' ' A' ' 19' ' ' ASP . 28.4 t -112.69 7.16 18.56 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.848 -179.886 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 30.7 p -154.05 153.36 31.78 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.312 179.947 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 44.0 pt -147.65 149.16 15.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.344 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -99.52 80.56 0.52 Allowed Glycine 0 CA--C 1.526 0.744 0 N-CA-C 111.3 -0.72 . . . . 0.0 111.3 -179.898 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 62.1 mt -68.35 127.83 34.39 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.891 0.377 . . . . 0.0 110.041 -179.919 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 55.9 ttp180 -142.63 136.05 28.74 Favored 'General case' 0 CA--C 1.518 -0.252 0 CA-C-O 121.095 0.474 . . . . 0.0 110.493 -179.819 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' TRP . . . . . 0.55 ' CD2' ' O ' ' A' ' 60' ' ' GLY . 43.0 p90 -140.78 155.79 46.32 Favored 'General case' 0 CA--C 1.518 -0.284 0 CA-C-N 115.835 -0.621 . . . . 0.0 109.85 179.932 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 2.7 m -110.23 101.85 49.3 Favored Pre-proline 0 CA--C 1.534 0.358 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.839 -179.476 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_exo -56.34 150.59 49.29 Favored 'Trans proline' 0 C--N 1.308 -1.576 0 C-N-CA 122.078 1.852 . . . . 0.0 112.518 178.854 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 72.8 mt -87.3 134.9 33.5 Favored 'General case' 0 N--CA 1.465 0.281 0 CA-C-O 121.718 0.771 . . . . 0.0 110.671 -179.881 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 18.6 t-20 -47.13 -32.63 4.42 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-N 115.214 -0.903 . . . . 0.0 110.199 -179.923 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 75.8 m -82.38 -33.43 28.77 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.65 179.273 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 4.3 m -56.47 130.76 46.3 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-O 120.982 0.42 . . . . 0.0 110.221 -179.96 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 33' ' ' THR . . . . . 0.477 ' OG1' ' N ' ' A' ' 82' ' ' ASN . 6.6 m -54.37 139.53 36.52 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.586 -0.734 . . . . 0.0 109.776 -179.494 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 30.7 mm -93.57 88.97 2.54 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 CA-C-O 121.133 0.492 . . . . 0.0 110.608 -179.275 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.42 HD11 ' HA ' ' A' ' 81' ' ' ILE . 7.9 pt -139.65 149.18 22.64 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.184 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.408 179.588 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -48.68 136.88 17.77 Favored Glycine 0 CA--C 1.519 0.305 0 N-CA-C 110.918 -0.873 . . . . 0.0 110.918 -179.437 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 73.1 m-85 -104.6 160.44 14.95 Favored 'General case' 0 CA--C 1.517 -0.294 0 CA-C-O 120.826 0.346 . . . . 0.0 110.13 -179.818 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 5.3 tmm_? -124.32 124.5 42.52 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.791 -179.789 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.434 ' O ' ' CG1' ' A' ' 39' ' ' ILE . 2.5 pt -99.12 124.77 52.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.075 -0.511 . . . . 0.0 109.936 179.749 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 16.6 m -106.33 135.4 47.89 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.493 -179.545 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.4 p -133.9 142.2 41.94 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.25 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.162 179.878 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 42' ' ' VAL . . . . . 0.527 ' O ' ' N ' ' A' ' 74' ' ' ASP . 38.3 t -132.55 131.87 60.05 Favored 'Isoleucine or valine' 0 C--N 1.34 0.167 0 N-CA-C 110.06 -0.348 . . . . 0.0 110.06 179.46 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.554 ' HB2' ' CE2' ' A' ' 73' ' ' TYR . . . -98.98 142.47 30.43 Favored 'General case' 0 C--N 1.327 -0.406 0 N-CA-C 109.366 -0.605 . . . . 0.0 109.366 179.158 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.549 ' HB3' ' O ' ' A' ' 72' ' ' ASP . . . -101.06 -21.41 15.01 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.876 0.369 . . . . 0.0 110.959 179.412 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -94.07 30.6 7.41 Favored Glycine 0 N--CA 1.465 0.586 0 N-CA-C 110.958 -0.857 . . . . 0.0 110.958 -179.709 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 86.9 mt-10 -150.98 150.74 31.15 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-O 120.966 0.413 . . . . 0.0 110.626 -179.57 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -70.9 -16.46 74.65 Favored Glycine 0 CA--C 1.519 0.339 0 N-CA-C 110.567 -1.013 . . . . 0.0 110.567 179.879 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -137.63 139.32 26.64 Favored Pre-proline 0 CA--C 1.539 0.524 0 C-N-CA 121.058 -0.257 . . . . 0.0 110.401 179.632 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 63.3 Cg_endo -73.76 160.61 43.37 Favored 'Trans proline' 0 N--CA 1.49 1.291 0 C-N-CA 122.44 2.094 . . . . 0.0 112.326 177.833 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 96.7 mt -71.53 150.54 9.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.285 179.334 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 85.9 m-85 -73.1 140.86 47.44 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.728 179.938 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 52' ' ' GLU . . . . . 0.42 ' N ' ' CD ' ' A' ' 52' ' ' GLU . 0.3 OUTLIER -68.26 -177.21 0.84 Allowed 'General case' 0 CA--C 1.514 -0.408 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.653 179.575 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 53' ' ' ASP . . . . . 0.41 ' CG ' ' OH ' ' A' ' 62' ' ' TYR . 3.5 t70 -149.47 143.38 25.63 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.6 179.361 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 92.7 m-85 -111.33 122.82 48.85 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.366 179.854 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 5.3 p -129.41 139.13 52.54 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.292 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.293 -179.894 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 91.5 m-20 -55.29 158.12 3.29 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.483 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 38.5 t -66.25 -37.01 84.49 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.66 179.937 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 37.9 m -51.59 -33.4 32.55 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.311 -179.598 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.571 ' C ' ' H ' ' A' ' 61' ' ' TYR . 1.9 t -91.78 68.76 0.58 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.179 179.291 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 60' ' ' GLY . . . . . 0.55 ' O ' ' CD2' ' A' ' 26' ' ' TRP . . . -53.24 -2.64 0.1 Allowed Glycine 0 CA--C 1.528 0.873 0 N-CA-C 110.946 -0.862 . . . . 0.0 110.946 -179.983 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 61' ' ' TYR . . . . . 0.571 ' H ' ' C ' ' A' ' 59' ' ' VAL . 41.2 p90 -122.57 151.64 41.2 Favored 'General case' 0 N--CA 1.464 0.243 0 CA-C-O 121.103 0.478 . . . . 0.0 111.0 -179.6 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 62' ' ' TYR . . . . . 0.41 ' OH ' ' CG ' ' A' ' 53' ' ' ASP . 33.6 t80 -155.78 156.79 35.41 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.726 -0.67 . . . . 0.0 109.772 179.553 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 88.0 m -119.92 136.44 54.51 Favored 'General case' 0 N--CA 1.465 0.301 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.402 -179.569 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -131.9 110.95 17.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.018 -0.537 . . . . 0.0 109.863 178.956 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 2.0 p -122.26 164.15 18.38 Favored 'General case' 0 N--CA 1.464 0.256 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.617 -179.94 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 112.86 8.65 20.15 Favored Glycine 0 CA--C 1.529 0.943 0 CA-C-N 115.561 -0.745 . . . . 0.0 111.74 -179.12 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 10.5 mt -75.48 178.94 5.57 Favored 'General case' 0 C--N 1.325 -0.483 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 178.583 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 58.7 mm-40 -128.04 137.62 31.21 Favored Pre-proline 0 CA--C 1.54 0.584 0 C-N-CA 121.019 -0.272 . . . . 0.0 111.076 179.295 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -73.34 148.67 43.81 Favored 'Trans proline' 0 N--CA 1.496 1.619 0 C-N-CA 122.801 2.334 . . . . 0.0 111.83 179.193 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 75.51 3.83 73.03 Favored Glycine 0 CA--C 1.526 0.768 0 CA-C-N 115.619 -0.719 . . . . 0.0 111.411 179.226 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 2.0 mp -112.23 141.26 28.31 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.401 0 CA-C-O 121.495 0.664 . . . . 0.0 109.579 -179.618 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 72' ' ' ASP . . . . . 0.549 ' O ' ' HB3' ' A' ' 44' ' ' ALA . 1.9 t70 -82.06 111.52 18.28 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 115.137 -0.938 . . . . 0.0 110.633 179.854 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 73' ' ' TYR . . . . . 0.554 ' CE2' ' HB2' ' A' ' 43' ' ' ALA . 14.7 m-85 -105.86 119.56 39.48 Favored 'General case' 0 C--O 1.219 -0.546 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.568 179.791 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 74' ' ' ASP . . . . . 0.527 ' N ' ' O ' ' A' ' 42' ' ' VAL . 5.5 m-20 -89.32 118.82 29.27 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.572 -0.74 . . . . 0.0 109.326 179.838 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.629 HD11 ' N ' ' B' ' 223' ' ' ARG . 0.0 OUTLIER -115.45 163.81 12.38 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.404 0 CA-C-O 121.066 0.46 . . . . 0.0 110.163 -179.082 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 20.6 t -155.91 121.44 4.9 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.508 -0.769 . . . . 0.0 110.681 178.899 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 5.2 t -101.35 101.09 11.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 N-CA-C 109.901 -0.407 . . . . 0.0 109.901 179.341 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 96.8 mt -91.96 133.46 33.37 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.267 179.763 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 79' ' ' THR . . . . . 0.473 ' CG2' ' O ' ' B' ' 216' ' ' TRP . 0.0 OUTLIER -111.91 107.54 16.59 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 121.108 0.48 . . . . 0.0 109.755 179.551 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 38.3 tp -104.22 115.37 30.28 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.724 -0.671 . . . . 0.0 110.458 179.937 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 81' ' ' ILE . . . . . 0.42 ' HA ' HD11 ' A' ' 35' ' ' ILE . 2.1 pp -145.95 146.26 19.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.068 -0.514 . . . . 0.0 110.275 179.33 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 82' ' ' ASN . . . . . 0.477 ' N ' ' OG1' ' A' ' 33' ' ' THR . 18.9 t-20 -69.32 -48.71 60.68 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.844 0.354 . . . . 0.0 111.256 -179.902 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 83' ' ' GLY . . . . . 0.422 ' H ' ' HG1' ' A' ' 33' ' ' THR . . . 106.91 165.31 22.33 Favored Glycine 0 N--CA 1.465 0.618 0 N-CA-C 110.843 -0.903 . . . . 0.0 110.843 179.745 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -72.66 175.56 43.87 Favored Glycine 0 CA--C 1.525 0.676 0 N-CA-C 110.753 -0.939 . . . . 0.0 110.753 -179.97 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 48.0 mp0 -63.84 123.73 19.68 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.829 0.347 . . . . 0.0 110.419 -179.81 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 86' ' ' SER . . . . . 0.545 ' O ' ' HB3' ' A' ' 87' ' ' ALA . 23.2 p -79.57 168.47 19.36 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.519 179.831 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.545 ' HB3' ' O ' ' A' ' 86' ' ' SER . . . 72.74 58.41 0.36 Allowed Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.493 179.977 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -71.22 -88.73 0.0 OUTLIER 'Trans proline' 0 C--N 1.306 -1.695 0 C-N-CA 122.587 2.191 . . . . 0.0 111.934 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -138.26 122.34 17.96 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.56 179.932 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 16.3 p -147.54 -176.58 5.3 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.492 179.828 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 45.4 tp -90.15 125.81 35.58 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.384 179.941 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 92' ' ' THR . . . . . 0.418 HG22 ' H ' ' A' ' 92' ' ' THR . 0.1 OUTLIER -90.02 134.05 34.47 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.446 179.948 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 35.4 mt-30 -73.12 127.86 33.81 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.53 -179.931 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 50.8 tt0 -170.31 126.66 0.79 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.393 179.927 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 41.9 m . . . . . 0 C--O 1.22 -0.474 0 CA-C-O 118.057 -0.973 . . . . 0.0 110.486 179.953 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' B' B ' 201' ' ' SER . . . . . . . . . . . . . 48.1 p . . . . . 0 N--CA 1.491 1.597 0 N-CA-C 109.346 -0.613 . . . . 0.0 109.346 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' B' B ' 202' ' ' SER . . . . . . . . . . . . . 17.5 m -70.18 139.33 52.35 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.019 -179.988 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 203' ' ' SER . . . . . . . . . . . . . 1.4 p -105.95 151.13 39.95 Favored Pre-proline 0 CA--C 1.536 0.433 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.586 -179.726 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 204' ' ' PRO . . . . . . . . . . . . . 75.0 Cg_exo -45.33 -47.37 12.92 Favored 'Trans proline' 0 N--CA 1.492 1.421 0 C-N-CA 122.485 2.123 . . . . 0.0 112.116 179.381 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 205' ' ' ILE . . . . . 0.415 HG21 ' H ' ' B' ' 225' ' ' GLU . 0.0 OUTLIER -151.23 148.68 14.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.398 179.823 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 206' ' ' GLN . . . . . . . . . . . . . 17.9 pt20 -144.91 144.78 31.26 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.871 0.367 . . . . 0.0 110.25 178.604 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 207' ' ' GLY . . . . . . . . . . . . . . . -104.95 -130.55 6.82 Favored Glycine 0 N--CA 1.467 0.736 0 N-CA-C 111.088 -0.805 . . . . 0.0 111.088 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 208' ' ' SER . . . . . 0.556 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 59.7 p -166.74 171.78 11.15 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.823 0.344 . . . . 0.0 110.825 179.795 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 209' ' ' TRP . . . . . 0.521 ' CZ2' HD11 ' A' ' 12' ' ' LEU . 44.4 m95 -83.66 146.33 28.31 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.593 179.041 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 32.0 p -128.64 130.11 46.8 Favored 'General case' 0 N--CA 1.463 0.199 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.287 179.752 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 39.1 t-105 -95.37 117.72 30.83 Favored 'General case' 0 N--CA 1.463 0.221 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.376 179.834 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 212' ' ' GLU . . . . . 0.443 ' O ' ' O ' ' B' ' 215' ' ' LYS . 0.6 OUTLIER -163.81 164.57 23.55 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.708 179.13 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 213' ' ' ASN . . . . . . . . . . . . . 78.9 m-20 52.62 39.92 29.12 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.616 176.302 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 49.64 21.68 3.52 Favored Glycine 0 CA--C 1.524 0.647 0 N-CA-C 111.084 -0.806 . . . . 0.0 111.084 179.605 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 215' ' ' LYS . . . . . 0.443 ' O ' ' O ' ' B' ' 212' ' ' GLU . 24.9 mtpt -148.02 152.73 37.93 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.063 0.459 . . . . 0.0 111.51 -179.694 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 216' ' ' TRP . . . . . 0.483 ' CD1' ' N ' ' B' ' 216' ' ' TRP . 24.4 m95 -92.17 119.08 31.47 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.959 -0.564 . . . . 0.0 109.729 179.165 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 217' ' ' THR . . . . . . . . . . . . . 12.4 m -132.72 145.02 50.68 Favored 'General case' 0 N--CA 1.465 0.32 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.469 -179.732 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 218' ' ' TRP . . . . . 0.556 ' CH2' ' N ' ' B' ' 208' ' ' SER . 14.5 t-105 -103.34 118.12 36.03 Favored 'General case' 0 N--CA 1.463 0.199 0 CA-C-N 116.008 -0.542 . . . . 0.0 109.922 179.563 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 95.7 mttt -141.15 165.74 26.7 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.952 -179.729 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -176.03 -161.02 24.47 Favored Glycine 0 CA--C 1.521 0.435 0 CA-C-N 115.492 -0.776 . . . . 0.0 111.421 -179.589 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 221' ' ' ILE . . . . . 0.546 ' O ' HG23 ' B' ' 222' ' ' ILE . 22.6 mt -52.75 -74.74 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 C-N-CA 120.598 -0.441 . . . . 0.0 110.295 -177.839 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 222' ' ' ILE . . . . . 0.546 HG23 ' O ' ' B' ' 221' ' ' ILE . 22.1 pt -160.47 -166.72 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.389 -0.369 . . . . 0.0 110.064 179.776 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 223' ' ' ARG . . . . . 0.629 ' N ' HD11 ' A' ' 75' ' ' ILE . 34.1 ptt85 -42.01 175.17 0.0 OUTLIER 'General case' 0 C--N 1.333 -0.129 0 CA-C-O 121.525 0.678 . . . . 0.0 110.532 178.842 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 224' ' ' LEU . . . . . 0.704 HD22 ' N ' ' B' ' 224' ' ' LEU . 3.1 mm? -60.55 122.68 15.27 Favored 'General case' 0 C--N 1.315 -0.905 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.954 -179.379 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 225' ' ' GLU . . . . . 0.415 ' H ' HG21 ' B' ' 205' ' ' ILE . 43.1 tt0 -85.22 140.51 30.83 Favored 'General case' 0 CA--C 1.517 -0.315 0 CA-C-N 115.623 -0.717 . . . . 0.0 110.343 179.678 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 226' ' ' GLN . . . . . . . . . . . . . 74.1 mt-30 . . . . . 0 C--O 1.22 -0.461 0 CA-C-O 117.926 -1.035 . . . . 0.0 111.071 -179.852 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.317 0 N-CA-C 109.404 -1.479 . . . . 0.0 109.404 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 37.9 t -63.22 138.89 58.69 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.804 0.335 . . . . 0.0 110.204 179.861 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -108.67 117.38 34.03 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-N 116.163 -0.472 . . . . 0.0 109.966 179.729 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.415 ' H ' HG22 ' A' ' 6' ' ' VAL . 5.5 m -90.29 153.34 46.44 Favored Pre-proline 0 CA--C 1.536 0.438 0 CA-C-N 116.561 -0.291 . . . . 0.0 110.566 -179.468 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_exo -52.59 146.8 32.7 Favored 'Trans proline' 0 N--CA 1.498 1.757 0 C-N-CA 121.851 1.701 . . . . 0.0 112.232 179.128 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' GLN . . . . . 0.613 ' CD ' ' H ' ' A' ' 8' ' ' GLN . 0.1 OUTLIER -65.44 -84.79 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.778 -0.646 . . . . 0.0 110.198 179.872 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 74.8 mt -99.31 127.25 45.29 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.914 -0.585 . . . . 0.0 110.233 -179.95 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' THR . . . . . 0.681 HG22 HD21 ' A' ' 29' ' ' LEU . 14.9 t -84.56 177.68 7.99 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.341 -179.915 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 11' ' ' ASP . . . . . 0.537 ' OD1' ' N ' ' A' ' 12' ' ' LEU . 55.9 t0 -132.32 153.07 51.08 Favored 'General case' 0 N--CA 1.465 0.277 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.241 179.97 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.537 ' N ' ' OD1' ' A' ' 11' ' ' ASP . 6.0 tp -65.3 142.8 58.13 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.49 -179.963 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 13' ' ' SER . . . . . 0.456 ' O ' ' O ' ' A' ' 25' ' ' ARG . 93.5 p -141.99 152.53 43.52 Favored 'General case' 0 N--CA 1.463 0.214 0 CA-C-O 121.076 0.465 . . . . 0.0 110.544 179.325 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 14' ' ' PHE . . . . . 0.538 ' CD2' HD11 ' B' ' 224' ' ' LEU . 24.3 m-85 -111.46 146.25 37.57 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.511 -179.251 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 31.9 m -147.06 153.86 12.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-O 120.818 0.342 . . . . 0.0 110.395 179.285 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 32.6 t70 58.89 56.87 3.85 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.426 179.854 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 94.0 mt -83.51 133.31 29.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 115.914 -0.585 . . . . 0.0 110.393 179.667 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.44 HG22 ' H ' ' A' ' 19' ' ' ASP . 0.2 OUTLIER -131.17 -167.73 1.89 Allowed 'General case' 0 N--CA 1.471 0.606 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.206 -179.74 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 19' ' ' ASP . . . . . 0.474 ' OD1' ' N ' ' A' ' 19' ' ' ASP . 0.4 OUTLIER -75.89 -53.24 8.74 Favored 'General case' 0 CA--C 1.517 -0.307 0 CA-C-O 120.993 0.425 . . . . 0.0 110.876 179.21 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 20' ' ' SER . . . . . 0.427 ' CB ' ' O ' ' A' ' 67' ' ' LEU . 33.4 p -121.13 14.31 11.37 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.968 -177.796 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 21' ' ' SER . . . . . 0.401 ' HB2' HG22 ' A' ' 65' ' ' THR . 95.5 p -144.96 125.05 13.61 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.116 0.484 . . . . 0.0 110.112 179.953 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 47.1 pt -127.39 140.67 48.46 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.323 0 CA-C-N 115.912 -0.586 . . . . 0.0 109.492 -179.823 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -103.69 91.57 0.83 Allowed Glycine 0 N--CA 1.467 0.704 0 N-CA-C 111.436 -0.665 . . . . 0.0 111.436 -179.397 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.506 HD22 ' N ' ' A' ' 24' ' ' LEU . 4.0 mm? -61.51 138.53 58.28 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.793 0.33 . . . . 0.0 110.234 -179.812 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 25' ' ' ARG . . . . . 0.456 ' O ' ' O ' ' A' ' 13' ' ' SER . 13.9 tpt180 -145.38 134.89 23.22 Favored 'General case' 0 C--N 1.334 -0.091 0 CA-C-O 121.455 0.645 . . . . 0.0 110.288 179.873 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 26' ' ' TRP . . . . . 0.511 ' CE2' ' O ' ' A' ' 60' ' ' GLY . 18.7 p90 -145.81 156.3 43.49 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.47 -0.786 . . . . 0.0 109.519 179.21 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 2.7 m -105.5 104.4 47.9 Favored Pre-proline 0 CA--C 1.534 0.344 0 CA-C-O 119.546 -0.264 . . . . 0.0 111.161 -179.153 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_exo -54.48 153.2 23.83 Favored 'Trans proline' 0 C--N 1.31 -1.483 0 C-N-CA 121.381 1.388 . . . . 0.0 113.011 178.523 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.681 HD21 HG22 ' A' ' 10' ' ' THR . 75.2 mt -102.57 134.86 45.22 Favored 'General case' 0 N--CA 1.467 0.392 0 CA-C-N 114.946 -1.024 . . . . 0.0 111.04 179.854 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 18.3 t-20 -45.39 -31.1 1.52 Allowed 'General case' 0 C--N 1.314 -0.964 0 CA-C-N 114.86 -1.063 . . . . 0.0 110.263 179.883 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 50.8 m -87.79 -28.85 21.42 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.292 178.998 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 32' ' ' SER . . . . . 0.464 ' N ' ' O ' ' A' ' 29' ' ' LEU . 3.4 m -56.23 117.56 3.89 Favored 'General case' 0 CA--C 1.529 0.162 0 CA-C-O 121.318 0.58 . . . . 0.0 110.145 179.935 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 33' ' ' THR . . . . . 0.631 ' CB ' ' H ' ' A' ' 82' ' ' ASN . 12.2 m -51.83 145.55 9.51 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-N 114.919 -1.037 . . . . 0.0 109.182 -179.126 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 30.1 mm -92.08 93.42 4.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.998 0.428 . . . . 0.0 110.825 -178.113 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.597 HD11 ' HA ' ' A' ' 81' ' ' ILE . 8.1 pt -150.97 128.84 2.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 115.871 -0.604 . . . . 0.0 109.875 179.027 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -47.01 130.38 12.75 Favored Glycine 0 CA--C 1.521 0.413 0 N-CA-C 111.4 -0.68 . . . . 0.0 111.4 -178.941 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 95.2 m-85 -87.36 179.64 6.56 Favored 'General case' 0 C--N 1.33 -0.279 0 N-CA-C 109.976 -0.379 . . . . 0.0 109.976 179.551 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 38' ' ' ARG . . . . . 0.683 ' NH2' ' H ' ' A' ' 40' ' ' THR . 0.0 OUTLIER -131.59 123.08 27.17 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.93 179.885 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.49 ' O ' ' CG1' ' A' ' 39' ' ' ILE . 1.7 pt -107.08 118.0 53.99 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.532 0 CA-C-O 121.203 0.525 . . . . 0.0 110.103 179.546 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 40' ' ' THR . . . . . 0.683 ' H ' ' NH2' ' A' ' 38' ' ' ARG . 52.9 m -103.25 138.94 39.36 Favored 'General case' 0 N--CA 1.47 0.537 0 O-C-N 122.037 -0.415 . . . . 0.0 110.127 -179.39 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.4 p -129.1 141.13 47.4 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.476 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.351 -179.873 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 42' ' ' VAL . . . . . 0.495 ' O ' ' N ' ' A' ' 74' ' ' ASP . 37.4 t -131.9 132.73 61.53 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.166 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.203 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -96.66 132.91 41.83 Favored 'General case' 0 C--N 1.327 -0.401 0 N-CA-C 109.468 -0.567 . . . . 0.0 109.468 179.173 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.607 ' HB3' ' O ' ' A' ' 72' ' ' ASP . . . -91.65 -19.16 22.97 Favored 'General case' 0 C--N 1.328 -0.333 0 C-N-CA 120.748 -0.381 . . . . 0.0 110.681 179.994 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -99.07 25.04 29.82 Favored Glycine 0 N--CA 1.466 0.67 0 N-CA-C 111.208 -0.757 . . . . 0.0 111.208 -179.729 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -138.96 146.95 41.6 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 120.853 0.358 . . . . 0.0 110.587 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -66.99 -21.18 71.4 Favored Glycine 0 CA--C 1.526 0.728 0 N-CA-C 111.126 -0.79 . . . . 0.0 111.126 179.811 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -138.16 140.59 29.26 Favored Pre-proline 0 CA--C 1.545 0.784 0 O-C-N 122.66 -0.318 . . . . 0.0 110.553 -179.977 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -74.11 163.79 35.86 Favored 'Trans proline' 0 N--CA 1.495 1.589 0 C-N-CA 122.656 2.238 . . . . 0.0 112.051 178.478 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 50' ' ' ILE . . . . . 0.556 HG22 ' N ' ' A' ' 51' ' ' PHE . 5.1 mp -86.66 159.99 3.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 115.693 -0.685 . . . . 0.0 111.103 -179.733 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 51' ' ' PHE . . . . . 0.556 ' N ' HG22 ' A' ' 50' ' ' ILE . 88.8 m-85 -73.13 142.77 47.47 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.782 -0.645 . . . . 0.0 111.091 -179.802 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -64.32 -175.25 0.15 Allowed 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 115.492 -0.776 . . . . 0.0 110.412 179.007 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -142.74 134.26 26.45 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.123 179.891 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 96.0 m-85 -111.01 119.98 40.84 Favored 'General case' 0 N--CA 1.465 0.322 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.675 -179.809 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 9.8 p -130.42 142.28 44.13 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.414 0 CA-C-O 120.557 0.218 . . . . 0.0 110.592 -179.906 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 99.4 m-20 -63.4 149.35 46.13 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.384 179.925 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 57' ' ' SER . . . . . 0.44 ' OG ' ' O ' ' A' ' 35' ' ' ILE . 13.8 m -63.24 -32.49 73.91 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.72 0.295 . . . . 0.0 110.984 179.757 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 70.9 m -54.36 -40.45 68.12 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.352 -0.386 . . . . 0.0 110.581 -179.538 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.56 ' C ' ' H ' ' A' ' 61' ' ' TYR . 35.1 t -61.29 -44.08 97.77 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 -179.638 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 60' ' ' GLY . . . . . 0.511 ' O ' ' CE2' ' A' ' 26' ' ' TRP . . . 68.96 -29.78 0.3 Allowed Glycine 0 CA--C 1.529 0.945 0 N-CA-C 111.346 -0.702 . . . . 0.0 111.346 179.846 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 61' ' ' TYR . . . . . 0.56 ' H ' ' C ' ' A' ' 59' ' ' VAL . 44.9 t80 -112.6 155.48 24.32 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-O 121.225 0.536 . . . . 0.0 111.163 -179.15 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 62' ' ' TYR . . . . . 0.474 ' CD2' ' CD1' ' A' ' 39' ' ' ILE . 24.2 t80 -155.68 159.37 39.49 Favored 'General case' 0 N--CA 1.454 -0.227 0 CA-C-N 115.539 -0.755 . . . . 0.0 109.694 178.617 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 90.9 m -127.7 135.47 50.22 Favored 'General case' 0 N--CA 1.465 0.307 0 CA-C-O 120.834 0.349 . . . . 0.0 110.34 -179.924 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -131.46 107.01 12.8 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 N-CA-C 109.172 -0.677 . . . . 0.0 109.172 178.489 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.401 HG22 ' HB2' ' A' ' 21' ' ' SER . 2.3 p -120.89 162.88 19.09 Favored 'General case' 0 CA--C 1.514 -0.428 0 CA-C-O 120.911 0.386 . . . . 0.0 110.469 -179.707 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 106.62 24.67 6.6 Favored Glycine 0 CA--C 1.52 0.365 0 N-CA-C 110.889 -0.884 . . . . 0.0 110.889 179.873 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.427 ' O ' ' CB ' ' A' ' 20' ' ' SER . 6.9 mt -97.64 107.58 20.1 Favored 'General case' 0 CA--C 1.53 0.175 0 N-CA-C 109.405 -0.591 . . . . 0.0 109.405 179.897 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 66.8 mm-40 -46.36 135.53 7.29 Favored Pre-proline 0 C--N 1.319 -0.753 0 N-CA-C 112.019 0.377 . . . . 0.0 112.019 -178.44 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 95.1 Cg_endo -74.28 156.25 46.3 Favored 'Trans proline' 0 N--CA 1.498 1.789 0 C-N-CA 122.718 2.278 . . . . 0.0 111.219 178.753 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 72.56 -7.39 8.87 Favored Glycine 0 CA--C 1.528 0.864 0 C-N-CA 121.08 -0.581 . . . . 0.0 111.792 179.145 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 1.7 mp -103.74 143.32 15.82 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.366 0 CA-C-O 121.236 0.541 . . . . 0.0 109.702 -179.739 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 72' ' ' ASP . . . . . 0.607 ' O ' ' HB3' ' A' ' 44' ' ' ALA . 1.7 t0 -82.02 118.7 23.2 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.152 -0.931 . . . . 0.0 110.651 179.891 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 73' ' ' TYR . . . . . 0.506 ' O ' HD13 ' A' ' 75' ' ' ILE . 13.8 m-85 -109.74 120.59 42.96 Favored 'General case' 0 C--O 1.221 -0.4 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.899 -179.784 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 74' ' ' ASP . . . . . 0.495 ' N ' ' O ' ' A' ' 42' ' ' VAL . 69.6 m-20 -89.55 116.63 27.85 Favored 'General case' 0 C--N 1.318 -0.783 0 CA-C-N 115.565 -0.743 . . . . 0.0 109.862 179.357 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.6 HD11 ' N ' ' B' ' 223' ' ' ARG . 0.0 OUTLIER -116.1 165.58 11.23 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.383 0 CA-C-O 121.098 0.475 . . . . 0.0 110.262 -179.658 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 11.1 p -153.18 148.85 27.39 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.559 -0.746 . . . . 0.0 110.274 179.08 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.535 ' O ' HG23 ' B' ' 217' ' ' THR . 53.5 t -129.33 135.61 61.33 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 N-CA-C 109.26 -0.644 . . . . 0.0 109.26 179.3 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 78' ' ' ILE . . . . . 0.663 HD12 ' NH1' ' A' ' 38' ' ' ARG . 93.9 mt -127.49 128.11 69.49 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.314 0 CA-C-O 120.854 0.359 . . . . 0.0 110.849 179.315 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 97.1 m -100.93 109.6 21.56 Favored 'General case' 0 C--N 1.331 -0.219 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 179.037 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 37.0 tp -117.95 118.97 33.43 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.638 -179.792 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 81' ' ' ILE . . . . . 0.676 ' O ' HD12 ' A' ' 81' ' ' ILE . 2.2 pp -137.41 161.61 34.13 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.166 0 CA-C-N 115.957 -0.565 . . . . 0.0 109.786 178.801 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 82' ' ' ASN . . . . . 0.631 ' H ' ' CB ' ' A' ' 33' ' ' THR . 16.2 t-20 -64.9 -43.36 93.1 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.772 0.32 . . . . 0.0 110.899 -179.928 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 151.71 123.41 1.05 Allowed Glycine 0 CA--C 1.525 0.666 0 N-CA-C 110.97 -0.852 . . . . 0.0 110.97 179.755 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -96.45 -179.45 35.19 Favored Glycine 0 CA--C 1.525 0.695 0 N-CA-C 110.814 -0.914 . . . . 0.0 110.814 179.806 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -71.35 153.82 42.05 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.884 0.373 . . . . 0.0 110.322 179.848 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 19.7 m -61.55 146.36 49.04 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.483 -179.973 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -167.32 74.17 1.01 Allowed Pre-proline 0 C--N 1.329 -0.285 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.423 -179.986 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 34.3 Cg_exo -59.51 145.51 97.78 Favored 'Trans proline' 0 C--N 1.306 -1.671 0 C-N-CA 122.675 2.25 . . . . 0.0 111.927 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 2.0 t -122.65 127.86 49.88 Favored 'General case' 0 N--CA 1.467 0.402 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.635 -179.881 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 17.5 p -87.51 175.34 7.99 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.549 179.88 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 91' ' ' LEU . . . . . 0.578 HD12 ' N ' ' A' ' 91' ' ' LEU . 9.6 mp -56.32 174.11 0.15 Allowed 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.0 -0.545 . . . . 0.0 110.205 179.793 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -42.2 141.89 0.85 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.868 -0.606 . . . . 0.0 110.786 -179.87 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 18.4 pt20 -65.31 151.53 46.01 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.7 -179.957 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 58.5 tt0 53.01 80.62 0.1 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.488 -179.973 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 70.2 p . . . . . 0 C--O 1.221 -0.42 0 CA-C-O 117.942 -1.027 . . . . 0.0 110.532 -179.997 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' B' B ' 201' ' ' SER . . . . . . . . . . . . . 74.7 m . . . . . 0 N--CA 1.49 1.565 0 N-CA-C 109.405 -0.591 . . . . 0.0 109.405 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' B' B ' 202' ' ' SER . . . . . . . . . . . . . 30.7 t -66.68 141.68 57.69 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.193 179.527 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 203' ' ' SER . . . . . . . . . . . . . 60.5 p -126.05 108.89 24.66 Favored Pre-proline 0 CA--C 1.537 0.48 0 N-CA-C 109.878 -0.415 . . . . 0.0 109.878 179.728 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 204' ' ' PRO . . . . . . . . . . . . . 66.6 Cg_endo -76.22 -58.54 0.04 OUTLIER 'Trans proline' 0 N--CA 1.491 1.375 0 C-N-CA 121.384 1.39 . . . . 0.0 112.136 -179.472 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 205' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -150.28 146.36 16.65 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.168 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.133 -179.765 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 206' ' ' GLN . . . . . . . . . . . . . 50.6 mt-30 -137.17 137.46 39.19 Favored 'General case' 0 C--N 1.327 -0.403 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 178.828 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 207' ' ' GLY . . . . . . . . . . . . . . . -97.88 -141.45 12.24 Favored Glycine 0 N--CA 1.463 0.48 0 N-CA-C 111.098 -0.801 . . . . 0.0 111.098 -179.685 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 208' ' ' SER . . . . . 0.533 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 38.7 p -165.13 169.33 16.28 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.624 0.249 . . . . 0.0 110.778 179.591 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 209' ' ' TRP . . . . . . . . . . . . . 86.3 m95 -88.05 150.07 23.61 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.202 179.632 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 69.3 p -129.03 129.76 45.74 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-O 120.801 0.334 . . . . 0.0 110.481 179.522 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 52.0 t-105 -91.75 110.32 21.65 Favored 'General case' 0 N--CA 1.463 0.219 0 CA-C-N 116.477 -0.329 . . . . 0.0 110.272 179.609 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 212' ' ' GLU . . . . . 0.527 ' O ' ' O ' ' B' ' 215' ' ' LYS . 2.0 pt-20 -162.78 171.74 16.29 Favored 'General case' 0 C--O 1.22 -0.457 0 CA-C-O 120.977 0.418 . . . . 0.0 110.582 179.454 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 213' ' ' ASN . . . . . 0.492 ' C ' ' H ' ' B' ' 215' ' ' LYS . 13.8 m120 49.77 30.26 3.68 Favored 'General case' 0 C--N 1.317 -0.834 0 C-N-CA 120.237 -0.585 . . . . 0.0 111.721 176.788 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 66.48 -13.13 0.43 Allowed Glycine 0 CA--C 1.532 1.105 0 C-N-CA 121.087 -0.578 . . . . 0.0 111.973 179.229 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 215' ' ' LYS . . . . . 0.527 ' O ' ' O ' ' B' ' 212' ' ' GLU . 67.5 mttm -126.05 156.25 40.25 Favored 'General case' 0 N--CA 1.468 0.432 0 CA-C-O 121.143 0.497 . . . . 0.0 110.67 -179.445 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 216' ' ' TRP . . . . . 0.475 ' CD1' ' N ' ' B' ' 216' ' ' TRP . 32.4 m95 -86.53 125.12 33.54 Favored 'General case' 0 C--N 1.328 -0.348 0 C-N-CA 120.837 -0.345 . . . . 0.0 110.095 179.796 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 217' ' ' THR . . . . . 0.535 HG23 ' O ' ' A' ' 77' ' ' VAL . 18.5 m -124.42 138.42 54.36 Favored 'General case' 0 N--CA 1.468 0.427 0 CA-C-O 120.893 0.378 . . . . 0.0 110.359 -179.45 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 218' ' ' TRP . . . . . 0.533 ' CH2' ' N ' ' B' ' 208' ' ' SER . 24.5 t-105 -105.7 106.7 17.32 Favored 'General case' 0 N--CA 1.462 0.148 0 CA-C-N 116.13 -0.486 . . . . 0.0 109.88 179.343 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 74.4 mttt -135.46 171.47 14.4 Favored 'General case' 0 N--CA 1.466 0.355 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.646 -179.331 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -177.86 -162.75 28.4 Favored Glycine 0 CA--C 1.526 0.765 0 N-CA-C 110.857 -0.897 . . . . 0.0 110.857 179.57 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 221' ' ' ILE . . . . . 0.548 ' O ' HG23 ' B' ' 222' ' ' ILE . 0.8 OUTLIER -53.6 -74.2 0.05 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.384 0 C-N-CA 120.98 -0.288 . . . . 0.0 111.082 -178.73 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' B' B ' 222' ' ' ILE . . . . . 0.548 HG23 ' O ' ' B' ' 221' ' ' ILE . 20.6 pt -160.75 -165.79 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 116.276 -0.42 . . . . 0.0 109.895 -179.545 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 223' ' ' ARG . . . . . 0.6 ' N ' HD11 ' A' ' 75' ' ' ILE . 0.7 OUTLIER -43.37 174.9 0.0 OUTLIER 'General case' 0 N--CA 1.452 -0.363 0 CA-C-O 121.52 0.676 . . . . 0.0 110.814 179.154 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' B' B ' 224' ' ' LEU . . . . . 0.744 HD22 ' N ' ' B' ' 224' ' ' LEU . 2.6 mm? -61.28 116.11 4.36 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-N 115.51 -0.768 . . . . 0.0 110.634 -179.78 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 80.8 tt0 -103.59 149.31 25.02 Favored 'General case' 0 N--CA 1.465 0.277 0 CA-C-N 115.407 -0.815 . . . . 0.0 110.315 -179.987 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 226' ' ' GLN . . . . . . . . . . . . . 88.8 mt-30 . . . . . 0 C--N 1.325 -0.471 0 CA-C-O 117.986 -1.007 . . . . 0.0 110.724 -179.822 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.324 0 N-CA-C 109.422 -1.471 . . . . 0.0 109.422 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 97.1 p -76.67 -118.72 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.312 0 N-CA-C 110.258 -0.275 . . . . 0.0 110.258 179.916 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -67.2 141.4 57.33 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.475 179.839 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 12.1 t -138.2 75.87 39.51 Favored Pre-proline 0 N--CA 1.465 0.302 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.203 179.979 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_exo -53.82 135.42 62.81 Favored 'Trans proline' 0 C--N 1.307 -1.628 0 C-N-CA 122.328 2.019 . . . . 0.0 111.537 179.958 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 1.9 pt20 -119.14 -88.93 0.61 Allowed 'General case' 0 N--CA 1.467 0.375 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.307 -179.709 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 59.1 mt -87.6 115.41 25.02 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.413 -179.789 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' THR . . . . . 0.655 HG22 HD21 ' A' ' 29' ' ' LEU . 8.8 t -75.61 143.98 42.02 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.764 -179.916 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 98.0 m-20 -82.9 150.49 26.45 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.801 179.981 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 7.2 tt -75.84 154.07 36.4 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.273 179.754 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' SER . . . . . 0.433 ' O ' ' O ' ' A' ' 25' ' ' ARG . 17.7 p -140.26 151.39 45.09 Favored 'General case' 0 N--CA 1.462 0.156 0 CA-C-O 121.093 0.473 . . . . 0.0 110.226 178.862 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 14' ' ' PHE . . . . . 0.547 ' CD1' ' N ' ' A' ' 14' ' ' PHE . 18.0 m-85 -111.48 148.41 33.22 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.707 -0.679 . . . . 0.0 110.747 -179.194 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 25.3 m -148.25 155.57 9.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 120.966 0.412 . . . . 0.0 110.305 179.172 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 39.3 t0 62.72 29.9 16.8 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.6 -0.727 . . . . 0.0 110.891 -179.968 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 68.1 mt -56.68 131.97 20.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 179.716 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.414 ' CB ' ' O ' ' A' ' 21' ' ' SER . 0.2 OUTLIER -132.13 -168.78 2.1 Favored 'General case' 0 N--CA 1.47 0.538 0 CA-C-N 116.385 -0.37 . . . . 0.0 110.246 -179.551 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 19' ' ' ASP . . . . . 0.47 ' N ' ' OD1' ' A' ' 19' ' ' ASP . 22.4 p-10 -78.72 -48.47 14.86 Favored 'General case' 0 C--N 1.332 -0.169 0 C-N-CA 120.811 -0.356 . . . . 0.0 110.951 179.295 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 20' ' ' SER . . . . . 0.484 ' OG ' ' N ' ' A' ' 67' ' ' LEU . 27.8 t -120.73 12.78 11.45 Favored 'General case' 0 N--CA 1.462 0.165 0 CA-C-O 120.518 0.199 . . . . 0.0 110.734 -178.882 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 21' ' ' SER . . . . . 0.549 ' HB2' HG22 ' A' ' 65' ' ' THR . 92.8 p -146.63 131.03 17.62 Favored 'General case' 0 N--CA 1.463 0.19 0 CA-C-O 120.83 0.348 . . . . 0.0 110.095 -179.9 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 47.5 pt -127.5 142.14 44.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.159 -0.473 . . . . 0.0 109.991 -179.687 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -100.53 83.01 0.52 Allowed Glycine 0 N--CA 1.465 0.596 0 N-CA-C 110.414 -1.074 . . . . 0.0 110.414 179.951 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 16.7 mt -69.42 125.31 26.31 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.895 0.379 . . . . 0.0 110.0 -179.719 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 25' ' ' ARG . . . . . 0.433 ' O ' ' O ' ' A' ' 13' ' ' SER . 66.8 ttt180 -140.01 142.7 36.25 Favored 'General case' 0 N--CA 1.464 0.233 0 CA-C-O 121.268 0.556 . . . . 0.0 110.915 179.998 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 26' ' ' TRP . . . . . 0.528 ' CD2' ' O ' ' A' ' 60' ' ' GLY . 8.8 p90 -142.94 158.08 43.95 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.483 -0.78 . . . . 0.0 109.755 -179.61 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 4.1 m -103.06 103.92 37.06 Favored Pre-proline 0 CA--C 1.536 0.413 0 CA-C-O 119.592 -0.242 . . . . 0.0 111.058 -179.351 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 31.9 Cg_exo -55.17 153.7 25.76 Favored 'Trans proline' 0 C--N 1.312 -1.37 0 C-N-CA 121.616 1.544 . . . . 0.0 113.103 178.828 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.655 HD21 HG22 ' A' ' 10' ' ' THR . 75.1 mt -100.98 133.32 45.65 Favored 'General case' 0 N--CA 1.466 0.342 0 CA-C-N 115.047 -0.979 . . . . 0.0 110.966 179.658 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 26.4 t-20 -44.79 -30.57 0.99 Allowed 'General case' 0 C--N 1.315 -0.898 0 CA-C-N 114.695 -1.138 . . . . 0.0 110.258 179.772 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 64.3 m -89.16 -27.45 20.69 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 115.797 -0.638 . . . . 0.0 110.718 178.978 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 32' ' ' SER . . . . . 0.484 ' N ' ' O ' ' A' ' 29' ' ' LEU . 3.3 m -56.38 120.65 8.0 Favored 'General case' 0 N--CA 1.462 0.155 0 CA-C-O 121.575 0.703 . . . . 0.0 110.262 179.876 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 33' ' ' THR . . . . . 0.474 ' CB ' ' H ' ' A' ' 82' ' ' ASN . 6.4 m -52.9 147.27 9.38 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 114.866 -1.061 . . . . 0.0 109.725 -179.103 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 25.0 mm -93.18 93.35 4.11 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 116.4 -0.363 . . . . 0.0 110.888 -178.632 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.539 ' O ' ' CE1' ' A' ' 37' ' ' TYR . 9.0 pt -151.17 131.15 3.69 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.175 179.477 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -54.61 136.32 44.41 Favored Glycine 0 CA--C 1.524 0.609 0 N-CA-C 111.096 -0.802 . . . . 0.0 111.096 -179.252 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 37' ' ' TYR . . . . . 0.539 ' CE1' ' O ' ' A' ' 35' ' ' ILE . 5.0 m-85 -97.87 179.92 4.64 Favored 'General case' 0 C--N 1.332 -0.18 0 N-CA-C 109.683 -0.488 . . . . 0.0 109.683 179.679 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 38' ' ' ARG . . . . . 0.526 ' NH1' ' OE2' ' A' ' 52' ' ' GLU . 5.1 tmm_? -129.14 124.81 35.65 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.492 179.728 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.47 ' CD1' ' CD2' ' A' ' 62' ' ' TYR . 1.8 pt -101.51 118.54 48.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 115.96 -0.564 . . . . 0.0 109.871 179.68 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 35.2 m -102.7 134.35 46.22 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.578 -179.032 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.663 HG22 HD13 ' A' ' 50' ' ' ILE . 2.6 p -130.89 143.53 40.61 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.522 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.424 -179.691 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 42' ' ' VAL . . . . . 0.526 ' O ' ' N ' ' A' ' 74' ' ' ASP . 43.0 t -134.4 135.06 54.46 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.261 0 CA-C-O 120.875 0.369 . . . . 0.0 110.369 179.834 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.83 ' HB2' HD11 ' A' ' 50' ' ' ILE . . . -97.34 133.27 42.17 Favored 'General case' 0 C--N 1.33 -0.256 0 N-CA-C 109.515 -0.55 . . . . 0.0 109.515 179.169 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.578 ' HB3' ' O ' ' A' ' 72' ' ' ASP . . . -89.87 -40.74 12.23 Favored 'General case' 0 C--N 1.33 -0.246 0 C-N-CA 120.577 -0.449 . . . . 0.0 110.635 179.444 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -80.72 30.21 2.58 Favored Glycine 0 CA--C 1.524 0.602 0 N-CA-C 111.405 -0.678 . . . . 0.0 111.405 -179.817 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 80.0 mm-40 -140.42 146.76 38.72 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 121.079 0.466 . . . . 0.0 110.415 179.753 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -69.98 -20.37 76.17 Favored Glycine 0 CA--C 1.527 0.785 0 N-CA-C 111.133 -0.787 . . . . 0.0 111.133 179.711 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -135.6 142.46 41.08 Favored Pre-proline 0 CA--C 1.545 0.779 0 CA-C-N 116.735 0.268 . . . . 0.0 110.361 -179.482 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -72.14 164.86 34.35 Favored 'Trans proline' 0 N--CA 1.495 1.583 0 C-N-CA 122.457 2.105 . . . . 0.0 111.573 178.451 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 50' ' ' ILE . . . . . 1.037 ' H ' HD12 ' A' ' 50' ' ' ILE . 0.6 OUTLIER -86.65 159.72 3.11 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 116.022 -0.536 . . . . 0.0 110.619 -179.579 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 84.8 m-85 -75.02 141.32 43.92 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.752 179.893 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 52' ' ' GLU . . . . . 0.526 ' OE2' ' NH1' ' A' ' 38' ' ' ARG . 4.4 pt-20 -70.23 -175.88 1.07 Allowed 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.501 179.54 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -147.1 141.39 26.27 Favored 'General case' 0 CA--C 1.534 0.337 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.172 179.803 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 34.3 m-85 -113.56 119.56 37.93 Favored 'General case' 0 N--CA 1.469 0.481 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.452 -179.866 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 9.3 p -128.21 140.62 48.69 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.462 0 CA-C-O 120.966 0.412 . . . . 0.0 110.554 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 97.4 m-20 -65.04 153.77 39.76 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.556 179.964 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 57' ' ' SER . . . . . 0.425 ' OG ' ' OH ' ' A' ' 37' ' ' TYR . 4.0 t -64.22 -33.51 75.96 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.662 179.921 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 52.1 m -52.99 -40.59 63.88 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.638 -179.419 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.5 ' O ' ' CD2' ' A' ' 61' ' ' TYR . 21.1 t -61.28 -43.55 96.74 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 N-CA-C 110.019 -0.363 . . . . 0.0 110.019 -179.582 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 60' ' ' GLY . . . . . 0.528 ' O ' ' CD2' ' A' ' 26' ' ' TRP . . . 72.5 -38.11 0.71 Allowed Glycine 0 CA--C 1.525 0.7 0 N-CA-C 111.359 -0.696 . . . . 0.0 111.359 179.389 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 61' ' ' TYR . . . . . 0.5 ' CD2' ' O ' ' A' ' 59' ' ' VAL . 32.1 p90 -114.62 158.82 21.21 Favored 'General case' 0 N--CA 1.47 0.54 0 CA-C-O 121.016 0.436 . . . . 0.0 110.993 -179.026 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 62' ' ' TYR . . . . . 0.47 ' CD2' ' CD1' ' A' ' 39' ' ' ILE . 29.1 t80 -151.62 158.37 43.39 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 109.394 -0.595 . . . . 0.0 109.394 179.336 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 53.8 m -120.65 133.68 55.34 Favored 'General case' 0 N--CA 1.465 0.297 0 CA-C-O 120.831 0.348 . . . . 0.0 110.095 179.74 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -131.81 103.46 6.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 N-CA-C 109.373 -0.603 . . . . 0.0 109.373 178.845 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.549 HG22 ' HB2' ' A' ' 21' ' ' SER . 3.4 p -116.36 162.48 17.46 Favored 'General case' 0 CA--C 1.512 -0.514 0 CA-C-O 121.077 0.465 . . . . 0.0 110.452 179.772 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 106.38 23.53 7.23 Favored Glycine 0 CA--C 1.521 0.424 0 N-CA-C 111.177 -0.769 . . . . 0.0 111.177 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.484 ' N ' ' OG ' ' A' ' 20' ' ' SER . 10.8 mt -97.43 109.91 22.57 Favored 'General case' 0 C--O 1.227 -0.115 0 N-CA-C 109.063 -0.717 . . . . 0.0 109.063 179.499 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 66.4 mm-40 -51.18 135.18 30.52 Favored Pre-proline 0 C--N 1.319 -0.745 0 C-N-CA 120.611 -0.435 . . . . 0.0 111.843 -178.039 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 96.8 Cg_endo -74.08 157.46 46.6 Favored 'Trans proline' 0 N--CA 1.499 1.85 0 C-N-CA 122.878 2.385 . . . . 0.0 111.132 178.83 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 72.31 -8.74 6.44 Favored Glycine 0 CA--C 1.525 0.678 0 C-N-CA 120.879 -0.677 . . . . 0.0 111.594 179.306 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 1.8 mp -103.88 140.67 21.37 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.373 0 CA-C-O 121.496 0.665 . . . . 0.0 109.642 -179.683 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 72' ' ' ASP . . . . . 0.578 ' O ' ' HB3' ' A' ' 44' ' ' ALA . 2.3 t0 -79.54 116.99 20.07 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 114.783 -1.098 . . . . 0.0 110.457 -179.524 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 73' ' ' TYR . . . . . 0.519 ' O ' HD13 ' A' ' 75' ' ' ILE . 11.5 m-85 -108.11 120.78 43.32 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.495 -179.771 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 74' ' ' ASP . . . . . 0.526 ' N ' ' O ' ' A' ' 42' ' ' VAL . 23.1 m-20 -88.51 114.63 25.33 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 115.275 -0.875 . . . . 0.0 109.831 -179.903 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.602 HD11 ' N ' ' B' ' 223' ' ' ARG . 0.0 OUTLIER -113.26 164.05 9.68 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.36 0 CA-C-O 121.217 0.532 . . . . 0.0 110.363 -179.747 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 2.6 p -152.42 124.63 8.13 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.183 -0.917 . . . . 0.0 109.918 179.539 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 70.7 t -106.14 131.45 55.73 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 N-CA-C 109.11 -0.7 . . . . 0.0 109.11 179.818 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 97.4 mt -128.17 131.25 69.47 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.317 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.898 -179.886 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 79' ' ' THR . . . . . 0.535 HG23 ' O ' ' A' ' 79' ' ' THR . 9.0 t -106.95 122.41 46.37 Favored 'General case' 0 N--CA 1.463 0.192 0 CA-C-N 115.76 -0.654 . . . . 0.0 109.529 179.122 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 42.4 mt -119.86 113.01 19.94 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.478 -179.312 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 81' ' ' ILE . . . . . 0.505 ' HA ' HD11 ' A' ' 35' ' ' ILE . 2.2 pp -146.66 144.26 20.28 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.25 0 CA-C-O 120.725 0.298 . . . . 0.0 110.327 178.651 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 82' ' ' ASN . . . . . 0.474 ' H ' ' CB ' ' A' ' 33' ' ' THR . 42.3 t30 -66.77 -47.7 71.34 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.381 -0.372 . . . . 0.0 111.509 -179.683 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 88.06 8.69 71.79 Favored Glycine 0 CA--C 1.525 0.71 0 N-CA-C 111.191 -0.764 . . . . 0.0 111.191 179.661 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -71.94 166.5 53.35 Favored Glycine 0 CA--C 1.527 0.793 0 N-CA-C 110.815 -0.914 . . . . 0.0 110.815 179.887 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 96.0 mt-10 -74.26 83.79 1.88 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.837 0.351 . . . . 0.0 110.485 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 18.7 m -83.85 153.74 23.86 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.529 179.874 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . 61.86 56.09 2.87 Favored Pre-proline 0 C--N 1.327 -0.383 0 CA-C-N 116.341 -0.391 . . . . 0.0 110.599 179.892 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo -66.8 149.8 83.4 Favored 'Trans proline' 0 C--N 1.307 -1.621 0 C-N-CA 122.647 2.231 . . . . 0.0 111.99 -179.847 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 89' ' ' THR . . . . . 0.43 HG22 ' H ' ' A' ' 89' ' ' THR . 0.5 OUTLIER -69.79 133.25 47.23 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.466 179.989 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 53.2 p -137.61 162.9 32.55 Favored 'General case' 0 N--CA 1.464 0.248 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.401 -179.972 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 91' ' ' LEU . . . . . 0.563 HD12 ' N ' ' A' ' 91' ' ' LEU . 10.5 mp -81.56 124.97 29.97 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.05 -179.934 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 92' ' ' THR . . . . . 0.4 HG22 ' H ' ' A' ' 92' ' ' THR . 0.3 OUTLIER -96.48 138.69 33.7 Favored 'General case' 0 N--CA 1.463 0.199 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.423 179.779 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 52.0 mt-30 -69.92 127.59 33.41 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.43 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 55.1 tt0 48.26 86.73 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.59 -179.853 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 95' ' ' THR . . . . . 0.415 ' H ' HG22 ' A' ' 95' ' ' THR . 2.7 t . . . . . 0 C--O 1.218 -0.562 0 CA-C-O 118.108 -0.949 . . . . 0.0 110.572 179.869 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 201' ' ' SER . . . . . . . . . . . . . 17.3 t . . . . . 0 N--CA 1.49 1.546 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' B' B ' 202' ' ' SER . . . . . . . . . . . . . 20.2 m -70.56 142.14 51.79 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.419 -0.355 . . . . 0.0 110.243 179.754 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 203' ' ' SER . . . . . 0.403 ' OG ' ' CG ' ' B' ' 206' ' ' GLN . 2.1 p -104.15 152.08 39.11 Favored Pre-proline 0 CA--C 1.539 0.52 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.356 -179.661 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 204' ' ' PRO . . . . . . . . . . . . . 76.5 Cg_exo -45.42 -45.85 15.05 Favored 'Trans proline' 0 N--CA 1.494 1.541 0 C-N-CA 121.998 1.799 . . . . 0.0 112.247 179.876 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 205' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -149.65 144.74 17.79 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.186 0 CA-C-N 116.434 -0.348 . . . . 0.0 110.449 179.954 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 206' ' ' GLN . . . . . 0.403 ' CG ' ' OG ' ' B' ' 203' ' ' SER . 33.4 mt-30 -137.96 139.06 39.52 Favored 'General case' 0 C--N 1.329 -0.296 0 N-CA-C 109.973 -0.38 . . . . 0.0 109.973 179.476 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 207' ' ' GLY . . . . . . . . . . . . . . . -102.39 -130.62 7.06 Favored Glycine 0 N--CA 1.466 0.645 0 N-CA-C 110.99 -0.844 . . . . 0.0 110.99 -179.864 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 208' ' ' SER . . . . . 0.567 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 46.4 p -166.16 170.38 13.41 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.975 0.417 . . . . 0.0 110.794 179.384 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 209' ' ' TRP . . . . . . . . . . . . . 76.4 m95 -90.77 154.87 19.21 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.385 179.505 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 61.5 p -129.75 129.85 44.65 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.43 179.471 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 51.5 t-105 -90.99 109.62 20.86 Favored 'General case' 0 N--CA 1.465 0.283 0 CA-C-N 116.352 -0.386 . . . . 0.0 110.314 179.696 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 212' ' ' GLU . . . . . 0.493 ' O ' ' O ' ' B' ' 215' ' ' LYS . 1.8 pt-20 -162.26 170.54 18.79 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.332 -0.394 . . . . 0.0 110.571 179.515 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 213' ' ' ASN . . . . . 0.528 ' C ' ' H ' ' B' ' 215' ' ' LYS . 93.9 m-20 49.68 30.09 3.48 Favored 'General case' 0 C--N 1.318 -0.793 0 C-N-CA 120.393 -0.523 . . . . 0.0 111.467 177.259 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 64.04 -10.25 0.26 Allowed Glycine 0 CA--C 1.529 0.944 0 C-N-CA 120.97 -0.634 . . . . 0.0 111.732 179.415 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 215' ' ' LYS . . . . . 0.528 ' H ' ' C ' ' B' ' 213' ' ' ASN . 27.1 mtpt -123.92 153.73 40.74 Favored 'General case' 0 N--CA 1.467 0.424 0 CA-C-O 121.056 0.455 . . . . 0.0 111.004 -179.411 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 216' ' ' TRP . . . . . 0.448 ' CD1' ' N ' ' B' ' 216' ' ' TRP . 39.5 m95 -86.62 120.84 28.37 Favored 'General case' 0 C--N 1.326 -0.415 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 179.599 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 217' ' ' THR . . . . . . . . . . . . . 22.7 m -123.89 136.81 54.59 Favored 'General case' 0 N--CA 1.467 0.415 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.27 -179.512 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 218' ' ' TRP . . . . . 0.567 ' CH2' ' N ' ' B' ' 208' ' ' SER . 18.6 t-105 -104.16 108.77 20.3 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.034 179.628 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 76.5 mttt -133.11 169.61 16.61 Favored 'General case' 0 CA--C 1.515 -0.37 0 CA-C-N 115.828 -0.624 . . . . 0.0 110.425 -179.791 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -178.1 -161.8 26.83 Favored Glycine 0 N--CA 1.446 -0.64 0 N-CA-C 110.688 -0.965 . . . . 0.0 110.688 179.612 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 221' ' ' ILE . . . . . 0.533 ' O ' HG23 ' B' ' 222' ' ' ILE . 24.8 mt -53.91 -72.84 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 C-N-CA 120.702 -0.399 . . . . 0.0 110.33 -178.431 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 222' ' ' ILE . . . . . 0.533 HG23 ' O ' ' B' ' 221' ' ' ILE . 22.8 pt -160.3 -166.36 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.172 -0.467 . . . . 0.0 109.859 179.932 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 223' ' ' ARG . . . . . 0.602 ' N ' HD11 ' A' ' 75' ' ' ILE . 23.5 ptt180 -40.87 174.16 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 121.57 0.7 . . . . 0.0 110.999 178.883 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 224' ' ' LEU . . . . . 0.733 HD22 ' N ' ' B' ' 224' ' ' LEU . 2.7 mm? -61.97 109.79 1.37 Allowed 'General case' 0 C--N 1.315 -0.901 0 CA-C-N 115.398 -0.819 . . . . 0.0 110.531 -179.839 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 43.4 tt0 -83.04 143.93 30.26 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.219 -0.9 . . . . 0.0 110.328 -179.939 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 226' ' ' GLN . . . . . . . . . . . . . 8.8 tp-100 . . . . . 0 N--CA 1.448 -0.571 0 CA-C-O 117.879 -1.057 . . . . 0.0 110.374 -179.876 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.28 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 30.9 p -154.99 162.96 40.94 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.808 0.337 . . . . 0.0 110.57 -179.889 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -73.85 145.29 45.01 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.465 179.95 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 21.6 t -145.37 75.38 13.71 Favored Pre-proline 0 C--N 1.331 -0.226 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.314 179.99 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 39.3 Cg_exo -59.97 144.9 99.42 Favored 'Trans proline' 0 C--N 1.307 -1.653 0 C-N-CA 122.879 2.386 . . . . 0.0 111.862 179.957 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 87.1 mt-30 -132.01 3.59 4.06 Favored 'General case' 0 N--CA 1.467 0.386 0 CA-C-O 121.088 0.47 . . . . 0.0 110.828 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.44 ' CD1' ' H ' ' A' ' 9' ' ' LEU . 0.3 OUTLIER -97.23 98.29 9.88 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.934 -0.576 . . . . 0.0 110.259 -179.853 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 10' ' ' THR . . . . . 0.617 HG22 ' N ' ' A' ' 11' ' ' ASP . 90.3 m -77.3 165.3 24.64 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.215 179.703 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 11' ' ' ASP . . . . . 0.617 ' N ' HG22 ' A' ' 10' ' ' THR . 45.5 t0 -121.68 155.46 35.13 Favored 'General case' 0 N--CA 1.465 0.289 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.579 -179.911 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 47.6 tp -63.51 140.3 58.86 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.968 -0.56 . . . . 0.0 109.986 -179.339 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 86.2 p -139.51 154.99 47.8 Favored 'General case' 0 C--O 1.234 0.238 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.456 179.823 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' PHE . . . . . 0.564 ' CD2' HD11 ' B' ' 224' ' ' LEU . 18.4 m-85 -111.92 145.47 39.49 Favored 'General case' 0 N--CA 1.464 0.257 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.589 -179.76 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 26.7 m -146.04 161.36 11.09 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.401 179.707 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 97.1 m-20 52.56 30.81 9.03 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.796 179.683 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 84.1 mt -58.39 141.11 15.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 115.98 -0.554 . . . . 0.0 110.246 179.994 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.47 ' CB ' ' O ' ' A' ' 21' ' ' SER . 0.2 OUTLIER -140.98 -166.34 2.14 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.652 -179.621 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 7.6 p-10 -88.76 -46.92 8.6 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.71 -0.677 . . . . 0.0 110.946 179.653 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 41.3 m -115.23 8.42 15.51 Favored 'General case' 0 N--CA 1.468 0.449 0 CA-C-N 116.47 -0.332 . . . . 0.0 110.593 -179.648 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 21' ' ' SER . . . . . 0.47 ' O ' ' CB ' ' A' ' 18' ' ' THR . 29.6 p -151.09 145.44 25.48 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.986 0.422 . . . . 0.0 110.553 179.691 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 22' ' ' ILE . . . . . 0.466 HD12 HD21 ' A' ' 24' ' ' LEU . 41.4 pt -142.49 146.95 21.61 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.113 179.839 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -102.1 84.46 0.5 Allowed Glycine 0 CA--C 1.522 0.518 0 N-CA-C 111.1 -0.8 . . . . 0.0 111.1 179.957 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.466 HD21 HD12 ' A' ' 22' ' ' ILE . 92.5 mt -69.86 122.48 19.34 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.817 0.341 . . . . 0.0 110.159 -179.865 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 65.7 ttt-85 -136.0 144.47 45.35 Favored 'General case' 0 CA--C 1.517 -0.291 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.116 -179.844 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 26' ' ' TRP . . . . . 0.447 ' HE1' ' HG3' ' A' ' 28' ' ' PRO . 35.1 p90 -145.99 157.27 43.88 Favored 'General case' 0 CA--C 1.518 -0.26 0 CA-C-N 116.407 -0.361 . . . . 0.0 110.074 -179.9 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 4.6 m -111.85 96.33 32.9 Favored Pre-proline 0 C--O 1.234 0.268 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.475 179.545 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.447 ' HG3' ' HE1' ' A' ' 26' ' ' TRP . 46.4 Cg_exo -54.1 143.72 61.42 Favored 'Trans proline' 0 C--N 1.307 -1.653 0 C-N-CA 122.177 1.918 . . . . 0.0 112.496 179.39 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 66.5 mt -79.4 140.01 37.55 Favored 'General case' 0 CA--C 1.517 -0.291 0 CA-C-O 121.481 0.658 . . . . 0.0 111.014 -179.841 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 30' ' ' ASN . . . . . 0.437 ' OD1' ' O ' ' A' ' 30' ' ' ASN . 59.8 t-20 -51.67 -33.95 36.1 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.243 -0.889 . . . . 0.0 109.806 179.902 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 51.4 m -79.43 -32.94 42.89 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.52 179.41 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 14.0 m -62.32 136.99 58.17 Favored 'General case' 0 CA--C 1.528 0.129 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.178 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 33' ' ' THR . . . . . 0.591 ' H ' ' HB ' ' A' ' 81' ' ' ILE . 7.1 m -64.89 141.59 58.72 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.967 -0.561 . . . . 0.0 110.395 179.857 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 15.5 mm -95.03 95.36 4.99 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.201 0 CA-C-O 120.936 0.398 . . . . 0.0 110.548 -179.962 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.494 ' O ' ' OG ' ' A' ' 57' ' ' SER . 11.3 pt -142.47 132.12 22.75 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.192 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.402 179.723 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -38.11 122.05 1.11 Allowed Glycine 0 CA--C 1.524 0.603 0 N-CA-C 111.424 -0.671 . . . . 0.0 111.424 -179.595 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 76.4 m-85 -89.48 176.47 6.89 Favored 'General case' 0 CA--C 1.515 -0.391 0 CA-C-O 120.907 0.384 . . . . 0.0 110.113 -179.946 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 6.2 tmm_? -135.35 126.74 28.51 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.635 179.946 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.452 ' O ' ' CG1' ' A' ' 39' ' ' ILE . 1.8 pt -102.43 125.27 56.71 Favored 'Isoleucine or valine' 0 C--O 1.233 0.208 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.003 179.603 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 15.9 m -106.81 133.02 52.1 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.448 -179.858 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.2 p -128.34 138.9 53.36 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.312 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.108 179.925 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 42' ' ' VAL . . . . . 0.526 ' O ' ' N ' ' A' ' 74' ' ' ASP . 39.2 t -133.27 133.78 57.79 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.114 0 CA-C-N 116.418 -0.356 . . . . 0.0 110.195 179.671 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -95.95 136.53 36.27 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.269 179.292 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.592 ' HB3' ' O ' ' A' ' 72' ' ' ASP . . . -90.35 -46.29 8.48 Favored 'General case' 0 N--CA 1.464 0.256 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.545 179.844 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -64.82 -30.65 78.55 Favored Glycine 0 CA--C 1.523 0.577 0 N-CA-C 111.042 -0.823 . . . . 0.0 111.042 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 36.6 mm-40 -96.07 134.73 38.76 Favored 'General case' 0 C--N 1.331 -0.197 0 N-CA-C 109.482 -0.562 . . . . 0.0 109.482 -179.24 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -63.69 -21.81 65.47 Favored Glycine 0 CA--C 1.51 -0.242 0 N-CA-C 111.087 -0.805 . . . . 0.0 111.087 -178.922 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -114.46 136.11 22.33 Favored Pre-proline 0 CA--C 1.54 0.574 0 C-N-CA 120.983 -0.287 . . . . 0.0 110.577 179.709 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -78.58 169.75 19.34 Favored 'Trans proline' 0 C--N 1.309 -1.523 0 C-N-CA 122.792 2.328 . . . . 0.0 112.002 176.498 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 4.7 mp -96.43 133.53 37.43 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.183 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.561 179.564 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 83.0 m-85 -49.71 149.31 2.54 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.617 -179.871 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 5.9 pt-20 -75.3 -178.06 3.79 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.204 179.766 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -143.76 132.57 22.61 Favored 'General case' 0 N--CA 1.45 -0.429 0 CA-C-N 115.848 -0.614 . . . . 0.0 110.855 179.839 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 96.9 m-85 -104.6 119.47 39.06 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.206 179.449 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 10.6 p -126.27 134.22 66.95 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.295 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.295 179.979 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 98.2 m-20 -56.87 138.46 53.64 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.417 -179.866 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 57' ' ' SER . . . . . 0.494 ' OG ' ' O ' ' A' ' 35' ' ' ILE . 5.0 m -59.04 -32.49 69.8 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.38 179.871 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 59.2 m -55.31 -33.59 63.44 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.395 -179.904 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 95.6 t -64.2 -45.74 95.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.438 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 61.58 26.75 67.03 Favored Glycine 0 CA--C 1.527 0.792 0 N-CA-C 110.656 -0.978 . . . . 0.0 110.656 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 61' ' ' TYR . . . . . 0.413 ' CG ' ' N ' ' A' ' 62' ' ' TYR . 48.5 t80 -167.88 152.2 6.45 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 121.275 0.56 . . . . 0.0 111.134 -179.333 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 62' ' ' TYR . . . . . 0.413 ' N ' ' CG ' ' A' ' 61' ' ' TYR . 23.6 t80 -158.59 159.04 35.02 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.069 178.827 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 85.8 m -126.6 135.75 51.64 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.711 -179.819 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -132.04 108.1 13.56 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.334 0 CA-C-N 115.946 -0.57 . . . . 0.0 109.743 179.127 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 2.6 p -116.98 159.64 22.18 Favored 'General case' 0 CA--C 1.518 -0.259 0 CA-C-O 121.0 0.429 . . . . 0.0 110.844 179.971 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 109.21 3.03 31.43 Favored Glycine 0 CA--C 1.527 0.802 0 CA-C-N 115.7 -0.682 . . . . 0.0 111.528 -179.503 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 3.8 mt -79.49 110.86 15.19 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 121.067 0.461 . . . . 0.0 110.024 -179.259 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 9.3 mt-10 -48.09 139.1 10.08 Favored Pre-proline 0 C--N 1.319 -0.741 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.013 -178.834 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -75.09 162.41 36.93 Favored 'Trans proline' 0 N--CA 1.494 1.558 0 C-N-CA 122.888 2.392 . . . . 0.0 112.401 179.426 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 46.7 22.15 1.03 Allowed Glycine 0 N--CA 1.443 -0.885 0 CA-C-N 115.27 -0.877 . . . . 0.0 111.617 179.2 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 71' ' ' ILE . . . . . 0.442 ' CG2' ' CD1' ' A' ' 73' ' ' TYR . 0.9 OUTLIER -109.5 166.2 4.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 121.349 0.595 . . . . 0.0 109.814 -179.708 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 72' ' ' ASP . . . . . 0.592 ' O ' ' HB3' ' A' ' 44' ' ' ALA . 4.3 t0 -102.05 101.02 11.34 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.355 -0.839 . . . . 0.0 111.82 179.476 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 73' ' ' TYR . . . . . 0.55 ' O ' HD13 ' A' ' 75' ' ' ILE . 2.2 m-30 -109.58 125.38 52.48 Favored 'General case' 0 C--O 1.219 -0.537 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.585 179.049 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 74' ' ' ASP . . . . . 0.526 ' N ' ' O ' ' A' ' 42' ' ' VAL . 79.7 m-20 -89.0 117.05 27.74 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 114.993 -1.003 . . . . 0.0 109.397 179.891 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.641 HD11 ' N ' ' B' ' 223' ' ' ARG . 0.0 OUTLIER -116.54 168.63 7.89 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.306 0 CA-C-O 121.155 0.502 . . . . 0.0 110.079 -179.019 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 45.3 t -154.66 150.46 27.68 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.445 -0.798 . . . . 0.0 110.877 179.539 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.408 ' O ' HG23 ' B' ' 217' ' ' THR . 12.0 t -130.38 100.97 5.34 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.272 0 N-CA-C 109.613 -0.514 . . . . 0.0 109.613 178.958 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 96.2 mt -88.82 130.44 38.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.59 -179.782 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 91.8 m -112.53 106.66 15.16 Favored 'General case' 0 CA--C 1.518 -0.276 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 179.59 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 80' ' ' LEU . . . . . 0.535 ' C ' HD23 ' A' ' 80' ' ' LEU . 6.6 tt -121.3 122.29 39.56 Favored 'General case' 0 CA--C 1.519 -0.249 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.315 -179.906 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 81' ' ' ILE . . . . . 0.591 ' HB ' ' H ' ' A' ' 33' ' ' THR . 2.2 pp -134.19 151.29 32.05 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.175 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.295 179.611 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 82' ' ' ASN . . . . . 0.535 ' H ' ' CB ' ' A' ' 33' ' ' THR . 57.1 t-20 -66.64 -54.57 21.89 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.478 -0.328 . . . . 0.0 111.193 179.94 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 42.57 -103.46 0.04 OUTLIER Glycine 0 CA--C 1.523 0.581 0 N-CA-C 110.986 -0.846 . . . . 0.0 110.986 179.822 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -80.24 -172.46 44.69 Favored Glycine 0 CA--C 1.522 0.527 0 N-CA-C 110.96 -0.856 . . . . 0.0 110.96 179.919 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 93.5 mt-10 -49.63 133.46 21.01 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.91 0.386 . . . . 0.0 110.326 -179.578 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 30.2 t -82.15 167.12 19.05 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.435 -179.932 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.527 ' HB1' ' HD2' ' A' ' 88' ' ' PRO . . . 57.53 162.21 0.08 OUTLIER Pre-proline 0 C--N 1.325 -0.468 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.567 179.919 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 88' ' ' PRO . . . . . 0.527 ' HD2' ' HB1' ' A' ' 87' ' ' ALA . 57.7 Cg_endo -73.82 10.64 1.3 Allowed 'Trans proline' 0 C--N 1.309 -1.507 0 C-N-CA 122.605 2.204 . . . . 0.0 111.957 179.187 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 37.2 m -61.88 131.56 50.15 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.421 179.941 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 83.0 m -125.61 129.3 49.38 Favored 'General case' 0 N--CA 1.464 0.229 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.528 -179.981 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 91' ' ' LEU . . . . . 0.566 HD12 ' N ' ' A' ' 91' ' ' LEU . 10.1 mp -77.32 143.24 38.94 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.489 -179.881 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 66.8 p -67.49 137.12 55.56 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.47 180.0 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 77.5 mt-30 -57.69 105.41 0.25 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.414 -179.805 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 65.7 tt0 -64.6 -42.88 95.26 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.535 -179.961 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 93.0 m . . . . . 0 C--O 1.22 -0.488 0 CA-C-O 117.929 -1.034 . . . . 0.0 110.482 -179.896 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' B' B ' 201' ' ' SER . . . . . . . . . . . . . 41.5 t . . . . . 0 N--CA 1.491 1.581 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' B' B ' 202' ' ' SER . . . . . . . . . . . . . 29.7 t -66.99 132.89 48.85 Favored 'General case' 0 CA--C 1.517 -0.299 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.143 -179.985 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 203' ' ' SER . . . . . . . . . . . . . 79.3 p -129.84 109.12 17.01 Favored Pre-proline 0 CA--C 1.539 0.541 0 CA-C-N 116.4 -0.364 . . . . 0.0 110.657 179.449 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 204' ' ' PRO . . . . . . . . . . . . . 58.6 Cg_endo -75.99 -49.23 0.13 Allowed 'Trans proline' 0 N--CA 1.494 1.511 0 C-N-CA 122.454 2.103 . . . . 0.0 112.213 -179.933 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 205' ' ' ILE . . . . . 0.417 ' CG1' ' N ' ' B' ' 206' ' ' GLN . 15.5 tt -102.5 162.42 3.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 115.967 -0.56 . . . . 0.0 109.542 -178.616 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 206' ' ' GLN . . . . . 0.417 ' N ' ' CG1' ' B' ' 205' ' ' ILE . 63.7 tt0 -176.48 87.67 0.03 OUTLIER 'General case' 0 N--CA 1.45 -0.457 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.262 -179.184 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 207' ' ' GLY . . . . . 0.427 ' C ' ' CH2' ' B' ' 218' ' ' TRP . . . -110.87 -145.97 10.53 Favored Glycine 0 N--CA 1.467 0.736 0 N-CA-C 111.174 -0.771 . . . . 0.0 111.174 179.884 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 208' ' ' SER . . . . . 0.458 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 97.4 p -162.92 170.28 18.39 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.829 0.347 . . . . 0.0 110.717 179.759 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 209' ' ' TRP . . . . . . . . . . . . . 79.0 m95 -85.32 131.42 34.41 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.183 179.682 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 44.6 p -113.8 140.69 48.1 Favored 'General case' 0 N--CA 1.463 0.221 0 CA-C-N 116.409 -0.359 . . . . 0.0 110.61 -179.752 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 54.5 t-105 -96.55 118.26 32.66 Favored 'General case' 0 N--CA 1.464 0.226 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.134 179.914 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 212' ' ' GLU . . . . . 0.477 ' O ' ' O ' ' B' ' 215' ' ' LYS . 0.9 OUTLIER -165.72 167.75 16.79 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.971 179.076 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' B' B ' 213' ' ' ASN . . . . . . . . . . . . . 12.7 m120 50.41 35.23 10.54 Favored 'General case' 0 C--N 1.321 -0.648 0 C-N-CA 120.603 -0.439 . . . . 0.0 111.02 176.168 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 52.24 14.75 2.29 Favored Glycine 0 CA--C 1.525 0.66 0 N-CA-C 111.364 -0.694 . . . . 0.0 111.364 179.661 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 215' ' ' LYS . . . . . 0.477 ' O ' ' O ' ' B' ' 212' ' ' GLU . 8.1 mtmp? -144.52 151.38 39.04 Favored 'General case' 0 C--N 1.333 -0.124 0 CA-C-O 121.161 0.505 . . . . 0.0 110.657 179.793 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 216' ' ' TRP . . . . . . . . . . . . . 66.2 m95 -85.58 120.95 27.59 Favored 'General case' 0 C--N 1.329 -0.289 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 -179.911 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 217' ' ' THR . . . . . 0.408 HG23 ' O ' ' A' ' 77' ' ' VAL . 21.5 m -130.75 142.29 50.41 Favored 'General case' 0 C--O 1.233 0.229 0 CA-C-O 121.051 0.453 . . . . 0.0 110.617 -179.578 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 218' ' ' TRP . . . . . 0.458 ' CH2' ' N ' ' B' ' 208' ' ' SER . 16.4 t-105 -104.31 121.45 43.38 Favored 'General case' 0 N--CA 1.462 0.137 0 CA-C-N 115.925 -0.579 . . . . 0.0 109.921 179.501 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 52.1 mtmt -144.73 171.56 14.23 Favored 'General case' 0 N--CA 1.464 0.246 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.826 -179.524 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -175.44 -161.03 24.2 Favored Glycine 0 CA--C 1.524 0.627 0 CA-C-N 115.614 -0.721 . . . . 0.0 111.322 -179.663 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 221' ' ' ILE . . . . . 0.547 ' O ' HG23 ' B' ' 222' ' ' ILE . 18.8 mt -51.29 -73.27 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 C-N-CA 120.737 -0.385 . . . . 0.0 110.592 -177.973 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 222' ' ' ILE . . . . . 0.547 HG23 ' O ' ' B' ' 221' ' ' ILE . 16.2 pt -158.89 -167.26 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.451 179.808 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 223' ' ' ARG . . . . . 0.641 ' N ' HD11 ' A' ' 75' ' ' ILE . 0.1 OUTLIER -46.12 177.08 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.651 -0.704 . . . . 0.0 110.399 179.146 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' B' B ' 224' ' ' LEU . . . . . 0.683 HD22 ' N ' ' B' ' 224' ' ' LEU . 3.4 mm? -58.68 126.14 26.39 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.414 -178.833 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 225' ' ' GLU . . . . . 0.508 ' OE1' ' NH1' ' B' ' 223' ' ' ARG . 29.7 tp10 -101.97 152.96 20.33 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.167 -179.758 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 226' ' ' GLN . . . . . . . . . . . . . 95.9 mt-30 . . . . . 0 C--O 1.219 -0.503 0 CA-C-O 118.031 -0.985 . . . . 0.0 110.549 -179.883 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.309 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 12.0 p -74.56 157.52 35.32 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.968 0.413 . . . . 0.0 110.523 179.919 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 32.6 tp10 -74.39 145.87 43.41 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.202 -179.864 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 4.1 t -132.35 76.51 72.3 Favored Pre-proline 0 N--CA 1.466 0.348 0 CA-C-O 120.719 0.295 . . . . 0.0 110.48 -179.841 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -78.61 143.73 19.24 Favored 'Trans proline' 0 C--N 1.311 -1.411 0 C-N-CA 122.627 2.218 . . . . 0.0 111.922 -179.946 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' GLN . . . . . 0.506 ' CD ' ' H ' ' A' ' 8' ' ' GLN . 0.4 OUTLIER -100.7 7.39 43.91 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.234 179.766 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 54.7 mt -89.9 114.22 25.97 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.179 -179.793 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 76.4 p -130.24 156.45 44.6 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 116.013 -0.539 . . . . 0.0 110.241 -179.9 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 97.6 m-20 -116.82 153.83 31.79 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.336 -179.823 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 7.4 tt -64.81 144.65 57.11 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.383 -179.74 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' SER . . . . . 0.458 ' O ' ' O ' ' A' ' 25' ' ' ARG . 87.1 p -139.18 159.54 41.91 Favored 'General case' 0 N--CA 1.462 0.125 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.653 179.734 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 14' ' ' PHE . . . . . 0.424 ' CD1' ' N ' ' A' ' 14' ' ' PHE . 19.1 m-85 -111.35 145.47 38.81 Favored 'General case' 0 N--CA 1.465 0.308 0 CA-C-N 115.978 -0.556 . . . . 0.0 110.572 -179.775 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 17.4 m -144.9 157.4 14.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.463 179.659 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 98.9 m-20 47.76 60.24 3.66 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.314 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 98.2 mt -82.46 140.51 16.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.538 179.757 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.438 ' CB ' ' O ' ' A' ' 21' ' ' SER . 0.3 OUTLIER -138.54 -168.33 2.37 Favored 'General case' 0 N--CA 1.466 0.325 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.449 179.917 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 19' ' ' ASP . . . . . 0.475 ' OD1' ' N ' ' A' ' 19' ' ' ASP . 15.8 p-10 -88.55 -43.63 11.26 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.618 179.509 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 20' ' ' SER . . . . . 0.417 ' OG ' ' O ' ' A' ' 67' ' ' LEU . 50.8 m -117.51 9.77 13.32 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.833 -179.65 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 21' ' ' SER . . . . . 0.438 ' O ' ' CB ' ' A' ' 18' ' ' THR . 9.4 m -150.1 141.76 23.58 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.262 179.829 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 44.3 pt -136.76 146.17 28.96 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.417 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.337 179.915 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -101.63 81.3 0.43 Allowed Glycine 0 CA--C 1.524 0.621 0 N-CA-C 110.887 -0.885 . . . . 0.0 110.887 179.692 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 16.4 mt -67.23 123.91 21.62 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 110.025 -0.361 . . . . 0.0 110.025 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 25' ' ' ARG . . . . . 0.458 ' O ' ' O ' ' A' ' 13' ' ' SER . 72.5 ttp85 -142.24 135.82 29.22 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.381 -179.804 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 26' ' ' TRP . . . . . . . . . . . . . 3.8 p90 -141.28 158.74 43.48 Favored 'General case' 0 C--N 1.326 -0.444 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 -179.811 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 4.1 m -108.03 102.35 45.51 Favored Pre-proline 0 CA--C 1.537 0.461 0 CA-C-N 116.725 -0.216 . . . . 0.0 110.418 179.504 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_exo -54.91 145.85 60.1 Favored 'Trans proline' 0 C--N 1.308 -1.571 0 C-N-CA 121.8 1.667 . . . . 0.0 112.874 179.547 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 71.1 mt -85.07 138.3 32.51 Favored 'General case' 0 CA--C 1.515 -0.371 0 CA-C-O 121.44 0.638 . . . . 0.0 110.567 179.866 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 30' ' ' ASN . . . . . 0.421 ' OD1' ' O ' ' A' ' 30' ' ' ASN . 61.2 t-20 -48.63 -34.54 11.91 Favored 'General case' 0 C--N 1.314 -0.946 0 CA-C-N 115.187 -0.915 . . . . 0.0 110.152 -179.962 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 38.3 m -80.68 -33.05 35.78 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.508 179.03 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 6.9 m -59.17 131.64 51.64 Favored 'General case' 0 CA--C 1.528 0.116 0 CA-C-O 120.963 0.411 . . . . 0.0 110.368 -179.839 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 33' ' ' THR . . . . . 0.494 ' CB ' ' H ' ' A' ' 82' ' ' ASN . 4.3 m -62.14 145.41 53.44 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.032 179.984 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 12.5 mm -93.92 94.42 4.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-O 120.921 0.391 . . . . 0.0 110.645 -179.606 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.478 ' O ' ' OG ' ' A' ' 57' ' ' SER . 15.8 pt -147.57 133.04 11.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.844 -0.617 . . . . 0.0 110.563 -179.88 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -47.86 130.43 17.43 Favored Glycine 0 CA--C 1.52 0.357 0 N-CA-C 110.979 -0.848 . . . . 0.0 110.979 -179.864 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 37' ' ' TYR . . . . . 0.468 ' CE2' HG22 ' A' ' 39' ' ' ILE . 3.8 p90 -106.25 126.84 52.73 Favored 'General case' 0 C--N 1.33 -0.278 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 179.377 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 38' ' ' ARG . . . . . 0.529 ' NH1' ' OG1' ' A' ' 40' ' ' THR . 3.3 tmm_? -76.4 131.31 39.04 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.275 -0.421 . . . . 0.0 111.128 -179.321 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.468 HG22 ' CE2' ' A' ' 37' ' ' TYR . 2.2 pt -98.19 123.94 50.98 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.159 0 CA-C-N 115.956 -0.566 . . . . 0.0 109.531 179.526 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 40' ' ' THR . . . . . 0.529 ' OG1' ' NH1' ' A' ' 38' ' ' ARG . 1.6 m -103.38 131.12 50.72 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 120.802 0.334 . . . . 0.0 110.56 -179.303 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.3 p -130.48 138.68 53.19 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.052 179.442 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 42' ' ' VAL . . . . . 0.517 ' N ' ' O ' ' A' ' 74' ' ' ASP . 39.7 t -133.1 131.88 58.64 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.248 0 N-CA-C 110.101 -0.333 . . . . 0.0 110.101 -179.99 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.596 ' HB2' ' CE2' ' A' ' 73' ' ' TYR . . . -96.25 139.54 32.25 Favored 'General case' 0 C--N 1.327 -0.377 0 N-CA-C 109.54 -0.541 . . . . 0.0 109.54 179.099 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.537 ' HB3' ' O ' ' A' ' 72' ' ' ASP . . . -92.21 -41.71 10.28 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.762 0.315 . . . . 0.0 110.857 179.636 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -65.66 -31.73 80.87 Favored Glycine 0 CA--C 1.526 0.735 0 N-CA-C 111.388 -0.685 . . . . 0.0 111.388 -179.357 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 32.0 mt-10 -97.94 129.66 44.84 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 121.168 0.509 . . . . 0.0 109.651 -179.64 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -60.37 -8.55 9.42 Favored Glycine 0 CA--C 1.518 0.233 0 N-CA-C 110.701 -0.959 . . . . 0.0 110.701 -179.272 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -124.08 134.39 25.39 Favored Pre-proline 0 CA--C 1.538 0.512 0 C-N-CA 121.298 -0.161 . . . . 0.0 110.588 179.529 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -77.99 160.63 30.26 Favored 'Trans proline' 0 C--N 1.314 -1.273 0 C-N-CA 122.477 2.118 . . . . 0.0 112.054 177.602 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 96.1 mt -80.71 137.69 20.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.199 179.188 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 90.0 m-85 -55.88 142.05 36.79 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.949 0.404 . . . . 0.0 110.724 -179.702 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 52' ' ' GLU . . . . . 0.518 ' CD ' ' H ' ' A' ' 52' ' ' GLU . 0.4 OUTLIER -77.72 146.21 36.08 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.376 179.778 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -109.81 144.83 37.69 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.406 179.829 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 93.5 m-85 -109.46 118.82 37.65 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.266 179.944 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 9.3 p -125.95 137.47 57.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.441 -179.747 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 84.1 m-20 -67.63 141.41 56.75 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.297 179.592 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 57' ' ' SER . . . . . 0.478 ' OG ' ' O ' ' A' ' 35' ' ' ILE . 9.6 m -57.98 -28.5 64.44 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.417 179.886 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 23.4 m -55.94 -33.64 64.92 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.542 179.959 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.473 ' O ' ' CD2' ' A' ' 61' ' ' TYR . 50.6 t -60.49 -45.18 97.34 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 116.394 -0.367 . . . . 0.0 110.15 -179.395 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 71.36 14.51 74.44 Favored Glycine 0 CA--C 1.529 0.922 0 N-CA-C 111.074 -0.81 . . . . 0.0 111.074 179.388 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 61' ' ' TYR . . . . . 0.473 ' CD2' ' O ' ' A' ' 59' ' ' VAL . 27.6 p90 -172.27 158.34 4.43 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.795 0.331 . . . . 0.0 111.348 179.43 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 23.6 t80 -155.94 155.6 33.09 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.356 -0.384 . . . . 0.0 110.144 177.955 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 94.4 m -121.09 134.7 55.27 Favored 'General case' 0 N--CA 1.463 0.224 0 CA-C-O 121.072 0.463 . . . . 0.0 110.429 -179.814 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -131.86 103.35 6.78 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.197 0 CA-C-N 115.954 -0.566 . . . . 0.0 109.862 178.961 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 2.3 p -112.84 162.87 15.3 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 121.031 0.444 . . . . 0.0 110.683 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 111.38 5.62 26.2 Favored Glycine 0 CA--C 1.527 0.83 0 CA-C-N 115.482 -0.781 . . . . 0.0 111.583 -179.272 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.425 ' CB ' HH21 ' B' ' 223' ' ' ARG . 9.1 mt -81.21 109.04 15.36 Favored 'General case' 0 C--N 1.329 -0.286 0 N-CA-C 109.479 -0.563 . . . . 0.0 109.479 179.379 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 17.5 mm-40 -57.81 137.42 83.11 Favored Pre-proline 0 C--N 1.321 -0.651 0 CA-C-N 116.288 -0.414 . . . . 0.0 111.569 -178.303 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 69' ' ' PRO . . . . . 0.411 ' O ' HD12 ' A' ' 71' ' ' ILE . 80.8 Cg_endo -74.29 151.76 43.7 Favored 'Trans proline' 0 N--CA 1.494 1.542 0 C-N-CA 122.695 2.263 . . . . 0.0 111.732 178.93 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 76.58 6.41 84.44 Favored Glycine 0 CA--C 1.528 0.856 0 CA-C-N 115.644 -0.707 . . . . 0.0 111.413 179.229 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 71' ' ' ILE . . . . . 0.411 HD12 ' O ' ' A' ' 69' ' ' PRO . 2.4 mp -117.05 143.99 25.93 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.392 0 CA-C-O 121.398 0.618 . . . . 0.0 109.728 -179.717 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 72' ' ' ASP . . . . . 0.537 ' O ' ' HB3' ' A' ' 44' ' ' ALA . 4.4 t70 -84.06 112.26 20.05 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 114.987 -1.006 . . . . 0.0 110.626 -179.657 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 73' ' ' TYR . . . . . 0.596 ' CE2' ' HB2' ' A' ' 43' ' ' ALA . 11.9 m-85 -107.54 120.61 42.68 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.467 179.73 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 74' ' ' ASP . . . . . 0.517 ' O ' ' N ' ' A' ' 42' ' ' VAL . 72.6 m-20 -88.04 119.42 28.4 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.348 -0.842 . . . . 0.0 109.414 179.474 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.907 ' N ' HD13 ' A' ' 75' ' ' ILE . 0.0 OUTLIER -120.15 166.44 14.57 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-O 121.005 0.431 . . . . 0.0 110.311 -178.521 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 21.2 t -155.92 125.61 6.39 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.659 -0.701 . . . . 0.0 110.623 179.204 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 11.4 t -102.0 100.79 11.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 N-CA-C 109.621 -0.511 . . . . 0.0 109.621 179.126 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 90.4 mt -87.95 126.3 41.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.717 -179.766 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 79' ' ' THR . . . . . 0.431 ' OG1' ' O ' ' B' ' 216' ' ' TRP . 16.4 p -106.93 110.03 22.08 Favored 'General case' 0 N--CA 1.464 0.235 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 179.514 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 35.9 tp -117.57 124.58 49.01 Favored 'General case' 0 N--CA 1.464 0.231 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.445 179.98 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 81' ' ' ILE . . . . . 0.483 ' HB ' ' H ' ' A' ' 33' ' ' THR . 2.1 pp -145.9 145.34 20.28 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-N 116.004 -0.543 . . . . 0.0 110.259 179.338 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 82' ' ' ASN . . . . . 0.494 ' H ' ' CB ' ' A' ' 33' ' ' THR . 47.2 t30 -62.44 -58.96 5.73 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.522 -0.308 . . . . 0.0 110.808 -179.743 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 83' ' ' GLY . . . . . 0.403 ' N ' ' OG1' ' A' ' 33' ' ' THR . . . 71.67 -158.42 53.5 Favored Glycine 0 CA--C 1.522 0.507 0 N-CA-C 110.896 -0.882 . . . . 0.0 110.896 179.629 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -89.87 114.43 4.36 Favored Glycine 0 CA--C 1.522 0.507 0 N-CA-C 110.707 -0.957 . . . . 0.0 110.707 179.793 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 76.7 mt-10 -88.66 140.29 29.6 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.726 0.298 . . . . 0.0 110.337 179.964 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 39.7 t -96.05 119.58 34.8 Favored 'General case' 0 C--N 1.332 -0.155 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.24 179.851 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.644 ' H ' ' CD ' ' A' ' 88' ' ' PRO . . . -105.48 -42.86 0.16 Allowed Pre-proline 0 N--CA 1.466 0.355 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.188 179.844 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 88' ' ' PRO . . . . . 0.644 ' CD ' ' H ' ' A' ' 87' ' ' ALA . 26.6 Cg_exo -61.12 14.25 0.05 OUTLIER 'Trans proline' 0 N--CA 1.496 1.631 0 C-N-CA 122.792 2.328 . . . . 0.0 112.532 -179.782 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 89' ' ' THR . . . . . 0.57 ' H ' ' C ' ' A' ' 87' ' ' ALA . 14.8 t -113.6 128.05 56.29 Favored 'General case' 0 C--N 1.334 -0.1 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.268 179.974 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 68.8 p -129.55 121.54 27.35 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.109 179.847 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 4.9 mp -103.21 132.65 49.3 Favored 'General case' 0 CA--C 1.52 -0.198 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.58 179.818 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 70.1 p -81.1 164.97 22.03 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.467 179.959 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 93' ' ' GLN . . . . . 0.424 ' O ' ' O ' ' A' ' 94' ' ' GLN . 99.0 mm-40 -76.74 130.28 37.48 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.456 -179.937 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 0.424 ' O ' ' O ' ' A' ' 93' ' ' GLN . 98.5 mm-40 52.79 170.76 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.52 179.925 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 48.2 p . . . . . 0 C--O 1.219 -0.509 0 CA-C-O 117.977 -1.011 . . . . 0.0 110.542 179.965 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' B' B ' 201' ' ' SER . . . . . . . . . . . . . 95.4 p . . . . . 0 N--CA 1.49 1.546 0 N-CA-C 109.354 -0.61 . . . . 0.0 109.354 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' B' B ' 202' ' ' SER . . . . . . . . . . . . . 25.8 p -77.27 154.44 32.95 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.248 179.849 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 203' ' ' SER . . . . . 0.413 ' C ' ' H ' ' B' ' 205' ' ' ILE . 2.3 p -117.45 151.76 48.56 Favored Pre-proline 0 N--CA 1.466 0.339 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.548 -179.831 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 204' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -66.04 6.06 0.55 Allowed 'Trans proline' 0 N--CA 1.495 1.574 0 C-N-CA 122.591 2.194 . . . . 0.0 111.82 179.831 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 205' ' ' ILE . . . . . 0.413 ' H ' ' C ' ' B' ' 203' ' ' SER . 2.6 tp -142.28 141.58 28.28 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.286 0 CA-C-O 121.144 0.497 . . . . 0.0 111.286 179.717 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 206' ' ' GLN . . . . . . . . . . . . . 12.2 pt20 -174.28 75.55 0.03 OUTLIER 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 115.519 -0.764 . . . . 0.0 111.096 178.894 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 207' ' ' GLY . . . . . . . . . . . . . . . -110.52 -140.32 8.46 Favored Glycine 0 N--CA 1.465 0.615 0 N-CA-C 110.818 -0.913 . . . . 0.0 110.818 179.834 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 208' ' ' SER . . . . . 0.455 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 53.9 p -164.35 171.67 14.48 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 120.876 0.37 . . . . 0.0 110.686 -179.893 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 209' ' ' TRP . . . . . . . . . . . . . 76.5 m95 -87.51 134.98 33.53 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.216 179.575 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 70.2 p -110.62 131.74 54.79 Favored 'General case' 0 N--CA 1.467 0.423 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.552 -179.847 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 50.5 t-105 -93.16 115.2 27.84 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 120.875 0.369 . . . . 0.0 110.432 179.689 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 212' ' ' GLU . . . . . 0.484 ' O ' ' O ' ' B' ' 215' ' ' LYS . 1.4 pt-20 -164.89 170.54 15.21 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.077 -0.51 . . . . 0.0 111.085 179.199 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 213' ' ' ASN . . . . . . . . . . . . . 16.3 m120 48.58 34.19 4.76 Favored 'General case' 0 C--N 1.322 -0.619 0 C-N-CA 120.398 -0.521 . . . . 0.0 111.342 176.384 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 54.27 11.75 2.65 Favored Glycine 0 CA--C 1.529 0.932 0 N-CA-C 111.627 -0.589 . . . . 0.0 111.627 179.794 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 215' ' ' LYS . . . . . 0.484 ' O ' ' O ' ' B' ' 212' ' ' GLU . 65.9 mttm -142.86 150.77 40.31 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 121.038 0.446 . . . . 0.0 110.732 179.995 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 216' ' ' TRP . . . . . 0.436 ' CD1' ' N ' ' B' ' 216' ' ' TRP . 35.0 m95 -87.74 127.15 35.31 Favored 'General case' 0 C--N 1.33 -0.281 0 N-CA-C 109.954 -0.387 . . . . 0.0 109.954 179.742 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 217' ' ' THR . . . . . . . . . . . . . 21.7 m -136.14 145.0 45.34 Favored 'General case' 0 N--CA 1.463 0.217 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.359 -179.784 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 218' ' ' TRP . . . . . 0.455 ' CH2' ' N ' ' B' ' 208' ' ' SER . 24.8 t-105 -102.6 120.83 41.23 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 116.048 -0.524 . . . . 0.0 109.796 179.53 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 97.4 mttt -136.56 164.33 28.44 Favored 'General case' 0 N--CA 1.465 0.308 0 CA-C-O 121.083 0.468 . . . . 0.0 110.739 -179.62 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -176.13 -162.75 27.55 Favored Glycine 0 CA--C 1.523 0.575 0 N-CA-C 111.134 -0.786 . . . . 0.0 111.134 -179.942 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 221' ' ' ILE . . . . . 0.533 ' O ' HG23 ' B' ' 222' ' ' ILE . 0.9 OUTLIER -58.75 -78.71 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 C-N-CA 120.459 -0.496 . . . . 0.0 110.965 -178.254 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' B' B ' 222' ' ' ILE . . . . . 0.533 HG23 ' O ' ' B' ' 221' ' ' ILE . 19.1 pt -159.12 -162.84 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 N-CA-C 110.043 -0.355 . . . . 0.0 110.043 -179.085 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 223' ' ' ARG . . . . . 0.544 ' HD2' ' H ' ' B' ' 223' ' ' ARG . 0.0 OUTLIER -43.76 173.64 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 121.271 0.558 . . . . 0.0 110.545 178.648 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' B' B ' 224' ' ' LEU . . . . . 0.747 HD22 ' N ' ' B' ' 224' ' ' LEU . 2.6 mm? -59.42 138.46 57.65 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-N 115.67 -0.695 . . . . 0.0 110.581 -179.707 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 80.0 tt0 -112.03 149.72 31.65 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 115.389 -0.823 . . . . 0.0 110.41 -179.492 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 226' ' ' GLN . . . . . . . . . . . . . 7.6 tp-100 . . . . . 0 N--CA 1.448 -0.574 0 CA-C-O 117.874 -1.06 . . . . 0.0 110.418 -179.98 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.258 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 39.0 t -86.94 103.64 15.51 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.742 0.306 . . . . 0.0 110.264 179.84 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -125.31 122.29 36.46 Favored 'General case' 0 N--CA 1.465 0.325 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.311 179.817 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 4.9 m -144.95 148.48 38.96 Favored Pre-proline 0 CA--C 1.533 0.289 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.513 179.756 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -67.64 144.52 66.46 Favored 'Trans proline' 0 N--CA 1.494 1.556 0 C-N-CA 122.446 2.097 . . . . 0.0 111.834 179.857 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' GLN . . . . . 0.541 ' NE2' ' O ' ' A' ' 8' ' ' GLN . 0.0 OUTLIER -168.5 65.19 0.07 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.426 179.976 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 3.9 mp -114.67 126.06 54.46 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 121.054 0.454 . . . . 0.0 110.439 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' THR . . . . . 0.45 ' O ' HG23 ' A' ' 10' ' ' THR . 13.8 t -95.62 130.75 42.4 Favored 'General case' 0 CA--C 1.52 -0.198 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.542 -179.547 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 45.2 t0 -115.85 101.54 8.89 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.271 179.926 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 5.7 tt -70.22 134.96 48.57 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.552 179.846 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 82.5 p -142.61 162.32 35.78 Favored 'General case' 0 N--CA 1.462 0.143 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.401 179.631 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' PHE . . . . . 0.411 ' CD1' ' N ' ' A' ' 14' ' ' PHE . 57.3 m-85 -110.27 147.64 33.45 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.905 -0.588 . . . . 0.0 110.67 -179.642 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 17.7 m -144.19 152.93 15.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.399 179.737 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 24.9 t70 60.66 34.24 20.1 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.544 -179.823 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 96.4 mt -57.02 134.65 21.3 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.191 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.035 179.709 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.438 ' OG1' ' O ' ' A' ' 21' ' ' SER . 0.2 OUTLIER -136.49 -168.89 2.34 Favored 'General case' 0 N--CA 1.469 0.478 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.388 -179.831 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 19' ' ' ASP . . . . . 0.485 ' N ' ' OD1' ' A' ' 19' ' ' ASP . 18.6 p-10 -76.48 -50.62 13.58 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.798 179.49 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 20' ' ' SER . . . . . 0.441 ' CB ' ' O ' ' A' ' 67' ' ' LEU . 69.8 m -121.61 15.76 11.13 Favored 'General case' 0 N--CA 1.462 0.173 0 CA-C-N 116.677 -0.238 . . . . 0.0 110.679 -179.33 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 21' ' ' SER . . . . . 0.527 ' HB2' HG22 ' A' ' 65' ' ' THR . 25.2 p -145.97 127.09 14.69 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-O 121.041 0.448 . . . . 0.0 110.545 -179.612 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 38.4 pt -128.69 141.29 46.96 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.3 0 CA-C-N 115.947 -0.569 . . . . 0.0 109.57 -179.81 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -102.29 88.73 0.7 Allowed Glycine 0 CA--C 1.523 0.566 0 N-CA-C 111.8 -0.52 . . . . 0.0 111.8 -179.316 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 10.3 mp -61.06 148.59 39.79 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 121.072 0.463 . . . . 0.0 110.349 179.963 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 50.2 ttt180 -157.4 136.57 11.83 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.683 -0.69 . . . . 0.0 110.98 179.827 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' TRP . . . . . 0.521 ' CH2' ' OH ' ' A' ' 37' ' ' TYR . 34.5 p90 -139.74 159.39 42.28 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.821 -0.627 . . . . 0.0 109.915 -179.93 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 3.7 m -107.71 99.77 31.31 Favored Pre-proline 0 CA--C 1.537 0.443 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.986 -179.363 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 38.7 Cg_exo -56.64 153.39 36.2 Favored 'Trans proline' 0 C--N 1.31 -1.454 0 C-N-CA 122.093 1.862 . . . . 0.0 112.956 178.84 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.513 ' H ' ' HB2' ' A' ' 32' ' ' SER . 41.7 mt -110.41 135.91 50.38 Favored 'General case' 0 N--CA 1.469 0.492 0 CA-C-O 121.76 0.79 . . . . 0.0 110.876 -179.845 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 28.1 t-20 -45.61 -30.05 1.4 Allowed 'General case' 0 C--N 1.315 -0.902 0 CA-C-N 114.902 -1.045 . . . . 0.0 110.477 179.852 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 69.3 m -89.83 -23.83 21.59 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.623 179.282 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 32' ' ' SER . . . . . 0.513 ' HB2' ' H ' ' A' ' 29' ' ' LEU . 4.7 m -65.09 120.03 11.91 Favored 'General case' 0 N--CA 1.464 0.233 0 CA-C-O 121.204 0.525 . . . . 0.0 110.163 179.998 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 23.7 m -55.82 140.69 41.42 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.602 -0.727 . . . . 0.0 109.516 179.578 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 29.8 mm -94.7 99.01 8.73 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.343 0 CA-C-O 120.854 0.359 . . . . 0.0 111.367 -178.625 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.56 HD11 ' HA ' ' A' ' 81' ' ' ILE . 0.1 OUTLIER -140.11 155.78 24.28 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.21 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.152 179.466 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -74.55 97.74 1.0 Allowed Glycine 0 CA--C 1.524 0.609 0 N-CA-C 110.793 -0.923 . . . . 0.0 110.793 179.877 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 37' ' ' TYR . . . . . 0.521 ' OH ' ' CH2' ' A' ' 26' ' ' TRP . 2.0 p90 -78.79 126.99 31.45 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 110.01 -0.367 . . . . 0.0 110.01 179.787 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 5.4 tmm_? -78.01 132.39 37.78 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 120.975 0.417 . . . . 0.0 111.092 -179.69 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.458 ' O ' ' CG1' ' A' ' 39' ' ' ILE . 1.9 pt -98.46 121.27 48.83 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.217 0 N-CA-C 109.155 -0.683 . . . . 0.0 109.155 179.146 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 13.6 m -99.66 135.81 40.52 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 120.852 0.358 . . . . 0.0 110.948 -179.04 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.3 p -133.15 139.88 48.38 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.364 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.031 179.531 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 42' ' ' VAL . . . . . 0.511 ' O ' ' N ' ' A' ' 74' ' ' ASP . 38.7 t -131.68 131.66 62.27 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.252 0 N-CA-C 109.969 -0.382 . . . . 0.0 109.969 179.616 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -97.91 133.51 42.31 Favored 'General case' 0 C--N 1.326 -0.414 0 N-CA-C 109.448 -0.575 . . . . 0.0 109.448 179.148 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.627 ' HB3' ' O ' ' A' ' 72' ' ' ASP . . . -94.01 -14.14 26.2 Favored 'General case' 0 C--N 1.329 -0.309 0 C-N-CA 120.956 -0.298 . . . . 0.0 111.005 -179.57 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -99.38 21.81 43.67 Favored Glycine 0 N--CA 1.465 0.609 0 N-CA-C 111.293 -0.723 . . . . 0.0 111.293 -179.518 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -143.74 150.25 38.34 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 121.163 0.506 . . . . 0.0 110.316 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -68.4 -19.35 72.49 Favored Glycine 0 CA--C 1.524 0.647 0 N-CA-C 110.822 -0.911 . . . . 0.0 110.822 179.976 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -134.06 139.73 34.08 Favored Pre-proline 0 CA--C 1.542 0.642 0 O-C-N 122.828 -0.219 . . . . 0.0 110.658 179.943 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_endo -73.79 164.47 34.61 Favored 'Trans proline' 0 N--CA 1.491 1.363 0 C-N-CA 122.613 2.209 . . . . 0.0 111.902 178.102 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 50' ' ' ILE . . . . . 0.434 HG22 ' N ' ' A' ' 51' ' ' PHE . 96.6 mt -79.16 155.01 4.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.608 179.603 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 51' ' ' PHE . . . . . 0.434 ' N ' HG22 ' A' ' 50' ' ' ILE . 98.3 m-85 -71.59 141.64 50.01 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.42 179.986 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 52' ' ' GLU . . . . . 0.529 ' CD ' ' H ' ' A' ' 52' ' ' GLU . 0.4 OUTLIER -77.21 144.09 38.54 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.729 179.603 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -104.05 148.57 26.08 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.521 179.7 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 54' ' ' PHE . . . . . 0.465 ' CD1' ' N ' ' A' ' 54' ' ' PHE . 15.9 m-85 -115.48 120.25 38.9 Favored 'General case' 0 N--CA 1.462 0.144 0 CA-C-N 115.758 -0.655 . . . . 0.0 110.038 179.664 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 8.3 p -130.41 144.05 39.13 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.307 0 CA-C-O 120.64 0.257 . . . . 0.0 110.381 -179.957 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 98.7 m-20 -66.27 146.75 54.25 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.591 179.51 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -65.92 -31.89 73.08 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.602 179.841 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 42.9 m -53.84 -36.19 62.3 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.619 -179.579 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 86.9 t -59.27 -43.66 90.38 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 116.438 -0.346 . . . . 0.0 110.41 -179.558 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 64.93 23.94 69.73 Favored Glycine 0 CA--C 1.526 0.721 0 N-CA-C 110.403 -1.079 . . . . 0.0 110.403 179.65 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 61' ' ' TYR . . . . . 0.416 ' CG ' ' N ' ' A' ' 62' ' ' TYR . 38.0 t80 -170.42 153.81 4.47 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 121.018 0.437 . . . . 0.0 111.495 -179.549 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 62' ' ' TYR . . . . . 0.417 ' CD2' ' CD1' ' A' ' 39' ' ' ILE . 19.1 t80 -158.73 160.96 36.96 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.337 178.582 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 85.5 m -126.26 134.35 51.2 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.068 -0.514 . . . . 0.0 110.271 179.881 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -133.05 100.64 3.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.033 -0.53 . . . . 0.0 109.684 178.972 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.527 HG22 ' HB2' ' A' ' 21' ' ' SER . 1.4 p -114.68 164.21 14.37 Favored 'General case' 0 CA--C 1.513 -0.478 0 CA-C-O 120.969 0.414 . . . . 0.0 110.507 -179.89 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 107.34 23.75 6.81 Favored Glycine 0 CA--C 1.519 0.319 0 N-CA-C 111.162 -0.775 . . . . 0.0 111.162 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.441 ' O ' ' CB ' ' A' ' 20' ' ' SER . 10.0 mt -97.22 106.38 18.7 Favored 'General case' 0 N--CA 1.464 0.226 0 N-CA-C 109.532 -0.544 . . . . 0.0 109.532 179.804 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 5.2 mm-40 -46.63 137.34 7.27 Favored Pre-proline 0 C--N 1.316 -0.854 0 CA-C-N 116.101 -0.5 . . . . 0.0 111.827 -178.421 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -73.98 156.67 47.59 Favored 'Trans proline' 0 N--CA 1.497 1.705 0 C-N-CA 122.674 2.249 . . . . 0.0 111.255 178.665 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 71.69 -5.68 10.99 Favored Glycine 0 CA--C 1.527 0.789 0 C-N-CA 120.947 -0.645 . . . . 0.0 111.685 179.307 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 71' ' ' ILE . . . . . 0.473 ' O ' ' NH1' ' B' ' 223' ' ' ARG . 1.7 mp -103.61 144.32 14.27 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.437 0 CA-C-O 121.26 0.552 . . . . 0.0 109.611 -179.807 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 72' ' ' ASP . . . . . 0.627 ' O ' ' HB3' ' A' ' 44' ' ' ALA . 2.3 t70 -84.39 119.19 24.82 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.14 -0.936 . . . . 0.0 110.469 179.291 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 73' ' ' TYR . . . . . 0.479 ' O ' HD13 ' A' ' 75' ' ' ILE . 19.0 m-85 -110.14 120.22 41.76 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.75 -179.999 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 74' ' ' ASP . . . . . 0.511 ' N ' ' O ' ' A' ' 42' ' ' VAL . 14.8 m-20 -90.17 117.1 28.67 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 115.619 -0.719 . . . . 0.0 109.788 179.639 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.484 ' N ' HD13 ' A' ' 75' ' ' ILE . 0.0 OUTLIER -114.05 165.2 9.34 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-O 121.147 0.498 . . . . 0.0 110.059 -179.29 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 1.3 p -154.59 121.36 5.49 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.721 -0.672 . . . . 0.0 110.525 179.681 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.443 ' O ' HG23 ' B' ' 217' ' ' THR . 14.2 t -96.5 99.66 9.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 179.057 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 95.4 mt -88.35 115.62 28.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.115 179.634 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 79' ' ' THR . . . . . 0.456 ' OG1' ' O ' ' B' ' 216' ' ' TRP . 43.4 p -99.21 117.39 33.57 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.249 179.95 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 20.1 mt -121.4 110.32 15.94 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.864 179.904 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 81' ' ' ILE . . . . . 0.594 ' C ' HD12 ' A' ' 81' ' ' ILE . 1.2 pp -142.24 138.15 29.8 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.088 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.383 179.211 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 59.7 t-20 -65.72 -50.47 64.73 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.955 -0.566 . . . . 0.0 111.244 -179.249 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 83' ' ' GLY . . . . . 0.444 ' N ' HD12 ' A' ' 81' ' ' ILE . . . 83.77 -162.5 39.38 Favored Glycine 0 CA--C 1.521 0.428 0 N-CA-C 110.951 -0.86 . . . . 0.0 110.951 179.257 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -80.43 175.22 54.95 Favored Glycine 0 CA--C 1.525 0.683 0 N-CA-C 110.762 -0.935 . . . . 0.0 110.762 -179.99 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.66 ' CD ' ' H ' ' A' ' 85' ' ' GLU . 1.2 pm0 -69.75 149.4 48.03 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 120.898 0.38 . . . . 0.0 110.528 179.922 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 52.9 p -48.88 109.36 0.25 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.379 -179.914 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.448 ' N ' ' CD ' ' A' ' 88' ' ' PRO . . . -172.9 53.38 0.16 Allowed Pre-proline 0 C--N 1.328 -0.35 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.587 179.837 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 88' ' ' PRO . . . . . 0.448 ' CD ' ' N ' ' A' ' 87' ' ' ALA . 51.9 Cg_endo -68.17 157.1 63.25 Favored 'Trans proline' 0 C--N 1.308 -1.574 0 C-N-CA 122.627 2.218 . . . . 0.0 111.877 179.824 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 4.9 t -138.85 157.84 45.31 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.259 -179.881 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 88.7 m -116.52 128.66 55.64 Favored 'General case' 0 N--CA 1.467 0.386 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.266 -179.868 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 91' ' ' LEU . . . . . 0.613 HD12 ' N ' ' A' ' 91' ' ' LEU . 9.4 mp -75.67 156.83 34.39 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.855 -0.612 . . . . 0.0 110.397 -179.819 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 62.2 p -64.89 164.43 12.53 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.318 -179.638 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 93' ' ' GLN . . . . . 0.448 ' O ' ' O ' ' A' ' 94' ' ' GLN . 7.8 tp-100 -79.74 118.63 21.72 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.321 -179.734 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 0.448 ' O ' ' O ' ' A' ' 93' ' ' GLN . 67.3 tp60 56.77 116.97 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.47 179.961 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 29.7 m . . . . . 0 C--O 1.22 -0.493 0 CA-C-O 117.991 -1.004 . . . . 0.0 110.555 179.939 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' B' B ' 201' ' ' SER . . . . . . . . . . . . . 31.1 m . . . . . 0 N--CA 1.489 1.487 0 N-CA-C 109.411 -0.589 . . . . 0.0 109.411 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' B' B ' 202' ' ' SER . . . . . . . . . . . . . 40.4 t -68.89 146.89 52.43 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.288 179.805 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 203' ' ' SER . . . . . . . . . . . . . 5.5 t -131.92 101.66 15.17 Favored Pre-proline 0 CA--C 1.534 0.337 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 178.277 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 204' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_exo -58.09 -58.76 0.68 Allowed 'Trans proline' 0 N--CA 1.498 1.75 0 C-N-CA 122.09 1.86 . . . . 0.0 112.389 178.165 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 205' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -150.17 144.73 17.4 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.3 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.391 -179.867 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 206' ' ' GLN . . . . . . . . . . . . . 26.8 mt-30 -138.2 139.27 39.23 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.193 -0.458 . . . . 0.0 109.981 178.948 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 207' ' ' GLY . . . . . . . . . . . . . . . -100.0 -136.1 9.21 Favored Glycine 0 N--CA 1.465 0.598 0 N-CA-C 111.142 -0.783 . . . . 0.0 111.142 -179.774 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 208' ' ' SER . . . . . 0.538 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 30.7 p -166.47 170.04 13.27 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 120.829 0.347 . . . . 0.0 110.831 179.626 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 209' ' ' TRP . . . . . . . . . . . . . 86.1 m95 -86.29 149.32 25.14 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.373 179.637 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 59.1 p -129.06 128.78 44.26 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.345 179.247 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 54.1 t-105 -91.61 111.55 23.11 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.215 -179.977 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 212' ' ' GLU . . . . . 0.424 ' O ' ' O ' ' B' ' 215' ' ' LYS . 1.7 pt-20 -161.78 167.02 25.65 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.543 179.322 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 213' ' ' ASN . . . . . . . . . . . . . 93.7 m-20 49.79 35.05 8.38 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.929 -0.578 . . . . 0.0 111.159 176.722 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 51.46 17.93 3.29 Favored Glycine 0 CA--C 1.527 0.843 0 N-CA-C 111.37 -0.692 . . . . 0.0 111.37 179.934 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 215' ' ' LYS . . . . . 0.424 ' O ' ' O ' ' B' ' 212' ' ' GLU . 54.1 mtmt -142.58 149.45 39.03 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 120.851 0.357 . . . . 0.0 110.963 179.662 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 216' ' ' TRP . . . . . 0.456 ' O ' ' OG1' ' A' ' 79' ' ' THR . 59.8 m95 -88.83 116.4 27.08 Favored 'General case' 0 C--N 1.331 -0.23 0 N-CA-C 109.444 -0.576 . . . . 0.0 109.444 179.249 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 217' ' ' THR . . . . . 0.443 HG23 ' O ' ' A' ' 77' ' ' VAL . 17.8 m -124.81 140.34 53.02 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-O 120.976 0.417 . . . . 0.0 110.804 -179.265 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 218' ' ' TRP . . . . . 0.538 ' CH2' ' N ' ' B' ' 208' ' ' SER . 30.6 t-105 -102.8 105.35 15.75 Favored 'General case' 0 C--N 1.333 -0.121 0 CA-C-N 115.74 -0.664 . . . . 0.0 109.473 179.229 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 75.8 mttt -131.11 167.06 19.75 Favored 'General case' 0 N--CA 1.467 0.418 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.753 -179.375 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -178.24 -162.76 28.58 Favored Glycine 0 CA--C 1.523 0.588 0 N-CA-C 111.018 -0.833 . . . . 0.0 111.018 179.447 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 221' ' ' ILE . . . . . 0.555 ' O ' HG23 ' B' ' 222' ' ' ILE . 2.1 mp -55.24 -73.87 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 C-N-CA 120.66 -0.416 . . . . 0.0 110.694 -178.565 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 222' ' ' ILE . . . . . 0.555 HG23 ' O ' ' B' ' 221' ' ' ILE . 23.1 pt -160.61 -164.64 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.268 -179.599 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 223' ' ' ARG . . . . . 0.487 ' O ' ' O ' ' B' ' 222' ' ' ILE . 35.5 ptt-85 -41.73 173.1 0.0 OUTLIER 'General case' 0 CA--C 1.529 0.168 0 CA-C-O 121.352 0.596 . . . . 0.0 110.554 178.54 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 224' ' ' LEU . . . . . 0.988 ' H ' HD22 ' B' ' 224' ' ' LEU . 1.4 mm? -64.83 110.42 2.41 Favored 'General case' 0 C--N 1.313 -0.982 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.826 -179.597 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 83.5 tt0 -97.97 151.53 20.2 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.252 -0.886 . . . . 0.0 110.365 179.849 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 226' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.219 -0.524 0 CA-C-O 117.95 -1.024 . . . . 0.0 110.402 179.953 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.392 0 N-CA-C 109.456 -1.458 . . . . 0.0 109.456 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 4.6 m 47.39 41.5 12.65 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.743 0.306 . . . . 0.0 110.689 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 17.3 pt-20 -52.03 140.58 20.14 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.388 -179.924 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 4.5 m -82.71 148.71 58.57 Favored Pre-proline 0 C--N 1.327 -0.403 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.721 -179.726 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -69.09 113.45 3.27 Favored 'Trans proline' 0 N--CA 1.495 1.584 0 C-N-CA 122.502 2.134 . . . . 0.0 111.705 179.673 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 87.0 mt-30 -95.81 123.58 39.44 Favored 'General case' 0 C--N 1.333 -0.149 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.106 179.61 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 56.8 mt -97.88 114.32 26.36 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.256 -179.95 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 77.9 p -84.2 164.0 19.38 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.278 179.875 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' ASP . . . . . 0.428 ' OD1' ' O ' ' A' ' 11' ' ' ASP . 53.9 p-10 -108.55 144.62 35.97 Favored 'General case' 0 N--CA 1.464 0.244 0 CA-C-O 121.148 0.499 . . . . 0.0 110.522 -179.952 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.433 ' H ' ' HE1' ' B' ' 209' ' ' TRP . 4.9 tt -66.47 144.43 56.5 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.592 179.922 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 13' ' ' SER . . . . . 0.499 ' O ' ' O ' ' A' ' 25' ' ' ARG . 85.5 p -141.44 156.07 45.81 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.98 0.419 . . . . 0.0 110.749 179.67 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 14' ' ' PHE . . . . . 0.532 ' CD1' ' N ' ' A' ' 14' ' ' PHE . 1.9 m-85 -112.64 153.31 27.83 Favored 'General case' 0 N--CA 1.464 0.263 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.337 -179.813 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 10.5 m -147.7 151.5 13.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.345 179.669 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 26.8 t0 62.89 37.07 12.36 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.622 -179.946 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 43.7 mt -56.94 133.45 21.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.055 179.698 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -136.54 -171.09 2.82 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.242 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 19' ' ' ASP . . . . . 0.47 ' N ' ' OD1' ' A' ' 19' ' ' ASP . 20.5 p-10 -75.85 -49.72 17.17 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.91 179.743 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 20' ' ' SER . . . . . 0.47 ' OG ' ' O ' ' A' ' 67' ' ' LEU . 51.0 m -122.36 17.11 10.59 Favored 'General case' 0 N--CA 1.465 0.324 0 CA-C-N 116.437 -0.347 . . . . 0.0 110.805 -179.698 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 1.5 m -145.62 129.83 17.6 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.706 0.289 . . . . 0.0 110.265 -179.425 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' ILE . . . . . 0.678 HD12 HD21 ' A' ' 24' ' ' LEU . 36.5 pt -132.42 142.78 41.74 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 N-CA-C 109.599 -0.519 . . . . 0.0 109.599 179.67 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -101.48 85.9 0.58 Allowed Glycine 0 CA--C 1.523 0.541 0 N-CA-C 111.055 -0.818 . . . . 0.0 111.055 -179.413 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.678 HD21 HD12 ' A' ' 22' ' ' ILE . 55.4 mt -69.82 118.48 12.73 Favored 'General case' 0 C--N 1.33 -0.255 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 179.996 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 25' ' ' ARG . . . . . 0.585 ' HE ' ' CB ' ' A' ' 61' ' ' TYR . 31.5 ttm180 -142.99 132.5 23.6 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 121.004 0.431 . . . . 0.0 111.188 179.973 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 26' ' ' TRP . . . . . 0.468 ' CD1' ' O ' ' A' ' 26' ' ' TRP . 35.3 p90 -147.6 133.88 19.52 Favored 'General case' 0 C--N 1.326 -0.444 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 179.643 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 1.9 m -68.36 115.99 35.22 Favored Pre-proline 0 C--N 1.326 -0.43 0 C-N-CA 120.218 -0.593 . . . . 0.0 111.292 -178.97 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_exo -53.49 154.55 15.1 Favored 'Trans proline' 0 N--CA 1.492 1.431 0 C-N-CA 122.171 1.914 . . . . 0.0 112.709 178.258 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.464 ' O ' ' N ' ' A' ' 32' ' ' SER . 75.4 mt -93.66 132.03 38.4 Favored 'General case' 0 N--CA 1.467 0.404 0 CA-C-O 122.006 0.907 . . . . 0.0 110.89 179.926 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 40.4 t30 -43.13 -32.26 0.69 Allowed 'General case' 0 C--N 1.316 -0.863 0 CA-C-N 115.336 -0.847 . . . . 0.0 110.502 179.984 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 20.8 m -86.96 -30.44 21.29 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.692 179.365 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 32' ' ' SER . . . . . 0.464 ' N ' ' O ' ' A' ' 29' ' ' LEU . 2.1 m -50.26 111.32 0.51 Allowed 'General case' 0 CA--C 1.529 0.166 0 CA-C-O 121.11 0.481 . . . . 0.0 110.524 -179.783 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 33' ' ' THR . . . . . 0.449 ' CB ' ' H ' ' A' ' 82' ' ' ASN . 8.1 m -51.12 148.7 4.27 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.554 -0.748 . . . . 0.0 109.348 -179.646 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 5.3 mm -92.88 91.36 3.33 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.277 0 CA-C-O 121.391 0.615 . . . . 0.0 111.168 -178.825 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.541 HD11 ' HA ' ' A' ' 81' ' ' ILE . 12.0 pt -147.96 126.15 3.5 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 115.24 -0.891 . . . . 0.0 110.565 179.554 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -46.89 126.41 10.03 Favored Glycine 0 CA--C 1.521 0.465 0 N-CA-C 110.847 -0.901 . . . . 0.0 110.847 -179.718 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 37' ' ' TYR . . . . . 0.482 ' CE1' ' CG1' ' A' ' 55' ' ' VAL . 28.3 p90 -95.8 175.24 6.59 Favored 'General case' 0 C--N 1.329 -0.307 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 179.851 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 9.0 tmm_? -126.36 123.0 36.99 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.718 -179.843 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.471 ' O ' ' CG1' ' A' ' 39' ' ' ILE . 1.9 pt -94.14 120.22 43.21 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 N-CA-C 109.602 -0.518 . . . . 0.0 109.602 -179.856 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 10.1 m -96.14 128.48 43.08 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.15 -179.289 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.0 p -123.06 134.12 67.09 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 CA-C-N 116.077 -0.511 . . . . 0.0 109.873 -179.981 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 42' ' ' VAL . . . . . 0.407 ' O ' ' N ' ' A' ' 74' ' ' ASP . 24.5 t -129.35 128.45 66.42 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.173 0 CA-C-O 120.831 0.348 . . . . 0.0 110.132 179.846 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.511 ' HB2' ' CE2' ' A' ' 73' ' ' TYR . . . -97.36 128.99 44.66 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 109.054 -0.721 . . . . 0.0 109.054 179.372 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.606 ' HB3' ' O ' ' A' ' 72' ' ' ASP . . . -88.12 -24.27 23.43 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 120.869 0.366 . . . . 0.0 110.981 -179.624 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -86.43 20.59 21.66 Favored Glycine 0 N--CA 1.462 0.375 0 N-CA-C 111.202 -0.759 . . . . 0.0 111.202 -179.696 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 79.8 mm-40 -144.75 150.12 36.69 Favored 'General case' 0 C--O 1.233 0.224 0 CA-C-O 121.041 0.448 . . . . 0.0 110.324 -179.702 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -69.32 -20.33 75.09 Favored Glycine 0 N--CA 1.452 -0.269 0 N-CA-C 110.645 -0.982 . . . . 0.0 110.645 -179.852 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -131.42 139.01 34.05 Favored Pre-proline 0 N--CA 1.469 0.495 0 C-N-CA 120.952 -0.299 . . . . 0.0 110.528 179.673 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 68.6 Cg_endo -75.27 165.06 31.69 Favored 'Trans proline' 0 C--N 1.31 -1.458 0 C-N-CA 122.734 2.289 . . . . 0.0 112.027 177.676 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 50' ' ' ILE . . . . . 0.527 HG22 ' N ' ' A' ' 51' ' ' PHE . 96.6 mt -79.6 160.42 4.29 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-N 115.782 -0.644 . . . . 0.0 110.229 179.55 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 51' ' ' PHE . . . . . 0.527 ' N ' HG22 ' A' ' 50' ' ' ILE . 92.5 m-85 -74.36 142.33 45.09 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.734 179.918 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 52' ' ' GLU . . . . . 0.532 ' CD ' ' H ' ' A' ' 52' ' ' GLU . 0.2 OUTLIER -77.58 142.07 39.17 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.15 179.561 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 53' ' ' ASP . . . . . 0.42 ' CG ' ' OH ' ' A' ' 62' ' ' TYR . 0.5 OUTLIER -100.57 151.55 21.47 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 120.993 0.425 . . . . 0.0 110.051 -179.827 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 90.0 m-85 -115.09 122.06 44.98 Favored 'General case' 0 C--O 1.232 0.17 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.352 179.738 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.482 ' CG1' ' CE1' ' A' ' 37' ' ' TYR . 9.5 p -131.96 142.22 43.49 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.295 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.393 -179.974 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 99.3 m-20 -63.66 150.0 45.28 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.793 -0.64 . . . . 0.0 110.37 179.69 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 57' ' ' SER . . . . . 0.487 ' OG ' ' O ' ' A' ' 35' ' ' ILE . 4.7 m -64.71 -34.84 79.27 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.875 179.909 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 68.0 m -51.17 -36.54 41.59 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.303 -179.026 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.48 ' C ' ' H ' ' A' ' 61' ' ' TYR . 22.7 t -64.38 -42.39 95.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.092 179.884 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 72.01 -40.05 0.69 Allowed Glycine 0 CA--C 1.531 1.069 0 N-CA-C 111.048 -0.821 . . . . 0.0 111.048 179.766 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 61' ' ' TYR . . . . . 0.585 ' CB ' ' HE ' ' A' ' 25' ' ' ARG . 31.1 p90 -110.68 161.01 16.17 Favored 'General case' 0 N--CA 1.466 0.368 0 CA-C-O 121.093 0.473 . . . . 0.0 111.08 -179.035 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 62' ' ' TYR . . . . . 0.42 ' OH ' ' CG ' ' A' ' 53' ' ' ASP . 31.5 t80 -155.95 163.04 40.24 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.015 -0.539 . . . . 0.0 109.949 179.492 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 57.6 m -119.6 131.47 55.5 Favored 'General case' 0 N--CA 1.467 0.422 0 CA-C-O 121.025 0.44 . . . . 0.0 110.628 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -134.27 108.91 11.76 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 115.765 -0.652 . . . . 0.0 109.981 179.324 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 1.2 p -128.35 167.37 17.06 Favored 'General case' 0 CA--C 1.514 -0.441 0 CA-C-O 121.023 0.44 . . . . 0.0 110.47 179.939 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 108.33 24.34 6.25 Favored Glycine 0 CA--C 1.522 0.496 0 CA-C-N 115.614 -0.721 . . . . 0.0 111.502 -179.793 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.47 ' O ' ' OG ' ' A' ' 20' ' ' SER . 3.9 mt -99.61 106.42 18.38 Favored 'General case' 0 CA--C 1.517 -0.29 0 N-CA-C 109.197 -0.668 . . . . 0.0 109.197 -179.401 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 68' ' ' GLU . . . . . 0.423 ' HG2' ' H ' ' A' ' 68' ' ' GLU . 0.0 OUTLIER -48.19 140.08 9.65 Favored Pre-proline 0 C--N 1.311 -1.097 0 CA-C-N 115.669 -0.696 . . . . 0.0 111.112 -178.247 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 68.5 Cg_endo -73.38 156.29 50.48 Favored 'Trans proline' 0 N--CA 1.5 1.896 0 C-N-CA 122.993 2.462 . . . . 0.0 111.596 178.344 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 74.61 -2.09 49.25 Favored Glycine 0 CA--C 1.525 0.718 0 CA-C-N 115.563 -0.744 . . . . 0.0 111.698 179.259 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 1.6 mp -110.46 140.5 29.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-O 121.557 0.694 . . . . 0.0 109.582 -179.283 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 72' ' ' ASP . . . . . 0.606 ' O ' ' HB3' ' A' ' 44' ' ' ALA . 1.6 t70 -80.54 122.78 27.46 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 114.877 -1.056 . . . . 0.0 110.297 179.649 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 73' ' ' TYR . . . . . 0.522 ' O ' HD13 ' A' ' 75' ' ' ILE . 12.5 m-85 -114.94 122.65 46.91 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.686 -0.688 . . . . 0.0 110.809 179.785 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 74' ' ' ASP . . . . . 0.407 ' N ' ' O ' ' A' ' 42' ' ' VAL . 66.3 m-20 -94.32 110.78 22.52 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 108.597 -0.89 . . . . 0.0 108.597 178.692 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.522 HD13 ' O ' ' A' ' 73' ' ' TYR . 0.0 OUTLIER -126.39 111.95 28.11 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.249 0 CA-C-N 116.654 -0.248 . . . . 0.0 111.27 179.954 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 23.8 t -105.43 125.66 51.24 Favored 'General case' 0 CA--C 1.518 -0.253 0 N-CA-C 109.576 -0.527 . . . . 0.0 109.576 179.247 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 84.4 t -88.71 99.52 9.24 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-O 120.939 0.4 . . . . 0.0 110.06 179.747 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 94.4 mt -82.52 135.99 23.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.356 179.914 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 30.5 p -113.26 117.71 32.62 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.231 179.623 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 1.8 mp -109.77 110.78 21.89 Favored 'General case' 0 N--CA 1.467 0.386 0 CA-C-O 121.194 0.521 . . . . 0.0 110.648 -179.822 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 81' ' ' ILE . . . . . 0.541 ' HA ' HD11 ' A' ' 35' ' ' ILE . 2.0 pp -146.55 143.69 20.62 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.213 179.274 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 82' ' ' ASN . . . . . 0.449 ' H ' ' CB ' ' A' ' 33' ' ' THR . 22.5 t-20 -66.37 -49.43 66.92 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.876 0.369 . . . . 0.0 111.213 179.821 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 111.66 109.51 3.08 Favored Glycine 0 N--CA 1.465 0.597 0 N-CA-C 110.79 -0.924 . . . . 0.0 110.79 179.657 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -63.22 105.51 1.06 Allowed Glycine 0 CA--C 1.525 0.716 0 N-CA-C 110.676 -0.97 . . . . 0.0 110.676 179.967 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -93.49 128.7 39.7 Favored 'General case' 0 N--CA 1.463 0.209 0 CA-C-O 120.79 0.329 . . . . 0.0 110.339 179.929 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 66.0 m -62.85 140.81 58.82 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.101 -0.5 . . . . 0.0 109.997 -179.871 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -122.65 150.42 58.14 Favored Pre-proline 0 CA--C 1.535 0.402 0 CA-C-N 116.321 -0.399 . . . . 0.0 110.525 -179.862 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -69.27 161.85 44.2 Favored 'Trans proline' 0 N--CA 1.496 1.639 0 C-N-CA 122.816 2.344 . . . . 0.0 111.82 179.152 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 41.4 p -129.79 150.6 51.02 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.34 -179.823 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 45.0 p -138.45 172.02 13.5 Favored 'General case' 0 CA--C 1.52 -0.186 0 CA-C-N 115.894 -0.593 . . . . 0.0 110.72 -179.832 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 91' ' ' LEU . . . . . 0.607 HD22 ' N ' ' A' ' 91' ' ' LEU . 3.7 mm? -76.95 140.74 40.55 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.537 -179.543 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 64.6 p -69.77 137.25 51.75 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.47 -179.988 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 99.4 mm-40 -74.85 134.47 41.68 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.5 179.917 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 0.582 ' CD ' ' H ' ' A' ' 94' ' ' GLN . 2.2 pm0 -67.32 143.21 56.52 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.648 179.867 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 78.6 p . . . . . 0 C--O 1.221 -0.434 0 CA-C-O 118.086 -0.959 . . . . 0.0 110.371 179.744 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' B' B ' 201' ' ' SER . . . . . . . . . . . . . 3.7 p . . . . . 0 N--CA 1.491 1.592 0 N-CA-C 109.348 -0.612 . . . . 0.0 109.348 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' B' B ' 202' ' ' SER . . . . . . . . . . . . . 38.2 t -71.31 149.17 46.38 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.318 -179.936 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 203' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -90.44 151.29 44.14 Favored Pre-proline 0 CA--C 1.533 0.315 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.536 -179.888 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 204' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -65.19 -43.81 10.55 Favored 'Trans proline' 0 N--CA 1.495 1.614 0 C-N-CA 122.909 2.406 . . . . 0.0 112.1 -179.758 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 205' ' ' ILE . . . . . . . . . . . . . 1.6 tt -149.77 145.55 17.39 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.193 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.629 -179.523 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 206' ' ' GLN . . . . . . . . . . . . . 15.3 pt20 -146.77 144.35 29.32 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.995 -0.548 . . . . 0.0 109.781 178.873 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 207' ' ' GLY . . . . . . . . . . . . . . . -105.81 -131.16 6.85 Favored Glycine 0 N--CA 1.466 0.672 0 N-CA-C 111.054 -0.818 . . . . 0.0 111.054 -179.919 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 208' ' ' SER . . . . . 0.589 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 97.6 p -167.07 170.88 11.53 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.805 0.336 . . . . 0.0 110.622 179.748 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 209' ' ' TRP . . . . . 0.433 ' HE1' ' H ' ' A' ' 12' ' ' LEU . 79.5 m95 -86.99 155.86 20.0 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.45 179.67 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 31.6 p -133.47 133.52 42.37 Favored 'General case' 0 N--CA 1.463 0.217 0 CA-C-N 116.434 -0.348 . . . . 0.0 110.414 179.745 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 58.0 t-105 -95.78 113.85 25.52 Favored 'General case' 0 N--CA 1.463 0.214 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.627 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 212' ' ' GLU . . . . . 0.43 ' O ' ' O ' ' B' ' 215' ' ' LYS . 0.9 OUTLIER -162.29 163.1 28.26 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.5 179.591 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' B' B ' 213' ' ' ASN . . . . . . . . . . . . . 17.8 m120 51.31 34.14 11.12 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.067 177.346 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 55.21 18.17 12.73 Favored Glycine 0 CA--C 1.527 0.808 0 N-CA-C 111.298 -0.721 . . . . 0.0 111.298 179.831 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 215' ' ' LYS . . . . . 0.43 ' O ' ' O ' ' B' ' 212' ' ' GLU . 56.1 mtmt -143.3 149.76 38.27 Favored 'General case' 0 C--O 1.232 0.165 0 CA-C-O 120.834 0.349 . . . . 0.0 110.95 179.895 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 216' ' ' TRP . . . . . . . . . . . . . 48.9 m95 -87.67 113.71 23.6 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.179 -0.464 . . . . 0.0 109.764 179.507 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 217' ' ' THR . . . . . . . . . . . . . 16.3 m -119.82 134.93 55.06 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.519 -179.339 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 218' ' ' TRP . . . . . 0.589 ' CH2' ' N ' ' B' ' 208' ' ' SER . 29.1 t-105 -95.88 105.0 16.96 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.875 -0.602 . . . . 0.0 109.907 179.27 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 6.9 mtmt -130.5 167.8 18.07 Favored 'General case' 0 CA--C 1.515 -0.398 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.778 -179.357 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -178.45 -163.35 29.68 Favored Glycine 0 CA--C 1.524 0.625 0 N-CA-C 111.138 -0.785 . . . . 0.0 111.138 179.41 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 221' ' ' ILE . . . . . 0.575 ' O ' HG23 ' B' ' 222' ' ' ILE . 20.1 mt -55.86 -73.24 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 C-N-CA 120.645 -0.422 . . . . 0.0 110.263 -178.146 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 222' ' ' ILE . . . . . 0.575 HG23 ' O ' ' B' ' 221' ' ' ILE . 18.9 pt -160.53 -166.8 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 O-C-N 123.402 0.439 . . . . 0.0 110.462 179.994 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 223' ' ' ARG . . . . . 0.479 ' O ' ' O ' ' B' ' 222' ' ' ILE . 33.4 ptt180 -43.3 172.71 0.0 OUTLIER 'General case' 0 C--O 1.231 0.098 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.497 179.082 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 224' ' ' LEU . . . . . 0.79 HD22 ' N ' ' B' ' 224' ' ' LEU . 2.2 mm? -65.5 107.2 1.61 Allowed 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 121.48 0.657 . . . . 0.0 110.322 -178.766 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 82.0 tt0 -90.04 154.23 19.97 Favored 'General case' 0 N--CA 1.452 -0.336 0 CA-C-N 115.084 -0.962 . . . . 0.0 110.01 179.919 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 226' ' ' GLN . . . . . . . . . . . . . 57.1 tt0 . . . . . 0 C--O 1.221 -0.438 0 CA-C-O 117.958 -1.02 . . . . 0.0 110.898 179.987 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.22 0 N-CA-C 109.469 -1.453 . . . . 0.0 109.469 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 29.5 m -137.02 -49.87 0.63 Allowed 'General case' 0 N--CA 1.464 0.262 0 CA-C-O 120.615 0.245 . . . . 0.0 110.751 -179.973 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 66.1 tt0 -129.68 119.27 23.24 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-O 120.918 0.39 . . . . 0.0 110.153 -179.877 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.639 ' O ' HG13 ' A' ' 6' ' ' VAL . 7.3 p -145.41 85.44 7.96 Favored Pre-proline 0 C--N 1.332 -0.18 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.396 -179.883 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_exo -56.93 139.37 89.39 Favored 'Trans proline' 0 C--N 1.307 -1.624 0 C-N-CA 122.472 2.115 . . . . 0.0 111.669 -179.784 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 59.5 tt0 -104.76 -21.59 13.34 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.376 179.915 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.535 HD23 ' N ' ' A' ' 10' ' ' THR . 1.9 tt -106.79 112.43 25.4 Favored 'General case' 0 C--O 1.232 0.151 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 -179.769 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 10' ' ' THR . . . . . 0.587 HG21 ' O ' ' A' ' 27' ' ' THR . 9.0 t -97.99 172.78 7.42 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.257 179.936 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 11' ' ' ASP . . . . . 0.424 ' OD1' ' O ' ' A' ' 11' ' ' ASP . 51.2 p-10 -137.4 142.59 41.69 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.996 0.426 . . . . 0.0 110.561 179.961 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 6.9 tt -63.86 142.56 58.36 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.135 -179.542 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 83.9 p -139.4 155.47 47.61 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.665 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' PHE . . . . . 0.563 ' CZ ' HD13 ' B' ' 205' ' ' ILE . 20.9 m-85 -110.79 144.66 39.43 Favored 'General case' 0 C--O 1.233 0.204 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.498 -179.691 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 15.5 m -145.49 162.28 12.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.598 -179.973 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 98.4 m-20 51.6 32.65 9.4 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.524 179.621 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 86.5 mt -58.84 140.29 17.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.267 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.438 ' CB ' ' O ' ' A' ' 21' ' ' SER . 0.2 OUTLIER -143.25 -166.3 2.28 Favored 'General case' 0 N--CA 1.465 0.305 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.601 -179.653 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 19' ' ' ASP . . . . . 0.441 ' OD1' ' N ' ' A' ' 20' ' ' SER . 28.7 p-10 -90.73 -45.25 8.96 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.693 -0.685 . . . . 0.0 110.875 179.546 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 20' ' ' SER . . . . . 0.441 ' N ' ' OD1' ' A' ' 19' ' ' ASP . 10.2 t -114.39 7.17 16.25 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-O 120.821 0.343 . . . . 0.0 110.92 -179.513 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 21' ' ' SER . . . . . 0.438 ' O ' ' CB ' ' A' ' 18' ' ' THR . 45.2 m -151.62 146.52 25.88 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.976 0.417 . . . . 0.0 110.439 179.898 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 22' ' ' ILE . . . . . 0.459 HD12 HD21 ' A' ' 24' ' ' LEU . 40.8 pt -144.98 147.88 18.45 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-N 116.469 -0.332 . . . . 0.0 110.291 179.847 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -101.41 84.04 0.51 Allowed Glycine 0 CA--C 1.525 0.675 0 N-CA-C 111.038 -0.825 . . . . 0.0 111.038 -179.678 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.459 HD21 HD12 ' A' ' 22' ' ' ILE . 83.7 mt -71.39 124.6 24.96 Favored 'General case' 0 C--N 1.33 -0.282 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 -179.752 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 73.8 ttt-85 -138.94 139.92 38.14 Favored 'General case' 0 CA--C 1.52 -0.177 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.464 -179.593 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' TRP . . . . . . . . . . . . . 49.0 p90 -146.48 154.77 41.96 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.073 179.745 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 27' ' ' THR . . . . . 0.587 ' O ' HG21 ' A' ' 10' ' ' THR . 2.9 m -109.97 103.31 53.21 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-N 116.466 -0.334 . . . . 0.0 110.583 179.888 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_exo -53.87 145.03 52.85 Favored 'Trans proline' 0 C--N 1.307 -1.642 0 C-N-CA 122.07 1.846 . . . . 0.0 112.591 179.172 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 64.6 mt -78.91 139.86 38.2 Favored 'General case' 0 CA--C 1.518 -0.252 0 CA-C-O 121.697 0.76 . . . . 0.0 110.789 -179.643 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 38.1 t30 -51.07 -37.1 43.59 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-N 115.131 -0.94 . . . . 0.0 109.916 179.656 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 15.5 m -75.75 -34.86 60.29 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.64 178.975 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 10.8 m -60.11 132.95 55.51 Favored 'General case' 0 C--O 1.232 0.158 0 CA-C-O 120.975 0.417 . . . . 0.0 110.179 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 33' ' ' THR . . . . . 0.503 ' H ' ' HB ' ' A' ' 81' ' ' ILE . 5.6 m -57.78 145.22 35.59 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.17 -179.886 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 26.8 mm -93.99 91.29 3.11 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 CA-C-O 121.012 0.434 . . . . 0.0 110.631 -179.513 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 21.6 pt -143.39 140.41 26.36 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.498 179.707 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -44.33 128.47 6.95 Favored Glycine 0 CA--C 1.521 0.463 0 N-CA-C 111.096 -0.801 . . . . 0.0 111.096 -179.781 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 75.0 m-85 -91.54 175.9 6.74 Favored 'General case' 0 CA--C 1.517 -0.302 0 CA-C-O 120.89 0.376 . . . . 0.0 110.187 179.849 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -137.26 125.49 23.15 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.588 -179.939 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.438 ' O ' ' CG1' ' A' ' 39' ' ' ILE . 2.3 pt -101.68 124.81 55.71 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.251 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.1 -179.97 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 8.4 m -104.07 133.49 48.93 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.384 -179.275 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.3 p -132.98 139.38 49.67 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.296 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.319 179.756 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 42' ' ' VAL . . . . . 0.543 ' N ' ' O ' ' A' ' 74' ' ' ASP . 39.5 t -133.9 132.88 56.58 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.175 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.245 179.74 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.426 ' HB2' ' CE1' ' A' ' 73' ' ' TYR . . . -97.04 141.72 29.85 Favored 'General case' 0 C--N 1.326 -0.414 0 N-CA-C 109.702 -0.481 . . . . 0.0 109.702 179.15 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.501 ' HB3' ' O ' ' A' ' 72' ' ' ASP . . . -95.13 -40.43 9.61 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.821 0.344 . . . . 0.0 110.769 179.659 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -66.17 -32.64 82.87 Favored Glycine 0 CA--C 1.526 0.758 0 N-CA-C 111.295 -0.722 . . . . 0.0 111.295 -179.737 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 63.2 mt-10 -98.16 131.42 44.55 Favored 'General case' 0 C--N 1.333 -0.146 0 N-CA-C 109.598 -0.519 . . . . 0.0 109.598 -179.694 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -59.01 -21.64 53.33 Favored Glycine 0 N--CA 1.454 -0.117 0 N-CA-C 110.609 -0.997 . . . . 0.0 110.609 -179.079 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -111.72 134.46 21.29 Favored Pre-proline 0 CA--C 1.535 0.4 0 C-N-CA 121.133 -0.227 . . . . 0.0 110.474 179.556 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 63.9 Cg_endo -76.71 163.92 30.91 Favored 'Trans proline' 0 C--N 1.31 -1.47 0 C-N-CA 122.638 2.226 . . . . 0.0 111.884 177.751 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 96.6 mt -82.93 133.97 27.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 115.975 -0.557 . . . . 0.0 109.949 179.134 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 76.0 m-85 -56.15 136.54 52.6 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 121.054 0.454 . . . . 0.0 110.824 -179.355 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 4.7 pt-20 -68.79 -175.08 0.65 Allowed 'General case' 0 CA--C 1.516 -0.33 0 CA-C-N 115.706 -0.679 . . . . 0.0 110.372 179.461 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 53' ' ' ASP . . . . . 0.426 ' CG ' ' OH ' ' A' ' 62' ' ' TYR . 3.6 t70 -156.38 156.0 33.14 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.674 179.04 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 54' ' ' PHE . . . . . 0.578 ' CD1' ' N ' ' A' ' 54' ' ' PHE . 2.1 m-85 -122.12 130.85 53.6 Favored 'General case' 0 N--CA 1.465 0.324 0 CA-C-O 120.889 0.376 . . . . 0.0 110.114 179.729 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 9.7 p -130.01 138.19 54.63 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.186 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.418 -179.836 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 97.8 m-20 -53.66 144.33 18.02 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.457 -179.702 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 38.7 t -63.33 -35.81 81.61 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.703 179.994 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 36.6 m -57.11 -31.88 65.76 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.551 -179.717 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 94.0 t -64.96 -46.47 91.57 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.537 -179.913 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 56.19 25.89 48.52 Favored Glycine 0 CA--C 1.525 0.713 0 N-CA-C 110.7 -0.96 . . . . 0.0 110.7 -179.899 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 61' ' ' TYR . . . . . 0.493 ' CD1' ' C ' ' A' ' 61' ' ' TYR . 7.7 t80 -159.52 146.79 16.9 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-O 121.208 0.528 . . . . 0.0 111.035 -179.201 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 62' ' ' TYR . . . . . 0.435 ' CD2' ' CD1' ' A' ' 39' ' ' ILE . 33.9 t80 -159.99 161.79 34.18 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.152 178.611 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 96.5 m -131.15 139.17 49.74 Favored 'General case' 0 N--CA 1.464 0.244 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.689 179.995 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -131.14 104.63 9.5 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.263 0 CA-C-N 116.188 -0.46 . . . . 0.0 109.982 179.061 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 4.6 p -109.05 155.45 20.92 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.342 179.78 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 108.32 44.38 1.17 Allowed Glycine 0 CA--C 1.525 0.682 0 N-CA-C 111.184 -0.766 . . . . 0.0 111.184 -179.705 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 19.9 mt -116.45 103.57 10.58 Favored 'General case' 0 CA--C 1.519 -0.222 0 CA-C-O 121.194 0.521 . . . . 0.0 109.827 179.679 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 55.4 mm-40 -51.24 138.19 27.68 Favored Pre-proline 0 C--N 1.317 -0.806 0 CA-C-N 115.783 -0.644 . . . . 0.0 111.44 -178.433 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 69' ' ' PRO . . . . . 0.41 ' O ' HD12 ' A' ' 71' ' ' ILE . 72.1 Cg_endo -75.35 150.54 36.82 Favored 'Trans proline' 0 N--CA 1.496 1.665 0 C-N-CA 122.725 2.284 . . . . 0.0 111.635 178.687 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 70.69 17.32 74.86 Favored Glycine 0 CA--C 1.527 0.803 0 CA-C-N 115.55 -0.75 . . . . 0.0 111.361 179.14 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 71' ' ' ILE . . . . . 0.41 HD12 ' O ' ' A' ' 69' ' ' PRO . 1.5 mp -119.66 149.62 22.27 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.337 0 CA-C-O 121.413 0.625 . . . . 0.0 109.36 -179.503 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 72' ' ' ASP . . . . . 0.501 ' O ' ' HB3' ' A' ' 44' ' ' ALA . 2.4 t70 -89.39 108.97 19.94 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.15 -0.932 . . . . 0.0 110.652 -179.902 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 73' ' ' TYR . . . . . 0.554 ' O ' HD13 ' A' ' 75' ' ' ILE . 22.4 m-85 -104.3 119.53 39.17 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.348 179.772 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 74' ' ' ASP . . . . . 0.543 ' O ' ' N ' ' A' ' 42' ' ' VAL . 8.5 m-20 -88.2 118.43 27.78 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.531 -0.758 . . . . 0.0 109.247 179.466 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.624 HD11 ' N ' ' B' ' 223' ' ' ARG . 0.0 OUTLIER -120.02 167.22 13.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-O 121.098 0.475 . . . . 0.0 110.272 -179.124 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 1.8 m -154.92 126.92 7.64 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.622 -0.717 . . . . 0.0 110.591 179.248 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.486 ' O ' HG23 ' B' ' 217' ' ' THR . 21.7 t -106.02 100.26 10.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 179.178 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 78' ' ' ILE . . . . . 0.427 HG22 ' CD2' ' A' ' 80' ' ' LEU . 23.8 mt -101.9 140.9 19.27 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.225 0 CA-C-N 116.052 -0.522 . . . . 0.0 109.909 -179.651 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 79' ' ' THR . . . . . 0.48 ' C ' HD22 ' A' ' 80' ' ' LEU . 19.5 m -120.05 113.59 20.73 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.571 -179.767 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 80' ' ' LEU . . . . . 0.48 HD22 ' C ' ' A' ' 79' ' ' THR . 4.4 mm? -106.68 127.93 53.77 Favored 'General case' 0 N--CA 1.463 0.22 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.434 179.796 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 81' ' ' ILE . . . . . 0.503 ' HB ' ' H ' ' A' ' 33' ' ' THR . 1.9 pp -141.38 145.01 25.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 115.632 -0.713 . . . . 0.0 110.219 179.565 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 82' ' ' ASN . . . . . 0.409 ' H ' ' CB ' ' A' ' 33' ' ' THR . 37.6 t30 -56.24 -66.18 0.48 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.707 -179.73 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 157.44 103.36 0.2 Allowed Glycine 0 CA--C 1.522 0.53 0 N-CA-C 110.873 -0.891 . . . . 0.0 110.873 179.849 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -90.4 177.36 42.38 Favored Glycine 0 CA--C 1.524 0.607 0 N-CA-C 110.827 -0.909 . . . . 0.0 110.827 179.919 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.48 ' OE1' ' N ' ' A' ' 85' ' ' GLU . 55.9 mp0 -80.96 122.66 27.54 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.86 0.362 . . . . 0.0 110.466 -179.944 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 83.0 p -74.3 157.89 34.99 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.409 -179.913 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.495 ' HB1' ' HD2' ' A' ' 88' ' ' PRO . . . -78.11 160.46 73.46 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.364 -179.807 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 88' ' ' PRO . . . . . 0.495 ' HD2' ' HB1' ' A' ' 87' ' ' ALA . 44.7 Cg_endo -68.83 -14.51 39.1 Favored 'Trans proline' 0 C--N 1.309 -1.551 0 C-N-CA 122.857 2.372 . . . . 0.0 111.956 179.347 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 4.9 t -141.83 161.87 36.89 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.565 -179.632 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 68.5 p -132.07 152.35 51.24 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.434 179.94 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 91' ' ' LEU . . . . . 0.577 HD12 ' N ' ' A' ' 91' ' ' LEU . 10.1 mp -93.14 144.09 25.62 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.406 -179.855 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 34.6 p -64.8 137.31 57.7 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.066 -0.516 . . . . 0.0 110.329 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 29.2 pt20 -95.34 160.76 14.38 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.553 179.917 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 45.5 tt0 63.09 -125.87 0.59 Allowed 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.175 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 15.8 p . . . . . 0 C--O 1.222 -0.361 0 CA-C-O 117.892 -1.051 . . . . 0.0 110.335 179.983 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' B' B ' 201' ' ' SER . . . . . . . . . . . . . 57.6 p . . . . . 0 N--CA 1.49 1.534 0 N-CA-C 109.323 -0.621 . . . . 0.0 109.323 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' B' B ' 202' ' ' SER . . . . . . . . . . . . . 41.5 t -70.58 138.13 50.62 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.185 179.903 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 203' ' ' SER . . . . . . . . . . . . . 10.3 m -111.2 150.13 41.55 Favored Pre-proline 0 CA--C 1.532 0.274 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.578 179.921 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 204' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_exo -41.25 -33.91 1.56 Allowed 'Trans proline' 0 C--N 1.312 -1.38 0 C-N-CA 122.771 2.314 . . . . 0.0 112.165 179.432 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 205' ' ' ILE . . . . . 0.563 HD13 ' CZ ' ' A' ' 14' ' ' PHE . 11.7 tt -152.79 159.02 3.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.266 179.883 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 206' ' ' GLN . . . . . 0.427 ' N ' ' CG1' ' B' ' 205' ' ' ILE . 9.2 pt20 -170.68 78.66 0.08 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.463 179.25 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 207' ' ' GLY . . . . . . . . . . . . . . . -110.32 -147.3 11.38 Favored Glycine 0 N--CA 1.464 0.555 0 N-CA-C 111.088 -0.805 . . . . 0.0 111.088 -179.936 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 208' ' ' SER . . . . . 0.432 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 92.3 p -165.37 171.57 13.28 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.866 0.365 . . . . 0.0 110.746 -179.922 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 209' ' ' TRP . . . . . . . . . . . . . 80.0 m95 -81.43 146.18 30.39 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.456 179.784 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 65.2 p -128.76 132.42 47.92 Favored 'General case' 0 N--CA 1.464 0.255 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.616 -179.951 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 50.3 t-105 -91.94 116.54 29.01 Favored 'General case' 0 C--O 1.232 0.15 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.241 179.649 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 212' ' ' GLU . . . . . 0.489 ' O ' ' O ' ' B' ' 215' ' ' LYS . 1.7 pt-20 -165.46 168.19 16.85 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.972 179.261 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 213' ' ' ASN . . . . . . . . . . . . . 91.8 m-20 49.51 36.73 10.72 Favored 'General case' 0 C--N 1.322 -0.602 0 C-N-CA 120.525 -0.47 . . . . 0.0 111.217 176.634 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 50.86 16.32 1.71 Allowed Glycine 0 CA--C 1.525 0.671 0 N-CA-C 111.266 -0.734 . . . . 0.0 111.266 179.658 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 215' ' ' LYS . . . . . 0.489 ' O ' ' O ' ' B' ' 212' ' ' GLU . 50.3 mtmt -145.66 151.45 38.07 Favored 'General case' 0 C--N 1.333 -0.142 0 CA-C-O 120.942 0.401 . . . . 0.0 110.81 179.704 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 216' ' ' TRP . . . . . . . . . . . . . 53.8 m95 -87.79 123.3 32.43 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.044 179.58 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 217' ' ' THR . . . . . 0.486 HG23 ' O ' ' A' ' 77' ' ' VAL . 12.9 m -133.7 145.21 49.69 Favored 'General case' 0 N--CA 1.464 0.269 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.502 -179.607 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 218' ' ' TRP . . . . . 0.432 ' CH2' ' N ' ' B' ' 208' ' ' SER . 14.4 t-105 -106.08 119.58 39.58 Favored 'General case' 0 N--CA 1.463 0.175 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.018 179.188 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 47.3 mtpt -141.26 169.79 16.95 Favored 'General case' 0 CA--C 1.52 -0.198 0 CA-C-O 120.92 0.39 . . . . 0.0 110.464 -179.49 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -176.04 -161.38 25.12 Favored Glycine 0 CA--C 1.526 0.732 0 N-CA-C 111.279 -0.729 . . . . 0.0 111.279 -179.883 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 221' ' ' ILE . . . . . 0.58 ' H ' HD12 ' B' ' 221' ' ' ILE . 2.2 mp -51.03 -73.24 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 C-N-CA 120.678 -0.409 . . . . 0.0 110.679 -178.283 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 222' ' ' ILE . . . . . 0.552 HG23 ' O ' ' B' ' 221' ' ' ILE . 21.8 pt -159.75 -166.34 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.624 -179.584 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 223' ' ' ARG . . . . . 0.624 ' N ' HD11 ' A' ' 75' ' ' ILE . 46.9 ptt85 -46.03 178.32 0.0 OUTLIER 'General case' 0 CA--C 1.516 -0.337 0 CA-C-N 115.756 -0.657 . . . . 0.0 110.563 179.281 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 224' ' ' LEU . . . . . 0.688 HD22 ' N ' ' B' ' 224' ' ' LEU . 3.1 mm? -59.41 121.71 12.16 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 115.687 -0.688 . . . . 0.0 110.533 -179.135 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 78.5 tt0 -104.2 152.87 21.64 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.4 179.986 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 226' ' ' GLN . . . . . . . . . . . . . 35.8 mt-30 . . . . . 0 C--O 1.219 -0.517 0 CA-C-O 118.023 -0.989 . . . . 0.0 110.583 -179.868 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.246 0 N-CA-C 109.431 -1.468 . . . . 0.0 109.431 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 25.8 t 54.07 78.91 0.15 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.834 0.35 . . . . 0.0 110.52 -179.868 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 80.3 mm-40 -109.7 120.4 42.37 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.43 -179.906 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.4 HG22 ' H ' ' A' ' 6' ' ' VAL . 1.2 m -88.98 151.09 46.6 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.451 -179.644 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 41.6 Cg_endo -66.56 148.74 83.97 Favored 'Trans proline' 0 C--N 1.311 -1.437 0 C-N-CA 122.702 2.268 . . . . 0.0 111.865 179.556 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 77.9 mt-30 -127.24 121.64 31.77 Favored 'General case' 0 N--CA 1.464 0.256 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.31 179.618 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.578 HD12 ' N ' ' A' ' 9' ' ' LEU . 9.1 mp -90.13 130.61 36.27 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.043 -0.526 . . . . 0.0 109.855 -179.962 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -87.64 133.49 33.81 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.203 -179.957 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 54.7 p30 -79.77 163.24 24.61 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.667 -179.77 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 70.4 mt -63.57 151.89 40.25 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.343 -179.291 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 85.9 p -141.13 149.83 42.04 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-N 116.059 -0.518 . . . . 0.0 110.31 179.916 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' PHE . . . . . 0.519 ' CD1' ' N ' ' A' ' 14' ' ' PHE . 18.3 m-85 -111.37 145.8 38.26 Favored 'General case' 0 N--CA 1.464 0.235 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.569 -179.627 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 18.2 m -147.71 161.75 7.36 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.117 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.495 179.88 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 41.0 t0 56.06 29.32 14.29 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.66 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 96.5 mt -56.19 138.97 16.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.249 179.797 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.45 ' CB ' ' O ' ' A' ' 21' ' ' SER . 0.2 OUTLIER -139.96 -167.12 2.23 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.479 -179.69 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 19' ' ' ASP . . . . . 0.506 ' OD1' ' N ' ' A' ' 20' ' ' SER . 32.3 p-10 -89.63 -43.47 10.73 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.731 179.601 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 20' ' ' SER . . . . . 0.506 ' N ' ' OD1' ' A' ' 19' ' ' ASP . 10.2 t -117.54 8.75 13.0 Favored 'General case' 0 N--CA 1.465 0.317 0 CA-C-O 120.754 0.312 . . . . 0.0 110.889 -179.716 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 21' ' ' SER . . . . . 0.45 ' O ' ' CB ' ' A' ' 18' ' ' THR . 18.2 p -150.56 137.69 19.36 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.974 0.416 . . . . 0.0 110.35 -179.919 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 41.9 pt -132.07 145.68 34.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.467 -0.333 . . . . 0.0 110.159 179.921 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -97.86 81.96 0.66 Allowed Glycine 0 CA--C 1.525 0.675 0 N-CA-C 110.965 -0.854 . . . . 0.0 110.965 -179.805 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 94.9 mt -70.95 119.5 15.16 Favored 'General case' 0 C--N 1.33 -0.274 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 -179.882 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 70.1 ttt180 -138.15 142.08 40.11 Favored 'General case' 0 CA--C 1.519 -0.229 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.988 179.901 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 26' ' ' TRP . . . . . 0.543 ' CD2' ' O ' ' A' ' 60' ' ' GLY . 25.4 p90 -143.11 156.08 44.73 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.763 -0.653 . . . . 0.0 109.977 -179.87 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 3.2 m -109.84 101.96 48.71 Favored Pre-proline 0 N--CA 1.465 0.322 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.757 179.828 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 42.4 Cg_exo -54.94 144.57 67.07 Favored 'Trans proline' 0 C--N 1.304 -1.769 0 C-N-CA 122.108 1.872 . . . . 0.0 112.34 179.153 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 65.8 mt -83.47 139.77 32.73 Favored 'General case' 0 CA--C 1.52 -0.196 0 CA-C-O 121.813 0.816 . . . . 0.0 110.718 179.801 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 26.0 t-20 -47.94 -33.05 7.14 Favored 'General case' 0 C--N 1.319 -0.75 0 CA-C-N 115.268 -0.878 . . . . 0.0 110.19 -179.914 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 52.5 m -84.86 -30.9 24.08 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.627 179.506 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 4.9 m -58.15 131.23 49.92 Favored 'General case' 0 N--CA 1.462 0.144 0 CA-C-O 121.25 0.547 . . . . 0.0 110.444 179.912 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 33' ' ' THR . . . . . 0.461 ' HG1' ' H ' ' A' ' 83' ' ' GLY . 3.9 m -59.78 140.17 56.75 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.505 -0.77 . . . . 0.0 110.021 -179.801 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 58.2 mt -94.11 92.26 3.47 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.19 0 CA-C-O 120.865 0.364 . . . . 0.0 110.774 -179.778 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.433 ' O ' ' OG ' ' A' ' 57' ' ' SER . 9.5 pt -142.29 131.85 23.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.43 179.408 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -37.95 114.85 0.33 Allowed Glycine 0 CA--C 1.523 0.553 0 N-CA-C 111.442 -0.663 . . . . 0.0 111.442 -179.297 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 96.5 m-85 -79.8 177.27 9.02 Favored 'General case' 0 CA--C 1.515 -0.392 0 N-CA-C 110.019 -0.363 . . . . 0.0 110.019 -179.901 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 5.5 tmm_? -135.01 126.21 28.09 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.039 179.922 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 6.5 pt -95.35 155.33 3.33 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.391 0 N-CA-C 109.472 -0.566 . . . . 0.0 109.472 179.892 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 3.4 m -136.29 131.34 34.28 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.627 0.251 . . . . 0.0 110.624 -179.713 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.691 HG22 HD13 ' A' ' 50' ' ' ILE . 2.1 p -134.56 137.82 50.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.314 179.464 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 42' ' ' VAL . . . . . 0.538 ' N ' ' O ' ' A' ' 74' ' ' ASP . 41.5 t -134.83 135.92 52.66 Favored 'Isoleucine or valine' 0 C--O 1.23 0.058 0 CA-C-N 116.509 -0.314 . . . . 0.0 110.369 179.621 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.787 ' HB2' HD11 ' A' ' 50' ' ' ILE . . . -97.3 138.05 35.36 Favored 'General case' 0 C--N 1.33 -0.269 0 N-CA-C 109.628 -0.508 . . . . 0.0 109.628 179.231 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.518 ' HB3' ' O ' ' A' ' 72' ' ' ASP . . . -90.54 -47.51 7.65 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.783 0.325 . . . . 0.0 110.708 179.723 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -61.64 -29.39 71.84 Favored Glycine 0 CA--C 1.525 0.711 0 N-CA-C 111.084 -0.806 . . . . 0.0 111.084 -179.863 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 91.2 mt-10 -95.94 127.56 42.06 Favored 'General case' 0 CA--C 1.52 -0.203 0 N-CA-C 109.357 -0.609 . . . . 0.0 109.357 -179.424 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -59.2 -22.0 54.69 Favored Glycine 0 CA--C 1.508 -0.389 0 N-CA-C 110.82 -0.912 . . . . 0.0 110.82 -179.229 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -110.16 135.04 20.58 Favored Pre-proline 0 CA--C 1.539 0.543 0 C-N-CA 120.858 -0.337 . . . . 0.0 110.235 179.702 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 62.3 Cg_endo -75.8 167.8 25.56 Favored 'Trans proline' 0 C--N 1.309 -1.517 0 C-N-CA 122.605 2.203 . . . . 0.0 111.732 177.344 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 50' ' ' ILE . . . . . 0.88 ' H ' HD12 ' A' ' 50' ' ' ILE . 1.7 mp -91.58 144.85 8.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 115.598 -0.728 . . . . 0.0 110.152 179.526 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 96.0 m-85 -65.84 142.2 58.01 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.702 -179.534 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 52' ' ' GLU . . . . . 0.578 ' CD ' ' H ' ' A' ' 52' ' ' GLU . 0.0 OUTLIER -73.87 -176.84 2.59 Favored 'General case' 0 CA--C 1.514 -0.424 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.602 179.664 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 3.6 t70 -151.45 147.45 26.88 Favored 'General case' 0 N--CA 1.452 -0.34 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.78 179.475 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 54.2 m-85 -115.7 124.8 51.76 Favored 'General case' 0 N--CA 1.463 0.219 0 CA-C-N 116.466 -0.334 . . . . 0.0 110.204 179.725 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 9.9 p -127.4 136.52 60.35 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.211 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.425 -179.886 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 99.8 m-20 -57.15 145.7 30.4 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.015 -0.538 . . . . 0.0 110.502 -179.707 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 57' ' ' SER . . . . . 0.433 ' OG ' ' O ' ' A' ' 35' ' ' ILE . 35.3 m -59.49 -33.46 71.36 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.61 179.917 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 49.5 m -52.68 -35.92 56.12 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.596 -179.901 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.522 HG12 ' O ' ' A' ' 61' ' ' TYR . 21.2 t -69.68 -43.72 79.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.348 179.853 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 60' ' ' GLY . . . . . 0.543 ' O ' ' CD2' ' A' ' 26' ' ' TRP . . . 68.68 -43.94 0.36 Allowed Glycine 0 CA--C 1.531 1.046 0 N-CA-C 110.943 -0.863 . . . . 0.0 110.943 179.903 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 61' ' ' TYR . . . . . 0.522 ' O ' HG12 ' A' ' 59' ' ' VAL . 25.0 p90 -102.49 157.71 16.73 Favored 'General case' 0 N--CA 1.463 0.223 0 CA-C-O 121.257 0.551 . . . . 0.0 111.139 -179.208 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 32.5 t80 -156.67 160.33 39.26 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.979 -0.555 . . . . 0.0 109.907 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 91.2 m -123.45 136.04 54.4 Favored 'General case' 0 C--O 1.233 0.206 0 CA-C-O 120.887 0.375 . . . . 0.0 110.699 -179.882 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -132.01 99.68 3.81 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 CA-C-N 116.035 -0.53 . . . . 0.0 109.818 179.249 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 2.2 p -106.73 159.25 16.36 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.91 0.386 . . . . 0.0 110.6 179.91 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 108.74 41.47 1.45 Allowed Glycine 0 CA--C 1.523 0.544 0 N-CA-C 111.41 -0.676 . . . . 0.0 111.41 -179.674 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 10.3 mt -116.43 107.88 15.34 Favored 'General case' 0 CA--C 1.517 -0.307 0 CA-C-O 121.346 0.593 . . . . 0.0 109.728 -179.868 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 53.0 mm-40 -53.85 136.07 55.95 Favored Pre-proline 0 C--N 1.318 -0.795 0 CA-C-N 115.611 -0.722 . . . . 0.0 111.622 -178.209 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo -75.34 155.43 41.37 Favored 'Trans proline' 0 N--CA 1.498 1.774 0 C-N-CA 122.952 2.434 . . . . 0.0 111.722 178.783 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 71.66 8.37 67.33 Favored Glycine 0 CA--C 1.526 0.777 0 CA-C-N 115.375 -0.829 . . . . 0.0 111.477 179.153 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 1.6 mp -118.03 145.4 24.0 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.298 0 CA-C-O 121.541 0.686 . . . . 0.0 109.381 -179.416 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 72' ' ' ASP . . . . . 0.518 ' O ' ' HB3' ' A' ' 44' ' ' ALA . 2.9 t70 -82.13 112.53 19.25 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-N 114.768 -1.105 . . . . 0.0 110.829 -179.579 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 73' ' ' TYR . . . . . 0.547 ' O ' HD13 ' A' ' 75' ' ' ILE . 13.3 m-85 -105.29 120.57 41.89 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.507 179.648 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 74' ' ' ASP . . . . . 0.538 ' O ' ' N ' ' A' ' 42' ' ' VAL . 74.0 m-20 -88.48 117.62 27.55 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.338 -0.846 . . . . 0.0 109.417 179.808 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.562 HD11 ' N ' ' B' ' 223' ' ' ARG . 0.0 OUTLIER -117.97 163.57 15.03 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.362 0 CA-C-O 121.075 0.464 . . . . 0.0 110.011 -179.194 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -154.91 123.5 6.08 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.42 -0.809 . . . . 0.0 110.583 179.29 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 88.5 t -102.14 104.15 16.02 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 178.709 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 92.8 mt -96.95 132.71 40.79 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.224 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.349 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 79' ' ' THR . . . . . 0.609 HG23 ' O ' ' A' ' 79' ' ' THR . 14.0 t -112.15 120.25 41.17 Favored 'General case' 0 CA--C 1.514 -0.41 0 CA-C-N 116.173 -0.467 . . . . 0.0 109.946 -179.823 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 80' ' ' LEU . . . . . 0.577 HD13 ' N ' ' A' ' 81' ' ' ILE . 0.2 OUTLIER -121.54 115.46 22.87 Favored 'General case' 0 N--CA 1.464 0.234 0 CA-C-N 116.306 -0.407 . . . . 0.0 110.422 -179.781 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 81' ' ' ILE . . . . . 0.577 ' N ' HD13 ' A' ' 80' ' ' LEU . 1.9 pp -138.25 145.14 28.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.268 -0.424 . . . . 0.0 109.921 179.049 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 82' ' ' ASN . . . . . 0.406 ' H ' ' CB ' ' A' ' 33' ' ' THR . 60.7 t30 -65.34 -58.85 4.88 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.792 179.965 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 83' ' ' GLY . . . . . 0.461 ' H ' ' HG1' ' A' ' 33' ' ' THR . . . 63.66 69.76 1.24 Allowed Glycine 0 CA--C 1.523 0.553 0 N-CA-C 110.881 -0.888 . . . . 0.0 110.881 179.897 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -46.29 123.02 6.69 Favored Glycine 0 CA--C 1.523 0.577 0 N-CA-C 110.806 -0.918 . . . . 0.0 110.806 -179.942 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -93.25 148.21 22.24 Favored 'General case' 0 N--CA 1.463 0.194 0 CA-C-O 120.801 0.334 . . . . 0.0 110.475 -179.923 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 21.1 m -66.21 144.79 56.41 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.37 -179.851 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . 58.64 74.83 0.57 Allowed Pre-proline 0 C--N 1.329 -0.293 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.591 179.956 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_exo -59.34 144.38 99.42 Favored 'Trans proline' 0 C--N 1.305 -1.737 0 C-N-CA 122.942 2.428 . . . . 0.0 111.982 179.793 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 4.6 p -83.86 164.48 19.44 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.128 -179.901 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 75.8 m -130.01 133.95 47.09 Favored 'General case' 0 N--CA 1.465 0.284 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.647 -179.94 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 91' ' ' LEU . . . . . 0.593 HD12 ' N ' ' A' ' 91' ' ' LEU . 8.8 mp -73.31 132.7 43.4 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.137 -179.736 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 61.6 p -84.21 166.89 17.18 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.516 179.919 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 28.9 mm100 -60.16 100.42 0.09 Allowed 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.284 -0.417 . . . . 0.0 110.514 179.99 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 52.0 mt-30 -64.74 -40.2 94.91 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.577 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 13.2 m . . . . . 0 C--O 1.219 -0.501 0 CA-C-O 117.804 -1.093 . . . . 0.0 110.374 -179.91 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' B' B ' 201' ' ' SER . . . . . . . . . . . . . 65.0 p . . . . . 0 N--CA 1.491 1.599 0 N-CA-C 109.291 -0.633 . . . . 0.0 109.291 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' B' B ' 202' ' ' SER . . . . . . . . . . . . . 88.3 p -66.65 153.29 43.52 Favored 'General case' 0 CA--C 1.515 -0.386 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.3 -179.901 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 203' ' ' SER . . . . . . . . . . . . . 4.8 p -107.7 150.63 40.46 Favored Pre-proline 0 CA--C 1.538 0.492 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.575 -179.857 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 204' ' ' PRO . . . . . . . . . . . . . 74.8 Cg_exo -45.67 -48.02 12.74 Favored 'Trans proline' 0 N--CA 1.494 1.505 0 C-N-CA 122.226 1.95 . . . . 0.0 112.182 179.424 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 205' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -151.36 147.35 15.51 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.469 179.825 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 206' ' ' GLN . . . . . . . . . . . . . 14.3 pt20 -143.06 144.17 32.15 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.465 -0.334 . . . . 0.0 110.509 178.943 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 207' ' ' GLY . . . . . 0.416 ' C ' ' CH2' ' B' ' 218' ' ' TRP . . . -105.67 -135.59 8.25 Favored Glycine 0 N--CA 1.465 0.62 0 N-CA-C 110.99 -0.844 . . . . 0.0 110.99 179.827 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 208' ' ' SER . . . . . 0.535 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 52.0 p -166.46 171.81 11.5 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.711 0.291 . . . . 0.0 110.703 179.664 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 209' ' ' TRP . . . . . . . . . . . . . 42.6 m95 -85.22 147.33 26.64 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.504 179.052 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 51.1 p -129.47 129.86 45.13 Favored 'General case' 0 C--O 1.232 0.176 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.7 179.876 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 42.5 t-105 -91.82 118.11 30.4 Favored 'General case' 0 C--N 1.334 -0.074 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.137 179.801 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 212' ' ' GLU . . . . . 0.443 ' O ' ' O ' ' B' ' 215' ' ' LYS . 1.0 OUTLIER -166.09 168.44 15.47 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.829 179.321 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' B' B ' 213' ' ' ASN . . . . . . . . . . . . . 93.1 m-20 49.47 37.55 12.36 Favored 'General case' 0 C--N 1.323 -0.566 0 C-N-CA 120.471 -0.492 . . . . 0.0 111.404 176.671 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 49.61 17.1 1.21 Allowed Glycine 0 CA--C 1.526 0.744 0 N-CA-C 111.337 -0.705 . . . . 0.0 111.337 179.703 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 215' ' ' LYS . . . . . 0.443 ' O ' ' O ' ' B' ' 212' ' ' GLU . 53.0 mtmt -142.99 150.25 39.4 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-O 121.169 0.509 . . . . 0.0 110.798 179.935 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 216' ' ' TRP . . . . . 0.534 ' O ' HG22 ' A' ' 79' ' ' THR . 59.5 m95 -89.49 118.48 29.17 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.012 -0.54 . . . . 0.0 109.818 179.631 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 217' ' ' THR . . . . . . . . . . . . . 17.7 m -131.23 144.51 51.38 Favored 'General case' 0 N--CA 1.466 0.328 0 CA-C-O 120.924 0.392 . . . . 0.0 110.524 -179.634 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 218' ' ' TRP . . . . . 0.535 ' CH2' ' N ' ' B' ' 208' ' ' SER . 12.0 t-105 -104.83 117.4 33.97 Favored 'General case' 0 C--N 1.328 -0.346 0 N-CA-C 109.532 -0.544 . . . . 0.0 109.532 179.262 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 50.5 mtpt -142.98 168.77 18.93 Favored 'General case' 0 CA--C 1.518 -0.253 0 CA-C-O 121.112 0.482 . . . . 0.0 110.485 -179.275 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -175.76 -162.25 26.5 Favored Glycine 0 CA--C 1.523 0.571 0 CA-C-N 115.603 -0.726 . . . . 0.0 111.389 -179.861 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 221' ' ' ILE . . . . . 0.521 ' O ' HG23 ' B' ' 222' ' ' ILE . 0.8 OUTLIER -53.34 -75.96 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 C-N-CA 120.641 -0.423 . . . . 0.0 110.872 -178.648 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' B' B ' 222' ' ' ILE . . . . . 0.521 HG23 ' O ' ' B' ' 221' ' ' ILE . 23.1 pt -158.97 -165.37 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.323 -179.232 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 223' ' ' ARG . . . . . 0.562 ' N ' HD11 ' A' ' 75' ' ' ILE . 52.7 ptt85 -42.94 172.87 0.0 OUTLIER 'General case' 0 C--O 1.234 0.276 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.299 179.133 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 224' ' ' LEU . . . . . 0.872 ' H ' HD22 ' B' ' 224' ' ' LEU . 1.7 mm? -68.37 111.59 4.72 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-O 121.296 0.57 . . . . 0.0 110.461 -179.378 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 26.7 tp10 -82.63 151.04 26.48 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.196 -0.911 . . . . 0.0 110.37 179.745 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 226' ' ' GLN . . . . . . . . . . . . . 94.5 mt-30 . . . . . 0 C--N 1.326 -0.448 0 CA-C-O 117.938 -1.029 . . . . 0.0 110.654 -179.823 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.174 0 N-CA-C 109.538 -1.425 . . . . 0.0 109.538 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 87.8 p -155.08 129.31 8.93 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.802 0.334 . . . . 0.0 110.385 179.799 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 72.0 mm-40 -108.62 76.43 1.02 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.218 -0.446 . . . . 0.0 109.93 179.66 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 22.4 t -76.61 116.6 58.03 Favored Pre-proline 0 CA--C 1.539 0.526 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.823 -179.674 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_exo -55.37 128.11 29.08 Favored 'Trans proline' 0 N--CA 1.5 1.901 0 C-N-CA 121.646 1.564 . . . . 0.0 112.077 179.341 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' GLN . . . . . 0.426 ' H ' ' H ' ' A' ' 9' ' ' LEU . 0.5 OUTLIER 170.67 -0.75 0.0 OUTLIER 'General case' 0 N--CA 1.465 0.297 0 CA-C-O 120.694 0.283 . . . . 0.0 110.465 179.312 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.527 HD12 ' N ' ' A' ' 9' ' ' LEU . 10.6 mp -91.04 122.12 33.43 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 120.952 0.406 . . . . 0.0 109.908 179.851 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 33.9 p -107.9 125.3 51.32 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.421 -179.861 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -88.82 143.27 27.01 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.446 179.715 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.403 HD23 ' N ' ' A' ' 12' ' ' LEU . 0.1 OUTLIER -74.18 153.26 39.57 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 114.965 -1.016 . . . . 0.0 109.806 -179.923 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 49.1 p -140.1 154.8 47.14 Favored 'General case' 0 C--N 1.333 -0.13 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.28 179.056 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' PHE . . . . . 0.472 ' CD1' ' N ' ' A' ' 14' ' ' PHE . 32.2 m-85 -103.69 146.35 28.73 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.562 -179.645 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 20.8 m -149.17 162.81 4.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.251 -0.432 . . . . 0.0 110.373 179.863 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 97.4 m-20 54.85 26.97 8.35 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.769 179.991 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 96.6 mt -56.06 136.16 18.87 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-O 121.007 0.432 . . . . 0.0 110.085 179.951 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.653 ' HG1' ' H ' ' A' ' 21' ' ' SER . 1.1 p -135.62 -166.79 1.91 Allowed 'General case' 0 CA--C 1.511 -0.548 0 CA-C-N 115.678 -0.692 . . . . 0.0 110.137 -179.977 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 19' ' ' ASP . . . . . 0.532 ' OD1' ' N ' ' A' ' 20' ' ' SER . 37.0 p-10 -90.46 -41.45 11.43 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.244 -0.889 . . . . 0.0 111.12 178.979 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 20' ' ' SER . . . . . 0.532 ' N ' ' OD1' ' A' ' 19' ' ' ASP . 5.7 t -114.8 9.44 16.3 Favored 'General case' 0 N--CA 1.468 0.432 0 CA-C-N 116.323 -0.398 . . . . 0.0 110.984 -179.012 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 21' ' ' SER . . . . . 0.653 ' H ' ' HG1' ' A' ' 18' ' ' THR . 27.9 p -154.85 158.05 38.79 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.118 179.61 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 42.9 pt -148.69 148.83 15.59 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.15 -179.912 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -100.88 78.82 0.42 Allowed Glycine 0 N--CA 1.467 0.721 0 N-CA-C 110.889 -0.884 . . . . 0.0 110.889 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.442 ' O ' ' CD1' ' A' ' 61' ' ' TYR . 20.9 mt -63.78 130.65 45.05 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.875 0.369 . . . . 0.0 110.233 -179.474 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 18.0 tpt180 -144.72 134.21 23.26 Favored 'General case' 0 CA--C 1.515 -0.372 0 CA-C-O 121.302 0.572 . . . . 0.0 110.201 -179.61 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 26' ' ' TRP . . . . . . . . . . . . . 39.8 p90 -147.82 153.83 39.68 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.082 -0.963 . . . . 0.0 110.015 179.213 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 3.1 m -110.32 100.61 45.19 Favored Pre-proline 0 CA--C 1.532 0.266 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.652 -179.964 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_exo -54.32 149.44 37.41 Favored 'Trans proline' 0 C--N 1.305 -1.752 0 C-N-CA 121.505 1.47 . . . . 0.0 112.877 179.347 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 64.1 mt -79.98 135.81 36.48 Favored 'General case' 0 CA--C 1.513 -0.471 0 CA-C-O 121.906 0.86 . . . . 0.0 110.67 -179.833 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 37.8 t30 -49.81 -34.88 20.92 Favored 'General case' 0 C--N 1.312 -1.054 0 CA-C-N 114.814 -1.084 . . . . 0.0 110.116 179.971 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 63.5 m -78.55 -33.74 47.59 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.721 -0.672 . . . . 0.0 110.784 179.027 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 4.9 m -57.87 133.82 55.77 Favored 'General case' 0 N--CA 1.462 0.147 0 CA-C-O 121.132 0.492 . . . . 0.0 110.138 -179.857 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 33' ' ' THR . . . . . 0.518 ' OG1' ' N ' ' A' ' 82' ' ' ASN . 5.2 m -58.33 143.55 44.52 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.84 -0.618 . . . . 0.0 109.845 -179.801 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 20.9 mm -94.19 90.97 2.95 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-O 120.925 0.393 . . . . 0.0 110.802 -179.428 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.466 ' O ' ' OG ' ' A' ' 57' ' ' SER . 8.8 pt -143.36 127.02 13.67 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.212 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.204 179.582 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -40.58 121.27 1.81 Allowed Glycine 0 CA--C 1.521 0.441 0 N-CA-C 111.372 -0.691 . . . . 0.0 111.372 -179.571 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 37' ' ' TYR . . . . . 0.443 ' CE2' ' OG ' ' A' ' 57' ' ' SER . 98.9 m-85 -85.37 178.26 7.52 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.548 -0.326 . . . . 0.0 110.168 179.796 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 6.6 tmm_? -131.44 128.52 39.67 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.448 179.741 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.479 ' CD1' ' CD2' ' A' ' 62' ' ' TYR . 1.8 pt -101.24 123.56 54.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.045 179.827 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 11.8 m -103.67 130.46 51.14 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.441 -0.345 . . . . 0.0 110.44 -179.862 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.1 p -128.59 138.12 55.47 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.55 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.023 179.919 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 42' ' ' VAL . . . . . 0.513 ' O ' ' N ' ' A' ' 74' ' ' ASP . 39.2 t -132.19 130.96 61.04 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.319 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 179.486 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.471 ' HB2' ' CE2' ' A' ' 73' ' ' TYR . . . -95.87 141.09 29.72 Favored 'General case' 0 C--N 1.324 -0.516 0 N-CA-C 109.207 -0.664 . . . . 0.0 109.207 179.199 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.491 ' HB3' ' O ' ' A' ' 72' ' ' ASP . . . -93.84 -39.4 10.73 Favored 'General case' 0 C--N 1.327 -0.371 0 C-N-CA 120.652 -0.419 . . . . 0.0 110.69 179.652 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -66.13 -31.2 78.56 Favored Glycine 0 CA--C 1.526 0.78 0 N-CA-C 111.623 -0.591 . . . . 0.0 111.623 -179.545 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 51.6 mt-10 -98.3 133.05 43.25 Favored 'General case' 0 CA--C 1.518 -0.253 0 N-CA-C 109.539 -0.541 . . . . 0.0 109.539 -179.626 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -59.51 -21.73 55.0 Favored Glycine 0 CA--C 1.521 0.44 0 N-CA-C 110.845 -0.902 . . . . 0.0 110.845 -179.217 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -114.03 135.27 22.08 Favored Pre-proline 0 N--CA 1.473 0.685 0 CA-C-N 116.672 0.236 . . . . 0.0 110.626 179.854 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -76.49 162.33 33.4 Favored 'Trans proline' 0 N--CA 1.492 1.433 0 C-N-CA 122.519 2.146 . . . . 0.0 111.426 178.258 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 96.3 mt -81.74 134.34 27.29 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-N 116.151 -0.477 . . . . 0.0 109.953 179.335 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 97.9 m-85 -54.85 141.93 31.24 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.942 0.401 . . . . 0.0 110.797 -179.492 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 2.9 pt-20 -80.99 151.97 28.2 Favored 'General case' 0 CA--C 1.517 -0.296 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.262 179.796 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 2.0 t70 -120.52 160.3 23.45 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.764 179.714 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 54' ' ' PHE . . . . . 0.549 ' CD1' ' N ' ' A' ' 54' ' ' PHE . 6.1 m-85 -121.18 128.66 52.69 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.089 179.839 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 9.8 p -128.23 138.12 55.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 116.352 -0.385 . . . . 0.0 110.361 -179.701 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 98.8 m-20 -56.92 143.36 37.94 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.666 -179.662 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 57' ' ' SER . . . . . 0.466 ' OG ' ' O ' ' A' ' 35' ' ' ILE . 17.7 m -61.72 -34.24 75.44 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.889 179.893 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 37.5 m -57.04 -32.91 66.67 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.441 -179.808 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 92.8 t -65.55 -45.65 91.93 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.683 179.892 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 56.56 25.1 49.5 Favored Glycine 0 CA--C 1.527 0.821 0 N-CA-C 110.937 -0.865 . . . . 0.0 110.937 179.892 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 61' ' ' TYR . . . . . 0.442 ' CD1' ' O ' ' A' ' 24' ' ' LEU . 52.5 t80 -160.28 146.24 15.34 Favored 'General case' 0 N--CA 1.464 0.236 0 CA-C-O 121.141 0.496 . . . . 0.0 111.178 -179.359 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 62' ' ' TYR . . . . . 0.479 ' CD2' ' CD1' ' A' ' 39' ' ' ILE . 30.9 t80 -158.26 159.38 35.93 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.139 179.011 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 48.9 m -128.07 137.29 52.09 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.486 -179.423 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -131.13 101.75 5.68 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.34 0 CA-C-N 115.95 -0.568 . . . . 0.0 109.615 178.912 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 4.7 p -110.54 162.44 14.7 Favored 'General case' 0 N--CA 1.464 0.23 0 CA-C-O 121.006 0.432 . . . . 0.0 110.558 179.868 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 109.05 5.88 30.35 Favored Glycine 0 CA--C 1.527 0.832 0 CA-C-N 115.639 -0.709 . . . . 0.0 111.335 -179.655 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 12.1 mt -79.24 109.2 13.34 Favored 'General case' 0 C--N 1.329 -0.315 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.841 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 7.4 mm-40 -55.25 138.89 66.37 Favored Pre-proline 0 C--N 1.321 -0.65 0 C-N-CA 120.63 -0.428 . . . . 0.0 111.576 -178.236 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 95.8 Cg_endo -74.56 151.59 42.06 Favored 'Trans proline' 0 N--CA 1.493 1.495 0 C-N-CA 122.627 2.218 . . . . 0.0 111.725 179.113 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 72.4 10.15 74.41 Favored Glycine 0 CA--C 1.528 0.877 0 CA-C-N 115.161 -0.927 . . . . 0.0 111.642 179.229 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 1.7 mp -115.48 142.6 27.92 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.655 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 -179.727 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 72' ' ' ASP . . . . . 0.491 ' O ' ' HB3' ' A' ' 44' ' ' ALA . 2.3 t70 -81.73 110.88 17.47 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-N 115.162 -0.926 . . . . 0.0 110.311 179.977 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 73' ' ' TYR . . . . . 0.526 ' O ' ' CD1' ' A' ' 75' ' ' ILE . 14.8 m-85 -106.07 117.95 35.35 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.198 -179.911 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 74' ' ' ASP . . . . . 0.513 ' N ' ' O ' ' A' ' 42' ' ' VAL . 72.2 m-20 -88.16 119.83 28.93 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.145 -0.934 . . . . 0.0 109.331 179.754 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.901 ' N ' HD13 ' A' ' 75' ' ' ILE . 0.0 OUTLIER -121.36 166.27 16.06 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.307 0 CA-C-O 121.067 0.46 . . . . 0.0 110.424 -179.103 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 22.5 t -155.15 151.3 28.07 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.745 -0.661 . . . . 0.0 110.122 179.26 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.429 ' O ' HG23 ' B' ' 217' ' ' THR . 2.4 t -125.3 109.7 22.65 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.335 0 N-CA-C 109.25 -0.648 . . . . 0.0 109.25 178.899 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 90.8 mt -97.27 123.11 49.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-O 120.891 0.377 . . . . 0.0 110.239 179.924 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 79' ' ' THR . . . . . 0.426 ' OG1' ' O ' ' B' ' 216' ' ' TRP . 19.6 p -103.48 111.4 23.83 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.059 179.752 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 35.4 tp -120.44 121.13 37.84 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.096 179.646 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 81' ' ' ILE . . . . . 0.513 ' HB ' ' H ' ' A' ' 33' ' ' THR . 2.3 pp -143.05 149.87 18.23 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 CA-C-N 116.081 -0.508 . . . . 0.0 110.189 179.634 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 82' ' ' ASN . . . . . 0.518 ' N ' ' OG1' ' A' ' 33' ' ' THR . 40.9 t30 -68.23 -47.45 67.77 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.443 -0.344 . . . . 0.0 111.159 179.916 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 83' ' ' GLY . . . . . 0.487 ' H ' ' HG1' ' A' ' 33' ' ' THR . . . 107.81 -126.68 8.4 Favored Glycine 0 CA--C 1.526 0.775 0 N-CA-C 110.876 -0.889 . . . . 0.0 110.876 179.729 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -66.73 146.24 48.09 Favored Glycine 0 CA--C 1.524 0.608 0 N-CA-C 110.875 -0.89 . . . . 0.0 110.875 -179.892 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -67.61 154.23 41.92 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.808 0.337 . . . . 0.0 110.6 -179.928 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 25.1 p -71.32 162.82 28.81 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.339 179.916 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.568 ' N ' ' CD ' ' A' ' 88' ' ' PRO . . . -179.26 -44.45 0.0 OUTLIER Pre-proline 0 CA--C 1.535 0.385 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.193 -179.689 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 88' ' ' PRO . . . . . 0.568 ' CD ' ' N ' ' A' ' 87' ' ' ALA . 35.2 Cg_exo -60.21 -177.56 0.16 Allowed 'Trans proline' 0 N--CA 1.497 1.68 0 C-N-CA 122.569 2.179 . . . . 0.0 112.235 -179.648 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 26.3 m -61.82 130.61 46.54 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.174 -179.961 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.4 m -142.29 162.65 34.93 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.036 179.897 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 2.2 pp -58.0 135.29 56.93 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.182 -179.897 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 64.3 p -89.38 122.58 32.74 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.476 -179.866 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 54.7 tt0 -78.77 143.24 36.31 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.39 179.949 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 0.489 ' CD ' ' H ' ' A' ' 94' ' ' GLN . 27.0 mp0 -65.75 130.46 43.34 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.446 179.957 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 36.7 p . . . . . 0 C--O 1.22 -0.467 0 CA-C-O 118.013 -0.994 . . . . 0.0 110.533 179.975 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' B' B ' 201' ' ' SER . . . . . . . . . . . . . 14.7 p . . . . . 0 N--CA 1.491 1.611 0 N-CA-C 109.278 -0.638 . . . . 0.0 109.278 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' B' B ' 202' ' ' SER . . . . . . . . . . . . . 70.4 m -69.02 146.86 52.33 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.195 -0.457 . . . . 0.0 109.855 179.852 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 203' ' ' SER . . . . . . . . . . . . . 82.6 p -123.82 107.54 31.1 Favored Pre-proline 0 CA--C 1.541 0.617 0 N-CA-C 110.096 -0.335 . . . . 0.0 110.096 179.351 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 204' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo -77.22 -57.23 0.04 OUTLIER 'Trans proline' 0 N--CA 1.493 1.468 0 C-N-CA 121.964 1.776 . . . . 0.0 112.024 -179.865 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 205' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -150.77 147.36 15.83 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.22 179.868 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 206' ' ' GLN . . . . . . . . . . . . . 61.3 tt0 -146.14 144.61 30.08 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.148 179.245 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 207' ' ' GLY . . . . . . . . . . . . . . . -107.12 -132.28 6.93 Favored Glycine 0 N--CA 1.466 0.648 0 N-CA-C 111.125 -0.79 . . . . 0.0 111.125 179.993 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 208' ' ' SER . . . . . 0.52 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 90.6 p -169.67 172.96 6.55 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.892 0.377 . . . . 0.0 110.864 -179.553 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 209' ' ' TRP . . . . . . . . . . . . . 69.1 m95 -92.74 153.52 18.86 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-N 115.815 -0.63 . . . . 0.0 110.488 179.289 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 49.8 p -135.04 140.27 45.45 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.521 179.631 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 61.0 t-105 -90.18 114.7 26.73 Favored 'General case' 0 C--N 1.332 -0.154 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.214 179.583 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 212' ' ' GLU . . . . . 0.522 ' O ' ' O ' ' B' ' 215' ' ' LYS . 3.8 tt0 -161.85 154.06 19.52 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.583 179.684 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 213' ' ' ASN . . . . . 0.446 ' N ' ' HG3' ' B' ' 212' ' ' GLU . 83.5 m-20 56.72 40.62 29.07 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 115.421 -0.809 . . . . 0.0 111.78 177.022 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 51.19 11.41 0.64 Allowed Glycine 0 CA--C 1.528 0.854 0 N-CA-C 111.64 -0.584 . . . . 0.0 111.64 179.571 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 215' ' ' LYS . . . . . 0.522 ' O ' ' O ' ' B' ' 212' ' ' GLU . 80.6 mttt -141.61 151.33 43.03 Favored 'General case' 0 C--O 1.225 -0.212 0 CA-C-O 121.109 0.481 . . . . 0.0 110.963 -179.854 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 216' ' ' TRP . . . . . 0.479 ' CD1' ' N ' ' B' ' 216' ' ' TRP . 24.8 m95 -85.85 119.42 26.14 Favored 'General case' 0 C--N 1.327 -0.406 0 C-N-CA 120.731 -0.387 . . . . 0.0 110.049 179.701 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 217' ' ' THR . . . . . 0.429 HG23 ' O ' ' A' ' 77' ' ' VAL . 16.7 m -125.86 142.1 51.67 Favored 'General case' 0 N--CA 1.467 0.395 0 N-CA-C 110.109 -0.33 . . . . 0.0 110.109 -179.525 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 218' ' ' TRP . . . . . 0.52 ' CH2' ' N ' ' B' ' 208' ' ' SER . 13.7 t-105 -103.49 117.15 33.78 Favored 'General case' 0 N--CA 1.463 0.186 0 CA-C-N 115.906 -0.588 . . . . 0.0 109.439 179.445 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 8.1 mtmp? -143.24 163.01 34.12 Favored 'General case' 0 CA--C 1.516 -0.355 0 CA-C-O 121.21 0.529 . . . . 0.0 110.634 -179.477 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -176.56 -160.27 23.46 Favored Glycine 0 CA--C 1.523 0.568 0 N-CA-C 111.185 -0.766 . . . . 0.0 111.185 -179.536 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 221' ' ' ILE . . . . . 0.529 ' O ' HG23 ' B' ' 222' ' ' ILE . 0.7 OUTLIER -51.05 -75.38 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 C-N-CA 120.778 -0.369 . . . . 0.0 110.566 -178.854 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' B' B ' 222' ' ' ILE . . . . . 0.529 HG23 ' O ' ' B' ' 221' ' ' ILE . 17.0 pt -160.25 -165.76 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 CA-C-N 116.327 -0.397 . . . . 0.0 109.991 -179.653 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 223' ' ' ARG . . . . . 0.508 ' O ' ' O ' ' B' ' 222' ' ' ILE . 22.5 ptt180 -42.33 175.38 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 121.472 0.653 . . . . 0.0 110.841 178.864 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 224' ' ' LEU . . . . . 0.644 HD22 ' N ' ' B' ' 224' ' ' LEU . 3.6 mm? -61.31 123.5 17.93 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 115.497 -0.774 . . . . 0.0 110.65 -179.753 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 79.9 tt0 -80.39 143.21 33.67 Favored 'General case' 0 CA--C 1.518 -0.282 0 CA-C-N 115.385 -0.825 . . . . 0.0 110.221 179.817 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 226' ' ' GLN . . . . . 0.511 ' N ' ' OE1' ' B' ' 226' ' ' GLN . 0.9 OUTLIER . . . . . 0 C--N 1.323 -0.547 0 CA-C-O 118.016 -0.992 . . . . 0.0 110.569 -179.618 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.285 0 N-CA-C 109.571 -1.411 . . . . 0.0 109.571 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 97.4 p -76.69 164.57 25.75 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 120.728 0.299 . . . . 0.0 110.656 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 80.7 mm-40 -67.01 147.49 53.16 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.749 -179.914 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.524 ' O ' HG13 ' A' ' 6' ' ' VAL . 12.2 p -66.33 124.23 87.52 Favored Pre-proline 0 CA--C 1.54 0.565 0 C-N-CA 120.525 -0.47 . . . . 0.0 110.709 -179.435 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 66.2 Cg_endo -75.97 126.01 9.06 Favored 'Trans proline' 0 N--CA 1.495 1.612 0 C-N-CA 121.902 1.734 . . . . 0.0 112.027 179.679 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 98.0 mt-30 -102.42 138.03 39.88 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.065 179.727 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 5.7 tp -80.82 108.92 14.89 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.294 -179.684 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 74.4 p -84.93 164.22 18.47 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.471 179.568 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 99.3 m-20 -128.9 155.43 45.29 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.355 -179.958 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 6.3 tt -64.2 142.99 58.22 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.154 -179.31 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 83.6 p -140.49 154.43 46.59 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.648 179.697 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 14' ' ' PHE . . . . . 0.505 ' CD1' ' N ' ' A' ' 14' ' ' PHE . 21.5 m-85 -111.41 144.77 40.09 Favored 'General case' 0 N--CA 1.464 0.274 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.668 -179.739 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.409 HG11 ' NH2' ' A' ' 25' ' ' ARG . 31.2 m -146.27 161.75 10.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.321 -0.399 . . . . 0.0 110.614 179.793 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 98.2 m-20 53.87 31.08 12.55 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.499 179.764 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 99.2 mt -57.09 140.91 14.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.258 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.444 ' CB ' ' O ' ' A' ' 21' ' ' SER . 0.2 OUTLIER -141.28 -168.11 2.55 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-N 116.009 -0.542 . . . . 0.0 110.326 -179.778 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 19' ' ' ASP . . . . . 0.477 ' N ' ' OD1' ' A' ' 19' ' ' ASP . 21.0 p-10 -88.88 -45.23 9.87 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.874 179.467 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 22.4 m -114.45 7.99 16.39 Favored 'General case' 0 N--CA 1.468 0.465 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.882 -179.543 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 21' ' ' SER . . . . . 0.444 ' O ' ' CB ' ' A' ' 18' ' ' THR . 34.4 t -151.55 145.53 25.21 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.156 0.503 . . . . 0.0 110.232 179.551 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 22' ' ' ILE . . . . . 0.425 HD12 HD21 ' A' ' 24' ' ' LEU . 45.3 pt -138.89 146.29 26.39 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.587 0 CA-C-N 115.802 -0.635 . . . . 0.0 110.352 -179.618 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -99.1 82.19 0.57 Allowed Glycine 0 CA--C 1.524 0.612 0 N-CA-C 110.903 -0.879 . . . . 0.0 110.903 -179.953 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.425 HD21 HD12 ' A' ' 22' ' ' ILE . 94.2 mt -70.02 121.8 18.13 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.856 0.36 . . . . 0.0 110.182 179.884 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 25' ' ' ARG . . . . . 0.409 ' NH2' HG11 ' A' ' 15' ' ' VAL . 59.9 ttp180 -141.28 136.14 31.32 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.164 179.949 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 26' ' ' TRP . . . . . . . . . . . . . 37.8 p90 -139.21 156.04 47.38 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.897 -0.592 . . . . 0.0 109.925 -179.795 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 3.5 m -110.59 98.89 39.09 Favored Pre-proline 0 C--N 1.33 -0.239 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.481 179.718 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 39.9 Cg_exo -53.66 147.63 39.01 Favored 'Trans proline' 0 C--N 1.303 -1.821 0 C-N-CA 121.63 1.554 . . . . 0.0 112.911 179.772 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 59.9 mt -87.76 141.93 28.22 Favored 'General case' 0 CA--C 1.511 -0.55 0 CA-C-N 115.437 -0.801 . . . . 0.0 110.398 -179.873 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 18.3 t-20 -50.07 -37.14 32.1 Favored 'General case' 0 C--N 1.315 -0.909 0 CA-C-N 114.908 -1.042 . . . . 0.0 110.067 -179.831 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 70.3 m -78.24 -33.5 49.74 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.547 178.755 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 14.1 m -60.83 131.09 49.58 Favored 'General case' 0 N--CA 1.463 0.194 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.067 -179.881 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 33' ' ' THR . . . . . 0.455 ' H ' ' HB ' ' A' ' 81' ' ' ILE . 5.1 m -65.91 142.18 57.98 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.253 -179.971 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 16.3 mm -94.82 90.75 2.79 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.19 0 CA-C-N 116.339 -0.392 . . . . 0.0 110.616 -179.848 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.473 ' O ' ' OG ' ' A' ' 57' ' ' SER . 24.9 pt -134.25 144.43 35.3 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.381 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.25 179.923 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -43.4 112.66 0.57 Allowed Glycine 0 CA--C 1.517 0.169 0 C-N-CA 120.59 -0.814 . . . . 0.0 111.58 -179.167 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 37' ' ' TYR . . . . . 0.866 ' OH ' HG23 ' A' ' 77' ' ' VAL . 0.9 OUTLIER -91.4 120.46 32.27 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 109.062 -0.718 . . . . 0.0 109.062 179.205 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 38' ' ' ARG . . . . . 0.516 ' O ' ' CE1' ' A' ' 37' ' ' TYR . 4.7 tmm_? -90.07 133.87 34.59 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.912 -0.586 . . . . 0.0 110.65 179.941 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 6.3 pt -93.67 154.76 3.24 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.314 0 CA-C-N 116.153 -0.476 . . . . 0.0 109.806 179.926 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 2.1 m -131.19 130.03 42.46 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.486 -0.325 . . . . 0.0 110.394 179.409 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.3 p -134.47 136.1 53.17 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.496 0 CA-C-O 120.94 0.4 . . . . 0.0 110.697 179.83 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 42' ' ' VAL . . . . . 0.511 ' O ' ' N ' ' A' ' 74' ' ' ASP . 32.1 t -131.15 127.6 60.87 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.319 0 N-CA-C 109.5 -0.556 . . . . 0.0 109.5 179.362 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -94.58 141.22 28.85 Favored 'General case' 0 C--N 1.324 -0.539 0 N-CA-C 109.516 -0.549 . . . . 0.0 109.516 179.357 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.557 ' HB3' ' O ' ' A' ' 72' ' ' ASP . . . -96.63 -43.5 7.55 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.922 0.391 . . . . 0.0 110.872 179.783 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -74.24 30.82 0.97 Allowed Glycine 0 CA--C 1.525 0.659 0 N-CA-C 110.863 -0.895 . . . . 0.0 110.863 -179.957 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 46' ' ' GLU . . . . . 0.486 ' H ' ' C ' ' A' ' 44' ' ' ALA . 79.8 mm-40 -146.17 150.73 36.42 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 121.11 0.481 . . . . 0.0 110.695 -179.526 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -76.25 -14.67 82.1 Favored Glycine 0 CA--C 1.521 0.448 0 N-CA-C 110.711 -0.956 . . . . 0.0 110.711 179.752 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -138.34 139.5 25.38 Favored Pre-proline 0 CA--C 1.54 0.589 0 C-N-CA 120.961 -0.296 . . . . 0.0 110.464 179.581 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 70.6 Cg_endo -75.27 161.92 37.22 Favored 'Trans proline' 0 N--CA 1.491 1.349 0 C-N-CA 122.64 2.227 . . . . 0.0 111.84 177.957 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 96.3 mt -76.63 140.8 16.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.431 179.129 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 88.8 m-85 -62.84 141.7 58.54 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.459 -179.76 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 52' ' ' GLU . . . . . 0.534 ' CD ' ' H ' ' A' ' 52' ' ' GLU . 0.1 OUTLIER -76.92 146.36 37.63 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.46 179.714 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 4.8 t70 -113.18 150.94 31.55 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.66 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 72.7 m-85 -111.03 122.03 46.85 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.237 179.708 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 10.8 p -127.89 137.97 56.06 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.366 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.482 -179.963 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 89.7 m-20 -64.38 139.8 58.8 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.203 179.368 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 57' ' ' SER . . . . . 0.473 ' OG ' ' O ' ' A' ' 35' ' ' ILE . 2.8 m -59.47 -28.94 67.45 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.467 -179.83 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 37.6 m -55.8 -32.01 63.14 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.573 -179.998 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.498 ' O ' ' CD2' ' A' ' 61' ' ' TYR . 50.1 t -61.88 -44.2 98.51 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 -179.099 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 70.39 13.73 71.09 Favored Glycine 0 CA--C 1.53 0.977 0 N-CA-C 111.033 -0.827 . . . . 0.0 111.033 179.473 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 61' ' ' TYR . . . . . 0.498 ' CD2' ' O ' ' A' ' 59' ' ' VAL . 26.4 p90 -171.9 158.56 4.84 Favored 'General case' 0 C--O 1.225 -0.226 0 CA-C-O 120.993 0.425 . . . . 0.0 111.583 179.594 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 35.1 t80 -155.99 154.72 31.55 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.054 177.972 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 86.3 m -116.32 133.04 56.46 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.4 -179.456 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -131.08 100.84 4.91 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.275 0 N-CA-C 109.475 -0.565 . . . . 0.0 109.475 179.152 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.42 HG22 ' OG ' ' A' ' 21' ' ' SER . 2.4 p -110.33 163.47 13.62 Favored 'General case' 0 N--CA 1.464 0.239 0 CA-C-O 121.007 0.432 . . . . 0.0 110.706 -179.869 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 110.08 9.79 23.56 Favored Glycine 0 CA--C 1.528 0.851 0 CA-C-N 115.496 -0.775 . . . . 0.0 111.49 -179.56 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 8.1 mt -83.52 107.61 16.11 Favored 'General case' 0 C--N 1.33 -0.274 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 179.829 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 17.5 mm-40 -57.58 138.53 81.81 Favored Pre-proline 0 C--N 1.32 -0.694 0 C-N-CA 120.321 -0.552 . . . . 0.0 111.609 -178.295 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 90.2 Cg_endo -74.54 154.65 45.02 Favored 'Trans proline' 0 N--CA 1.496 1.637 0 C-N-CA 122.762 2.308 . . . . 0.0 111.825 178.942 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 73.35 7.92 73.92 Favored Glycine 0 CA--C 1.528 0.865 0 CA-C-N 115.282 -0.872 . . . . 0.0 111.767 179.075 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 71' ' ' ILE . . . . . 0.547 ' O ' ' NH1' ' B' ' 223' ' ' ARG . 1.7 mp -117.11 147.24 20.62 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.406 0 N-CA-C 109.291 -0.633 . . . . 0.0 109.291 -179.504 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 72' ' ' ASP . . . . . 0.557 ' O ' ' HB3' ' A' ' 44' ' ' ALA . 2.8 t0 -84.76 113.99 21.73 Favored 'General case' 0 C--N 1.318 -0.766 0 CA-C-N 115.176 -0.92 . . . . 0.0 110.402 -179.6 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 73' ' ' TYR . . . . . 0.507 ' O ' HD13 ' A' ' 75' ' ' ILE . 15.6 m-85 -107.93 119.88 40.7 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.324 -179.966 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 74' ' ' ASP . . . . . 0.511 ' N ' ' O ' ' A' ' 42' ' ' VAL . 14.8 m-20 -89.71 118.96 29.71 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 115.327 -0.851 . . . . 0.0 108.805 179.535 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.625 HD11 ' N ' ' B' ' 223' ' ' ARG . 0.0 OUTLIER -113.24 162.65 11.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-O 121.282 0.563 . . . . 0.0 110.263 -178.642 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -153.53 118.89 5.18 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.289 -0.869 . . . . 0.0 110.484 179.708 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.866 HG23 ' OH ' ' A' ' 37' ' ' TYR . 8.7 p -103.39 101.38 12.13 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.242 0 N-CA-C 109.517 -0.549 . . . . 0.0 109.517 178.995 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 91.4 mt -92.0 101.13 12.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.621 -179.847 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 44.9 p -77.68 111.64 13.67 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.807 -0.633 . . . . 0.0 109.388 179.049 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 80' ' ' LEU . . . . . 0.587 HD12 ' NZ ' ' B' ' 215' ' ' LYS . 4.8 tp -111.54 120.63 42.77 Favored 'General case' 0 N--CA 1.465 0.288 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.963 -179.234 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 81' ' ' ILE . . . . . 0.455 ' HB ' ' H ' ' A' ' 33' ' ' THR . 2.1 pp -146.61 142.3 20.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.065 -0.516 . . . . 0.0 109.974 179.095 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 56.0 t-20 -60.41 -56.25 23.69 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 120.721 0.296 . . . . 0.0 110.9 -179.648 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 71.42 108.82 0.05 OUTLIER Glycine 0 CA--C 1.524 0.635 0 N-CA-C 110.855 -0.898 . . . . 0.0 110.855 179.317 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -55.05 176.16 0.54 Allowed Glycine 0 CA--C 1.525 0.698 0 N-CA-C 110.766 -0.933 . . . . 0.0 110.766 179.872 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 98.5 mt-10 -64.17 141.1 58.89 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.789 0.328 . . . . 0.0 110.675 -179.734 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 6.5 m -70.82 141.92 51.32 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.493 179.866 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.472 ' N ' ' CD ' ' A' ' 88' ' ' PRO . . . -178.59 52.48 0.06 OUTLIER Pre-proline 0 C--N 1.329 -0.294 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.475 179.892 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 88' ' ' PRO . . . . . 0.472 ' CD ' ' N ' ' A' ' 87' ' ' ALA . 42.4 Cg_endo -66.3 151.02 84.35 Favored 'Trans proline' 0 C--N 1.309 -1.514 0 C-N-CA 122.743 2.295 . . . . 0.0 111.732 179.882 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 96.4 m -95.7 120.2 35.54 Favored 'General case' 0 N--CA 1.463 0.189 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.14 179.938 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.571 HG22 ' N ' ' A' ' 91' ' ' LEU . 53.4 m -86.99 162.9 17.38 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.337 -179.998 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 91' ' ' LEU . . . . . 0.588 HD12 ' N ' ' A' ' 91' ' ' LEU . 9.9 mp -75.85 138.81 41.35 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.296 -179.946 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 68.6 p -81.06 163.79 22.94 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.368 -179.923 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 99.3 mm-40 -83.26 139.15 33.26 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.42 -179.793 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 37.4 tp60 -69.72 -137.51 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.28 -179.841 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.22 -0.497 0 CA-C-O 118.089 -0.958 . . . . 0.0 110.328 -179.954 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 201' ' ' SER . . . . . . . . . . . . . 51.7 m . . . . . 0 N--CA 1.489 1.493 0 N-CA-C 109.285 -0.635 . . . . 0.0 109.285 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' B' B ' 202' ' ' SER . . . . . . . . . . . . . 14.9 m -72.77 141.8 48.11 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.021 179.819 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 203' ' ' SER . . . . . . . . . . . . . 25.9 t -129.77 106.62 16.92 Favored Pre-proline 0 CA--C 1.539 0.534 0 N-CA-C 110.092 -0.336 . . . . 0.0 110.092 179.128 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 204' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -81.19 7.15 5.13 Favored 'Trans proline' 0 N--CA 1.493 1.449 0 C-N-CA 122.177 1.918 . . . . 0.0 111.97 179.466 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 205' ' ' ILE . . . . . . . . . . . . . 9.9 tp -144.69 144.15 22.26 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.328 0 CA-C-O 121.144 0.497 . . . . 0.0 111.225 179.866 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 206' ' ' GLN . . . . . . . . . . . . . 8.5 pt20 -179.05 76.31 0.01 OUTLIER 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 115.242 -0.89 . . . . 0.0 110.775 179.272 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 207' ' ' GLY . . . . . . . . . . . . . . . -109.52 -139.53 8.51 Favored Glycine 0 N--CA 1.466 0.637 0 N-CA-C 111.174 -0.77 . . . . 0.0 111.174 -179.882 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 208' ' ' SER . . . . . 0.539 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 91.7 p -166.88 172.14 10.62 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 120.907 0.384 . . . . 0.0 110.701 -179.805 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 209' ' ' TRP . . . . . . . . . . . . . 78.4 m95 -88.63 130.66 35.23 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.189 179.369 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 82.1 p -109.5 132.81 53.79 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-N 116.392 -0.367 . . . . 0.0 110.496 -179.796 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 47.7 t-105 -93.73 117.81 30.58 Favored 'General case' 0 N--CA 1.463 0.208 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.072 179.796 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 212' ' ' GLU . . . . . 0.44 ' O ' ' O ' ' B' ' 215' ' ' LYS . 0.8 OUTLIER -164.22 167.41 20.04 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.779 179.035 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' B' B ' 213' ' ' ASN . . . . . . . . . . . . . 92.4 m-20 49.06 37.11 9.88 Favored 'General case' 0 C--N 1.324 -0.516 0 C-N-CA 120.522 -0.471 . . . . 0.0 111.349 176.603 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 50.89 16.85 1.93 Allowed Glycine 0 CA--C 1.526 0.723 0 N-CA-C 111.335 -0.706 . . . . 0.0 111.335 179.868 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 215' ' ' LYS . . . . . 0.587 ' NZ ' HD12 ' A' ' 80' ' ' LEU . 20.3 mtpt -143.0 149.75 38.72 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.986 0.422 . . . . 0.0 110.889 -179.839 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 216' ' ' TRP . . . . . . . . . . . . . 50.1 m95 -86.12 115.76 23.9 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.028 -0.533 . . . . 0.0 109.712 179.115 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 217' ' ' THR . . . . . . . . . . . . . 18.1 m -126.95 139.92 52.7 Favored 'General case' 0 N--CA 1.466 0.343 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.439 -179.512 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 218' ' ' TRP . . . . . 0.626 ' O ' HG12 ' A' ' 77' ' ' VAL . 12.9 t-105 -106.45 116.38 31.82 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.016 178.984 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 52.8 mtmt -143.9 174.5 10.78 Favored 'General case' 0 CA--C 1.514 -0.432 0 CA-C-O 121.137 0.494 . . . . 0.0 110.644 -179.85 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -176.38 -160.21 23.27 Favored Glycine 0 CA--C 1.523 0.572 0 C-N-CA 120.544 -0.836 . . . . 0.0 111.226 -179.576 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 221' ' ' ILE . . . . . 0.532 ' O ' HG23 ' B' ' 222' ' ' ILE . 10.2 mm -51.27 -73.59 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.892 0.377 . . . . 0.0 110.485 -178.059 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 222' ' ' ILE . . . . . 0.532 HG23 ' O ' ' B' ' 221' ' ' ILE . 23.7 pt -159.48 -166.39 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.755 0 CA-C-N 115.646 -0.706 . . . . 0.0 110.706 -179.943 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 223' ' ' ARG . . . . . 0.625 ' N ' HD11 ' A' ' 75' ' ' ILE . 32.0 ptt-85 -42.76 174.6 0.0 OUTLIER 'General case' 0 CA--C 1.52 -0.186 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.77 179.003 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 224' ' ' LEU . . . . . 0.759 HD22 ' N ' ' B' ' 224' ' ' LEU . 2.4 mm? -59.67 128.23 35.91 Favored 'General case' 0 C--N 1.315 -0.906 0 CA-C-N 115.786 -0.643 . . . . 0.0 110.542 -179.517 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 42.5 tt0 -107.36 145.88 32.31 Favored 'General case' 0 CA--C 1.52 -0.188 0 CA-C-N 115.349 -0.841 . . . . 0.0 110.391 -179.843 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 226' ' ' GLN . . . . . . . . . . . . . 64.8 tp60 . . . . . 0 N--CA 1.451 -0.406 0 CA-C-O 117.925 -1.036 . . . . 0.0 110.197 179.947 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.341 0 N-CA-C 109.6 -1.4 . . . . 0.0 109.6 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 41.0 t -152.02 95.38 2.07 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.865 0.364 . . . . 0.0 110.618 179.933 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 19.0 pt-20 -84.78 152.58 23.56 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.498 179.809 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.652 ' O ' HG13 ' A' ' 6' ' ' VAL . 9.1 p -145.07 77.95 12.73 Favored Pre-proline 0 N--CA 1.463 0.215 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.458 -179.968 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 32.2 Cg_exo -56.57 139.33 87.49 Favored 'Trans proline' 0 C--N 1.309 -1.538 0 C-N-CA 122.354 2.036 . . . . 0.0 111.911 -179.797 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 8' ' ' GLN . . . . . 0.412 HE21 ' HB3' ' A' ' 30' ' ' ASN . 64.8 tt0 -84.95 -32.09 23.24 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.361 179.951 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 81.6 mt -84.94 129.97 34.71 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.465 179.991 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 75.0 p -130.8 159.41 37.41 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.526 179.968 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 97.2 m-20 -104.37 155.46 18.76 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.395 -179.834 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 6.7 tt -63.92 149.15 47.82 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.396 -179.74 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' SER . . . . . 0.419 ' O ' ' O ' ' A' ' 25' ' ' ARG . 83.3 p -139.15 156.85 46.83 Favored 'General case' 0 N--CA 1.461 0.114 0 CA-C-O 121.166 0.508 . . . . 0.0 110.42 179.757 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 14' ' ' PHE . . . . . 0.501 ' CD1' ' N ' ' A' ' 14' ' ' PHE . 30.6 m-85 -110.84 146.37 36.57 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.555 -0.748 . . . . 0.0 110.81 -179.515 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 15.6 m -146.74 157.01 10.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.447 -0.342 . . . . 0.0 110.649 179.4 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 98.9 m-20 54.59 31.53 15.23 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.934 179.656 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 97.2 mt -56.92 140.89 14.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.383 -179.803 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.418 ' CB ' ' O ' ' A' ' 21' ' ' SER . 0.2 OUTLIER -140.87 -168.6 2.63 Favored 'General case' 0 CA--C 1.533 0.292 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.509 -179.798 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 19' ' ' ASP . . . . . 0.483 ' OD1' ' N ' ' A' ' 19' ' ' ASP . 11.8 p-10 -90.3 -41.91 11.27 Favored 'General case' 0 N--CA 1.465 0.299 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.689 179.509 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 15.1 m -114.62 5.74 15.51 Favored 'General case' 0 N--CA 1.464 0.252 0 CA-C-N 116.014 -0.539 . . . . 0.0 111.152 -179.395 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 21' ' ' SER . . . . . 0.418 ' O ' ' CB ' ' A' ' 18' ' ' THR . 29.2 t -151.68 148.43 27.92 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 121.046 0.45 . . . . 0.0 110.365 179.624 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 42.6 pt -140.71 145.53 25.42 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.194 179.789 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -102.27 81.42 0.4 Allowed Glycine 0 CA--C 1.524 0.618 0 N-CA-C 110.998 -0.841 . . . . 0.0 110.998 -179.991 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 96.3 mt -68.54 121.6 16.73 Favored 'General case' 0 C--N 1.33 -0.272 0 C-N-CA 120.775 -0.37 . . . . 0.0 110.015 -179.992 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 25' ' ' ARG . . . . . 0.419 ' O ' ' O ' ' A' ' 13' ' ' SER . 58.8 ttt85 -142.75 137.64 29.93 Favored 'General case' 0 C--N 1.333 -0.123 0 CA-C-O 120.956 0.407 . . . . 0.0 110.372 -179.806 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 26' ' ' TRP . . . . . 0.454 ' C ' ' CD1' ' A' ' 26' ' ' TRP . 0.1 OUTLIER -143.0 161.54 37.85 Favored 'General case' 0 N--CA 1.466 0.349 0 N-CA-C 109.089 -0.708 . . . . 0.0 109.089 179.599 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 5.0 m -100.88 103.18 23.17 Favored Pre-proline 0 C--N 1.327 -0.379 0 N-CA-C 108.612 -0.885 . . . . 0.0 108.612 178.73 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 33.4 Cg_exo -54.72 149.62 39.84 Favored 'Trans proline' 0 C--N 1.308 -1.594 0 C-N-CA 120.883 1.055 . . . . 0.0 112.754 -179.03 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 69.6 mt -87.49 133.06 33.82 Favored 'General case' 0 CA--C 1.51 -0.569 0 CA-C-O 121.601 0.715 . . . . 0.0 111.066 -179.637 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 30' ' ' ASN . . . . . 0.412 ' HB3' HE21 ' A' ' 8' ' ' GLN . 24.3 t-20 -46.9 -33.69 4.79 Favored 'General case' 0 C--N 1.314 -0.94 0 CA-C-N 115.064 -0.971 . . . . 0.0 110.225 179.527 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 63.4 m -80.74 -34.18 34.59 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.53 178.83 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 5.2 m -56.57 127.12 29.73 Favored 'General case' 0 C--O 1.232 0.136 0 C-N-CA 120.732 -0.387 . . . . 0.0 109.998 -179.715 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 33' ' ' THR . . . . . 0.495 ' H ' ' HB ' ' A' ' 81' ' ' ILE . 33.2 m -61.61 152.5 30.47 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.048 179.875 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 24.4 mm -97.5 94.05 3.71 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.343 0 CA-C-N 116.579 -0.282 . . . . 0.0 111.49 -178.24 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.485 ' N ' HD13 ' A' ' 35' ' ' ILE . 0.1 OUTLIER -137.59 155.09 30.55 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.324 0 CA-C-O 120.792 0.329 . . . . 0.0 110.511 179.305 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -63.22 113.57 6.02 Favored Glycine 0 CA--C 1.521 0.457 0 C-N-CA 120.472 -0.871 . . . . 0.0 111.178 179.785 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 69.2 m-85 -80.73 141.53 34.73 Favored 'General case' 0 C--N 1.328 -0.358 0 N-CA-C 110.072 -0.344 . . . . 0.0 110.072 179.525 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 38' ' ' ARG . . . . . 0.43 HH11 ' HG3' ' A' ' 52' ' ' GLU . 5.3 tmm_? -105.54 119.84 40.14 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.549 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.474 ' O ' ' CG1' ' A' ' 39' ' ' ILE . 1.9 pt -95.47 122.88 47.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 115.835 -0.62 . . . . 0.0 109.693 179.79 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 94.8 m -109.61 131.64 54.87 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.824 0.345 . . . . 0.0 110.511 -179.276 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.417 HG13 ' HB ' ' A' ' 50' ' ' ILE . 1.8 p -128.8 144.12 39.05 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.349 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.523 -179.505 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 42' ' ' VAL . . . . . 0.506 ' O ' ' N ' ' A' ' 74' ' ' ASP . 40.4 t -132.45 131.87 60.3 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.191 0 CA-C-O 120.899 0.38 . . . . 0.0 110.019 179.542 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.526 ' HB2' ' CE2' ' A' ' 73' ' ' TYR . . . -98.44 140.01 33.33 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 109.296 -0.631 . . . . 0.0 109.296 179.22 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.552 ' HB3' ' O ' ' A' ' 72' ' ' ASP . . . -98.26 -18.44 18.39 Favored 'General case' 0 CA--C 1.529 0.135 0 C-N-CA 120.67 -0.412 . . . . 0.0 110.776 179.926 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -98.54 30.73 9.1 Favored Glycine 0 CA--C 1.529 0.956 0 N-CA-C 110.753 -0.939 . . . . 0.0 110.753 179.821 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 45.1 mt-10 -146.78 149.01 32.51 Favored 'General case' 0 CA--C 1.521 -0.16 0 CA-C-O 121.131 0.491 . . . . 0.0 110.691 179.97 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -68.96 -20.95 75.09 Favored Glycine 0 CA--C 1.527 0.823 0 N-CA-C 111.014 -0.834 . . . . 0.0 111.014 179.736 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -136.61 141.11 34.21 Favored Pre-proline 0 CA--C 1.54 0.579 0 C-N-CA 121.131 -0.228 . . . . 0.0 110.476 179.995 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 69.4 Cg_endo -73.36 162.22 40.8 Favored 'Trans proline' 0 N--CA 1.496 1.672 0 C-N-CA 122.752 2.301 . . . . 0.0 111.821 179.059 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 50' ' ' ILE . . . . . 0.417 ' HB ' HG13 ' A' ' 41' ' ' VAL . 96.7 mt -76.49 151.77 5.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.522 179.793 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 82.6 m-85 -70.75 146.41 49.83 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.707 -179.54 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 52' ' ' GLU . . . . . 0.522 ' CD ' ' H ' ' A' ' 52' ' ' GLU . 0.5 OUTLIER -82.96 145.0 29.61 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.682 179.55 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -112.4 153.14 27.76 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.492 -0.777 . . . . 0.0 110.388 -179.717 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 54' ' ' PHE . . . . . 0.581 ' CD1' ' N ' ' A' ' 54' ' ' PHE . 2.7 m-85 -119.0 128.7 54.64 Favored 'General case' 0 N--CA 1.466 0.356 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.227 -179.758 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 9.6 p -131.26 139.06 51.8 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.3 0 CA-C-O 120.683 0.277 . . . . 0.0 110.828 -179.65 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 71.4 m-20 -58.51 142.47 48.82 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.262 179.581 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 7.2 t -60.88 -35.21 76.04 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.733 179.86 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 58.5 m -56.31 -34.11 66.2 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.923 -179.603 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 90.7 t -62.38 -45.8 97.93 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.389 -179.84 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 61.75 23.17 62.87 Favored Glycine 0 CA--C 1.525 0.713 0 N-CA-C 110.745 -0.942 . . . . 0.0 110.745 179.942 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 37.2 t80 -164.65 150.16 10.09 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-O 121.095 0.474 . . . . 0.0 111.423 -179.412 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 62' ' ' TYR . . . . . 0.432 ' CD2' ' CD1' ' A' ' 39' ' ' ILE . 18.4 t80 -156.7 154.32 29.87 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.73 -0.668 . . . . 0.0 110.33 178.715 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 73.1 m -117.55 132.55 56.51 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.16 -0.473 . . . . 0.0 109.893 179.472 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -130.63 113.63 25.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 N-CA-C 109.327 -0.62 . . . . 0.0 109.327 178.914 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.412 HG22 ' OG ' ' A' ' 21' ' ' SER . 2.1 p -124.76 158.83 32.33 Favored 'General case' 0 CA--C 1.516 -0.331 0 CA-C-O 120.987 0.422 . . . . 0.0 110.394 -179.83 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 108.11 39.61 1.8 Allowed Glycine 0 CA--C 1.525 0.682 0 N-CA-C 110.818 -0.913 . . . . 0.0 110.818 -179.937 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 14.5 mt -112.52 106.96 15.53 Favored 'General case' 0 N--CA 1.467 0.404 0 N-CA-C 108.742 -0.836 . . . . 0.0 108.742 179.087 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 4.1 mm-40 -54.34 136.79 60.37 Favored Pre-proline 0 C--N 1.323 -0.561 0 C-N-CA 120.86 -0.336 . . . . 0.0 111.727 -178.095 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 90.0 Cg_endo -74.26 154.52 46.38 Favored 'Trans proline' 0 N--CA 1.493 1.466 0 C-N-CA 122.779 2.319 . . . . 0.0 111.54 178.877 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 71.05 8.42 64.66 Favored Glycine 0 CA--C 1.529 0.963 0 CA-C-N 115.533 -0.758 . . . . 0.0 111.507 179.563 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 1.6 mp -116.05 143.9 24.97 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.543 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 -179.975 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 72' ' ' ASP . . . . . 0.552 ' O ' ' HB3' ' A' ' 44' ' ' ALA . 2.0 t0 -81.93 112.59 19.17 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-N 115.307 -0.861 . . . . 0.0 110.149 -179.849 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 73' ' ' TYR . . . . . 0.526 ' CE2' ' HB2' ' A' ' 43' ' ' ALA . 13.7 m-85 -107.38 120.01 40.97 Favored 'General case' 0 C--O 1.223 -0.326 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.354 -179.814 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 74' ' ' ASP . . . . . 0.506 ' N ' ' O ' ' A' ' 42' ' ' VAL . 7.3 m-20 -89.04 114.86 26.12 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 115.34 -0.845 . . . . 0.0 109.375 179.601 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.675 HD11 ' N ' ' B' ' 223' ' ' ARG . 0.0 OUTLIER -112.35 167.31 5.8 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.198 0 CA-C-O 121.273 0.558 . . . . 0.0 110.405 -179.434 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 11.6 p -154.46 151.65 29.2 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 115.124 -0.944 . . . . 0.0 110.283 179.392 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -131.32 101.75 5.56 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.351 0 N-CA-C 108.744 -0.836 . . . . 0.0 108.744 179.49 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 96.2 mt -86.62 123.87 40.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 C-N-CA 120.913 -0.315 . . . . 0.0 110.34 -179.673 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 90.5 m -105.26 109.02 20.85 Favored 'General case' 0 N--CA 1.465 0.301 0 CA-C-N 116.358 -0.383 . . . . 0.0 109.971 179.66 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 6.7 tt -121.09 119.02 31.24 Favored 'General case' 0 CA--C 1.517 -0.292 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.449 179.965 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 81' ' ' ILE . . . . . 0.495 ' HB ' ' H ' ' A' ' 33' ' ' THR . 2.0 pp -140.28 143.44 29.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.289 179.22 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 82' ' ' ASN . . . . . 0.481 ' C ' ' H ' ' A' ' 84' ' ' GLY . 56.8 t-20 -65.22 -54.19 33.14 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.803 -179.476 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 61.53 -1.28 1.13 Allowed Glycine 0 CA--C 1.525 0.712 0 N-CA-C 111.037 -0.825 . . . . 0.0 111.037 179.289 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 84' ' ' GLY . . . . . 0.481 ' H ' ' C ' ' A' ' 82' ' ' ASN . . . -96.23 105.83 3.28 Favored Glycine 0 CA--C 1.525 0.685 0 N-CA-C 110.939 -0.865 . . . . 0.0 110.939 -179.903 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 17.0 pt-20 -84.09 155.98 22.39 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.836 0.35 . . . . 0.0 110.37 179.821 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 86' ' ' SER . . . . . 0.515 ' O ' ' HB3' ' A' ' 87' ' ' ALA . 8.6 m -72.38 153.04 41.67 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.702 179.988 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.682 ' HB1' ' CD ' ' A' ' 88' ' ' PRO . . . 71.67 -179.85 0.05 OUTLIER Pre-proline 0 CA--C 1.537 0.455 0 CA-C-N 115.879 -0.601 . . . . 0.0 110.571 179.656 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 88' ' ' PRO . . . . . 0.682 ' CD ' ' HB1' ' A' ' 87' ' ' ALA . 22.1 Cg_exo -63.33 153.28 75.37 Favored 'Trans proline' 0 N--CA 1.497 1.713 0 C-N-CA 122.548 2.166 . . . . 0.0 111.93 179.723 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.7 p -129.18 158.75 38.13 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.179 -179.637 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -142.4 -177.73 5.41 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.186 179.983 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 91' ' ' LEU . . . . . 0.623 HD22 ' N ' ' A' ' 91' ' ' LEU . 3.6 mm? -90.83 133.05 35.51 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.468 179.963 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 92' ' ' THR . . . . . 0.452 HG22 ' H ' ' A' ' 92' ' ' THR . 0.9 OUTLIER -79.04 153.02 30.55 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.813 -0.631 . . . . 0.0 110.319 -179.792 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 98.7 mm-40 -76.82 137.25 39.11 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.528 -179.993 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 97.3 mt-30 -64.76 90.3 0.08 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.39 -179.948 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 18.6 p . . . . . 0 C--O 1.22 -0.452 0 CA-C-O 118.001 -1.0 . . . . 0.0 110.515 179.982 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' B' B ' 201' ' ' SER . . . . . . . . . . . . . 18.7 p . . . . . 0 N--CA 1.492 1.636 0 N-CA-C 109.435 -0.58 . . . . 0.0 109.435 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' B' B ' 202' ' ' SER . . . . . . . . . . . . . 38.7 t -70.94 155.58 40.64 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.149 179.9 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 203' ' ' SER . . . . . . . . . . . . . 2.8 p -89.23 150.91 45.84 Favored Pre-proline 0 CA--C 1.538 0.491 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.317 -179.617 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 204' ' ' PRO . . . . . . . . . . . . . 56.9 Cg_endo -70.49 6.45 1.55 Allowed 'Trans proline' 0 N--CA 1.5 1.893 0 C-N-CA 122.443 2.095 . . . . 0.0 112.008 179.984 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 205' ' ' ILE . . . . . 0.446 HD13 ' CZ ' ' A' ' 14' ' ' PHE . 10.9 tt -150.79 151.13 12.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-O 121.032 0.444 . . . . 0.0 111.075 179.699 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 206' ' ' GLN . . . . . . . . . . . . . 69.3 mt-30 -156.83 75.61 0.84 Allowed 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.692 -0.685 . . . . 0.0 110.534 178.711 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 207' ' ' GLY . . . . . . . . . . . . . . . -107.65 -159.9 20.86 Favored Glycine 0 N--CA 1.464 0.515 0 N-CA-C 110.838 -0.905 . . . . 0.0 110.838 -179.847 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 208' ' ' SER . . . . . . . . . . . . . 44.6 p -163.82 170.33 17.02 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 120.717 0.294 . . . . 0.0 110.701 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 209' ' ' TRP . . . . . . . . . . . . . 86.5 m95 -83.33 126.56 32.83 Favored 'General case' 0 C--N 1.329 -0.286 0 C-N-CA 120.845 -0.342 . . . . 0.0 110.167 179.34 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 77.4 p -108.94 138.91 44.54 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-N 116.514 -0.312 . . . . 0.0 110.723 -179.745 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 58.2 t-105 -95.67 116.09 28.36 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-N 116.033 -0.531 . . . . 0.0 110.337 179.68 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 212' ' ' GLU . . . . . 0.469 ' O ' ' O ' ' B' ' 215' ' ' LYS . 1.4 pt-20 -163.46 167.03 22.06 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.509 179.312 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 213' ' ' ASN . . . . . . . . . . . . . 78.9 m-20 49.3 34.23 6.11 Favored 'General case' 0 C--N 1.324 -0.522 0 C-N-CA 120.53 -0.468 . . . . 0.0 111.698 176.962 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 54.73 12.34 3.48 Favored Glycine 0 CA--C 1.528 0.865 0 C-N-CA 120.917 -0.659 . . . . 0.0 111.604 179.463 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 215' ' ' LYS . . . . . 0.469 ' O ' ' O ' ' B' ' 212' ' ' GLU . 67.6 mttm -141.86 150.98 42.29 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-O 120.863 0.364 . . . . 0.0 110.76 -179.798 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 216' ' ' TRP . . . . . 0.437 ' CD1' ' N ' ' B' ' 216' ' ' TRP . 37.4 m95 -84.91 117.54 23.98 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.174 179.875 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 217' ' ' THR . . . . . . . . . . . . . 26.7 m -125.85 137.49 53.76 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.531 -179.568 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 218' ' ' TRP . . . . . . . . . . . . . 25.0 t-105 -98.53 120.02 38.25 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.234 179.483 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 53.7 mtmt -141.69 165.79 26.51 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.72 -179.809 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -176.44 -160.97 24.59 Favored Glycine 0 CA--C 1.522 0.504 0 N-CA-C 111.185 -0.766 . . . . 0.0 111.185 -179.887 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 221' ' ' ILE . . . . . 0.555 ' O ' HG23 ' B' ' 222' ' ' ILE . 0.8 OUTLIER -53.43 -76.73 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.387 0 C-N-CA 120.682 -0.407 . . . . 0.0 110.987 -178.44 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' B' B ' 222' ' ' ILE . . . . . 0.555 HG23 ' O ' ' B' ' 221' ' ' ILE . 20.2 pt -160.72 -166.24 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 N-CA-C 109.994 -0.373 . . . . 0.0 109.994 -179.633 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 223' ' ' ARG . . . . . 0.675 ' N ' HD11 ' A' ' 75' ' ' ILE . 33.2 ptt85 -45.41 174.57 0.0 OUTLIER 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.805 178.362 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 224' ' ' LEU . . . . . 0.679 HD22 ' N ' ' B' ' 224' ' ' LEU . 3.0 mm? -59.44 123.46 16.89 Favored 'General case' 0 C--N 1.318 -0.791 0 CA-C-N 115.317 -0.856 . . . . 0.0 110.211 -179.244 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 79.7 tt0 -115.97 150.15 37.64 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.387 -0.824 . . . . 0.0 110.167 -179.648 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 226' ' ' GLN . . . . . . . . . . . . . 68.0 tp60 . . . . . 0 N--CA 1.448 -0.54 0 CA-C-O 117.979 -1.01 . . . . 0.0 110.263 -179.798 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.158 0 N-CA-C 109.603 -1.399 . . . . 0.0 109.603 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 31.0 m -150.02 105.44 3.39 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.854 0.359 . . . . 0.0 110.381 179.962 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 4.6 pt-20 -98.96 100.01 11.13 Favored 'General case' 0 N--CA 1.464 0.264 0 CA-C-O 121.085 0.469 . . . . 0.0 110.479 179.995 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.439 ' H ' HG22 ' A' ' 6' ' ' VAL . 3.3 m -81.09 153.2 72.01 Favored Pre-proline 0 N--CA 1.449 -0.495 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.529 -179.778 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_exo -50.58 143.64 27.7 Favored 'Trans proline' 0 N--CA 1.491 1.381 0 C-N-CA 122.546 2.164 . . . . 0.0 112.194 179.047 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 15.2 pt20 -160.58 -147.29 0.15 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.059 -0.518 . . . . 0.0 110.61 -179.838 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 26.6 tp -57.33 130.4 46.07 Favored 'General case' 0 N--CA 1.449 -0.493 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.29 -179.567 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 43.6 p -82.01 167.46 18.83 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.424 -179.96 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 96.5 m-20 -135.81 142.89 44.92 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-O 120.984 0.421 . . . . 0.0 110.438 -179.879 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 6.6 tt -64.27 145.16 56.46 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.429 -179.676 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 86.8 p -140.3 153.01 46.33 Favored 'General case' 0 N--CA 1.463 0.212 0 CA-C-N 116.328 -0.397 . . . . 0.0 110.662 179.909 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 14' ' ' PHE . . . . . 0.533 ' CD1' ' N ' ' A' ' 14' ' ' PHE . 12.5 m-85 -111.17 146.74 36.35 Favored 'General case' 0 N--CA 1.465 0.301 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.379 -179.612 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 21.9 m -146.01 160.88 11.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.633 179.81 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 38.2 t0 55.46 31.53 17.15 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.66 179.636 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 96.5 mt -56.57 137.77 18.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 121.07 0.462 . . . . 0.0 110.148 179.962 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.461 ' CB ' ' O ' ' A' ' 21' ' ' SER . 0.3 OUTLIER -140.32 -167.01 2.23 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.817 -0.628 . . . . 0.0 110.651 -179.559 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 19' ' ' ASP . . . . . 0.525 ' OD1' ' N ' ' A' ' 19' ' ' ASP . 14.5 p-10 -91.6 -41.97 10.47 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 115.691 -0.686 . . . . 0.0 111.006 179.468 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 13.7 m -116.97 6.88 13.05 Favored 'General case' 0 N--CA 1.466 0.344 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.677 -179.584 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 21' ' ' SER . . . . . 0.461 ' O ' ' CB ' ' A' ' 18' ' ' THR . 16.8 p -151.65 145.79 25.33 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 121.101 0.477 . . . . 0.0 110.443 179.968 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 44.2 pt -140.26 146.29 24.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.02 179.941 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -99.31 81.76 0.56 Allowed Glycine 0 CA--C 1.523 0.593 0 N-CA-C 111.419 -0.672 . . . . 0.0 111.419 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 84.0 mt -66.79 121.98 16.65 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.768 0.318 . . . . 0.0 110.296 -179.967 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 4.6 tmm_? -139.62 138.69 36.37 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.62 179.877 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 26' ' ' TRP . . . . . . . . . . . . . 42.0 p90 -143.0 158.28 43.75 Favored 'General case' 0 CA--C 1.517 -0.308 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.399 179.921 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 3.5 m -111.16 97.1 33.67 Favored Pre-proline 0 CA--C 1.534 0.337 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.393 179.854 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_exo -53.23 146.3 40.2 Favored 'Trans proline' 0 C--N 1.308 -1.581 0 C-N-CA 122.476 2.117 . . . . 0.0 112.23 179.879 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 52.3 mt -84.32 138.53 32.84 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 121.337 0.589 . . . . 0.0 111.039 -179.96 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 31.8 t30 -49.08 -33.49 11.71 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.47 -0.786 . . . . 0.0 110.152 179.829 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 70.6 m -81.63 -34.17 31.02 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.593 179.667 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 9.1 m -58.24 134.92 56.96 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 121.103 0.478 . . . . 0.0 110.185 -179.881 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 33' ' ' THR . . . . . 0.585 ' HG1' ' H ' ' A' ' 83' ' ' GLY . 3.7 m -61.44 142.74 56.78 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.465 179.912 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 28.9 mm -94.37 92.69 3.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.969 0.414 . . . . 0.0 110.324 -179.896 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 15.2 pt -143.09 135.86 25.13 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.155 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.359 179.697 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -39.24 132.4 1.95 Allowed Glycine 0 CA--C 1.524 0.642 0 N-CA-C 111.171 -0.771 . . . . 0.0 111.171 -179.705 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 95.6 m-85 -103.03 138.98 39.17 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.844 0.354 . . . . 0.0 110.197 -179.771 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 5.3 tmm_? -99.1 124.64 44.27 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.629 -179.699 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.451 ' O ' ' CG1' ' A' ' 39' ' ' ILE . 2.1 pt -99.09 124.51 52.39 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 116.341 -0.391 . . . . 0.0 109.97 179.701 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 5.4 m -105.52 134.0 49.35 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.621 -179.822 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.1 p -132.39 141.52 45.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.308 179.541 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 42' ' ' VAL . . . . . 0.538 ' O ' ' N ' ' A' ' 74' ' ' ASP . 41.4 t -133.41 133.47 57.64 Favored 'Isoleucine or valine' 0 C--O 1.231 0.104 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.339 179.6 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.548 ' HB2' ' CE2' ' A' ' 73' ' ' TYR . . . -98.55 139.58 34.07 Favored 'General case' 0 C--N 1.328 -0.33 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 178.732 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.513 ' HB3' ' O ' ' A' ' 72' ' ' ASP . . . -91.81 -43.91 9.26 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.284 -0.417 . . . . 0.0 111.027 179.815 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -63.49 -32.35 83.84 Favored Glycine 0 CA--C 1.524 0.614 0 N-CA-C 111.275 -0.73 . . . . 0.0 111.275 -179.477 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 38.4 mm-40 -97.92 126.53 43.36 Favored 'General case' 0 C--N 1.332 -0.19 0 N-CA-C 109.616 -0.512 . . . . 0.0 109.616 -179.582 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -59.17 -6.92 4.57 Favored Glycine 0 CA--C 1.511 -0.187 0 N-CA-C 110.918 -0.873 . . . . 0.0 110.918 -179.082 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -124.23 133.44 24.7 Favored Pre-proline 0 CA--C 1.537 0.477 0 C-N-CA 120.905 -0.318 . . . . 0.0 110.257 179.461 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 60.7 Cg_endo -76.71 164.22 30.52 Favored 'Trans proline' 0 C--N 1.307 -1.618 0 C-N-CA 122.59 2.193 . . . . 0.0 112.286 177.48 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 95.9 mt -85.22 145.38 8.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 115.771 -0.65 . . . . 0.0 110.268 179.023 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 79.7 m-85 -63.79 142.81 58.27 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.527 -179.886 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 52' ' ' GLU . . . . . 0.446 ' N ' ' CD ' ' A' ' 52' ' ' GLU . 0.1 OUTLIER -70.58 -178.01 1.68 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.582 179.776 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 53' ' ' ASP . . . . . 0.411 ' HB2' HD11 ' A' ' 39' ' ' ILE . 4.0 m-20 -146.51 138.25 24.68 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.884 179.499 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 89.3 m-85 -108.13 120.01 41.13 Favored 'General case' 0 N--CA 1.463 0.187 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.279 179.266 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 9.9 p -127.28 136.52 60.42 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.285 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.377 179.881 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 97.4 m-20 -56.89 142.99 39.26 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.463 -179.855 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 11.4 t -61.79 -35.15 77.34 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.716 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 37.7 m -55.44 -32.33 62.65 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.724 -179.718 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 98.6 t -63.76 -46.14 95.32 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.587 -179.889 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 59.36 27.09 62.65 Favored Glycine 0 CA--C 1.527 0.827 0 N-CA-C 110.859 -0.896 . . . . 0.0 110.859 -179.931 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 52.7 t80 -166.52 149.89 7.09 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 121.224 0.535 . . . . 0.0 110.945 -179.415 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 62' ' ' TYR . . . . . 0.412 ' CD2' ' CD1' ' A' ' 39' ' ' ILE . 25.7 t80 -158.81 159.26 34.92 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.971 -0.558 . . . . 0.0 110.141 179.003 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 85.3 m -125.28 136.28 53.36 Favored 'General case' 0 N--CA 1.464 0.233 0 CA-C-N 116.378 -0.373 . . . . 0.0 110.392 -179.714 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -131.87 105.93 10.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.185 179.37 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 3.2 p -114.1 156.23 24.56 Favored 'General case' 0 CA--C 1.516 -0.358 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.515 179.632 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 109.63 40.46 1.46 Allowed Glycine 0 CA--C 1.523 0.589 0 N-CA-C 111.245 -0.742 . . . . 0.0 111.245 -179.754 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 18.5 mt -113.69 102.34 10.16 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-O 121.126 0.488 . . . . 0.0 109.918 179.579 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 12.3 mm-40 -48.66 135.42 13.41 Favored Pre-proline 0 C--N 1.317 -0.805 0 CA-C-N 115.609 -0.723 . . . . 0.0 111.042 -178.558 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 69' ' ' PRO . . . . . 0.407 ' O ' HD12 ' A' ' 71' ' ' ILE . 70.9 Cg_endo -75.33 153.01 39.92 Favored 'Trans proline' 0 N--CA 1.496 1.673 0 C-N-CA 122.882 2.388 . . . . 0.0 111.61 178.8 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 72.43 12.04 76.72 Favored Glycine 0 CA--C 1.521 0.425 0 N-CA-C 111.186 -0.766 . . . . 0.0 111.186 179.479 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 71' ' ' ILE . . . . . 0.537 ' O ' ' NH1' ' B' ' 223' ' ' ARG . 1.7 mp -118.38 147.92 21.56 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.381 0 CA-C-O 121.251 0.548 . . . . 0.0 109.897 -179.878 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 72' ' ' ASP . . . . . 0.513 ' O ' ' HB3' ' A' ' 44' ' ' ALA . 3.1 t70 -86.51 112.39 21.49 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.257 -0.883 . . . . 0.0 110.752 179.947 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 73' ' ' TYR . . . . . 0.548 ' CE2' ' HB2' ' A' ' 43' ' ' ALA . 14.8 m-85 -106.25 119.58 39.62 Favored 'General case' 0 C--O 1.218 -0.601 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.027 179.494 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 74' ' ' ASP . . . . . 0.538 ' N ' ' O ' ' A' ' 42' ' ' VAL . 72.1 m-20 -88.29 117.53 27.27 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.741 -0.663 . . . . 0.0 109.576 179.442 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.643 HD11 ' N ' ' B' ' 223' ' ' ARG . 0.0 OUTLIER -114.59 165.97 9.03 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-O 121.038 0.447 . . . . 0.0 110.344 -179.457 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -155.14 120.73 5.04 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.586 -0.734 . . . . 0.0 110.976 179.273 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.448 ' O ' HG23 ' B' ' 217' ' ' THR . 8.9 t -100.31 101.88 12.69 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 N-CA-C 109.835 -0.431 . . . . 0.0 109.835 179.22 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 95.7 mt -88.8 126.86 41.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.648 -179.756 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 96.6 m -108.36 111.31 23.17 Favored 'General case' 0 CA--C 1.517 -0.303 0 CA-C-O 121.011 0.434 . . . . 0.0 109.984 179.7 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 51.4 tp -120.73 125.04 46.63 Favored 'General case' 0 CA--C 1.519 -0.234 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.875 179.965 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 81' ' ' ILE . . . . . 0.526 ' HB ' ' H ' ' A' ' 33' ' ' THR . 2.0 pp -144.69 143.83 22.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.279 178.991 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 82' ' ' ASN . . . . . 0.459 ' N ' ' OG1' ' A' ' 33' ' ' THR . 62.8 t-20 -64.47 -53.01 54.92 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.334 -0.394 . . . . 0.0 111.204 -179.856 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 83' ' ' GLY . . . . . 0.585 ' H ' ' HG1' ' A' ' 33' ' ' THR . . . 106.45 155.08 20.84 Favored Glycine 0 CA--C 1.521 0.461 0 N-CA-C 110.665 -0.974 . . . . 0.0 110.665 179.457 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -91.23 112.95 4.22 Favored Glycine 0 CA--C 1.524 0.634 0 N-CA-C 110.823 -0.911 . . . . 0.0 110.823 179.889 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.532 ' OE1' ' N ' ' A' ' 85' ' ' GLU . 58.2 mp0 -84.71 147.63 26.81 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.871 0.367 . . . . 0.0 110.663 179.933 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 30.5 t -78.05 131.01 37.14 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.352 179.904 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.676 ' HB3' ' HD3' ' A' ' 88' ' ' PRO . . . -67.96 -61.39 4.23 Favored Pre-proline 0 C--N 1.325 -0.468 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.232 179.187 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 88' ' ' PRO . . . . . 0.676 ' HD3' ' HB3' ' A' ' 87' ' ' ALA . 26.5 Cg_endo -61.11 144.76 99.32 Favored 'Trans proline' 0 C--N 1.308 -1.571 0 C-N-CA 122.642 2.228 . . . . 0.0 111.781 -179.757 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -136.04 124.58 23.59 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.484 179.546 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 92.9 m -133.1 132.34 41.6 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.368 179.872 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 91' ' ' LEU . . . . . 0.596 HD12 ' O ' ' A' ' 91' ' ' LEU . 0.3 OUTLIER -89.84 154.78 19.62 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.194 -179.894 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 76.9 p -68.99 136.67 52.84 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.481 179.77 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 29.4 mm100 -95.71 116.6 29.11 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.446 179.904 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 84.9 mt-30 -67.24 -34.23 77.0 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.481 179.829 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 60.3 p . . . . . 0 C--O 1.22 -0.496 0 CA-C-O 117.958 -1.02 . . . . 0.0 110.486 -179.79 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' B' B ' 201' ' ' SER . . . . . . . . . . . . . 59.4 p . . . . . 0 N--CA 1.49 1.567 0 N-CA-C 109.326 -0.62 . . . . 0.0 109.326 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' B' B ' 202' ' ' SER . . . . . . . . . . . . . 28.3 m -72.2 145.63 47.88 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.4 -179.961 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 203' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -95.25 151.67 38.88 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.552 -179.872 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 204' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -71.43 4.17 3.12 Favored 'Trans proline' 0 C--N 1.312 -1.369 0 C-N-CA 122.711 2.274 . . . . 0.0 112.04 179.773 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 205' ' ' ILE . . . . . 0.419 HD12 ' HA ' ' B' ' 205' ' ' ILE . 10.7 tp -148.4 151.36 13.38 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.328 0 CA-C-O 120.755 0.312 . . . . 0.0 111.173 179.754 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 206' ' ' GLN . . . . . . . . . . . . . 8.8 pt20 -173.87 78.47 0.03 OUTLIER 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.623 179.501 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 207' ' ' GLY . . . . . . . . . . . . . . . -108.63 -147.05 12.3 Favored Glycine 0 N--CA 1.464 0.551 0 N-CA-C 111.241 -0.743 . . . . 0.0 111.241 179.879 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 208' ' ' SER . . . . . 0.5 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 33.2 p -164.49 172.26 13.55 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.726 0.298 . . . . 0.0 110.767 -179.676 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 209' ' ' TRP . . . . . . . . . . . . . 73.2 m95 -85.35 151.15 24.24 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.284 -0.417 . . . . 0.0 110.357 179.529 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 81.6 p -131.66 137.64 48.42 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.387 -0.37 . . . . 0.0 110.903 -179.964 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 47.4 t-105 -95.54 115.45 27.44 Favored 'General case' 0 C--N 1.331 -0.199 0 N-CA-C 109.87 -0.418 . . . . 0.0 109.87 179.402 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 212' ' ' GLU . . . . . 0.512 ' O ' ' O ' ' B' ' 215' ' ' LYS . 2.8 tt0 -161.33 150.7 16.54 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.578 179.59 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 213' ' ' ASN . . . . . 0.425 ' N ' ' HG3' ' B' ' 212' ' ' GLU . 13.2 m120 59.68 42.2 17.37 Favored 'General case' 0 N--CA 1.448 -0.53 0 CA-C-N 115.901 -0.591 . . . . 0.0 111.166 177.145 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 49.86 12.95 0.5 Allowed Glycine 0 CA--C 1.521 0.417 0 N-CA-C 111.63 -0.588 . . . . 0.0 111.63 179.161 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 215' ' ' LYS . . . . . 0.512 ' O ' ' O ' ' B' ' 212' ' ' GLU . 68.1 mttm -142.04 150.58 41.46 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.054 0.454 . . . . 0.0 110.457 -179.997 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 216' ' ' TRP . . . . . . . . . . . . . 45.7 m95 -86.13 122.31 29.97 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.42 -0.355 . . . . 0.0 110.119 -179.941 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 217' ' ' THR . . . . . 0.448 HG23 ' O ' ' A' ' 77' ' ' VAL . 18.8 m -129.19 141.51 51.14 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.934 0.397 . . . . 0.0 110.426 -179.677 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 218' ' ' TRP . . . . . 0.5 ' CH2' ' N ' ' B' ' 208' ' ' SER . 16.7 t-105 -105.43 118.02 35.5 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-N 115.888 -0.596 . . . . 0.0 109.742 179.477 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 24.0 mtmm -142.13 173.76 11.23 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.798 -179.882 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -176.39 -161.27 25.09 Favored Glycine 0 CA--C 1.523 0.57 0 N-CA-C 111.243 -0.743 . . . . 0.0 111.243 -179.698 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 221' ' ' ILE . . . . . 0.561 ' O ' HG23 ' B' ' 222' ' ' ILE . 30.5 mt -52.39 -73.39 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 C-N-CA 120.812 -0.355 . . . . 0.0 110.228 -178.534 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 222' ' ' ILE . . . . . 0.561 HG23 ' O ' ' B' ' 221' ' ' ILE . 20.5 pt -158.97 -165.89 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.208 0 CA-C-N 116.301 -0.408 . . . . 0.0 110.458 -179.932 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 223' ' ' ARG . . . . . 0.643 ' N ' HD11 ' A' ' 75' ' ' ILE . 30.7 ptt-85 -44.31 174.55 0.0 OUTLIER 'General case' 0 N--CA 1.456 -0.17 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.281 179.378 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 224' ' ' LEU . . . . . 0.787 HD22 ' N ' ' B' ' 224' ' ' LEU . 2.6 mm? -62.13 117.97 6.73 Favored 'General case' 0 C--N 1.316 -0.886 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.768 -179.516 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 81.7 tt0 -85.0 149.8 25.34 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.612 -0.722 . . . . 0.0 110.642 -179.93 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 226' ' ' GLN . . . . . . . . . . . . . 53.4 tt0 . . . . . 0 C--O 1.22 -0.453 0 CA-C-O 117.951 -1.024 . . . . 0.0 110.485 179.958 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.411 0 N-CA-C 109.479 -1.449 . . . . 0.0 109.479 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 21.6 m -69.83 142.33 53.13 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.855 0.359 . . . . 0.0 110.307 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 15.9 pt-20 -69.15 137.3 53.23 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.483 -179.942 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.527 ' O ' HG13 ' A' ' 6' ' ' VAL . 7.3 p -84.01 116.64 65.77 Favored Pre-proline 0 CA--C 1.54 0.571 0 C-N-CA 120.863 -0.335 . . . . 0.0 110.677 -179.561 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 71.3 Cg_endo -75.54 143.05 26.98 Favored 'Trans proline' 0 N--CA 1.495 1.575 0 C-N-CA 121.997 1.798 . . . . 0.0 112.21 -179.993 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 96.9 mm-40 -82.02 -163.78 0.71 Allowed 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.383 -0.371 . . . . 0.0 110.083 179.842 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.564 HD12 ' N ' ' A' ' 9' ' ' LEU . 10.2 mp -77.06 129.4 36.0 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.263 -179.998 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 6.1 p -81.53 149.44 28.68 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.329 179.832 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 4.1 p30 -92.2 165.03 13.34 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.494 179.929 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.622 HD23 ' H ' ' A' ' 13' ' ' SER . 0.5 OUTLIER -68.02 151.41 47.11 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.307 -179.784 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 13' ' ' SER . . . . . 0.622 ' H ' HD23 ' A' ' 12' ' ' LEU . 61.6 p -143.25 149.39 37.83 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.608 179.568 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 14' ' ' PHE . . . . . 0.527 ' CD1' ' N ' ' A' ' 14' ' ' PHE . 17.4 m-85 -112.34 147.02 37.24 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.879 -0.6 . . . . 0.0 110.649 -179.599 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 23.3 m -147.54 156.61 9.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.398 179.43 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 38.2 t0 60.78 28.47 18.21 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.616 179.897 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 96.5 mt -55.88 132.39 19.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.062 179.799 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.437 HG22 ' H ' ' A' ' 19' ' ' ASP . 0.2 OUTLIER -131.12 -169.36 2.16 Favored 'General case' 0 N--CA 1.467 0.409 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.469 -179.839 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 19' ' ' ASP . . . . . 0.477 ' N ' ' OD1' ' A' ' 19' ' ' ASP . 17.5 p-10 -77.65 -49.26 14.9 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.963 179.513 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 20' ' ' SER . . . . . 0.513 ' OG ' ' N ' ' A' ' 67' ' ' LEU . 31.1 t -120.46 13.39 11.79 Favored 'General case' 0 N--CA 1.466 0.358 0 CA-C-N 116.511 -0.313 . . . . 0.0 110.704 -179.252 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 21' ' ' SER . . . . . 0.529 ' HB3' HG22 ' A' ' 65' ' ' THR . 3.8 m -146.56 129.8 16.62 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.237 -179.307 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 22' ' ' ILE . . . . . 0.516 HD12 HD21 ' A' ' 24' ' ' LEU . 47.7 pt -125.78 142.25 43.09 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-N 116.288 -0.415 . . . . 0.0 109.979 179.756 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -98.28 83.08 0.65 Allowed Glycine 0 CA--C 1.523 0.593 0 N-CA-C 110.507 -1.037 . . . . 0.0 110.507 -179.345 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.516 HD21 HD12 ' A' ' 22' ' ' ILE . 92.0 mt -65.57 128.09 34.52 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 110.013 -0.365 . . . . 0.0 110.013 -179.634 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 25' ' ' ARG . . . . . 0.44 ' O ' ' O ' ' A' ' 13' ' ' SER . 1.2 tpp180 -147.75 134.86 20.4 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.045 179.832 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 26' ' ' TRP . . . . . 0.554 ' CE3' ' O ' ' A' ' 60' ' ' GLY . 4.9 p90 -140.29 128.45 22.32 Favored 'General case' 0 C--O 1.223 -0.299 0 N-CA-C 109.223 -0.658 . . . . 0.0 109.223 177.73 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 1.9 m -68.34 113.27 14.32 Favored Pre-proline 0 CA--C 1.538 0.49 0 C-N-CA 120.528 -0.469 . . . . 0.0 111.011 -179.633 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 32.7 Cg_exo -59.53 152.39 62.28 Favored 'Trans proline' 0 N--CA 1.498 1.744 0 C-N-CA 121.993 1.795 . . . . 0.0 112.599 178.473 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.433 ' H ' ' HB2' ' A' ' 32' ' ' SER . 77.9 mt -102.16 133.43 47.03 Favored 'General case' 0 CA--C 1.518 -0.254 0 CA-C-O 121.682 0.754 . . . . 0.0 110.651 179.728 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 11.7 t-20 -42.79 -30.54 0.4 Allowed 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 115.352 -0.84 . . . . 0.0 110.47 -179.725 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 58.1 m -87.88 -36.64 17.07 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.483 179.087 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 32' ' ' SER . . . . . 0.433 ' HB2' ' H ' ' A' ' 29' ' ' LEU . 3.1 m -45.73 113.54 0.62 Allowed 'General case' 0 N--CA 1.461 0.115 0 CA-C-O 121.091 0.472 . . . . 0.0 110.306 -179.661 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 33' ' ' THR . . . . . 0.519 ' OG1' ' N ' ' A' ' 82' ' ' ASN . 7.2 m -52.24 150.01 4.97 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.601 -0.727 . . . . 0.0 109.448 -179.251 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 19.6 mm -93.92 92.65 3.66 Favored 'Isoleucine or valine' 0 C--O 1.232 0.135 0 CA-C-O 121.11 0.481 . . . . 0.0 110.995 -178.51 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.6 HD11 ' HA ' ' A' ' 81' ' ' ILE . 6.6 pt -151.23 124.84 1.34 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.252 179.288 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -48.25 131.4 19.84 Favored Glycine 0 CA--C 1.519 0.336 0 N-CA-C 110.786 -0.925 . . . . 0.0 110.786 -179.624 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 37' ' ' TYR . . . . . 0.571 ' O ' ' CD1' ' A' ' 37' ' ' TYR . 0.6 OUTLIER -104.13 130.07 51.85 Favored 'General case' 0 C--N 1.329 -0.322 0 N-CA-C 109.691 -0.485 . . . . 0.0 109.691 -179.895 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 38' ' ' ARG . . . . . 0.516 ' NH1' ' OG1' ' A' ' 40' ' ' THR . 7.9 tmm_? -79.59 132.27 36.23 Favored 'General case' 0 C--N 1.325 -0.472 0 C-N-CA 120.743 -0.383 . . . . 0.0 111.003 -179.895 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.559 HG22 ' CE2' ' A' ' 37' ' ' TYR . 1.9 pt -104.51 122.58 57.65 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.329 0 N-CA-C 109.585 -0.524 . . . . 0.0 109.585 179.179 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 40' ' ' THR . . . . . 0.516 ' OG1' ' NH1' ' A' ' 38' ' ' ARG . 7.1 m -99.44 136.52 39.26 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.425 -179.022 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.4 p -133.31 141.55 44.25 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.288 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.133 179.855 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 42' ' ' VAL . . . . . 0.499 ' O ' ' N ' ' A' ' 74' ' ' ASP . 39.9 t -132.59 132.48 59.96 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.24 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 179.607 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.438 ' HB2' ' CE2' ' A' ' 73' ' ' TYR . . . -99.35 136.62 39.03 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 116.09 -0.504 . . . . 0.0 109.651 178.921 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.632 ' HB3' ' O ' ' A' ' 72' ' ' ASP . . . -99.02 -15.43 19.07 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-O 120.806 0.336 . . . . 0.0 110.85 -179.801 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -99.62 24.99 30.0 Favored Glycine 0 CA--C 1.525 0.7 0 N-CA-C 111.093 -0.803 . . . . 0.0 111.093 -179.44 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 93.5 mt-10 -145.95 149.37 34.05 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.97 0.414 . . . . 0.0 110.337 179.936 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -66.59 -21.06 70.54 Favored Glycine 0 CA--C 1.519 0.302 0 N-CA-C 110.67 -0.972 . . . . 0.0 110.67 179.896 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -132.23 139.58 35.35 Favored Pre-proline 0 CA--C 1.539 0.527 0 C-N-CA 121.224 -0.19 . . . . 0.0 110.524 179.873 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 61.3 Cg_endo -73.93 161.87 40.4 Favored 'Trans proline' 0 N--CA 1.49 1.281 0 C-N-CA 122.469 2.113 . . . . 0.0 111.96 177.613 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 96.8 mt -77.48 149.96 5.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.461 179.354 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 76.1 m-85 -72.47 141.59 48.59 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.678 179.78 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 52' ' ' GLU . . . . . 0.414 ' N ' ' CD ' ' A' ' 52' ' ' GLU . 0.2 OUTLIER -61.77 -177.07 0.1 Allowed 'General case' 0 CA--C 1.517 -0.321 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.418 179.275 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -144.33 135.29 25.16 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 115.637 -0.71 . . . . 0.0 110.301 179.706 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 86.7 m-85 -108.46 116.55 32.19 Favored 'General case' 0 N--CA 1.465 0.287 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.374 179.697 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 9.2 p -130.35 143.77 39.99 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.291 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.145 179.77 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 95.5 m-20 -66.79 151.16 48.02 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.595 179.626 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 4.4 t -64.99 -32.04 73.58 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.628 179.86 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 50.4 m -52.57 -38.58 60.23 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.485 -179.703 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.467 HG12 ' O ' ' A' ' 61' ' ' TYR . 23.8 t -60.66 -43.03 94.0 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 -179.942 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 60' ' ' GLY . . . . . 0.554 ' O ' ' CE3' ' A' ' 26' ' ' TRP . . . 75.19 -40.91 1.27 Allowed Glycine 0 CA--C 1.529 0.919 0 N-CA-C 110.846 -0.902 . . . . 0.0 110.846 179.651 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 61' ' ' TYR . . . . . 0.467 ' O ' HG12 ' A' ' 59' ' ' VAL . 26.9 p90 -113.46 158.64 20.43 Favored 'General case' 0 N--CA 1.469 0.495 0 CA-C-O 121.048 0.451 . . . . 0.0 111.245 -178.881 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 62' ' ' TYR . . . . . 0.411 ' CD2' ' CD1' ' A' ' 39' ' ' ILE . 33.3 t80 -152.93 149.5 28.29 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 179.541 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 79.8 m -112.4 133.93 54.22 Favored 'General case' 0 CA--C 1.52 -0.195 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.468 -179.445 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -132.36 100.09 3.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 115.854 -0.612 . . . . 0.0 109.834 178.762 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.529 HG22 ' HB3' ' A' ' 21' ' ' SER . 2.0 p -114.37 164.18 14.29 Favored 'General case' 0 CA--C 1.515 -0.38 0 CA-C-O 120.908 0.385 . . . . 0.0 110.524 -179.942 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 107.79 25.63 5.87 Favored Glycine 0 CA--C 1.524 0.622 0 N-CA-C 111.172 -0.771 . . . . 0.0 111.172 179.75 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.513 ' N ' ' OG ' ' A' ' 20' ' ' SER . 11.9 mt -100.72 109.44 21.47 Favored 'General case' 0 N--CA 1.465 0.318 0 N-CA-C 109.284 -0.636 . . . . 0.0 109.284 179.944 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 55.5 mm-40 -52.04 139.53 33.57 Favored Pre-proline 0 C--N 1.316 -0.887 0 C-N-CA 120.496 -0.482 . . . . 0.0 112.054 -178.589 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 69' ' ' PRO . . . . . 0.428 ' C ' ' H ' ' A' ' 71' ' ' ILE . 74.4 Cg_endo -73.91 157.52 47.24 Favored 'Trans proline' 0 N--CA 1.498 1.748 0 C-N-CA 122.86 2.373 . . . . 0.0 111.253 178.574 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 69.97 -8.54 3.49 Favored Glycine 0 CA--C 1.527 0.822 0 CA-C-N 115.844 -0.616 . . . . 0.0 111.653 178.855 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 71' ' ' ILE . . . . . 0.524 ' O ' ' NH1' ' B' ' 223' ' ' ARG . 1.6 mp -98.76 149.19 5.53 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 N-CA-C 109.229 -0.656 . . . . 0.0 109.229 -179.702 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 72' ' ' ASP . . . . . 0.632 ' O ' ' HB3' ' A' ' 44' ' ' ALA . 2.7 t70 -89.51 115.61 27.06 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.165 -0.925 . . . . 0.0 110.422 179.657 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 73' ' ' TYR . . . . . 0.493 ' O ' HD13 ' A' ' 75' ' ' ILE . 20.9 m-85 -108.48 119.74 40.38 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.425 179.951 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 74' ' ' ASP . . . . . 0.499 ' N ' ' O ' ' A' ' 42' ' ' VAL . 13.4 m-20 -89.8 118.13 29.16 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 115.548 -0.751 . . . . 0.0 109.646 179.824 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.493 HD13 ' O ' ' A' ' 73' ' ' TYR . 0.0 OUTLIER -115.9 164.24 12.42 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-O 121.192 0.52 . . . . 0.0 109.919 -179.139 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -152.92 128.88 10.3 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.659 -0.7 . . . . 0.0 110.216 179.667 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 62.8 t -108.27 131.79 57.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 179.461 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 96.5 mt -124.51 124.45 68.32 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 115.991 -0.549 . . . . 0.0 110.344 179.458 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 95.1 m -100.86 114.41 28.23 Favored 'General case' 0 C--O 1.232 0.181 0 CA-C-O 120.922 0.391 . . . . 0.0 110.081 179.636 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 80' ' ' LEU . . . . . 0.754 HD23 ' HZ1' ' B' ' 215' ' ' LYS . 9.6 mt -118.68 113.96 22.0 Favored 'General case' 0 CA--C 1.518 -0.251 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.253 -179.988 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 81' ' ' ILE . . . . . 0.6 ' HA ' HD11 ' A' ' 35' ' ' ILE . 2.3 pp -147.47 144.84 19.4 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.042 179.146 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 82' ' ' ASN . . . . . 0.519 ' N ' ' OG1' ' A' ' 33' ' ' THR . 39.9 t30 -64.66 -47.55 78.06 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 120.942 0.401 . . . . 0.0 111.189 179.892 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 90.71 161.92 37.8 Favored Glycine 0 CA--C 1.521 0.466 0 N-CA-C 110.923 -0.871 . . . . 0.0 110.923 179.578 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -78.87 176.95 54.4 Favored Glycine 0 CA--C 1.524 0.63 0 N-CA-C 110.76 -0.936 . . . . 0.0 110.76 179.914 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 80.1 mm-40 -52.25 166.07 0.19 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.879 0.371 . . . . 0.0 110.442 -179.984 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 33.2 t -59.62 139.74 56.94 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.588 -179.659 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . 60.03 72.47 0.76 Allowed Pre-proline 0 C--N 1.328 -0.333 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.456 -179.895 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_exo -52.81 -37.67 76.93 Favored 'Trans proline' 0 C--N 1.308 -1.575 0 C-N-CA 122.937 2.424 . . . . 0.0 112.283 -179.86 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 89' ' ' THR . . . . . 0.434 ' O ' HG23 ' A' ' 89' ' ' THR . 6.2 t -130.65 125.33 33.75 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.528 179.994 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 9.6 p -86.73 168.03 13.91 Favored 'General case' 0 C--N 1.333 -0.15 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.302 179.707 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 91' ' ' LEU . . . . . 0.55 HD12 ' N ' ' A' ' 91' ' ' LEU . 10.0 mp -89.39 121.79 31.98 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-O 121.07 0.462 . . . . 0.0 110.086 -179.785 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 61.5 p -84.86 164.9 18.14 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.921 -0.582 . . . . 0.0 110.337 179.893 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 88.4 mt-30 -72.73 136.6 45.57 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.462 -179.94 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 8.5 tp-100 -63.15 -40.5 97.73 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.403 -179.792 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 13.4 m . . . . . 0 C--O 1.222 -0.354 0 CA-C-O 117.999 -1.0 . . . . 0.0 110.543 -179.983 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' B' B ' 201' ' ' SER . . . . . . . . . . . . . 22.0 t . . . . . 0 N--CA 1.49 1.538 0 N-CA-C 109.337 -0.616 . . . . 0.0 109.337 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' B' B ' 202' ' ' SER . . . . . . . . . . . . . 15.9 p -69.08 141.11 54.83 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.624 -179.828 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 203' ' ' SER . . . . . . . . . . . . . 1.8 m -89.54 152.04 46.74 Favored Pre-proline 0 CA--C 1.535 0.388 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.616 -179.625 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 204' ' ' PRO . . . . . . . . . . . . . 25.9 Cg_endo -60.67 -48.69 10.35 Favored 'Trans proline' 0 N--CA 1.496 1.664 0 C-N-CA 122.733 2.288 . . . . 0.0 111.744 -179.744 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 205' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -149.69 145.14 17.66 Favored 'Isoleucine or valine' 0 C--O 1.233 0.212 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.402 -179.893 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 206' ' ' GLN . . . . . . . . . . . . . 49.4 tt0 -138.54 139.46 38.7 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.374 178.894 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 207' ' ' GLY . . . . . . . . . . . . . . . -97.61 -133.66 7.97 Favored Glycine 0 N--CA 1.463 0.486 0 N-CA-C 110.957 -0.857 . . . . 0.0 110.957 180.0 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 208' ' ' SER . . . . . 0.536 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 98.9 p -164.52 168.35 18.41 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.862 0.363 . . . . 0.0 110.711 179.238 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 209' ' ' TRP . . . . . . . . . . . . . 85.4 m95 -88.89 150.95 22.63 Favored 'General case' 0 C--O 1.233 0.205 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.522 179.54 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 82.3 p -129.09 129.0 44.67 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-N 116.487 -0.324 . . . . 0.0 110.394 179.532 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 58.7 t-105 -91.41 110.62 21.93 Favored 'General case' 0 C--N 1.333 -0.112 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.586 179.82 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 212' ' ' GLU . . . . . 0.437 ' O ' ' O ' ' B' ' 215' ' ' LYS . 0.6 OUTLIER -161.26 165.93 28.45 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.541 179.654 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' B' B ' 213' ' ' ASN . . . . . . . . . . . . . 69.7 m-20 51.02 35.25 12.33 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.89 -0.595 . . . . 0.0 110.978 176.436 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 51.17 19.97 4.35 Favored Glycine 0 CA--C 1.525 0.661 0 N-CA-C 110.954 -0.858 . . . . 0.0 110.954 179.946 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 215' ' ' LYS . . . . . 0.754 ' HZ1' HD23 ' A' ' 80' ' ' LEU . 14.9 mtpt -145.79 150.58 36.46 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 121.066 0.46 . . . . 0.0 110.985 179.983 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 216' ' ' TRP . . . . . . . . . . . . . 52.4 m95 -87.19 114.43 23.79 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.866 -0.606 . . . . 0.0 109.883 179.233 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 217' ' ' THR . . . . . . . . . . . . . 46.4 m -118.36 135.07 54.54 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.694 -179.587 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 218' ' ' TRP . . . . . 0.536 ' CH2' ' N ' ' B' ' 208' ' ' SER . 29.5 t-105 -106.39 104.0 13.59 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 115.907 -0.588 . . . . 0.0 109.876 178.868 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 16.7 mtpp -134.38 173.8 11.23 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.558 -179.303 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -179.53 -160.94 26.05 Favored Glycine 0 CA--C 1.524 0.599 0 N-CA-C 110.761 -0.936 . . . . 0.0 110.761 179.819 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 221' ' ' ILE . . . . . 0.688 ' H ' HD12 ' B' ' 221' ' ' ILE . 1.9 mp -54.1 -73.14 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 C-N-CA 120.66 -0.416 . . . . 0.0 110.261 -178.804 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 222' ' ' ILE . . . . . 0.553 HG23 ' O ' ' B' ' 221' ' ' ILE . 21.8 pt -160.51 -165.28 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.212 -179.799 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 223' ' ' ARG . . . . . 0.536 ' O ' ' O ' ' B' ' 222' ' ' ILE . 35.9 ptt-85 -40.28 174.03 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.973 178.605 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 224' ' ' LEU . . . . . 0.789 HD22 ' N ' ' B' ' 224' ' ' LEU . 2.2 mm? -63.45 110.16 1.86 Allowed 'General case' 0 N--CA 1.447 -0.613 0 CA-C-N 115.799 -0.637 . . . . 0.0 111.079 -179.673 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 33.8 tp10 -95.83 148.52 22.51 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.394 -0.821 . . . . 0.0 110.002 -179.865 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 226' ' ' GLN . . . . . . . . . . . . . 15.7 tt0 . . . . . 0 C--O 1.22 -0.482 0 CA-C-O 118.076 -0.964 . . . . 0.0 110.749 -179.873 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.306 0 N-CA-C 109.536 -1.426 . . . . 0.0 109.536 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 34.7 t -66.64 140.74 57.94 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.736 0.303 . . . . 0.0 110.549 179.977 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 42.4 tt0 -75.06 148.39 39.84 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.328 179.875 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.0 m -129.22 81.29 70.77 Favored Pre-proline 0 N--CA 1.464 0.264 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.243 -179.966 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_exo -56.46 140.99 90.18 Favored 'Trans proline' 0 N--CA 1.495 1.581 0 C-N-CA 122.426 2.084 . . . . 0.0 111.605 -179.97 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 87.7 mt-30 -108.97 123.31 48.91 Favored 'General case' 0 CA--C 1.52 -0.2 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.33 -179.875 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 55.3 tp -84.8 108.04 17.27 Favored 'General case' 0 C--N 1.33 -0.26 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 179.546 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 10' ' ' THR . . . . . 0.646 HG21 ' HB ' ' A' ' 27' ' ' THR . 7.1 t -103.79 173.48 6.29 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.949 -0.569 . . . . 0.0 109.939 179.908 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 11' ' ' ASP . . . . . 0.406 ' OD1' ' O ' ' A' ' 10' ' ' THR . 97.7 m-20 -138.04 163.76 30.78 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.254 179.994 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 56.5 tp -66.27 138.35 57.59 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.562 -179.969 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 16.1 p -139.6 152.93 47.22 Favored 'General case' 0 N--CA 1.463 0.192 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.384 179.555 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 14' ' ' PHE . . . . . 0.516 ' CD1' ' N ' ' A' ' 14' ' ' PHE . 27.7 m-85 -111.54 144.12 41.29 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.837 -179.407 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 27.6 m -143.49 164.29 15.52 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.415 179.527 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 98.8 m-20 50.37 30.46 4.55 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.95 179.79 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 96.7 mt -55.78 138.51 16.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-O 120.921 0.391 . . . . 0.0 110.202 179.507 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.464 ' CB ' ' O ' ' A' ' 21' ' ' SER . 0.2 OUTLIER -135.7 -166.75 1.91 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.034 -179.48 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 19' ' ' ASP . . . . . 0.469 ' N ' ' OD1' ' A' ' 19' ' ' ASP . 27.8 p-10 -84.94 -46.58 11.11 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.831 179.489 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 20' ' ' SER . . . . . 0.464 ' N ' ' OD1' ' A' ' 19' ' ' ASP . 43.0 m -120.74 12.56 11.41 Favored 'General case' 0 N--CA 1.467 0.389 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.852 179.99 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 21' ' ' SER . . . . . 0.464 ' O ' ' CB ' ' A' ' 18' ' ' THR . 85.9 p -150.26 143.55 25.01 Favored 'General case' 0 N--CA 1.465 0.283 0 CA-C-O 121.037 0.446 . . . . 0.0 110.335 -179.943 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 40.7 pt -140.46 145.0 26.47 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.361 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.217 -179.992 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -96.31 85.85 0.89 Allowed Glycine 0 CA--C 1.522 0.497 0 N-CA-C 110.882 -0.887 . . . . 0.0 110.882 -179.906 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 89.9 mt -62.3 121.02 12.12 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 120.905 0.383 . . . . 0.0 110.05 -179.782 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 25' ' ' ARG . . . . . 0.503 ' NH1' ' O ' ' A' ' 26' ' ' TRP . 28.0 tpt85 -138.03 135.25 35.71 Favored 'General case' 0 CA--C 1.517 -0.301 0 CA-C-O 121.115 0.483 . . . . 0.0 110.199 -179.468 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 26' ' ' TRP . . . . . 0.503 ' O ' ' NH1' ' A' ' 25' ' ' ARG . 46.1 p90 -147.52 155.45 41.88 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.555 -0.748 . . . . 0.0 109.604 179.851 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 27' ' ' THR . . . . . 0.646 ' HB ' HG21 ' A' ' 10' ' ' THR . 6.2 m -111.34 98.12 38.62 Favored Pre-proline 0 C--N 1.33 -0.249 0 N-CA-C 110.102 -0.332 . . . . 0.0 110.102 179.66 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 32.5 Cg_exo -54.53 144.81 61.31 Favored 'Trans proline' 0 C--N 1.306 -1.692 0 C-N-CA 121.604 1.536 . . . . 0.0 113.275 179.909 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 57.1 mt -79.01 138.16 37.9 Favored 'General case' 0 CA--C 1.506 -0.743 0 CA-C-N 115.49 -0.777 . . . . 0.0 110.627 -179.567 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 34.1 t30 -50.45 -34.21 23.93 Favored 'General case' 0 C--N 1.313 -1.021 0 CA-C-N 114.856 -1.066 . . . . 0.0 110.098 179.523 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 49.2 m -79.82 -32.58 40.7 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.629 -0.714 . . . . 0.0 110.412 179.118 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 8.0 m -60.0 137.7 58.02 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.197 -179.932 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 33' ' ' THR . . . . . 0.611 ' CB ' ' H ' ' A' ' 82' ' ' ASN . 11.7 m -67.41 143.1 56.47 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.22 -179.645 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 28.8 mm -94.05 94.04 4.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 121.0 0.429 . . . . 0.0 110.176 -179.564 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 10.7 pt -143.49 131.4 18.67 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.274 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.416 -179.973 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -41.84 118.23 1.46 Allowed Glycine 0 CA--C 1.519 0.328 0 N-CA-C 111.318 -0.713 . . . . 0.0 111.318 -179.599 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 94.6 m-85 -85.09 178.88 7.39 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.875 0.369 . . . . 0.0 110.11 179.376 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 38' ' ' ARG . . . . . 0.549 ' NE ' ' OE1' ' A' ' 52' ' ' GLU . 0.0 OUTLIER -132.48 125.99 31.95 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.727 179.92 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.46 ' CD1' ' CD2' ' A' ' 62' ' ' TYR . 2.5 pt -100.24 123.81 53.35 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 115.657 -0.701 . . . . 0.0 110.018 179.78 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 40' ' ' THR . . . . . 0.449 ' OG1' ' NE ' ' A' ' 38' ' ' ARG . 28.2 m -109.04 133.09 53.46 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.612 -179.07 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.2 p -130.51 138.44 53.74 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.305 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.288 179.844 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 42' ' ' VAL . . . . . 0.467 ' O ' ' N ' ' A' ' 74' ' ' ASP . 31.7 t -131.94 130.95 61.69 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.269 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 179.979 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.455 ' HB1' ' CE1' ' A' ' 73' ' ' TYR . . . -96.44 135.87 37.73 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.765 -0.652 . . . . 0.0 109.32 179.677 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.607 ' HB3' ' O ' ' A' ' 72' ' ' ASP . . . -92.57 -47.24 7.22 Favored 'General case' 0 N--CA 1.464 0.24 0 C-N-CA 120.673 -0.411 . . . . 0.0 110.839 179.93 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -62.09 -29.55 73.09 Favored Glycine 0 N--CA 1.464 0.559 0 N-CA-C 110.891 -0.883 . . . . 0.0 110.891 179.997 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 46' ' ' GLU . . . . . 0.429 ' OE2' ' OH ' ' A' ' 73' ' ' TYR . 84.8 mt-10 -95.57 130.44 42.43 Favored 'General case' 0 C--N 1.328 -0.369 0 N-CA-C 109.477 -0.564 . . . . 0.0 109.477 -179.552 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -58.18 -21.17 45.98 Favored Glycine 0 CA--C 1.528 0.869 0 N-CA-C 110.857 -0.897 . . . . 0.0 110.857 -178.941 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -119.25 136.32 24.42 Favored Pre-proline 0 N--CA 1.472 0.661 0 CA-C-N 116.715 0.258 . . . . 0.0 110.543 179.676 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -77.9 167.5 23.63 Favored 'Trans proline' 0 N--CA 1.49 1.295 0 C-N-CA 122.409 2.072 . . . . 0.0 111.428 178.079 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 87.2 mt -86.22 141.66 14.14 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.235 0 CA-C-O 120.826 0.346 . . . . 0.0 110.245 179.081 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 76.3 m-85 -60.85 138.95 58.09 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.633 179.986 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 52' ' ' GLU . . . . . 0.549 ' OE1' ' NE ' ' A' ' 38' ' ' ARG . 5.9 pt-20 -69.64 -178.62 1.51 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.455 179.798 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 4.5 t70 -153.38 148.7 27.02 Favored 'General case' 0 N--CA 1.45 -0.444 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.748 179.367 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 58.0 m-85 -115.93 125.28 52.36 Favored 'General case' 0 N--CA 1.464 0.257 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.139 -179.929 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.9 p -125.64 134.49 66.56 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.341 0 CA-C-N 116.471 -0.331 . . . . 0.0 110.208 -179.985 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 98.9 m-20 -53.41 140.15 28.46 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.322 -179.653 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 10.4 t -60.4 -34.16 73.54 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.002 -0.544 . . . . 0.0 110.573 -179.763 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 43.7 m -55.24 -34.34 63.91 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.547 -179.731 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 99.9 t -62.31 -46.51 96.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.579 -179.871 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 61.25 26.38 65.98 Favored Glycine 0 CA--C 1.527 0.796 0 N-CA-C 110.568 -1.013 . . . . 0.0 110.568 179.635 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 52.6 t80 -167.44 152.03 6.89 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 121.121 0.486 . . . . 0.0 111.091 -179.513 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 62' ' ' TYR . . . . . 0.46 ' CD2' ' CD1' ' A' ' 39' ' ' ILE . 29.1 t80 -159.64 162.05 35.11 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 115.724 -0.671 . . . . 0.0 110.281 178.702 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 99.0 m -127.44 134.68 49.84 Favored 'General case' 0 N--CA 1.463 0.217 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.296 179.835 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -130.76 113.83 25.9 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.334 0 N-CA-C 109.513 -0.551 . . . . 0.0 109.513 178.877 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 1.9 p -122.93 157.33 32.84 Favored 'General case' 0 N--CA 1.467 0.418 0 CA-C-O 120.907 0.384 . . . . 0.0 110.413 -179.66 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 107.59 40.62 1.72 Allowed Glycine 0 CA--C 1.523 0.581 0 N-CA-C 110.628 -0.989 . . . . 0.0 110.628 -179.729 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 1.4 mt -116.79 110.83 18.9 Favored 'General case' 0 N--CA 1.465 0.304 0 N-CA-C 109.502 -0.555 . . . . 0.0 109.502 -179.896 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 27.6 mm-40 -48.84 141.34 10.27 Favored Pre-proline 0 C--N 1.322 -0.628 0 C-N-CA 120.862 -0.335 . . . . 0.0 111.249 -178.486 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 91.4 Cg_endo -74.89 158.37 42.66 Favored 'Trans proline' 0 N--CA 1.491 1.341 0 C-N-CA 122.481 2.121 . . . . 0.0 112.558 179.511 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 70' ' ' GLY . . . . . 0.409 ' N ' ' NH2' ' B' ' 223' ' ' ARG . . . 48.53 27.55 6.01 Favored Glycine 0 CA--C 1.529 0.951 0 CA-C-N 114.837 -1.074 . . . . 0.0 111.182 179.305 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 71' ' ' ILE . . . . . 0.736 ' H ' HH21 ' B' ' 223' ' ' ARG . 0.9 OUTLIER -114.0 166.36 7.93 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.483 0 CA-C-O 121.13 0.491 . . . . 0.0 109.698 -179.578 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 72' ' ' ASP . . . . . 0.607 ' O ' ' HB3' ' A' ' 44' ' ' ALA . 3.2 t70 -101.17 100.27 10.8 Favored 'General case' 0 N--CA 1.446 -0.649 0 CA-C-N 115.6 -0.727 . . . . 0.0 111.411 -178.715 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 73' ' ' TYR . . . . . 0.503 ' O ' HD13 ' A' ' 75' ' ' ILE . 2.2 m-30 -110.81 124.69 52.51 Favored 'General case' 0 C--O 1.22 -0.472 0 CA-C-O 121.322 0.582 . . . . 0.0 110.341 179.16 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 74' ' ' ASP . . . . . 0.467 ' N ' ' O ' ' A' ' 42' ' ' VAL . 21.5 m-20 -89.11 116.11 27.13 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 114.894 -1.048 . . . . 0.0 109.485 -179.909 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.578 HD11 ' N ' ' B' ' 223' ' ' ARG . 0.0 OUTLIER -116.17 162.1 14.43 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.221 0 CA-C-O 121.219 0.533 . . . . 0.0 110.084 -179.383 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 3.0 m -154.04 150.69 28.51 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.259 -0.882 . . . . 0.0 110.755 179.502 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.511 ' O ' HG13 ' A' ' 77' ' ' VAL . 4.1 p -132.9 101.14 4.2 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.245 0 CA-C-N 115.824 -0.625 . . . . 0.0 109.398 178.421 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 94.6 mt -82.95 127.81 39.32 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.183 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.451 -179.522 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 5.0 p -108.21 105.89 15.82 Favored 'General case' 0 N--CA 1.464 0.251 0 CA-C-N 116.143 -0.481 . . . . 0.0 109.709 179.422 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 7.0 tp -121.68 130.59 53.57 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.353 -179.867 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 81' ' ' ILE . . . . . 0.581 ' O ' HD12 ' A' ' 81' ' ' ILE . 1.6 pp -131.3 168.37 24.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.098 -0.501 . . . . 0.0 109.908 179.136 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 82' ' ' ASN . . . . . 0.611 ' H ' ' CB ' ' A' ' 33' ' ' THR . 9.8 t-20 -64.53 -43.03 95.31 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.813 0.34 . . . . 0.0 110.634 -179.992 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 157.8 115.85 0.46 Allowed Glycine 0 CA--C 1.526 0.753 0 N-CA-C 111.277 -0.729 . . . . 0.0 111.277 179.864 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -97.01 -174.6 34.75 Favored Glycine 0 CA--C 1.526 0.763 0 N-CA-C 110.85 -0.9 . . . . 0.0 110.85 179.74 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 16.6 pt-20 -75.52 132.38 40.7 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.845 0.355 . . . . 0.0 110.414 179.934 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 86' ' ' SER . . . . . 0.589 ' O ' ' HB2' ' A' ' 87' ' ' ALA . 90.3 p -81.4 164.25 22.23 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.34 179.914 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.589 ' HB2' ' O ' ' A' ' 86' ' ' SER . . . 169.02 154.0 0.15 Allowed Pre-proline 0 CA--C 1.534 0.359 0 CA-C-N 116.401 -0.363 . . . . 0.0 110.418 179.617 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 43.4 Cg_endo -67.04 151.8 81.27 Favored 'Trans proline' 0 N--CA 1.495 1.608 0 C-N-CA 122.72 2.28 . . . . 0.0 111.656 179.791 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 71.8 m -81.72 121.68 26.7 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.271 179.942 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 38.2 p -144.72 163.04 35.21 Favored 'General case' 0 C--N 1.332 -0.163 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.304 -179.94 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 91' ' ' LEU . . . . . 0.567 HD12 ' N ' ' A' ' 91' ' ' LEU . 9.6 mp -89.9 128.95 36.31 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.394 -0.366 . . . . 0.0 110.081 179.914 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 42.1 p -89.61 135.35 33.66 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.46 179.99 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 3.8 pt20 -75.07 139.87 43.1 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.593 -180.0 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 97.7 mt-30 -85.23 61.47 6.89 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.519 179.989 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 88.5 m . . . . . 0 C--O 1.219 -0.504 0 CA-C-O 118.042 -0.98 . . . . 0.0 110.558 179.982 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' B' B ' 201' ' ' SER . . . . . . . . . . . . . 39.4 t . . . . . 0 N--CA 1.489 1.496 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' B' B ' 202' ' ' SER . . . . . . . . . . . . . 48.5 t -65.17 141.69 58.59 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.192 -0.458 . . . . 0.0 109.825 179.626 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 203' ' ' SER . . . . . . . . . . . . . 27.6 p -123.83 108.24 30.71 Favored Pre-proline 0 CA--C 1.54 0.593 0 N-CA-C 110.067 -0.346 . . . . 0.0 110.067 179.795 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 204' ' ' PRO . . . . . . . . . . . . . 58.6 Cg_endo -76.73 -56.82 0.05 OUTLIER 'Trans proline' 0 N--CA 1.495 1.563 0 C-N-CA 121.729 1.619 . . . . 0.0 112.009 -179.758 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 205' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -150.17 144.69 17.41 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.3 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.107 -179.995 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 206' ' ' GLN . . . . . 0.437 ' N ' ' OE1' ' B' ' 206' ' ' GLN . 5.7 pm0 -146.38 145.28 30.22 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.999 -0.546 . . . . 0.0 109.795 179.572 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 207' ' ' GLY . . . . . . . . . . . . . . . -109.31 -131.9 6.36 Favored Glycine 0 N--CA 1.464 0.536 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 -179.793 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 208' ' ' SER . . . . . 0.497 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 97.1 p -164.14 170.03 16.96 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.81 0.338 . . . . 0.0 110.741 179.636 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 209' ' ' TRP . . . . . . . . . . . . . 71.9 m95 -82.93 145.59 29.3 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.412 179.529 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 40.3 p -127.33 131.29 50.45 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.565 179.942 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 41.4 t-105 -91.68 118.58 30.78 Favored 'General case' 0 N--CA 1.466 0.366 0 CA-C-N 116.18 -0.463 . . . . 0.0 109.928 179.596 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 212' ' ' GLU . . . . . 0.487 ' O ' ' O ' ' B' ' 215' ' ' LYS . 1.9 pt-20 -165.75 171.61 12.71 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.898 178.893 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 213' ' ' ASN . . . . . . . . . . . . . 93.9 m-20 48.07 38.08 8.99 Favored 'General case' 0 C--N 1.324 -0.537 0 C-N-CA 120.338 -0.545 . . . . 0.0 111.997 176.629 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 51.34 12.46 0.91 Allowed Glycine 0 CA--C 1.53 0.974 0 N-CA-C 111.536 -0.626 . . . . 0.0 111.536 179.644 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 215' ' ' LYS . . . . . 0.487 ' O ' ' O ' ' B' ' 212' ' ' GLU . 7.5 mtmp? -143.95 151.37 39.68 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.849 0.357 . . . . 0.0 110.962 -179.778 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 216' ' ' TRP . . . . . . . . . . . . . 49.0 m95 -87.0 124.93 33.72 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.25 179.285 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 217' ' ' THR . . . . . . . . . . . . . 5.0 m -138.63 148.1 43.69 Favored 'General case' 0 C--O 1.235 0.293 0 CA-C-O 121.052 0.453 . . . . 0.0 110.341 -179.809 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 218' ' ' TRP . . . . . 0.497 ' CH2' ' N ' ' B' ' 208' ' ' SER . 15.5 t-105 -105.25 121.66 44.32 Favored 'General case' 0 C--N 1.332 -0.167 0 CA-C-N 115.894 -0.593 . . . . 0.0 110.156 179.797 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 97.5 mttt -147.17 169.56 19.07 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.899 -179.996 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -174.83 -162.22 25.94 Favored Glycine 0 CA--C 1.522 0.496 0 N-CA-C 111.155 -0.778 . . . . 0.0 111.155 -179.884 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 221' ' ' ILE . . . . . 0.837 HG23 ' H ' ' B' ' 222' ' ' ILE . 12.2 tt -50.35 -69.71 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 C-N-CA 121.073 -0.251 . . . . 0.0 110.971 -177.977 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 222' ' ' ILE . . . . . 0.837 ' H ' HG23 ' B' ' 221' ' ' ILE . 9.6 pt -159.55 -165.2 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.317 -0.83 0 N-CA-C 109.327 -0.62 . . . . 0.0 109.327 178.377 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 223' ' ' ARG . . . . . 0.736 HH21 ' H ' ' A' ' 71' ' ' ILE . 39.1 ptt85 -44.47 174.98 0.0 OUTLIER 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 121.445 0.641 . . . . 0.0 111.04 178.717 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 224' ' ' LEU . . . . . 0.686 HD22 ' N ' ' B' ' 224' ' ' LEU . 3.2 mm? -59.95 127.48 32.1 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-N 115.046 -0.979 . . . . 0.0 110.377 -179.737 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 31.0 tp10 -83.03 150.56 26.27 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.738 -0.665 . . . . 0.0 110.155 -179.959 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 226' ' ' GLN . . . . . . . . . . . . . 54.1 tt0 . . . . . 0 C--N 1.326 -0.455 0 CA-C-O 117.891 -1.052 . . . . 0.0 110.625 -179.72 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.24 0 N-CA-C 109.525 -1.43 . . . . 0.0 109.525 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 59.9 p -79.5 80.53 5.87 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.842 0.353 . . . . 0.0 110.357 179.845 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 72.0 mm-40 -86.18 85.39 7.35 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.26 179.782 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.442 HG22 ' H ' ' A' ' 6' ' ' VAL . 3.3 m -86.57 149.18 48.27 Favored Pre-proline 0 CA--C 1.532 0.283 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.516 -179.732 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -66.7 145.47 75.69 Favored 'Trans proline' 0 N--CA 1.494 1.536 0 C-N-CA 122.517 2.145 . . . . 0.0 111.907 179.598 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 8.3 pt20 -137.55 130.66 30.57 Favored 'General case' 0 N--CA 1.463 0.193 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.146 179.459 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -103.71 125.07 49.95 Favored 'General case' 0 C--N 1.33 -0.25 0 N-CA-C 109.619 -0.512 . . . . 0.0 109.619 -179.848 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 55.3 p -130.97 154.77 47.8 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 121.026 0.441 . . . . 0.0 110.25 179.355 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 99.4 m-20 -84.8 171.16 12.5 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.385 -179.986 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.551 HD13 ' H ' ' A' ' 13' ' ' SER . 0.1 OUTLIER -60.85 139.0 58.09 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.152 -178.16 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 13' ' ' SER . . . . . 0.551 ' H ' HD13 ' A' ' 12' ' ' LEU . 96.3 p -143.27 144.55 32.17 Favored 'General case' 0 CA--C 1.521 -0.168 0 CA-C-N 115.837 -0.62 . . . . 0.0 110.621 179.931 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 14' ' ' PHE . . . . . 0.517 ' CD1' HD13 ' B' ' 205' ' ' ILE . 11.5 m-85 -112.34 143.77 42.89 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.397 -0.82 . . . . 0.0 110.754 -179.22 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 30.1 m -141.27 164.28 20.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.346 179.712 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 27.7 t70 53.63 34.22 18.24 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.08 179.849 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.49 ' N ' HD12 ' A' ' 17' ' ' ILE . 1.9 mp -56.51 132.06 20.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 N-CA-C 109.57 -0.53 . . . . 0.0 109.57 179.936 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -132.8 -169.13 2.19 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-N 116.021 -0.536 . . . . 0.0 109.916 179.711 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 20.7 p-10 -91.24 -41.84 10.74 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.698 179.388 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 43.1 t -113.52 6.44 17.07 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-N 116.363 -0.38 . . . . 0.0 110.99 -179.304 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 21' ' ' SER . . . . . 0.432 ' OG ' HG22 ' A' ' 65' ' ' THR . 38.3 t -154.1 152.61 30.64 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 121.131 0.491 . . . . 0.0 110.202 179.971 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 38.2 pt -142.2 146.26 22.76 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.049 179.816 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -94.75 82.82 0.92 Allowed Glycine 0 CA--C 1.524 0.652 0 N-CA-C 111.076 -0.81 . . . . 0.0 111.076 -179.723 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 76.1 mt -71.14 118.33 13.8 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 121.043 0.449 . . . . 0.0 110.211 179.901 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 56.4 ttt-85 -140.83 137.03 32.98 Favored 'General case' 0 CA--C 1.517 -0.318 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.436 179.935 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 26' ' ' TRP . . . . . . . . . . . . . 41.3 p90 -144.5 156.56 44.23 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.624 -0.716 . . . . 0.0 110.278 -179.36 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 2.2 m -108.05 102.31 45.35 Favored Pre-proline 0 CA--C 1.533 0.302 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.676 -179.953 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 41.7 Cg_exo -53.8 150.04 30.99 Favored 'Trans proline' 0 C--N 1.305 -1.761 0 C-N-CA 121.464 1.443 . . . . 0.0 112.673 179.274 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 60.9 mt -92.3 137.9 31.97 Favored 'General case' 0 CA--C 1.514 -0.425 0 CA-C-O 121.811 0.815 . . . . 0.0 110.809 -179.764 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 28.8 t-20 -47.56 -35.44 9.05 Favored 'General case' 0 C--N 1.313 -1.007 0 CA-C-N 115.056 -0.974 . . . . 0.0 110.092 179.952 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 53.0 m -79.8 -33.72 40.24 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.438 178.847 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 6.0 m -58.36 124.27 18.94 Favored 'General case' 0 CA--C 1.529 0.146 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.055 -179.86 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 33' ' ' THR . . . . . 0.587 ' CB ' ' H ' ' A' ' 82' ' ' ASN . 5.6 m -57.22 146.57 27.85 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.102 -179.762 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 20.5 mm -94.37 91.37 3.08 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.173 0 CA-C-O 121.047 0.451 . . . . 0.0 110.765 -179.377 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.486 HD11 ' HA ' ' A' ' 81' ' ' ILE . 22.1 pt -145.21 128.76 11.51 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.244 0 CA-C-N 115.714 -0.675 . . . . 0.0 110.597 179.815 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -42.65 125.84 4.44 Favored Glycine 0 CA--C 1.523 0.572 0 N-CA-C 111.086 -0.805 . . . . 0.0 111.086 -179.512 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 35.9 m-85 -90.83 -179.9 5.62 Favored 'General case' 0 CA--C 1.517 -0.29 0 N-CA-C 110.024 -0.362 . . . . 0.0 110.024 -179.88 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -131.45 121.34 24.37 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.553 179.753 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.439 ' O ' ' CG1' ' A' ' 39' ' ' ILE . 2.3 pt -95.95 124.29 48.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.008 -0.542 . . . . 0.0 109.716 179.828 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 4.8 m -106.74 132.77 52.33 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.398 -179.361 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.4 p -130.07 137.75 55.69 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.319 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.287 -179.979 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 42' ' ' VAL . . . . . 0.524 ' O ' ' N ' ' A' ' 74' ' ' ASP . 40.1 t -131.02 131.65 63.95 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.298 0 N-CA-C 109.743 -0.465 . . . . 0.0 109.743 179.671 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -97.92 141.26 31.11 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.137 -0.483 . . . . 0.0 109.817 179.273 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.565 ' HB3' ' O ' ' A' ' 72' ' ' ASP . . . -100.29 -23.68 14.73 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-O 120.828 0.347 . . . . 0.0 110.672 179.874 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -90.88 31.06 5.78 Favored Glycine 0 N--CA 1.466 0.636 0 N-CA-C 110.776 -0.93 . . . . 0.0 110.776 -179.963 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 64.2 mt-10 -151.8 150.8 30.55 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.951 0.405 . . . . 0.0 110.649 -179.738 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -72.1 -17.67 77.39 Favored Glycine 0 CA--C 1.524 0.62 0 N-CA-C 110.781 -0.928 . . . . 0.0 110.781 179.633 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -133.94 139.04 32.14 Favored Pre-proline 0 CA--C 1.544 0.738 0 CA-C-N 116.772 0.286 . . . . 0.0 110.507 -179.978 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 68.4 Cg_endo -73.89 161.84 40.54 Favored 'Trans proline' 0 N--CA 1.494 1.558 0 C-N-CA 122.631 2.221 . . . . 0.0 111.949 178.31 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 50' ' ' ILE . . . . . 0.492 HG22 ' N ' ' A' ' 51' ' ' PHE . 96.3 mt -75.72 159.26 5.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.381 179.419 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 51' ' ' PHE . . . . . 0.492 ' N ' HG22 ' A' ' 50' ' ' ILE . 0.9 OUTLIER -78.32 142.21 37.9 Favored 'General case' 0 CA--C 1.531 0.24 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.727 179.871 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 52' ' ' GLU . . . . . 0.51 ' CD ' ' H ' ' A' ' 52' ' ' GLU . 0.0 OUTLIER -71.01 -178.48 1.97 Allowed 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.39 179.433 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 53' ' ' ASP . . . . . 0.428 ' OD1' ' OH ' ' A' ' 62' ' ' TYR . 0.2 OUTLIER -148.27 139.74 23.56 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.147 179.75 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 96.2 m-85 -109.32 123.58 49.53 Favored 'General case' 0 N--CA 1.464 0.241 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.478 -179.94 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 5.9 p -131.48 141.29 46.2 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.245 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.215 -179.976 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 84.9 m-20 -58.92 151.03 22.71 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.591 -179.777 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 57' ' ' SER . . . . . 0.478 ' OG ' ' O ' ' A' ' 35' ' ' ILE . 3.7 m -61.66 -34.48 75.78 Favored 'General case' 0 C--O 1.233 0.22 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.84 179.839 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 69.2 m -53.5 -34.59 58.63 Favored 'General case' 0 C--N 1.326 -0.444 0 N-CA-C 109.943 -0.392 . . . . 0.0 109.943 -179.661 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.672 ' C ' ' H ' ' A' ' 61' ' ' TYR . 4.1 t -83.19 76.06 1.09 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.859 -179.826 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -58.72 26.53 0.02 OUTLIER Glycine 0 CA--C 1.539 1.589 0 N-CA-C 111.549 -0.62 . . . . 0.0 111.549 -179.641 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 61' ' ' TYR . . . . . 0.672 ' H ' ' C ' ' A' ' 59' ' ' VAL . 35.8 p90 -160.69 150.58 17.61 Favored 'General case' 0 N--CA 1.453 -0.325 0 CA-C-O 121.125 0.488 . . . . 0.0 111.6 179.986 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 62' ' ' TYR . . . . . 0.428 ' OH ' ' OD1' ' A' ' 53' ' ' ASP . 37.1 t80 -153.6 147.85 25.83 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.688 -0.687 . . . . 0.0 109.583 179.093 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 29.8 m -108.74 132.63 53.76 Favored 'General case' 0 N--CA 1.464 0.235 0 CA-C-O 121.037 0.446 . . . . 0.0 110.563 -179.31 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -132.03 106.16 10.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 115.924 -0.58 . . . . 0.0 109.723 178.662 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.432 HG22 ' OG ' ' A' ' 21' ' ' SER . 2.6 p -114.55 162.06 17.22 Favored 'General case' 0 N--CA 1.465 0.283 0 CA-C-O 120.978 0.418 . . . . 0.0 110.543 179.95 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 108.58 41.07 1.52 Allowed Glycine 0 CA--C 1.524 0.655 0 N-CA-C 111.256 -0.737 . . . . 0.0 111.256 -179.942 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 14.3 mt -115.2 109.07 17.45 Favored 'General case' 0 N--CA 1.466 0.353 0 N-CA-C 109.211 -0.662 . . . . 0.0 109.211 179.456 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 33.6 mm-40 -60.11 140.83 90.74 Favored Pre-proline 0 C--N 1.321 -0.642 0 C-N-CA 120.623 -0.431 . . . . 0.0 111.788 -178.403 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 93.8 Cg_endo -74.63 155.74 44.74 Favored 'Trans proline' 0 N--CA 1.497 1.682 0 C-N-CA 122.686 2.258 . . . . 0.0 111.73 178.802 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 71.61 7.55 65.15 Favored Glycine 0 CA--C 1.525 0.694 0 CA-C-N 115.635 -0.711 . . . . 0.0 111.629 179.128 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 1.6 mp -116.18 144.0 24.9 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.469 0 CA-C-O 121.441 0.639 . . . . 0.0 109.463 -179.934 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 72' ' ' ASP . . . . . 0.565 ' O ' ' HB3' ' A' ' 44' ' ' ALA . 2.1 t70 -84.73 114.18 21.86 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.143 -0.935 . . . . 0.0 110.869 179.943 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 73' ' ' TYR . . . . . 0.467 ' O ' HD13 ' A' ' 75' ' ' ILE . 23.7 m-85 -106.53 122.16 45.74 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 121.251 0.548 . . . . 0.0 110.306 179.849 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 74' ' ' ASP . . . . . 0.524 ' N ' ' O ' ' A' ' 42' ' ' VAL . 11.7 m-20 -91.42 117.5 29.74 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.209 -0.905 . . . . 0.0 109.432 179.625 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.556 HD11 ' N ' ' B' ' 223' ' ' ARG . 0.0 OUTLIER -115.27 165.92 9.85 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.422 0 CA-C-O 120.957 0.408 . . . . 0.0 110.267 -179.045 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -154.84 121.94 5.56 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.391 179.208 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.467 ' O ' HG23 ' B' ' 217' ' ' THR . 63.1 t -101.1 102.6 13.68 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 N-CA-C 109.335 -0.617 . . . . 0.0 109.335 179.011 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 95.9 mt -93.64 131.05 41.69 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.229 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.571 -179.591 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 71.3 m -109.28 111.27 22.75 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.078 -0.51 . . . . 0.0 109.917 179.391 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 37.6 tp -116.47 120.72 39.69 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.496 179.915 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 81' ' ' ILE . . . . . 0.707 ' O ' HD12 ' A' ' 81' ' ' ILE . 2.8 pp -142.68 153.97 17.65 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.278 179.397 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 82' ' ' ASN . . . . . 0.587 ' H ' ' CB ' ' A' ' 33' ' ' THR . 14.3 t-20 -65.69 -44.17 87.01 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 121.028 0.442 . . . . 0.0 110.932 179.963 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 90.14 158.23 34.24 Favored Glycine 0 CA--C 1.524 0.647 0 N-CA-C 111.0 -0.84 . . . . 0.0 111.0 179.761 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -81.63 156.74 37.18 Favored Glycine 0 CA--C 1.523 0.533 0 N-CA-C 110.757 -0.937 . . . . 0.0 110.757 179.868 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -88.88 137.6 32.17 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.822 0.344 . . . . 0.0 110.412 179.86 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 45.0 t -65.68 147.76 52.86 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.444 179.952 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.553 ' HB1' ' HD2' ' A' ' 88' ' ' PRO . . . -155.05 162.33 27.46 Favored Pre-proline 0 CA--C 1.534 0.35 0 CA-C-N 116.449 -0.341 . . . . 0.0 110.332 179.995 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 88' ' ' PRO . . . . . 0.553 ' HD2' ' HB1' ' A' ' 87' ' ' ALA . 56.8 Cg_endo -71.12 113.58 3.63 Favored 'Trans proline' 0 N--CA 1.494 1.523 0 C-N-CA 122.5 2.133 . . . . 0.0 111.705 179.494 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 29.8 m -142.13 147.55 36.86 Favored 'General case' 0 N--CA 1.464 0.235 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.387 179.843 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 12.9 p -85.91 -175.42 5.57 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.324 179.979 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 44.3 tp -57.58 125.4 22.74 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.293 -179.528 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 69.3 p -84.27 166.75 17.22 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.407 179.975 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 88.6 mt-30 -57.29 103.01 0.1 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.583 -179.856 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 65.0 tt0 -152.21 124.01 7.95 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.442 179.946 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 2.7 t . . . . . 0 C--O 1.219 -0.501 0 CA-C-O 118.008 -0.996 . . . . 0.0 110.598 179.883 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' B' B ' 201' ' ' SER . . . . . . . . . . . . . 30.7 t . . . . . 0 N--CA 1.491 1.577 0 N-CA-C 109.33 -0.618 . . . . 0.0 109.33 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' B' B ' 202' ' ' SER . . . . . . . . . . . . . 11.1 p -73.19 159.8 32.92 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.369 -179.816 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 203' ' ' SER . . . . . . . . . . . . . 1.4 p -89.73 152.59 47.05 Favored Pre-proline 0 CA--C 1.535 0.392 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.435 -179.692 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 204' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_endo -64.57 -6.81 12.88 Favored 'Trans proline' 0 N--CA 1.496 1.634 0 C-N-CA 122.702 2.268 . . . . 0.0 111.846 179.951 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 205' ' ' ILE . . . . . 0.721 HD12 HD12 ' B' ' 224' ' ' LEU . 18.2 tt -150.33 152.5 11.53 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.258 0 CA-C-O 121.114 0.483 . . . . 0.0 111.181 -179.972 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 206' ' ' GLN . . . . . . . . . . . . . 6.4 pt20 -178.37 76.4 0.02 OUTLIER 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.757 -0.656 . . . . 0.0 110.82 179.329 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 207' ' ' GLY . . . . . . . . . . . . . . . -108.44 -142.85 10.2 Favored Glycine 0 N--CA 1.464 0.501 0 N-CA-C 111.021 -0.831 . . . . 0.0 111.021 -179.776 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 208' ' ' SER . . . . . 0.531 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 98.7 p -165.17 170.9 14.37 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 120.706 0.288 . . . . 0.0 110.734 179.83 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 209' ' ' TRP . . . . . . . . . . . . . 72.2 m95 -87.58 131.43 34.4 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.315 179.607 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 68.8 p -110.15 133.39 53.27 Favored 'General case' 0 N--CA 1.465 0.313 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.405 -179.951 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 49.8 t-105 -94.93 118.36 31.68 Favored 'General case' 0 N--CA 1.463 0.199 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.059 179.795 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 212' ' ' GLU . . . . . 0.469 ' O ' ' O ' ' B' ' 215' ' ' LYS . 1.7 pt-20 -164.7 170.64 15.36 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.731 178.903 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 213' ' ' ASN . . . . . . . . . . . . . 13.8 m120 48.82 36.18 7.68 Favored 'General case' 0 C--N 1.323 -0.577 0 C-N-CA 120.321 -0.552 . . . . 0.0 111.615 175.951 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 51.88 13.82 1.64 Allowed Glycine 0 CA--C 1.529 0.94 0 N-CA-C 111.536 -0.626 . . . . 0.0 111.536 179.676 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 215' ' ' LYS . . . . . 0.469 ' O ' ' O ' ' B' ' 212' ' ' GLU . 67.5 mttm -143.09 150.87 40.1 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-O 121.082 0.468 . . . . 0.0 110.625 179.875 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 216' ' ' TRP . . . . . . . . . . . . . 64.4 m95 -84.82 118.03 24.23 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.013 179.856 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 217' ' ' THR . . . . . 0.467 HG23 ' O ' ' A' ' 77' ' ' VAL . 19.3 m -127.5 139.86 52.52 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-O 121.197 0.522 . . . . 0.0 110.452 -179.393 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 218' ' ' TRP . . . . . 0.531 ' CH2' ' N ' ' B' ' 208' ' ' SER . 19.7 t-105 -106.22 117.25 33.55 Favored 'General case' 0 C--O 1.231 0.1 0 CA-C-N 115.849 -0.614 . . . . 0.0 109.922 179.227 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 54.4 mtmt -143.71 172.07 13.33 Favored 'General case' 0 CA--C 1.516 -0.343 0 CA-C-O 120.989 0.423 . . . . 0.0 110.642 -179.748 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -176.42 -160.73 24.18 Favored Glycine 0 CA--C 1.525 0.669 0 C-N-CA 120.585 -0.817 . . . . 0.0 111.305 -179.727 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 221' ' ' ILE . . . . . 0.544 ' O ' HG23 ' B' ' 222' ' ' ILE . 20.2 mt -54.7 -73.65 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 C-N-CA 120.649 -0.42 . . . . 0.0 110.448 -178.046 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 222' ' ' ILE . . . . . 0.544 HG23 ' O ' ' B' ' 221' ' ' ILE . 21.7 pt -159.85 -165.08 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 N-CA-C 109.907 -0.405 . . . . 0.0 109.907 -179.761 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 223' ' ' ARG . . . . . 0.556 ' N ' HD11 ' A' ' 75' ' ' ILE . 37.0 ptt180 -40.9 172.13 0.0 OUTLIER 'General case' 0 N--CA 1.456 -0.174 0 CA-C-O 121.175 0.512 . . . . 0.0 110.923 178.89 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 224' ' ' LEU . . . . . 1.072 ' H ' HD22 ' B' ' 224' ' ' LEU . 0.4 OUTLIER -58.55 147.8 30.86 Favored 'General case' 0 C--N 1.318 -0.794 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.638 -179.091 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 23.5 tp10 -78.17 148.94 33.86 Favored 'General case' 0 CA--C 1.515 -0.392 0 CA-C-N 115.551 -0.75 . . . . 0.0 110.511 -178.858 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 226' ' ' GLN . . . . . . . . . . . . . 90.9 mm-40 . . . . . 0 C--O 1.219 -0.518 0 CA-C-O 118.029 -0.986 . . . . 0.0 110.461 -179.372 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 3' ' ' GLY . . . . . 0.427 ' O ' ' O ' ' A' ' 4' ' ' SER . . . . . . . . 0 N--CA 1.488 2.16 0 N-CA-C 109.456 -1.458 . . . . 0.0 109.456 . . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 4' ' ' SER . . . . . 0.427 ' O ' ' O ' ' A' ' 3' ' ' GLY . 6.8 p 57.56 116.31 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.914 0.388 . . . . 0.0 110.491 -179.892 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -74.81 176.28 7.21 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.409 179.911 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.634 ' O ' HG13 ' A' ' 6' ' ' VAL . 7.4 p -125.03 82.68 61.25 Favored Pre-proline 0 N--CA 1.466 0.368 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.343 179.923 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_exo -56.71 162.49 8.48 Favored 'Trans proline' 0 N--CA 1.494 1.532 0 C-N-CA 122.594 2.196 . . . . 0.0 111.835 179.605 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 52.6 tp60 69.79 72.3 0.23 Allowed 'General case' 0 C--N 1.332 -0.155 0 CA-C-N 115.958 -0.565 . . . . 0.0 110.38 -179.739 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.567 HD12 ' N ' ' A' ' 9' ' ' LEU . 10.5 mp -90.45 130.64 36.5 Favored 'General case' 0 C--N 1.333 -0.133 0 CA-C-N 116.202 -0.454 . . . . 0.0 109.894 -179.991 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -123.8 120.96 34.15 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.266 -179.737 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 11' ' ' ASP . . . . . 0.421 ' HB2' ' HE1' ' B' ' 209' ' ' TRP . 55.2 p-10 -86.81 165.67 15.81 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.673 179.941 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 7.3 tt -65.1 150.9 47.32 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.444 -179.679 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 13' ' ' SER . . . . . 0.417 ' O ' ' O ' ' A' ' 25' ' ' ARG . 18.1 p -139.85 157.53 45.56 Favored 'General case' 0 N--CA 1.463 0.204 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.385 179.696 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 14' ' ' PHE . . . . . 0.48 ' CD1' ' N ' ' A' ' 14' ' ' PHE . 31.5 m-85 -110.33 144.77 38.57 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.652 -179.325 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 16.7 m -145.69 156.62 12.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.294 179.402 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 98.8 m-20 55.75 35.93 26.28 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.64 -179.885 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 96.4 mt -61.12 139.07 20.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.31 179.816 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.473 ' CB ' ' O ' ' A' ' 21' ' ' SER . 0.2 OUTLIER -140.84 -167.33 2.34 Favored 'General case' 0 N--CA 1.469 0.494 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.194 -179.986 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 19' ' ' ASP . . . . . 0.496 ' OD1' ' N ' ' A' ' 20' ' ' SER . 30.9 p-10 -88.75 -43.54 11.2 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.819 179.384 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 20' ' ' SER . . . . . 0.496 ' N ' ' OD1' ' A' ' 19' ' ' ASP . 4.4 t -116.41 6.73 13.68 Favored 'General case' 0 N--CA 1.466 0.353 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.976 -179.42 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 21' ' ' SER . . . . . 0.473 ' O ' ' CB ' ' A' ' 18' ' ' THR . 16.4 p -150.57 140.3 21.74 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 121.257 0.551 . . . . 0.0 110.508 179.853 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 28.4 pt -139.65 144.13 29.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 N-CA-C 109.394 -0.595 . . . . 0.0 109.394 -179.868 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -106.4 91.33 0.72 Allowed Glycine 0 N--CA 1.466 0.637 0 N-CA-C 111.496 -0.642 . . . . 0.0 111.496 -179.323 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.466 ' N ' HD12 ' A' ' 24' ' ' LEU . 11.2 mp -69.63 130.55 42.69 Favored 'General case' 0 C--N 1.328 -0.354 0 C-N-CA 120.478 -0.489 . . . . 0.0 109.842 179.844 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 25' ' ' ARG . . . . . 0.417 ' O ' ' O ' ' A' ' 13' ' ' SER . 67.5 ttp85 -140.83 135.26 31.22 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.196 179.615 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 26' ' ' TRP . . . . . . . . . . . . . 48.3 p90 -143.51 156.47 44.63 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.988 -0.551 . . . . 0.0 109.983 179.719 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 4.4 m -109.54 101.11 44.9 Favored Pre-proline 0 CA--C 1.531 0.23 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.162 179.906 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 42.0 Cg_exo -53.14 150.84 23.41 Favored 'Trans proline' 0 C--N 1.307 -1.613 0 C-N-CA 121.635 1.557 . . . . 0.0 113.199 179.823 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 54.2 mt -91.3 141.94 28.24 Favored 'General case' 0 CA--C 1.513 -0.466 0 CA-C-N 115.127 -0.942 . . . . 0.0 110.885 179.867 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 53.6 t-20 -50.87 -38.14 47.7 Favored 'General case' 0 C--N 1.314 -0.976 0 CA-C-N 114.743 -1.117 . . . . 0.0 110.149 179.575 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 23.2 m -76.98 -33.57 57.61 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.454 178.874 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 15.1 m -60.48 127.84 33.71 Favored 'General case' 0 N--CA 1.461 0.108 0 CA-C-O 121.027 0.441 . . . . 0.0 110.16 179.893 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 33' ' ' THR . . . . . 0.487 ' OG1' ' N ' ' A' ' 82' ' ' ASN . 5.5 m -57.96 142.98 44.68 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.292 179.99 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 20.6 mm -93.82 89.24 2.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 120.904 0.383 . . . . 0.0 110.839 -179.299 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.469 ' O ' ' OG ' ' A' ' 57' ' ' SER . 14.7 pt -142.04 129.76 20.88 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.341 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.498 179.633 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -39.87 121.08 1.5 Allowed Glycine 0 CA--C 1.523 0.543 0 N-CA-C 111.555 -0.618 . . . . 0.0 111.555 -179.56 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 37' ' ' TYR . . . . . 0.423 ' CE2' ' OG ' ' A' ' 57' ' ' SER . 97.7 m-85 -83.19 178.92 7.88 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.942 0.401 . . . . 0.0 110.09 179.91 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 38' ' ' ARG . . . . . 0.54 ' NH1' ' OG1' ' A' ' 40' ' ' THR . 4.2 tmt_? -134.21 123.74 24.81 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 121.134 0.492 . . . . 0.0 110.561 179.775 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 2.8 pt -94.46 152.95 3.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 115.894 -0.593 . . . . 0.0 109.537 -179.856 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 40' ' ' THR . . . . . 0.54 ' OG1' ' NH1' ' A' ' 38' ' ' ARG . 27.3 m -136.09 133.12 36.98 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.75 0.31 . . . . 0.0 110.491 179.814 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.415 HG13 ' HB ' ' A' ' 50' ' ' ILE . 2.0 p -132.59 134.95 58.31 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.326 0 CA-C-O 120.812 0.339 . . . . 0.0 110.577 179.796 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 42' ' ' VAL . . . . . 0.488 ' O ' ' N ' ' A' ' 74' ' ' ASP . 30.0 t -129.44 126.68 63.89 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.216 0 N-CA-C 110.017 -0.364 . . . . 0.0 110.017 179.307 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.548 ' HB2' ' CE2' ' A' ' 73' ' ' TYR . . . -93.33 138.67 31.46 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 109.32 -0.622 . . . . 0.0 109.32 179.504 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.578 ' HB3' ' O ' ' A' ' 72' ' ' ASP . . . -97.53 -19.25 18.49 Favored 'General case' 0 C--N 1.329 -0.286 0 C-N-CA 120.695 -0.402 . . . . 0.0 110.877 -179.97 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -96.61 30.95 8.03 Favored Glycine 0 CA--C 1.525 0.701 0 N-CA-C 110.971 -0.852 . . . . 0.0 110.971 179.906 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 71.5 mt-10 -146.21 149.92 34.84 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.974 0.416 . . . . 0.0 110.556 179.996 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -68.28 -21.11 73.87 Favored Glycine 0 CA--C 1.523 0.54 0 N-CA-C 111.073 -0.811 . . . . 0.0 111.073 179.571 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -137.86 140.21 28.77 Favored Pre-proline 0 CA--C 1.546 0.814 0 CA-C-N 116.833 0.316 . . . . 0.0 110.603 179.672 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 68.9 Cg_endo -72.78 163.03 39.6 Favored 'Trans proline' 0 N--CA 1.495 1.569 0 C-N-CA 122.768 2.312 . . . . 0.0 112.107 178.755 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 50' ' ' ILE . . . . . 0.502 HG22 ' N ' ' A' ' 51' ' ' PHE . 96.8 mt -75.58 158.6 5.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.551 179.602 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 51' ' ' PHE . . . . . 0.502 ' N ' HG22 ' A' ' 50' ' ' ILE . 96.7 m-85 -75.94 147.77 38.67 Favored 'General case' 0 C--N 1.333 -0.143 0 CA-C-O 121.019 0.438 . . . . 0.0 111.134 -179.72 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 52' ' ' GLU . . . . . 0.556 ' CD ' ' H ' ' A' ' 52' ' ' GLU . 0.3 OUTLIER -83.28 146.94 28.26 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.441 179.478 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -116.91 153.55 32.37 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.756 -0.656 . . . . 0.0 110.499 -179.492 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 54' ' ' PHE . . . . . 0.565 ' CD1' ' N ' ' A' ' 54' ' ' PHE . 5.7 m-85 -119.79 129.47 54.47 Favored 'General case' 0 N--CA 1.462 0.132 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.146 -179.85 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 9.4 p -129.77 138.91 52.95 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.393 0 CA-C-O 120.73 0.3 . . . . 0.0 110.843 -179.769 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 94.4 m-20 -61.08 144.86 52.69 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.695 179.964 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 57' ' ' SER . . . . . 0.469 ' OG ' ' O ' ' A' ' 35' ' ' ILE . 10.2 m -61.94 -32.14 72.53 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.706 179.878 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 75.5 m -56.2 -36.43 68.4 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.582 -179.756 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 74.3 t -62.32 -45.05 99.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.511 -179.848 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 60.45 24.87 62.17 Favored Glycine 0 CA--C 1.528 0.864 0 N-CA-C 110.507 -1.037 . . . . 0.0 110.507 -179.95 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 61' ' ' TYR . . . . . 0.432 ' OH ' ' OG1' ' A' ' 63' ' ' THR . 52.6 t80 -166.34 151.09 7.92 Favored 'General case' 0 CA--C 1.53 0.176 0 CA-C-O 121.214 0.531 . . . . 0.0 111.423 -179.513 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 17.4 t80 -158.01 158.25 34.52 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.672 -0.694 . . . . 0.0 110.378 178.566 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 63' ' ' THR . . . . . 0.432 ' OG1' ' OH ' ' A' ' 61' ' ' TYR . 69.3 m -127.7 136.74 51.98 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.198 179.728 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -130.16 104.62 10.45 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 N-CA-C 109.33 -0.619 . . . . 0.0 109.33 179.413 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 4.2 p -111.75 157.38 20.59 Favored 'General case' 0 N--CA 1.466 0.335 0 CA-C-O 120.946 0.403 . . . . 0.0 110.498 -179.849 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 107.68 40.79 1.68 Allowed Glycine 0 CA--C 1.524 0.594 0 N-CA-C 111.074 -0.81 . . . . 0.0 111.074 179.94 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 16.6 mt -113.0 106.65 14.95 Favored 'General case' 0 N--CA 1.462 0.168 0 N-CA-C 108.99 -0.744 . . . . 0.0 108.99 179.215 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 52.4 mm-40 -51.97 135.91 37.8 Favored Pre-proline 0 C--N 1.319 -0.72 0 CA-C-N 116.376 -0.375 . . . . 0.0 111.626 -178.059 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 93.4 Cg_endo -74.98 155.44 43.03 Favored 'Trans proline' 0 N--CA 1.496 1.658 0 C-N-CA 122.55 2.166 . . . . 0.0 111.476 178.602 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 70' ' ' GLY . . . . . 0.515 ' H ' HH22 ' B' ' 223' ' ' ARG . . . 71.11 5.66 59.1 Favored Glycine 0 CA--C 1.525 0.671 0 CA-C-N 115.65 -0.705 . . . . 0.0 111.54 179.469 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 1.6 mp -113.43 143.39 23.21 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.47 0 N-CA-C 109.315 -0.624 . . . . 0.0 109.315 179.859 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 72' ' ' ASP . . . . . 0.578 ' O ' ' HB3' ' A' ' 44' ' ' ALA . 1.8 t70 -80.26 113.86 18.75 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.387 -0.824 . . . . 0.0 110.683 179.949 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 73' ' ' TYR . . . . . 0.548 ' CE2' ' HB2' ' A' ' 43' ' ' ALA . 14.0 m-85 -109.14 120.19 41.78 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 121.264 0.554 . . . . 0.0 110.694 -179.699 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 74' ' ' ASP . . . . . 0.488 ' N ' ' O ' ' A' ' 42' ' ' VAL . 9.6 m-20 -89.11 119.55 29.72 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-N 115.378 -0.828 . . . . 0.0 109.175 179.387 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.535 HD11 ' N ' ' B' ' 223' ' ' ARG . 0.0 OUTLIER -119.17 166.38 13.61 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.466 0 CA-C-O 121.019 0.438 . . . . 0.0 110.304 -179.306 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 22.9 t -156.13 152.41 27.89 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.574 -0.739 . . . . 0.0 110.312 178.529 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 2.4 t -128.78 101.95 7.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 N-CA-C 109.556 -0.535 . . . . 0.0 109.556 178.664 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 72.4 mt -88.47 127.56 41.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 N-CA-C 109.974 -0.38 . . . . 0.0 109.974 -179.433 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 87.3 m -105.66 114.22 28.25 Favored 'General case' 0 N--CA 1.465 0.284 0 CA-C-N 116.213 -0.449 . . . . 0.0 109.963 179.967 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 49.1 mt -118.2 117.42 29.11 Favored 'General case' 0 N--CA 1.464 0.229 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.533 -179.722 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 81' ' ' ILE . . . . . 0.474 ' HB ' ' H ' ' A' ' 33' ' ' THR . 2.3 pp -145.26 146.67 19.52 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.181 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.39 179.032 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 82' ' ' ASN . . . . . 0.487 ' N ' ' OG1' ' A' ' 33' ' ' THR . 23.0 t-20 -65.87 -48.45 71.5 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.259 -179.578 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 102.45 -108.3 3.3 Favored Glycine 0 CA--C 1.523 0.566 0 N-CA-C 110.921 -0.872 . . . . 0.0 110.921 179.606 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -71.79 134.23 21.85 Favored Glycine 0 CA--C 1.523 0.535 0 N-CA-C 110.81 -0.916 . . . . 0.0 110.81 -179.918 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -70.19 117.39 11.69 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.731 0.301 . . . . 0.0 110.311 179.955 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 86' ' ' SER . . . . . 0.441 ' O ' ' O ' ' A' ' 87' ' ' ALA . 46.0 t -67.38 134.61 51.79 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.428 -179.908 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.441 ' O ' ' O ' ' A' ' 86' ' ' SER . . . 56.23 155.0 0.07 OUTLIER Pre-proline 0 CA--C 1.534 0.36 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.609 179.803 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_endo -66.62 143.34 67.94 Favored 'Trans proline' 0 N--CA 1.493 1.478 0 C-N-CA 122.485 2.123 . . . . 0.0 111.886 179.701 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 7.6 p -85.25 167.65 15.45 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.595 -0.73 . . . . 0.0 110.356 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 63.9 p -128.92 152.15 48.87 Favored 'General case' 0 N--CA 1.466 0.334 0 CA-C-O 121.239 0.542 . . . . 0.0 110.588 179.874 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 91' ' ' LEU . . . . . 0.63 ' H ' ' CD2' ' A' ' 91' ' ' LEU . 1.6 pt? -74.6 150.66 39.58 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.712 -0.676 . . . . 0.0 110.799 179.852 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 82.7 p -74.65 139.24 43.42 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.169 179.443 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 50.2 tt0 -69.62 125.18 25.93 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.437 -0.347 . . . . 0.0 110.402 -179.896 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 94.5 mm-40 -101.79 129.64 48.04 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.517 -179.864 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 40.4 p . . . . . 0 C--O 1.22 -0.47 0 CA-C-O 117.974 -1.013 . . . . 0.0 110.684 179.956 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' B' B ' 201' ' ' SER . . . . . . . . . . . . . 24.6 p . . . . . 0 N--CA 1.491 1.614 0 N-CA-C 109.439 -0.578 . . . . 0.0 109.439 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' B' B ' 202' ' ' SER . . . . . . . . . . . . . 40.6 t -68.01 139.13 56.31 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.267 179.5 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 203' ' ' SER . . . . . . . . . . . . . 78.1 p -126.0 108.9 24.8 Favored Pre-proline 0 CA--C 1.537 0.479 0 N-CA-C 110.068 -0.345 . . . . 0.0 110.068 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 204' ' ' PRO . . . . . . . . . . . . . 60.8 Cg_endo -76.1 -58.25 0.05 OUTLIER 'Trans proline' 0 N--CA 1.492 1.402 0 C-N-CA 121.561 1.507 . . . . 0.0 112.069 -179.592 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 205' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -149.1 143.47 18.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.312 179.864 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 206' ' ' GLN . . . . . . . . . . . . . 18.5 pt20 -141.06 141.95 34.22 Favored 'General case' 0 C--N 1.329 -0.315 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 179.623 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 207' ' ' GLY . . . . . . . . . . . . . . . -103.92 -130.75 6.98 Favored Glycine 0 N--CA 1.462 0.428 0 N-CA-C 111.125 -0.79 . . . . 0.0 111.125 -179.791 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 208' ' ' SER . . . . . 0.536 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 97.1 p -165.86 170.58 13.67 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.809 0.337 . . . . 0.0 110.818 179.877 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 209' ' ' TRP . . . . . 0.421 ' HE1' ' HB2' ' A' ' 11' ' ' ASP . 66.9 m95 -88.27 147.6 24.74 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.462 179.666 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 82.4 p -127.96 129.26 46.5 Favored 'General case' 0 C--O 1.234 0.257 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.631 179.868 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 48.9 t-105 -89.62 116.67 27.93 Favored 'General case' 0 N--CA 1.463 0.176 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.04 179.5 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 212' ' ' GLU . . . . . 0.457 ' O ' ' O ' ' B' ' 215' ' ' LYS . 1.0 OUTLIER -164.91 170.24 15.55 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.556 179.073 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' B' B ' 213' ' ' ASN . . . . . . . . . . . . . 14.2 m120 48.23 35.96 6.16 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.916 176.56 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 51.97 13.65 1.64 Allowed Glycine 0 CA--C 1.528 0.899 0 C-N-CA 120.992 -0.623 . . . . 0.0 111.668 179.656 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 215' ' ' LYS . . . . . 0.457 ' O ' ' O ' ' B' ' 212' ' ' GLU . 66.8 mttm -142.84 150.81 40.4 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-O 120.994 0.426 . . . . 0.0 110.839 179.826 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 216' ' ' TRP . . . . . . . . . . . . . 52.1 m95 -86.81 118.77 26.42 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.089 179.86 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 217' ' ' THR . . . . . . . . . . . . . 19.6 m -128.85 142.42 50.97 Favored 'General case' 0 N--CA 1.467 0.387 0 CA-C-O 120.938 0.399 . . . . 0.0 110.184 -179.772 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 218' ' ' TRP . . . . . 0.536 ' CH2' ' N ' ' B' ' 208' ' ' SER . 15.2 t-105 -104.91 118.51 36.72 Favored 'General case' 0 C--N 1.33 -0.269 0 N-CA-C 109.356 -0.609 . . . . 0.0 109.356 179.246 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 52.5 mtmt -145.86 167.4 23.33 Favored 'General case' 0 CA--C 1.517 -0.305 0 CA-C-O 121.33 0.586 . . . . 0.0 110.704 -179.411 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -175.81 -161.13 24.56 Favored Glycine 0 CA--C 1.523 0.573 0 CA-C-N 115.383 -0.826 . . . . 0.0 111.486 -179.736 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 221' ' ' ILE . . . . . 0.548 ' O ' HG23 ' B' ' 222' ' ' ILE . 0.8 OUTLIER -52.59 -75.71 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 C-N-CA 120.69 -0.404 . . . . 0.0 111.065 -178.667 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' B' B ' 222' ' ' ILE . . . . . 0.548 HG23 ' O ' ' B' ' 221' ' ' ILE . 22.1 pt -160.87 -165.08 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 N-CA-C 109.97 -0.382 . . . . 0.0 109.97 -179.405 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 223' ' ' ARG . . . . . 0.535 ' N ' HD11 ' A' ' 75' ' ' ILE . 39.5 ptt180 -43.28 173.5 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.804 -0.635 . . . . 0.0 110.669 178.579 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 224' ' ' LEU . . . . . 1.053 ' H ' HD22 ' B' ' 224' ' ' LEU . 0.7 OUTLIER -61.67 126.09 26.12 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.33 -179.859 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 35.5 tp10 -82.54 149.15 27.67 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.712 -0.676 . . . . 0.0 110.277 179.803 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 226' ' ' GLN . . . . . . . . . . . . . 15.0 mm100 . . . . . 0 C--N 1.324 -0.522 0 CA-C-O 118.062 -0.971 . . . . 0.0 110.672 -179.875 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.222 0 N-CA-C 109.548 -1.421 . . . . 0.0 109.548 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 22.4 t -149.51 93.7 2.1 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 120.729 0.299 . . . . 0.0 110.377 179.878 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 95.3 mt-10 -105.99 115.85 30.93 Favored 'General case' 0 CA--C 1.519 -0.249 0 CA-C-N 116.237 -0.438 . . . . 0.0 109.998 179.929 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 5.7 m -145.12 149.2 41.08 Favored Pre-proline 0 CA--C 1.532 0.265 0 CA-C-N 116.401 -0.363 . . . . 0.0 110.589 179.968 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 42.4 Cg_endo -67.19 84.42 0.34 Allowed 'Trans proline' 0 N--CA 1.495 1.602 0 C-N-CA 122.558 2.172 . . . . 0.0 111.815 179.7 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 12.0 pt20 -66.08 -36.86 84.33 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.363 179.48 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 45.0 tp -98.84 125.44 44.22 Favored 'General case' 0 N--CA 1.463 0.186 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.333 -179.785 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 34.4 p -125.11 129.77 50.88 Favored 'General case' 0 C--O 1.234 0.254 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.513 179.739 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -88.6 154.05 20.63 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.899 -0.591 . . . . 0.0 110.372 179.808 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.528 ' CD2' ' CZ ' ' A' ' 14' ' ' PHE . 7.0 tt -67.15 145.34 55.38 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.579 -179.83 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 13' ' ' SER . . . . . 0.431 ' O ' ' O ' ' A' ' 25' ' ' ARG . 53.9 p -143.09 152.79 42.23 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.497 179.642 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 14' ' ' PHE . . . . . 0.554 ' CD1' ' N ' ' A' ' 14' ' ' PHE . 8.3 m-85 -111.77 148.73 32.9 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.391 -179.763 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 18.5 m -146.37 158.01 11.32 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.205 179.711 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 95.2 m-20 58.91 30.27 19.95 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.613 -0.721 . . . . 0.0 110.849 -179.921 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 83.2 mt -56.3 130.5 18.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 N-CA-C 109.862 -0.422 . . . . 0.0 109.862 179.65 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.441 HG22 ' H ' ' A' ' 19' ' ' ASP . 0.2 OUTLIER -129.52 -169.1 2.05 Favored 'General case' 0 N--CA 1.466 0.374 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.579 -179.886 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 19' ' ' ASP . . . . . 0.488 ' N ' ' OD1' ' A' ' 19' ' ' ASP . 16.2 p-10 -78.35 -48.52 15.41 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.997 179.428 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 20' ' ' SER . . . . . 0.47 ' OG ' ' N ' ' A' ' 67' ' ' LEU . 28.2 t -121.16 13.35 11.2 Favored 'General case' 0 N--CA 1.464 0.231 0 CA-C-O 120.728 0.299 . . . . 0.0 110.596 -179.161 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 21' ' ' SER . . . . . 0.463 ' HB2' HG22 ' A' ' 65' ' ' THR . 25.1 p -146.69 129.14 15.91 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 116.475 -0.329 . . . . 0.0 110.352 -179.625 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 22' ' ' ILE . . . . . 0.595 HD12 HD21 ' A' ' 24' ' ' LEU . 46.4 pt -126.25 142.57 42.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.239 0 CA-C-N 116.2 -0.455 . . . . 0.0 109.959 -179.886 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -97.1 82.26 0.72 Allowed Glycine 0 CA--C 1.523 0.542 0 N-CA-C 110.873 -0.891 . . . . 0.0 110.873 -179.563 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.595 HD21 HD12 ' A' ' 22' ' ' ILE . 90.7 mt -65.26 122.53 17.31 Favored 'General case' 0 C--N 1.33 -0.276 0 N-CA-C 109.945 -0.391 . . . . 0.0 109.945 -179.815 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 25' ' ' ARG . . . . . 0.431 ' O ' ' O ' ' A' ' 13' ' ' SER . 72.2 ttt180 -141.2 138.78 33.58 Favored 'General case' 0 N--CA 1.462 0.168 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.722 -179.873 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 26' ' ' TRP . . . . . 0.534 ' CE2' ' O ' ' A' ' 60' ' ' GLY . 33.3 p90 -146.33 121.06 9.86 Favored 'General case' 0 CA--C 1.513 -0.453 0 CA-C-N 115.792 -0.64 . . . . 0.0 109.764 179.882 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 2.1 m -66.49 113.91 14.9 Favored Pre-proline 0 CA--C 1.536 0.412 0 C-N-CA 120.642 -0.423 . . . . 0.0 111.091 -178.619 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 36.1 Cg_exo -58.84 153.07 52.86 Favored 'Trans proline' 0 N--CA 1.493 1.461 0 C-N-CA 122.101 1.867 . . . . 0.0 112.742 178.693 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.459 ' H ' ' HB2' ' A' ' 32' ' ' SER . 80.2 mt -104.94 136.05 45.15 Favored 'General case' 0 N--CA 1.469 0.479 0 CA-C-O 122.008 0.909 . . . . 0.0 110.833 179.876 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 42.4 t30 -44.88 -32.43 1.59 Allowed 'General case' 0 C--N 1.316 -0.877 0 CA-C-N 115.064 -0.971 . . . . 0.0 110.223 -179.709 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 58.7 m -85.64 -33.84 21.51 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.868 -0.606 . . . . 0.0 110.582 179.198 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 32' ' ' SER . . . . . 0.459 ' HB2' ' H ' ' A' ' 29' ' ' LEU . 3.6 m -51.52 115.48 1.63 Allowed 'General case' 0 N--CA 1.461 0.095 0 CA-C-O 121.261 0.553 . . . . 0.0 110.17 -179.929 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 33' ' ' THR . . . . . 0.522 ' OG1' ' N ' ' A' ' 82' ' ' ASN . 11.7 m -50.94 143.54 10.04 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.561 -0.745 . . . . 0.0 109.264 -179.081 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 32.8 mm -92.45 90.95 3.23 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.215 0 CA-C-O 121.236 0.541 . . . . 0.0 111.258 -178.156 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.576 ' O ' ' CE1' ' A' ' 37' ' ' TYR . 6.7 pt -149.19 125.95 2.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 115.507 -0.77 . . . . 0.0 110.241 179.225 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -39.56 140.45 0.78 Allowed Glycine 0 CA--C 1.527 0.788 0 N-CA-C 110.957 -0.857 . . . . 0.0 110.957 -179.72 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 37' ' ' TYR . . . . . 0.576 ' CE1' ' O ' ' A' ' 35' ' ' ILE . 16.8 m-85 -110.49 144.83 38.72 Favored 'General case' 0 CA--C 1.518 -0.286 0 N-CA-C 109.867 -0.42 . . . . 0.0 109.867 -179.504 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 38' ' ' ARG . . . . . 0.516 ' NH1' ' OG1' ' A' ' 40' ' ' THR . 2.3 tmm_? -98.86 125.93 44.39 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.612 -179.834 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.419 ' O ' ' CG1' ' A' ' 39' ' ' ILE . 2.8 pt -98.45 121.07 48.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.1 -0.5 . . . . 0.0 109.834 179.777 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 40' ' ' THR . . . . . 0.516 ' OG1' ' NH1' ' A' ' 38' ' ' ARG . 20.7 m -101.29 136.2 41.53 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.288 -179.175 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.2 p -134.22 142.76 40.06 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.338 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.249 179.965 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 42' ' ' VAL . . . . . 0.485 ' O ' ' N ' ' A' ' 74' ' ' ASP . 37.7 t -131.73 130.54 61.98 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.145 0 N-CA-C 109.984 -0.376 . . . . 0.0 109.984 179.46 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -97.49 133.63 41.81 Favored 'General case' 0 C--N 1.327 -0.379 0 N-CA-C 109.434 -0.58 . . . . 0.0 109.434 179.216 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.626 ' HB3' ' O ' ' A' ' 72' ' ' ASP . . . -94.57 -21.21 18.99 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.769 0.318 . . . . 0.0 110.738 179.912 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -91.4 18.07 53.55 Favored Glycine 0 CA--C 1.523 0.588 0 N-CA-C 110.912 -0.875 . . . . 0.0 110.912 -179.682 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 33.2 mm-40 -139.93 149.53 43.44 Favored 'General case' 0 C--N 1.333 -0.136 0 CA-C-O 121.106 0.479 . . . . 0.0 110.521 -179.559 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -69.5 -18.94 74.12 Favored Glycine 0 N--CA 1.453 -0.194 0 N-CA-C 110.518 -1.033 . . . . 0.0 110.518 179.941 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -132.26 140.06 36.82 Favored Pre-proline 0 N--CA 1.468 0.446 0 C-N-CA 121.119 -0.232 . . . . 0.0 110.585 179.699 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 59.6 Cg_endo -73.22 159.39 47.32 Favored 'Trans proline' 0 N--CA 1.49 1.307 0 C-N-CA 122.431 2.087 . . . . 0.0 112.051 177.685 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 50' ' ' ILE . . . . . 0.407 HG22 ' N ' ' A' ' 51' ' ' PHE . 96.7 mt -75.49 153.41 6.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.193 179.484 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 51' ' ' PHE . . . . . 0.407 ' N ' HG22 ' A' ' 50' ' ' ILE . 80.5 m-85 -72.51 142.29 48.51 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.676 179.912 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 52' ' ' GLU . . . . . 0.422 ' N ' ' CD ' ' A' ' 52' ' ' GLU . 0.0 OUTLIER -65.77 -176.15 0.35 Allowed 'General case' 0 CA--C 1.514 -0.441 0 CA-C-N 115.739 -0.664 . . . . 0.0 110.405 179.441 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 53' ' ' ASP . . . . . 0.416 ' CG ' ' OH ' ' A' ' 62' ' ' TYR . 1.0 OUTLIER -145.59 138.66 26.14 Favored 'General case' 0 N--CA 1.452 -0.34 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.358 179.392 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 61.4 m-85 -110.0 116.42 31.56 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.397 179.898 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 10.5 p -128.18 140.82 48.15 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.348 0 CA-C-O 120.934 0.397 . . . . 0.0 110.118 179.949 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 83.9 m-20 -62.9 150.49 41.85 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.248 179.734 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 15.3 t -64.12 -33.8 76.6 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.663 -179.932 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 69.5 m -51.43 -37.69 49.83 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.382 -179.51 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.525 ' C ' ' H ' ' A' ' 61' ' ' TYR . 11.3 t -63.74 -42.97 97.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.362 179.68 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 60' ' ' GLY . . . . . 0.534 ' O ' ' CE2' ' A' ' 26' ' ' TRP . . . 70.44 -36.38 0.45 Allowed Glycine 0 CA--C 1.532 1.116 0 N-CA-C 111.037 -0.825 . . . . 0.0 111.037 179.653 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 61' ' ' TYR . . . . . 0.525 ' H ' ' C ' ' A' ' 59' ' ' VAL . 25.9 p90 -115.99 159.76 21.19 Favored 'General case' 0 N--CA 1.466 0.373 0 CA-C-O 121.146 0.498 . . . . 0.0 111.007 -179.084 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 62' ' ' TYR . . . . . 0.416 ' OH ' ' CG ' ' A' ' 53' ' ' ASP . 31.1 t80 -154.47 162.28 41.23 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.107 -0.497 . . . . 0.0 109.755 179.599 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 99.2 m -119.36 132.77 55.91 Favored 'General case' 0 N--CA 1.467 0.376 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.414 -179.781 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -133.06 107.57 11.75 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.311 0 CA-C-N 115.859 -0.61 . . . . 0.0 109.647 179.046 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.463 HG22 ' HB2' ' A' ' 21' ' ' SER . 1.1 p -123.46 164.52 18.76 Favored 'General case' 0 CA--C 1.513 -0.443 0 CA-C-O 121.019 0.438 . . . . 0.0 110.34 -179.836 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 108.81 24.41 6.09 Favored Glycine 0 CA--C 1.524 0.598 0 CA-C-N 115.396 -0.82 . . . . 0.0 111.48 -179.773 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.47 ' N ' ' OG ' ' A' ' 20' ' ' SER . 11.8 mt -100.66 109.14 21.17 Favored 'General case' 0 CA--C 1.517 -0.322 0 N-CA-C 109.31 -0.626 . . . . 0.0 109.31 179.909 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 31.9 mm-40 -52.5 139.73 37.88 Favored Pre-proline 0 C--N 1.312 -1.023 0 C-N-CA 120.486 -0.485 . . . . 0.0 112.011 -178.214 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -73.08 155.47 52.39 Favored 'Trans proline' 0 N--CA 1.498 1.755 0 C-N-CA 122.857 2.371 . . . . 0.0 111.387 178.63 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 72.93 -5.96 15.48 Favored Glycine 0 CA--C 1.525 0.702 0 CA-C-N 115.637 -0.71 . . . . 0.0 111.927 179.269 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 1.7 mp -101.27 149.15 6.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 N-CA-C 109.346 -0.613 . . . . 0.0 109.346 -179.551 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 72' ' ' ASP . . . . . 0.626 ' O ' ' HB3' ' A' ' 44' ' ' ALA . 2.5 t70 -89.68 115.99 27.46 Favored 'General case' 0 C--N 1.32 -0.7 0 CA-C-N 114.979 -1.01 . . . . 0.0 110.269 179.686 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 73' ' ' TYR . . . . . 0.507 ' O ' HD13 ' A' ' 75' ' ' ILE . 25.6 m-85 -109.81 119.55 39.69 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.453 179.899 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 74' ' ' ASP . . . . . 0.485 ' N ' ' O ' ' A' ' 42' ' ' VAL . 8.9 m-20 -89.94 116.79 28.26 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.702 -0.681 . . . . 0.0 109.426 179.887 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.569 HD11 ' N ' ' B' ' 223' ' ' ARG . 0.0 OUTLIER -113.98 165.4 9.02 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.293 0 CA-C-O 121.171 0.51 . . . . 0.0 109.995 -179.094 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 33.5 t -155.97 118.56 4.15 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.6 -0.727 . . . . 0.0 110.584 179.0 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 2.7 t -92.16 100.77 11.76 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 C-N-CA 120.479 -0.488 . . . . 0.0 109.73 179.498 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 96.3 mt -87.44 115.79 28.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.075 -179.99 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 70.3 m -100.44 118.8 37.41 Favored 'General case' 0 CA--C 1.517 -0.318 0 CA-C-N 116.211 -0.45 . . . . 0.0 109.938 179.725 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 80' ' ' LEU . . . . . 0.447 ' C ' HD23 ' A' ' 80' ' ' LEU . 2.1 tt -122.66 108.74 13.43 Favored 'General case' 0 N--CA 1.463 0.201 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.628 -179.892 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 81' ' ' ILE . . . . . 0.44 ' N ' HD23 ' A' ' 80' ' ' LEU . 2.1 pp -139.37 142.93 32.13 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 N-CA-C 109.974 -0.38 . . . . 0.0 109.974 178.936 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 82' ' ' ASN . . . . . 0.522 ' N ' ' OG1' ' A' ' 33' ' ' THR . 39.5 t-20 -66.37 -49.8 65.67 Favored 'General case' 0 C--N 1.328 -0.333 0 C-N-CA 120.89 -0.324 . . . . 0.0 111.233 -179.894 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 83' ' ' GLY . . . . . 0.431 ' H ' ' HG1' ' A' ' 33' ' ' THR . . . 82.13 -150.67 29.22 Favored Glycine 0 CA--C 1.523 0.538 0 N-CA-C 110.956 -0.858 . . . . 0.0 110.956 179.781 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -73.54 -171.65 23.08 Favored Glycine 0 CA--C 1.527 0.801 0 N-CA-C 110.768 -0.933 . . . . 0.0 110.768 -179.993 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 5.5 pm0 -57.55 140.76 49.99 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.839 0.352 . . . . 0.0 110.335 179.929 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 94.0 p -56.23 108.47 0.47 Allowed 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.32 179.895 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.665 ' HB1' ' HD2' ' A' ' 88' ' ' PRO . . . -174.88 176.0 0.73 Allowed Pre-proline 0 C--N 1.327 -0.385 0 C-N-CA 120.529 -0.469 . . . . 0.0 110.653 179.475 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 88' ' ' PRO . . . . . 0.665 ' HD2' ' HB1' ' A' ' 87' ' ' ALA . 31.7 Cg_exo -58.22 138.1 84.14 Favored 'Trans proline' 0 N--CA 1.495 1.609 0 C-N-CA 122.375 2.05 . . . . 0.0 111.63 179.132 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 86.9 m -134.19 127.83 32.76 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.341 -0.39 . . . . 0.0 110.428 179.43 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 47.9 p -150.1 131.38 14.58 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.232 179.824 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 91' ' ' LEU . . . . . 0.523 HD12 ' N ' ' A' ' 91' ' ' LEU . 10.6 mp -97.17 129.19 44.57 Favored 'General case' 0 N--CA 1.463 0.201 0 CA-C-O 121.002 0.429 . . . . 0.0 110.193 179.864 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 67.5 p -75.47 134.88 40.73 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.437 179.903 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 98.9 mt-30 -78.52 133.04 37.42 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.53 179.902 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 99.0 mm-40 46.55 -168.03 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.628 179.997 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 6.5 m . . . . . 0 C--O 1.218 -0.56 0 CA-C-O 118.04 -0.981 . . . . 0.0 110.483 -179.875 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' B' B ' 201' ' ' SER . . . . . . . . . . . . . 33.0 t . . . . . 0 N--CA 1.489 1.514 0 N-CA-C 109.414 -0.587 . . . . 0.0 109.414 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' B' B ' 202' ' ' SER . . . . . . . . . . . . . 40.6 t -71.37 148.99 46.45 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.582 179.972 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 203' ' ' SER . . . . . . . . . . . . . 2.3 p -88.89 150.76 46.23 Favored Pre-proline 0 CA--C 1.533 0.327 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.373 -179.413 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 204' ' ' PRO . . . . . . . . . . . . . 32.6 Cg_endo -63.93 -45.71 9.97 Favored 'Trans proline' 0 N--CA 1.497 1.705 0 C-N-CA 122.842 2.361 . . . . 0.0 111.809 -179.779 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 205' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -149.55 144.86 17.85 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.351 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.409 -179.698 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 206' ' ' GLN . . . . . 0.474 ' N ' ' CD ' ' B' ' 206' ' ' GLN . 2.2 pm0 -143.4 143.32 31.58 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.192 178.925 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 207' ' ' GLY . . . . . . . . . . . . . . . -107.52 -125.66 5.38 Favored Glycine 0 N--CA 1.467 0.712 0 N-CA-C 111.105 -0.798 . . . . 0.0 111.105 -179.888 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 208' ' ' SER . . . . . 0.555 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 54.8 p -165.66 170.83 13.71 Favored 'General case' 0 N--CA 1.454 -0.248 0 CA-C-O 120.804 0.335 . . . . 0.0 110.719 179.287 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 209' ' ' TRP . . . . . . . . . . . . . 59.0 m95 -88.13 156.08 19.44 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.531 179.473 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 66.9 p -130.19 131.77 45.74 Favored 'General case' 0 N--CA 1.464 0.247 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.447 179.558 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 53.0 t-105 -95.81 110.41 22.58 Favored 'General case' 0 N--CA 1.464 0.269 0 CA-C-N 116.29 -0.413 . . . . 0.0 110.591 -179.988 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 212' ' ' GLU . . . . . 0.44 ' O ' ' O ' ' B' ' 215' ' ' LYS . 1.8 pt-20 -162.0 168.45 22.76 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.669 179.516 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 213' ' ' ASN . . . . . . . . . . . . . 14.8 m120 51.53 34.5 12.5 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.955 -0.566 . . . . 0.0 111.066 176.966 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 50.56 19.89 3.46 Favored Glycine 0 CA--C 1.526 0.745 0 N-CA-C 111.156 -0.777 . . . . 0.0 111.156 179.981 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 215' ' ' LYS . . . . . 0.44 ' O ' ' O ' ' B' ' 212' ' ' GLU . 80.1 mttt -146.21 150.81 36.54 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 120.933 0.397 . . . . 0.0 110.602 179.723 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 216' ' ' TRP . . . . . . . . . . . . . 53.5 m95 -87.39 117.38 26.12 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.055 179.789 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 217' ' ' THR . . . . . . . . . . . . . 17.1 m -128.5 136.91 51.44 Favored 'General case' 0 C--O 1.234 0.248 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.129 -179.798 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 218' ' ' TRP . . . . . 0.555 ' CH2' ' N ' ' B' ' 208' ' ' SER . 14.2 t-105 -100.34 112.98 25.36 Favored 'General case' 0 N--CA 1.463 0.199 0 CA-C-N 116.044 -0.526 . . . . 0.0 109.99 179.606 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 92.7 mttt -130.24 167.52 18.31 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.74 -179.912 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -178.29 -162.89 28.83 Favored Glycine 0 CA--C 1.524 0.605 0 N-CA-C 111.089 -0.804 . . . . 0.0 111.089 179.878 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 221' ' ' ILE . . . . . 0.551 ' O ' HG23 ' B' ' 222' ' ' ILE . 21.5 mt -56.0 -73.52 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 C-N-CA 120.422 -0.511 . . . . 0.0 110.307 -178.116 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 222' ' ' ILE . . . . . 0.551 HG23 ' O ' ' B' ' 221' ' ' ILE . 22.6 pt -160.37 -165.2 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.086 179.797 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 223' ' ' ARG . . . . . 0.569 ' N ' HD11 ' A' ' 75' ' ' ILE . 26.7 ptt180 -40.24 172.18 0.0 OUTLIER 'General case' 0 CA--C 1.52 -0.201 0 CA-C-O 121.278 0.561 . . . . 0.0 110.88 179.293 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 224' ' ' LEU . . . . . 0.725 HD22 ' N ' ' B' ' 224' ' ' LEU . 2.8 mm? -61.38 120.73 11.01 Favored 'General case' 0 C--N 1.316 -0.861 0 CA-C-O 121.428 0.632 . . . . 0.0 110.929 -178.924 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 83.1 tt0 -79.47 136.36 36.9 Favored 'General case' 0 N--CA 1.452 -0.35 0 CA-C-N 115.295 -0.866 . . . . 0.0 109.935 -179.988 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 226' ' ' GLN . . . . . . . . . . . . . 32.4 tp60 . . . . . 0 N--CA 1.446 -0.667 0 CA-C-O 117.921 -1.038 . . . . 0.0 110.755 179.89 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.254 0 N-CA-C 109.623 -1.391 . . . . 0.0 109.623 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 78.8 p -77.6 -9.4 58.93 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.893 0.378 . . . . 0.0 110.758 -179.909 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 58.1 mp0 -61.05 138.08 58.21 Favored 'General case' 0 CA--C 1.514 -0.433 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.18 179.968 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.478 ' O ' HG13 ' A' ' 6' ' ' VAL . 8.1 p -114.72 127.63 26.65 Favored Pre-proline 0 CA--C 1.54 0.586 0 CA-C-N 116.268 -0.423 . . . . 0.0 110.628 -179.965 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -76.08 117.0 4.52 Favored 'Trans proline' 0 N--CA 1.493 1.458 0 C-N-CA 122.411 2.074 . . . . 0.0 112.036 179.721 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 54.0 tt0 -174.45 138.86 0.55 Allowed 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.298 179.733 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 40.5 tp -118.57 107.28 13.56 Favored 'General case' 0 N--CA 1.462 0.13 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.526 179.449 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 52.3 p -88.32 168.03 13.03 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.451 179.462 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 56.0 p30 -140.28 163.94 31.43 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-O 121.054 0.454 . . . . 0.0 110.448 -179.908 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.485 ' CD2' ' CE1' ' A' ' 14' ' ' PHE . 6.9 tt -67.55 139.77 56.95 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.938 -0.573 . . . . 0.0 110.493 -179.637 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 13' ' ' SER . . . . . 0.434 ' O ' ' O ' ' A' ' 25' ' ' ARG . 83.1 p -138.95 154.16 48.28 Favored 'General case' 0 N--CA 1.463 0.208 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.589 179.35 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 14' ' ' PHE . . . . . 0.713 ' CE1' HD13 ' B' ' 205' ' ' ILE . 15.9 m-85 -111.31 146.15 37.57 Favored 'General case' 0 N--CA 1.463 0.188 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.514 -179.645 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 19.0 m -144.7 163.93 13.42 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.511 179.902 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 99.4 m-20 54.64 33.29 18.94 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.023 -0.535 . . . . 0.0 111.062 179.647 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 1.6 mp -58.42 132.17 23.04 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.542 0 CA-C-O 121.222 0.534 . . . . 0.0 109.883 -179.759 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.457 ' CB ' ' O ' ' A' ' 21' ' ' SER . 0.2 OUTLIER -136.2 -166.26 1.85 Allowed 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.212 -0.904 . . . . 0.0 110.652 -179.872 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 19' ' ' ASP . . . . . 0.522 ' OD1' ' N ' ' A' ' 20' ' ' SER . 34.3 p-10 -91.87 -41.95 10.33 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.495 -0.775 . . . . 0.0 111.115 179.366 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 20' ' ' SER . . . . . 0.522 ' N ' ' OD1' ' A' ' 19' ' ' ASP . 25.9 t -118.51 6.85 11.74 Favored 'General case' 0 N--CA 1.467 0.378 0 CA-C-N 116.444 -0.344 . . . . 0.0 110.848 -179.431 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 21' ' ' SER . . . . . 0.457 ' O ' ' CB ' ' A' ' 18' ' ' THR . 48.0 m -151.57 147.92 27.37 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.437 179.961 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 22' ' ' ILE . . . . . 0.52 HD12 HD21 ' A' ' 24' ' ' LEU . 35.8 pt -147.22 147.7 17.29 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 N-CA-C 109.897 -0.408 . . . . 0.0 109.897 179.558 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -101.83 83.43 0.48 Allowed Glycine 0 CA--C 1.524 0.603 0 N-CA-C 111.507 -0.637 . . . . 0.0 111.507 -179.647 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.52 HD21 HD12 ' A' ' 22' ' ' ILE . 84.6 mt -66.37 124.56 23.05 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 109.656 -0.498 . . . . 0.0 109.656 179.899 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 25' ' ' ARG . . . . . 0.434 ' O ' ' O ' ' A' ' 13' ' ' SER . 69.6 ttt180 -139.11 141.13 38.11 Favored 'General case' 0 N--CA 1.463 0.188 0 CA-C-O 120.948 0.404 . . . . 0.0 110.49 -179.714 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 26' ' ' TRP . . . . . . . . . . . . . 35.1 p90 -144.04 155.01 43.83 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.106 179.795 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 2.5 m -111.77 97.9 39.29 Favored Pre-proline 0 CA--C 1.534 0.336 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.507 179.82 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_exo -53.35 142.62 57.0 Favored 'Trans proline' 0 C--N 1.305 -1.728 0 C-N-CA 122.081 1.854 . . . . 0.0 112.478 179.472 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 59.9 mt -81.21 144.24 31.75 Favored 'General case' 0 CA--C 1.518 -0.274 0 CA-C-O 121.412 0.625 . . . . 0.0 110.91 179.877 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 21.0 t-20 -52.04 -36.9 51.73 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 115.392 -0.822 . . . . 0.0 109.799 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 38.5 m -78.28 -35.17 48.32 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.518 179.257 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 14.4 m -58.14 134.17 56.24 Favored 'General case' 0 N--CA 1.461 0.096 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.231 -179.872 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 33' ' ' THR . . . . . 0.452 ' H ' ' HB ' ' A' ' 81' ' ' ILE . 2.7 m -61.82 140.02 58.29 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.084 -179.718 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 6.0 mm -94.28 90.17 2.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 121.065 0.459 . . . . 0.0 110.693 -179.696 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 19.0 pt -139.19 138.11 41.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.549 179.742 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -42.23 135.81 3.56 Favored Glycine 0 CA--C 1.52 0.406 0 N-CA-C 111.004 -0.838 . . . . 0.0 111.004 -179.622 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 -103.2 174.62 5.79 Favored 'General case' 0 CA--C 1.517 -0.317 0 CA-C-O 120.898 0.38 . . . . 0.0 110.179 -179.846 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 2.3 tmm_? -134.92 126.25 28.31 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.592 179.961 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.475 ' O ' ' CG1' ' A' ' 39' ' ' ILE . 1.8 pt -99.92 122.2 51.52 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.176 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.127 179.684 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 24.2 m -104.95 134.38 48.15 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.451 -179.846 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.1 p -133.14 140.65 46.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.351 179.839 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 42' ' ' VAL . . . . . 0.528 ' O ' ' N ' ' A' ' 74' ' ' ASP . 37.6 t -133.25 131.67 58.18 Favored 'Isoleucine or valine' 0 N--CA 1.458 -0.074 0 N-CA-C 110.158 -0.312 . . . . 0.0 110.158 179.714 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.604 ' HB2' ' CE2' ' A' ' 73' ' ' TYR . . . -96.5 138.86 33.45 Favored 'General case' 0 C--N 1.329 -0.304 0 N-CA-C 109.709 -0.478 . . . . 0.0 109.709 178.947 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.564 ' HB3' ' O ' ' A' ' 72' ' ' ASP . . . -93.81 -41.17 9.79 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.487 -0.324 . . . . 0.0 110.835 179.617 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -65.35 -31.85 81.76 Favored Glycine 0 CA--C 1.525 0.689 0 N-CA-C 111.256 -0.738 . . . . 0.0 111.256 -179.763 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 42.3 mm-40 -97.46 133.44 42.05 Favored 'General case' 0 C--N 1.33 -0.24 0 N-CA-C 109.576 -0.528 . . . . 0.0 109.576 -179.483 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -60.32 -21.92 57.72 Favored Glycine 0 CA--C 1.511 -0.217 0 N-CA-C 111.021 -0.832 . . . . 0.0 111.021 -178.987 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -113.11 134.7 21.78 Favored Pre-proline 0 CA--C 1.536 0.407 0 C-N-CA 120.961 -0.295 . . . . 0.0 110.59 179.665 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 71.2 Cg_endo -77.24 163.51 30.21 Favored 'Trans proline' 0 C--N 1.308 -1.564 0 C-N-CA 122.592 2.194 . . . . 0.0 112.202 177.006 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 87.0 mt -83.03 138.26 19.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.044 179.062 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 93.7 m-85 -60.74 142.03 56.31 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.623 -179.829 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 5.6 pt-20 -82.96 151.49 25.87 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.166 179.92 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 53' ' ' ASP . . . . . 0.417 ' CG ' ' OH ' ' A' ' 62' ' ' TYR . 1.7 t70 -120.05 162.91 18.47 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.683 179.451 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 54' ' ' PHE . . . . . 0.59 ' CD1' ' N ' ' A' ' 54' ' ' PHE . 2.4 m-85 -124.02 130.79 53.16 Favored 'General case' 0 C--O 1.232 0.169 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.195 179.662 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 8.7 p -127.69 136.4 60.52 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.449 -179.914 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 97.6 m-20 -58.84 141.29 53.67 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.482 -179.847 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 39.9 t -58.77 -32.84 69.66 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.58 179.857 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 69.1 m -56.23 -35.54 67.46 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.622 -179.836 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 84.1 t -63.44 -46.33 95.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.523 179.982 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 60.86 26.24 65.03 Favored Glycine 0 CA--C 1.528 0.895 0 N-CA-C 110.745 -0.942 . . . . 0.0 110.745 179.863 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 42.6 t80 -167.93 150.58 5.68 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 121.206 0.527 . . . . 0.0 111.103 -179.621 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 62' ' ' TYR . . . . . 0.417 ' OH ' ' CG ' ' A' ' 53' ' ' ASP . 26.7 t80 -157.58 156.27 31.63 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.092 178.831 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 76.3 m -122.64 136.2 54.81 Favored 'General case' 0 N--CA 1.465 0.282 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.728 -179.938 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -130.75 124.9 57.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.026 179.195 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 3.3 p -131.46 155.06 48.02 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.656 179.791 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 109.99 40.63 1.39 Allowed Glycine 0 CA--C 1.524 0.622 0 CA-C-N 115.719 -0.673 . . . . 0.0 111.522 -179.708 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 14.3 mt -112.91 99.31 7.78 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-O 121.274 0.559 . . . . 0.0 109.661 179.47 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 10.6 mm-40 -47.14 135.27 8.88 Favored Pre-proline 0 C--N 1.316 -0.849 0 CA-C-N 115.486 -0.779 . . . . 0.0 111.45 -178.382 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 69' ' ' PRO . . . . . 0.446 ' O ' HD12 ' A' ' 71' ' ' ILE . 72.4 Cg_endo -75.5 149.89 35.32 Favored 'Trans proline' 0 N--CA 1.496 1.646 0 C-N-CA 122.764 2.309 . . . . 0.0 111.761 178.86 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 70' ' ' GLY . . . . . 0.413 ' C ' HD12 ' A' ' 71' ' ' ILE . . . 75.39 13.61 82.71 Favored Glycine 0 CA--C 1.524 0.648 0 N-CA-C 111.23 -0.748 . . . . 0.0 111.23 179.202 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 71' ' ' ILE . . . . . 0.446 HD12 ' O ' ' A' ' 69' ' ' PRO . 2.2 mp -121.0 149.71 23.93 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.354 0 CA-C-O 121.528 0.68 . . . . 0.0 109.629 -179.637 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 72' ' ' ASP . . . . . 0.564 ' O ' ' HB3' ' A' ' 44' ' ' ALA . 2.3 t70 -87.25 112.08 21.67 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 114.854 -1.066 . . . . 0.0 110.621 -179.76 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 73' ' ' TYR . . . . . 0.604 ' CE2' ' HB2' ' A' ' 43' ' ' ALA . 11.8 m-85 -107.87 118.33 36.46 Favored 'General case' 0 C--O 1.216 -0.69 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.735 179.71 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 74' ' ' ASP . . . . . 0.528 ' N ' ' O ' ' A' ' 42' ' ' VAL . 76.6 m-20 -86.97 119.01 26.74 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.495 -0.775 . . . . 0.0 109.496 179.708 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.615 HD11 ' N ' ' B' ' 223' ' ' ARG . 0.0 OUTLIER -116.02 164.43 12.37 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.344 0 CA-C-O 121.171 0.51 . . . . 0.0 110.155 -179.166 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 3.0 m -154.43 121.52 5.63 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 115.466 -0.788 . . . . 0.0 110.849 179.394 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 11.9 t -101.44 102.23 13.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 179.272 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 94.5 mt -89.84 127.32 42.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.405 -0.361 . . . . 0.0 110.517 -179.684 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 99.7 m -109.41 111.68 23.36 Favored 'General case' 0 N--CA 1.465 0.319 0 CA-C-N 116.12 -0.491 . . . . 0.0 109.996 179.708 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 13.9 mt -117.93 122.11 42.42 Favored 'General case' 0 CA--C 1.517 -0.297 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.693 -179.968 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 81' ' ' ILE . . . . . 0.452 ' HB ' ' H ' ' A' ' 33' ' ' THR . 2.1 pp -145.45 134.66 17.66 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.15 179.533 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 82' ' ' ASN . . . . . 0.421 ' O ' ' O ' ' A' ' 83' ' ' GLY . 24.1 t-20 -45.6 -73.26 0.04 OUTLIER 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.777 179.851 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 83' ' ' GLY . . . . . 0.421 ' O ' ' O ' ' A' ' 82' ' ' ASN . . . 37.51 93.27 0.01 OUTLIER Glycine 0 CA--C 1.527 0.783 0 N-CA-C 111.109 -0.796 . . . . 0.0 111.109 179.863 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -50.38 120.19 8.21 Favored Glycine 0 CA--C 1.524 0.621 0 N-CA-C 110.805 -0.918 . . . . 0.0 110.805 -179.49 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -98.97 127.46 44.89 Favored 'General case' 0 N--CA 1.465 0.285 0 CA-C-O 120.786 0.327 . . . . 0.0 110.579 179.793 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 22.1 p -74.12 157.49 35.92 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.392 -179.859 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.423 ' N ' ' CD ' ' A' ' 88' ' ' PRO . . . 54.53 55.02 11.37 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.587 -179.978 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 88' ' ' PRO . . . . . 0.423 ' CD ' ' N ' ' A' ' 87' ' ' ALA . 42.9 Cg_endo -67.31 148.21 79.55 Favored 'Trans proline' 0 C--N 1.307 -1.642 0 C-N-CA 122.849 2.366 . . . . 0.0 111.914 179.951 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 86.6 m -82.02 127.87 33.52 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.2 179.621 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 74.9 p -114.22 135.85 53.6 Favored 'General case' 0 N--CA 1.464 0.235 0 CA-C-O 120.942 0.401 . . . . 0.0 110.455 179.89 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 91' ' ' LEU . . . . . 0.583 HD12 ' N ' ' A' ' 91' ' ' LEU . 10.0 mp -76.92 147.1 37.18 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.398 -179.732 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 82.7 p -73.63 168.56 19.09 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.407 179.952 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 57.6 tt0 -64.22 114.1 4.0 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.457 -179.79 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 99.2 mt-30 -66.0 -40.32 91.02 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.614 179.892 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 41.1 p . . . . . 0 C--O 1.219 -0.521 0 CA-C-O 118.099 -0.953 . . . . 0.0 110.56 -179.945 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' B' B ' 201' ' ' SER . . . . . . . . . . . . . 23.4 m . . . . . 0 N--CA 1.489 1.475 0 N-CA-C 109.384 -0.599 . . . . 0.0 109.384 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' B' B ' 202' ' ' SER . . . . . . . . . . . . . 23.1 m -72.46 149.41 44.22 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.231 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 203' ' ' SER . . . . . . . . . . . . . 5.4 m -130.03 150.21 75.35 Favored Pre-proline 0 CA--C 1.533 0.319 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.62 179.769 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 204' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_exo -39.83 -28.42 0.24 Allowed 'Trans proline' 0 C--N 1.311 -1.421 0 C-N-CA 122.928 2.418 . . . . 0.0 112.193 179.324 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 205' ' ' ILE . . . . . 0.713 HD13 ' CE1' ' A' ' 14' ' ' PHE . 15.3 tt -151.28 155.98 6.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.092 -0.504 . . . . 0.0 111.412 179.765 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 206' ' ' GLN . . . . . . . . . . . . . 9.1 tp-100 -173.28 77.7 0.04 OUTLIER 'General case' 0 N--CA 1.452 -0.35 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.084 179.052 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 207' ' ' GLY . . . . . . . . . . . . . . . -111.42 -142.65 9.0 Favored Glycine 0 N--CA 1.466 0.665 0 N-CA-C 111.204 -0.758 . . . . 0.0 111.204 179.639 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 208' ' ' SER . . . . . 0.493 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 94.7 p -165.76 172.79 11.37 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.861 0.362 . . . . 0.0 110.697 -179.718 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 209' ' ' TRP . . . . . . . . . . . . . 79.1 m95 -84.44 131.53 34.66 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.309 179.656 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 81.4 p -109.41 130.02 55.52 Favored 'General case' 0 N--CA 1.464 0.273 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.546 -179.95 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 52.9 t-105 -92.38 116.91 29.39 Favored 'General case' 0 C--O 1.233 0.204 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.232 179.832 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 212' ' ' GLU . . . . . 0.458 ' O ' ' O ' ' B' ' 215' ' ' LYS . 1.7 pt-20 -165.82 167.53 16.8 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.948 179.333 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 213' ' ' ASN . . . . . . . . . . . . . 96.7 m-20 50.4 36.46 13.21 Favored 'General case' 0 C--N 1.321 -0.641 0 C-N-CA 120.605 -0.438 . . . . 0.0 111.012 176.325 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 50.21 17.07 1.59 Allowed Glycine 0 CA--C 1.523 0.56 0 N-CA-C 111.476 -0.65 . . . . 0.0 111.476 179.853 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 215' ' ' LYS . . . . . 0.458 ' O ' ' O ' ' B' ' 212' ' ' GLU . 52.1 mtmt -144.99 151.13 38.1 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 121.055 0.455 . . . . 0.0 110.684 179.652 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 216' ' ' TRP . . . . . 0.48 ' CD1' ' N ' ' B' ' 216' ' ' TRP . 24.2 m95 -87.27 119.79 27.89 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.053 179.945 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 217' ' ' THR . . . . . . . . . . . . . 21.6 m -130.95 142.81 50.38 Favored 'General case' 0 N--CA 1.464 0.238 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.432 -179.707 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 218' ' ' TRP . . . . . 0.493 ' CH2' ' N ' ' B' ' 208' ' ' SER . 15.7 t-105 -105.57 119.57 39.45 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-N 115.854 -0.612 . . . . 0.0 109.856 179.407 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 51.3 mtmt -142.95 171.78 13.58 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.817 -179.766 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -176.84 -160.28 23.62 Favored Glycine 0 CA--C 1.522 0.497 0 N-CA-C 111.237 -0.745 . . . . 0.0 111.237 -179.544 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 221' ' ' ILE . . . . . 0.535 ' O ' HG23 ' B' ' 222' ' ' ILE . 10.1 mm -50.7 -73.53 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 C-N-CA 120.781 -0.368 . . . . 0.0 110.638 -178.237 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 222' ' ' ILE . . . . . 0.535 HG23 ' O ' ' B' ' 221' ' ' ILE . 21.4 pt -158.8 -166.65 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.723 0 CA-C-N 115.707 -0.678 . . . . 0.0 110.949 -179.795 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 223' ' ' ARG . . . . . 0.615 ' N ' HD11 ' A' ' 75' ' ' ILE . 21.2 ptt-85 -43.42 175.77 0.0 OUTLIER 'General case' 0 CA--C 1.521 -0.164 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.692 179.353 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 224' ' ' LEU . . . . . 0.694 HD22 ' N ' ' B' ' 224' ' ' LEU . 3.4 mm? -62.14 115.89 4.51 Favored 'General case' 0 C--N 1.317 -0.807 0 CA-C-N 115.989 -0.55 . . . . 0.0 110.789 -179.738 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 78.5 tt0 -84.58 148.79 26.28 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.564 -0.744 . . . . 0.0 110.529 179.81 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 226' ' ' GLN . . . . . . . . . . . . . 11.5 tt0 . . . . . 0 C--O 1.221 -0.443 0 CA-C-O 118.023 -0.989 . . . . 0.0 110.583 179.821 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.263 0 N-CA-C 109.481 -1.447 . . . . 0.0 109.481 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 49.2 m -60.14 -42.87 95.78 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.721 0.296 . . . . 0.0 110.745 179.987 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 12.5 pt-20 -118.78 59.65 0.82 Allowed 'General case' 0 N--CA 1.466 0.365 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.546 179.96 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 10.8 t -141.25 76.17 22.01 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.484 179.749 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 35.1 Cg_exo -58.89 144.13 99.02 Favored 'Trans proline' 0 N--CA 1.495 1.585 0 C-N-CA 122.666 2.244 . . . . 0.0 112.006 179.826 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 98.9 mm-40 -75.31 131.24 40.16 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.147 179.84 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 2.5 pp -121.11 129.97 53.53 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.339 -179.943 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 61.1 p -130.68 158.15 40.84 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.194 179.888 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 52.6 p30 -109.33 167.34 10.19 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.388 179.942 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 59.8 tp -65.31 145.98 55.51 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.024 -0.534 . . . . 0.0 110.397 -179.985 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 13' ' ' SER . . . . . 0.47 ' O ' ' O ' ' A' ' 25' ' ' ARG . 14.2 p -143.49 150.16 38.56 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-O 121.184 0.516 . . . . 0.0 110.614 179.299 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 14' ' ' PHE . . . . . 0.566 ' CD1' ' N ' ' A' ' 14' ' ' PHE . 9.4 m-85 -112.16 145.74 39.3 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.0 -0.545 . . . . 0.0 110.625 -179.714 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 19.1 m -142.07 159.47 20.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.353 179.417 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 94.5 m-20 56.9 31.42 19.69 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.69 -0.686 . . . . 0.0 110.94 -179.66 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 96.3 mt -55.6 131.83 18.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.93 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.433 HG22 ' H ' ' A' ' 19' ' ' ASP . 0.2 OUTLIER -131.72 -169.52 2.21 Favored 'General case' 0 N--CA 1.468 0.463 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.47 -179.562 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 19' ' ' ASP . . . . . 0.476 ' N ' ' OD1' ' A' ' 19' ' ' ASP . 17.9 p-10 -77.19 -49.67 14.65 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.982 179.594 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 20' ' ' SER . . . . . 0.457 ' CB ' ' O ' ' A' ' 67' ' ' LEU . 70.7 m -121.43 14.62 11.17 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 116.622 -0.263 . . . . 0.0 110.661 -179.176 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 21' ' ' SER . . . . . 0.514 ' HB3' HG22 ' A' ' 65' ' ' THR . 2.4 m -146.48 129.87 16.75 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.088 -179.525 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 22' ' ' ILE . . . . . 0.702 HD12 HD21 ' A' ' 24' ' ' LEU . 44.6 pt -125.95 141.75 44.69 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.322 0 CA-C-N 116.078 -0.51 . . . . 0.0 109.715 179.681 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -99.41 82.39 0.56 Allowed Glycine 0 CA--C 1.522 0.531 0 N-CA-C 110.953 -0.859 . . . . 0.0 110.953 -179.537 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.702 HD21 HD12 ' A' ' 22' ' ' ILE . 76.5 mt -63.32 124.38 21.1 Favored 'General case' 0 C--N 1.328 -0.354 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 -179.834 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 25' ' ' ARG . . . . . 0.47 ' O ' ' O ' ' A' ' 13' ' ' SER . 67.9 ttp85 -140.66 140.01 34.9 Favored 'General case' 0 C--N 1.332 -0.155 0 CA-C-O 121.245 0.545 . . . . 0.0 110.736 -179.868 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 26' ' ' TRP . . . . . . . . . . . . . 22.0 p90 -144.49 157.99 43.97 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.108 -179.56 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 2.6 m -103.92 105.29 47.61 Favored Pre-proline 0 CA--C 1.536 0.438 0 CA-C-N 116.56 -0.291 . . . . 0.0 110.686 -179.903 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 31.6 Cg_exo -55.02 153.15 26.87 Favored 'Trans proline' 0 N--CA 1.493 1.484 0 C-N-CA 122.041 1.827 . . . . 0.0 112.972 178.802 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.442 ' H ' ' HB2' ' A' ' 32' ' ' SER . 74.5 mt -103.55 135.25 45.5 Favored 'General case' 0 CA--C 1.515 -0.372 0 CA-C-O 121.832 0.825 . . . . 0.0 110.597 -179.941 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 19.2 t-20 -44.18 -31.46 0.98 Allowed 'General case' 0 C--N 1.318 -0.764 0 CA-C-N 115.09 -0.959 . . . . 0.0 110.436 -179.844 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 66.2 m -86.93 -35.9 18.65 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.395 179.151 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 32' ' ' SER . . . . . 0.442 ' HB2' ' H ' ' A' ' 29' ' ' LEU . 3.4 m -47.66 114.34 0.88 Allowed 'General case' 0 CA--C 1.528 0.127 0 CA-C-O 121.167 0.508 . . . . 0.0 110.051 -179.819 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 7.8 m -52.77 146.03 11.24 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.499 -0.773 . . . . 0.0 109.633 -179.483 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 27.6 mm -93.38 91.68 3.37 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.199 0 CA-C-O 121.167 0.508 . . . . 0.0 110.932 -178.45 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.53 ' O ' ' CE1' ' A' ' 37' ' ' TYR . 9.0 pt -145.8 128.17 9.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.232 179.645 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -47.84 135.93 14.88 Favored Glycine 0 CA--C 1.52 0.371 0 N-CA-C 110.805 -0.918 . . . . 0.0 110.805 -179.456 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 37' ' ' TYR . . . . . 0.53 ' CE1' ' O ' ' A' ' 35' ' ' ILE . 10.1 m-85 -100.97 179.86 4.26 Favored 'General case' 0 C--N 1.33 -0.241 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 -179.898 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 5.4 tmm_? -132.43 122.37 24.87 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.473 179.731 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.469 ' O ' ' CG1' ' A' ' 39' ' ' ILE . 1.8 pt -97.84 118.17 43.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 115.924 -0.58 . . . . 0.0 109.89 179.633 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 20.9 m -98.3 134.16 41.71 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.216 -179.383 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.4 p -132.01 140.97 46.68 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.262 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.369 -179.999 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 42' ' ' VAL . . . . . 0.49 ' O ' ' N ' ' A' ' 74' ' ' ASP . 36.2 t -132.21 131.72 60.93 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.177 0 CA-C-O 120.979 0.419 . . . . 0.0 109.903 179.311 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.468 ' HB2' ' CE2' ' A' ' 73' ' ' TYR . . . -96.85 132.98 42.05 Favored 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 109.46 -0.571 . . . . 0.0 109.46 178.987 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.62 ' HB3' ' O ' ' A' ' 72' ' ' ASP . . . -93.93 -14.68 25.71 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.766 0.317 . . . . 0.0 110.825 -179.843 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -99.86 18.88 55.27 Favored Glycine 0 CA--C 1.525 0.678 0 N-CA-C 111.025 -0.83 . . . . 0.0 111.025 -179.495 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 29.4 mm-40 -138.86 149.17 44.58 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 121.179 0.514 . . . . 0.0 110.368 -179.919 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -68.87 -17.3 71.31 Favored Glycine 0 CA--C 1.519 0.283 0 N-CA-C 110.552 -1.019 . . . . 0.0 110.552 179.864 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -135.31 139.03 30.35 Favored Pre-proline 0 CA--C 1.538 0.518 0 C-N-CA 121.192 -0.203 . . . . 0.0 110.683 179.842 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -73.31 158.65 48.21 Favored 'Trans proline' 0 N--CA 1.491 1.351 0 C-N-CA 122.565 2.176 . . . . 0.0 111.813 178.252 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 96.4 mt -73.87 150.2 7.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.247 179.254 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 86.0 m-85 -70.04 137.19 51.07 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.715 179.94 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 52' ' ' GLU . . . . . 0.421 ' N ' ' CD ' ' A' ' 52' ' ' GLU . 0.0 OUTLIER -59.28 -175.65 0.03 OUTLIER 'General case' 0 CA--C 1.513 -0.446 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.449 179.212 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 53' ' ' ASP . . . . . 0.41 ' CG ' ' OH ' ' A' ' 62' ' ' TYR . 2.4 t0 -148.06 144.13 27.67 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.802 -0.636 . . . . 0.0 110.486 179.173 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 89.0 m-85 -116.74 122.93 45.9 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-N 116.363 -0.381 . . . . 0.0 110.572 179.812 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 9.5 p -132.06 142.7 42.18 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.425 0 CA-C-N 116.405 -0.361 . . . . 0.0 110.126 179.972 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 94.8 m-20 -61.13 151.87 30.03 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.377 179.952 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 11.3 t -62.72 -35.57 80.15 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.661 179.89 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 42.9 m -50.89 -37.21 42.3 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.162 -179.623 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.639 ' C ' ' H ' ' A' ' 61' ' ' TYR . 3.3 t -79.86 83.85 1.23 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.55 179.826 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -62.37 28.39 0.07 OUTLIER Glycine 0 CA--C 1.535 1.286 0 N-CA-C 111.103 -0.799 . . . . 0.0 111.103 179.672 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 61' ' ' TYR . . . . . 0.639 ' H ' ' C ' ' A' ' 59' ' ' VAL . 55.2 p90 -166.27 154.19 10.29 Favored 'General case' 0 N--CA 1.451 -0.389 0 CA-C-O 121.14 0.495 . . . . 0.0 111.879 -179.527 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 62' ' ' TYR . . . . . 0.41 ' OH ' ' CG ' ' A' ' 53' ' ' ASP . 23.6 t80 -154.74 148.91 25.94 Favored 'General case' 0 N--CA 1.454 -0.27 0 CA-C-N 115.727 -0.67 . . . . 0.0 109.731 178.794 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 50.1 m -110.69 132.97 53.74 Favored 'General case' 0 N--CA 1.463 0.224 0 CA-C-O 120.909 0.385 . . . . 0.0 110.325 -179.189 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -133.1 100.86 3.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 115.826 -0.625 . . . . 0.0 109.84 178.166 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.514 HG22 ' HB3' ' A' ' 21' ' ' SER . 1.7 p -114.26 165.25 12.87 Favored 'General case' 0 CA--C 1.514 -0.441 0 CA-C-O 121.227 0.536 . . . . 0.0 110.445 179.882 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 108.67 24.33 6.16 Favored Glycine 0 CA--C 1.525 0.68 0 CA-C-N 115.444 -0.798 . . . . 0.0 111.295 -179.933 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.457 ' O ' ' CB ' ' A' ' 20' ' ' SER . 12.7 mt -98.69 106.55 18.83 Favored 'General case' 0 C--O 1.225 -0.22 0 N-CA-C 109.335 -0.617 . . . . 0.0 109.335 179.388 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 49.3 mm-40 -48.43 138.42 11.41 Favored Pre-proline 0 C--N 1.318 -0.792 0 CA-C-N 116.319 -0.4 . . . . 0.0 111.971 -178.323 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -73.36 154.04 50.81 Favored 'Trans proline' 0 N--CA 1.498 1.743 0 C-N-CA 122.749 2.299 . . . . 0.0 111.298 178.736 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 73.76 -6.0 20.95 Favored Glycine 0 CA--C 1.527 0.809 0 CA-C-N 115.839 -0.619 . . . . 0.0 111.647 179.209 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 1.8 mp -102.53 140.53 20.67 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.424 0 CA-C-O 121.326 0.584 . . . . 0.0 109.626 -179.847 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 72' ' ' ASP . . . . . 0.62 ' O ' ' HB3' ' A' ' 44' ' ' ALA . 1.9 t70 -81.42 118.7 22.9 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-N 114.995 -1.002 . . . . 0.0 109.922 179.434 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 73' ' ' TYR . . . . . 0.499 ' O ' HD13 ' A' ' 75' ' ' ILE . 17.6 m-85 -110.85 119.68 39.9 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.828 -0.623 . . . . 0.0 110.44 179.949 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 74' ' ' ASP . . . . . 0.49 ' N ' ' O ' ' A' ' 42' ' ' VAL . 24.8 m-20 -89.43 117.42 28.34 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.613 -0.721 . . . . 0.0 109.574 179.579 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.522 HD11 ' N ' ' B' ' 223' ' ' ARG . 0.0 OUTLIER -114.64 166.23 8.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 121.041 0.448 . . . . 0.0 110.179 -179.339 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 1.1 p -155.11 122.64 5.65 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.589 -0.732 . . . . 0.0 110.559 179.243 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.61 ' O ' HG23 ' B' ' 217' ' ' THR . 20.6 t -96.7 127.35 48.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 N-CA-C 109.355 -0.609 . . . . 0.0 109.355 178.962 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 96.7 mt -117.19 120.02 63.69 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.416 0 CA-C-N 116.479 -0.328 . . . . 0.0 110.485 179.974 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 93.4 m -101.54 116.79 33.56 Favored 'General case' 0 C--N 1.331 -0.21 0 N-CA-C 109.715 -0.476 . . . . 0.0 109.715 179.265 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 16.9 tp -121.35 116.8 25.48 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.724 -179.931 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 81' ' ' ILE . . . . . 0.503 ' HA ' HD11 ' A' ' 35' ' ' ILE . 2.2 pp -147.15 143.29 20.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.321 178.553 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 27.2 t-20 -64.72 -48.9 72.92 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.83 0.348 . . . . 0.0 111.05 -179.818 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 97.73 126.02 5.32 Favored Glycine 0 N--CA 1.465 0.572 0 N-CA-C 111.082 -0.807 . . . . 0.0 111.082 179.671 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -68.27 161.63 50.14 Favored Glycine 0 CA--C 1.523 0.568 0 N-CA-C 110.748 -0.941 . . . . 0.0 110.748 179.947 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 96.4 mt-10 -58.17 134.98 56.97 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.803 0.335 . . . . 0.0 110.57 -179.897 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 20.1 m -72.03 144.88 48.62 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.09 179.898 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.55 ' N ' ' CD ' ' A' ' 88' ' ' PRO . . . 177.19 -46.19 0.0 OUTLIER Pre-proline 0 C--N 1.328 -0.357 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.176 -179.573 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 88' ' ' PRO . . . . . 0.55 ' CD ' ' N ' ' A' ' 87' ' ' ALA . 50.1 Cg_exo -54.14 -39.71 84.83 Favored 'Trans proline' 0 N--CA 1.497 1.694 0 C-N-CA 122.472 2.115 . . . . 0.0 112.387 -179.176 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 39.1 m -138.77 128.48 24.86 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 115.738 -0.664 . . . . 0.0 110.6 179.969 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 44.5 p -140.53 169.8 16.98 Favored 'General case' 0 C--N 1.332 -0.167 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.328 179.494 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 69.5 mt -88.33 129.51 35.37 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.178 -179.774 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 68.7 p -83.37 165.43 19.27 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.362 -179.931 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 99.3 mt-30 -81.96 130.06 34.96 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.526 -179.987 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 29.8 mm100 55.06 -162.1 0.15 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.524 179.927 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 18.7 m . . . . . 0 C--O 1.218 -0.56 0 CA-C-O 117.997 -1.001 . . . . 0.0 110.487 -179.917 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' B' B ' 201' ' ' SER . . . . . . . . . . . . . 5.5 m . . . . . 0 N--CA 1.488 1.443 0 N-CA-C 109.412 -0.588 . . . . 0.0 109.412 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' B' B ' 202' ' ' SER . . . . . . . . . . . . . 85.2 p -72.07 150.7 43.69 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.425 -179.876 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 203' ' ' SER . . . . . . . . . . . . . 1.6 m -93.29 152.21 40.95 Favored Pre-proline 0 CA--C 1.537 0.459 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.631 -179.716 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 204' ' ' PRO . . . . . . . . . . . . . 19.8 Cg_endo -59.38 -44.75 30.79 Favored 'Trans proline' 0 N--CA 1.498 1.763 0 C-N-CA 122.689 2.259 . . . . 0.0 111.659 -179.661 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 205' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -149.45 144.07 18.02 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.358 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.575 -179.993 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 206' ' ' GLN . . . . . . . . . . . . . 16.6 pt20 -136.22 138.72 42.14 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.137 179.086 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 207' ' ' GLY . . . . . 0.417 ' C ' ' CH2' ' B' ' 218' ' ' TRP . . . -100.87 -135.89 9.11 Favored Glycine 0 N--CA 1.466 0.654 0 N-CA-C 110.802 -0.919 . . . . 0.0 110.802 -179.855 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 208' ' ' SER . . . . . 0.532 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 45.1 p -162.2 166.16 25.93 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.803 0.335 . . . . 0.0 110.643 179.068 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 209' ' ' TRP . . . . . . . . . . . . . 84.7 m95 -85.23 152.84 23.03 Favored 'General case' 0 C--N 1.332 -0.167 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.463 179.603 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 210' ' ' THR . . . . . 0.428 ' OG1' ' O ' ' B' ' 217' ' ' THR . 49.4 p -129.47 129.79 45.05 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-N 116.354 -0.385 . . . . 0.0 110.355 179.504 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 57.8 t-105 -92.54 110.17 21.58 Favored 'General case' 0 N--CA 1.462 0.17 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.761 179.657 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 212' ' ' GLU . . . . . 0.443 ' O ' ' O ' ' B' ' 215' ' ' LYS . 1.4 pt-20 -161.17 165.8 28.89 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.54 179.745 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 213' ' ' ASN . . . . . . . . . . . . . 15.9 m120 51.07 33.77 9.75 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.118 176.906 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 53.35 14.79 3.49 Favored Glycine 0 CA--C 1.527 0.814 0 N-CA-C 111.502 -0.639 . . . . 0.0 111.502 179.993 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 215' ' ' LYS . . . . . 0.443 ' O ' ' O ' ' B' ' 212' ' ' GLU . 9.7 mtmp? -140.91 149.33 41.75 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-O 121.047 0.451 . . . . 0.0 110.663 179.895 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 216' ' ' TRP . . . . . . . . . . . . . 48.3 m95 -84.73 114.73 22.26 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.079 -0.51 . . . . 0.0 109.932 179.757 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 217' ' ' THR . . . . . 0.61 HG23 ' O ' ' A' ' 77' ' ' VAL . 18.3 m -119.25 133.03 55.97 Favored 'General case' 0 N--CA 1.464 0.263 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.279 -179.312 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 218' ' ' TRP . . . . . 0.532 ' CH2' ' N ' ' B' ' 208' ' ' SER . 19.6 t-105 -105.33 107.5 18.52 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.014 -0.539 . . . . 0.0 109.874 179.5 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 219' ' ' LYS . . . . . 0.481 ' HG3' HG22 ' B' ' 217' ' ' THR . 51.1 mtmt -132.82 176.2 8.68 Favored 'General case' 0 CA--C 1.514 -0.44 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.285 -179.48 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -178.87 -162.38 28.2 Favored Glycine 0 CA--C 1.525 0.685 0 N-CA-C 110.998 -0.841 . . . . 0.0 110.998 179.288 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 221' ' ' ILE . . . . . 0.597 ' H ' HD12 ' B' ' 221' ' ' ILE . 2.3 mp -55.84 -73.11 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 C-N-CA 120.817 -0.353 . . . . 0.0 110.466 -178.321 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 222' ' ' ILE . . . . . 0.54 HG23 ' O ' ' B' ' 221' ' ' ILE . 23.0 pt -160.1 -165.27 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.167 -179.685 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 223' ' ' ARG . . . . . 0.522 ' N ' HD11 ' A' ' 75' ' ' ILE . 39.1 ptt180 -41.12 171.54 0.0 OUTLIER 'General case' 0 C--N 1.334 -0.092 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.956 178.778 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 224' ' ' LEU . . . . . 0.834 ' H ' HD22 ' B' ' 224' ' ' LEU . 1.9 mm? -65.16 110.61 2.6 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-O 121.383 0.611 . . . . 0.0 110.941 -179.642 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 82.7 tt0 -86.35 148.28 25.67 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.251 -0.886 . . . . 0.0 109.966 179.656 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 226' ' ' GLN . . . . . . . . . . . . . 99.6 mm-40 . . . . . 0 C--O 1.218 -0.572 0 CA-C-O 118.063 -0.97 . . . . 0.0 110.389 -179.798 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 97.6 m-20 . . . . . 0 N--CA 1.457 -0.121 0 CA-C-O 120.802 0.334 . . . . 0.0 110.501 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.521 HD11 ' CZ2' ' B' ' 209' ' ' TRP . 70.1 mt -62.0 151.3 35.55 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.192 -179.054 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 53.5 p -142.55 152.54 42.71 Favored 'General case' 0 CA--C 1.521 -0.152 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.311 -179.825 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . 0.56 ' CD2' HD11 ' B' ' 224' ' ' LEU . 24.7 m-85 -112.16 143.54 43.05 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.972 -179.552 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 28.5 m -142.87 162.06 17.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.326 179.496 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 91.5 m-20 45.57 61.6 2.54 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.499 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 95.5 mt -85.61 135.54 24.72 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.611 179.316 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.4 HG22 ' H ' ' A' ' 19' ' ' ASP . 0.2 OUTLIER -132.37 -168.78 2.11 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.394 179.505 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' ASP . . . . . 0.458 ' OD1' ' N ' ' A' ' 20' ' ' SER . 28.7 p-10 -90.58 -42.38 10.83 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.748 179.312 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . 0.458 ' N ' ' OD1' ' A' ' 19' ' ' ASP . 28.4 t -112.69 7.16 18.56 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.848 -179.886 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 30.7 p -154.05 153.36 31.78 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.312 179.947 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 44.0 pt -147.65 149.16 15.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.344 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -99.52 80.56 0.52 Allowed Glycine 0 CA--C 1.526 0.744 0 N-CA-C 111.3 -0.72 . . . . 0.0 111.3 -179.898 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 62.1 mt -68.35 127.83 34.39 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.891 0.377 . . . . 0.0 110.041 -179.919 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 55.9 ttp180 -142.63 136.05 28.74 Favored 'General case' 0 CA--C 1.518 -0.252 0 CA-C-O 121.095 0.474 . . . . 0.0 110.493 -179.819 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' TRP . . . . . 0.55 ' CD2' ' O ' ' A' ' 60' ' ' GLY . 43.0 p90 -140.78 155.79 46.32 Favored 'General case' 0 CA--C 1.518 -0.284 0 CA-C-N 115.835 -0.621 . . . . 0.0 109.85 179.932 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 2.7 m -110.23 101.85 49.3 Favored Pre-proline 0 CA--C 1.534 0.358 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.839 -179.476 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_exo -56.34 150.59 49.29 Favored 'Trans proline' 0 C--N 1.308 -1.576 0 C-N-CA 122.078 1.852 . . . . 0.0 112.518 178.854 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 72.8 mt -87.3 134.9 33.5 Favored 'General case' 0 N--CA 1.465 0.281 0 CA-C-O 121.718 0.771 . . . . 0.0 110.671 -179.881 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 18.6 t-20 -47.13 -32.63 4.42 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-N 115.214 -0.903 . . . . 0.0 110.199 -179.923 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 75.8 m -82.38 -33.43 28.77 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.65 179.273 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 4.3 m -56.47 130.76 46.3 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-O 120.982 0.42 . . . . 0.0 110.221 -179.96 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' THR . . . . . 0.477 ' OG1' ' N ' ' A' ' 82' ' ' ASN . 6.6 m -54.37 139.53 36.52 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.586 -0.734 . . . . 0.0 109.776 -179.494 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 30.7 mm -93.57 88.97 2.54 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 CA-C-O 121.133 0.492 . . . . 0.0 110.608 -179.275 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.42 HD11 ' HA ' ' A' ' 81' ' ' ILE . 7.9 pt -139.65 149.18 22.64 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.184 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.408 179.588 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -48.68 136.88 17.77 Favored Glycine 0 CA--C 1.519 0.305 0 N-CA-C 110.918 -0.873 . . . . 0.0 110.918 -179.437 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 73.1 m-85 -104.6 160.44 14.95 Favored 'General case' 0 CA--C 1.517 -0.294 0 CA-C-O 120.826 0.346 . . . . 0.0 110.13 -179.818 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 5.3 tmm_? -124.32 124.5 42.52 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.791 -179.789 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.434 ' O ' ' CG1' ' A' ' 39' ' ' ILE . 2.5 pt -99.12 124.77 52.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.075 -0.511 . . . . 0.0 109.936 179.749 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 16.6 m -106.33 135.4 47.89 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.493 -179.545 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.4 p -133.9 142.2 41.94 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.25 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.162 179.878 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . 0.527 ' O ' ' N ' ' A' ' 74' ' ' ASP . 38.3 t -132.55 131.87 60.05 Favored 'Isoleucine or valine' 0 C--N 1.34 0.167 0 N-CA-C 110.06 -0.348 . . . . 0.0 110.06 179.46 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.554 ' HB2' ' CE2' ' A' ' 73' ' ' TYR . . . -98.98 142.47 30.43 Favored 'General case' 0 C--N 1.327 -0.406 0 N-CA-C 109.366 -0.605 . . . . 0.0 109.366 179.158 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . 0.549 ' HB3' ' O ' ' A' ' 72' ' ' ASP . . . -101.06 -21.41 15.01 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.876 0.369 . . . . 0.0 110.959 179.412 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -94.07 30.6 7.41 Favored Glycine 0 N--CA 1.465 0.586 0 N-CA-C 110.958 -0.857 . . . . 0.0 110.958 -179.709 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 86.9 mt-10 -150.98 150.74 31.15 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-O 120.966 0.413 . . . . 0.0 110.626 -179.57 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -70.9 -16.46 74.65 Favored Glycine 0 CA--C 1.519 0.339 0 N-CA-C 110.567 -1.013 . . . . 0.0 110.567 179.879 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -137.63 139.32 26.64 Favored Pre-proline 0 CA--C 1.539 0.524 0 C-N-CA 121.058 -0.257 . . . . 0.0 110.401 179.632 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 63.3 Cg_endo -73.76 160.61 43.37 Favored 'Trans proline' 0 N--CA 1.49 1.291 0 C-N-CA 122.44 2.094 . . . . 0.0 112.326 177.833 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 96.7 mt -71.53 150.54 9.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.285 179.334 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 85.9 m-85 -73.1 140.86 47.44 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.728 179.938 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . 0.42 ' N ' ' CD ' ' A' ' 52' ' ' GLU . 0.3 OUTLIER -68.26 -177.21 0.84 Allowed 'General case' 0 CA--C 1.514 -0.408 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.653 179.575 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' ASP . . . . . 0.41 ' CG ' ' OH ' ' A' ' 62' ' ' TYR . 3.5 t70 -149.47 143.38 25.63 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.6 179.361 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 92.7 m-85 -111.33 122.82 48.85 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.366 179.854 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 5.3 p -129.41 139.13 52.54 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.292 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.293 -179.894 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 91.5 m-20 -55.29 158.12 3.29 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.483 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 38.5 t -66.25 -37.01 84.49 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.66 179.937 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 37.9 m -51.59 -33.4 32.55 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.311 -179.598 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.571 ' C ' ' H ' ' A' ' 61' ' ' TYR . 1.9 t -91.78 68.76 0.58 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.179 179.291 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . 0.55 ' O ' ' CD2' ' A' ' 26' ' ' TRP . . . -53.24 -2.64 0.1 Allowed Glycine 0 CA--C 1.528 0.873 0 N-CA-C 110.946 -0.862 . . . . 0.0 110.946 -179.983 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' TYR . . . . . 0.571 ' H ' ' C ' ' A' ' 59' ' ' VAL . 41.2 p90 -122.57 151.64 41.2 Favored 'General case' 0 N--CA 1.464 0.243 0 CA-C-O 121.103 0.478 . . . . 0.0 111.0 -179.6 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' TYR . . . . . 0.41 ' OH ' ' CG ' ' A' ' 53' ' ' ASP . 33.6 t80 -155.78 156.79 35.41 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.726 -0.67 . . . . 0.0 109.772 179.553 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 88.0 m -119.92 136.44 54.51 Favored 'General case' 0 N--CA 1.465 0.301 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.402 -179.569 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -131.9 110.95 17.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.018 -0.537 . . . . 0.0 109.863 178.956 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 2.0 p -122.26 164.15 18.38 Favored 'General case' 0 N--CA 1.464 0.256 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.617 -179.94 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 112.86 8.65 20.15 Favored Glycine 0 CA--C 1.529 0.943 0 CA-C-N 115.561 -0.745 . . . . 0.0 111.74 -179.12 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 10.5 mt -75.48 178.94 5.57 Favored 'General case' 0 C--N 1.325 -0.483 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 178.583 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 58.7 mm-40 -128.04 137.62 31.21 Favored Pre-proline 0 CA--C 1.54 0.584 0 C-N-CA 121.019 -0.272 . . . . 0.0 111.076 179.295 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -73.34 148.67 43.81 Favored 'Trans proline' 0 N--CA 1.496 1.619 0 C-N-CA 122.801 2.334 . . . . 0.0 111.83 179.193 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 75.51 3.83 73.03 Favored Glycine 0 CA--C 1.526 0.768 0 CA-C-N 115.619 -0.719 . . . . 0.0 111.411 179.226 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 2.0 mp -112.23 141.26 28.31 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.401 0 CA-C-O 121.495 0.664 . . . . 0.0 109.579 -179.618 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 72' ' ' ASP . . . . . 0.549 ' O ' ' HB3' ' A' ' 44' ' ' ALA . 1.9 t70 -82.06 111.52 18.28 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 115.137 -0.938 . . . . 0.0 110.633 179.854 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 73' ' ' TYR . . . . . 0.554 ' CE2' ' HB2' ' A' ' 43' ' ' ALA . 14.7 m-85 -105.86 119.56 39.48 Favored 'General case' 0 C--O 1.219 -0.546 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.568 179.791 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 74' ' ' ASP . . . . . 0.527 ' N ' ' O ' ' A' ' 42' ' ' VAL . 5.5 m-20 -89.32 118.82 29.27 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.572 -0.74 . . . . 0.0 109.326 179.838 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . 0.629 HD11 ' N ' ' B' ' 223' ' ' ARG . 0.0 OUTLIER -115.45 163.81 12.38 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.404 0 CA-C-O 121.066 0.46 . . . . 0.0 110.163 -179.082 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 20.6 t -155.91 121.44 4.9 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.508 -0.769 . . . . 0.0 110.681 178.899 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 5.2 t -101.35 101.09 11.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 N-CA-C 109.901 -0.407 . . . . 0.0 109.901 179.341 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 96.8 mt -91.96 133.46 33.37 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.267 179.763 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . 0.473 ' CG2' ' O ' ' B' ' 216' ' ' TRP . 0.0 OUTLIER -111.91 107.54 16.59 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 121.108 0.48 . . . . 0.0 109.755 179.551 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 38.3 tp -104.22 115.37 30.28 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.724 -0.671 . . . . 0.0 110.458 179.937 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 81' ' ' ILE . . . . . 0.42 ' HA ' HD11 ' A' ' 35' ' ' ILE . 2.1 pp -145.95 146.26 19.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.068 -0.514 . . . . 0.0 110.275 179.33 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 82' ' ' ASN . . . . . 0.477 ' N ' ' OG1' ' A' ' 33' ' ' THR . 18.9 t-20 . . . . . 0 C--N 1.328 -0.332 0 CA-C-O 120.844 0.354 . . . . 0.0 111.256 -179.902 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 207' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.467 0.736 0 N-CA-C 111.088 -0.805 . . . . 0.0 111.088 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' B' B ' 208' ' ' SER . . . . . 0.556 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 59.7 p -166.74 171.78 11.15 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.823 0.344 . . . . 0.0 110.825 179.795 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 209' ' ' TRP . . . . . 0.521 ' CZ2' HD11 ' A' ' 12' ' ' LEU . 44.4 m95 -83.66 146.33 28.31 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.593 179.041 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 32.0 p -128.64 130.11 46.8 Favored 'General case' 0 N--CA 1.463 0.199 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.287 179.752 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 39.1 t-105 -95.37 117.72 30.83 Favored 'General case' 0 N--CA 1.463 0.221 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.376 179.834 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 212' ' ' GLU . . . . . 0.443 ' O ' ' O ' ' B' ' 215' ' ' LYS . 0.6 OUTLIER -163.81 164.57 23.55 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.708 179.13 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' B' B ' 213' ' ' ASN . . . . . . . . . . . . . 11.7 m120 52.62 39.92 29.12 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.616 176.302 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 49.64 21.68 3.52 Favored Glycine 0 CA--C 1.524 0.647 0 N-CA-C 111.084 -0.806 . . . . 0.0 111.084 179.605 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 215' ' ' LYS . . . . . 0.443 ' O ' ' O ' ' B' ' 212' ' ' GLU . 24.9 mtpt -148.02 152.73 37.93 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.063 0.459 . . . . 0.0 111.51 -179.694 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 216' ' ' TRP . . . . . 0.483 ' N ' ' CD1' ' B' ' 216' ' ' TRP . 24.4 m95 -92.17 119.08 31.47 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.959 -0.564 . . . . 0.0 109.729 179.165 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 217' ' ' THR . . . . . . . . . . . . . 12.4 m -132.72 145.02 50.68 Favored 'General case' 0 N--CA 1.465 0.32 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.469 -179.732 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 218' ' ' TRP . . . . . 0.556 ' CH2' ' N ' ' B' ' 208' ' ' SER . 14.5 t-105 -103.34 118.12 36.03 Favored 'General case' 0 N--CA 1.463 0.199 0 CA-C-N 116.008 -0.542 . . . . 0.0 109.922 179.563 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 95.7 mttt -141.15 165.74 26.7 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.952 -179.729 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -176.03 -161.02 24.47 Favored Glycine 0 CA--C 1.521 0.435 0 CA-C-N 115.492 -0.776 . . . . 0.0 111.421 -179.589 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 221' ' ' ILE . . . . . 0.546 ' O ' HG23 ' B' ' 222' ' ' ILE . 22.6 mt -52.75 -74.74 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 C-N-CA 120.598 -0.441 . . . . 0.0 110.295 -177.839 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 222' ' ' ILE . . . . . 0.546 HG23 ' O ' ' B' ' 221' ' ' ILE . 22.1 pt -160.47 -166.72 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.389 -0.369 . . . . 0.0 110.064 179.776 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 223' ' ' ARG . . . . . 0.629 ' N ' HD11 ' A' ' 75' ' ' ILE . 34.1 ptt85 -42.01 175.17 0.0 OUTLIER 'General case' 0 C--N 1.333 -0.129 0 CA-C-O 121.525 0.678 . . . . 0.0 110.532 178.842 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 224' ' ' LEU . . . . . 0.704 ' N ' HD22 ' B' ' 224' ' ' LEU . 3.1 mm? -60.55 122.68 15.27 Favored 'General case' 0 C--N 1.315 -0.905 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.954 -179.379 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 43.1 tt0 . . . . . 0 CA--C 1.517 -0.315 0 CA-C-N 115.623 -0.717 . . . . 0.0 110.343 179.678 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . 0.537 ' OD1' ' N ' ' A' ' 12' ' ' LEU . 55.9 t0 . . . . . 0 N--CA 1.465 0.277 0 CA-C-O 120.801 0.334 . . . . 0.0 110.241 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.537 ' N ' ' OD1' ' A' ' 11' ' ' ASP . 6.0 tp -65.3 142.8 58.13 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.49 -179.963 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . 0.456 ' O ' ' O ' ' A' ' 25' ' ' ARG . 93.5 p -141.99 152.53 43.52 Favored 'General case' 0 N--CA 1.463 0.214 0 CA-C-O 121.076 0.465 . . . . 0.0 110.544 179.325 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . 0.538 ' CD2' HD11 ' B' ' 224' ' ' LEU . 24.3 m-85 -111.46 146.25 37.57 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.511 -179.251 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 31.9 m -147.06 153.86 12.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-O 120.818 0.342 . . . . 0.0 110.395 179.285 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 32.6 t70 58.89 56.87 3.85 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.426 179.854 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 94.0 mt -83.51 133.31 29.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 115.914 -0.585 . . . . 0.0 110.393 179.667 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.44 HG22 ' H ' ' A' ' 19' ' ' ASP . 0.2 OUTLIER -131.17 -167.73 1.89 Allowed 'General case' 0 N--CA 1.471 0.606 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.206 -179.74 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' ASP . . . . . 0.474 ' OD1' ' N ' ' A' ' 19' ' ' ASP . 0.4 OUTLIER -75.89 -53.24 8.74 Favored 'General case' 0 CA--C 1.517 -0.307 0 CA-C-O 120.993 0.425 . . . . 0.0 110.876 179.21 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . 0.427 ' CB ' ' O ' ' A' ' 67' ' ' LEU . 33.4 p -121.13 14.31 11.37 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.968 -177.796 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . 0.401 ' HB2' HG22 ' A' ' 65' ' ' THR . 95.5 p -144.96 125.05 13.61 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.116 0.484 . . . . 0.0 110.112 179.953 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 47.1 pt -127.39 140.67 48.46 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.323 0 CA-C-N 115.912 -0.586 . . . . 0.0 109.492 -179.823 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -103.69 91.57 0.83 Allowed Glycine 0 N--CA 1.467 0.704 0 N-CA-C 111.436 -0.665 . . . . 0.0 111.436 -179.397 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.506 ' N ' HD22 ' A' ' 24' ' ' LEU . 4.0 mm? -61.51 138.53 58.28 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.793 0.33 . . . . 0.0 110.234 -179.812 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . 0.456 ' O ' ' O ' ' A' ' 13' ' ' SER . 13.9 tpt180 -145.38 134.89 23.22 Favored 'General case' 0 C--N 1.334 -0.091 0 CA-C-O 121.455 0.645 . . . . 0.0 110.288 179.873 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' TRP . . . . . 0.511 ' CE2' ' O ' ' A' ' 60' ' ' GLY . 18.7 p90 -145.81 156.3 43.49 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.47 -0.786 . . . . 0.0 109.519 179.21 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 2.7 m -105.5 104.4 47.9 Favored Pre-proline 0 CA--C 1.534 0.344 0 CA-C-O 119.546 -0.264 . . . . 0.0 111.161 -179.153 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_exo -54.48 153.2 23.83 Favored 'Trans proline' 0 C--N 1.31 -1.483 0 C-N-CA 121.381 1.388 . . . . 0.0 113.011 178.523 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.464 ' O ' ' N ' ' A' ' 32' ' ' SER . 75.2 mt -102.57 134.86 45.22 Favored 'General case' 0 N--CA 1.467 0.392 0 CA-C-N 114.946 -1.024 . . . . 0.0 111.04 179.854 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 18.3 t-20 -45.39 -31.1 1.52 Allowed 'General case' 0 C--N 1.314 -0.964 0 CA-C-N 114.86 -1.063 . . . . 0.0 110.263 179.883 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 50.8 m -87.79 -28.85 21.42 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.292 178.998 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . 0.464 ' N ' ' O ' ' A' ' 29' ' ' LEU . 3.4 m -56.23 117.56 3.89 Favored 'General case' 0 CA--C 1.529 0.162 0 CA-C-O 121.318 0.58 . . . . 0.0 110.145 179.935 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' THR . . . . . 0.631 ' CB ' ' H ' ' A' ' 82' ' ' ASN . 12.2 m -51.83 145.55 9.51 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-N 114.919 -1.037 . . . . 0.0 109.182 -179.126 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 30.1 mm -92.08 93.42 4.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.998 0.428 . . . . 0.0 110.825 -178.113 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.597 HD11 ' HA ' ' A' ' 81' ' ' ILE . 8.1 pt -150.97 128.84 2.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 115.871 -0.604 . . . . 0.0 109.875 179.027 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -47.01 130.38 12.75 Favored Glycine 0 CA--C 1.521 0.413 0 N-CA-C 111.4 -0.68 . . . . 0.0 111.4 -178.941 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 95.2 m-85 -87.36 179.64 6.56 Favored 'General case' 0 C--N 1.33 -0.279 0 N-CA-C 109.976 -0.379 . . . . 0.0 109.976 179.551 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' ARG . . . . . 0.683 ' NH2' ' H ' ' A' ' 40' ' ' THR . 0.0 OUTLIER -131.59 123.08 27.17 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.93 179.885 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.49 ' CG1' ' O ' ' A' ' 39' ' ' ILE . 1.7 pt -107.08 118.0 53.99 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.532 0 CA-C-O 121.203 0.525 . . . . 0.0 110.103 179.546 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . 0.683 ' H ' ' NH2' ' A' ' 38' ' ' ARG . 52.9 m -103.25 138.94 39.36 Favored 'General case' 0 N--CA 1.47 0.537 0 O-C-N 122.037 -0.415 . . . . 0.0 110.127 -179.39 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.4 p -129.1 141.13 47.4 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.476 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.351 -179.873 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . 0.495 ' O ' ' N ' ' A' ' 74' ' ' ASP . 37.4 t -131.9 132.73 61.53 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.166 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.203 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -96.66 132.91 41.83 Favored 'General case' 0 C--N 1.327 -0.401 0 N-CA-C 109.468 -0.567 . . . . 0.0 109.468 179.173 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . 0.607 ' HB3' ' O ' ' A' ' 72' ' ' ASP . . . -91.65 -19.16 22.97 Favored 'General case' 0 C--N 1.328 -0.333 0 C-N-CA 120.748 -0.381 . . . . 0.0 110.681 179.994 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -99.07 25.04 29.82 Favored Glycine 0 N--CA 1.466 0.67 0 N-CA-C 111.208 -0.757 . . . . 0.0 111.208 -179.729 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -138.96 146.95 41.6 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 120.853 0.358 . . . . 0.0 110.587 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -66.99 -21.18 71.4 Favored Glycine 0 CA--C 1.526 0.728 0 N-CA-C 111.126 -0.79 . . . . 0.0 111.126 179.811 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -138.16 140.59 29.26 Favored Pre-proline 0 CA--C 1.545 0.784 0 O-C-N 122.66 -0.318 . . . . 0.0 110.553 -179.977 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -74.11 163.79 35.86 Favored 'Trans proline' 0 N--CA 1.495 1.589 0 C-N-CA 122.656 2.238 . . . . 0.0 112.051 178.478 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . 0.556 HG22 ' N ' ' A' ' 51' ' ' PHE . 5.1 mp -86.66 159.99 3.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 115.693 -0.685 . . . . 0.0 111.103 -179.733 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' PHE . . . . . 0.556 ' N ' HG22 ' A' ' 50' ' ' ILE . 88.8 m-85 -73.13 142.77 47.47 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.782 -0.645 . . . . 0.0 111.091 -179.802 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -64.32 -175.25 0.15 Allowed 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 115.492 -0.776 . . . . 0.0 110.412 179.007 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -142.74 134.26 26.45 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.123 179.891 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 96.0 m-85 -111.01 119.98 40.84 Favored 'General case' 0 N--CA 1.465 0.322 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.675 -179.809 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 9.8 p -130.42 142.28 44.13 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.414 0 CA-C-O 120.557 0.218 . . . . 0.0 110.592 -179.906 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 99.4 m-20 -63.4 149.35 46.13 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.384 179.925 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' SER . . . . . 0.44 ' OG ' ' O ' ' A' ' 35' ' ' ILE . 13.8 m -63.24 -32.49 73.91 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.72 0.295 . . . . 0.0 110.984 179.757 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 70.9 m -54.36 -40.45 68.12 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.352 -0.386 . . . . 0.0 110.581 -179.538 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.56 ' C ' ' H ' ' A' ' 61' ' ' TYR . 35.1 t -61.29 -44.08 97.77 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 -179.638 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . 0.511 ' O ' ' CE2' ' A' ' 26' ' ' TRP . . . 68.96 -29.78 0.3 Allowed Glycine 0 CA--C 1.529 0.945 0 N-CA-C 111.346 -0.702 . . . . 0.0 111.346 179.846 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' TYR . . . . . 0.56 ' H ' ' C ' ' A' ' 59' ' ' VAL . 44.9 t80 -112.6 155.48 24.32 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-O 121.225 0.536 . . . . 0.0 111.163 -179.15 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' TYR . . . . . 0.474 ' CD2' ' CD1' ' A' ' 39' ' ' ILE . 24.2 t80 -155.68 159.37 39.49 Favored 'General case' 0 N--CA 1.454 -0.227 0 CA-C-N 115.539 -0.755 . . . . 0.0 109.694 178.617 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 90.9 m -127.7 135.47 50.22 Favored 'General case' 0 N--CA 1.465 0.307 0 CA-C-O 120.834 0.349 . . . . 0.0 110.34 -179.924 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -131.46 107.01 12.8 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 N-CA-C 109.172 -0.677 . . . . 0.0 109.172 178.489 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.401 HG22 ' HB2' ' A' ' 21' ' ' SER . 2.3 p -120.89 162.88 19.09 Favored 'General case' 0 CA--C 1.514 -0.428 0 CA-C-O 120.911 0.386 . . . . 0.0 110.469 -179.707 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 106.62 24.67 6.6 Favored Glycine 0 CA--C 1.52 0.365 0 N-CA-C 110.889 -0.884 . . . . 0.0 110.889 179.873 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.427 ' O ' ' CB ' ' A' ' 20' ' ' SER . 6.9 mt -97.64 107.58 20.1 Favored 'General case' 0 CA--C 1.53 0.175 0 N-CA-C 109.405 -0.591 . . . . 0.0 109.405 179.897 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 66.8 mm-40 -46.36 135.53 7.29 Favored Pre-proline 0 C--N 1.319 -0.753 0 N-CA-C 112.019 0.377 . . . . 0.0 112.019 -178.44 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 95.1 Cg_endo -74.28 156.25 46.3 Favored 'Trans proline' 0 N--CA 1.498 1.789 0 C-N-CA 122.718 2.278 . . . . 0.0 111.219 178.753 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 72.56 -7.39 8.87 Favored Glycine 0 CA--C 1.528 0.864 0 C-N-CA 121.08 -0.581 . . . . 0.0 111.792 179.145 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 1.7 mp -103.74 143.32 15.82 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.366 0 CA-C-O 121.236 0.541 . . . . 0.0 109.702 -179.739 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 72' ' ' ASP . . . . . 0.607 ' O ' ' HB3' ' A' ' 44' ' ' ALA . 1.7 t0 -82.02 118.7 23.2 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.152 -0.931 . . . . 0.0 110.651 179.891 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 73' ' ' TYR . . . . . 0.506 ' O ' HD13 ' A' ' 75' ' ' ILE . 13.8 m-85 -109.74 120.59 42.96 Favored 'General case' 0 C--O 1.221 -0.4 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.899 -179.784 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 74' ' ' ASP . . . . . 0.495 ' N ' ' O ' ' A' ' 42' ' ' VAL . 69.6 m-20 -89.55 116.63 27.85 Favored 'General case' 0 C--N 1.318 -0.783 0 CA-C-N 115.565 -0.743 . . . . 0.0 109.862 179.357 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . 0.6 HD11 ' N ' ' B' ' 223' ' ' ARG . 0.0 OUTLIER -116.1 165.58 11.23 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.383 0 CA-C-O 121.098 0.475 . . . . 0.0 110.262 -179.658 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 11.1 p -153.18 148.85 27.39 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.559 -0.746 . . . . 0.0 110.274 179.08 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.535 ' O ' HG23 ' B' ' 217' ' ' THR . 53.5 t -129.33 135.61 61.33 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 N-CA-C 109.26 -0.644 . . . . 0.0 109.26 179.3 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 78' ' ' ILE . . . . . 0.663 HD12 ' NH1' ' A' ' 38' ' ' ARG . 93.9 mt -127.49 128.11 69.49 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.314 0 CA-C-O 120.854 0.359 . . . . 0.0 110.849 179.315 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 97.1 m -100.93 109.6 21.56 Favored 'General case' 0 C--N 1.331 -0.219 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 179.037 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 37.0 tp -117.95 118.97 33.43 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.638 -179.792 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 81' ' ' ILE . . . . . 0.676 ' O ' HD12 ' A' ' 81' ' ' ILE . 2.2 pp -137.41 161.61 34.13 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.166 0 CA-C-N 115.957 -0.565 . . . . 0.0 109.786 178.801 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 82' ' ' ASN . . . . . 0.631 ' H ' ' CB ' ' A' ' 33' ' ' THR . 16.2 t-20 . . . . . 0 C--N 1.329 -0.304 0 CA-C-O 120.772 0.32 . . . . 0.0 110.899 -179.928 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 207' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.463 0.48 0 N-CA-C 111.098 -0.801 . . . . 0.0 111.098 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' B' B ' 208' ' ' SER . . . . . 0.533 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 38.7 p -165.13 169.33 16.28 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.624 0.249 . . . . 0.0 110.778 179.591 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 209' ' ' TRP . . . . . . . . . . . . . 86.3 m95 -88.05 150.07 23.61 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.202 179.632 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 69.3 p -129.03 129.76 45.74 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-O 120.801 0.334 . . . . 0.0 110.481 179.522 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 52.0 t-105 -91.75 110.32 21.65 Favored 'General case' 0 N--CA 1.463 0.219 0 CA-C-N 116.477 -0.329 . . . . 0.0 110.272 179.609 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 212' ' ' GLU . . . . . 0.527 ' O ' ' O ' ' B' ' 215' ' ' LYS . 2.0 pt-20 -162.78 171.74 16.29 Favored 'General case' 0 C--O 1.22 -0.457 0 CA-C-O 120.977 0.418 . . . . 0.0 110.582 179.454 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 213' ' ' ASN . . . . . 0.492 ' C ' ' H ' ' B' ' 215' ' ' LYS . 13.8 m120 49.77 30.26 3.68 Favored 'General case' 0 C--N 1.317 -0.834 0 C-N-CA 120.237 -0.585 . . . . 0.0 111.721 176.788 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 66.48 -13.13 0.43 Allowed Glycine 0 CA--C 1.532 1.105 0 C-N-CA 121.087 -0.578 . . . . 0.0 111.973 179.229 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 215' ' ' LYS . . . . . 0.527 ' O ' ' O ' ' B' ' 212' ' ' GLU . 67.5 mttm -126.05 156.25 40.25 Favored 'General case' 0 N--CA 1.468 0.432 0 CA-C-O 121.143 0.497 . . . . 0.0 110.67 -179.445 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 216' ' ' TRP . . . . . 0.475 ' N ' ' CD1' ' B' ' 216' ' ' TRP . 32.4 m95 -86.53 125.12 33.54 Favored 'General case' 0 C--N 1.328 -0.348 0 C-N-CA 120.837 -0.345 . . . . 0.0 110.095 179.796 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 217' ' ' THR . . . . . 0.535 HG23 ' O ' ' A' ' 77' ' ' VAL . 18.5 m -124.42 138.42 54.36 Favored 'General case' 0 N--CA 1.468 0.427 0 CA-C-O 120.893 0.378 . . . . 0.0 110.359 -179.45 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 218' ' ' TRP . . . . . 0.533 ' CH2' ' N ' ' B' ' 208' ' ' SER . 24.5 t-105 -105.7 106.7 17.32 Favored 'General case' 0 N--CA 1.462 0.148 0 CA-C-N 116.13 -0.486 . . . . 0.0 109.88 179.343 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 74.4 mttt -135.46 171.47 14.4 Favored 'General case' 0 N--CA 1.466 0.355 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.646 -179.331 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -177.86 -162.75 28.4 Favored Glycine 0 CA--C 1.526 0.765 0 N-CA-C 110.857 -0.897 . . . . 0.0 110.857 179.57 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 221' ' ' ILE . . . . . 0.548 ' O ' HG23 ' B' ' 222' ' ' ILE . 0.8 OUTLIER -53.6 -74.2 0.05 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.384 0 C-N-CA 120.98 -0.288 . . . . 0.0 111.082 -178.73 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' B' B ' 222' ' ' ILE . . . . . 0.548 HG23 ' O ' ' B' ' 221' ' ' ILE . 20.6 pt -160.75 -165.79 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 116.276 -0.42 . . . . 0.0 109.895 -179.545 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 223' ' ' ARG . . . . . 0.6 ' N ' HD11 ' A' ' 75' ' ' ILE . 0.7 OUTLIER -43.37 174.9 0.0 OUTLIER 'General case' 0 N--CA 1.452 -0.363 0 CA-C-O 121.52 0.676 . . . . 0.0 110.814 179.154 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' B' B ' 224' ' ' LEU . . . . . 0.744 ' N ' HD22 ' B' ' 224' ' ' LEU . 2.6 mm? -61.28 116.11 4.36 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-N 115.51 -0.768 . . . . 0.0 110.634 -179.78 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 80.8 tt0 . . . . . 0 N--CA 1.465 0.277 0 CA-C-N 115.407 -0.815 . . . . 0.0 110.315 -179.987 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 98.0 m-20 . . . . . 0 CA--C 1.529 0.155 0 CA-C-O 120.931 0.396 . . . . 0.0 110.801 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 7.2 tt -75.84 154.07 36.4 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.273 179.754 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . 0.433 ' O ' ' O ' ' A' ' 25' ' ' ARG . 17.7 p -140.26 151.39 45.09 Favored 'General case' 0 N--CA 1.462 0.156 0 CA-C-O 121.093 0.473 . . . . 0.0 110.226 178.862 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . 0.547 ' N ' ' CD1' ' A' ' 14' ' ' PHE . 18.0 m-85 -111.48 148.41 33.22 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.707 -0.679 . . . . 0.0 110.747 -179.194 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 25.3 m -148.25 155.57 9.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 120.966 0.412 . . . . 0.0 110.305 179.172 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 39.3 t0 62.72 29.9 16.8 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.6 -0.727 . . . . 0.0 110.891 -179.968 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 68.1 mt -56.68 131.97 20.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 179.716 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.414 ' CB ' ' O ' ' A' ' 21' ' ' SER . 0.2 OUTLIER -132.13 -168.78 2.1 Favored 'General case' 0 N--CA 1.47 0.538 0 CA-C-N 116.385 -0.37 . . . . 0.0 110.246 -179.551 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' ASP . . . . . 0.47 ' N ' ' OD1' ' A' ' 19' ' ' ASP . 22.4 p-10 -78.72 -48.47 14.86 Favored 'General case' 0 C--N 1.332 -0.169 0 C-N-CA 120.811 -0.356 . . . . 0.0 110.951 179.295 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . 0.484 ' OG ' ' N ' ' A' ' 67' ' ' LEU . 27.8 t -120.73 12.78 11.45 Favored 'General case' 0 N--CA 1.462 0.165 0 CA-C-O 120.518 0.199 . . . . 0.0 110.734 -178.882 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . 0.549 ' HB2' HG22 ' A' ' 65' ' ' THR . 92.8 p -146.63 131.03 17.62 Favored 'General case' 0 N--CA 1.463 0.19 0 CA-C-O 120.83 0.348 . . . . 0.0 110.095 -179.9 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 47.5 pt -127.5 142.14 44.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.159 -0.473 . . . . 0.0 109.991 -179.687 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -100.53 83.01 0.52 Allowed Glycine 0 N--CA 1.465 0.596 0 N-CA-C 110.414 -1.074 . . . . 0.0 110.414 179.951 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 16.7 mt -69.42 125.31 26.31 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.895 0.379 . . . . 0.0 110.0 -179.719 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . 0.433 ' O ' ' O ' ' A' ' 13' ' ' SER . 66.8 ttt180 -140.01 142.7 36.25 Favored 'General case' 0 N--CA 1.464 0.233 0 CA-C-O 121.268 0.556 . . . . 0.0 110.915 179.998 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' TRP . . . . . 0.528 ' CD2' ' O ' ' A' ' 60' ' ' GLY . 8.8 p90 -142.94 158.08 43.95 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.483 -0.78 . . . . 0.0 109.755 -179.61 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 4.1 m -103.06 103.92 37.06 Favored Pre-proline 0 CA--C 1.536 0.413 0 CA-C-O 119.592 -0.242 . . . . 0.0 111.058 -179.351 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 31.9 Cg_exo -55.17 153.7 25.76 Favored 'Trans proline' 0 C--N 1.312 -1.37 0 C-N-CA 121.616 1.544 . . . . 0.0 113.103 178.828 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.484 ' O ' ' N ' ' A' ' 32' ' ' SER . 75.1 mt -100.98 133.32 45.65 Favored 'General case' 0 N--CA 1.466 0.342 0 CA-C-N 115.047 -0.979 . . . . 0.0 110.966 179.658 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 26.4 t-20 -44.79 -30.57 0.99 Allowed 'General case' 0 C--N 1.315 -0.898 0 CA-C-N 114.695 -1.138 . . . . 0.0 110.258 179.772 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 64.3 m -89.16 -27.45 20.69 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 115.797 -0.638 . . . . 0.0 110.718 178.978 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . 0.484 ' N ' ' O ' ' A' ' 29' ' ' LEU . 3.3 m -56.38 120.65 8.0 Favored 'General case' 0 N--CA 1.462 0.155 0 CA-C-O 121.575 0.703 . . . . 0.0 110.262 179.876 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' THR . . . . . 0.474 ' CB ' ' H ' ' A' ' 82' ' ' ASN . 6.4 m -52.9 147.27 9.38 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 114.866 -1.061 . . . . 0.0 109.725 -179.103 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 25.0 mm -93.18 93.35 4.11 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 116.4 -0.363 . . . . 0.0 110.888 -178.632 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.539 ' O ' ' CE1' ' A' ' 37' ' ' TYR . 9.0 pt -151.17 131.15 3.69 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.175 179.477 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -54.61 136.32 44.41 Favored Glycine 0 CA--C 1.524 0.609 0 N-CA-C 111.096 -0.802 . . . . 0.0 111.096 -179.252 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' TYR . . . . . 0.539 ' CE1' ' O ' ' A' ' 35' ' ' ILE . 5.0 m-85 -97.87 179.92 4.64 Favored 'General case' 0 C--N 1.332 -0.18 0 N-CA-C 109.683 -0.488 . . . . 0.0 109.683 179.679 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' ARG . . . . . 0.526 ' NH1' ' OE2' ' A' ' 52' ' ' GLU . 5.1 tmm_? -129.14 124.81 35.65 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.492 179.728 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.47 ' CD1' ' CD2' ' A' ' 62' ' ' TYR . 1.8 pt -101.51 118.54 48.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 115.96 -0.564 . . . . 0.0 109.871 179.68 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 35.2 m -102.7 134.35 46.22 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.578 -179.032 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.663 HG22 HD13 ' A' ' 50' ' ' ILE . 2.6 p -130.89 143.53 40.61 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.522 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.424 -179.691 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . 0.526 ' O ' ' N ' ' A' ' 74' ' ' ASP . 43.0 t -134.4 135.06 54.46 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.261 0 CA-C-O 120.875 0.369 . . . . 0.0 110.369 179.834 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.83 ' HB2' HD11 ' A' ' 50' ' ' ILE . . . -97.34 133.27 42.17 Favored 'General case' 0 C--N 1.33 -0.256 0 N-CA-C 109.515 -0.55 . . . . 0.0 109.515 179.169 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . 0.578 ' HB3' ' O ' ' A' ' 72' ' ' ASP . . . -89.87 -40.74 12.23 Favored 'General case' 0 C--N 1.33 -0.246 0 C-N-CA 120.577 -0.449 . . . . 0.0 110.635 179.444 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -80.72 30.21 2.58 Favored Glycine 0 CA--C 1.524 0.602 0 N-CA-C 111.405 -0.678 . . . . 0.0 111.405 -179.817 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 80.0 mm-40 -140.42 146.76 38.72 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 121.079 0.466 . . . . 0.0 110.415 179.753 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -69.98 -20.37 76.17 Favored Glycine 0 CA--C 1.527 0.785 0 N-CA-C 111.133 -0.787 . . . . 0.0 111.133 179.711 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -135.6 142.46 41.08 Favored Pre-proline 0 CA--C 1.545 0.779 0 CA-C-N 116.735 0.268 . . . . 0.0 110.361 -179.482 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -72.14 164.86 34.35 Favored 'Trans proline' 0 N--CA 1.495 1.583 0 C-N-CA 122.457 2.105 . . . . 0.0 111.573 178.451 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . 1.037 ' H ' HD12 ' A' ' 50' ' ' ILE . 0.6 OUTLIER -86.65 159.72 3.11 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 116.022 -0.536 . . . . 0.0 110.619 -179.579 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 84.8 m-85 -75.02 141.32 43.92 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.752 179.893 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . 0.526 ' OE2' ' NH1' ' A' ' 38' ' ' ARG . 4.4 pt-20 -70.23 -175.88 1.07 Allowed 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.501 179.54 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -147.1 141.39 26.27 Favored 'General case' 0 CA--C 1.534 0.337 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.172 179.803 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 34.3 m-85 -113.56 119.56 37.93 Favored 'General case' 0 N--CA 1.469 0.481 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.452 -179.866 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 9.3 p -128.21 140.62 48.69 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.462 0 CA-C-O 120.966 0.412 . . . . 0.0 110.554 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 97.4 m-20 -65.04 153.77 39.76 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.556 179.964 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' SER . . . . . 0.425 ' OG ' ' OH ' ' A' ' 37' ' ' TYR . 4.0 t -64.22 -33.51 75.96 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.662 179.921 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 52.1 m -52.99 -40.59 63.88 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.638 -179.419 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.5 ' O ' ' CD2' ' A' ' 61' ' ' TYR . 21.1 t -61.28 -43.55 96.74 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 N-CA-C 110.019 -0.363 . . . . 0.0 110.019 -179.582 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . 0.528 ' O ' ' CD2' ' A' ' 26' ' ' TRP . . . 72.5 -38.11 0.71 Allowed Glycine 0 CA--C 1.525 0.7 0 N-CA-C 111.359 -0.696 . . . . 0.0 111.359 179.389 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' TYR . . . . . 0.5 ' CD2' ' O ' ' A' ' 59' ' ' VAL . 32.1 p90 -114.62 158.82 21.21 Favored 'General case' 0 N--CA 1.47 0.54 0 CA-C-O 121.016 0.436 . . . . 0.0 110.993 -179.026 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' TYR . . . . . 0.47 ' CD2' ' CD1' ' A' ' 39' ' ' ILE . 29.1 t80 -151.62 158.37 43.39 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 109.394 -0.595 . . . . 0.0 109.394 179.336 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 53.8 m -120.65 133.68 55.34 Favored 'General case' 0 N--CA 1.465 0.297 0 CA-C-O 120.831 0.348 . . . . 0.0 110.095 179.74 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -131.81 103.46 6.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 N-CA-C 109.373 -0.603 . . . . 0.0 109.373 178.845 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.549 HG22 ' HB2' ' A' ' 21' ' ' SER . 3.4 p -116.36 162.48 17.46 Favored 'General case' 0 CA--C 1.512 -0.514 0 CA-C-O 121.077 0.465 . . . . 0.0 110.452 179.772 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 106.38 23.53 7.23 Favored Glycine 0 CA--C 1.521 0.424 0 N-CA-C 111.177 -0.769 . . . . 0.0 111.177 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.484 ' N ' ' OG ' ' A' ' 20' ' ' SER . 10.8 mt -97.43 109.91 22.57 Favored 'General case' 0 C--O 1.227 -0.115 0 N-CA-C 109.063 -0.717 . . . . 0.0 109.063 179.499 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 66.4 mm-40 -51.18 135.18 30.52 Favored Pre-proline 0 C--N 1.319 -0.745 0 C-N-CA 120.611 -0.435 . . . . 0.0 111.843 -178.039 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 96.8 Cg_endo -74.08 157.46 46.6 Favored 'Trans proline' 0 N--CA 1.499 1.85 0 C-N-CA 122.878 2.385 . . . . 0.0 111.132 178.83 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 72.31 -8.74 6.44 Favored Glycine 0 CA--C 1.525 0.678 0 C-N-CA 120.879 -0.677 . . . . 0.0 111.594 179.306 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 1.8 mp -103.88 140.67 21.37 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.373 0 CA-C-O 121.496 0.665 . . . . 0.0 109.642 -179.683 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 72' ' ' ASP . . . . . 0.578 ' O ' ' HB3' ' A' ' 44' ' ' ALA . 2.3 t0 -79.54 116.99 20.07 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 114.783 -1.098 . . . . 0.0 110.457 -179.524 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 73' ' ' TYR . . . . . 0.519 ' O ' HD13 ' A' ' 75' ' ' ILE . 11.5 m-85 -108.11 120.78 43.32 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.495 -179.771 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 74' ' ' ASP . . . . . 0.526 ' N ' ' O ' ' A' ' 42' ' ' VAL . 23.1 m-20 -88.51 114.63 25.33 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 115.275 -0.875 . . . . 0.0 109.831 -179.903 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . 0.602 HD11 ' N ' ' B' ' 223' ' ' ARG . 0.0 OUTLIER -113.26 164.05 9.68 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.36 0 CA-C-O 121.217 0.532 . . . . 0.0 110.363 -179.747 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 2.6 p -152.42 124.63 8.13 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.183 -0.917 . . . . 0.0 109.918 179.539 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 70.7 t -106.14 131.45 55.73 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 N-CA-C 109.11 -0.7 . . . . 0.0 109.11 179.818 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 97.4 mt -128.17 131.25 69.47 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.317 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.898 -179.886 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . 0.535 HG23 ' O ' ' A' ' 79' ' ' THR . 9.0 t -106.95 122.41 46.37 Favored 'General case' 0 N--CA 1.463 0.192 0 CA-C-N 115.76 -0.654 . . . . 0.0 109.529 179.122 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 42.4 mt -119.86 113.01 19.94 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.478 -179.312 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 81' ' ' ILE . . . . . 0.505 ' HA ' HD11 ' A' ' 35' ' ' ILE . 2.2 pp -146.66 144.26 20.28 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.25 0 CA-C-O 120.725 0.298 . . . . 0.0 110.327 178.651 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 82' ' ' ASN . . . . . 0.474 ' H ' ' CB ' ' A' ' 33' ' ' THR . 42.3 t30 . . . . . 0 C--N 1.33 -0.279 0 CA-C-N 116.381 -0.372 . . . . 0.0 111.509 -179.683 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 207' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.466 0.645 0 N-CA-C 110.99 -0.844 . . . . 0.0 110.99 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' B' B ' 208' ' ' SER . . . . . 0.567 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 46.4 p -166.16 170.38 13.41 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.975 0.417 . . . . 0.0 110.794 179.384 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 209' ' ' TRP . . . . . . . . . . . . . 76.4 m95 -90.77 154.87 19.21 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.385 179.505 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 61.5 p -129.75 129.85 44.65 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.43 179.471 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 51.5 t-105 -90.99 109.62 20.86 Favored 'General case' 0 N--CA 1.465 0.283 0 CA-C-N 116.352 -0.386 . . . . 0.0 110.314 179.696 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 212' ' ' GLU . . . . . 0.493 ' O ' ' O ' ' B' ' 215' ' ' LYS . 1.8 pt-20 -162.26 170.54 18.79 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.332 -0.394 . . . . 0.0 110.571 179.515 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 213' ' ' ASN . . . . . 0.528 ' C ' ' H ' ' B' ' 215' ' ' LYS . 93.9 m-20 49.68 30.09 3.48 Favored 'General case' 0 C--N 1.318 -0.793 0 C-N-CA 120.393 -0.523 . . . . 0.0 111.467 177.259 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 64.04 -10.25 0.26 Allowed Glycine 0 CA--C 1.529 0.944 0 C-N-CA 120.97 -0.634 . . . . 0.0 111.732 179.415 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 215' ' ' LYS . . . . . 0.528 ' H ' ' C ' ' B' ' 213' ' ' ASN . 27.1 mtpt -123.92 153.73 40.74 Favored 'General case' 0 N--CA 1.467 0.424 0 CA-C-O 121.056 0.455 . . . . 0.0 111.004 -179.411 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 216' ' ' TRP . . . . . 0.448 ' N ' ' CD1' ' B' ' 216' ' ' TRP . 39.5 m95 -86.62 120.84 28.37 Favored 'General case' 0 C--N 1.326 -0.415 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 179.599 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 217' ' ' THR . . . . . . . . . . . . . 22.7 m -123.89 136.81 54.59 Favored 'General case' 0 N--CA 1.467 0.415 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.27 -179.512 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 218' ' ' TRP . . . . . 0.567 ' CH2' ' N ' ' B' ' 208' ' ' SER . 18.6 t-105 -104.16 108.77 20.3 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.034 179.628 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 76.5 mttt -133.11 169.61 16.61 Favored 'General case' 0 CA--C 1.515 -0.37 0 CA-C-N 115.828 -0.624 . . . . 0.0 110.425 -179.791 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -178.1 -161.8 26.83 Favored Glycine 0 N--CA 1.446 -0.64 0 N-CA-C 110.688 -0.965 . . . . 0.0 110.688 179.612 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 221' ' ' ILE . . . . . 0.533 ' O ' HG23 ' B' ' 222' ' ' ILE . 24.8 mt -53.91 -72.84 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 C-N-CA 120.702 -0.399 . . . . 0.0 110.33 -178.431 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 222' ' ' ILE . . . . . 0.533 HG23 ' O ' ' B' ' 221' ' ' ILE . 22.8 pt -160.3 -166.36 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.172 -0.467 . . . . 0.0 109.859 179.932 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 223' ' ' ARG . . . . . 0.602 ' N ' HD11 ' A' ' 75' ' ' ILE . 23.5 ptt180 -40.87 174.16 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 121.57 0.7 . . . . 0.0 110.999 178.883 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 224' ' ' LEU . . . . . 0.733 ' N ' HD22 ' B' ' 224' ' ' LEU . 2.7 mm? -61.97 109.79 1.37 Allowed 'General case' 0 C--N 1.315 -0.901 0 CA-C-N 115.398 -0.819 . . . . 0.0 110.531 -179.839 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 43.4 tt0 . . . . . 0 C--N 1.33 -0.278 0 CA-C-N 115.219 -0.9 . . . . 0.0 110.328 -179.939 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 45.5 t0 . . . . . 0 N--CA 1.465 0.289 0 CA-C-O 120.906 0.384 . . . . 0.0 110.579 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 47.6 tp -63.51 140.3 58.86 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.968 -0.56 . . . . 0.0 109.986 -179.339 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 86.2 p -139.51 154.99 47.8 Favored 'General case' 0 C--O 1.234 0.238 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.456 179.823 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . 0.564 ' CD2' HD11 ' B' ' 224' ' ' LEU . 18.4 m-85 -111.92 145.47 39.49 Favored 'General case' 0 N--CA 1.464 0.257 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.589 -179.76 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 26.7 m -146.04 161.36 11.09 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.401 179.707 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 97.1 m-20 52.56 30.81 9.03 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.796 179.683 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 84.1 mt -58.39 141.11 15.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 115.98 -0.554 . . . . 0.0 110.246 179.994 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.47 ' CB ' ' O ' ' A' ' 21' ' ' SER . 0.2 OUTLIER -140.98 -166.34 2.14 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.652 -179.621 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 7.6 p-10 -88.76 -46.92 8.6 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.71 -0.677 . . . . 0.0 110.946 179.653 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 41.3 m -115.23 8.42 15.51 Favored 'General case' 0 N--CA 1.468 0.449 0 CA-C-N 116.47 -0.332 . . . . 0.0 110.593 -179.648 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . 0.47 ' O ' ' CB ' ' A' ' 18' ' ' THR . 29.6 p -151.09 145.44 25.48 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.986 0.422 . . . . 0.0 110.553 179.691 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . 0.466 HD12 HD21 ' A' ' 24' ' ' LEU . 41.4 pt -142.49 146.95 21.61 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.113 179.839 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -102.1 84.46 0.5 Allowed Glycine 0 CA--C 1.522 0.518 0 N-CA-C 111.1 -0.8 . . . . 0.0 111.1 179.957 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.466 HD21 HD12 ' A' ' 22' ' ' ILE . 92.5 mt -69.86 122.48 19.34 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.817 0.341 . . . . 0.0 110.159 -179.865 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 65.7 ttt-85 -136.0 144.47 45.35 Favored 'General case' 0 CA--C 1.517 -0.291 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.116 -179.844 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' TRP . . . . . 0.447 ' HE1' ' HG3' ' A' ' 28' ' ' PRO . 35.1 p90 -145.99 157.27 43.88 Favored 'General case' 0 CA--C 1.518 -0.26 0 CA-C-N 116.407 -0.361 . . . . 0.0 110.074 -179.9 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 4.6 m -111.85 96.33 32.9 Favored Pre-proline 0 C--O 1.234 0.268 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.475 179.545 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.447 ' HG3' ' HE1' ' A' ' 26' ' ' TRP . 46.4 Cg_exo -54.1 143.72 61.42 Favored 'Trans proline' 0 C--N 1.307 -1.653 0 C-N-CA 122.177 1.918 . . . . 0.0 112.496 179.39 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 66.5 mt -79.4 140.01 37.55 Favored 'General case' 0 CA--C 1.517 -0.291 0 CA-C-O 121.481 0.658 . . . . 0.0 111.014 -179.841 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . 0.437 ' O ' ' OD1' ' A' ' 30' ' ' ASN . 59.8 t-20 -51.67 -33.95 36.1 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.243 -0.889 . . . . 0.0 109.806 179.902 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 51.4 m -79.43 -32.94 42.89 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.52 179.41 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 14.0 m -62.32 136.99 58.17 Favored 'General case' 0 CA--C 1.528 0.129 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.178 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' THR . . . . . 0.591 ' H ' ' HB ' ' A' ' 81' ' ' ILE . 7.1 m -64.89 141.59 58.72 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.967 -0.561 . . . . 0.0 110.395 179.857 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 15.5 mm -95.03 95.36 4.99 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.201 0 CA-C-O 120.936 0.398 . . . . 0.0 110.548 -179.962 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.494 ' O ' ' OG ' ' A' ' 57' ' ' SER . 11.3 pt -142.47 132.12 22.75 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.192 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.402 179.723 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -38.11 122.05 1.11 Allowed Glycine 0 CA--C 1.524 0.603 0 N-CA-C 111.424 -0.671 . . . . 0.0 111.424 -179.595 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 76.4 m-85 -89.48 176.47 6.89 Favored 'General case' 0 CA--C 1.515 -0.391 0 CA-C-O 120.907 0.384 . . . . 0.0 110.113 -179.946 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 6.2 tmm_? -135.35 126.74 28.51 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.635 179.946 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.452 ' CG1' ' O ' ' A' ' 39' ' ' ILE . 1.8 pt -102.43 125.27 56.71 Favored 'Isoleucine or valine' 0 C--O 1.233 0.208 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.003 179.603 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 15.9 m -106.81 133.02 52.1 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.448 -179.858 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.2 p -128.34 138.9 53.36 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.312 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.108 179.925 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . 0.526 ' O ' ' N ' ' A' ' 74' ' ' ASP . 39.2 t -133.27 133.78 57.79 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.114 0 CA-C-N 116.418 -0.356 . . . . 0.0 110.195 179.671 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -95.95 136.53 36.27 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.269 179.292 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . 0.592 ' HB3' ' O ' ' A' ' 72' ' ' ASP . . . -90.35 -46.29 8.48 Favored 'General case' 0 N--CA 1.464 0.256 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.545 179.844 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -64.82 -30.65 78.55 Favored Glycine 0 CA--C 1.523 0.577 0 N-CA-C 111.042 -0.823 . . . . 0.0 111.042 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 36.6 mm-40 -96.07 134.73 38.76 Favored 'General case' 0 C--N 1.331 -0.197 0 N-CA-C 109.482 -0.562 . . . . 0.0 109.482 -179.24 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -63.69 -21.81 65.47 Favored Glycine 0 CA--C 1.51 -0.242 0 N-CA-C 111.087 -0.805 . . . . 0.0 111.087 -178.922 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -114.46 136.11 22.33 Favored Pre-proline 0 CA--C 1.54 0.574 0 C-N-CA 120.983 -0.287 . . . . 0.0 110.577 179.709 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -78.58 169.75 19.34 Favored 'Trans proline' 0 C--N 1.309 -1.523 0 C-N-CA 122.792 2.328 . . . . 0.0 112.002 176.498 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 4.7 mp -96.43 133.53 37.43 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.183 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.561 179.564 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 83.0 m-85 -49.71 149.31 2.54 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.617 -179.871 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 5.9 pt-20 -75.3 -178.06 3.79 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.204 179.766 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -143.76 132.57 22.61 Favored 'General case' 0 N--CA 1.45 -0.429 0 CA-C-N 115.848 -0.614 . . . . 0.0 110.855 179.839 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 96.9 m-85 -104.6 119.47 39.06 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.206 179.449 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 10.6 p -126.27 134.22 66.95 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.295 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.295 179.979 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 98.2 m-20 -56.87 138.46 53.64 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.417 -179.866 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' SER . . . . . 0.494 ' OG ' ' O ' ' A' ' 35' ' ' ILE . 5.0 m -59.04 -32.49 69.8 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.38 179.871 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 59.2 m -55.31 -33.59 63.44 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.395 -179.904 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 95.6 t -64.2 -45.74 95.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.438 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 61.58 26.75 67.03 Favored Glycine 0 CA--C 1.527 0.792 0 N-CA-C 110.656 -0.978 . . . . 0.0 110.656 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' TYR . . . . . 0.413 ' CG ' ' N ' ' A' ' 62' ' ' TYR . 48.5 t80 -167.88 152.2 6.45 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 121.275 0.56 . . . . 0.0 111.134 -179.333 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' TYR . . . . . 0.413 ' N ' ' CG ' ' A' ' 61' ' ' TYR . 23.6 t80 -158.59 159.04 35.02 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.069 178.827 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 85.8 m -126.6 135.75 51.64 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.711 -179.819 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -132.04 108.1 13.56 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.334 0 CA-C-N 115.946 -0.57 . . . . 0.0 109.743 179.127 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 2.6 p -116.98 159.64 22.18 Favored 'General case' 0 CA--C 1.518 -0.259 0 CA-C-O 121.0 0.429 . . . . 0.0 110.844 179.971 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 109.21 3.03 31.43 Favored Glycine 0 CA--C 1.527 0.802 0 CA-C-N 115.7 -0.682 . . . . 0.0 111.528 -179.503 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 3.8 mt -79.49 110.86 15.19 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 121.067 0.461 . . . . 0.0 110.024 -179.259 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 9.3 mt-10 -48.09 139.1 10.08 Favored Pre-proline 0 C--N 1.319 -0.741 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.013 -178.834 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -75.09 162.41 36.93 Favored 'Trans proline' 0 N--CA 1.494 1.558 0 C-N-CA 122.888 2.392 . . . . 0.0 112.401 179.426 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 46.7 22.15 1.03 Allowed Glycine 0 N--CA 1.443 -0.885 0 CA-C-N 115.27 -0.877 . . . . 0.0 111.617 179.2 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . 0.442 ' CG2' ' CD1' ' A' ' 73' ' ' TYR . 0.9 OUTLIER -109.5 166.2 4.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 121.349 0.595 . . . . 0.0 109.814 -179.708 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 72' ' ' ASP . . . . . 0.592 ' O ' ' HB3' ' A' ' 44' ' ' ALA . 4.3 t0 -102.05 101.02 11.34 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.355 -0.839 . . . . 0.0 111.82 179.476 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 73' ' ' TYR . . . . . 0.55 ' O ' HD13 ' A' ' 75' ' ' ILE . 2.2 m-30 -109.58 125.38 52.48 Favored 'General case' 0 C--O 1.219 -0.537 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.585 179.049 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 74' ' ' ASP . . . . . 0.526 ' N ' ' O ' ' A' ' 42' ' ' VAL . 79.7 m-20 -89.0 117.05 27.74 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 114.993 -1.003 . . . . 0.0 109.397 179.891 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . 0.641 HD11 ' N ' ' B' ' 223' ' ' ARG . 0.0 OUTLIER -116.54 168.63 7.89 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.306 0 CA-C-O 121.155 0.502 . . . . 0.0 110.079 -179.019 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 45.3 t -154.66 150.46 27.68 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.445 -0.798 . . . . 0.0 110.877 179.539 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.408 ' O ' HG23 ' B' ' 217' ' ' THR . 12.0 t -130.38 100.97 5.34 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.272 0 N-CA-C 109.613 -0.514 . . . . 0.0 109.613 178.958 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 96.2 mt -88.82 130.44 38.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.59 -179.782 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 91.8 m -112.53 106.66 15.16 Favored 'General case' 0 CA--C 1.518 -0.276 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 179.59 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . 0.535 HD23 ' C ' ' A' ' 80' ' ' LEU . 6.6 tt -121.3 122.29 39.56 Favored 'General case' 0 CA--C 1.519 -0.249 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.315 -179.906 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 81' ' ' ILE . . . . . 0.591 ' HB ' ' H ' ' A' ' 33' ' ' THR . 2.2 pp -134.19 151.29 32.05 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.175 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.295 179.611 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 82' ' ' ASN . . . . . 0.535 ' H ' ' CB ' ' A' ' 33' ' ' THR . 57.1 t-20 . . . . . 0 C--N 1.329 -0.29 0 CA-C-N 116.478 -0.328 . . . . 0.0 111.193 179.94 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 207' ' ' GLY . . . . . 0.427 ' C ' ' CH2' ' B' ' 218' ' ' TRP . . . . . . . . 0 N--CA 1.467 0.736 0 N-CA-C 111.174 -0.771 . . . . 0.0 111.174 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 208' ' ' SER . . . . . 0.458 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 97.4 p -162.92 170.28 18.39 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.829 0.347 . . . . 0.0 110.717 179.759 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 209' ' ' TRP . . . . . . . . . . . . . 79.0 m95 -85.32 131.42 34.41 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.183 179.682 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 44.6 p -113.8 140.69 48.1 Favored 'General case' 0 N--CA 1.463 0.221 0 CA-C-N 116.409 -0.359 . . . . 0.0 110.61 -179.752 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 54.5 t-105 -96.55 118.26 32.66 Favored 'General case' 0 N--CA 1.464 0.226 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.134 179.914 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 212' ' ' GLU . . . . . 0.477 ' O ' ' O ' ' B' ' 215' ' ' LYS . 0.9 OUTLIER -165.72 167.75 16.79 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.971 179.076 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' B' B ' 213' ' ' ASN . . . . . . . . . . . . . 12.7 m120 50.41 35.23 10.54 Favored 'General case' 0 C--N 1.321 -0.648 0 C-N-CA 120.603 -0.439 . . . . 0.0 111.02 176.168 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 52.24 14.75 2.29 Favored Glycine 0 CA--C 1.525 0.66 0 N-CA-C 111.364 -0.694 . . . . 0.0 111.364 179.661 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 215' ' ' LYS . . . . . 0.477 ' O ' ' O ' ' B' ' 212' ' ' GLU . 8.1 mtmp? -144.52 151.38 39.04 Favored 'General case' 0 C--N 1.333 -0.124 0 CA-C-O 121.161 0.505 . . . . 0.0 110.657 179.793 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 216' ' ' TRP . . . . . . . . . . . . . 66.2 m95 -85.58 120.95 27.59 Favored 'General case' 0 C--N 1.329 -0.289 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 -179.911 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 217' ' ' THR . . . . . 0.408 HG23 ' O ' ' A' ' 77' ' ' VAL . 21.5 m -130.75 142.29 50.41 Favored 'General case' 0 C--O 1.233 0.229 0 CA-C-O 121.051 0.453 . . . . 0.0 110.617 -179.578 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 218' ' ' TRP . . . . . 0.458 ' CH2' ' N ' ' B' ' 208' ' ' SER . 16.4 t-105 -104.31 121.45 43.38 Favored 'General case' 0 N--CA 1.462 0.137 0 CA-C-N 115.925 -0.579 . . . . 0.0 109.921 179.501 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 52.1 mtmt -144.73 171.56 14.23 Favored 'General case' 0 N--CA 1.464 0.246 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.826 -179.524 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -175.44 -161.03 24.2 Favored Glycine 0 CA--C 1.524 0.627 0 CA-C-N 115.614 -0.721 . . . . 0.0 111.322 -179.663 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 221' ' ' ILE . . . . . 0.547 ' O ' HG23 ' B' ' 222' ' ' ILE . 18.8 mt -51.29 -73.27 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 C-N-CA 120.737 -0.385 . . . . 0.0 110.592 -177.973 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 222' ' ' ILE . . . . . 0.547 HG23 ' O ' ' B' ' 221' ' ' ILE . 16.2 pt -158.89 -167.26 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.451 179.808 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 223' ' ' ARG . . . . . 0.641 ' N ' HD11 ' A' ' 75' ' ' ILE . 0.1 OUTLIER -46.12 177.08 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.651 -0.704 . . . . 0.0 110.399 179.146 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' B' B ' 224' ' ' LEU . . . . . 0.683 ' N ' HD22 ' B' ' 224' ' ' LEU . 3.4 mm? -58.68 126.14 26.39 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.414 -178.833 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 225' ' ' GLU . . . . . 0.508 ' OE1' ' NH1' ' B' ' 223' ' ' ARG . 29.7 tp10 . . . . . 0 C--N 1.332 -0.162 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.167 -179.758 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 97.6 m-20 . . . . . 0 N--CA 1.464 0.227 0 CA-C-O 120.915 0.388 . . . . 0.0 110.336 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 7.4 tt -64.81 144.65 57.11 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.383 -179.74 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . 0.458 ' O ' ' O ' ' A' ' 25' ' ' ARG . 87.1 p -139.18 159.54 41.91 Favored 'General case' 0 N--CA 1.462 0.125 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.653 179.734 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . 0.424 ' N ' ' CD1' ' A' ' 14' ' ' PHE . 19.1 m-85 -111.35 145.47 38.81 Favored 'General case' 0 N--CA 1.465 0.308 0 CA-C-N 115.978 -0.556 . . . . 0.0 110.572 -179.775 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 17.4 m -144.9 157.4 14.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.463 179.659 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 98.9 m-20 47.76 60.24 3.66 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.314 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 98.2 mt -82.46 140.51 16.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.538 179.757 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.438 ' CB ' ' O ' ' A' ' 21' ' ' SER . 0.3 OUTLIER -138.54 -168.33 2.37 Favored 'General case' 0 N--CA 1.466 0.325 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.449 179.917 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' ASP . . . . . 0.475 ' OD1' ' N ' ' A' ' 19' ' ' ASP . 15.8 p-10 -88.55 -43.63 11.26 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.618 179.509 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . 0.417 ' OG ' ' O ' ' A' ' 67' ' ' LEU . 50.8 m -117.51 9.77 13.32 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.833 -179.65 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . 0.438 ' O ' ' CB ' ' A' ' 18' ' ' THR . 9.4 m -150.1 141.76 23.58 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.262 179.829 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 44.3 pt -136.76 146.17 28.96 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.417 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.337 179.915 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -101.63 81.3 0.43 Allowed Glycine 0 CA--C 1.524 0.621 0 N-CA-C 110.887 -0.885 . . . . 0.0 110.887 179.692 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 16.4 mt -67.23 123.91 21.62 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 110.025 -0.361 . . . . 0.0 110.025 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . 0.458 ' O ' ' O ' ' A' ' 13' ' ' SER . 72.5 ttp85 -142.24 135.82 29.22 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.381 -179.804 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' TRP . . . . . . . . . . . . . 3.8 p90 -141.28 158.74 43.48 Favored 'General case' 0 C--N 1.326 -0.444 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 -179.811 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 4.1 m -108.03 102.35 45.51 Favored Pre-proline 0 CA--C 1.537 0.461 0 CA-C-N 116.725 -0.216 . . . . 0.0 110.418 179.504 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_exo -54.91 145.85 60.1 Favored 'Trans proline' 0 C--N 1.308 -1.571 0 C-N-CA 121.8 1.667 . . . . 0.0 112.874 179.547 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 71.1 mt -85.07 138.3 32.51 Favored 'General case' 0 CA--C 1.515 -0.371 0 CA-C-O 121.44 0.638 . . . . 0.0 110.567 179.866 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . 0.421 ' O ' ' OD1' ' A' ' 30' ' ' ASN . 61.2 t-20 -48.63 -34.54 11.91 Favored 'General case' 0 C--N 1.314 -0.946 0 CA-C-N 115.187 -0.915 . . . . 0.0 110.152 -179.962 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 38.3 m -80.68 -33.05 35.78 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.508 179.03 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 6.9 m -59.17 131.64 51.64 Favored 'General case' 0 CA--C 1.528 0.116 0 CA-C-O 120.963 0.411 . . . . 0.0 110.368 -179.839 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' THR . . . . . 0.494 ' CB ' ' H ' ' A' ' 82' ' ' ASN . 4.3 m -62.14 145.41 53.44 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.032 179.984 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 12.5 mm -93.92 94.42 4.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-O 120.921 0.391 . . . . 0.0 110.645 -179.606 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.478 ' O ' ' OG ' ' A' ' 57' ' ' SER . 15.8 pt -147.57 133.04 11.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.844 -0.617 . . . . 0.0 110.563 -179.88 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -47.86 130.43 17.43 Favored Glycine 0 CA--C 1.52 0.357 0 N-CA-C 110.979 -0.848 . . . . 0.0 110.979 -179.864 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' TYR . . . . . 0.468 ' CE2' HG22 ' A' ' 39' ' ' ILE . 3.8 p90 -106.25 126.84 52.73 Favored 'General case' 0 C--N 1.33 -0.278 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 179.377 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' ARG . . . . . 0.529 ' NH1' ' OG1' ' A' ' 40' ' ' THR . 3.3 tmm_? -76.4 131.31 39.04 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.275 -0.421 . . . . 0.0 111.128 -179.321 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.468 HG22 ' CE2' ' A' ' 37' ' ' TYR . 2.2 pt -98.19 123.94 50.98 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.159 0 CA-C-N 115.956 -0.566 . . . . 0.0 109.531 179.526 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . 0.529 ' OG1' ' NH1' ' A' ' 38' ' ' ARG . 1.6 m -103.38 131.12 50.72 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 120.802 0.334 . . . . 0.0 110.56 -179.303 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.3 p -130.48 138.68 53.19 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.052 179.442 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . 0.517 ' N ' ' O ' ' A' ' 74' ' ' ASP . 39.7 t -133.1 131.88 58.64 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.248 0 N-CA-C 110.101 -0.333 . . . . 0.0 110.101 -179.99 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.596 ' HB2' ' CE2' ' A' ' 73' ' ' TYR . . . -96.25 139.54 32.25 Favored 'General case' 0 C--N 1.327 -0.377 0 N-CA-C 109.54 -0.541 . . . . 0.0 109.54 179.099 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . 0.537 ' HB3' ' O ' ' A' ' 72' ' ' ASP . . . -92.21 -41.71 10.28 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.762 0.315 . . . . 0.0 110.857 179.636 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -65.66 -31.73 80.87 Favored Glycine 0 CA--C 1.526 0.735 0 N-CA-C 111.388 -0.685 . . . . 0.0 111.388 -179.357 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 32.0 mt-10 -97.94 129.66 44.84 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 121.168 0.509 . . . . 0.0 109.651 -179.64 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -60.37 -8.55 9.42 Favored Glycine 0 CA--C 1.518 0.233 0 N-CA-C 110.701 -0.959 . . . . 0.0 110.701 -179.272 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -124.08 134.39 25.39 Favored Pre-proline 0 CA--C 1.538 0.512 0 C-N-CA 121.298 -0.161 . . . . 0.0 110.588 179.529 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -77.99 160.63 30.26 Favored 'Trans proline' 0 C--N 1.314 -1.273 0 C-N-CA 122.477 2.118 . . . . 0.0 112.054 177.602 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 96.1 mt -80.71 137.69 20.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.199 179.188 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 90.0 m-85 -55.88 142.05 36.79 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.949 0.404 . . . . 0.0 110.724 -179.702 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . 0.518 ' H ' ' CD ' ' A' ' 52' ' ' GLU . 0.4 OUTLIER -77.72 146.21 36.08 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.376 179.778 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -109.81 144.83 37.69 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.406 179.829 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 93.5 m-85 -109.46 118.82 37.65 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.266 179.944 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 9.3 p -125.95 137.47 57.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.441 -179.747 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 84.1 m-20 -67.63 141.41 56.75 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.297 179.592 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' SER . . . . . 0.478 ' OG ' ' O ' ' A' ' 35' ' ' ILE . 9.6 m -57.98 -28.5 64.44 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.417 179.886 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 23.4 m -55.94 -33.64 64.92 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.542 179.959 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.473 ' O ' ' CD2' ' A' ' 61' ' ' TYR . 50.6 t -60.49 -45.18 97.34 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 116.394 -0.367 . . . . 0.0 110.15 -179.395 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 71.36 14.51 74.44 Favored Glycine 0 CA--C 1.529 0.922 0 N-CA-C 111.074 -0.81 . . . . 0.0 111.074 179.388 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' TYR . . . . . 0.473 ' CD2' ' O ' ' A' ' 59' ' ' VAL . 27.6 p90 -172.27 158.34 4.43 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.795 0.331 . . . . 0.0 111.348 179.43 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 23.6 t80 -155.94 155.6 33.09 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.356 -0.384 . . . . 0.0 110.144 177.955 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 94.4 m -121.09 134.7 55.27 Favored 'General case' 0 N--CA 1.463 0.224 0 CA-C-O 121.072 0.463 . . . . 0.0 110.429 -179.814 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -131.86 103.35 6.78 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.197 0 CA-C-N 115.954 -0.566 . . . . 0.0 109.862 178.961 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 2.3 p -112.84 162.87 15.3 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 121.031 0.444 . . . . 0.0 110.683 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 111.38 5.62 26.2 Favored Glycine 0 CA--C 1.527 0.83 0 CA-C-N 115.482 -0.781 . . . . 0.0 111.583 -179.272 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.425 ' CB ' HH21 ' B' ' 223' ' ' ARG . 9.1 mt -81.21 109.04 15.36 Favored 'General case' 0 C--N 1.329 -0.286 0 N-CA-C 109.479 -0.563 . . . . 0.0 109.479 179.379 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 17.5 mm-40 -57.81 137.42 83.11 Favored Pre-proline 0 C--N 1.321 -0.651 0 CA-C-N 116.288 -0.414 . . . . 0.0 111.569 -178.303 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 69' ' ' PRO . . . . . 0.411 ' O ' HD12 ' A' ' 71' ' ' ILE . 80.8 Cg_endo -74.29 151.76 43.7 Favored 'Trans proline' 0 N--CA 1.494 1.542 0 C-N-CA 122.695 2.263 . . . . 0.0 111.732 178.93 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 76.58 6.41 84.44 Favored Glycine 0 CA--C 1.528 0.856 0 CA-C-N 115.644 -0.707 . . . . 0.0 111.413 179.229 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . 0.411 HD12 ' O ' ' A' ' 69' ' ' PRO . 2.4 mp -117.05 143.99 25.93 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.392 0 CA-C-O 121.398 0.618 . . . . 0.0 109.728 -179.717 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 72' ' ' ASP . . . . . 0.537 ' O ' ' HB3' ' A' ' 44' ' ' ALA . 4.4 t70 -84.06 112.26 20.05 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 114.987 -1.006 . . . . 0.0 110.626 -179.657 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 73' ' ' TYR . . . . . 0.596 ' CE2' ' HB2' ' A' ' 43' ' ' ALA . 11.9 m-85 -107.54 120.61 42.68 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.467 179.73 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 74' ' ' ASP . . . . . 0.517 ' O ' ' N ' ' A' ' 42' ' ' VAL . 72.6 m-20 -88.04 119.42 28.4 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.348 -0.842 . . . . 0.0 109.414 179.474 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . 0.907 HD13 ' N ' ' A' ' 75' ' ' ILE . 0.0 OUTLIER -120.15 166.44 14.57 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-O 121.005 0.431 . . . . 0.0 110.311 -178.521 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 21.2 t -155.92 125.61 6.39 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.659 -0.701 . . . . 0.0 110.623 179.204 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 11.4 t -102.0 100.79 11.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 N-CA-C 109.621 -0.511 . . . . 0.0 109.621 179.126 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 90.4 mt -87.95 126.3 41.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.717 -179.766 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . 0.431 ' OG1' ' O ' ' B' ' 216' ' ' TRP . 16.4 p -106.93 110.03 22.08 Favored 'General case' 0 N--CA 1.464 0.235 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 179.514 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 35.9 tp -117.57 124.58 49.01 Favored 'General case' 0 N--CA 1.464 0.231 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.445 179.98 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 81' ' ' ILE . . . . . 0.483 ' HB ' ' H ' ' A' ' 33' ' ' THR . 2.1 pp -145.9 145.34 20.28 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-N 116.004 -0.543 . . . . 0.0 110.259 179.338 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 82' ' ' ASN . . . . . 0.494 ' H ' ' CB ' ' A' ' 33' ' ' THR . 47.2 t30 . . . . . 0 C--N 1.329 -0.311 0 CA-C-N 116.522 -0.308 . . . . 0.0 110.808 -179.743 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 207' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.465 0.615 0 N-CA-C 110.818 -0.913 . . . . 0.0 110.818 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' B' B ' 208' ' ' SER . . . . . 0.455 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 53.9 p -164.35 171.67 14.48 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 120.876 0.37 . . . . 0.0 110.686 -179.893 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 209' ' ' TRP . . . . . . . . . . . . . 76.5 m95 -87.51 134.98 33.53 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.216 179.575 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 70.2 p -110.62 131.74 54.79 Favored 'General case' 0 N--CA 1.467 0.423 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.552 -179.847 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 50.5 t-105 -93.16 115.2 27.84 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 120.875 0.369 . . . . 0.0 110.432 179.689 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 212' ' ' GLU . . . . . 0.484 ' O ' ' O ' ' B' ' 215' ' ' LYS . 1.4 pt-20 -164.89 170.54 15.21 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.077 -0.51 . . . . 0.0 111.085 179.199 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 213' ' ' ASN . . . . . . . . . . . . . 16.3 m120 48.58 34.19 4.76 Favored 'General case' 0 C--N 1.322 -0.619 0 C-N-CA 120.398 -0.521 . . . . 0.0 111.342 176.384 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 54.27 11.75 2.65 Favored Glycine 0 CA--C 1.529 0.932 0 N-CA-C 111.627 -0.589 . . . . 0.0 111.627 179.794 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 215' ' ' LYS . . . . . 0.484 ' O ' ' O ' ' B' ' 212' ' ' GLU . 65.9 mttm -142.86 150.77 40.31 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 121.038 0.446 . . . . 0.0 110.732 179.995 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 216' ' ' TRP . . . . . 0.436 ' CD1' ' N ' ' B' ' 216' ' ' TRP . 35.0 m95 -87.74 127.15 35.31 Favored 'General case' 0 C--N 1.33 -0.281 0 N-CA-C 109.954 -0.387 . . . . 0.0 109.954 179.742 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 217' ' ' THR . . . . . . . . . . . . . 21.7 m -136.14 145.0 45.34 Favored 'General case' 0 N--CA 1.463 0.217 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.359 -179.784 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 218' ' ' TRP . . . . . 0.455 ' CH2' ' N ' ' B' ' 208' ' ' SER . 24.8 t-105 -102.6 120.83 41.23 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 116.048 -0.524 . . . . 0.0 109.796 179.53 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 97.4 mttt -136.56 164.33 28.44 Favored 'General case' 0 N--CA 1.465 0.308 0 CA-C-O 121.083 0.468 . . . . 0.0 110.739 -179.62 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -176.13 -162.75 27.55 Favored Glycine 0 CA--C 1.523 0.575 0 N-CA-C 111.134 -0.786 . . . . 0.0 111.134 -179.942 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 221' ' ' ILE . . . . . 0.533 ' O ' HG23 ' B' ' 222' ' ' ILE . 0.9 OUTLIER -58.75 -78.71 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 C-N-CA 120.459 -0.496 . . . . 0.0 110.965 -178.254 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' B' B ' 222' ' ' ILE . . . . . 0.533 HG23 ' O ' ' B' ' 221' ' ' ILE . 19.1 pt -159.12 -162.84 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 N-CA-C 110.043 -0.355 . . . . 0.0 110.043 -179.085 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 223' ' ' ARG . . . . . 0.544 ' HD2' ' H ' ' B' ' 223' ' ' ARG . 0.0 OUTLIER -43.76 173.64 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 121.271 0.558 . . . . 0.0 110.545 178.648 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' B' B ' 224' ' ' LEU . . . . . 0.747 ' N ' HD22 ' B' ' 224' ' ' LEU . 2.6 mm? -59.42 138.46 57.65 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-N 115.67 -0.695 . . . . 0.0 110.581 -179.707 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 80.0 tt0 . . . . . 0 C--N 1.332 -0.178 0 CA-C-N 115.389 -0.823 . . . . 0.0 110.41 -179.492 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 45.2 t0 . . . . . 0 N--CA 1.463 0.223 0 CA-C-O 120.809 0.338 . . . . 0.0 110.271 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 5.7 tt -70.22 134.96 48.57 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.552 179.846 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 82.5 p -142.61 162.32 35.78 Favored 'General case' 0 N--CA 1.462 0.143 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.401 179.631 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . 0.411 ' CD1' ' N ' ' A' ' 14' ' ' PHE . 57.3 m-85 -110.27 147.64 33.45 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.905 -0.588 . . . . 0.0 110.67 -179.642 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 17.7 m -144.19 152.93 15.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.399 179.737 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 24.9 t70 60.66 34.24 20.1 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.544 -179.823 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 96.4 mt -57.02 134.65 21.3 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.191 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.035 179.709 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.438 ' OG1' ' O ' ' A' ' 21' ' ' SER . 0.2 OUTLIER -136.49 -168.89 2.34 Favored 'General case' 0 N--CA 1.469 0.478 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.388 -179.831 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' ASP . . . . . 0.485 ' N ' ' OD1' ' A' ' 19' ' ' ASP . 18.6 p-10 -76.48 -50.62 13.58 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.798 179.49 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . 0.441 ' CB ' ' O ' ' A' ' 67' ' ' LEU . 69.8 m -121.61 15.76 11.13 Favored 'General case' 0 N--CA 1.462 0.173 0 CA-C-N 116.677 -0.238 . . . . 0.0 110.679 -179.33 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . 0.527 ' HB2' HG22 ' A' ' 65' ' ' THR . 25.2 p -145.97 127.09 14.69 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-O 121.041 0.448 . . . . 0.0 110.545 -179.612 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 38.4 pt -128.69 141.29 46.96 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.3 0 CA-C-N 115.947 -0.569 . . . . 0.0 109.57 -179.81 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -102.29 88.73 0.7 Allowed Glycine 0 CA--C 1.523 0.566 0 N-CA-C 111.8 -0.52 . . . . 0.0 111.8 -179.316 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 10.3 mp -61.06 148.59 39.79 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 121.072 0.463 . . . . 0.0 110.349 179.963 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 50.2 ttt180 -157.4 136.57 11.83 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.683 -0.69 . . . . 0.0 110.98 179.827 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' TRP . . . . . 0.521 ' CH2' ' OH ' ' A' ' 37' ' ' TYR . 34.5 p90 -139.74 159.39 42.28 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.821 -0.627 . . . . 0.0 109.915 -179.93 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 3.7 m -107.71 99.77 31.31 Favored Pre-proline 0 CA--C 1.537 0.443 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.986 -179.363 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 38.7 Cg_exo -56.64 153.39 36.2 Favored 'Trans proline' 0 C--N 1.31 -1.454 0 C-N-CA 122.093 1.862 . . . . 0.0 112.956 178.84 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.513 ' H ' ' HB2' ' A' ' 32' ' ' SER . 41.7 mt -110.41 135.91 50.38 Favored 'General case' 0 N--CA 1.469 0.492 0 CA-C-O 121.76 0.79 . . . . 0.0 110.876 -179.845 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 28.1 t-20 -45.61 -30.05 1.4 Allowed 'General case' 0 C--N 1.315 -0.902 0 CA-C-N 114.902 -1.045 . . . . 0.0 110.477 179.852 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 69.3 m -89.83 -23.83 21.59 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.623 179.282 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . 0.513 ' HB2' ' H ' ' A' ' 29' ' ' LEU . 4.7 m -65.09 120.03 11.91 Favored 'General case' 0 N--CA 1.464 0.233 0 CA-C-O 121.204 0.525 . . . . 0.0 110.163 179.998 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 23.7 m -55.82 140.69 41.42 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.602 -0.727 . . . . 0.0 109.516 179.578 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 29.8 mm -94.7 99.01 8.73 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.343 0 CA-C-O 120.854 0.359 . . . . 0.0 111.367 -178.625 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.56 HD11 ' HA ' ' A' ' 81' ' ' ILE . 0.1 OUTLIER -140.11 155.78 24.28 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.21 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.152 179.466 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -74.55 97.74 1.0 Allowed Glycine 0 CA--C 1.524 0.609 0 N-CA-C 110.793 -0.923 . . . . 0.0 110.793 179.877 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' TYR . . . . . 0.521 ' OH ' ' CH2' ' A' ' 26' ' ' TRP . 2.0 p90 -78.79 126.99 31.45 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 110.01 -0.367 . . . . 0.0 110.01 179.787 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 5.4 tmm_? -78.01 132.39 37.78 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 120.975 0.417 . . . . 0.0 111.092 -179.69 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.458 ' CG1' ' O ' ' A' ' 39' ' ' ILE . 1.9 pt -98.46 121.27 48.83 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.217 0 N-CA-C 109.155 -0.683 . . . . 0.0 109.155 179.146 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 13.6 m -99.66 135.81 40.52 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 120.852 0.358 . . . . 0.0 110.948 -179.04 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.3 p -133.15 139.88 48.38 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.364 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.031 179.531 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . 0.511 ' O ' ' N ' ' A' ' 74' ' ' ASP . 38.7 t -131.68 131.66 62.27 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.252 0 N-CA-C 109.969 -0.382 . . . . 0.0 109.969 179.616 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -97.91 133.51 42.31 Favored 'General case' 0 C--N 1.326 -0.414 0 N-CA-C 109.448 -0.575 . . . . 0.0 109.448 179.148 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . 0.627 ' HB3' ' O ' ' A' ' 72' ' ' ASP . . . -94.01 -14.14 26.2 Favored 'General case' 0 C--N 1.329 -0.309 0 C-N-CA 120.956 -0.298 . . . . 0.0 111.005 -179.57 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -99.38 21.81 43.67 Favored Glycine 0 N--CA 1.465 0.609 0 N-CA-C 111.293 -0.723 . . . . 0.0 111.293 -179.518 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -143.74 150.25 38.34 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 121.163 0.506 . . . . 0.0 110.316 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -68.4 -19.35 72.49 Favored Glycine 0 CA--C 1.524 0.647 0 N-CA-C 110.822 -0.911 . . . . 0.0 110.822 179.976 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -134.06 139.73 34.08 Favored Pre-proline 0 CA--C 1.542 0.642 0 O-C-N 122.828 -0.219 . . . . 0.0 110.658 179.943 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_endo -73.79 164.47 34.61 Favored 'Trans proline' 0 N--CA 1.491 1.363 0 C-N-CA 122.613 2.209 . . . . 0.0 111.902 178.102 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . 0.434 HG22 ' N ' ' A' ' 51' ' ' PHE . 96.6 mt -79.16 155.01 4.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.608 179.603 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' PHE . . . . . 0.434 ' N ' HG22 ' A' ' 50' ' ' ILE . 98.3 m-85 -71.59 141.64 50.01 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.42 179.986 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . 0.529 ' H ' ' CD ' ' A' ' 52' ' ' GLU . 0.4 OUTLIER -77.21 144.09 38.54 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.729 179.603 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -104.05 148.57 26.08 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.521 179.7 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' PHE . . . . . 0.465 ' CD1' ' N ' ' A' ' 54' ' ' PHE . 15.9 m-85 -115.48 120.25 38.9 Favored 'General case' 0 N--CA 1.462 0.144 0 CA-C-N 115.758 -0.655 . . . . 0.0 110.038 179.664 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 8.3 p -130.41 144.05 39.13 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.307 0 CA-C-O 120.64 0.257 . . . . 0.0 110.381 -179.957 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 98.7 m-20 -66.27 146.75 54.25 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.591 179.51 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -65.92 -31.89 73.08 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.602 179.841 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 42.9 m -53.84 -36.19 62.3 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.619 -179.579 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 86.9 t -59.27 -43.66 90.38 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 116.438 -0.346 . . . . 0.0 110.41 -179.558 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 64.93 23.94 69.73 Favored Glycine 0 CA--C 1.526 0.721 0 N-CA-C 110.403 -1.079 . . . . 0.0 110.403 179.65 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' TYR . . . . . 0.416 ' CG ' ' N ' ' A' ' 62' ' ' TYR . 38.0 t80 -170.42 153.81 4.47 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 121.018 0.437 . . . . 0.0 111.495 -179.549 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' TYR . . . . . 0.417 ' CD2' ' CD1' ' A' ' 39' ' ' ILE . 19.1 t80 -158.73 160.96 36.96 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.337 178.582 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 85.5 m -126.26 134.35 51.2 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.068 -0.514 . . . . 0.0 110.271 179.881 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -133.05 100.64 3.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.033 -0.53 . . . . 0.0 109.684 178.972 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.527 HG22 ' HB2' ' A' ' 21' ' ' SER . 1.4 p -114.68 164.21 14.37 Favored 'General case' 0 CA--C 1.513 -0.478 0 CA-C-O 120.969 0.414 . . . . 0.0 110.507 -179.89 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 107.34 23.75 6.81 Favored Glycine 0 CA--C 1.519 0.319 0 N-CA-C 111.162 -0.775 . . . . 0.0 111.162 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.441 ' O ' ' CB ' ' A' ' 20' ' ' SER . 10.0 mt -97.22 106.38 18.7 Favored 'General case' 0 N--CA 1.464 0.226 0 N-CA-C 109.532 -0.544 . . . . 0.0 109.532 179.804 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 5.2 mm-40 -46.63 137.34 7.27 Favored Pre-proline 0 C--N 1.316 -0.854 0 CA-C-N 116.101 -0.5 . . . . 0.0 111.827 -178.421 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -73.98 156.67 47.59 Favored 'Trans proline' 0 N--CA 1.497 1.705 0 C-N-CA 122.674 2.249 . . . . 0.0 111.255 178.665 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 71.69 -5.68 10.99 Favored Glycine 0 CA--C 1.527 0.789 0 C-N-CA 120.947 -0.645 . . . . 0.0 111.685 179.307 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . 0.473 ' O ' ' NH1' ' B' ' 223' ' ' ARG . 1.7 mp -103.61 144.32 14.27 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.437 0 CA-C-O 121.26 0.552 . . . . 0.0 109.611 -179.807 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 72' ' ' ASP . . . . . 0.627 ' O ' ' HB3' ' A' ' 44' ' ' ALA . 2.3 t70 -84.39 119.19 24.82 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.14 -0.936 . . . . 0.0 110.469 179.291 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 73' ' ' TYR . . . . . 0.479 ' O ' HD13 ' A' ' 75' ' ' ILE . 19.0 m-85 -110.14 120.22 41.76 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.75 -179.999 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 74' ' ' ASP . . . . . 0.511 ' N ' ' O ' ' A' ' 42' ' ' VAL . 14.8 m-20 -90.17 117.1 28.67 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 115.619 -0.719 . . . . 0.0 109.788 179.639 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . 0.484 HD13 ' N ' ' A' ' 75' ' ' ILE . 0.0 OUTLIER -114.05 165.2 9.34 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-O 121.147 0.498 . . . . 0.0 110.059 -179.29 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 1.3 p -154.59 121.36 5.49 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.721 -0.672 . . . . 0.0 110.525 179.681 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.443 ' O ' HG23 ' B' ' 217' ' ' THR . 14.2 t -96.5 99.66 9.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 179.057 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 95.4 mt -88.35 115.62 28.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.115 179.634 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . 0.456 ' OG1' ' O ' ' B' ' 216' ' ' TRP . 43.4 p -99.21 117.39 33.57 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.249 179.95 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 20.1 mt -121.4 110.32 15.94 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.864 179.904 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 81' ' ' ILE . . . . . 0.594 ' C ' HD12 ' A' ' 81' ' ' ILE . 1.2 pp -142.24 138.15 29.8 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.088 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.383 179.211 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 59.7 t-20 . . . . . 0 C--N 1.33 -0.28 0 CA-C-N 115.955 -0.566 . . . . 0.0 111.244 -179.249 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' B' B ' 207' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.465 0.598 0 N-CA-C 111.142 -0.783 . . . . 0.0 111.142 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' B' B ' 208' ' ' SER . . . . . 0.538 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 30.7 p -166.47 170.04 13.27 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 120.829 0.347 . . . . 0.0 110.831 179.626 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 209' ' ' TRP . . . . . . . . . . . . . 86.1 m95 -86.29 149.32 25.14 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.373 179.637 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 59.1 p -129.06 128.78 44.26 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.345 179.247 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 54.1 t-105 -91.61 111.55 23.11 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.215 -179.977 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 212' ' ' GLU . . . . . 0.424 ' O ' ' O ' ' B' ' 215' ' ' LYS . 1.7 pt-20 -161.78 167.02 25.65 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.543 179.322 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 213' ' ' ASN . . . . . . . . . . . . . 93.7 m-20 49.79 35.05 8.38 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.929 -0.578 . . . . 0.0 111.159 176.722 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 51.46 17.93 3.29 Favored Glycine 0 CA--C 1.527 0.843 0 N-CA-C 111.37 -0.692 . . . . 0.0 111.37 179.934 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 215' ' ' LYS . . . . . 0.424 ' O ' ' O ' ' B' ' 212' ' ' GLU . 54.1 mtmt -142.58 149.45 39.03 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 120.851 0.357 . . . . 0.0 110.963 179.662 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 216' ' ' TRP . . . . . 0.456 ' O ' ' OG1' ' A' ' 79' ' ' THR . 59.8 m95 -88.83 116.4 27.08 Favored 'General case' 0 C--N 1.331 -0.23 0 N-CA-C 109.444 -0.576 . . . . 0.0 109.444 179.249 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 217' ' ' THR . . . . . 0.443 HG23 ' O ' ' A' ' 77' ' ' VAL . 17.8 m -124.81 140.34 53.02 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-O 120.976 0.417 . . . . 0.0 110.804 -179.265 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 218' ' ' TRP . . . . . 0.538 ' CH2' ' N ' ' B' ' 208' ' ' SER . 30.6 t-105 -102.8 105.35 15.75 Favored 'General case' 0 C--N 1.333 -0.121 0 CA-C-N 115.74 -0.664 . . . . 0.0 109.473 179.229 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 75.8 mttt -131.11 167.06 19.75 Favored 'General case' 0 N--CA 1.467 0.418 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.753 -179.375 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -178.24 -162.76 28.58 Favored Glycine 0 CA--C 1.523 0.588 0 N-CA-C 111.018 -0.833 . . . . 0.0 111.018 179.447 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 221' ' ' ILE . . . . . 0.555 ' O ' HG23 ' B' ' 222' ' ' ILE . 2.1 mp -55.24 -73.87 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 C-N-CA 120.66 -0.416 . . . . 0.0 110.694 -178.565 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 222' ' ' ILE . . . . . 0.555 HG23 ' O ' ' B' ' 221' ' ' ILE . 23.1 pt -160.61 -164.64 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.268 -179.599 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 223' ' ' ARG . . . . . 0.487 ' O ' ' O ' ' B' ' 222' ' ' ILE . 35.5 ptt-85 -41.73 173.1 0.0 OUTLIER 'General case' 0 CA--C 1.529 0.168 0 CA-C-O 121.352 0.596 . . . . 0.0 110.554 178.54 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 224' ' ' LEU . . . . . 0.988 HD22 ' H ' ' B' ' 224' ' ' LEU . 1.4 mm? -64.83 110.42 2.41 Favored 'General case' 0 C--N 1.313 -0.982 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.826 -179.597 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 83.5 tt0 . . . . . 0 C--N 1.33 -0.271 0 CA-C-N 115.252 -0.886 . . . . 0.0 110.365 179.849 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . 0.428 ' O ' ' OD1' ' A' ' 11' ' ' ASP . 53.9 p-10 . . . . . 0 N--CA 1.464 0.244 0 CA-C-O 121.148 0.499 . . . . 0.0 110.522 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.433 ' H ' ' HE1' ' B' ' 209' ' ' TRP . 4.9 tt -66.47 144.43 56.5 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.592 179.922 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . 0.499 ' O ' ' O ' ' A' ' 25' ' ' ARG . 85.5 p -141.44 156.07 45.81 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.98 0.419 . . . . 0.0 110.749 179.67 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . 0.532 ' N ' ' CD1' ' A' ' 14' ' ' PHE . 1.9 m-85 -112.64 153.31 27.83 Favored 'General case' 0 N--CA 1.464 0.263 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.337 -179.813 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 10.5 m -147.7 151.5 13.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.345 179.669 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 26.8 t0 62.89 37.07 12.36 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.622 -179.946 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 43.7 mt -56.94 133.45 21.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.055 179.698 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -136.54 -171.09 2.82 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.242 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' ASP . . . . . 0.47 ' N ' ' OD1' ' A' ' 19' ' ' ASP . 20.5 p-10 -75.85 -49.72 17.17 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.91 179.743 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . 0.47 ' OG ' ' O ' ' A' ' 67' ' ' LEU . 51.0 m -122.36 17.11 10.59 Favored 'General case' 0 N--CA 1.465 0.324 0 CA-C-N 116.437 -0.347 . . . . 0.0 110.805 -179.698 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 1.5 m -145.62 129.83 17.6 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.706 0.289 . . . . 0.0 110.265 -179.425 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . 0.678 HD12 HD21 ' A' ' 24' ' ' LEU . 36.5 pt -132.42 142.78 41.74 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 N-CA-C 109.599 -0.519 . . . . 0.0 109.599 179.67 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -101.48 85.9 0.58 Allowed Glycine 0 CA--C 1.523 0.541 0 N-CA-C 111.055 -0.818 . . . . 0.0 111.055 -179.413 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.678 HD21 HD12 ' A' ' 22' ' ' ILE . 55.4 mt -69.82 118.48 12.73 Favored 'General case' 0 C--N 1.33 -0.255 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 179.996 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . 0.585 ' HE ' ' CB ' ' A' ' 61' ' ' TYR . 31.5 ttm180 -142.99 132.5 23.6 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 121.004 0.431 . . . . 0.0 111.188 179.973 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' TRP . . . . . 0.468 ' O ' ' CD1' ' A' ' 26' ' ' TRP . 35.3 p90 -147.6 133.88 19.52 Favored 'General case' 0 C--N 1.326 -0.444 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 179.643 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 1.9 m -68.36 115.99 35.22 Favored Pre-proline 0 C--N 1.326 -0.43 0 C-N-CA 120.218 -0.593 . . . . 0.0 111.292 -178.97 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_exo -53.49 154.55 15.1 Favored 'Trans proline' 0 N--CA 1.492 1.431 0 C-N-CA 122.171 1.914 . . . . 0.0 112.709 178.258 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.464 ' O ' ' N ' ' A' ' 32' ' ' SER . 75.4 mt -93.66 132.03 38.4 Favored 'General case' 0 N--CA 1.467 0.404 0 CA-C-O 122.006 0.907 . . . . 0.0 110.89 179.926 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 40.4 t30 -43.13 -32.26 0.69 Allowed 'General case' 0 C--N 1.316 -0.863 0 CA-C-N 115.336 -0.847 . . . . 0.0 110.502 179.984 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 20.8 m -86.96 -30.44 21.29 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.692 179.365 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . 0.464 ' N ' ' O ' ' A' ' 29' ' ' LEU . 2.1 m -50.26 111.32 0.51 Allowed 'General case' 0 CA--C 1.529 0.166 0 CA-C-O 121.11 0.481 . . . . 0.0 110.524 -179.783 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' THR . . . . . 0.449 ' CB ' ' H ' ' A' ' 82' ' ' ASN . 8.1 m -51.12 148.7 4.27 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.554 -0.748 . . . . 0.0 109.348 -179.646 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 5.3 mm -92.88 91.36 3.33 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.277 0 CA-C-O 121.391 0.615 . . . . 0.0 111.168 -178.825 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.541 HD11 ' HA ' ' A' ' 81' ' ' ILE . 12.0 pt -147.96 126.15 3.5 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 115.24 -0.891 . . . . 0.0 110.565 179.554 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -46.89 126.41 10.03 Favored Glycine 0 CA--C 1.521 0.465 0 N-CA-C 110.847 -0.901 . . . . 0.0 110.847 -179.718 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' TYR . . . . . 0.482 ' CE1' ' CG1' ' A' ' 55' ' ' VAL . 28.3 p90 -95.8 175.24 6.59 Favored 'General case' 0 C--N 1.329 -0.307 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 179.851 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 9.0 tmm_? -126.36 123.0 36.99 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.718 -179.843 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.471 ' CG1' ' O ' ' A' ' 39' ' ' ILE . 1.9 pt -94.14 120.22 43.21 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 N-CA-C 109.602 -0.518 . . . . 0.0 109.602 -179.856 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 10.1 m -96.14 128.48 43.08 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.15 -179.289 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.0 p -123.06 134.12 67.09 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 CA-C-N 116.077 -0.511 . . . . 0.0 109.873 -179.981 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . 0.407 ' O ' ' N ' ' A' ' 74' ' ' ASP . 24.5 t -129.35 128.45 66.42 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.173 0 CA-C-O 120.831 0.348 . . . . 0.0 110.132 179.846 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.511 ' HB2' ' CE2' ' A' ' 73' ' ' TYR . . . -97.36 128.99 44.66 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 109.054 -0.721 . . . . 0.0 109.054 179.372 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . 0.606 ' HB3' ' O ' ' A' ' 72' ' ' ASP . . . -88.12 -24.27 23.43 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 120.869 0.366 . . . . 0.0 110.981 -179.624 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -86.43 20.59 21.66 Favored Glycine 0 N--CA 1.462 0.375 0 N-CA-C 111.202 -0.759 . . . . 0.0 111.202 -179.696 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 79.8 mm-40 -144.75 150.12 36.69 Favored 'General case' 0 C--O 1.233 0.224 0 CA-C-O 121.041 0.448 . . . . 0.0 110.324 -179.702 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -69.32 -20.33 75.09 Favored Glycine 0 N--CA 1.452 -0.269 0 N-CA-C 110.645 -0.982 . . . . 0.0 110.645 -179.852 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -131.42 139.01 34.05 Favored Pre-proline 0 N--CA 1.469 0.495 0 C-N-CA 120.952 -0.299 . . . . 0.0 110.528 179.673 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 68.6 Cg_endo -75.27 165.06 31.69 Favored 'Trans proline' 0 C--N 1.31 -1.458 0 C-N-CA 122.734 2.289 . . . . 0.0 112.027 177.676 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . 0.527 HG22 ' N ' ' A' ' 51' ' ' PHE . 96.6 mt -79.6 160.42 4.29 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-N 115.782 -0.644 . . . . 0.0 110.229 179.55 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' PHE . . . . . 0.527 ' N ' HG22 ' A' ' 50' ' ' ILE . 92.5 m-85 -74.36 142.33 45.09 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.734 179.918 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . 0.532 ' H ' ' CD ' ' A' ' 52' ' ' GLU . 0.2 OUTLIER -77.58 142.07 39.17 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.15 179.561 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' ASP . . . . . 0.42 ' CG ' ' OH ' ' A' ' 62' ' ' TYR . 0.5 OUTLIER -100.57 151.55 21.47 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 120.993 0.425 . . . . 0.0 110.051 -179.827 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 90.0 m-85 -115.09 122.06 44.98 Favored 'General case' 0 C--O 1.232 0.17 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.352 179.738 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.482 ' CG1' ' CE1' ' A' ' 37' ' ' TYR . 9.5 p -131.96 142.22 43.49 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.295 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.393 -179.974 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 99.3 m-20 -63.66 150.0 45.28 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.793 -0.64 . . . . 0.0 110.37 179.69 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' SER . . . . . 0.487 ' OG ' ' O ' ' A' ' 35' ' ' ILE . 4.7 m -64.71 -34.84 79.27 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.875 179.909 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 68.0 m -51.17 -36.54 41.59 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.303 -179.026 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.48 ' C ' ' H ' ' A' ' 61' ' ' TYR . 22.7 t -64.38 -42.39 95.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.092 179.884 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 72.01 -40.05 0.69 Allowed Glycine 0 CA--C 1.531 1.069 0 N-CA-C 111.048 -0.821 . . . . 0.0 111.048 179.766 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' TYR . . . . . 0.585 ' CB ' ' HE ' ' A' ' 25' ' ' ARG . 31.1 p90 -110.68 161.01 16.17 Favored 'General case' 0 N--CA 1.466 0.368 0 CA-C-O 121.093 0.473 . . . . 0.0 111.08 -179.035 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' TYR . . . . . 0.42 ' OH ' ' CG ' ' A' ' 53' ' ' ASP . 31.5 t80 -155.95 163.04 40.24 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.015 -0.539 . . . . 0.0 109.949 179.492 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 57.6 m -119.6 131.47 55.5 Favored 'General case' 0 N--CA 1.467 0.422 0 CA-C-O 121.025 0.44 . . . . 0.0 110.628 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -134.27 108.91 11.76 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 115.765 -0.652 . . . . 0.0 109.981 179.324 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 1.2 p -128.35 167.37 17.06 Favored 'General case' 0 CA--C 1.514 -0.441 0 CA-C-O 121.023 0.44 . . . . 0.0 110.47 179.939 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 108.33 24.34 6.25 Favored Glycine 0 CA--C 1.522 0.496 0 CA-C-N 115.614 -0.721 . . . . 0.0 111.502 -179.793 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.47 ' O ' ' OG ' ' A' ' 20' ' ' SER . 3.9 mt -99.61 106.42 18.38 Favored 'General case' 0 CA--C 1.517 -0.29 0 N-CA-C 109.197 -0.668 . . . . 0.0 109.197 -179.401 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 68' ' ' GLU . . . . . 0.423 ' HG2' ' H ' ' A' ' 68' ' ' GLU . 0.0 OUTLIER -48.19 140.08 9.65 Favored Pre-proline 0 C--N 1.311 -1.097 0 CA-C-N 115.669 -0.696 . . . . 0.0 111.112 -178.247 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 68.5 Cg_endo -73.38 156.29 50.48 Favored 'Trans proline' 0 N--CA 1.5 1.896 0 C-N-CA 122.993 2.462 . . . . 0.0 111.596 178.344 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 74.61 -2.09 49.25 Favored Glycine 0 CA--C 1.525 0.718 0 CA-C-N 115.563 -0.744 . . . . 0.0 111.698 179.259 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 1.6 mp -110.46 140.5 29.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-O 121.557 0.694 . . . . 0.0 109.582 -179.283 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 72' ' ' ASP . . . . . 0.606 ' O ' ' HB3' ' A' ' 44' ' ' ALA . 1.6 t70 -80.54 122.78 27.46 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 114.877 -1.056 . . . . 0.0 110.297 179.649 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 73' ' ' TYR . . . . . 0.522 ' O ' HD13 ' A' ' 75' ' ' ILE . 12.5 m-85 -114.94 122.65 46.91 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.686 -0.688 . . . . 0.0 110.809 179.785 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 74' ' ' ASP . . . . . 0.407 ' N ' ' O ' ' A' ' 42' ' ' VAL . 66.3 m-20 -94.32 110.78 22.52 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 108.597 -0.89 . . . . 0.0 108.597 178.692 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . 0.522 HD13 ' O ' ' A' ' 73' ' ' TYR . 0.0 OUTLIER -126.39 111.95 28.11 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.249 0 CA-C-N 116.654 -0.248 . . . . 0.0 111.27 179.954 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 23.8 t -105.43 125.66 51.24 Favored 'General case' 0 CA--C 1.518 -0.253 0 N-CA-C 109.576 -0.527 . . . . 0.0 109.576 179.247 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 84.4 t -88.71 99.52 9.24 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-O 120.939 0.4 . . . . 0.0 110.06 179.747 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 94.4 mt -82.52 135.99 23.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.356 179.914 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 30.5 p -113.26 117.71 32.62 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.231 179.623 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 1.8 mp -109.77 110.78 21.89 Favored 'General case' 0 N--CA 1.467 0.386 0 CA-C-O 121.194 0.521 . . . . 0.0 110.648 -179.822 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 81' ' ' ILE . . . . . 0.541 ' HA ' HD11 ' A' ' 35' ' ' ILE . 2.0 pp -146.55 143.69 20.62 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.213 179.274 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 82' ' ' ASN . . . . . 0.449 ' H ' ' CB ' ' A' ' 33' ' ' THR . 22.5 t-20 . . . . . 0 C--N 1.328 -0.333 0 CA-C-O 120.876 0.369 . . . . 0.0 111.213 179.821 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 207' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.466 0.672 0 N-CA-C 111.054 -0.818 . . . . 0.0 111.054 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' B' B ' 208' ' ' SER . . . . . 0.589 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 97.6 p -167.07 170.88 11.53 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.805 0.336 . . . . 0.0 110.622 179.748 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 209' ' ' TRP . . . . . 0.433 ' HE1' ' H ' ' A' ' 12' ' ' LEU . 79.5 m95 -86.99 155.86 20.0 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.45 179.67 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 31.6 p -133.47 133.52 42.37 Favored 'General case' 0 N--CA 1.463 0.217 0 CA-C-N 116.434 -0.348 . . . . 0.0 110.414 179.745 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 58.0 t-105 -95.78 113.85 25.52 Favored 'General case' 0 N--CA 1.463 0.214 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.627 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 212' ' ' GLU . . . . . 0.43 ' O ' ' O ' ' B' ' 215' ' ' LYS . 0.9 OUTLIER -162.29 163.1 28.26 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.5 179.591 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' B' B ' 213' ' ' ASN . . . . . . . . . . . . . 17.8 m120 51.31 34.14 11.12 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.067 177.346 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 55.21 18.17 12.73 Favored Glycine 0 CA--C 1.527 0.808 0 N-CA-C 111.298 -0.721 . . . . 0.0 111.298 179.831 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 215' ' ' LYS . . . . . 0.43 ' O ' ' O ' ' B' ' 212' ' ' GLU . 56.1 mtmt -143.3 149.76 38.27 Favored 'General case' 0 C--O 1.232 0.165 0 CA-C-O 120.834 0.349 . . . . 0.0 110.95 179.895 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 216' ' ' TRP . . . . . . . . . . . . . 48.9 m95 -87.67 113.71 23.6 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.179 -0.464 . . . . 0.0 109.764 179.507 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 217' ' ' THR . . . . . . . . . . . . . 16.3 m -119.82 134.93 55.06 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.519 -179.339 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 218' ' ' TRP . . . . . 0.589 ' CH2' ' N ' ' B' ' 208' ' ' SER . 29.1 t-105 -95.88 105.0 16.96 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.875 -0.602 . . . . 0.0 109.907 179.27 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 6.9 mtmt -130.5 167.8 18.07 Favored 'General case' 0 CA--C 1.515 -0.398 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.778 -179.357 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -178.45 -163.35 29.68 Favored Glycine 0 CA--C 1.524 0.625 0 N-CA-C 111.138 -0.785 . . . . 0.0 111.138 179.41 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 221' ' ' ILE . . . . . 0.575 ' O ' HG23 ' B' ' 222' ' ' ILE . 20.1 mt -55.86 -73.24 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 C-N-CA 120.645 -0.422 . . . . 0.0 110.263 -178.146 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 222' ' ' ILE . . . . . 0.575 HG23 ' O ' ' B' ' 221' ' ' ILE . 18.9 pt -160.53 -166.8 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 O-C-N 123.402 0.439 . . . . 0.0 110.462 179.994 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 223' ' ' ARG . . . . . 0.479 ' O ' ' O ' ' B' ' 222' ' ' ILE . 33.4 ptt180 -43.3 172.71 0.0 OUTLIER 'General case' 0 C--O 1.231 0.098 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.497 179.082 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 224' ' ' LEU . . . . . 0.79 ' N ' HD22 ' B' ' 224' ' ' LEU . 2.2 mm? -65.5 107.2 1.61 Allowed 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 121.48 0.657 . . . . 0.0 110.322 -178.766 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 82.0 tt0 . . . . . 0 N--CA 1.452 -0.336 0 CA-C-N 115.084 -0.962 . . . . 0.0 110.01 179.919 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . 0.424 ' O ' ' OD1' ' A' ' 11' ' ' ASP . 51.2 p-10 . . . . . 0 CA--C 1.518 -0.26 0 CA-C-O 120.996 0.426 . . . . 0.0 110.561 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 6.9 tt -63.86 142.56 58.36 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.135 -179.542 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 83.9 p -139.4 155.47 47.61 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.665 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . 0.52 ' CD2' HD11 ' B' ' 224' ' ' LEU . 20.9 m-85 -110.79 144.66 39.43 Favored 'General case' 0 C--O 1.233 0.204 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.498 -179.691 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 15.5 m -145.49 162.28 12.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.598 -179.973 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 98.4 m-20 51.6 32.65 9.4 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.524 179.621 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 86.5 mt -58.84 140.29 17.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.267 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.438 ' CB ' ' O ' ' A' ' 21' ' ' SER . 0.2 OUTLIER -143.25 -166.3 2.28 Favored 'General case' 0 N--CA 1.465 0.305 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.601 -179.653 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' ASP . . . . . 0.441 ' OD1' ' N ' ' A' ' 20' ' ' SER . 28.7 p-10 -90.73 -45.25 8.96 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.693 -0.685 . . . . 0.0 110.875 179.546 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . 0.441 ' N ' ' OD1' ' A' ' 19' ' ' ASP . 10.2 t -114.39 7.17 16.25 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-O 120.821 0.343 . . . . 0.0 110.92 -179.513 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . 0.438 ' O ' ' CB ' ' A' ' 18' ' ' THR . 45.2 m -151.62 146.52 25.88 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.976 0.417 . . . . 0.0 110.439 179.898 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . 0.459 HD12 HD21 ' A' ' 24' ' ' LEU . 40.8 pt -144.98 147.88 18.45 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-N 116.469 -0.332 . . . . 0.0 110.291 179.847 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -101.41 84.04 0.51 Allowed Glycine 0 CA--C 1.525 0.675 0 N-CA-C 111.038 -0.825 . . . . 0.0 111.038 -179.678 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.459 HD21 HD12 ' A' ' 22' ' ' ILE . 83.7 mt -71.39 124.6 24.96 Favored 'General case' 0 C--N 1.33 -0.282 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 -179.752 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 73.8 ttt-85 -138.94 139.92 38.14 Favored 'General case' 0 CA--C 1.52 -0.177 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.464 -179.593 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' TRP . . . . . . . . . . . . . 49.0 p90 -146.48 154.77 41.96 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.073 179.745 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 2.9 m -109.97 103.31 53.21 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-N 116.466 -0.334 . . . . 0.0 110.583 179.888 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_exo -53.87 145.03 52.85 Favored 'Trans proline' 0 C--N 1.307 -1.642 0 C-N-CA 122.07 1.846 . . . . 0.0 112.591 179.172 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 64.6 mt -78.91 139.86 38.2 Favored 'General case' 0 CA--C 1.518 -0.252 0 CA-C-O 121.697 0.76 . . . . 0.0 110.789 -179.643 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 38.1 t30 -51.07 -37.1 43.59 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-N 115.131 -0.94 . . . . 0.0 109.916 179.656 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 15.5 m -75.75 -34.86 60.29 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.64 178.975 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 10.8 m -60.11 132.95 55.51 Favored 'General case' 0 C--O 1.232 0.158 0 CA-C-O 120.975 0.417 . . . . 0.0 110.179 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' THR . . . . . 0.503 ' H ' ' HB ' ' A' ' 81' ' ' ILE . 5.6 m -57.78 145.22 35.59 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.17 -179.886 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 26.8 mm -93.99 91.29 3.11 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 CA-C-O 121.012 0.434 . . . . 0.0 110.631 -179.513 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 21.6 pt -143.39 140.41 26.36 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.498 179.707 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -44.33 128.47 6.95 Favored Glycine 0 CA--C 1.521 0.463 0 N-CA-C 111.096 -0.801 . . . . 0.0 111.096 -179.781 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 75.0 m-85 -91.54 175.9 6.74 Favored 'General case' 0 CA--C 1.517 -0.302 0 CA-C-O 120.89 0.376 . . . . 0.0 110.187 179.849 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -137.26 125.49 23.15 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.588 -179.939 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.438 ' CG1' ' O ' ' A' ' 39' ' ' ILE . 2.3 pt -101.68 124.81 55.71 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.251 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.1 -179.97 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 8.4 m -104.07 133.49 48.93 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.384 -179.275 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.3 p -132.98 139.38 49.67 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.296 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.319 179.756 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . 0.543 ' N ' ' O ' ' A' ' 74' ' ' ASP . 39.5 t -133.9 132.88 56.58 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.175 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.245 179.74 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.426 ' HB2' ' CE1' ' A' ' 73' ' ' TYR . . . -97.04 141.72 29.85 Favored 'General case' 0 C--N 1.326 -0.414 0 N-CA-C 109.702 -0.481 . . . . 0.0 109.702 179.15 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . 0.501 ' HB3' ' O ' ' A' ' 72' ' ' ASP . . . -95.13 -40.43 9.61 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.821 0.344 . . . . 0.0 110.769 179.659 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -66.17 -32.64 82.87 Favored Glycine 0 CA--C 1.526 0.758 0 N-CA-C 111.295 -0.722 . . . . 0.0 111.295 -179.737 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 63.2 mt-10 -98.16 131.42 44.55 Favored 'General case' 0 C--N 1.333 -0.146 0 N-CA-C 109.598 -0.519 . . . . 0.0 109.598 -179.694 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -59.01 -21.64 53.33 Favored Glycine 0 N--CA 1.454 -0.117 0 N-CA-C 110.609 -0.997 . . . . 0.0 110.609 -179.079 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -111.72 134.46 21.29 Favored Pre-proline 0 CA--C 1.535 0.4 0 C-N-CA 121.133 -0.227 . . . . 0.0 110.474 179.556 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 63.9 Cg_endo -76.71 163.92 30.91 Favored 'Trans proline' 0 C--N 1.31 -1.47 0 C-N-CA 122.638 2.226 . . . . 0.0 111.884 177.751 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 96.6 mt -82.93 133.97 27.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 115.975 -0.557 . . . . 0.0 109.949 179.134 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 76.0 m-85 -56.15 136.54 52.6 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 121.054 0.454 . . . . 0.0 110.824 -179.355 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 4.7 pt-20 -68.79 -175.08 0.65 Allowed 'General case' 0 CA--C 1.516 -0.33 0 CA-C-N 115.706 -0.679 . . . . 0.0 110.372 179.461 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' ASP . . . . . 0.426 ' CG ' ' OH ' ' A' ' 62' ' ' TYR . 3.6 t70 -156.38 156.0 33.14 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.674 179.04 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' PHE . . . . . 0.578 ' CD1' ' N ' ' A' ' 54' ' ' PHE . 2.1 m-85 -122.12 130.85 53.6 Favored 'General case' 0 N--CA 1.465 0.324 0 CA-C-O 120.889 0.376 . . . . 0.0 110.114 179.729 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 9.7 p -130.01 138.19 54.63 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.186 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.418 -179.836 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 97.8 m-20 -53.66 144.33 18.02 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.457 -179.702 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 38.7 t -63.33 -35.81 81.61 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.703 179.994 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 36.6 m -57.11 -31.88 65.76 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.551 -179.717 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 94.0 t -64.96 -46.47 91.57 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.537 -179.913 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 56.19 25.89 48.52 Favored Glycine 0 CA--C 1.525 0.713 0 N-CA-C 110.7 -0.96 . . . . 0.0 110.7 -179.899 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' TYR . . . . . 0.493 ' C ' ' CD1' ' A' ' 61' ' ' TYR . 7.7 t80 -159.52 146.79 16.9 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-O 121.208 0.528 . . . . 0.0 111.035 -179.201 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' TYR . . . . . 0.435 ' CD2' ' CD1' ' A' ' 39' ' ' ILE . 33.9 t80 -159.99 161.79 34.18 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.152 178.611 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 96.5 m -131.15 139.17 49.74 Favored 'General case' 0 N--CA 1.464 0.244 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.689 179.995 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -131.14 104.63 9.5 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.263 0 CA-C-N 116.188 -0.46 . . . . 0.0 109.982 179.061 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 4.6 p -109.05 155.45 20.92 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.342 179.78 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 108.32 44.38 1.17 Allowed Glycine 0 CA--C 1.525 0.682 0 N-CA-C 111.184 -0.766 . . . . 0.0 111.184 -179.705 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 19.9 mt -116.45 103.57 10.58 Favored 'General case' 0 CA--C 1.519 -0.222 0 CA-C-O 121.194 0.521 . . . . 0.0 109.827 179.679 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 55.4 mm-40 -51.24 138.19 27.68 Favored Pre-proline 0 C--N 1.317 -0.806 0 CA-C-N 115.783 -0.644 . . . . 0.0 111.44 -178.433 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 69' ' ' PRO . . . . . 0.41 ' O ' HD12 ' A' ' 71' ' ' ILE . 72.1 Cg_endo -75.35 150.54 36.82 Favored 'Trans proline' 0 N--CA 1.496 1.665 0 C-N-CA 122.725 2.284 . . . . 0.0 111.635 178.687 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 70.69 17.32 74.86 Favored Glycine 0 CA--C 1.527 0.803 0 CA-C-N 115.55 -0.75 . . . . 0.0 111.361 179.14 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . 0.41 HD12 ' O ' ' A' ' 69' ' ' PRO . 1.5 mp -119.66 149.62 22.27 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.337 0 CA-C-O 121.413 0.625 . . . . 0.0 109.36 -179.503 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 72' ' ' ASP . . . . . 0.501 ' O ' ' HB3' ' A' ' 44' ' ' ALA . 2.4 t70 -89.39 108.97 19.94 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.15 -0.932 . . . . 0.0 110.652 -179.902 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 73' ' ' TYR . . . . . 0.554 ' O ' HD13 ' A' ' 75' ' ' ILE . 22.4 m-85 -104.3 119.53 39.17 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.348 179.772 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 74' ' ' ASP . . . . . 0.543 ' O ' ' N ' ' A' ' 42' ' ' VAL . 8.5 m-20 -88.2 118.43 27.78 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.531 -0.758 . . . . 0.0 109.247 179.466 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . 0.624 HD11 ' N ' ' B' ' 223' ' ' ARG . 0.0 OUTLIER -120.02 167.22 13.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-O 121.098 0.475 . . . . 0.0 110.272 -179.124 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 1.8 m -154.92 126.92 7.64 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.622 -0.717 . . . . 0.0 110.591 179.248 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.486 ' O ' HG23 ' B' ' 217' ' ' THR . 21.7 t -106.02 100.26 10.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 179.178 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 78' ' ' ILE . . . . . 0.427 HG22 ' CD2' ' A' ' 80' ' ' LEU . 23.8 mt -101.9 140.9 19.27 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.225 0 CA-C-N 116.052 -0.522 . . . . 0.0 109.909 -179.651 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . 0.48 ' C ' HD22 ' A' ' 80' ' ' LEU . 19.5 m -120.05 113.59 20.73 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.571 -179.767 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . 0.48 HD22 ' C ' ' A' ' 79' ' ' THR . 4.4 mm? -106.68 127.93 53.77 Favored 'General case' 0 N--CA 1.463 0.22 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.434 179.796 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 81' ' ' ILE . . . . . 0.503 ' HB ' ' H ' ' A' ' 33' ' ' THR . 1.9 pp -141.38 145.01 25.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 115.632 -0.713 . . . . 0.0 110.219 179.565 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 82' ' ' ASN . . . . . 0.409 ' H ' ' CB ' ' A' ' 33' ' ' THR . 37.6 t30 . . . . . 0 C--N 1.329 -0.286 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.707 -179.73 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 207' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.464 0.555 0 N-CA-C 111.088 -0.805 . . . . 0.0 111.088 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' B' B ' 208' ' ' SER . . . . . 0.432 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 92.3 p -165.37 171.57 13.28 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.866 0.365 . . . . 0.0 110.746 -179.922 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 209' ' ' TRP . . . . . . . . . . . . . 80.0 m95 -81.43 146.18 30.39 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.456 179.784 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 65.2 p -128.76 132.42 47.92 Favored 'General case' 0 N--CA 1.464 0.255 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.616 -179.951 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 50.3 t-105 -91.94 116.54 29.01 Favored 'General case' 0 C--O 1.232 0.15 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.241 179.649 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 212' ' ' GLU . . . . . 0.489 ' O ' ' O ' ' B' ' 215' ' ' LYS . 1.7 pt-20 -165.46 168.19 16.85 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.972 179.261 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 213' ' ' ASN . . . . . . . . . . . . . 91.8 m-20 49.51 36.73 10.72 Favored 'General case' 0 C--N 1.322 -0.602 0 C-N-CA 120.525 -0.47 . . . . 0.0 111.217 176.634 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 50.86 16.32 1.71 Allowed Glycine 0 CA--C 1.525 0.671 0 N-CA-C 111.266 -0.734 . . . . 0.0 111.266 179.658 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 215' ' ' LYS . . . . . 0.489 ' O ' ' O ' ' B' ' 212' ' ' GLU . 50.3 mtmt -145.66 151.45 38.07 Favored 'General case' 0 C--N 1.333 -0.142 0 CA-C-O 120.942 0.401 . . . . 0.0 110.81 179.704 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 216' ' ' TRP . . . . . . . . . . . . . 53.8 m95 -87.79 123.3 32.43 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.044 179.58 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 217' ' ' THR . . . . . 0.486 HG23 ' O ' ' A' ' 77' ' ' VAL . 12.9 m -133.7 145.21 49.69 Favored 'General case' 0 N--CA 1.464 0.269 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.502 -179.607 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 218' ' ' TRP . . . . . 0.432 ' CH2' ' N ' ' B' ' 208' ' ' SER . 14.4 t-105 -106.08 119.58 39.58 Favored 'General case' 0 N--CA 1.463 0.175 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.018 179.188 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 47.3 mtpt -141.26 169.79 16.95 Favored 'General case' 0 CA--C 1.52 -0.198 0 CA-C-O 120.92 0.39 . . . . 0.0 110.464 -179.49 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -176.04 -161.38 25.12 Favored Glycine 0 CA--C 1.526 0.732 0 N-CA-C 111.279 -0.729 . . . . 0.0 111.279 -179.883 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 221' ' ' ILE . . . . . 0.58 ' H ' HD12 ' B' ' 221' ' ' ILE . 2.2 mp -51.03 -73.24 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 C-N-CA 120.678 -0.409 . . . . 0.0 110.679 -178.283 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 222' ' ' ILE . . . . . 0.552 HG23 ' O ' ' B' ' 221' ' ' ILE . 21.8 pt -159.75 -166.34 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.624 -179.584 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 223' ' ' ARG . . . . . 0.624 ' N ' HD11 ' A' ' 75' ' ' ILE . 46.9 ptt85 -46.03 178.32 0.0 OUTLIER 'General case' 0 CA--C 1.516 -0.337 0 CA-C-N 115.756 -0.657 . . . . 0.0 110.563 179.281 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 224' ' ' LEU . . . . . 0.688 ' N ' HD22 ' B' ' 224' ' ' LEU . 3.1 mm? -59.41 121.71 12.16 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 115.687 -0.688 . . . . 0.0 110.533 -179.135 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 78.5 tt0 . . . . . 0 C--N 1.331 -0.228 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.4 179.986 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 54.7 p30 . . . . . 0 C--O 1.231 0.102 0 CA-C-O 120.822 0.344 . . . . 0.0 110.667 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 70.4 mt -63.57 151.89 40.25 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.343 -179.291 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 85.9 p -141.13 149.83 42.04 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-N 116.059 -0.518 . . . . 0.0 110.31 179.916 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . 0.519 ' N ' ' CD1' ' A' ' 14' ' ' PHE . 18.3 m-85 -111.37 145.8 38.26 Favored 'General case' 0 N--CA 1.464 0.235 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.569 -179.627 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 18.2 m -147.71 161.75 7.36 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.117 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.495 179.88 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 41.0 t0 56.06 29.32 14.29 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.66 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 96.5 mt -56.19 138.97 16.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.249 179.797 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.45 ' CB ' ' O ' ' A' ' 21' ' ' SER . 0.2 OUTLIER -139.96 -167.12 2.23 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.479 -179.69 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' ASP . . . . . 0.506 ' OD1' ' N ' ' A' ' 20' ' ' SER . 32.3 p-10 -89.63 -43.47 10.73 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.731 179.601 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . 0.506 ' N ' ' OD1' ' A' ' 19' ' ' ASP . 10.2 t -117.54 8.75 13.0 Favored 'General case' 0 N--CA 1.465 0.317 0 CA-C-O 120.754 0.312 . . . . 0.0 110.889 -179.716 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . 0.45 ' O ' ' CB ' ' A' ' 18' ' ' THR . 18.2 p -150.56 137.69 19.36 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.974 0.416 . . . . 0.0 110.35 -179.919 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 41.9 pt -132.07 145.68 34.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.467 -0.333 . . . . 0.0 110.159 179.921 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -97.86 81.96 0.66 Allowed Glycine 0 CA--C 1.525 0.675 0 N-CA-C 110.965 -0.854 . . . . 0.0 110.965 -179.805 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 94.9 mt -70.95 119.5 15.16 Favored 'General case' 0 C--N 1.33 -0.274 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 -179.882 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 70.1 ttt180 -138.15 142.08 40.11 Favored 'General case' 0 CA--C 1.519 -0.229 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.988 179.901 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' TRP . . . . . 0.543 ' CD2' ' O ' ' A' ' 60' ' ' GLY . 25.4 p90 -143.11 156.08 44.73 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.763 -0.653 . . . . 0.0 109.977 -179.87 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 3.2 m -109.84 101.96 48.71 Favored Pre-proline 0 N--CA 1.465 0.322 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.757 179.828 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 42.4 Cg_exo -54.94 144.57 67.07 Favored 'Trans proline' 0 C--N 1.304 -1.769 0 C-N-CA 122.108 1.872 . . . . 0.0 112.34 179.153 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 65.8 mt -83.47 139.77 32.73 Favored 'General case' 0 CA--C 1.52 -0.196 0 CA-C-O 121.813 0.816 . . . . 0.0 110.718 179.801 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 26.0 t-20 -47.94 -33.05 7.14 Favored 'General case' 0 C--N 1.319 -0.75 0 CA-C-N 115.268 -0.878 . . . . 0.0 110.19 -179.914 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 52.5 m -84.86 -30.9 24.08 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.627 179.506 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 4.9 m -58.15 131.23 49.92 Favored 'General case' 0 N--CA 1.462 0.144 0 CA-C-O 121.25 0.547 . . . . 0.0 110.444 179.912 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' THR . . . . . 0.448 ' H ' ' HB ' ' A' ' 81' ' ' ILE . 3.9 m -59.78 140.17 56.75 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.505 -0.77 . . . . 0.0 110.021 -179.801 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 58.2 mt -94.11 92.26 3.47 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.19 0 CA-C-O 120.865 0.364 . . . . 0.0 110.774 -179.778 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.433 ' O ' ' OG ' ' A' ' 57' ' ' SER . 9.5 pt -142.29 131.85 23.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.43 179.408 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -37.95 114.85 0.33 Allowed Glycine 0 CA--C 1.523 0.553 0 N-CA-C 111.442 -0.663 . . . . 0.0 111.442 -179.297 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 96.5 m-85 -79.8 177.27 9.02 Favored 'General case' 0 CA--C 1.515 -0.392 0 N-CA-C 110.019 -0.363 . . . . 0.0 110.019 -179.901 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 5.5 tmm_? -135.01 126.21 28.09 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.039 179.922 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 6.5 pt -95.35 155.33 3.33 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.391 0 N-CA-C 109.472 -0.566 . . . . 0.0 109.472 179.892 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 3.4 m -136.29 131.34 34.28 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.627 0.251 . . . . 0.0 110.624 -179.713 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.691 HG22 HD13 ' A' ' 50' ' ' ILE . 2.1 p -134.56 137.82 50.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.314 179.464 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . 0.538 ' N ' ' O ' ' A' ' 74' ' ' ASP . 41.5 t -134.83 135.92 52.66 Favored 'Isoleucine or valine' 0 C--O 1.23 0.058 0 CA-C-N 116.509 -0.314 . . . . 0.0 110.369 179.621 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.787 ' HB2' HD11 ' A' ' 50' ' ' ILE . . . -97.3 138.05 35.36 Favored 'General case' 0 C--N 1.33 -0.269 0 N-CA-C 109.628 -0.508 . . . . 0.0 109.628 179.231 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . 0.518 ' HB3' ' O ' ' A' ' 72' ' ' ASP . . . -90.54 -47.51 7.65 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.783 0.325 . . . . 0.0 110.708 179.723 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -61.64 -29.39 71.84 Favored Glycine 0 CA--C 1.525 0.711 0 N-CA-C 111.084 -0.806 . . . . 0.0 111.084 -179.863 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 91.2 mt-10 -95.94 127.56 42.06 Favored 'General case' 0 CA--C 1.52 -0.203 0 N-CA-C 109.357 -0.609 . . . . 0.0 109.357 -179.424 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -59.2 -22.0 54.69 Favored Glycine 0 CA--C 1.508 -0.389 0 N-CA-C 110.82 -0.912 . . . . 0.0 110.82 -179.229 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -110.16 135.04 20.58 Favored Pre-proline 0 CA--C 1.539 0.543 0 C-N-CA 120.858 -0.337 . . . . 0.0 110.235 179.702 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 62.3 Cg_endo -75.8 167.8 25.56 Favored 'Trans proline' 0 C--N 1.309 -1.517 0 C-N-CA 122.605 2.203 . . . . 0.0 111.732 177.344 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . 0.88 ' H ' HD12 ' A' ' 50' ' ' ILE . 1.7 mp -91.58 144.85 8.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 115.598 -0.728 . . . . 0.0 110.152 179.526 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 96.0 m-85 -65.84 142.2 58.01 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.702 -179.534 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . 0.578 ' H ' ' CD ' ' A' ' 52' ' ' GLU . 0.0 OUTLIER -73.87 -176.84 2.59 Favored 'General case' 0 CA--C 1.514 -0.424 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.602 179.664 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 3.6 t70 -151.45 147.45 26.88 Favored 'General case' 0 N--CA 1.452 -0.34 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.78 179.475 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 54.2 m-85 -115.7 124.8 51.76 Favored 'General case' 0 N--CA 1.463 0.219 0 CA-C-N 116.466 -0.334 . . . . 0.0 110.204 179.725 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 9.9 p -127.4 136.52 60.35 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.211 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.425 -179.886 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 99.8 m-20 -57.15 145.7 30.4 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.015 -0.538 . . . . 0.0 110.502 -179.707 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' SER . . . . . 0.433 ' OG ' ' O ' ' A' ' 35' ' ' ILE . 35.3 m -59.49 -33.46 71.36 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.61 179.917 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 49.5 m -52.68 -35.92 56.12 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.596 -179.901 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.522 HG12 ' O ' ' A' ' 61' ' ' TYR . 21.2 t -69.68 -43.72 79.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.348 179.853 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . 0.543 ' O ' ' CD2' ' A' ' 26' ' ' TRP . . . 68.68 -43.94 0.36 Allowed Glycine 0 CA--C 1.531 1.046 0 N-CA-C 110.943 -0.863 . . . . 0.0 110.943 179.903 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' TYR . . . . . 0.522 ' O ' HG12 ' A' ' 59' ' ' VAL . 25.0 p90 -102.49 157.71 16.73 Favored 'General case' 0 N--CA 1.463 0.223 0 CA-C-O 121.257 0.551 . . . . 0.0 111.139 -179.208 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 32.5 t80 -156.67 160.33 39.26 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.979 -0.555 . . . . 0.0 109.907 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 91.2 m -123.45 136.04 54.4 Favored 'General case' 0 C--O 1.233 0.206 0 CA-C-O 120.887 0.375 . . . . 0.0 110.699 -179.882 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -132.01 99.68 3.81 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 CA-C-N 116.035 -0.53 . . . . 0.0 109.818 179.249 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 2.2 p -106.73 159.25 16.36 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.91 0.386 . . . . 0.0 110.6 179.91 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 108.74 41.47 1.45 Allowed Glycine 0 CA--C 1.523 0.544 0 N-CA-C 111.41 -0.676 . . . . 0.0 111.41 -179.674 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 10.3 mt -116.43 107.88 15.34 Favored 'General case' 0 CA--C 1.517 -0.307 0 CA-C-O 121.346 0.593 . . . . 0.0 109.728 -179.868 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 53.0 mm-40 -53.85 136.07 55.95 Favored Pre-proline 0 C--N 1.318 -0.795 0 CA-C-N 115.611 -0.722 . . . . 0.0 111.622 -178.209 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo -75.34 155.43 41.37 Favored 'Trans proline' 0 N--CA 1.498 1.774 0 C-N-CA 122.952 2.434 . . . . 0.0 111.722 178.783 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 71.66 8.37 67.33 Favored Glycine 0 CA--C 1.526 0.777 0 CA-C-N 115.375 -0.829 . . . . 0.0 111.477 179.153 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 1.6 mp -118.03 145.4 24.0 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.298 0 CA-C-O 121.541 0.686 . . . . 0.0 109.381 -179.416 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 72' ' ' ASP . . . . . 0.518 ' O ' ' HB3' ' A' ' 44' ' ' ALA . 2.9 t70 -82.13 112.53 19.25 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-N 114.768 -1.105 . . . . 0.0 110.829 -179.579 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 73' ' ' TYR . . . . . 0.547 ' O ' HD13 ' A' ' 75' ' ' ILE . 13.3 m-85 -105.29 120.57 41.89 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.507 179.648 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 74' ' ' ASP . . . . . 0.538 ' O ' ' N ' ' A' ' 42' ' ' VAL . 74.0 m-20 -88.48 117.62 27.55 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.338 -0.846 . . . . 0.0 109.417 179.808 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . 0.562 HD11 ' N ' ' B' ' 223' ' ' ARG . 0.0 OUTLIER -117.97 163.57 15.03 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.362 0 CA-C-O 121.075 0.464 . . . . 0.0 110.011 -179.194 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -154.91 123.5 6.08 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.42 -0.809 . . . . 0.0 110.583 179.29 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 88.5 t -102.14 104.15 16.02 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 178.709 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 92.8 mt -96.95 132.71 40.79 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.224 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.349 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . 0.609 HG23 ' O ' ' A' ' 79' ' ' THR . 14.0 t -112.15 120.25 41.17 Favored 'General case' 0 CA--C 1.514 -0.41 0 CA-C-N 116.173 -0.467 . . . . 0.0 109.946 -179.823 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . 0.577 HD13 ' N ' ' A' ' 81' ' ' ILE . 0.2 OUTLIER -121.54 115.46 22.87 Favored 'General case' 0 N--CA 1.464 0.234 0 CA-C-N 116.306 -0.407 . . . . 0.0 110.422 -179.781 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 81' ' ' ILE . . . . . 0.577 ' N ' HD13 ' A' ' 80' ' ' LEU . 1.9 pp -138.25 145.14 28.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.268 -0.424 . . . . 0.0 109.921 179.049 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 82' ' ' ASN . . . . . 0.406 ' H ' ' CB ' ' A' ' 33' ' ' THR . 60.7 t30 . . . . . 0 C--N 1.329 -0.298 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.792 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 207' ' ' GLY . . . . . 0.416 ' C ' ' CH2' ' B' ' 218' ' ' TRP . . . . . . . . 0 N--CA 1.465 0.62 0 N-CA-C 110.99 -0.844 . . . . 0.0 110.99 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 208' ' ' SER . . . . . 0.535 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 52.0 p -166.46 171.81 11.5 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.711 0.291 . . . . 0.0 110.703 179.664 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 209' ' ' TRP . . . . . . . . . . . . . 42.6 m95 -85.22 147.33 26.64 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.504 179.052 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 51.1 p -129.47 129.86 45.13 Favored 'General case' 0 C--O 1.232 0.176 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.7 179.876 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 42.5 t-105 -91.82 118.11 30.4 Favored 'General case' 0 C--N 1.334 -0.074 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.137 179.801 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 212' ' ' GLU . . . . . 0.443 ' O ' ' O ' ' B' ' 215' ' ' LYS . 1.0 OUTLIER -166.09 168.44 15.47 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.829 179.321 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' B' B ' 213' ' ' ASN . . . . . . . . . . . . . 93.1 m-20 49.47 37.55 12.36 Favored 'General case' 0 C--N 1.323 -0.566 0 C-N-CA 120.471 -0.492 . . . . 0.0 111.404 176.671 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 49.61 17.1 1.21 Allowed Glycine 0 CA--C 1.526 0.744 0 N-CA-C 111.337 -0.705 . . . . 0.0 111.337 179.703 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 215' ' ' LYS . . . . . 0.443 ' O ' ' O ' ' B' ' 212' ' ' GLU . 53.0 mtmt -142.99 150.25 39.4 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-O 121.169 0.509 . . . . 0.0 110.798 179.935 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 216' ' ' TRP . . . . . 0.534 ' O ' HG22 ' A' ' 79' ' ' THR . 59.5 m95 -89.49 118.48 29.17 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.012 -0.54 . . . . 0.0 109.818 179.631 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 217' ' ' THR . . . . . . . . . . . . . 17.7 m -131.23 144.51 51.38 Favored 'General case' 0 N--CA 1.466 0.328 0 CA-C-O 120.924 0.392 . . . . 0.0 110.524 -179.634 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 218' ' ' TRP . . . . . 0.535 ' CH2' ' N ' ' B' ' 208' ' ' SER . 12.0 t-105 -104.83 117.4 33.97 Favored 'General case' 0 C--N 1.328 -0.346 0 N-CA-C 109.532 -0.544 . . . . 0.0 109.532 179.262 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 50.5 mtpt -142.98 168.77 18.93 Favored 'General case' 0 CA--C 1.518 -0.253 0 CA-C-O 121.112 0.482 . . . . 0.0 110.485 -179.275 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -175.76 -162.25 26.5 Favored Glycine 0 CA--C 1.523 0.571 0 CA-C-N 115.603 -0.726 . . . . 0.0 111.389 -179.861 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 221' ' ' ILE . . . . . 0.521 ' O ' HG23 ' B' ' 222' ' ' ILE . 0.8 OUTLIER -53.34 -75.96 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 C-N-CA 120.641 -0.423 . . . . 0.0 110.872 -178.648 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' B' B ' 222' ' ' ILE . . . . . 0.521 HG23 ' O ' ' B' ' 221' ' ' ILE . 23.1 pt -158.97 -165.37 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.323 -179.232 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 223' ' ' ARG . . . . . 0.562 ' N ' HD11 ' A' ' 75' ' ' ILE . 52.7 ptt85 -42.94 172.87 0.0 OUTLIER 'General case' 0 C--O 1.234 0.276 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.299 179.133 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 224' ' ' LEU . . . . . 0.872 HD22 ' H ' ' B' ' 224' ' ' LEU . 1.7 mm? -68.37 111.59 4.72 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-O 121.296 0.57 . . . . 0.0 110.461 -179.378 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 26.7 tp10 . . . . . 0 C--N 1.329 -0.324 0 CA-C-N 115.196 -0.911 . . . . 0.0 110.37 179.745 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 . . . . . 0 C--O 1.234 0.255 0 CA-C-O 121.387 0.613 . . . . 0.0 110.446 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.403 HD23 ' N ' ' A' ' 12' ' ' LEU . 0.1 OUTLIER -74.18 153.26 39.57 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 114.965 -1.016 . . . . 0.0 109.806 -179.923 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 49.1 p -140.1 154.8 47.14 Favored 'General case' 0 C--N 1.333 -0.13 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.28 179.056 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . 0.472 ' N ' ' CD1' ' A' ' 14' ' ' PHE . 32.2 m-85 -103.69 146.35 28.73 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.562 -179.645 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 20.8 m -149.17 162.81 4.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.251 -0.432 . . . . 0.0 110.373 179.863 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 97.4 m-20 54.85 26.97 8.35 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.769 179.991 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 96.6 mt -56.06 136.16 18.87 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-O 121.007 0.432 . . . . 0.0 110.085 179.951 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.653 ' HG1' ' H ' ' A' ' 21' ' ' SER . 1.1 p -135.62 -166.79 1.91 Allowed 'General case' 0 CA--C 1.511 -0.548 0 CA-C-N 115.678 -0.692 . . . . 0.0 110.137 -179.977 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' ASP . . . . . 0.532 ' OD1' ' N ' ' A' ' 20' ' ' SER . 37.0 p-10 -90.46 -41.45 11.43 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.244 -0.889 . . . . 0.0 111.12 178.979 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . 0.532 ' N ' ' OD1' ' A' ' 19' ' ' ASP . 5.7 t -114.8 9.44 16.3 Favored 'General case' 0 N--CA 1.468 0.432 0 CA-C-N 116.323 -0.398 . . . . 0.0 110.984 -179.012 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . 0.653 ' H ' ' HG1' ' A' ' 18' ' ' THR . 27.9 p -154.85 158.05 38.79 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.118 179.61 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 42.9 pt -148.69 148.83 15.59 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.15 -179.912 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -100.88 78.82 0.42 Allowed Glycine 0 N--CA 1.467 0.721 0 N-CA-C 110.889 -0.884 . . . . 0.0 110.889 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.442 ' O ' ' CD1' ' A' ' 61' ' ' TYR . 20.9 mt -63.78 130.65 45.05 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.875 0.369 . . . . 0.0 110.233 -179.474 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 18.0 tpt180 -144.72 134.21 23.26 Favored 'General case' 0 CA--C 1.515 -0.372 0 CA-C-O 121.302 0.572 . . . . 0.0 110.201 -179.61 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' TRP . . . . . . . . . . . . . 39.8 p90 -147.82 153.83 39.68 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.082 -0.963 . . . . 0.0 110.015 179.213 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 3.1 m -110.32 100.61 45.19 Favored Pre-proline 0 CA--C 1.532 0.266 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.652 -179.964 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_exo -54.32 149.44 37.41 Favored 'Trans proline' 0 C--N 1.305 -1.752 0 C-N-CA 121.505 1.47 . . . . 0.0 112.877 179.347 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 64.1 mt -79.98 135.81 36.48 Favored 'General case' 0 CA--C 1.513 -0.471 0 CA-C-O 121.906 0.86 . . . . 0.0 110.67 -179.833 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 37.8 t30 -49.81 -34.88 20.92 Favored 'General case' 0 C--N 1.312 -1.054 0 CA-C-N 114.814 -1.084 . . . . 0.0 110.116 179.971 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 63.5 m -78.55 -33.74 47.59 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.721 -0.672 . . . . 0.0 110.784 179.027 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 4.9 m -57.87 133.82 55.77 Favored 'General case' 0 N--CA 1.462 0.147 0 CA-C-O 121.132 0.492 . . . . 0.0 110.138 -179.857 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' THR . . . . . 0.518 ' OG1' ' N ' ' A' ' 82' ' ' ASN . 5.2 m -58.33 143.55 44.52 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.84 -0.618 . . . . 0.0 109.845 -179.801 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 20.9 mm -94.19 90.97 2.95 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-O 120.925 0.393 . . . . 0.0 110.802 -179.428 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.466 ' O ' ' OG ' ' A' ' 57' ' ' SER . 8.8 pt -143.36 127.02 13.67 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.212 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.204 179.582 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -40.58 121.27 1.81 Allowed Glycine 0 CA--C 1.521 0.441 0 N-CA-C 111.372 -0.691 . . . . 0.0 111.372 -179.571 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' TYR . . . . . 0.443 ' CE2' ' OG ' ' A' ' 57' ' ' SER . 98.9 m-85 -85.37 178.26 7.52 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.548 -0.326 . . . . 0.0 110.168 179.796 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 6.6 tmm_? -131.44 128.52 39.67 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.448 179.741 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.479 ' CD1' ' CD2' ' A' ' 62' ' ' TYR . 1.8 pt -101.24 123.56 54.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.045 179.827 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 11.8 m -103.67 130.46 51.14 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.441 -0.345 . . . . 0.0 110.44 -179.862 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.1 p -128.59 138.12 55.47 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.55 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.023 179.919 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . 0.513 ' O ' ' N ' ' A' ' 74' ' ' ASP . 39.2 t -132.19 130.96 61.04 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.319 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 179.486 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.471 ' HB2' ' CE2' ' A' ' 73' ' ' TYR . . . -95.87 141.09 29.72 Favored 'General case' 0 C--N 1.324 -0.516 0 N-CA-C 109.207 -0.664 . . . . 0.0 109.207 179.199 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . 0.491 ' HB3' ' O ' ' A' ' 72' ' ' ASP . . . -93.84 -39.4 10.73 Favored 'General case' 0 C--N 1.327 -0.371 0 C-N-CA 120.652 -0.419 . . . . 0.0 110.69 179.652 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -66.13 -31.2 78.56 Favored Glycine 0 CA--C 1.526 0.78 0 N-CA-C 111.623 -0.591 . . . . 0.0 111.623 -179.545 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 51.6 mt-10 -98.3 133.05 43.25 Favored 'General case' 0 CA--C 1.518 -0.253 0 N-CA-C 109.539 -0.541 . . . . 0.0 109.539 -179.626 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -59.51 -21.73 55.0 Favored Glycine 0 CA--C 1.521 0.44 0 N-CA-C 110.845 -0.902 . . . . 0.0 110.845 -179.217 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -114.03 135.27 22.08 Favored Pre-proline 0 N--CA 1.473 0.685 0 CA-C-N 116.672 0.236 . . . . 0.0 110.626 179.854 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -76.49 162.33 33.4 Favored 'Trans proline' 0 N--CA 1.492 1.433 0 C-N-CA 122.519 2.146 . . . . 0.0 111.426 178.258 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 96.3 mt -81.74 134.34 27.29 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-N 116.151 -0.477 . . . . 0.0 109.953 179.335 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 97.9 m-85 -54.85 141.93 31.24 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.942 0.401 . . . . 0.0 110.797 -179.492 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 2.9 pt-20 -80.99 151.97 28.2 Favored 'General case' 0 CA--C 1.517 -0.296 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.262 179.796 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 2.0 t70 -120.52 160.3 23.45 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.764 179.714 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' PHE . . . . . 0.549 ' CD1' ' N ' ' A' ' 54' ' ' PHE . 6.1 m-85 -121.18 128.66 52.69 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.089 179.839 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 9.8 p -128.23 138.12 55.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 116.352 -0.385 . . . . 0.0 110.361 -179.701 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 98.8 m-20 -56.92 143.36 37.94 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.666 -179.662 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' SER . . . . . 0.466 ' OG ' ' O ' ' A' ' 35' ' ' ILE . 17.7 m -61.72 -34.24 75.44 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.889 179.893 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 37.5 m -57.04 -32.91 66.67 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.441 -179.808 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 92.8 t -65.55 -45.65 91.93 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.683 179.892 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 56.56 25.1 49.5 Favored Glycine 0 CA--C 1.527 0.821 0 N-CA-C 110.937 -0.865 . . . . 0.0 110.937 179.892 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' TYR . . . . . 0.442 ' CD1' ' O ' ' A' ' 24' ' ' LEU . 52.5 t80 -160.28 146.24 15.34 Favored 'General case' 0 N--CA 1.464 0.236 0 CA-C-O 121.141 0.496 . . . . 0.0 111.178 -179.359 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' TYR . . . . . 0.479 ' CD2' ' CD1' ' A' ' 39' ' ' ILE . 30.9 t80 -158.26 159.38 35.93 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.139 179.011 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 48.9 m -128.07 137.29 52.09 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.486 -179.423 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -131.13 101.75 5.68 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.34 0 CA-C-N 115.95 -0.568 . . . . 0.0 109.615 178.912 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 4.7 p -110.54 162.44 14.7 Favored 'General case' 0 N--CA 1.464 0.23 0 CA-C-O 121.006 0.432 . . . . 0.0 110.558 179.868 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 109.05 5.88 30.35 Favored Glycine 0 CA--C 1.527 0.832 0 CA-C-N 115.639 -0.709 . . . . 0.0 111.335 -179.655 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 12.1 mt -79.24 109.2 13.34 Favored 'General case' 0 C--N 1.329 -0.315 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.841 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 7.4 mm-40 -55.25 138.89 66.37 Favored Pre-proline 0 C--N 1.321 -0.65 0 C-N-CA 120.63 -0.428 . . . . 0.0 111.576 -178.236 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 95.8 Cg_endo -74.56 151.59 42.06 Favored 'Trans proline' 0 N--CA 1.493 1.495 0 C-N-CA 122.627 2.218 . . . . 0.0 111.725 179.113 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 72.4 10.15 74.41 Favored Glycine 0 CA--C 1.528 0.877 0 CA-C-N 115.161 -0.927 . . . . 0.0 111.642 179.229 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 1.7 mp -115.48 142.6 27.92 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.655 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 -179.727 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 72' ' ' ASP . . . . . 0.491 ' O ' ' HB3' ' A' ' 44' ' ' ALA . 2.3 t70 -81.73 110.88 17.47 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-N 115.162 -0.926 . . . . 0.0 110.311 179.977 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 73' ' ' TYR . . . . . 0.526 ' O ' ' CD1' ' A' ' 75' ' ' ILE . 14.8 m-85 -106.07 117.95 35.35 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.198 -179.911 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 74' ' ' ASP . . . . . 0.513 ' N ' ' O ' ' A' ' 42' ' ' VAL . 72.2 m-20 -88.16 119.83 28.93 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.145 -0.934 . . . . 0.0 109.331 179.754 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . 0.901 HD13 ' N ' ' A' ' 75' ' ' ILE . 0.0 OUTLIER -121.36 166.27 16.06 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.307 0 CA-C-O 121.067 0.46 . . . . 0.0 110.424 -179.103 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 22.5 t -155.15 151.3 28.07 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.745 -0.661 . . . . 0.0 110.122 179.26 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.429 ' O ' HG23 ' B' ' 217' ' ' THR . 2.4 t -125.3 109.7 22.65 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.335 0 N-CA-C 109.25 -0.648 . . . . 0.0 109.25 178.899 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 90.8 mt -97.27 123.11 49.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-O 120.891 0.377 . . . . 0.0 110.239 179.924 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . 0.426 ' OG1' ' O ' ' B' ' 216' ' ' TRP . 19.6 p -103.48 111.4 23.83 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.059 179.752 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 35.4 tp -120.44 121.13 37.84 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.096 179.646 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 81' ' ' ILE . . . . . 0.513 ' HB ' ' H ' ' A' ' 33' ' ' THR . 2.3 pp -143.05 149.87 18.23 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 CA-C-N 116.081 -0.508 . . . . 0.0 110.189 179.634 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 82' ' ' ASN . . . . . 0.518 ' N ' ' OG1' ' A' ' 33' ' ' THR . 40.9 t30 . . . . . 0 C--N 1.33 -0.262 0 CA-C-N 116.443 -0.344 . . . . 0.0 111.159 179.916 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 207' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.466 0.648 0 N-CA-C 111.125 -0.79 . . . . 0.0 111.125 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' B' B ' 208' ' ' SER . . . . . 0.52 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 90.6 p -169.67 172.96 6.55 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.892 0.377 . . . . 0.0 110.864 -179.553 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 209' ' ' TRP . . . . . . . . . . . . . 69.1 m95 -92.74 153.52 18.86 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-N 115.815 -0.63 . . . . 0.0 110.488 179.289 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 49.8 p -135.04 140.27 45.45 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.521 179.631 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 61.0 t-105 -90.18 114.7 26.73 Favored 'General case' 0 C--N 1.332 -0.154 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.214 179.583 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 212' ' ' GLU . . . . . 0.522 ' O ' ' O ' ' B' ' 215' ' ' LYS . 3.8 tt0 -161.85 154.06 19.52 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.583 179.684 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 213' ' ' ASN . . . . . 0.446 ' N ' ' HG3' ' B' ' 212' ' ' GLU . 83.5 m-20 56.72 40.62 29.07 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 115.421 -0.809 . . . . 0.0 111.78 177.022 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 51.19 11.41 0.64 Allowed Glycine 0 CA--C 1.528 0.854 0 N-CA-C 111.64 -0.584 . . . . 0.0 111.64 179.571 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 215' ' ' LYS . . . . . 0.522 ' O ' ' O ' ' B' ' 212' ' ' GLU . 80.6 mttt -141.61 151.33 43.03 Favored 'General case' 0 C--O 1.225 -0.212 0 CA-C-O 121.109 0.481 . . . . 0.0 110.963 -179.854 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 216' ' ' TRP . . . . . 0.479 ' N ' ' CD1' ' B' ' 216' ' ' TRP . 24.8 m95 -85.85 119.42 26.14 Favored 'General case' 0 C--N 1.327 -0.406 0 C-N-CA 120.731 -0.387 . . . . 0.0 110.049 179.701 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 217' ' ' THR . . . . . 0.429 HG23 ' O ' ' A' ' 77' ' ' VAL . 16.7 m -125.86 142.1 51.67 Favored 'General case' 0 N--CA 1.467 0.395 0 N-CA-C 110.109 -0.33 . . . . 0.0 110.109 -179.525 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 218' ' ' TRP . . . . . 0.52 ' CH2' ' N ' ' B' ' 208' ' ' SER . 13.7 t-105 -103.49 117.15 33.78 Favored 'General case' 0 N--CA 1.463 0.186 0 CA-C-N 115.906 -0.588 . . . . 0.0 109.439 179.445 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 8.1 mtmp? -143.24 163.01 34.12 Favored 'General case' 0 CA--C 1.516 -0.355 0 CA-C-O 121.21 0.529 . . . . 0.0 110.634 -179.477 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -176.56 -160.27 23.46 Favored Glycine 0 CA--C 1.523 0.568 0 N-CA-C 111.185 -0.766 . . . . 0.0 111.185 -179.536 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 221' ' ' ILE . . . . . 0.529 ' O ' HG23 ' B' ' 222' ' ' ILE . 0.7 OUTLIER -51.05 -75.38 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 C-N-CA 120.778 -0.369 . . . . 0.0 110.566 -178.854 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' B' B ' 222' ' ' ILE . . . . . 0.529 HG23 ' O ' ' B' ' 221' ' ' ILE . 17.0 pt -160.25 -165.76 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 CA-C-N 116.327 -0.397 . . . . 0.0 109.991 -179.653 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 223' ' ' ARG . . . . . 0.508 ' O ' ' O ' ' B' ' 222' ' ' ILE . 22.5 ptt180 -42.33 175.38 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 121.472 0.653 . . . . 0.0 110.841 178.864 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 224' ' ' LEU . . . . . 0.644 ' N ' HD22 ' B' ' 224' ' ' LEU . 3.6 mm? -61.31 123.5 17.93 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 115.497 -0.774 . . . . 0.0 110.65 -179.753 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 79.9 tt0 . . . . . 0 CA--C 1.518 -0.282 0 CA-C-N 115.385 -0.825 . . . . 0.0 110.221 179.817 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 99.3 m-20 . . . . . 0 CA--C 1.519 -0.23 0 CA-C-O 120.873 0.368 . . . . 0.0 110.355 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 6.3 tt -64.2 142.99 58.22 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.154 -179.31 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 83.6 p -140.49 154.43 46.59 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.648 179.697 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . 0.505 ' N ' ' CD1' ' A' ' 14' ' ' PHE . 21.5 m-85 -111.41 144.77 40.09 Favored 'General case' 0 N--CA 1.464 0.274 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.668 -179.739 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.409 HG11 ' NH2' ' A' ' 25' ' ' ARG . 31.2 m -146.27 161.75 10.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.321 -0.399 . . . . 0.0 110.614 179.793 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 98.2 m-20 53.87 31.08 12.55 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.499 179.764 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 99.2 mt -57.09 140.91 14.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.258 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.444 ' CB ' ' O ' ' A' ' 21' ' ' SER . 0.2 OUTLIER -141.28 -168.11 2.55 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-N 116.009 -0.542 . . . . 0.0 110.326 -179.778 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' ASP . . . . . 0.477 ' N ' ' OD1' ' A' ' 19' ' ' ASP . 21.0 p-10 -88.88 -45.23 9.87 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.874 179.467 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 22.4 m -114.45 7.99 16.39 Favored 'General case' 0 N--CA 1.468 0.465 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.882 -179.543 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . 0.444 ' O ' ' CB ' ' A' ' 18' ' ' THR . 34.4 t -151.55 145.53 25.21 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.156 0.503 . . . . 0.0 110.232 179.551 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . 0.425 HD12 HD21 ' A' ' 24' ' ' LEU . 45.3 pt -138.89 146.29 26.39 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.587 0 CA-C-N 115.802 -0.635 . . . . 0.0 110.352 -179.618 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -99.1 82.19 0.57 Allowed Glycine 0 CA--C 1.524 0.612 0 N-CA-C 110.903 -0.879 . . . . 0.0 110.903 -179.953 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.425 HD21 HD12 ' A' ' 22' ' ' ILE . 94.2 mt -70.02 121.8 18.13 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.856 0.36 . . . . 0.0 110.182 179.884 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . 0.409 ' NH2' HG11 ' A' ' 15' ' ' VAL . 59.9 ttp180 -141.28 136.14 31.32 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.164 179.949 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' TRP . . . . . . . . . . . . . 37.8 p90 -139.21 156.04 47.38 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.897 -0.592 . . . . 0.0 109.925 -179.795 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 3.5 m -110.59 98.89 39.09 Favored Pre-proline 0 C--N 1.33 -0.239 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.481 179.718 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 39.9 Cg_exo -53.66 147.63 39.01 Favored 'Trans proline' 0 C--N 1.303 -1.821 0 C-N-CA 121.63 1.554 . . . . 0.0 112.911 179.772 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 59.9 mt -87.76 141.93 28.22 Favored 'General case' 0 CA--C 1.511 -0.55 0 CA-C-N 115.437 -0.801 . . . . 0.0 110.398 -179.873 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 18.3 t-20 -50.07 -37.14 32.1 Favored 'General case' 0 C--N 1.315 -0.909 0 CA-C-N 114.908 -1.042 . . . . 0.0 110.067 -179.831 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 70.3 m -78.24 -33.5 49.74 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.547 178.755 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 14.1 m -60.83 131.09 49.58 Favored 'General case' 0 N--CA 1.463 0.194 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.067 -179.881 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' THR . . . . . 0.455 ' H ' ' HB ' ' A' ' 81' ' ' ILE . 5.1 m -65.91 142.18 57.98 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.253 -179.971 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 16.3 mm -94.82 90.75 2.79 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.19 0 CA-C-N 116.339 -0.392 . . . . 0.0 110.616 -179.848 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.473 ' O ' ' OG ' ' A' ' 57' ' ' SER . 24.9 pt -134.25 144.43 35.3 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.381 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.25 179.923 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -43.4 112.66 0.57 Allowed Glycine 0 CA--C 1.517 0.169 0 C-N-CA 120.59 -0.814 . . . . 0.0 111.58 -179.167 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' TYR . . . . . 0.866 ' OH ' HG23 ' A' ' 77' ' ' VAL . 0.9 OUTLIER -91.4 120.46 32.27 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 109.062 -0.718 . . . . 0.0 109.062 179.205 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' ARG . . . . . 0.516 ' O ' ' CE1' ' A' ' 37' ' ' TYR . 4.7 tmm_? -90.07 133.87 34.59 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.912 -0.586 . . . . 0.0 110.65 179.941 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 6.3 pt -93.67 154.76 3.24 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.314 0 CA-C-N 116.153 -0.476 . . . . 0.0 109.806 179.926 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 2.1 m -131.19 130.03 42.46 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.486 -0.325 . . . . 0.0 110.394 179.409 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.3 p -134.47 136.1 53.17 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.496 0 CA-C-O 120.94 0.4 . . . . 0.0 110.697 179.83 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . 0.511 ' O ' ' N ' ' A' ' 74' ' ' ASP . 32.1 t -131.15 127.6 60.87 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.319 0 N-CA-C 109.5 -0.556 . . . . 0.0 109.5 179.362 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -94.58 141.22 28.85 Favored 'General case' 0 C--N 1.324 -0.539 0 N-CA-C 109.516 -0.549 . . . . 0.0 109.516 179.357 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . 0.557 ' HB3' ' O ' ' A' ' 72' ' ' ASP . . . -96.63 -43.5 7.55 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.922 0.391 . . . . 0.0 110.872 179.783 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -74.24 30.82 0.97 Allowed Glycine 0 CA--C 1.525 0.659 0 N-CA-C 110.863 -0.895 . . . . 0.0 110.863 -179.957 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . 0.486 ' H ' ' C ' ' A' ' 44' ' ' ALA . 79.8 mm-40 -146.17 150.73 36.42 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 121.11 0.481 . . . . 0.0 110.695 -179.526 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -76.25 -14.67 82.1 Favored Glycine 0 CA--C 1.521 0.448 0 N-CA-C 110.711 -0.956 . . . . 0.0 110.711 179.752 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -138.34 139.5 25.38 Favored Pre-proline 0 CA--C 1.54 0.589 0 C-N-CA 120.961 -0.296 . . . . 0.0 110.464 179.581 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 70.6 Cg_endo -75.27 161.92 37.22 Favored 'Trans proline' 0 N--CA 1.491 1.349 0 C-N-CA 122.64 2.227 . . . . 0.0 111.84 177.957 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 96.3 mt -76.63 140.8 16.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.431 179.129 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 88.8 m-85 -62.84 141.7 58.54 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.459 -179.76 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . 0.534 ' H ' ' CD ' ' A' ' 52' ' ' GLU . 0.1 OUTLIER -76.92 146.36 37.63 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.46 179.714 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 4.8 t70 -113.18 150.94 31.55 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.66 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 72.7 m-85 -111.03 122.03 46.85 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.237 179.708 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 10.8 p -127.89 137.97 56.06 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.366 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.482 -179.963 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 89.7 m-20 -64.38 139.8 58.8 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.203 179.368 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 57' ' ' SER . . . . . 0.473 ' OG ' ' O ' ' A' ' 35' ' ' ILE . 2.8 m -59.47 -28.94 67.45 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.467 -179.83 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 37.6 m -55.8 -32.01 63.14 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.573 -179.998 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.498 ' O ' ' CD2' ' A' ' 61' ' ' TYR . 50.1 t -61.88 -44.2 98.51 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 -179.099 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 70.39 13.73 71.09 Favored Glycine 0 CA--C 1.53 0.977 0 N-CA-C 111.033 -0.827 . . . . 0.0 111.033 179.473 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 61' ' ' TYR . . . . . 0.498 ' CD2' ' O ' ' A' ' 59' ' ' VAL . 26.4 p90 -171.9 158.56 4.84 Favored 'General case' 0 C--O 1.225 -0.226 0 CA-C-O 120.993 0.425 . . . . 0.0 111.583 179.594 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 35.1 t80 -155.99 154.72 31.55 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.054 177.972 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 86.3 m -116.32 133.04 56.46 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.4 -179.456 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -131.08 100.84 4.91 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.275 0 N-CA-C 109.475 -0.565 . . . . 0.0 109.475 179.152 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.42 HG22 ' OG ' ' A' ' 21' ' ' SER . 2.4 p -110.33 163.47 13.62 Favored 'General case' 0 N--CA 1.464 0.239 0 CA-C-O 121.007 0.432 . . . . 0.0 110.706 -179.869 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 110.08 9.79 23.56 Favored Glycine 0 CA--C 1.528 0.851 0 CA-C-N 115.496 -0.775 . . . . 0.0 111.49 -179.56 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 8.1 mt -83.52 107.61 16.11 Favored 'General case' 0 C--N 1.33 -0.274 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 179.829 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 17.5 mm-40 -57.58 138.53 81.81 Favored Pre-proline 0 C--N 1.32 -0.694 0 C-N-CA 120.321 -0.552 . . . . 0.0 111.609 -178.295 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 90.2 Cg_endo -74.54 154.65 45.02 Favored 'Trans proline' 0 N--CA 1.496 1.637 0 C-N-CA 122.762 2.308 . . . . 0.0 111.825 178.942 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 73.35 7.92 73.92 Favored Glycine 0 CA--C 1.528 0.865 0 CA-C-N 115.282 -0.872 . . . . 0.0 111.767 179.075 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . 0.547 ' O ' ' NH1' ' B' ' 223' ' ' ARG . 1.7 mp -117.11 147.24 20.62 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.406 0 N-CA-C 109.291 -0.633 . . . . 0.0 109.291 -179.504 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 72' ' ' ASP . . . . . 0.557 ' O ' ' HB3' ' A' ' 44' ' ' ALA . 2.8 t0 -84.76 113.99 21.73 Favored 'General case' 0 C--N 1.318 -0.766 0 CA-C-N 115.176 -0.92 . . . . 0.0 110.402 -179.6 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 73' ' ' TYR . . . . . 0.507 ' O ' HD13 ' A' ' 75' ' ' ILE . 15.6 m-85 -107.93 119.88 40.7 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.324 -179.966 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 74' ' ' ASP . . . . . 0.511 ' N ' ' O ' ' A' ' 42' ' ' VAL . 14.8 m-20 -89.71 118.96 29.71 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 115.327 -0.851 . . . . 0.0 108.805 179.535 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . 0.625 HD11 ' N ' ' B' ' 223' ' ' ARG . 0.0 OUTLIER -113.24 162.65 11.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-O 121.282 0.563 . . . . 0.0 110.263 -178.642 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -153.53 118.89 5.18 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.289 -0.869 . . . . 0.0 110.484 179.708 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.866 HG23 ' OH ' ' A' ' 37' ' ' TYR . 8.7 p -103.39 101.38 12.13 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.242 0 N-CA-C 109.517 -0.549 . . . . 0.0 109.517 178.995 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 91.4 mt -92.0 101.13 12.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.621 -179.847 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 44.9 p -77.68 111.64 13.67 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.807 -0.633 . . . . 0.0 109.388 179.049 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . 0.587 HD12 ' NZ ' ' B' ' 215' ' ' LYS . 4.8 tp -111.54 120.63 42.77 Favored 'General case' 0 N--CA 1.465 0.288 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.963 -179.234 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 81' ' ' ILE . . . . . 0.455 ' HB ' ' H ' ' A' ' 33' ' ' THR . 2.1 pp -146.61 142.3 20.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.065 -0.516 . . . . 0.0 109.974 179.095 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 56.0 t-20 . . . . . 0 C--N 1.331 -0.234 0 CA-C-O 120.721 0.296 . . . . 0.0 110.9 -179.648 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' B' B ' 207' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.466 0.637 0 N-CA-C 111.174 -0.77 . . . . 0.0 111.174 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' B' B ' 208' ' ' SER . . . . . 0.539 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 91.7 p -166.88 172.14 10.62 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 120.907 0.384 . . . . 0.0 110.701 -179.805 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 209' ' ' TRP . . . . . . . . . . . . . 78.4 m95 -88.63 130.66 35.23 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.189 179.369 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 82.1 p -109.5 132.81 53.79 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-N 116.392 -0.367 . . . . 0.0 110.496 -179.796 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 47.7 t-105 -93.73 117.81 30.58 Favored 'General case' 0 N--CA 1.463 0.208 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.072 179.796 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 212' ' ' GLU . . . . . 0.44 ' O ' ' O ' ' B' ' 215' ' ' LYS . 0.8 OUTLIER -164.22 167.41 20.04 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.779 179.035 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' B' B ' 213' ' ' ASN . . . . . . . . . . . . . 92.4 m-20 49.06 37.11 9.88 Favored 'General case' 0 C--N 1.324 -0.516 0 C-N-CA 120.522 -0.471 . . . . 0.0 111.349 176.603 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 50.89 16.85 1.93 Allowed Glycine 0 CA--C 1.526 0.723 0 N-CA-C 111.335 -0.706 . . . . 0.0 111.335 179.868 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 215' ' ' LYS . . . . . 0.587 ' NZ ' HD12 ' A' ' 80' ' ' LEU . 20.3 mtpt -143.0 149.75 38.72 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.986 0.422 . . . . 0.0 110.889 -179.839 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 216' ' ' TRP . . . . . . . . . . . . . 50.1 m95 -86.12 115.76 23.9 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.028 -0.533 . . . . 0.0 109.712 179.115 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 217' ' ' THR . . . . . . . . . . . . . 18.1 m -126.95 139.92 52.7 Favored 'General case' 0 N--CA 1.466 0.343 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.439 -179.512 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 218' ' ' TRP . . . . . 0.626 ' O ' HG12 ' A' ' 77' ' ' VAL . 12.9 t-105 -106.45 116.38 31.82 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.016 178.984 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 52.8 mtmt -143.9 174.5 10.78 Favored 'General case' 0 CA--C 1.514 -0.432 0 CA-C-O 121.137 0.494 . . . . 0.0 110.644 -179.85 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -176.38 -160.21 23.27 Favored Glycine 0 CA--C 1.523 0.572 0 C-N-CA 120.544 -0.836 . . . . 0.0 111.226 -179.576 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 221' ' ' ILE . . . . . 0.532 ' O ' HG23 ' B' ' 222' ' ' ILE . 10.2 mm -51.27 -73.59 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.892 0.377 . . . . 0.0 110.485 -178.059 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 222' ' ' ILE . . . . . 0.532 HG23 ' O ' ' B' ' 221' ' ' ILE . 23.7 pt -159.48 -166.39 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.755 0 CA-C-N 115.646 -0.706 . . . . 0.0 110.706 -179.943 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 223' ' ' ARG . . . . . 0.625 ' N ' HD11 ' A' ' 75' ' ' ILE . 32.0 ptt-85 -42.76 174.6 0.0 OUTLIER 'General case' 0 CA--C 1.52 -0.186 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.77 179.003 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 224' ' ' LEU . . . . . 0.759 ' N ' HD22 ' B' ' 224' ' ' LEU . 2.4 mm? -59.67 128.23 35.91 Favored 'General case' 0 C--N 1.315 -0.906 0 CA-C-N 115.786 -0.643 . . . . 0.0 110.542 -179.517 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 42.5 tt0 . . . . . 0 CA--C 1.52 -0.188 0 CA-C-N 115.349 -0.841 . . . . 0.0 110.391 -179.843 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 97.2 m-20 . . . . . 0 N--CA 1.463 0.199 0 CA-C-O 120.876 0.369 . . . . 0.0 110.395 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 6.7 tt -63.92 149.15 47.82 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.396 -179.74 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . 0.419 ' O ' ' O ' ' A' ' 25' ' ' ARG . 83.3 p -139.15 156.85 46.83 Favored 'General case' 0 N--CA 1.461 0.114 0 CA-C-O 121.166 0.508 . . . . 0.0 110.42 179.757 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . 0.501 ' N ' ' CD1' ' A' ' 14' ' ' PHE . 30.6 m-85 -110.84 146.37 36.57 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.555 -0.748 . . . . 0.0 110.81 -179.515 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 15.6 m -146.74 157.01 10.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.447 -0.342 . . . . 0.0 110.649 179.4 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 98.9 m-20 54.59 31.53 15.23 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.934 179.656 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 97.2 mt -56.92 140.89 14.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.383 -179.803 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.418 ' CB ' ' O ' ' A' ' 21' ' ' SER . 0.2 OUTLIER -140.87 -168.6 2.63 Favored 'General case' 0 CA--C 1.533 0.292 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.509 -179.798 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' ASP . . . . . 0.483 ' OD1' ' N ' ' A' ' 19' ' ' ASP . 11.8 p-10 -90.3 -41.91 11.27 Favored 'General case' 0 N--CA 1.465 0.299 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.689 179.509 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 15.1 m -114.62 5.74 15.51 Favored 'General case' 0 N--CA 1.464 0.252 0 CA-C-N 116.014 -0.539 . . . . 0.0 111.152 -179.395 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . 0.418 ' O ' ' CB ' ' A' ' 18' ' ' THR . 29.2 t -151.68 148.43 27.92 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 121.046 0.45 . . . . 0.0 110.365 179.624 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 42.6 pt -140.71 145.53 25.42 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.194 179.789 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -102.27 81.42 0.4 Allowed Glycine 0 CA--C 1.524 0.618 0 N-CA-C 110.998 -0.841 . . . . 0.0 110.998 -179.991 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 96.3 mt -68.54 121.6 16.73 Favored 'General case' 0 C--N 1.33 -0.272 0 C-N-CA 120.775 -0.37 . . . . 0.0 110.015 -179.992 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . 0.419 ' O ' ' O ' ' A' ' 13' ' ' SER . 58.8 ttt85 -142.75 137.64 29.93 Favored 'General case' 0 C--N 1.333 -0.123 0 CA-C-O 120.956 0.407 . . . . 0.0 110.372 -179.806 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' TRP . . . . . 0.454 ' C ' ' CD1' ' A' ' 26' ' ' TRP . 0.1 OUTLIER -143.0 161.54 37.85 Favored 'General case' 0 N--CA 1.466 0.349 0 N-CA-C 109.089 -0.708 . . . . 0.0 109.089 179.599 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 5.0 m -100.88 103.18 23.17 Favored Pre-proline 0 C--N 1.327 -0.379 0 N-CA-C 108.612 -0.885 . . . . 0.0 108.612 178.73 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 33.4 Cg_exo -54.72 149.62 39.84 Favored 'Trans proline' 0 C--N 1.308 -1.594 0 C-N-CA 120.883 1.055 . . . . 0.0 112.754 -179.03 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 69.6 mt -87.49 133.06 33.82 Favored 'General case' 0 CA--C 1.51 -0.569 0 CA-C-O 121.601 0.715 . . . . 0.0 111.066 -179.637 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 24.3 t-20 -46.9 -33.69 4.79 Favored 'General case' 0 C--N 1.314 -0.94 0 CA-C-N 115.064 -0.971 . . . . 0.0 110.225 179.527 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 63.4 m -80.74 -34.18 34.59 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.53 178.83 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 5.2 m -56.57 127.12 29.73 Favored 'General case' 0 C--O 1.232 0.136 0 C-N-CA 120.732 -0.387 . . . . 0.0 109.998 -179.715 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' THR . . . . . 0.495 ' H ' ' HB ' ' A' ' 81' ' ' ILE . 33.2 m -61.61 152.5 30.47 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.048 179.875 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 24.4 mm -97.5 94.05 3.71 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.343 0 CA-C-N 116.579 -0.282 . . . . 0.0 111.49 -178.24 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.485 HD13 ' N ' ' A' ' 35' ' ' ILE . 0.1 OUTLIER -137.59 155.09 30.55 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.324 0 CA-C-O 120.792 0.329 . . . . 0.0 110.511 179.305 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -63.22 113.57 6.02 Favored Glycine 0 CA--C 1.521 0.457 0 C-N-CA 120.472 -0.871 . . . . 0.0 111.178 179.785 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 69.2 m-85 -80.73 141.53 34.73 Favored 'General case' 0 C--N 1.328 -0.358 0 N-CA-C 110.072 -0.344 . . . . 0.0 110.072 179.525 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' ARG . . . . . 0.43 HH11 ' HG3' ' A' ' 52' ' ' GLU . 5.3 tmm_? -105.54 119.84 40.14 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.549 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.474 ' CG1' ' O ' ' A' ' 39' ' ' ILE . 1.9 pt -95.47 122.88 47.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 115.835 -0.62 . . . . 0.0 109.693 179.79 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 94.8 m -109.61 131.64 54.87 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.824 0.345 . . . . 0.0 110.511 -179.276 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.417 HG13 ' HB ' ' A' ' 50' ' ' ILE . 1.8 p -128.8 144.12 39.05 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.349 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.523 -179.505 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . 0.506 ' O ' ' N ' ' A' ' 74' ' ' ASP . 40.4 t -132.45 131.87 60.3 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.191 0 CA-C-O 120.899 0.38 . . . . 0.0 110.019 179.542 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.526 ' HB2' ' CE2' ' A' ' 73' ' ' TYR . . . -98.44 140.01 33.33 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 109.296 -0.631 . . . . 0.0 109.296 179.22 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . 0.552 ' HB3' ' O ' ' A' ' 72' ' ' ASP . . . -98.26 -18.44 18.39 Favored 'General case' 0 CA--C 1.529 0.135 0 C-N-CA 120.67 -0.412 . . . . 0.0 110.776 179.926 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -98.54 30.73 9.1 Favored Glycine 0 CA--C 1.529 0.956 0 N-CA-C 110.753 -0.939 . . . . 0.0 110.753 179.821 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 45.1 mt-10 -146.78 149.01 32.51 Favored 'General case' 0 CA--C 1.521 -0.16 0 CA-C-O 121.131 0.491 . . . . 0.0 110.691 179.97 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -68.96 -20.95 75.09 Favored Glycine 0 CA--C 1.527 0.823 0 N-CA-C 111.014 -0.834 . . . . 0.0 111.014 179.736 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -136.61 141.11 34.21 Favored Pre-proline 0 CA--C 1.54 0.579 0 C-N-CA 121.131 -0.228 . . . . 0.0 110.476 179.995 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 69.4 Cg_endo -73.36 162.22 40.8 Favored 'Trans proline' 0 N--CA 1.496 1.672 0 C-N-CA 122.752 2.301 . . . . 0.0 111.821 179.059 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . 0.417 ' HB ' HG13 ' A' ' 41' ' ' VAL . 96.7 mt -76.49 151.77 5.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.522 179.793 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 82.6 m-85 -70.75 146.41 49.83 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.707 -179.54 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . 0.522 ' H ' ' CD ' ' A' ' 52' ' ' GLU . 0.5 OUTLIER -82.96 145.0 29.61 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.682 179.55 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -112.4 153.14 27.76 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.492 -0.777 . . . . 0.0 110.388 -179.717 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 54' ' ' PHE . . . . . 0.581 ' CD1' ' N ' ' A' ' 54' ' ' PHE . 2.7 m-85 -119.0 128.7 54.64 Favored 'General case' 0 N--CA 1.466 0.356 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.227 -179.758 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 9.6 p -131.26 139.06 51.8 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.3 0 CA-C-O 120.683 0.277 . . . . 0.0 110.828 -179.65 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 71.4 m-20 -58.51 142.47 48.82 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.262 179.581 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 7.2 t -60.88 -35.21 76.04 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.733 179.86 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 58.5 m -56.31 -34.11 66.2 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.923 -179.603 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 90.7 t -62.38 -45.8 97.93 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.389 -179.84 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 61.75 23.17 62.87 Favored Glycine 0 CA--C 1.525 0.713 0 N-CA-C 110.745 -0.942 . . . . 0.0 110.745 179.942 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 37.2 t80 -164.65 150.16 10.09 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-O 121.095 0.474 . . . . 0.0 111.423 -179.412 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 62' ' ' TYR . . . . . 0.432 ' CD2' ' CD1' ' A' ' 39' ' ' ILE . 18.4 t80 -156.7 154.32 29.87 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.73 -0.668 . . . . 0.0 110.33 178.715 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 73.1 m -117.55 132.55 56.51 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.16 -0.473 . . . . 0.0 109.893 179.472 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -130.63 113.63 25.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 N-CA-C 109.327 -0.62 . . . . 0.0 109.327 178.914 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.412 HG22 ' OG ' ' A' ' 21' ' ' SER . 2.1 p -124.76 158.83 32.33 Favored 'General case' 0 CA--C 1.516 -0.331 0 CA-C-O 120.987 0.422 . . . . 0.0 110.394 -179.83 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 108.11 39.61 1.8 Allowed Glycine 0 CA--C 1.525 0.682 0 N-CA-C 110.818 -0.913 . . . . 0.0 110.818 -179.937 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 14.5 mt -112.52 106.96 15.53 Favored 'General case' 0 N--CA 1.467 0.404 0 N-CA-C 108.742 -0.836 . . . . 0.0 108.742 179.087 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 4.1 mm-40 -54.34 136.79 60.37 Favored Pre-proline 0 C--N 1.323 -0.561 0 C-N-CA 120.86 -0.336 . . . . 0.0 111.727 -178.095 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 90.0 Cg_endo -74.26 154.52 46.38 Favored 'Trans proline' 0 N--CA 1.493 1.466 0 C-N-CA 122.779 2.319 . . . . 0.0 111.54 178.877 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 71.05 8.42 64.66 Favored Glycine 0 CA--C 1.529 0.963 0 CA-C-N 115.533 -0.758 . . . . 0.0 111.507 179.563 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 1.6 mp -116.05 143.9 24.97 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.543 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 -179.975 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 72' ' ' ASP . . . . . 0.552 ' O ' ' HB3' ' A' ' 44' ' ' ALA . 2.0 t0 -81.93 112.59 19.17 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-N 115.307 -0.861 . . . . 0.0 110.149 -179.849 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 73' ' ' TYR . . . . . 0.526 ' CE2' ' HB2' ' A' ' 43' ' ' ALA . 13.7 m-85 -107.38 120.01 40.97 Favored 'General case' 0 C--O 1.223 -0.326 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.354 -179.814 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 74' ' ' ASP . . . . . 0.506 ' N ' ' O ' ' A' ' 42' ' ' VAL . 7.3 m-20 -89.04 114.86 26.12 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 115.34 -0.845 . . . . 0.0 109.375 179.601 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . 0.675 HD11 ' N ' ' B' ' 223' ' ' ARG . 0.0 OUTLIER -112.35 167.31 5.8 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.198 0 CA-C-O 121.273 0.558 . . . . 0.0 110.405 -179.434 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 11.6 p -154.46 151.65 29.2 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 115.124 -0.944 . . . . 0.0 110.283 179.392 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -131.32 101.75 5.56 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.351 0 N-CA-C 108.744 -0.836 . . . . 0.0 108.744 179.49 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 96.2 mt -86.62 123.87 40.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 C-N-CA 120.913 -0.315 . . . . 0.0 110.34 -179.673 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 90.5 m -105.26 109.02 20.85 Favored 'General case' 0 N--CA 1.465 0.301 0 CA-C-N 116.358 -0.383 . . . . 0.0 109.971 179.66 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 6.7 tt -121.09 119.02 31.24 Favored 'General case' 0 CA--C 1.517 -0.292 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.449 179.965 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 81' ' ' ILE . . . . . 0.495 ' HB ' ' H ' ' A' ' 33' ' ' THR . 2.0 pp -140.28 143.44 29.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.289 179.22 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 82' ' ' ASN . . . . . 0.404 ' C ' HD22 ' A' ' 82' ' ' ASN . 0.7 OUTLIER . . . . . 0 C--N 1.327 -0.384 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.803 -179.476 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 207' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.464 0.515 0 N-CA-C 110.838 -0.905 . . . . 0.0 110.838 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' B' B ' 208' ' ' SER . . . . . . . . . . . . . 44.6 p -163.82 170.33 17.02 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 120.717 0.294 . . . . 0.0 110.701 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 209' ' ' TRP . . . . . . . . . . . . . 86.5 m95 -83.33 126.56 32.83 Favored 'General case' 0 C--N 1.329 -0.286 0 C-N-CA 120.845 -0.342 . . . . 0.0 110.167 179.34 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 77.4 p -108.94 138.91 44.54 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-N 116.514 -0.312 . . . . 0.0 110.723 -179.745 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 58.2 t-105 -95.67 116.09 28.36 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-N 116.033 -0.531 . . . . 0.0 110.337 179.68 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 212' ' ' GLU . . . . . 0.469 ' O ' ' O ' ' B' ' 215' ' ' LYS . 1.4 pt-20 -163.46 167.03 22.06 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.509 179.312 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 213' ' ' ASN . . . . . . . . . . . . . 12.4 m120 49.3 34.23 6.11 Favored 'General case' 0 C--N 1.324 -0.522 0 C-N-CA 120.53 -0.468 . . . . 0.0 111.698 176.962 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 54.73 12.34 3.48 Favored Glycine 0 CA--C 1.528 0.865 0 C-N-CA 120.917 -0.659 . . . . 0.0 111.604 179.463 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 215' ' ' LYS . . . . . 0.469 ' O ' ' O ' ' B' ' 212' ' ' GLU . 67.6 mttm -141.86 150.98 42.29 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-O 120.863 0.364 . . . . 0.0 110.76 -179.798 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 216' ' ' TRP . . . . . 0.437 ' N ' ' CD1' ' B' ' 216' ' ' TRP . 37.4 m95 -84.91 117.54 23.98 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.174 179.875 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 217' ' ' THR . . . . . . . . . . . . . 26.7 m -125.85 137.49 53.76 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.531 -179.568 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 218' ' ' TRP . . . . . . . . . . . . . 25.0 t-105 -98.53 120.02 38.25 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.234 179.483 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 53.7 mtmt -141.69 165.79 26.51 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.72 -179.809 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -176.44 -160.97 24.59 Favored Glycine 0 CA--C 1.522 0.504 0 N-CA-C 111.185 -0.766 . . . . 0.0 111.185 -179.887 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 221' ' ' ILE . . . . . 0.555 ' O ' HG23 ' B' ' 222' ' ' ILE . 0.8 OUTLIER -53.43 -76.73 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.387 0 C-N-CA 120.682 -0.407 . . . . 0.0 110.987 -178.44 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' B' B ' 222' ' ' ILE . . . . . 0.555 HG23 ' O ' ' B' ' 221' ' ' ILE . 20.2 pt -160.72 -166.24 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 N-CA-C 109.994 -0.373 . . . . 0.0 109.994 -179.633 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 223' ' ' ARG . . . . . 0.675 ' N ' HD11 ' A' ' 75' ' ' ILE . 33.2 ptt85 -45.41 174.57 0.0 OUTLIER 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.805 178.362 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 224' ' ' LEU . . . . . 0.679 ' N ' HD22 ' B' ' 224' ' ' LEU . 3.0 mm? -59.44 123.46 16.89 Favored 'General case' 0 C--N 1.318 -0.791 0 CA-C-N 115.317 -0.856 . . . . 0.0 110.211 -179.244 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 79.7 tt0 . . . . . 0 C--N 1.33 -0.265 0 CA-C-N 115.387 -0.824 . . . . 0.0 110.167 -179.648 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 96.5 m-20 . . . . . 0 N--CA 1.464 0.259 0 CA-C-O 120.984 0.421 . . . . 0.0 110.438 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 6.6 tt -64.27 145.16 56.46 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.429 -179.676 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 86.8 p -140.3 153.01 46.33 Favored 'General case' 0 N--CA 1.463 0.212 0 CA-C-N 116.328 -0.397 . . . . 0.0 110.662 179.909 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . 0.533 ' N ' ' CD1' ' A' ' 14' ' ' PHE . 12.5 m-85 -111.17 146.74 36.35 Favored 'General case' 0 N--CA 1.465 0.301 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.379 -179.612 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 21.9 m -146.01 160.88 11.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.633 179.81 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 38.2 t0 55.46 31.53 17.15 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.66 179.636 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 96.5 mt -56.57 137.77 18.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 121.07 0.462 . . . . 0.0 110.148 179.962 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.461 ' CB ' ' O ' ' A' ' 21' ' ' SER . 0.3 OUTLIER -140.32 -167.01 2.23 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.817 -0.628 . . . . 0.0 110.651 -179.559 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' ASP . . . . . 0.525 ' OD1' ' N ' ' A' ' 19' ' ' ASP . 14.5 p-10 -91.6 -41.97 10.47 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 115.691 -0.686 . . . . 0.0 111.006 179.468 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 13.7 m -116.97 6.88 13.05 Favored 'General case' 0 N--CA 1.466 0.344 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.677 -179.584 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . 0.461 ' O ' ' CB ' ' A' ' 18' ' ' THR . 16.8 p -151.65 145.79 25.33 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 121.101 0.477 . . . . 0.0 110.443 179.968 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 44.2 pt -140.26 146.29 24.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.02 179.941 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -99.31 81.76 0.56 Allowed Glycine 0 CA--C 1.523 0.593 0 N-CA-C 111.419 -0.672 . . . . 0.0 111.419 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 84.0 mt -66.79 121.98 16.65 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.768 0.318 . . . . 0.0 110.296 -179.967 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 4.6 tmm_? -139.62 138.69 36.37 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.62 179.877 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' TRP . . . . . . . . . . . . . 42.0 p90 -143.0 158.28 43.75 Favored 'General case' 0 CA--C 1.517 -0.308 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.399 179.921 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 3.5 m -111.16 97.1 33.67 Favored Pre-proline 0 CA--C 1.534 0.337 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.393 179.854 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_exo -53.23 146.3 40.2 Favored 'Trans proline' 0 C--N 1.308 -1.581 0 C-N-CA 122.476 2.117 . . . . 0.0 112.23 179.879 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 52.3 mt -84.32 138.53 32.84 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 121.337 0.589 . . . . 0.0 111.039 -179.96 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 2.3 t-20 -49.08 -33.49 11.71 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.47 -0.786 . . . . 0.0 110.152 179.829 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 70.6 m -81.63 -34.17 31.02 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.593 179.667 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 9.1 m -58.24 134.92 56.96 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 121.103 0.478 . . . . 0.0 110.185 -179.881 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' THR . . . . . 0.526 ' H ' ' HB ' ' A' ' 81' ' ' ILE . 3.7 m -61.44 142.74 56.78 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.465 179.912 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 28.9 mm -94.37 92.69 3.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.969 0.414 . . . . 0.0 110.324 -179.896 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 15.2 pt -143.09 135.86 25.13 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.155 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.359 179.697 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -39.24 132.4 1.95 Allowed Glycine 0 CA--C 1.524 0.642 0 N-CA-C 111.171 -0.771 . . . . 0.0 111.171 -179.705 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 95.6 m-85 -103.03 138.98 39.17 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.844 0.354 . . . . 0.0 110.197 -179.771 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 5.3 tmm_? -99.1 124.64 44.27 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.629 -179.699 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.451 ' CG1' ' O ' ' A' ' 39' ' ' ILE . 2.1 pt -99.09 124.51 52.39 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 116.341 -0.391 . . . . 0.0 109.97 179.701 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 5.4 m -105.52 134.0 49.35 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.621 -179.822 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.1 p -132.39 141.52 45.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.308 179.541 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . 0.538 ' O ' ' N ' ' A' ' 74' ' ' ASP . 41.4 t -133.41 133.47 57.64 Favored 'Isoleucine or valine' 0 C--O 1.231 0.104 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.339 179.6 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.548 ' HB2' ' CE2' ' A' ' 73' ' ' TYR . . . -98.55 139.58 34.07 Favored 'General case' 0 C--N 1.328 -0.33 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 178.732 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . 0.513 ' HB3' ' O ' ' A' ' 72' ' ' ASP . . . -91.81 -43.91 9.26 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.284 -0.417 . . . . 0.0 111.027 179.815 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -63.49 -32.35 83.84 Favored Glycine 0 CA--C 1.524 0.614 0 N-CA-C 111.275 -0.73 . . . . 0.0 111.275 -179.477 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 38.4 mm-40 -97.92 126.53 43.36 Favored 'General case' 0 C--N 1.332 -0.19 0 N-CA-C 109.616 -0.512 . . . . 0.0 109.616 -179.582 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -59.17 -6.92 4.57 Favored Glycine 0 CA--C 1.511 -0.187 0 N-CA-C 110.918 -0.873 . . . . 0.0 110.918 -179.082 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -124.23 133.44 24.7 Favored Pre-proline 0 CA--C 1.537 0.477 0 C-N-CA 120.905 -0.318 . . . . 0.0 110.257 179.461 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 60.7 Cg_endo -76.71 164.22 30.52 Favored 'Trans proline' 0 C--N 1.307 -1.618 0 C-N-CA 122.59 2.193 . . . . 0.0 112.286 177.48 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 95.9 mt -85.22 145.38 8.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 115.771 -0.65 . . . . 0.0 110.268 179.023 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 79.7 m-85 -63.79 142.81 58.27 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.527 -179.886 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . 0.446 ' N ' ' CD ' ' A' ' 52' ' ' GLU . 0.1 OUTLIER -70.58 -178.01 1.68 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.582 179.776 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 53' ' ' ASP . . . . . 0.411 ' HB2' HD11 ' A' ' 39' ' ' ILE . 4.0 m-20 -146.51 138.25 24.68 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.884 179.499 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 89.3 m-85 -108.13 120.01 41.13 Favored 'General case' 0 N--CA 1.463 0.187 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.279 179.266 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 9.9 p -127.28 136.52 60.42 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.285 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.377 179.881 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 97.4 m-20 -56.89 142.99 39.26 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.463 -179.855 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 11.4 t -61.79 -35.15 77.34 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.716 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 37.7 m -55.44 -32.33 62.65 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.724 -179.718 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 98.6 t -63.76 -46.14 95.32 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.587 -179.889 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 59.36 27.09 62.65 Favored Glycine 0 CA--C 1.527 0.827 0 N-CA-C 110.859 -0.896 . . . . 0.0 110.859 -179.931 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 52.7 t80 -166.52 149.89 7.09 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 121.224 0.535 . . . . 0.0 110.945 -179.415 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 62' ' ' TYR . . . . . 0.412 ' CD2' ' CD1' ' A' ' 39' ' ' ILE . 25.7 t80 -158.81 159.26 34.92 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.971 -0.558 . . . . 0.0 110.141 179.003 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 85.3 m -125.28 136.28 53.36 Favored 'General case' 0 N--CA 1.464 0.233 0 CA-C-N 116.378 -0.373 . . . . 0.0 110.392 -179.714 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -131.87 105.93 10.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.185 179.37 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 3.2 p -114.1 156.23 24.56 Favored 'General case' 0 CA--C 1.516 -0.358 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.515 179.632 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 109.63 40.46 1.46 Allowed Glycine 0 CA--C 1.523 0.589 0 N-CA-C 111.245 -0.742 . . . . 0.0 111.245 -179.754 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 18.5 mt -113.69 102.34 10.16 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-O 121.126 0.488 . . . . 0.0 109.918 179.579 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 12.3 mm-40 -48.66 135.42 13.41 Favored Pre-proline 0 C--N 1.317 -0.805 0 CA-C-N 115.609 -0.723 . . . . 0.0 111.042 -178.558 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 69' ' ' PRO . . . . . 0.407 ' O ' HD12 ' A' ' 71' ' ' ILE . 70.9 Cg_endo -75.33 153.01 39.92 Favored 'Trans proline' 0 N--CA 1.496 1.673 0 C-N-CA 122.882 2.388 . . . . 0.0 111.61 178.8 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 72.43 12.04 76.72 Favored Glycine 0 CA--C 1.521 0.425 0 N-CA-C 111.186 -0.766 . . . . 0.0 111.186 179.479 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . 0.537 ' O ' ' NH1' ' B' ' 223' ' ' ARG . 1.7 mp -118.38 147.92 21.56 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.381 0 CA-C-O 121.251 0.548 . . . . 0.0 109.897 -179.878 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 72' ' ' ASP . . . . . 0.513 ' O ' ' HB3' ' A' ' 44' ' ' ALA . 3.1 t70 -86.51 112.39 21.49 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.257 -0.883 . . . . 0.0 110.752 179.947 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 73' ' ' TYR . . . . . 0.548 ' CE2' ' HB2' ' A' ' 43' ' ' ALA . 14.8 m-85 -106.25 119.58 39.62 Favored 'General case' 0 C--O 1.218 -0.601 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.027 179.494 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 74' ' ' ASP . . . . . 0.538 ' N ' ' O ' ' A' ' 42' ' ' VAL . 72.1 m-20 -88.29 117.53 27.27 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.741 -0.663 . . . . 0.0 109.576 179.442 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . 0.643 HD11 ' N ' ' B' ' 223' ' ' ARG . 0.0 OUTLIER -114.59 165.97 9.03 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-O 121.038 0.447 . . . . 0.0 110.344 -179.457 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -155.14 120.73 5.04 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.586 -0.734 . . . . 0.0 110.976 179.273 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.448 ' O ' HG23 ' B' ' 217' ' ' THR . 8.9 t -100.31 101.88 12.69 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 N-CA-C 109.835 -0.431 . . . . 0.0 109.835 179.22 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 95.7 mt -88.8 126.86 41.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.648 -179.756 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 96.6 m -108.36 111.31 23.17 Favored 'General case' 0 CA--C 1.517 -0.303 0 CA-C-O 121.011 0.434 . . . . 0.0 109.984 179.7 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 51.4 tp -120.73 125.04 46.63 Favored 'General case' 0 CA--C 1.519 -0.234 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.875 179.965 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 81' ' ' ILE . . . . . 0.526 ' HB ' ' H ' ' A' ' 33' ' ' THR . 2.0 pp -144.69 143.83 22.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.279 178.991 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 82' ' ' ASN . . . . . 0.459 ' N ' ' OG1' ' A' ' 33' ' ' THR . 62.8 t-20 . . . . . 0 C--N 1.328 -0.331 0 CA-C-N 116.334 -0.394 . . . . 0.0 111.204 -179.856 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 207' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.464 0.551 0 N-CA-C 111.241 -0.743 . . . . 0.0 111.241 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' B' B ' 208' ' ' SER . . . . . 0.5 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 33.2 p -164.49 172.26 13.55 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.726 0.298 . . . . 0.0 110.767 -179.676 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 209' ' ' TRP . . . . . . . . . . . . . 73.2 m95 -85.35 151.15 24.24 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.284 -0.417 . . . . 0.0 110.357 179.529 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 81.6 p -131.66 137.64 48.42 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.387 -0.37 . . . . 0.0 110.903 -179.964 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 47.4 t-105 -95.54 115.45 27.44 Favored 'General case' 0 C--N 1.331 -0.199 0 N-CA-C 109.87 -0.418 . . . . 0.0 109.87 179.402 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 212' ' ' GLU . . . . . 0.512 ' O ' ' O ' ' B' ' 215' ' ' LYS . 2.8 tt0 -161.33 150.7 16.54 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.578 179.59 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 213' ' ' ASN . . . . . 0.425 ' N ' ' HG3' ' B' ' 212' ' ' GLU . 13.2 m120 59.68 42.2 17.37 Favored 'General case' 0 N--CA 1.448 -0.53 0 CA-C-N 115.901 -0.591 . . . . 0.0 111.166 177.145 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 49.86 12.95 0.5 Allowed Glycine 0 CA--C 1.521 0.417 0 N-CA-C 111.63 -0.588 . . . . 0.0 111.63 179.161 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 215' ' ' LYS . . . . . 0.512 ' O ' ' O ' ' B' ' 212' ' ' GLU . 68.1 mttm -142.04 150.58 41.46 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.054 0.454 . . . . 0.0 110.457 -179.997 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 216' ' ' TRP . . . . . . . . . . . . . 45.7 m95 -86.13 122.31 29.97 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.42 -0.355 . . . . 0.0 110.119 -179.941 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 217' ' ' THR . . . . . 0.448 HG23 ' O ' ' A' ' 77' ' ' VAL . 18.8 m -129.19 141.51 51.14 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.934 0.397 . . . . 0.0 110.426 -179.677 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 218' ' ' TRP . . . . . 0.5 ' CH2' ' N ' ' B' ' 208' ' ' SER . 16.7 t-105 -105.43 118.02 35.5 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-N 115.888 -0.596 . . . . 0.0 109.742 179.477 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 24.0 mtmm -142.13 173.76 11.23 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.798 -179.882 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -176.39 -161.27 25.09 Favored Glycine 0 CA--C 1.523 0.57 0 N-CA-C 111.243 -0.743 . . . . 0.0 111.243 -179.698 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 221' ' ' ILE . . . . . 0.561 ' O ' HG23 ' B' ' 222' ' ' ILE . 30.5 mt -52.39 -73.39 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 C-N-CA 120.812 -0.355 . . . . 0.0 110.228 -178.534 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 222' ' ' ILE . . . . . 0.561 HG23 ' O ' ' B' ' 221' ' ' ILE . 20.5 pt -158.97 -165.89 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.208 0 CA-C-N 116.301 -0.408 . . . . 0.0 110.458 -179.932 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 223' ' ' ARG . . . . . 0.643 ' N ' HD11 ' A' ' 75' ' ' ILE . 30.7 ptt-85 -44.31 174.55 0.0 OUTLIER 'General case' 0 N--CA 1.456 -0.17 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.281 179.378 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 224' ' ' LEU . . . . . 0.787 ' N ' HD22 ' B' ' 224' ' ' LEU . 2.6 mm? -62.13 117.97 6.73 Favored 'General case' 0 C--N 1.316 -0.886 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.768 -179.516 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 81.7 tt0 . . . . . 0 C--N 1.329 -0.298 0 CA-C-N 115.612 -0.722 . . . . 0.0 110.642 -179.93 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 4.1 p30 . . . . . 0 CA--C 1.52 -0.2 0 CA-C-O 120.772 0.32 . . . . 0.0 110.494 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.622 HD23 ' H ' ' A' ' 13' ' ' SER . 0.5 OUTLIER -68.02 151.41 47.11 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.307 -179.784 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . 0.622 ' H ' HD23 ' A' ' 12' ' ' LEU . 61.6 p -143.25 149.39 37.83 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.608 179.568 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . 0.527 ' N ' ' CD1' ' A' ' 14' ' ' PHE . 17.4 m-85 -112.34 147.02 37.24 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.879 -0.6 . . . . 0.0 110.649 -179.599 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 23.3 m -147.54 156.61 9.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.398 179.43 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 38.2 t0 60.78 28.47 18.21 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.616 179.897 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 96.5 mt -55.88 132.39 19.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.062 179.799 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.437 HG22 ' H ' ' A' ' 19' ' ' ASP . 0.2 OUTLIER -131.12 -169.36 2.16 Favored 'General case' 0 N--CA 1.467 0.409 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.469 -179.839 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' ASP . . . . . 0.477 ' N ' ' OD1' ' A' ' 19' ' ' ASP . 17.5 p-10 -77.65 -49.26 14.9 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.963 179.513 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . 0.513 ' OG ' ' N ' ' A' ' 67' ' ' LEU . 31.1 t -120.46 13.39 11.79 Favored 'General case' 0 N--CA 1.466 0.358 0 CA-C-N 116.511 -0.313 . . . . 0.0 110.704 -179.252 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . 0.529 ' HB3' HG22 ' A' ' 65' ' ' THR . 3.8 m -146.56 129.8 16.62 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.237 -179.307 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . 0.516 HD12 HD21 ' A' ' 24' ' ' LEU . 47.7 pt -125.78 142.25 43.09 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-N 116.288 -0.415 . . . . 0.0 109.979 179.756 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -98.28 83.08 0.65 Allowed Glycine 0 CA--C 1.523 0.593 0 N-CA-C 110.507 -1.037 . . . . 0.0 110.507 -179.345 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.516 HD21 HD12 ' A' ' 22' ' ' ILE . 92.0 mt -65.57 128.09 34.52 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 110.013 -0.365 . . . . 0.0 110.013 -179.634 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . 0.44 ' O ' ' O ' ' A' ' 13' ' ' SER . 1.2 tpp180 -147.75 134.86 20.4 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.045 179.832 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' TRP . . . . . 0.554 ' CE3' ' O ' ' A' ' 60' ' ' GLY . 4.9 p90 -140.29 128.45 22.32 Favored 'General case' 0 C--O 1.223 -0.299 0 N-CA-C 109.223 -0.658 . . . . 0.0 109.223 177.73 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 1.9 m -68.34 113.27 14.32 Favored Pre-proline 0 CA--C 1.538 0.49 0 C-N-CA 120.528 -0.469 . . . . 0.0 111.011 -179.633 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 32.7 Cg_exo -59.53 152.39 62.28 Favored 'Trans proline' 0 N--CA 1.498 1.744 0 C-N-CA 121.993 1.795 . . . . 0.0 112.599 178.473 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.433 ' H ' ' HB2' ' A' ' 32' ' ' SER . 77.9 mt -102.16 133.43 47.03 Favored 'General case' 0 CA--C 1.518 -0.254 0 CA-C-O 121.682 0.754 . . . . 0.0 110.651 179.728 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 11.7 t-20 -42.79 -30.54 0.4 Allowed 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 115.352 -0.84 . . . . 0.0 110.47 -179.725 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 58.1 m -87.88 -36.64 17.07 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.483 179.087 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . 0.433 ' HB2' ' H ' ' A' ' 29' ' ' LEU . 3.1 m -45.73 113.54 0.62 Allowed 'General case' 0 N--CA 1.461 0.115 0 CA-C-O 121.091 0.472 . . . . 0.0 110.306 -179.661 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' THR . . . . . 0.519 ' OG1' ' N ' ' A' ' 82' ' ' ASN . 7.2 m -52.24 150.01 4.97 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.601 -0.727 . . . . 0.0 109.448 -179.251 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 19.6 mm -93.92 92.65 3.66 Favored 'Isoleucine or valine' 0 C--O 1.232 0.135 0 CA-C-O 121.11 0.481 . . . . 0.0 110.995 -178.51 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.6 HD11 ' HA ' ' A' ' 81' ' ' ILE . 6.6 pt -151.23 124.84 1.34 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.252 179.288 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -48.25 131.4 19.84 Favored Glycine 0 CA--C 1.519 0.336 0 N-CA-C 110.786 -0.925 . . . . 0.0 110.786 -179.624 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' TYR . . . . . 0.571 ' CD1' ' O ' ' A' ' 37' ' ' TYR . 0.6 OUTLIER -104.13 130.07 51.85 Favored 'General case' 0 C--N 1.329 -0.322 0 N-CA-C 109.691 -0.485 . . . . 0.0 109.691 -179.895 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' ARG . . . . . 0.516 ' NH1' ' OG1' ' A' ' 40' ' ' THR . 7.9 tmm_? -79.59 132.27 36.23 Favored 'General case' 0 C--N 1.325 -0.472 0 C-N-CA 120.743 -0.383 . . . . 0.0 111.003 -179.895 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.559 HG22 ' CE2' ' A' ' 37' ' ' TYR . 1.9 pt -104.51 122.58 57.65 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.329 0 N-CA-C 109.585 -0.524 . . . . 0.0 109.585 179.179 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . 0.516 ' OG1' ' NH1' ' A' ' 38' ' ' ARG . 7.1 m -99.44 136.52 39.26 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.425 -179.022 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.4 p -133.31 141.55 44.25 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.288 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.133 179.855 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . 0.499 ' O ' ' N ' ' A' ' 74' ' ' ASP . 39.9 t -132.59 132.48 59.96 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.24 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 179.607 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.438 ' HB2' ' CE2' ' A' ' 73' ' ' TYR . . . -99.35 136.62 39.03 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 116.09 -0.504 . . . . 0.0 109.651 178.921 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . 0.632 ' HB3' ' O ' ' A' ' 72' ' ' ASP . . . -99.02 -15.43 19.07 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-O 120.806 0.336 . . . . 0.0 110.85 -179.801 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -99.62 24.99 30.0 Favored Glycine 0 CA--C 1.525 0.7 0 N-CA-C 111.093 -0.803 . . . . 0.0 111.093 -179.44 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 93.5 mt-10 -145.95 149.37 34.05 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.97 0.414 . . . . 0.0 110.337 179.936 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -66.59 -21.06 70.54 Favored Glycine 0 CA--C 1.519 0.302 0 N-CA-C 110.67 -0.972 . . . . 0.0 110.67 179.896 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -132.23 139.58 35.35 Favored Pre-proline 0 CA--C 1.539 0.527 0 C-N-CA 121.224 -0.19 . . . . 0.0 110.524 179.873 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 61.3 Cg_endo -73.93 161.87 40.4 Favored 'Trans proline' 0 N--CA 1.49 1.281 0 C-N-CA 122.469 2.113 . . . . 0.0 111.96 177.613 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 96.8 mt -77.48 149.96 5.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.461 179.354 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 76.1 m-85 -72.47 141.59 48.59 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.678 179.78 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . 0.414 ' N ' ' CD ' ' A' ' 52' ' ' GLU . 0.2 OUTLIER -61.77 -177.07 0.1 Allowed 'General case' 0 CA--C 1.517 -0.321 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.418 179.275 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -144.33 135.29 25.16 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 115.637 -0.71 . . . . 0.0 110.301 179.706 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 86.7 m-85 -108.46 116.55 32.19 Favored 'General case' 0 N--CA 1.465 0.287 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.374 179.697 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 9.2 p -130.35 143.77 39.99 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.291 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.145 179.77 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 95.5 m-20 -66.79 151.16 48.02 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.595 179.626 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 4.4 t -64.99 -32.04 73.58 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.628 179.86 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 50.4 m -52.57 -38.58 60.23 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.485 -179.703 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.467 HG12 ' O ' ' A' ' 61' ' ' TYR . 23.8 t -60.66 -43.03 94.0 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 -179.942 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . 0.554 ' O ' ' CE3' ' A' ' 26' ' ' TRP . . . 75.19 -40.91 1.27 Allowed Glycine 0 CA--C 1.529 0.919 0 N-CA-C 110.846 -0.902 . . . . 0.0 110.846 179.651 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 61' ' ' TYR . . . . . 0.467 ' O ' HG12 ' A' ' 59' ' ' VAL . 26.9 p90 -113.46 158.64 20.43 Favored 'General case' 0 N--CA 1.469 0.495 0 CA-C-O 121.048 0.451 . . . . 0.0 111.245 -178.881 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 62' ' ' TYR . . . . . 0.411 ' CD2' ' CD1' ' A' ' 39' ' ' ILE . 33.3 t80 -152.93 149.5 28.29 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 179.541 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 79.8 m -112.4 133.93 54.22 Favored 'General case' 0 CA--C 1.52 -0.195 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.468 -179.445 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -132.36 100.09 3.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 115.854 -0.612 . . . . 0.0 109.834 178.762 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.529 HG22 ' HB3' ' A' ' 21' ' ' SER . 2.0 p -114.37 164.18 14.29 Favored 'General case' 0 CA--C 1.515 -0.38 0 CA-C-O 120.908 0.385 . . . . 0.0 110.524 -179.942 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 107.79 25.63 5.87 Favored Glycine 0 CA--C 1.524 0.622 0 N-CA-C 111.172 -0.771 . . . . 0.0 111.172 179.75 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.513 ' N ' ' OG ' ' A' ' 20' ' ' SER . 11.9 mt -100.72 109.44 21.47 Favored 'General case' 0 N--CA 1.465 0.318 0 N-CA-C 109.284 -0.636 . . . . 0.0 109.284 179.944 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 55.5 mm-40 -52.04 139.53 33.57 Favored Pre-proline 0 C--N 1.316 -0.887 0 C-N-CA 120.496 -0.482 . . . . 0.0 112.054 -178.589 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 69' ' ' PRO . . . . . 0.428 ' C ' ' H ' ' A' ' 71' ' ' ILE . 74.4 Cg_endo -73.91 157.52 47.24 Favored 'Trans proline' 0 N--CA 1.498 1.748 0 C-N-CA 122.86 2.373 . . . . 0.0 111.253 178.574 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 69.97 -8.54 3.49 Favored Glycine 0 CA--C 1.527 0.822 0 CA-C-N 115.844 -0.616 . . . . 0.0 111.653 178.855 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . 0.524 ' O ' ' NH1' ' B' ' 223' ' ' ARG . 1.6 mp -98.76 149.19 5.53 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 N-CA-C 109.229 -0.656 . . . . 0.0 109.229 -179.702 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 72' ' ' ASP . . . . . 0.632 ' O ' ' HB3' ' A' ' 44' ' ' ALA . 2.7 t70 -89.51 115.61 27.06 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.165 -0.925 . . . . 0.0 110.422 179.657 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 73' ' ' TYR . . . . . 0.493 ' O ' HD13 ' A' ' 75' ' ' ILE . 20.9 m-85 -108.48 119.74 40.38 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.425 179.951 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 74' ' ' ASP . . . . . 0.499 ' N ' ' O ' ' A' ' 42' ' ' VAL . 13.4 m-20 -89.8 118.13 29.16 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 115.548 -0.751 . . . . 0.0 109.646 179.824 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . 0.493 HD13 ' O ' ' A' ' 73' ' ' TYR . 0.0 OUTLIER -115.9 164.24 12.42 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-O 121.192 0.52 . . . . 0.0 109.919 -179.139 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -152.92 128.88 10.3 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.659 -0.7 . . . . 0.0 110.216 179.667 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 62.8 t -108.27 131.79 57.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 179.461 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 96.5 mt -124.51 124.45 68.32 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 115.991 -0.549 . . . . 0.0 110.344 179.458 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 95.1 m -100.86 114.41 28.23 Favored 'General case' 0 C--O 1.232 0.181 0 CA-C-O 120.922 0.391 . . . . 0.0 110.081 179.636 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . 0.754 HD23 ' HZ1' ' B' ' 215' ' ' LYS . 9.6 mt -118.68 113.96 22.0 Favored 'General case' 0 CA--C 1.518 -0.251 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.253 -179.988 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 81' ' ' ILE . . . . . 0.6 ' HA ' HD11 ' A' ' 35' ' ' ILE . 2.3 pp -147.47 144.84 19.4 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.042 179.146 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 82' ' ' ASN . . . . . 0.519 ' N ' ' OG1' ' A' ' 33' ' ' THR . 39.9 t30 . . . . . 0 C--N 1.327 -0.391 0 CA-C-O 120.942 0.401 . . . . 0.0 111.189 179.892 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 207' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.463 0.486 0 N-CA-C 110.957 -0.857 . . . . 0.0 110.957 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' B' B ' 208' ' ' SER . . . . . 0.536 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 98.9 p -164.52 168.35 18.41 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.862 0.363 . . . . 0.0 110.711 179.238 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 209' ' ' TRP . . . . . . . . . . . . . 85.4 m95 -88.89 150.95 22.63 Favored 'General case' 0 C--O 1.233 0.205 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.522 179.54 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 82.3 p -129.09 129.0 44.67 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-N 116.487 -0.324 . . . . 0.0 110.394 179.532 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 58.7 t-105 -91.41 110.62 21.93 Favored 'General case' 0 C--N 1.333 -0.112 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.586 179.82 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 212' ' ' GLU . . . . . 0.437 ' O ' ' O ' ' B' ' 215' ' ' LYS . 0.6 OUTLIER -161.26 165.93 28.45 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.541 179.654 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' B' B ' 213' ' ' ASN . . . . . . . . . . . . . 69.7 m-20 51.02 35.25 12.33 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.89 -0.595 . . . . 0.0 110.978 176.436 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 51.17 19.97 4.35 Favored Glycine 0 CA--C 1.525 0.661 0 N-CA-C 110.954 -0.858 . . . . 0.0 110.954 179.946 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 215' ' ' LYS . . . . . 0.754 ' HZ1' HD23 ' A' ' 80' ' ' LEU . 14.9 mtpt -145.79 150.58 36.46 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 121.066 0.46 . . . . 0.0 110.985 179.983 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 216' ' ' TRP . . . . . . . . . . . . . 52.4 m95 -87.19 114.43 23.79 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.866 -0.606 . . . . 0.0 109.883 179.233 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 217' ' ' THR . . . . . . . . . . . . . 46.4 m -118.36 135.07 54.54 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.694 -179.587 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 218' ' ' TRP . . . . . 0.536 ' CH2' ' N ' ' B' ' 208' ' ' SER . 29.5 t-105 -106.39 104.0 13.59 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 115.907 -0.588 . . . . 0.0 109.876 178.868 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 16.7 mtpp -134.38 173.8 11.23 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.558 -179.303 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -179.53 -160.94 26.05 Favored Glycine 0 CA--C 1.524 0.599 0 N-CA-C 110.761 -0.936 . . . . 0.0 110.761 179.819 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 221' ' ' ILE . . . . . 0.688 ' H ' HD12 ' B' ' 221' ' ' ILE . 1.9 mp -54.1 -73.14 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 C-N-CA 120.66 -0.416 . . . . 0.0 110.261 -178.804 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 222' ' ' ILE . . . . . 0.553 HG23 ' O ' ' B' ' 221' ' ' ILE . 21.8 pt -160.51 -165.28 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.212 -179.799 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 223' ' ' ARG . . . . . 0.536 ' O ' ' O ' ' B' ' 222' ' ' ILE . 35.9 ptt-85 -40.28 174.03 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.973 178.605 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 224' ' ' LEU . . . . . 0.789 ' N ' HD22 ' B' ' 224' ' ' LEU . 2.2 mm? -63.45 110.16 1.86 Allowed 'General case' 0 N--CA 1.447 -0.613 0 CA-C-N 115.799 -0.637 . . . . 0.0 111.079 -179.673 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 33.8 tp10 . . . . . 0 C--N 1.329 -0.325 0 CA-C-N 115.394 -0.821 . . . . 0.0 110.002 -179.865 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 97.7 m-20 . . . . . 0 N--CA 1.463 0.201 0 CA-C-O 120.717 0.294 . . . . 0.0 110.254 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 56.5 tp -66.27 138.35 57.59 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.562 -179.969 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 16.1 p -139.6 152.93 47.22 Favored 'General case' 0 N--CA 1.463 0.192 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.384 179.555 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . 0.516 ' N ' ' CD1' ' A' ' 14' ' ' PHE . 27.7 m-85 -111.54 144.12 41.29 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.837 -179.407 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 27.6 m -143.49 164.29 15.52 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.415 179.527 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 98.8 m-20 50.37 30.46 4.55 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.95 179.79 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 96.7 mt -55.78 138.51 16.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-O 120.921 0.391 . . . . 0.0 110.202 179.507 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.464 ' CB ' ' O ' ' A' ' 21' ' ' SER . 0.2 OUTLIER -135.7 -166.75 1.91 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.034 -179.48 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' ASP . . . . . 0.469 ' N ' ' OD1' ' A' ' 19' ' ' ASP . 27.8 p-10 -84.94 -46.58 11.11 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.831 179.489 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . 0.464 ' N ' ' OD1' ' A' ' 19' ' ' ASP . 43.0 m -120.74 12.56 11.41 Favored 'General case' 0 N--CA 1.467 0.389 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.852 179.99 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . 0.464 ' O ' ' CB ' ' A' ' 18' ' ' THR . 85.9 p -150.26 143.55 25.01 Favored 'General case' 0 N--CA 1.465 0.283 0 CA-C-O 121.037 0.446 . . . . 0.0 110.335 -179.943 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 40.7 pt -140.46 145.0 26.47 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.361 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.217 -179.992 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -96.31 85.85 0.89 Allowed Glycine 0 CA--C 1.522 0.497 0 N-CA-C 110.882 -0.887 . . . . 0.0 110.882 -179.906 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 89.9 mt -62.3 121.02 12.12 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 120.905 0.383 . . . . 0.0 110.05 -179.782 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . 0.503 ' NH1' ' O ' ' A' ' 26' ' ' TRP . 28.0 tpt85 -138.03 135.25 35.71 Favored 'General case' 0 CA--C 1.517 -0.301 0 CA-C-O 121.115 0.483 . . . . 0.0 110.199 -179.468 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' TRP . . . . . 0.503 ' O ' ' NH1' ' A' ' 25' ' ' ARG . 46.1 p90 -147.52 155.45 41.88 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.555 -0.748 . . . . 0.0 109.604 179.851 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 6.2 m -111.34 98.12 38.62 Favored Pre-proline 0 C--N 1.33 -0.249 0 N-CA-C 110.102 -0.332 . . . . 0.0 110.102 179.66 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 32.5 Cg_exo -54.53 144.81 61.31 Favored 'Trans proline' 0 C--N 1.306 -1.692 0 C-N-CA 121.604 1.536 . . . . 0.0 113.275 179.909 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 57.1 mt -79.01 138.16 37.9 Favored 'General case' 0 CA--C 1.506 -0.743 0 CA-C-N 115.49 -0.777 . . . . 0.0 110.627 -179.567 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 34.1 t30 -50.45 -34.21 23.93 Favored 'General case' 0 C--N 1.313 -1.021 0 CA-C-N 114.856 -1.066 . . . . 0.0 110.098 179.523 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 49.2 m -79.82 -32.58 40.7 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.629 -0.714 . . . . 0.0 110.412 179.118 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 8.0 m -60.0 137.7 58.02 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.197 -179.932 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' THR . . . . . 0.611 ' CB ' ' H ' ' A' ' 82' ' ' ASN . 11.7 m -67.41 143.1 56.47 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.22 -179.645 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 28.8 mm -94.05 94.04 4.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 121.0 0.429 . . . . 0.0 110.176 -179.564 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 10.7 pt -143.49 131.4 18.67 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.274 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.416 -179.973 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -41.84 118.23 1.46 Allowed Glycine 0 CA--C 1.519 0.328 0 N-CA-C 111.318 -0.713 . . . . 0.0 111.318 -179.599 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 94.6 m-85 -85.09 178.88 7.39 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.875 0.369 . . . . 0.0 110.11 179.376 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' ARG . . . . . 0.549 ' NE ' ' OE1' ' A' ' 52' ' ' GLU . 0.0 OUTLIER -132.48 125.99 31.95 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.727 179.92 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.46 ' CD1' ' CD2' ' A' ' 62' ' ' TYR . 2.5 pt -100.24 123.81 53.35 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 115.657 -0.701 . . . . 0.0 110.018 179.78 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . 0.449 ' OG1' ' NE ' ' A' ' 38' ' ' ARG . 28.2 m -109.04 133.09 53.46 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.612 -179.07 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.2 p -130.51 138.44 53.74 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.305 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.288 179.844 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . 0.467 ' O ' ' N ' ' A' ' 74' ' ' ASP . 31.7 t -131.94 130.95 61.69 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.269 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 179.979 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.455 ' HB1' ' CE1' ' A' ' 73' ' ' TYR . . . -96.44 135.87 37.73 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.765 -0.652 . . . . 0.0 109.32 179.677 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . 0.607 ' HB3' ' O ' ' A' ' 72' ' ' ASP . . . -92.57 -47.24 7.22 Favored 'General case' 0 N--CA 1.464 0.24 0 C-N-CA 120.673 -0.411 . . . . 0.0 110.839 179.93 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -62.09 -29.55 73.09 Favored Glycine 0 N--CA 1.464 0.559 0 N-CA-C 110.891 -0.883 . . . . 0.0 110.891 179.997 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . 0.429 ' OE2' ' OH ' ' A' ' 73' ' ' TYR . 84.8 mt-10 -95.57 130.44 42.43 Favored 'General case' 0 C--N 1.328 -0.369 0 N-CA-C 109.477 -0.564 . . . . 0.0 109.477 -179.552 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -58.18 -21.17 45.98 Favored Glycine 0 CA--C 1.528 0.869 0 N-CA-C 110.857 -0.897 . . . . 0.0 110.857 -178.941 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -119.25 136.32 24.42 Favored Pre-proline 0 N--CA 1.472 0.661 0 CA-C-N 116.715 0.258 . . . . 0.0 110.543 179.676 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -77.9 167.5 23.63 Favored 'Trans proline' 0 N--CA 1.49 1.295 0 C-N-CA 122.409 2.072 . . . . 0.0 111.428 178.079 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 87.2 mt -86.22 141.66 14.14 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.235 0 CA-C-O 120.826 0.346 . . . . 0.0 110.245 179.081 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 76.3 m-85 -60.85 138.95 58.09 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.633 179.986 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . 0.549 ' OE1' ' NE ' ' A' ' 38' ' ' ARG . 5.9 pt-20 -69.64 -178.62 1.51 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.455 179.798 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 4.5 t70 -153.38 148.7 27.02 Favored 'General case' 0 N--CA 1.45 -0.444 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.748 179.367 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 58.0 m-85 -115.93 125.28 52.36 Favored 'General case' 0 N--CA 1.464 0.257 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.139 -179.929 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.9 p -125.64 134.49 66.56 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.341 0 CA-C-N 116.471 -0.331 . . . . 0.0 110.208 -179.985 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 98.9 m-20 -53.41 140.15 28.46 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.322 -179.653 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 10.4 t -60.4 -34.16 73.54 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.002 -0.544 . . . . 0.0 110.573 -179.763 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 43.7 m -55.24 -34.34 63.91 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.547 -179.731 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 99.9 t -62.31 -46.51 96.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.579 -179.871 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 61.25 26.38 65.98 Favored Glycine 0 CA--C 1.527 0.796 0 N-CA-C 110.568 -1.013 . . . . 0.0 110.568 179.635 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 52.6 t80 -167.44 152.03 6.89 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 121.121 0.486 . . . . 0.0 111.091 -179.513 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 62' ' ' TYR . . . . . 0.46 ' CD2' ' CD1' ' A' ' 39' ' ' ILE . 29.1 t80 -159.64 162.05 35.11 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 115.724 -0.671 . . . . 0.0 110.281 178.702 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 99.0 m -127.44 134.68 49.84 Favored 'General case' 0 N--CA 1.463 0.217 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.296 179.835 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -130.76 113.83 25.9 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.334 0 N-CA-C 109.513 -0.551 . . . . 0.0 109.513 178.877 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 1.9 p -122.93 157.33 32.84 Favored 'General case' 0 N--CA 1.467 0.418 0 CA-C-O 120.907 0.384 . . . . 0.0 110.413 -179.66 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 107.59 40.62 1.72 Allowed Glycine 0 CA--C 1.523 0.581 0 N-CA-C 110.628 -0.989 . . . . 0.0 110.628 -179.729 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 1.4 mt -116.79 110.83 18.9 Favored 'General case' 0 N--CA 1.465 0.304 0 N-CA-C 109.502 -0.555 . . . . 0.0 109.502 -179.896 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 27.6 mm-40 -48.84 141.34 10.27 Favored Pre-proline 0 C--N 1.322 -0.628 0 C-N-CA 120.862 -0.335 . . . . 0.0 111.249 -178.486 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 91.4 Cg_endo -74.89 158.37 42.66 Favored 'Trans proline' 0 N--CA 1.491 1.341 0 C-N-CA 122.481 2.121 . . . . 0.0 112.558 179.511 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 70' ' ' GLY . . . . . 0.409 ' N ' ' NH2' ' B' ' 223' ' ' ARG . . . 48.53 27.55 6.01 Favored Glycine 0 CA--C 1.529 0.951 0 CA-C-N 114.837 -1.074 . . . . 0.0 111.182 179.305 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . 0.736 ' H ' HH21 ' B' ' 223' ' ' ARG . 0.9 OUTLIER -114.0 166.36 7.93 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.483 0 CA-C-O 121.13 0.491 . . . . 0.0 109.698 -179.578 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 72' ' ' ASP . . . . . 0.607 ' O ' ' HB3' ' A' ' 44' ' ' ALA . 3.2 t70 -101.17 100.27 10.8 Favored 'General case' 0 N--CA 1.446 -0.649 0 CA-C-N 115.6 -0.727 . . . . 0.0 111.411 -178.715 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 73' ' ' TYR . . . . . 0.503 ' O ' HD13 ' A' ' 75' ' ' ILE . 2.2 m-30 -110.81 124.69 52.51 Favored 'General case' 0 C--O 1.22 -0.472 0 CA-C-O 121.322 0.582 . . . . 0.0 110.341 179.16 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 74' ' ' ASP . . . . . 0.467 ' N ' ' O ' ' A' ' 42' ' ' VAL . 21.5 m-20 -89.11 116.11 27.13 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 114.894 -1.048 . . . . 0.0 109.485 -179.909 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . 0.578 HD11 ' N ' ' B' ' 223' ' ' ARG . 0.0 OUTLIER -116.17 162.1 14.43 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.221 0 CA-C-O 121.219 0.533 . . . . 0.0 110.084 -179.383 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 3.0 m -154.04 150.69 28.51 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.259 -0.882 . . . . 0.0 110.755 179.502 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.511 HG13 ' O ' ' A' ' 77' ' ' VAL . 4.1 p -132.9 101.14 4.2 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.245 0 CA-C-N 115.824 -0.625 . . . . 0.0 109.398 178.421 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 94.6 mt -82.95 127.81 39.32 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.183 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.451 -179.522 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 5.0 p -108.21 105.89 15.82 Favored 'General case' 0 N--CA 1.464 0.251 0 CA-C-N 116.143 -0.481 . . . . 0.0 109.709 179.422 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 7.0 tp -121.68 130.59 53.57 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.353 -179.867 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 81' ' ' ILE . . . . . 0.581 ' O ' HD12 ' A' ' 81' ' ' ILE . 1.6 pp -131.3 168.37 24.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.098 -0.501 . . . . 0.0 109.908 179.136 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 82' ' ' ASN . . . . . 0.611 ' H ' ' CB ' ' A' ' 33' ' ' THR . 9.8 t-20 . . . . . 0 C--N 1.33 -0.263 0 CA-C-O 120.813 0.34 . . . . 0.0 110.634 -179.992 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 207' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.464 0.536 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' B' B ' 208' ' ' SER . . . . . 0.497 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 97.1 p -164.14 170.03 16.96 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.81 0.338 . . . . 0.0 110.741 179.636 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 209' ' ' TRP . . . . . . . . . . . . . 71.9 m95 -82.93 145.59 29.3 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.412 179.529 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 40.3 p -127.33 131.29 50.45 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.565 179.942 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 41.4 t-105 -91.68 118.58 30.78 Favored 'General case' 0 N--CA 1.466 0.366 0 CA-C-N 116.18 -0.463 . . . . 0.0 109.928 179.596 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 212' ' ' GLU . . . . . 0.487 ' O ' ' O ' ' B' ' 215' ' ' LYS . 1.9 pt-20 -165.75 171.61 12.71 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.898 178.893 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 213' ' ' ASN . . . . . . . . . . . . . 93.9 m-20 48.07 38.08 8.99 Favored 'General case' 0 C--N 1.324 -0.537 0 C-N-CA 120.338 -0.545 . . . . 0.0 111.997 176.629 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 51.34 12.46 0.91 Allowed Glycine 0 CA--C 1.53 0.974 0 N-CA-C 111.536 -0.626 . . . . 0.0 111.536 179.644 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 215' ' ' LYS . . . . . 0.487 ' O ' ' O ' ' B' ' 212' ' ' GLU . 7.5 mtmp? -143.95 151.37 39.68 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.849 0.357 . . . . 0.0 110.962 -179.778 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 216' ' ' TRP . . . . . . . . . . . . . 49.0 m95 -87.0 124.93 33.72 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.25 179.285 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 217' ' ' THR . . . . . . . . . . . . . 5.0 m -138.63 148.1 43.69 Favored 'General case' 0 C--O 1.235 0.293 0 CA-C-O 121.052 0.453 . . . . 0.0 110.341 -179.809 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 218' ' ' TRP . . . . . 0.497 ' CH2' ' N ' ' B' ' 208' ' ' SER . 15.5 t-105 -105.25 121.66 44.32 Favored 'General case' 0 C--N 1.332 -0.167 0 CA-C-N 115.894 -0.593 . . . . 0.0 110.156 179.797 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 97.5 mttt -147.17 169.56 19.07 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.899 -179.996 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -174.83 -162.22 25.94 Favored Glycine 0 CA--C 1.522 0.496 0 N-CA-C 111.155 -0.778 . . . . 0.0 111.155 -179.884 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 221' ' ' ILE . . . . . 0.837 HG23 ' H ' ' B' ' 222' ' ' ILE . 12.2 tt -50.35 -69.71 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 C-N-CA 121.073 -0.251 . . . . 0.0 110.971 -177.977 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 222' ' ' ILE . . . . . 0.837 ' H ' HG23 ' B' ' 221' ' ' ILE . 9.6 pt -159.55 -165.2 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.317 -0.83 0 N-CA-C 109.327 -0.62 . . . . 0.0 109.327 178.377 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 223' ' ' ARG . . . . . 0.736 HH21 ' H ' ' A' ' 71' ' ' ILE . 39.1 ptt85 -44.47 174.98 0.0 OUTLIER 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 121.445 0.641 . . . . 0.0 111.04 178.717 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 224' ' ' LEU . . . . . 0.686 ' N ' HD22 ' B' ' 224' ' ' LEU . 3.2 mm? -59.95 127.48 32.1 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-N 115.046 -0.979 . . . . 0.0 110.377 -179.737 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 31.0 tp10 . . . . . 0 C--N 1.327 -0.41 0 CA-C-N 115.738 -0.665 . . . . 0.0 110.155 -179.959 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 99.4 m-20 . . . . . 0 C--O 1.233 0.185 0 CA-C-O 120.691 0.282 . . . . 0.0 110.385 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.551 HD13 ' H ' ' A' ' 13' ' ' SER . 0.1 OUTLIER -60.85 139.0 58.09 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.152 -178.16 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . 0.551 ' H ' HD13 ' A' ' 12' ' ' LEU . 96.3 p -143.27 144.55 32.17 Favored 'General case' 0 CA--C 1.521 -0.168 0 CA-C-N 115.837 -0.62 . . . . 0.0 110.621 179.931 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . 0.512 ' N ' ' CD1' ' A' ' 14' ' ' PHE . 11.5 m-85 -112.34 143.77 42.89 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.397 -0.82 . . . . 0.0 110.754 -179.22 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 30.1 m -141.27 164.28 20.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.346 179.712 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 27.7 t70 53.63 34.22 18.24 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.08 179.849 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.49 HD12 ' N ' ' A' ' 17' ' ' ILE . 1.9 mp -56.51 132.06 20.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 N-CA-C 109.57 -0.53 . . . . 0.0 109.57 179.936 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -132.8 -169.13 2.19 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-N 116.021 -0.536 . . . . 0.0 109.916 179.711 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 20.7 p-10 -91.24 -41.84 10.74 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.698 179.388 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 43.1 t -113.52 6.44 17.07 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-N 116.363 -0.38 . . . . 0.0 110.99 -179.304 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . 0.432 ' OG ' HG22 ' A' ' 65' ' ' THR . 38.3 t -154.1 152.61 30.64 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 121.131 0.491 . . . . 0.0 110.202 179.971 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 38.2 pt -142.2 146.26 22.76 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.049 179.816 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -94.75 82.82 0.92 Allowed Glycine 0 CA--C 1.524 0.652 0 N-CA-C 111.076 -0.81 . . . . 0.0 111.076 -179.723 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 76.1 mt -71.14 118.33 13.8 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 121.043 0.449 . . . . 0.0 110.211 179.901 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 56.4 ttt-85 -140.83 137.03 32.98 Favored 'General case' 0 CA--C 1.517 -0.318 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.436 179.935 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' TRP . . . . . . . . . . . . . 41.3 p90 -144.5 156.56 44.23 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.624 -0.716 . . . . 0.0 110.278 -179.36 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 2.2 m -108.05 102.31 45.35 Favored Pre-proline 0 CA--C 1.533 0.302 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.676 -179.953 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 41.7 Cg_exo -53.8 150.04 30.99 Favored 'Trans proline' 0 C--N 1.305 -1.761 0 C-N-CA 121.464 1.443 . . . . 0.0 112.673 179.274 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 60.9 mt -92.3 137.9 31.97 Favored 'General case' 0 CA--C 1.514 -0.425 0 CA-C-O 121.811 0.815 . . . . 0.0 110.809 -179.764 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 28.8 t-20 -47.56 -35.44 9.05 Favored 'General case' 0 C--N 1.313 -1.007 0 CA-C-N 115.056 -0.974 . . . . 0.0 110.092 179.952 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 53.0 m -79.8 -33.72 40.24 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.438 178.847 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 6.0 m -58.36 124.27 18.94 Favored 'General case' 0 CA--C 1.529 0.146 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.055 -179.86 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' THR . . . . . 0.587 ' CB ' ' H ' ' A' ' 82' ' ' ASN . 5.6 m -57.22 146.57 27.85 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.102 -179.762 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 20.5 mm -94.37 91.37 3.08 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.173 0 CA-C-O 121.047 0.451 . . . . 0.0 110.765 -179.377 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.486 HD11 ' HA ' ' A' ' 81' ' ' ILE . 22.1 pt -145.21 128.76 11.51 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.244 0 CA-C-N 115.714 -0.675 . . . . 0.0 110.597 179.815 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -42.65 125.84 4.44 Favored Glycine 0 CA--C 1.523 0.572 0 N-CA-C 111.086 -0.805 . . . . 0.0 111.086 -179.512 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 35.9 m-85 -90.83 -179.9 5.62 Favored 'General case' 0 CA--C 1.517 -0.29 0 N-CA-C 110.024 -0.362 . . . . 0.0 110.024 -179.88 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -131.45 121.34 24.37 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.553 179.753 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.439 ' CG1' ' O ' ' A' ' 39' ' ' ILE . 2.3 pt -95.95 124.29 48.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.008 -0.542 . . . . 0.0 109.716 179.828 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 4.8 m -106.74 132.77 52.33 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.398 -179.361 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.4 p -130.07 137.75 55.69 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.319 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.287 -179.979 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . 0.524 ' O ' ' N ' ' A' ' 74' ' ' ASP . 40.1 t -131.02 131.65 63.95 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.298 0 N-CA-C 109.743 -0.465 . . . . 0.0 109.743 179.671 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -97.92 141.26 31.11 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.137 -0.483 . . . . 0.0 109.817 179.273 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . 0.565 ' HB3' ' O ' ' A' ' 72' ' ' ASP . . . -100.29 -23.68 14.73 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-O 120.828 0.347 . . . . 0.0 110.672 179.874 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -90.88 31.06 5.78 Favored Glycine 0 N--CA 1.466 0.636 0 N-CA-C 110.776 -0.93 . . . . 0.0 110.776 -179.963 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 64.2 mt-10 -151.8 150.8 30.55 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.951 0.405 . . . . 0.0 110.649 -179.738 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -72.1 -17.67 77.39 Favored Glycine 0 CA--C 1.524 0.62 0 N-CA-C 110.781 -0.928 . . . . 0.0 110.781 179.633 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -133.94 139.04 32.14 Favored Pre-proline 0 CA--C 1.544 0.738 0 CA-C-N 116.772 0.286 . . . . 0.0 110.507 -179.978 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 68.4 Cg_endo -73.89 161.84 40.54 Favored 'Trans proline' 0 N--CA 1.494 1.558 0 C-N-CA 122.631 2.221 . . . . 0.0 111.949 178.31 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . 0.492 HG22 ' N ' ' A' ' 51' ' ' PHE . 96.3 mt -75.72 159.26 5.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.381 179.419 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 51' ' ' PHE . . . . . 0.492 ' N ' HG22 ' A' ' 50' ' ' ILE . 0.9 OUTLIER -78.32 142.21 37.9 Favored 'General case' 0 CA--C 1.531 0.24 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.727 179.871 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . 0.51 ' H ' ' CD ' ' A' ' 52' ' ' GLU . 0.0 OUTLIER -71.01 -178.48 1.97 Allowed 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.39 179.433 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 53' ' ' ASP . . . . . 0.428 ' OD1' ' OH ' ' A' ' 62' ' ' TYR . 0.2 OUTLIER -148.27 139.74 23.56 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.147 179.75 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 96.2 m-85 -109.32 123.58 49.53 Favored 'General case' 0 N--CA 1.464 0.241 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.478 -179.94 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 5.9 p -131.48 141.29 46.2 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.245 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.215 -179.976 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 84.9 m-20 -58.92 151.03 22.71 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.591 -179.777 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 57' ' ' SER . . . . . 0.478 ' OG ' ' O ' ' A' ' 35' ' ' ILE . 3.7 m -61.66 -34.48 75.78 Favored 'General case' 0 C--O 1.233 0.22 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.84 179.839 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 69.2 m -53.5 -34.59 58.63 Favored 'General case' 0 C--N 1.326 -0.444 0 N-CA-C 109.943 -0.392 . . . . 0.0 109.943 -179.661 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.672 ' C ' ' H ' ' A' ' 61' ' ' TYR . 4.1 t -83.19 76.06 1.09 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.859 -179.826 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -58.72 26.53 0.02 OUTLIER Glycine 0 CA--C 1.539 1.589 0 N-CA-C 111.549 -0.62 . . . . 0.0 111.549 -179.641 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 61' ' ' TYR . . . . . 0.672 ' H ' ' C ' ' A' ' 59' ' ' VAL . 35.8 p90 -160.69 150.58 17.61 Favored 'General case' 0 N--CA 1.453 -0.325 0 CA-C-O 121.125 0.488 . . . . 0.0 111.6 179.986 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 62' ' ' TYR . . . . . 0.428 ' OH ' ' OD1' ' A' ' 53' ' ' ASP . 37.1 t80 -153.6 147.85 25.83 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.688 -0.687 . . . . 0.0 109.583 179.093 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 29.8 m -108.74 132.63 53.76 Favored 'General case' 0 N--CA 1.464 0.235 0 CA-C-O 121.037 0.446 . . . . 0.0 110.563 -179.31 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -132.03 106.16 10.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 115.924 -0.58 . . . . 0.0 109.723 178.662 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.432 HG22 ' OG ' ' A' ' 21' ' ' SER . 2.6 p -114.55 162.06 17.22 Favored 'General case' 0 N--CA 1.465 0.283 0 CA-C-O 120.978 0.418 . . . . 0.0 110.543 179.95 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 108.58 41.07 1.52 Allowed Glycine 0 CA--C 1.524 0.655 0 N-CA-C 111.256 -0.737 . . . . 0.0 111.256 -179.942 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 14.3 mt -115.2 109.07 17.45 Favored 'General case' 0 N--CA 1.466 0.353 0 N-CA-C 109.211 -0.662 . . . . 0.0 109.211 179.456 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 33.6 mm-40 -60.11 140.83 90.74 Favored Pre-proline 0 C--N 1.321 -0.642 0 C-N-CA 120.623 -0.431 . . . . 0.0 111.788 -178.403 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 93.8 Cg_endo -74.63 155.74 44.74 Favored 'Trans proline' 0 N--CA 1.497 1.682 0 C-N-CA 122.686 2.258 . . . . 0.0 111.73 178.802 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 71.61 7.55 65.15 Favored Glycine 0 CA--C 1.525 0.694 0 CA-C-N 115.635 -0.711 . . . . 0.0 111.629 179.128 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 1.6 mp -116.18 144.0 24.9 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.469 0 CA-C-O 121.441 0.639 . . . . 0.0 109.463 -179.934 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 72' ' ' ASP . . . . . 0.565 ' O ' ' HB3' ' A' ' 44' ' ' ALA . 2.1 t70 -84.73 114.18 21.86 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.143 -0.935 . . . . 0.0 110.869 179.943 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 73' ' ' TYR . . . . . 0.467 ' O ' HD13 ' A' ' 75' ' ' ILE . 23.7 m-85 -106.53 122.16 45.74 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 121.251 0.548 . . . . 0.0 110.306 179.849 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 74' ' ' ASP . . . . . 0.524 ' N ' ' O ' ' A' ' 42' ' ' VAL . 11.7 m-20 -91.42 117.5 29.74 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.209 -0.905 . . . . 0.0 109.432 179.625 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . 0.556 HD11 ' N ' ' B' ' 223' ' ' ARG . 0.0 OUTLIER -115.27 165.92 9.85 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.422 0 CA-C-O 120.957 0.408 . . . . 0.0 110.267 -179.045 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -154.84 121.94 5.56 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.391 179.208 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.467 ' O ' HG23 ' B' ' 217' ' ' THR . 63.1 t -101.1 102.6 13.68 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 N-CA-C 109.335 -0.617 . . . . 0.0 109.335 179.011 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 95.9 mt -93.64 131.05 41.69 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.229 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.571 -179.591 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 71.3 m -109.28 111.27 22.75 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.078 -0.51 . . . . 0.0 109.917 179.391 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 37.6 tp -116.47 120.72 39.69 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.496 179.915 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 81' ' ' ILE . . . . . 0.707 ' O ' HD12 ' A' ' 81' ' ' ILE . 2.8 pp -142.68 153.97 17.65 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.278 179.397 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 82' ' ' ASN . . . . . 0.587 ' H ' ' CB ' ' A' ' 33' ' ' THR . 14.3 t-20 . . . . . 0 C--N 1.33 -0.279 0 CA-C-O 121.028 0.442 . . . . 0.0 110.932 179.963 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 207' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.464 0.501 0 N-CA-C 111.021 -0.831 . . . . 0.0 111.021 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' B' B ' 208' ' ' SER . . . . . 0.531 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 98.7 p -165.17 170.9 14.37 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 120.706 0.288 . . . . 0.0 110.734 179.83 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 209' ' ' TRP . . . . . . . . . . . . . 72.2 m95 -87.58 131.43 34.4 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.315 179.607 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 68.8 p -110.15 133.39 53.27 Favored 'General case' 0 N--CA 1.465 0.313 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.405 -179.951 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 49.8 t-105 -94.93 118.36 31.68 Favored 'General case' 0 N--CA 1.463 0.199 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.059 179.795 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 212' ' ' GLU . . . . . 0.469 ' O ' ' O ' ' B' ' 215' ' ' LYS . 1.7 pt-20 -164.7 170.64 15.36 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.731 178.903 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 213' ' ' ASN . . . . . . . . . . . . . 13.8 m120 48.82 36.18 7.68 Favored 'General case' 0 C--N 1.323 -0.577 0 C-N-CA 120.321 -0.552 . . . . 0.0 111.615 175.951 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 51.88 13.82 1.64 Allowed Glycine 0 CA--C 1.529 0.94 0 N-CA-C 111.536 -0.626 . . . . 0.0 111.536 179.676 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 215' ' ' LYS . . . . . 0.469 ' O ' ' O ' ' B' ' 212' ' ' GLU . 67.5 mttm -143.09 150.87 40.1 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-O 121.082 0.468 . . . . 0.0 110.625 179.875 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 216' ' ' TRP . . . . . . . . . . . . . 64.4 m95 -84.82 118.03 24.23 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.013 179.856 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 217' ' ' THR . . . . . 0.467 HG23 ' O ' ' A' ' 77' ' ' VAL . 19.3 m -127.5 139.86 52.52 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-O 121.197 0.522 . . . . 0.0 110.452 -179.393 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 218' ' ' TRP . . . . . 0.531 ' CH2' ' N ' ' B' ' 208' ' ' SER . 19.7 t-105 -106.22 117.25 33.55 Favored 'General case' 0 C--O 1.231 0.1 0 CA-C-N 115.849 -0.614 . . . . 0.0 109.922 179.227 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 54.4 mtmt -143.71 172.07 13.33 Favored 'General case' 0 CA--C 1.516 -0.343 0 CA-C-O 120.989 0.423 . . . . 0.0 110.642 -179.748 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -176.42 -160.73 24.18 Favored Glycine 0 CA--C 1.525 0.669 0 C-N-CA 120.585 -0.817 . . . . 0.0 111.305 -179.727 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 221' ' ' ILE . . . . . 0.544 ' O ' HG23 ' B' ' 222' ' ' ILE . 20.2 mt -54.7 -73.65 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 C-N-CA 120.649 -0.42 . . . . 0.0 110.448 -178.046 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 222' ' ' ILE . . . . . 0.544 HG23 ' O ' ' B' ' 221' ' ' ILE . 21.7 pt -159.85 -165.08 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 N-CA-C 109.907 -0.405 . . . . 0.0 109.907 -179.761 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 223' ' ' ARG . . . . . 0.556 ' N ' HD11 ' A' ' 75' ' ' ILE . 37.0 ptt180 -40.9 172.13 0.0 OUTLIER 'General case' 0 N--CA 1.456 -0.174 0 CA-C-O 121.175 0.512 . . . . 0.0 110.923 178.89 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 224' ' ' LEU . . . . . 1.072 HD22 ' H ' ' B' ' 224' ' ' LEU . 0.4 OUTLIER -58.55 147.8 30.86 Favored 'General case' 0 C--N 1.318 -0.794 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.638 -179.091 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 23.5 tp10 . . . . . 0 CA--C 1.515 -0.392 0 CA-C-N 115.551 -0.75 . . . . 0.0 110.511 -178.858 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . 0.421 ' HB2' ' HE1' ' B' ' 209' ' ' TRP . 55.2 p-10 . . . . . 0 C--O 1.231 0.116 0 CA-C-O 120.746 0.308 . . . . 0.0 110.673 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 7.3 tt -65.1 150.9 47.32 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.444 -179.679 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . 0.417 ' O ' ' O ' ' A' ' 25' ' ' ARG . 18.1 p -139.85 157.53 45.56 Favored 'General case' 0 N--CA 1.463 0.204 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.385 179.696 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . 0.48 ' N ' ' CD1' ' A' ' 14' ' ' PHE . 31.5 m-85 -110.33 144.77 38.57 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.652 -179.325 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 16.7 m -145.69 156.62 12.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.294 179.402 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 98.8 m-20 55.75 35.93 26.28 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.64 -179.885 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 96.4 mt -61.12 139.07 20.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.31 179.816 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.473 ' CB ' ' O ' ' A' ' 21' ' ' SER . 0.2 OUTLIER -140.84 -167.33 2.34 Favored 'General case' 0 N--CA 1.469 0.494 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.194 -179.986 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' ASP . . . . . 0.496 ' OD1' ' N ' ' A' ' 20' ' ' SER . 30.9 p-10 -88.75 -43.54 11.2 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.819 179.384 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . 0.496 ' N ' ' OD1' ' A' ' 19' ' ' ASP . 4.4 t -116.41 6.73 13.68 Favored 'General case' 0 N--CA 1.466 0.353 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.976 -179.42 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . 0.473 ' O ' ' CB ' ' A' ' 18' ' ' THR . 16.4 p -150.57 140.3 21.74 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 121.257 0.551 . . . . 0.0 110.508 179.853 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 28.4 pt -139.65 144.13 29.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 N-CA-C 109.394 -0.595 . . . . 0.0 109.394 -179.868 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -106.4 91.33 0.72 Allowed Glycine 0 N--CA 1.466 0.637 0 N-CA-C 111.496 -0.642 . . . . 0.0 111.496 -179.323 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.466 ' N ' HD12 ' A' ' 24' ' ' LEU . 11.2 mp -69.63 130.55 42.69 Favored 'General case' 0 C--N 1.328 -0.354 0 C-N-CA 120.478 -0.489 . . . . 0.0 109.842 179.844 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . 0.417 ' O ' ' O ' ' A' ' 13' ' ' SER . 67.5 ttp85 -140.83 135.26 31.22 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.196 179.615 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' TRP . . . . . . . . . . . . . 48.3 p90 -143.51 156.47 44.63 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.988 -0.551 . . . . 0.0 109.983 179.719 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 4.4 m -109.54 101.11 44.9 Favored Pre-proline 0 CA--C 1.531 0.23 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.162 179.906 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 42.0 Cg_exo -53.14 150.84 23.41 Favored 'Trans proline' 0 C--N 1.307 -1.613 0 C-N-CA 121.635 1.557 . . . . 0.0 113.199 179.823 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 54.2 mt -91.3 141.94 28.24 Favored 'General case' 0 CA--C 1.513 -0.466 0 CA-C-N 115.127 -0.942 . . . . 0.0 110.885 179.867 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 53.6 t-20 -50.87 -38.14 47.7 Favored 'General case' 0 C--N 1.314 -0.976 0 CA-C-N 114.743 -1.117 . . . . 0.0 110.149 179.575 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 23.2 m -76.98 -33.57 57.61 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.454 178.874 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 15.1 m -60.48 127.84 33.71 Favored 'General case' 0 N--CA 1.461 0.108 0 CA-C-O 121.027 0.441 . . . . 0.0 110.16 179.893 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' THR . . . . . 0.487 ' OG1' ' N ' ' A' ' 82' ' ' ASN . 5.5 m -57.96 142.98 44.68 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.292 179.99 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 20.6 mm -93.82 89.24 2.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 120.904 0.383 . . . . 0.0 110.839 -179.299 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.469 ' O ' ' OG ' ' A' ' 57' ' ' SER . 14.7 pt -142.04 129.76 20.88 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.341 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.498 179.633 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -39.87 121.08 1.5 Allowed Glycine 0 CA--C 1.523 0.543 0 N-CA-C 111.555 -0.618 . . . . 0.0 111.555 -179.56 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 37' ' ' TYR . . . . . 0.423 ' CE2' ' OG ' ' A' ' 57' ' ' SER . 97.7 m-85 -83.19 178.92 7.88 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.942 0.401 . . . . 0.0 110.09 179.91 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 38' ' ' ARG . . . . . 0.54 ' NH1' ' OG1' ' A' ' 40' ' ' THR . 4.2 tmt_? -134.21 123.74 24.81 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 121.134 0.492 . . . . 0.0 110.561 179.775 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 2.8 pt -94.46 152.95 3.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 115.894 -0.593 . . . . 0.0 109.537 -179.856 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . 0.54 ' OG1' ' NH1' ' A' ' 38' ' ' ARG . 27.3 m -136.09 133.12 36.98 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.75 0.31 . . . . 0.0 110.491 179.814 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.415 HG13 ' HB ' ' A' ' 50' ' ' ILE . 2.0 p -132.59 134.95 58.31 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.326 0 CA-C-O 120.812 0.339 . . . . 0.0 110.577 179.796 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . 0.488 ' O ' ' N ' ' A' ' 74' ' ' ASP . 30.0 t -129.44 126.68 63.89 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.216 0 N-CA-C 110.017 -0.364 . . . . 0.0 110.017 179.307 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.548 ' HB2' ' CE2' ' A' ' 73' ' ' TYR . . . -93.33 138.67 31.46 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 109.32 -0.622 . . . . 0.0 109.32 179.504 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . 0.578 ' HB3' ' O ' ' A' ' 72' ' ' ASP . . . -97.53 -19.25 18.49 Favored 'General case' 0 C--N 1.329 -0.286 0 C-N-CA 120.695 -0.402 . . . . 0.0 110.877 -179.97 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -96.61 30.95 8.03 Favored Glycine 0 CA--C 1.525 0.701 0 N-CA-C 110.971 -0.852 . . . . 0.0 110.971 179.906 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 71.5 mt-10 -146.21 149.92 34.84 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.974 0.416 . . . . 0.0 110.556 179.996 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -68.28 -21.11 73.87 Favored Glycine 0 CA--C 1.523 0.54 0 N-CA-C 111.073 -0.811 . . . . 0.0 111.073 179.571 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -137.86 140.21 28.77 Favored Pre-proline 0 CA--C 1.546 0.814 0 CA-C-N 116.833 0.316 . . . . 0.0 110.603 179.672 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 68.9 Cg_endo -72.78 163.03 39.6 Favored 'Trans proline' 0 N--CA 1.495 1.569 0 C-N-CA 122.768 2.312 . . . . 0.0 112.107 178.755 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . 0.502 HG22 ' N ' ' A' ' 51' ' ' PHE . 96.8 mt -75.58 158.6 5.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.551 179.602 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 51' ' ' PHE . . . . . 0.502 ' N ' HG22 ' A' ' 50' ' ' ILE . 96.7 m-85 -75.94 147.77 38.67 Favored 'General case' 0 C--N 1.333 -0.143 0 CA-C-O 121.019 0.438 . . . . 0.0 111.134 -179.72 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . 0.556 ' H ' ' CD ' ' A' ' 52' ' ' GLU . 0.3 OUTLIER -83.28 146.94 28.26 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.441 179.478 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -116.91 153.55 32.37 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.756 -0.656 . . . . 0.0 110.499 -179.492 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 54' ' ' PHE . . . . . 0.565 ' CD1' ' N ' ' A' ' 54' ' ' PHE . 5.7 m-85 -119.79 129.47 54.47 Favored 'General case' 0 N--CA 1.462 0.132 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.146 -179.85 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 9.4 p -129.77 138.91 52.95 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.393 0 CA-C-O 120.73 0.3 . . . . 0.0 110.843 -179.769 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 94.4 m-20 -61.08 144.86 52.69 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.695 179.964 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 57' ' ' SER . . . . . 0.469 ' OG ' ' O ' ' A' ' 35' ' ' ILE . 10.2 m -61.94 -32.14 72.53 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.706 179.878 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 75.5 m -56.2 -36.43 68.4 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.582 -179.756 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 74.3 t -62.32 -45.05 99.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.511 -179.848 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 60.45 24.87 62.17 Favored Glycine 0 CA--C 1.528 0.864 0 N-CA-C 110.507 -1.037 . . . . 0.0 110.507 -179.95 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 61' ' ' TYR . . . . . 0.432 ' OH ' ' OG1' ' A' ' 63' ' ' THR . 52.6 t80 -166.34 151.09 7.92 Favored 'General case' 0 CA--C 1.53 0.176 0 CA-C-O 121.214 0.531 . . . . 0.0 111.423 -179.513 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 17.4 t80 -158.01 158.25 34.52 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.672 -0.694 . . . . 0.0 110.378 178.566 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . 0.432 ' OG1' ' OH ' ' A' ' 61' ' ' TYR . 69.3 m -127.7 136.74 51.98 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.198 179.728 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -130.16 104.62 10.45 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 N-CA-C 109.33 -0.619 . . . . 0.0 109.33 179.413 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 4.2 p -111.75 157.38 20.59 Favored 'General case' 0 N--CA 1.466 0.335 0 CA-C-O 120.946 0.403 . . . . 0.0 110.498 -179.849 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 107.68 40.79 1.68 Allowed Glycine 0 CA--C 1.524 0.594 0 N-CA-C 111.074 -0.81 . . . . 0.0 111.074 179.94 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 16.6 mt -113.0 106.65 14.95 Favored 'General case' 0 N--CA 1.462 0.168 0 N-CA-C 108.99 -0.744 . . . . 0.0 108.99 179.215 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 52.4 mm-40 -51.97 135.91 37.8 Favored Pre-proline 0 C--N 1.319 -0.72 0 CA-C-N 116.376 -0.375 . . . . 0.0 111.626 -178.059 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 93.4 Cg_endo -74.98 155.44 43.03 Favored 'Trans proline' 0 N--CA 1.496 1.658 0 C-N-CA 122.55 2.166 . . . . 0.0 111.476 178.602 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 70' ' ' GLY . . . . . 0.515 ' H ' HH22 ' B' ' 223' ' ' ARG . . . 71.11 5.66 59.1 Favored Glycine 0 CA--C 1.525 0.671 0 CA-C-N 115.65 -0.705 . . . . 0.0 111.54 179.469 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 1.6 mp -113.43 143.39 23.21 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.47 0 N-CA-C 109.315 -0.624 . . . . 0.0 109.315 179.859 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 72' ' ' ASP . . . . . 0.578 ' O ' ' HB3' ' A' ' 44' ' ' ALA . 1.8 t70 -80.26 113.86 18.75 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.387 -0.824 . . . . 0.0 110.683 179.949 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 73' ' ' TYR . . . . . 0.548 ' CE2' ' HB2' ' A' ' 43' ' ' ALA . 14.0 m-85 -109.14 120.19 41.78 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 121.264 0.554 . . . . 0.0 110.694 -179.699 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 74' ' ' ASP . . . . . 0.488 ' N ' ' O ' ' A' ' 42' ' ' VAL . 9.6 m-20 -89.11 119.55 29.72 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-N 115.378 -0.828 . . . . 0.0 109.175 179.387 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . 0.535 HD11 ' N ' ' B' ' 223' ' ' ARG . 0.0 OUTLIER -119.17 166.38 13.61 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.466 0 CA-C-O 121.019 0.438 . . . . 0.0 110.304 -179.306 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 22.9 t -156.13 152.41 27.89 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.574 -0.739 . . . . 0.0 110.312 178.529 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 2.4 t -128.78 101.95 7.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 N-CA-C 109.556 -0.535 . . . . 0.0 109.556 178.664 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 72.4 mt -88.47 127.56 41.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 N-CA-C 109.974 -0.38 . . . . 0.0 109.974 -179.433 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 87.3 m -105.66 114.22 28.25 Favored 'General case' 0 N--CA 1.465 0.284 0 CA-C-N 116.213 -0.449 . . . . 0.0 109.963 179.967 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 49.1 mt -118.2 117.42 29.11 Favored 'General case' 0 N--CA 1.464 0.229 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.533 -179.722 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 81' ' ' ILE . . . . . 0.474 ' HB ' ' H ' ' A' ' 33' ' ' THR . 2.3 pp -145.26 146.67 19.52 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.181 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.39 179.032 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 82' ' ' ASN . . . . . 0.487 ' N ' ' OG1' ' A' ' 33' ' ' THR . 23.0 t-20 . . . . . 0 C--N 1.329 -0.294 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.259 -179.578 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 207' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.462 0.428 0 N-CA-C 111.125 -0.79 . . . . 0.0 111.125 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' B' B ' 208' ' ' SER . . . . . 0.536 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 97.1 p -165.86 170.58 13.67 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.809 0.337 . . . . 0.0 110.818 179.877 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 209' ' ' TRP . . . . . 0.421 ' HE1' ' HB2' ' A' ' 11' ' ' ASP . 66.9 m95 -88.27 147.6 24.74 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.462 179.666 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 82.4 p -127.96 129.26 46.5 Favored 'General case' 0 C--O 1.234 0.257 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.631 179.868 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 48.9 t-105 -89.62 116.67 27.93 Favored 'General case' 0 N--CA 1.463 0.176 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.04 179.5 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 212' ' ' GLU . . . . . 0.457 ' O ' ' O ' ' B' ' 215' ' ' LYS . 1.0 OUTLIER -164.91 170.24 15.55 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.556 179.073 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' B' B ' 213' ' ' ASN . . . . . . . . . . . . . 14.2 m120 48.23 35.96 6.16 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.916 176.56 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 51.97 13.65 1.64 Allowed Glycine 0 CA--C 1.528 0.899 0 C-N-CA 120.992 -0.623 . . . . 0.0 111.668 179.656 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 215' ' ' LYS . . . . . 0.457 ' O ' ' O ' ' B' ' 212' ' ' GLU . 66.8 mttm -142.84 150.81 40.4 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-O 120.994 0.426 . . . . 0.0 110.839 179.826 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 216' ' ' TRP . . . . . . . . . . . . . 52.1 m95 -86.81 118.77 26.42 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.089 179.86 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 217' ' ' THR . . . . . . . . . . . . . 19.6 m -128.85 142.42 50.97 Favored 'General case' 0 N--CA 1.467 0.387 0 CA-C-O 120.938 0.399 . . . . 0.0 110.184 -179.772 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 218' ' ' TRP . . . . . 0.536 ' CH2' ' N ' ' B' ' 208' ' ' SER . 15.2 t-105 -104.91 118.51 36.72 Favored 'General case' 0 C--N 1.33 -0.269 0 N-CA-C 109.356 -0.609 . . . . 0.0 109.356 179.246 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 52.5 mtmt -145.86 167.4 23.33 Favored 'General case' 0 CA--C 1.517 -0.305 0 CA-C-O 121.33 0.586 . . . . 0.0 110.704 -179.411 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -175.81 -161.13 24.56 Favored Glycine 0 CA--C 1.523 0.573 0 CA-C-N 115.383 -0.826 . . . . 0.0 111.486 -179.736 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 221' ' ' ILE . . . . . 0.548 ' O ' HG23 ' B' ' 222' ' ' ILE . 0.8 OUTLIER -52.59 -75.71 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 C-N-CA 120.69 -0.404 . . . . 0.0 111.065 -178.667 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' B' B ' 222' ' ' ILE . . . . . 0.548 HG23 ' O ' ' B' ' 221' ' ' ILE . 22.1 pt -160.87 -165.08 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 N-CA-C 109.97 -0.382 . . . . 0.0 109.97 -179.405 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 223' ' ' ARG . . . . . 0.535 ' N ' HD11 ' A' ' 75' ' ' ILE . 39.5 ptt180 -43.28 173.5 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.804 -0.635 . . . . 0.0 110.669 178.579 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 224' ' ' LEU . . . . . 1.053 HD22 ' H ' ' B' ' 224' ' ' LEU . 0.7 OUTLIER -61.67 126.09 26.12 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.33 -179.859 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 35.5 tp10 . . . . . 0 C--N 1.329 -0.303 0 CA-C-N 115.712 -0.676 . . . . 0.0 110.277 179.803 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 . . . . . 0 CA--C 1.519 -0.216 0 CA-C-O 120.956 0.407 . . . . 0.0 110.372 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.528 ' CD2' ' CZ ' ' A' ' 14' ' ' PHE . 7.0 tt -67.15 145.34 55.38 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.579 -179.83 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . 0.431 ' O ' ' O ' ' A' ' 25' ' ' ARG . 53.9 p -143.09 152.79 42.23 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.497 179.642 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . 0.554 ' N ' ' CD1' ' A' ' 14' ' ' PHE . 8.3 m-85 -111.77 148.73 32.9 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.391 -179.763 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 18.5 m -146.37 158.01 11.32 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.205 179.711 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 95.2 m-20 58.91 30.27 19.95 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.613 -0.721 . . . . 0.0 110.849 -179.921 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 83.2 mt -56.3 130.5 18.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 N-CA-C 109.862 -0.422 . . . . 0.0 109.862 179.65 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.441 HG22 ' H ' ' A' ' 19' ' ' ASP . 0.2 OUTLIER -129.52 -169.1 2.05 Favored 'General case' 0 N--CA 1.466 0.374 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.579 -179.886 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' ASP . . . . . 0.488 ' N ' ' OD1' ' A' ' 19' ' ' ASP . 16.2 p-10 -78.35 -48.52 15.41 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.997 179.428 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . 0.47 ' OG ' ' N ' ' A' ' 67' ' ' LEU . 28.2 t -121.16 13.35 11.2 Favored 'General case' 0 N--CA 1.464 0.231 0 CA-C-O 120.728 0.299 . . . . 0.0 110.596 -179.161 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . 0.463 ' HB2' HG22 ' A' ' 65' ' ' THR . 25.1 p -146.69 129.14 15.91 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 116.475 -0.329 . . . . 0.0 110.352 -179.625 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . 0.595 HD12 HD21 ' A' ' 24' ' ' LEU . 46.4 pt -126.25 142.57 42.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.239 0 CA-C-N 116.2 -0.455 . . . . 0.0 109.959 -179.886 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -97.1 82.26 0.72 Allowed Glycine 0 CA--C 1.523 0.542 0 N-CA-C 110.873 -0.891 . . . . 0.0 110.873 -179.563 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.595 HD21 HD12 ' A' ' 22' ' ' ILE . 90.7 mt -65.26 122.53 17.31 Favored 'General case' 0 C--N 1.33 -0.276 0 N-CA-C 109.945 -0.391 . . . . 0.0 109.945 -179.815 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . 0.431 ' O ' ' O ' ' A' ' 13' ' ' SER . 72.2 ttt180 -141.2 138.78 33.58 Favored 'General case' 0 N--CA 1.462 0.168 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.722 -179.873 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' TRP . . . . . 0.534 ' CE2' ' O ' ' A' ' 60' ' ' GLY . 33.3 p90 -146.33 121.06 9.86 Favored 'General case' 0 CA--C 1.513 -0.453 0 CA-C-N 115.792 -0.64 . . . . 0.0 109.764 179.882 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 2.1 m -66.49 113.91 14.9 Favored Pre-proline 0 CA--C 1.536 0.412 0 C-N-CA 120.642 -0.423 . . . . 0.0 111.091 -178.619 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 36.1 Cg_exo -58.84 153.07 52.86 Favored 'Trans proline' 0 N--CA 1.493 1.461 0 C-N-CA 122.101 1.867 . . . . 0.0 112.742 178.693 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.459 ' H ' ' HB2' ' A' ' 32' ' ' SER . 80.2 mt -104.94 136.05 45.15 Favored 'General case' 0 N--CA 1.469 0.479 0 CA-C-O 122.008 0.909 . . . . 0.0 110.833 179.876 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 42.4 t30 -44.88 -32.43 1.59 Allowed 'General case' 0 C--N 1.316 -0.877 0 CA-C-N 115.064 -0.971 . . . . 0.0 110.223 -179.709 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 58.7 m -85.64 -33.84 21.51 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.868 -0.606 . . . . 0.0 110.582 179.198 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . 0.459 ' HB2' ' H ' ' A' ' 29' ' ' LEU . 3.6 m -51.52 115.48 1.63 Allowed 'General case' 0 N--CA 1.461 0.095 0 CA-C-O 121.261 0.553 . . . . 0.0 110.17 -179.929 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' THR . . . . . 0.522 ' OG1' ' N ' ' A' ' 82' ' ' ASN . 11.7 m -50.94 143.54 10.04 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.561 -0.745 . . . . 0.0 109.264 -179.081 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 32.8 mm -92.45 90.95 3.23 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.215 0 CA-C-O 121.236 0.541 . . . . 0.0 111.258 -178.156 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.576 ' O ' ' CE1' ' A' ' 37' ' ' TYR . 6.7 pt -149.19 125.95 2.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 115.507 -0.77 . . . . 0.0 110.241 179.225 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -39.56 140.45 0.78 Allowed Glycine 0 CA--C 1.527 0.788 0 N-CA-C 110.957 -0.857 . . . . 0.0 110.957 -179.72 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 37' ' ' TYR . . . . . 0.576 ' CE1' ' O ' ' A' ' 35' ' ' ILE . 16.8 m-85 -110.49 144.83 38.72 Favored 'General case' 0 CA--C 1.518 -0.286 0 N-CA-C 109.867 -0.42 . . . . 0.0 109.867 -179.504 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 38' ' ' ARG . . . . . 0.516 ' NH1' ' OG1' ' A' ' 40' ' ' THR . 2.3 tmm_? -98.86 125.93 44.39 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.612 -179.834 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.419 ' CG1' ' O ' ' A' ' 39' ' ' ILE . 2.8 pt -98.45 121.07 48.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.1 -0.5 . . . . 0.0 109.834 179.777 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . 0.516 ' OG1' ' NH1' ' A' ' 38' ' ' ARG . 20.7 m -101.29 136.2 41.53 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.288 -179.175 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.2 p -134.22 142.76 40.06 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.338 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.249 179.965 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . 0.485 ' O ' ' N ' ' A' ' 74' ' ' ASP . 37.7 t -131.73 130.54 61.98 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.145 0 N-CA-C 109.984 -0.376 . . . . 0.0 109.984 179.46 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -97.49 133.63 41.81 Favored 'General case' 0 C--N 1.327 -0.379 0 N-CA-C 109.434 -0.58 . . . . 0.0 109.434 179.216 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . 0.626 ' HB3' ' O ' ' A' ' 72' ' ' ASP . . . -94.57 -21.21 18.99 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.769 0.318 . . . . 0.0 110.738 179.912 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -91.4 18.07 53.55 Favored Glycine 0 CA--C 1.523 0.588 0 N-CA-C 110.912 -0.875 . . . . 0.0 110.912 -179.682 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 33.2 mm-40 -139.93 149.53 43.44 Favored 'General case' 0 C--N 1.333 -0.136 0 CA-C-O 121.106 0.479 . . . . 0.0 110.521 -179.559 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -69.5 -18.94 74.12 Favored Glycine 0 N--CA 1.453 -0.194 0 N-CA-C 110.518 -1.033 . . . . 0.0 110.518 179.941 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -132.26 140.06 36.82 Favored Pre-proline 0 N--CA 1.468 0.446 0 C-N-CA 121.119 -0.232 . . . . 0.0 110.585 179.699 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 59.6 Cg_endo -73.22 159.39 47.32 Favored 'Trans proline' 0 N--CA 1.49 1.307 0 C-N-CA 122.431 2.087 . . . . 0.0 112.051 177.685 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . 0.407 HG22 ' N ' ' A' ' 51' ' ' PHE . 96.7 mt -75.49 153.41 6.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.193 179.484 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 51' ' ' PHE . . . . . 0.407 ' N ' HG22 ' A' ' 50' ' ' ILE . 80.5 m-85 -72.51 142.29 48.51 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.676 179.912 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . 0.422 ' N ' ' CD ' ' A' ' 52' ' ' GLU . 0.0 OUTLIER -65.77 -176.15 0.35 Allowed 'General case' 0 CA--C 1.514 -0.441 0 CA-C-N 115.739 -0.664 . . . . 0.0 110.405 179.441 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 53' ' ' ASP . . . . . 0.416 ' CG ' ' OH ' ' A' ' 62' ' ' TYR . 1.0 OUTLIER -145.59 138.66 26.14 Favored 'General case' 0 N--CA 1.452 -0.34 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.358 179.392 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 61.4 m-85 -110.0 116.42 31.56 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.397 179.898 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 10.5 p -128.18 140.82 48.15 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.348 0 CA-C-O 120.934 0.397 . . . . 0.0 110.118 179.949 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 83.9 m-20 -62.9 150.49 41.85 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.248 179.734 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 15.3 t -64.12 -33.8 76.6 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.663 -179.932 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 69.5 m -51.43 -37.69 49.83 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.382 -179.51 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.525 ' C ' ' H ' ' A' ' 61' ' ' TYR . 11.3 t -63.74 -42.97 97.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.362 179.68 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . 0.534 ' O ' ' CE2' ' A' ' 26' ' ' TRP . . . 70.44 -36.38 0.45 Allowed Glycine 0 CA--C 1.532 1.116 0 N-CA-C 111.037 -0.825 . . . . 0.0 111.037 179.653 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 61' ' ' TYR . . . . . 0.525 ' H ' ' C ' ' A' ' 59' ' ' VAL . 25.9 p90 -115.99 159.76 21.19 Favored 'General case' 0 N--CA 1.466 0.373 0 CA-C-O 121.146 0.498 . . . . 0.0 111.007 -179.084 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 62' ' ' TYR . . . . . 0.416 ' OH ' ' CG ' ' A' ' 53' ' ' ASP . 31.1 t80 -154.47 162.28 41.23 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.107 -0.497 . . . . 0.0 109.755 179.599 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 99.2 m -119.36 132.77 55.91 Favored 'General case' 0 N--CA 1.467 0.376 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.414 -179.781 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -133.06 107.57 11.75 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.311 0 CA-C-N 115.859 -0.61 . . . . 0.0 109.647 179.046 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.463 HG22 ' HB2' ' A' ' 21' ' ' SER . 1.1 p -123.46 164.52 18.76 Favored 'General case' 0 CA--C 1.513 -0.443 0 CA-C-O 121.019 0.438 . . . . 0.0 110.34 -179.836 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 108.81 24.41 6.09 Favored Glycine 0 CA--C 1.524 0.598 0 CA-C-N 115.396 -0.82 . . . . 0.0 111.48 -179.773 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.47 ' N ' ' OG ' ' A' ' 20' ' ' SER . 11.8 mt -100.66 109.14 21.17 Favored 'General case' 0 CA--C 1.517 -0.322 0 N-CA-C 109.31 -0.626 . . . . 0.0 109.31 179.909 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 31.9 mm-40 -52.5 139.73 37.88 Favored Pre-proline 0 C--N 1.312 -1.023 0 C-N-CA 120.486 -0.485 . . . . 0.0 112.011 -178.214 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -73.08 155.47 52.39 Favored 'Trans proline' 0 N--CA 1.498 1.755 0 C-N-CA 122.857 2.371 . . . . 0.0 111.387 178.63 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 72.93 -5.96 15.48 Favored Glycine 0 CA--C 1.525 0.702 0 CA-C-N 115.637 -0.71 . . . . 0.0 111.927 179.269 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 1.7 mp -101.27 149.15 6.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 N-CA-C 109.346 -0.613 . . . . 0.0 109.346 -179.551 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 72' ' ' ASP . . . . . 0.626 ' O ' ' HB3' ' A' ' 44' ' ' ALA . 2.5 t70 -89.68 115.99 27.46 Favored 'General case' 0 C--N 1.32 -0.7 0 CA-C-N 114.979 -1.01 . . . . 0.0 110.269 179.686 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 73' ' ' TYR . . . . . 0.507 ' O ' HD13 ' A' ' 75' ' ' ILE . 25.6 m-85 -109.81 119.55 39.69 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.453 179.899 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 74' ' ' ASP . . . . . 0.485 ' N ' ' O ' ' A' ' 42' ' ' VAL . 8.9 m-20 -89.94 116.79 28.26 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.702 -0.681 . . . . 0.0 109.426 179.887 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . 0.569 HD11 ' N ' ' B' ' 223' ' ' ARG . 0.0 OUTLIER -113.98 165.4 9.02 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.293 0 CA-C-O 121.171 0.51 . . . . 0.0 109.995 -179.094 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 33.5 t -155.97 118.56 4.15 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.6 -0.727 . . . . 0.0 110.584 179.0 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 2.7 t -92.16 100.77 11.76 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 C-N-CA 120.479 -0.488 . . . . 0.0 109.73 179.498 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 96.3 mt -87.44 115.79 28.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.075 -179.99 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 70.3 m -100.44 118.8 37.41 Favored 'General case' 0 CA--C 1.517 -0.318 0 CA-C-N 116.211 -0.45 . . . . 0.0 109.938 179.725 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . 0.447 HD23 ' C ' ' A' ' 80' ' ' LEU . 2.1 tt -122.66 108.74 13.43 Favored 'General case' 0 N--CA 1.463 0.201 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.628 -179.892 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 81' ' ' ILE . . . . . 0.44 ' N ' HD23 ' A' ' 80' ' ' LEU . 2.1 pp -139.37 142.93 32.13 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 N-CA-C 109.974 -0.38 . . . . 0.0 109.974 178.936 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 82' ' ' ASN . . . . . 0.522 ' N ' ' OG1' ' A' ' 33' ' ' THR . 39.5 t-20 . . . . . 0 C--N 1.328 -0.333 0 C-N-CA 120.89 -0.324 . . . . 0.0 111.233 -179.894 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 207' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.467 0.712 0 N-CA-C 111.105 -0.798 . . . . 0.0 111.105 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' B' B ' 208' ' ' SER . . . . . 0.555 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 54.8 p -165.66 170.83 13.71 Favored 'General case' 0 N--CA 1.454 -0.248 0 CA-C-O 120.804 0.335 . . . . 0.0 110.719 179.287 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 209' ' ' TRP . . . . . . . . . . . . . 59.0 m95 -88.13 156.08 19.44 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.531 179.473 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 66.9 p -130.19 131.77 45.74 Favored 'General case' 0 N--CA 1.464 0.247 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.447 179.558 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 53.0 t-105 -95.81 110.41 22.58 Favored 'General case' 0 N--CA 1.464 0.269 0 CA-C-N 116.29 -0.413 . . . . 0.0 110.591 -179.988 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 212' ' ' GLU . . . . . 0.44 ' O ' ' O ' ' B' ' 215' ' ' LYS . 1.8 pt-20 -162.0 168.45 22.76 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.669 179.516 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 213' ' ' ASN . . . . . . . . . . . . . 14.8 m120 51.53 34.5 12.5 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.955 -0.566 . . . . 0.0 111.066 176.966 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 50.56 19.89 3.46 Favored Glycine 0 CA--C 1.526 0.745 0 N-CA-C 111.156 -0.777 . . . . 0.0 111.156 179.981 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 215' ' ' LYS . . . . . 0.44 ' O ' ' O ' ' B' ' 212' ' ' GLU . 80.1 mttt -146.21 150.81 36.54 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 120.933 0.397 . . . . 0.0 110.602 179.723 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 216' ' ' TRP . . . . . . . . . . . . . 53.5 m95 -87.39 117.38 26.12 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.055 179.789 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 217' ' ' THR . . . . . . . . . . . . . 17.1 m -128.5 136.91 51.44 Favored 'General case' 0 C--O 1.234 0.248 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.129 -179.798 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 218' ' ' TRP . . . . . 0.555 ' CH2' ' N ' ' B' ' 208' ' ' SER . 14.2 t-105 -100.34 112.98 25.36 Favored 'General case' 0 N--CA 1.463 0.199 0 CA-C-N 116.044 -0.526 . . . . 0.0 109.99 179.606 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 92.7 mttt -130.24 167.52 18.31 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.74 -179.912 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -178.29 -162.89 28.83 Favored Glycine 0 CA--C 1.524 0.605 0 N-CA-C 111.089 -0.804 . . . . 0.0 111.089 179.878 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 221' ' ' ILE . . . . . 0.551 ' O ' HG23 ' B' ' 222' ' ' ILE . 21.5 mt -56.0 -73.52 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 C-N-CA 120.422 -0.511 . . . . 0.0 110.307 -178.116 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 222' ' ' ILE . . . . . 0.551 HG23 ' O ' ' B' ' 221' ' ' ILE . 22.6 pt -160.37 -165.2 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.086 179.797 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 223' ' ' ARG . . . . . 0.569 ' N ' HD11 ' A' ' 75' ' ' ILE . 26.7 ptt180 -40.24 172.18 0.0 OUTLIER 'General case' 0 CA--C 1.52 -0.201 0 CA-C-O 121.278 0.561 . . . . 0.0 110.88 179.293 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 224' ' ' LEU . . . . . 0.725 ' N ' HD22 ' B' ' 224' ' ' LEU . 2.8 mm? -61.38 120.73 11.01 Favored 'General case' 0 C--N 1.316 -0.861 0 CA-C-O 121.428 0.632 . . . . 0.0 110.929 -178.924 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 83.1 tt0 . . . . . 0 N--CA 1.452 -0.35 0 CA-C-N 115.295 -0.866 . . . . 0.0 109.935 -179.988 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 56.0 p30 . . . . . 0 CA--C 1.52 -0.185 0 CA-C-O 121.054 0.454 . . . . 0.0 110.448 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.485 ' CD2' ' CE1' ' A' ' 14' ' ' PHE . 6.9 tt -67.55 139.77 56.95 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.938 -0.573 . . . . 0.0 110.493 -179.637 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . 0.434 ' O ' ' O ' ' A' ' 25' ' ' ARG . 83.1 p -138.95 154.16 48.28 Favored 'General case' 0 N--CA 1.463 0.208 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.589 179.35 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . 0.501 ' N ' ' CD1' ' A' ' 14' ' ' PHE . 15.9 m-85 -111.31 146.15 37.57 Favored 'General case' 0 N--CA 1.463 0.188 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.514 -179.645 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 19.0 m -144.7 163.93 13.42 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.511 179.902 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 99.4 m-20 54.64 33.29 18.94 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.023 -0.535 . . . . 0.0 111.062 179.647 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 1.6 mp -58.42 132.17 23.04 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.542 0 CA-C-O 121.222 0.534 . . . . 0.0 109.883 -179.759 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.457 ' CB ' ' O ' ' A' ' 21' ' ' SER . 0.2 OUTLIER -136.2 -166.26 1.85 Allowed 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.212 -0.904 . . . . 0.0 110.652 -179.872 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' ASP . . . . . 0.522 ' OD1' ' N ' ' A' ' 20' ' ' SER . 34.3 p-10 -91.87 -41.95 10.33 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.495 -0.775 . . . . 0.0 111.115 179.366 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . 0.522 ' N ' ' OD1' ' A' ' 19' ' ' ASP . 25.9 t -118.51 6.85 11.74 Favored 'General case' 0 N--CA 1.467 0.378 0 CA-C-N 116.444 -0.344 . . . . 0.0 110.848 -179.431 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . 0.457 ' O ' ' CB ' ' A' ' 18' ' ' THR . 48.0 m -151.57 147.92 27.37 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.437 179.961 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . 0.52 HD12 HD21 ' A' ' 24' ' ' LEU . 35.8 pt -147.22 147.7 17.29 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 N-CA-C 109.897 -0.408 . . . . 0.0 109.897 179.558 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -101.83 83.43 0.48 Allowed Glycine 0 CA--C 1.524 0.603 0 N-CA-C 111.507 -0.637 . . . . 0.0 111.507 -179.647 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.52 HD21 HD12 ' A' ' 22' ' ' ILE . 84.6 mt -66.37 124.56 23.05 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 109.656 -0.498 . . . . 0.0 109.656 179.899 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . 0.434 ' O ' ' O ' ' A' ' 13' ' ' SER . 69.6 ttt180 -139.11 141.13 38.11 Favored 'General case' 0 N--CA 1.463 0.188 0 CA-C-O 120.948 0.404 . . . . 0.0 110.49 -179.714 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' TRP . . . . . . . . . . . . . 35.1 p90 -144.04 155.01 43.83 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.106 179.795 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 2.5 m -111.77 97.9 39.29 Favored Pre-proline 0 CA--C 1.534 0.336 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.507 179.82 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_exo -53.35 142.62 57.0 Favored 'Trans proline' 0 C--N 1.305 -1.728 0 C-N-CA 122.081 1.854 . . . . 0.0 112.478 179.472 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 59.9 mt -81.21 144.24 31.75 Favored 'General case' 0 CA--C 1.518 -0.274 0 CA-C-O 121.412 0.625 . . . . 0.0 110.91 179.877 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 21.0 t-20 -52.04 -36.9 51.73 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 115.392 -0.822 . . . . 0.0 109.799 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 38.5 m -78.28 -35.17 48.32 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.518 179.257 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 14.4 m -58.14 134.17 56.24 Favored 'General case' 0 N--CA 1.461 0.096 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.231 -179.872 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' THR . . . . . 0.452 ' H ' ' HB ' ' A' ' 81' ' ' ILE . 2.7 m -61.82 140.02 58.29 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.084 -179.718 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 6.0 mm -94.28 90.17 2.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 121.065 0.459 . . . . 0.0 110.693 -179.696 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 19.0 pt -139.19 138.11 41.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.549 179.742 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -42.23 135.81 3.56 Favored Glycine 0 CA--C 1.52 0.406 0 N-CA-C 111.004 -0.838 . . . . 0.0 111.004 -179.622 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 -103.2 174.62 5.79 Favored 'General case' 0 CA--C 1.517 -0.317 0 CA-C-O 120.898 0.38 . . . . 0.0 110.179 -179.846 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 2.3 tmm_? -134.92 126.25 28.31 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.592 179.961 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.475 ' CG1' ' O ' ' A' ' 39' ' ' ILE . 1.8 pt -99.92 122.2 51.52 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.176 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.127 179.684 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 24.2 m -104.95 134.38 48.15 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.451 -179.846 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.1 p -133.14 140.65 46.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.351 179.839 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . 0.528 ' O ' ' N ' ' A' ' 74' ' ' ASP . 37.6 t -133.25 131.67 58.18 Favored 'Isoleucine or valine' 0 N--CA 1.458 -0.074 0 N-CA-C 110.158 -0.312 . . . . 0.0 110.158 179.714 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.604 ' HB2' ' CE2' ' A' ' 73' ' ' TYR . . . -96.5 138.86 33.45 Favored 'General case' 0 C--N 1.329 -0.304 0 N-CA-C 109.709 -0.478 . . . . 0.0 109.709 178.947 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . 0.564 ' HB3' ' O ' ' A' ' 72' ' ' ASP . . . -93.81 -41.17 9.79 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.487 -0.324 . . . . 0.0 110.835 179.617 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -65.35 -31.85 81.76 Favored Glycine 0 CA--C 1.525 0.689 0 N-CA-C 111.256 -0.738 . . . . 0.0 111.256 -179.763 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 42.3 mm-40 -97.46 133.44 42.05 Favored 'General case' 0 C--N 1.33 -0.24 0 N-CA-C 109.576 -0.528 . . . . 0.0 109.576 -179.483 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -60.32 -21.92 57.72 Favored Glycine 0 CA--C 1.511 -0.217 0 N-CA-C 111.021 -0.832 . . . . 0.0 111.021 -178.987 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -113.11 134.7 21.78 Favored Pre-proline 0 CA--C 1.536 0.407 0 C-N-CA 120.961 -0.295 . . . . 0.0 110.59 179.665 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 71.2 Cg_endo -77.24 163.51 30.21 Favored 'Trans proline' 0 C--N 1.308 -1.564 0 C-N-CA 122.592 2.194 . . . . 0.0 112.202 177.006 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 87.0 mt -83.03 138.26 19.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.044 179.062 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 93.7 m-85 -60.74 142.03 56.31 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.623 -179.829 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 5.6 pt-20 -82.96 151.49 25.87 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.166 179.92 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 53' ' ' ASP . . . . . 0.417 ' CG ' ' OH ' ' A' ' 62' ' ' TYR . 1.7 t70 -120.05 162.91 18.47 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.683 179.451 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 54' ' ' PHE . . . . . 0.59 ' CD1' ' N ' ' A' ' 54' ' ' PHE . 2.4 m-85 -124.02 130.79 53.16 Favored 'General case' 0 C--O 1.232 0.169 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.195 179.662 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 8.7 p -127.69 136.4 60.52 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.449 -179.914 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 97.6 m-20 -58.84 141.29 53.67 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.482 -179.847 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 39.9 t -58.77 -32.84 69.66 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.58 179.857 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 69.1 m -56.23 -35.54 67.46 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.622 -179.836 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 84.1 t -63.44 -46.33 95.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.523 179.982 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 60.86 26.24 65.03 Favored Glycine 0 CA--C 1.528 0.895 0 N-CA-C 110.745 -0.942 . . . . 0.0 110.745 179.863 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 42.6 t80 -167.93 150.58 5.68 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 121.206 0.527 . . . . 0.0 111.103 -179.621 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 62' ' ' TYR . . . . . 0.417 ' OH ' ' CG ' ' A' ' 53' ' ' ASP . 26.7 t80 -157.58 156.27 31.63 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.092 178.831 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 76.3 m -122.64 136.2 54.81 Favored 'General case' 0 N--CA 1.465 0.282 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.728 -179.938 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -130.75 124.9 57.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.026 179.195 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 3.3 p -131.46 155.06 48.02 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.656 179.791 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 109.99 40.63 1.39 Allowed Glycine 0 CA--C 1.524 0.622 0 CA-C-N 115.719 -0.673 . . . . 0.0 111.522 -179.708 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 14.3 mt -112.91 99.31 7.78 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-O 121.274 0.559 . . . . 0.0 109.661 179.47 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 10.6 mm-40 -47.14 135.27 8.88 Favored Pre-proline 0 C--N 1.316 -0.849 0 CA-C-N 115.486 -0.779 . . . . 0.0 111.45 -178.382 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 69' ' ' PRO . . . . . 0.446 ' O ' HD12 ' A' ' 71' ' ' ILE . 72.4 Cg_endo -75.5 149.89 35.32 Favored 'Trans proline' 0 N--CA 1.496 1.646 0 C-N-CA 122.764 2.309 . . . . 0.0 111.761 178.86 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 70' ' ' GLY . . . . . 0.413 ' C ' HD12 ' A' ' 71' ' ' ILE . . . 75.39 13.61 82.71 Favored Glycine 0 CA--C 1.524 0.648 0 N-CA-C 111.23 -0.748 . . . . 0.0 111.23 179.202 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . 0.446 HD12 ' O ' ' A' ' 69' ' ' PRO . 2.2 mp -121.0 149.71 23.93 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.354 0 CA-C-O 121.528 0.68 . . . . 0.0 109.629 -179.637 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 72' ' ' ASP . . . . . 0.564 ' O ' ' HB3' ' A' ' 44' ' ' ALA . 2.3 t70 -87.25 112.08 21.67 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 114.854 -1.066 . . . . 0.0 110.621 -179.76 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 73' ' ' TYR . . . . . 0.604 ' CE2' ' HB2' ' A' ' 43' ' ' ALA . 11.8 m-85 -107.87 118.33 36.46 Favored 'General case' 0 C--O 1.216 -0.69 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.735 179.71 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 74' ' ' ASP . . . . . 0.528 ' N ' ' O ' ' A' ' 42' ' ' VAL . 76.6 m-20 -86.97 119.01 26.74 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.495 -0.775 . . . . 0.0 109.496 179.708 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . 0.615 HD11 ' N ' ' B' ' 223' ' ' ARG . 0.0 OUTLIER -116.02 164.43 12.37 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.344 0 CA-C-O 121.171 0.51 . . . . 0.0 110.155 -179.166 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 3.0 m -154.43 121.52 5.63 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 115.466 -0.788 . . . . 0.0 110.849 179.394 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 11.9 t -101.44 102.23 13.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 179.272 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 94.5 mt -89.84 127.32 42.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.405 -0.361 . . . . 0.0 110.517 -179.684 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 99.7 m -109.41 111.68 23.36 Favored 'General case' 0 N--CA 1.465 0.319 0 CA-C-N 116.12 -0.491 . . . . 0.0 109.996 179.708 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 13.9 mt -117.93 122.11 42.42 Favored 'General case' 0 CA--C 1.517 -0.297 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.693 -179.968 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 81' ' ' ILE . . . . . 0.452 ' HB ' ' H ' ' A' ' 33' ' ' THR . 2.1 pp -145.45 134.66 17.66 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.15 179.533 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 24.1 t-20 . . . . . 0 C--N 1.323 -0.58 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.777 179.851 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' B' B ' 207' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.466 0.665 0 N-CA-C 111.204 -0.758 . . . . 0.0 111.204 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' B' B ' 208' ' ' SER . . . . . 0.493 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 94.7 p -165.76 172.79 11.37 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.861 0.362 . . . . 0.0 110.697 -179.718 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 209' ' ' TRP . . . . . . . . . . . . . 79.1 m95 -84.44 131.53 34.66 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.309 179.656 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 81.4 p -109.41 130.02 55.52 Favored 'General case' 0 N--CA 1.464 0.273 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.546 -179.95 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 52.9 t-105 -92.38 116.91 29.39 Favored 'General case' 0 C--O 1.233 0.204 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.232 179.832 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 212' ' ' GLU . . . . . 0.458 ' O ' ' O ' ' B' ' 215' ' ' LYS . 1.7 pt-20 -165.82 167.53 16.8 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.948 179.333 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 213' ' ' ASN . . . . . . . . . . . . . 96.7 m-20 50.4 36.46 13.21 Favored 'General case' 0 C--N 1.321 -0.641 0 C-N-CA 120.605 -0.438 . . . . 0.0 111.012 176.325 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 50.21 17.07 1.59 Allowed Glycine 0 CA--C 1.523 0.56 0 N-CA-C 111.476 -0.65 . . . . 0.0 111.476 179.853 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 215' ' ' LYS . . . . . 0.458 ' O ' ' O ' ' B' ' 212' ' ' GLU . 52.1 mtmt -144.99 151.13 38.1 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 121.055 0.455 . . . . 0.0 110.684 179.652 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 216' ' ' TRP . . . . . 0.48 ' N ' ' CD1' ' B' ' 216' ' ' TRP . 24.2 m95 -87.27 119.79 27.89 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.053 179.945 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 217' ' ' THR . . . . . . . . . . . . . 21.6 m -130.95 142.81 50.38 Favored 'General case' 0 N--CA 1.464 0.238 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.432 -179.707 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 218' ' ' TRP . . . . . 0.493 ' CH2' ' N ' ' B' ' 208' ' ' SER . 15.7 t-105 -105.57 119.57 39.45 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-N 115.854 -0.612 . . . . 0.0 109.856 179.407 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 51.3 mtmt -142.95 171.78 13.58 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.817 -179.766 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -176.84 -160.28 23.62 Favored Glycine 0 CA--C 1.522 0.497 0 N-CA-C 111.237 -0.745 . . . . 0.0 111.237 -179.544 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 221' ' ' ILE . . . . . 0.535 ' O ' HG23 ' B' ' 222' ' ' ILE . 10.1 mm -50.7 -73.53 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 C-N-CA 120.781 -0.368 . . . . 0.0 110.638 -178.237 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 222' ' ' ILE . . . . . 0.535 HG23 ' O ' ' B' ' 221' ' ' ILE . 21.4 pt -158.8 -166.65 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.723 0 CA-C-N 115.707 -0.678 . . . . 0.0 110.949 -179.795 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 223' ' ' ARG . . . . . 0.615 ' N ' HD11 ' A' ' 75' ' ' ILE . 21.2 ptt-85 -43.42 175.77 0.0 OUTLIER 'General case' 0 CA--C 1.521 -0.164 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.692 179.353 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 224' ' ' LEU . . . . . 0.694 ' N ' HD22 ' B' ' 224' ' ' LEU . 3.4 mm? -62.14 115.89 4.51 Favored 'General case' 0 C--N 1.317 -0.807 0 CA-C-N 115.989 -0.55 . . . . 0.0 110.789 -179.738 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 78.5 tt0 . . . . . 0 C--N 1.33 -0.272 0 CA-C-N 115.564 -0.744 . . . . 0.0 110.529 179.81 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 52.6 p30 . . . . . 0 N--CA 1.464 0.23 0 CA-C-O 120.948 0.404 . . . . 0.0 110.388 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 59.8 tp -65.31 145.98 55.51 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.024 -0.534 . . . . 0.0 110.397 -179.985 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . 0.47 ' O ' ' O ' ' A' ' 25' ' ' ARG . 14.2 p -143.49 150.16 38.56 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-O 121.184 0.516 . . . . 0.0 110.614 179.299 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . 0.566 ' N ' ' CD1' ' A' ' 14' ' ' PHE . 9.4 m-85 -112.16 145.74 39.3 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.0 -0.545 . . . . 0.0 110.625 -179.714 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 19.1 m -142.07 159.47 20.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.353 179.417 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 94.5 m-20 56.9 31.42 19.69 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.69 -0.686 . . . . 0.0 110.94 -179.66 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 96.3 mt -55.6 131.83 18.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.93 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.433 HG22 ' H ' ' A' ' 19' ' ' ASP . 0.2 OUTLIER -131.72 -169.52 2.21 Favored 'General case' 0 N--CA 1.468 0.463 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.47 -179.562 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' ASP . . . . . 0.476 ' N ' ' OD1' ' A' ' 19' ' ' ASP . 17.9 p-10 -77.19 -49.67 14.65 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.982 179.594 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . 0.457 ' CB ' ' O ' ' A' ' 67' ' ' LEU . 70.7 m -121.43 14.62 11.17 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 116.622 -0.263 . . . . 0.0 110.661 -179.176 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . 0.514 ' HB3' HG22 ' A' ' 65' ' ' THR . 2.4 m -146.48 129.87 16.75 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.088 -179.525 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . 0.702 HD12 HD21 ' A' ' 24' ' ' LEU . 44.6 pt -125.95 141.75 44.69 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.322 0 CA-C-N 116.078 -0.51 . . . . 0.0 109.715 179.681 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -99.41 82.39 0.56 Allowed Glycine 0 CA--C 1.522 0.531 0 N-CA-C 110.953 -0.859 . . . . 0.0 110.953 -179.537 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.702 HD21 HD12 ' A' ' 22' ' ' ILE . 76.5 mt -63.32 124.38 21.1 Favored 'General case' 0 C--N 1.328 -0.354 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 -179.834 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . 0.47 ' O ' ' O ' ' A' ' 13' ' ' SER . 67.9 ttp85 -140.66 140.01 34.9 Favored 'General case' 0 C--N 1.332 -0.155 0 CA-C-O 121.245 0.545 . . . . 0.0 110.736 -179.868 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' TRP . . . . . . . . . . . . . 22.0 p90 -144.49 157.99 43.97 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.108 -179.56 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 2.6 m -103.92 105.29 47.61 Favored Pre-proline 0 CA--C 1.536 0.438 0 CA-C-N 116.56 -0.291 . . . . 0.0 110.686 -179.903 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 31.6 Cg_exo -55.02 153.15 26.87 Favored 'Trans proline' 0 N--CA 1.493 1.484 0 C-N-CA 122.041 1.827 . . . . 0.0 112.972 178.802 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.442 ' H ' ' HB2' ' A' ' 32' ' ' SER . 74.5 mt -103.55 135.25 45.5 Favored 'General case' 0 CA--C 1.515 -0.372 0 CA-C-O 121.832 0.825 . . . . 0.0 110.597 -179.941 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 19.2 t-20 -44.18 -31.46 0.98 Allowed 'General case' 0 C--N 1.318 -0.764 0 CA-C-N 115.09 -0.959 . . . . 0.0 110.436 -179.844 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 66.2 m -86.93 -35.9 18.65 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.395 179.151 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . 0.442 ' HB2' ' H ' ' A' ' 29' ' ' LEU . 3.4 m -47.66 114.34 0.88 Allowed 'General case' 0 CA--C 1.528 0.127 0 CA-C-O 121.167 0.508 . . . . 0.0 110.051 -179.819 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 7.8 m -52.77 146.03 11.24 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.499 -0.773 . . . . 0.0 109.633 -179.483 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 27.6 mm -93.38 91.68 3.37 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.199 0 CA-C-O 121.167 0.508 . . . . 0.0 110.932 -178.45 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.53 ' O ' ' CE1' ' A' ' 37' ' ' TYR . 9.0 pt -145.8 128.17 9.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.232 179.645 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -47.84 135.93 14.88 Favored Glycine 0 CA--C 1.52 0.371 0 N-CA-C 110.805 -0.918 . . . . 0.0 110.805 -179.456 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 37' ' ' TYR . . . . . 0.53 ' CE1' ' O ' ' A' ' 35' ' ' ILE . 10.1 m-85 -100.97 179.86 4.26 Favored 'General case' 0 C--N 1.33 -0.241 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 -179.898 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 5.4 tmm_? -132.43 122.37 24.87 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.473 179.731 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.469 ' CG1' ' O ' ' A' ' 39' ' ' ILE . 1.8 pt -97.84 118.17 43.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 115.924 -0.58 . . . . 0.0 109.89 179.633 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 20.9 m -98.3 134.16 41.71 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.216 -179.383 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.4 p -132.01 140.97 46.68 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.262 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.369 -179.999 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . 0.49 ' O ' ' N ' ' A' ' 74' ' ' ASP . 36.2 t -132.21 131.72 60.93 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.177 0 CA-C-O 120.979 0.419 . . . . 0.0 109.903 179.311 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.468 ' HB2' ' CE2' ' A' ' 73' ' ' TYR . . . -96.85 132.98 42.05 Favored 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 109.46 -0.571 . . . . 0.0 109.46 178.987 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . 0.62 ' HB3' ' O ' ' A' ' 72' ' ' ASP . . . -93.93 -14.68 25.71 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.766 0.317 . . . . 0.0 110.825 -179.843 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -99.86 18.88 55.27 Favored Glycine 0 CA--C 1.525 0.678 0 N-CA-C 111.025 -0.83 . . . . 0.0 111.025 -179.495 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 29.4 mm-40 -138.86 149.17 44.58 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 121.179 0.514 . . . . 0.0 110.368 -179.919 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -68.87 -17.3 71.31 Favored Glycine 0 CA--C 1.519 0.283 0 N-CA-C 110.552 -1.019 . . . . 0.0 110.552 179.864 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -135.31 139.03 30.35 Favored Pre-proline 0 CA--C 1.538 0.518 0 C-N-CA 121.192 -0.203 . . . . 0.0 110.683 179.842 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -73.31 158.65 48.21 Favored 'Trans proline' 0 N--CA 1.491 1.351 0 C-N-CA 122.565 2.176 . . . . 0.0 111.813 178.252 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 96.4 mt -73.87 150.2 7.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.247 179.254 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 86.0 m-85 -70.04 137.19 51.07 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.715 179.94 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . 0.421 ' N ' ' CD ' ' A' ' 52' ' ' GLU . 0.0 OUTLIER -59.28 -175.65 0.03 OUTLIER 'General case' 0 CA--C 1.513 -0.446 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.449 179.212 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 53' ' ' ASP . . . . . 0.41 ' CG ' ' OH ' ' A' ' 62' ' ' TYR . 2.4 t0 -148.06 144.13 27.67 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.802 -0.636 . . . . 0.0 110.486 179.173 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 89.0 m-85 -116.74 122.93 45.9 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-N 116.363 -0.381 . . . . 0.0 110.572 179.812 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 9.5 p -132.06 142.7 42.18 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.425 0 CA-C-N 116.405 -0.361 . . . . 0.0 110.126 179.972 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 94.8 m-20 -61.13 151.87 30.03 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.377 179.952 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 11.3 t -62.72 -35.57 80.15 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.661 179.89 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 42.9 m -50.89 -37.21 42.3 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.162 -179.623 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.639 ' C ' ' H ' ' A' ' 61' ' ' TYR . 3.3 t -79.86 83.85 1.23 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.55 179.826 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -62.37 28.39 0.07 OUTLIER Glycine 0 CA--C 1.535 1.286 0 N-CA-C 111.103 -0.799 . . . . 0.0 111.103 179.672 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 61' ' ' TYR . . . . . 0.639 ' H ' ' C ' ' A' ' 59' ' ' VAL . 55.2 p90 -166.27 154.19 10.29 Favored 'General case' 0 N--CA 1.451 -0.389 0 CA-C-O 121.14 0.495 . . . . 0.0 111.879 -179.527 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 62' ' ' TYR . . . . . 0.41 ' OH ' ' CG ' ' A' ' 53' ' ' ASP . 23.6 t80 -154.74 148.91 25.94 Favored 'General case' 0 N--CA 1.454 -0.27 0 CA-C-N 115.727 -0.67 . . . . 0.0 109.731 178.794 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 50.1 m -110.69 132.97 53.74 Favored 'General case' 0 N--CA 1.463 0.224 0 CA-C-O 120.909 0.385 . . . . 0.0 110.325 -179.189 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -133.1 100.86 3.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 115.826 -0.625 . . . . 0.0 109.84 178.166 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.514 HG22 ' HB3' ' A' ' 21' ' ' SER . 1.7 p -114.26 165.25 12.87 Favored 'General case' 0 CA--C 1.514 -0.441 0 CA-C-O 121.227 0.536 . . . . 0.0 110.445 179.882 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 108.67 24.33 6.16 Favored Glycine 0 CA--C 1.525 0.68 0 CA-C-N 115.444 -0.798 . . . . 0.0 111.295 -179.933 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.457 ' O ' ' CB ' ' A' ' 20' ' ' SER . 12.7 mt -98.69 106.55 18.83 Favored 'General case' 0 C--O 1.225 -0.22 0 N-CA-C 109.335 -0.617 . . . . 0.0 109.335 179.388 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 49.3 mm-40 -48.43 138.42 11.41 Favored Pre-proline 0 C--N 1.318 -0.792 0 CA-C-N 116.319 -0.4 . . . . 0.0 111.971 -178.323 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -73.36 154.04 50.81 Favored 'Trans proline' 0 N--CA 1.498 1.743 0 C-N-CA 122.749 2.299 . . . . 0.0 111.298 178.736 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 73.76 -6.0 20.95 Favored Glycine 0 CA--C 1.527 0.809 0 CA-C-N 115.839 -0.619 . . . . 0.0 111.647 179.209 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 1.8 mp -102.53 140.53 20.67 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.424 0 CA-C-O 121.326 0.584 . . . . 0.0 109.626 -179.847 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 72' ' ' ASP . . . . . 0.62 ' O ' ' HB3' ' A' ' 44' ' ' ALA . 1.9 t70 -81.42 118.7 22.9 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-N 114.995 -1.002 . . . . 0.0 109.922 179.434 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 73' ' ' TYR . . . . . 0.499 ' O ' HD13 ' A' ' 75' ' ' ILE . 17.6 m-85 -110.85 119.68 39.9 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.828 -0.623 . . . . 0.0 110.44 179.949 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 74' ' ' ASP . . . . . 0.49 ' N ' ' O ' ' A' ' 42' ' ' VAL . 24.8 m-20 -89.43 117.42 28.34 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.613 -0.721 . . . . 0.0 109.574 179.579 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . 0.522 HD11 ' N ' ' B' ' 223' ' ' ARG . 0.0 OUTLIER -114.64 166.23 8.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 121.041 0.448 . . . . 0.0 110.179 -179.339 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 1.1 p -155.11 122.64 5.65 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.589 -0.732 . . . . 0.0 110.559 179.243 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.61 ' O ' HG23 ' B' ' 217' ' ' THR . 20.6 t -96.7 127.35 48.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 N-CA-C 109.355 -0.609 . . . . 0.0 109.355 178.962 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 96.7 mt -117.19 120.02 63.69 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.416 0 CA-C-N 116.479 -0.328 . . . . 0.0 110.485 179.974 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 93.4 m -101.54 116.79 33.56 Favored 'General case' 0 C--N 1.331 -0.21 0 N-CA-C 109.715 -0.476 . . . . 0.0 109.715 179.265 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 16.9 tp -121.35 116.8 25.48 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.724 -179.931 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 81' ' ' ILE . . . . . 0.503 ' HA ' HD11 ' A' ' 35' ' ' ILE . 2.2 pp -147.15 143.29 20.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.321 178.553 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 27.2 t-20 . . . . . 0 C--N 1.329 -0.287 0 CA-C-O 120.83 0.348 . . . . 0.0 111.05 -179.818 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' B' B ' 207' ' ' GLY . . . . . 0.417 ' C ' ' CH2' ' B' ' 218' ' ' TRP . . . . . . . . 0 N--CA 1.466 0.654 0 N-CA-C 110.802 -0.919 . . . . 0.0 110.802 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 208' ' ' SER . . . . . 0.532 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 45.1 p -162.2 166.16 25.93 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.803 0.335 . . . . 0.0 110.643 179.068 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 209' ' ' TRP . . . . . . . . . . . . . 84.7 m95 -85.23 152.84 23.03 Favored 'General case' 0 C--N 1.332 -0.167 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.463 179.603 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 210' ' ' THR . . . . . 0.428 ' OG1' ' O ' ' B' ' 217' ' ' THR . 49.4 p -129.47 129.79 45.05 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-N 116.354 -0.385 . . . . 0.0 110.355 179.504 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 57.8 t-105 -92.54 110.17 21.58 Favored 'General case' 0 N--CA 1.462 0.17 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.761 179.657 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 212' ' ' GLU . . . . . 0.443 ' O ' ' O ' ' B' ' 215' ' ' LYS . 1.4 pt-20 -161.17 165.8 28.89 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.54 179.745 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 213' ' ' ASN . . . . . . . . . . . . . 15.9 m120 51.07 33.77 9.75 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.118 176.906 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 53.35 14.79 3.49 Favored Glycine 0 CA--C 1.527 0.814 0 N-CA-C 111.502 -0.639 . . . . 0.0 111.502 179.993 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 215' ' ' LYS . . . . . 0.443 ' O ' ' O ' ' B' ' 212' ' ' GLU . 9.7 mtmp? -140.91 149.33 41.75 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-O 121.047 0.451 . . . . 0.0 110.663 179.895 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 216' ' ' TRP . . . . . . . . . . . . . 48.3 m95 -84.73 114.73 22.26 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.079 -0.51 . . . . 0.0 109.932 179.757 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 217' ' ' THR . . . . . 0.61 HG23 ' O ' ' A' ' 77' ' ' VAL . 18.3 m -119.25 133.03 55.97 Favored 'General case' 0 N--CA 1.464 0.263 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.279 -179.312 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 218' ' ' TRP . . . . . 0.532 ' CH2' ' N ' ' B' ' 208' ' ' SER . 19.6 t-105 -105.33 107.5 18.52 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.014 -0.539 . . . . 0.0 109.874 179.5 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 219' ' ' LYS . . . . . 0.481 ' HG3' HG22 ' B' ' 217' ' ' THR . 51.1 mtmt -132.82 176.2 8.68 Favored 'General case' 0 CA--C 1.514 -0.44 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.285 -179.48 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -178.87 -162.38 28.2 Favored Glycine 0 CA--C 1.525 0.685 0 N-CA-C 110.998 -0.841 . . . . 0.0 110.998 179.288 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 221' ' ' ILE . . . . . 0.597 ' H ' HD12 ' B' ' 221' ' ' ILE . 2.3 mp -55.84 -73.11 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 C-N-CA 120.817 -0.353 . . . . 0.0 110.466 -178.321 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 222' ' ' ILE . . . . . 0.54 HG23 ' O ' ' B' ' 221' ' ' ILE . 23.0 pt -160.1 -165.27 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.167 -179.685 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 223' ' ' ARG . . . . . 0.522 ' N ' HD11 ' A' ' 75' ' ' ILE . 39.1 ptt180 -41.12 171.54 0.0 OUTLIER 'General case' 0 C--N 1.334 -0.092 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.956 178.778 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 224' ' ' LEU . . . . . 0.834 HD22 ' H ' ' B' ' 224' ' ' LEU . 1.9 mm? -65.16 110.61 2.6 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-O 121.383 0.611 . . . . 0.0 110.941 -179.642 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 82.7 tt0 . . . . . 0 C--N 1.329 -0.307 0 CA-C-N 115.251 -0.886 . . . . 0.0 109.966 179.656 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.338 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 32.8 p -156.55 -157.25 0.69 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.743 0.306 . . . . 0.0 110.542 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 69.7 mm-40 -75.87 88.28 2.88 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.765 179.825 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.6 m -146.0 74.49 13.22 Favored Pre-proline 0 C--N 1.331 -0.2 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.417 179.696 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 62.8 Cg_endo -80.81 118.63 3.47 Favored 'Trans proline' 0 C--N 1.31 -1.459 0 C-N-CA 122.516 2.144 . . . . 0.0 112.079 179.803 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 89.2 mm-40 -87.95 -169.88 2.76 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.372 179.936 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 70.3 mt -75.68 127.15 32.44 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.236 -179.819 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 18.5 p -90.19 133.98 34.56 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.532 -179.908 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 97.6 m-20 -85.16 149.52 25.47 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.978 -0.556 . . . . 0.0 110.501 179.928 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.521 HD11 ' CZ2' ' B' ' 209' ' ' TRP . 70.1 mt -62.0 151.3 35.55 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.192 -179.054 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 53.5 p -142.55 152.54 42.71 Favored 'General case' 0 CA--C 1.521 -0.152 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.311 -179.825 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . 0.56 ' CD2' HD11 ' B' ' 224' ' ' LEU . 24.7 m-85 -112.16 143.54 43.05 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.972 -179.552 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 28.5 m -142.87 162.06 17.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.326 179.496 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 91.5 m-20 45.57 61.6 2.54 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.499 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 95.5 mt -85.61 135.54 24.72 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.611 179.316 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.4 HG22 ' H ' ' A' ' 19' ' ' ASP . 0.2 OUTLIER -132.37 -168.78 2.11 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.394 179.505 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . 0.458 ' OD1' ' N ' ' A' ' 20' ' ' SER . 28.7 p-10 -90.58 -42.38 10.83 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.748 179.312 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . 0.458 ' N ' ' OD1' ' A' ' 19' ' ' ASP . 28.4 t -112.69 7.16 18.56 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.848 -179.886 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 30.7 p -154.05 153.36 31.78 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.312 179.947 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 44.0 pt -147.65 149.16 15.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.344 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -99.52 80.56 0.52 Allowed Glycine 0 CA--C 1.526 0.744 0 N-CA-C 111.3 -0.72 . . . . 0.0 111.3 -179.898 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 62.1 mt -68.35 127.83 34.39 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.891 0.377 . . . . 0.0 110.041 -179.919 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 55.9 ttp180 -142.63 136.05 28.74 Favored 'General case' 0 CA--C 1.518 -0.252 0 CA-C-O 121.095 0.474 . . . . 0.0 110.493 -179.819 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' TRP . . . . . 0.55 ' CD2' ' O ' ' A' ' 60' ' ' GLY . 43.0 p90 -140.78 155.79 46.32 Favored 'General case' 0 CA--C 1.518 -0.284 0 CA-C-N 115.835 -0.621 . . . . 0.0 109.85 179.932 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 2.7 m -110.23 101.85 49.3 Favored Pre-proline 0 CA--C 1.534 0.358 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.839 -179.476 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_exo -56.34 150.59 49.29 Favored 'Trans proline' 0 C--N 1.308 -1.576 0 C-N-CA 122.078 1.852 . . . . 0.0 112.518 178.854 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 72.8 mt -87.3 134.9 33.5 Favored 'General case' 0 N--CA 1.465 0.281 0 CA-C-O 121.718 0.771 . . . . 0.0 110.671 -179.881 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 18.6 t-20 -47.13 -32.63 4.42 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-N 115.214 -0.903 . . . . 0.0 110.199 -179.923 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 75.8 m -82.38 -33.43 28.77 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.65 179.273 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 4.3 m -56.47 130.76 46.3 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-O 120.982 0.42 . . . . 0.0 110.221 -179.96 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . 0.477 ' OG1' ' N ' ' A' ' 82' ' ' ASN . 6.6 m -54.37 139.53 36.52 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.586 -0.734 . . . . 0.0 109.776 -179.494 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 30.7 mm -93.57 88.97 2.54 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 CA-C-O 121.133 0.492 . . . . 0.0 110.608 -179.275 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.42 HD11 ' HA ' ' A' ' 81' ' ' ILE . 7.9 pt -139.65 149.18 22.64 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.184 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.408 179.588 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -48.68 136.88 17.77 Favored Glycine 0 CA--C 1.519 0.305 0 N-CA-C 110.918 -0.873 . . . . 0.0 110.918 -179.437 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 73.1 m-85 -104.6 160.44 14.95 Favored 'General case' 0 CA--C 1.517 -0.294 0 CA-C-O 120.826 0.346 . . . . 0.0 110.13 -179.818 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 5.3 tmm_? -124.32 124.5 42.52 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.791 -179.789 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.434 ' O ' ' CG1' ' A' ' 39' ' ' ILE . 2.5 pt -99.12 124.77 52.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.075 -0.511 . . . . 0.0 109.936 179.749 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 16.6 m -106.33 135.4 47.89 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.493 -179.545 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.4 p -133.9 142.2 41.94 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.25 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.162 179.878 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . 0.527 ' O ' ' N ' ' A' ' 74' ' ' ASP . 38.3 t -132.55 131.87 60.05 Favored 'Isoleucine or valine' 0 C--N 1.34 0.167 0 N-CA-C 110.06 -0.348 . . . . 0.0 110.06 179.46 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.554 ' HB2' ' CE2' ' A' ' 73' ' ' TYR . . . -98.98 142.47 30.43 Favored 'General case' 0 C--N 1.327 -0.406 0 N-CA-C 109.366 -0.605 . . . . 0.0 109.366 179.158 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.549 ' HB3' ' O ' ' A' ' 72' ' ' ASP . . . -101.06 -21.41 15.01 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.876 0.369 . . . . 0.0 110.959 179.412 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -94.07 30.6 7.41 Favored Glycine 0 N--CA 1.465 0.586 0 N-CA-C 110.958 -0.857 . . . . 0.0 110.958 -179.709 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 86.9 mt-10 -150.98 150.74 31.15 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-O 120.966 0.413 . . . . 0.0 110.626 -179.57 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -70.9 -16.46 74.65 Favored Glycine 0 CA--C 1.519 0.339 0 N-CA-C 110.567 -1.013 . . . . 0.0 110.567 179.879 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -137.63 139.32 26.64 Favored Pre-proline 0 CA--C 1.539 0.524 0 C-N-CA 121.058 -0.257 . . . . 0.0 110.401 179.632 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 63.3 Cg_endo -73.76 160.61 43.37 Favored 'Trans proline' 0 N--CA 1.49 1.291 0 C-N-CA 122.44 2.094 . . . . 0.0 112.326 177.833 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 96.7 mt -71.53 150.54 9.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.285 179.334 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 85.9 m-85 -73.1 140.86 47.44 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.728 179.938 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . 0.42 ' N ' ' CD ' ' A' ' 52' ' ' GLU . 0.3 OUTLIER -68.26 -177.21 0.84 Allowed 'General case' 0 CA--C 1.514 -0.408 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.653 179.575 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . 0.41 ' CG ' ' OH ' ' A' ' 62' ' ' TYR . 3.5 t70 -149.47 143.38 25.63 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.6 179.361 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 92.7 m-85 -111.33 122.82 48.85 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.366 179.854 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 5.3 p -129.41 139.13 52.54 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.292 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.293 -179.894 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 91.5 m-20 -55.29 158.12 3.29 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.483 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 38.5 t -66.25 -37.01 84.49 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.66 179.937 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 37.9 m -51.59 -33.4 32.55 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.311 -179.598 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.571 ' C ' ' H ' ' A' ' 61' ' ' TYR . 1.9 t -91.78 68.76 0.58 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.179 179.291 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . 0.55 ' O ' ' CD2' ' A' ' 26' ' ' TRP . . . -53.24 -2.64 0.1 Allowed Glycine 0 CA--C 1.528 0.873 0 N-CA-C 110.946 -0.862 . . . . 0.0 110.946 -179.983 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . 0.571 ' H ' ' C ' ' A' ' 59' ' ' VAL . 41.2 p90 -122.57 151.64 41.2 Favored 'General case' 0 N--CA 1.464 0.243 0 CA-C-O 121.103 0.478 . . . . 0.0 111.0 -179.6 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' TYR . . . . . 0.41 ' OH ' ' CG ' ' A' ' 53' ' ' ASP . 33.6 t80 -155.78 156.79 35.41 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.726 -0.67 . . . . 0.0 109.772 179.553 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 88.0 m -119.92 136.44 54.51 Favored 'General case' 0 N--CA 1.465 0.301 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.402 -179.569 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -131.9 110.95 17.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.018 -0.537 . . . . 0.0 109.863 178.956 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 2.0 p -122.26 164.15 18.38 Favored 'General case' 0 N--CA 1.464 0.256 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.617 -179.94 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 112.86 8.65 20.15 Favored Glycine 0 CA--C 1.529 0.943 0 CA-C-N 115.561 -0.745 . . . . 0.0 111.74 -179.12 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 10.5 mt -75.48 178.94 5.57 Favored 'General case' 0 C--N 1.325 -0.483 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 178.583 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 58.7 mm-40 -128.04 137.62 31.21 Favored Pre-proline 0 CA--C 1.54 0.584 0 C-N-CA 121.019 -0.272 . . . . 0.0 111.076 179.295 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -73.34 148.67 43.81 Favored 'Trans proline' 0 N--CA 1.496 1.619 0 C-N-CA 122.801 2.334 . . . . 0.0 111.83 179.193 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 75.51 3.83 73.03 Favored Glycine 0 CA--C 1.526 0.768 0 CA-C-N 115.619 -0.719 . . . . 0.0 111.411 179.226 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 2.0 mp -112.23 141.26 28.31 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.401 0 CA-C-O 121.495 0.664 . . . . 0.0 109.579 -179.618 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' ASP . . . . . 0.549 ' O ' ' HB3' ' A' ' 44' ' ' ALA . 1.9 t70 -82.06 111.52 18.28 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 115.137 -0.938 . . . . 0.0 110.633 179.854 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' TYR . . . . . 0.554 ' CE2' ' HB2' ' A' ' 43' ' ' ALA . 14.7 m-85 -105.86 119.56 39.48 Favored 'General case' 0 C--O 1.219 -0.546 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.568 179.791 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' ASP . . . . . 0.527 ' N ' ' O ' ' A' ' 42' ' ' VAL . 5.5 m-20 -89.32 118.82 29.27 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.572 -0.74 . . . . 0.0 109.326 179.838 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.629 HD11 ' N ' ' B' ' 223' ' ' ARG . 0.0 OUTLIER -115.45 163.81 12.38 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.404 0 CA-C-O 121.066 0.46 . . . . 0.0 110.163 -179.082 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 20.6 t -155.91 121.44 4.9 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.508 -0.769 . . . . 0.0 110.681 178.899 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 5.2 t -101.35 101.09 11.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 N-CA-C 109.901 -0.407 . . . . 0.0 109.901 179.341 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 96.8 mt -91.96 133.46 33.37 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.267 179.763 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . 0.473 ' CG2' ' O ' ' B' ' 216' ' ' TRP . 0.0 OUTLIER -111.91 107.54 16.59 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 121.108 0.48 . . . . 0.0 109.755 179.551 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 38.3 tp -104.22 115.37 30.28 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.724 -0.671 . . . . 0.0 110.458 179.937 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' ILE . . . . . 0.42 ' HA ' HD11 ' A' ' 35' ' ' ILE . 2.1 pp -145.95 146.26 19.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.068 -0.514 . . . . 0.0 110.275 179.33 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' ASN . . . . . 0.477 ' N ' ' OG1' ' A' ' 33' ' ' THR . 18.9 t-20 -69.32 -48.71 60.68 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.844 0.354 . . . . 0.0 111.256 -179.902 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . 0.422 ' H ' ' HG1' ' A' ' 33' ' ' THR . . . 106.91 165.31 22.33 Favored Glycine 0 N--CA 1.465 0.618 0 N-CA-C 110.843 -0.903 . . . . 0.0 110.843 179.745 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -72.66 175.56 43.87 Favored Glycine 0 CA--C 1.525 0.676 0 N-CA-C 110.753 -0.939 . . . . 0.0 110.753 -179.97 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 48.0 mp0 -63.84 123.73 19.68 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.829 0.347 . . . . 0.0 110.419 -179.81 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . 0.545 ' O ' ' HB3' ' A' ' 87' ' ' ALA . 23.2 p -79.57 168.47 19.36 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.519 179.831 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.545 ' HB3' ' O ' ' A' ' 86' ' ' SER . . . 72.74 58.41 0.36 Allowed Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.493 179.977 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -71.22 -88.73 0.0 OUTLIER 'Trans proline' 0 C--N 1.306 -1.695 0 C-N-CA 122.587 2.191 . . . . 0.0 111.934 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -138.26 122.34 17.96 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.56 179.932 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 16.3 p -147.54 -176.58 5.3 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.492 179.828 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 45.4 tp -90.15 125.81 35.58 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.384 179.941 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' THR . . . . . 0.418 ' H ' HG22 ' A' ' 92' ' ' THR . 0.1 OUTLIER -90.02 134.05 34.47 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.446 179.948 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 35.4 mt-30 -73.12 127.86 33.81 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.53 -179.931 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 50.8 tt0 -170.31 126.66 0.79 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.393 179.927 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 41.9 m . . . . . 0 C--O 1.22 -0.474 0 CA-C-O 118.057 -0.973 . . . . 0.0 110.486 179.953 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' B' B ' 201' ' ' SER . . . . . . . . . . . . . 48.1 p . . . . . 0 N--CA 1.491 1.597 0 N-CA-C 109.346 -0.613 . . . . 0.0 109.346 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' B' B ' 202' ' ' SER . . . . . . . . . . . . . 17.5 m -70.18 139.33 52.35 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.019 -179.988 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 203' ' ' SER . . . . . . . . . . . . . 1.4 p -105.95 151.13 39.95 Favored Pre-proline 0 CA--C 1.536 0.433 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.586 -179.726 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 204' ' ' PRO . . . . . . . . . . . . . 75.0 Cg_exo -45.33 -47.37 12.92 Favored 'Trans proline' 0 N--CA 1.492 1.421 0 C-N-CA 122.485 2.123 . . . . 0.0 112.116 179.381 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 205' ' ' ILE . . . . . 0.415 HG21 ' H ' ' B' ' 225' ' ' GLU . 0.0 OUTLIER -151.23 148.68 14.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.398 179.823 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 206' ' ' GLN . . . . . . . . . . . . . 17.9 pt20 -144.91 144.78 31.26 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.871 0.367 . . . . 0.0 110.25 178.604 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 207' ' ' GLY . . . . . . . . . . . . . . . -104.95 -130.55 6.82 Favored Glycine 0 N--CA 1.467 0.736 0 N-CA-C 111.088 -0.805 . . . . 0.0 111.088 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 208' ' ' SER . . . . . 0.556 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 59.7 p -166.74 171.78 11.15 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.823 0.344 . . . . 0.0 110.825 179.795 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 209' ' ' TRP . . . . . 0.521 ' CZ2' HD11 ' A' ' 12' ' ' LEU . 44.4 m95 -83.66 146.33 28.31 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.593 179.041 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 32.0 p -128.64 130.11 46.8 Favored 'General case' 0 N--CA 1.463 0.199 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.287 179.752 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 39.1 t-105 -95.37 117.72 30.83 Favored 'General case' 0 N--CA 1.463 0.221 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.376 179.834 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 212' ' ' GLU . . . . . 0.443 ' O ' ' O ' ' B' ' 215' ' ' LYS . 0.6 OUTLIER -163.81 164.57 23.55 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.708 179.13 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 213' ' ' ASN . . . . . . . . . . . . . 11.7 m120 52.62 39.92 29.12 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.616 176.302 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 49.64 21.68 3.52 Favored Glycine 0 CA--C 1.524 0.647 0 N-CA-C 111.084 -0.806 . . . . 0.0 111.084 179.605 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 215' ' ' LYS . . . . . 0.443 ' O ' ' O ' ' B' ' 212' ' ' GLU . 24.9 mtpt -148.02 152.73 37.93 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.063 0.459 . . . . 0.0 111.51 -179.694 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 216' ' ' TRP . . . . . 0.483 ' N ' ' CD1' ' B' ' 216' ' ' TRP . 24.4 m95 -92.17 119.08 31.47 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.959 -0.564 . . . . 0.0 109.729 179.165 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 217' ' ' THR . . . . . . . . . . . . . 12.4 m -132.72 145.02 50.68 Favored 'General case' 0 N--CA 1.465 0.32 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.469 -179.732 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 218' ' ' TRP . . . . . 0.556 ' CH2' ' N ' ' B' ' 208' ' ' SER . 14.5 t-105 -103.34 118.12 36.03 Favored 'General case' 0 N--CA 1.463 0.199 0 CA-C-N 116.008 -0.542 . . . . 0.0 109.922 179.563 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 95.7 mttt -141.15 165.74 26.7 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.952 -179.729 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -176.03 -161.02 24.47 Favored Glycine 0 CA--C 1.521 0.435 0 CA-C-N 115.492 -0.776 . . . . 0.0 111.421 -179.589 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 221' ' ' ILE . . . . . 0.546 ' O ' HG23 ' B' ' 222' ' ' ILE . 22.6 mt -52.75 -74.74 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 C-N-CA 120.598 -0.441 . . . . 0.0 110.295 -177.839 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 222' ' ' ILE . . . . . 0.546 HG23 ' O ' ' B' ' 221' ' ' ILE . 22.1 pt -160.47 -166.72 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.389 -0.369 . . . . 0.0 110.064 179.776 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 223' ' ' ARG . . . . . 0.629 ' N ' HD11 ' A' ' 75' ' ' ILE . 34.1 ptt85 -42.01 175.17 0.0 OUTLIER 'General case' 0 C--N 1.333 -0.129 0 CA-C-O 121.525 0.678 . . . . 0.0 110.532 178.842 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 224' ' ' LEU . . . . . 0.704 ' N ' HD22 ' B' ' 224' ' ' LEU . 3.1 mm? -60.55 122.68 15.27 Favored 'General case' 0 C--N 1.315 -0.905 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.954 -179.379 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 225' ' ' GLU . . . . . 0.415 ' H ' HG21 ' B' ' 205' ' ' ILE . 43.1 tt0 -85.22 140.51 30.83 Favored 'General case' 0 CA--C 1.517 -0.315 0 CA-C-N 115.623 -0.717 . . . . 0.0 110.343 179.678 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 226' ' ' GLN . . . . . . . . . . . . . 74.1 mt-30 . . . . . 0 C--O 1.22 -0.461 0 CA-C-O 117.926 -1.035 . . . . 0.0 111.071 -179.852 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.317 0 N-CA-C 109.404 -1.479 . . . . 0.0 109.404 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 37.9 t -63.22 138.89 58.69 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.804 0.335 . . . . 0.0 110.204 179.861 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -108.67 117.38 34.03 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-N 116.163 -0.472 . . . . 0.0 109.966 179.729 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.415 ' H ' HG22 ' A' ' 6' ' ' VAL . 5.5 m -90.29 153.34 46.44 Favored Pre-proline 0 CA--C 1.536 0.438 0 CA-C-N 116.561 -0.291 . . . . 0.0 110.566 -179.468 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_exo -52.59 146.8 32.7 Favored 'Trans proline' 0 N--CA 1.498 1.757 0 C-N-CA 121.851 1.701 . . . . 0.0 112.232 179.128 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . 0.613 ' CD ' ' H ' ' A' ' 8' ' ' GLN . 0.1 OUTLIER -65.44 -84.79 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.778 -0.646 . . . . 0.0 110.198 179.872 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 74.8 mt -99.31 127.25 45.29 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.914 -0.585 . . . . 0.0 110.233 -179.95 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . 0.681 HG22 HD21 ' A' ' 29' ' ' LEU . 14.9 t -84.56 177.68 7.99 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.341 -179.915 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . 0.537 ' OD1' ' N ' ' A' ' 12' ' ' LEU . 55.9 t0 -132.32 153.07 51.08 Favored 'General case' 0 N--CA 1.465 0.277 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.241 179.97 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.537 ' N ' ' OD1' ' A' ' 11' ' ' ASP . 6.0 tp -65.3 142.8 58.13 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.49 -179.963 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . 0.456 ' O ' ' O ' ' A' ' 25' ' ' ARG . 93.5 p -141.99 152.53 43.52 Favored 'General case' 0 N--CA 1.463 0.214 0 CA-C-O 121.076 0.465 . . . . 0.0 110.544 179.325 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . 0.538 ' CD2' HD11 ' B' ' 224' ' ' LEU . 24.3 m-85 -111.46 146.25 37.57 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.511 -179.251 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 31.9 m -147.06 153.86 12.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-O 120.818 0.342 . . . . 0.0 110.395 179.285 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 32.6 t70 58.89 56.87 3.85 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.426 179.854 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 94.0 mt -83.51 133.31 29.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 115.914 -0.585 . . . . 0.0 110.393 179.667 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.44 HG22 ' H ' ' A' ' 19' ' ' ASP . 0.2 OUTLIER -131.17 -167.73 1.89 Allowed 'General case' 0 N--CA 1.471 0.606 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.206 -179.74 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . 0.474 ' OD1' ' N ' ' A' ' 19' ' ' ASP . 0.4 OUTLIER -75.89 -53.24 8.74 Favored 'General case' 0 CA--C 1.517 -0.307 0 CA-C-O 120.993 0.425 . . . . 0.0 110.876 179.21 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . 0.427 ' CB ' ' O ' ' A' ' 67' ' ' LEU . 33.4 p -121.13 14.31 11.37 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.968 -177.796 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . 0.401 ' HB2' HG22 ' A' ' 65' ' ' THR . 95.5 p -144.96 125.05 13.61 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.116 0.484 . . . . 0.0 110.112 179.953 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 47.1 pt -127.39 140.67 48.46 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.323 0 CA-C-N 115.912 -0.586 . . . . 0.0 109.492 -179.823 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -103.69 91.57 0.83 Allowed Glycine 0 N--CA 1.467 0.704 0 N-CA-C 111.436 -0.665 . . . . 0.0 111.436 -179.397 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.506 ' N ' HD22 ' A' ' 24' ' ' LEU . 4.0 mm? -61.51 138.53 58.28 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.793 0.33 . . . . 0.0 110.234 -179.812 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . 0.456 ' O ' ' O ' ' A' ' 13' ' ' SER . 13.9 tpt180 -145.38 134.89 23.22 Favored 'General case' 0 C--N 1.334 -0.091 0 CA-C-O 121.455 0.645 . . . . 0.0 110.288 179.873 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' TRP . . . . . 0.511 ' CE2' ' O ' ' A' ' 60' ' ' GLY . 18.7 p90 -145.81 156.3 43.49 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.47 -0.786 . . . . 0.0 109.519 179.21 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 2.7 m -105.5 104.4 47.9 Favored Pre-proline 0 CA--C 1.534 0.344 0 CA-C-O 119.546 -0.264 . . . . 0.0 111.161 -179.153 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_exo -54.48 153.2 23.83 Favored 'Trans proline' 0 C--N 1.31 -1.483 0 C-N-CA 121.381 1.388 . . . . 0.0 113.011 178.523 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.681 HD21 HG22 ' A' ' 10' ' ' THR . 75.2 mt -102.57 134.86 45.22 Favored 'General case' 0 N--CA 1.467 0.392 0 CA-C-N 114.946 -1.024 . . . . 0.0 111.04 179.854 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 18.3 t-20 -45.39 -31.1 1.52 Allowed 'General case' 0 C--N 1.314 -0.964 0 CA-C-N 114.86 -1.063 . . . . 0.0 110.263 179.883 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 50.8 m -87.79 -28.85 21.42 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.292 178.998 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . 0.464 ' N ' ' O ' ' A' ' 29' ' ' LEU . 3.4 m -56.23 117.56 3.89 Favored 'General case' 0 CA--C 1.529 0.162 0 CA-C-O 121.318 0.58 . . . . 0.0 110.145 179.935 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . 0.631 ' CB ' ' H ' ' A' ' 82' ' ' ASN . 12.2 m -51.83 145.55 9.51 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-N 114.919 -1.037 . . . . 0.0 109.182 -179.126 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 30.1 mm -92.08 93.42 4.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.998 0.428 . . . . 0.0 110.825 -178.113 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.597 HD11 ' HA ' ' A' ' 81' ' ' ILE . 8.1 pt -150.97 128.84 2.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 115.871 -0.604 . . . . 0.0 109.875 179.027 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -47.01 130.38 12.75 Favored Glycine 0 CA--C 1.521 0.413 0 N-CA-C 111.4 -0.68 . . . . 0.0 111.4 -178.941 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 95.2 m-85 -87.36 179.64 6.56 Favored 'General case' 0 C--N 1.33 -0.279 0 N-CA-C 109.976 -0.379 . . . . 0.0 109.976 179.551 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . 0.683 ' NH2' ' H ' ' A' ' 40' ' ' THR . 0.0 OUTLIER -131.59 123.08 27.17 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.93 179.885 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.49 ' CG1' ' O ' ' A' ' 39' ' ' ILE . 1.7 pt -107.08 118.0 53.99 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.532 0 CA-C-O 121.203 0.525 . . . . 0.0 110.103 179.546 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . 0.683 ' H ' ' NH2' ' A' ' 38' ' ' ARG . 52.9 m -103.25 138.94 39.36 Favored 'General case' 0 N--CA 1.47 0.537 0 O-C-N 122.037 -0.415 . . . . 0.0 110.127 -179.39 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.4 p -129.1 141.13 47.4 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.476 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.351 -179.873 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . 0.495 ' O ' ' N ' ' A' ' 74' ' ' ASP . 37.4 t -131.9 132.73 61.53 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.166 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.203 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -96.66 132.91 41.83 Favored 'General case' 0 C--N 1.327 -0.401 0 N-CA-C 109.468 -0.567 . . . . 0.0 109.468 179.173 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.607 ' HB3' ' O ' ' A' ' 72' ' ' ASP . . . -91.65 -19.16 22.97 Favored 'General case' 0 C--N 1.328 -0.333 0 C-N-CA 120.748 -0.381 . . . . 0.0 110.681 179.994 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -99.07 25.04 29.82 Favored Glycine 0 N--CA 1.466 0.67 0 N-CA-C 111.208 -0.757 . . . . 0.0 111.208 -179.729 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -138.96 146.95 41.6 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 120.853 0.358 . . . . 0.0 110.587 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -66.99 -21.18 71.4 Favored Glycine 0 CA--C 1.526 0.728 0 N-CA-C 111.126 -0.79 . . . . 0.0 111.126 179.811 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -138.16 140.59 29.26 Favored Pre-proline 0 CA--C 1.545 0.784 0 O-C-N 122.66 -0.318 . . . . 0.0 110.553 -179.977 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -74.11 163.79 35.86 Favored 'Trans proline' 0 N--CA 1.495 1.589 0 C-N-CA 122.656 2.238 . . . . 0.0 112.051 178.478 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . 0.556 HG22 ' N ' ' A' ' 51' ' ' PHE . 5.1 mp -86.66 159.99 3.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 115.693 -0.685 . . . . 0.0 111.103 -179.733 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' PHE . . . . . 0.556 ' N ' HG22 ' A' ' 50' ' ' ILE . 88.8 m-85 -73.13 142.77 47.47 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.782 -0.645 . . . . 0.0 111.091 -179.802 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -64.32 -175.25 0.15 Allowed 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 115.492 -0.776 . . . . 0.0 110.412 179.007 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -142.74 134.26 26.45 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.123 179.891 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 96.0 m-85 -111.01 119.98 40.84 Favored 'General case' 0 N--CA 1.465 0.322 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.675 -179.809 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 9.8 p -130.42 142.28 44.13 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.414 0 CA-C-O 120.557 0.218 . . . . 0.0 110.592 -179.906 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 99.4 m-20 -63.4 149.35 46.13 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.384 179.925 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . 0.44 ' OG ' ' O ' ' A' ' 35' ' ' ILE . 13.8 m -63.24 -32.49 73.91 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.72 0.295 . . . . 0.0 110.984 179.757 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 70.9 m -54.36 -40.45 68.12 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.352 -0.386 . . . . 0.0 110.581 -179.538 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.56 ' C ' ' H ' ' A' ' 61' ' ' TYR . 35.1 t -61.29 -44.08 97.77 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 -179.638 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . 0.511 ' O ' ' CE2' ' A' ' 26' ' ' TRP . . . 68.96 -29.78 0.3 Allowed Glycine 0 CA--C 1.529 0.945 0 N-CA-C 111.346 -0.702 . . . . 0.0 111.346 179.846 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . 0.56 ' H ' ' C ' ' A' ' 59' ' ' VAL . 44.9 t80 -112.6 155.48 24.32 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-O 121.225 0.536 . . . . 0.0 111.163 -179.15 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' TYR . . . . . 0.474 ' CD2' ' CD1' ' A' ' 39' ' ' ILE . 24.2 t80 -155.68 159.37 39.49 Favored 'General case' 0 N--CA 1.454 -0.227 0 CA-C-N 115.539 -0.755 . . . . 0.0 109.694 178.617 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 90.9 m -127.7 135.47 50.22 Favored 'General case' 0 N--CA 1.465 0.307 0 CA-C-O 120.834 0.349 . . . . 0.0 110.34 -179.924 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -131.46 107.01 12.8 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 N-CA-C 109.172 -0.677 . . . . 0.0 109.172 178.489 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.401 HG22 ' HB2' ' A' ' 21' ' ' SER . 2.3 p -120.89 162.88 19.09 Favored 'General case' 0 CA--C 1.514 -0.428 0 CA-C-O 120.911 0.386 . . . . 0.0 110.469 -179.707 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 106.62 24.67 6.6 Favored Glycine 0 CA--C 1.52 0.365 0 N-CA-C 110.889 -0.884 . . . . 0.0 110.889 179.873 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.427 ' O ' ' CB ' ' A' ' 20' ' ' SER . 6.9 mt -97.64 107.58 20.1 Favored 'General case' 0 CA--C 1.53 0.175 0 N-CA-C 109.405 -0.591 . . . . 0.0 109.405 179.897 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 66.8 mm-40 -46.36 135.53 7.29 Favored Pre-proline 0 C--N 1.319 -0.753 0 N-CA-C 112.019 0.377 . . . . 0.0 112.019 -178.44 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 95.1 Cg_endo -74.28 156.25 46.3 Favored 'Trans proline' 0 N--CA 1.498 1.789 0 C-N-CA 122.718 2.278 . . . . 0.0 111.219 178.753 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 72.56 -7.39 8.87 Favored Glycine 0 CA--C 1.528 0.864 0 C-N-CA 121.08 -0.581 . . . . 0.0 111.792 179.145 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 1.7 mp -103.74 143.32 15.82 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.366 0 CA-C-O 121.236 0.541 . . . . 0.0 109.702 -179.739 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' ASP . . . . . 0.607 ' O ' ' HB3' ' A' ' 44' ' ' ALA . 1.7 t0 -82.02 118.7 23.2 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.152 -0.931 . . . . 0.0 110.651 179.891 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' TYR . . . . . 0.506 ' O ' HD13 ' A' ' 75' ' ' ILE . 13.8 m-85 -109.74 120.59 42.96 Favored 'General case' 0 C--O 1.221 -0.4 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.899 -179.784 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' ASP . . . . . 0.495 ' N ' ' O ' ' A' ' 42' ' ' VAL . 69.6 m-20 -89.55 116.63 27.85 Favored 'General case' 0 C--N 1.318 -0.783 0 CA-C-N 115.565 -0.743 . . . . 0.0 109.862 179.357 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.6 HD11 ' N ' ' B' ' 223' ' ' ARG . 0.0 OUTLIER -116.1 165.58 11.23 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.383 0 CA-C-O 121.098 0.475 . . . . 0.0 110.262 -179.658 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 11.1 p -153.18 148.85 27.39 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.559 -0.746 . . . . 0.0 110.274 179.08 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.535 ' O ' HG23 ' B' ' 217' ' ' THR . 53.5 t -129.33 135.61 61.33 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 N-CA-C 109.26 -0.644 . . . . 0.0 109.26 179.3 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . 0.663 HD12 ' NH1' ' A' ' 38' ' ' ARG . 93.9 mt -127.49 128.11 69.49 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.314 0 CA-C-O 120.854 0.359 . . . . 0.0 110.849 179.315 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 97.1 m -100.93 109.6 21.56 Favored 'General case' 0 C--N 1.331 -0.219 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 179.037 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 37.0 tp -117.95 118.97 33.43 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.638 -179.792 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' ILE . . . . . 0.676 ' O ' HD12 ' A' ' 81' ' ' ILE . 2.2 pp -137.41 161.61 34.13 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.166 0 CA-C-N 115.957 -0.565 . . . . 0.0 109.786 178.801 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' ASN . . . . . 0.631 ' H ' ' CB ' ' A' ' 33' ' ' THR . 16.2 t-20 -64.9 -43.36 93.1 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.772 0.32 . . . . 0.0 110.899 -179.928 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 151.71 123.41 1.05 Allowed Glycine 0 CA--C 1.525 0.666 0 N-CA-C 110.97 -0.852 . . . . 0.0 110.97 179.755 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -96.45 -179.45 35.19 Favored Glycine 0 CA--C 1.525 0.695 0 N-CA-C 110.814 -0.914 . . . . 0.0 110.814 179.806 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -71.35 153.82 42.05 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.884 0.373 . . . . 0.0 110.322 179.848 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 19.7 m -61.55 146.36 49.04 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.483 -179.973 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -167.32 74.17 1.01 Allowed Pre-proline 0 C--N 1.329 -0.285 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.423 -179.986 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 34.3 Cg_exo -59.51 145.51 97.78 Favored 'Trans proline' 0 C--N 1.306 -1.671 0 C-N-CA 122.675 2.25 . . . . 0.0 111.927 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 2.0 t -122.65 127.86 49.88 Favored 'General case' 0 N--CA 1.467 0.402 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.635 -179.881 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 17.5 p -87.51 175.34 7.99 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.549 179.88 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . 0.578 ' N ' HD12 ' A' ' 91' ' ' LEU . 9.6 mp -56.32 174.11 0.15 Allowed 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.0 -0.545 . . . . 0.0 110.205 179.793 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -42.2 141.89 0.85 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.868 -0.606 . . . . 0.0 110.786 -179.87 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 18.4 pt20 -65.31 151.53 46.01 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.7 -179.957 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 58.5 tt0 53.01 80.62 0.1 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.488 -179.973 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 70.2 p . . . . . 0 C--O 1.221 -0.42 0 CA-C-O 117.942 -1.027 . . . . 0.0 110.532 -179.997 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' B' B ' 201' ' ' SER . . . . . . . . . . . . . 74.7 m . . . . . 0 N--CA 1.49 1.565 0 N-CA-C 109.405 -0.591 . . . . 0.0 109.405 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' B' B ' 202' ' ' SER . . . . . . . . . . . . . 30.7 t -66.68 141.68 57.69 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.193 179.527 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 203' ' ' SER . . . . . . . . . . . . . 60.5 p -126.05 108.89 24.66 Favored Pre-proline 0 CA--C 1.537 0.48 0 N-CA-C 109.878 -0.415 . . . . 0.0 109.878 179.728 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 204' ' ' PRO . . . . . . . . . . . . . 66.6 Cg_endo -76.22 -58.54 0.04 OUTLIER 'Trans proline' 0 N--CA 1.491 1.375 0 C-N-CA 121.384 1.39 . . . . 0.0 112.136 -179.472 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 205' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -150.28 146.36 16.65 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.168 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.133 -179.765 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 206' ' ' GLN . . . . . . . . . . . . . 50.6 mt-30 -137.17 137.46 39.19 Favored 'General case' 0 C--N 1.327 -0.403 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 178.828 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 207' ' ' GLY . . . . . . . . . . . . . . . -97.88 -141.45 12.24 Favored Glycine 0 N--CA 1.463 0.48 0 N-CA-C 111.098 -0.801 . . . . 0.0 111.098 -179.685 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 208' ' ' SER . . . . . 0.533 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 38.7 p -165.13 169.33 16.28 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.624 0.249 . . . . 0.0 110.778 179.591 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 209' ' ' TRP . . . . . . . . . . . . . 86.3 m95 -88.05 150.07 23.61 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.202 179.632 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 69.3 p -129.03 129.76 45.74 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-O 120.801 0.334 . . . . 0.0 110.481 179.522 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 52.0 t-105 -91.75 110.32 21.65 Favored 'General case' 0 N--CA 1.463 0.219 0 CA-C-N 116.477 -0.329 . . . . 0.0 110.272 179.609 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 212' ' ' GLU . . . . . 0.527 ' O ' ' O ' ' B' ' 215' ' ' LYS . 2.0 pt-20 -162.78 171.74 16.29 Favored 'General case' 0 C--O 1.22 -0.457 0 CA-C-O 120.977 0.418 . . . . 0.0 110.582 179.454 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 213' ' ' ASN . . . . . 0.492 ' C ' ' H ' ' B' ' 215' ' ' LYS . 13.8 m120 49.77 30.26 3.68 Favored 'General case' 0 C--N 1.317 -0.834 0 C-N-CA 120.237 -0.585 . . . . 0.0 111.721 176.788 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 66.48 -13.13 0.43 Allowed Glycine 0 CA--C 1.532 1.105 0 C-N-CA 121.087 -0.578 . . . . 0.0 111.973 179.229 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 215' ' ' LYS . . . . . 0.527 ' O ' ' O ' ' B' ' 212' ' ' GLU . 67.5 mttm -126.05 156.25 40.25 Favored 'General case' 0 N--CA 1.468 0.432 0 CA-C-O 121.143 0.497 . . . . 0.0 110.67 -179.445 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 216' ' ' TRP . . . . . 0.475 ' N ' ' CD1' ' B' ' 216' ' ' TRP . 32.4 m95 -86.53 125.12 33.54 Favored 'General case' 0 C--N 1.328 -0.348 0 C-N-CA 120.837 -0.345 . . . . 0.0 110.095 179.796 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 217' ' ' THR . . . . . 0.535 HG23 ' O ' ' A' ' 77' ' ' VAL . 18.5 m -124.42 138.42 54.36 Favored 'General case' 0 N--CA 1.468 0.427 0 CA-C-O 120.893 0.378 . . . . 0.0 110.359 -179.45 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 218' ' ' TRP . . . . . 0.533 ' CH2' ' N ' ' B' ' 208' ' ' SER . 24.5 t-105 -105.7 106.7 17.32 Favored 'General case' 0 N--CA 1.462 0.148 0 CA-C-N 116.13 -0.486 . . . . 0.0 109.88 179.343 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 74.4 mttt -135.46 171.47 14.4 Favored 'General case' 0 N--CA 1.466 0.355 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.646 -179.331 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -177.86 -162.75 28.4 Favored Glycine 0 CA--C 1.526 0.765 0 N-CA-C 110.857 -0.897 . . . . 0.0 110.857 179.57 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 221' ' ' ILE . . . . . 0.548 ' O ' HG23 ' B' ' 222' ' ' ILE . 0.8 OUTLIER -53.6 -74.2 0.05 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.384 0 C-N-CA 120.98 -0.288 . . . . 0.0 111.082 -178.73 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' B' B ' 222' ' ' ILE . . . . . 0.548 HG23 ' O ' ' B' ' 221' ' ' ILE . 20.6 pt -160.75 -165.79 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 116.276 -0.42 . . . . 0.0 109.895 -179.545 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 223' ' ' ARG . . . . . 0.6 ' N ' HD11 ' A' ' 75' ' ' ILE . 0.7 OUTLIER -43.37 174.9 0.0 OUTLIER 'General case' 0 N--CA 1.452 -0.363 0 CA-C-O 121.52 0.676 . . . . 0.0 110.814 179.154 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' B' B ' 224' ' ' LEU . . . . . 0.744 ' N ' HD22 ' B' ' 224' ' ' LEU . 2.6 mm? -61.28 116.11 4.36 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-N 115.51 -0.768 . . . . 0.0 110.634 -179.78 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 80.8 tt0 -103.59 149.31 25.02 Favored 'General case' 0 N--CA 1.465 0.277 0 CA-C-N 115.407 -0.815 . . . . 0.0 110.315 -179.987 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 226' ' ' GLN . . . . . . . . . . . . . 88.8 mt-30 . . . . . 0 C--N 1.325 -0.471 0 CA-C-O 117.986 -1.007 . . . . 0.0 110.724 -179.822 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.324 0 N-CA-C 109.422 -1.471 . . . . 0.0 109.422 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 97.1 p -76.67 -118.72 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.312 0 N-CA-C 110.258 -0.275 . . . . 0.0 110.258 179.916 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -67.2 141.4 57.33 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.475 179.839 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 12.1 t -138.2 75.87 39.51 Favored Pre-proline 0 N--CA 1.465 0.302 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.203 179.979 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_exo -53.82 135.42 62.81 Favored 'Trans proline' 0 C--N 1.307 -1.628 0 C-N-CA 122.328 2.019 . . . . 0.0 111.537 179.958 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 1.9 pt20 -119.14 -88.93 0.61 Allowed 'General case' 0 N--CA 1.467 0.375 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.307 -179.709 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 59.1 mt -87.6 115.41 25.02 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.413 -179.789 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . 0.655 HG22 HD21 ' A' ' 29' ' ' LEU . 8.8 t -75.61 143.98 42.02 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.764 -179.916 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 98.0 m-20 -82.9 150.49 26.45 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.801 179.981 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 7.2 tt -75.84 154.07 36.4 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.273 179.754 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . 0.433 ' O ' ' O ' ' A' ' 25' ' ' ARG . 17.7 p -140.26 151.39 45.09 Favored 'General case' 0 N--CA 1.462 0.156 0 CA-C-O 121.093 0.473 . . . . 0.0 110.226 178.862 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . 0.547 ' N ' ' CD1' ' A' ' 14' ' ' PHE . 18.0 m-85 -111.48 148.41 33.22 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.707 -0.679 . . . . 0.0 110.747 -179.194 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 25.3 m -148.25 155.57 9.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 120.966 0.412 . . . . 0.0 110.305 179.172 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 39.3 t0 62.72 29.9 16.8 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.6 -0.727 . . . . 0.0 110.891 -179.968 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 68.1 mt -56.68 131.97 20.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 179.716 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.414 ' CB ' ' O ' ' A' ' 21' ' ' SER . 0.2 OUTLIER -132.13 -168.78 2.1 Favored 'General case' 0 N--CA 1.47 0.538 0 CA-C-N 116.385 -0.37 . . . . 0.0 110.246 -179.551 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . 0.47 ' N ' ' OD1' ' A' ' 19' ' ' ASP . 22.4 p-10 -78.72 -48.47 14.86 Favored 'General case' 0 C--N 1.332 -0.169 0 C-N-CA 120.811 -0.356 . . . . 0.0 110.951 179.295 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . 0.484 ' OG ' ' N ' ' A' ' 67' ' ' LEU . 27.8 t -120.73 12.78 11.45 Favored 'General case' 0 N--CA 1.462 0.165 0 CA-C-O 120.518 0.199 . . . . 0.0 110.734 -178.882 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . 0.549 ' HB2' HG22 ' A' ' 65' ' ' THR . 92.8 p -146.63 131.03 17.62 Favored 'General case' 0 N--CA 1.463 0.19 0 CA-C-O 120.83 0.348 . . . . 0.0 110.095 -179.9 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 47.5 pt -127.5 142.14 44.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.159 -0.473 . . . . 0.0 109.991 -179.687 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -100.53 83.01 0.52 Allowed Glycine 0 N--CA 1.465 0.596 0 N-CA-C 110.414 -1.074 . . . . 0.0 110.414 179.951 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 16.7 mt -69.42 125.31 26.31 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.895 0.379 . . . . 0.0 110.0 -179.719 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . 0.433 ' O ' ' O ' ' A' ' 13' ' ' SER . 66.8 ttt180 -140.01 142.7 36.25 Favored 'General case' 0 N--CA 1.464 0.233 0 CA-C-O 121.268 0.556 . . . . 0.0 110.915 179.998 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' TRP . . . . . 0.528 ' CD2' ' O ' ' A' ' 60' ' ' GLY . 8.8 p90 -142.94 158.08 43.95 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.483 -0.78 . . . . 0.0 109.755 -179.61 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 4.1 m -103.06 103.92 37.06 Favored Pre-proline 0 CA--C 1.536 0.413 0 CA-C-O 119.592 -0.242 . . . . 0.0 111.058 -179.351 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 31.9 Cg_exo -55.17 153.7 25.76 Favored 'Trans proline' 0 C--N 1.312 -1.37 0 C-N-CA 121.616 1.544 . . . . 0.0 113.103 178.828 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.655 HD21 HG22 ' A' ' 10' ' ' THR . 75.1 mt -100.98 133.32 45.65 Favored 'General case' 0 N--CA 1.466 0.342 0 CA-C-N 115.047 -0.979 . . . . 0.0 110.966 179.658 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 26.4 t-20 -44.79 -30.57 0.99 Allowed 'General case' 0 C--N 1.315 -0.898 0 CA-C-N 114.695 -1.138 . . . . 0.0 110.258 179.772 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 64.3 m -89.16 -27.45 20.69 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 115.797 -0.638 . . . . 0.0 110.718 178.978 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . 0.484 ' N ' ' O ' ' A' ' 29' ' ' LEU . 3.3 m -56.38 120.65 8.0 Favored 'General case' 0 N--CA 1.462 0.155 0 CA-C-O 121.575 0.703 . . . . 0.0 110.262 179.876 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . 0.474 ' CB ' ' H ' ' A' ' 82' ' ' ASN . 6.4 m -52.9 147.27 9.38 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 114.866 -1.061 . . . . 0.0 109.725 -179.103 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 25.0 mm -93.18 93.35 4.11 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 116.4 -0.363 . . . . 0.0 110.888 -178.632 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.539 ' O ' ' CE1' ' A' ' 37' ' ' TYR . 9.0 pt -151.17 131.15 3.69 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.175 179.477 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -54.61 136.32 44.41 Favored Glycine 0 CA--C 1.524 0.609 0 N-CA-C 111.096 -0.802 . . . . 0.0 111.096 -179.252 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' TYR . . . . . 0.539 ' CE1' ' O ' ' A' ' 35' ' ' ILE . 5.0 m-85 -97.87 179.92 4.64 Favored 'General case' 0 C--N 1.332 -0.18 0 N-CA-C 109.683 -0.488 . . . . 0.0 109.683 179.679 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . 0.526 ' NH1' ' OE2' ' A' ' 52' ' ' GLU . 5.1 tmm_? -129.14 124.81 35.65 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.492 179.728 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.47 ' CD1' ' CD2' ' A' ' 62' ' ' TYR . 1.8 pt -101.51 118.54 48.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 115.96 -0.564 . . . . 0.0 109.871 179.68 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 35.2 m -102.7 134.35 46.22 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.578 -179.032 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.663 HG22 HD13 ' A' ' 50' ' ' ILE . 2.6 p -130.89 143.53 40.61 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.522 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.424 -179.691 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . 0.526 ' O ' ' N ' ' A' ' 74' ' ' ASP . 43.0 t -134.4 135.06 54.46 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.261 0 CA-C-O 120.875 0.369 . . . . 0.0 110.369 179.834 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.83 ' HB2' HD11 ' A' ' 50' ' ' ILE . . . -97.34 133.27 42.17 Favored 'General case' 0 C--N 1.33 -0.256 0 N-CA-C 109.515 -0.55 . . . . 0.0 109.515 179.169 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.578 ' HB3' ' O ' ' A' ' 72' ' ' ASP . . . -89.87 -40.74 12.23 Favored 'General case' 0 C--N 1.33 -0.246 0 C-N-CA 120.577 -0.449 . . . . 0.0 110.635 179.444 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -80.72 30.21 2.58 Favored Glycine 0 CA--C 1.524 0.602 0 N-CA-C 111.405 -0.678 . . . . 0.0 111.405 -179.817 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 80.0 mm-40 -140.42 146.76 38.72 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 121.079 0.466 . . . . 0.0 110.415 179.753 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -69.98 -20.37 76.17 Favored Glycine 0 CA--C 1.527 0.785 0 N-CA-C 111.133 -0.787 . . . . 0.0 111.133 179.711 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -135.6 142.46 41.08 Favored Pre-proline 0 CA--C 1.545 0.779 0 CA-C-N 116.735 0.268 . . . . 0.0 110.361 -179.482 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -72.14 164.86 34.35 Favored 'Trans proline' 0 N--CA 1.495 1.583 0 C-N-CA 122.457 2.105 . . . . 0.0 111.573 178.451 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . 1.037 ' H ' HD12 ' A' ' 50' ' ' ILE . 0.6 OUTLIER -86.65 159.72 3.11 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 116.022 -0.536 . . . . 0.0 110.619 -179.579 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 84.8 m-85 -75.02 141.32 43.92 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.752 179.893 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . 0.526 ' OE2' ' NH1' ' A' ' 38' ' ' ARG . 4.4 pt-20 -70.23 -175.88 1.07 Allowed 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.501 179.54 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -147.1 141.39 26.27 Favored 'General case' 0 CA--C 1.534 0.337 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.172 179.803 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 34.3 m-85 -113.56 119.56 37.93 Favored 'General case' 0 N--CA 1.469 0.481 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.452 -179.866 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 9.3 p -128.21 140.62 48.69 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.462 0 CA-C-O 120.966 0.412 . . . . 0.0 110.554 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 97.4 m-20 -65.04 153.77 39.76 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.556 179.964 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . 0.425 ' OG ' ' OH ' ' A' ' 37' ' ' TYR . 4.0 t -64.22 -33.51 75.96 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.662 179.921 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 52.1 m -52.99 -40.59 63.88 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.638 -179.419 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.5 ' O ' ' CD2' ' A' ' 61' ' ' TYR . 21.1 t -61.28 -43.55 96.74 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 N-CA-C 110.019 -0.363 . . . . 0.0 110.019 -179.582 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . 0.528 ' O ' ' CD2' ' A' ' 26' ' ' TRP . . . 72.5 -38.11 0.71 Allowed Glycine 0 CA--C 1.525 0.7 0 N-CA-C 111.359 -0.696 . . . . 0.0 111.359 179.389 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . 0.5 ' CD2' ' O ' ' A' ' 59' ' ' VAL . 32.1 p90 -114.62 158.82 21.21 Favored 'General case' 0 N--CA 1.47 0.54 0 CA-C-O 121.016 0.436 . . . . 0.0 110.993 -179.026 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' TYR . . . . . 0.47 ' CD2' ' CD1' ' A' ' 39' ' ' ILE . 29.1 t80 -151.62 158.37 43.39 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 109.394 -0.595 . . . . 0.0 109.394 179.336 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 53.8 m -120.65 133.68 55.34 Favored 'General case' 0 N--CA 1.465 0.297 0 CA-C-O 120.831 0.348 . . . . 0.0 110.095 179.74 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -131.81 103.46 6.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 N-CA-C 109.373 -0.603 . . . . 0.0 109.373 178.845 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.549 HG22 ' HB2' ' A' ' 21' ' ' SER . 3.4 p -116.36 162.48 17.46 Favored 'General case' 0 CA--C 1.512 -0.514 0 CA-C-O 121.077 0.465 . . . . 0.0 110.452 179.772 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 106.38 23.53 7.23 Favored Glycine 0 CA--C 1.521 0.424 0 N-CA-C 111.177 -0.769 . . . . 0.0 111.177 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.484 ' N ' ' OG ' ' A' ' 20' ' ' SER . 10.8 mt -97.43 109.91 22.57 Favored 'General case' 0 C--O 1.227 -0.115 0 N-CA-C 109.063 -0.717 . . . . 0.0 109.063 179.499 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 66.4 mm-40 -51.18 135.18 30.52 Favored Pre-proline 0 C--N 1.319 -0.745 0 C-N-CA 120.611 -0.435 . . . . 0.0 111.843 -178.039 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 96.8 Cg_endo -74.08 157.46 46.6 Favored 'Trans proline' 0 N--CA 1.499 1.85 0 C-N-CA 122.878 2.385 . . . . 0.0 111.132 178.83 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 72.31 -8.74 6.44 Favored Glycine 0 CA--C 1.525 0.678 0 C-N-CA 120.879 -0.677 . . . . 0.0 111.594 179.306 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 1.8 mp -103.88 140.67 21.37 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.373 0 CA-C-O 121.496 0.665 . . . . 0.0 109.642 -179.683 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' ASP . . . . . 0.578 ' O ' ' HB3' ' A' ' 44' ' ' ALA . 2.3 t0 -79.54 116.99 20.07 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 114.783 -1.098 . . . . 0.0 110.457 -179.524 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' TYR . . . . . 0.519 ' O ' HD13 ' A' ' 75' ' ' ILE . 11.5 m-85 -108.11 120.78 43.32 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.495 -179.771 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' ASP . . . . . 0.526 ' N ' ' O ' ' A' ' 42' ' ' VAL . 23.1 m-20 -88.51 114.63 25.33 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 115.275 -0.875 . . . . 0.0 109.831 -179.903 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.602 HD11 ' N ' ' B' ' 223' ' ' ARG . 0.0 OUTLIER -113.26 164.05 9.68 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.36 0 CA-C-O 121.217 0.532 . . . . 0.0 110.363 -179.747 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 2.6 p -152.42 124.63 8.13 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.183 -0.917 . . . . 0.0 109.918 179.539 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 70.7 t -106.14 131.45 55.73 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 N-CA-C 109.11 -0.7 . . . . 0.0 109.11 179.818 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 97.4 mt -128.17 131.25 69.47 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.317 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.898 -179.886 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . 0.535 HG23 ' O ' ' A' ' 79' ' ' THR . 9.0 t -106.95 122.41 46.37 Favored 'General case' 0 N--CA 1.463 0.192 0 CA-C-N 115.76 -0.654 . . . . 0.0 109.529 179.122 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 42.4 mt -119.86 113.01 19.94 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.478 -179.312 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' ILE . . . . . 0.505 ' HA ' HD11 ' A' ' 35' ' ' ILE . 2.2 pp -146.66 144.26 20.28 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.25 0 CA-C-O 120.725 0.298 . . . . 0.0 110.327 178.651 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' ASN . . . . . 0.474 ' H ' ' CB ' ' A' ' 33' ' ' THR . 42.3 t30 -66.77 -47.7 71.34 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.381 -0.372 . . . . 0.0 111.509 -179.683 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 88.06 8.69 71.79 Favored Glycine 0 CA--C 1.525 0.71 0 N-CA-C 111.191 -0.764 . . . . 0.0 111.191 179.661 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -71.94 166.5 53.35 Favored Glycine 0 CA--C 1.527 0.793 0 N-CA-C 110.815 -0.914 . . . . 0.0 110.815 179.887 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 96.0 mt-10 -74.26 83.79 1.88 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.837 0.351 . . . . 0.0 110.485 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 18.7 m -83.85 153.74 23.86 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.529 179.874 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . 61.86 56.09 2.87 Favored Pre-proline 0 C--N 1.327 -0.383 0 CA-C-N 116.341 -0.391 . . . . 0.0 110.599 179.892 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo -66.8 149.8 83.4 Favored 'Trans proline' 0 C--N 1.307 -1.621 0 C-N-CA 122.647 2.231 . . . . 0.0 111.99 -179.847 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . 0.43 ' H ' HG22 ' A' ' 89' ' ' THR . 0.5 OUTLIER -69.79 133.25 47.23 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.466 179.989 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 53.2 p -137.61 162.9 32.55 Favored 'General case' 0 N--CA 1.464 0.248 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.401 -179.972 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . 0.563 ' N ' HD12 ' A' ' 91' ' ' LEU . 10.5 mp -81.56 124.97 29.97 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.05 -179.934 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 92' ' ' THR . . . . . 0.4 HG22 ' H ' ' A' ' 92' ' ' THR . 0.3 OUTLIER -96.48 138.69 33.7 Favored 'General case' 0 N--CA 1.463 0.199 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.423 179.779 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 52.0 mt-30 -69.92 127.59 33.41 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.43 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 55.1 tt0 48.26 86.73 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.59 -179.853 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . 0.415 ' H ' HG22 ' A' ' 95' ' ' THR . 2.7 t . . . . . 0 C--O 1.218 -0.562 0 CA-C-O 118.108 -0.949 . . . . 0.0 110.572 179.869 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 201' ' ' SER . . . . . . . . . . . . . 17.3 t . . . . . 0 N--CA 1.49 1.546 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' B' B ' 202' ' ' SER . . . . . . . . . . . . . 20.2 m -70.56 142.14 51.79 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.419 -0.355 . . . . 0.0 110.243 179.754 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 203' ' ' SER . . . . . 0.403 ' OG ' ' CG ' ' B' ' 206' ' ' GLN . 2.1 p -104.15 152.08 39.11 Favored Pre-proline 0 CA--C 1.539 0.52 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.356 -179.661 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 204' ' ' PRO . . . . . . . . . . . . . 76.5 Cg_exo -45.42 -45.85 15.05 Favored 'Trans proline' 0 N--CA 1.494 1.541 0 C-N-CA 121.998 1.799 . . . . 0.0 112.247 179.876 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 205' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -149.65 144.74 17.79 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.186 0 CA-C-N 116.434 -0.348 . . . . 0.0 110.449 179.954 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 206' ' ' GLN . . . . . 0.403 ' CG ' ' OG ' ' B' ' 203' ' ' SER . 33.4 mt-30 -137.96 139.06 39.52 Favored 'General case' 0 C--N 1.329 -0.296 0 N-CA-C 109.973 -0.38 . . . . 0.0 109.973 179.476 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 207' ' ' GLY . . . . . . . . . . . . . . . -102.39 -130.62 7.06 Favored Glycine 0 N--CA 1.466 0.645 0 N-CA-C 110.99 -0.844 . . . . 0.0 110.99 -179.864 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 208' ' ' SER . . . . . 0.567 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 46.4 p -166.16 170.38 13.41 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.975 0.417 . . . . 0.0 110.794 179.384 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 209' ' ' TRP . . . . . . . . . . . . . 76.4 m95 -90.77 154.87 19.21 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.385 179.505 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 61.5 p -129.75 129.85 44.65 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.43 179.471 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 51.5 t-105 -90.99 109.62 20.86 Favored 'General case' 0 N--CA 1.465 0.283 0 CA-C-N 116.352 -0.386 . . . . 0.0 110.314 179.696 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 212' ' ' GLU . . . . . 0.493 ' O ' ' O ' ' B' ' 215' ' ' LYS . 1.8 pt-20 -162.26 170.54 18.79 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.332 -0.394 . . . . 0.0 110.571 179.515 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 213' ' ' ASN . . . . . 0.528 ' C ' ' H ' ' B' ' 215' ' ' LYS . 93.9 m-20 49.68 30.09 3.48 Favored 'General case' 0 C--N 1.318 -0.793 0 C-N-CA 120.393 -0.523 . . . . 0.0 111.467 177.259 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 64.04 -10.25 0.26 Allowed Glycine 0 CA--C 1.529 0.944 0 C-N-CA 120.97 -0.634 . . . . 0.0 111.732 179.415 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 215' ' ' LYS . . . . . 0.528 ' H ' ' C ' ' B' ' 213' ' ' ASN . 27.1 mtpt -123.92 153.73 40.74 Favored 'General case' 0 N--CA 1.467 0.424 0 CA-C-O 121.056 0.455 . . . . 0.0 111.004 -179.411 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 216' ' ' TRP . . . . . 0.448 ' N ' ' CD1' ' B' ' 216' ' ' TRP . 39.5 m95 -86.62 120.84 28.37 Favored 'General case' 0 C--N 1.326 -0.415 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 179.599 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 217' ' ' THR . . . . . . . . . . . . . 22.7 m -123.89 136.81 54.59 Favored 'General case' 0 N--CA 1.467 0.415 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.27 -179.512 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 218' ' ' TRP . . . . . 0.567 ' CH2' ' N ' ' B' ' 208' ' ' SER . 18.6 t-105 -104.16 108.77 20.3 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.034 179.628 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 76.5 mttt -133.11 169.61 16.61 Favored 'General case' 0 CA--C 1.515 -0.37 0 CA-C-N 115.828 -0.624 . . . . 0.0 110.425 -179.791 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -178.1 -161.8 26.83 Favored Glycine 0 N--CA 1.446 -0.64 0 N-CA-C 110.688 -0.965 . . . . 0.0 110.688 179.612 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 221' ' ' ILE . . . . . 0.533 ' O ' HG23 ' B' ' 222' ' ' ILE . 24.8 mt -53.91 -72.84 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 C-N-CA 120.702 -0.399 . . . . 0.0 110.33 -178.431 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 222' ' ' ILE . . . . . 0.533 HG23 ' O ' ' B' ' 221' ' ' ILE . 22.8 pt -160.3 -166.36 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.172 -0.467 . . . . 0.0 109.859 179.932 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 223' ' ' ARG . . . . . 0.602 ' N ' HD11 ' A' ' 75' ' ' ILE . 23.5 ptt180 -40.87 174.16 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 121.57 0.7 . . . . 0.0 110.999 178.883 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 224' ' ' LEU . . . . . 0.733 ' N ' HD22 ' B' ' 224' ' ' LEU . 2.7 mm? -61.97 109.79 1.37 Allowed 'General case' 0 C--N 1.315 -0.901 0 CA-C-N 115.398 -0.819 . . . . 0.0 110.531 -179.839 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 43.4 tt0 -83.04 143.93 30.26 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.219 -0.9 . . . . 0.0 110.328 -179.939 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 226' ' ' GLN . . . . . . . . . . . . . 8.8 tp-100 . . . . . 0 N--CA 1.448 -0.571 0 CA-C-O 117.879 -1.057 . . . . 0.0 110.374 -179.876 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.28 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 30.9 p -154.99 162.96 40.94 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.808 0.337 . . . . 0.0 110.57 -179.889 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -73.85 145.29 45.01 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.465 179.95 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 21.6 t -145.37 75.38 13.71 Favored Pre-proline 0 C--N 1.331 -0.226 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.314 179.99 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 39.3 Cg_exo -59.97 144.9 99.42 Favored 'Trans proline' 0 C--N 1.307 -1.653 0 C-N-CA 122.879 2.386 . . . . 0.0 111.862 179.957 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 87.1 mt-30 -132.01 3.59 4.06 Favored 'General case' 0 N--CA 1.467 0.386 0 CA-C-O 121.088 0.47 . . . . 0.0 110.828 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.44 ' H ' ' CD1' ' A' ' 9' ' ' LEU . 0.3 OUTLIER -97.23 98.29 9.88 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.934 -0.576 . . . . 0.0 110.259 -179.853 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . 0.617 HG22 ' N ' ' A' ' 11' ' ' ASP . 90.3 m -77.3 165.3 24.64 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.215 179.703 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . 0.617 ' N ' HG22 ' A' ' 10' ' ' THR . 45.5 t0 -121.68 155.46 35.13 Favored 'General case' 0 N--CA 1.465 0.289 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.579 -179.911 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 47.6 tp -63.51 140.3 58.86 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.968 -0.56 . . . . 0.0 109.986 -179.339 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 86.2 p -139.51 154.99 47.8 Favored 'General case' 0 C--O 1.234 0.238 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.456 179.823 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . 0.564 ' CD2' HD11 ' B' ' 224' ' ' LEU . 18.4 m-85 -111.92 145.47 39.49 Favored 'General case' 0 N--CA 1.464 0.257 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.589 -179.76 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 26.7 m -146.04 161.36 11.09 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.401 179.707 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 97.1 m-20 52.56 30.81 9.03 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.796 179.683 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 84.1 mt -58.39 141.11 15.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 115.98 -0.554 . . . . 0.0 110.246 179.994 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.47 ' CB ' ' O ' ' A' ' 21' ' ' SER . 0.2 OUTLIER -140.98 -166.34 2.14 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.652 -179.621 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 7.6 p-10 -88.76 -46.92 8.6 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.71 -0.677 . . . . 0.0 110.946 179.653 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 41.3 m -115.23 8.42 15.51 Favored 'General case' 0 N--CA 1.468 0.449 0 CA-C-N 116.47 -0.332 . . . . 0.0 110.593 -179.648 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . 0.47 ' O ' ' CB ' ' A' ' 18' ' ' THR . 29.6 p -151.09 145.44 25.48 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.986 0.422 . . . . 0.0 110.553 179.691 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . 0.466 HD12 HD21 ' A' ' 24' ' ' LEU . 41.4 pt -142.49 146.95 21.61 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.113 179.839 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -102.1 84.46 0.5 Allowed Glycine 0 CA--C 1.522 0.518 0 N-CA-C 111.1 -0.8 . . . . 0.0 111.1 179.957 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.466 HD21 HD12 ' A' ' 22' ' ' ILE . 92.5 mt -69.86 122.48 19.34 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.817 0.341 . . . . 0.0 110.159 -179.865 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 65.7 ttt-85 -136.0 144.47 45.35 Favored 'General case' 0 CA--C 1.517 -0.291 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.116 -179.844 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' TRP . . . . . 0.447 ' HE1' ' HG3' ' A' ' 28' ' ' PRO . 35.1 p90 -145.99 157.27 43.88 Favored 'General case' 0 CA--C 1.518 -0.26 0 CA-C-N 116.407 -0.361 . . . . 0.0 110.074 -179.9 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 4.6 m -111.85 96.33 32.9 Favored Pre-proline 0 C--O 1.234 0.268 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.475 179.545 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.447 ' HG3' ' HE1' ' A' ' 26' ' ' TRP . 46.4 Cg_exo -54.1 143.72 61.42 Favored 'Trans proline' 0 C--N 1.307 -1.653 0 C-N-CA 122.177 1.918 . . . . 0.0 112.496 179.39 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 66.5 mt -79.4 140.01 37.55 Favored 'General case' 0 CA--C 1.517 -0.291 0 CA-C-O 121.481 0.658 . . . . 0.0 111.014 -179.841 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . 0.437 ' O ' ' OD1' ' A' ' 30' ' ' ASN . 59.8 t-20 -51.67 -33.95 36.1 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.243 -0.889 . . . . 0.0 109.806 179.902 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 51.4 m -79.43 -32.94 42.89 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.52 179.41 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 14.0 m -62.32 136.99 58.17 Favored 'General case' 0 CA--C 1.528 0.129 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.178 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . 0.591 ' H ' ' HB ' ' A' ' 81' ' ' ILE . 7.1 m -64.89 141.59 58.72 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.967 -0.561 . . . . 0.0 110.395 179.857 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 15.5 mm -95.03 95.36 4.99 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.201 0 CA-C-O 120.936 0.398 . . . . 0.0 110.548 -179.962 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.494 ' O ' ' OG ' ' A' ' 57' ' ' SER . 11.3 pt -142.47 132.12 22.75 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.192 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.402 179.723 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -38.11 122.05 1.11 Allowed Glycine 0 CA--C 1.524 0.603 0 N-CA-C 111.424 -0.671 . . . . 0.0 111.424 -179.595 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 76.4 m-85 -89.48 176.47 6.89 Favored 'General case' 0 CA--C 1.515 -0.391 0 CA-C-O 120.907 0.384 . . . . 0.0 110.113 -179.946 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 6.2 tmm_? -135.35 126.74 28.51 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.635 179.946 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.452 ' CG1' ' O ' ' A' ' 39' ' ' ILE . 1.8 pt -102.43 125.27 56.71 Favored 'Isoleucine or valine' 0 C--O 1.233 0.208 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.003 179.603 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 15.9 m -106.81 133.02 52.1 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.448 -179.858 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.2 p -128.34 138.9 53.36 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.312 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.108 179.925 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . 0.526 ' O ' ' N ' ' A' ' 74' ' ' ASP . 39.2 t -133.27 133.78 57.79 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.114 0 CA-C-N 116.418 -0.356 . . . . 0.0 110.195 179.671 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -95.95 136.53 36.27 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.269 179.292 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.592 ' HB3' ' O ' ' A' ' 72' ' ' ASP . . . -90.35 -46.29 8.48 Favored 'General case' 0 N--CA 1.464 0.256 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.545 179.844 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -64.82 -30.65 78.55 Favored Glycine 0 CA--C 1.523 0.577 0 N-CA-C 111.042 -0.823 . . . . 0.0 111.042 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 36.6 mm-40 -96.07 134.73 38.76 Favored 'General case' 0 C--N 1.331 -0.197 0 N-CA-C 109.482 -0.562 . . . . 0.0 109.482 -179.24 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -63.69 -21.81 65.47 Favored Glycine 0 CA--C 1.51 -0.242 0 N-CA-C 111.087 -0.805 . . . . 0.0 111.087 -178.922 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -114.46 136.11 22.33 Favored Pre-proline 0 CA--C 1.54 0.574 0 C-N-CA 120.983 -0.287 . . . . 0.0 110.577 179.709 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -78.58 169.75 19.34 Favored 'Trans proline' 0 C--N 1.309 -1.523 0 C-N-CA 122.792 2.328 . . . . 0.0 112.002 176.498 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 4.7 mp -96.43 133.53 37.43 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.183 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.561 179.564 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 83.0 m-85 -49.71 149.31 2.54 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.617 -179.871 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 5.9 pt-20 -75.3 -178.06 3.79 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.204 179.766 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -143.76 132.57 22.61 Favored 'General case' 0 N--CA 1.45 -0.429 0 CA-C-N 115.848 -0.614 . . . . 0.0 110.855 179.839 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 96.9 m-85 -104.6 119.47 39.06 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.206 179.449 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 10.6 p -126.27 134.22 66.95 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.295 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.295 179.979 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 98.2 m-20 -56.87 138.46 53.64 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.417 -179.866 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . 0.494 ' OG ' ' O ' ' A' ' 35' ' ' ILE . 5.0 m -59.04 -32.49 69.8 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.38 179.871 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 59.2 m -55.31 -33.59 63.44 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.395 -179.904 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 95.6 t -64.2 -45.74 95.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.438 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 61.58 26.75 67.03 Favored Glycine 0 CA--C 1.527 0.792 0 N-CA-C 110.656 -0.978 . . . . 0.0 110.656 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . 0.413 ' CG ' ' N ' ' A' ' 62' ' ' TYR . 48.5 t80 -167.88 152.2 6.45 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 121.275 0.56 . . . . 0.0 111.134 -179.333 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' TYR . . . . . 0.413 ' N ' ' CG ' ' A' ' 61' ' ' TYR . 23.6 t80 -158.59 159.04 35.02 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.069 178.827 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 85.8 m -126.6 135.75 51.64 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.711 -179.819 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -132.04 108.1 13.56 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.334 0 CA-C-N 115.946 -0.57 . . . . 0.0 109.743 179.127 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 2.6 p -116.98 159.64 22.18 Favored 'General case' 0 CA--C 1.518 -0.259 0 CA-C-O 121.0 0.429 . . . . 0.0 110.844 179.971 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 109.21 3.03 31.43 Favored Glycine 0 CA--C 1.527 0.802 0 CA-C-N 115.7 -0.682 . . . . 0.0 111.528 -179.503 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 3.8 mt -79.49 110.86 15.19 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 121.067 0.461 . . . . 0.0 110.024 -179.259 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 9.3 mt-10 -48.09 139.1 10.08 Favored Pre-proline 0 C--N 1.319 -0.741 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.013 -178.834 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -75.09 162.41 36.93 Favored 'Trans proline' 0 N--CA 1.494 1.558 0 C-N-CA 122.888 2.392 . . . . 0.0 112.401 179.426 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 46.7 22.15 1.03 Allowed Glycine 0 N--CA 1.443 -0.885 0 CA-C-N 115.27 -0.877 . . . . 0.0 111.617 179.2 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . 0.442 ' CG2' ' CD1' ' A' ' 73' ' ' TYR . 0.9 OUTLIER -109.5 166.2 4.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 121.349 0.595 . . . . 0.0 109.814 -179.708 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' ASP . . . . . 0.592 ' O ' ' HB3' ' A' ' 44' ' ' ALA . 4.3 t0 -102.05 101.02 11.34 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.355 -0.839 . . . . 0.0 111.82 179.476 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' TYR . . . . . 0.55 ' O ' HD13 ' A' ' 75' ' ' ILE . 2.2 m-30 -109.58 125.38 52.48 Favored 'General case' 0 C--O 1.219 -0.537 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.585 179.049 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' ASP . . . . . 0.526 ' N ' ' O ' ' A' ' 42' ' ' VAL . 79.7 m-20 -89.0 117.05 27.74 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 114.993 -1.003 . . . . 0.0 109.397 179.891 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.641 HD11 ' N ' ' B' ' 223' ' ' ARG . 0.0 OUTLIER -116.54 168.63 7.89 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.306 0 CA-C-O 121.155 0.502 . . . . 0.0 110.079 -179.019 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 45.3 t -154.66 150.46 27.68 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.445 -0.798 . . . . 0.0 110.877 179.539 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.408 ' O ' HG23 ' B' ' 217' ' ' THR . 12.0 t -130.38 100.97 5.34 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.272 0 N-CA-C 109.613 -0.514 . . . . 0.0 109.613 178.958 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 96.2 mt -88.82 130.44 38.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.59 -179.782 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 91.8 m -112.53 106.66 15.16 Favored 'General case' 0 CA--C 1.518 -0.276 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 179.59 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . 0.535 HD23 ' C ' ' A' ' 80' ' ' LEU . 6.6 tt -121.3 122.29 39.56 Favored 'General case' 0 CA--C 1.519 -0.249 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.315 -179.906 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' ILE . . . . . 0.591 ' HB ' ' H ' ' A' ' 33' ' ' THR . 2.2 pp -134.19 151.29 32.05 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.175 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.295 179.611 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' ASN . . . . . 0.535 ' H ' ' CB ' ' A' ' 33' ' ' THR . 57.1 t-20 -66.64 -54.57 21.89 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.478 -0.328 . . . . 0.0 111.193 179.94 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 42.57 -103.46 0.04 OUTLIER Glycine 0 CA--C 1.523 0.581 0 N-CA-C 110.986 -0.846 . . . . 0.0 110.986 179.822 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -80.24 -172.46 44.69 Favored Glycine 0 CA--C 1.522 0.527 0 N-CA-C 110.96 -0.856 . . . . 0.0 110.96 179.919 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 93.5 mt-10 -49.63 133.46 21.01 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.91 0.386 . . . . 0.0 110.326 -179.578 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 30.2 t -82.15 167.12 19.05 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.435 -179.932 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.527 ' HB1' ' HD2' ' A' ' 88' ' ' PRO . . . 57.53 162.21 0.08 OUTLIER Pre-proline 0 C--N 1.325 -0.468 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.567 179.919 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . 0.527 ' HD2' ' HB1' ' A' ' 87' ' ' ALA . 57.7 Cg_endo -73.82 10.64 1.3 Allowed 'Trans proline' 0 C--N 1.309 -1.507 0 C-N-CA 122.605 2.204 . . . . 0.0 111.957 179.187 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 37.2 m -61.88 131.56 50.15 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.421 179.941 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 83.0 m -125.61 129.3 49.38 Favored 'General case' 0 N--CA 1.464 0.229 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.528 -179.981 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . 0.566 ' N ' HD12 ' A' ' 91' ' ' LEU . 10.1 mp -77.32 143.24 38.94 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.489 -179.881 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 66.8 p -67.49 137.12 55.56 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.47 180.0 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 77.5 mt-30 -57.69 105.41 0.25 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.414 -179.805 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 65.7 tt0 -64.6 -42.88 95.26 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.535 -179.961 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 93.0 m . . . . . 0 C--O 1.22 -0.488 0 CA-C-O 117.929 -1.034 . . . . 0.0 110.482 -179.896 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' B' B ' 201' ' ' SER . . . . . . . . . . . . . 41.5 t . . . . . 0 N--CA 1.491 1.581 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' B' B ' 202' ' ' SER . . . . . . . . . . . . . 29.7 t -66.99 132.89 48.85 Favored 'General case' 0 CA--C 1.517 -0.299 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.143 -179.985 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 203' ' ' SER . . . . . . . . . . . . . 79.3 p -129.84 109.12 17.01 Favored Pre-proline 0 CA--C 1.539 0.541 0 CA-C-N 116.4 -0.364 . . . . 0.0 110.657 179.449 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 204' ' ' PRO . . . . . . . . . . . . . 58.6 Cg_endo -75.99 -49.23 0.13 Allowed 'Trans proline' 0 N--CA 1.494 1.511 0 C-N-CA 122.454 2.103 . . . . 0.0 112.213 -179.933 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 205' ' ' ILE . . . . . 0.417 ' CG1' ' N ' ' B' ' 206' ' ' GLN . 15.5 tt -102.5 162.42 3.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 115.967 -0.56 . . . . 0.0 109.542 -178.616 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 206' ' ' GLN . . . . . 0.417 ' N ' ' CG1' ' B' ' 205' ' ' ILE . 63.7 tt0 -176.48 87.67 0.03 OUTLIER 'General case' 0 N--CA 1.45 -0.457 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.262 -179.184 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 207' ' ' GLY . . . . . 0.427 ' C ' ' CH2' ' B' ' 218' ' ' TRP . . . -110.87 -145.97 10.53 Favored Glycine 0 N--CA 1.467 0.736 0 N-CA-C 111.174 -0.771 . . . . 0.0 111.174 179.884 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 208' ' ' SER . . . . . 0.458 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 97.4 p -162.92 170.28 18.39 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.829 0.347 . . . . 0.0 110.717 179.759 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 209' ' ' TRP . . . . . . . . . . . . . 79.0 m95 -85.32 131.42 34.41 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.183 179.682 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 44.6 p -113.8 140.69 48.1 Favored 'General case' 0 N--CA 1.463 0.221 0 CA-C-N 116.409 -0.359 . . . . 0.0 110.61 -179.752 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 54.5 t-105 -96.55 118.26 32.66 Favored 'General case' 0 N--CA 1.464 0.226 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.134 179.914 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 212' ' ' GLU . . . . . 0.477 ' O ' ' O ' ' B' ' 215' ' ' LYS . 0.9 OUTLIER -165.72 167.75 16.79 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.971 179.076 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 213' ' ' ASN . . . . . . . . . . . . . 12.7 m120 50.41 35.23 10.54 Favored 'General case' 0 C--N 1.321 -0.648 0 C-N-CA 120.603 -0.439 . . . . 0.0 111.02 176.168 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 52.24 14.75 2.29 Favored Glycine 0 CA--C 1.525 0.66 0 N-CA-C 111.364 -0.694 . . . . 0.0 111.364 179.661 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 215' ' ' LYS . . . . . 0.477 ' O ' ' O ' ' B' ' 212' ' ' GLU . 8.1 mtmp? -144.52 151.38 39.04 Favored 'General case' 0 C--N 1.333 -0.124 0 CA-C-O 121.161 0.505 . . . . 0.0 110.657 179.793 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 216' ' ' TRP . . . . . . . . . . . . . 66.2 m95 -85.58 120.95 27.59 Favored 'General case' 0 C--N 1.329 -0.289 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 -179.911 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 217' ' ' THR . . . . . 0.408 HG23 ' O ' ' A' ' 77' ' ' VAL . 21.5 m -130.75 142.29 50.41 Favored 'General case' 0 C--O 1.233 0.229 0 CA-C-O 121.051 0.453 . . . . 0.0 110.617 -179.578 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 218' ' ' TRP . . . . . 0.458 ' CH2' ' N ' ' B' ' 208' ' ' SER . 16.4 t-105 -104.31 121.45 43.38 Favored 'General case' 0 N--CA 1.462 0.137 0 CA-C-N 115.925 -0.579 . . . . 0.0 109.921 179.501 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 52.1 mtmt -144.73 171.56 14.23 Favored 'General case' 0 N--CA 1.464 0.246 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.826 -179.524 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -175.44 -161.03 24.2 Favored Glycine 0 CA--C 1.524 0.627 0 CA-C-N 115.614 -0.721 . . . . 0.0 111.322 -179.663 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 221' ' ' ILE . . . . . 0.547 ' O ' HG23 ' B' ' 222' ' ' ILE . 18.8 mt -51.29 -73.27 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 C-N-CA 120.737 -0.385 . . . . 0.0 110.592 -177.973 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 222' ' ' ILE . . . . . 0.547 HG23 ' O ' ' B' ' 221' ' ' ILE . 16.2 pt -158.89 -167.26 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.451 179.808 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 223' ' ' ARG . . . . . 0.641 ' N ' HD11 ' A' ' 75' ' ' ILE . 0.1 OUTLIER -46.12 177.08 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.651 -0.704 . . . . 0.0 110.399 179.146 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 224' ' ' LEU . . . . . 0.683 ' N ' HD22 ' B' ' 224' ' ' LEU . 3.4 mm? -58.68 126.14 26.39 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.414 -178.833 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 225' ' ' GLU . . . . . 0.508 ' OE1' ' NH1' ' B' ' 223' ' ' ARG . 29.7 tp10 -101.97 152.96 20.33 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.167 -179.758 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 226' ' ' GLN . . . . . . . . . . . . . 95.9 mt-30 . . . . . 0 C--O 1.219 -0.503 0 CA-C-O 118.031 -0.985 . . . . 0.0 110.549 -179.883 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.309 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 12.0 p -74.56 157.52 35.32 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.968 0.413 . . . . 0.0 110.523 179.919 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 32.6 tp10 -74.39 145.87 43.41 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.202 -179.864 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 4.1 t -132.35 76.51 72.3 Favored Pre-proline 0 N--CA 1.466 0.348 0 CA-C-O 120.719 0.295 . . . . 0.0 110.48 -179.841 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -78.61 143.73 19.24 Favored 'Trans proline' 0 C--N 1.311 -1.411 0 C-N-CA 122.627 2.218 . . . . 0.0 111.922 -179.946 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . 0.506 ' CD ' ' H ' ' A' ' 8' ' ' GLN . 0.4 OUTLIER -100.7 7.39 43.91 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.234 179.766 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 54.7 mt -89.9 114.22 25.97 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.179 -179.793 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 76.4 p -130.24 156.45 44.6 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 116.013 -0.539 . . . . 0.0 110.241 -179.9 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 97.6 m-20 -116.82 153.83 31.79 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.336 -179.823 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 7.4 tt -64.81 144.65 57.11 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.383 -179.74 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . 0.458 ' O ' ' O ' ' A' ' 25' ' ' ARG . 87.1 p -139.18 159.54 41.91 Favored 'General case' 0 N--CA 1.462 0.125 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.653 179.734 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . 0.424 ' N ' ' CD1' ' A' ' 14' ' ' PHE . 19.1 m-85 -111.35 145.47 38.81 Favored 'General case' 0 N--CA 1.465 0.308 0 CA-C-N 115.978 -0.556 . . . . 0.0 110.572 -179.775 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 17.4 m -144.9 157.4 14.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.463 179.659 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 98.9 m-20 47.76 60.24 3.66 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.314 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 98.2 mt -82.46 140.51 16.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.538 179.757 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.438 ' CB ' ' O ' ' A' ' 21' ' ' SER . 0.3 OUTLIER -138.54 -168.33 2.37 Favored 'General case' 0 N--CA 1.466 0.325 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.449 179.917 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . 0.475 ' OD1' ' N ' ' A' ' 19' ' ' ASP . 15.8 p-10 -88.55 -43.63 11.26 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.618 179.509 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . 0.417 ' OG ' ' O ' ' A' ' 67' ' ' LEU . 50.8 m -117.51 9.77 13.32 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.833 -179.65 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . 0.438 ' O ' ' CB ' ' A' ' 18' ' ' THR . 9.4 m -150.1 141.76 23.58 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.262 179.829 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 44.3 pt -136.76 146.17 28.96 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.417 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.337 179.915 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -101.63 81.3 0.43 Allowed Glycine 0 CA--C 1.524 0.621 0 N-CA-C 110.887 -0.885 . . . . 0.0 110.887 179.692 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 16.4 mt -67.23 123.91 21.62 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 110.025 -0.361 . . . . 0.0 110.025 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . 0.458 ' O ' ' O ' ' A' ' 13' ' ' SER . 72.5 ttp85 -142.24 135.82 29.22 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.381 -179.804 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' TRP . . . . . . . . . . . . . 3.8 p90 -141.28 158.74 43.48 Favored 'General case' 0 C--N 1.326 -0.444 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 -179.811 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 4.1 m -108.03 102.35 45.51 Favored Pre-proline 0 CA--C 1.537 0.461 0 CA-C-N 116.725 -0.216 . . . . 0.0 110.418 179.504 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_exo -54.91 145.85 60.1 Favored 'Trans proline' 0 C--N 1.308 -1.571 0 C-N-CA 121.8 1.667 . . . . 0.0 112.874 179.547 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 71.1 mt -85.07 138.3 32.51 Favored 'General case' 0 CA--C 1.515 -0.371 0 CA-C-O 121.44 0.638 . . . . 0.0 110.567 179.866 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . 0.421 ' O ' ' OD1' ' A' ' 30' ' ' ASN . 61.2 t-20 -48.63 -34.54 11.91 Favored 'General case' 0 C--N 1.314 -0.946 0 CA-C-N 115.187 -0.915 . . . . 0.0 110.152 -179.962 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 38.3 m -80.68 -33.05 35.78 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.508 179.03 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 6.9 m -59.17 131.64 51.64 Favored 'General case' 0 CA--C 1.528 0.116 0 CA-C-O 120.963 0.411 . . . . 0.0 110.368 -179.839 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . 0.494 ' CB ' ' H ' ' A' ' 82' ' ' ASN . 4.3 m -62.14 145.41 53.44 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.032 179.984 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 12.5 mm -93.92 94.42 4.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-O 120.921 0.391 . . . . 0.0 110.645 -179.606 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.478 ' O ' ' OG ' ' A' ' 57' ' ' SER . 15.8 pt -147.57 133.04 11.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.844 -0.617 . . . . 0.0 110.563 -179.88 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -47.86 130.43 17.43 Favored Glycine 0 CA--C 1.52 0.357 0 N-CA-C 110.979 -0.848 . . . . 0.0 110.979 -179.864 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' TYR . . . . . 0.468 ' CE2' HG22 ' A' ' 39' ' ' ILE . 3.8 p90 -106.25 126.84 52.73 Favored 'General case' 0 C--N 1.33 -0.278 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 179.377 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . 0.529 ' NH1' ' OG1' ' A' ' 40' ' ' THR . 3.3 tmm_? -76.4 131.31 39.04 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.275 -0.421 . . . . 0.0 111.128 -179.321 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.468 HG22 ' CE2' ' A' ' 37' ' ' TYR . 2.2 pt -98.19 123.94 50.98 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.159 0 CA-C-N 115.956 -0.566 . . . . 0.0 109.531 179.526 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . 0.529 ' OG1' ' NH1' ' A' ' 38' ' ' ARG . 1.6 m -103.38 131.12 50.72 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 120.802 0.334 . . . . 0.0 110.56 -179.303 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.3 p -130.48 138.68 53.19 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.052 179.442 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . 0.517 ' N ' ' O ' ' A' ' 74' ' ' ASP . 39.7 t -133.1 131.88 58.64 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.248 0 N-CA-C 110.101 -0.333 . . . . 0.0 110.101 -179.99 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.596 ' HB2' ' CE2' ' A' ' 73' ' ' TYR . . . -96.25 139.54 32.25 Favored 'General case' 0 C--N 1.327 -0.377 0 N-CA-C 109.54 -0.541 . . . . 0.0 109.54 179.099 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.537 ' HB3' ' O ' ' A' ' 72' ' ' ASP . . . -92.21 -41.71 10.28 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.762 0.315 . . . . 0.0 110.857 179.636 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -65.66 -31.73 80.87 Favored Glycine 0 CA--C 1.526 0.735 0 N-CA-C 111.388 -0.685 . . . . 0.0 111.388 -179.357 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 32.0 mt-10 -97.94 129.66 44.84 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 121.168 0.509 . . . . 0.0 109.651 -179.64 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -60.37 -8.55 9.42 Favored Glycine 0 CA--C 1.518 0.233 0 N-CA-C 110.701 -0.959 . . . . 0.0 110.701 -179.272 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -124.08 134.39 25.39 Favored Pre-proline 0 CA--C 1.538 0.512 0 C-N-CA 121.298 -0.161 . . . . 0.0 110.588 179.529 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -77.99 160.63 30.26 Favored 'Trans proline' 0 C--N 1.314 -1.273 0 C-N-CA 122.477 2.118 . . . . 0.0 112.054 177.602 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 96.1 mt -80.71 137.69 20.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.199 179.188 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 90.0 m-85 -55.88 142.05 36.79 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.949 0.404 . . . . 0.0 110.724 -179.702 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . 0.518 ' H ' ' CD ' ' A' ' 52' ' ' GLU . 0.4 OUTLIER -77.72 146.21 36.08 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.376 179.778 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -109.81 144.83 37.69 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.406 179.829 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 93.5 m-85 -109.46 118.82 37.65 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.266 179.944 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 9.3 p -125.95 137.47 57.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.441 -179.747 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 84.1 m-20 -67.63 141.41 56.75 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.297 179.592 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . 0.478 ' OG ' ' O ' ' A' ' 35' ' ' ILE . 9.6 m -57.98 -28.5 64.44 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.417 179.886 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 23.4 m -55.94 -33.64 64.92 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.542 179.959 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.473 ' O ' ' CD2' ' A' ' 61' ' ' TYR . 50.6 t -60.49 -45.18 97.34 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 116.394 -0.367 . . . . 0.0 110.15 -179.395 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 71.36 14.51 74.44 Favored Glycine 0 CA--C 1.529 0.922 0 N-CA-C 111.074 -0.81 . . . . 0.0 111.074 179.388 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . 0.473 ' CD2' ' O ' ' A' ' 59' ' ' VAL . 27.6 p90 -172.27 158.34 4.43 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.795 0.331 . . . . 0.0 111.348 179.43 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 23.6 t80 -155.94 155.6 33.09 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.356 -0.384 . . . . 0.0 110.144 177.955 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 94.4 m -121.09 134.7 55.27 Favored 'General case' 0 N--CA 1.463 0.224 0 CA-C-O 121.072 0.463 . . . . 0.0 110.429 -179.814 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -131.86 103.35 6.78 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.197 0 CA-C-N 115.954 -0.566 . . . . 0.0 109.862 178.961 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 2.3 p -112.84 162.87 15.3 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 121.031 0.444 . . . . 0.0 110.683 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 111.38 5.62 26.2 Favored Glycine 0 CA--C 1.527 0.83 0 CA-C-N 115.482 -0.781 . . . . 0.0 111.583 -179.272 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.425 ' CB ' HH21 ' B' ' 223' ' ' ARG . 9.1 mt -81.21 109.04 15.36 Favored 'General case' 0 C--N 1.329 -0.286 0 N-CA-C 109.479 -0.563 . . . . 0.0 109.479 179.379 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 17.5 mm-40 -57.81 137.42 83.11 Favored Pre-proline 0 C--N 1.321 -0.651 0 CA-C-N 116.288 -0.414 . . . . 0.0 111.569 -178.303 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . 0.411 ' O ' HD12 ' A' ' 71' ' ' ILE . 80.8 Cg_endo -74.29 151.76 43.7 Favored 'Trans proline' 0 N--CA 1.494 1.542 0 C-N-CA 122.695 2.263 . . . . 0.0 111.732 178.93 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 76.58 6.41 84.44 Favored Glycine 0 CA--C 1.528 0.856 0 CA-C-N 115.644 -0.707 . . . . 0.0 111.413 179.229 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . 0.411 HD12 ' O ' ' A' ' 69' ' ' PRO . 2.4 mp -117.05 143.99 25.93 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.392 0 CA-C-O 121.398 0.618 . . . . 0.0 109.728 -179.717 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' ASP . . . . . 0.537 ' O ' ' HB3' ' A' ' 44' ' ' ALA . 4.4 t70 -84.06 112.26 20.05 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 114.987 -1.006 . . . . 0.0 110.626 -179.657 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' TYR . . . . . 0.596 ' CE2' ' HB2' ' A' ' 43' ' ' ALA . 11.9 m-85 -107.54 120.61 42.68 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.467 179.73 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' ASP . . . . . 0.517 ' O ' ' N ' ' A' ' 42' ' ' VAL . 72.6 m-20 -88.04 119.42 28.4 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.348 -0.842 . . . . 0.0 109.414 179.474 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.907 HD13 ' N ' ' A' ' 75' ' ' ILE . 0.0 OUTLIER -120.15 166.44 14.57 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-O 121.005 0.431 . . . . 0.0 110.311 -178.521 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 21.2 t -155.92 125.61 6.39 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.659 -0.701 . . . . 0.0 110.623 179.204 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 11.4 t -102.0 100.79 11.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 N-CA-C 109.621 -0.511 . . . . 0.0 109.621 179.126 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 90.4 mt -87.95 126.3 41.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.717 -179.766 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . 0.431 ' OG1' ' O ' ' B' ' 216' ' ' TRP . 16.4 p -106.93 110.03 22.08 Favored 'General case' 0 N--CA 1.464 0.235 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 179.514 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 35.9 tp -117.57 124.58 49.01 Favored 'General case' 0 N--CA 1.464 0.231 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.445 179.98 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' ILE . . . . . 0.483 ' HB ' ' H ' ' A' ' 33' ' ' THR . 2.1 pp -145.9 145.34 20.28 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-N 116.004 -0.543 . . . . 0.0 110.259 179.338 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' ASN . . . . . 0.494 ' H ' ' CB ' ' A' ' 33' ' ' THR . 47.2 t30 -62.44 -58.96 5.73 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.522 -0.308 . . . . 0.0 110.808 -179.743 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . 0.403 ' N ' ' OG1' ' A' ' 33' ' ' THR . . . 71.67 -158.42 53.5 Favored Glycine 0 CA--C 1.522 0.507 0 N-CA-C 110.896 -0.882 . . . . 0.0 110.896 179.629 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -89.87 114.43 4.36 Favored Glycine 0 CA--C 1.522 0.507 0 N-CA-C 110.707 -0.957 . . . . 0.0 110.707 179.793 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 76.7 mt-10 -88.66 140.29 29.6 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.726 0.298 . . . . 0.0 110.337 179.964 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 39.7 t -96.05 119.58 34.8 Favored 'General case' 0 C--N 1.332 -0.155 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.24 179.851 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.644 ' H ' ' CD ' ' A' ' 88' ' ' PRO . . . -105.48 -42.86 0.16 Allowed Pre-proline 0 N--CA 1.466 0.355 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.188 179.844 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . 0.644 ' CD ' ' H ' ' A' ' 87' ' ' ALA . 26.6 Cg_exo -61.12 14.25 0.05 OUTLIER 'Trans proline' 0 N--CA 1.496 1.631 0 C-N-CA 122.792 2.328 . . . . 0.0 112.532 -179.782 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . 0.57 ' H ' ' C ' ' A' ' 87' ' ' ALA . 14.8 t -113.6 128.05 56.29 Favored 'General case' 0 C--N 1.334 -0.1 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.268 179.974 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 68.8 p -129.55 121.54 27.35 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.109 179.847 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 4.9 mp -103.21 132.65 49.3 Favored 'General case' 0 CA--C 1.52 -0.198 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.58 179.818 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 70.1 p -81.1 164.97 22.03 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.467 179.959 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 93' ' ' GLN . . . . . 0.424 ' O ' ' O ' ' A' ' 94' ' ' GLN . 99.0 mm-40 -76.74 130.28 37.48 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.456 -179.937 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.424 ' O ' ' O ' ' A' ' 93' ' ' GLN . 98.5 mm-40 52.79 170.76 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.52 179.925 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 48.2 p . . . . . 0 C--O 1.219 -0.509 0 CA-C-O 117.977 -1.011 . . . . 0.0 110.542 179.965 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' B' B ' 201' ' ' SER . . . . . . . . . . . . . 95.4 p . . . . . 0 N--CA 1.49 1.546 0 N-CA-C 109.354 -0.61 . . . . 0.0 109.354 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' B' B ' 202' ' ' SER . . . . . . . . . . . . . 25.8 p -77.27 154.44 32.95 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.248 179.849 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 203' ' ' SER . . . . . 0.413 ' C ' ' H ' ' B' ' 205' ' ' ILE . 2.3 p -117.45 151.76 48.56 Favored Pre-proline 0 N--CA 1.466 0.339 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.548 -179.831 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 204' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -66.04 6.06 0.55 Allowed 'Trans proline' 0 N--CA 1.495 1.574 0 C-N-CA 122.591 2.194 . . . . 0.0 111.82 179.831 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 205' ' ' ILE . . . . . 0.413 ' H ' ' C ' ' B' ' 203' ' ' SER . 2.6 tp -142.28 141.58 28.28 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.286 0 CA-C-O 121.144 0.497 . . . . 0.0 111.286 179.717 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 206' ' ' GLN . . . . . . . . . . . . . 12.2 pt20 -174.28 75.55 0.03 OUTLIER 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 115.519 -0.764 . . . . 0.0 111.096 178.894 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 207' ' ' GLY . . . . . . . . . . . . . . . -110.52 -140.32 8.46 Favored Glycine 0 N--CA 1.465 0.615 0 N-CA-C 110.818 -0.913 . . . . 0.0 110.818 179.834 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 208' ' ' SER . . . . . 0.455 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 53.9 p -164.35 171.67 14.48 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 120.876 0.37 . . . . 0.0 110.686 -179.893 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 209' ' ' TRP . . . . . . . . . . . . . 76.5 m95 -87.51 134.98 33.53 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.216 179.575 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 70.2 p -110.62 131.74 54.79 Favored 'General case' 0 N--CA 1.467 0.423 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.552 -179.847 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 50.5 t-105 -93.16 115.2 27.84 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 120.875 0.369 . . . . 0.0 110.432 179.689 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 212' ' ' GLU . . . . . 0.484 ' O ' ' O ' ' B' ' 215' ' ' LYS . 1.4 pt-20 -164.89 170.54 15.21 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.077 -0.51 . . . . 0.0 111.085 179.199 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 213' ' ' ASN . . . . . . . . . . . . . 16.3 m120 48.58 34.19 4.76 Favored 'General case' 0 C--N 1.322 -0.619 0 C-N-CA 120.398 -0.521 . . . . 0.0 111.342 176.384 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 54.27 11.75 2.65 Favored Glycine 0 CA--C 1.529 0.932 0 N-CA-C 111.627 -0.589 . . . . 0.0 111.627 179.794 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 215' ' ' LYS . . . . . 0.484 ' O ' ' O ' ' B' ' 212' ' ' GLU . 65.9 mttm -142.86 150.77 40.31 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 121.038 0.446 . . . . 0.0 110.732 179.995 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 216' ' ' TRP . . . . . 0.436 ' CD1' ' N ' ' B' ' 216' ' ' TRP . 35.0 m95 -87.74 127.15 35.31 Favored 'General case' 0 C--N 1.33 -0.281 0 N-CA-C 109.954 -0.387 . . . . 0.0 109.954 179.742 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 217' ' ' THR . . . . . . . . . . . . . 21.7 m -136.14 145.0 45.34 Favored 'General case' 0 N--CA 1.463 0.217 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.359 -179.784 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 218' ' ' TRP . . . . . 0.455 ' CH2' ' N ' ' B' ' 208' ' ' SER . 24.8 t-105 -102.6 120.83 41.23 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 116.048 -0.524 . . . . 0.0 109.796 179.53 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 97.4 mttt -136.56 164.33 28.44 Favored 'General case' 0 N--CA 1.465 0.308 0 CA-C-O 121.083 0.468 . . . . 0.0 110.739 -179.62 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -176.13 -162.75 27.55 Favored Glycine 0 CA--C 1.523 0.575 0 N-CA-C 111.134 -0.786 . . . . 0.0 111.134 -179.942 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 221' ' ' ILE . . . . . 0.533 ' O ' HG23 ' B' ' 222' ' ' ILE . 0.9 OUTLIER -58.75 -78.71 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 C-N-CA 120.459 -0.496 . . . . 0.0 110.965 -178.254 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' B' B ' 222' ' ' ILE . . . . . 0.533 HG23 ' O ' ' B' ' 221' ' ' ILE . 19.1 pt -159.12 -162.84 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 N-CA-C 110.043 -0.355 . . . . 0.0 110.043 -179.085 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 223' ' ' ARG . . . . . 0.544 ' HD2' ' H ' ' B' ' 223' ' ' ARG . 0.0 OUTLIER -43.76 173.64 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 121.271 0.558 . . . . 0.0 110.545 178.648 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' B' B ' 224' ' ' LEU . . . . . 0.747 ' N ' HD22 ' B' ' 224' ' ' LEU . 2.6 mm? -59.42 138.46 57.65 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-N 115.67 -0.695 . . . . 0.0 110.581 -179.707 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 80.0 tt0 -112.03 149.72 31.65 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 115.389 -0.823 . . . . 0.0 110.41 -179.492 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 226' ' ' GLN . . . . . . . . . . . . . 7.6 tp-100 . . . . . 0 N--CA 1.448 -0.574 0 CA-C-O 117.874 -1.06 . . . . 0.0 110.418 -179.98 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.258 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 39.0 t -86.94 103.64 15.51 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.742 0.306 . . . . 0.0 110.264 179.84 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -125.31 122.29 36.46 Favored 'General case' 0 N--CA 1.465 0.325 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.311 179.817 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 4.9 m -144.95 148.48 38.96 Favored Pre-proline 0 CA--C 1.533 0.289 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.513 179.756 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -67.64 144.52 66.46 Favored 'Trans proline' 0 N--CA 1.494 1.556 0 C-N-CA 122.446 2.097 . . . . 0.0 111.834 179.857 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . 0.48 ' H ' ' NE2' ' A' ' 8' ' ' GLN . 0.0 OUTLIER -168.5 65.19 0.07 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.426 179.976 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 3.9 mp -114.67 126.06 54.46 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 121.054 0.454 . . . . 0.0 110.439 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . 0.45 HG23 ' O ' ' A' ' 10' ' ' THR . 13.8 t -95.62 130.75 42.4 Favored 'General case' 0 CA--C 1.52 -0.198 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.542 -179.547 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 45.2 t0 -115.85 101.54 8.89 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.271 179.926 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 5.7 tt -70.22 134.96 48.57 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.552 179.846 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 82.5 p -142.61 162.32 35.78 Favored 'General case' 0 N--CA 1.462 0.143 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.401 179.631 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . 0.411 ' CD1' ' N ' ' A' ' 14' ' ' PHE . 57.3 m-85 -110.27 147.64 33.45 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.905 -0.588 . . . . 0.0 110.67 -179.642 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 17.7 m -144.19 152.93 15.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.399 179.737 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 24.9 t70 60.66 34.24 20.1 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.544 -179.823 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 96.4 mt -57.02 134.65 21.3 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.191 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.035 179.709 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.438 ' OG1' ' O ' ' A' ' 21' ' ' SER . 0.2 OUTLIER -136.49 -168.89 2.34 Favored 'General case' 0 N--CA 1.469 0.478 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.388 -179.831 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . 0.485 ' N ' ' OD1' ' A' ' 19' ' ' ASP . 18.6 p-10 -76.48 -50.62 13.58 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.798 179.49 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . 0.441 ' CB ' ' O ' ' A' ' 67' ' ' LEU . 69.8 m -121.61 15.76 11.13 Favored 'General case' 0 N--CA 1.462 0.173 0 CA-C-N 116.677 -0.238 . . . . 0.0 110.679 -179.33 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . 0.527 ' HB2' HG22 ' A' ' 65' ' ' THR . 25.2 p -145.97 127.09 14.69 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-O 121.041 0.448 . . . . 0.0 110.545 -179.612 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 38.4 pt -128.69 141.29 46.96 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.3 0 CA-C-N 115.947 -0.569 . . . . 0.0 109.57 -179.81 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -102.29 88.73 0.7 Allowed Glycine 0 CA--C 1.523 0.566 0 N-CA-C 111.8 -0.52 . . . . 0.0 111.8 -179.316 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 10.3 mp -61.06 148.59 39.79 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 121.072 0.463 . . . . 0.0 110.349 179.963 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 50.2 ttt180 -157.4 136.57 11.83 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.683 -0.69 . . . . 0.0 110.98 179.827 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' TRP . . . . . 0.521 ' CH2' ' OH ' ' A' ' 37' ' ' TYR . 34.5 p90 -139.74 159.39 42.28 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.821 -0.627 . . . . 0.0 109.915 -179.93 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 3.7 m -107.71 99.77 31.31 Favored Pre-proline 0 CA--C 1.537 0.443 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.986 -179.363 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 38.7 Cg_exo -56.64 153.39 36.2 Favored 'Trans proline' 0 C--N 1.31 -1.454 0 C-N-CA 122.093 1.862 . . . . 0.0 112.956 178.84 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.513 ' H ' ' HB2' ' A' ' 32' ' ' SER . 41.7 mt -110.41 135.91 50.38 Favored 'General case' 0 N--CA 1.469 0.492 0 CA-C-O 121.76 0.79 . . . . 0.0 110.876 -179.845 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 28.1 t-20 -45.61 -30.05 1.4 Allowed 'General case' 0 C--N 1.315 -0.902 0 CA-C-N 114.902 -1.045 . . . . 0.0 110.477 179.852 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 69.3 m -89.83 -23.83 21.59 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.623 179.282 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . 0.513 ' HB2' ' H ' ' A' ' 29' ' ' LEU . 4.7 m -65.09 120.03 11.91 Favored 'General case' 0 N--CA 1.464 0.233 0 CA-C-O 121.204 0.525 . . . . 0.0 110.163 179.998 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 23.7 m -55.82 140.69 41.42 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.602 -0.727 . . . . 0.0 109.516 179.578 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 29.8 mm -94.7 99.01 8.73 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.343 0 CA-C-O 120.854 0.359 . . . . 0.0 111.367 -178.625 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.56 HD11 ' HA ' ' A' ' 81' ' ' ILE . 0.1 OUTLIER -140.11 155.78 24.28 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.21 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.152 179.466 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -74.55 97.74 1.0 Allowed Glycine 0 CA--C 1.524 0.609 0 N-CA-C 110.793 -0.923 . . . . 0.0 110.793 179.877 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' TYR . . . . . 0.521 ' OH ' ' CH2' ' A' ' 26' ' ' TRP . 2.0 p90 -78.79 126.99 31.45 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 110.01 -0.367 . . . . 0.0 110.01 179.787 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 5.4 tmm_? -78.01 132.39 37.78 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 120.975 0.417 . . . . 0.0 111.092 -179.69 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.458 ' CG1' ' O ' ' A' ' 39' ' ' ILE . 1.9 pt -98.46 121.27 48.83 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.217 0 N-CA-C 109.155 -0.683 . . . . 0.0 109.155 179.146 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 13.6 m -99.66 135.81 40.52 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 120.852 0.358 . . . . 0.0 110.948 -179.04 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.3 p -133.15 139.88 48.38 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.364 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.031 179.531 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . 0.511 ' O ' ' N ' ' A' ' 74' ' ' ASP . 38.7 t -131.68 131.66 62.27 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.252 0 N-CA-C 109.969 -0.382 . . . . 0.0 109.969 179.616 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -97.91 133.51 42.31 Favored 'General case' 0 C--N 1.326 -0.414 0 N-CA-C 109.448 -0.575 . . . . 0.0 109.448 179.148 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.627 ' HB3' ' O ' ' A' ' 72' ' ' ASP . . . -94.01 -14.14 26.2 Favored 'General case' 0 C--N 1.329 -0.309 0 C-N-CA 120.956 -0.298 . . . . 0.0 111.005 -179.57 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -99.38 21.81 43.67 Favored Glycine 0 N--CA 1.465 0.609 0 N-CA-C 111.293 -0.723 . . . . 0.0 111.293 -179.518 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -143.74 150.25 38.34 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 121.163 0.506 . . . . 0.0 110.316 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -68.4 -19.35 72.49 Favored Glycine 0 CA--C 1.524 0.647 0 N-CA-C 110.822 -0.911 . . . . 0.0 110.822 179.976 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -134.06 139.73 34.08 Favored Pre-proline 0 CA--C 1.542 0.642 0 O-C-N 122.828 -0.219 . . . . 0.0 110.658 179.943 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_endo -73.79 164.47 34.61 Favored 'Trans proline' 0 N--CA 1.491 1.363 0 C-N-CA 122.613 2.209 . . . . 0.0 111.902 178.102 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . 0.434 HG22 ' N ' ' A' ' 51' ' ' PHE . 96.6 mt -79.16 155.01 4.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.608 179.603 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' PHE . . . . . 0.434 ' N ' HG22 ' A' ' 50' ' ' ILE . 98.3 m-85 -71.59 141.64 50.01 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.42 179.986 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . 0.529 ' H ' ' CD ' ' A' ' 52' ' ' GLU . 0.4 OUTLIER -77.21 144.09 38.54 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.729 179.603 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -104.05 148.57 26.08 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.521 179.7 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' PHE . . . . . 0.465 ' CD1' ' N ' ' A' ' 54' ' ' PHE . 15.9 m-85 -115.48 120.25 38.9 Favored 'General case' 0 N--CA 1.462 0.144 0 CA-C-N 115.758 -0.655 . . . . 0.0 110.038 179.664 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 8.3 p -130.41 144.05 39.13 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.307 0 CA-C-O 120.64 0.257 . . . . 0.0 110.381 -179.957 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 98.7 m-20 -66.27 146.75 54.25 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.591 179.51 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -65.92 -31.89 73.08 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.602 179.841 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 42.9 m -53.84 -36.19 62.3 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.619 -179.579 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 86.9 t -59.27 -43.66 90.38 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 116.438 -0.346 . . . . 0.0 110.41 -179.558 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 64.93 23.94 69.73 Favored Glycine 0 CA--C 1.526 0.721 0 N-CA-C 110.403 -1.079 . . . . 0.0 110.403 179.65 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . 0.416 ' CG ' ' N ' ' A' ' 62' ' ' TYR . 38.0 t80 -170.42 153.81 4.47 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 121.018 0.437 . . . . 0.0 111.495 -179.549 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' TYR . . . . . 0.417 ' CD2' ' CD1' ' A' ' 39' ' ' ILE . 19.1 t80 -158.73 160.96 36.96 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.337 178.582 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 85.5 m -126.26 134.35 51.2 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.068 -0.514 . . . . 0.0 110.271 179.881 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -133.05 100.64 3.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.033 -0.53 . . . . 0.0 109.684 178.972 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.527 HG22 ' HB2' ' A' ' 21' ' ' SER . 1.4 p -114.68 164.21 14.37 Favored 'General case' 0 CA--C 1.513 -0.478 0 CA-C-O 120.969 0.414 . . . . 0.0 110.507 -179.89 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 107.34 23.75 6.81 Favored Glycine 0 CA--C 1.519 0.319 0 N-CA-C 111.162 -0.775 . . . . 0.0 111.162 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.441 ' O ' ' CB ' ' A' ' 20' ' ' SER . 10.0 mt -97.22 106.38 18.7 Favored 'General case' 0 N--CA 1.464 0.226 0 N-CA-C 109.532 -0.544 . . . . 0.0 109.532 179.804 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 5.2 mm-40 -46.63 137.34 7.27 Favored Pre-proline 0 C--N 1.316 -0.854 0 CA-C-N 116.101 -0.5 . . . . 0.0 111.827 -178.421 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -73.98 156.67 47.59 Favored 'Trans proline' 0 N--CA 1.497 1.705 0 C-N-CA 122.674 2.249 . . . . 0.0 111.255 178.665 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 71.69 -5.68 10.99 Favored Glycine 0 CA--C 1.527 0.789 0 C-N-CA 120.947 -0.645 . . . . 0.0 111.685 179.307 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . 0.473 ' O ' ' NH1' ' B' ' 223' ' ' ARG . 1.7 mp -103.61 144.32 14.27 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.437 0 CA-C-O 121.26 0.552 . . . . 0.0 109.611 -179.807 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' ASP . . . . . 0.627 ' O ' ' HB3' ' A' ' 44' ' ' ALA . 2.3 t70 -84.39 119.19 24.82 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.14 -0.936 . . . . 0.0 110.469 179.291 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' TYR . . . . . 0.479 ' O ' HD13 ' A' ' 75' ' ' ILE . 19.0 m-85 -110.14 120.22 41.76 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.75 -179.999 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' ASP . . . . . 0.511 ' N ' ' O ' ' A' ' 42' ' ' VAL . 14.8 m-20 -90.17 117.1 28.67 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 115.619 -0.719 . . . . 0.0 109.788 179.639 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.484 HD13 ' N ' ' A' ' 75' ' ' ILE . 0.0 OUTLIER -114.05 165.2 9.34 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-O 121.147 0.498 . . . . 0.0 110.059 -179.29 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 1.3 p -154.59 121.36 5.49 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.721 -0.672 . . . . 0.0 110.525 179.681 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.443 ' O ' HG23 ' B' ' 217' ' ' THR . 14.2 t -96.5 99.66 9.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 179.057 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 95.4 mt -88.35 115.62 28.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.115 179.634 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . 0.456 ' OG1' ' O ' ' B' ' 216' ' ' TRP . 43.4 p -99.21 117.39 33.57 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.249 179.95 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 20.1 mt -121.4 110.32 15.94 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.864 179.904 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' ILE . . . . . 0.594 ' C ' HD12 ' A' ' 81' ' ' ILE . 1.2 pp -142.24 138.15 29.8 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.088 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.383 179.211 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 59.7 t-20 -65.72 -50.47 64.73 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.955 -0.566 . . . . 0.0 111.244 -179.249 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . 0.444 ' N ' HD12 ' A' ' 81' ' ' ILE . . . 83.77 -162.5 39.38 Favored Glycine 0 CA--C 1.521 0.428 0 N-CA-C 110.951 -0.86 . . . . 0.0 110.951 179.257 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -80.43 175.22 54.95 Favored Glycine 0 CA--C 1.525 0.683 0 N-CA-C 110.762 -0.935 . . . . 0.0 110.762 -179.99 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.66 ' CD ' ' H ' ' A' ' 85' ' ' GLU . 1.2 pm0 -69.75 149.4 48.03 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 120.898 0.38 . . . . 0.0 110.528 179.922 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 52.9 p -48.88 109.36 0.25 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.379 -179.914 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.448 ' N ' ' CD ' ' A' ' 88' ' ' PRO . . . -172.9 53.38 0.16 Allowed Pre-proline 0 C--N 1.328 -0.35 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.587 179.837 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . 0.448 ' CD ' ' N ' ' A' ' 87' ' ' ALA . 51.9 Cg_endo -68.17 157.1 63.25 Favored 'Trans proline' 0 C--N 1.308 -1.574 0 C-N-CA 122.627 2.218 . . . . 0.0 111.877 179.824 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 4.9 t -138.85 157.84 45.31 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.259 -179.881 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 88.7 m -116.52 128.66 55.64 Favored 'General case' 0 N--CA 1.467 0.386 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.266 -179.868 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . 0.613 ' N ' HD12 ' A' ' 91' ' ' LEU . 9.4 mp -75.67 156.83 34.39 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.855 -0.612 . . . . 0.0 110.397 -179.819 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 62.2 p -64.89 164.43 12.53 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.318 -179.638 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 93' ' ' GLN . . . . . 0.448 ' O ' ' O ' ' A' ' 94' ' ' GLN . 7.8 tp-100 -79.74 118.63 21.72 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.321 -179.734 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.448 ' O ' ' O ' ' A' ' 93' ' ' GLN . 67.3 tp60 56.77 116.97 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.47 179.961 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 29.7 m . . . . . 0 C--O 1.22 -0.493 0 CA-C-O 117.991 -1.004 . . . . 0.0 110.555 179.939 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' B' B ' 201' ' ' SER . . . . . . . . . . . . . 31.1 m . . . . . 0 N--CA 1.489 1.487 0 N-CA-C 109.411 -0.589 . . . . 0.0 109.411 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' B' B ' 202' ' ' SER . . . . . . . . . . . . . 40.4 t -68.89 146.89 52.43 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.288 179.805 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 203' ' ' SER . . . . . . . . . . . . . 5.5 t -131.92 101.66 15.17 Favored Pre-proline 0 CA--C 1.534 0.337 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 178.277 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 204' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_exo -58.09 -58.76 0.68 Allowed 'Trans proline' 0 N--CA 1.498 1.75 0 C-N-CA 122.09 1.86 . . . . 0.0 112.389 178.165 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 205' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -150.17 144.73 17.4 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.3 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.391 -179.867 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 206' ' ' GLN . . . . . . . . . . . . . 88.1 mt-30 -138.2 139.27 39.23 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.193 -0.458 . . . . 0.0 109.981 178.948 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 207' ' ' GLY . . . . . . . . . . . . . . . -100.0 -136.1 9.21 Favored Glycine 0 N--CA 1.465 0.598 0 N-CA-C 111.142 -0.783 . . . . 0.0 111.142 -179.774 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 208' ' ' SER . . . . . 0.538 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 30.7 p -166.47 170.04 13.27 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 120.829 0.347 . . . . 0.0 110.831 179.626 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 209' ' ' TRP . . . . . . . . . . . . . 86.1 m95 -86.29 149.32 25.14 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.373 179.637 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 59.1 p -129.06 128.78 44.26 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.345 179.247 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 54.1 t-105 -91.61 111.55 23.11 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.215 -179.977 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 212' ' ' GLU . . . . . 0.424 ' O ' ' O ' ' B' ' 215' ' ' LYS . 1.7 pt-20 -161.78 167.02 25.65 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.543 179.322 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 213' ' ' ASN . . . . . . . . . . . . . 93.7 m-20 49.79 35.05 8.38 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.929 -0.578 . . . . 0.0 111.159 176.722 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 51.46 17.93 3.29 Favored Glycine 0 CA--C 1.527 0.843 0 N-CA-C 111.37 -0.692 . . . . 0.0 111.37 179.934 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 215' ' ' LYS . . . . . 0.424 ' O ' ' O ' ' B' ' 212' ' ' GLU . 54.1 mtmt -142.58 149.45 39.03 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 120.851 0.357 . . . . 0.0 110.963 179.662 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 216' ' ' TRP . . . . . 0.456 ' O ' ' OG1' ' A' ' 79' ' ' THR . 59.8 m95 -88.83 116.4 27.08 Favored 'General case' 0 C--N 1.331 -0.23 0 N-CA-C 109.444 -0.576 . . . . 0.0 109.444 179.249 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 217' ' ' THR . . . . . 0.443 HG23 ' O ' ' A' ' 77' ' ' VAL . 17.8 m -124.81 140.34 53.02 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-O 120.976 0.417 . . . . 0.0 110.804 -179.265 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 218' ' ' TRP . . . . . 0.538 ' CH2' ' N ' ' B' ' 208' ' ' SER . 30.6 t-105 -102.8 105.35 15.75 Favored 'General case' 0 C--N 1.333 -0.121 0 CA-C-N 115.74 -0.664 . . . . 0.0 109.473 179.229 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 75.8 mttt -131.11 167.06 19.75 Favored 'General case' 0 N--CA 1.467 0.418 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.753 -179.375 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -178.24 -162.76 28.58 Favored Glycine 0 CA--C 1.523 0.588 0 N-CA-C 111.018 -0.833 . . . . 0.0 111.018 179.447 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 221' ' ' ILE . . . . . 0.555 ' O ' HG23 ' B' ' 222' ' ' ILE . 2.1 mp -55.24 -73.87 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 C-N-CA 120.66 -0.416 . . . . 0.0 110.694 -178.565 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 222' ' ' ILE . . . . . 0.555 HG23 ' O ' ' B' ' 221' ' ' ILE . 23.1 pt -160.61 -164.64 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.268 -179.599 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 223' ' ' ARG . . . . . 0.487 ' O ' ' O ' ' B' ' 222' ' ' ILE . 35.5 ptt-85 -41.73 173.1 0.0 OUTLIER 'General case' 0 CA--C 1.529 0.168 0 CA-C-O 121.352 0.596 . . . . 0.0 110.554 178.54 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 224' ' ' LEU . . . . . 0.988 HD22 ' H ' ' B' ' 224' ' ' LEU . 1.4 mm? -64.83 110.42 2.41 Favored 'General case' 0 C--N 1.313 -0.982 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.826 -179.597 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 83.5 tt0 -97.97 151.53 20.2 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.252 -0.886 . . . . 0.0 110.365 179.849 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 226' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.219 -0.524 0 CA-C-O 117.95 -1.024 . . . . 0.0 110.402 179.953 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.392 0 N-CA-C 109.456 -1.458 . . . . 0.0 109.456 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 4.6 m 47.39 41.5 12.65 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.743 0.306 . . . . 0.0 110.689 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 17.3 pt-20 -52.03 140.58 20.14 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.388 -179.924 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 4.5 m -82.71 148.71 58.57 Favored Pre-proline 0 C--N 1.327 -0.403 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.721 -179.726 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -69.09 113.45 3.27 Favored 'Trans proline' 0 N--CA 1.495 1.584 0 C-N-CA 122.502 2.134 . . . . 0.0 111.705 179.673 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 87.0 mt-30 -95.81 123.58 39.44 Favored 'General case' 0 C--N 1.333 -0.149 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.106 179.61 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 56.8 mt -97.88 114.32 26.36 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.256 -179.95 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 77.9 p -84.2 164.0 19.38 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.278 179.875 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . 0.428 ' O ' ' OD1' ' A' ' 11' ' ' ASP . 53.9 p-10 -108.55 144.62 35.97 Favored 'General case' 0 N--CA 1.464 0.244 0 CA-C-O 121.148 0.499 . . . . 0.0 110.522 -179.952 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.433 ' H ' ' HE1' ' B' ' 209' ' ' TRP . 4.9 tt -66.47 144.43 56.5 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.592 179.922 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . 0.499 ' O ' ' O ' ' A' ' 25' ' ' ARG . 85.5 p -141.44 156.07 45.81 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.98 0.419 . . . . 0.0 110.749 179.67 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . 0.532 ' N ' ' CD1' ' A' ' 14' ' ' PHE . 1.9 m-85 -112.64 153.31 27.83 Favored 'General case' 0 N--CA 1.464 0.263 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.337 -179.813 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 10.5 m -147.7 151.5 13.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.345 179.669 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 26.8 t0 62.89 37.07 12.36 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.622 -179.946 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 43.7 mt -56.94 133.45 21.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.055 179.698 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -136.54 -171.09 2.82 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.242 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . 0.47 ' N ' ' OD1' ' A' ' 19' ' ' ASP . 20.5 p-10 -75.85 -49.72 17.17 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.91 179.743 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . 0.47 ' OG ' ' O ' ' A' ' 67' ' ' LEU . 51.0 m -122.36 17.11 10.59 Favored 'General case' 0 N--CA 1.465 0.324 0 CA-C-N 116.437 -0.347 . . . . 0.0 110.805 -179.698 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 1.5 m -145.62 129.83 17.6 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.706 0.289 . . . . 0.0 110.265 -179.425 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . 0.678 HD12 HD21 ' A' ' 24' ' ' LEU . 36.5 pt -132.42 142.78 41.74 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 N-CA-C 109.599 -0.519 . . . . 0.0 109.599 179.67 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -101.48 85.9 0.58 Allowed Glycine 0 CA--C 1.523 0.541 0 N-CA-C 111.055 -0.818 . . . . 0.0 111.055 -179.413 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.678 HD21 HD12 ' A' ' 22' ' ' ILE . 55.4 mt -69.82 118.48 12.73 Favored 'General case' 0 C--N 1.33 -0.255 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 179.996 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . 0.585 ' HE ' ' CB ' ' A' ' 61' ' ' TYR . 31.5 ttm180 -142.99 132.5 23.6 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 121.004 0.431 . . . . 0.0 111.188 179.973 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' TRP . . . . . 0.468 ' O ' ' CD1' ' A' ' 26' ' ' TRP . 35.3 p90 -147.6 133.88 19.52 Favored 'General case' 0 C--N 1.326 -0.444 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 179.643 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 1.9 m -68.36 115.99 35.22 Favored Pre-proline 0 C--N 1.326 -0.43 0 C-N-CA 120.218 -0.593 . . . . 0.0 111.292 -178.97 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_exo -53.49 154.55 15.1 Favored 'Trans proline' 0 N--CA 1.492 1.431 0 C-N-CA 122.171 1.914 . . . . 0.0 112.709 178.258 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.464 ' O ' ' N ' ' A' ' 32' ' ' SER . 75.4 mt -93.66 132.03 38.4 Favored 'General case' 0 N--CA 1.467 0.404 0 CA-C-O 122.006 0.907 . . . . 0.0 110.89 179.926 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 40.4 t30 -43.13 -32.26 0.69 Allowed 'General case' 0 C--N 1.316 -0.863 0 CA-C-N 115.336 -0.847 . . . . 0.0 110.502 179.984 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 20.8 m -86.96 -30.44 21.29 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.692 179.365 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . 0.464 ' N ' ' O ' ' A' ' 29' ' ' LEU . 2.1 m -50.26 111.32 0.51 Allowed 'General case' 0 CA--C 1.529 0.166 0 CA-C-O 121.11 0.481 . . . . 0.0 110.524 -179.783 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . 0.449 ' CB ' ' H ' ' A' ' 82' ' ' ASN . 8.1 m -51.12 148.7 4.27 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.554 -0.748 . . . . 0.0 109.348 -179.646 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 5.3 mm -92.88 91.36 3.33 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.277 0 CA-C-O 121.391 0.615 . . . . 0.0 111.168 -178.825 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.541 HD11 ' HA ' ' A' ' 81' ' ' ILE . 12.0 pt -147.96 126.15 3.5 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 115.24 -0.891 . . . . 0.0 110.565 179.554 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -46.89 126.41 10.03 Favored Glycine 0 CA--C 1.521 0.465 0 N-CA-C 110.847 -0.901 . . . . 0.0 110.847 -179.718 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' TYR . . . . . 0.482 ' CE1' ' CG1' ' A' ' 55' ' ' VAL . 28.3 p90 -95.8 175.24 6.59 Favored 'General case' 0 C--N 1.329 -0.307 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 179.851 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 9.0 tmm_? -126.36 123.0 36.99 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.718 -179.843 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.471 ' CG1' ' O ' ' A' ' 39' ' ' ILE . 1.9 pt -94.14 120.22 43.21 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 N-CA-C 109.602 -0.518 . . . . 0.0 109.602 -179.856 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 10.1 m -96.14 128.48 43.08 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.15 -179.289 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.0 p -123.06 134.12 67.09 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 CA-C-N 116.077 -0.511 . . . . 0.0 109.873 -179.981 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . 0.407 ' O ' ' N ' ' A' ' 74' ' ' ASP . 24.5 t -129.35 128.45 66.42 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.173 0 CA-C-O 120.831 0.348 . . . . 0.0 110.132 179.846 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.511 ' HB2' ' CE2' ' A' ' 73' ' ' TYR . . . -97.36 128.99 44.66 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 109.054 -0.721 . . . . 0.0 109.054 179.372 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.606 ' HB3' ' O ' ' A' ' 72' ' ' ASP . . . -88.12 -24.27 23.43 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 120.869 0.366 . . . . 0.0 110.981 -179.624 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -86.43 20.59 21.66 Favored Glycine 0 N--CA 1.462 0.375 0 N-CA-C 111.202 -0.759 . . . . 0.0 111.202 -179.696 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 79.8 mm-40 -144.75 150.12 36.69 Favored 'General case' 0 C--O 1.233 0.224 0 CA-C-O 121.041 0.448 . . . . 0.0 110.324 -179.702 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -69.32 -20.33 75.09 Favored Glycine 0 N--CA 1.452 -0.269 0 N-CA-C 110.645 -0.982 . . . . 0.0 110.645 -179.852 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -131.42 139.01 34.05 Favored Pre-proline 0 N--CA 1.469 0.495 0 C-N-CA 120.952 -0.299 . . . . 0.0 110.528 179.673 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 68.6 Cg_endo -75.27 165.06 31.69 Favored 'Trans proline' 0 C--N 1.31 -1.458 0 C-N-CA 122.734 2.289 . . . . 0.0 112.027 177.676 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . 0.527 HG22 ' N ' ' A' ' 51' ' ' PHE . 96.6 mt -79.6 160.42 4.29 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-N 115.782 -0.644 . . . . 0.0 110.229 179.55 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' PHE . . . . . 0.527 ' N ' HG22 ' A' ' 50' ' ' ILE . 92.5 m-85 -74.36 142.33 45.09 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.734 179.918 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . 0.532 ' H ' ' CD ' ' A' ' 52' ' ' GLU . 0.2 OUTLIER -77.58 142.07 39.17 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.15 179.561 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . 0.42 ' CG ' ' OH ' ' A' ' 62' ' ' TYR . 0.5 OUTLIER -100.57 151.55 21.47 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 120.993 0.425 . . . . 0.0 110.051 -179.827 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 90.0 m-85 -115.09 122.06 44.98 Favored 'General case' 0 C--O 1.232 0.17 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.352 179.738 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.482 ' CG1' ' CE1' ' A' ' 37' ' ' TYR . 9.5 p -131.96 142.22 43.49 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.295 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.393 -179.974 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 99.3 m-20 -63.66 150.0 45.28 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.793 -0.64 . . . . 0.0 110.37 179.69 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . 0.487 ' OG ' ' O ' ' A' ' 35' ' ' ILE . 4.7 m -64.71 -34.84 79.27 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.875 179.909 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 68.0 m -51.17 -36.54 41.59 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.303 -179.026 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.48 ' C ' ' H ' ' A' ' 61' ' ' TYR . 22.7 t -64.38 -42.39 95.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.092 179.884 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 72.01 -40.05 0.69 Allowed Glycine 0 CA--C 1.531 1.069 0 N-CA-C 111.048 -0.821 . . . . 0.0 111.048 179.766 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . 0.585 ' CB ' ' HE ' ' A' ' 25' ' ' ARG . 31.1 p90 -110.68 161.01 16.17 Favored 'General case' 0 N--CA 1.466 0.368 0 CA-C-O 121.093 0.473 . . . . 0.0 111.08 -179.035 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' TYR . . . . . 0.42 ' OH ' ' CG ' ' A' ' 53' ' ' ASP . 31.5 t80 -155.95 163.04 40.24 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.015 -0.539 . . . . 0.0 109.949 179.492 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 57.6 m -119.6 131.47 55.5 Favored 'General case' 0 N--CA 1.467 0.422 0 CA-C-O 121.025 0.44 . . . . 0.0 110.628 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -134.27 108.91 11.76 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 115.765 -0.652 . . . . 0.0 109.981 179.324 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 1.2 p -128.35 167.37 17.06 Favored 'General case' 0 CA--C 1.514 -0.441 0 CA-C-O 121.023 0.44 . . . . 0.0 110.47 179.939 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 108.33 24.34 6.25 Favored Glycine 0 CA--C 1.522 0.496 0 CA-C-N 115.614 -0.721 . . . . 0.0 111.502 -179.793 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.47 ' O ' ' OG ' ' A' ' 20' ' ' SER . 3.9 mt -99.61 106.42 18.38 Favored 'General case' 0 CA--C 1.517 -0.29 0 N-CA-C 109.197 -0.668 . . . . 0.0 109.197 -179.401 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . 0.423 ' HG2' ' H ' ' A' ' 68' ' ' GLU . 0.0 OUTLIER -48.19 140.08 9.65 Favored Pre-proline 0 C--N 1.311 -1.097 0 CA-C-N 115.669 -0.696 . . . . 0.0 111.112 -178.247 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 68.5 Cg_endo -73.38 156.29 50.48 Favored 'Trans proline' 0 N--CA 1.5 1.896 0 C-N-CA 122.993 2.462 . . . . 0.0 111.596 178.344 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 74.61 -2.09 49.25 Favored Glycine 0 CA--C 1.525 0.718 0 CA-C-N 115.563 -0.744 . . . . 0.0 111.698 179.259 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 1.6 mp -110.46 140.5 29.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-O 121.557 0.694 . . . . 0.0 109.582 -179.283 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' ASP . . . . . 0.606 ' O ' ' HB3' ' A' ' 44' ' ' ALA . 1.6 t70 -80.54 122.78 27.46 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 114.877 -1.056 . . . . 0.0 110.297 179.649 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' TYR . . . . . 0.522 ' O ' HD13 ' A' ' 75' ' ' ILE . 12.5 m-85 -114.94 122.65 46.91 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.686 -0.688 . . . . 0.0 110.809 179.785 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' ASP . . . . . 0.407 ' N ' ' O ' ' A' ' 42' ' ' VAL . 66.3 m-20 -94.32 110.78 22.52 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 108.597 -0.89 . . . . 0.0 108.597 178.692 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.522 HD13 ' O ' ' A' ' 73' ' ' TYR . 0.0 OUTLIER -126.39 111.95 28.11 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.249 0 CA-C-N 116.654 -0.248 . . . . 0.0 111.27 179.954 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 23.8 t -105.43 125.66 51.24 Favored 'General case' 0 CA--C 1.518 -0.253 0 N-CA-C 109.576 -0.527 . . . . 0.0 109.576 179.247 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 84.4 t -88.71 99.52 9.24 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-O 120.939 0.4 . . . . 0.0 110.06 179.747 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 94.4 mt -82.52 135.99 23.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.356 179.914 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 30.5 p -113.26 117.71 32.62 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.231 179.623 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 1.8 mp -109.77 110.78 21.89 Favored 'General case' 0 N--CA 1.467 0.386 0 CA-C-O 121.194 0.521 . . . . 0.0 110.648 -179.822 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' ILE . . . . . 0.541 ' HA ' HD11 ' A' ' 35' ' ' ILE . 2.0 pp -146.55 143.69 20.62 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.213 179.274 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' ASN . . . . . 0.449 ' H ' ' CB ' ' A' ' 33' ' ' THR . 22.5 t-20 -66.37 -49.43 66.92 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.876 0.369 . . . . 0.0 111.213 179.821 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 111.66 109.51 3.08 Favored Glycine 0 N--CA 1.465 0.597 0 N-CA-C 110.79 -0.924 . . . . 0.0 110.79 179.657 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -63.22 105.51 1.06 Allowed Glycine 0 CA--C 1.525 0.716 0 N-CA-C 110.676 -0.97 . . . . 0.0 110.676 179.967 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -93.49 128.7 39.7 Favored 'General case' 0 N--CA 1.463 0.209 0 CA-C-O 120.79 0.329 . . . . 0.0 110.339 179.929 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 66.0 m -62.85 140.81 58.82 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.101 -0.5 . . . . 0.0 109.997 -179.871 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -122.65 150.42 58.14 Favored Pre-proline 0 CA--C 1.535 0.402 0 CA-C-N 116.321 -0.399 . . . . 0.0 110.525 -179.862 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -69.27 161.85 44.2 Favored 'Trans proline' 0 N--CA 1.496 1.639 0 C-N-CA 122.816 2.344 . . . . 0.0 111.82 179.152 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 41.4 p -129.79 150.6 51.02 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.34 -179.823 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 45.0 p -138.45 172.02 13.5 Favored 'General case' 0 CA--C 1.52 -0.186 0 CA-C-N 115.894 -0.593 . . . . 0.0 110.72 -179.832 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . 0.607 ' N ' HD22 ' A' ' 91' ' ' LEU . 3.7 mm? -76.95 140.74 40.55 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.537 -179.543 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 64.6 p -69.77 137.25 51.75 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.47 -179.988 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 99.4 mm-40 -74.85 134.47 41.68 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.5 179.917 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.582 ' CD ' ' H ' ' A' ' 94' ' ' GLN . 2.2 pm0 -67.32 143.21 56.52 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.648 179.867 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 78.6 p . . . . . 0 C--O 1.221 -0.434 0 CA-C-O 118.086 -0.959 . . . . 0.0 110.371 179.744 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' B' B ' 201' ' ' SER . . . . . . . . . . . . . 3.7 p . . . . . 0 N--CA 1.491 1.592 0 N-CA-C 109.348 -0.612 . . . . 0.0 109.348 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' B' B ' 202' ' ' SER . . . . . . . . . . . . . 38.2 t -71.31 149.17 46.38 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.318 -179.936 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 203' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -90.44 151.29 44.14 Favored Pre-proline 0 CA--C 1.533 0.315 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.536 -179.888 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 204' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -65.19 -43.81 10.55 Favored 'Trans proline' 0 N--CA 1.495 1.614 0 C-N-CA 122.909 2.406 . . . . 0.0 112.1 -179.758 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 205' ' ' ILE . . . . . . . . . . . . . 1.6 tt -149.77 145.55 17.39 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.193 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.629 -179.523 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 206' ' ' GLN . . . . . . . . . . . . . 15.3 pt20 -146.77 144.35 29.32 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.995 -0.548 . . . . 0.0 109.781 178.873 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 207' ' ' GLY . . . . . . . . . . . . . . . -105.81 -131.16 6.85 Favored Glycine 0 N--CA 1.466 0.672 0 N-CA-C 111.054 -0.818 . . . . 0.0 111.054 -179.919 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 208' ' ' SER . . . . . 0.589 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 97.6 p -167.07 170.88 11.53 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.805 0.336 . . . . 0.0 110.622 179.748 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 209' ' ' TRP . . . . . 0.433 ' HE1' ' H ' ' A' ' 12' ' ' LEU . 79.5 m95 -86.99 155.86 20.0 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.45 179.67 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 31.6 p -133.47 133.52 42.37 Favored 'General case' 0 N--CA 1.463 0.217 0 CA-C-N 116.434 -0.348 . . . . 0.0 110.414 179.745 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 58.0 t-105 -95.78 113.85 25.52 Favored 'General case' 0 N--CA 1.463 0.214 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.627 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 212' ' ' GLU . . . . . 0.43 ' O ' ' O ' ' B' ' 215' ' ' LYS . 0.9 OUTLIER -162.29 163.1 28.26 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.5 179.591 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' B' B ' 213' ' ' ASN . . . . . . . . . . . . . 17.8 m120 51.31 34.14 11.12 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.067 177.346 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 55.21 18.17 12.73 Favored Glycine 0 CA--C 1.527 0.808 0 N-CA-C 111.298 -0.721 . . . . 0.0 111.298 179.831 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 215' ' ' LYS . . . . . 0.43 ' O ' ' O ' ' B' ' 212' ' ' GLU . 56.1 mtmt -143.3 149.76 38.27 Favored 'General case' 0 C--O 1.232 0.165 0 CA-C-O 120.834 0.349 . . . . 0.0 110.95 179.895 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 216' ' ' TRP . . . . . . . . . . . . . 48.9 m95 -87.67 113.71 23.6 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.179 -0.464 . . . . 0.0 109.764 179.507 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 217' ' ' THR . . . . . . . . . . . . . 16.3 m -119.82 134.93 55.06 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.519 -179.339 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 218' ' ' TRP . . . . . 0.589 ' CH2' ' N ' ' B' ' 208' ' ' SER . 29.1 t-105 -95.88 105.0 16.96 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.875 -0.602 . . . . 0.0 109.907 179.27 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 6.9 mtmt -130.5 167.8 18.07 Favored 'General case' 0 CA--C 1.515 -0.398 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.778 -179.357 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -178.45 -163.35 29.68 Favored Glycine 0 CA--C 1.524 0.625 0 N-CA-C 111.138 -0.785 . . . . 0.0 111.138 179.41 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 221' ' ' ILE . . . . . 0.575 ' O ' HG23 ' B' ' 222' ' ' ILE . 20.1 mt -55.86 -73.24 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 C-N-CA 120.645 -0.422 . . . . 0.0 110.263 -178.146 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 222' ' ' ILE . . . . . 0.575 HG23 ' O ' ' B' ' 221' ' ' ILE . 18.9 pt -160.53 -166.8 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 O-C-N 123.402 0.439 . . . . 0.0 110.462 179.994 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 223' ' ' ARG . . . . . 0.479 ' O ' ' O ' ' B' ' 222' ' ' ILE . 33.4 ptt180 -43.3 172.71 0.0 OUTLIER 'General case' 0 C--O 1.231 0.098 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.497 179.082 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 224' ' ' LEU . . . . . 0.79 ' N ' HD22 ' B' ' 224' ' ' LEU . 2.2 mm? -65.5 107.2 1.61 Allowed 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 121.48 0.657 . . . . 0.0 110.322 -178.766 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 82.0 tt0 -90.04 154.23 19.97 Favored 'General case' 0 N--CA 1.452 -0.336 0 CA-C-N 115.084 -0.962 . . . . 0.0 110.01 179.919 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 226' ' ' GLN . . . . . . . . . . . . . 57.1 tt0 . . . . . 0 C--O 1.221 -0.438 0 CA-C-O 117.958 -1.02 . . . . 0.0 110.898 179.987 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.22 0 N-CA-C 109.469 -1.453 . . . . 0.0 109.469 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 29.5 m -137.02 -49.87 0.63 Allowed 'General case' 0 N--CA 1.464 0.262 0 CA-C-O 120.615 0.245 . . . . 0.0 110.751 -179.973 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 66.1 tt0 -129.68 119.27 23.24 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-O 120.918 0.39 . . . . 0.0 110.153 -179.877 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.639 ' O ' HG13 ' A' ' 6' ' ' VAL . 7.3 p -145.41 85.44 7.96 Favored Pre-proline 0 C--N 1.332 -0.18 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.396 -179.883 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_exo -56.93 139.37 89.39 Favored 'Trans proline' 0 C--N 1.307 -1.624 0 C-N-CA 122.472 2.115 . . . . 0.0 111.669 -179.784 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 59.5 tt0 -104.76 -21.59 13.34 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.376 179.915 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.535 HD23 ' N ' ' A' ' 10' ' ' THR . 1.9 tt -106.79 112.43 25.4 Favored 'General case' 0 C--O 1.232 0.151 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 -179.769 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . 0.587 HG21 ' O ' ' A' ' 27' ' ' THR . 9.0 t -97.99 172.78 7.42 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.257 179.936 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . 0.424 ' O ' ' OD1' ' A' ' 11' ' ' ASP . 51.2 p-10 -137.4 142.59 41.69 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.996 0.426 . . . . 0.0 110.561 179.961 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 6.9 tt -63.86 142.56 58.36 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.135 -179.542 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 83.9 p -139.4 155.47 47.61 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.665 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . 0.563 ' CZ ' HD13 ' B' ' 205' ' ' ILE . 20.9 m-85 -110.79 144.66 39.43 Favored 'General case' 0 C--O 1.233 0.204 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.498 -179.691 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 15.5 m -145.49 162.28 12.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.598 -179.973 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 98.4 m-20 51.6 32.65 9.4 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.524 179.621 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 86.5 mt -58.84 140.29 17.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.267 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.438 ' CB ' ' O ' ' A' ' 21' ' ' SER . 0.2 OUTLIER -143.25 -166.3 2.28 Favored 'General case' 0 N--CA 1.465 0.305 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.601 -179.653 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . 0.441 ' OD1' ' N ' ' A' ' 20' ' ' SER . 28.7 p-10 -90.73 -45.25 8.96 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.693 -0.685 . . . . 0.0 110.875 179.546 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . 0.441 ' N ' ' OD1' ' A' ' 19' ' ' ASP . 10.2 t -114.39 7.17 16.25 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-O 120.821 0.343 . . . . 0.0 110.92 -179.513 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . 0.438 ' O ' ' CB ' ' A' ' 18' ' ' THR . 45.2 m -151.62 146.52 25.88 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.976 0.417 . . . . 0.0 110.439 179.898 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . 0.459 HD12 HD21 ' A' ' 24' ' ' LEU . 40.8 pt -144.98 147.88 18.45 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-N 116.469 -0.332 . . . . 0.0 110.291 179.847 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -101.41 84.04 0.51 Allowed Glycine 0 CA--C 1.525 0.675 0 N-CA-C 111.038 -0.825 . . . . 0.0 111.038 -179.678 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.459 HD21 HD12 ' A' ' 22' ' ' ILE . 83.7 mt -71.39 124.6 24.96 Favored 'General case' 0 C--N 1.33 -0.282 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 -179.752 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 73.8 ttt-85 -138.94 139.92 38.14 Favored 'General case' 0 CA--C 1.52 -0.177 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.464 -179.593 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' TRP . . . . . . . . . . . . . 49.0 p90 -146.48 154.77 41.96 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.073 179.745 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . 0.587 ' O ' HG21 ' A' ' 10' ' ' THR . 2.9 m -109.97 103.31 53.21 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-N 116.466 -0.334 . . . . 0.0 110.583 179.888 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_exo -53.87 145.03 52.85 Favored 'Trans proline' 0 C--N 1.307 -1.642 0 C-N-CA 122.07 1.846 . . . . 0.0 112.591 179.172 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 64.6 mt -78.91 139.86 38.2 Favored 'General case' 0 CA--C 1.518 -0.252 0 CA-C-O 121.697 0.76 . . . . 0.0 110.789 -179.643 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 38.1 t30 -51.07 -37.1 43.59 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-N 115.131 -0.94 . . . . 0.0 109.916 179.656 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 15.5 m -75.75 -34.86 60.29 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.64 178.975 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 10.8 m -60.11 132.95 55.51 Favored 'General case' 0 C--O 1.232 0.158 0 CA-C-O 120.975 0.417 . . . . 0.0 110.179 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . 0.503 ' H ' ' HB ' ' A' ' 81' ' ' ILE . 5.6 m -57.78 145.22 35.59 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.17 -179.886 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 26.8 mm -93.99 91.29 3.11 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 CA-C-O 121.012 0.434 . . . . 0.0 110.631 -179.513 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 21.6 pt -143.39 140.41 26.36 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.498 179.707 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -44.33 128.47 6.95 Favored Glycine 0 CA--C 1.521 0.463 0 N-CA-C 111.096 -0.801 . . . . 0.0 111.096 -179.781 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 75.0 m-85 -91.54 175.9 6.74 Favored 'General case' 0 CA--C 1.517 -0.302 0 CA-C-O 120.89 0.376 . . . . 0.0 110.187 179.849 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -137.26 125.49 23.15 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.588 -179.939 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.438 ' CG1' ' O ' ' A' ' 39' ' ' ILE . 2.3 pt -101.68 124.81 55.71 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.251 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.1 -179.97 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 8.4 m -104.07 133.49 48.93 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.384 -179.275 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.3 p -132.98 139.38 49.67 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.296 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.319 179.756 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . 0.543 ' N ' ' O ' ' A' ' 74' ' ' ASP . 39.5 t -133.9 132.88 56.58 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.175 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.245 179.74 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.426 ' HB2' ' CE1' ' A' ' 73' ' ' TYR . . . -97.04 141.72 29.85 Favored 'General case' 0 C--N 1.326 -0.414 0 N-CA-C 109.702 -0.481 . . . . 0.0 109.702 179.15 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.501 ' HB3' ' O ' ' A' ' 72' ' ' ASP . . . -95.13 -40.43 9.61 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.821 0.344 . . . . 0.0 110.769 179.659 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -66.17 -32.64 82.87 Favored Glycine 0 CA--C 1.526 0.758 0 N-CA-C 111.295 -0.722 . . . . 0.0 111.295 -179.737 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 63.2 mt-10 -98.16 131.42 44.55 Favored 'General case' 0 C--N 1.333 -0.146 0 N-CA-C 109.598 -0.519 . . . . 0.0 109.598 -179.694 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -59.01 -21.64 53.33 Favored Glycine 0 N--CA 1.454 -0.117 0 N-CA-C 110.609 -0.997 . . . . 0.0 110.609 -179.079 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -111.72 134.46 21.29 Favored Pre-proline 0 CA--C 1.535 0.4 0 C-N-CA 121.133 -0.227 . . . . 0.0 110.474 179.556 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 63.9 Cg_endo -76.71 163.92 30.91 Favored 'Trans proline' 0 C--N 1.31 -1.47 0 C-N-CA 122.638 2.226 . . . . 0.0 111.884 177.751 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 96.6 mt -82.93 133.97 27.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 115.975 -0.557 . . . . 0.0 109.949 179.134 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 76.0 m-85 -56.15 136.54 52.6 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 121.054 0.454 . . . . 0.0 110.824 -179.355 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 4.7 pt-20 -68.79 -175.08 0.65 Allowed 'General case' 0 CA--C 1.516 -0.33 0 CA-C-N 115.706 -0.679 . . . . 0.0 110.372 179.461 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . 0.426 ' CG ' ' OH ' ' A' ' 62' ' ' TYR . 3.6 t70 -156.38 156.0 33.14 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.674 179.04 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' PHE . . . . . 0.578 ' CD1' ' N ' ' A' ' 54' ' ' PHE . 2.1 m-85 -122.12 130.85 53.6 Favored 'General case' 0 N--CA 1.465 0.324 0 CA-C-O 120.889 0.376 . . . . 0.0 110.114 179.729 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 9.7 p -130.01 138.19 54.63 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.186 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.418 -179.836 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 97.8 m-20 -53.66 144.33 18.02 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.457 -179.702 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 38.7 t -63.33 -35.81 81.61 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.703 179.994 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 36.6 m -57.11 -31.88 65.76 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.551 -179.717 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 94.0 t -64.96 -46.47 91.57 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.537 -179.913 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 56.19 25.89 48.52 Favored Glycine 0 CA--C 1.525 0.713 0 N-CA-C 110.7 -0.96 . . . . 0.0 110.7 -179.899 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . 0.493 ' C ' ' CD1' ' A' ' 61' ' ' TYR . 7.7 t80 -159.52 146.79 16.9 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-O 121.208 0.528 . . . . 0.0 111.035 -179.201 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' TYR . . . . . 0.435 ' CD2' ' CD1' ' A' ' 39' ' ' ILE . 33.9 t80 -159.99 161.79 34.18 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.152 178.611 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 96.5 m -131.15 139.17 49.74 Favored 'General case' 0 N--CA 1.464 0.244 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.689 179.995 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -131.14 104.63 9.5 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.263 0 CA-C-N 116.188 -0.46 . . . . 0.0 109.982 179.061 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 4.6 p -109.05 155.45 20.92 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.342 179.78 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 108.32 44.38 1.17 Allowed Glycine 0 CA--C 1.525 0.682 0 N-CA-C 111.184 -0.766 . . . . 0.0 111.184 -179.705 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 19.9 mt -116.45 103.57 10.58 Favored 'General case' 0 CA--C 1.519 -0.222 0 CA-C-O 121.194 0.521 . . . . 0.0 109.827 179.679 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 55.4 mm-40 -51.24 138.19 27.68 Favored Pre-proline 0 C--N 1.317 -0.806 0 CA-C-N 115.783 -0.644 . . . . 0.0 111.44 -178.433 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . 0.41 ' O ' HD12 ' A' ' 71' ' ' ILE . 72.1 Cg_endo -75.35 150.54 36.82 Favored 'Trans proline' 0 N--CA 1.496 1.665 0 C-N-CA 122.725 2.284 . . . . 0.0 111.635 178.687 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 70.69 17.32 74.86 Favored Glycine 0 CA--C 1.527 0.803 0 CA-C-N 115.55 -0.75 . . . . 0.0 111.361 179.14 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . 0.41 HD12 ' O ' ' A' ' 69' ' ' PRO . 1.5 mp -119.66 149.62 22.27 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.337 0 CA-C-O 121.413 0.625 . . . . 0.0 109.36 -179.503 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' ASP . . . . . 0.501 ' O ' ' HB3' ' A' ' 44' ' ' ALA . 2.4 t70 -89.39 108.97 19.94 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.15 -0.932 . . . . 0.0 110.652 -179.902 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' TYR . . . . . 0.554 ' O ' HD13 ' A' ' 75' ' ' ILE . 22.4 m-85 -104.3 119.53 39.17 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.348 179.772 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' ASP . . . . . 0.543 ' O ' ' N ' ' A' ' 42' ' ' VAL . 8.5 m-20 -88.2 118.43 27.78 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.531 -0.758 . . . . 0.0 109.247 179.466 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.624 HD11 ' N ' ' B' ' 223' ' ' ARG . 0.0 OUTLIER -120.02 167.22 13.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-O 121.098 0.475 . . . . 0.0 110.272 -179.124 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 1.8 m -154.92 126.92 7.64 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.622 -0.717 . . . . 0.0 110.591 179.248 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.486 ' O ' HG23 ' B' ' 217' ' ' THR . 21.7 t -106.02 100.26 10.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 179.178 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . 0.427 HG22 ' CD2' ' A' ' 80' ' ' LEU . 23.8 mt -101.9 140.9 19.27 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.225 0 CA-C-N 116.052 -0.522 . . . . 0.0 109.909 -179.651 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . 0.48 ' C ' HD22 ' A' ' 80' ' ' LEU . 19.5 m -120.05 113.59 20.73 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.571 -179.767 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . 0.48 HD22 ' C ' ' A' ' 79' ' ' THR . 4.4 mm? -106.68 127.93 53.77 Favored 'General case' 0 N--CA 1.463 0.22 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.434 179.796 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' ILE . . . . . 0.503 ' HB ' ' H ' ' A' ' 33' ' ' THR . 1.9 pp -141.38 145.01 25.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 115.632 -0.713 . . . . 0.0 110.219 179.565 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' ASN . . . . . 0.409 ' H ' ' CB ' ' A' ' 33' ' ' THR . 37.6 t30 -56.24 -66.18 0.48 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.707 -179.73 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 157.44 103.36 0.2 Allowed Glycine 0 CA--C 1.522 0.53 0 N-CA-C 110.873 -0.891 . . . . 0.0 110.873 179.849 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -90.4 177.36 42.38 Favored Glycine 0 CA--C 1.524 0.607 0 N-CA-C 110.827 -0.909 . . . . 0.0 110.827 179.919 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.48 ' OE1' ' N ' ' A' ' 85' ' ' GLU . 55.9 mp0 -80.96 122.66 27.54 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.86 0.362 . . . . 0.0 110.466 -179.944 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 83.0 p -74.3 157.89 34.99 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.409 -179.913 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.495 ' HB1' ' HD2' ' A' ' 88' ' ' PRO . . . -78.11 160.46 73.46 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.364 -179.807 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . 0.495 ' HD2' ' HB1' ' A' ' 87' ' ' ALA . 44.7 Cg_endo -68.83 -14.51 39.1 Favored 'Trans proline' 0 C--N 1.309 -1.551 0 C-N-CA 122.857 2.372 . . . . 0.0 111.956 179.347 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 4.9 t -141.83 161.87 36.89 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.565 -179.632 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 68.5 p -132.07 152.35 51.24 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.434 179.94 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . 0.577 ' N ' HD12 ' A' ' 91' ' ' LEU . 10.1 mp -93.14 144.09 25.62 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.406 -179.855 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 34.6 p -64.8 137.31 57.7 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.066 -0.516 . . . . 0.0 110.329 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 29.2 pt20 -95.34 160.76 14.38 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.553 179.917 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 45.5 tt0 63.09 -125.87 0.59 Allowed 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.175 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 15.8 p . . . . . 0 C--O 1.222 -0.361 0 CA-C-O 117.892 -1.051 . . . . 0.0 110.335 179.983 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' B' B ' 201' ' ' SER . . . . . . . . . . . . . 57.6 p . . . . . 0 N--CA 1.49 1.534 0 N-CA-C 109.323 -0.621 . . . . 0.0 109.323 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' B' B ' 202' ' ' SER . . . . . . . . . . . . . 41.5 t -70.58 138.13 50.62 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.185 179.903 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 203' ' ' SER . . . . . . . . . . . . . 10.3 m -111.2 150.13 41.55 Favored Pre-proline 0 CA--C 1.532 0.274 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.578 179.921 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 204' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_exo -41.25 -33.91 1.56 Allowed 'Trans proline' 0 C--N 1.312 -1.38 0 C-N-CA 122.771 2.314 . . . . 0.0 112.165 179.432 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 205' ' ' ILE . . . . . 0.563 HD13 ' CZ ' ' A' ' 14' ' ' PHE . 11.7 tt -152.79 159.02 3.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.266 179.883 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 206' ' ' GLN . . . . . 0.427 ' N ' ' CG1' ' B' ' 205' ' ' ILE . 9.2 pt20 -170.68 78.66 0.08 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.463 179.25 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 207' ' ' GLY . . . . . . . . . . . . . . . -110.32 -147.3 11.38 Favored Glycine 0 N--CA 1.464 0.555 0 N-CA-C 111.088 -0.805 . . . . 0.0 111.088 -179.936 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 208' ' ' SER . . . . . 0.432 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 92.3 p -165.37 171.57 13.28 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.866 0.365 . . . . 0.0 110.746 -179.922 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 209' ' ' TRP . . . . . . . . . . . . . 80.0 m95 -81.43 146.18 30.39 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.456 179.784 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 65.2 p -128.76 132.42 47.92 Favored 'General case' 0 N--CA 1.464 0.255 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.616 -179.951 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 50.3 t-105 -91.94 116.54 29.01 Favored 'General case' 0 C--O 1.232 0.15 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.241 179.649 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 212' ' ' GLU . . . . . 0.489 ' O ' ' O ' ' B' ' 215' ' ' LYS . 1.7 pt-20 -165.46 168.19 16.85 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.972 179.261 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 213' ' ' ASN . . . . . . . . . . . . . 91.8 m-20 49.51 36.73 10.72 Favored 'General case' 0 C--N 1.322 -0.602 0 C-N-CA 120.525 -0.47 . . . . 0.0 111.217 176.634 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 50.86 16.32 1.71 Allowed Glycine 0 CA--C 1.525 0.671 0 N-CA-C 111.266 -0.734 . . . . 0.0 111.266 179.658 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 215' ' ' LYS . . . . . 0.489 ' O ' ' O ' ' B' ' 212' ' ' GLU . 50.3 mtmt -145.66 151.45 38.07 Favored 'General case' 0 C--N 1.333 -0.142 0 CA-C-O 120.942 0.401 . . . . 0.0 110.81 179.704 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 216' ' ' TRP . . . . . . . . . . . . . 53.8 m95 -87.79 123.3 32.43 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.044 179.58 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 217' ' ' THR . . . . . 0.486 HG23 ' O ' ' A' ' 77' ' ' VAL . 12.9 m -133.7 145.21 49.69 Favored 'General case' 0 N--CA 1.464 0.269 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.502 -179.607 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 218' ' ' TRP . . . . . 0.432 ' CH2' ' N ' ' B' ' 208' ' ' SER . 14.4 t-105 -106.08 119.58 39.58 Favored 'General case' 0 N--CA 1.463 0.175 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.018 179.188 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 47.3 mtpt -141.26 169.79 16.95 Favored 'General case' 0 CA--C 1.52 -0.198 0 CA-C-O 120.92 0.39 . . . . 0.0 110.464 -179.49 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -176.04 -161.38 25.12 Favored Glycine 0 CA--C 1.526 0.732 0 N-CA-C 111.279 -0.729 . . . . 0.0 111.279 -179.883 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 221' ' ' ILE . . . . . 0.58 ' H ' HD12 ' B' ' 221' ' ' ILE . 2.2 mp -51.03 -73.24 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 C-N-CA 120.678 -0.409 . . . . 0.0 110.679 -178.283 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 222' ' ' ILE . . . . . 0.552 HG23 ' O ' ' B' ' 221' ' ' ILE . 21.8 pt -159.75 -166.34 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.624 -179.584 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 223' ' ' ARG . . . . . 0.624 ' N ' HD11 ' A' ' 75' ' ' ILE . 46.9 ptt85 -46.03 178.32 0.0 OUTLIER 'General case' 0 CA--C 1.516 -0.337 0 CA-C-N 115.756 -0.657 . . . . 0.0 110.563 179.281 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 224' ' ' LEU . . . . . 0.688 ' N ' HD22 ' B' ' 224' ' ' LEU . 3.1 mm? -59.41 121.71 12.16 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 115.687 -0.688 . . . . 0.0 110.533 -179.135 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 78.5 tt0 -104.2 152.87 21.64 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.4 179.986 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 226' ' ' GLN . . . . . . . . . . . . . 35.8 mt-30 . . . . . 0 C--O 1.219 -0.517 0 CA-C-O 118.023 -0.989 . . . . 0.0 110.583 -179.868 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.246 0 N-CA-C 109.431 -1.468 . . . . 0.0 109.431 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 25.8 t 54.07 78.91 0.15 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.834 0.35 . . . . 0.0 110.52 -179.868 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 80.3 mm-40 -109.7 120.4 42.37 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.43 -179.906 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.4 HG22 ' H ' ' A' ' 6' ' ' VAL . 1.2 m -88.98 151.09 46.6 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.451 -179.644 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 41.6 Cg_endo -66.56 148.74 83.97 Favored 'Trans proline' 0 C--N 1.311 -1.437 0 C-N-CA 122.702 2.268 . . . . 0.0 111.865 179.556 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 77.9 mt-30 -127.24 121.64 31.77 Favored 'General case' 0 N--CA 1.464 0.256 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.31 179.618 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.578 ' N ' HD12 ' A' ' 9' ' ' LEU . 9.1 mp -90.13 130.61 36.27 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.043 -0.526 . . . . 0.0 109.855 -179.962 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -87.64 133.49 33.81 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.203 -179.957 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 54.7 p30 -79.77 163.24 24.61 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.667 -179.77 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 70.4 mt -63.57 151.89 40.25 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.343 -179.291 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 85.9 p -141.13 149.83 42.04 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-N 116.059 -0.518 . . . . 0.0 110.31 179.916 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . 0.519 ' N ' ' CD1' ' A' ' 14' ' ' PHE . 18.3 m-85 -111.37 145.8 38.26 Favored 'General case' 0 N--CA 1.464 0.235 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.569 -179.627 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 18.2 m -147.71 161.75 7.36 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.117 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.495 179.88 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 41.0 t0 56.06 29.32 14.29 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.66 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 96.5 mt -56.19 138.97 16.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.249 179.797 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.45 ' CB ' ' O ' ' A' ' 21' ' ' SER . 0.2 OUTLIER -139.96 -167.12 2.23 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.479 -179.69 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . 0.506 ' OD1' ' N ' ' A' ' 20' ' ' SER . 32.3 p-10 -89.63 -43.47 10.73 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.731 179.601 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . 0.506 ' N ' ' OD1' ' A' ' 19' ' ' ASP . 10.2 t -117.54 8.75 13.0 Favored 'General case' 0 N--CA 1.465 0.317 0 CA-C-O 120.754 0.312 . . . . 0.0 110.889 -179.716 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . 0.45 ' O ' ' CB ' ' A' ' 18' ' ' THR . 18.2 p -150.56 137.69 19.36 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.974 0.416 . . . . 0.0 110.35 -179.919 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 41.9 pt -132.07 145.68 34.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.467 -0.333 . . . . 0.0 110.159 179.921 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -97.86 81.96 0.66 Allowed Glycine 0 CA--C 1.525 0.675 0 N-CA-C 110.965 -0.854 . . . . 0.0 110.965 -179.805 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 94.9 mt -70.95 119.5 15.16 Favored 'General case' 0 C--N 1.33 -0.274 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 -179.882 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 70.1 ttt180 -138.15 142.08 40.11 Favored 'General case' 0 CA--C 1.519 -0.229 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.988 179.901 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' TRP . . . . . 0.543 ' CD2' ' O ' ' A' ' 60' ' ' GLY . 25.4 p90 -143.11 156.08 44.73 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.763 -0.653 . . . . 0.0 109.977 -179.87 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 3.2 m -109.84 101.96 48.71 Favored Pre-proline 0 N--CA 1.465 0.322 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.757 179.828 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 42.4 Cg_exo -54.94 144.57 67.07 Favored 'Trans proline' 0 C--N 1.304 -1.769 0 C-N-CA 122.108 1.872 . . . . 0.0 112.34 179.153 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 65.8 mt -83.47 139.77 32.73 Favored 'General case' 0 CA--C 1.52 -0.196 0 CA-C-O 121.813 0.816 . . . . 0.0 110.718 179.801 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 26.0 t-20 -47.94 -33.05 7.14 Favored 'General case' 0 C--N 1.319 -0.75 0 CA-C-N 115.268 -0.878 . . . . 0.0 110.19 -179.914 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 52.5 m -84.86 -30.9 24.08 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.627 179.506 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 4.9 m -58.15 131.23 49.92 Favored 'General case' 0 N--CA 1.462 0.144 0 CA-C-O 121.25 0.547 . . . . 0.0 110.444 179.912 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . 0.461 ' HG1' ' H ' ' A' ' 83' ' ' GLY . 3.9 m -59.78 140.17 56.75 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.505 -0.77 . . . . 0.0 110.021 -179.801 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 58.2 mt -94.11 92.26 3.47 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.19 0 CA-C-O 120.865 0.364 . . . . 0.0 110.774 -179.778 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.433 ' O ' ' OG ' ' A' ' 57' ' ' SER . 9.5 pt -142.29 131.85 23.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.43 179.408 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -37.95 114.85 0.33 Allowed Glycine 0 CA--C 1.523 0.553 0 N-CA-C 111.442 -0.663 . . . . 0.0 111.442 -179.297 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 96.5 m-85 -79.8 177.27 9.02 Favored 'General case' 0 CA--C 1.515 -0.392 0 N-CA-C 110.019 -0.363 . . . . 0.0 110.019 -179.901 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 5.5 tmm_? -135.01 126.21 28.09 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.039 179.922 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 6.5 pt -95.35 155.33 3.33 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.391 0 N-CA-C 109.472 -0.566 . . . . 0.0 109.472 179.892 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 3.4 m -136.29 131.34 34.28 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.627 0.251 . . . . 0.0 110.624 -179.713 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.691 HG22 HD13 ' A' ' 50' ' ' ILE . 2.1 p -134.56 137.82 50.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.314 179.464 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . 0.538 ' N ' ' O ' ' A' ' 74' ' ' ASP . 41.5 t -134.83 135.92 52.66 Favored 'Isoleucine or valine' 0 C--O 1.23 0.058 0 CA-C-N 116.509 -0.314 . . . . 0.0 110.369 179.621 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.787 ' HB2' HD11 ' A' ' 50' ' ' ILE . . . -97.3 138.05 35.36 Favored 'General case' 0 C--N 1.33 -0.269 0 N-CA-C 109.628 -0.508 . . . . 0.0 109.628 179.231 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.518 ' HB3' ' O ' ' A' ' 72' ' ' ASP . . . -90.54 -47.51 7.65 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.783 0.325 . . . . 0.0 110.708 179.723 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -61.64 -29.39 71.84 Favored Glycine 0 CA--C 1.525 0.711 0 N-CA-C 111.084 -0.806 . . . . 0.0 111.084 -179.863 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 91.2 mt-10 -95.94 127.56 42.06 Favored 'General case' 0 CA--C 1.52 -0.203 0 N-CA-C 109.357 -0.609 . . . . 0.0 109.357 -179.424 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -59.2 -22.0 54.69 Favored Glycine 0 CA--C 1.508 -0.389 0 N-CA-C 110.82 -0.912 . . . . 0.0 110.82 -179.229 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -110.16 135.04 20.58 Favored Pre-proline 0 CA--C 1.539 0.543 0 C-N-CA 120.858 -0.337 . . . . 0.0 110.235 179.702 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 62.3 Cg_endo -75.8 167.8 25.56 Favored 'Trans proline' 0 C--N 1.309 -1.517 0 C-N-CA 122.605 2.203 . . . . 0.0 111.732 177.344 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . 0.88 ' H ' HD12 ' A' ' 50' ' ' ILE . 1.7 mp -91.58 144.85 8.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 115.598 -0.728 . . . . 0.0 110.152 179.526 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 96.0 m-85 -65.84 142.2 58.01 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.702 -179.534 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . 0.578 ' H ' ' CD ' ' A' ' 52' ' ' GLU . 0.0 OUTLIER -73.87 -176.84 2.59 Favored 'General case' 0 CA--C 1.514 -0.424 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.602 179.664 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 3.6 t70 -151.45 147.45 26.88 Favored 'General case' 0 N--CA 1.452 -0.34 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.78 179.475 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 54.2 m-85 -115.7 124.8 51.76 Favored 'General case' 0 N--CA 1.463 0.219 0 CA-C-N 116.466 -0.334 . . . . 0.0 110.204 179.725 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 9.9 p -127.4 136.52 60.35 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.211 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.425 -179.886 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 99.8 m-20 -57.15 145.7 30.4 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.015 -0.538 . . . . 0.0 110.502 -179.707 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . 0.433 ' OG ' ' O ' ' A' ' 35' ' ' ILE . 35.3 m -59.49 -33.46 71.36 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.61 179.917 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 49.5 m -52.68 -35.92 56.12 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.596 -179.901 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.522 HG12 ' O ' ' A' ' 61' ' ' TYR . 21.2 t -69.68 -43.72 79.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.348 179.853 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . 0.543 ' O ' ' CD2' ' A' ' 26' ' ' TRP . . . 68.68 -43.94 0.36 Allowed Glycine 0 CA--C 1.531 1.046 0 N-CA-C 110.943 -0.863 . . . . 0.0 110.943 179.903 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . 0.522 ' O ' HG12 ' A' ' 59' ' ' VAL . 25.0 p90 -102.49 157.71 16.73 Favored 'General case' 0 N--CA 1.463 0.223 0 CA-C-O 121.257 0.551 . . . . 0.0 111.139 -179.208 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 32.5 t80 -156.67 160.33 39.26 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.979 -0.555 . . . . 0.0 109.907 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 91.2 m -123.45 136.04 54.4 Favored 'General case' 0 C--O 1.233 0.206 0 CA-C-O 120.887 0.375 . . . . 0.0 110.699 -179.882 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -132.01 99.68 3.81 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 CA-C-N 116.035 -0.53 . . . . 0.0 109.818 179.249 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 2.2 p -106.73 159.25 16.36 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.91 0.386 . . . . 0.0 110.6 179.91 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 108.74 41.47 1.45 Allowed Glycine 0 CA--C 1.523 0.544 0 N-CA-C 111.41 -0.676 . . . . 0.0 111.41 -179.674 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 10.3 mt -116.43 107.88 15.34 Favored 'General case' 0 CA--C 1.517 -0.307 0 CA-C-O 121.346 0.593 . . . . 0.0 109.728 -179.868 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 53.0 mm-40 -53.85 136.07 55.95 Favored Pre-proline 0 C--N 1.318 -0.795 0 CA-C-N 115.611 -0.722 . . . . 0.0 111.622 -178.209 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo -75.34 155.43 41.37 Favored 'Trans proline' 0 N--CA 1.498 1.774 0 C-N-CA 122.952 2.434 . . . . 0.0 111.722 178.783 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 71.66 8.37 67.33 Favored Glycine 0 CA--C 1.526 0.777 0 CA-C-N 115.375 -0.829 . . . . 0.0 111.477 179.153 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 1.6 mp -118.03 145.4 24.0 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.298 0 CA-C-O 121.541 0.686 . . . . 0.0 109.381 -179.416 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' ASP . . . . . 0.518 ' O ' ' HB3' ' A' ' 44' ' ' ALA . 2.9 t70 -82.13 112.53 19.25 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-N 114.768 -1.105 . . . . 0.0 110.829 -179.579 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' TYR . . . . . 0.547 ' O ' HD13 ' A' ' 75' ' ' ILE . 13.3 m-85 -105.29 120.57 41.89 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.507 179.648 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' ASP . . . . . 0.538 ' O ' ' N ' ' A' ' 42' ' ' VAL . 74.0 m-20 -88.48 117.62 27.55 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.338 -0.846 . . . . 0.0 109.417 179.808 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.562 HD11 ' N ' ' B' ' 223' ' ' ARG . 0.0 OUTLIER -117.97 163.57 15.03 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.362 0 CA-C-O 121.075 0.464 . . . . 0.0 110.011 -179.194 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -154.91 123.5 6.08 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.42 -0.809 . . . . 0.0 110.583 179.29 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 88.5 t -102.14 104.15 16.02 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 178.709 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 92.8 mt -96.95 132.71 40.79 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.224 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.349 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . 0.609 HG23 ' O ' ' A' ' 79' ' ' THR . 14.0 t -112.15 120.25 41.17 Favored 'General case' 0 CA--C 1.514 -0.41 0 CA-C-N 116.173 -0.467 . . . . 0.0 109.946 -179.823 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . 0.577 HD13 ' N ' ' A' ' 81' ' ' ILE . 0.2 OUTLIER -121.54 115.46 22.87 Favored 'General case' 0 N--CA 1.464 0.234 0 CA-C-N 116.306 -0.407 . . . . 0.0 110.422 -179.781 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' ILE . . . . . 0.577 ' N ' HD13 ' A' ' 80' ' ' LEU . 1.9 pp -138.25 145.14 28.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.268 -0.424 . . . . 0.0 109.921 179.049 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' ASN . . . . . 0.406 ' H ' ' CB ' ' A' ' 33' ' ' THR . 60.7 t30 -65.34 -58.85 4.88 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.792 179.965 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . 0.461 ' H ' ' HG1' ' A' ' 33' ' ' THR . . . 63.66 69.76 1.24 Allowed Glycine 0 CA--C 1.523 0.553 0 N-CA-C 110.881 -0.888 . . . . 0.0 110.881 179.897 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -46.29 123.02 6.69 Favored Glycine 0 CA--C 1.523 0.577 0 N-CA-C 110.806 -0.918 . . . . 0.0 110.806 -179.942 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -93.25 148.21 22.24 Favored 'General case' 0 N--CA 1.463 0.194 0 CA-C-O 120.801 0.334 . . . . 0.0 110.475 -179.923 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 21.1 m -66.21 144.79 56.41 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.37 -179.851 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . 58.64 74.83 0.57 Allowed Pre-proline 0 C--N 1.329 -0.293 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.591 179.956 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_exo -59.34 144.38 99.42 Favored 'Trans proline' 0 C--N 1.305 -1.737 0 C-N-CA 122.942 2.428 . . . . 0.0 111.982 179.793 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 4.6 p -83.86 164.48 19.44 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.128 -179.901 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 75.8 m -130.01 133.95 47.09 Favored 'General case' 0 N--CA 1.465 0.284 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.647 -179.94 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . 0.593 ' N ' HD12 ' A' ' 91' ' ' LEU . 8.8 mp -73.31 132.7 43.4 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.137 -179.736 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 61.6 p -84.21 166.89 17.18 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.516 179.919 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 28.9 mm100 -60.16 100.42 0.09 Allowed 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.284 -0.417 . . . . 0.0 110.514 179.99 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 52.0 mt-30 -64.74 -40.2 94.91 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.577 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 13.2 m . . . . . 0 C--O 1.219 -0.501 0 CA-C-O 117.804 -1.093 . . . . 0.0 110.374 -179.91 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' B' B ' 201' ' ' SER . . . . . . . . . . . . . 65.0 p . . . . . 0 N--CA 1.491 1.599 0 N-CA-C 109.291 -0.633 . . . . 0.0 109.291 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' B' B ' 202' ' ' SER . . . . . . . . . . . . . 88.3 p -66.65 153.29 43.52 Favored 'General case' 0 CA--C 1.515 -0.386 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.3 -179.901 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 203' ' ' SER . . . . . . . . . . . . . 4.8 p -107.7 150.63 40.46 Favored Pre-proline 0 CA--C 1.538 0.492 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.575 -179.857 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 204' ' ' PRO . . . . . . . . . . . . . 74.8 Cg_exo -45.67 -48.02 12.74 Favored 'Trans proline' 0 N--CA 1.494 1.505 0 C-N-CA 122.226 1.95 . . . . 0.0 112.182 179.424 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 205' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -151.36 147.35 15.51 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.469 179.825 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 206' ' ' GLN . . . . . . . . . . . . . 14.3 pt20 -143.06 144.17 32.15 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.465 -0.334 . . . . 0.0 110.509 178.943 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 207' ' ' GLY . . . . . 0.416 ' C ' ' CH2' ' B' ' 218' ' ' TRP . . . -105.67 -135.59 8.25 Favored Glycine 0 N--CA 1.465 0.62 0 N-CA-C 110.99 -0.844 . . . . 0.0 110.99 179.827 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 208' ' ' SER . . . . . 0.535 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 52.0 p -166.46 171.81 11.5 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.711 0.291 . . . . 0.0 110.703 179.664 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 209' ' ' TRP . . . . . . . . . . . . . 42.6 m95 -85.22 147.33 26.64 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.504 179.052 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 51.1 p -129.47 129.86 45.13 Favored 'General case' 0 C--O 1.232 0.176 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.7 179.876 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 42.5 t-105 -91.82 118.11 30.4 Favored 'General case' 0 C--N 1.334 -0.074 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.137 179.801 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 212' ' ' GLU . . . . . 0.443 ' O ' ' O ' ' B' ' 215' ' ' LYS . 1.0 OUTLIER -166.09 168.44 15.47 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.829 179.321 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' B' B ' 213' ' ' ASN . . . . . . . . . . . . . 93.1 m-20 49.47 37.55 12.36 Favored 'General case' 0 C--N 1.323 -0.566 0 C-N-CA 120.471 -0.492 . . . . 0.0 111.404 176.671 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 49.61 17.1 1.21 Allowed Glycine 0 CA--C 1.526 0.744 0 N-CA-C 111.337 -0.705 . . . . 0.0 111.337 179.703 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 215' ' ' LYS . . . . . 0.443 ' O ' ' O ' ' B' ' 212' ' ' GLU . 53.0 mtmt -142.99 150.25 39.4 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-O 121.169 0.509 . . . . 0.0 110.798 179.935 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 216' ' ' TRP . . . . . 0.534 ' O ' HG22 ' A' ' 79' ' ' THR . 59.5 m95 -89.49 118.48 29.17 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.012 -0.54 . . . . 0.0 109.818 179.631 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 217' ' ' THR . . . . . . . . . . . . . 17.7 m -131.23 144.51 51.38 Favored 'General case' 0 N--CA 1.466 0.328 0 CA-C-O 120.924 0.392 . . . . 0.0 110.524 -179.634 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 218' ' ' TRP . . . . . 0.535 ' CH2' ' N ' ' B' ' 208' ' ' SER . 12.0 t-105 -104.83 117.4 33.97 Favored 'General case' 0 C--N 1.328 -0.346 0 N-CA-C 109.532 -0.544 . . . . 0.0 109.532 179.262 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 50.5 mtpt -142.98 168.77 18.93 Favored 'General case' 0 CA--C 1.518 -0.253 0 CA-C-O 121.112 0.482 . . . . 0.0 110.485 -179.275 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -175.76 -162.25 26.5 Favored Glycine 0 CA--C 1.523 0.571 0 CA-C-N 115.603 -0.726 . . . . 0.0 111.389 -179.861 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 221' ' ' ILE . . . . . 0.521 ' O ' HG23 ' B' ' 222' ' ' ILE . 0.8 OUTLIER -53.34 -75.96 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 C-N-CA 120.641 -0.423 . . . . 0.0 110.872 -178.648 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' B' B ' 222' ' ' ILE . . . . . 0.521 HG23 ' O ' ' B' ' 221' ' ' ILE . 23.1 pt -158.97 -165.37 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.323 -179.232 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 223' ' ' ARG . . . . . 0.562 ' N ' HD11 ' A' ' 75' ' ' ILE . 52.7 ptt85 -42.94 172.87 0.0 OUTLIER 'General case' 0 C--O 1.234 0.276 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.299 179.133 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 224' ' ' LEU . . . . . 0.872 HD22 ' H ' ' B' ' 224' ' ' LEU . 1.7 mm? -68.37 111.59 4.72 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-O 121.296 0.57 . . . . 0.0 110.461 -179.378 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 26.7 tp10 -82.63 151.04 26.48 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.196 -0.911 . . . . 0.0 110.37 179.745 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 226' ' ' GLN . . . . . . . . . . . . . 94.5 mt-30 . . . . . 0 C--N 1.326 -0.448 0 CA-C-O 117.938 -1.029 . . . . 0.0 110.654 -179.823 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.174 0 N-CA-C 109.538 -1.425 . . . . 0.0 109.538 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 87.8 p -155.08 129.31 8.93 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.802 0.334 . . . . 0.0 110.385 179.799 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 72.0 mm-40 -108.62 76.43 1.02 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.218 -0.446 . . . . 0.0 109.93 179.66 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 22.4 t -76.61 116.6 58.03 Favored Pre-proline 0 CA--C 1.539 0.526 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.823 -179.674 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_exo -55.37 128.11 29.08 Favored 'Trans proline' 0 N--CA 1.5 1.901 0 C-N-CA 121.646 1.564 . . . . 0.0 112.077 179.341 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . 0.426 ' H ' ' H ' ' A' ' 9' ' ' LEU . 0.5 OUTLIER 170.67 -0.75 0.0 OUTLIER 'General case' 0 N--CA 1.465 0.297 0 CA-C-O 120.694 0.283 . . . . 0.0 110.465 179.312 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.527 ' N ' HD12 ' A' ' 9' ' ' LEU . 10.6 mp -91.04 122.12 33.43 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 120.952 0.406 . . . . 0.0 109.908 179.851 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 33.9 p -107.9 125.3 51.32 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.421 -179.861 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -88.82 143.27 27.01 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.446 179.715 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.403 HD23 ' N ' ' A' ' 12' ' ' LEU . 0.1 OUTLIER -74.18 153.26 39.57 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 114.965 -1.016 . . . . 0.0 109.806 -179.923 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 49.1 p -140.1 154.8 47.14 Favored 'General case' 0 C--N 1.333 -0.13 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.28 179.056 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . 0.472 ' N ' ' CD1' ' A' ' 14' ' ' PHE . 32.2 m-85 -103.69 146.35 28.73 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.562 -179.645 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 20.8 m -149.17 162.81 4.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.251 -0.432 . . . . 0.0 110.373 179.863 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 97.4 m-20 54.85 26.97 8.35 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.769 179.991 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 96.6 mt -56.06 136.16 18.87 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-O 121.007 0.432 . . . . 0.0 110.085 179.951 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.653 ' HG1' ' H ' ' A' ' 21' ' ' SER . 1.1 p -135.62 -166.79 1.91 Allowed 'General case' 0 CA--C 1.511 -0.548 0 CA-C-N 115.678 -0.692 . . . . 0.0 110.137 -179.977 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . 0.532 ' OD1' ' N ' ' A' ' 20' ' ' SER . 37.0 p-10 -90.46 -41.45 11.43 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.244 -0.889 . . . . 0.0 111.12 178.979 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . 0.532 ' N ' ' OD1' ' A' ' 19' ' ' ASP . 5.7 t -114.8 9.44 16.3 Favored 'General case' 0 N--CA 1.468 0.432 0 CA-C-N 116.323 -0.398 . . . . 0.0 110.984 -179.012 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . 0.653 ' H ' ' HG1' ' A' ' 18' ' ' THR . 27.9 p -154.85 158.05 38.79 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.118 179.61 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 42.9 pt -148.69 148.83 15.59 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.15 -179.912 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -100.88 78.82 0.42 Allowed Glycine 0 N--CA 1.467 0.721 0 N-CA-C 110.889 -0.884 . . . . 0.0 110.889 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.442 ' O ' ' CD1' ' A' ' 61' ' ' TYR . 20.9 mt -63.78 130.65 45.05 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.875 0.369 . . . . 0.0 110.233 -179.474 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 18.0 tpt180 -144.72 134.21 23.26 Favored 'General case' 0 CA--C 1.515 -0.372 0 CA-C-O 121.302 0.572 . . . . 0.0 110.201 -179.61 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' TRP . . . . . . . . . . . . . 39.8 p90 -147.82 153.83 39.68 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.082 -0.963 . . . . 0.0 110.015 179.213 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 3.1 m -110.32 100.61 45.19 Favored Pre-proline 0 CA--C 1.532 0.266 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.652 -179.964 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_exo -54.32 149.44 37.41 Favored 'Trans proline' 0 C--N 1.305 -1.752 0 C-N-CA 121.505 1.47 . . . . 0.0 112.877 179.347 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 64.1 mt -79.98 135.81 36.48 Favored 'General case' 0 CA--C 1.513 -0.471 0 CA-C-O 121.906 0.86 . . . . 0.0 110.67 -179.833 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 37.8 t30 -49.81 -34.88 20.92 Favored 'General case' 0 C--N 1.312 -1.054 0 CA-C-N 114.814 -1.084 . . . . 0.0 110.116 179.971 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 63.5 m -78.55 -33.74 47.59 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.721 -0.672 . . . . 0.0 110.784 179.027 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 4.9 m -57.87 133.82 55.77 Favored 'General case' 0 N--CA 1.462 0.147 0 CA-C-O 121.132 0.492 . . . . 0.0 110.138 -179.857 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . 0.518 ' OG1' ' N ' ' A' ' 82' ' ' ASN . 5.2 m -58.33 143.55 44.52 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.84 -0.618 . . . . 0.0 109.845 -179.801 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 20.9 mm -94.19 90.97 2.95 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-O 120.925 0.393 . . . . 0.0 110.802 -179.428 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.466 ' O ' ' OG ' ' A' ' 57' ' ' SER . 8.8 pt -143.36 127.02 13.67 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.212 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.204 179.582 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -40.58 121.27 1.81 Allowed Glycine 0 CA--C 1.521 0.441 0 N-CA-C 111.372 -0.691 . . . . 0.0 111.372 -179.571 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' TYR . . . . . 0.443 ' CE2' ' OG ' ' A' ' 57' ' ' SER . 98.9 m-85 -85.37 178.26 7.52 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.548 -0.326 . . . . 0.0 110.168 179.796 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 6.6 tmm_? -131.44 128.52 39.67 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.448 179.741 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.479 ' CD1' ' CD2' ' A' ' 62' ' ' TYR . 1.8 pt -101.24 123.56 54.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.045 179.827 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 11.8 m -103.67 130.46 51.14 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.441 -0.345 . . . . 0.0 110.44 -179.862 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.1 p -128.59 138.12 55.47 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.55 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.023 179.919 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . 0.513 ' O ' ' N ' ' A' ' 74' ' ' ASP . 39.2 t -132.19 130.96 61.04 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.319 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 179.486 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.471 ' HB2' ' CE2' ' A' ' 73' ' ' TYR . . . -95.87 141.09 29.72 Favored 'General case' 0 C--N 1.324 -0.516 0 N-CA-C 109.207 -0.664 . . . . 0.0 109.207 179.199 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.491 ' HB3' ' O ' ' A' ' 72' ' ' ASP . . . -93.84 -39.4 10.73 Favored 'General case' 0 C--N 1.327 -0.371 0 C-N-CA 120.652 -0.419 . . . . 0.0 110.69 179.652 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -66.13 -31.2 78.56 Favored Glycine 0 CA--C 1.526 0.78 0 N-CA-C 111.623 -0.591 . . . . 0.0 111.623 -179.545 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 51.6 mt-10 -98.3 133.05 43.25 Favored 'General case' 0 CA--C 1.518 -0.253 0 N-CA-C 109.539 -0.541 . . . . 0.0 109.539 -179.626 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -59.51 -21.73 55.0 Favored Glycine 0 CA--C 1.521 0.44 0 N-CA-C 110.845 -0.902 . . . . 0.0 110.845 -179.217 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -114.03 135.27 22.08 Favored Pre-proline 0 N--CA 1.473 0.685 0 CA-C-N 116.672 0.236 . . . . 0.0 110.626 179.854 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -76.49 162.33 33.4 Favored 'Trans proline' 0 N--CA 1.492 1.433 0 C-N-CA 122.519 2.146 . . . . 0.0 111.426 178.258 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 96.3 mt -81.74 134.34 27.29 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-N 116.151 -0.477 . . . . 0.0 109.953 179.335 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 97.9 m-85 -54.85 141.93 31.24 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.942 0.401 . . . . 0.0 110.797 -179.492 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 2.9 pt-20 -80.99 151.97 28.2 Favored 'General case' 0 CA--C 1.517 -0.296 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.262 179.796 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 2.0 t70 -120.52 160.3 23.45 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.764 179.714 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' PHE . . . . . 0.549 ' CD1' ' N ' ' A' ' 54' ' ' PHE . 6.1 m-85 -121.18 128.66 52.69 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.089 179.839 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 9.8 p -128.23 138.12 55.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 116.352 -0.385 . . . . 0.0 110.361 -179.701 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 98.8 m-20 -56.92 143.36 37.94 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.666 -179.662 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . 0.466 ' OG ' ' O ' ' A' ' 35' ' ' ILE . 17.7 m -61.72 -34.24 75.44 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.889 179.893 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 37.5 m -57.04 -32.91 66.67 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.441 -179.808 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 92.8 t -65.55 -45.65 91.93 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.683 179.892 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 56.56 25.1 49.5 Favored Glycine 0 CA--C 1.527 0.821 0 N-CA-C 110.937 -0.865 . . . . 0.0 110.937 179.892 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . 0.442 ' CD1' ' O ' ' A' ' 24' ' ' LEU . 52.5 t80 -160.28 146.24 15.34 Favored 'General case' 0 N--CA 1.464 0.236 0 CA-C-O 121.141 0.496 . . . . 0.0 111.178 -179.359 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' TYR . . . . . 0.479 ' CD2' ' CD1' ' A' ' 39' ' ' ILE . 30.9 t80 -158.26 159.38 35.93 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.139 179.011 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 48.9 m -128.07 137.29 52.09 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.486 -179.423 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -131.13 101.75 5.68 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.34 0 CA-C-N 115.95 -0.568 . . . . 0.0 109.615 178.912 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 4.7 p -110.54 162.44 14.7 Favored 'General case' 0 N--CA 1.464 0.23 0 CA-C-O 121.006 0.432 . . . . 0.0 110.558 179.868 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 109.05 5.88 30.35 Favored Glycine 0 CA--C 1.527 0.832 0 CA-C-N 115.639 -0.709 . . . . 0.0 111.335 -179.655 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 12.1 mt -79.24 109.2 13.34 Favored 'General case' 0 C--N 1.329 -0.315 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.841 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 7.4 mm-40 -55.25 138.89 66.37 Favored Pre-proline 0 C--N 1.321 -0.65 0 C-N-CA 120.63 -0.428 . . . . 0.0 111.576 -178.236 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 95.8 Cg_endo -74.56 151.59 42.06 Favored 'Trans proline' 0 N--CA 1.493 1.495 0 C-N-CA 122.627 2.218 . . . . 0.0 111.725 179.113 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 72.4 10.15 74.41 Favored Glycine 0 CA--C 1.528 0.877 0 CA-C-N 115.161 -0.927 . . . . 0.0 111.642 179.229 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 1.7 mp -115.48 142.6 27.92 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.655 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 -179.727 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' ASP . . . . . 0.491 ' O ' ' HB3' ' A' ' 44' ' ' ALA . 2.3 t70 -81.73 110.88 17.47 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-N 115.162 -0.926 . . . . 0.0 110.311 179.977 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' TYR . . . . . 0.526 ' O ' ' CD1' ' A' ' 75' ' ' ILE . 14.8 m-85 -106.07 117.95 35.35 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.198 -179.911 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' ASP . . . . . 0.513 ' N ' ' O ' ' A' ' 42' ' ' VAL . 72.2 m-20 -88.16 119.83 28.93 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.145 -0.934 . . . . 0.0 109.331 179.754 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.901 HD13 ' N ' ' A' ' 75' ' ' ILE . 0.0 OUTLIER -121.36 166.27 16.06 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.307 0 CA-C-O 121.067 0.46 . . . . 0.0 110.424 -179.103 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 22.5 t -155.15 151.3 28.07 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.745 -0.661 . . . . 0.0 110.122 179.26 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.429 ' O ' HG23 ' B' ' 217' ' ' THR . 2.4 t -125.3 109.7 22.65 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.335 0 N-CA-C 109.25 -0.648 . . . . 0.0 109.25 178.899 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 90.8 mt -97.27 123.11 49.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-O 120.891 0.377 . . . . 0.0 110.239 179.924 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . 0.426 ' OG1' ' O ' ' B' ' 216' ' ' TRP . 19.6 p -103.48 111.4 23.83 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.059 179.752 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 35.4 tp -120.44 121.13 37.84 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.096 179.646 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' ILE . . . . . 0.513 ' HB ' ' H ' ' A' ' 33' ' ' THR . 2.3 pp -143.05 149.87 18.23 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 CA-C-N 116.081 -0.508 . . . . 0.0 110.189 179.634 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' ASN . . . . . 0.518 ' N ' ' OG1' ' A' ' 33' ' ' THR . 40.9 t30 -68.23 -47.45 67.77 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.443 -0.344 . . . . 0.0 111.159 179.916 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . 0.487 ' H ' ' HG1' ' A' ' 33' ' ' THR . . . 107.81 -126.68 8.4 Favored Glycine 0 CA--C 1.526 0.775 0 N-CA-C 110.876 -0.889 . . . . 0.0 110.876 179.729 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -66.73 146.24 48.09 Favored Glycine 0 CA--C 1.524 0.608 0 N-CA-C 110.875 -0.89 . . . . 0.0 110.875 -179.892 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -67.61 154.23 41.92 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.808 0.337 . . . . 0.0 110.6 -179.928 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 25.1 p -71.32 162.82 28.81 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.339 179.916 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.568 ' N ' ' CD ' ' A' ' 88' ' ' PRO . . . -179.26 -44.45 0.0 OUTLIER Pre-proline 0 CA--C 1.535 0.385 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.193 -179.689 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . 0.568 ' CD ' ' N ' ' A' ' 87' ' ' ALA . 35.2 Cg_exo -60.21 -177.56 0.16 Allowed 'Trans proline' 0 N--CA 1.497 1.68 0 C-N-CA 122.569 2.179 . . . . 0.0 112.235 -179.648 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 26.3 m -61.82 130.61 46.54 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.174 -179.961 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.4 m -142.29 162.65 34.93 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.036 179.897 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 2.2 pp -58.0 135.29 56.93 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.182 -179.897 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 64.3 p -89.38 122.58 32.74 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.476 -179.866 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 54.7 tt0 -78.77 143.24 36.31 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.39 179.949 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.489 ' CD ' ' H ' ' A' ' 94' ' ' GLN . 27.0 mp0 -65.75 130.46 43.34 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.446 179.957 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 36.7 p . . . . . 0 C--O 1.22 -0.467 0 CA-C-O 118.013 -0.994 . . . . 0.0 110.533 179.975 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' B' B ' 201' ' ' SER . . . . . . . . . . . . . 14.7 p . . . . . 0 N--CA 1.491 1.611 0 N-CA-C 109.278 -0.638 . . . . 0.0 109.278 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' B' B ' 202' ' ' SER . . . . . . . . . . . . . 70.4 m -69.02 146.86 52.33 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.195 -0.457 . . . . 0.0 109.855 179.852 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 203' ' ' SER . . . . . . . . . . . . . 82.6 p -123.82 107.54 31.1 Favored Pre-proline 0 CA--C 1.541 0.617 0 N-CA-C 110.096 -0.335 . . . . 0.0 110.096 179.351 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 204' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo -77.22 -57.23 0.04 OUTLIER 'Trans proline' 0 N--CA 1.493 1.468 0 C-N-CA 121.964 1.776 . . . . 0.0 112.024 -179.865 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 205' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -150.77 147.36 15.83 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.22 179.868 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 206' ' ' GLN . . . . . . . . . . . . . 61.3 tt0 -146.14 144.61 30.08 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.148 179.245 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 207' ' ' GLY . . . . . . . . . . . . . . . -107.12 -132.28 6.93 Favored Glycine 0 N--CA 1.466 0.648 0 N-CA-C 111.125 -0.79 . . . . 0.0 111.125 179.993 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 208' ' ' SER . . . . . 0.52 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 90.6 p -169.67 172.96 6.55 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.892 0.377 . . . . 0.0 110.864 -179.553 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 209' ' ' TRP . . . . . . . . . . . . . 69.1 m95 -92.74 153.52 18.86 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-N 115.815 -0.63 . . . . 0.0 110.488 179.289 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 49.8 p -135.04 140.27 45.45 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.521 179.631 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 61.0 t-105 -90.18 114.7 26.73 Favored 'General case' 0 C--N 1.332 -0.154 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.214 179.583 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 212' ' ' GLU . . . . . 0.522 ' O ' ' O ' ' B' ' 215' ' ' LYS . 3.8 tt0 -161.85 154.06 19.52 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.583 179.684 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 213' ' ' ASN . . . . . 0.446 ' N ' ' HG3' ' B' ' 212' ' ' GLU . 83.5 m-20 56.72 40.62 29.07 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 115.421 -0.809 . . . . 0.0 111.78 177.022 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 51.19 11.41 0.64 Allowed Glycine 0 CA--C 1.528 0.854 0 N-CA-C 111.64 -0.584 . . . . 0.0 111.64 179.571 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 215' ' ' LYS . . . . . 0.522 ' O ' ' O ' ' B' ' 212' ' ' GLU . 80.6 mttt -141.61 151.33 43.03 Favored 'General case' 0 C--O 1.225 -0.212 0 CA-C-O 121.109 0.481 . . . . 0.0 110.963 -179.854 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 216' ' ' TRP . . . . . 0.479 ' N ' ' CD1' ' B' ' 216' ' ' TRP . 24.8 m95 -85.85 119.42 26.14 Favored 'General case' 0 C--N 1.327 -0.406 0 C-N-CA 120.731 -0.387 . . . . 0.0 110.049 179.701 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 217' ' ' THR . . . . . 0.429 HG23 ' O ' ' A' ' 77' ' ' VAL . 16.7 m -125.86 142.1 51.67 Favored 'General case' 0 N--CA 1.467 0.395 0 N-CA-C 110.109 -0.33 . . . . 0.0 110.109 -179.525 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 218' ' ' TRP . . . . . 0.52 ' CH2' ' N ' ' B' ' 208' ' ' SER . 13.7 t-105 -103.49 117.15 33.78 Favored 'General case' 0 N--CA 1.463 0.186 0 CA-C-N 115.906 -0.588 . . . . 0.0 109.439 179.445 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 8.1 mtmp? -143.24 163.01 34.12 Favored 'General case' 0 CA--C 1.516 -0.355 0 CA-C-O 121.21 0.529 . . . . 0.0 110.634 -179.477 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -176.56 -160.27 23.46 Favored Glycine 0 CA--C 1.523 0.568 0 N-CA-C 111.185 -0.766 . . . . 0.0 111.185 -179.536 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 221' ' ' ILE . . . . . 0.529 ' O ' HG23 ' B' ' 222' ' ' ILE . 0.7 OUTLIER -51.05 -75.38 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 C-N-CA 120.778 -0.369 . . . . 0.0 110.566 -178.854 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' B' B ' 222' ' ' ILE . . . . . 0.529 HG23 ' O ' ' B' ' 221' ' ' ILE . 17.0 pt -160.25 -165.76 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 CA-C-N 116.327 -0.397 . . . . 0.0 109.991 -179.653 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 223' ' ' ARG . . . . . 0.508 ' O ' ' O ' ' B' ' 222' ' ' ILE . 22.5 ptt180 -42.33 175.38 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 121.472 0.653 . . . . 0.0 110.841 178.864 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 224' ' ' LEU . . . . . 0.644 ' N ' HD22 ' B' ' 224' ' ' LEU . 3.6 mm? -61.31 123.5 17.93 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 115.497 -0.774 . . . . 0.0 110.65 -179.753 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 79.9 tt0 -80.39 143.21 33.67 Favored 'General case' 0 CA--C 1.518 -0.282 0 CA-C-N 115.385 -0.825 . . . . 0.0 110.221 179.817 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 226' ' ' GLN . . . . . 0.511 ' OE1' ' N ' ' B' ' 226' ' ' GLN . 0.9 OUTLIER . . . . . 0 C--N 1.323 -0.547 0 CA-C-O 118.016 -0.992 . . . . 0.0 110.569 -179.618 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.285 0 N-CA-C 109.571 -1.411 . . . . 0.0 109.571 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 97.4 p -76.69 164.57 25.75 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 120.728 0.299 . . . . 0.0 110.656 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 80.7 mm-40 -67.01 147.49 53.16 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.749 -179.914 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.524 ' O ' HG13 ' A' ' 6' ' ' VAL . 12.2 p -66.33 124.23 87.52 Favored Pre-proline 0 CA--C 1.54 0.565 0 C-N-CA 120.525 -0.47 . . . . 0.0 110.709 -179.435 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 66.2 Cg_endo -75.97 126.01 9.06 Favored 'Trans proline' 0 N--CA 1.495 1.612 0 C-N-CA 121.902 1.734 . . . . 0.0 112.027 179.679 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 98.0 mt-30 -102.42 138.03 39.88 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.065 179.727 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 5.7 tp -80.82 108.92 14.89 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.294 -179.684 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 74.4 p -84.93 164.22 18.47 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.471 179.568 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 99.3 m-20 -128.9 155.43 45.29 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.355 -179.958 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 6.3 tt -64.2 142.99 58.22 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.154 -179.31 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 83.6 p -140.49 154.43 46.59 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.648 179.697 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . 0.505 ' N ' ' CD1' ' A' ' 14' ' ' PHE . 21.5 m-85 -111.41 144.77 40.09 Favored 'General case' 0 N--CA 1.464 0.274 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.668 -179.739 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.409 HG11 ' NH2' ' A' ' 25' ' ' ARG . 31.2 m -146.27 161.75 10.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.321 -0.399 . . . . 0.0 110.614 179.793 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 98.2 m-20 53.87 31.08 12.55 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.499 179.764 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 99.2 mt -57.09 140.91 14.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.258 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.444 ' CB ' ' O ' ' A' ' 21' ' ' SER . 0.2 OUTLIER -141.28 -168.11 2.55 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-N 116.009 -0.542 . . . . 0.0 110.326 -179.778 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . 0.477 ' N ' ' OD1' ' A' ' 19' ' ' ASP . 21.0 p-10 -88.88 -45.23 9.87 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.874 179.467 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 22.4 m -114.45 7.99 16.39 Favored 'General case' 0 N--CA 1.468 0.465 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.882 -179.543 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . 0.444 ' O ' ' CB ' ' A' ' 18' ' ' THR . 34.4 t -151.55 145.53 25.21 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.156 0.503 . . . . 0.0 110.232 179.551 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . 0.425 HD12 HD21 ' A' ' 24' ' ' LEU . 45.3 pt -138.89 146.29 26.39 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.587 0 CA-C-N 115.802 -0.635 . . . . 0.0 110.352 -179.618 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -99.1 82.19 0.57 Allowed Glycine 0 CA--C 1.524 0.612 0 N-CA-C 110.903 -0.879 . . . . 0.0 110.903 -179.953 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.425 HD21 HD12 ' A' ' 22' ' ' ILE . 94.2 mt -70.02 121.8 18.13 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.856 0.36 . . . . 0.0 110.182 179.884 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . 0.409 ' NH2' HG11 ' A' ' 15' ' ' VAL . 59.9 ttp180 -141.28 136.14 31.32 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.164 179.949 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' TRP . . . . . . . . . . . . . 37.8 p90 -139.21 156.04 47.38 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.897 -0.592 . . . . 0.0 109.925 -179.795 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 3.5 m -110.59 98.89 39.09 Favored Pre-proline 0 C--N 1.33 -0.239 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.481 179.718 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 39.9 Cg_exo -53.66 147.63 39.01 Favored 'Trans proline' 0 C--N 1.303 -1.821 0 C-N-CA 121.63 1.554 . . . . 0.0 112.911 179.772 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 59.9 mt -87.76 141.93 28.22 Favored 'General case' 0 CA--C 1.511 -0.55 0 CA-C-N 115.437 -0.801 . . . . 0.0 110.398 -179.873 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 18.3 t-20 -50.07 -37.14 32.1 Favored 'General case' 0 C--N 1.315 -0.909 0 CA-C-N 114.908 -1.042 . . . . 0.0 110.067 -179.831 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 70.3 m -78.24 -33.5 49.74 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.547 178.755 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 14.1 m -60.83 131.09 49.58 Favored 'General case' 0 N--CA 1.463 0.194 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.067 -179.881 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . 0.455 ' H ' ' HB ' ' A' ' 81' ' ' ILE . 5.1 m -65.91 142.18 57.98 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.253 -179.971 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 16.3 mm -94.82 90.75 2.79 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.19 0 CA-C-N 116.339 -0.392 . . . . 0.0 110.616 -179.848 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.473 ' O ' ' OG ' ' A' ' 57' ' ' SER . 24.9 pt -134.25 144.43 35.3 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.381 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.25 179.923 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -43.4 112.66 0.57 Allowed Glycine 0 CA--C 1.517 0.169 0 C-N-CA 120.59 -0.814 . . . . 0.0 111.58 -179.167 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' TYR . . . . . 0.866 ' OH ' HG23 ' A' ' 77' ' ' VAL . 0.9 OUTLIER -91.4 120.46 32.27 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 109.062 -0.718 . . . . 0.0 109.062 179.205 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . 0.516 ' O ' ' CE1' ' A' ' 37' ' ' TYR . 4.7 tmm_? -90.07 133.87 34.59 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.912 -0.586 . . . . 0.0 110.65 179.941 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 6.3 pt -93.67 154.76 3.24 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.314 0 CA-C-N 116.153 -0.476 . . . . 0.0 109.806 179.926 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 2.1 m -131.19 130.03 42.46 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.486 -0.325 . . . . 0.0 110.394 179.409 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.3 p -134.47 136.1 53.17 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.496 0 CA-C-O 120.94 0.4 . . . . 0.0 110.697 179.83 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . 0.511 ' O ' ' N ' ' A' ' 74' ' ' ASP . 32.1 t -131.15 127.6 60.87 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.319 0 N-CA-C 109.5 -0.556 . . . . 0.0 109.5 179.362 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -94.58 141.22 28.85 Favored 'General case' 0 C--N 1.324 -0.539 0 N-CA-C 109.516 -0.549 . . . . 0.0 109.516 179.357 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.557 ' HB3' ' O ' ' A' ' 72' ' ' ASP . . . -96.63 -43.5 7.55 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.922 0.391 . . . . 0.0 110.872 179.783 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -74.24 30.82 0.97 Allowed Glycine 0 CA--C 1.525 0.659 0 N-CA-C 110.863 -0.895 . . . . 0.0 110.863 -179.957 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . 0.486 ' H ' ' C ' ' A' ' 44' ' ' ALA . 79.8 mm-40 -146.17 150.73 36.42 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 121.11 0.481 . . . . 0.0 110.695 -179.526 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -76.25 -14.67 82.1 Favored Glycine 0 CA--C 1.521 0.448 0 N-CA-C 110.711 -0.956 . . . . 0.0 110.711 179.752 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -138.34 139.5 25.38 Favored Pre-proline 0 CA--C 1.54 0.589 0 C-N-CA 120.961 -0.296 . . . . 0.0 110.464 179.581 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 70.6 Cg_endo -75.27 161.92 37.22 Favored 'Trans proline' 0 N--CA 1.491 1.349 0 C-N-CA 122.64 2.227 . . . . 0.0 111.84 177.957 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 96.3 mt -76.63 140.8 16.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.431 179.129 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 88.8 m-85 -62.84 141.7 58.54 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.459 -179.76 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . 0.534 ' H ' ' CD ' ' A' ' 52' ' ' GLU . 0.1 OUTLIER -76.92 146.36 37.63 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.46 179.714 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 4.8 t70 -113.18 150.94 31.55 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.66 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 72.7 m-85 -111.03 122.03 46.85 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.237 179.708 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 10.8 p -127.89 137.97 56.06 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.366 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.482 -179.963 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 89.7 m-20 -64.38 139.8 58.8 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.203 179.368 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . 0.473 ' OG ' ' O ' ' A' ' 35' ' ' ILE . 2.8 m -59.47 -28.94 67.45 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.467 -179.83 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 37.6 m -55.8 -32.01 63.14 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.573 -179.998 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.498 ' O ' ' CD2' ' A' ' 61' ' ' TYR . 50.1 t -61.88 -44.2 98.51 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 -179.099 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 70.39 13.73 71.09 Favored Glycine 0 CA--C 1.53 0.977 0 N-CA-C 111.033 -0.827 . . . . 0.0 111.033 179.473 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . 0.498 ' CD2' ' O ' ' A' ' 59' ' ' VAL . 26.4 p90 -171.9 158.56 4.84 Favored 'General case' 0 C--O 1.225 -0.226 0 CA-C-O 120.993 0.425 . . . . 0.0 111.583 179.594 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 35.1 t80 -155.99 154.72 31.55 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.054 177.972 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 86.3 m -116.32 133.04 56.46 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.4 -179.456 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -131.08 100.84 4.91 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.275 0 N-CA-C 109.475 -0.565 . . . . 0.0 109.475 179.152 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.42 HG22 ' OG ' ' A' ' 21' ' ' SER . 2.4 p -110.33 163.47 13.62 Favored 'General case' 0 N--CA 1.464 0.239 0 CA-C-O 121.007 0.432 . . . . 0.0 110.706 -179.869 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 110.08 9.79 23.56 Favored Glycine 0 CA--C 1.528 0.851 0 CA-C-N 115.496 -0.775 . . . . 0.0 111.49 -179.56 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 8.1 mt -83.52 107.61 16.11 Favored 'General case' 0 C--N 1.33 -0.274 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 179.829 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 17.5 mm-40 -57.58 138.53 81.81 Favored Pre-proline 0 C--N 1.32 -0.694 0 C-N-CA 120.321 -0.552 . . . . 0.0 111.609 -178.295 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 90.2 Cg_endo -74.54 154.65 45.02 Favored 'Trans proline' 0 N--CA 1.496 1.637 0 C-N-CA 122.762 2.308 . . . . 0.0 111.825 178.942 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 73.35 7.92 73.92 Favored Glycine 0 CA--C 1.528 0.865 0 CA-C-N 115.282 -0.872 . . . . 0.0 111.767 179.075 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . 0.547 ' O ' ' NH1' ' B' ' 223' ' ' ARG . 1.7 mp -117.11 147.24 20.62 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.406 0 N-CA-C 109.291 -0.633 . . . . 0.0 109.291 -179.504 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 72' ' ' ASP . . . . . 0.557 ' O ' ' HB3' ' A' ' 44' ' ' ALA . 2.8 t0 -84.76 113.99 21.73 Favored 'General case' 0 C--N 1.318 -0.766 0 CA-C-N 115.176 -0.92 . . . . 0.0 110.402 -179.6 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 73' ' ' TYR . . . . . 0.507 ' O ' HD13 ' A' ' 75' ' ' ILE . 15.6 m-85 -107.93 119.88 40.7 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.324 -179.966 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 74' ' ' ASP . . . . . 0.511 ' N ' ' O ' ' A' ' 42' ' ' VAL . 14.8 m-20 -89.71 118.96 29.71 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 115.327 -0.851 . . . . 0.0 108.805 179.535 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.625 HD11 ' N ' ' B' ' 223' ' ' ARG . 0.0 OUTLIER -113.24 162.65 11.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-O 121.282 0.563 . . . . 0.0 110.263 -178.642 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -153.53 118.89 5.18 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.289 -0.869 . . . . 0.0 110.484 179.708 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.866 HG23 ' OH ' ' A' ' 37' ' ' TYR . 8.7 p -103.39 101.38 12.13 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.242 0 N-CA-C 109.517 -0.549 . . . . 0.0 109.517 178.995 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 91.4 mt -92.0 101.13 12.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.621 -179.847 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 44.9 p -77.68 111.64 13.67 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.807 -0.633 . . . . 0.0 109.388 179.049 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . 0.587 HD12 ' NZ ' ' B' ' 215' ' ' LYS . 4.8 tp -111.54 120.63 42.77 Favored 'General case' 0 N--CA 1.465 0.288 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.963 -179.234 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 81' ' ' ILE . . . . . 0.455 ' HB ' ' H ' ' A' ' 33' ' ' THR . 2.1 pp -146.61 142.3 20.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.065 -0.516 . . . . 0.0 109.974 179.095 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 56.0 t-20 -60.41 -56.25 23.69 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 120.721 0.296 . . . . 0.0 110.9 -179.648 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 71.42 108.82 0.05 OUTLIER Glycine 0 CA--C 1.524 0.635 0 N-CA-C 110.855 -0.898 . . . . 0.0 110.855 179.317 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -55.05 176.16 0.54 Allowed Glycine 0 CA--C 1.525 0.698 0 N-CA-C 110.766 -0.933 . . . . 0.0 110.766 179.872 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 98.5 mt-10 -64.17 141.1 58.89 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.789 0.328 . . . . 0.0 110.675 -179.734 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 6.5 m -70.82 141.92 51.32 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.493 179.866 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.472 ' N ' ' CD ' ' A' ' 88' ' ' PRO . . . -178.59 52.48 0.06 OUTLIER Pre-proline 0 C--N 1.329 -0.294 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.475 179.892 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . 0.472 ' CD ' ' N ' ' A' ' 87' ' ' ALA . 42.4 Cg_endo -66.3 151.02 84.35 Favored 'Trans proline' 0 C--N 1.309 -1.514 0 C-N-CA 122.743 2.295 . . . . 0.0 111.732 179.882 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 96.4 m -95.7 120.2 35.54 Favored 'General case' 0 N--CA 1.463 0.189 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.14 179.938 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.571 HG22 ' N ' ' A' ' 91' ' ' LEU . 53.4 m -86.99 162.9 17.38 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.337 -179.998 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . 0.588 ' N ' HD12 ' A' ' 91' ' ' LEU . 9.9 mp -75.85 138.81 41.35 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.296 -179.946 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 68.6 p -81.06 163.79 22.94 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.368 -179.923 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 99.3 mm-40 -83.26 139.15 33.26 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.42 -179.793 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 37.4 tp60 -69.72 -137.51 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.28 -179.841 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.22 -0.497 0 CA-C-O 118.089 -0.958 . . . . 0.0 110.328 -179.954 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 201' ' ' SER . . . . . . . . . . . . . 51.7 m . . . . . 0 N--CA 1.489 1.493 0 N-CA-C 109.285 -0.635 . . . . 0.0 109.285 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' B' B ' 202' ' ' SER . . . . . . . . . . . . . 14.9 m -72.77 141.8 48.11 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.021 179.819 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 203' ' ' SER . . . . . . . . . . . . . 25.9 t -129.77 106.62 16.92 Favored Pre-proline 0 CA--C 1.539 0.534 0 N-CA-C 110.092 -0.336 . . . . 0.0 110.092 179.128 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 204' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -81.19 7.15 5.13 Favored 'Trans proline' 0 N--CA 1.493 1.449 0 C-N-CA 122.177 1.918 . . . . 0.0 111.97 179.466 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 205' ' ' ILE . . . . . . . . . . . . . 9.9 tp -144.69 144.15 22.26 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.328 0 CA-C-O 121.144 0.497 . . . . 0.0 111.225 179.866 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 206' ' ' GLN . . . . . . . . . . . . . 8.5 pt20 -179.05 76.31 0.01 OUTLIER 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 115.242 -0.89 . . . . 0.0 110.775 179.272 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 207' ' ' GLY . . . . . . . . . . . . . . . -109.52 -139.53 8.51 Favored Glycine 0 N--CA 1.466 0.637 0 N-CA-C 111.174 -0.77 . . . . 0.0 111.174 -179.882 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 208' ' ' SER . . . . . 0.539 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 91.7 p -166.88 172.14 10.62 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 120.907 0.384 . . . . 0.0 110.701 -179.805 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 209' ' ' TRP . . . . . . . . . . . . . 78.4 m95 -88.63 130.66 35.23 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.189 179.369 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 82.1 p -109.5 132.81 53.79 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-N 116.392 -0.367 . . . . 0.0 110.496 -179.796 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 47.7 t-105 -93.73 117.81 30.58 Favored 'General case' 0 N--CA 1.463 0.208 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.072 179.796 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 212' ' ' GLU . . . . . 0.44 ' O ' ' O ' ' B' ' 215' ' ' LYS . 0.8 OUTLIER -164.22 167.41 20.04 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.779 179.035 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' B' B ' 213' ' ' ASN . . . . . . . . . . . . . 92.4 m-20 49.06 37.11 9.88 Favored 'General case' 0 C--N 1.324 -0.516 0 C-N-CA 120.522 -0.471 . . . . 0.0 111.349 176.603 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 50.89 16.85 1.93 Allowed Glycine 0 CA--C 1.526 0.723 0 N-CA-C 111.335 -0.706 . . . . 0.0 111.335 179.868 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 215' ' ' LYS . . . . . 0.587 ' NZ ' HD12 ' A' ' 80' ' ' LEU . 20.3 mtpt -143.0 149.75 38.72 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.986 0.422 . . . . 0.0 110.889 -179.839 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 216' ' ' TRP . . . . . . . . . . . . . 50.1 m95 -86.12 115.76 23.9 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.028 -0.533 . . . . 0.0 109.712 179.115 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 217' ' ' THR . . . . . . . . . . . . . 18.1 m -126.95 139.92 52.7 Favored 'General case' 0 N--CA 1.466 0.343 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.439 -179.512 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 218' ' ' TRP . . . . . 0.626 ' O ' HG12 ' A' ' 77' ' ' VAL . 12.9 t-105 -106.45 116.38 31.82 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.016 178.984 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 52.8 mtmt -143.9 174.5 10.78 Favored 'General case' 0 CA--C 1.514 -0.432 0 CA-C-O 121.137 0.494 . . . . 0.0 110.644 -179.85 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -176.38 -160.21 23.27 Favored Glycine 0 CA--C 1.523 0.572 0 C-N-CA 120.544 -0.836 . . . . 0.0 111.226 -179.576 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 221' ' ' ILE . . . . . 0.532 ' O ' HG23 ' B' ' 222' ' ' ILE . 10.2 mm -51.27 -73.59 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.892 0.377 . . . . 0.0 110.485 -178.059 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 222' ' ' ILE . . . . . 0.532 HG23 ' O ' ' B' ' 221' ' ' ILE . 23.7 pt -159.48 -166.39 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.755 0 CA-C-N 115.646 -0.706 . . . . 0.0 110.706 -179.943 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 223' ' ' ARG . . . . . 0.625 ' N ' HD11 ' A' ' 75' ' ' ILE . 32.0 ptt-85 -42.76 174.6 0.0 OUTLIER 'General case' 0 CA--C 1.52 -0.186 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.77 179.003 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 224' ' ' LEU . . . . . 0.759 ' N ' HD22 ' B' ' 224' ' ' LEU . 2.4 mm? -59.67 128.23 35.91 Favored 'General case' 0 C--N 1.315 -0.906 0 CA-C-N 115.786 -0.643 . . . . 0.0 110.542 -179.517 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 42.5 tt0 -107.36 145.88 32.31 Favored 'General case' 0 CA--C 1.52 -0.188 0 CA-C-N 115.349 -0.841 . . . . 0.0 110.391 -179.843 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 226' ' ' GLN . . . . . . . . . . . . . 64.8 tp60 . . . . . 0 N--CA 1.451 -0.406 0 CA-C-O 117.925 -1.036 . . . . 0.0 110.197 179.947 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.341 0 N-CA-C 109.6 -1.4 . . . . 0.0 109.6 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 41.0 t -152.02 95.38 2.07 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.865 0.364 . . . . 0.0 110.618 179.933 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 19.0 pt-20 -84.78 152.58 23.56 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.498 179.809 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.652 ' O ' HG13 ' A' ' 6' ' ' VAL . 9.1 p -145.07 77.95 12.73 Favored Pre-proline 0 N--CA 1.463 0.215 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.458 -179.968 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 32.2 Cg_exo -56.57 139.33 87.49 Favored 'Trans proline' 0 C--N 1.309 -1.538 0 C-N-CA 122.354 2.036 . . . . 0.0 111.911 -179.797 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . 0.412 HE21 ' HB3' ' A' ' 30' ' ' ASN . 64.8 tt0 -84.95 -32.09 23.24 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.361 179.951 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 81.6 mt -84.94 129.97 34.71 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.465 179.991 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 75.0 p -130.8 159.41 37.41 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.526 179.968 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 97.2 m-20 -104.37 155.46 18.76 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.395 -179.834 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 6.7 tt -63.92 149.15 47.82 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.396 -179.74 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . 0.419 ' O ' ' O ' ' A' ' 25' ' ' ARG . 83.3 p -139.15 156.85 46.83 Favored 'General case' 0 N--CA 1.461 0.114 0 CA-C-O 121.166 0.508 . . . . 0.0 110.42 179.757 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . 0.501 ' N ' ' CD1' ' A' ' 14' ' ' PHE . 30.6 m-85 -110.84 146.37 36.57 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.555 -0.748 . . . . 0.0 110.81 -179.515 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 15.6 m -146.74 157.01 10.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.447 -0.342 . . . . 0.0 110.649 179.4 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 98.9 m-20 54.59 31.53 15.23 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.934 179.656 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 97.2 mt -56.92 140.89 14.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.383 -179.803 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.418 ' CB ' ' O ' ' A' ' 21' ' ' SER . 0.2 OUTLIER -140.87 -168.6 2.63 Favored 'General case' 0 CA--C 1.533 0.292 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.509 -179.798 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . 0.483 ' OD1' ' N ' ' A' ' 19' ' ' ASP . 11.8 p-10 -90.3 -41.91 11.27 Favored 'General case' 0 N--CA 1.465 0.299 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.689 179.509 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 15.1 m -114.62 5.74 15.51 Favored 'General case' 0 N--CA 1.464 0.252 0 CA-C-N 116.014 -0.539 . . . . 0.0 111.152 -179.395 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . 0.418 ' O ' ' CB ' ' A' ' 18' ' ' THR . 29.2 t -151.68 148.43 27.92 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 121.046 0.45 . . . . 0.0 110.365 179.624 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 42.6 pt -140.71 145.53 25.42 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.194 179.789 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -102.27 81.42 0.4 Allowed Glycine 0 CA--C 1.524 0.618 0 N-CA-C 110.998 -0.841 . . . . 0.0 110.998 -179.991 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 96.3 mt -68.54 121.6 16.73 Favored 'General case' 0 C--N 1.33 -0.272 0 C-N-CA 120.775 -0.37 . . . . 0.0 110.015 -179.992 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . 0.419 ' O ' ' O ' ' A' ' 13' ' ' SER . 58.8 ttt85 -142.75 137.64 29.93 Favored 'General case' 0 C--N 1.333 -0.123 0 CA-C-O 120.956 0.407 . . . . 0.0 110.372 -179.806 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' TRP . . . . . 0.454 ' C ' ' CD1' ' A' ' 26' ' ' TRP . 0.1 OUTLIER -143.0 161.54 37.85 Favored 'General case' 0 N--CA 1.466 0.349 0 N-CA-C 109.089 -0.708 . . . . 0.0 109.089 179.599 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 5.0 m -100.88 103.18 23.17 Favored Pre-proline 0 C--N 1.327 -0.379 0 N-CA-C 108.612 -0.885 . . . . 0.0 108.612 178.73 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 33.4 Cg_exo -54.72 149.62 39.84 Favored 'Trans proline' 0 C--N 1.308 -1.594 0 C-N-CA 120.883 1.055 . . . . 0.0 112.754 -179.03 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 69.6 mt -87.49 133.06 33.82 Favored 'General case' 0 CA--C 1.51 -0.569 0 CA-C-O 121.601 0.715 . . . . 0.0 111.066 -179.637 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . 0.412 ' HB3' HE21 ' A' ' 8' ' ' GLN . 24.3 t-20 -46.9 -33.69 4.79 Favored 'General case' 0 C--N 1.314 -0.94 0 CA-C-N 115.064 -0.971 . . . . 0.0 110.225 179.527 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 63.4 m -80.74 -34.18 34.59 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.53 178.83 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 5.2 m -56.57 127.12 29.73 Favored 'General case' 0 C--O 1.232 0.136 0 C-N-CA 120.732 -0.387 . . . . 0.0 109.998 -179.715 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . 0.495 ' H ' ' HB ' ' A' ' 81' ' ' ILE . 33.2 m -61.61 152.5 30.47 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.048 179.875 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 24.4 mm -97.5 94.05 3.71 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.343 0 CA-C-N 116.579 -0.282 . . . . 0.0 111.49 -178.24 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.485 HD13 ' N ' ' A' ' 35' ' ' ILE . 0.1 OUTLIER -137.59 155.09 30.55 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.324 0 CA-C-O 120.792 0.329 . . . . 0.0 110.511 179.305 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -63.22 113.57 6.02 Favored Glycine 0 CA--C 1.521 0.457 0 C-N-CA 120.472 -0.871 . . . . 0.0 111.178 179.785 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 69.2 m-85 -80.73 141.53 34.73 Favored 'General case' 0 C--N 1.328 -0.358 0 N-CA-C 110.072 -0.344 . . . . 0.0 110.072 179.525 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . 0.43 HH11 ' HG3' ' A' ' 52' ' ' GLU . 5.3 tmm_? -105.54 119.84 40.14 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.549 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.474 ' CG1' ' O ' ' A' ' 39' ' ' ILE . 1.9 pt -95.47 122.88 47.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 115.835 -0.62 . . . . 0.0 109.693 179.79 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 94.8 m -109.61 131.64 54.87 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.824 0.345 . . . . 0.0 110.511 -179.276 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.417 HG13 ' HB ' ' A' ' 50' ' ' ILE . 1.8 p -128.8 144.12 39.05 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.349 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.523 -179.505 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . 0.506 ' O ' ' N ' ' A' ' 74' ' ' ASP . 40.4 t -132.45 131.87 60.3 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.191 0 CA-C-O 120.899 0.38 . . . . 0.0 110.019 179.542 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.526 ' HB2' ' CE2' ' A' ' 73' ' ' TYR . . . -98.44 140.01 33.33 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 109.296 -0.631 . . . . 0.0 109.296 179.22 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.552 ' HB3' ' O ' ' A' ' 72' ' ' ASP . . . -98.26 -18.44 18.39 Favored 'General case' 0 CA--C 1.529 0.135 0 C-N-CA 120.67 -0.412 . . . . 0.0 110.776 179.926 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -98.54 30.73 9.1 Favored Glycine 0 CA--C 1.529 0.956 0 N-CA-C 110.753 -0.939 . . . . 0.0 110.753 179.821 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 45.1 mt-10 -146.78 149.01 32.51 Favored 'General case' 0 CA--C 1.521 -0.16 0 CA-C-O 121.131 0.491 . . . . 0.0 110.691 179.97 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -68.96 -20.95 75.09 Favored Glycine 0 CA--C 1.527 0.823 0 N-CA-C 111.014 -0.834 . . . . 0.0 111.014 179.736 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -136.61 141.11 34.21 Favored Pre-proline 0 CA--C 1.54 0.579 0 C-N-CA 121.131 -0.228 . . . . 0.0 110.476 179.995 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 69.4 Cg_endo -73.36 162.22 40.8 Favored 'Trans proline' 0 N--CA 1.496 1.672 0 C-N-CA 122.752 2.301 . . . . 0.0 111.821 179.059 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . 0.417 ' HB ' HG13 ' A' ' 41' ' ' VAL . 96.7 mt -76.49 151.77 5.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.522 179.793 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 82.6 m-85 -70.75 146.41 49.83 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.707 -179.54 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . 0.522 ' H ' ' CD ' ' A' ' 52' ' ' GLU . 0.5 OUTLIER -82.96 145.0 29.61 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.682 179.55 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -112.4 153.14 27.76 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.492 -0.777 . . . . 0.0 110.388 -179.717 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' PHE . . . . . 0.581 ' CD1' ' N ' ' A' ' 54' ' ' PHE . 2.7 m-85 -119.0 128.7 54.64 Favored 'General case' 0 N--CA 1.466 0.356 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.227 -179.758 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 9.6 p -131.26 139.06 51.8 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.3 0 CA-C-O 120.683 0.277 . . . . 0.0 110.828 -179.65 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 71.4 m-20 -58.51 142.47 48.82 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.262 179.581 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 7.2 t -60.88 -35.21 76.04 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.733 179.86 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 58.5 m -56.31 -34.11 66.2 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.923 -179.603 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 90.7 t -62.38 -45.8 97.93 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.389 -179.84 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 61.75 23.17 62.87 Favored Glycine 0 CA--C 1.525 0.713 0 N-CA-C 110.745 -0.942 . . . . 0.0 110.745 179.942 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 37.2 t80 -164.65 150.16 10.09 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-O 121.095 0.474 . . . . 0.0 111.423 -179.412 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' TYR . . . . . 0.432 ' CD2' ' CD1' ' A' ' 39' ' ' ILE . 18.4 t80 -156.7 154.32 29.87 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.73 -0.668 . . . . 0.0 110.33 178.715 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 73.1 m -117.55 132.55 56.51 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.16 -0.473 . . . . 0.0 109.893 179.472 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -130.63 113.63 25.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 N-CA-C 109.327 -0.62 . . . . 0.0 109.327 178.914 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.412 HG22 ' OG ' ' A' ' 21' ' ' SER . 2.1 p -124.76 158.83 32.33 Favored 'General case' 0 CA--C 1.516 -0.331 0 CA-C-O 120.987 0.422 . . . . 0.0 110.394 -179.83 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 108.11 39.61 1.8 Allowed Glycine 0 CA--C 1.525 0.682 0 N-CA-C 110.818 -0.913 . . . . 0.0 110.818 -179.937 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 14.5 mt -112.52 106.96 15.53 Favored 'General case' 0 N--CA 1.467 0.404 0 N-CA-C 108.742 -0.836 . . . . 0.0 108.742 179.087 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 4.1 mm-40 -54.34 136.79 60.37 Favored Pre-proline 0 C--N 1.323 -0.561 0 C-N-CA 120.86 -0.336 . . . . 0.0 111.727 -178.095 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 90.0 Cg_endo -74.26 154.52 46.38 Favored 'Trans proline' 0 N--CA 1.493 1.466 0 C-N-CA 122.779 2.319 . . . . 0.0 111.54 178.877 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 71.05 8.42 64.66 Favored Glycine 0 CA--C 1.529 0.963 0 CA-C-N 115.533 -0.758 . . . . 0.0 111.507 179.563 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 1.6 mp -116.05 143.9 24.97 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.543 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 -179.975 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 72' ' ' ASP . . . . . 0.552 ' O ' ' HB3' ' A' ' 44' ' ' ALA . 2.0 t0 -81.93 112.59 19.17 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-N 115.307 -0.861 . . . . 0.0 110.149 -179.849 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 73' ' ' TYR . . . . . 0.526 ' CE2' ' HB2' ' A' ' 43' ' ' ALA . 13.7 m-85 -107.38 120.01 40.97 Favored 'General case' 0 C--O 1.223 -0.326 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.354 -179.814 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 74' ' ' ASP . . . . . 0.506 ' N ' ' O ' ' A' ' 42' ' ' VAL . 7.3 m-20 -89.04 114.86 26.12 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 115.34 -0.845 . . . . 0.0 109.375 179.601 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.675 HD11 ' N ' ' B' ' 223' ' ' ARG . 0.0 OUTLIER -112.35 167.31 5.8 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.198 0 CA-C-O 121.273 0.558 . . . . 0.0 110.405 -179.434 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 11.6 p -154.46 151.65 29.2 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 115.124 -0.944 . . . . 0.0 110.283 179.392 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -131.32 101.75 5.56 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.351 0 N-CA-C 108.744 -0.836 . . . . 0.0 108.744 179.49 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 96.2 mt -86.62 123.87 40.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 C-N-CA 120.913 -0.315 . . . . 0.0 110.34 -179.673 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 90.5 m -105.26 109.02 20.85 Favored 'General case' 0 N--CA 1.465 0.301 0 CA-C-N 116.358 -0.383 . . . . 0.0 109.971 179.66 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 6.7 tt -121.09 119.02 31.24 Favored 'General case' 0 CA--C 1.517 -0.292 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.449 179.965 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 81' ' ' ILE . . . . . 0.495 ' HB ' ' H ' ' A' ' 33' ' ' THR . 2.0 pp -140.28 143.44 29.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.289 179.22 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 82' ' ' ASN . . . . . 0.481 ' C ' ' H ' ' A' ' 84' ' ' GLY . 0.7 OUTLIER -65.22 -54.19 33.14 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.803 -179.476 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 61.53 -1.28 1.13 Allowed Glycine 0 CA--C 1.525 0.712 0 N-CA-C 111.037 -0.825 . . . . 0.0 111.037 179.289 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . 0.481 ' H ' ' C ' ' A' ' 82' ' ' ASN . . . -96.23 105.83 3.28 Favored Glycine 0 CA--C 1.525 0.685 0 N-CA-C 110.939 -0.865 . . . . 0.0 110.939 -179.903 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 17.0 pt-20 -84.09 155.98 22.39 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.836 0.35 . . . . 0.0 110.37 179.821 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . 0.515 ' O ' ' HB3' ' A' ' 87' ' ' ALA . 8.6 m -72.38 153.04 41.67 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.702 179.988 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.682 ' HB1' ' CD ' ' A' ' 88' ' ' PRO . . . 71.67 -179.85 0.05 OUTLIER Pre-proline 0 CA--C 1.537 0.455 0 CA-C-N 115.879 -0.601 . . . . 0.0 110.571 179.656 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . 0.682 ' CD ' ' HB1' ' A' ' 87' ' ' ALA . 22.1 Cg_exo -63.33 153.28 75.37 Favored 'Trans proline' 0 N--CA 1.497 1.713 0 C-N-CA 122.548 2.166 . . . . 0.0 111.93 179.723 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.7 p -129.18 158.75 38.13 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.179 -179.637 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -142.4 -177.73 5.41 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.186 179.983 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . 0.623 ' N ' HD22 ' A' ' 91' ' ' LEU . 3.6 mm? -90.83 133.05 35.51 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.468 179.963 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 92' ' ' THR . . . . . 0.452 HG22 ' H ' ' A' ' 92' ' ' THR . 0.9 OUTLIER -79.04 153.02 30.55 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.813 -0.631 . . . . 0.0 110.319 -179.792 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 98.7 mm-40 -76.82 137.25 39.11 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.528 -179.993 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 97.3 mt-30 -64.76 90.3 0.08 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.39 -179.948 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 18.6 p . . . . . 0 C--O 1.22 -0.452 0 CA-C-O 118.001 -1.0 . . . . 0.0 110.515 179.982 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' B' B ' 201' ' ' SER . . . . . . . . . . . . . 18.7 p . . . . . 0 N--CA 1.492 1.636 0 N-CA-C 109.435 -0.58 . . . . 0.0 109.435 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' B' B ' 202' ' ' SER . . . . . . . . . . . . . 38.7 t -70.94 155.58 40.64 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.149 179.9 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 203' ' ' SER . . . . . . . . . . . . . 2.8 p -89.23 150.91 45.84 Favored Pre-proline 0 CA--C 1.538 0.491 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.317 -179.617 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 204' ' ' PRO . . . . . . . . . . . . . 56.9 Cg_endo -70.49 6.45 1.55 Allowed 'Trans proline' 0 N--CA 1.5 1.893 0 C-N-CA 122.443 2.095 . . . . 0.0 112.008 179.984 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 205' ' ' ILE . . . . . 0.446 HD13 ' CZ ' ' A' ' 14' ' ' PHE . 10.9 tt -150.79 151.13 12.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-O 121.032 0.444 . . . . 0.0 111.075 179.699 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 206' ' ' GLN . . . . . . . . . . . . . 69.3 mt-30 -156.83 75.61 0.84 Allowed 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.692 -0.685 . . . . 0.0 110.534 178.711 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 207' ' ' GLY . . . . . . . . . . . . . . . -107.65 -159.9 20.86 Favored Glycine 0 N--CA 1.464 0.515 0 N-CA-C 110.838 -0.905 . . . . 0.0 110.838 -179.847 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 208' ' ' SER . . . . . . . . . . . . . 44.6 p -163.82 170.33 17.02 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 120.717 0.294 . . . . 0.0 110.701 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 209' ' ' TRP . . . . . . . . . . . . . 86.5 m95 -83.33 126.56 32.83 Favored 'General case' 0 C--N 1.329 -0.286 0 C-N-CA 120.845 -0.342 . . . . 0.0 110.167 179.34 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 77.4 p -108.94 138.91 44.54 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-N 116.514 -0.312 . . . . 0.0 110.723 -179.745 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 58.2 t-105 -95.67 116.09 28.36 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-N 116.033 -0.531 . . . . 0.0 110.337 179.68 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 212' ' ' GLU . . . . . 0.469 ' O ' ' O ' ' B' ' 215' ' ' LYS . 1.4 pt-20 -163.46 167.03 22.06 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.509 179.312 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 213' ' ' ASN . . . . . . . . . . . . . 12.4 m120 49.3 34.23 6.11 Favored 'General case' 0 C--N 1.324 -0.522 0 C-N-CA 120.53 -0.468 . . . . 0.0 111.698 176.962 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 54.73 12.34 3.48 Favored Glycine 0 CA--C 1.528 0.865 0 C-N-CA 120.917 -0.659 . . . . 0.0 111.604 179.463 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 215' ' ' LYS . . . . . 0.469 ' O ' ' O ' ' B' ' 212' ' ' GLU . 67.6 mttm -141.86 150.98 42.29 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-O 120.863 0.364 . . . . 0.0 110.76 -179.798 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 216' ' ' TRP . . . . . 0.437 ' N ' ' CD1' ' B' ' 216' ' ' TRP . 37.4 m95 -84.91 117.54 23.98 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.174 179.875 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 217' ' ' THR . . . . . . . . . . . . . 26.7 m -125.85 137.49 53.76 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.531 -179.568 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 218' ' ' TRP . . . . . . . . . . . . . 25.0 t-105 -98.53 120.02 38.25 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.234 179.483 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 53.7 mtmt -141.69 165.79 26.51 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.72 -179.809 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -176.44 -160.97 24.59 Favored Glycine 0 CA--C 1.522 0.504 0 N-CA-C 111.185 -0.766 . . . . 0.0 111.185 -179.887 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 221' ' ' ILE . . . . . 0.555 ' O ' HG23 ' B' ' 222' ' ' ILE . 0.8 OUTLIER -53.43 -76.73 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.387 0 C-N-CA 120.682 -0.407 . . . . 0.0 110.987 -178.44 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' B' B ' 222' ' ' ILE . . . . . 0.555 HG23 ' O ' ' B' ' 221' ' ' ILE . 20.2 pt -160.72 -166.24 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 N-CA-C 109.994 -0.373 . . . . 0.0 109.994 -179.633 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 223' ' ' ARG . . . . . 0.675 ' N ' HD11 ' A' ' 75' ' ' ILE . 33.2 ptt85 -45.41 174.57 0.0 OUTLIER 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.805 178.362 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 224' ' ' LEU . . . . . 0.679 ' N ' HD22 ' B' ' 224' ' ' LEU . 3.0 mm? -59.44 123.46 16.89 Favored 'General case' 0 C--N 1.318 -0.791 0 CA-C-N 115.317 -0.856 . . . . 0.0 110.211 -179.244 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 79.7 tt0 -115.97 150.15 37.64 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.387 -0.824 . . . . 0.0 110.167 -179.648 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 226' ' ' GLN . . . . . . . . . . . . . 68.0 tp60 . . . . . 0 N--CA 1.448 -0.54 0 CA-C-O 117.979 -1.01 . . . . 0.0 110.263 -179.798 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.158 0 N-CA-C 109.603 -1.399 . . . . 0.0 109.603 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 31.0 m -150.02 105.44 3.39 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.854 0.359 . . . . 0.0 110.381 179.962 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 4.6 pt-20 -98.96 100.01 11.13 Favored 'General case' 0 N--CA 1.464 0.264 0 CA-C-O 121.085 0.469 . . . . 0.0 110.479 179.995 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.439 ' H ' HG22 ' A' ' 6' ' ' VAL . 3.3 m -81.09 153.2 72.01 Favored Pre-proline 0 N--CA 1.449 -0.495 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.529 -179.778 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_exo -50.58 143.64 27.7 Favored 'Trans proline' 0 N--CA 1.491 1.381 0 C-N-CA 122.546 2.164 . . . . 0.0 112.194 179.047 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 15.2 pt20 -160.58 -147.29 0.15 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.059 -0.518 . . . . 0.0 110.61 -179.838 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 26.6 tp -57.33 130.4 46.07 Favored 'General case' 0 N--CA 1.449 -0.493 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.29 -179.567 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 43.6 p -82.01 167.46 18.83 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.424 -179.96 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 96.5 m-20 -135.81 142.89 44.92 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-O 120.984 0.421 . . . . 0.0 110.438 -179.879 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 6.6 tt -64.27 145.16 56.46 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.429 -179.676 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 86.8 p -140.3 153.01 46.33 Favored 'General case' 0 N--CA 1.463 0.212 0 CA-C-N 116.328 -0.397 . . . . 0.0 110.662 179.909 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . 0.533 ' N ' ' CD1' ' A' ' 14' ' ' PHE . 12.5 m-85 -111.17 146.74 36.35 Favored 'General case' 0 N--CA 1.465 0.301 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.379 -179.612 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 21.9 m -146.01 160.88 11.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.633 179.81 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 38.2 t0 55.46 31.53 17.15 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.66 179.636 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 96.5 mt -56.57 137.77 18.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 121.07 0.462 . . . . 0.0 110.148 179.962 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.461 ' CB ' ' O ' ' A' ' 21' ' ' SER . 0.3 OUTLIER -140.32 -167.01 2.23 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.817 -0.628 . . . . 0.0 110.651 -179.559 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . 0.525 ' OD1' ' N ' ' A' ' 19' ' ' ASP . 14.5 p-10 -91.6 -41.97 10.47 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 115.691 -0.686 . . . . 0.0 111.006 179.468 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 13.7 m -116.97 6.88 13.05 Favored 'General case' 0 N--CA 1.466 0.344 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.677 -179.584 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . 0.461 ' O ' ' CB ' ' A' ' 18' ' ' THR . 16.8 p -151.65 145.79 25.33 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 121.101 0.477 . . . . 0.0 110.443 179.968 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 44.2 pt -140.26 146.29 24.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.02 179.941 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -99.31 81.76 0.56 Allowed Glycine 0 CA--C 1.523 0.593 0 N-CA-C 111.419 -0.672 . . . . 0.0 111.419 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 84.0 mt -66.79 121.98 16.65 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.768 0.318 . . . . 0.0 110.296 -179.967 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 4.6 tmm_? -139.62 138.69 36.37 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.62 179.877 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' TRP . . . . . . . . . . . . . 42.0 p90 -143.0 158.28 43.75 Favored 'General case' 0 CA--C 1.517 -0.308 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.399 179.921 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 3.5 m -111.16 97.1 33.67 Favored Pre-proline 0 CA--C 1.534 0.337 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.393 179.854 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_exo -53.23 146.3 40.2 Favored 'Trans proline' 0 C--N 1.308 -1.581 0 C-N-CA 122.476 2.117 . . . . 0.0 112.23 179.879 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 52.3 mt -84.32 138.53 32.84 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 121.337 0.589 . . . . 0.0 111.039 -179.96 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 2.3 t-20 -49.08 -33.49 11.71 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.47 -0.786 . . . . 0.0 110.152 179.829 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 70.6 m -81.63 -34.17 31.02 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.593 179.667 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 9.1 m -58.24 134.92 56.96 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 121.103 0.478 . . . . 0.0 110.185 -179.881 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . 0.585 ' HG1' ' H ' ' A' ' 83' ' ' GLY . 3.7 m -61.44 142.74 56.78 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.465 179.912 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 28.9 mm -94.37 92.69 3.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.969 0.414 . . . . 0.0 110.324 -179.896 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 15.2 pt -143.09 135.86 25.13 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.155 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.359 179.697 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -39.24 132.4 1.95 Allowed Glycine 0 CA--C 1.524 0.642 0 N-CA-C 111.171 -0.771 . . . . 0.0 111.171 -179.705 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 95.6 m-85 -103.03 138.98 39.17 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.844 0.354 . . . . 0.0 110.197 -179.771 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 5.3 tmm_? -99.1 124.64 44.27 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.629 -179.699 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.451 ' CG1' ' O ' ' A' ' 39' ' ' ILE . 2.1 pt -99.09 124.51 52.39 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 116.341 -0.391 . . . . 0.0 109.97 179.701 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 5.4 m -105.52 134.0 49.35 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.621 -179.822 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.1 p -132.39 141.52 45.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.308 179.541 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . 0.538 ' O ' ' N ' ' A' ' 74' ' ' ASP . 41.4 t -133.41 133.47 57.64 Favored 'Isoleucine or valine' 0 C--O 1.231 0.104 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.339 179.6 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.548 ' HB2' ' CE2' ' A' ' 73' ' ' TYR . . . -98.55 139.58 34.07 Favored 'General case' 0 C--N 1.328 -0.33 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 178.732 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.513 ' HB3' ' O ' ' A' ' 72' ' ' ASP . . . -91.81 -43.91 9.26 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.284 -0.417 . . . . 0.0 111.027 179.815 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -63.49 -32.35 83.84 Favored Glycine 0 CA--C 1.524 0.614 0 N-CA-C 111.275 -0.73 . . . . 0.0 111.275 -179.477 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 38.4 mm-40 -97.92 126.53 43.36 Favored 'General case' 0 C--N 1.332 -0.19 0 N-CA-C 109.616 -0.512 . . . . 0.0 109.616 -179.582 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -59.17 -6.92 4.57 Favored Glycine 0 CA--C 1.511 -0.187 0 N-CA-C 110.918 -0.873 . . . . 0.0 110.918 -179.082 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -124.23 133.44 24.7 Favored Pre-proline 0 CA--C 1.537 0.477 0 C-N-CA 120.905 -0.318 . . . . 0.0 110.257 179.461 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 60.7 Cg_endo -76.71 164.22 30.52 Favored 'Trans proline' 0 C--N 1.307 -1.618 0 C-N-CA 122.59 2.193 . . . . 0.0 112.286 177.48 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 95.9 mt -85.22 145.38 8.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 115.771 -0.65 . . . . 0.0 110.268 179.023 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 79.7 m-85 -63.79 142.81 58.27 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.527 -179.886 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . 0.446 ' N ' ' CD ' ' A' ' 52' ' ' GLU . 0.1 OUTLIER -70.58 -178.01 1.68 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.582 179.776 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . 0.411 ' HB2' HD11 ' A' ' 39' ' ' ILE . 4.0 m-20 -146.51 138.25 24.68 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.884 179.499 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 89.3 m-85 -108.13 120.01 41.13 Favored 'General case' 0 N--CA 1.463 0.187 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.279 179.266 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 9.9 p -127.28 136.52 60.42 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.285 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.377 179.881 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 97.4 m-20 -56.89 142.99 39.26 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.463 -179.855 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 11.4 t -61.79 -35.15 77.34 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.716 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 37.7 m -55.44 -32.33 62.65 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.724 -179.718 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 98.6 t -63.76 -46.14 95.32 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.587 -179.889 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 59.36 27.09 62.65 Favored Glycine 0 CA--C 1.527 0.827 0 N-CA-C 110.859 -0.896 . . . . 0.0 110.859 -179.931 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 52.7 t80 -166.52 149.89 7.09 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 121.224 0.535 . . . . 0.0 110.945 -179.415 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' TYR . . . . . 0.412 ' CD2' ' CD1' ' A' ' 39' ' ' ILE . 25.7 t80 -158.81 159.26 34.92 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.971 -0.558 . . . . 0.0 110.141 179.003 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 85.3 m -125.28 136.28 53.36 Favored 'General case' 0 N--CA 1.464 0.233 0 CA-C-N 116.378 -0.373 . . . . 0.0 110.392 -179.714 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -131.87 105.93 10.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.185 179.37 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 3.2 p -114.1 156.23 24.56 Favored 'General case' 0 CA--C 1.516 -0.358 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.515 179.632 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 109.63 40.46 1.46 Allowed Glycine 0 CA--C 1.523 0.589 0 N-CA-C 111.245 -0.742 . . . . 0.0 111.245 -179.754 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 18.5 mt -113.69 102.34 10.16 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-O 121.126 0.488 . . . . 0.0 109.918 179.579 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 12.3 mm-40 -48.66 135.42 13.41 Favored Pre-proline 0 C--N 1.317 -0.805 0 CA-C-N 115.609 -0.723 . . . . 0.0 111.042 -178.558 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . 0.407 ' O ' HD12 ' A' ' 71' ' ' ILE . 70.9 Cg_endo -75.33 153.01 39.92 Favored 'Trans proline' 0 N--CA 1.496 1.673 0 C-N-CA 122.882 2.388 . . . . 0.0 111.61 178.8 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 72.43 12.04 76.72 Favored Glycine 0 CA--C 1.521 0.425 0 N-CA-C 111.186 -0.766 . . . . 0.0 111.186 179.479 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . 0.537 ' O ' ' NH1' ' B' ' 223' ' ' ARG . 1.7 mp -118.38 147.92 21.56 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.381 0 CA-C-O 121.251 0.548 . . . . 0.0 109.897 -179.878 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 72' ' ' ASP . . . . . 0.513 ' O ' ' HB3' ' A' ' 44' ' ' ALA . 3.1 t70 -86.51 112.39 21.49 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.257 -0.883 . . . . 0.0 110.752 179.947 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 73' ' ' TYR . . . . . 0.548 ' CE2' ' HB2' ' A' ' 43' ' ' ALA . 14.8 m-85 -106.25 119.58 39.62 Favored 'General case' 0 C--O 1.218 -0.601 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.027 179.494 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 74' ' ' ASP . . . . . 0.538 ' N ' ' O ' ' A' ' 42' ' ' VAL . 72.1 m-20 -88.29 117.53 27.27 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.741 -0.663 . . . . 0.0 109.576 179.442 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.643 HD11 ' N ' ' B' ' 223' ' ' ARG . 0.0 OUTLIER -114.59 165.97 9.03 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-O 121.038 0.447 . . . . 0.0 110.344 -179.457 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -155.14 120.73 5.04 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.586 -0.734 . . . . 0.0 110.976 179.273 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.448 ' O ' HG23 ' B' ' 217' ' ' THR . 8.9 t -100.31 101.88 12.69 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 N-CA-C 109.835 -0.431 . . . . 0.0 109.835 179.22 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 95.7 mt -88.8 126.86 41.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.648 -179.756 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 96.6 m -108.36 111.31 23.17 Favored 'General case' 0 CA--C 1.517 -0.303 0 CA-C-O 121.011 0.434 . . . . 0.0 109.984 179.7 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 51.4 tp -120.73 125.04 46.63 Favored 'General case' 0 CA--C 1.519 -0.234 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.875 179.965 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 81' ' ' ILE . . . . . 0.526 ' HB ' ' H ' ' A' ' 33' ' ' THR . 2.0 pp -144.69 143.83 22.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.279 178.991 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 82' ' ' ASN . . . . . 0.459 ' N ' ' OG1' ' A' ' 33' ' ' THR . 62.8 t-20 -64.47 -53.01 54.92 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.334 -0.394 . . . . 0.0 111.204 -179.856 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . 0.585 ' H ' ' HG1' ' A' ' 33' ' ' THR . . . 106.45 155.08 20.84 Favored Glycine 0 CA--C 1.521 0.461 0 N-CA-C 110.665 -0.974 . . . . 0.0 110.665 179.457 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -91.23 112.95 4.22 Favored Glycine 0 CA--C 1.524 0.634 0 N-CA-C 110.823 -0.911 . . . . 0.0 110.823 179.889 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.532 ' OE1' ' N ' ' A' ' 85' ' ' GLU . 58.2 mp0 -84.71 147.63 26.81 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.871 0.367 . . . . 0.0 110.663 179.933 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 30.5 t -78.05 131.01 37.14 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.352 179.904 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.676 ' HB3' ' HD3' ' A' ' 88' ' ' PRO . . . -67.96 -61.39 4.23 Favored Pre-proline 0 C--N 1.325 -0.468 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.232 179.187 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . 0.676 ' HD3' ' HB3' ' A' ' 87' ' ' ALA . 26.5 Cg_endo -61.11 144.76 99.32 Favored 'Trans proline' 0 C--N 1.308 -1.571 0 C-N-CA 122.642 2.228 . . . . 0.0 111.781 -179.757 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -136.04 124.58 23.59 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.484 179.546 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 92.9 m -133.1 132.34 41.6 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.368 179.872 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . 0.596 HD12 ' O ' ' A' ' 91' ' ' LEU . 0.3 OUTLIER -89.84 154.78 19.62 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.194 -179.894 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 76.9 p -68.99 136.67 52.84 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.481 179.77 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 29.4 mm100 -95.71 116.6 29.11 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.446 179.904 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 84.9 mt-30 -67.24 -34.23 77.0 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.481 179.829 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 60.3 p . . . . . 0 C--O 1.22 -0.496 0 CA-C-O 117.958 -1.02 . . . . 0.0 110.486 -179.79 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' B' B ' 201' ' ' SER . . . . . . . . . . . . . 59.4 p . . . . . 0 N--CA 1.49 1.567 0 N-CA-C 109.326 -0.62 . . . . 0.0 109.326 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' B' B ' 202' ' ' SER . . . . . . . . . . . . . 28.3 m -72.2 145.63 47.88 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.4 -179.961 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 203' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -95.25 151.67 38.88 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.552 -179.872 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 204' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -71.43 4.17 3.12 Favored 'Trans proline' 0 C--N 1.312 -1.369 0 C-N-CA 122.711 2.274 . . . . 0.0 112.04 179.773 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 205' ' ' ILE . . . . . 0.419 HD12 ' HA ' ' B' ' 205' ' ' ILE . 10.7 tp -148.4 151.36 13.38 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.328 0 CA-C-O 120.755 0.312 . . . . 0.0 111.173 179.754 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 206' ' ' GLN . . . . . . . . . . . . . 8.8 pt20 -173.87 78.47 0.03 OUTLIER 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.623 179.501 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 207' ' ' GLY . . . . . . . . . . . . . . . -108.63 -147.05 12.3 Favored Glycine 0 N--CA 1.464 0.551 0 N-CA-C 111.241 -0.743 . . . . 0.0 111.241 179.879 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 208' ' ' SER . . . . . 0.5 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 33.2 p -164.49 172.26 13.55 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.726 0.298 . . . . 0.0 110.767 -179.676 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 209' ' ' TRP . . . . . . . . . . . . . 73.2 m95 -85.35 151.15 24.24 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.284 -0.417 . . . . 0.0 110.357 179.529 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 81.6 p -131.66 137.64 48.42 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.387 -0.37 . . . . 0.0 110.903 -179.964 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 47.4 t-105 -95.54 115.45 27.44 Favored 'General case' 0 C--N 1.331 -0.199 0 N-CA-C 109.87 -0.418 . . . . 0.0 109.87 179.402 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 212' ' ' GLU . . . . . 0.512 ' O ' ' O ' ' B' ' 215' ' ' LYS . 2.8 tt0 -161.33 150.7 16.54 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.578 179.59 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 213' ' ' ASN . . . . . 0.425 ' N ' ' HG3' ' B' ' 212' ' ' GLU . 13.2 m120 59.68 42.2 17.37 Favored 'General case' 0 N--CA 1.448 -0.53 0 CA-C-N 115.901 -0.591 . . . . 0.0 111.166 177.145 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 49.86 12.95 0.5 Allowed Glycine 0 CA--C 1.521 0.417 0 N-CA-C 111.63 -0.588 . . . . 0.0 111.63 179.161 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 215' ' ' LYS . . . . . 0.512 ' O ' ' O ' ' B' ' 212' ' ' GLU . 68.1 mttm -142.04 150.58 41.46 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.054 0.454 . . . . 0.0 110.457 -179.997 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 216' ' ' TRP . . . . . . . . . . . . . 45.7 m95 -86.13 122.31 29.97 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.42 -0.355 . . . . 0.0 110.119 -179.941 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 217' ' ' THR . . . . . 0.448 HG23 ' O ' ' A' ' 77' ' ' VAL . 18.8 m -129.19 141.51 51.14 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.934 0.397 . . . . 0.0 110.426 -179.677 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 218' ' ' TRP . . . . . 0.5 ' CH2' ' N ' ' B' ' 208' ' ' SER . 16.7 t-105 -105.43 118.02 35.5 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-N 115.888 -0.596 . . . . 0.0 109.742 179.477 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 24.0 mtmm -142.13 173.76 11.23 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.798 -179.882 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -176.39 -161.27 25.09 Favored Glycine 0 CA--C 1.523 0.57 0 N-CA-C 111.243 -0.743 . . . . 0.0 111.243 -179.698 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 221' ' ' ILE . . . . . 0.561 ' O ' HG23 ' B' ' 222' ' ' ILE . 30.5 mt -52.39 -73.39 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 C-N-CA 120.812 -0.355 . . . . 0.0 110.228 -178.534 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 222' ' ' ILE . . . . . 0.561 HG23 ' O ' ' B' ' 221' ' ' ILE . 20.5 pt -158.97 -165.89 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.208 0 CA-C-N 116.301 -0.408 . . . . 0.0 110.458 -179.932 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 223' ' ' ARG . . . . . 0.643 ' N ' HD11 ' A' ' 75' ' ' ILE . 30.7 ptt-85 -44.31 174.55 0.0 OUTLIER 'General case' 0 N--CA 1.456 -0.17 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.281 179.378 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 224' ' ' LEU . . . . . 0.787 ' N ' HD22 ' B' ' 224' ' ' LEU . 2.6 mm? -62.13 117.97 6.73 Favored 'General case' 0 C--N 1.316 -0.886 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.768 -179.516 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 81.7 tt0 -85.0 149.8 25.34 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.612 -0.722 . . . . 0.0 110.642 -179.93 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 226' ' ' GLN . . . . . . . . . . . . . 53.4 tt0 . . . . . 0 C--O 1.22 -0.453 0 CA-C-O 117.951 -1.024 . . . . 0.0 110.485 179.958 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.411 0 N-CA-C 109.479 -1.449 . . . . 0.0 109.479 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 21.6 m -69.83 142.33 53.13 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.855 0.359 . . . . 0.0 110.307 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 15.9 pt-20 -69.15 137.3 53.23 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.483 -179.942 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.527 ' O ' HG13 ' A' ' 6' ' ' VAL . 7.3 p -84.01 116.64 65.77 Favored Pre-proline 0 CA--C 1.54 0.571 0 C-N-CA 120.863 -0.335 . . . . 0.0 110.677 -179.561 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 71.3 Cg_endo -75.54 143.05 26.98 Favored 'Trans proline' 0 N--CA 1.495 1.575 0 C-N-CA 121.997 1.798 . . . . 0.0 112.21 -179.993 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 96.9 mm-40 -82.02 -163.78 0.71 Allowed 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.383 -0.371 . . . . 0.0 110.083 179.842 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.564 ' N ' HD12 ' A' ' 9' ' ' LEU . 10.2 mp -77.06 129.4 36.0 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.263 -179.998 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 6.1 p -81.53 149.44 28.68 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.329 179.832 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 4.1 p30 -92.2 165.03 13.34 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.494 179.929 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.622 HD23 ' H ' ' A' ' 13' ' ' SER . 0.5 OUTLIER -68.02 151.41 47.11 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.307 -179.784 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . 0.622 ' H ' HD23 ' A' ' 12' ' ' LEU . 61.6 p -143.25 149.39 37.83 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.608 179.568 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . 0.527 ' N ' ' CD1' ' A' ' 14' ' ' PHE . 17.4 m-85 -112.34 147.02 37.24 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.879 -0.6 . . . . 0.0 110.649 -179.599 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 23.3 m -147.54 156.61 9.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.398 179.43 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 38.2 t0 60.78 28.47 18.21 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.616 179.897 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 96.5 mt -55.88 132.39 19.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.062 179.799 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.437 HG22 ' H ' ' A' ' 19' ' ' ASP . 0.2 OUTLIER -131.12 -169.36 2.16 Favored 'General case' 0 N--CA 1.467 0.409 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.469 -179.839 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . 0.477 ' N ' ' OD1' ' A' ' 19' ' ' ASP . 17.5 p-10 -77.65 -49.26 14.9 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.963 179.513 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . 0.513 ' OG ' ' N ' ' A' ' 67' ' ' LEU . 31.1 t -120.46 13.39 11.79 Favored 'General case' 0 N--CA 1.466 0.358 0 CA-C-N 116.511 -0.313 . . . . 0.0 110.704 -179.252 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . 0.529 ' HB3' HG22 ' A' ' 65' ' ' THR . 3.8 m -146.56 129.8 16.62 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.237 -179.307 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . 0.516 HD12 HD21 ' A' ' 24' ' ' LEU . 47.7 pt -125.78 142.25 43.09 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-N 116.288 -0.415 . . . . 0.0 109.979 179.756 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -98.28 83.08 0.65 Allowed Glycine 0 CA--C 1.523 0.593 0 N-CA-C 110.507 -1.037 . . . . 0.0 110.507 -179.345 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.516 HD21 HD12 ' A' ' 22' ' ' ILE . 92.0 mt -65.57 128.09 34.52 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 110.013 -0.365 . . . . 0.0 110.013 -179.634 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . 0.44 ' O ' ' O ' ' A' ' 13' ' ' SER . 1.2 tpp180 -147.75 134.86 20.4 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.045 179.832 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' TRP . . . . . 0.554 ' CE3' ' O ' ' A' ' 60' ' ' GLY . 4.9 p90 -140.29 128.45 22.32 Favored 'General case' 0 C--O 1.223 -0.299 0 N-CA-C 109.223 -0.658 . . . . 0.0 109.223 177.73 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 1.9 m -68.34 113.27 14.32 Favored Pre-proline 0 CA--C 1.538 0.49 0 C-N-CA 120.528 -0.469 . . . . 0.0 111.011 -179.633 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 32.7 Cg_exo -59.53 152.39 62.28 Favored 'Trans proline' 0 N--CA 1.498 1.744 0 C-N-CA 121.993 1.795 . . . . 0.0 112.599 178.473 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.433 ' H ' ' HB2' ' A' ' 32' ' ' SER . 77.9 mt -102.16 133.43 47.03 Favored 'General case' 0 CA--C 1.518 -0.254 0 CA-C-O 121.682 0.754 . . . . 0.0 110.651 179.728 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 11.7 t-20 -42.79 -30.54 0.4 Allowed 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 115.352 -0.84 . . . . 0.0 110.47 -179.725 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 58.1 m -87.88 -36.64 17.07 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.483 179.087 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . 0.433 ' HB2' ' H ' ' A' ' 29' ' ' LEU . 3.1 m -45.73 113.54 0.62 Allowed 'General case' 0 N--CA 1.461 0.115 0 CA-C-O 121.091 0.472 . . . . 0.0 110.306 -179.661 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . 0.519 ' OG1' ' N ' ' A' ' 82' ' ' ASN . 7.2 m -52.24 150.01 4.97 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.601 -0.727 . . . . 0.0 109.448 -179.251 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 19.6 mm -93.92 92.65 3.66 Favored 'Isoleucine or valine' 0 C--O 1.232 0.135 0 CA-C-O 121.11 0.481 . . . . 0.0 110.995 -178.51 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.6 HD11 ' HA ' ' A' ' 81' ' ' ILE . 6.6 pt -151.23 124.84 1.34 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.252 179.288 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -48.25 131.4 19.84 Favored Glycine 0 CA--C 1.519 0.336 0 N-CA-C 110.786 -0.925 . . . . 0.0 110.786 -179.624 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' TYR . . . . . 0.571 ' CD1' ' O ' ' A' ' 37' ' ' TYR . 0.6 OUTLIER -104.13 130.07 51.85 Favored 'General case' 0 C--N 1.329 -0.322 0 N-CA-C 109.691 -0.485 . . . . 0.0 109.691 -179.895 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . 0.516 ' NH1' ' OG1' ' A' ' 40' ' ' THR . 7.9 tmm_? -79.59 132.27 36.23 Favored 'General case' 0 C--N 1.325 -0.472 0 C-N-CA 120.743 -0.383 . . . . 0.0 111.003 -179.895 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.559 HG22 ' CE2' ' A' ' 37' ' ' TYR . 1.9 pt -104.51 122.58 57.65 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.329 0 N-CA-C 109.585 -0.524 . . . . 0.0 109.585 179.179 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . 0.516 ' OG1' ' NH1' ' A' ' 38' ' ' ARG . 7.1 m -99.44 136.52 39.26 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.425 -179.022 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.4 p -133.31 141.55 44.25 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.288 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.133 179.855 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . 0.499 ' O ' ' N ' ' A' ' 74' ' ' ASP . 39.9 t -132.59 132.48 59.96 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.24 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 179.607 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.438 ' HB2' ' CE2' ' A' ' 73' ' ' TYR . . . -99.35 136.62 39.03 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 116.09 -0.504 . . . . 0.0 109.651 178.921 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.632 ' HB3' ' O ' ' A' ' 72' ' ' ASP . . . -99.02 -15.43 19.07 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-O 120.806 0.336 . . . . 0.0 110.85 -179.801 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -99.62 24.99 30.0 Favored Glycine 0 CA--C 1.525 0.7 0 N-CA-C 111.093 -0.803 . . . . 0.0 111.093 -179.44 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 93.5 mt-10 -145.95 149.37 34.05 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.97 0.414 . . . . 0.0 110.337 179.936 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -66.59 -21.06 70.54 Favored Glycine 0 CA--C 1.519 0.302 0 N-CA-C 110.67 -0.972 . . . . 0.0 110.67 179.896 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -132.23 139.58 35.35 Favored Pre-proline 0 CA--C 1.539 0.527 0 C-N-CA 121.224 -0.19 . . . . 0.0 110.524 179.873 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 61.3 Cg_endo -73.93 161.87 40.4 Favored 'Trans proline' 0 N--CA 1.49 1.281 0 C-N-CA 122.469 2.113 . . . . 0.0 111.96 177.613 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 96.8 mt -77.48 149.96 5.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.461 179.354 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 76.1 m-85 -72.47 141.59 48.59 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.678 179.78 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . 0.414 ' N ' ' CD ' ' A' ' 52' ' ' GLU . 0.2 OUTLIER -61.77 -177.07 0.1 Allowed 'General case' 0 CA--C 1.517 -0.321 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.418 179.275 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -144.33 135.29 25.16 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 115.637 -0.71 . . . . 0.0 110.301 179.706 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 86.7 m-85 -108.46 116.55 32.19 Favored 'General case' 0 N--CA 1.465 0.287 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.374 179.697 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 9.2 p -130.35 143.77 39.99 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.291 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.145 179.77 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 95.5 m-20 -66.79 151.16 48.02 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.595 179.626 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 4.4 t -64.99 -32.04 73.58 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.628 179.86 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 50.4 m -52.57 -38.58 60.23 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.485 -179.703 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.467 HG12 ' O ' ' A' ' 61' ' ' TYR . 23.8 t -60.66 -43.03 94.0 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 -179.942 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . 0.554 ' O ' ' CE3' ' A' ' 26' ' ' TRP . . . 75.19 -40.91 1.27 Allowed Glycine 0 CA--C 1.529 0.919 0 N-CA-C 110.846 -0.902 . . . . 0.0 110.846 179.651 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . 0.467 ' O ' HG12 ' A' ' 59' ' ' VAL . 26.9 p90 -113.46 158.64 20.43 Favored 'General case' 0 N--CA 1.469 0.495 0 CA-C-O 121.048 0.451 . . . . 0.0 111.245 -178.881 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' TYR . . . . . 0.411 ' CD2' ' CD1' ' A' ' 39' ' ' ILE . 33.3 t80 -152.93 149.5 28.29 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 179.541 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 79.8 m -112.4 133.93 54.22 Favored 'General case' 0 CA--C 1.52 -0.195 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.468 -179.445 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -132.36 100.09 3.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 115.854 -0.612 . . . . 0.0 109.834 178.762 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.529 HG22 ' HB3' ' A' ' 21' ' ' SER . 2.0 p -114.37 164.18 14.29 Favored 'General case' 0 CA--C 1.515 -0.38 0 CA-C-O 120.908 0.385 . . . . 0.0 110.524 -179.942 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 107.79 25.63 5.87 Favored Glycine 0 CA--C 1.524 0.622 0 N-CA-C 111.172 -0.771 . . . . 0.0 111.172 179.75 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.513 ' N ' ' OG ' ' A' ' 20' ' ' SER . 11.9 mt -100.72 109.44 21.47 Favored 'General case' 0 N--CA 1.465 0.318 0 N-CA-C 109.284 -0.636 . . . . 0.0 109.284 179.944 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 55.5 mm-40 -52.04 139.53 33.57 Favored Pre-proline 0 C--N 1.316 -0.887 0 C-N-CA 120.496 -0.482 . . . . 0.0 112.054 -178.589 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . 0.428 ' C ' ' H ' ' A' ' 71' ' ' ILE . 74.4 Cg_endo -73.91 157.52 47.24 Favored 'Trans proline' 0 N--CA 1.498 1.748 0 C-N-CA 122.86 2.373 . . . . 0.0 111.253 178.574 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 69.97 -8.54 3.49 Favored Glycine 0 CA--C 1.527 0.822 0 CA-C-N 115.844 -0.616 . . . . 0.0 111.653 178.855 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . 0.524 ' O ' ' NH1' ' B' ' 223' ' ' ARG . 1.6 mp -98.76 149.19 5.53 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 N-CA-C 109.229 -0.656 . . . . 0.0 109.229 -179.702 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 72' ' ' ASP . . . . . 0.632 ' O ' ' HB3' ' A' ' 44' ' ' ALA . 2.7 t70 -89.51 115.61 27.06 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.165 -0.925 . . . . 0.0 110.422 179.657 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 73' ' ' TYR . . . . . 0.493 ' O ' HD13 ' A' ' 75' ' ' ILE . 20.9 m-85 -108.48 119.74 40.38 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.425 179.951 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 74' ' ' ASP . . . . . 0.499 ' N ' ' O ' ' A' ' 42' ' ' VAL . 13.4 m-20 -89.8 118.13 29.16 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 115.548 -0.751 . . . . 0.0 109.646 179.824 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.493 HD13 ' O ' ' A' ' 73' ' ' TYR . 0.0 OUTLIER -115.9 164.24 12.42 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-O 121.192 0.52 . . . . 0.0 109.919 -179.139 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -152.92 128.88 10.3 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.659 -0.7 . . . . 0.0 110.216 179.667 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 62.8 t -108.27 131.79 57.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 179.461 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 96.5 mt -124.51 124.45 68.32 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 115.991 -0.549 . . . . 0.0 110.344 179.458 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 95.1 m -100.86 114.41 28.23 Favored 'General case' 0 C--O 1.232 0.181 0 CA-C-O 120.922 0.391 . . . . 0.0 110.081 179.636 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . 0.754 HD23 ' HZ1' ' B' ' 215' ' ' LYS . 9.6 mt -118.68 113.96 22.0 Favored 'General case' 0 CA--C 1.518 -0.251 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.253 -179.988 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 81' ' ' ILE . . . . . 0.6 ' HA ' HD11 ' A' ' 35' ' ' ILE . 2.3 pp -147.47 144.84 19.4 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.042 179.146 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 82' ' ' ASN . . . . . 0.519 ' N ' ' OG1' ' A' ' 33' ' ' THR . 39.9 t30 -64.66 -47.55 78.06 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 120.942 0.401 . . . . 0.0 111.189 179.892 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 90.71 161.92 37.8 Favored Glycine 0 CA--C 1.521 0.466 0 N-CA-C 110.923 -0.871 . . . . 0.0 110.923 179.578 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -78.87 176.95 54.4 Favored Glycine 0 CA--C 1.524 0.63 0 N-CA-C 110.76 -0.936 . . . . 0.0 110.76 179.914 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 80.1 mm-40 -52.25 166.07 0.19 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.879 0.371 . . . . 0.0 110.442 -179.984 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 33.2 t -59.62 139.74 56.94 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.588 -179.659 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . 60.03 72.47 0.76 Allowed Pre-proline 0 C--N 1.328 -0.333 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.456 -179.895 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_exo -52.81 -37.67 76.93 Favored 'Trans proline' 0 C--N 1.308 -1.575 0 C-N-CA 122.937 2.424 . . . . 0.0 112.283 -179.86 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . 0.434 ' O ' HG23 ' A' ' 89' ' ' THR . 6.2 t -130.65 125.33 33.75 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.528 179.994 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 9.6 p -86.73 168.03 13.91 Favored 'General case' 0 C--N 1.333 -0.15 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.302 179.707 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . 0.55 ' N ' HD12 ' A' ' 91' ' ' LEU . 10.0 mp -89.39 121.79 31.98 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-O 121.07 0.462 . . . . 0.0 110.086 -179.785 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 61.5 p -84.86 164.9 18.14 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.921 -0.582 . . . . 0.0 110.337 179.893 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 88.4 mt-30 -72.73 136.6 45.57 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.462 -179.94 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 8.5 tp-100 -63.15 -40.5 97.73 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.403 -179.792 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 13.4 m . . . . . 0 C--O 1.222 -0.354 0 CA-C-O 117.999 -1.0 . . . . 0.0 110.543 -179.983 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' B' B ' 201' ' ' SER . . . . . . . . . . . . . 22.0 t . . . . . 0 N--CA 1.49 1.538 0 N-CA-C 109.337 -0.616 . . . . 0.0 109.337 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' B' B ' 202' ' ' SER . . . . . . . . . . . . . 15.9 p -69.08 141.11 54.83 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.624 -179.828 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 203' ' ' SER . . . . . . . . . . . . . 1.8 m -89.54 152.04 46.74 Favored Pre-proline 0 CA--C 1.535 0.388 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.616 -179.625 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 204' ' ' PRO . . . . . . . . . . . . . 25.9 Cg_endo -60.67 -48.69 10.35 Favored 'Trans proline' 0 N--CA 1.496 1.664 0 C-N-CA 122.733 2.288 . . . . 0.0 111.744 -179.744 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 205' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -149.69 145.14 17.66 Favored 'Isoleucine or valine' 0 C--O 1.233 0.212 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.402 -179.893 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 206' ' ' GLN . . . . . . . . . . . . . 49.4 tt0 -138.54 139.46 38.7 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.374 178.894 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 207' ' ' GLY . . . . . . . . . . . . . . . -97.61 -133.66 7.97 Favored Glycine 0 N--CA 1.463 0.486 0 N-CA-C 110.957 -0.857 . . . . 0.0 110.957 180.0 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 208' ' ' SER . . . . . 0.536 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 98.9 p -164.52 168.35 18.41 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.862 0.363 . . . . 0.0 110.711 179.238 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 209' ' ' TRP . . . . . . . . . . . . . 85.4 m95 -88.89 150.95 22.63 Favored 'General case' 0 C--O 1.233 0.205 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.522 179.54 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 82.3 p -129.09 129.0 44.67 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-N 116.487 -0.324 . . . . 0.0 110.394 179.532 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 58.7 t-105 -91.41 110.62 21.93 Favored 'General case' 0 C--N 1.333 -0.112 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.586 179.82 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 212' ' ' GLU . . . . . 0.437 ' O ' ' O ' ' B' ' 215' ' ' LYS . 0.6 OUTLIER -161.26 165.93 28.45 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.541 179.654 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' B' B ' 213' ' ' ASN . . . . . . . . . . . . . 69.7 m-20 51.02 35.25 12.33 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.89 -0.595 . . . . 0.0 110.978 176.436 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 51.17 19.97 4.35 Favored Glycine 0 CA--C 1.525 0.661 0 N-CA-C 110.954 -0.858 . . . . 0.0 110.954 179.946 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 215' ' ' LYS . . . . . 0.754 ' HZ1' HD23 ' A' ' 80' ' ' LEU . 14.9 mtpt -145.79 150.58 36.46 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 121.066 0.46 . . . . 0.0 110.985 179.983 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 216' ' ' TRP . . . . . . . . . . . . . 52.4 m95 -87.19 114.43 23.79 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.866 -0.606 . . . . 0.0 109.883 179.233 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 217' ' ' THR . . . . . . . . . . . . . 46.4 m -118.36 135.07 54.54 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.694 -179.587 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 218' ' ' TRP . . . . . 0.536 ' CH2' ' N ' ' B' ' 208' ' ' SER . 29.5 t-105 -106.39 104.0 13.59 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 115.907 -0.588 . . . . 0.0 109.876 178.868 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 16.7 mtpp -134.38 173.8 11.23 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.558 -179.303 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -179.53 -160.94 26.05 Favored Glycine 0 CA--C 1.524 0.599 0 N-CA-C 110.761 -0.936 . . . . 0.0 110.761 179.819 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 221' ' ' ILE . . . . . 0.688 ' H ' HD12 ' B' ' 221' ' ' ILE . 1.9 mp -54.1 -73.14 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 C-N-CA 120.66 -0.416 . . . . 0.0 110.261 -178.804 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 222' ' ' ILE . . . . . 0.553 HG23 ' O ' ' B' ' 221' ' ' ILE . 21.8 pt -160.51 -165.28 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.212 -179.799 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 223' ' ' ARG . . . . . 0.536 ' O ' ' O ' ' B' ' 222' ' ' ILE . 35.9 ptt-85 -40.28 174.03 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.973 178.605 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 224' ' ' LEU . . . . . 0.789 ' N ' HD22 ' B' ' 224' ' ' LEU . 2.2 mm? -63.45 110.16 1.86 Allowed 'General case' 0 N--CA 1.447 -0.613 0 CA-C-N 115.799 -0.637 . . . . 0.0 111.079 -179.673 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 33.8 tp10 -95.83 148.52 22.51 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.394 -0.821 . . . . 0.0 110.002 -179.865 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 226' ' ' GLN . . . . . . . . . . . . . 15.7 tt0 . . . . . 0 C--O 1.22 -0.482 0 CA-C-O 118.076 -0.964 . . . . 0.0 110.749 -179.873 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.306 0 N-CA-C 109.536 -1.426 . . . . 0.0 109.536 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 34.7 t -66.64 140.74 57.94 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.736 0.303 . . . . 0.0 110.549 179.977 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 42.4 tt0 -75.06 148.39 39.84 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.328 179.875 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.0 m -129.22 81.29 70.77 Favored Pre-proline 0 N--CA 1.464 0.264 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.243 -179.966 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_exo -56.46 140.99 90.18 Favored 'Trans proline' 0 N--CA 1.495 1.581 0 C-N-CA 122.426 2.084 . . . . 0.0 111.605 -179.97 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 26.1 mt-30 -108.97 123.31 48.91 Favored 'General case' 0 CA--C 1.52 -0.2 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.33 -179.875 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 55.3 tp -84.8 108.04 17.27 Favored 'General case' 0 C--N 1.33 -0.26 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 179.546 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . 0.646 HG21 ' HB ' ' A' ' 27' ' ' THR . 7.1 t -103.79 173.48 6.29 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.949 -0.569 . . . . 0.0 109.939 179.908 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . 0.406 ' OD1' ' O ' ' A' ' 10' ' ' THR . 97.7 m-20 -138.04 163.76 30.78 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.254 179.994 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 56.5 tp -66.27 138.35 57.59 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.562 -179.969 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 16.1 p -139.6 152.93 47.22 Favored 'General case' 0 N--CA 1.463 0.192 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.384 179.555 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . 0.516 ' N ' ' CD1' ' A' ' 14' ' ' PHE . 27.7 m-85 -111.54 144.12 41.29 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.837 -179.407 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 27.6 m -143.49 164.29 15.52 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.415 179.527 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 98.8 m-20 50.37 30.46 4.55 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.95 179.79 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 96.7 mt -55.78 138.51 16.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-O 120.921 0.391 . . . . 0.0 110.202 179.507 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.464 ' CB ' ' O ' ' A' ' 21' ' ' SER . 0.2 OUTLIER -135.7 -166.75 1.91 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.034 -179.48 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . 0.469 ' N ' ' OD1' ' A' ' 19' ' ' ASP . 27.8 p-10 -84.94 -46.58 11.11 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.831 179.489 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . 0.464 ' N ' ' OD1' ' A' ' 19' ' ' ASP . 43.0 m -120.74 12.56 11.41 Favored 'General case' 0 N--CA 1.467 0.389 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.852 179.99 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . 0.464 ' O ' ' CB ' ' A' ' 18' ' ' THR . 85.9 p -150.26 143.55 25.01 Favored 'General case' 0 N--CA 1.465 0.283 0 CA-C-O 121.037 0.446 . . . . 0.0 110.335 -179.943 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 40.7 pt -140.46 145.0 26.47 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.361 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.217 -179.992 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -96.31 85.85 0.89 Allowed Glycine 0 CA--C 1.522 0.497 0 N-CA-C 110.882 -0.887 . . . . 0.0 110.882 -179.906 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 89.9 mt -62.3 121.02 12.12 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 120.905 0.383 . . . . 0.0 110.05 -179.782 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . 0.503 ' NH1' ' O ' ' A' ' 26' ' ' TRP . 28.0 tpt85 -138.03 135.25 35.71 Favored 'General case' 0 CA--C 1.517 -0.301 0 CA-C-O 121.115 0.483 . . . . 0.0 110.199 -179.468 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' TRP . . . . . 0.503 ' O ' ' NH1' ' A' ' 25' ' ' ARG . 46.1 p90 -147.52 155.45 41.88 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.555 -0.748 . . . . 0.0 109.604 179.851 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . 0.646 ' HB ' HG21 ' A' ' 10' ' ' THR . 6.2 m -111.34 98.12 38.62 Favored Pre-proline 0 C--N 1.33 -0.249 0 N-CA-C 110.102 -0.332 . . . . 0.0 110.102 179.66 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 32.5 Cg_exo -54.53 144.81 61.31 Favored 'Trans proline' 0 C--N 1.306 -1.692 0 C-N-CA 121.604 1.536 . . . . 0.0 113.275 179.909 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 57.1 mt -79.01 138.16 37.9 Favored 'General case' 0 CA--C 1.506 -0.743 0 CA-C-N 115.49 -0.777 . . . . 0.0 110.627 -179.567 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 34.1 t30 -50.45 -34.21 23.93 Favored 'General case' 0 C--N 1.313 -1.021 0 CA-C-N 114.856 -1.066 . . . . 0.0 110.098 179.523 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 49.2 m -79.82 -32.58 40.7 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.629 -0.714 . . . . 0.0 110.412 179.118 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 8.0 m -60.0 137.7 58.02 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.197 -179.932 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . 0.611 ' CB ' ' H ' ' A' ' 82' ' ' ASN . 11.7 m -67.41 143.1 56.47 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.22 -179.645 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 28.8 mm -94.05 94.04 4.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 121.0 0.429 . . . . 0.0 110.176 -179.564 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 10.7 pt -143.49 131.4 18.67 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.274 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.416 -179.973 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -41.84 118.23 1.46 Allowed Glycine 0 CA--C 1.519 0.328 0 N-CA-C 111.318 -0.713 . . . . 0.0 111.318 -179.599 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 94.6 m-85 -85.09 178.88 7.39 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.875 0.369 . . . . 0.0 110.11 179.376 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . 0.549 ' NE ' ' OE1' ' A' ' 52' ' ' GLU . 0.0 OUTLIER -132.48 125.99 31.95 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.727 179.92 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.46 ' CD1' ' CD2' ' A' ' 62' ' ' TYR . 2.5 pt -100.24 123.81 53.35 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 115.657 -0.701 . . . . 0.0 110.018 179.78 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . 0.449 ' OG1' ' NE ' ' A' ' 38' ' ' ARG . 28.2 m -109.04 133.09 53.46 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.612 -179.07 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.2 p -130.51 138.44 53.74 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.305 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.288 179.844 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . 0.467 ' O ' ' N ' ' A' ' 74' ' ' ASP . 31.7 t -131.94 130.95 61.69 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.269 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 179.979 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.455 ' HB1' ' CE1' ' A' ' 73' ' ' TYR . . . -96.44 135.87 37.73 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.765 -0.652 . . . . 0.0 109.32 179.677 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.607 ' HB3' ' O ' ' A' ' 72' ' ' ASP . . . -92.57 -47.24 7.22 Favored 'General case' 0 N--CA 1.464 0.24 0 C-N-CA 120.673 -0.411 . . . . 0.0 110.839 179.93 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -62.09 -29.55 73.09 Favored Glycine 0 N--CA 1.464 0.559 0 N-CA-C 110.891 -0.883 . . . . 0.0 110.891 179.997 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . 0.429 ' OE2' ' OH ' ' A' ' 73' ' ' TYR . 84.8 mt-10 -95.57 130.44 42.43 Favored 'General case' 0 C--N 1.328 -0.369 0 N-CA-C 109.477 -0.564 . . . . 0.0 109.477 -179.552 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -58.18 -21.17 45.98 Favored Glycine 0 CA--C 1.528 0.869 0 N-CA-C 110.857 -0.897 . . . . 0.0 110.857 -178.941 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -119.25 136.32 24.42 Favored Pre-proline 0 N--CA 1.472 0.661 0 CA-C-N 116.715 0.258 . . . . 0.0 110.543 179.676 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -77.9 167.5 23.63 Favored 'Trans proline' 0 N--CA 1.49 1.295 0 C-N-CA 122.409 2.072 . . . . 0.0 111.428 178.079 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 87.2 mt -86.22 141.66 14.14 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.235 0 CA-C-O 120.826 0.346 . . . . 0.0 110.245 179.081 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 76.3 m-85 -60.85 138.95 58.09 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.633 179.986 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . 0.549 ' OE1' ' NE ' ' A' ' 38' ' ' ARG . 5.9 pt-20 -69.64 -178.62 1.51 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.455 179.798 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 4.5 t70 -153.38 148.7 27.02 Favored 'General case' 0 N--CA 1.45 -0.444 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.748 179.367 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 58.0 m-85 -115.93 125.28 52.36 Favored 'General case' 0 N--CA 1.464 0.257 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.139 -179.929 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.9 p -125.64 134.49 66.56 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.341 0 CA-C-N 116.471 -0.331 . . . . 0.0 110.208 -179.985 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 98.9 m-20 -53.41 140.15 28.46 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.322 -179.653 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 10.4 t -60.4 -34.16 73.54 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.002 -0.544 . . . . 0.0 110.573 -179.763 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 43.7 m -55.24 -34.34 63.91 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.547 -179.731 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 99.9 t -62.31 -46.51 96.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.579 -179.871 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 61.25 26.38 65.98 Favored Glycine 0 CA--C 1.527 0.796 0 N-CA-C 110.568 -1.013 . . . . 0.0 110.568 179.635 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 52.6 t80 -167.44 152.03 6.89 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 121.121 0.486 . . . . 0.0 111.091 -179.513 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' TYR . . . . . 0.46 ' CD2' ' CD1' ' A' ' 39' ' ' ILE . 29.1 t80 -159.64 162.05 35.11 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 115.724 -0.671 . . . . 0.0 110.281 178.702 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 99.0 m -127.44 134.68 49.84 Favored 'General case' 0 N--CA 1.463 0.217 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.296 179.835 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -130.76 113.83 25.9 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.334 0 N-CA-C 109.513 -0.551 . . . . 0.0 109.513 178.877 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 1.9 p -122.93 157.33 32.84 Favored 'General case' 0 N--CA 1.467 0.418 0 CA-C-O 120.907 0.384 . . . . 0.0 110.413 -179.66 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 107.59 40.62 1.72 Allowed Glycine 0 CA--C 1.523 0.581 0 N-CA-C 110.628 -0.989 . . . . 0.0 110.628 -179.729 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 1.4 mt -116.79 110.83 18.9 Favored 'General case' 0 N--CA 1.465 0.304 0 N-CA-C 109.502 -0.555 . . . . 0.0 109.502 -179.896 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 27.6 mm-40 -48.84 141.34 10.27 Favored Pre-proline 0 C--N 1.322 -0.628 0 C-N-CA 120.862 -0.335 . . . . 0.0 111.249 -178.486 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 91.4 Cg_endo -74.89 158.37 42.66 Favored 'Trans proline' 0 N--CA 1.491 1.341 0 C-N-CA 122.481 2.121 . . . . 0.0 112.558 179.511 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . 0.409 ' N ' ' NH2' ' B' ' 223' ' ' ARG . . . 48.53 27.55 6.01 Favored Glycine 0 CA--C 1.529 0.951 0 CA-C-N 114.837 -1.074 . . . . 0.0 111.182 179.305 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . 0.736 ' H ' HH21 ' B' ' 223' ' ' ARG . 0.9 OUTLIER -114.0 166.36 7.93 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.483 0 CA-C-O 121.13 0.491 . . . . 0.0 109.698 -179.578 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 72' ' ' ASP . . . . . 0.607 ' O ' ' HB3' ' A' ' 44' ' ' ALA . 3.2 t70 -101.17 100.27 10.8 Favored 'General case' 0 N--CA 1.446 -0.649 0 CA-C-N 115.6 -0.727 . . . . 0.0 111.411 -178.715 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 73' ' ' TYR . . . . . 0.503 ' O ' HD13 ' A' ' 75' ' ' ILE . 2.2 m-30 -110.81 124.69 52.51 Favored 'General case' 0 C--O 1.22 -0.472 0 CA-C-O 121.322 0.582 . . . . 0.0 110.341 179.16 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 74' ' ' ASP . . . . . 0.467 ' N ' ' O ' ' A' ' 42' ' ' VAL . 21.5 m-20 -89.11 116.11 27.13 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 114.894 -1.048 . . . . 0.0 109.485 -179.909 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.578 HD11 ' N ' ' B' ' 223' ' ' ARG . 0.0 OUTLIER -116.17 162.1 14.43 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.221 0 CA-C-O 121.219 0.533 . . . . 0.0 110.084 -179.383 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 3.0 m -154.04 150.69 28.51 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.259 -0.882 . . . . 0.0 110.755 179.502 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.511 HG13 ' O ' ' A' ' 77' ' ' VAL . 4.1 p -132.9 101.14 4.2 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.245 0 CA-C-N 115.824 -0.625 . . . . 0.0 109.398 178.421 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 94.6 mt -82.95 127.81 39.32 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.183 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.451 -179.522 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 5.0 p -108.21 105.89 15.82 Favored 'General case' 0 N--CA 1.464 0.251 0 CA-C-N 116.143 -0.481 . . . . 0.0 109.709 179.422 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 7.0 tp -121.68 130.59 53.57 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.353 -179.867 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 81' ' ' ILE . . . . . 0.581 ' O ' HD12 ' A' ' 81' ' ' ILE . 1.6 pp -131.3 168.37 24.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.098 -0.501 . . . . 0.0 109.908 179.136 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 82' ' ' ASN . . . . . 0.611 ' H ' ' CB ' ' A' ' 33' ' ' THR . 9.8 t-20 -64.53 -43.03 95.31 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.813 0.34 . . . . 0.0 110.634 -179.992 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 157.8 115.85 0.46 Allowed Glycine 0 CA--C 1.526 0.753 0 N-CA-C 111.277 -0.729 . . . . 0.0 111.277 179.864 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -97.01 -174.6 34.75 Favored Glycine 0 CA--C 1.526 0.763 0 N-CA-C 110.85 -0.9 . . . . 0.0 110.85 179.74 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 16.6 pt-20 -75.52 132.38 40.7 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.845 0.355 . . . . 0.0 110.414 179.934 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . 0.589 ' O ' ' HB2' ' A' ' 87' ' ' ALA . 90.3 p -81.4 164.25 22.23 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.34 179.914 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.589 ' HB2' ' O ' ' A' ' 86' ' ' SER . . . 169.02 154.0 0.15 Allowed Pre-proline 0 CA--C 1.534 0.359 0 CA-C-N 116.401 -0.363 . . . . 0.0 110.418 179.617 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 43.4 Cg_endo -67.04 151.8 81.27 Favored 'Trans proline' 0 N--CA 1.495 1.608 0 C-N-CA 122.72 2.28 . . . . 0.0 111.656 179.791 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 71.8 m -81.72 121.68 26.7 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.271 179.942 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 38.2 p -144.72 163.04 35.21 Favored 'General case' 0 C--N 1.332 -0.163 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.304 -179.94 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . 0.567 ' N ' HD12 ' A' ' 91' ' ' LEU . 9.6 mp -89.9 128.95 36.31 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.394 -0.366 . . . . 0.0 110.081 179.914 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 42.1 p -89.61 135.35 33.66 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.46 179.99 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 14.1 pt20 -75.07 139.87 43.1 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.593 -180.0 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 97.7 mt-30 -85.23 61.47 6.89 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.519 179.989 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 88.5 m . . . . . 0 C--O 1.219 -0.504 0 CA-C-O 118.042 -0.98 . . . . 0.0 110.558 179.982 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' B' B ' 201' ' ' SER . . . . . . . . . . . . . 39.4 t . . . . . 0 N--CA 1.489 1.496 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' B' B ' 202' ' ' SER . . . . . . . . . . . . . 48.5 t -65.17 141.69 58.59 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.192 -0.458 . . . . 0.0 109.825 179.626 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 203' ' ' SER . . . . . . . . . . . . . 27.6 p -123.83 108.24 30.71 Favored Pre-proline 0 CA--C 1.54 0.593 0 N-CA-C 110.067 -0.346 . . . . 0.0 110.067 179.795 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 204' ' ' PRO . . . . . . . . . . . . . 58.6 Cg_endo -76.73 -56.82 0.05 OUTLIER 'Trans proline' 0 N--CA 1.495 1.563 0 C-N-CA 121.729 1.619 . . . . 0.0 112.009 -179.758 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 205' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -150.17 144.69 17.41 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.3 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.107 -179.995 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 206' ' ' GLN . . . . . 0.437 ' OE1' ' N ' ' B' ' 206' ' ' GLN . 5.7 pm0 -146.38 145.28 30.22 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.999 -0.546 . . . . 0.0 109.795 179.572 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 207' ' ' GLY . . . . . . . . . . . . . . . -109.31 -131.9 6.36 Favored Glycine 0 N--CA 1.464 0.536 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 -179.793 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 208' ' ' SER . . . . . 0.497 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 97.1 p -164.14 170.03 16.96 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.81 0.338 . . . . 0.0 110.741 179.636 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 209' ' ' TRP . . . . . . . . . . . . . 71.9 m95 -82.93 145.59 29.3 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.412 179.529 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 40.3 p -127.33 131.29 50.45 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.565 179.942 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 41.4 t-105 -91.68 118.58 30.78 Favored 'General case' 0 N--CA 1.466 0.366 0 CA-C-N 116.18 -0.463 . . . . 0.0 109.928 179.596 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 212' ' ' GLU . . . . . 0.487 ' O ' ' O ' ' B' ' 215' ' ' LYS . 1.9 pt-20 -165.75 171.61 12.71 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.898 178.893 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 213' ' ' ASN . . . . . . . . . . . . . 93.9 m-20 48.07 38.08 8.99 Favored 'General case' 0 C--N 1.324 -0.537 0 C-N-CA 120.338 -0.545 . . . . 0.0 111.997 176.629 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 51.34 12.46 0.91 Allowed Glycine 0 CA--C 1.53 0.974 0 N-CA-C 111.536 -0.626 . . . . 0.0 111.536 179.644 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 215' ' ' LYS . . . . . 0.487 ' O ' ' O ' ' B' ' 212' ' ' GLU . 7.5 mtmp? -143.95 151.37 39.68 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.849 0.357 . . . . 0.0 110.962 -179.778 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 216' ' ' TRP . . . . . . . . . . . . . 49.0 m95 -87.0 124.93 33.72 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.25 179.285 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 217' ' ' THR . . . . . . . . . . . . . 5.0 m -138.63 148.1 43.69 Favored 'General case' 0 C--O 1.235 0.293 0 CA-C-O 121.052 0.453 . . . . 0.0 110.341 -179.809 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 218' ' ' TRP . . . . . 0.497 ' CH2' ' N ' ' B' ' 208' ' ' SER . 15.5 t-105 -105.25 121.66 44.32 Favored 'General case' 0 C--N 1.332 -0.167 0 CA-C-N 115.894 -0.593 . . . . 0.0 110.156 179.797 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 97.5 mttt -147.17 169.56 19.07 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.899 -179.996 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -174.83 -162.22 25.94 Favored Glycine 0 CA--C 1.522 0.496 0 N-CA-C 111.155 -0.778 . . . . 0.0 111.155 -179.884 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 221' ' ' ILE . . . . . 0.837 HG23 ' H ' ' B' ' 222' ' ' ILE . 12.2 tt -50.35 -69.71 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 C-N-CA 121.073 -0.251 . . . . 0.0 110.971 -177.977 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 222' ' ' ILE . . . . . 0.837 ' H ' HG23 ' B' ' 221' ' ' ILE . 9.6 pt -159.55 -165.2 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.317 -0.83 0 N-CA-C 109.327 -0.62 . . . . 0.0 109.327 178.377 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 223' ' ' ARG . . . . . 0.736 HH21 ' H ' ' A' ' 71' ' ' ILE . 39.1 ptt85 -44.47 174.98 0.0 OUTLIER 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 121.445 0.641 . . . . 0.0 111.04 178.717 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 224' ' ' LEU . . . . . 0.686 ' N ' HD22 ' B' ' 224' ' ' LEU . 3.2 mm? -59.95 127.48 32.1 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-N 115.046 -0.979 . . . . 0.0 110.377 -179.737 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 31.0 tp10 -83.03 150.56 26.27 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.738 -0.665 . . . . 0.0 110.155 -179.959 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 226' ' ' GLN . . . . . . . . . . . . . 54.1 tt0 . . . . . 0 C--N 1.326 -0.455 0 CA-C-O 117.891 -1.052 . . . . 0.0 110.625 -179.72 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.24 0 N-CA-C 109.525 -1.43 . . . . 0.0 109.525 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 59.9 p -79.5 80.53 5.87 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.842 0.353 . . . . 0.0 110.357 179.845 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 72.0 mm-40 -86.18 85.39 7.35 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.26 179.782 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.442 HG22 ' H ' ' A' ' 6' ' ' VAL . 3.3 m -86.57 149.18 48.27 Favored Pre-proline 0 CA--C 1.532 0.283 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.516 -179.732 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -66.7 145.47 75.69 Favored 'Trans proline' 0 N--CA 1.494 1.536 0 C-N-CA 122.517 2.145 . . . . 0.0 111.907 179.598 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 2.9 pt20 -137.55 130.66 30.57 Favored 'General case' 0 N--CA 1.463 0.193 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.146 179.459 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -103.71 125.07 49.95 Favored 'General case' 0 C--N 1.33 -0.25 0 N-CA-C 109.619 -0.512 . . . . 0.0 109.619 -179.848 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 55.3 p -130.97 154.77 47.8 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 121.026 0.441 . . . . 0.0 110.25 179.355 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 99.4 m-20 -84.8 171.16 12.5 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.385 -179.986 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.551 HD13 ' H ' ' A' ' 13' ' ' SER . 0.1 OUTLIER -60.85 139.0 58.09 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.152 -178.16 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . 0.551 ' H ' HD13 ' A' ' 12' ' ' LEU . 96.3 p -143.27 144.55 32.17 Favored 'General case' 0 CA--C 1.521 -0.168 0 CA-C-N 115.837 -0.62 . . . . 0.0 110.621 179.931 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . 0.517 ' CD1' HD13 ' B' ' 205' ' ' ILE . 11.5 m-85 -112.34 143.77 42.89 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.397 -0.82 . . . . 0.0 110.754 -179.22 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 30.1 m -141.27 164.28 20.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.346 179.712 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 27.7 t70 53.63 34.22 18.24 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.08 179.849 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.49 HD12 ' N ' ' A' ' 17' ' ' ILE . 1.9 mp -56.51 132.06 20.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 N-CA-C 109.57 -0.53 . . . . 0.0 109.57 179.936 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -132.8 -169.13 2.19 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-N 116.021 -0.536 . . . . 0.0 109.916 179.711 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 20.7 p-10 -91.24 -41.84 10.74 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.698 179.388 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 43.1 t -113.52 6.44 17.07 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-N 116.363 -0.38 . . . . 0.0 110.99 -179.304 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . 0.432 ' OG ' HG22 ' A' ' 65' ' ' THR . 38.3 t -154.1 152.61 30.64 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 121.131 0.491 . . . . 0.0 110.202 179.971 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 38.2 pt -142.2 146.26 22.76 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.049 179.816 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -94.75 82.82 0.92 Allowed Glycine 0 CA--C 1.524 0.652 0 N-CA-C 111.076 -0.81 . . . . 0.0 111.076 -179.723 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 76.1 mt -71.14 118.33 13.8 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 121.043 0.449 . . . . 0.0 110.211 179.901 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 56.4 ttt-85 -140.83 137.03 32.98 Favored 'General case' 0 CA--C 1.517 -0.318 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.436 179.935 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' TRP . . . . . . . . . . . . . 41.3 p90 -144.5 156.56 44.23 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.624 -0.716 . . . . 0.0 110.278 -179.36 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 2.2 m -108.05 102.31 45.35 Favored Pre-proline 0 CA--C 1.533 0.302 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.676 -179.953 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 41.7 Cg_exo -53.8 150.04 30.99 Favored 'Trans proline' 0 C--N 1.305 -1.761 0 C-N-CA 121.464 1.443 . . . . 0.0 112.673 179.274 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 60.9 mt -92.3 137.9 31.97 Favored 'General case' 0 CA--C 1.514 -0.425 0 CA-C-O 121.811 0.815 . . . . 0.0 110.809 -179.764 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 28.8 t-20 -47.56 -35.44 9.05 Favored 'General case' 0 C--N 1.313 -1.007 0 CA-C-N 115.056 -0.974 . . . . 0.0 110.092 179.952 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 53.0 m -79.8 -33.72 40.24 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.438 178.847 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 6.0 m -58.36 124.27 18.94 Favored 'General case' 0 CA--C 1.529 0.146 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.055 -179.86 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . 0.587 ' CB ' ' H ' ' A' ' 82' ' ' ASN . 5.6 m -57.22 146.57 27.85 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.102 -179.762 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 20.5 mm -94.37 91.37 3.08 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.173 0 CA-C-O 121.047 0.451 . . . . 0.0 110.765 -179.377 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.486 HD11 ' HA ' ' A' ' 81' ' ' ILE . 22.1 pt -145.21 128.76 11.51 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.244 0 CA-C-N 115.714 -0.675 . . . . 0.0 110.597 179.815 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -42.65 125.84 4.44 Favored Glycine 0 CA--C 1.523 0.572 0 N-CA-C 111.086 -0.805 . . . . 0.0 111.086 -179.512 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 35.9 m-85 -90.83 -179.9 5.62 Favored 'General case' 0 CA--C 1.517 -0.29 0 N-CA-C 110.024 -0.362 . . . . 0.0 110.024 -179.88 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -131.45 121.34 24.37 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.553 179.753 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.439 ' CG1' ' O ' ' A' ' 39' ' ' ILE . 2.3 pt -95.95 124.29 48.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.008 -0.542 . . . . 0.0 109.716 179.828 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 4.8 m -106.74 132.77 52.33 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.398 -179.361 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.4 p -130.07 137.75 55.69 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.319 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.287 -179.979 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . 0.524 ' O ' ' N ' ' A' ' 74' ' ' ASP . 40.1 t -131.02 131.65 63.95 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.298 0 N-CA-C 109.743 -0.465 . . . . 0.0 109.743 179.671 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -97.92 141.26 31.11 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.137 -0.483 . . . . 0.0 109.817 179.273 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.565 ' HB3' ' O ' ' A' ' 72' ' ' ASP . . . -100.29 -23.68 14.73 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-O 120.828 0.347 . . . . 0.0 110.672 179.874 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -90.88 31.06 5.78 Favored Glycine 0 N--CA 1.466 0.636 0 N-CA-C 110.776 -0.93 . . . . 0.0 110.776 -179.963 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 64.2 mt-10 -151.8 150.8 30.55 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.951 0.405 . . . . 0.0 110.649 -179.738 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -72.1 -17.67 77.39 Favored Glycine 0 CA--C 1.524 0.62 0 N-CA-C 110.781 -0.928 . . . . 0.0 110.781 179.633 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -133.94 139.04 32.14 Favored Pre-proline 0 CA--C 1.544 0.738 0 CA-C-N 116.772 0.286 . . . . 0.0 110.507 -179.978 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 68.4 Cg_endo -73.89 161.84 40.54 Favored 'Trans proline' 0 N--CA 1.494 1.558 0 C-N-CA 122.631 2.221 . . . . 0.0 111.949 178.31 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . 0.492 HG22 ' N ' ' A' ' 51' ' ' PHE . 96.3 mt -75.72 159.26 5.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.381 179.419 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' PHE . . . . . 0.492 ' N ' HG22 ' A' ' 50' ' ' ILE . 0.9 OUTLIER -78.32 142.21 37.9 Favored 'General case' 0 CA--C 1.531 0.24 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.727 179.871 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . 0.51 ' H ' ' CD ' ' A' ' 52' ' ' GLU . 0.0 OUTLIER -71.01 -178.48 1.97 Allowed 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.39 179.433 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . 0.428 ' OD1' ' OH ' ' A' ' 62' ' ' TYR . 0.2 OUTLIER -148.27 139.74 23.56 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.147 179.75 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 96.2 m-85 -109.32 123.58 49.53 Favored 'General case' 0 N--CA 1.464 0.241 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.478 -179.94 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 5.9 p -131.48 141.29 46.2 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.245 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.215 -179.976 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 84.9 m-20 -58.92 151.03 22.71 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.591 -179.777 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . 0.478 ' OG ' ' O ' ' A' ' 35' ' ' ILE . 3.7 m -61.66 -34.48 75.78 Favored 'General case' 0 C--O 1.233 0.22 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.84 179.839 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 69.2 m -53.5 -34.59 58.63 Favored 'General case' 0 C--N 1.326 -0.444 0 N-CA-C 109.943 -0.392 . . . . 0.0 109.943 -179.661 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.672 ' C ' ' H ' ' A' ' 61' ' ' TYR . 4.1 t -83.19 76.06 1.09 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.859 -179.826 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -58.72 26.53 0.02 OUTLIER Glycine 0 CA--C 1.539 1.589 0 N-CA-C 111.549 -0.62 . . . . 0.0 111.549 -179.641 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . 0.672 ' H ' ' C ' ' A' ' 59' ' ' VAL . 35.8 p90 -160.69 150.58 17.61 Favored 'General case' 0 N--CA 1.453 -0.325 0 CA-C-O 121.125 0.488 . . . . 0.0 111.6 179.986 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 62' ' ' TYR . . . . . 0.428 ' OH ' ' OD1' ' A' ' 53' ' ' ASP . 37.1 t80 -153.6 147.85 25.83 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.688 -0.687 . . . . 0.0 109.583 179.093 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 29.8 m -108.74 132.63 53.76 Favored 'General case' 0 N--CA 1.464 0.235 0 CA-C-O 121.037 0.446 . . . . 0.0 110.563 -179.31 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -132.03 106.16 10.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 115.924 -0.58 . . . . 0.0 109.723 178.662 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.432 HG22 ' OG ' ' A' ' 21' ' ' SER . 2.6 p -114.55 162.06 17.22 Favored 'General case' 0 N--CA 1.465 0.283 0 CA-C-O 120.978 0.418 . . . . 0.0 110.543 179.95 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 108.58 41.07 1.52 Allowed Glycine 0 CA--C 1.524 0.655 0 N-CA-C 111.256 -0.737 . . . . 0.0 111.256 -179.942 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 14.3 mt -115.2 109.07 17.45 Favored 'General case' 0 N--CA 1.466 0.353 0 N-CA-C 109.211 -0.662 . . . . 0.0 109.211 179.456 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 33.6 mm-40 -60.11 140.83 90.74 Favored Pre-proline 0 C--N 1.321 -0.642 0 C-N-CA 120.623 -0.431 . . . . 0.0 111.788 -178.403 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 93.8 Cg_endo -74.63 155.74 44.74 Favored 'Trans proline' 0 N--CA 1.497 1.682 0 C-N-CA 122.686 2.258 . . . . 0.0 111.73 178.802 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 71.61 7.55 65.15 Favored Glycine 0 CA--C 1.525 0.694 0 CA-C-N 115.635 -0.711 . . . . 0.0 111.629 179.128 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 1.6 mp -116.18 144.0 24.9 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.469 0 CA-C-O 121.441 0.639 . . . . 0.0 109.463 -179.934 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 72' ' ' ASP . . . . . 0.565 ' O ' ' HB3' ' A' ' 44' ' ' ALA . 2.1 t70 -84.73 114.18 21.86 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.143 -0.935 . . . . 0.0 110.869 179.943 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 73' ' ' TYR . . . . . 0.467 ' O ' HD13 ' A' ' 75' ' ' ILE . 23.7 m-85 -106.53 122.16 45.74 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 121.251 0.548 . . . . 0.0 110.306 179.849 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 74' ' ' ASP . . . . . 0.524 ' N ' ' O ' ' A' ' 42' ' ' VAL . 11.7 m-20 -91.42 117.5 29.74 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.209 -0.905 . . . . 0.0 109.432 179.625 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.556 HD11 ' N ' ' B' ' 223' ' ' ARG . 0.0 OUTLIER -115.27 165.92 9.85 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.422 0 CA-C-O 120.957 0.408 . . . . 0.0 110.267 -179.045 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -154.84 121.94 5.56 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.391 179.208 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.467 ' O ' HG23 ' B' ' 217' ' ' THR . 63.1 t -101.1 102.6 13.68 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 N-CA-C 109.335 -0.617 . . . . 0.0 109.335 179.011 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 95.9 mt -93.64 131.05 41.69 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.229 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.571 -179.591 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 71.3 m -109.28 111.27 22.75 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.078 -0.51 . . . . 0.0 109.917 179.391 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 37.6 tp -116.47 120.72 39.69 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.496 179.915 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 81' ' ' ILE . . . . . 0.707 ' O ' HD12 ' A' ' 81' ' ' ILE . 2.8 pp -142.68 153.97 17.65 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.278 179.397 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 82' ' ' ASN . . . . . 0.587 ' H ' ' CB ' ' A' ' 33' ' ' THR . 14.3 t-20 -65.69 -44.17 87.01 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 121.028 0.442 . . . . 0.0 110.932 179.963 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 90.14 158.23 34.24 Favored Glycine 0 CA--C 1.524 0.647 0 N-CA-C 111.0 -0.84 . . . . 0.0 111.0 179.761 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -81.63 156.74 37.18 Favored Glycine 0 CA--C 1.523 0.533 0 N-CA-C 110.757 -0.937 . . . . 0.0 110.757 179.868 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -88.88 137.6 32.17 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.822 0.344 . . . . 0.0 110.412 179.86 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 45.0 t -65.68 147.76 52.86 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.444 179.952 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.553 ' HB1' ' HD2' ' A' ' 88' ' ' PRO . . . -155.05 162.33 27.46 Favored Pre-proline 0 CA--C 1.534 0.35 0 CA-C-N 116.449 -0.341 . . . . 0.0 110.332 179.995 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . 0.553 ' HD2' ' HB1' ' A' ' 87' ' ' ALA . 56.8 Cg_endo -71.12 113.58 3.63 Favored 'Trans proline' 0 N--CA 1.494 1.523 0 C-N-CA 122.5 2.133 . . . . 0.0 111.705 179.494 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 29.8 m -142.13 147.55 36.86 Favored 'General case' 0 N--CA 1.464 0.235 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.387 179.843 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 12.9 p -85.91 -175.42 5.57 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.324 179.979 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 44.3 tp -57.58 125.4 22.74 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.293 -179.528 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 69.3 p -84.27 166.75 17.22 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.407 179.975 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 88.6 mt-30 -57.29 103.01 0.1 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.583 -179.856 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 65.0 tt0 -152.21 124.01 7.95 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.442 179.946 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 2.7 t . . . . . 0 C--O 1.219 -0.501 0 CA-C-O 118.008 -0.996 . . . . 0.0 110.598 179.883 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' B' B ' 201' ' ' SER . . . . . . . . . . . . . 30.7 t . . . . . 0 N--CA 1.491 1.577 0 N-CA-C 109.33 -0.618 . . . . 0.0 109.33 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' B' B ' 202' ' ' SER . . . . . . . . . . . . . 11.1 p -73.19 159.8 32.92 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.369 -179.816 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 203' ' ' SER . . . . . . . . . . . . . 1.4 p -89.73 152.59 47.05 Favored Pre-proline 0 CA--C 1.535 0.392 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.435 -179.692 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 204' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_endo -64.57 -6.81 12.88 Favored 'Trans proline' 0 N--CA 1.496 1.634 0 C-N-CA 122.702 2.268 . . . . 0.0 111.846 179.951 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 205' ' ' ILE . . . . . 0.721 HD12 HD12 ' B' ' 224' ' ' LEU . 18.2 tt -150.33 152.5 11.53 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.258 0 CA-C-O 121.114 0.483 . . . . 0.0 111.181 -179.972 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 206' ' ' GLN . . . . . . . . . . . . . 6.4 pt20 -178.37 76.4 0.02 OUTLIER 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.757 -0.656 . . . . 0.0 110.82 179.329 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 207' ' ' GLY . . . . . . . . . . . . . . . -108.44 -142.85 10.2 Favored Glycine 0 N--CA 1.464 0.501 0 N-CA-C 111.021 -0.831 . . . . 0.0 111.021 -179.776 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 208' ' ' SER . . . . . 0.531 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 98.7 p -165.17 170.9 14.37 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 120.706 0.288 . . . . 0.0 110.734 179.83 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 209' ' ' TRP . . . . . . . . . . . . . 72.2 m95 -87.58 131.43 34.4 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.315 179.607 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 68.8 p -110.15 133.39 53.27 Favored 'General case' 0 N--CA 1.465 0.313 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.405 -179.951 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 49.8 t-105 -94.93 118.36 31.68 Favored 'General case' 0 N--CA 1.463 0.199 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.059 179.795 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 212' ' ' GLU . . . . . 0.469 ' O ' ' O ' ' B' ' 215' ' ' LYS . 1.7 pt-20 -164.7 170.64 15.36 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.731 178.903 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 213' ' ' ASN . . . . . . . . . . . . . 13.8 m120 48.82 36.18 7.68 Favored 'General case' 0 C--N 1.323 -0.577 0 C-N-CA 120.321 -0.552 . . . . 0.0 111.615 175.951 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 51.88 13.82 1.64 Allowed Glycine 0 CA--C 1.529 0.94 0 N-CA-C 111.536 -0.626 . . . . 0.0 111.536 179.676 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 215' ' ' LYS . . . . . 0.469 ' O ' ' O ' ' B' ' 212' ' ' GLU . 67.5 mttm -143.09 150.87 40.1 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-O 121.082 0.468 . . . . 0.0 110.625 179.875 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 216' ' ' TRP . . . . . . . . . . . . . 64.4 m95 -84.82 118.03 24.23 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.013 179.856 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 217' ' ' THR . . . . . 0.467 HG23 ' O ' ' A' ' 77' ' ' VAL . 19.3 m -127.5 139.86 52.52 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-O 121.197 0.522 . . . . 0.0 110.452 -179.393 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 218' ' ' TRP . . . . . 0.531 ' CH2' ' N ' ' B' ' 208' ' ' SER . 19.7 t-105 -106.22 117.25 33.55 Favored 'General case' 0 C--O 1.231 0.1 0 CA-C-N 115.849 -0.614 . . . . 0.0 109.922 179.227 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 54.4 mtmt -143.71 172.07 13.33 Favored 'General case' 0 CA--C 1.516 -0.343 0 CA-C-O 120.989 0.423 . . . . 0.0 110.642 -179.748 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -176.42 -160.73 24.18 Favored Glycine 0 CA--C 1.525 0.669 0 C-N-CA 120.585 -0.817 . . . . 0.0 111.305 -179.727 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 221' ' ' ILE . . . . . 0.544 ' O ' HG23 ' B' ' 222' ' ' ILE . 20.2 mt -54.7 -73.65 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 C-N-CA 120.649 -0.42 . . . . 0.0 110.448 -178.046 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 222' ' ' ILE . . . . . 0.544 HG23 ' O ' ' B' ' 221' ' ' ILE . 21.7 pt -159.85 -165.08 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 N-CA-C 109.907 -0.405 . . . . 0.0 109.907 -179.761 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 223' ' ' ARG . . . . . 0.556 ' N ' HD11 ' A' ' 75' ' ' ILE . 37.0 ptt180 -40.9 172.13 0.0 OUTLIER 'General case' 0 N--CA 1.456 -0.174 0 CA-C-O 121.175 0.512 . . . . 0.0 110.923 178.89 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 224' ' ' LEU . . . . . 1.072 HD22 ' H ' ' B' ' 224' ' ' LEU . 0.4 OUTLIER -58.55 147.8 30.86 Favored 'General case' 0 C--N 1.318 -0.794 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.638 -179.091 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 23.5 tp10 -78.17 148.94 33.86 Favored 'General case' 0 CA--C 1.515 -0.392 0 CA-C-N 115.551 -0.75 . . . . 0.0 110.511 -178.858 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 226' ' ' GLN . . . . . . . . . . . . . 90.9 mm-40 . . . . . 0 C--O 1.219 -0.518 0 CA-C-O 118.029 -0.986 . . . . 0.0 110.461 -179.372 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . 0.427 ' O ' ' O ' ' A' ' 4' ' ' SER . . . . . . . . 0 N--CA 1.488 2.16 0 N-CA-C 109.456 -1.458 . . . . 0.0 109.456 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . 0.427 ' O ' ' O ' ' A' ' 3' ' ' GLY . 6.8 p 57.56 116.31 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.914 0.388 . . . . 0.0 110.491 -179.892 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -74.81 176.28 7.21 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.409 179.911 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.634 ' O ' HG13 ' A' ' 6' ' ' VAL . 7.4 p -125.03 82.68 61.25 Favored Pre-proline 0 N--CA 1.466 0.368 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.343 179.923 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_exo -56.71 162.49 8.48 Favored 'Trans proline' 0 N--CA 1.494 1.532 0 C-N-CA 122.594 2.196 . . . . 0.0 111.835 179.605 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 52.6 tp60 69.79 72.3 0.23 Allowed 'General case' 0 C--N 1.332 -0.155 0 CA-C-N 115.958 -0.565 . . . . 0.0 110.38 -179.739 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.567 ' N ' HD12 ' A' ' 9' ' ' LEU . 10.5 mp -90.45 130.64 36.5 Favored 'General case' 0 C--N 1.333 -0.133 0 CA-C-N 116.202 -0.454 . . . . 0.0 109.894 -179.991 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -123.8 120.96 34.15 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.266 -179.737 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . 0.421 ' HB2' ' HE1' ' B' ' 209' ' ' TRP . 55.2 p-10 -86.81 165.67 15.81 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.673 179.941 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 7.3 tt -65.1 150.9 47.32 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.444 -179.679 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . 0.417 ' O ' ' O ' ' A' ' 25' ' ' ARG . 18.1 p -139.85 157.53 45.56 Favored 'General case' 0 N--CA 1.463 0.204 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.385 179.696 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . 0.48 ' N ' ' CD1' ' A' ' 14' ' ' PHE . 31.5 m-85 -110.33 144.77 38.57 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.652 -179.325 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 16.7 m -145.69 156.62 12.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.294 179.402 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 98.8 m-20 55.75 35.93 26.28 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.64 -179.885 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 96.4 mt -61.12 139.07 20.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.31 179.816 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.473 ' CB ' ' O ' ' A' ' 21' ' ' SER . 0.2 OUTLIER -140.84 -167.33 2.34 Favored 'General case' 0 N--CA 1.469 0.494 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.194 -179.986 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . 0.496 ' OD1' ' N ' ' A' ' 20' ' ' SER . 30.9 p-10 -88.75 -43.54 11.2 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.819 179.384 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . 0.496 ' N ' ' OD1' ' A' ' 19' ' ' ASP . 4.4 t -116.41 6.73 13.68 Favored 'General case' 0 N--CA 1.466 0.353 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.976 -179.42 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . 0.473 ' O ' ' CB ' ' A' ' 18' ' ' THR . 16.4 p -150.57 140.3 21.74 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 121.257 0.551 . . . . 0.0 110.508 179.853 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 28.4 pt -139.65 144.13 29.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 N-CA-C 109.394 -0.595 . . . . 0.0 109.394 -179.868 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -106.4 91.33 0.72 Allowed Glycine 0 N--CA 1.466 0.637 0 N-CA-C 111.496 -0.642 . . . . 0.0 111.496 -179.323 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.466 ' N ' HD12 ' A' ' 24' ' ' LEU . 11.2 mp -69.63 130.55 42.69 Favored 'General case' 0 C--N 1.328 -0.354 0 C-N-CA 120.478 -0.489 . . . . 0.0 109.842 179.844 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . 0.417 ' O ' ' O ' ' A' ' 13' ' ' SER . 67.5 ttp85 -140.83 135.26 31.22 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.196 179.615 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' TRP . . . . . . . . . . . . . 48.3 p90 -143.51 156.47 44.63 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.988 -0.551 . . . . 0.0 109.983 179.719 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 4.4 m -109.54 101.11 44.9 Favored Pre-proline 0 CA--C 1.531 0.23 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.162 179.906 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 42.0 Cg_exo -53.14 150.84 23.41 Favored 'Trans proline' 0 C--N 1.307 -1.613 0 C-N-CA 121.635 1.557 . . . . 0.0 113.199 179.823 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 54.2 mt -91.3 141.94 28.24 Favored 'General case' 0 CA--C 1.513 -0.466 0 CA-C-N 115.127 -0.942 . . . . 0.0 110.885 179.867 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 53.6 t-20 -50.87 -38.14 47.7 Favored 'General case' 0 C--N 1.314 -0.976 0 CA-C-N 114.743 -1.117 . . . . 0.0 110.149 179.575 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 23.2 m -76.98 -33.57 57.61 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.454 178.874 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 15.1 m -60.48 127.84 33.71 Favored 'General case' 0 N--CA 1.461 0.108 0 CA-C-O 121.027 0.441 . . . . 0.0 110.16 179.893 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . 0.487 ' OG1' ' N ' ' A' ' 82' ' ' ASN . 5.5 m -57.96 142.98 44.68 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.292 179.99 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 20.6 mm -93.82 89.24 2.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 120.904 0.383 . . . . 0.0 110.839 -179.299 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.469 ' O ' ' OG ' ' A' ' 57' ' ' SER . 14.7 pt -142.04 129.76 20.88 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.341 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.498 179.633 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -39.87 121.08 1.5 Allowed Glycine 0 CA--C 1.523 0.543 0 N-CA-C 111.555 -0.618 . . . . 0.0 111.555 -179.56 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' TYR . . . . . 0.423 ' CE2' ' OG ' ' A' ' 57' ' ' SER . 97.7 m-85 -83.19 178.92 7.88 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.942 0.401 . . . . 0.0 110.09 179.91 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . 0.54 ' NH1' ' OG1' ' A' ' 40' ' ' THR . 4.2 tmt_? -134.21 123.74 24.81 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 121.134 0.492 . . . . 0.0 110.561 179.775 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 2.8 pt -94.46 152.95 3.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 115.894 -0.593 . . . . 0.0 109.537 -179.856 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . 0.54 ' OG1' ' NH1' ' A' ' 38' ' ' ARG . 27.3 m -136.09 133.12 36.98 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.75 0.31 . . . . 0.0 110.491 179.814 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.415 HG13 ' HB ' ' A' ' 50' ' ' ILE . 2.0 p -132.59 134.95 58.31 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.326 0 CA-C-O 120.812 0.339 . . . . 0.0 110.577 179.796 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . 0.488 ' O ' ' N ' ' A' ' 74' ' ' ASP . 30.0 t -129.44 126.68 63.89 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.216 0 N-CA-C 110.017 -0.364 . . . . 0.0 110.017 179.307 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.548 ' HB2' ' CE2' ' A' ' 73' ' ' TYR . . . -93.33 138.67 31.46 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 109.32 -0.622 . . . . 0.0 109.32 179.504 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.578 ' HB3' ' O ' ' A' ' 72' ' ' ASP . . . -97.53 -19.25 18.49 Favored 'General case' 0 C--N 1.329 -0.286 0 C-N-CA 120.695 -0.402 . . . . 0.0 110.877 -179.97 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -96.61 30.95 8.03 Favored Glycine 0 CA--C 1.525 0.701 0 N-CA-C 110.971 -0.852 . . . . 0.0 110.971 179.906 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 71.5 mt-10 -146.21 149.92 34.84 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.974 0.416 . . . . 0.0 110.556 179.996 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -68.28 -21.11 73.87 Favored Glycine 0 CA--C 1.523 0.54 0 N-CA-C 111.073 -0.811 . . . . 0.0 111.073 179.571 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -137.86 140.21 28.77 Favored Pre-proline 0 CA--C 1.546 0.814 0 CA-C-N 116.833 0.316 . . . . 0.0 110.603 179.672 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 68.9 Cg_endo -72.78 163.03 39.6 Favored 'Trans proline' 0 N--CA 1.495 1.569 0 C-N-CA 122.768 2.312 . . . . 0.0 112.107 178.755 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . 0.502 HG22 ' N ' ' A' ' 51' ' ' PHE . 96.8 mt -75.58 158.6 5.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.551 179.602 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' PHE . . . . . 0.502 ' N ' HG22 ' A' ' 50' ' ' ILE . 96.7 m-85 -75.94 147.77 38.67 Favored 'General case' 0 C--N 1.333 -0.143 0 CA-C-O 121.019 0.438 . . . . 0.0 111.134 -179.72 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . 0.556 ' H ' ' CD ' ' A' ' 52' ' ' GLU . 0.3 OUTLIER -83.28 146.94 28.26 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.441 179.478 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -116.91 153.55 32.37 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.756 -0.656 . . . . 0.0 110.499 -179.492 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 54' ' ' PHE . . . . . 0.565 ' CD1' ' N ' ' A' ' 54' ' ' PHE . 5.7 m-85 -119.79 129.47 54.47 Favored 'General case' 0 N--CA 1.462 0.132 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.146 -179.85 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 9.4 p -129.77 138.91 52.95 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.393 0 CA-C-O 120.73 0.3 . . . . 0.0 110.843 -179.769 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 94.4 m-20 -61.08 144.86 52.69 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.695 179.964 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . 0.469 ' OG ' ' O ' ' A' ' 35' ' ' ILE . 10.2 m -61.94 -32.14 72.53 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.706 179.878 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 75.5 m -56.2 -36.43 68.4 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.582 -179.756 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 74.3 t -62.32 -45.05 99.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.511 -179.848 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 60.45 24.87 62.17 Favored Glycine 0 CA--C 1.528 0.864 0 N-CA-C 110.507 -1.037 . . . . 0.0 110.507 -179.95 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . 0.432 ' OH ' ' OG1' ' A' ' 63' ' ' THR . 52.6 t80 -166.34 151.09 7.92 Favored 'General case' 0 CA--C 1.53 0.176 0 CA-C-O 121.214 0.531 . . . . 0.0 111.423 -179.513 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 17.4 t80 -158.01 158.25 34.52 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.672 -0.694 . . . . 0.0 110.378 178.566 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . 0.432 ' OG1' ' OH ' ' A' ' 61' ' ' TYR . 69.3 m -127.7 136.74 51.98 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.198 179.728 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -130.16 104.62 10.45 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 N-CA-C 109.33 -0.619 . . . . 0.0 109.33 179.413 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 4.2 p -111.75 157.38 20.59 Favored 'General case' 0 N--CA 1.466 0.335 0 CA-C-O 120.946 0.403 . . . . 0.0 110.498 -179.849 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 107.68 40.79 1.68 Allowed Glycine 0 CA--C 1.524 0.594 0 N-CA-C 111.074 -0.81 . . . . 0.0 111.074 179.94 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 16.6 mt -113.0 106.65 14.95 Favored 'General case' 0 N--CA 1.462 0.168 0 N-CA-C 108.99 -0.744 . . . . 0.0 108.99 179.215 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 52.4 mm-40 -51.97 135.91 37.8 Favored Pre-proline 0 C--N 1.319 -0.72 0 CA-C-N 116.376 -0.375 . . . . 0.0 111.626 -178.059 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 93.4 Cg_endo -74.98 155.44 43.03 Favored 'Trans proline' 0 N--CA 1.496 1.658 0 C-N-CA 122.55 2.166 . . . . 0.0 111.476 178.602 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . 0.515 ' H ' HH22 ' B' ' 223' ' ' ARG . . . 71.11 5.66 59.1 Favored Glycine 0 CA--C 1.525 0.671 0 CA-C-N 115.65 -0.705 . . . . 0.0 111.54 179.469 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 1.6 mp -113.43 143.39 23.21 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.47 0 N-CA-C 109.315 -0.624 . . . . 0.0 109.315 179.859 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 72' ' ' ASP . . . . . 0.578 ' O ' ' HB3' ' A' ' 44' ' ' ALA . 1.8 t70 -80.26 113.86 18.75 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.387 -0.824 . . . . 0.0 110.683 179.949 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 73' ' ' TYR . . . . . 0.548 ' CE2' ' HB2' ' A' ' 43' ' ' ALA . 14.0 m-85 -109.14 120.19 41.78 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 121.264 0.554 . . . . 0.0 110.694 -179.699 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 74' ' ' ASP . . . . . 0.488 ' N ' ' O ' ' A' ' 42' ' ' VAL . 9.6 m-20 -89.11 119.55 29.72 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-N 115.378 -0.828 . . . . 0.0 109.175 179.387 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.535 HD11 ' N ' ' B' ' 223' ' ' ARG . 0.0 OUTLIER -119.17 166.38 13.61 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.466 0 CA-C-O 121.019 0.438 . . . . 0.0 110.304 -179.306 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 22.9 t -156.13 152.41 27.89 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.574 -0.739 . . . . 0.0 110.312 178.529 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 2.4 t -128.78 101.95 7.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 N-CA-C 109.556 -0.535 . . . . 0.0 109.556 178.664 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 72.4 mt -88.47 127.56 41.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 N-CA-C 109.974 -0.38 . . . . 0.0 109.974 -179.433 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 87.3 m -105.66 114.22 28.25 Favored 'General case' 0 N--CA 1.465 0.284 0 CA-C-N 116.213 -0.449 . . . . 0.0 109.963 179.967 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 49.1 mt -118.2 117.42 29.11 Favored 'General case' 0 N--CA 1.464 0.229 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.533 -179.722 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 81' ' ' ILE . . . . . 0.474 ' HB ' ' H ' ' A' ' 33' ' ' THR . 2.3 pp -145.26 146.67 19.52 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.181 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.39 179.032 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 82' ' ' ASN . . . . . 0.487 ' N ' ' OG1' ' A' ' 33' ' ' THR . 23.0 t-20 -65.87 -48.45 71.5 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.259 -179.578 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 102.45 -108.3 3.3 Favored Glycine 0 CA--C 1.523 0.566 0 N-CA-C 110.921 -0.872 . . . . 0.0 110.921 179.606 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -71.79 134.23 21.85 Favored Glycine 0 CA--C 1.523 0.535 0 N-CA-C 110.81 -0.916 . . . . 0.0 110.81 -179.918 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -70.19 117.39 11.69 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.731 0.301 . . . . 0.0 110.311 179.955 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . 0.441 ' O ' ' O ' ' A' ' 87' ' ' ALA . 46.0 t -67.38 134.61 51.79 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.428 -179.908 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.441 ' O ' ' O ' ' A' ' 86' ' ' SER . . . 56.23 155.0 0.07 OUTLIER Pre-proline 0 CA--C 1.534 0.36 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.609 179.803 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_endo -66.62 143.34 67.94 Favored 'Trans proline' 0 N--CA 1.493 1.478 0 C-N-CA 122.485 2.123 . . . . 0.0 111.886 179.701 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 7.6 p -85.25 167.65 15.45 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.595 -0.73 . . . . 0.0 110.356 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 63.9 p -128.92 152.15 48.87 Favored 'General case' 0 N--CA 1.466 0.334 0 CA-C-O 121.239 0.542 . . . . 0.0 110.588 179.874 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . 0.63 ' CD2' ' H ' ' A' ' 91' ' ' LEU . 1.6 pt? -74.6 150.66 39.58 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.712 -0.676 . . . . 0.0 110.799 179.852 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 82.7 p -74.65 139.24 43.42 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.169 179.443 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 50.2 tt0 -69.62 125.18 25.93 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.437 -0.347 . . . . 0.0 110.402 -179.896 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 94.5 mm-40 -101.79 129.64 48.04 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.517 -179.864 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 40.4 p . . . . . 0 C--O 1.22 -0.47 0 CA-C-O 117.974 -1.013 . . . . 0.0 110.684 179.956 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' B' B ' 201' ' ' SER . . . . . . . . . . . . . 24.6 p . . . . . 0 N--CA 1.491 1.614 0 N-CA-C 109.439 -0.578 . . . . 0.0 109.439 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' B' B ' 202' ' ' SER . . . . . . . . . . . . . 40.6 t -68.01 139.13 56.31 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.267 179.5 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 203' ' ' SER . . . . . . . . . . . . . 78.1 p -126.0 108.9 24.8 Favored Pre-proline 0 CA--C 1.537 0.479 0 N-CA-C 110.068 -0.345 . . . . 0.0 110.068 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 204' ' ' PRO . . . . . . . . . . . . . 60.8 Cg_endo -76.1 -58.25 0.05 OUTLIER 'Trans proline' 0 N--CA 1.492 1.402 0 C-N-CA 121.561 1.507 . . . . 0.0 112.069 -179.592 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 205' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -149.1 143.47 18.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.312 179.864 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 206' ' ' GLN . . . . . . . . . . . . . 3.4 pt20 -141.06 141.95 34.22 Favored 'General case' 0 C--N 1.329 -0.315 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 179.623 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 207' ' ' GLY . . . . . . . . . . . . . . . -103.92 -130.75 6.98 Favored Glycine 0 N--CA 1.462 0.428 0 N-CA-C 111.125 -0.79 . . . . 0.0 111.125 -179.791 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 208' ' ' SER . . . . . 0.536 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 97.1 p -165.86 170.58 13.67 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.809 0.337 . . . . 0.0 110.818 179.877 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 209' ' ' TRP . . . . . 0.421 ' HE1' ' HB2' ' A' ' 11' ' ' ASP . 66.9 m95 -88.27 147.6 24.74 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.462 179.666 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 82.4 p -127.96 129.26 46.5 Favored 'General case' 0 C--O 1.234 0.257 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.631 179.868 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 48.9 t-105 -89.62 116.67 27.93 Favored 'General case' 0 N--CA 1.463 0.176 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.04 179.5 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 212' ' ' GLU . . . . . 0.457 ' O ' ' O ' ' B' ' 215' ' ' LYS . 1.0 OUTLIER -164.91 170.24 15.55 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.556 179.073 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' B' B ' 213' ' ' ASN . . . . . . . . . . . . . 14.2 m120 48.23 35.96 6.16 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.916 176.56 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 51.97 13.65 1.64 Allowed Glycine 0 CA--C 1.528 0.899 0 C-N-CA 120.992 -0.623 . . . . 0.0 111.668 179.656 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 215' ' ' LYS . . . . . 0.457 ' O ' ' O ' ' B' ' 212' ' ' GLU . 66.8 mttm -142.84 150.81 40.4 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-O 120.994 0.426 . . . . 0.0 110.839 179.826 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 216' ' ' TRP . . . . . . . . . . . . . 52.1 m95 -86.81 118.77 26.42 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.089 179.86 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 217' ' ' THR . . . . . . . . . . . . . 19.6 m -128.85 142.42 50.97 Favored 'General case' 0 N--CA 1.467 0.387 0 CA-C-O 120.938 0.399 . . . . 0.0 110.184 -179.772 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 218' ' ' TRP . . . . . 0.536 ' CH2' ' N ' ' B' ' 208' ' ' SER . 15.2 t-105 -104.91 118.51 36.72 Favored 'General case' 0 C--N 1.33 -0.269 0 N-CA-C 109.356 -0.609 . . . . 0.0 109.356 179.246 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 52.5 mtmt -145.86 167.4 23.33 Favored 'General case' 0 CA--C 1.517 -0.305 0 CA-C-O 121.33 0.586 . . . . 0.0 110.704 -179.411 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -175.81 -161.13 24.56 Favored Glycine 0 CA--C 1.523 0.573 0 CA-C-N 115.383 -0.826 . . . . 0.0 111.486 -179.736 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 221' ' ' ILE . . . . . 0.548 ' O ' HG23 ' B' ' 222' ' ' ILE . 0.8 OUTLIER -52.59 -75.71 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 C-N-CA 120.69 -0.404 . . . . 0.0 111.065 -178.667 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' B' B ' 222' ' ' ILE . . . . . 0.548 HG23 ' O ' ' B' ' 221' ' ' ILE . 22.1 pt -160.87 -165.08 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 N-CA-C 109.97 -0.382 . . . . 0.0 109.97 -179.405 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 223' ' ' ARG . . . . . 0.535 ' N ' HD11 ' A' ' 75' ' ' ILE . 39.5 ptt180 -43.28 173.5 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.804 -0.635 . . . . 0.0 110.669 178.579 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 224' ' ' LEU . . . . . 1.053 HD22 ' H ' ' B' ' 224' ' ' LEU . 0.7 OUTLIER -61.67 126.09 26.12 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.33 -179.859 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 35.5 tp10 -82.54 149.15 27.67 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.712 -0.676 . . . . 0.0 110.277 179.803 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 226' ' ' GLN . . . . . . . . . . . . . 15.0 mm100 . . . . . 0 C--N 1.324 -0.522 0 CA-C-O 118.062 -0.971 . . . . 0.0 110.672 -179.875 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.222 0 N-CA-C 109.548 -1.421 . . . . 0.0 109.548 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 22.4 t -149.51 93.7 2.1 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 120.729 0.299 . . . . 0.0 110.377 179.878 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 95.3 mt-10 -105.99 115.85 30.93 Favored 'General case' 0 CA--C 1.519 -0.249 0 CA-C-N 116.237 -0.438 . . . . 0.0 109.998 179.929 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 5.7 m -145.12 149.2 41.08 Favored Pre-proline 0 CA--C 1.532 0.265 0 CA-C-N 116.401 -0.363 . . . . 0.0 110.589 179.968 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 42.4 Cg_endo -67.19 84.42 0.34 Allowed 'Trans proline' 0 N--CA 1.495 1.602 0 C-N-CA 122.558 2.172 . . . . 0.0 111.815 179.7 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 12.0 pt20 -66.08 -36.86 84.33 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.363 179.48 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 45.0 tp -98.84 125.44 44.22 Favored 'General case' 0 N--CA 1.463 0.186 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.333 -179.785 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 34.4 p -125.11 129.77 50.88 Favored 'General case' 0 C--O 1.234 0.254 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.513 179.739 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -88.6 154.05 20.63 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.899 -0.591 . . . . 0.0 110.372 179.808 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.528 ' CD2' ' CZ ' ' A' ' 14' ' ' PHE . 7.0 tt -67.15 145.34 55.38 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.579 -179.83 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . 0.431 ' O ' ' O ' ' A' ' 25' ' ' ARG . 53.9 p -143.09 152.79 42.23 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.497 179.642 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . 0.554 ' N ' ' CD1' ' A' ' 14' ' ' PHE . 8.3 m-85 -111.77 148.73 32.9 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.391 -179.763 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 18.5 m -146.37 158.01 11.32 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.205 179.711 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 95.2 m-20 58.91 30.27 19.95 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.613 -0.721 . . . . 0.0 110.849 -179.921 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 83.2 mt -56.3 130.5 18.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 N-CA-C 109.862 -0.422 . . . . 0.0 109.862 179.65 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.441 HG22 ' H ' ' A' ' 19' ' ' ASP . 0.2 OUTLIER -129.52 -169.1 2.05 Favored 'General case' 0 N--CA 1.466 0.374 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.579 -179.886 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . 0.488 ' N ' ' OD1' ' A' ' 19' ' ' ASP . 16.2 p-10 -78.35 -48.52 15.41 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.997 179.428 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . 0.47 ' OG ' ' N ' ' A' ' 67' ' ' LEU . 28.2 t -121.16 13.35 11.2 Favored 'General case' 0 N--CA 1.464 0.231 0 CA-C-O 120.728 0.299 . . . . 0.0 110.596 -179.161 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . 0.463 ' HB2' HG22 ' A' ' 65' ' ' THR . 25.1 p -146.69 129.14 15.91 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 116.475 -0.329 . . . . 0.0 110.352 -179.625 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . 0.595 HD12 HD21 ' A' ' 24' ' ' LEU . 46.4 pt -126.25 142.57 42.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.239 0 CA-C-N 116.2 -0.455 . . . . 0.0 109.959 -179.886 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -97.1 82.26 0.72 Allowed Glycine 0 CA--C 1.523 0.542 0 N-CA-C 110.873 -0.891 . . . . 0.0 110.873 -179.563 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.595 HD21 HD12 ' A' ' 22' ' ' ILE . 90.7 mt -65.26 122.53 17.31 Favored 'General case' 0 C--N 1.33 -0.276 0 N-CA-C 109.945 -0.391 . . . . 0.0 109.945 -179.815 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . 0.431 ' O ' ' O ' ' A' ' 13' ' ' SER . 72.2 ttt180 -141.2 138.78 33.58 Favored 'General case' 0 N--CA 1.462 0.168 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.722 -179.873 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' TRP . . . . . 0.534 ' CE2' ' O ' ' A' ' 60' ' ' GLY . 33.3 p90 -146.33 121.06 9.86 Favored 'General case' 0 CA--C 1.513 -0.453 0 CA-C-N 115.792 -0.64 . . . . 0.0 109.764 179.882 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 2.1 m -66.49 113.91 14.9 Favored Pre-proline 0 CA--C 1.536 0.412 0 C-N-CA 120.642 -0.423 . . . . 0.0 111.091 -178.619 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 36.1 Cg_exo -58.84 153.07 52.86 Favored 'Trans proline' 0 N--CA 1.493 1.461 0 C-N-CA 122.101 1.867 . . . . 0.0 112.742 178.693 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.459 ' H ' ' HB2' ' A' ' 32' ' ' SER . 80.2 mt -104.94 136.05 45.15 Favored 'General case' 0 N--CA 1.469 0.479 0 CA-C-O 122.008 0.909 . . . . 0.0 110.833 179.876 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 42.4 t30 -44.88 -32.43 1.59 Allowed 'General case' 0 C--N 1.316 -0.877 0 CA-C-N 115.064 -0.971 . . . . 0.0 110.223 -179.709 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 58.7 m -85.64 -33.84 21.51 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.868 -0.606 . . . . 0.0 110.582 179.198 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . 0.459 ' HB2' ' H ' ' A' ' 29' ' ' LEU . 3.6 m -51.52 115.48 1.63 Allowed 'General case' 0 N--CA 1.461 0.095 0 CA-C-O 121.261 0.553 . . . . 0.0 110.17 -179.929 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . 0.522 ' OG1' ' N ' ' A' ' 82' ' ' ASN . 11.7 m -50.94 143.54 10.04 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.561 -0.745 . . . . 0.0 109.264 -179.081 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 32.8 mm -92.45 90.95 3.23 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.215 0 CA-C-O 121.236 0.541 . . . . 0.0 111.258 -178.156 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.576 ' O ' ' CE1' ' A' ' 37' ' ' TYR . 6.7 pt -149.19 125.95 2.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 115.507 -0.77 . . . . 0.0 110.241 179.225 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -39.56 140.45 0.78 Allowed Glycine 0 CA--C 1.527 0.788 0 N-CA-C 110.957 -0.857 . . . . 0.0 110.957 -179.72 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' TYR . . . . . 0.576 ' CE1' ' O ' ' A' ' 35' ' ' ILE . 16.8 m-85 -110.49 144.83 38.72 Favored 'General case' 0 CA--C 1.518 -0.286 0 N-CA-C 109.867 -0.42 . . . . 0.0 109.867 -179.504 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . 0.516 ' NH1' ' OG1' ' A' ' 40' ' ' THR . 2.3 tmm_? -98.86 125.93 44.39 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.612 -179.834 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.419 ' CG1' ' O ' ' A' ' 39' ' ' ILE . 2.8 pt -98.45 121.07 48.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.1 -0.5 . . . . 0.0 109.834 179.777 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . 0.516 ' OG1' ' NH1' ' A' ' 38' ' ' ARG . 20.7 m -101.29 136.2 41.53 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.288 -179.175 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.2 p -134.22 142.76 40.06 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.338 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.249 179.965 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . 0.485 ' O ' ' N ' ' A' ' 74' ' ' ASP . 37.7 t -131.73 130.54 61.98 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.145 0 N-CA-C 109.984 -0.376 . . . . 0.0 109.984 179.46 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -97.49 133.63 41.81 Favored 'General case' 0 C--N 1.327 -0.379 0 N-CA-C 109.434 -0.58 . . . . 0.0 109.434 179.216 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.626 ' HB3' ' O ' ' A' ' 72' ' ' ASP . . . -94.57 -21.21 18.99 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.769 0.318 . . . . 0.0 110.738 179.912 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -91.4 18.07 53.55 Favored Glycine 0 CA--C 1.523 0.588 0 N-CA-C 110.912 -0.875 . . . . 0.0 110.912 -179.682 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 33.2 mm-40 -139.93 149.53 43.44 Favored 'General case' 0 C--N 1.333 -0.136 0 CA-C-O 121.106 0.479 . . . . 0.0 110.521 -179.559 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -69.5 -18.94 74.12 Favored Glycine 0 N--CA 1.453 -0.194 0 N-CA-C 110.518 -1.033 . . . . 0.0 110.518 179.941 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -132.26 140.06 36.82 Favored Pre-proline 0 N--CA 1.468 0.446 0 C-N-CA 121.119 -0.232 . . . . 0.0 110.585 179.699 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 59.6 Cg_endo -73.22 159.39 47.32 Favored 'Trans proline' 0 N--CA 1.49 1.307 0 C-N-CA 122.431 2.087 . . . . 0.0 112.051 177.685 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . 0.407 HG22 ' N ' ' A' ' 51' ' ' PHE . 96.7 mt -75.49 153.41 6.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.193 179.484 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' PHE . . . . . 0.407 ' N ' HG22 ' A' ' 50' ' ' ILE . 80.5 m-85 -72.51 142.29 48.51 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.676 179.912 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . 0.422 ' N ' ' CD ' ' A' ' 52' ' ' GLU . 0.0 OUTLIER -65.77 -176.15 0.35 Allowed 'General case' 0 CA--C 1.514 -0.441 0 CA-C-N 115.739 -0.664 . . . . 0.0 110.405 179.441 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . 0.416 ' CG ' ' OH ' ' A' ' 62' ' ' TYR . 1.0 OUTLIER -145.59 138.66 26.14 Favored 'General case' 0 N--CA 1.452 -0.34 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.358 179.392 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 61.4 m-85 -110.0 116.42 31.56 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.397 179.898 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 10.5 p -128.18 140.82 48.15 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.348 0 CA-C-O 120.934 0.397 . . . . 0.0 110.118 179.949 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 83.9 m-20 -62.9 150.49 41.85 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.248 179.734 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 15.3 t -64.12 -33.8 76.6 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.663 -179.932 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 69.5 m -51.43 -37.69 49.83 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.382 -179.51 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.525 ' C ' ' H ' ' A' ' 61' ' ' TYR . 11.3 t -63.74 -42.97 97.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.362 179.68 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . 0.534 ' O ' ' CE2' ' A' ' 26' ' ' TRP . . . 70.44 -36.38 0.45 Allowed Glycine 0 CA--C 1.532 1.116 0 N-CA-C 111.037 -0.825 . . . . 0.0 111.037 179.653 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . 0.525 ' H ' ' C ' ' A' ' 59' ' ' VAL . 25.9 p90 -115.99 159.76 21.19 Favored 'General case' 0 N--CA 1.466 0.373 0 CA-C-O 121.146 0.498 . . . . 0.0 111.007 -179.084 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 62' ' ' TYR . . . . . 0.416 ' OH ' ' CG ' ' A' ' 53' ' ' ASP . 31.1 t80 -154.47 162.28 41.23 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.107 -0.497 . . . . 0.0 109.755 179.599 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 99.2 m -119.36 132.77 55.91 Favored 'General case' 0 N--CA 1.467 0.376 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.414 -179.781 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -133.06 107.57 11.75 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.311 0 CA-C-N 115.859 -0.61 . . . . 0.0 109.647 179.046 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.463 HG22 ' HB2' ' A' ' 21' ' ' SER . 1.1 p -123.46 164.52 18.76 Favored 'General case' 0 CA--C 1.513 -0.443 0 CA-C-O 121.019 0.438 . . . . 0.0 110.34 -179.836 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 108.81 24.41 6.09 Favored Glycine 0 CA--C 1.524 0.598 0 CA-C-N 115.396 -0.82 . . . . 0.0 111.48 -179.773 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.47 ' N ' ' OG ' ' A' ' 20' ' ' SER . 11.8 mt -100.66 109.14 21.17 Favored 'General case' 0 CA--C 1.517 -0.322 0 N-CA-C 109.31 -0.626 . . . . 0.0 109.31 179.909 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 31.9 mm-40 -52.5 139.73 37.88 Favored Pre-proline 0 C--N 1.312 -1.023 0 C-N-CA 120.486 -0.485 . . . . 0.0 112.011 -178.214 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -73.08 155.47 52.39 Favored 'Trans proline' 0 N--CA 1.498 1.755 0 C-N-CA 122.857 2.371 . . . . 0.0 111.387 178.63 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 72.93 -5.96 15.48 Favored Glycine 0 CA--C 1.525 0.702 0 CA-C-N 115.637 -0.71 . . . . 0.0 111.927 179.269 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 1.7 mp -101.27 149.15 6.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 N-CA-C 109.346 -0.613 . . . . 0.0 109.346 -179.551 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 72' ' ' ASP . . . . . 0.626 ' O ' ' HB3' ' A' ' 44' ' ' ALA . 2.5 t70 -89.68 115.99 27.46 Favored 'General case' 0 C--N 1.32 -0.7 0 CA-C-N 114.979 -1.01 . . . . 0.0 110.269 179.686 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 73' ' ' TYR . . . . . 0.507 ' O ' HD13 ' A' ' 75' ' ' ILE . 25.6 m-85 -109.81 119.55 39.69 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.453 179.899 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 74' ' ' ASP . . . . . 0.485 ' N ' ' O ' ' A' ' 42' ' ' VAL . 8.9 m-20 -89.94 116.79 28.26 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.702 -0.681 . . . . 0.0 109.426 179.887 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.569 HD11 ' N ' ' B' ' 223' ' ' ARG . 0.0 OUTLIER -113.98 165.4 9.02 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.293 0 CA-C-O 121.171 0.51 . . . . 0.0 109.995 -179.094 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 33.5 t -155.97 118.56 4.15 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.6 -0.727 . . . . 0.0 110.584 179.0 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 2.7 t -92.16 100.77 11.76 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 C-N-CA 120.479 -0.488 . . . . 0.0 109.73 179.498 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 96.3 mt -87.44 115.79 28.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.075 -179.99 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 70.3 m -100.44 118.8 37.41 Favored 'General case' 0 CA--C 1.517 -0.318 0 CA-C-N 116.211 -0.45 . . . . 0.0 109.938 179.725 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . 0.447 HD23 ' C ' ' A' ' 80' ' ' LEU . 2.1 tt -122.66 108.74 13.43 Favored 'General case' 0 N--CA 1.463 0.201 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.628 -179.892 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 81' ' ' ILE . . . . . 0.44 ' N ' HD23 ' A' ' 80' ' ' LEU . 2.1 pp -139.37 142.93 32.13 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 N-CA-C 109.974 -0.38 . . . . 0.0 109.974 178.936 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 82' ' ' ASN . . . . . 0.522 ' N ' ' OG1' ' A' ' 33' ' ' THR . 39.5 t-20 -66.37 -49.8 65.67 Favored 'General case' 0 C--N 1.328 -0.333 0 C-N-CA 120.89 -0.324 . . . . 0.0 111.233 -179.894 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . 0.431 ' H ' ' HG1' ' A' ' 33' ' ' THR . . . 82.13 -150.67 29.22 Favored Glycine 0 CA--C 1.523 0.538 0 N-CA-C 110.956 -0.858 . . . . 0.0 110.956 179.781 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -73.54 -171.65 23.08 Favored Glycine 0 CA--C 1.527 0.801 0 N-CA-C 110.768 -0.933 . . . . 0.0 110.768 -179.993 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 5.5 pm0 -57.55 140.76 49.99 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.839 0.352 . . . . 0.0 110.335 179.929 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 94.0 p -56.23 108.47 0.47 Allowed 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.32 179.895 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.665 ' HB1' ' HD2' ' A' ' 88' ' ' PRO . . . -174.88 176.0 0.73 Allowed Pre-proline 0 C--N 1.327 -0.385 0 C-N-CA 120.529 -0.469 . . . . 0.0 110.653 179.475 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . 0.665 ' HD2' ' HB1' ' A' ' 87' ' ' ALA . 31.7 Cg_exo -58.22 138.1 84.14 Favored 'Trans proline' 0 N--CA 1.495 1.609 0 C-N-CA 122.375 2.05 . . . . 0.0 111.63 179.132 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 86.9 m -134.19 127.83 32.76 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.341 -0.39 . . . . 0.0 110.428 179.43 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 47.9 p -150.1 131.38 14.58 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.232 179.824 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . 0.523 ' N ' HD12 ' A' ' 91' ' ' LEU . 10.6 mp -97.17 129.19 44.57 Favored 'General case' 0 N--CA 1.463 0.201 0 CA-C-O 121.002 0.429 . . . . 0.0 110.193 179.864 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 67.5 p -75.47 134.88 40.73 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.437 179.903 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 98.9 mt-30 -78.52 133.04 37.42 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.53 179.902 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 99.0 mm-40 46.55 -168.03 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.628 179.997 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 6.5 m . . . . . 0 C--O 1.218 -0.56 0 CA-C-O 118.04 -0.981 . . . . 0.0 110.483 -179.875 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' B' B ' 201' ' ' SER . . . . . . . . . . . . . 33.0 t . . . . . 0 N--CA 1.489 1.514 0 N-CA-C 109.414 -0.587 . . . . 0.0 109.414 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' B' B ' 202' ' ' SER . . . . . . . . . . . . . 40.6 t -71.37 148.99 46.45 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.582 179.972 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 203' ' ' SER . . . . . . . . . . . . . 2.3 p -88.89 150.76 46.23 Favored Pre-proline 0 CA--C 1.533 0.327 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.373 -179.413 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 204' ' ' PRO . . . . . . . . . . . . . 32.6 Cg_endo -63.93 -45.71 9.97 Favored 'Trans proline' 0 N--CA 1.497 1.705 0 C-N-CA 122.842 2.361 . . . . 0.0 111.809 -179.779 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 205' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -149.55 144.86 17.85 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.351 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.409 -179.698 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 206' ' ' GLN . . . . . 0.474 ' N ' ' CD ' ' B' ' 206' ' ' GLN . 2.2 pm0 -143.4 143.32 31.58 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.192 178.925 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 207' ' ' GLY . . . . . . . . . . . . . . . -107.52 -125.66 5.38 Favored Glycine 0 N--CA 1.467 0.712 0 N-CA-C 111.105 -0.798 . . . . 0.0 111.105 -179.888 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 208' ' ' SER . . . . . 0.555 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 54.8 p -165.66 170.83 13.71 Favored 'General case' 0 N--CA 1.454 -0.248 0 CA-C-O 120.804 0.335 . . . . 0.0 110.719 179.287 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 209' ' ' TRP . . . . . . . . . . . . . 59.0 m95 -88.13 156.08 19.44 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.531 179.473 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 66.9 p -130.19 131.77 45.74 Favored 'General case' 0 N--CA 1.464 0.247 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.447 179.558 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 53.0 t-105 -95.81 110.41 22.58 Favored 'General case' 0 N--CA 1.464 0.269 0 CA-C-N 116.29 -0.413 . . . . 0.0 110.591 -179.988 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 212' ' ' GLU . . . . . 0.44 ' O ' ' O ' ' B' ' 215' ' ' LYS . 1.8 pt-20 -162.0 168.45 22.76 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.669 179.516 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 213' ' ' ASN . . . . . . . . . . . . . 14.8 m120 51.53 34.5 12.5 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.955 -0.566 . . . . 0.0 111.066 176.966 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 50.56 19.89 3.46 Favored Glycine 0 CA--C 1.526 0.745 0 N-CA-C 111.156 -0.777 . . . . 0.0 111.156 179.981 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 215' ' ' LYS . . . . . 0.44 ' O ' ' O ' ' B' ' 212' ' ' GLU . 80.1 mttt -146.21 150.81 36.54 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 120.933 0.397 . . . . 0.0 110.602 179.723 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 216' ' ' TRP . . . . . . . . . . . . . 53.5 m95 -87.39 117.38 26.12 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.055 179.789 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 217' ' ' THR . . . . . . . . . . . . . 17.1 m -128.5 136.91 51.44 Favored 'General case' 0 C--O 1.234 0.248 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.129 -179.798 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 218' ' ' TRP . . . . . 0.555 ' CH2' ' N ' ' B' ' 208' ' ' SER . 14.2 t-105 -100.34 112.98 25.36 Favored 'General case' 0 N--CA 1.463 0.199 0 CA-C-N 116.044 -0.526 . . . . 0.0 109.99 179.606 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 92.7 mttt -130.24 167.52 18.31 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.74 -179.912 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -178.29 -162.89 28.83 Favored Glycine 0 CA--C 1.524 0.605 0 N-CA-C 111.089 -0.804 . . . . 0.0 111.089 179.878 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 221' ' ' ILE . . . . . 0.551 ' O ' HG23 ' B' ' 222' ' ' ILE . 21.5 mt -56.0 -73.52 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 C-N-CA 120.422 -0.511 . . . . 0.0 110.307 -178.116 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 222' ' ' ILE . . . . . 0.551 HG23 ' O ' ' B' ' 221' ' ' ILE . 22.6 pt -160.37 -165.2 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.086 179.797 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 223' ' ' ARG . . . . . 0.569 ' N ' HD11 ' A' ' 75' ' ' ILE . 26.7 ptt180 -40.24 172.18 0.0 OUTLIER 'General case' 0 CA--C 1.52 -0.201 0 CA-C-O 121.278 0.561 . . . . 0.0 110.88 179.293 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 224' ' ' LEU . . . . . 0.725 ' N ' HD22 ' B' ' 224' ' ' LEU . 2.8 mm? -61.38 120.73 11.01 Favored 'General case' 0 C--N 1.316 -0.861 0 CA-C-O 121.428 0.632 . . . . 0.0 110.929 -178.924 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 83.1 tt0 -79.47 136.36 36.9 Favored 'General case' 0 N--CA 1.452 -0.35 0 CA-C-N 115.295 -0.866 . . . . 0.0 109.935 -179.988 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 226' ' ' GLN . . . . . . . . . . . . . 32.4 tp60 . . . . . 0 N--CA 1.446 -0.667 0 CA-C-O 117.921 -1.038 . . . . 0.0 110.755 179.89 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.254 0 N-CA-C 109.623 -1.391 . . . . 0.0 109.623 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 78.8 p -77.6 -9.4 58.93 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.893 0.378 . . . . 0.0 110.758 -179.909 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 58.1 mp0 -61.05 138.08 58.21 Favored 'General case' 0 CA--C 1.514 -0.433 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.18 179.968 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.478 ' O ' HG13 ' A' ' 6' ' ' VAL . 8.1 p -114.72 127.63 26.65 Favored Pre-proline 0 CA--C 1.54 0.586 0 CA-C-N 116.268 -0.423 . . . . 0.0 110.628 -179.965 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -76.08 117.0 4.52 Favored 'Trans proline' 0 N--CA 1.493 1.458 0 C-N-CA 122.411 2.074 . . . . 0.0 112.036 179.721 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 54.0 tt0 -174.45 138.86 0.55 Allowed 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.298 179.733 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 40.5 tp -118.57 107.28 13.56 Favored 'General case' 0 N--CA 1.462 0.13 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.526 179.449 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 52.3 p -88.32 168.03 13.03 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.451 179.462 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 56.0 p30 -140.28 163.94 31.43 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-O 121.054 0.454 . . . . 0.0 110.448 -179.908 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.485 ' CD2' ' CE1' ' A' ' 14' ' ' PHE . 6.9 tt -67.55 139.77 56.95 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.938 -0.573 . . . . 0.0 110.493 -179.637 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . 0.434 ' O ' ' O ' ' A' ' 25' ' ' ARG . 83.1 p -138.95 154.16 48.28 Favored 'General case' 0 N--CA 1.463 0.208 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.589 179.35 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . 0.713 ' CE1' HD13 ' B' ' 205' ' ' ILE . 15.9 m-85 -111.31 146.15 37.57 Favored 'General case' 0 N--CA 1.463 0.188 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.514 -179.645 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 19.0 m -144.7 163.93 13.42 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.511 179.902 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 99.4 m-20 54.64 33.29 18.94 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.023 -0.535 . . . . 0.0 111.062 179.647 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 1.6 mp -58.42 132.17 23.04 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.542 0 CA-C-O 121.222 0.534 . . . . 0.0 109.883 -179.759 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.457 ' CB ' ' O ' ' A' ' 21' ' ' SER . 0.2 OUTLIER -136.2 -166.26 1.85 Allowed 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.212 -0.904 . . . . 0.0 110.652 -179.872 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . 0.522 ' OD1' ' N ' ' A' ' 20' ' ' SER . 34.3 p-10 -91.87 -41.95 10.33 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.495 -0.775 . . . . 0.0 111.115 179.366 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . 0.522 ' N ' ' OD1' ' A' ' 19' ' ' ASP . 25.9 t -118.51 6.85 11.74 Favored 'General case' 0 N--CA 1.467 0.378 0 CA-C-N 116.444 -0.344 . . . . 0.0 110.848 -179.431 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . 0.457 ' O ' ' CB ' ' A' ' 18' ' ' THR . 48.0 m -151.57 147.92 27.37 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.437 179.961 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . 0.52 HD12 HD21 ' A' ' 24' ' ' LEU . 35.8 pt -147.22 147.7 17.29 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 N-CA-C 109.897 -0.408 . . . . 0.0 109.897 179.558 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -101.83 83.43 0.48 Allowed Glycine 0 CA--C 1.524 0.603 0 N-CA-C 111.507 -0.637 . . . . 0.0 111.507 -179.647 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.52 HD21 HD12 ' A' ' 22' ' ' ILE . 84.6 mt -66.37 124.56 23.05 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 109.656 -0.498 . . . . 0.0 109.656 179.899 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . 0.434 ' O ' ' O ' ' A' ' 13' ' ' SER . 69.6 ttt180 -139.11 141.13 38.11 Favored 'General case' 0 N--CA 1.463 0.188 0 CA-C-O 120.948 0.404 . . . . 0.0 110.49 -179.714 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' TRP . . . . . . . . . . . . . 35.1 p90 -144.04 155.01 43.83 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.106 179.795 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 2.5 m -111.77 97.9 39.29 Favored Pre-proline 0 CA--C 1.534 0.336 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.507 179.82 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_exo -53.35 142.62 57.0 Favored 'Trans proline' 0 C--N 1.305 -1.728 0 C-N-CA 122.081 1.854 . . . . 0.0 112.478 179.472 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 59.9 mt -81.21 144.24 31.75 Favored 'General case' 0 CA--C 1.518 -0.274 0 CA-C-O 121.412 0.625 . . . . 0.0 110.91 179.877 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 21.0 t-20 -52.04 -36.9 51.73 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 115.392 -0.822 . . . . 0.0 109.799 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 38.5 m -78.28 -35.17 48.32 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.518 179.257 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 14.4 m -58.14 134.17 56.24 Favored 'General case' 0 N--CA 1.461 0.096 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.231 -179.872 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . 0.452 ' H ' ' HB ' ' A' ' 81' ' ' ILE . 2.7 m -61.82 140.02 58.29 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.084 -179.718 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 6.0 mm -94.28 90.17 2.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 121.065 0.459 . . . . 0.0 110.693 -179.696 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 19.0 pt -139.19 138.11 41.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.549 179.742 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -42.23 135.81 3.56 Favored Glycine 0 CA--C 1.52 0.406 0 N-CA-C 111.004 -0.838 . . . . 0.0 111.004 -179.622 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 -103.2 174.62 5.79 Favored 'General case' 0 CA--C 1.517 -0.317 0 CA-C-O 120.898 0.38 . . . . 0.0 110.179 -179.846 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 2.3 tmm_? -134.92 126.25 28.31 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.592 179.961 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.475 ' CG1' ' O ' ' A' ' 39' ' ' ILE . 1.8 pt -99.92 122.2 51.52 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.176 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.127 179.684 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 24.2 m -104.95 134.38 48.15 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.451 -179.846 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.1 p -133.14 140.65 46.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.351 179.839 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . 0.528 ' O ' ' N ' ' A' ' 74' ' ' ASP . 37.6 t -133.25 131.67 58.18 Favored 'Isoleucine or valine' 0 N--CA 1.458 -0.074 0 N-CA-C 110.158 -0.312 . . . . 0.0 110.158 179.714 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.604 ' HB2' ' CE2' ' A' ' 73' ' ' TYR . . . -96.5 138.86 33.45 Favored 'General case' 0 C--N 1.329 -0.304 0 N-CA-C 109.709 -0.478 . . . . 0.0 109.709 178.947 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.564 ' HB3' ' O ' ' A' ' 72' ' ' ASP . . . -93.81 -41.17 9.79 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.487 -0.324 . . . . 0.0 110.835 179.617 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -65.35 -31.85 81.76 Favored Glycine 0 CA--C 1.525 0.689 0 N-CA-C 111.256 -0.738 . . . . 0.0 111.256 -179.763 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 42.3 mm-40 -97.46 133.44 42.05 Favored 'General case' 0 C--N 1.33 -0.24 0 N-CA-C 109.576 -0.528 . . . . 0.0 109.576 -179.483 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -60.32 -21.92 57.72 Favored Glycine 0 CA--C 1.511 -0.217 0 N-CA-C 111.021 -0.832 . . . . 0.0 111.021 -178.987 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -113.11 134.7 21.78 Favored Pre-proline 0 CA--C 1.536 0.407 0 C-N-CA 120.961 -0.295 . . . . 0.0 110.59 179.665 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 71.2 Cg_endo -77.24 163.51 30.21 Favored 'Trans proline' 0 C--N 1.308 -1.564 0 C-N-CA 122.592 2.194 . . . . 0.0 112.202 177.006 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 87.0 mt -83.03 138.26 19.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.044 179.062 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 93.7 m-85 -60.74 142.03 56.31 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.623 -179.829 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 5.6 pt-20 -82.96 151.49 25.87 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.166 179.92 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . 0.417 ' CG ' ' OH ' ' A' ' 62' ' ' TYR . 1.7 t70 -120.05 162.91 18.47 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.683 179.451 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 54' ' ' PHE . . . . . 0.59 ' CD1' ' N ' ' A' ' 54' ' ' PHE . 2.4 m-85 -124.02 130.79 53.16 Favored 'General case' 0 C--O 1.232 0.169 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.195 179.662 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 8.7 p -127.69 136.4 60.52 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.449 -179.914 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 97.6 m-20 -58.84 141.29 53.67 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.482 -179.847 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 39.9 t -58.77 -32.84 69.66 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.58 179.857 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 69.1 m -56.23 -35.54 67.46 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.622 -179.836 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 84.1 t -63.44 -46.33 95.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.523 179.982 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 60.86 26.24 65.03 Favored Glycine 0 CA--C 1.528 0.895 0 N-CA-C 110.745 -0.942 . . . . 0.0 110.745 179.863 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 42.6 t80 -167.93 150.58 5.68 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 121.206 0.527 . . . . 0.0 111.103 -179.621 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 62' ' ' TYR . . . . . 0.417 ' OH ' ' CG ' ' A' ' 53' ' ' ASP . 26.7 t80 -157.58 156.27 31.63 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.092 178.831 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 76.3 m -122.64 136.2 54.81 Favored 'General case' 0 N--CA 1.465 0.282 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.728 -179.938 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -130.75 124.9 57.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.026 179.195 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 3.3 p -131.46 155.06 48.02 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.656 179.791 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 109.99 40.63 1.39 Allowed Glycine 0 CA--C 1.524 0.622 0 CA-C-N 115.719 -0.673 . . . . 0.0 111.522 -179.708 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 14.3 mt -112.91 99.31 7.78 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-O 121.274 0.559 . . . . 0.0 109.661 179.47 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 10.6 mm-40 -47.14 135.27 8.88 Favored Pre-proline 0 C--N 1.316 -0.849 0 CA-C-N 115.486 -0.779 . . . . 0.0 111.45 -178.382 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . 0.446 ' O ' HD12 ' A' ' 71' ' ' ILE . 72.4 Cg_endo -75.5 149.89 35.32 Favored 'Trans proline' 0 N--CA 1.496 1.646 0 C-N-CA 122.764 2.309 . . . . 0.0 111.761 178.86 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . 0.413 ' C ' HD12 ' A' ' 71' ' ' ILE . . . 75.39 13.61 82.71 Favored Glycine 0 CA--C 1.524 0.648 0 N-CA-C 111.23 -0.748 . . . . 0.0 111.23 179.202 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . 0.446 HD12 ' O ' ' A' ' 69' ' ' PRO . 2.2 mp -121.0 149.71 23.93 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.354 0 CA-C-O 121.528 0.68 . . . . 0.0 109.629 -179.637 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 72' ' ' ASP . . . . . 0.564 ' O ' ' HB3' ' A' ' 44' ' ' ALA . 2.3 t70 -87.25 112.08 21.67 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 114.854 -1.066 . . . . 0.0 110.621 -179.76 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 73' ' ' TYR . . . . . 0.604 ' CE2' ' HB2' ' A' ' 43' ' ' ALA . 11.8 m-85 -107.87 118.33 36.46 Favored 'General case' 0 C--O 1.216 -0.69 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.735 179.71 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 74' ' ' ASP . . . . . 0.528 ' N ' ' O ' ' A' ' 42' ' ' VAL . 76.6 m-20 -86.97 119.01 26.74 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.495 -0.775 . . . . 0.0 109.496 179.708 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.615 HD11 ' N ' ' B' ' 223' ' ' ARG . 0.0 OUTLIER -116.02 164.43 12.37 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.344 0 CA-C-O 121.171 0.51 . . . . 0.0 110.155 -179.166 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 3.0 m -154.43 121.52 5.63 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 115.466 -0.788 . . . . 0.0 110.849 179.394 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 11.9 t -101.44 102.23 13.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 179.272 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 94.5 mt -89.84 127.32 42.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.405 -0.361 . . . . 0.0 110.517 -179.684 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 99.7 m -109.41 111.68 23.36 Favored 'General case' 0 N--CA 1.465 0.319 0 CA-C-N 116.12 -0.491 . . . . 0.0 109.996 179.708 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 13.9 mt -117.93 122.11 42.42 Favored 'General case' 0 CA--C 1.517 -0.297 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.693 -179.968 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 81' ' ' ILE . . . . . 0.452 ' HB ' ' H ' ' A' ' 33' ' ' THR . 2.1 pp -145.45 134.66 17.66 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.15 179.533 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 82' ' ' ASN . . . . . 0.421 ' O ' ' O ' ' A' ' 83' ' ' GLY . 24.1 t-20 -45.6 -73.26 0.04 OUTLIER 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.777 179.851 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . 0.421 ' O ' ' O ' ' A' ' 82' ' ' ASN . . . 37.51 93.27 0.01 OUTLIER Glycine 0 CA--C 1.527 0.783 0 N-CA-C 111.109 -0.796 . . . . 0.0 111.109 179.863 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -50.38 120.19 8.21 Favored Glycine 0 CA--C 1.524 0.621 0 N-CA-C 110.805 -0.918 . . . . 0.0 110.805 -179.49 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -98.97 127.46 44.89 Favored 'General case' 0 N--CA 1.465 0.285 0 CA-C-O 120.786 0.327 . . . . 0.0 110.579 179.793 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 22.1 p -74.12 157.49 35.92 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.392 -179.859 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.423 ' N ' ' CD ' ' A' ' 88' ' ' PRO . . . 54.53 55.02 11.37 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.587 -179.978 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . 0.423 ' CD ' ' N ' ' A' ' 87' ' ' ALA . 42.9 Cg_endo -67.31 148.21 79.55 Favored 'Trans proline' 0 C--N 1.307 -1.642 0 C-N-CA 122.849 2.366 . . . . 0.0 111.914 179.951 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 86.6 m -82.02 127.87 33.52 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.2 179.621 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 74.9 p -114.22 135.85 53.6 Favored 'General case' 0 N--CA 1.464 0.235 0 CA-C-O 120.942 0.401 . . . . 0.0 110.455 179.89 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . 0.583 ' N ' HD12 ' A' ' 91' ' ' LEU . 10.0 mp -76.92 147.1 37.18 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.398 -179.732 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 82.7 p -73.63 168.56 19.09 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.407 179.952 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 57.6 tt0 -64.22 114.1 4.0 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.457 -179.79 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 99.2 mt-30 -66.0 -40.32 91.02 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.614 179.892 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 41.1 p . . . . . 0 C--O 1.219 -0.521 0 CA-C-O 118.099 -0.953 . . . . 0.0 110.56 -179.945 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' B' B ' 201' ' ' SER . . . . . . . . . . . . . 23.4 m . . . . . 0 N--CA 1.489 1.475 0 N-CA-C 109.384 -0.599 . . . . 0.0 109.384 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' B' B ' 202' ' ' SER . . . . . . . . . . . . . 23.1 m -72.46 149.41 44.22 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.231 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 203' ' ' SER . . . . . . . . . . . . . 5.4 m -130.03 150.21 75.35 Favored Pre-proline 0 CA--C 1.533 0.319 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.62 179.769 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 204' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_exo -39.83 -28.42 0.24 Allowed 'Trans proline' 0 C--N 1.311 -1.421 0 C-N-CA 122.928 2.418 . . . . 0.0 112.193 179.324 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 205' ' ' ILE . . . . . 0.713 HD13 ' CE1' ' A' ' 14' ' ' PHE . 15.3 tt -151.28 155.98 6.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.092 -0.504 . . . . 0.0 111.412 179.765 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 206' ' ' GLN . . . . . . . . . . . . . 9.1 tp-100 -173.28 77.7 0.04 OUTLIER 'General case' 0 N--CA 1.452 -0.35 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.084 179.052 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 207' ' ' GLY . . . . . . . . . . . . . . . -111.42 -142.65 9.0 Favored Glycine 0 N--CA 1.466 0.665 0 N-CA-C 111.204 -0.758 . . . . 0.0 111.204 179.639 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 208' ' ' SER . . . . . 0.493 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 94.7 p -165.76 172.79 11.37 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.861 0.362 . . . . 0.0 110.697 -179.718 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 209' ' ' TRP . . . . . . . . . . . . . 79.1 m95 -84.44 131.53 34.66 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.309 179.656 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 210' ' ' THR . . . . . . . . . . . . . 81.4 p -109.41 130.02 55.52 Favored 'General case' 0 N--CA 1.464 0.273 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.546 -179.95 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 52.9 t-105 -92.38 116.91 29.39 Favored 'General case' 0 C--O 1.233 0.204 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.232 179.832 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 212' ' ' GLU . . . . . 0.458 ' O ' ' O ' ' B' ' 215' ' ' LYS . 1.7 pt-20 -165.82 167.53 16.8 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.948 179.333 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 213' ' ' ASN . . . . . . . . . . . . . 96.7 m-20 50.4 36.46 13.21 Favored 'General case' 0 C--N 1.321 -0.641 0 C-N-CA 120.605 -0.438 . . . . 0.0 111.012 176.325 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 50.21 17.07 1.59 Allowed Glycine 0 CA--C 1.523 0.56 0 N-CA-C 111.476 -0.65 . . . . 0.0 111.476 179.853 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 215' ' ' LYS . . . . . 0.458 ' O ' ' O ' ' B' ' 212' ' ' GLU . 52.1 mtmt -144.99 151.13 38.1 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 121.055 0.455 . . . . 0.0 110.684 179.652 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 216' ' ' TRP . . . . . 0.48 ' N ' ' CD1' ' B' ' 216' ' ' TRP . 24.2 m95 -87.27 119.79 27.89 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.053 179.945 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 217' ' ' THR . . . . . . . . . . . . . 21.6 m -130.95 142.81 50.38 Favored 'General case' 0 N--CA 1.464 0.238 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.432 -179.707 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 218' ' ' TRP . . . . . 0.493 ' CH2' ' N ' ' B' ' 208' ' ' SER . 15.7 t-105 -105.57 119.57 39.45 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-N 115.854 -0.612 . . . . 0.0 109.856 179.407 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 219' ' ' LYS . . . . . . . . . . . . . 51.3 mtmt -142.95 171.78 13.58 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.817 -179.766 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -176.84 -160.28 23.62 Favored Glycine 0 CA--C 1.522 0.497 0 N-CA-C 111.237 -0.745 . . . . 0.0 111.237 -179.544 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 221' ' ' ILE . . . . . 0.535 ' O ' HG23 ' B' ' 222' ' ' ILE . 10.1 mm -50.7 -73.53 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 C-N-CA 120.781 -0.368 . . . . 0.0 110.638 -178.237 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 222' ' ' ILE . . . . . 0.535 HG23 ' O ' ' B' ' 221' ' ' ILE . 21.4 pt -158.8 -166.65 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.723 0 CA-C-N 115.707 -0.678 . . . . 0.0 110.949 -179.795 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 223' ' ' ARG . . . . . 0.615 ' N ' HD11 ' A' ' 75' ' ' ILE . 21.2 ptt-85 -43.42 175.77 0.0 OUTLIER 'General case' 0 CA--C 1.521 -0.164 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.692 179.353 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 224' ' ' LEU . . . . . 0.694 ' N ' HD22 ' B' ' 224' ' ' LEU . 3.4 mm? -62.14 115.89 4.51 Favored 'General case' 0 C--N 1.317 -0.807 0 CA-C-N 115.989 -0.55 . . . . 0.0 110.789 -179.738 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 78.5 tt0 -84.58 148.79 26.28 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.564 -0.744 . . . . 0.0 110.529 179.81 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 226' ' ' GLN . . . . . . . . . . . . . 11.5 tt0 . . . . . 0 C--O 1.221 -0.443 0 CA-C-O 118.023 -0.989 . . . . 0.0 110.583 179.821 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.263 0 N-CA-C 109.481 -1.447 . . . . 0.0 109.481 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 49.2 m -60.14 -42.87 95.78 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.721 0.296 . . . . 0.0 110.745 179.987 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 12.5 pt-20 -118.78 59.65 0.82 Allowed 'General case' 0 N--CA 1.466 0.365 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.546 179.96 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 10.8 t -141.25 76.17 22.01 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.484 179.749 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 35.1 Cg_exo -58.89 144.13 99.02 Favored 'Trans proline' 0 N--CA 1.495 1.585 0 C-N-CA 122.666 2.244 . . . . 0.0 112.006 179.826 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 98.9 mm-40 -75.31 131.24 40.16 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.147 179.84 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 2.5 pp -121.11 129.97 53.53 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.339 -179.943 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 61.1 p -130.68 158.15 40.84 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.194 179.888 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 52.6 p30 -109.33 167.34 10.19 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.388 179.942 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 59.8 tp -65.31 145.98 55.51 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.024 -0.534 . . . . 0.0 110.397 -179.985 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . 0.47 ' O ' ' O ' ' A' ' 25' ' ' ARG . 14.2 p -143.49 150.16 38.56 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-O 121.184 0.516 . . . . 0.0 110.614 179.299 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . 0.566 ' N ' ' CD1' ' A' ' 14' ' ' PHE . 9.4 m-85 -112.16 145.74 39.3 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.0 -0.545 . . . . 0.0 110.625 -179.714 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 19.1 m -142.07 159.47 20.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.353 179.417 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 94.5 m-20 56.9 31.42 19.69 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.69 -0.686 . . . . 0.0 110.94 -179.66 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 96.3 mt -55.6 131.83 18.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.93 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.433 HG22 ' H ' ' A' ' 19' ' ' ASP . 0.2 OUTLIER -131.72 -169.52 2.21 Favored 'General case' 0 N--CA 1.468 0.463 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.47 -179.562 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . 0.476 ' N ' ' OD1' ' A' ' 19' ' ' ASP . 17.9 p-10 -77.19 -49.67 14.65 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.982 179.594 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . 0.457 ' CB ' ' O ' ' A' ' 67' ' ' LEU . 70.7 m -121.43 14.62 11.17 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 116.622 -0.263 . . . . 0.0 110.661 -179.176 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . 0.514 ' HB3' HG22 ' A' ' 65' ' ' THR . 2.4 m -146.48 129.87 16.75 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.088 -179.525 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . 0.702 HD12 HD21 ' A' ' 24' ' ' LEU . 44.6 pt -125.95 141.75 44.69 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.322 0 CA-C-N 116.078 -0.51 . . . . 0.0 109.715 179.681 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -99.41 82.39 0.56 Allowed Glycine 0 CA--C 1.522 0.531 0 N-CA-C 110.953 -0.859 . . . . 0.0 110.953 -179.537 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.702 HD21 HD12 ' A' ' 22' ' ' ILE . 76.5 mt -63.32 124.38 21.1 Favored 'General case' 0 C--N 1.328 -0.354 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 -179.834 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . 0.47 ' O ' ' O ' ' A' ' 13' ' ' SER . 67.9 ttp85 -140.66 140.01 34.9 Favored 'General case' 0 C--N 1.332 -0.155 0 CA-C-O 121.245 0.545 . . . . 0.0 110.736 -179.868 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' TRP . . . . . . . . . . . . . 22.0 p90 -144.49 157.99 43.97 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.108 -179.56 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 2.6 m -103.92 105.29 47.61 Favored Pre-proline 0 CA--C 1.536 0.438 0 CA-C-N 116.56 -0.291 . . . . 0.0 110.686 -179.903 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 31.6 Cg_exo -55.02 153.15 26.87 Favored 'Trans proline' 0 N--CA 1.493 1.484 0 C-N-CA 122.041 1.827 . . . . 0.0 112.972 178.802 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.442 ' H ' ' HB2' ' A' ' 32' ' ' SER . 74.5 mt -103.55 135.25 45.5 Favored 'General case' 0 CA--C 1.515 -0.372 0 CA-C-O 121.832 0.825 . . . . 0.0 110.597 -179.941 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 19.2 t-20 -44.18 -31.46 0.98 Allowed 'General case' 0 C--N 1.318 -0.764 0 CA-C-N 115.09 -0.959 . . . . 0.0 110.436 -179.844 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 66.2 m -86.93 -35.9 18.65 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.395 179.151 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . 0.442 ' HB2' ' H ' ' A' ' 29' ' ' LEU . 3.4 m -47.66 114.34 0.88 Allowed 'General case' 0 CA--C 1.528 0.127 0 CA-C-O 121.167 0.508 . . . . 0.0 110.051 -179.819 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 7.8 m -52.77 146.03 11.24 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.499 -0.773 . . . . 0.0 109.633 -179.483 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 27.6 mm -93.38 91.68 3.37 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.199 0 CA-C-O 121.167 0.508 . . . . 0.0 110.932 -178.45 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.53 ' O ' ' CE1' ' A' ' 37' ' ' TYR . 9.0 pt -145.8 128.17 9.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.232 179.645 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -47.84 135.93 14.88 Favored Glycine 0 CA--C 1.52 0.371 0 N-CA-C 110.805 -0.918 . . . . 0.0 110.805 -179.456 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' TYR . . . . . 0.53 ' CE1' ' O ' ' A' ' 35' ' ' ILE . 10.1 m-85 -100.97 179.86 4.26 Favored 'General case' 0 C--N 1.33 -0.241 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 -179.898 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 5.4 tmm_? -132.43 122.37 24.87 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.473 179.731 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.469 ' CG1' ' O ' ' A' ' 39' ' ' ILE . 1.8 pt -97.84 118.17 43.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 115.924 -0.58 . . . . 0.0 109.89 179.633 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 20.9 m -98.3 134.16 41.71 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.216 -179.383 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.4 p -132.01 140.97 46.68 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.262 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.369 -179.999 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . 0.49 ' O ' ' N ' ' A' ' 74' ' ' ASP . 36.2 t -132.21 131.72 60.93 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.177 0 CA-C-O 120.979 0.419 . . . . 0.0 109.903 179.311 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.468 ' HB2' ' CE2' ' A' ' 73' ' ' TYR . . . -96.85 132.98 42.05 Favored 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 109.46 -0.571 . . . . 0.0 109.46 178.987 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.62 ' HB3' ' O ' ' A' ' 72' ' ' ASP . . . -93.93 -14.68 25.71 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.766 0.317 . . . . 0.0 110.825 -179.843 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -99.86 18.88 55.27 Favored Glycine 0 CA--C 1.525 0.678 0 N-CA-C 111.025 -0.83 . . . . 0.0 111.025 -179.495 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 29.4 mm-40 -138.86 149.17 44.58 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 121.179 0.514 . . . . 0.0 110.368 -179.919 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -68.87 -17.3 71.31 Favored Glycine 0 CA--C 1.519 0.283 0 N-CA-C 110.552 -1.019 . . . . 0.0 110.552 179.864 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -135.31 139.03 30.35 Favored Pre-proline 0 CA--C 1.538 0.518 0 C-N-CA 121.192 -0.203 . . . . 0.0 110.683 179.842 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -73.31 158.65 48.21 Favored 'Trans proline' 0 N--CA 1.491 1.351 0 C-N-CA 122.565 2.176 . . . . 0.0 111.813 178.252 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 96.4 mt -73.87 150.2 7.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.247 179.254 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 86.0 m-85 -70.04 137.19 51.07 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.715 179.94 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . 0.421 ' N ' ' CD ' ' A' ' 52' ' ' GLU . 0.0 OUTLIER -59.28 -175.65 0.03 OUTLIER 'General case' 0 CA--C 1.513 -0.446 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.449 179.212 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . 0.41 ' CG ' ' OH ' ' A' ' 62' ' ' TYR . 2.4 t0 -148.06 144.13 27.67 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.802 -0.636 . . . . 0.0 110.486 179.173 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 89.0 m-85 -116.74 122.93 45.9 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-N 116.363 -0.381 . . . . 0.0 110.572 179.812 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 9.5 p -132.06 142.7 42.18 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.425 0 CA-C-N 116.405 -0.361 . . . . 0.0 110.126 179.972 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 94.8 m-20 -61.13 151.87 30.03 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.377 179.952 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 11.3 t -62.72 -35.57 80.15 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.661 179.89 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 42.9 m -50.89 -37.21 42.3 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.162 -179.623 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.639 ' C ' ' H ' ' A' ' 61' ' ' TYR . 3.3 t -79.86 83.85 1.23 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.55 179.826 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -62.37 28.39 0.07 OUTLIER Glycine 0 CA--C 1.535 1.286 0 N-CA-C 111.103 -0.799 . . . . 0.0 111.103 179.672 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . 0.639 ' H ' ' C ' ' A' ' 59' ' ' VAL . 55.2 p90 -166.27 154.19 10.29 Favored 'General case' 0 N--CA 1.451 -0.389 0 CA-C-O 121.14 0.495 . . . . 0.0 111.879 -179.527 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 62' ' ' TYR . . . . . 0.41 ' OH ' ' CG ' ' A' ' 53' ' ' ASP . 23.6 t80 -154.74 148.91 25.94 Favored 'General case' 0 N--CA 1.454 -0.27 0 CA-C-N 115.727 -0.67 . . . . 0.0 109.731 178.794 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 50.1 m -110.69 132.97 53.74 Favored 'General case' 0 N--CA 1.463 0.224 0 CA-C-O 120.909 0.385 . . . . 0.0 110.325 -179.189 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -133.1 100.86 3.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 115.826 -0.625 . . . . 0.0 109.84 178.166 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.514 HG22 ' HB3' ' A' ' 21' ' ' SER . 1.7 p -114.26 165.25 12.87 Favored 'General case' 0 CA--C 1.514 -0.441 0 CA-C-O 121.227 0.536 . . . . 0.0 110.445 179.882 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 108.67 24.33 6.16 Favored Glycine 0 CA--C 1.525 0.68 0 CA-C-N 115.444 -0.798 . . . . 0.0 111.295 -179.933 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.457 ' O ' ' CB ' ' A' ' 20' ' ' SER . 12.7 mt -98.69 106.55 18.83 Favored 'General case' 0 C--O 1.225 -0.22 0 N-CA-C 109.335 -0.617 . . . . 0.0 109.335 179.388 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 49.3 mm-40 -48.43 138.42 11.41 Favored Pre-proline 0 C--N 1.318 -0.792 0 CA-C-N 116.319 -0.4 . . . . 0.0 111.971 -178.323 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -73.36 154.04 50.81 Favored 'Trans proline' 0 N--CA 1.498 1.743 0 C-N-CA 122.749 2.299 . . . . 0.0 111.298 178.736 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 73.76 -6.0 20.95 Favored Glycine 0 CA--C 1.527 0.809 0 CA-C-N 115.839 -0.619 . . . . 0.0 111.647 179.209 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 1.8 mp -102.53 140.53 20.67 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.424 0 CA-C-O 121.326 0.584 . . . . 0.0 109.626 -179.847 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 72' ' ' ASP . . . . . 0.62 ' O ' ' HB3' ' A' ' 44' ' ' ALA . 1.9 t70 -81.42 118.7 22.9 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-N 114.995 -1.002 . . . . 0.0 109.922 179.434 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 73' ' ' TYR . . . . . 0.499 ' O ' HD13 ' A' ' 75' ' ' ILE . 17.6 m-85 -110.85 119.68 39.9 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.828 -0.623 . . . . 0.0 110.44 179.949 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 74' ' ' ASP . . . . . 0.49 ' N ' ' O ' ' A' ' 42' ' ' VAL . 24.8 m-20 -89.43 117.42 28.34 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.613 -0.721 . . . . 0.0 109.574 179.579 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.522 HD11 ' N ' ' B' ' 223' ' ' ARG . 0.0 OUTLIER -114.64 166.23 8.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 121.041 0.448 . . . . 0.0 110.179 -179.339 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 1.1 p -155.11 122.64 5.65 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.589 -0.732 . . . . 0.0 110.559 179.243 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.61 ' O ' HG23 ' B' ' 217' ' ' THR . 20.6 t -96.7 127.35 48.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 N-CA-C 109.355 -0.609 . . . . 0.0 109.355 178.962 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 96.7 mt -117.19 120.02 63.69 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.416 0 CA-C-N 116.479 -0.328 . . . . 0.0 110.485 179.974 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 93.4 m -101.54 116.79 33.56 Favored 'General case' 0 C--N 1.331 -0.21 0 N-CA-C 109.715 -0.476 . . . . 0.0 109.715 179.265 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 16.9 tp -121.35 116.8 25.48 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.724 -179.931 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 81' ' ' ILE . . . . . 0.503 ' HA ' HD11 ' A' ' 35' ' ' ILE . 2.2 pp -147.15 143.29 20.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.321 178.553 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 27.2 t-20 -64.72 -48.9 72.92 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.83 0.348 . . . . 0.0 111.05 -179.818 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 97.73 126.02 5.32 Favored Glycine 0 N--CA 1.465 0.572 0 N-CA-C 111.082 -0.807 . . . . 0.0 111.082 179.671 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -68.27 161.63 50.14 Favored Glycine 0 CA--C 1.523 0.568 0 N-CA-C 110.748 -0.941 . . . . 0.0 110.748 179.947 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 96.4 mt-10 -58.17 134.98 56.97 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.803 0.335 . . . . 0.0 110.57 -179.897 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 20.1 m -72.03 144.88 48.62 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.09 179.898 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.55 ' N ' ' CD ' ' A' ' 88' ' ' PRO . . . 177.19 -46.19 0.0 OUTLIER Pre-proline 0 C--N 1.328 -0.357 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.176 -179.573 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . 0.55 ' CD ' ' N ' ' A' ' 87' ' ' ALA . 50.1 Cg_exo -54.14 -39.71 84.83 Favored 'Trans proline' 0 N--CA 1.497 1.694 0 C-N-CA 122.472 2.115 . . . . 0.0 112.387 -179.176 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 39.1 m -138.77 128.48 24.86 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 115.738 -0.664 . . . . 0.0 110.6 179.969 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 44.5 p -140.53 169.8 16.98 Favored 'General case' 0 C--N 1.332 -0.167 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.328 179.494 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 69.5 mt -88.33 129.51 35.37 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.178 -179.774 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 68.7 p -83.37 165.43 19.27 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.362 -179.931 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 99.3 mt-30 -81.96 130.06 34.96 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.526 -179.987 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 29.8 mm100 55.06 -162.1 0.15 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.524 179.927 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 18.7 m . . . . . 0 C--O 1.218 -0.56 0 CA-C-O 117.997 -1.001 . . . . 0.0 110.487 -179.917 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' B' B ' 201' ' ' SER . . . . . . . . . . . . . 5.5 m . . . . . 0 N--CA 1.488 1.443 0 N-CA-C 109.412 -0.588 . . . . 0.0 109.412 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' B' B ' 202' ' ' SER . . . . . . . . . . . . . 85.2 p -72.07 150.7 43.69 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.425 -179.876 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 203' ' ' SER . . . . . . . . . . . . . 1.6 m -93.29 152.21 40.95 Favored Pre-proline 0 CA--C 1.537 0.459 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.631 -179.716 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 204' ' ' PRO . . . . . . . . . . . . . 19.8 Cg_endo -59.38 -44.75 30.79 Favored 'Trans proline' 0 N--CA 1.498 1.763 0 C-N-CA 122.689 2.259 . . . . 0.0 111.659 -179.661 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 205' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -149.45 144.07 18.02 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.358 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.575 -179.993 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 206' ' ' GLN . . . . . . . . . . . . . 16.6 pt20 -136.22 138.72 42.14 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.137 179.086 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 207' ' ' GLY . . . . . 0.417 ' C ' ' CH2' ' B' ' 218' ' ' TRP . . . -100.87 -135.89 9.11 Favored Glycine 0 N--CA 1.466 0.654 0 N-CA-C 110.802 -0.919 . . . . 0.0 110.802 -179.855 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 208' ' ' SER . . . . . 0.532 ' N ' ' CH2' ' B' ' 218' ' ' TRP . 45.1 p -162.2 166.16 25.93 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.803 0.335 . . . . 0.0 110.643 179.068 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 209' ' ' TRP . . . . . . . . . . . . . 84.7 m95 -85.23 152.84 23.03 Favored 'General case' 0 C--N 1.332 -0.167 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.463 179.603 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 210' ' ' THR . . . . . 0.428 ' OG1' ' O ' ' B' ' 217' ' ' THR . 49.4 p -129.47 129.79 45.05 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-N 116.354 -0.385 . . . . 0.0 110.355 179.504 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 211' ' ' TRP . . . . . . . . . . . . . 57.8 t-105 -92.54 110.17 21.58 Favored 'General case' 0 N--CA 1.462 0.17 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.761 179.657 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 212' ' ' GLU . . . . . 0.443 ' O ' ' O ' ' B' ' 215' ' ' LYS . 1.4 pt-20 -161.17 165.8 28.89 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.54 179.745 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 213' ' ' ASN . . . . . . . . . . . . . 15.9 m120 51.07 33.77 9.75 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.118 176.906 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 214' ' ' GLY . . . . . . . . . . . . . . . 53.35 14.79 3.49 Favored Glycine 0 CA--C 1.527 0.814 0 N-CA-C 111.502 -0.639 . . . . 0.0 111.502 179.993 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 215' ' ' LYS . . . . . 0.443 ' O ' ' O ' ' B' ' 212' ' ' GLU . 9.7 mtmp? -140.91 149.33 41.75 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-O 121.047 0.451 . . . . 0.0 110.663 179.895 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 216' ' ' TRP . . . . . . . . . . . . . 48.3 m95 -84.73 114.73 22.26 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.079 -0.51 . . . . 0.0 109.932 179.757 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 217' ' ' THR . . . . . 0.61 HG23 ' O ' ' A' ' 77' ' ' VAL . 18.3 m -119.25 133.03 55.97 Favored 'General case' 0 N--CA 1.464 0.263 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.279 -179.312 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 218' ' ' TRP . . . . . 0.532 ' CH2' ' N ' ' B' ' 208' ' ' SER . 19.6 t-105 -105.33 107.5 18.52 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.014 -0.539 . . . . 0.0 109.874 179.5 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 219' ' ' LYS . . . . . 0.481 ' HG3' HG22 ' B' ' 217' ' ' THR . 51.1 mtmt -132.82 176.2 8.68 Favored 'General case' 0 CA--C 1.514 -0.44 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.285 -179.48 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 220' ' ' GLY . . . . . . . . . . . . . . . -178.87 -162.38 28.2 Favored Glycine 0 CA--C 1.525 0.685 0 N-CA-C 110.998 -0.841 . . . . 0.0 110.998 179.288 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 221' ' ' ILE . . . . . 0.597 ' H ' HD12 ' B' ' 221' ' ' ILE . 2.3 mp -55.84 -73.11 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 C-N-CA 120.817 -0.353 . . . . 0.0 110.466 -178.321 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 222' ' ' ILE . . . . . 0.54 HG23 ' O ' ' B' ' 221' ' ' ILE . 23.0 pt -160.1 -165.27 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.167 -179.685 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 223' ' ' ARG . . . . . 0.522 ' N ' HD11 ' A' ' 75' ' ' ILE . 39.1 ptt180 -41.12 171.54 0.0 OUTLIER 'General case' 0 C--N 1.334 -0.092 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.956 178.778 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 224' ' ' LEU . . . . . 0.834 HD22 ' H ' ' B' ' 224' ' ' LEU . 1.9 mm? -65.16 110.61 2.6 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-O 121.383 0.611 . . . . 0.0 110.941 -179.642 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 225' ' ' GLU . . . . . . . . . . . . . 82.7 tt0 -86.35 148.28 25.67 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.251 -0.886 . . . . 0.0 109.966 179.656 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 226' ' ' GLN . . . . . . . . . . . . . 99.6 mm-40 . . . . . 0 C--O 1.218 -0.572 0 CA-C-O 118.063 -0.97 . . . . 0.0 110.389 -179.798 . . . . . . . . 0 0 . 1 stop_ save_